<SEC-DOCUMENT>0001372514-23-000050.txt : 20230323
<SEC-HEADER>0001372514-23-000050.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323070154
ACCESSION NUMBER:		0001372514-23-000050
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		23754426

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>kprx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d,d:33c11c03affd49a6944ca837f3a73528--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:kprx="http://www.eyegatepharma.com/20221231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-31">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-32">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:AmendmentFlag" id="f-34">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-373">0.025</ix:nonFraction><ix:nonNumeric contextRef="i231e710e53a94b32bd4380968717a154_I20210811" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-587">5.5</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726" decimals="3" name="kprx:WarrantConvertibleIntoCommonStockBasis" scale="0" id="f-588">0.025</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i350f7b5583cf4743990fb1864cba9f04_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-716">33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i13faae7dbf404c9ca4a7ad27545e7d7a_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-717">0.67</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-718">33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-719">0.67</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d290f7be9574bcebf7238844379effd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0c689070f3d244078fb089421b239bab_I20230320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia02f437734fd4e36ae0a425508221c0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746a7934f1634bada7a8c67124affa16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0ac3e47fbb9a40e6b33136687271985e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id89f9ff5bb924034b3dbe3c193c9f394_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6f1204652347fdb415623b23490c21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1b90f6e26145af8ecb19e5f10688ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideebc6d462dd43b39f1bc22f874315c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2257b859754445a88c5a21dc111b650_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic684d7ddcbac43d0820e53df9cc25544_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee011cd1891496fa9edd4ad779a10f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830b531b6bc24dd2a949f55a286c6888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeed21e0a98842d1987142fe74d1f345_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320d385ba935451a894515e3831f68bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24398d9d387448899d7d6f67b0d18e73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89f9810f6e54da3941651bc0c466491_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16e66ce7c40470481151ae6a1bdec32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibae2553f4c6147269d9f2446ff9cecb5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6098f944e849dd8e3b695e81997494_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbd708d2acc4d68a5639a37269bcebc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb69a13a02f74a679635fb5e795a3515_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9bdcba91c8451886d8aabf630b77e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icced56a3f28a49989883d98b093dc865_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2e47ef018340cb8ebed40d2781bd4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07337b2a24d34ea8bce4d5b0b5d79397_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85228c389d248878079223a2e81bf4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6321cfacdde541d6bcb432afea175641_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3616262e1e274a0f808b0eec4ef7eea2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8af2f5766874a71b1cf8cc1ee00516a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6800052e1e5a4f7ca848d35a11c2a8c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ec6781878b4a5aa00aba09602df9ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib39304336073457096a0aab8825b9dfa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73daca2444e47508725f0b023021fae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4129640388714f6cb33e9916567cc679_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b19d9d48e644670b62130a82a554097_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb9245348984b9c8801dc1000c6f9d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf8b4d600b847b3b4b65b1860728288_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602889283bfb43d69fbac7a5f9edd564_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447a4d73b07c4e98b072bfab8d19e602_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88c374fff9b4b1e86655b1b374c77e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if598f7f07da9469aa774b84729f5f86f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d1531c5c8a44fba658fb9b271b9635_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9abe9e1f4348a593e3702b5ad4bcdd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73652b7324f410eb0a236c5ab74f270_I20220927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-27</xbrli:startDate><xbrli:endDate>2022-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab476c35d5854b3288e7c65fae86f033_I20220926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic6dde5f6b02b4d3a8d35d27b3c627622_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe5ad0fbdd64d0f90e7fbe407e4018e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>kprx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7816963ef37e49fc9b2b1b915da2a22f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7564a47a7da94e13b7282837ea444347_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce5880d70044e6b8f03f31c86c7583d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e93985e88d14fc2822a56282e1b4674_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vendor"><xbrli:measure>kprx:vendor</xbrli:measure></xbrli:unit><xbrli:unit id="consultant"><xbrli:measure>kprx:consultant</xbrli:measure></xbrli:unit><xbrli:context id="ib210e42a94504411b696b6898cff71fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kprx:ClinicalStudiesServicesKIO301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>kprx:director</xbrli:measure></xbrli:unit><xbrli:context id="i4f1302ad90ae4297bfaa1b3b75847254_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kprx:ClinicalStudiesServicesKIO301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="university"><xbrli:measure>kprx:university</xbrli:measure></xbrli:unit><xbrli:context id="id831adc4181743088eae7312ce945c05_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86727de4c5a4926a0e5747099589716_I20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c22c28aff144ee595d728f32589250e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6d43f133f747a0ab9dc998896d995e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ecf2b2ec16422cbacb311f726e1ec3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia50f44856f9c4fb8b1538310decf01f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888435cf3f784a9ba1bf3f83b65808c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:BeginningOfPhase3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaed018232ee4376af66b1bb3f267c0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0c249357514cff9aace25f8d87b162_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799e66b122254b9fb460f1351862d609_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bb67e607cc4f0c9c84c43c78f4efea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef5b9cdc86b4a77beddae9c62c61595_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23180588e9524c849bdffc35ee9bd8aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d2cd5eafe44865832330aec4043e6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e744283a104e7aab5283d862fa0714_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb04f42eb4c42bcb708df3c9ab9d6cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddd33b6700f4b608668df77f0df0cf9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a6ef5429de4056adb997f7e9262826_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087a5072b67a4c169cb7911c09453420_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c178a39c69548fda2705ef06500514f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ee76833e9c428f9fd3ad7f7192e706_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e51232f4a14c209d9c5df6ff177065_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea89645f1894b4fba9d2c548706de5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9cbc32704e41d09a92d143608ba5eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2411b19d85894c33a481ac01c23e03de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7b63c35c834b628a7731a06aee8457_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie954ef05d7134b6f9d9dd90ee01b1211_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834e6138cf4c45329319e7013dad7d7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebe6a805c674f3d9d16186d17a8debc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5e4b8cf2b145ab8c2f3941f240109c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c79b49342e4aae897b21feea0ee57d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87329af756f41a9bd8bee769f08e565_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75764a07c6654ad08928cf4027c83f17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f21e2cac0424fd79527f4ae97483cb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf5f9545aff4296b09d8d3d1ded4f0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59768bc60bf14b3495f61e99faa48435_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifafd19d03e684311a9182b00ff277098_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c2af17f178f4edbb10c214f6d710e09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c18db8d117144d1bf9d77fdd49e90ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc53dd0efce433fadbcbca72c48963e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8140c0eecc74d328848491bed2731d0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied744319bcce42c2947e7cb3c0d9b546_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96515979ddcd4f16b4c0312d1f057eae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">kprx:SentrXAnimalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia067078212ed44749f27634d5c3506d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b8a4fc1832247a586bd7f78fc809839_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb912acb7a84e7f899a898ef68025da_I20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if363cd03c440489cae184e83db725dbe_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbef246b73ec4853aedf59d7fa6d83ce_D20210727-20210727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ff746adaba4d52862cc8fe8045f21a_D20210727-20210727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-27</xbrli:startDate><xbrli:endDate>2021-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231e710e53a94b32bd4380968717a154_I20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea08751701bc47a9bdc29cf167c3a9b4_I20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94882f0f19bc4f1a9ba8053af45015f0_D20210917-20210917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesdConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGesMbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-18</xbrli:startDate><xbrli:endDate>2022-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd47b9b3e10d46d29b71583d4dafc1d5_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ded37b921e452b99960ea388a4e60d_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c59bdff9d148dda84d10448e82d282_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f91e8319c64ff39768af4b6a7f2366_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i487e6598d77f4f0b96574b8f7d9e0080_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantsExerciseOfOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55104f5329234e7f8ec5172aa858ce3c_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib036afd5d8a7483089c4510b19eba804_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassBWarrantExerciseOfOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bde319e174f4eaf85b6f29075e81c13_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62af4e98e26040bb88a1fcc90172c191_D20221117-20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-17</xbrli:startDate><xbrli:endDate>2022-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia811bfae64784023b2eb006045403cbe_I20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e97479594434d06b760d7fa074563be_I20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58366d417e1645fab574b8a7fe469157_D20221117-20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-17</xbrli:startDate><xbrli:endDate>2022-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-17</xbrli:startDate><xbrli:endDate>2022-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85689dc882234a148ea4e1af5e916f2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e7fecaf8fd4207806af45324ae8f90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e36c5ec60743bb983183d644c22f6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6b9d5d260c46978aec252087242f31_I20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3330bdda247340909ef880086af2dc10_D20100101-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9bdfc674f144df89195e7f413c9078_D20100101-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba894cd6b144b8f9075e713823ec483_D20100101-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7b6258bd17457592b81acc9062273f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38a833f22f24032be3a7e78950e921a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795d0aceb7c54c7293c21cba1406d938_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1283a1942d49d3a4dbd18de8e7917c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4ef98046ac4ad4bfb9fb4488c8e276_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55c57edb8428421a821f6bc68bf101ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a48c50139c4eb598eca8ffd0d33853_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40cc4e02cb1e43849c0b6c2e74f65db2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b08f940273a487b92ac968165f4687b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ca6dd2eaac461ca903428aa88ce1da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc96ca35437b4369949f0a093fabcb10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d74368d0d343e6a4e730cc009f7c82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cea2dd17233476fbcf15949d7520ede_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50cfa066a22f4226b954687d13a1302a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa3ab539c714dae87e11ec896cca4d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie678dc82cc1b44fdaea24b535ce33f39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350f7b5583cf4743990fb1864cba9f04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13faae7dbf404c9ca4a7ad27545e7d7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7386b4156e64f10a54ecf9bdd879e97_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53772301813341239fac34a54517b47d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6091ba41f5734ea4ba9b5aadee940665_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1316295f29124fd8882adbcf2ad44e82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92bb8ffea2e14d55ab953dcb6895cbc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a467fc4202c4b38b702366fd2de3793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatinglease"><xbrli:measure>kprx:operatingLease</xbrli:measure></xbrli:unit><xbrli:context id="i13150472ec5a4562a80ec73c18d52b3b_I20231130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic4a8d3ef8ffa49ccb26b949764fa8fee_I20231031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="licenseagreement"><xbrli:measure>kprx:licenseAgreement</xbrli:measure></xbrli:unit><xbrli:context id="i48105e35cedb4703a776e5dc694b2952_I20130702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26ec064aa5b44919c5571e6926241b3_D20130702-20130702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-02</xbrli:startDate><xbrli:endDate>2013-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i076a9cb935ea4b94bb35bfd4c2edad1e_D20130912-20130912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-12</xbrli:startDate><xbrli:endDate>2013-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia857601644d14861b27f01abd39ba087_I20130912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33078441568940d896f1f0dc9f50a202_I20141117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:MediolanumAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:Kio101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:MediolanumAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:Kio101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-17</xbrli:startDate><xbrli:endDate>2014-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dcf2ad2cdd04f2e8c2e583db3d2594b_I20180926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">kprx:SentrXAnimalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfb95e5fdd6415fa8eab70b36245efa_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd19ae6f91940c681c6752beffda62a_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:ForFirst250MillionNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0bef4b71f5f45e382bf6c1ac713c7c7_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:Between250And500MillionNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if750165f4c9d4109955ee668d01b093e_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:NetSalesOver500MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf18c208a9d143518246d68a22a96f9b_I20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-21</xbrli:startDate><xbrli:endDate>2021-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e569234706a4ea9b4ffdd899380ebbb_D20211021-20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">kprx:EarnOutConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-21</xbrli:startDate><xbrli:endDate>2021-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30888c172c61432abf146a3c8dd8bcc5_I20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:IfMilestonePaymentsAreExercisedForSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:MilestoneTypeAxis">kprx:PhaseOneBMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fef671ae73846238e24d7b9e5c28b89_I20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:IfMilestonePaymentsAreExercisedForSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="kprx:MilestoneTypeAxis">kprx:RemainingMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id863c423f1fb4e25825a1e8a560df47a_D20211021-20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">kprx:DueToCreditorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-21</xbrli:startDate><xbrli:endDate>2021-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>kprx:day</xbrli:measure></xbrli:unit><xbrli:context id="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-21</xbrli:startDate><xbrli:endDate>2021-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e223d2316642d58da08e015cef85be_I20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-03</xbrli:startDate><xbrli:endDate>2023-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7604460adc254f1e9a1bf2330d64d148_I20230203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370500edd4064c70bf772759a785cc00_D20230203-20230203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-03</xbrli:startDate><xbrli:endDate>2023-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-10</xbrli:startDate><xbrli:endDate>2023-02-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i33c11c03affd49a6944ca837f3a73528_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.727%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.727%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:2.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Mark One)</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:2.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-36672</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.727%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #6d6d6d;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">KIORA PHARMACEUTICALS, INC</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.727%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">332 Encinitas Blvd.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="f-11">Suite 102</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-12">Encinitas</ix:nonNumeric>, <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="f-13">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-14">92024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:CityAreaCode" id="f-15">781</ix:nonNumeric>) <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-16">788-8869</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.787%"><tr><td style="width:1.0%"></td><td style="width:26.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:Security12bTitle" id="f-17">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:TradingSymbol" id="f-18">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">The <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:SecurityExchangeName" id="f-19">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">None.</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Yes</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Yes  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.060%"><tr><td style="width:1.0%"></td><td style="width:28.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Large Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#168;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of June 30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i7d290f7be9574bcebf7238844379effd_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">6,117,599</ix:nonFraction>. Shares of the registrant&#8217;s common stock held by each officer and director and each person known to the registrant to own 10% or more of the outstanding voting power of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At March&#160;20, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i0c689070f3d244078fb089421b239bab_I20230320" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">1,919,270</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-bottom:12pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_13">Forward</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_13">-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_13">Looking Statements</a></span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_13">2</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_19">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_22">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_25">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_25">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_28">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_31">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_31">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_31">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_34">51</a></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_40">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_40">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_43">Reser</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_43">ved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_43">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_46">Item 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_46">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_76">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_76">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_79">Item 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_79">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_79">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_82">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_82">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_82">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_85">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_85">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_85">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_88">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_88">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_88">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_660">Item 9</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_660">C</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_660">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_660">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_660">65</a></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_91">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_94">Item 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_94">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_94">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_97">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_97">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_97">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_100">Item 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_100">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_100">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_103">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_103">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_103">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_106">Item 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_106">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_106">66</a></span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_109">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_112">Item 15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_112">Exhibits, Consolidated Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_112">67</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_115">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_115">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_190">Item 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_190">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_190">72</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_193">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_193">92</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The forward-looking statements are principally, but not exclusively, contained in Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management&#8217;s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;goals,&#8221; &#8220;sees,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;think,&#8221; &#8220;potential,&#8221; &#8220;objectives,&#8221; &#8220;optimistic,&#8221; &#8220;strategy,&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the timing and success of pre-clinical studies and clinical trials conducted by us and our development partners;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the scope, progress, expansion, and costs of developing and commercializing our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates and the ability to serve those markets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the rate and degree of market acceptance of any of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our expectations regarding competition;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our anticipated growth strategies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our ability to attract or retain key personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our ability to establish and maintain development partnerships;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our expectations regarding federal, state and foreign regulatory requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">regulatory developments in the United States (U.S.) and foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the anticipated trends and challenges in our business and the market in which we operate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the impact of the evolving COVID-19 pandemic and the global response thereto.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We discuss many of these risks in detail under the heading &#8220;Item 1A. Risk Factors&#8221; beginning on page of <a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_22">23</a> this Annual Report on Form 10-K. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora Pharmaceuticals, Inc. is referred to herein as &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and &#8220;the Company.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART I</span></div><div id="i33c11c03affd49a6944ca837f3a73528_19"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 1.  BUSINESS</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. We were formed as a Delaware corporation on December 26, 2004, under the name of EyeGate Pharmaceuticals, Inc., and changed our name to Kiora Pharmaceuticals, Inc. effective November 8, 2021. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. Our lead product is KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (RP, any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#8220;photoswitch&#8221; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP. The molecule is designed to restore the eyes&#8217; ability to perceive and interpret light in visually impaired patients through selectively entering viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and turning them into light sensing cells, capable of signaling the brain as to the presence or absence of light. We initiated a Phase 1b clinical trial in the third quarter of 2022 and dosed the first patient in November 2022. On March 17, 2022, we were granted orphan drug designation (ODD) by the United States Food and Drug Administration (FDA) for the active pharmaceutical ingredient (API) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (Bayon) transaction which closed October 21, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis and, as such, is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+). KIO-101 is a next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). We believe KIO-101 to be best-in-class with picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In a 14-day good laboratory practice (GLP) intravenous (IV) repeated dose toxicity study in rats, no adverse or test item related effects were observed in any of the tested parameters (mortality, clinical observations, ophthalmoscopy, body weight and food consumption, hematology and coagulation, clinical biochemistry, organ weight, pathology, and histopathology) at the highest doses tested (1.0 mg/kg). In the fourth quarter of 2021, we reported top-line safety and tolerability data from a Phase 1b proof-of-concept (POC) study evaluating KIO-101 in patients with ocular surface inflammation. As a further sign of safety, there were zero clinically significant laboratory (including liver enzymes) findings observed in both healthy patients and those with ocular surface inflammation. We expect to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma GmbH (Panoptes) in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are developing KIO-201 for patients with persistent corneal epithelial defects (PCED). PCED is an orphan disease and as such, we are currently seeking orphan drug designation (ODD). KIO-201 is also being evaluated for patients recovering from surgical wounds, such as those undergoing the laser vision correction procedure, photorefractive keratectomy (PRK). KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. We are currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. We are in planning stages of a Phase 3b trial for patients recovering from PRK and plan to initiate the study before the end of 2023.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market Opportunity</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retinitis Pigmentosa Market Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">More than 3.4 million patients globally are estimated to have an inherited retinal disease leading to significant or permanent vision loss. RP is the largest family of these inherited diseases. RP affects about 1 in 3,500 people worldwide. Thus, with a population of about 330 million in the U.S. as of February 2021, about 96,250 people in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the U.S. would be expected to have RP. With a worldwide population presently estimated at over 7.7 billion, it can be estimated that approximately 2.3 million people around the world have RP.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">RP is a group of hereditary progressive disorders that may be inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Maternally inherited variants of RP transmitted via the mitochondrial DNA can also exist. About half of all RP cases are isolated (that is, they have no family history of the condition). RP may appear alone or in conjunction with one of several other rare disorders. Patients with RP have a progressive loss of photoreceptors (rods and cones) and therefore patients with late-stage RP have a substantial loss of peripheral and central visual function.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">While no approved therapies are available for the treatment of RP, current therapeutics in development primarily rely on genetic approaches to introduce light sensing channels into viable downstream cells, a field termed optogenetics. KIO-301 is a small molecule photoswitch, that confers light sensitivity to downstream cells, specifically the retinal ganglion cells (RGCs), potentially triggering the same phototransduction signaling as if the photoreceptors were present and viable.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our Solution: KIO-301</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-301 is a novel small molecule with the potential to confer light sensitivity to patients with degenerated retinas due to either inherited or age-related diseases, which has received orphan drug designation from the FDA. Many retinal diseases result in the death of the retinal photoreceptors, the light sensing cells in the retina. However, downstream retinal neurons, such as the bipolar and RGCs remain viable for long periods after photoreceptor death. KIO-301 selectively enters these cells and non-covalently resides on the intracellular domains of potassium and hyperpolarization-activated, cyclic nucleotide-gated (HCN) voltage gated ion channels. As KIO-301 has an azobenzene core, visible light causes a rapid and reversible change in the isomeric state of the molecule, transforming from a linear molecule to an orthogonal molecule. When this happens, the voltage gated ion channels and current efflux are blocked, causing cellular depolarization and signaling to the brain as to the presence of light. When light is no longer touching the molecule, it reverts back to its linear state, allowing ion efflux from the cells and thus promoting repolarization and a turning &#8220;off&#8221; of the brain signaling.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This novel mechanism of action enables potential application to multiple diseases. RP is a group of inherited eye diseases that cause photoreceptor cell death. In the U.S., RP is considered an orphan disease with a prevalence of fewer than 200,000. This prevalence enables consideration for KIO-301 to qualify for orphan drug designation in the treatment of RP, conferring increased regulatory collaboration with the FDA, and market exclusivity if clinical trials demonstrate safety and efficacy. On March 17, 2022, we were granted orphan drug designation by the FDA for the active ingredient in KIO-301. Currently, no therapeutics are approved to treat patients with RP.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A possible market expansion from RP would be to evaluate KIO-301 in patients with geographic atrophy (GA), the late stage of age-related dry macular degeneration. There are about 1,000,000 patients in the U.S. with GA and to date, no therapeutics are approved to treat this disease.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ocular Presentation of Rheumatoid Arthritis Market Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Patients with systemic autoimmune diseases including Rheumatoid Arthritis (RA), are known to suffer from ocular presentation of their underlying autoimmune conditions. Secondary to inflammation and associated pathologies in the joint synovium, the eye carries significant morbidity and impact on eye health and quality of life. These ocular presentations can include signs and symptoms similar to keratoconjunctivitis sicca (KCS), episcleritis, scleritis, peripheral ulcerative keratitis (PUK), anterior uveitis, as well as retinal vasculitis. In patients with OPRA+, the surface of the eye often has significant irritation accompanied by symptoms of soreness, grittiness, light sensitivity, and dryness. Patients with RA suffer from ocular signs and symptoms at a rate reported to be 2-3X that of the general population. Furthermore, in those OPRA+ patients, up to 50% report moderate to severe signs and symptoms. Today, there are approximately 1.8 million RA patients in the U.S. Approximately one-third of these patients present with OPRA+ (more than 0.5 million in the U.S.), with more than 90% seeking prescription medication to address these ophthalmic manifestations. Unfortunately, today's </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ocular surface anti-inflammatory medicines are usually not sufficient to treat OPRA+ as they are broad and not targeted to the underlying pathophysiology.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As noted above, KIO-101 is a member of a family of DHODH inhibitors, known to be disease modifying agents in autoimmune diseases. RA, as well as OPRA+, are T-cell mediated auto-inflammatory diseases and whilst rheumatologists are helping the systemic manifestations of this disease with approved targeted t-cell modulators, including DHODH inhibitors, ophthalmologists do not have the same toolbox of treatments designed specifically to help patients with ocular presentation.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our Solution: KIO-101</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 is a third-generation small molecule DHODH inhibitor. DHODH is extensively exploited as potential drug targets for immunological disorders, oncology, and infectious diseases. DHODH is a key enzyme in the de novo pyrimidine synthesis pathway. This enzyme is located in the mitochondria and catalyzes the conversion of dihydroorotate (DHO) to orotate as the fourth step in the de novo synthesis of pyrimidines that are ultimately used in the production of nucleotides.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nucleotides are required for cell growth and replication. Nucleotides are the activated precursors of nucleic acids and are necessary for the replication of the genome and the transcription of the genetic information into RNA. Nucleotides also serve as an energy source for a more select group of biological processes (ATP and GTP). They also play a role in the formation of glycogen, signal-transduction pathways, and as components of co-enzymes (NAD and FAD). An ample supply of nucleotides in the cell is essential for all cellular processes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There are two pathways for the biosynthesis of nucleotides: salvage and de novo. The main difference is where the nucleotide bases come from. In the salvage pathway, the bases are recovered (salvaged) from RNA and DNA degradation. In the de novo pathway, the bases are assembled from simple precursor molecules (made from scratch).</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">One critical requirement of fast-growing or proliferating cells, such as the expansion of activated B- and T-cells, cancer cells, and pathogen infected host cells, is the requirement of an abundance of nucleotide bases. These metabolic activities will predominately utilize the de novo pathway for nucleotide biosynthesis. A key advantage of DHODH inhibition is the selectivity towards metabolically activated cells (with a high need for RNA and DNA production), which should mitigate any negative impact on normal cells. Depletion of cellular pyrimidine pools through the selective inhibition of DHODH has been shown to be a successful approach for therapeutic development.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Currently, two first generation DHODH inhibitors have been approved in the U.S. and abroad and are marketed by Sanofi as leflunomide (Arava</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">) and the active metabolite teriflunomide (Aubagio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">). These oral tablets are approved for the treatment of rheumatoid and psoriatic arthritis and multiple sclerosis (MS), respectively. These diseases are autoimmune disorders. One potential explanation for the therapeutic effects of Arava&#174; in arthritis is the reduction in the numbers or reactivity of activated T-cells, which are involved in the pathogenesis of arthritis. The generally accepted view of human MS pathogenesis implicates peripheral activation of myelin-specific autoreactive T-cells that lead to inflammatory disease in the central nervous system (CNS). By blocking the de novo pyrimidine synthesis pathway via DHODH inhibition, it is suggested that Aubagio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> reduces T-cell proliferation in the periphery. Arava</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> and Aubagio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> are formulated as oral drugs and it is established that leflunomide will be metabolized in the liver to the active metabolite teriflunomide. Hepatotoxicity was reported as a major side effect after oral administration, possibly as a result of the extent of liver metabolism. Moreover, it was shown that apart from DHODH, a series of protein kinases are inhibited by Arava</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> and Aubagio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ocular Surgery Market Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There are multiple surgical procedures involving the ocular surface that have long recovery, whereby acceleration of that period would benefit the patients. PRK surgery is an efficacious alternative to patients seeking surgical correction of refractive errors who are not suitable candidates for Laser-Assisted In Situ Keratomileusis (LASIK) due to inadequate corneal thickness, larger pupil size, history of KCS, or anterior basement membrane disease. PRK surgery involves controlled mechanical removal of corneal epithelium with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">subsequent excimer laser photoablation of the underlying Bowman&#8217;s layer and anterior stroma, including the subepithelial nerve plexus.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The military prefers PRK as a refractive procedure due to the stability of the PRK incision and the absence of risk for flap dislocation during military active duty. Although this procedure yields desirable visual acuity results, common complications of the procedure include post-operative pain secondary to the epithelial defects, risk of corneal infection prior to re-epithelization of the large epithelial defect, corneal haze formation, decreased contrast sensitivity, and slower visual recovery. The number of laser vision correction procedures is on the rise, estimated in 2021 at over 2.1 million in the U.S., according to the National Organization for Rare Disorders (NORD). Whilst PRK comprises a fraction of these procedures, there are about 160,000 surgeries performed annually in the U.S according to NORD. These surgeries are heavily consolidated to a few corporate umbrellas, such as TLC Laser Eye Centers, enabling a targeted commercial campaign once a therapeutic is approved.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keratoconus is an orphan disease of the ocular surface, affecting approximately 165,000 patients in the U.S. alone according to NORD. Keratoconus progression involves the structure of the cornea which bulges outward, directly affecting vision. Whilst the etiology of the disease is unknown, there are multiple approaches to helping these patients, involving the use of vision correction prothesis such as contact lenses and glasses, to surgical approaches involving collagen cross-linking the corneal surface to provide more rigidity and slow progression. One of these corneal cross-linking approaches, termed epi-off, involves the removal of about 8 mm of the epithelium on the cornea and a riboflavin solution is applied to the exposed corneal stroma. This procedure is not free of side effects, which often include corneal infections, subepithelial haze, sterile infiltrates, reactivation of herpetic keratitis, and endothelial damage. Thus, accelerating the re-epithelialization would carry significant value.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our Solution: KIO-201</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. This prolongs residence time of the bandage on the ocular surface, thereby addressing one of the limitations of current non-cross-linked HA formulations. Additionally, cross-linking allows the product&#8217;s viscosity to be modified to meet optimum ocular needs. The improved viscoelasticity and non-covalent muco-adhesive interfacial forces improve residence time in the tear film, thus providing a coating that aids re-epithelization of the ocular surface via physical protection. If KIO-201 is approved by the FDA, we expect that it will be the only wound healing prescription eye drop available in the U.S. based on HA.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-201 exhibits significant shear thinning properties. This feature allows the modified HA to act as a more concentrated, viscous barrier at low shear rates in a resting tear film, but also as a lower resistance fluid (therefore thinned) during high shear events such as blinking. This property enables better residence time and a more favorable ocular surface coating with less optical blur. We have demonstrated in animal studies that KIO-201 remains on the ocular surface for up to two hours, and further demonstrated in a human clinical study that KIO-201 does not cause blurriness while on the ocular surface. This enhances ocular surface protection and patient comfort, while maintaining good visual function.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-201 has been shown to provide a mechanical barrier that aids in the management of corneal epithelial defects and re-epithelization in both preclinical studies and in clinical ophthalmic veterinary use. As such, PRK surgery was chosen as the subject population which is best suited to demonstrate this effect. PRK is an efficacious alternative to patients seeking surgical correction of refractive errors who are not suitable candidates for LASIK due to inadequate corneal thickness, larger pupil size, history of KCS, or anterior basement membrane disease. KIO-201 has demonstrated statistical significance in a pivotal clinical study for its ability to accelerate wound healing against the current standard-of-care, a bandage contact lens.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A possible market expansion from PRK surgical recovery would be to evaluate KIO-201 in patients with keratoconus, an ocular disease that affects the structure of the cornea and can cause blindness. Currently patients undergo a mechanical reshaping of the cornea, however this approach causes significant damage to the epithelial layer. As KIO-201 has demonstrated the ability to accelerate wound healing to the ocular surface, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the underlying mechanism of action would be a congruent fit. There are about 170,000 patients in the U.S. with keratoconus according to NORD.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our goal is to develop products for treating disorders of the eye. The key elements of this strategy are to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Develop Core Assets</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:12.44pt">Continue clinical development of KIO-301 in a Phase 1b clinical study in patients with mid to late stage retinitis pigmentosa.</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:12.44pt">Continue clinical development of KIO-101 in a Phase 2 clinical study for the treatment of the ocular manifestations of autoimmune diseases (e.g., rheumatoid arthritis). In the first quarter of 2023, we received approval to initiate a Phase 2 study, slated to start enrollment in the second quarter of 2023.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:12.44pt">Continue clinical development of KIO-201 in patients with PCEDs and advance our late stage program for patients undergoing surgical vision correction including PRK and certain types of keratoconus surgical procedures. These programs will benefit from discussions with the FDA regarding clinical trial designs and approvable endpoints.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Expand Portfolio through Collaborations</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:12.44pt">Pursue strategic collaborations to further the Company&#8217;s existing assets with respect to new indication potential and more detailed mechanism of action, which can result in new intellectual property.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Development Pipeline</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><img src="kprx-20221231_g1.jpg" alt="kprx-20221231_g1.jpg" style="height:294px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-101: Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+)</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Mechanism of Action</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 is a promising novel third generation DHODH inhibitor, with a half-maximal inhibitory concentration IC50-value of 0.3 nM. Based on internal work completed, we believe this means that 1,000-fold more potent than teriflunomide (IC50 DHODH 415 nM). Furthermore, KIO-101 suppresses the expression of key pro-inflammatory cytokines such as IL-17, IFN-g, VEGF and others, potentially as a consequence of inhibiting DHODH. IL-17 and IFN-g are the hallmark cytokines expressed by Th1 and Th17 T-cells, respectively, and play a crucial role in initiating the inflammatory processes in several ocular diseases, including dry eye disease </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(including the association with autoimmune conditions such as rheumatoid arthritis) and non-noninfectious uveitis. KIO-101 is structurally and mechanistically different from Arava</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, a drug currently approved by the FDA for the treatment of rheumatoid arthritis. The IC50 of KIO-101 on selected tyrosine kinases, such as PI3K, AKT and JAK, is more than 10,000-fold above the IC50 of KIO-101 for DHODH. In general, side effects are not expected and have not been observed to date in animal and human studies after KIO-101 administration.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The postulated mode of action of KIO-101 is depicted below.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><img src="kprx-20221231_g2.jpg" alt="kprx-20221231_g2.jpg" style="height:386px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Phase 1b Study:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The results of a Phase 1b study of KIO-101 eye drops in adults with and without ocular surface inflammation were reported in Q4 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Design</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The first part of this single center, randomized, double-masked study was to explore safety and tolerability of KIO-101 in a healthy population; and the second part was to investigate a potential efficacy signal in patients with ocular surface inflammation and hyperemia. Part 1 (cohorts 1 through 3) consisted of healthy volunteers receiving dose escalating concentrations of KIO-101 as noted on the figure below. Specifically, healthy volunteers were repeatedly treated with ascending doses of KIO-101 (0.05%, 0.15%, 0.30%) and placebo eyedrops. Subjects receiving 0.05% and 0.15% eyedrops showed excellent tolerability. Both doses can be used for future studies in patients having an infection or inflammation on the ocular surface. No Severe Adverse Events (SAEs) or severe ocular Adverse Events (AEs) were reported in any patients. In the 0.3% group, two patients withdrew for epistaxis and further dosing in the entire 0.3% group was stopped. No lab abnormalities in these two or any patients were observed and further toxicology studies are ongoing, including the 0.3% dose.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the second part (cohort 4) of this study, 21 patients diagnosed with ocular surface inflammation, a key driver of ocular surface disease including dry eye disease, were evaluated. These patients were treated BID for 12 days with 0.15% of KIO-101 (n=14) or vehicle (n=7). The key inclusion criteria were conjunctival hyperemia score &gt;2 (on the Efron scale of 0-5) and an Ocular Surface Disease Index</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">&#169;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> (OSDI) score of &gt; 22. Primary endpoints included safety and tolerability. Secondary and exploratory endpoints included </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">pharmacokinetics of KIO-101 as well as change from baseline in OSDI, conjunctival hyperemia, tear break up time (TBUT), corneal staining (fluorescein), conjunctival staining (lissamine green), ocular discomfort, lid edema, and lid erythema.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><img src="kprx-20221231_g3.jpg" alt="kprx-20221231_g3.jpg" style="height:386px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Study Results</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The results demonstrated favorable safety and tolerability of KIO-101, as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients enrolled with ocular surface inflammation and a recognized clinical sign in patients with ocular surface inflammation. At Day 13, 100% (Figure 1 below) of patients treated with KIO-101 (14/14) saw a reduction &gt;1 from baseline, measured on the Efron scale (0-5), versus only 42.8% with vehicle control (3/7) (p &lt; 0.006). The mean reduction in conjunctival hyperemia score from baseline to Day 13 demonstrated statistically significant difference in active treatment vs. vehicle control groups (-1.055 vs. -0.604; p = 0.0316). This apparent drug effect on conjunctival hyperemia was lost when patients were assessed at the Day 20 post-treatment follow-up, which occurred 8 days after the last dose was administered, further supporting a potential positive drug effect. There was a numerical trend favoring KIO-101 in OSDI, but no statistically significant differences were observed in TBUT, corneal staining, conjunctival staining, or other exploratory endpoints. A larger sample size and dosing period longer than two weeks will likely be necessary to effectively evaluate a statistical drug effect on these additional efficacy endpoints.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><img src="kprx-20221231_g4.jpg" alt="kprx-20221231_g4.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:18pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1: Percent of patients with reduction of &gt;1</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">No SAEs or severe ocular AEs were reported. In the 0.3% group, 2 patients withdrew for epistaxis (nose bleeds) and dosing was stopped, with no lab abnormalities in these 2 or any patients observed. In cohort 4, no difference was observed in the frequency of ocular AEs in active vs. control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Clinical Development Plan</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We received conditional approval to initiate a Phase 2 clinical trial with KIO-101 eye drops in Q4 2022. In February 2023 we received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of OPRA+ and expect to initiate enrollment in Q2 2023. The study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-101: Non-Infectious Posterior Uveitis</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Phase 1a/2b Safety Study:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A first, in human clinical study to evaluate the safety of intravitreally applied KIO-101 in patients with chronic, non-infectious uveitis was conducted and the final study report was completed in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Design</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 was applied as a single, intravitreal injection of 300, 600, and 1,200 ng per eye. The primary objective of the study was to assess the safety and tolerability of ascending doses of KIO-101 in patients. The secondary objectives were to assess improvement of intraocular inflammation and to evaluate the pharmacokinetics of KIO-101 in patients. For this study, KIO-101 was formulated as a sterile, aqueous solution for intravitreal injection.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The purpose of this study was to assess safety, pharmacokinetic (PK), and efficacy data of 12 treated patients. KIO-101 showed an excellent safety profile and promising efficacy signals in improvement of inflammatory parameters and visual acuity in uveitis patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Study Results</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The assessment of the evaluated efficacy parameters shows a clear dose dependent treatment effect in improvement of visual acuity at Day 14 post dosing. Figure 2 shows the mean change in letters read from baseline for patients treated in cohorts 1, 2, and 3 (300, 600, and 1,200 ng per eye).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><img src="kprx-20221231_g5.jpg" alt="kprx-20221231_g5.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:18pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2: Improvement of visual acuity in cohorts 1, 2, and 3 at Day 14 post dose</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Upon analyzing only the highest dose group (1,200 ng per eye, cohort 3), a fundamental mean improvement of visual acuity is seen in the patients, which started within the first week post injection (Day 7) and lasted beyond the last study visit (Day 28). Figure 3 shows the mean letters read change from baseline to study Days 7, 14, and 28 for patients treated in cohort 3.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><img src="kprx-20221231_g6.jpg" alt="kprx-20221231_g6.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:18pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3: Improvement of visual acuity in cohort 3 on study Days 7, 14, and 28</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Apart from improved visual acuity, improvements in vitreous haze and reduction in macular edema were observed in the patients treated with KIO-101. We have no current plan to develop KIO-101 further for this indication.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-201: PRK Surgical Recovery Pivotal Study</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Pivotal Study:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In Q4 2019, we reported positive topline results from our corneal wound repair pivotal clinical trial of KIO-201 for the corneal re-epithelialization in patients having undergone PRK surgery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Design</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The prospective, controlled study randomized 234 patients undergoing bilateral PRK surgery and was designed to assess safety and efficacy by comparing KIO-201 to the current standard-of-care, a bandage contact lens (BCL). The primary endpoint was the proportion of study eyes achieving complete wound closure on Day 3 (and remaining closed). This assessment was evaluated by an independent masked reading center, using digital slit-lamp photographs of fluorescein staining in all treated eyes, and a protocol-driven method to quantify the outcomes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The enrolled patients were randomized into one of two study groups, with patients receiving the same treatment in both eyes:</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:23.5pt">Cohort 1 (n=117) was comprised of KIO-201 QID for two weeks after surgery.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:23.5pt">Cohort 2 (n=117) was comprised of BCL administered four times daily.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><img src="kprx-20221231_g7.jpg" alt="kprx-20221231_g7.jpg" style="height:106px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Study Results</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-201 demonstrated superiority for the primary endpoint with a p-value of 0.0203. The statistical significance measurement was based on the number of patients in each arm that achieved complete corneal defect closure three days post refractive surgery. At Day 3, 80.2% of eyes receiving the KIO-201 treatment regimen were completely healed, compared with 67.0% for BCL. Additionally, at Day 2, the average wound size for all eyes treated with KIO-201 was 3.61 mm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, compared to 6.66 mm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> for eyes treated with BCL, which is 46% smaller than the standard-of-care as noted in Figure 4. As described further, the use of KIO-201 resulted in smaller wounds in the acute healing phase after PRK surgery compared to the standard-of-care (BCL). This data gives confidence that patients will be able to resume normal activities earlier when treated with KIO-201 compared to BCL.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><img src="kprx-20221231_g8.jpg" alt="kprx-20221231_g8.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:18pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4: Mean wound size (mm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Clinical Development Plan</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are currently assessing the requirements on a registration clinical trial as well as evaluating the market opportunity. We expect to begin further clinical work in 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-201: Persistent Corneal Epithelial Defects</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Phase 2 Study:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In Q1 2022, we initiated a clinical trial of KIO-201 evaluating the potential to help patients with PCEDs. We expect results from this study in early-mid 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Design</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This single site clinical trial was designed to enroll up to 10 patients (20 eyes) with PCEDs, as defined by a duration of at least 14 days while on conventional therapies. The primary endpoint of the study is safety and tolerability with key secondary endpoints including assessing the number of patients with healing (defined by lesions being &lt;0.5mm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Clinical Development Plan</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PCED qualifies as a rare disease, and therefore we applied for orphan drug designation as part of our clinical development plan for KIO-201 in Q4 2022. We expect to receive ODD in 2023 and with the results from the aforementioned clinical trial, we plan to meet with the FDA to discuss next steps.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KIO-301: Retinitis Pigmentosa</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Phase 1b Study:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In Q4 2022, we initiated a clinical trial of KIO-301 in patients with later stage Retinitis Pigmentosa. We expect results from this study in late 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Design</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This is a Phase 1b open-label, single ascending dose clinical trial for people living with retinitis pigmentosa. The study will enroll six patients and evaluate 12 eyes. The first cohort of three patients will include individuals with no or bare light perception due to the progression of RP. The second cohort will include </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">patients able to detect hand motion and count fingers. Dose escalations will be performed in each patient's contralateral eye. The primary endpoints are safety and tolerability, with secondary efficacy endpoints including objective and subjective evaluations, such as object identification and contrast assessment, navigation, perimetry, functional MRI and other ophthalmic and quality-of-life assessments. This multi-site study is being conducted at The Royal Adelaide Hospital (RAH) in Adelaide, South Australia as well as multiple private ophthalmology clinics in Adelaide, South Australia.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Clinical Development Plan</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Retinitis pigmentosa is a rare inherited disease where patients typically present with loss of low light/night vision, followed by reduced visual field (loss of peripheral vision) and eventually loss of central vision. In Q1 2022, we received ODD from the FDA. We will assess the results from the Phase 1b clinical trial and determine next steps in the development of KIO-301 in late 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property and Proprietary Rights</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are building an intellectual property portfolio for our KIO-101, KIO-201, and KIO-301 platforms and any other product candidates that we may develop, as well as other devices and product candidates for treatment of ocular indications in the U.S. and abroad. We currently seek, and intend to continue to seek, patent protection in the U.S. and internationally for our product candidates, methods of use, and processes for manufacture, and for other technologies, where appropriate. Our current policy is to actively seek to protect our proprietary position by, among other things, filing patent applications in the U.S. and abroad relating to proprietary technologies that are important to the development of our business. We also rely on, and will continue to rely on, trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our technology.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for the technologies that we consider important to our business, our ability to defend our patents, and our ability to preserve the confidentiality of our trade secrets and operate our business without infringing the patents and proprietary rights of third parties.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Portfolio</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our patent portfolio includes patents covering KIO-101 including composition-of-matter, formulations thereof and its therapeutic uses in the treatment of ocular disorders and diseases and more. In addition, we hold a patent portfolio covering KIO-301 consisting of composition-of-matter, methods of use, and formulations thereof patents. Our KIO-201 portfolio of patents covers composition-of-matter and methods of use claims. These issued patents will expire between 2023 and 2036. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant new drug application or NDA. See &#8220;Government Regulation &#8212; Patent Term Restoration and Marketing Exclusivity&#8221; below.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Globally, we hold 26 active and valid patents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a party to seven license agreements as described below. These license agreements require us to pay or receive royalties or fees to or from the licensor based on revenue or milestones related to the licensed technology.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July 2, 2013, we (through our subsidiary, Kiora Pharmaceuticals, GmbH) entered into a patent and know-how assignment agreement with 4SC Discovery GmbH (4SC) transferring to us all patent rights and know-how to the compound KIO-101. We are responsible for paying royalties of 3.25% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July 2, 2013, we (through our subsidiary, Kiora Pharmaceuticals, GmbH) entered into an out-license agreement with 4SC granting 4SC the exclusive worldwide right to commercialize the compound KIO-101 for rheumatoid arthritis and inflammatory bowel disease, including Crohn&#8217;s disease and ulcerative colitis. We are eligible to receive milestone payments totaling up to &#8364;155 million, upon and subject to, the achievement of certain specified developmental and commercial milestones. We have not received any milestones from 4SC. In addition, we are eligible to receive royalties of 3.25% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September 12, 2013, we (through our subsidiary, Jade Therapeutics, Inc.) entered into an agreement with Lineage Cell Therapeutics, Inc. (Lineage), formerly known as BioTime, Inc., granting to us the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (modified HA) for ophthalmic treatments in humans. The agreement requires us to pay an annual fee of $30,000 and a royalty of 6% on net sales of KIO-201 to Lineage based on revenue relating to any product incorporating the modified HA technology. The agreement expires when patent protection for the modified HA technology lapses in August 2027.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November 17, 2014, we (through our subsidiary Kiora Pharmaceuticals GmbH) entered into an intellectual property and know-how licensing agreement with Laboratoires Leurquin Mediolanum S.A.S. (Mediolanum) for the commercialization of KIO-101 (the &#8220;Mediolanum Agreement&#8221;) in specific territories. Under the Mediolanum agreement, we out-licensed rights to commercialize KIO-101 for uveitis, dry eye, and viral conjunctivitis in Italy and France. This agreement was amended on December 10, 2015, to also include Belgium and The Netherlands. Under the Mediolanum Agreement, Mediolanum is obligated to pay up to approximately &#8364;20 million in development and commercial milestones, and a 7% royalty on net sales of KIO-101 in the territories through the longer of the expiry of the valid patents covering KIO-101 or 10 years from the first commercial sale. The royalty is reduced to 5% after patent expiry.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September 26, 2018, we entered into an intellectual property licensing agreement (the &#8220;SentrX Agreement&#8221;) with SentrX, a veterinary medical device company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, we in-licensed the rights to trade secrets and know-how related to the manufacturing of KIO-201. The SentrX Agreement enables us to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use. Under the SentrX Agreement, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified developmental and commercial milestones. The term of the agreement is until the Product is no longer in the commercial marketplace.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May 1, 2020, we (through our subsidiary, Bayon Therapeutics, Inc.) entered into an agreement with the University of California (UC) granting to us the exclusive rights to its pipeline of photoswitch molecules. The agreement requires us to pay an annual fee to UC of $5,000, as well as payments to UC upon the achievement of certain development milestone and royalties based on revenue relating to any product incorporating KIO-301. The Company is obligated to pay royalties on net sales of 2% of the first $250 million of net sales, 1.25% of net sales between $250 million and $500 million, and 0.5% of net sales over $500 million. The agreement expires on the date of the last-to-expire patent included in the licensed patent portfolio which is January 2030.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May 1, 2020, we (through our subsidiary, Bayon Therapeutics, Inc) entered into an agreement with Photoswitch Therapeutics, Inc. (Photoswitch) granting to us access to certain patent applications and IP rights with last-to-expire patent terms of January 2030. The agreement calls for payments to Photoswitch upon the achievement of certain development milestones and upon first commercial sale of the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information and Inventions Assignment Agreements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We currently require, and will continue to require, each of our employees and consultants to execute confidentiality agreements upon the commencement of such individual&#8217;s employment, consulting, or collaborative relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the case of employees, the agreements provide that all inventions resulting from such individual&#8217;s work performed for us, utilizing our property, or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. Our consulting agreements also provide for assignment to us of any intellectual property resulting from services performed by a consultant for us.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If KIO-101, KIO-201 or KIO-301, is approved by the FDA for commercial sale, we may enter into agreements with third parties to sell KIO-101, KIO-201, or KIO-301, or we may choose to market these directly to physicians in the U.S. or globally through our own sales and marketing force and related internal commercialization infrastructure. If we market KIO-101, KIO-201, or KIO-301 directly, we will need to incur significant additional expenses and commit significant additional management resources to establish and train an internal sales and marketing force to market and sell KIO-101, KIO-201, or KIO-301.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We currently do not have an in-house manufacturing capability for our products and as a result, we will depend heavily on third-party contract manufacturers to produce and package our products. We currently do not have any contractual relationships with third-party manufacturers. We intend to rely on third-party suppliers that we have used in the past for the manufacturing of various components that comprise our KIO-101, KIO-201, KIO-301 and other contemplated clinical trials.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience, and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our potential competitors include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The key competitive factors affecting the success of each of our product candidates, if approved for marketing, are likely to be its efficacy, safety, method of administration, convenience, price, level of generic competition, and the availability of coverage and adequate reimbursement from government and other third-party payors.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. Generic products currently being used for the indications that we may pursue, and additional products are expected to become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Food Drug and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable FDA or other requirements may subject a company to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, a clinical hold, warning letters, recall or seizure of products, partial or total suspension of production, withdrawal of the product from the market, injunctions, fines, civil penalties, or criminal prosecution.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">FDA approval is required before any new drug can be marketed in the U.S. The process required by the FDA before a new drug product may be marketed in the U.S. generally involves:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">completion of pre-clinical laboratory and animal testing and formulation studies in compliance with the FDA&#8217;s good laboratory practice or GLP, regulation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug or IND, for human clinical testing which must become effective before human clinical trials may begin in the U.S.;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">approval by an independent Institutional Review Board or IRB, at each site where a clinical trial will be performed before the trial may be initiated at that site;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed product candidate for each intended use;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the facility or facilities at which the product is manufactured to assess compliance with the FDA&#8217;s current Good Manufacturing Practice or CGMP regulations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">submission to the FDA of a new drug application or NDA, which must be accepted for filing by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">payment of user fees, if applicable; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">FDA review and approval of the NDA.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The pre-clinical and clinical testing and approval process requires substantial time, effort, and financial resources. Pre-clinical tests include laboratory evaluation of product chemistry, formulation, manufacturing and control procedures, and stability, as well as animal studies to assess the toxicity and other safety characteristics of the product. The results of pre-clinical tests, together with manufacturing information, analytical data, and a proposed clinical trial protocol and other information, are submitted as part of an IND to the FDA. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria, and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually. In addition, timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB, at each institution participating in the clinical trial, must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed, and otherwise comply with IRB regulations.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sponsors of clinical trials generally must register and report the key parameters of certain clinical trials, at the National Institutes of Health-maintained website ClinicalTrials.gov. For purposes of an NDA submission and approval, human clinical trials are typically conducted in the following sequential phases, which may overlap or be combined:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Phase 1:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> The product is initially introduced into healthy human patients and tested for safety, dose tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Phase 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: The product is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications, and to determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive clinical trials.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Phase 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: These are commonly referred to as pivotal studies. When Phase 2 evaluations demonstrate that a dose range of the product appears to be effective and has an acceptable safety profile, trials are undertaken in large patient populations to further evaluate dosage, to obtain additional evidence of clinical efficacy and safety in an expanded patient population at multiple, geographically-dispersed clinical trial sites, to establish the overall risk-benefit relationship of the product, and to provide adequate information for the labeling of the product.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Phase 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: In some cases, the FDA may conditionally approve an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after NDA approval. Such post-approval trials are typically referred to as Phase 4 studies.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of user fees. A waiver of such fees may be obtained under certain limited circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease. A rare disease or condition is defined by the regulatory agency as one affecting fewer than 200,000 individuals in the U.S. or more than 200,000 individuals where there is no reasonable expectation that the product development cost will be recovered from product sales in the U.S. The request form for orphan drug designation must be filed before submitting an NDA and does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. On March 17, 2022, we were granted orphan drug designation by the FDA for the active pharmaceutical ingredient in KIO-301. On August 9, 2022, we submitted an application to the FDA for orphan drug designation for KIO-201. The FDA requested more information, which was provided in December 2022, and we are now awaiting a response.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If a product with orphan drug designation subsequently receives the first FDA approval for the disease for which it was studied, the sponsor will be entitled to seven years of product marketing exclusivity. This means that the FDA may not approve any other applications to market the same drug for the same indication, except in very limited and rare circumstances, for seven years. If a competitor obtains approval of the same drug, as defined by the FDA, or if KIO-301 is determined to be contained within a competitor&#8217;s product for the same indication or disease, the competitor&#8217;s exclusivity could block the approval of KIO-301 in the designated orphan indication for seven years, unless superior safety or efficacy of our drug is demonstrated.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to product/device listing, recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with CGMP requirements. Changes to the manufacturing process are strictly regulated and generally require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from CGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain CGMP compliance.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">fines, warning letters, or holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. While physicians may prescribe for off label uses, manufacturers may only promote for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, both at the federal and state levels.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Restoration and Marketing Exclusivity</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depending upon the timing, duration and specifics of FDA approval of the use of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of fourteen years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of an NDA, plus the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for extension must be made prior to expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an approved NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Requirements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We and our third-party manufacturers must comply with applicable FDA regulations relating to FDA CGMP regulations. The CGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, extensive records and reports, and returned or salvaged products. The manufacturing facilities for our products must meet CGMP requirements to the satisfaction of the FDA pursuant to a pre-approval inspection before we can use them to manufacture our products. We and our third-party manufacturers and certain key component suppliers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, including untitled letters, warning letters, determinations of product adulteration, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, and civil and criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval. Such perceived problems concerning safety or efficacy may arise in the context of clinical studies continued as a result of our post-marketing obligations, reports we or FDA receive from patients and healthcare providers, or literature published by third parties regarding our products or similar products.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Payor Coverage and Reimbursement</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reimbursement is expected to use standard approaches for ophthalmology. The commercial success of KIO-101, KIO-201, and KIO-301, if and when commercialized, and our other product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state, and private levels, including U.S. Government Payor programs, such as Medicare and Medicaid, private health care insurance companies, and managed care plans that have attempted to control costs by limiting coverage and the amount of reimbursement for particular procedures or drug treatments. The U.S. Congress and state legislatures from time to time propose and adopt initiatives aimed at cost containment, which could impact our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ability to sell our products profitably. Ongoing federal and state government initiatives directed at lowering the total cost of health care will likely continue to focus on healthcare reform, the cost of prescription pharmaceuticals and on the reform of the Medicare and Medicaid payment systems.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect that the pharmaceutical industry will continue to experience pricing pressures due to these initiatives and the trend toward managed healthcare and the increasing influence of managed care organizations. Our results of operations could be adversely affected by current and future healthcare reforms.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Some third-party payors also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop and operate profitably.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are also subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the applicable regulatory agency will have broad regulatory and enforcement powers, including, among other things, the ability to levy fines and civil penalties. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development, and production efforts, which could harm our business, operating results, and financial condition.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December 31, 2022, we had twelve full-time employees. None of our employees are represented by a collective bargaining agreement and we have never experienced any work stoppage. We believe that we maintain good relations with our employees. Our employees are highly skilled, and many hold advanced degrees and have experience with drug development. Our future performance depends significantly upon the continued service of our key scientific, technical, and senior management personnel and our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth, and a robust employment package that promotes well-being across all aspects of their lives. In addition to salaries, these programs include potential annual discretionary bonuses, equity awards, healthcare and insurance benefits, paid time off, family leave, and flexible work schedules, among other benefits. We have taken proactive steps throughout the COVID-19 pandemic to protect the health and safety of our employees. We may take further actions, in compliance with all appropriate government regulations, that we determine to be in the best interest of our employees.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Segment and Geographical Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment. We operate in one geographic segment.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora Pharmaceuticals, Inc. was formed in Delaware on December 26, 2004, under the name EyeGate Pharmaceuticals, Inc. On November 8, 2021, we completed a merger of our wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc. (incorporated in October 2021) into EyeGate Pharmaceuticals, Inc., which merger resulted in the amendment of our restated certificate of incorporation to change our name to &#8220;Kiora Pharmaceuticals, Inc.&#8221; effective November 8, 2021. In connection with the name change, we changed our symbol on the Nasdaq Capital Market to &#8220;KPRX&#8221; and began using a new CUSIP number for shares of our common stock (49721T101) effective at the market open on November 8, 2021. Following the reverse stock </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">split effective September 27, 2022, we began using a new CUSIP number for shares of our common stock (49721T309). We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. We have four wholly-owned subsidiaries: Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH (formerly known as Panoptes Pharma GmbH), Bayon Therapeutics, Inc., and Kiora Pharmaceuticals Pty Ltd (formerly known as Bayon Therapeutics Pty Ltd). Our former subsidiary, EyeGate Pharma S.A.S. was dissolved effective December 31, 2020. Our principal executive offices are located at 332 Encinitas Blvd., Suite 102, Encinitas, California, 92024, and our telephone number is (781) 788-8869.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Available Information and Website</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We maintain an internet website at www.kiorapharma.com and make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the United States Securities and Exchange Commission, or the SEC. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http://www.sec.gov. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors, and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part of this Annual Report on Form 10-K. Our website address is included in this Annual Report on Form 10-K as an inactive technical reference only.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September 23, 2022, we filed a Certificate of Amendment to our Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split of our outstanding common stock. The Amendment became effective at 12:01 a.m. Eastern Time on September 27, 2022. The Amendment was approved by our stockholders at our 2022 Annual Meeting of Stockholders held on September 23, 2022, and by our board of directors.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Amendment provided that, at the effective time of the Amendment, every forty (40) shares of our issued and outstanding common stock automatically combined into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of our common stock outstanding immediately prior to the effective time of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, and restricted stock awards issued by us and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, and restricted stock awards, and, in the case of stock options, a proportionate increase in the exercise price of all such stock options. In addition, the number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under our Restated Certificate of Incorporation, which remained at 50,000,000 shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of our common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share). As a result of the reverse stock split, the number of our outstanding shares of common stock as of September 27, 2022 decreased from 43,163,123 (pre-split) shares to 1,079,045 (post-split) shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All share and per share amounts in the accompanying financial statements, related footnotes, and management&#8217;s discussion and analysis have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are presented reflecting the split. Our common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on September 27, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making an investment decision regarding our common stock.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We have incurred significant operating losses since our inception, which have caused management to determine there is substantial doubt regarding our ability to continue as a going concern. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">The coronavirus pandemic could adversely impact our business, including clinical trials.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We depend heavily on the success of KIO-101, KIO-201, and KIO-301. If we are unable to successfully obtain marketing approval for KIO-101, KIO-201, or KIO-301, or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize KIO-101, KIO-201, or KIO-301, our business will be materially harmed.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">If clinical trials of KIO-101, KIO-201, KIO-301, or any other product candidate that we develop fail to demonstrate safety and efficacy to the satisfaction of the FDA or foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be delayed or unable to complete, the development and commercialization of KIO-101, KIO-201, KIO-301, or any other product candidate.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Even if KIO-101, KIO-201, KIO-301, or any other product candidate that we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for our product candidates may be smaller than we estimate.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">If we are unable to establish sales, marketing, and distribution capabilities, we may not be successful in KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop if and when they are approved.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Even if we are able to commercialize KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices, or healthcare reform initiatives which could harm our business.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">If we are not able to obtain required regulatory approvals, we will not be able to commercialize KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop; and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">We have identified a material weakness in our internal control over financial reporting. If we are unable to remediate this material weakness, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely requirements applicable to public companies, which may adversely affect investor confidence in us, and, as a result, the market price of our common stock.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">The following factors should be reviewed carefully, in conjunction with the other information contained in this Annual Report on Form 10-K. As previously discussed, our actual results could differ materially from our forward-looking statements. Our business faces a variety of risks. These risks include those described below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. If any of the events or circumstances described in the following risk factors occur, our business operations, performance, and financial condition could be adversely affected and the trading price of our common stock could decline.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We have incurred significant operating losses since our inception, which have caused management to determine there is substantial doubt regarding our ability to continue as a going concern. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Since inception, we have incurred significant operating losses. Our net loss was approximately $13.6 million for the year ended December&#160;31, 2022, $13.8 million for the year ended December&#160;31, 2021 and $134.5 million from the period of inception (December 26, 2004) through December 31, 2022. To date, we have financed our operations primarily through private placements and public offerings of our securities, and payments from our license agreements. We have devoted substantially all of our financial resources and efforts to research and development, including pre-clinical studies and, beginning in 2008, clinical trials. We are still in the development stage of our product candidates and we have not completed development of any drugs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. Our recurring losses from operations have caused management to determine there is substantial doubt regarding our ability to continue as a going concern, and as a result, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December 31, 2022, with respect to this uncertainty.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We anticipate that our expenses will continue to be significant with the clinical trials for the ongoing development of our KIO-101, KIO-201, and KIO-301 products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our expenses will also increase if and as we:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">seek marketing approval for KIO-101, KIO-201, and KIO-301, whether alone or in collaboration with third parties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">continue the research and development of KIO-101, KIO-201, KIO-301, and any of our other product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">seek to develop additional product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates, or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establish sales, marketing, and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize any products for which we may obtain marketing approval;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">hire additional clinical, quality control, scientific and management personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expand our operational, financial and management systems, and personnel, including personnel to support our clinical development, manufacturing, and planned future commercialization efforts and our operations as a public company; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">increase our insurance coverage as we expand our clinical trials and commence commercialization of KIO-101, KIO-201, and KIO-301.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">we are required by the FDA or foreign equivalents to perform studies or clinical trials in addition to those currently expected; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">there are any delays in enrollment of patients in or completing our clinical trials or the development of KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we obtain marketing approval for, and commercialize KIO-101, KIO-201, KIO-301, or other product candidates that we may develop, which may never occur. This will require us to be successful in a range of challenging activities, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establishing collaboration, distribution, or other marketing arrangements with third parties to commercialize KIO-101, KIO-201, and KIO-301 in markets outside the U.S.;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">achieving an adequate level of market acceptance of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">protecting our rights to our intellectual property portfolio related to our product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">ensuring the manufacture of commercial quantities of KIO-101, KIO-201, and KIO-301.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings, or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect to devote substantial financial resources to our ongoing and planned activities, particularly continuing the clinical development of our KIO-101, KIO-201, and KIO-301 products. In the future, we expect to raise additional financial resources for the continued clinical development of KIO-101, KIO-201, KIO-301, and other product candidates we may develop. In addition, if we obtain regulatory approval for any of our product candidates, we would need to devote substantial financial resources to commercialization efforts, including product manufacturing, marketing, sales, and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the progress, costs, and outcome of our clinical trials for our product candidates and of any clinical activities required for regulatory review of our product candidates outside of the U.S.;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the costs and timing of process development and manufacturing scale up and validation activities associated with our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates in the U.S., and in other jurisdictions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the costs and timing of commercialization activities for our product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution, and outsourced manufacturing capabilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">subject to receipt of marketing approval, the amount of revenue received from commercial sales of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our ability to establish collaborations on favorable terms, if at all, particularly manufacturing, marketing, and distribution arrangements for our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates, or technologies for the treatment of ophthalmic diseases.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, we had cash and cash equivalents of $6.0 million. We believe we will have sufficient cash to fund planned operations into July 2023, however, the acceleration or reduction of cash outflows by management can significantly impact the timing needed for raising additional capital to complete development of our products. To continue development, we will need to raise additional capital through debt and/or equity financing or access additional funding through U.S. or foreign grants. Although we completed our initial public offering and subsequent public offerings, registered direct offerings and private placements, additional capital may not be available on terms favorable to us, if at all. Accordingly, no assurances can be given that management will be successful in these endeavors. These conditions raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. Our commercial revenues, if any, will be derived from sales of KIO-101, KIO-201, KIO-301, or any other products that we successfully develop, none of which we expect to be commercially available for several years, if at all. In addition, if approved, any product candidate that we develop or any product that we in-license may not achieve </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">commercial success. Accordingly, we will need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, collaborations, strategic alliances, licensing arrangements, and marketing and distribution arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we cannot raise funds on acceptable terms, we may not be able to grow our business or respond to competitive pressures.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we raise additional funds through government or other third-party funding, collaborations, strategic alliances, licensing arrangements, or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts, or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a clinical-stage company with a limited operating history. Our operations to date have been limited to organizing and staffing our company, acquiring rights to intellectual property, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking preclinical studies, and conducting clinical trials of KIO-101, KIO-201, and KIO-301. We have not yet demonstrated our ability to successfully complete development of a product candidate, obtain marketing approvals, manufacture at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales, marketing, and distribution activities necessary for successful product commercialization.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, as a pre-revenue business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Foreign currency exchange rate fluctuations may have a negative impact on our financial results.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are subject to the risks of fluctuating foreign currency exchange rates, which could have an adverse effect on the costs and expenses of our foreign subsidiaries. As a result, currency fluctuations among the U.S. dollar, euro, Australian dollar, and the other currencies in which we do business have caused and will continue to cause foreign currency translation and transaction gains and losses. We have not used forward exchange contracts to hedge our foreign currency exposures. In the future, we may undertake to manage foreign currency risk through hedging methods, including foreign currency contracts. We recognize foreign currency gains or losses arising from our operations in the period incurred. We cannot guarantee that we will be successful in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">managing foreign currency risk or in predicting the effects of exchange rate fluctuations upon our future operating results because of the number of currencies involved, the variability of currency exposure, and the potential volatility of currency exchange rates. We cannot predict with any certainty changes in foreign currency exchange rates or the degree to which we can address these risks.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We depend heavily on the success of KIO-101, KIO-201, and KIO-301. If we are unable to successfully obtain marketing approval for KIO-101, KIO-201, and KIO-301, or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize KIO-101, KIO-201, and KIO-301, our business will be materially harmed.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have invested a significant portion of our efforts and financial resources in the development of KIO-201, and we expect to invest a significant portion of our efforts and financial resources in the development of KIO-101 and KIO-301 in the future. There remains a significant risk that we will fail to successfully develop either product candidate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We cannot accurately predict when or if KIO-101, KIO-201, or KIO-301 will prove effective or safe in humans or whether it will receive marketing approval. Our ability to generate product revenues, which may never occur, will depend heavily on our obtaining marketing approval for and commercializing KIO-101, KIO-201, and KIO-301.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The success of KIO-101, KIO-201, and KIO-301 will depend on several factors, including the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">obtaining favorable results from clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">applying for and receiving marketing approvals from applicable regulatory authorities for KIO-101, KIO-201, and KIO-301;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">making arrangements with third-party manufacturers for commercial quantities of KIO-101, KIO-201, and KIO-301 and receiving regulatory approval of our manufacturing processes and our third-party manufacturers&#8217; facilities from applicable regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establishing sales, marketing, and distribution capabilities and launching commercial sales of KIO-101, KIO-201, and KIO-301, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">acceptance of KIO-101, KIO-201, and KIO-301, if and when approved, by patients, the medical community, and third-party payors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">effectively competing with other therapies, including the existing standard-of-care;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">maintaining a continued acceptable safety profile of KIO-101, KIO-201, and KIO-301 following approval;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">obtaining and maintaining coverage and adequate reimbursement from third-party payors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio related to KIO-101, KIO-201, and KIO-301.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize KIO-101, KIO-201, and KIO-301, which would materially harm our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If clinical trials of KIO-101, KIO-201, KIO-301, or any other product candidate that we develop fail to demonstrate safety and efficacy to the satisfaction of the FDA or foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be delayed or unable to complete, the development and commercialization of KIO-101, KIO-201, KIO-301, or any other product candidate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">any third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">we may decide, or regulators or institutional review boards may require us, to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, or institutional review boards to suspend or terminate the trials.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not favorable or are only modestly favorable or if there are safety concerns, we may:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We may not be able to initiate or continue clinical trials for KIO-101, KIO-201, and KIO-301, or our other product candidates that we may develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. In addition, some of our competitors may have ongoing clinical trials for product candidates that treat the same indications as KIO-101, KIO-201, and KIO-301, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether, and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of such product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If KIO-101, KIO-201, KIO-301, or any of our other product candidates are associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects, or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or early-stage testing for treating ophthalmic disease have later been found to cause side effects that prevented further development of the compound.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. To the extent our contemplated trials are unsuccessful, we may not be able to raise additional funds for subsequent trials or pursuing other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Even if KIO-101, KIO-201, KIO-301, or any other product candidate that we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">others in the medical community necessary for commercial success and the market opportunity for our product candidates may be smaller than we estimate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If KIO-101, KIO-201, KIO-301, or any other product candidate that we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our assessment of the potential market opportunity for KIO-101, KIO-201, and KIO-301 is based on industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. If the actual market for KIO-101, KIO-201, and KIO-301 is smaller than we expect, our product revenue may be limited, and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop if and when they are approved.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We do not have a sales or marketing infrastructure. To achieve commercial success for any product for which we have obtained marketing approval and have not licensed the commercialization rights, we will need to establish sales, marketing, and distribution capabilities, either ourselves or through collaborations or other arrangements with third parties.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the future, we plan to build sales and marketing infrastructure to market or co-promote KIO-101, KIO-201, KIO-301, and possibly other product candidates that we develop, if and when they are approved. There are risks involved with establishing our own sales, marketing, and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of KIO-101, KIO-201, KIO-301, or any other product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Factors that may inhibit our efforts to commercialize product candidates on our own include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">our inability to recruit, train, and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect to enter into arrangements with third parties to perform consulting, sales, marketing, and distribution services in markets outside the U.S. We may also enter into arrangements with third parties to perform these services in the U.S. if we do not establish our own sales, marketing, and distribution capabilities in the U.S., or if we determine that such third-party arrangements are otherwise beneficial. Our product revenues and our profitability, if any, under any such third-party sales, marketing, or distribution arrangements are likely to be lower than if we were to market, sell, and distribute our product candidates. In addition, we may not be successful in entering into arrangements with third parties to sell, market, and distribute our product candidates, or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales, marketing, and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The development and commercialization of new drug products is highly competitive. We face competition with respect to KIO-101, KIO-201, KIO-301, and our other current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than our product candidates. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, our ability to compete may be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic products. Generic products are currently being used for the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop achieves marketing approval, we expect that it will be priced at a premium over competitive products.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Even if we are able to commercialize KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices, or healthcare reform initiatives, which could harm our business.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our ability to commercialize KIO-101, KIO-201, KIO-301, or any other product candidates that we may develop successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers, managed care plans, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for our product candidates and, even if they are available, the level of reimbursement may not be satisfactory.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inadequate reimbursement may adversely affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop would compromise our ability to generate revenues and become profitable.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The regulations that govern marketing approvals, pricing, coverage, and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There can be no assurance that our product candidates or any products that we may in-license, if they are approved for sale in the U.S. or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payors, that coverage and an adequate level of reimbursement will be available, or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our strategy of obtaining rights to product candidates and approved products through in-licenses and acquisitions may not be successful.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We may expand our product pipeline through opportunistically in-licensing or acquiring the rights to other products, product candidates, or technologies. The future growth of our business may depend in part on our ability to in-license or acquire the rights to approved products, additional product candidates, or technologies. However, we may be unable to in-license or acquire the rights to any such products, product candidates, or technologies from third parties. The in-licensing and acquisition of pharmaceutical products is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire products, product candidates, or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the rights to the relevant product, product candidate, or technology on terms that would allow us to make an appropriate return on our investment. Furthermore, we may be unable to identify suitable products, product candidates, or technologies within our area of focus. If we are unable to successfully obtain rights to suitable products, product candidates or technologies, our ability to pursue this element of our strategy could be impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we develop.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We face an inherent risk of product liability exposure related to the use of the product candidates that we develop in human clinical trials and will face an even greater risk if we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">decreased demand for any product candidates or products that we develop;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">reduced time and attention of our management to pursue our business strategy; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the inability to commercialize any products that we develop.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">While we obtain insurance for each clinical trial we perform, we may not be adequately insured to cover all liabilities that we may incur. We will need to increase our insurance coverage as we expand our clinical trials. We will need to further increase our insurance coverage if we commence commercialization of any product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may enter into collaborations with other third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect to utilize a variety of types of collaboration, distribution, and other marketing arrangements with third parties to commercialize KIO-101, KIO-201, and KIO-301 in markets outside the U.S. We also may enter into arrangements with third parties to perform these services in the U.S. if we do not establish our own sales, marketing, and distribution capabilities in the U.S., or if we determine that such third-party arrangements are otherwise beneficial. We also may seek third-party collaborators for development and commercialization of other product candidates. Our likely collaborators for any sales, marketing, distribution, development, licensing, or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If we do not receive the funding we expect under any future collaboration agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval, and commercialization described in this Annual Report on Form 10-K also apply to the activities of our collaborators.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might de-emphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">difficult to attract new collaborators and our perception in the business and financial communities could be harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we are not able to establish additional collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the U.S., the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have relied on third parties, such as contract research organizations (CROs) to conduct our completed trials of our product candidates, and do not plan to independently conduct clinical trials of our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our clinical trials. These agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development activities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We contract with third parties for the manufacture of KIO-101, KIO-201, and KIO-301 for clinical trials and expect to continue to do so in connection with the commercialization of KIO-101, KIO-201, KIO-301, and for clinical trials and commercialization of any other product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of KIO-101, KIO-201, KIO-301, or any other of our product candidates. We rely, and expect to continue to rely, on third parties to manufacture clinical and commercial supplies of KIO-101, KIO-201, and KIO-301, pre-clinical and clinical supplies of our other product candidates that we may develop, and commercial supplies of products if and when any of our product candidates receive marketing approval. Our current and anticipated future dependence upon others for the manufacture of KIO-101, KIO-201, KIO-301, and any other product candidate or product that we develop, may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. In addition, any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We currently rely exclusively on third-party manufacturers to assemble and prepare KIO-101, KIO-201, and KIO-301 on a purchase order basis. We do not currently have any contractual commitments for commercial supply of bulk drug substance for KIO-101, KIO-201, KIO-301, or fill-finish services. We also do not currently have arrangements in place for redundant supply or a second source for bulk drug substance for KIO-101, KIO-201, and KIO-301, or for fill-finish services. The prices at which we are able to obtain supplies of KIO-101, KIO-201, KIO-301, and fill-finish services may vary substantially over time and adversely affect our financial results.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If our third-party manufacturers for KIO-101, KIO-201, or KIO-301 fail to fulfill our purchase orders or should become unavailable to us for any reason, we believe that there are a limited number of potential replacement manufacturers, and we likely would incur added costs and delays in identifying or qualifying such replacements. We could also incur additional costs and delays in identifying or qualifying a replacement manufacturer for fill-finish services if our existing third-party manufacturer should become unavailable for any reason. We may be unable to establish any agreements with such replacement manufacturers or to do so on acceptable terms. Even if we could transfer manufacturing to a different third party, the shift would likely be expensive and time consuming, particularly since the new facility would need to comply with the necessary regulatory requirements and we would need FDA approval before using or selling any products manufactured at that facility.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In connection with our application for a license to market KIO-101, KIO-201, KIO-301, or other product candidates in the U.S., we may be required to conduct a comparability study if the product we intend to market is supplied by a manufacturer different from the one who supplied the product evaluated in our clinical studies. Delays in designing and completing this study to the satisfaction of the FDA could delay or preclude our development and commercialization plans and thereby limit our revenues and growth.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">KIO-101, KIO-201, KIO-301, and any other product candidates that we may develop may compete with other product candidates and products for access to a limited number of suitable manufacturing facilities that operate under current good manufacturing practices or CGMP regulations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Third-party manufacturers may not be able to comply with CGMP regulations or similar regulatory requirements outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. We and our licensors have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Maintaining patents in the U.S. is an expensive process and it is even more expensive to maintain patents and patent applications in foreign countries. As a result, it is possible that we and our licensors will fail to maintain such patents thereby reducing the rights of our portfolio.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The patent position of pharmaceutical, biotechnology, and medical device companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, or which effectively prevent others from commercializing competitive technologies and products. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases, not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our owned or licensed patent rights are highly uncertain. We currently have 41 pending patents. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional pre-clinical or clinical data that support the patentability of our proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringed their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly, or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market, and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the medical device, biotechnology, and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the U.S. Patent and Trademark Office. The risks of being involved in such litigation and proceedings may increase as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. We may not be aware of all such intellectual property rights potentially relating to our product candidates and their uses. Thus, we do not know with certainty that KIO-101, KIO-201, KIO-301, or any other product candidate, or our commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are party to licensing agreements that impose, and for a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines and milestone payment, royalty, insurance, and other obligations on us. Under certain of our existing licensing agreements, we are obligated to pay royalties or make specified milestone payments on net product sales to the extent they are covered by the agreements. We also are obligated under certain of our existing license agreements to pay maintenance and other fees. We also have diligence and development obligations under certain of those agreements that we are required to satisfy. If we fail to comply with our obligations under current or future license and collaboration agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture, or market any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could diminish the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Some of our employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we are not able to obtain required regulatory approvals, we will not be able to commercialize KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop, and our ability to generate revenue will be materially impaired. The marketing approval process is expensive, time-consuming, and uncertain. As a result, we cannot predict when or if we, or any collaborators we may have in the future, will obtain marketing approval to commercialize KIO-101, KIO-201, KIO-301, or any other product candidate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The activities associated with the development and commercialization of our product candidates, including KIO-101, KIO-201, and KIO-301, including design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the U.S. and similar regulatory authorities outside the U.S. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market KIO-101, KIO-201, KIO-301, or any other product candidate from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs and consultants to assist us in this process.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive and may take many years, especially if additional clinical trials are required, if approval is obtained at all. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety, purity, and potency. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other regulatory authorities may determine that KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop is not safe, effective or pure, is only moderately effective or has undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The regulatory process can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In order to market and sell KIO-101, KIO-201, KIO-301, and any other product candidate that we may develop in other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the U.S., it is required that the product be approved for reimbursement before the product can be sold in that country. We or these third parties may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Even if we, or any collaborators we may have in the future, obtain marketing approvals for KIO-101, KIO-201, KIO-301, or our other product candidates, the terms of those approvals, ongoing regulations and post-marketing restrictions may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any collaborators we may have in the future, must therefore comply with requirements concerning advertising and promotion for any of our products for which we or they obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, if KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to CGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our future collaborators, and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to physicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, such as the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion or manufacturing of prescription products may lead to investigations by the FDA, Department of Justice, and state Attorneys General alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various adverse results, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">restrictions on such products, manufacturers, or manufacturing processes;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">restrictions on product distribution or use;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">warning letters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">withdrawal of the products from the market;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">recall of products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">fines, restitution, or disgorgement of profits or revenues;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">product seizure; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our relationships with customers and third-party payors may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Healthcare providers, physicians, and third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any product candidates, including KIO-101, KIO-201, and KIO-301, for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws and regulations that may affect our ability to operate include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which imposes obligations, including mandatory contractual terms, on covered healthcare providers, health plans and healthcare clearinghouses, as well as their business associates, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, it may be subject to criminal, civil, or administrative sanctions, including exclusions from participation in government funded healthcare programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Previously enacted and future legislation may affect our ability to commercialize and the prices we obtain for any products that are approved in the U.S. or foreign jurisdictions.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could affect our ability to profitably sell or commercialize any product candidate, including KIO-101, KIO-201, and KIO-301, for which we obtain marketing approval or that we may in-license. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other provisions of this legislation could limit coverage of and reduce the price that we receive for any approved products. While the MMA applies only to product benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA or other healthcare reform measures may result in a similar reduction in payments from private payors.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In March 2010, former President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively &#8220;PPACA&#8221;). Among the provisions of PPACA of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our product candidates and that are approved for sale, are the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which participating manufacturers must agree to offer 50% point-of-sale discounts off negotiated drug prices during the coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, and the addition of new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, other legislative changes have been proposed and adopted since PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013, and will remain in effect through 2030 unless additional Congressional action is taken. In January 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding. In addition, it is possible that changes in administration and policy could result in additional proposals and/or changes to health care system legislation.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additionally, in light of the rising cost of prescription drugs and biologics, there has been heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At both the federal and state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, the legislation and regulations are designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect that these, and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The pricing of prescription pharmaceuticals is also subject to governmental control outside the U.S. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">If we or our third-party manufacturers fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We and our third-party manufacturers are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, this insurance may not provide adequate coverage against potential liabilities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health, and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm, or experience a disruption in the manufacture and supply of our product candidates or products.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are highly dependent on the research and development, clinical, and business development expertise of Brian M. Strem, our Chief Executive Officer, as well as the other principal members of our management, scientific, and clinical team and a number of third-party consultants. Although we have entered into an employment agreement with Dr. Strem, he may terminate his employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Recruiting and retaining qualified scientific, clinical, manufacturing, and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. The availability of qualified personnel in the markets in which we operate has declined in recent years and competition for such labor has increased. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We expect to expand our development capabilities and potentially implement sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We may experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing, and distribution. To manage our potential future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such potential growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We may fail to realize any benefits and incur losses related to any acquisition.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We regularly explore opportunities to grow our business, including through acquiring companies. The success of our strategic acquisitions will depend, in part, on our ability to successfully integrate the acquired businesses with our existing business. It is possible that the integration process could result in the loss of key employees; the disruption of ongoing business; or inconsistencies in standards, controls, procedures, and policies that adversely affect our ability to maintain relationships with vendors, customers, and employees or to achieve the anticipated benefits of the acquisition. Successful integration may also be hampered by any differences </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">between the operations and corporate culture of the two organizations. If we experience difficulties with the integration process, the anticipated benefits of the acquisition may not be realized fully, or at all, or may take longer to realize than expected.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, any future debt agreements that we may enter into, may preclude us from paying dividends without the lenders&#8217; consent or at all. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We could face delisting from Nasdaq in the event we do not meeting its minimum bid price rules.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February 23, 2022, we received a written notification (the &#8220;Notice Letter&#8221;) from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our Common Stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until August 22, 2022 (the &#8220;Initial Compliance Period&#8221;), to regain compliance with the minimum bid price requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we can regain compliance if the closing bid price of our Common Stock is at least $1.00 for a minimum of 10 consecutive business days.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On August 23, 2022, Nasdaq notified us in writing (the &#8220;Extension Letter&#8221;) that while we had not regained compliance with the Bid Price Rule, we were eligible for an additional 180-day compliance period, or until February 20, 2023, to regain compliance with the Bid Price Rule. Nasdaq&#8217;s determination was based on our having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on our written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On October 12, 2022, we received a letter from Nasdaq notifying us that the closing bid price of our common stock had been at $1.00 per share or greater for the last 10 consecutive business days and we had regained compliance with the Bid Price Rule and this matter had been closed.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the event that we lose compliance with Listing Rule 5450(a)(1) again and do not regain compliance prior to the expiration of the compliance period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. A delisting of our Common Stock would have an adverse effect on the market liquidity of our Common Stock and, as a result, the market price for our Common Stock could become more volatile. Further, a delisting also could make it more difficult for us to raise additional capital. We intend to monitor the closing bid price of our common stock and may conduct a reverse stock split, if necessary, to regain compliance with the Nasdaq bid price rule.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">The coronavirus pandemic could adversely impact our business, including clinical trials.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread globally. As the COVID-19 pandemic continues, we could experience disruptions that could impact our business and clinical trials, including:</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">delays or difficulties in enrolling patients in clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers, and others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of clinical trials, including sickness of employees or their families or the desire of employees to avoid contact with groups of people;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">interruption in global manufacturing and shipping that may affect the transport of clinical trial materials and materials, including testing equipment and personal protective equipment, used at our facilities;</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The global outbreak of the COVID-19 coronavirus continues to evolve. The extent to which COVID-19 may impact our business and clinical trials will depend on future developments which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the emergence of new variants, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Laws and regulations governing international operations may preclude us from developing, manufacturing, and selling certain products outside of the U.S. and require us to develop and implement costly compliance programs.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate, including our operations in Australia and Austria. The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or business from paying, offering, authorizing payment, or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Various laws, regulations, and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our foreign operations require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">require the affirmative vote of stockholders holding at least two-thirds of shares entitled to be cast to amend or repeal specified provisions of our restated certificate of incorporation or our amended and restated bylaws.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our stock price may be volatile. The stock market in general and the market for smaller specialty pharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for such shares. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">results of clinical trials of KIO-101, KIO-201, KIO-301, or any other product candidate that we may develop;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">results of clinical trials of product candidates of our competitors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">regulatory or legal developments in the U.S. and other countries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the recruitment or departure of key scientific or management personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire, or in-license additional products, product candidates, or technologies for the treatment of ophthalmic diseases, the costs of commercializing any such products, and the costs of development of any such product candidates or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">reduction in stock price could indicate impairment of the goodwill and intangible assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">general economic, industry, and market conditions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. We also may face securities class-action litigation if we cannot obtain regulatory approvals for or if we otherwise fail to commercialize KIO-101, KIO-201, or KIO-301. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, we had federal net operating loss carryforwards of approximately $80.5 million, state net operating loss carryforwards of approximately $52.6 million, and aggregate federal and state research and development tax credit carryforwards of approximately $2.5 million and $0.5 million, respectively, available to reduce future taxable income. Certain of these federal and state net operating loss carryforwards and federal and state tax credit carryforwards will expire at various dates through 2041, if not utilized. Federal net operating losses generated as of December 31, 2017, will carry-forward until 2037 and net operating losses generated during the year ended December 31, 2018, and later will be carried forward indefinitely until utilized, but their utilization will be limited to 80% of taxable income. Utilization of these net operating loss and tax credit carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and comparable provisions of state, local, and foreign tax laws due to changes in ownership of our company that have occurred previously or that could occur in the future. Under Section 382 of the Code and comparable provisions of state, local, and foreign tax laws, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research and development tax credits, to reduce its post-change income may be limited. We have not completed a study to determine whether our initial public offering, subsequent public and private offerings, and other transactions that have occurred may have triggered an ownership change limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we generate taxable income, our ability to use our pre-change net operating loss and tax credits carryforwards to reduce U.S. federal and state taxable income may be subject to limitations, which could result in increased future tax liability to us. In addition, the Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017, limits the amount of net operating losses that we are permitted to deduct in any taxable year to 80% of our taxable income in such year. The TCJA also eliminates the ability to carry back net operating losses to prior years, but allows net operating losses generated after 2017 to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">carried forward indefinitely. As such, there is a risk that due to such items, our existing net operating losses could expire or be unavailable to offset future income. Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a smaller reporting company (SRC) and a non-accelerated filer, which allows us to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not SRCs or non-accelerated filers, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, reduced disclosure obligations, including disclosures regarding executive compensation, in our Annual Report and our periodic reports and proxy statements and providing only two years of audited consolidated financial statements in our Annual Report and our periodic reports. We will remain an SRC until (a) the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day our most recently completed second fiscal quarter exceeds $250 million or (b) in the event we have over $100 million in annual revenues, the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day our most recently completed second fiscal quarter exceeds $700 million. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile and may decline.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, Financial Industry Regulatory Authority (FINRA) rules, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We continue to evaluate these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, and adopt a detailed work plan to continue to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">over financial reporting. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">A material amount of our assets represents intangible assets, and our net income would be reduced if our intangible assets become impaired.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, intangible assets, net, represented approximately $10.7 million, or 58% of our total assets. Goodwill is generated in our acquisitions when the cost of an acquisition exceeds the fair value of the net tangible and identifiable intangible assets we acquire. Goodwill and indefinite-lived intangible assets are subject to an impairment analysis at least annually based on fair value. Intangible assets relate primarily to in-process research and development (IPR&amp;D) and patents acquired by us as part of our acquisitions of other companies, and are subject to an impairment analysis whenever events or changes in circumstances exist that indicate that the carrying value of the intangible asset might not be recoverable. If market and economic conditions or business performance deteriorate, the likelihood that we would record an impairment charge would increase, which impairment charge could materially and adversely affect our financial condition and operating results.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_25"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">None.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_28"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We currently have three facilities, including our principal executive office located at 332 Encinitas Blvd., Suite 102, Encinitas, CA, 92024; our office located at 1371 East 2100 South, Suite 200, Salt Lake City, UT, 84105; and our office located at Reisnerstra&#223;e 34/1, 1030 Wien, Austria. Our office located at 271 Waverley Oaks Road, Suite 108, Waltham, MA, 02452 was closed on March 31, 2022. We conduct our operations using third-party manufacturing facilities and trial sites. We believe our current facilities are adequate for our needs for the foreseeable future.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_31"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">While we are not currently a party to any legal proceedings, from time to time we may be a party to a variety of legal proceedings that arise in the normal course of our business.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_34"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">51</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II</span></div><div id="i33c11c03affd49a6944ca837f3a73528_40"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our common stock currently trades on The Nasdaq Capital Market under the symbol &#8220;KPRX&#8221;. Our common stock began trading on the OTCQB Venture Marketplace on February 13, 2015, in connection with our initial public offering under the symbol &#8220;EYEG&#8221;. Prior to that time, there was no established public trading market for our common stock. On July 31, 2015, our common stock began trading on The Nasdaq Capital Market. In connection with our name change, we changed our symbol on The Nasdaq Capital Market to &#8220;KPRX&#8221; effective as of November 8, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There were 47 holders of record of our common stock as of March&#160;20, 2023. This number does not include beneficial owners whose shares were held in street name.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain future earnings, if any, and all currently available funds for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in our current or future financing instruments.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November 17, 2022, the Company entered into warrant exercise inducement offer letters with some of the Class A Warrant holders who agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of common stock originally issued in the Public Offering in exchange for the Company's agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) on substantially the same terms as the Class A Warrants to purchase up to 654,609 shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of common stock of $5.97. </span></div><div id="i33c11c03affd49a6944ca837f3a73528_43"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 6.  RESERVED</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Not applicable.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_46"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">The following section of this Annual Report on Form 10-K entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Factors that may cause our actual results to differ materially from those in the forward-looking statements include those factors described in &#8220;Item 1A. Risk Factors&#8221; beginning on page <a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_22">23</a> of this Annual Report on Form 10-K. You should carefully review all of these factor</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">s, as well as the comprehensive discussion of forward-looking statements on page <a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;text-decoration:none" href="#i33c11c03affd49a6944ca837f3a73528_13">2</a> of this Annual Report on Form 10-K.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_52"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a clinical-stage specialty pharmaceutical company developing and commercializing products for the treatment of ophthalmic diseases. We were formed as a Delaware corporation on December 26, 2004, under the name of EyeGate Pharmaceuticals, Inc., and changed our name to Kiora Pharmaceuticals, Inc. effective November 8, 2021. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. At that time, the name of the French corporation was changed to EyeGate Pharma S.A.S. and became a subsidiary of EyeGate Pharmaceuticals, Inc. EyeGate Pharma S.A.S. was dissolved effective December 30, 2020. We have four wholly-owned subsidiaries: Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH (formerly known as Panoptes Pharma GmbH), Bayon Therapeutics, Inc., and Kiora Pharmaceuticals Pty Ltd (formerly known as Bayon Therapeutics Pty Ltd).</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our lead product is KIO-301 with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (RP, any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#8220;photoswitch&#8221; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is designed to restore the eyes&#8217; ability to perceive and interpret light in visually impaired patients through selectively entering viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. We initiated a Phase 1b clinical trial in third quarter of 2022 and dosed the first patient in November 2022. On March 17, 2022, we were granted orphan drug designation by the FDA for the API in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon transaction which closed October 21, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 focuses on patients with OPRA+. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of DHODH. We believe KIO-101 to be best-in-class with picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In a 14-day good laboratory practice intravenous repeated dose toxicity study in rats, no adverse or test item related effects were observed in any of the tested parameters (mortality, clinical observations, ophthalmoscopy, body weight and food consumption, hematology and coagulation, clinical biochemistry, organ weight, pathology, and histopathology) at the highest doses tested (1.0 mg/kg). In the fourth quarter of 2021, we reported top-line safety and tolerability data from a Phase 1b proof-of-concept study evaluating KIO-101 in patients with ocular surface inflammation. As a further sign of safety, there were zero clinically significant laboratory (including liver enzymes) findings observed in both healthy patients and those with ocular surface inflammation. We expect to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma GmbH in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are developing KIO-201, for patients with persistent corneal epithelial defects. PCED is an orphan disease and as such, we are currently seeking orphan drug designation. KIO-201 is also being evaluated for patients recovering from surgical wounds, such as those undergoing the laser vision correction procedure, PRK. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. We are currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. We are in planning stages of a Phase 3b trial for patients recovering from PRK and plan to initiate the study before the end of 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2020, we were granted a loan (the &#8220;Loan&#8221;) from Silicon Valley Bank in the amount of $0.3 million pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which was enacted in March 2020. The Loan could have been prepaid by us at any time prior to maturity with no prepayment penalties. Funds from the Loan were only permitted to be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred before February 15, 2020 (&#8220;Qualifying Expenses&#8221;). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We used the entire Loan amount for Qualifying Expenses. Under the terms of the PPP, certain amounts of the Loan could be forgiven if they are used for Qualifying Expenses as described in the CARES Act. In April 2021, we were notified by the Small Business Administration (SBA) that this Loan was forgiven in full.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Throughout our history, we have not generated significant revenue. We have never been profitable, and from inception through December&#160;31, 2022, our losses from operations have aggregated $134.5 million. Our Net Loss was approximately $13.6 million and $13.8 million for the twelve months ended December&#160;31, 2022, and 2021, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and clinical trials of and seek regulatory approval for our KIO-101, KIO-201, and KIO-301 product candidates, and any other product candidates we advance to clinical development. If we obtain regulatory approval for KIO-101, KIO-201, and KIO-301, we expect to incur significant expenses to create an infrastructure to support the commercialization of KIO-101, KIO-201, and KIO-301 including sales, marketing, and distribution functions.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The continued spread of the COVID-19 pandemic could adversely impact our clinical studies. See &#8220;Item 1A. Risk Factors&#8221; above. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, and the effectiveness of actions to contain and treat COVID-19. We cannot presently predict the scope and severity of any potential disruptions to our business, including to our ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to our ability to conduct our business in the manner and on the timelines presently planned, which could have a material adverse impact on our business, results of operation, and financial condition. As of the date of this report, there have been no material adverse effects to our ongoing business operations from COVID-19.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity, debt financings, license and development agreements, or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. These conditions raise substantial doubt about our ability to continue as a going concern. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_55"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">To date, we have recognized collaboration revenue from U.S. and foreign government grants made to Jade and Panoptes, as well as from license agreements as performance obligations toward milestones that were met. We expect to continue to incur significant operating losses as we fund research and clinical trial activities relating to our therapeutic assets, consisting of our photoswitch, DHODH, and modified HA-based products, or any other product candidate that we may develop. There can be no guarantee that the losses incurred to fund these activities will succeed in generating revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expense all research and development expenses as they are incurred. Research and development expenses primarily include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">non-clinical development, pre-clinical research, and clinical trial and regulatory-related costs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expenses incurred under agreements with sites and consultants that conduct our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">expenses related to generating, filing, and maintaining intellectual property; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel, and stock-based compensation expense.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect our research and development expenses to increase for the near future as we advance KIO-101, KIO-201, KIO-301, and any other product candidate through clinical development, including the conduct of our planned clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We are unable to estimate with any certainty the costs we will incur in the continued development of our KIO-101, KIO-201, KIO-301, and any other product candidate that we may develop. Clinical development timelines, the probability of success and development costs can differ materially from expectations.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We may never succeed in achieving marketing approval for our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">per patient trial costs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the number of sites included in the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the countries in which the trials are conducted;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the number of patients that participate in the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the number of doses that patients receive;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the cost of comparative agents used in trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the duration of patient follow-up; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">the efficacy and safety profile of the product candidate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We do not expect our product candidates to be commercially available, if at all, for the next several years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation. Our general and administrative expenses consisted primarily of payroll expenses for our full-time employees. Other general and administrative expenses include professional fees for auditing, tax, patent costs, and legal services.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We expect that general and administrative expenses will remain consistent for the near future until commercialization of our photoswitch, DHODH, and modified HA-based products, which could lead to an increase in these expenses.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income, net consists primarily of warrant liability fair value changes, interest income we earn on interest-bearing accounts, and interest expense incurred on our outstanding financing arrangements.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_58"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We applied the provisions of Accounting Standards Codification (ASC) Topic 805, &#8220;Business Combinations,&#8221; in the accounting for our acquisitions of Bayon and Panoptes. It required us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values, which were determined using market, income, and cost approaches, or a combination. Goodwill as of the respective acquisition date was measured as the excess of consideration transferred over the net of the acquisition date fair value of the assets acquired and the liabilities assumed. Goodwill is generally the result of expected synergies of the combined company or an assembled workforce. Indefinite-lived intangible assets acquired were in-process research and development. The fair value for these intangible assets was determined using the income approach. Under the income approach, fair value reflects the present value of the projected cash flows that are expected to be generated by the products incorporating the in-process research and development, if successful.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goodwill represents the excess of the purchase price over the estimated fair value of the identifiable assets acquired and liabilities assumed in a business combination. The Company evaluates goodwill for impairment annually or when a triggering event occurs that could indicate a potential impairment. The evaluation for impairment includes assessing qualitative factors or performing a quantitative analysis to determine whether it is more-likely-than-not that the fair value of net assets is below the carrying amount. The goodwill was related to the 2021 acquisition of Bayon and 2020 acquisition of Panoptes, which represents the excess of the purchase price over the estimated fair value of the net assets acquired. For the year ended December 31, 2021, we incurred a $4.0 million impairment loss related to goodwill. As of December 31, 2022 and 2021, goodwill was $0.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at fair value at the acquisition date. The Company tests intangible assets for impairment as of December 31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As part of the process of preparing the consolidated financial statements, we are required to estimate and accrue research and development expenses. This process involves the following:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">estimating and accruing expenses in our consolidated financial statements as of each balance sheet date based on facts and circumstances known to us at the time; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Examples of estimated research and development expenses that we accrue include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">fees paid to contract research organizations and investigative sites in connection with clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">fees paid to contract manufacturing organizations in connection with non-clinical development, pre-clinical research, and the production of clinical study materials; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">professional service fees for consulting and related services.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We base our expense accruals related to non-clinical development, pre-clinical studies, and clinical trials on our estimates of the services received and efforts expended pursuant to contracts with organizations/consultants that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts may depend on many factors, such as the successful enrollment of patients, site initiation, and the completion of clinical study milestones. Our service providers invoice us as milestones are achieved and monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies and other research activities.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refunds for Research and Development</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We, through our Kiora Pharmaceuticals, GmbH and Kiora Pharmaceuticals Pty Ltd. subsidiaries, are eligible to receive certain refundable tax incentives associated with our research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp; development expenses. We record the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We initially value contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include the probability of success, discount rate, and updated timing of payment. After the initial valuation, we will use our best estimate to measure contingent consideration at each subsequent reporting period. Gains and losses are recorded in operating expenses within the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have issued options to purchase our common stock and restricted stock. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service/vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based payment awards require the use of highly subjective assumptions, including the expected life of the stock-based payment awards and stock price volatility.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We estimate the grant date fair value of stock options and the related compensation expense, using the Black-Scholes option valuation model. This option valuation model requires the input of subjective assumptions including: (1) expected life (estimated period of time outstanding) of the options granted, (2) volatility, (3) risk-free rate, and (4) dividends. In general, the assumptions used in calculating the fair value of stock-based payment awards represent management&#8217;s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Refer to Note 1. Business, Presentation and Recent Accounting Pronouncements, in the Notes to the audited consolidated financial statements of Part IV, Item 15. Exhibits, Financial Statement Schedules of this Form 10-K for detailed information regarding the status of recently issued accounting pronouncements.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_61"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss Carryforwards</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, the Company has federal and state net operating loss carryforwards of approximately $80.5 million and $52.6 million, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December&#160;31, 2017 totaling $46.1 million, and state NOL carryforwards as of December&#160;31, 2022 totaling $52.6 million will expire at various dates through 2042. Federal NOL carryforwards generated during the years ended December&#160;31, 2018 and forward totaling $34.4 million will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $10.7 million as of December&#160;31, 2022, which can be carried forward indefinitely. As of December&#160;31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $2.5 million and $0.5 million, respectively, to offset future income taxes, which expire at various times through 2042.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Utilization of these net operating loss and tax credit carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and comparable provisions of state, local, and foreign tax laws due to changes in ownership of our company that have occurred previously or that could occur in the future. Under Section 382 of the Code and comparable provisions of state, local, and foreign tax laws, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research and development tax credits, to reduce its post-change income may be limited. We have not completed a study to determine whether our initial public offering, our registered direct offering, our follow-on public offerings, and other transactions that have occurred over the past three years may have triggered an ownership change limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we generate taxable income, our ability to use our pre-change net operating loss and tax credits carryforwards to reduce U.S. federal and state taxable income may be subject to limitations, which could result in increased future tax liability to us. In addition, the TCJA enacted on December 22, 2017, limits the amount of NOLs that we are permitted to deduct in any taxable year to 80% of our taxable income in such year. The TCJA also eliminates the ability to carry back NOLs to prior years but allows NOLs generated after 2017 to be carried forward indefinitely. As such, there is a risk that due to such items, our existing NOLs could expire or be unavailable to offset future income.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_64"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table summarizes the results of our operations for the years ended December&#160;31, 2022 and 2021:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,448,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,350,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,901,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,277,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,323,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,954,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,037,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,037,811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">582,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(475,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,058,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Operating Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,309,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,235,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,926,245)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Loss Before Other Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,309,523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,235,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,926,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (Expense) Income, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,387,097)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">272,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,659,577)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss Before Income Tax Benefit (Expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,696,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,963,288)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income Tax Benefit (Expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">192,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,583,610)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,770,685)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Research and Development Expenses </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development expenses decreased by $1.9 million due to reduced development costs for KIO-101 and KIO-201 of approximately $1.1 million, decreased personnel costs of approximately $1.0 million and an increase in the research refundable credit of $1.0 million. These net decreases were partially offset by an increase in development costs related to KIO-301 of $1.3 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table summarizes our research and development expense by program:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expense by program</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-101</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,622,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,160,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(537,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-201</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">652,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(549,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-301</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,349,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,333,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,868,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,883,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,015,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,541,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(517,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,023,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">155,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,448,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,350,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,901,339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative expenses increased by $3.0 million due to increases in professional fees of $1.5 million, executive severance of $1.0 million, corporate costs of $0.3 million and travel related costs of $0.3 million.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Goodwill Impairment Loss</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goodwill impairment loss decreased by $4.0 million due to the write-off of goodwill in 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The change in fair value of contingent consideration increased $1.1 million. The change in fair value of contingent consideration is primarily due to a change in the probability of success related to a new indication that was added for KIO-201 (PCED) which increased the probability of success for the Jade milestone payment. Additionally, in March 2022 KIO-301 was granted orphan drug designation which increased the probability of success rate for the Bayon milestone payment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Other (Expense) Income, Net</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other (expense) income increased by $1.7 million due to a change in fair value of warrant liability. The change in fair value of the warrant liability between issuance and reclassification to equity was approximately $1.4 million in expense and was primarily due to a change in our stock price..</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Income Tax Benefit (Expense)</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax benefit (expense) decreased by $0.1 million.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_67"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Since becoming a public company in 2015, we have financed our operations from several registered offerings and private placements of our securities, payments from license agreements, and U.S. and foreign government grants. From inception through December&#160;31, 2022, we have raised a total of approximately $127.2 million from such sales of our equity and debt securities, both as a public company and prior to our IPO, as well as approximately $14.9 million in payments received under our license agreements and government grants and $0.3 million received pursuant to the Loan under the PPP, which was fully forgiven in April of 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On January 6, 2021, we completed a private placement of 38,278 shares of common stock and warrants to purchase up to 38,278 shares of common stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. The total net proceeds from the private placement were approximately $8.0 million. The warrants have an exercise price of $209.00 per share, subject to adjustments as provided under the terms of the warrants, and will be exercisable on the six-month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On August 11, 2021, we completed a registered direct offering for 116,721 shares of common stock with a purchase price of $92.10 per share. We also completed a concurrent private placement of unregistered warrants to purchase up to an aggregate of 58,361 shares of common stock at an exercise price of $89.60 per share that are exercisable immediately upon issuance and will expire five and one-half years following the date of issuance. In addition, the Company issued to the placement agent warrants to purchase up to 5,836 shares of Common Stock at an exercise price of $115.124 per share, which expire five years following the date of issuance. The total net proceeds to us from the offering were approximately $9.8 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On June&#160;18, 2022, in connection with our acquisition of Panoptes Pharma Ges.m.b.H in December 2020 (&#8220;Panoptes Acquisition&#8221;), we issued an aggregate of 10,087 shares of common stock to former shareholders of Panoptes, which had been held back for a period of eighteen months following the closing of the Panoptes acquisition to satisfy post-closing adjustment and indemnification obligations pursuant to the terms of the Share Purchase Agreement between us and the former shareholders of Panoptes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;22, 2022, we entered into an underwriting agreement to issue and sell stock and warrants in a public offering. On July&#160;25, 2022, the underwriter fully exercised the option granted by us to purchase stock and warrants. On July&#160;26, 2022, the Public Offering closed, and we issued and sold (i) 592,392 shares of common stock, (ii) 1,280 shares of Series E Convertible Preferred Stock convertible into up to 160,000 shares of common stock, (iii) 30,095,697 Class A Warrants, and (iv) 30,095,697 Class B Warrants. Upon exercise, the warrants will convert on a 40 for 1 basis into a total of 1,504,785 common shares. The public offering price of $8.00 per share of common stock, Class A Warrant and Class B Warrant or $1,000 per preferred share, 5,000 Class A Warrants and 5,000 Class B Warrants resulted in net proceeds to us of approximately $5.3 million net of underwriting discount and commissions of $0.4 million and expense of $0.3 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November&#160;17, 2022, we entered into warrant exercise inducement offer letters with some of the Class A warrant holders who agreed to exercise for cash, at a discounted exercise price of $4.77 per share, all of their Class A Warrants to purchase 654,609 shares of our common stock originally issued in the Public Offering in exchange for our agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) on substantially the same terms as the Class A Warrants to purchase up to 654,609 shares of common stock. Each Inducement Warrant is exercisable six months following its date of issuance at a price per share of common stock of $5.97 and will expire on the 18 month anniversary of their initial exercise date. We received aggregate gross proceeds of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">approximately $3.1 million from the exercise of the Class A Warrants by the selling stockholders and the sale of the Inducement Warrants.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">At December&#160;31, 2022, we had unrestricted cash and cash equivalents totaling approximately $6.0 million.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_70"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table sets forth the primary sources and uses of cash for the years ended December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Cash Used in Operating Activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,428,133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10,675,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Cash Provided by (Used in) Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,375&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(157,020)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,620,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,582,926&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Operating Activities</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, we recorded a net loss of $13.6 million and adjusted primarily for non-cash expense for stock-based compensation in the amount of $0.5 million, an increase in the change in fair value of contingent consideration of $0.6 million, an increase in the change in fair value of warrant liability of $1.4 million and a decrease in accounts payable of $0.8 million and accrued expenses of $0.6 million, which was partially offset by an increase in tax credits receivable of $0.9 million. During the year ended December 31, 2021, we recorded a net loss of $13.8 million and adjusted primarily for goodwill impairment loss of $4.0 million, non-cash expense for stock-based compensation in the amount of $0.8 million, which was partially offset by an increase in tax credits receivable of $0.4 million, a decrease in the change in fair value of contingent consideration of $0.5 million, and a decrease in accounts payable of $0.3 million.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, net cash provided by investing activities related to proceeds from the sale of equipment. During the year ended December 31, 2021, net cash used related to the acquisition of Bayon, as well as the purchase of office furniture and fixtures.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, we received net proceeds of $5.4 million from the completion of a public offering, as well as net proceeds of $2.7 million from the completion of a warrant inducement transaction. During the year ended December 31, 2021, we received net proceeds of $9.8 million from the completion of a registered direct offering, as well as net proceeds of $8.0 million from the completion of a private placement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements and Other Liquidity Matters</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our KIO-101, KIO-201, and KIO-301 product pipeline is still in various stages of clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">seek marketing approval for our KIO-101, KIO-201 or KIO-301 products, or any other products that we successfully develop;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">establish a sales and marketing infrastructure to commercialize our KIO-101, KIO-201, or KIO-301 products in the U.S., if approved; and</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">add operational, financial, and management information systems and personnel, including personnel to support our product development and future commercialization efforts.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, including our KIO-301, KIO-101, and KIO-201 products, on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market KIO-101, KIO-201, and KIO-301 products, or any other products that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on our cash on hand at December&#160;31, 2022, we believe we will have sufficient cash to fund planned operations into July 2023. However, the acceleration or reduction of cash outflows by management can significantly impact the timing needed for raising additional capital to complete development of its products. To continue development, we will need to raise additional capital through debt and/or equity financing, or access additional funding through grants. Although we successfully completed our IPO and several subsequent registered offerings and private placements of our securities, additional capital may not be available on terms favorable to us, if at all. We do not know if our future offerings will succeed. Accordingly, no assurances can be given that management will be successful in these endeavors. Our recurring losses from operations have caused management to determine there is substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_73"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We had no material off-balance sheet arrangements at December&#160;31, 2022.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_76"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Not applicable.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_79"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 8.  CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The information required by this item is contained in the consolidated financial statements filed as part of this Annual Report on Form 10-K are listed under Item 15 of Part IV below. Our auditors are EisnerAmper LLP, Iselin, New Jersey, with a PCAOB ID Number <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:AuditorFirmId" id="f-35">274</ix:nonNumeric>.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_82"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">None.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_85"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 9A.  CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">information is accumulated and communicated to our management, including our Chief Executive Officer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and Executive Vice President of Finance,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> to allow for timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In connection with this annual report, as required by Rules 13a-15I and 15d-15(e) under the Securities Exchange Act of 1934, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December&#160;31, 2022, our Chief Executive Officer, who is our Principal Executive Officer, and our Executive Vice President of Finance, who is our Principal Financial and Accounting Officer. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. This assessment included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls, and a conclusion on this evaluation. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. This assessment included review of the documentation of controls, evaluation of the design of effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based upon the evaluation described above, our Chief Executive Officer and Executive Vice President of Finance have concluded that our disclosure controls and procedures that support financial reporting were not effective as of the period ending  December&#160;31, 2022 due to material weaknesses described below.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company in accordance with as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management of the Company has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022. In making its assessment of internal control over financial reporting, management used the criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). As a result of that evaluation, management concluded our internal control over financial reporting was not effective as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In making this assessment, we identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Material weaknesses in the Company's internal control over financial reporting have been identified. Specifically, the Company did not maintain effective controls regarding:</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.11pt">information technology general controls (&#8220;ITGC&#8221;) which could result in misstatements potentially impacting all financial statement accounts and disclosures.  Specifically, user access controls were not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">appropriately designed and maintained to adequately restrict network user and privileged access to the appropriate personnel. In addition, there was a lack of sufficient segregation of duties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.11pt">the design and maintenance of formal accounting policies and processes to analyze, account for and disclose significant and unusual transactions in accordance with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:9.67pt">the execution of controls with a sufficient level of precision over the completeness and accuracy of financial information used in the preparation of the Company&#8217;s financial statements. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Remediation Efforts</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Subsequent to year-end the Company has implemented a new accounting system and through that process has designed role-specific permissions ensuring that there are appropriate access controls by function. Additionally, the Company has designed automated system workflows for journal entry approval, new vendor creation and modification, and procurement related approvals for PO&#8217;s and related invoices to ensure proper segregation of duties and appropriate evidence of approval.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Throughout the year we established and maintained accounting policies, procedures and controls to account for and disclose significant unusual transactions. Additionally, we engaged technical resources for technical advisory services and will continue to consult with technical resources to ensure that proper expertise is consulted as needed on complex accounting applications. This will be an ongoing area of remediation to ensure that significant transactions are appropriately analyzed and the accounting treatment is documented.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Subsequent to year-end, management is working toward a greater level of precision over the completeness and accuracy of information through the implementation of a new accounting system, as discussed above, which provides for greater automation related to previously manual tasks. Specifically, the new accounting system is being used to generate purchase orders for all material contracts and purchase commitments. The finance team is in the process of building reporting on all open contract commitments, which will be shared with management to verify the completeness and ensure accuracy of financial reporting.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The process of implementing an effective financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a financial reporting system that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over financial reporting, we may take additional actions to address control deficiencies or modify certain of the remediation measures described above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our consolidated financial statements. Our plans currently include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">While progress has been made to enhance our internal control over financial reporting, we are still in the process of implementing, documenting and testing these processes, procedures and controls. Additional time is required to complete implementation and to assess and ensure the sustainability of these procedures. We will continue to devote significant time and attention to these remedial efforts. However, the material weaknesses cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The scope of our management&#8217;s assessment of the effectiveness of internal control over financial reporting as of December&#160;31, 2022, includes all of our subsidiaries. As a smaller reporting company under under Rule 405 of the Securities Act of 1933, as amended and a non-accelerated filer, we are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. As a result, EisnerAmper LLP, our independent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">registered public accounting firm, has not audited or issued an attestation report with respect to the effectiveness of our internal control over financial reporting as of December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Accounting and Reporting</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Except for the above noted material weaknesses and the remediation activities that have since been undertaken, there were no other changes in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 that occurred during the quarter ended December&#160;31, 2022 that have materially affected or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_88"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 9B.  OTHER INFORMATION</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">None.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i33c11c03affd49a6944ca837f3a73528_660"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 9C.  DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Not applicable.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">65</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART III</span></div><div id="i33c11c03affd49a6944ca837f3a73528_94"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2023 Annual Meeting of Stockholders.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_97"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 11.  EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2023 Annual Meeting of Stockholders.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_100"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2023 Annual Meeting of Stockholders.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_103"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2023 Annual Meeting of Stockholders.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_106"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to our definitive Proxy Statement to be filed pursuant to Regulation 14A under the Exchange Act in connection with our 2023 Annual Meeting of Stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">66</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i33c11c03affd49a6944ca837f3a73528_112"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The consolidated financial statements filed as part of this report are listed on the Index to Financial Statements on page </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_115">F-1</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">None. Financial statement schedules have been omitted since the required information is included in our Consolidated Financial Statements contained elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> The exhibits listed in the Exhibit Index are filed as a part of this Annual Report on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">67</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_196"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following exhibits are filed as part of this Annual Report on Form 10-K. Where such filing is made by incorporation by reference to a previously filed document, such document is identified.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Exhibit</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420416086425/v433595_ex2-1.htm">Stock Purchase Agreement, dated as of March 7, 2016, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2016 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920137679/tm2039000d1_ex2-1.htm">Share Purchase Agreement, dated as of December 18, 2020, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/tm2130996d1_ex2-1.htm">Stock Purchase Agreement, dated as of October 21, 2021, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on October 26, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420415011139/v402059_ex3-1.htm">Restated Certificate of Incorporation of the Registrant (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 20, 2015 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420418038005/tv498331_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed July 10, 2018 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on July 11, 2018 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420419042362/tv528625_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed August 28, 2019 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on August 29, 2019 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920077470/tm2023551d1_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed June 25, 2020 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on November 8, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922102816/tm2226617d1_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed September 23, 2022 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on September 26, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921135333/tm2132125d1_ex3-1.htm">Certificate of Ownership and Merger of the Registrant, filed November 5, 2021 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on June 26, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922086182/tm2222278d1_ex3-1.htm">Third</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922086182/tm2222278d1_ex3-1.htm"> Amended and Restated By-laws of the Registrant (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922086182/tm2222278d1_ex3-1.htm">August 4, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922086182/tm2222278d1_ex3-1.htm"> and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420416109892/v443000_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on June 27, 2016 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420417032545/v468965_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on June 14, 2017 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.10</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420418020952/tv491244_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2018 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920137679/tm2039000d1_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.12</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922082802/tm2221834d1_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on July 26, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/tm205287d1_ex4-1.htm">Description of Securities (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 24, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414053333/v387928_ex4-1.htm">Specimen Stock Certificate evidencing the shares of common stock (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420417031012/v468395_ex4-3.htm">Form of Common Stock Purchase Warrant, dated June 14, 2017 (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on June 5, 2017 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420418020384/tv491024_ex4-1.htm">Form of Common Stock Purchase Warrant, dated April 17, 2018 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on April 13, 2018 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420419046375/tv530287_ex4-1.htm">Form of Common Stock Purchase Warrant, dated October 2, 2019 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2019 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465919077311/tm1928403d1_ex4-1.htm">Form of Common Stock Purchase Warrant, dated January 3, 2020 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on December 31, 2019 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921001243/tm211818d1_ex4-1.htm">Form of Common Stock Purchase Warrant, dated January 6, 2021 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on January 6, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921102512/tm2124627d1_ex4-1.htm">Form of Common Stock Purchase Warrant, dated August 11, 2021 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921102512/tm2124627d1_ex4-2.htm">Form of Placement Agent Warrant, dated August 11, 2021 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.11</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-9.htm">Form of Class A Warrant (previously filed as an exhibit to the Registrant&#8217;s Amendment No. 3 to Registration Statement on Form S-1 filed on July 21, 2022 and incorporated by reference thereto)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.12</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922081271/tm2213136d9_ex4-10.htm">Form of Class B Warrant (previously filed as an exhibit to the Registrant&#8217;s Amendment No. 3 to Registration Statement on Form S-1 filed on July 21, 2022 and incorporated by reference thereto)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.13</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922082802/tm2221834d1_ex4-3.htm">Warrant Agency Agreement, dated July 22, 2022, by and between the Registrant and VStock Transfer, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on July 26, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.14</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922120486/tm2230976d1_ex4-1.htm">Form of Common Stock Purchase Warrant, dated November 22, 2022 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on November 21, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.15</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/a8-klpcf020323exhibit41.htm">Form of Common Stock Purchase Warrant, dated February 3, 2023 (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414045707/v383973_ex10-1.htm">2005 Equity Incentive Plan, as amended (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922091303/tm2222663-2_def14a.htm#tAPB">2014 Equity Incentive Plan, as amended (previously filed as an exhibit to the Registrant&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922091303/tm2222663-2_def14a.htm#tAPB">definitive proxy statement on Schedule 14A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922091303/tm2222663-2_def14a.htm#tAPB"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922091303/tm2222663-2_def14a.htm#tAPB">August 15, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922091303/tm2222663-2_def14a.htm#tAPB"> and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414055714/v388785_ex10-3.htm">Employee Stock Purchase Plan (previously filed as an exhibit to Amendment No. 3 to the Registrant&#8217;s Registration Statement on Form S-1 filed on September 12, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414045707/v383973_ex10-6.htm">Form of Indemnification Agreement (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414045707/v383973_ex10-9.htm">Form of Notice of Stock Option Grant pertaining to the 2014 Equity Incentive Plan (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420414045707/v383973_ex10-10.htm">Form of Notice of Stock Unit Award pertaining to the 2014 Equity Incentive Plan (previously filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000114420418051919/tv503967_ex10-1.htm">Intellectual Property License Agreement, dated as of September 26, 2018, by and between the Registrant and SentrX Animal Care, Inc. (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on October 2, 2018 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465919069209/tm1924346d1_ex10-1.htm">Kiora Pharmaceuticals, Inc. Amended and Restated Change in Control Severance Plan (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on December 3, 2019 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/tm205287d1_ex10-20.htm">Exclusive Sub-License Agreement, dated as of September 12, 2013, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/tm205287d1_ex10-21.htm">Amendment No. 1 to Sub-License Agreement, dated as of September 18, 2015, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920029162/tm205287d1_ex10-22.htm">Amendment No. 2 to Sub-License Agreement, dated as of February 17, 2016, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465920137679/tm2039000d1_ex10-1.htm">Registration Rights Agreement, dated as of December 18, 2020, by and among the Registrant and the Sellers listed therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921001243/tm211818d1_ex10-2.htm">Registration Rights Agreement, dated as of January 5, 2021, by and among the Registrant and the Purchasers listed therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on January 6, 2021 and incorporated by reference herein).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001372514/000110465922010000/tm225039d1_ex10-1.htm">Separation Agreement, dated as of January 31, 2022, by and between the Registrant and Stephen From. (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 1, 2022 and incorporated by reference thereto)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921041515/tm211090d1_ex10-22.htm">Patent and Know How Assignment Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H and 4SC Discovery GmbH (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921041515/tm211090d1_ex10-23.htm">Patent License Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H. and 4SC Discovery GmbH (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/tm212316910d1_ex10-1.htm">Employment Agreement, dated as of July 22, 2021, by and between the Registrant and Brian M. Strem (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on July 26, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/tm2130996d1_ex10-1.htm">Employment Agreement, dated as of October 21, 2021, by and between the Registrant and Eric J. Daniels (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on October 26, 2021 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/tm2213276d1_ex10-1.htm">Consulting Agreement, dated as of March 9, 2022, by and between the Registrant and Danforth Advisors, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on April 26, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922100852/tm2226014d1_ex10-1.htm">Offer Letter, dated as of August 17, 2022, by and between the Registrant and Melissa Tosca (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on September 16, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000110465922120486/tm2230976d1_ex10-1.htm">Form of Inducement Letter, dated as of November 17, 2022, by and between the Registrant and the Holders named therein (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on November 21, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/a8-klpcf020323exhibit101.htm">Securities Purchase Agreement, dated as of February 2, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/a8-klpcf020323exhibit102.htm">Registration Rights Agreement, dated as of February 2, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/a8-klpcf020323exhibit103.htm">Purchase Agreement, dated as of February 3, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000137251423000008/a8-klpcf020323exhibit104.htm">Registration Rights Agreement, dated as of February 3, 2023, by and between the Registrant and Lincoln Park Capital Fund, LLC (previously filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1372514/000141057822000925/kprx-20211231xex21d1.htm">Subsidiaries of the Registrant (previously filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K filed on April 15, 2022 and incorporated by reference thereto).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex231-20221231xkprx.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311-20221231xkprx.htm">Certification of principal executive officer </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311-20221231xkprx.htm">pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312-20221231xkprx.htm">Certification of principal financial and accounting officer pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321-20221231xkprx.htm">Certification of principal executive officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321-20221231xkprx.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321-20221231xkprx.htm">pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322-20221231xkprx.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322-20221231xkprx.htm">principal financial and accounting officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;This certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission..</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain confidential portions of this exhibit were omitted because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;&#8224;&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div id="i33c11c03affd49a6944ca837f3a73528_190"></div><div style="margin-bottom:9pt;margin-top:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ITEM 16.  Form 10-K Summary</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">68</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_118">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_118">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_121">Consolidated Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_121">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_121"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_121">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_121">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_124">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_124">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_124"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_124">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_124">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_127">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_127">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_127"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_127">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_127">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_130">Consolidated Statements of Cash Flows for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_130">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_130"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_130">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_130">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_133">10</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-1</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">To the Board of Directors and Stockholders of</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Opinion on the Financial Statements </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have audited the accompanying consolidated balance sheets of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Going Concern</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As discussed in Note 1 to the financial statements, the Company has incurred losses from operations and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Management&#8217;s plans in regard to these matters are also described in Note 1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Basis for Opinion</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">These financial statements are the responsibility of the Company&#8217;s management.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We conducted our audits in accordance with the standards of the PCAOB.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accordingly, we express no such opinion.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Critical Audit Matters</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The communication of the critical audit matters does not alter in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">In-Process Research and Development Impairment Analysis</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December 31, 2022, the Company had in-process research and development assets of approximately $10.6 million. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As described in Note 2 to the financial statements, the Company performs its impairment test of these items annually, or whenever events or changes in circumstances indicate that the carrying value of the in-process research and development assets exceeds its fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performed its annual impairment test of these assets in the third quarter of 2022. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s impairment test involves comparing the carrying value of the in-process research and development assets to their estimated fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There was no impairment loss determined as a result of the Company&#8217;s annual testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s fair value estimates require management to make significant estimates and assumptions including the timing and amounts of projected cash flows, probability of success in reaching market and discount rates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We identified the impairment test of in-process research and development as a critical audit matter due to the significant judgments made by management in the estimates and assumptions used in developing the fair value estimates. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures to evaluate the reasonableness of management&#8217;s significant estimates and assumptions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additionally, the audit effort involved the use of professionals with specialized skill and knowledge. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We obtained an understanding and evaluated the design of controls over the Company&#8217;s impairment test of in-process research and development assets, including developing the estimate of fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We evaluated the current status of the Company&#8217;s active research and development programs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, we utilized our valuation specialists with specialized skills and knowledge, in evaluating the reasonableness of the Company&#8217;s methodology for estimating fair value using the income approach; evaluating the discount rates used by management by comparing it to a range of discount rates developed using the modified capital asset pricing model; and evaluating the mathematical accuracy of certain calculations included in the income approach.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Valuation of Warrant Liability</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For the year ended December 31, 2022, the Company recorded a change in fair value of warrant liability of $1.4 million.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As described in Note 2 to the financial statements, the Company recorded a liability for warrants issued in July 2022 and recorded the change in fair value of the warrants to the statement of operations from issuance through the date the warrants were reclassified to equity in September 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s fair value estimates require management to make significant estimates and assumptions including the appropriateness of the model used, the term of the warrants, the volatility of the Company&#8217;s stock, and the probability of securing shareholder approval to approve the issuance of warrants and a reverse stock split to make available sufficient authorized shares, subject to an adjustment based on evidence of market data. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We identified the valuation of the liability warrants as a critical audit matter due to the significant judgements made by management in the estimates and assumptions used in developing the fair value estimates. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This in turn led to a high degree of auditor judgement, subjectivity, and effort in performing procedures to evaluate the reasonableness of management&#8217;s significant estimates and assumptions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additionally, the audit effort involved the use of professionals with specialized skill and knowledge. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We obtained an understanding and evaluated the design of controls over the Company&#8217;s recording of the warrant instruments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, we utilized our valuation specialists with specialized skills and knowledge, in evaluating the reasonableness of the Company&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">methodology for estimating fair value; evaluating the assumptions used by Company and performing a sensitivity analysis of a range of inputs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ EisnerAmper LLP</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:AuditorName" id="f-36">EISNERAMPER LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="dei:AuditorLocation" id="f-37">Iselin, New Jersey</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">March&#160;23, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-4</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-38">5,964,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-39">7,854,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid Expenses and Other Current Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-40">343,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-41">606,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Tax Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-42">1,373,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-43">529,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-44">7,680,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-45">8,990,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Property and Equipment, Net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-46">55,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-47">73,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-48">49,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-49">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Intangible Assets and In-Process R&amp;D, Net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-50">10,743,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-51">10,768,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating Lease Assets with Right-of-Use</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-52">116,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-53">209,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">42,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-56">18,678,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-57">20,130,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts Payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">1,008,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">160,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accrued Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">1,835,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">1,330,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">105,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">118,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Contingent Consideration, short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-64">322,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-66">3,272,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-67">1,609,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Non-Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-68">3,309,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">3,048,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="f-70">689,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="f-71">802,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-Current Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-73">90,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Non-Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-74">3,998,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-75">3,941,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-76">7,270,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-77">5,551,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Commitments and Contingencies (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="f-78"></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="f-79"></ix:nonFraction>&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-81">0.01</ix:nonFraction></ix:nonFraction> Par Value: <ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-85">3,750</ix:nonFraction></ix:nonFraction> designated Series A, <ix:nonFraction unitRef="shares" contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-89">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="i6b6f1204652347fdb415623b23490c21_I20211231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-91">10,000</ix:nonFraction></ix:nonFraction> designated Series B, <ix:nonFraction unitRef="shares" contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="i6b6f1204652347fdb415623b23490c21_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="i6b6f1204652347fdb415623b23490c21_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-95">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-97">10,000</ix:nonFraction></ix:nonFraction> shares designated Series C, <ix:nonFraction unitRef="shares" contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-101">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="ic2257b859754445a88c5a21dc111b650_I20211231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-103">20,000</ix:nonFraction></ix:nonFraction> shares designated Series D, <ix:nonFraction unitRef="shares" contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="ic2257b859754445a88c5a21dc111b650_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="ic2257b859754445a88c5a21dc111b650_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-107">7</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-109">1,280</ix:nonFraction></ix:nonFraction> shares designated as Series E, <ix:nonFraction unitRef="shares" contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-113">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-116"><ix:nonFraction unitRef="usdPerShare" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-117">0.01</ix:nonFraction></ix:nonFraction> Par Value: <ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-119">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-121">1,796,472</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-123">316,599</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-124">17,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-125">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Additional Paid-In Capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-126">146,035,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-127">135,541,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated Deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-128">134,462,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-129">120,879,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated Other Comprehensive Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-130">182,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-131">86,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Stockholders&#8217; Equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-132">11,407,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-133">14,579,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-134">18,678,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-135">20,130,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">See Accompanying Notes to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-5</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and Development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-136">3,448,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-137">5,350,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-138">8,277,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-139">5,323,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-141">4,037,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-142">582,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-143">475,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Operating Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-144">12,309,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-145">14,235,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating Loss Before Other Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-146">12,309,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-147">14,235,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other (Expense) Income, Net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in Fair Value of Warrant Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-148">1,425,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gain on Forgiveness of Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="f-151">278,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gain on Disposal of Fixed Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="0" id="f-152">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="0" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-154">56,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-155">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-156">8,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-157">6,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign Currency Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-158">14,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Other (Expense) Income, Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-160">1,387,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-161">272,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss Before Income Tax Benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-162">13,696,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-163">13,963,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income Tax Benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-164">113,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-165">192,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net Loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-166">13,583,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-167">13,770,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net Loss per Common Share - Basic and Diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-169">18.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">57.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted Average Shares Outstanding - Basic and Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-172"><ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-173">732,303</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-174"><ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-175">241,099</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other Comprehensive Loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net Loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-176">13,583,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-177">13,770,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-178">96,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-179">85,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Comprehensive Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-180">13,679,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-181">13,856,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accompanying Notes to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-6</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.798%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231" decimals="0" name="us-gaap:SharesOutstanding" scale="0" id="f-182">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-183">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184">316,599</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-185">3,166</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-186">135,541,662</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i320d385ba935451a894515e3831f68bb_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-187">86,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i24398d9d387448899d7d6f67b0d18e73_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-188">120,879,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-189">14,579,048</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-190">462,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-191">462,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Panoptes Holdback Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodSharesFromHoldBackShares" format="ixt:num-dot-decimal" scale="0" id="f-192">10,087</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" scale="0" id="f-193">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231" decimals="0" sign="-" name="kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" scale="0" id="f-194">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" format="ixt:fixed-zero" scale="0" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Common Stock from Public Offering, Net of Offering Costs of $<ix:nonFraction unitRef="usd" contextRef="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-196">505,020</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id89f9810f6e54da3941651bc0c466491_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-197">592,392</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id89f9810f6e54da3941651bc0c466491_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-198">5,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id16e66ce7c40470481151ae6a1bdec32_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-199">2,456,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-200">2,462,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Series E Preferred Stock from Public Offering, Net of Offering Costs of $<ix:nonFraction unitRef="usd" contextRef="ibae2553f4c6147269d9f2446ff9cecb5_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-201">136,401</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-202">1,280</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-203">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="f-204">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-205">665,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-206">665,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series E Preferred Stock into Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-207">1,280</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-208">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-209">160,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-210">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-211">1,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification of Warrant Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231" decimals="0" name="kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" format="ixt:num-dot-decimal" scale="0" id="f-213">3,674,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" format="ixt:num-dot-decimal" scale="0" id="f-214">3,674,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cancellation of Reverse Stock Split Fractional Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="kprx:StockAdjustmentDuringPeriodSharesReverseStockSplits" format="ixt:num-dot-decimal" scale="0" id="f-215">2,215</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231" decimals="0" name="kprx:StockAdjustedDuringPeriodValueReverseStockSplits" format="ixt:num-dot-decimal" scale="0" id="f-216">15,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:StockAdjustedDuringPeriodValueReverseStockSplits" format="ixt:num-dot-decimal" scale="0" id="f-217">15,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Shares of Common Stock from Warrant Exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-218">65,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="f-219">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-220">519,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-221">520,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-222">381,360</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodSharesWarrantInducement" format="ixt:num-dot-decimal" scale="0" id="f-223">654,609</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantInducement" format="ixt:num-dot-decimal" scale="0" id="f-224">6,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantInducement" format="ixt:num-dot-decimal" scale="0" id="f-225">2,732,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantInducement" format="ixt:num-dot-decimal" scale="0" id="f-226">2,738,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6bbd708d2acc4d68a5639a37269bcebc_D20220101-20221231" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-227">96,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-228">96,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icb69a13a02f74a679635fb5e795a3515_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-229">13,583,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-230">13,583,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231" decimals="0" name="us-gaap:SharesOutstanding" scale="0" id="f-231">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-232">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4a9bdcba91c8451886d8aabf630b77e7_I20221231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-233">1,796,472</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4a9bdcba91c8451886d8aabf630b77e7_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-234">17,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icced56a3f28a49989883d98b093dc865_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-235">146,035,314</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5d2e47ef018340cb8ebed40d2781bd4c_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-236">182,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i07337b2a24d34ea8bce4d5b0b5d79397_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-237">134,462,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-238">11,407,600</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Accompanying Notes to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.798%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id85228c389d248878079223a2e81bf4a_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-239">4,138</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id85228c389d248878079223a2e81bf4a_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-240">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6321cfacdde541d6bcb432afea175641_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-241">138,910</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6321cfacdde541d6bcb432afea175641_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-242">1,389</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3616262e1e274a0f808b0eec4ef7eea2_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-243">116,837,777</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie8af2f5766874a71b1cf8cc1ee00516a_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" scale="0" id="f-244">802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6800052e1e5a4f7ca848d35a11c2a8c8_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-245">107,108,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-246">9,729,741</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-247">842,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-248">842,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of Common Stock from Private Placement, Net of Offering Costs of $<ix:nonFraction unitRef="usd" contextRef="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-249">11,142</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-250">38,278</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-251">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic73daca2444e47508725f0b023021fae_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-252">7,988,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-253">7,988,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Common Stock from Registered Direct Offering, Net of Offering Costs of $<ix:nonFraction unitRef="usd" contextRef="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-254">993,666</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4129640388714f6cb33e9916567cc679_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-255">116,721</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4129640388714f6cb33e9916567cc679_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-256">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1b19d9d48e644670b62130a82a554097_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-257">9,755,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-258">9,756,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issuance of Shares of Common Stock from Warrant Exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231" decimals="0" name="kprx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="f-259">260</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="f-260">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-261">49,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-262">50,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series C Preferred Stock into Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-263">4,092</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-264">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-265">21,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-266">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3eb9245348984b9c8801dc1000c6f9d8_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-267">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series D Preferred Stock into Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i3cf8b4d600b847b3b4b65b1860728288_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="f-269">39</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="f-270">273</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-271">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i602889283bfb43d69fbac7a5f9edd564_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-272">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Shares Issued to Bayon Shareholders at Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="f-274">845</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="f-275">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-276">67,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-277">67,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i447a4d73b07c4e98b072bfab8d19e602_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-278">85,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-279">85,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Loss </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib88c374fff9b4b1e86655b1b374c77e5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-280">13,770,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-281">13,770,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231" decimals="0" name="us-gaap:SharesOutstanding" scale="0" id="f-282">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-283">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-284">316,599</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-285">3,166</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-286">135,541,662</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i320d385ba935451a894515e3831f68bb_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-287">86,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i24398d9d387448899d7d6f67b0d18e73_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-288">120,879,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-289">14,579,048</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Accompanying Notes to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-8</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-290">13,583,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-291">13,770,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and Amortization of Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-292">41,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-293">45,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Reduction of Right-of-Use Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-294">92,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="kprx:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-295">181,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-296">462,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-297">842,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-298">582,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-299">505,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change in Fair Value of Warrant Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-300">1,425,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred Taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="0" id="f-302">113,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="0" id="f-303">192,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Paycheck Protection Program Loan Forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:CashOutflowFromLoanForgiveness" format="ixt:fixed-zero" scale="0" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="kprx:CashOutflowFromLoanForgiveness" format="ixt:num-dot-decimal" scale="0" id="f-305">278,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Goodwill Impairment Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-307">4,037,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Gain on Disposal of Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="0" id="f-308">4,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="0" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid Expenses and Other Current Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-310">275,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-311">156,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Tax Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-312">872,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-313">441,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-314">22,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-315">14,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-316">782,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-317">310,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-318">103,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-319">181,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accrued Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-320">609,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-321">40,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Cash Used in Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-322">10,428,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-323">10,675,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchase of Property and Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-325">63,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Acquisitions, Net of Cash Acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="0" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="0" id="f-327">93,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds on Sale of Equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-328">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Cash Provided by (Used in) Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-330">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-331">157,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from Public Offerings, Net of Offering Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-332">5,377,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-333">17,745,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from Warrant Inducement, Net of Issuance Costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-334">2,738,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="0" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Exercise of Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-336">520,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-337">50,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Payments Made for Fractional Shares Related to the Reverse Stock Split</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit" format="ixt:num-dot-decimal" scale="0" id="f-338">15,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit" format="ixt:fixed-zero" scale="0" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Repayment of Loan Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:fixed-zero" scale="0" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="0" id="f-341">212,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-342">8,620,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-343">17,582,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Effect of Exchange Rate Changes on Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-344">85,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-345">81,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net (Decrease) Increase in Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-346">1,885,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-347">6,669,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, Including Restricted Cash, Beginning of Year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-348">7,899,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-349">1,230,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash, Including Restricted Cash, End of Year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-350">6,013,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-351">7,899,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Supplemental Disclosures of Noncash Operating and Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series C Preferred Stock into Common Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if598f7f07da9469aa774b84729f5f86f_D20220101-20221231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="0" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" id="f-353">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series D Preferred Stock into Common Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1531c5c8a44fba658fb9b271b9635_D20220101-20221231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="0" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" id="f-355">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Conversion of Series E Preferred Stock into Common Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="0" id="f-356">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5b9abe9e1f4348a593e3702b5ad4bcdd_D20210101-20211231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="0" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Creation of Right-of-Use Assets and Related Lease Liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-358">55,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-359">313,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Grant of Restricted Stock Awards </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="kprx:GrantOfRestrictedStockAwards" scale="0" id="f-360">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="kprx:GrantOfRestrictedStockAwards" format="ixt:fixed-zero" scale="0" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">S</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ee Accompanying Notes to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-9</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_133"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i33c11c03affd49a6944ca837f3a73528_136"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:NatureOfOperations" id="f-362" continuedAt="i8acae27cdad9467e87566d6df353dc9a" escape="true">Business, Presentation and Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i8acae27cdad9467e87566d6df353dc9a" continuedAt="i38a46e3910fb48458e55009062cb94c9"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (&#8220;Kiora&#8221; or the &#8220;Company&#8221;) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company&#8217;s certificate of incorporation to change its name to &#8220;Kiora Pharmaceuticals, Inc.&#8221; effective November 8, 2021 (the &#8220;Name Change&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company's lead product is KIO-301 with an initial focus on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#8220;photoswitch&#8221; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes&#8217; ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. The Company initiated a Phase 1b clinical trial in the third quarter of 2022. On March 17, 2022, the Company was granted Orphan Drug Designation from the U.S. FDA for the Active Pharmaceutical Ingredient (&#8220;API&#8221;) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (&#8220;Bayon&#8221;) transaction which closed October 21, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 is a product that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (&#8220;OPRA+&#8221;). KIO-101 is a next-generation, non-steroidal, immune-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (&#8220;DHODH&#8221;) with what the Company believes to be best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In the fourth quarter of 2021, the Company reported top-line safety and tolerability from a phase 1b proof-of-concept (&#8220;POC&#8221;) study evaluating KIO-101 in patients with ocular surface inflammation. The Company expects to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma Ges.m.b.H &#8220;Panoptes&#8221; in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, the Company is developing KIO-201, for patients with Persistent Corneal Epithelial Defects ("PCED"), which is an orphan disease and as such, the Company is currently seeing orphan drug designation. The Company is also evaluating KIO-201 in patients recovering from surgical wounds, such as those undergoing photorefractive keratectomy ("PRK") surgery for corneal wound repair after refractive surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. The Company is currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. The Company is in planning stages of a Phase 3b trial for patients recovering from the laser vision correction procedure PRK and plans to initiate the study before the end of 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i38a46e3910fb48458e55009062cb94c9" continuedAt="ifbf70f6a6da9452d900639df6ea02fc2"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">course of business. At December&#160;31, 2022, Kiora had unrestricted Cash and Cash Equivalents of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-363">6.0</ix:nonFraction> million, and an Accumulated Deficit of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-364">134.5</ix:nonFraction> million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at December&#160;31, 2022, the Company anticipates having sufficient cash to fund planned operations into July 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-365">2.7</ix:nonFraction> million in a warrant inducement transaction that closed on November&#160;22, 2022, net of placement agent fees of $<ix:nonFraction unitRef="usd" contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122" decimals="-5" name="kprx:WarrantIssuancePlacementAgentFees" format="ixt:num-dot-decimal" scale="6" id="f-366">0.3</ix:nonFraction> million and expense of $<ix:nonFraction unitRef="usd" contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122" decimals="-5" name="kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-367">0.1</ix:nonFraction>&#160;million, additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company&#8217;s recurring losses from operations have caused management to determine there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Reverse Stock Split</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;23, 2022, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#8217;s stockholders at the Company&#8217;s 2022 Annual Meeting of Stockholders held on September&#160;23, 2022, and by the Company&#8217;s board of directors. The Amendment became effective on September&#160;27, 2022.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The reverse stock split affected all shares of the Company&#8217;s common stock outstanding immediately prior to the effective time of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, and restricted stock awards, and, in the case of stock options, a proportionate increase in the exercise price of all such stock options. In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plans immediately prior to the effective time of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#8217;s Amended and Restated Certificate of Incorporation, which remained at <ix:nonFraction unitRef="shares" contextRef="ie73652b7324f410eb0a236c5ab74f270_I20220927" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-368">50,000,000</ix:nonFraction> shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927" decimals="INF" name="kprx:StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" format="ixt:fixed-zero" scale="0" id="f-369">No</ix:nonFraction> fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share). As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock as of September&#160;27, 2022 decreased from <ix:nonFraction unitRef="shares" contextRef="iab476c35d5854b3288e7c65fae86f033_I20220926" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-370">43,163,123</ix:nonFraction> (pre-split) shares to <ix:nonFraction unitRef="shares" contextRef="ie73652b7324f410eb0a236c5ab74f270_I20220927" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-371">1,079,045</ix:nonFraction> (post-split) shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are presented reflecting the split. The Company&#8217;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on September&#160;27, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ifbf70f6a6da9452d900639df6ea02fc2"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-372" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.</span></div></ix:nonNumeric></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_142"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-374" continuedAt="i27a08944ec974f1787eaad169a0ada7d" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i27a08944ec974f1787eaad169a0ada7d" continuedAt="i4de0c951f5a94b46b80016af0ed17aa1"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" id="f-375" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, Jade Therapeutics, Inc. (&#8220;Jade&#8221;), Kiora Pharmaceuticals GmbH (&#8220;Kiora GmbH&#8221;) (formerly known as Panoptes Pharma Ges.m.b.H or &#8220;Panoptes&#8221;) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon Therapeutics, Inc. ("Bayon") (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (&#8220;Kiora Pty&#8221;) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as &#8220;the Company&#8221;. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-376" continuedAt="i769bb393649d4d8282104d9fbdcf22c8" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company&#8217;s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&amp;D), stock-based compensation, assumptions used to value warrants including warrant modifications and </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i4de0c951f5a94b46b80016af0ed17aa1" continuedAt="i92acd26a7d8c4707bf2cda5389faf4a8"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i769bb393649d4d8282104d9fbdcf22c8">inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</ix:continuation></span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-377" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operations of Kiora GmbH are conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets and a component of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-378" continuedAt="i43c50dcdd1244ac18f7c3c1fdaf7ab72" escape="true">Cash and Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i43c50dcdd1244ac18f7c3c1fdaf7ab72">The Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less.</ix:continuation> At December&#160;31, 2022 and 2021, the Company has classified $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-2" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-379">49.3</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="-2" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-380">45.0</ix:nonFraction> thousand as restricted cash, respectively.</span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-381" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="ic6dde5f6b02b4d3a8d35d27b3c627622_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-382">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i6fe5ad0fbdd64d0f90e7fbe407e4018e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-383">5</ix:nonNumeric> years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-384" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that <ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-385">no</ix:nonFraction> assets are impaired at December&#160;31, 2022. There is no assurance that management&#8217;s estimates and assumptions will not change in future periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-386" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company expenses research and development (&#8220;R&amp;D&#8221;) expenditures as incurred. R&amp;D expenses are comprised of costs incurred in performing R&amp;D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i92acd26a7d8c4707bf2cda5389faf4a8" continuedAt="i52106b0457cd48b1bc1ff2d941c3dbf3"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-387" continuedAt="i7173f00d5a834ccfa487469fb73eb9e0" escape="true">Goodwill</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i7173f00d5a834ccfa487469fb73eb9e0">Goodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-388">no</ix:nonFraction> goodwill. In 2021, this consisted of the goodwill of the Company&#8217;s subsidiaries Jade and Kiora GmbH and Bayon. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company had <ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-389">no</ix:nonFraction> goodwill as of December 31, 2022, and accordingly did not need to perform an impairment analysis. As of December&#160;31, 2021, the Company performed qualitative and quantitative impairment evaluations on its goodwill. As a result, goodwill as of December&#160;31, 2021 was reduced to <ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-390">zero</ix:nonFraction> after taking an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-391">4.0</ix:nonFraction>&#160;million. The fair value is determined using the income approach with a reconciliation to the Company&#8217;s market capitalization. The impairment is reported on the Consolidated Statements of Operations and Comprehensive Loss.</ix:continuation> </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-392" continuedAt="if352d5bbc82241bda6c45a7a7bed0318" escape="true">In-Process Research and Development</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="if352d5bbc82241bda6c45a7a7bed0318">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets. At December&#160;31, 2022 and 2021, there is $<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-393"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-394">10.6</ix:nonFraction></ix:nonFraction> million respectively of in-process R&amp;D as part of intangible assets and in-process R&amp;D, net on the Consolidated Balance Sheets.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:AccruedClinicalExpensesPolicyTextBlock" id="f-395" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As part of the Company&#8217;s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-396" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment and Geographical Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in <ix:nonFraction unitRef="segment" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-397">one</ix:nonFraction> business segment (research and development), and the Company operates in <ix:nonFraction unitRef="segment" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:NumberOfGeographicSegments" format="ixt-sec:numwordsen" scale="0" id="f-398">three</ix:nonFraction> geographic areas.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-399" continuedAt="i53ec60921d07488b8a4f5527c7c7f3c8" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i52106b0457cd48b1bc1ff2d941c3dbf3" continuedAt="if49239e44ad54257b85e553f6ab8112d"><ix:continuation id="i53ec60921d07488b8a4f5527c7c7f3c8"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">between the financial statement carrying, or &#8220;book&#8221;, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s net deferred income tax assets were subject to a full valuation allowance. As of December&#160;31, 2022 and 2021, the Company has a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-400">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-401">0.8</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-402">no</ix:nonFraction> unrecognized uncertain income tax positions.</span></div></ix:continuation><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:ClassOfWarrantOrRightPolicyPolicyTextBlock" id="f-403" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company classifies warrants to purchase shares of its common stock as a liability on its Consolidated Balance Sheets when the warrant is a free-standing financial instrument that may require the Company to transfer cash consideration upon exercise and that cash transfer event would be out of the Company&#8217;s control. Such a &#8220;warrant liability&#8221; is initially recorded at fair value on date of grant using the Black-Scholes model, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in the fair value of the warrant are recognized as a component of other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company will adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant or meeting the requirements to be reclassified to equity.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For warrants that do not meet the criteria of a liability warrant and are classified on the Company&#8217;s Consolidated Balance Sheets as equity instruments, the Company uses the Black-Scholes model to measure the value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferred stock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" id="f-404" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refunds for Research and Development</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora, through its Kiora GmbH and Kiora Pty Ltd. subsidiaries, is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp; development expenses. The Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. As of December&#160;31, 2022 and 2021, the Company has a research &amp; development tax receivable of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-405">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-406">0.5</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" id="f-407" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance-Sheet Risk</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-408" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Comprehensive loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company&#8217;s only component of other comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="if49239e44ad54257b85e553f6ab8112d" continuedAt="icdf0f5c457594b3d8407c738f0a8a2ab"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-409" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees and non-employees at grant date, based on the estimated fair value of the award. Compensation cost for employee awards is recognized as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company&#8217;s policy is to record forfeitures as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-410" continuedAt="i7708c562a89b45b1beeb8e898b188cc6" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share &#8211; Basic and Diluted</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of <ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-411">30,000</ix:nonFraction> shares for year ended December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="f-412">375</ix:nonFraction> shares for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i7708c562a89b45b1beeb8e898b188cc6">Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December&#160;31, 2022 and 2021, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive.</ix:continuation> <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-413" continuedAt="if46cbc191f454de1a903914177ddad08" escape="true">All shares of Common Stock that may potentially be issued in the future are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><ix:continuation id="if46cbc191f454de1a903914177ddad08"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common Stock Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-414">1,597,606</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-415">168,932</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7816963ef37e49fc9b2b1b915da2a22f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-416">84,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7564a47a7da94e13b7282837ea444347_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-417">12,954</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-418">30,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-419">375</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4ce5880d70044e6b8f03f31c86c7583d_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-420">52</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1e93985e88d14fc2822a56282e1b4674_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-421">52</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Shares of Common Stock Issuable</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-422">1,712,409</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-423">182,313</ix:nonFraction></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:RelatedPartyTransactionsPolicyTextBlock" id="f-424" continuedAt="ibf38fbbe8a804a328734790b8dfc6f0d" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Transactions</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, the Company entered into certain related-party transactions, making payments for services to <ix:nonFraction unitRef="vendor" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:RelatedPartyTransactionsNumberOfVendors" format="ixt-sec:numwordsen" scale="0" id="f-425">one</ix:nonFraction> vendor and <ix:nonFraction unitRef="consultant" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:RelatedPartyTransactionsNumberOfConsultants" format="ixt-sec:numwordsen" scale="0" id="f-426">six</ix:nonFraction> consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. The Company incurred expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ib210e42a94504411b696b6898cff71fe_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="f-427">0.1</ix:nonFraction> million for services to the related party vendor Ora, Inc. who is providing the Company with clinical study services for KIO-301. <ix:nonFraction unitRef="director" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" format="ixt-sec:numwordsen" scale="0" id="f-428">One</ix:nonFraction> of the Company&#8217;s directors is an executive at Ora, Inc. $<ix:nonFraction unitRef="usd" contextRef="i4f1302ad90ae4297bfaa1b3b75847254_I20221231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-429">0.1</ix:nonFraction> million of this amount was included in accounts payable at December 31, 2022 and was subsequently paid. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2021, the Company entered into certain related-party transactions, making payments for services to <ix:nonFraction unitRef="vendor" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="kprx:RelatedPartyTransactionsNumberOfVendors" format="ixt-sec:numwordsen" scale="0" id="f-430">one</ix:nonFraction> vendors, <ix:nonFraction unitRef="consultant" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="kprx:RelatedPartyTransactionsNumberOfConsultants" format="ixt-sec:numwordsen" scale="0" id="f-431">six</ix:nonFraction> consultants and <ix:nonFraction unitRef="university" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="kprx:RelatedPartyTransactionsNumberOfUniversities" format="ixt-sec:numwordsen" scale="0" id="f-432">two</ix:nonFraction> public universities, all of whom also are stockholders of the Company. Additionally, on January&#160;6, 2021, the Company completed a private placement of <ix:nonFraction unitRef="shares" contextRef="id831adc4181743088eae7312ce945c05_D20210106-20210106" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-433">38,278</ix:nonFraction> shares of Common Stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ia86727de4c5a4926a0e5747099589716_I20210106" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-434">38,278</ix:nonFraction> shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia86727de4c5a4926a0e5747099589716_I20210106" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-435">209.00</ix:nonFraction>. Steven J. Boyd and Keith Maher, each of whom were members of the Company&#8217;s board of directors through August 3, 2021, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="icdf0f5c457594b3d8407c738f0a8a2ab"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="ibf38fbbe8a804a328734790b8dfc6f0d">are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $<ix:nonFraction unitRef="usd" contextRef="id831adc4181743088eae7312ce945c05_D20210106-20210106" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-436">8.0</ix:nonFraction> million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company&#8217;s CEO, Brian M. Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December&#160;31, 2021 are not material to the accompanying Consolidated Financial Statements.</ix:continuation></span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-437" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Each period the Company revalues its contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-438" continuedAt="ie62b3b60aabb4b59a277aeffeb48d1b3" escape="true">Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="ie62b3b60aabb4b59a277aeffeb48d1b3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Milestone Achievement Condition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Contingent Consideration Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 1b</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c22c28aff144ee595d728f32589250e_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-439">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf6d43f133f747a0ab9dc998896d995e_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-440">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0ecf2b2ec16422cbacb311f726e1ec3_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-441">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia50f44856f9c4fb8b1538310decf01f4_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-442">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning of Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i888435cf3f784a9ba1bf3f83b65808c1_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-443">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaaed018232ee4376af66b1bb3f267c0f_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-444">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide0c249357514cff9aace25f8d87b162_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-445">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Changes in the fair value of contingent consideration are included within &#8220;Operating Expenses&#8221; in the Company's Consolidated Statements of Operations and Comprehensive Loss. Below are the status of each transaction's contingent consideration:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Bayon</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company recorded contingent consideration at fair value of $<ix:nonFraction unitRef="usd" contextRef="i799e66b122254b9fb460f1351862d609_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-446">0.9</ix:nonFraction> million as a result of the Bayon acquisition which closed on October 21, 2021. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i64bb67e607cc4f0c9c84c43c78f4efea_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="f-447">0.3</ix:nonFraction> million. As of December&#160;31, 2022, the Company had contingent consideration at fair value of $<ix:nonFraction unitRef="usd" contextRef="ieef5b9cdc86b4a77beddae9c62c61595_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-448">1.1</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Panoptes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: The Panoptes transaction closed December 18, 2020. As of December&#160;31, 2021, the Company recorded contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i23180588e9524c849bdffc35ee9bd8aa_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-449">1.6</ix:nonFraction> million. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i04d2cd5eafe44865832330aec4043e6e_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="f-450">0.1</ix:nonFraction> million. The estimated fair value of contingent consideration as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i42e744283a104e7aab5283d862fa0714_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-451">1.7</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Jade</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company had a fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i5fb04f42eb4c42bcb708df3c9ab9d6cf_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-452">0.6</ix:nonFraction> million. During the year ended December&#160;31, 2022, the contingent consideration was increased by $<ix:nonFraction unitRef="usd" contextRef="i9ddd33b6700f4b608668df77f0df0cf9_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="f-453">0.2</ix:nonFraction> million for a change in fair value. As of December&#160;31, 2022, the Company had fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i85a6ef5429de4056adb997f7e9262826_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-454">0.7</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">At December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" format="ixt:fixed-zero" scale="0" id="f-455"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" format="ixt:fixed-zero" scale="0" id="f-456">no</ix:nonFraction></ix:nonFraction> other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-17</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_145"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="f-457" continuedAt="i5bab1083d2a54b5db8ea39ae883032fc" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="i5bab1083d2a54b5db8ea39ae883032fc"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or 2 inputs. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-458" continuedAt="i71069aa93ef84e9fa91b4d04a3dfe9c7" escape="true">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i71069aa93ef84e9fa91b4d04a3dfe9c7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:59.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-459">322,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i087a5072b67a4c169cb7911c09453420_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-461">3,309,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i087a5072b67a4c169cb7911c09453420_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-462">3,048,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Contingent Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-463">3,631,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i087a5072b67a4c169cb7911c09453420_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-464">3,048,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets as discussed in Note 14. Acquisitions. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-465" continuedAt="i9866193e95694396b1b5992a7b982c69" escape="true">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i9866193e95694396b1b5992a7b982c69"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3c178a39c69548fda2705ef06500514f_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-466">14.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i92ee76833e9c428f9fd3ad7f7192e706_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-467">13.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id0e51232f4a14c209d9c5df6ff177065_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-468">17</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4ea89645f1894b4fba9d2c548706de5a_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-469">67</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0a9cbc32704e41d09a92d143608ba5eb_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-470">12</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2411b19d85894c33a481ac01c23e03de_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-471">72</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd7b63c35c834b628a7731a06aee8457_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-472">17</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie954ef05d7134b6f9d9dd90ee01b1211_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-473">36</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i834e6138cf4c45329319e7013dad7d7d_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-474">17</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1ebe6a805c674f3d9d16186d17a8debc_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-475">36</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ibb5e4b8cf2b145ab8c2f3941f240109c_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-476">56</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie8c79b49342e4aae897b21feea0ee57d_I20211231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-477">47</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table resulted is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The changes in contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="kprx:ChangeInContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="6" id="f-478">0.6</ix:nonFraction> million as of December&#160;31, 2022, was primarily driven by higher estimated probabilities of success and an increased discount factor and was recorded as a change in fair value of contingent consideration within the Consolidated Statements of Operations and Comprehensive Loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-18</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_148"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-479" continuedAt="i81ef826f4fc54353821c033f413e00d2" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i81ef826f4fc54353821c033f413e00d2"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-480" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Useful <br/>Life <br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id87329af756f41a9bd8bee769f08e565_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-481">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i75764a07c6654ad08928cf4027c83f17_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-482">88,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5f21e2cac0424fd79527f4ae97483cb8_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-483">88,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibaf5f9545aff4296b09d8d3d1ded4f0a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-484">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i59768bc60bf14b3495f61e99faa48435_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-485">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifafd19d03e684311a9182b00ff277098_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-486">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1c2af17f178f4edbb10c214f6d710e09_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-487">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7c18db8d117144d1bf9d77fdd49e90ab_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-488">58,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4dc53dd0efce433fadbcbca72c48963e_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-489">72,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8140c0eecc74d328848491bed2731d0_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-490">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied744319bcce42c2947e7cb3c0d9b546_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-491">22,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96515979ddcd4f16b4c0312d1f057eae_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-492">22,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-493">172,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-494">187,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less Accumulated Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-495">117,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-496">113,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-497">55,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-498">73,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-499">16,596</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-500">20,296</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_151"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-501" continuedAt="i50c971792e254523bc9384494622e1b7" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i50c971792e254523bc9384494622e1b7"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-502" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payroll and Benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-503">1,312,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-504">937,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-505">282,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-506">194,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="kprx:ClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-507">57,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="kprx:ClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-508">168,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-509">183,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-510">28,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-511">1,835,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-512">1,330,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_154"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="f-513" continuedAt="ib3593ddf9b7c43429a2549a06c4b44c4" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ib3593ddf9b7c43429a2549a06c4b44c4"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2020, the Company received loan funds (the &#8220;Loan&#8221;) from the Paycheck Protection Program (&#8220;PPP&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-514">0.3</ix:nonFraction> million. In April 2021, the Company was notified by the Small Business Administration (&#8220;SBA&#8221;) that this Loan was forgiven in full.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has no additional indebtedness at December&#160;31, 2022 and 2021.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_157"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-515" continuedAt="i9eb1ae6d4e62476695dc693d950a578a" escape="true">Intangible Assets and In-Process R&amp;D</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i9eb1ae6d4e62476695dc693d950a578a" continuedAt="ie4c0f447fb444f67aefe8616093f3fbd">Intangible assets at December&#160;31, 2022 consist of the rights to trade-secrets and know-how related to the manufacturing of KIO-201. During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (&#8220;SentrX&#8221;) with respect to certain rights relating to the manufacturing of KIO-201. The intangible assets were recorded at $<ix:nonFraction unitRef="usd" contextRef="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-516">0.3</ix:nonFraction> million, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930" decimals="-5" name="kprx:IntangibleAssetsExpectedMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="f-517">4.8</ix:nonFraction> million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company&#8217;s intangible assets are amortized on a straight-line basis over the estimated useful lives. Additionally, in-process R&amp;D as of December&#160;31, 2022 and 2021 consists of projects acquired from the acquisitions of Jade, Bayon and Panoptes that have not reached technological feasibility and which have no alternative future use. Once the </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ie4c0f447fb444f67aefe8616093f3fbd"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">R&amp;D process is complete, the Company will amortize the R&amp;D asset over its remaining useful life. The Company periodically evaluates these assets for impairment.</span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-518" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets and in-process R&amp;D at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated Useful <br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade Secrets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia067078212ed44749f27634d5c3506d2_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-519">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-520">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-521">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-522">106,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-523">81,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible Assets, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-524">143,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-525">168,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231" decimals="0" name="kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-526">10,599,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231" decimals="0" name="kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-527">10,599,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Intangible Assets and In-Process R&amp;D, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231" decimals="0" name="kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-528">10,743,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231" decimals="0" name="kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-529">10,768,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-530"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-531">25</ix:nonFraction></ix:nonFraction> thousand for each of the years ended December&#160;31, 2022 and 2021. </span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-532" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected future amortization expense is as follows for the years ending December 31,:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-533">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-534">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="f-535">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="f-536">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="0" id="f-537">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="f-538">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-539">143,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_160"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-540" continuedAt="icf48d2df214a4fa394011f1eb7f742fb" escape="true">Capital Stock</ix:nonNumeric></span></div><ix:continuation id="icf48d2df214a4fa394011f1eb7f742fb" continuedAt="i55b369d138124b9ea8663d4a7ee04f55"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On January&#160;6, 2021, the Company completed a private placement of <ix:nonFraction unitRef="shares" contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-541">38,278</ix:nonFraction> shares of Common Stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106" decimals="0" name="kprx:ClassOfWarrantOrRightNumberOfWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-542">38,278</ix:nonFraction> shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2eb912acb7a84e7f899a898ef68025da_I20210106" decimals="2" name="kprx:SharePurchasePriceOfCommonStockAndWarrant" scale="0" id="f-543">209.00</ix:nonFraction>. The total net proceeds from the private placement were approximately $<ix:nonFraction unitRef="usd" contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-544">8.0</ix:nonFraction> million. The warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106" decimals="2" name="kprx:WarrantExercisePricePerShareSubjectToAdjustment" scale="0" id="f-545">209.00</ix:nonFraction> per share, subject to adjustments as provided under the terms of the warrants and will be exercisable on the <ix:nonNumeric contextRef="if363cd03c440489cae184e83db725dbe_D20210106-20210106" name="kprx:WarrantTerm" format="ixt-sec:durwordsen" id="f-546">six-month</ix:nonNumeric> anniversary of their issuance date. The warrants are exercisable for <ix:nonNumeric contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106" name="kprx:WarrantTerm" format="ixt-sec:durwordsen" id="f-547">five years</ix:nonNumeric> from the issuance date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;27, 2021, a holder elected to convert <ix:nonFraction unitRef="shares" contextRef="ibbef246b73ec4853aedf59d7fa6d83ce_D20210727-20210727" decimals="0" name="kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" format="ixt:num-dot-decimal" scale="0" id="f-548">4,092</ix:nonFraction> shares of Series C Preferred stock that were issued in a public offering on April 17, 2018 into <ix:nonFraction unitRef="shares" contextRef="i20ff746adaba4d52862cc8fe8045f21a_D20210727-20210727" decimals="0" name="kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" format="ixt:num-dot-decimal" scale="0" id="f-549">21,313</ix:nonFraction> shares of Common Stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On August&#160;11, 2021, the Company completed a registered direct offering priced at-the-market under Nasdaq Rules for <ix:nonFraction unitRef="shares" contextRef="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-550">116,721</ix:nonFraction> shares of Common Stock with a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i231e710e53a94b32bd4380968717a154_I20210811" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-551">92.10</ix:nonFraction> per share. The Company also completed a concurrent private placement of unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-552">58,361</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-553">89.60</ix:nonFraction> per share that are exercisable immediately upon issuance and will expire five and one-half years following the date of issuance. In addition, the Company issued to the placement agent warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i231e710e53a94b32bd4380968717a154_I20210811" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-554">5,836</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i231e710e53a94b32bd4380968717a154_I20210811" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-555">115.124</ix:nonFraction> per share, which expire <ix:nonNumeric contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-556">five years</ix:nonNumeric> following the date of issuance. The total net proceeds to the Company from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-557">9.8</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;17, 2021, holders elected to convert <ix:nonFraction unitRef="shares" contextRef="i94882f0f19bc4f1a9ba8053af45015f0_D20210917-20210917" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="f-558">39</ix:nonFraction> shares of Series D Preferred stock that were issued in connection with the Panoptes acquisition into <ix:nonFraction unitRef="shares" contextRef="i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="f-559">273</ix:nonFraction> shares of Common Stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i55b369d138124b9ea8663d4a7ee04f55"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On June&#160;18, 2022, in connection with the Company&#8217;s acquisition of Panoptes Pharma Ges.m.b.H in December 2020 (&#8220;Panoptes Acquisition&#8221;), the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618" decimals="0" name="kprx:StockIssuedDuringPeriodSharesFromHoldBackShares" format="ixt:num-dot-decimal" scale="0" id="f-560">10,087</ix:nonFraction> shares of common stock to former shareholders of Panoptes, which had been held back for a period of <ix:nonNumeric contextRef="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618" name="kprx:BusinessAcquisitionHoldbackSharesTerm" format="ixt-sec:durwordsen" id="f-561">eighteen months</ix:nonNumeric> following the closing of the Panoptes acquisition to satisfy post-closing adjustment and indemnification obligations pursuant to the terms of the Share Purchase Agreement between the Company and the former shareholders of Panoptes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;22, 2022, the Company entered into an underwriting agreement to issue and sell stock and warrants in a public offering (the &#8220;Public Offering&#8221;). On July&#160;25, 2022, the underwriter fully exercised the over-allotment option granted by the Company to purchase stock and warrants (the &#8220;Option&#8221;). On July&#160;26, 2022, the Public Offering closed, and the Company issued and sold (i) <ix:nonFraction unitRef="shares" contextRef="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-562">592,392</ix:nonFraction> shares of common stock (the &#8220;Common Shares&#8221;) (including <ix:nonFraction unitRef="shares" contextRef="idd47b9b3e10d46d29b71583d4dafc1d5_I20220726" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-563">98,138</ix:nonFraction> Common Shares sold pursuant to the exercise of the Option), (ii) <ix:nonFraction unitRef="shares" contextRef="i19ded37b921e452b99960ea388a4e60d_I20220726" decimals="0" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-564">1,280</ix:nonFraction> shares of Series E Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;) convertible into up to <ix:nonFraction unitRef="shares" contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-565">160,000</ix:nonFraction> shares of common stock, (iii) <ix:nonFraction unitRef="shares" contextRef="ic8f91e8319c64ff39768af4b6a7f2366_I20220726" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-566">30,095,697</ix:nonFraction> Class A Warrants (including <ix:nonFraction unitRef="shares" contextRef="i487e6598d77f4f0b96574b8f7d9e0080_I20220726" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-567">3,925,525</ix:nonFraction> Class A Warrants sold pursuant to the exercise of the Option), and (iv) <span id="ie8d26f95c153412dbc0bee56ba637c99_16848"></span><ix:nonFraction unitRef="shares" contextRef="i55104f5329234e7f8ec5172aa858ce3c_I20220726" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-568">30,095,697</ix:nonFraction> Class B Warrants (including <ix:nonFraction unitRef="shares" contextRef="ib036afd5d8a7483089c4510b19eba804_I20220726" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-569">3,925,525</ix:nonFraction> Class B Warrants sold pursuant to the exercise of the Option) (the &#8220;Class B Warrants&#8221; and together with the Class A Warrants, the &#8220;Warrants&#8221;). Upon exercise, the warrants will convert on a 40 for 1 basis into a total of <ix:nonFraction unitRef="shares" contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726" decimals="0" name="kprx:WarrantsConvertibleIntoCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-570">1,504,785</ix:nonFraction> common shares. The public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726" decimals="2" name="kprx:SharesIssuedPricePerCommonShares" scale="0" id="f-571">8.00</ix:nonFraction> per Common Share, Class A Warrant and Class B Warrant or $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726" decimals="INF" name="kprx:SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" format="ixt:num-dot-decimal" scale="0" id="f-572">1,000</ix:nonFraction> per Preferred Share, <ix:nonFraction unitRef="shares" contextRef="ic8f91e8319c64ff39768af4b6a7f2366_I20220726" decimals="INF" name="kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" format="ixt:num-dot-decimal" scale="0" id="f-573">5,000</ix:nonFraction> Class A Warrants and <ix:nonFraction unitRef="shares" contextRef="i55104f5329234e7f8ec5172aa858ce3c_I20220726" decimals="INF" name="kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" format="ixt:num-dot-decimal" scale="0" id="f-574">5,000</ix:nonFraction> Class B Warrants resulted in net proceeds to the Company, of approximately $<ix:nonFraction unitRef="usd" contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-575">5.3</ix:nonFraction> million net of underwriting discount and commissions of $<ix:nonFraction unitRef="usd" contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726" decimals="-5" name="kprx:UnderwritingDiscountAndCommissions" format="ixt:num-dot-decimal" scale="6" id="f-576">0.4</ix:nonFraction>&#160;million and expense of $<ix:nonFraction unitRef="usd" contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726" decimals="-5" name="kprx:UnderwritingDiscountAndCommissionsExpenses" format="ixt:num-dot-decimal" scale="6" id="f-577">0.3</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Each Warrant is exercisable at a price per share of common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1bde319e174f4eaf85b6f29075e81c13_I20220726" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-578">8.00</ix:nonFraction>. The Class A Warrants will expire on September&#160;23, 2023 and the Class B Warrants will expire on September&#160;23, 2027. The exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During August 2022, all holders of the Series E Preferred Shares issued in the Public Offering, elected to convert their Series E Preferred Shares into <ix:nonFraction unitRef="shares" contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-579">160,000</ix:nonFraction> shares of Common Stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November&#160;17, 2022, the Company entered into warrant exercise inducement offer letters with some of the Class A Warrant holders who agreed to exercise for cash all of their Class A Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i62af4e98e26040bb88a1fcc90172c191_D20221117-20221117" decimals="0" name="kprx:ClassOfWarrantOrRightExercised" format="ixt:num-dot-decimal" scale="0" id="f-580">654,609</ix:nonFraction> shares of common stock originally issued in the Public Offering in exchange for the Company's agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) on substantially the same terms as the Class A Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ia811bfae64784023b2eb006045403cbe_I20221117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-581">654,609</ix:nonFraction> shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8e97479594434d06b760d7fa074563be_I20221117" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-582">5.97</ix:nonFraction>. Each Inducement Warrant will initially be exercisable <ix:nonNumeric contextRef="i58366d417e1645fab574b8a7fe469157_D20221117-20221117" name="kprx:ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" format="ixt-sec:durwordsen" id="f-583">six months</ix:nonNumeric> following its date of issuance, and will expire on the <ix:nonNumeric contextRef="i8e97479594434d06b760d7fa074563be_I20221117" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-584">eighteen month</ix:nonNumeric> anniversary of their initial exercise date. The Company received aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117" decimals="-5" name="kprx:ProceedsFromWarrantExercisesAndWarrantSales" format="ixt:num-dot-decimal" scale="6" id="f-585">3.1</ix:nonFraction> million from the exercise of the Class A Warrants by the selling stockholders and the sale of the Inducement Warrants. The Company paid its placement agent in connection with the inducement transactions a fee equal to <ix:nonFraction unitRef="number" contextRef="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117" decimals="INF" name="kprx:WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" scale="-2" id="f-586">8</ix:nonFraction>% of gross proceeds from the exercise of the Class A Warrants.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_163"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:WarrantsDisclosureTextBlock" id="f-589" continuedAt="i000b235f54754f58a732cc62bfb41ee0" escape="true">Warrants</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:continuation id="i000b235f54754f58a732cc62bfb41ee0" continuedAt="i094d24e73a9745108570b515e8026237"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-590" continuedAt="i780de55f27584f9e9e7982ae9a578102" escape="true">At December&#160;31, 2022 and 2021, the following warrants were outstanding:</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i094d24e73a9745108570b515e8026237"><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i780de55f27584f9e9e7982ae9a578102"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Remaining <br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-591">68,168</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" scale="0" id="f-592">336.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i85689dc882234a148ea4e1af5e916f2a_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-593">2.45</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-594">102,476</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" scale="0" id="f-595">135.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" name="kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" format="ixt-sec:duryear" id="f-596">4.68</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="f-597">260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="2" name="kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" scale="0" id="f-598">192.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="0" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-599">1,452</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-600">2,100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i95e7fecaf8fd4207806af45324ae8f90_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-601">168,932</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95e7fecaf8fd4207806af45324ae8f90_I20211231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" scale="0" id="f-602">199.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-603">3.42</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-604">2,159,395</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" scale="0" id="f-605">7.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" name="kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" format="ixt-sec:duryear" id="f-606">2.55</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-607">719,609</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="2" name="kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" scale="0" id="f-608">5.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-609">11,112</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" scale="0" id="f-610">900.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id5e36c5ec60743bb983183d644c22f6d_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-611">1,597,606</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5e36c5ec60743bb983183d644c22f6d_I20221231" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" scale="0" id="f-612">21.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-613">3.07</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of shares to be issued upon exercise of such warrants will be reduced based on the exercise price and the market value of the shares at the time of exercise. The outstanding warrants expire from 2023 through 2027.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_169"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-614" continuedAt="ice209d2e40754e4090df4933fbc808ed" escape="true">Equity Incentive Plan</ix:nonNumeric></span></div><ix:continuation id="ice209d2e40754e4090df4933fbc808ed" continuedAt="i864e7cdefdeb4b86b75f294efd307340"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In 2005, the Company approved the 2005 Equity Incentive Plan (the &#8220;2005 Plan&#8221;). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. During 2010, the maximum number of shares of Common Stock that may be issued pursuant to the 2005 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i5d6b9d5d260c46978aec252087242f31_I20101231" decimals="INF" name="us-gaap:ExcessStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-615">59,414</ix:nonFraction> shares. The Board of Directors (the &#8220;Board&#8221;) is responsible for administration of the 2005 Plan. The Company&#8217;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than <ix:nonFraction unitRef="number" contextRef="i3330bdda247340909ef880086af2dc10_D20100101-20101231" decimals="2" name="kprx:PercentageOfExercisePrice" scale="-2" id="f-616">110</ix:nonFraction>% of fair value in the case of holders of more than 10% of the Company&#8217;s voting stock) and with a term not to exceed <ix:nonNumeric contextRef="i1c9bdfc674f144df89195e7f413c9078_D20100101-20101231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-617">ten years</ix:nonNumeric> from the date of the grant (<ix:nonNumeric contextRef="i3ba894cd6b144b8f9075e713823ec483_D20100101-20101231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-618">five years</ix:nonNumeric> for incentive stock options granted to holders of more than 10% of the Company&#8217;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), no further grants were made under the 2005 Plan. General terms of the 2014 Plan remain the same as that of the 2005 plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s Board adopted the 2014 Plan and the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), and the Company&#8217;s Stockholders approved the 2014 Plan and the ESPP Plan in February 2015. As of December&#160;31, 2022, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP was <ix:nonFraction unitRef="shares" contextRef="ide7b6258bd17457592b81acc9062273f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-619">220,733</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id38a833f22f24032be3a7e78950e921a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="f-620">284</ix:nonFraction> shares, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In January 2022, the number of shares of common stock issuable under the 2014 Plan automatically increased by <ix:nonFraction unitRef="shares" contextRef="i795d0aceb7c54c7293c21cba1406d938_D20210101-20210131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="f-621">583</ix:nonFraction> shares pursuant to the terms of the 2014 Plan. Additionally, in September 2022, the number of shares of common stock issuable under the 2014 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="i1c1283a1942d49d3a4dbd18de8e7917c_I20220930" decimals="INF" name="us-gaap:ExcessStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-622">200,000</ix:nonFraction> shares, as approved by the Company&#8217;s Stockholders. These additional shares are included in the total of <ix:nonFraction unitRef="shares" contextRef="i4c4ef98046ac4ad4bfb9fb4488c8e276_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-623">220,733</ix:nonFraction> shares issuable under the 2014 Plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-624" continuedAt="i6b276127427c4692acee3fdb9ad225ce" escape="true">The following is a summary of stock option activity for the years ended December&#160;31, 2022 and 2021:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i864e7cdefdeb4b86b75f294efd307340" continuedAt="ib80266ffe7b84500ab23a0f8fe8baccf"><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="i6b276127427c4692acee3fdb9ad225ce"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Contractual Life<br/>(In Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-625">6,249</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-626">840.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i55c57edb8428421a821f6bc68bf101ed_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-627">2.30</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-628">8,654</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-629">164.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="f-630">825</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-631">1,046.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-632">1,124</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-633">259.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-634">12,954</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-635">426.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-636">5.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-637">5,087</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-638">847.31</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-639">3.09</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-640">12,954</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-641">426.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-642">5.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-643">78,641</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-644">8.49</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="f-645">14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-646">842.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-647">6,830</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-648">446.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-649">84,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-650">36.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-651">9.59</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-652">4,939</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-653">442.52</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-654">7.27</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-655">84,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-656">36.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-657">9.59</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of options to purchase <ix:nonFraction unitRef="shares" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-658">78,641</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-659">8,654</ix:nonFraction> shares of its Common Stock, respectively. All option grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest with respect to one-third of the underlying shares on the <ix:nonNumeric contextRef="i99a48c50139c4eb598eca8ffd0d33853_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-660">one-year</ix:nonNumeric> anniversary of the grant date and the remainder ratably over a <ix:nonNumeric contextRef="i40cc4e02cb1e43849c0b6c2e74f65db2_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-661">24-month</ix:nonNumeric> period. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-662" continuedAt="ifdd956bfe82a4dcb90185895f42ad01a" escape="true">For the years ended December&#160;31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt"><ix:continuation id="ifdd956bfe82a4dcb90185895f42ad01a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-663">2.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-664">1.82</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-665">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-666">10.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Average Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-667">140</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-668">140</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-669">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-670">0</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-671">27.08</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-672">145.63</ix:nonFraction> respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ib80266ffe7b84500ab23a0f8fe8baccf"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-673" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following is a summary of restricted stock activity for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Remaining <br/>Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1b08f940273a487b92ac968165f4687b_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-674">1,697</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b08f940273a487b92ac968165f4687b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-675">283.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60ca6dd2eaac461ca903428aa88ce1da_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-676">1.66</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-677">1,173</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-678">292.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-679">149</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-680">264.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibc96ca35437b4369949f0a093fabcb10_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="f-681">375</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc96ca35437b4369949f0a093fabcb10_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-682">261.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-683">1.09</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-684">30,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-685">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="f-686">248</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-687">261.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-688">127</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-689">261.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45d74368d0d343e6a4e730cc009f7c82_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-690">30,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45d74368d0d343e6a4e730cc009f7c82_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-691">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-692">2.79</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the years ended December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-693">127</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-694">149</ix:nonFraction> shares of restricted stock, which had not vested, were forfeited and returned to the Company, respectively. During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of <ix:nonFraction unitRef="shares" contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-695">30,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="f-696">0</ix:nonFraction> restricted shares of Common Stock, respectively. All grants of restricted shares were pursuant to the 2014 Plan. These vest with respect to one-third of the underlying shares on the <ix:nonNumeric contextRef="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-697">one-year</ix:nonNumeric> anniversary of the grant date and the remainder ratably over a <ix:nonNumeric contextRef="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-698">24-month</ix:nonNumeric> period.</span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" id="f-699" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1cea2dd17233476fbcf15949d7520ede_D20220101-20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-700">343,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50cfa066a22f4226b954687d13a1302a_D20210101-20211231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-701">246,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7aa3ab539c714dae87e11ec896cca4d3_D20220101-20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-702">118,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie678dc82cc1b44fdaea24b535ce33f39_D20210101-20211231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-703">596,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-704">462,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-705">842,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The fair value of options granted for the years ended December&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="-5" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" format="ixt:num-dot-decimal" scale="6" id="f-706">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-5" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" format="ixt:num-dot-decimal" scale="6" id="f-707">1.2</ix:nonFraction> million, respectively. As of December&#160;31, 2022 and 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-708">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-709">1.0</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-710">2.5</ix:nonNumeric> and <ix:nonNumeric contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-711">2.3</ix:nonNumeric> years, respectively. The aggregate intrinsic value of stock options outstanding at December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" scale="0" id="f-712"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" scale="0" id="f-713">0</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ide7b6258bd17457592b81acc9062273f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-714">101,850</ix:nonFraction> shares of Common Stock available for grant under the 2014 Plan and <ix:nonFraction unitRef="shares" contextRef="id38a833f22f24032be3a7e78950e921a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="f-715">191</ix:nonFraction> shares available under the Company&#8217;s ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-24</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_175"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-720" continuedAt="i84e830f400b049519828afa67e5fa4c8" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i84e830f400b049519828afa67e5fa4c8" continuedAt="id6e02dea28a8435a9bd5761cc6ce89f8"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-721" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of loss before income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="f-722">10,563,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="f-723">10,639,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="f-724">3,133,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="f-725">3,323,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-726">13,696,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-727">13,963,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-728" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of income tax (benefit) expense are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-729">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-730">24,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-731">117,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-732">168,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Taxes</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-733">113,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-734">192,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income Tax Benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-735">113,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-736">192,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-737" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States Federal Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-738">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-739">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Taxes, Net of Federal Benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-740">2.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-741">3.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent Differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-742">9.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-743">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="f-745">6.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in Valuation Allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-746">9.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-747">21.33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-748">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-749">1.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-750">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-751">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Non-Income Based Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" format="ixt:fixed-zero" scale="-2" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" scale="-2" id="f-753">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-754">0.26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-755">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective Tax Rate Expense </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-756">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-757">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="id6e02dea28a8435a9bd5761cc6ce89f8" continuedAt="i4c33d074333a4ddbaadeacbc47303f44"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-758" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s deferred tax assets and liabilities consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net Deferred Tax Liability:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Operating Loss Carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-759">22,809,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-760">20,689,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credit Carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-761">2,925,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-762">2,853,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-763">4,606,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-764">5,640,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-765">782,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-766">835,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash Versus Accrual Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-767">336,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-768">128,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Tax Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-769">31,461,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-770">30,146,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-771">29,593,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-772">28,298,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-773">1,867,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-774">1,848,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="f-775">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="f-776">956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process Research and Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="0" id="f-777">2,556,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="0" id="f-778">2,649,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-779">689,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-780">802,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, the Company has federal and state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-781">80.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-782">52.6</ix:nonFraction> million, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December&#160;31, 2017 totaling $<ix:nonFraction unitRef="usd" contextRef="id7386b4156e64f10a54ecf9bdd879e97_I20171231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-783">46.1</ix:nonFraction> million, and state NOL carryforwards as of December&#160;31, 2022 totaling $<ix:nonFraction unitRef="usd" contextRef="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-784">52.6</ix:nonFraction> million will expire at various dates through 2042. Federal NOL carryforwards generated during the years ended December&#160;31, 2018 and forward totaling $<ix:nonFraction unitRef="usd" contextRef="i53772301813341239fac34a54517b47d_I20181231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-785">34.4</ix:nonFraction> million will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i6091ba41f5734ea4ba9b5aadee940665_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-786">10.7</ix:nonFraction> million as of December&#160;31, 2022, which can be carried forward indefinitely. As of December&#160;31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1316295f29124fd8882adbcf2ad44e82_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-787">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92bb8ffea2e14d55ab953dcb6895cbc3_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-788">0.5</ix:nonFraction> million, respectively, to offset future income taxes, which expire at various times through 2042. The federal and state net operating loss and research tax credit carryforwards may be subject to the limitations provided in the Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383. Approximately $<ix:nonFraction unitRef="usd" contextRef="i3a467fc4202c4b38b702366fd2de3793_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-789">0.6</ix:nonFraction> million of the federal net operating loss attributable to Jade is subject to a Section 382 limitation. Jade&#8217;s carryover of its research and development credits will be subject to the Section 383 limitation.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company files United States federal income tax returns and income tax returns in the Commonwealth of Massachusetts, California, North Carolina and Utah, as well as foreign tax returns for its subsidiaries in Austria and Australia. The Company filed all foreign tax returns for its former French subsidiary EyeGate Pharma S.A.S., which was dissolved December&#160;31, 2021. The Company is not under examination by any jurisdiction for any tax year.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has recorded a valuation allowance against its United States and foreign deferred tax assets in each of the years ended December&#160;31, 2022, and 2021 because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-790">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-791">3.0</ix:nonFraction> million during the years ended December&#160;31, 2022 and 2021, respectively, primarily as a result of the increase in net operating losses and credits, adjustments for accrual to cash basis items, and capitalized research and development expenses. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-792"><ix:nonFraction unitRef="usd" contextRef="i746a7934f1634bada7a8c67124affa16_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-793">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits or related interest and penalties accrued. The Company will recognize interest and penalties related to income taxes in income tax expense. The Company has not, as yet, conducted a study of R&amp;D credit carryforwards, which are fully reserved for. This study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards and related </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i4c33d074333a4ddbaadeacbc47303f44"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">valuation allowance, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The net operating loss and tax credit carryforwards are subject to review by the Internal Revenue Service in accordance with the provisions of Section 382 of the Internal Revenue Code. Under this Internal Revenue Code section, substantial changes in the Company&#8217;s ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset the Company&#8217;s taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the Company&#8217;s net operating loss carryforwards before they expire. The closing of the Company&#8217;s initial public offering, alone or together with transactions that have occurred or that may occur in the future, may trigger an ownership change pursuant to Section 382, which could limit the amount of research and development tax credit and net operating loss carryforwards that could be utilized annually in the future to offset the Company&#8217;s taxable income, if any. Any such limitation as the result of the Company&#8217;s additional sales of common stock by the Company could have a material adverse effect on the Company&#8217;s results of operations in future years.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_178"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-794" continuedAt="i90e43513adaf40d6897f81ba3b238520" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i90e43513adaf40d6897f81ba3b238520" continuedAt="i0c0f301af22c434f89ac0b40b73502e6"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company is a party to <ix:nonFraction unitRef="operatinglease" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:LesseeNumberOfOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-795">three</ix:nonFraction> real property operating leases for the rental of office or lab space. In February 2022, the Company entered into a lease for an office facility in Encinitas, California with a term through October&#160;31, 2023, which is now used for its corporate headquarters. The Company recorded a right-of-use (ROU) asset and lease liability upon lease commencement in May 2022. The Company also has office and laboratory space of approximately <ix:nonFraction unitRef="sqft" contextRef="i13150472ec5a4562a80ec73c18d52b3b_I20231130" decimals="-1" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-796">3,540</ix:nonFraction> square feet in Salt Lake City, Utah with a term through November&#160;30, 2023. The Company has office space in Vienna, Austria of approximately <ix:nonFraction unitRef="sqft" contextRef="ic4a8d3ef8ffa49ccb26b949764fa8fee_I20231031" decimals="0" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-797">1,555</ix:nonFraction> square feet with a term through October&#160;31, 2023 as a result of the Panoptes acquisition effective December 18, 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional ROU assets and lease liabilities were recorded upon the new lease agreements or extensions that were effective as of December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease assets and liabilities are recognized at the lease commencement date at the present value of lease payments to be paid. Operating lease assets represent the Company&#8217;s right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments. To determine the present value of lease payments to be paid, the Company estimated incremental secured borrowing rates corresponding to the maturities of the leases. The Company estimated a rate of <ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="2" name="kprx:CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" scale="-2" id="f-798">10</ix:nonFraction>% based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company recognizes expense for its leases on a straight-line basis over the lease term. Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $<ix:nonFraction unitRef="usd" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="f-799">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-5" name="kprx:OperatingLeaseInterestOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-800">0.2</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-801" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Future annual minimum lease payments were as follows as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-802">105,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-803">1,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-804">103,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i0c0f301af22c434f89ac0b40b73502e6" continuedAt="i13aecd8120ea471aa37db1145bbc6c3c"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company is a party to <ix:nonFraction unitRef="licenseagreement" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="kprx:NumberOfLicenseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-805">seven</ix:nonFraction> license agreements as described below. These license agreements require the Company to pay or receive royalties or fees to or from the licensor based on revenue or milestones related to the licensed technology.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals GmbH) entered into a patent and know-how assignment agreement with 4SC Discovery GmbH (&#8220;4SC&#8221;) transferring to it all patent rights and know-how to the compound KIO-101. The Company is responsible for paying royalties of <ix:nonFraction unitRef="number" contextRef="i48105e35cedb4703a776e5dc694b2952_I20130702" decimals="4" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-806">3.25</ix:nonFraction>% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals, GmbH) entered into an out-license agreement with 4SC granting 4SC the exclusive worldwide right to commercialize the compound KIO-101 for rheumatoid arthritis and inflammatory bowel disease, including Crohn&#8217;s Disease and Ulcerative Colitis. The Company is eligible to receive milestone payments totaling up to &#8364;<ix:nonFraction unitRef="eur" contextRef="if26ec064aa5b44919c5571e6926241b3_D20130702-20130702" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-807">155</ix:nonFraction> million, upon and subject to the achievement of certain specified developmental and commercial milestones. We have not received any milestones from 4SC. In addition, the Company is eligible to receive royalties of <ix:nonFraction unitRef="number" contextRef="i48105e35cedb4703a776e5dc694b2952_I20130702" decimals="4" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-808">3.25</ix:nonFraction>% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;12, 2013, the Company (through its subsidiary, Jade Therapeutics, Inc.) entered into an agreement with Lineage Cell Therapeutics, Inc. (&#8220;Lineage&#8221;), formerly known as BioTime, Inc. granting to the Company the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (&#8220;modified HA&#8221;) for ophthalmic treatments in humans. The agreement requires the Company to pay an annual fee of $<ix:nonFraction unitRef="usd" contextRef="i076a9cb935ea4b94bb35bfd4c2edad1e_D20130912-20130912" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="f-809">30,000</ix:nonFraction> and a royalty of <ix:nonFraction unitRef="number" contextRef="ia857601644d14861b27f01abd39ba087_I20130912" decimals="2" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-810">6</ix:nonFraction>% on net sales of KIO-201 to Lineage based on revenue relating to any product incorporating the modified HA technology. The agreement expires when patent protection for the modified HA technology lapses in August 2027.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November&#160;17, 2014, the Company (through its subsidiary Kiora Pharmaceuticals GmbH) entered into an intellectual property and know-how licensing agreement with Laboratoires Leurquin Mediolanum S.A.S. (&#8220;Mediolanum&#8221;) for the commercialization of KIO-101 in specific territories. Under the Mediolanum agreement, the Company out-licensed rights to commercialize KIO-101 for uveitis, dry eye and viral conjunctivitis in Italy, and France. This agreement was amended on December 10, 2015 to also include Belgium and The Netherlands. Under the Mediolanum agreement, Mediolanum is obligated to pay up to approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="i33078441568940d896f1f0dc9f50a202_I20141117" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="f-811">20.0</ix:nonFraction>&#160;million in development and commercial milestones and a <ix:nonFraction unitRef="number" contextRef="i33078441568940d896f1f0dc9f50a202_I20141117" decimals="2" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-812">7</ix:nonFraction>% royalty on net sales of KIO-101 in the territories through the longer of the expiration of the valid patents covering KIO-101 or <ix:nonNumeric contextRef="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117" name="kprx:DevelopmentAndCommercialMilestonesTerm" format="ixt-sec:duryear" id="f-813">10</ix:nonNumeric> years from the first commercial sale. The royalty is reduced to <ix:nonFraction unitRef="number" contextRef="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117" decimals="2" name="kprx:PercentageOfDecreasedRoyaltyAfterPatentExpiry" scale="-2" id="f-814">5</ix:nonFraction>% after patent expiry.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;26, 2018, the Company entered into an intellectual property licensing agreement (the &#8220;SentrX Agreement&#8221;) with SentrX, a veterinary medical device company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, the Company in-licensed the rights to trade secrets and know-how related to the manufacturing of KIO-201. The SentrX Agreement enables the Company to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use. Under the SentrX Agreement, SentrX is eligible to receive milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i9dcf2ad2cdd04f2e8c2e583db3d2594b_I20180926" decimals="-4" name="kprx:IntangibleAssetsExpectedMilestonePayable" format="ixt:num-dot-decimal" scale="6" id="f-815">4.75</ix:nonFraction> million, upon and subject to the achievement of certain specified developmental and commercial milestones. The term of the agreement is until the product is no longer in the commercial marketplace.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May&#160;1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with the University of California (&#8220;UC&#8221;) granting to the Company the exclusive rights to its pipeline of photoswitch molecules. The agreement requires the Company to pay an annual fee to UC of $<ix:nonFraction unitRef="usd" contextRef="i7bfb95e5fdd6415fa8eab70b36245efa_D20200501-20200501" decimals="0" name="kprx:PaymentOfAnnualFee" format="ixt:num-dot-decimal" scale="0" id="f-816">5,000</ix:nonFraction>, as well as payments to UC upon the achievement of certain development milestone and royalties based on KIO-301 revenue. The Company is obligated to pay royalties on net sales of two percent (<ix:nonFraction unitRef="number" contextRef="icdd19ae6f91940c681c6752beffda62a_I20200501" decimals="2" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-817">2</ix:nonFraction>%) of the first $250 million of net sales, one and a quarter percent (<ix:nonFraction unitRef="number" contextRef="ic0bef4b71f5f45e382bf6c1ac713c7c7_I20200501" decimals="4" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-818">1.25</ix:nonFraction>%) of net sales between $250 million and $500 million, and one half of one percent (<ix:nonFraction unitRef="number" contextRef="if750165f4c9d4109955ee668d01b093e_I20200501" decimals="3" name="kprx:PercentageOfRoyaltiesOnNetSales" scale="-2" id="f-819">0.5</ix:nonFraction>%) of net sales over $500 million. The agreement expires on the date of the last-to-expire patent included in the licensed patent portfolio which is January 2030.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i13aecd8120ea471aa37db1145bbc6c3c"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May 1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with Photoswitch Therapeutics, Inc. (&#8220;Photoswitch&#8221;) granting to the Company access to certain patent applications and IP rights with last-to-expire patent terms of January 2030. The agreement calls for payments to Photoswitch upon the achievement of certain development and upon first commercial sale of the product.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The continued spread of the COVID-19 pandemic could adversely impact the Company&#8217;s clinical studies. In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, and business shutdowns. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which could negatively affect the Company&#8217;s ability to raise additional capital on attractive terms or at all. The extent to which COVID-19 may impact the Company&#8217;s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, and the effectiveness of actions to contain and treat COVID-19. The Company cannot presently predict the scope and severity of any potential disruptions to its business, including to ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to the Company&#8217;s ability to conduct its business in the manner and on the timelines presently planned, which could have a material adverse impact on its business, results of operation, and financial condition. As of the date of this report, there have been no material adverse effects to the Company&#8217;s ongoing business operations from COVID-19.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_181"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-820" continuedAt="i94110498538f452aba9be2d34a1b9e46" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i94110498538f452aba9be2d34a1b9e46"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made <ix:nonFraction unitRef="number" contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" format="ixt:fixed-zero" scale="-2" id="f-821">no</ix:nonFraction> matching contribution for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As a result of the 401(k) plan compliance review for the year ended December&#160;31, 2021, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231" decimals="-2" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-822">29.2</ix:nonFraction> thousand to eligible participants during the third quarter of 2022. As of December&#160;31, 2022, the Company has accrued an additional estimate of $<ix:nonFraction unitRef="usd" contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231" decimals="-2" name="kprx:DefinedBenefitPlanContributionsByEmployerAccrued" format="ixt:num-dot-decimal" scale="3" id="f-823">8.5</ix:nonFraction> thousand for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December&#160;31, 2022.</span></div></ix:continuation><div id="i33c11c03affd49a6944ca837f3a73528_184"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-824" continuedAt="i8537feef7f934a37b91ee1a7c83c228f" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="i8537feef7f934a37b91ee1a7c83c228f" continuedAt="i11b7f943d7c641db86ccb75473f5914e"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayon Therapeutics, Inc. Acquisition</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effective October 21, 2021, the Company acquired all of the capital stock of Bayon, a privately held ophthalmic specialty pharmaceutical company focused on developing light sensitive small molecules. With the Bayon acquisition, Bayon became a wholly-owned subsidiary of Kiora. The assets acquired and liabilities assumed have been recorded at fair value on the date of the acquisition. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill, which is not expected to be deductible for tax purposes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the terms of the Bayon acquisition agreement, in consideration for <ix:nonFraction unitRef="number" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-825">100</ix:nonFraction>% of the outstanding equity interests in Bayon, the Company paid cash in the amount of $<ix:nonFraction unitRef="usd" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-826">0.1</ix:nonFraction> million to certain sellers and creditors and issued <ix:nonFraction unitRef="shares" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="f-827">845</ix:nonFraction> shares of Kiora common stock. The former stockholders of Bayon are also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i0e569234706a4ea9b4ffdd899380ebbb_D20211021-20211021" decimals="-5" name="kprx:BusinessAcquisitionEarnoutConsideration" format="ixt:num-dot-decimal" scale="6" id="f-828">7.1</ix:nonFraction> million in additional cash or stock payments based on clinical trial and FDA approval milestones for Bayon&#8217;s product candidates, as set forth in the Purchase Agreement. If milestone payments are exercised for shares, shares will be issued at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i30888c172c61432abf146a3c8dd8bcc5_I20211021" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-829">80.40</ix:nonFraction> per share for the Phase 1b milestones. The remaining </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i11b7f943d7c641db86ccb75473f5914e"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">milestones will be calculated at a $<ix:nonFraction unitRef="usdPerShare" contextRef="i1fef671ae73846238e24d7b9e5c28b89_I20211021" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-830">132.00</ix:nonFraction> per share. The cash or stock earn-out payments were recorded as contingent consideration and fair valued at $<ix:nonFraction unitRef="usd" contextRef="id863c423f1fb4e25825a1e8a560df47a_D20211021-20211021" decimals="-5" name="kprx:PaymentsToAcquireBusinessesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-831">1.0</ix:nonFraction> million at the acquisition date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The fair value of the shares issued in the Bayon acquisition was approximately $<ix:nonFraction unitRef="usd" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-832">0.1</ix:nonFraction> million based on the average closing price of the Company&#8217;s Common Stock for <ix:nonFraction unitRef="day" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="INF" name="kprx:ThresholdPeriodOfVolumeWeightedAveragePrice" format="ixt-sec:numwordsen" scale="0" id="f-833">five</ix:nonFraction> trading days immediately preceding the closing date, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="2" name="kprx:VolumeWeightedAveragePrice" scale="0" id="f-834">80.40</ix:nonFraction> per share.</span></div><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-835" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayon</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-836">5,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-837">1,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="kprx:GoodwillAcquired" format="ixt:num-dot-decimal" scale="0" id="f-838">406,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="kprx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-839">36,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-840">265,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="0" id="f-841">1,172,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">_____________________________</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets include cash and receivables of $<ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="-2" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-842">3.9</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="-2" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-843">1.4</ix:nonFraction> thousand, respectively.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt"><ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="kprx:SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" id="f-844" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration at fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="0" name="kprx:BusinessCombinationContingentConsiderationArrangementsFairValue" format="ixt:num-dot-decimal" scale="0" id="f-845">1,007,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021" decimals="0" name="kprx:BusinessCombinationContingentConsiderationCashCurrent" format="ixt:num-dot-decimal" scale="0" id="f-846">97,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="f-847">845</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6e223d2316642d58da08e015cef85be_I20211021" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-848">80.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="0" id="f-849">67,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Fair Value of Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="0" id="f-850">1,172,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss in the Consolidated Statement of Operations for the twelve months ended December 31, 2021 includes net losses of Bayon of $<ix:nonFraction unitRef="usd" contextRef="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-851">0.1</ix:nonFraction> million from the date of acquisition. The acquired intangible assets, which consist solely of in-process research and development, will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the intangible assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-852">0.1</ix:nonFraction> million of acquisition-related costs for the Bayon acquisition that were expensed in the year ended December 31, 2021 as a component of general and administrative expense.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div id="i33c11c03affd49a6944ca837f3a73528_2748779070063"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="f-853" continuedAt="ie587b3e0921243c8874fde9a004a0ade" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="ie587b3e0921243c8874fde9a004a0ade" continuedAt="i9782175302714489802cbb713fcdb9f4"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;3, 2023, the Company completed a private placement with Lincoln Park for <ix:nonFraction unitRef="shares" contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-854">52,798</ix:nonFraction> shares of common stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i7604460adc254f1e9a1bf2330d64d148_I20230203" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-855">105,596</ix:nonFraction> shares of common stock. The total net proceeds from the private placement were approximately $<ix:nonFraction unitRef="usd" contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-856">0.2</ix:nonFraction> million. The warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7604460adc254f1e9a1bf2330d64d148_I20230203" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-857">3.538</ix:nonFraction> per share, subject to adjustments as provided under the terms of the warrants, and will be exercisable on the <ix:nonNumeric contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203" name="kprx:WarrantsExercisableAnniversaryOfClosingDatePeriod" format="ixt-sec:durwordsen" id="f-858">six-month</ix:nonNumeric> anniversary of the closing date. The warrants are exercisable for <ix:nonNumeric contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203" name="kprx:WarrantTerm" format="ixt-sec:durwordsen" id="f-859">five years</ix:nonNumeric> from the issuance date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;3, 2023, the Company entered into a purchase agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i370500edd4064c70bf772759a785cc00_D20230203-20230203" decimals="-5" name="kprx:SharePurchaseAgreementSaleOfStockMaximumAmount" format="ixt:num-dot-decimal" scale="6" id="f-860">10.0</ix:nonFraction> million of common stock (subject to certain limitations), from time to time and at the Company's sole discretion over the term of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i9782175302714489802cbb713fcdb9f4"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">purchase agreement. On February&#160;22, 2023, the Company completed its first issuance under this agreement for a total of <ix:nonFraction unitRef="shares" contextRef="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-861">20,000</ix:nonFraction> shares sold to Lincoln Park for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222" decimals="-5" name="kprx:ProceedsFromSaleOfStockSharePurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-862">0.1</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;10, 2023, a holder exercised Inducement Warrants resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210" decimals="INF" name="kprx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-863">50,000</ix:nonFraction> shares of common stock and proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="f-864">0.3</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">F-31</span></div></div></div><div id="i33c11c03affd49a6944ca837f3a73528_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#i33c11c03affd49a6944ca837f3a73528_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:24pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Brian M. Strem</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer </span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President of Finance</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:30.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Brian M. Strem</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian M. Strem</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Melissa Tosca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President of Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Melissa Tosca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Paul Chaney</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paul Chaney</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth Gayron</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth Gayron</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Praveen Tyle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praveen Tyle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Hollander</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Hollander</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Aron Shapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aron Shapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Erin Parsons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 23, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Erin Parsons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">92</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex231-20221231xkprx.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie192b2f0f178469c8f92708ad61f272e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exhibit 23.1</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements of Kiora Pharmaceuticals, Inc. (formerly Eyegate Pharmaceuticals, Inc.) on Form S-1 (Nos. 333-269570 and 333-268940), Form S-3 (Nos. 333-255311 and 333-234255) and on Form S-8 (Nos. 333-267754, 333-264640, 333-241657, 333-202207, 333-209441, 333-216227, 333-223431 and 333-231207) of our report dated March 23, 2023, on our audit of the financial statements as of December 31, 2022 and 2021, and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 23, 2023.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; EisnerAmper LLP</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EISNERAMPER LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Iselin, New Jersey</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;23, 2023</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311-20221231xkprx.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i13f80e8969844289a0d0ae7f148f845b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian M. Strem, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Kiora Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:14.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal executive officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312-20221231xkprx.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7fc22fdaf28b4549848dce28fe5166d1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Melissa Tosca, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Kiora Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:14.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Executive Vice President of Finance</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal financial and accounting officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321-20221231xkprx.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4f7e1ba54ea74cd38c569460666cac63_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC FINANCIAL REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officer of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) hereby certifies to his knowledge that the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (&#8220;Item 601(b)(32)&#8221;) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal executive officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex322-20221231xkprx.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ide5e03a7ecaf48d7b90f178221371086_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC FINANCIAL REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officer of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) hereby certifies to his knowledge that the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (&#8220;Item 601(b)(32)&#8221;) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Executive Vice President of Finance</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal financial and accounting officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>kprx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.eyegatepharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessPresentationandRecentAccountingPronouncements" roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements">
        <link:definition>0000009 - Disclosure - Business, Presentation and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.eyegatepharma.com/role/FairValue">
        <link:definition>0000011 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.eyegatepharma.com/role/PropertyandEquipment">
        <link:definition>0000012 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.eyegatepharma.com/role/AccruedExpenses">
        <link:definition>0000013 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.eyegatepharma.com/role/Debt">
        <link:definition>0000014 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandInProcessRD" roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD">
        <link:definition>0000015 - Disclosure - Intangible Assets and In-Process R&amp;D</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStock" roleURI="http://www.eyegatepharma.com/role/CapitalStock">
        <link:definition>0000016 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.eyegatepharma.com/role/Warrants">
        <link:definition>0000017 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlan" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlan">
        <link:definition>0000018 - Disclosure - Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.eyegatepharma.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.eyegatepharma.com/role/EmployeeBenefitPlans">
        <link:definition>0000021 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.eyegatepharma.com/role/Acquisitions">
        <link:definition>0000022 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.eyegatepharma.com/role/SubsequentEvents">
        <link:definition>0000023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.eyegatepharma.com/role/FairValueTables">
        <link:definition>0000026 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentTables">
        <link:definition>0000027 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.eyegatepharma.com/role/AccruedExpensesTables">
        <link:definition>0000028 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandInProcessRDTables" roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables">
        <link:definition>0000029 - Disclosure - Intangible Assets and In-Process R&amp;D (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.eyegatepharma.com/role/WarrantsTables">
        <link:definition>0000030 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanTables" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanTables">
        <link:definition>0000031 - Disclosure - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesTables">
        <link:definition>0000032 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.eyegatepharma.com/role/AcquisitionsTables">
        <link:definition>0000034 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessPresentationandRecentAccountingPronouncementsDetails" roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails">
        <link:definition>0000035 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails" roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails">
        <link:definition>0000038 - Disclosure - Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" roleURI="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details">
        <link:definition>0000039 - Disclosure - Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details" roleURI="http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details">
        <link:definition>0000040 - Disclosure - Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails">
        <link:definition>0000041 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.eyegatepharma.com/role/AccruedExpensesDetails">
        <link:definition>0000043 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.eyegatepharma.com/role/DebtDetails">
        <link:definition>0000044 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandInProcessRDAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails">
        <link:definition>0000045 - Disclosure - Intangible Assets and In-Process R&amp;D - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails">
        <link:definition>0000046 - Disclosure - Intangible Assets and In-Process R&amp;D -Intangible assets and in-process R&amp;D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails" roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails">
        <link:definition>0000047 - Disclosure - Intangible Assets and In-Process R&amp;D - Future Annual Intangible Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockDetails" roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails">
        <link:definition>0000048 - Disclosure - Capital Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsDetails" roleURI="http://www.eyegatepharma.com/role/WarrantsDetails">
        <link:definition>0000049 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanDetails" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanDetails">
        <link:definition>0000050 - Disclosure - Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails">
        <link:definition>0000051 - Disclosure - Equity Incentive Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanWeightedAverageAssumptionsDetails" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails">
        <link:definition>0000052 - Disclosure - Equity Incentive Plan - Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanRestrictedStockActivityDetails" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails">
        <link:definition>0000053 - Disclosure - Equity Incentive Plan - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlanStockbasedCompensationDetails" roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails">
        <link:definition>0000054 - Disclosure - Equity Incentive Plan - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoflossbeforeincometaxesDetails" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails">
        <link:definition>0000055 - Disclosure - Income Taxes -Components of loss before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofincometaxbenefitexpenseDetails" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Components of income tax (benefit) expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofeffectivetaxrateDetails" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredtaxassetsandliabilitiesDetails" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000058 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000060 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000061 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000062 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails">
        <link:definition>0000063 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPurchasepriceallocationDetails" roleURI="http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails">
        <link:definition>0000064 - Disclosure - Acquisitions - Purchase price allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsFairvalueofconsiderationDetails" roleURI="http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails">
        <link:definition>0000065 - Disclosure - Acquisitions - Fair value of consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.eyegatepharma.com/role/SubsequentEventsDetails">
        <link:definition>0000066 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="kprx_LesseeNumberOfOperatingLeases" abstract="false" name="LesseeNumberOfOperatingLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_SuccessfulCompletionOfPhase2Member" abstract="true" name="SuccessfulCompletionOfPhase2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_SuccessfulCompletionOfPhase3Member" abstract="true" name="SuccessfulCompletionOfPhase3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_BeginningOfPhase3Member" abstract="true" name="BeginningOfPhase3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_MilestoneTypeAxis" abstract="true" name="MilestoneTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_VolumeWeightedAveragePrice" abstract="false" name="VolumeWeightedAveragePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_Kio101Member" abstract="true" name="Kio101Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_BayonAcquisitionMember" abstract="true" name="BayonAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_PrivatePlacementWarrantsMember" abstract="true" name="PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" abstract="false" name="SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_UnderwritingDiscountAndCommissionsExpenses" abstract="false" name="UnderwritingDiscountAndCommissionsExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" abstract="false" name="ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_IntangibleAssetsExpectedMilestonePayable" abstract="false" name="IntangibleAssetsExpectedMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IfMilestonePaymentsAreExercisedForSharesMember" abstract="true" name="IfMilestonePaymentsAreExercisedForSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" abstract="true" name="ShareBasedCompensationOptionAndIncentivePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" abstract="false" name="WarrantsExercisableAnniversaryOfClosingDatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_NetSalesOver500MillionMember" abstract="true" name="NetSalesOver500MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" abstract="false" name="ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_ContingentConsiderationScenarioAxis" abstract="true" name="ContingentConsiderationScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_SuccessfulCompletionOfPhase1Member" abstract="true" name="SuccessfulCompletionOfPhase1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_WarrantsDisclosureTextBlock" abstract="false" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_DueToCreditorMember" abstract="true" name="DueToCreditorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_SharesIssuedPricePerCommonShares" abstract="false" name="SharesIssuedPricePerCommonShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_PreferredStockDesignatedShares" abstract="false" name="PreferredStockDesignatedShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_FdaApprovalMember" abstract="true" name="FdaApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_GoodwillAcquired" abstract="false" name="GoodwillAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_OperatingLeaseInterestOnLeaseLiabilities" abstract="false" name="OperatingLeaseInterestOnLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" abstract="false" name="StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" abstract="false" name="SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_EarnOutConsiderationMember" abstract="true" name="EarnOutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_MediolanumAgreementMember" abstract="true" name="MediolanumAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_JadeTherapeuticSIncMember" abstract="true" name="JadeTherapeuticSIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_CashOutflowFromLoanForgiveness" abstract="false" name="CashOutflowFromLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ClinicalStudiesServicesKIO301Member" abstract="true" name="ClinicalStudiesServicesKIO301Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_BayonMember" abstract="true" name="BayonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" abstract="false" name="ProceedsFromSaleOfStockSharePurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" abstract="false" name="NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_DefinedBenefitPlanContributionsByEmployerAccrued" abstract="false" name="DefinedBenefitPlanContributionsByEmployerAccrued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_BusinessAcquisitionEarnoutConsideration" abstract="false" name="BusinessAcquisitionEarnoutConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" abstract="false" name="IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" abstract="false" name="NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_ChangeInContingentConsiderationFairValue" abstract="false" name="ChangeInContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_RoyaltyScenarioAxis" abstract="true" name="RoyaltyScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_NumberOfGeographicSegments" abstract="false" name="NumberOfGeographicSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_FairValueContingentConsiderationAbstract" abstract="true" name="FairValueContingentConsiderationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_BusinessAcquisitionHoldbackSharesTerm" abstract="false" name="BusinessAcquisitionHoldbackSharesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_MilestoneTypeDomain" abstract="true" name="MilestoneTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_RemainingMilestonesMember" abstract="true" name="RemainingMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_PanoptesAcquisitionMember" abstract="true" name="PanoptesAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" abstract="false" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" abstract="false" name="FiniteLivedIntangibleAssetsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" abstract="true" name="HoldersOwingMoreThanTenPercentageVotingRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_AccruedClinicalExpensesPolicyTextBlock" abstract="false" name="AccruedClinicalExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_BusinessCombinationContingentConsiderationCashCurrent" abstract="false" name="BusinessCombinationContingentConsiderationCashCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClinicalTrialsCurrent" abstract="false" name="ClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_PercentageOfRoyaltiesOnNetSales" abstract="false" name="PercentageOfRoyaltiesOnNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_SentrXAnimalCareIncMember" abstract="true" name="SentrXAnimalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodValueWarrantInducement" abstract="false" name="StockIssuedDuringPeriodValueWarrantInducement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_NumberOfLicenseAgreements" abstract="false" name="NumberOfLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" abstract="false" name="PaymentsForFractionalSharesRelatedToReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" abstract="false" name="CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_UnderwritingDiscountAndCommissions" abstract="false" name="UnderwritingDiscountAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_PaymentsToAcquireBusinessesFairValue" abstract="false" name="PaymentsToAcquireBusinessesFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_Between250And500MillionNetSalesMember" abstract="true" name="Between250And500MillionNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" abstract="false" name="Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_SharePurchasePriceOfCommonStockAndWarrant" abstract="false" name="SharePurchasePriceOfCommonStockAndWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_WarrantsAbstract" abstract="true" name="WarrantsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_PaymentOfAnnualFee" abstract="false" name="PaymentOfAnnualFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" abstract="false" name="WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" abstract="false" name="StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_SeriesdConvertiblePreferredStockMember" abstract="true" name="SeriesdConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_IncreaseDecreaseInRightOfUseAssets" abstract="false" name="IncreaseDecreaseInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_AccountingPoliciesLineItems" abstract="true" name="AccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" abstract="false" name="StockIssuedDuringPeriodSharesFromHoldBackShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" abstract="false" name="PercentageOfDecreasedRoyaltyAfterPatentExpiry" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_PercentageOfExercisePrice" abstract="false" name="PercentageOfExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_RelatedPartyTransactionsNumberOfUniversities" abstract="false" name="RelatedPartyTransactionsNumberOfUniversities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_ClassAWarrantMember" abstract="true" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" abstract="false" name="StockAdjustmentDuringPeriodSharesReverseStockSplits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_PhaseOneBMilestonesMember" abstract="true" name="PhaseOneBMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" abstract="false" name="ClassOfWarrantOrRightPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_RelatedPartyTransactionsNumberOfConsultants" abstract="false" name="RelatedPartyTransactionsNumberOfConsultants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_RelatedPartyTransactionsPolicyTextBlock" abstract="false" name="RelatedPartyTransactionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_RelatedPartyTransactionsNumberOfVendors" abstract="false" name="RelatedPartyTransactionsNumberOfVendors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodSharesWarrantInducement" abstract="false" name="StockIssuedDuringPeriodSharesWarrantInducement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_PanoptesPharmaGes.m.b.h.Member" abstract="true" name="PanoptesPharmaGes.m.b.h.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_AccountingPoliciesTable" abstract="true" name="AccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_RoyaltyScenarioDomain" abstract="true" name="RoyaltyScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_WarrantConvertibleIntoCommonStockBasis" abstract="false" name="WarrantConvertibleIntoCommonStockBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_PanoptesPharmaGesMbhMember" abstract="true" name="PanoptesPharmaGesMbhMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ForFirst250MillionNetSalesMember" abstract="true" name="ForFirst250MillionNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" abstract="false" name="ThresholdPeriodOfVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" abstract="false" name="EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_WarrantsConvertibleIntoCommonStock" abstract="false" name="WarrantsConvertibleIntoCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_ContingentConsiderationScenarioDomain" abstract="true" name="ContingentConsiderationScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" abstract="true" name="ClassOfWarrantOrRightNumberOfAwardsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" abstract="true" name="MeasurementInputProbabilityOfSuccessForPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" abstract="false" name="SharePurchaseAgreementSaleOfStockMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_GrantOfRestrictedStockAwards" abstract="false" name="GrantOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_WarrantExercisePricePerShareSubjectToAdjustment" abstract="false" name="WarrantExercisePricePerShareSubjectToAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_StockAdjustedDuringPeriodValueReverseStockSplits" abstract="false" name="StockAdjustedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" abstract="false" name="AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_WarrantIssuancePlacementAgentFees" abstract="false" name="WarrantIssuancePlacementAgentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_JadeMember" abstract="true" name="JadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" abstract="false" name="Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_DevelopmentAndCommercialMilestonesTerm" abstract="false" name="DevelopmentAndCommercialMilestonesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_InducementWarrantMember" abstract="true" name="InducementWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassAWarrantsExerciseOfOptionMember" abstract="true" name="ClassAWarrantsExerciseOfOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_WarrantTerm" abstract="false" name="WarrantTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_ProceedsFromWarrantExercisesAndWarrantSales" abstract="false" name="ProceedsFromWarrantExercisesAndWarrantSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ClassBWarrantExerciseOfOptionMember" abstract="true" name="ClassBWarrantExerciseOfOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassBWarrantMember" abstract="true" name="ClassBWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_CommonSharesMember" abstract="true" name="CommonSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>kprx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_12a5ec06-bf98-48b2-9f5d-95c8c03cac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1645dd6f-8a4c-4d32-9cc4-4e1aac3b790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12a5ec06-bf98-48b2-9f5d-95c8c03cac7a" xlink:to="loc_us-gaap_AccountsPayableCurrent_1645dd6f-8a4c-4d32-9cc4-4e1aac3b790e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b422ce4d-5473-499f-912f-fc86dcd11340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12a5ec06-bf98-48b2-9f5d-95c8c03cac7a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b422ce4d-5473-499f-912f-fc86dcd11340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_05fce33c-f581-4b75-8127-51191855c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12a5ec06-bf98-48b2-9f5d-95c8c03cac7a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_05fce33c-f581-4b75-8127-51191855c5c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ef25711-e073-421f-92d3-bb65413cc01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12a5ec06-bf98-48b2-9f5d-95c8c03cac7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ef25711-e073-421f-92d3-bb65413cc01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_719e2210-d719-4072-84cb-ab1a1c1f293d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4ccbb040-8929-49e3-a5cd-4f78d99b44c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_719e2210-d719-4072-84cb-ab1a1c1f293d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4ccbb040-8929-49e3-a5cd-4f78d99b44c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f68ce303-4943-4c27-a766-51ae6046de37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_719e2210-d719-4072-84cb-ab1a1c1f293d" xlink:to="loc_us-gaap_LiabilitiesCurrent_f68ce303-4943-4c27-a766-51ae6046de37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_051f1a9f-99c7-4356-9695-2f7b59e9c7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_AssetsCurrent_051f1a9f-99c7-4356-9695-2f7b59e9c7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c7ce65e1-bff9-471f-ae25-8a182db67dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c7ce65e1-bff9-471f-ae25-8a182db67dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_17759f42-661a-4860-824b-b22e9eaabcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_17759f42-661a-4860-824b-b22e9eaabcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_126dd1d2-e408-4443-9c67-bd64a4c829f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_126dd1d2-e408-4443-9c67-bd64a4c829f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e9484fd6-8d48-47b6-b3f0-1054fe11cad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e9484fd6-8d48-47b6-b3f0-1054fe11cad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_080dd959-a133-4a79-b1f3-1cbf770d7f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8e214d46-1b27-484c-abf9-aee49d5978c3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_080dd959-a133-4a79-b1f3-1cbf770d7f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c86d82ad-ec15-45e4-b7ec-df960bf65aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb7ab02-24f1-4860-862c-790f15811b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c86d82ad-ec15-45e4-b7ec-df960bf65aad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb7ab02-24f1-4860-862c-790f15811b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_58028268-a82d-477c-b0ea-8552409dbcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c86d82ad-ec15-45e4-b7ec-df960bf65aad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_58028268-a82d-477c-b0ea-8552409dbcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_f96ddd94-8252-4e36-b79c-9698cef2d715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c86d82ad-ec15-45e4-b7ec-df960bf65aad" xlink:to="loc_us-gaap_IncomeTaxesReceivable_f96ddd94-8252-4e36-b79c-9698cef2d715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_512472ae-66a2-4a2a-8d20-9ec6bf1adb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0201ba9b-dbc7-491e-a88b-1b27d622a43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_512472ae-66a2-4a2a-8d20-9ec6bf1adb1a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0201ba9b-dbc7-491e-a88b-1b27d622a43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_28ccd61c-537c-4162-b7ba-34ccaf41fe08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_512472ae-66a2-4a2a-8d20-9ec6bf1adb1a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_28ccd61c-537c-4162-b7ba-34ccaf41fe08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e4b0fa4-1996-42d0-98da-5e87b9a377b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_512472ae-66a2-4a2a-8d20-9ec6bf1adb1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e4b0fa4-1996-42d0-98da-5e87b9a377b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7d0e171-02e8-443d-88ad-17092619895b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_299a2d37-fad9-4d9d-9839-b0f7a5a5ae70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7d0e171-02e8-443d-88ad-17092619895b" xlink:to="loc_us-gaap_Liabilities_299a2d37-fad9-4d9d-9839-b0f7a5a5ae70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff8682bd-cb51-4647-8502-1bbfb8f82edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7d0e171-02e8-443d-88ad-17092619895b" xlink:to="loc_us-gaap_StockholdersEquity_ff8682bd-cb51-4647-8502-1bbfb8f82edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3d0b9a94-bd30-40ce-993d-e78ce41ad89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7d0e171-02e8-443d-88ad-17092619895b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3d0b9a94-bd30-40ce-993d-e78ce41ad89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3f65329b-d043-4ac7-81bb-f9710136c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:to="loc_us-gaap_PreferredStockValue_3f65329b-d043-4ac7-81bb-f9710136c82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b0748fec-22e0-474c-b824-ac927b8ec30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:to="loc_us-gaap_CommonStockValue_b0748fec-22e0-474c-b824-ac927b8ec30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9238d86a-2693-4331-8290-efc025465c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9238d86a-2693-4331-8290-efc025465c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6991a745-135d-462b-9ea8-93958dd23df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6991a745-135d-462b-9ea8-93958dd23df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10890937-57d3-45bb-85ac-0947e7c49420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c8af618d-a23d-49c8-b26b-4ab64291147b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10890937-57d3-45bb-85ac-0947e7c49420" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74eac15e-705d-4cb1-a84c-12912c2c6da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e44d0334-548b-48cf-99f1-2450e7ffb287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74eac15e-705d-4cb1-a84c-12912c2c6da0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e44d0334-548b-48cf-99f1-2450e7ffb287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_971b9b1e-e57b-45a3-8b88-f3ce1fbc8dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74eac15e-705d-4cb1-a84c-12912c2c6da0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_971b9b1e-e57b-45a3-8b88-f3ce1fbc8dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6dba878f-f135-4009-9ad8-52e74dfa7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b1daaac-cd1b-4a52-b58c-b965b034034e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6dba878f-f135-4009-9ad8-52e74dfa7d84" xlink:to="loc_us-gaap_NetIncomeLoss_3b1daaac-cd1b-4a52-b58c-b965b034034e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ca010b35-a5cc-46f5-bcb7-9568ac327b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6dba878f-f135-4009-9ad8-52e74dfa7d84" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ca010b35-a5cc-46f5-bcb7-9568ac327b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_73bcb91f-56fa-42ce-b01d-daad3ba3e415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d8fe5c80-e98c-4fae-b3f6-3b6e22737383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73bcb91f-56fa-42ce-b01d-daad3ba3e415" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d8fe5c80-e98c-4fae-b3f6-3b6e22737383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9dca6cfa-2763-4dbb-bc25-36b2b84ff379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73bcb91f-56fa-42ce-b01d-daad3ba3e415" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9dca6cfa-2763-4dbb-bc25-36b2b84ff379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_830c6a18-4059-46d1-a9d9-b55914ab378f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73bcb91f-56fa-42ce-b01d-daad3ba3e415" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_830c6a18-4059-46d1-a9d9-b55914ab378f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fc442936-c44a-43f3-bb6e-5b15f3cabe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73bcb91f-56fa-42ce-b01d-daad3ba3e415" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fc442936-c44a-43f3-bb6e-5b15f3cabe79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f432182-4e40-4dc2-ba17-40b7c2ea2c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_04bce389-f4fc-470b-bde6-8db6682918ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f432182-4e40-4dc2-ba17-40b7c2ea2c67" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_04bce389-f4fc-470b-bde6-8db6682918ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60d3611c-d9c5-4dbc-affa-e83d7276a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f432182-4e40-4dc2-ba17-40b7c2ea2c67" xlink:to="loc_us-gaap_OperatingIncomeLoss_60d3611c-d9c5-4dbc-affa-e83d7276a8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_11322925-085a-4d53-b2dc-6e259fbd4d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_11322925-085a-4d53-b2dc-6e259fbd4d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_390a6a2a-8f0f-45f8-ae7a-7532589a94ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_390a6a2a-8f0f-45f8-ae7a-7532589a94ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f1fdd63-ff40-485f-8f92-b0af0592ec02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f1fdd63-ff40-485f-8f92-b0af0592ec02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a49482dd-4beb-416a-8f88-b9eebc571da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_InterestExpense_a49482dd-4beb-416a-8f88-b9eebc571da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ddf4c3f2-60f1-45ce-8930-6ba7acc03301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ddf4c3f2-60f1-45ce-8930-6ba7acc03301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_358b4a68-878c-46f2-a1e0-ef2940cb2af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_bda48976-d679-4d27-8b7c-e1537606b57e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_358b4a68-878c-46f2-a1e0-ef2940cb2af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef2fb557-c36e-4355-b68e-4d5c7751d322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_95d88026-b821-41ac-b75c-fd4813f5e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef2fb557-c36e-4355-b68e-4d5c7751d322" xlink:to="loc_us-gaap_OperatingExpenses_95d88026-b821-41ac-b75c-fd4813f5e3e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b5e9d8f-32fb-427d-a361-69d81bfbcb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2692d973-2b76-404d-9739-8d2ea0205ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b5e9d8f-32fb-427d-a361-69d81bfbcb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2692d973-2b76-404d-9739-8d2ea0205ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b33fdc-092f-4148-89f4-6d997db101ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b5e9d8f-32fb-427d-a361-69d81bfbcb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b33fdc-092f-4148-89f4-6d997db101ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b020a2e-bd45-45a0-899d-2ccce390300d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b5e9d8f-32fb-427d-a361-69d81bfbcb7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b020a2e-bd45-45a0-899d-2ccce390300d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26526330-0315-4f22-af12-1b22dabb2b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b5e9d8f-32fb-427d-a361-69d81bfbcb7a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26526330-0315-4f22-af12-1b22dabb2b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f1c4d3a-d78a-4882-850a-4df584082e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_NetIncomeLoss_4f1c4d3a-d78a-4882-850a-4df584082e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fdd126d-ab23-4119-a3d0-470f191a56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fdd126d-ab23-4119-a3d0-470f191a56f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_ad68dcb9-3df8-460a-8c87-438f2dcdf9d6" xlink:href="kprx-20221231.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_ad68dcb9-3df8-460a-8c87-438f2dcdf9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_b2b3c37e-22d4-4911-809f-0946a3cdbd28" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_b2b3c37e-22d4-4911-809f-0946a3cdbd28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd31d948-1cb5-43c6-b3c7-e38986f42685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_ShareBasedCompensation_cd31d948-1cb5-43c6-b3c7-e38986f42685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3c249c9a-dba3-4dd9-be40-40b1f3727f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3c249c9a-dba3-4dd9-be40-40b1f3727f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CashOutflowFromLoanForgiveness_47dcfc4f-dac6-4043-89bd-7c221dd5e36a" xlink:href="kprx-20221231.xsd#kprx_CashOutflowFromLoanForgiveness"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_kprx_CashOutflowFromLoanForgiveness_47dcfc4f-dac6-4043-89bd-7c221dd5e36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_11c458dd-2087-4686-bc81-02750dc1997d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_11c458dd-2087-4686-bc81-02750dc1997d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9b5eff4-6585-4512-a019-40830e5df057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9b5eff4-6585-4512-a019-40830e5df057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_47a57d8e-be65-4fe6-8ba5-a534c269534a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_47a57d8e-be65-4fe6-8ba5-a534c269534a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dc66996d-4997-4de0-bc7d-75cdab4da973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dc66996d-4997-4de0-bc7d-75cdab4da973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9528df4-48d8-4e97-bbd4-d4b5aaac6ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9528df4-48d8-4e97-bbd4-d4b5aaac6ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8ff59285-fa3f-44d5-976e-18f694a7a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8ff59285-fa3f-44d5-976e-18f694a7a97c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b00ece8b-651e-43ec-93da-f9cef3862c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b00ece8b-651e-43ec-93da-f9cef3862c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c4d2ee15-0674-4e4f-98d6-96fc71e5bda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c4d2ee15-0674-4e4f-98d6-96fc71e5bda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5f82ae8f-acfb-4265-8c01-293746d58750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24b03013-d20c-4f78-a580-7f424ef4026d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5f82ae8f-acfb-4265-8c01-293746d58750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c3cf55f4-bf99-411c-8a99-103ba618407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c3cf55f4-bf99-411c-8a99-103ba618407b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_387e63d4-e70f-476f-9794-ee4594adb114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_387e63d4-e70f-476f-9794-ee4594adb114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_edd5b178-0073-4973-b86d-f6a334da559f" xlink:href="kprx-20221231.xsd#kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:to="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_edd5b178-0073-4973-b86d-f6a334da559f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_6c904410-85fc-41bc-a467-b29dcde72222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_6c904410-85fc-41bc-a467-b29dcde72222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_380bccdb-a8ed-4269-8bf0-0e3c5279f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa882c5d-a20b-4a6f-966c-c019c01d98d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_380bccdb-a8ed-4269-8bf0-0e3c5279f10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6f04a3d-946a-4679-a57d-fb7bdf1525b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_219efe68-b2bf-4b99-a0f8-bffc00c99d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6f04a3d-946a-4679-a57d-fb7bdf1525b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_219efe68-b2bf-4b99-a0f8-bffc00c99d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_336daf88-72f0-42a4-b9dd-9145bcd40300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6f04a3d-946a-4679-a57d-fb7bdf1525b8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_336daf88-72f0-42a4-b9dd-9145bcd40300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_44eba940-ee59-49bd-a00c-4c93afa25f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6f04a3d-946a-4679-a57d-fb7bdf1525b8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_44eba940-ee59-49bd-a00c-4c93afa25f12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_25a7d27a-17f4-4afe-a667-6420520b74c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3a70c739-d34e-4678-bec5-b42e46a4f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_25a7d27a-17f4-4afe-a667-6420520b74c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_3a70c739-d34e-4678-bec5-b42e46a4f57c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_341fa139-e421-46f5-a472-df167ad591b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_25a7d27a-17f4-4afe-a667-6420520b74c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_341fa139-e421-46f5-a472-df167ad591b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c9adac4e-c330-42b8-9ee3-30af1bdbe0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4beb358e-2d48-48f5-b4ed-c64a3ad914de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c9adac4e-c330-42b8-9ee3-30af1bdbe0dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4beb358e-2d48-48f5-b4ed-c64a3ad914de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_34d83080-ed96-4df9-b506-2f5feef6d9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c9adac4e-c330-42b8-9ee3-30af1bdbe0dc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_34d83080-ed96-4df9-b506-2f5feef6d9cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2aa20ff5-20c1-4729-b042-53ab2530941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15bcabd1-372a-49db-9592-c3c15fd64ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2aa20ff5-20c1-4729-b042-53ab2530941e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15bcabd1-372a-49db-9592-c3c15fd64ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5bf87326-c1dd-414c-8730-0dfe027c89c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2aa20ff5-20c1-4729-b042-53ab2530941e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5bf87326-c1dd-414c-8730-0dfe027c89c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c6ae8b22-d33d-40c4-9120-5c29cf6222b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2aa20ff5-20c1-4729-b042-53ab2530941e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c6ae8b22-d33d-40c4-9120-5c29cf6222b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent_270f4a04-dc1d-4ae9-b31b-2a90f78cb7c7" xlink:href="kprx-20221231.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2aa20ff5-20c1-4729-b042-53ab2530941e" xlink:to="loc_kprx_ClinicalTrialsCurrent_270f4a04-dc1d-4ae9-b31b-2a90f78cb7c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f78f6987-f9d5-499c-8248-0d3be0e4d16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5751864-4d73-44f4-9b3f-c83a6a7f5bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f78f6987-f9d5-499c-8248-0d3be0e4d16a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5751864-4d73-44f4-9b3f-c83a6a7f5bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_430247ef-8275-4e5f-90ba-2f87b1d28e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f78f6987-f9d5-499c-8248-0d3be0e4d16a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_430247ef-8275-4e5f-90ba-2f87b1d28e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_56cc54b0-f6e3-4424-a115-06a2bfd90dca" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f72c8e76-4bac-44ae-ac5e-d43d1b2316a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_56cc54b0-f6e3-4424-a115-06a2bfd90dca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f72c8e76-4bac-44ae-ac5e-d43d1b2316a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_323f662e-5c13-4f1a-927d-94790e552fce" xlink:href="kprx-20221231.xsd#kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_56cc54b0-f6e3-4424-a115-06a2bfd90dca" xlink:to="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_323f662e-5c13-4f1a-927d-94790e552fce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ea959dbb-d478-48f9-8e20-88aff7c96034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ea959dbb-d478-48f9-8e20-88aff7c96034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02abb9d5-46d0-4fd0-b3a4-bf025a3b8aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02abb9d5-46d0-4fd0-b3a4-bf025a3b8aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d318c648-f4d9-4fe4-a283-7a1724581071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d318c648-f4d9-4fe4-a283-7a1724581071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_932443a6-b6c4-43ea-bf20-ffc34c3142e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_932443a6-b6c4-43ea-bf20-ffc34c3142e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9004f7e8-b2ec-436d-8eed-3c310e945de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9004f7e8-b2ec-436d-8eed-3c310e945de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0a13a8f6-1124-4012-92ca-781f4456d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d555c659-2be8-42a1-b26e-07313da4487c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0a13a8f6-1124-4012-92ca-781f4456d56d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesComponentsoflossbeforeincometaxesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be3cc604-0508-4072-832b-746d73873bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be6369a5-0485-4d93-acde-13c27a1c3507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be3cc604-0508-4072-832b-746d73873bc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be6369a5-0485-4d93-acde-13c27a1c3507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e26b9090-da1d-4ead-91a2-15c642fc17ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be3cc604-0508-4072-832b-746d73873bc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e26b9090-da1d-4ead-91a2-15c642fc17ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesComponentsofincometaxbenefitexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_530790f3-173c-4c5f-b99e-453fe7d8fb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_3b0308ac-2cdf-4b13-a0ef-1f90d74e0361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_530790f3-173c-4c5f-b99e-453fe7d8fb76" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_3b0308ac-2cdf-4b13-a0ef-1f90d74e0361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_a3990b0b-d45a-48b5-a882-f9db85c82972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ef3843ee-a44c-418e-8d7c-adb6e85ad6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_a3990b0b-d45a-48b5-a882-f9db85c82972" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ef3843ee-a44c-418e-8d7c-adb6e85ad6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b43944a6-1821-4de2-9187-d8e22f0f449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_a3990b0b-d45a-48b5-a882-f9db85c82972" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b43944a6-1821-4de2-9187-d8e22f0f449d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesReconciliationofeffectivetaxrateDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_508467fe-1143-478c-8c1f-7f7a8e84de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_508467fe-1143-478c-8c1f-7f7a8e84de7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b962d682-78ae-4dbf-b347-bf09a62b65de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b962d682-78ae-4dbf-b347-bf09a62b65de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dc8573ea-cb5a-4c86-958a-c33de73faf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dc8573ea-cb5a-4c86-958a-c33de73faf5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_b65f22be-7c35-431e-90e6-11b80665911a" xlink:href="kprx-20221231.xsd#kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_b65f22be-7c35-431e-90e6-11b80665911a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_76de06ef-3123-4918-93ec-1bb29b01b1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_76de06ef-3123-4918-93ec-1bb29b01b1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f1784b59-7738-443b-ad57-1d29c2dbaf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f1784b59-7738-443b-ad57-1d29c2dbaf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6a7b1441-f73d-4392-929a-387706c64f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6a7b1441-f73d-4392-929a-387706c64f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d24af8e6-c825-4fae-a485-111cb5a0b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d24af8e6-c825-4fae-a485-111cb5a0b6e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_ef1666a9-0077-443a-a0a3-9f4128bbdefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4ee78a-68f7-4d63-933e-cb7dc2b61a93" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_ef1666a9-0077-443a-a0a3-9f4128bbdefc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0d737bb3-415f-4ed4-b1e2-b1346b724ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_204c54ba-0d09-4aaa-8a9b-473d882a3b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0d737bb3-415f-4ed4-b1e2-b1346b724ca9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_204c54ba-0d09-4aaa-8a9b-473d882a3b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f2db3746-5edb-4670-9cbc-6886ee572344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0d737bb3-415f-4ed4-b1e2-b1346b724ca9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f2db3746-5edb-4670-9cbc-6886ee572344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761d9b75-7a95-4b05-b76c-38045517b742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761d9b75-7a95-4b05-b76c-38045517b742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84c5a796-66ff-448c-ada9-556fd2b93fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84c5a796-66ff-448c-ada9-556fd2b93fa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b5fcccf4-ccd6-43ae-8d24-19b00e26b720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b5fcccf4-ccd6-43ae-8d24-19b00e26b720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c44dd3fc-7a45-4c85-b4cc-6c70be3dd63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c44dd3fc-7a45-4c85-b4cc-6c70be3dd63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e417df84-e633-4035-9dad-1f0e04b941f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c9375440-055f-4895-973f-df03db6d7d70" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e417df84-e633-4035-9dad-1f0e04b941f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_10266e8d-8142-48d6-9d9b-559fdd9ece9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_81652556-cc62-4ed6-9faf-73f6e9fdb9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_10266e8d-8142-48d6-9d9b-559fdd9ece9c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_81652556-cc62-4ed6-9faf-73f6e9fdb9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_d36dfcc3-9cd5-4c11-81e0-71c12c75e102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_10266e8d-8142-48d6-9d9b-559fdd9ece9c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_d36dfcc3-9cd5-4c11-81e0-71c12c75e102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d1d083e8-d58e-4311-9d81-f4af30dc07e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_10266e8d-8142-48d6-9d9b-559fdd9ece9c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d1d083e8-d58e-4311-9d81-f4af30dc07e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_1859aafa-8fb9-43e9-8489-413201442fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_44d2bc8e-fde8-48f5-963c-61074e1c429b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_1859aafa-8fb9-43e9-8489-413201442fb4" xlink:to="loc_us-gaap_OperatingLeaseLiability_44d2bc8e-fde8-48f5-963c-61074e1c429b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e298b8b1-237a-4547-b2a7-27c62307c05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_1859aafa-8fb9-43e9-8489-413201442fb4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e298b8b1-237a-4547-b2a7-27c62307c05b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>kprx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i73e2dfb9e1ff4696aee8ca36449b2751_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5cc78a2c-04d0-4223-965a-ae75116d00db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5cc78a2c-04d0-4223-965a-ae75116d00db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ccdb12c3-b4b1-4a63-b2e0-b68d7f779a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ccdb12c3-b4b1-4a63-b2e0-b68d7f779a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares_c171d727-acb9-43d1-8884-4264ebaeec2c" xlink:href="kprx-20221231.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_kprx_PreferredStockDesignatedShares_c171d727-acb9-43d1-8884-4264ebaeec2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9ba8d63d-8761-40e4-ad30-0a58850e2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9ba8d63d-8761-40e4-ad30-0a58850e2c79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2c510996-bde9-4e3c-b4e8-c9d2e7faebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2c510996-bde9-4e3c-b4e8-c9d2e7faebc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60daaf35-589a-4118-9329-b86ac3c6a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60daaf35-589a-4118-9329-b86ac3c6a27e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_87707444-d4d2-43de-82c3-f343b1566307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_87707444-d4d2-43de-82c3-f343b1566307" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5b9fa54f-cb25-4ab7-924b-8ff265685978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesIssued_5b9fa54f-cb25-4ab7-924b-8ff265685978" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_540cdf85-a16b-4695-a8ac-31cd4ab0b115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_540cdf85-a16b-4695-a8ac-31cd4ab0b115" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_01f12439-01ef-43e9-bfdf-caf6d3aee937_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:to="loc_us-gaap_ClassOfStockDomain_01f12439-01ef-43e9-bfdf-caf6d3aee937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:to="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3f91991d-665c-4529-a32d-76fbd64d40be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3f91991d-665c-4529-a32d-76fbd64d40be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_f136e8f7-2192-49cd-b213-9338d12df354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_f136e8f7-2192-49cd-b213-9338d12df354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6a537aba-e4e7-463f-a9b7-39c7a354f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6a537aba-e4e7-463f-a9b7-39c7a354f0d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_c6f49fd2-8499-4318-92dc-f0dd338b84b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_c6f49fd2-8499-4318-92dc-f0dd338b84b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_f4e5a781-7822-49e3-8ca5-0800947d9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_f4e5a781-7822-49e3-8ca5-0800947d9c3f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="icd7b7a98f2294a9687c64686e93e6b2c_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_89560dc8-7324-468e-a1ad-791a4500000f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_SharesOutstanding_89560dc8-7324-468e-a1ad-791a4500000f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd7f2d95-b23d-4402-8f48-e53b5e976a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockholdersEquity_bd7f2d95-b23d-4402-8f48-e53b5e976a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9470ed5-5948-4d9c-b97c-c9124f5acef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9470ed5-5948-4d9c-b97c-c9124f5acef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_8e512985-d626-46db-916f-431d5cdeb8f8" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesFromHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_8e512985-d626-46db-916f-431d5cdeb8f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_a864222b-472f-438e-9899-a03da7115450" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_a864222b-472f-438e-9899-a03da7115450" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e40538e-70f6-4571-aad4-a0c439e8f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e40538e-70f6-4571-aad4-a0c439e8f3eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b02ca7dc-64a3-4642-83fd-4d5b1a328cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b02ca7dc-64a3-4642-83fd-4d5b1a328cc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31225ea3-743e-4ad6-ac83-07a65195e4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31225ea3-743e-4ad6-ac83-07a65195e4f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f845ee-aad2-434a-92d0-28516233a286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f845ee-aad2-434a-92d0-28516233a286" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_245df2c2-60fc-4d51-aef8-d4d4e08fb8db" xlink:href="kprx-20221231.xsd#kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_245df2c2-60fc-4d51-aef8-d4d4e08fb8db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_d32dc7b4-e467-476e-8db8-806499b3a448" xlink:href="kprx-20221231.xsd#kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_d32dc7b4-e467-476e-8db8-806499b3a448" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_01ed73f7-af52-471c-ae7e-1589a3241bf9" xlink:href="kprx-20221231.xsd#kprx_StockAdjustedDuringPeriodValueReverseStockSplits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_01ed73f7-af52-471c-ae7e-1589a3241bf9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_8e99d8c9-7eb0-45d8-bfb6-9ac46a3c9cb9" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_8e99d8c9-7eb0-45d8-bfb6-9ac46a3c9cb9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_16fef984-6728-4844-94b4-4c576bbe154d" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_16fef984-6728-4844-94b4-4c576bbe154d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement_8f6e9de6-93a9-43ea-bd26-cebaf8655e56" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantInducement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement_8f6e9de6-93a9-43ea-bd26-cebaf8655e56" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement_0f97119d-2c4c-45b6-9baa-d2237a5ee742" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantInducement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement_0f97119d-2c4c-45b6-9baa-d2237a5ee742" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c208c674-c2ba-45a2-bf15-3ce5db4c28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c208c674-c2ba-45a2-bf15-3ce5db4c28c3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5baa9c2a-acac-4671-8923-35aa22cfc81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5baa9c2a-acac-4671-8923-35aa22cfc81c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_0f2617c0-fd88-460c-b737-402890c139f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_0f2617c0-fd88-460c-b737-402890c139f7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4ab9324-fc03-42ed-8d94-836e880b8685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_NetIncomeLoss_f4ab9324-fc03-42ed-8d94-836e880b8685" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b81e7cc3-cb89-4980-8497-76ce7cd87577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f12a28de-a6ba-4527-afec-d53be9b80324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:to="loc_us-gaap_EquityComponentDomain_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:to="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4ecde722-1885-4d14-85a5-78b57f5d66d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_PreferredStockMember_4ecde722-1885-4d14-85a5-78b57f5d66d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f9dae68-9688-4c66-b58a-bab3f98a4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_CommonStockMember_3f9dae68-9688-4c66-b58a-bab3f98a4d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b127ea00-c932-4a20-b7e3-232ea9b8a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b127ea00-c932-4a20-b7e3-232ea9b8a7d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a584a636-2d56-434a-9b0d-665abfc12312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a584a636-2d56-434a-9b0d-665abfc12312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_410ba7f0-b503-4747-ac48-505aeb3c8554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_RetainedEarningsMember_410ba7f0-b503-4747-ac48-505aeb3c8554" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c66cd49f-b594-487d-b216-d45451e062bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:to="loc_us-gaap_ClassOfStockDomain_c66cd49f-b594-487d-b216-d45451e062bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:to="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_abac0435-6c0a-4106-a445-7796bd4d5956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_abac0435-6c0a-4106-a445-7796bd4d5956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1bbbb6ab-5dbb-4322-b347-3bd154216f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1bbbb6ab-5dbb-4322-b347-3bd154216f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_a5f92da1-71ec-4cfb-ba97-adc66fced026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_a5f92da1-71ec-4cfb-ba97-adc66fced026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a134e97f-8504-4f9a-b29f-fd3ae3cb2359_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a134e97f-8504-4f9a-b29f-fd3ae3cb2359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_b6bf985f-c3bf-4b0c-91d4-b8877bec4a3d" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_kprx_PublicOfferingMember_b6bf985f-c3bf-4b0c-91d4-b8877bec4a3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c5395554-71c0-420e-baca-1afb7f011c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_us-gaap_PrivatePlacementMember_c5395554-71c0-420e-baca-1afb7f011c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_9256ff55-859b-4932-9456-2aeebee02a9e" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_kprx_RegisteredDirectOfferingMember_9256ff55-859b-4932-9456-2aeebee02a9e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="ic8546b87b26d4be1b756032d3e329fa5_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3395bcfb-b063-46f9-abb4-4b83e08b4091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3395bcfb-b063-46f9-abb4-4b83e08b4091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e1816130-f5da-49c3-91ad-60c8ad601c24" xlink:href="kprx-20221231.xsd#kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:to="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e1816130-f5da-49c3-91ad-60c8ad601c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:to="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b620b13-93fb-40b2-b099-ff530c0c1021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b620b13-93fb-40b2-b099-ff530c0c1021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_46a00ef9-35fc-4afe-a4de-ecd32bdb5129" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_kprx_PublicOfferingMember_46a00ef9-35fc-4afe-a4de-ecd32bdb5129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_eb0f4738-0519-4f64-abc3-7894bafe6be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_us-gaap_PrivatePlacementMember_eb0f4738-0519-4f64-abc3-7894bafe6be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_d3caf683-f910-4254-ba36-80249b49d803" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_kprx_RegisteredDirectOfferingMember_d3caf683-f910-4254-ba36-80249b49d803" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0eefcc5-8f46-45ac-90f2-aa9c9445477a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:to="loc_us-gaap_ClassOfStockDomain_e0eefcc5-8f46-45ac-90f2-aa9c9445477a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:to="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesEConvertiblePreferredStockMember_22a9c3a6-c0af-49bf-9dda-dcd4d6d32c83" xlink:href="kprx-20221231.xsd#kprx_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:to="loc_kprx_SeriesEConvertiblePreferredStockMember_22a9c3a6-c0af-49bf-9dda-dcd4d6d32c83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ie3960a33692543188812d8de8b95abd6_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48fe2ddb-cf3b-4a90-a3a9-0656a0f7d006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_NetIncomeLoss_48fe2ddb-cf3b-4a90-a3a9-0656a0f7d006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6528ef67-0147-487a-aa9e-5a8c325c4920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6528ef67-0147-487a-aa9e-5a8c325c4920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_52676f07-f72c-45ad-b908-1c29d6a292b8" xlink:href="kprx-20221231.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_52676f07-f72c-45ad-b908-1c29d6a292b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8414c573-0118-4a8a-a587-d63512c82d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_ShareBasedCompensation_8414c573-0118-4a8a-a587-d63512c82d27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_0c3af22d-7a97-4c67-af80-4093c9b910a8" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_0c3af22d-7a97-4c67-af80-4093c9b910a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18ed3d21-f4b2-4fb8-8627-eadd78d86139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18ed3d21-f4b2-4fb8-8627-eadd78d86139" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0f060a1-de34-4add-a725-8c5875f79138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0f060a1-de34-4add-a725-8c5875f79138" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CashOutflowFromLoanForgiveness_7969993e-1042-4158-94e1-dc67b343aa22" xlink:href="kprx-20221231.xsd#kprx_CashOutflowFromLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_CashOutflowFromLoanForgiveness_7969993e-1042-4158-94e1-dc67b343aa22" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f2c56129-036e-48d5-8959-81453b2ec481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f2c56129-036e-48d5-8959-81453b2ec481" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_46b8d169-0415-4980-8766-493fbbf572a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_46b8d169-0415-4980-8766-493fbbf572a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f5e1df7-ab9e-402f-a9c4-e34987b9e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f5e1df7-ab9e-402f-a9c4-e34987b9e3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_95af8dad-3dca-455a-861d-e169c18bfeda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_95af8dad-3dca-455a-861d-e169c18bfeda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a713e63-5ab7-4253-b93b-4e495ba752ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a713e63-5ab7-4253-b93b-4e495ba752ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_db4fb545-ffd7-4969-87c1-81ddc8c546ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_db4fb545-ffd7-4969-87c1-81ddc8c546ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_287861f5-2af4-4e7c-be34-abaa2def6fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_287861f5-2af4-4e7c-be34-abaa2def6fa8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eeeb7dc-f8dc-487e-9899-eb0f2ba0cb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eeeb7dc-f8dc-487e-9899-eb0f2ba0cb32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6131e837-2eeb-4f2f-ae81-ece3acc078ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6131e837-2eeb-4f2f-ae81-ece3acc078ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e69af24c-1939-47b4-bc4f-d682554a391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e69af24c-1939-47b4-bc4f-d682554a391d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c2d5b38-95b6-4646-9b59-f770c0c8857b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c2d5b38-95b6-4646-9b59-f770c0c8857b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c82395a8-8cd8-43f6-b12b-76c10ac41f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c82395a8-8cd8-43f6-b12b-76c10ac41f0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2818940-6807-4c0a-90ec-ff2cebae8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2818940-6807-4c0a-90ec-ff2cebae8bb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9240ebe5-67b8-4ae7-8c57-5a8a436dc590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9240ebe5-67b8-4ae7-8c57-5a8a436dc590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07738fbd-3d48-4dc4-99b6-4716da22cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07738fbd-3d48-4dc4-99b6-4716da22cb68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1007c843-6901-4d37-b680-a45c093e0bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1007c843-6901-4d37-b680-a45c093e0bfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_47705bfe-9b82-4168-858a-d7594ed6f0f1" xlink:href="kprx-20221231.xsd#kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_47705bfe-9b82-4168-858a-d7594ed6f0f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8ca617b4-99e3-4a2a-8860-b2b7115c6874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8ca617b4-99e3-4a2a-8860-b2b7115c6874" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64843087-b649-45fc-926d-8e05b8cda20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64843087-b649-45fc-926d-8e05b8cda20f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b64a2b1-2a6c-4791-82c5-c66d3d1e14f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b64a2b1-2a6c-4791-82c5-c66d3d1e14f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa379d1f-935b-48b7-bcd6-3d18fac0be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa379d1f-935b-48b7-bcd6-3d18fac0be46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef7defa2-be4c-4ac0-b8b6-b4c048c55fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef7defa2-be4c-4ac0-b8b6-b4c048c55fa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6e5a0d5-b270-43b9-a9d8-695082cd7e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_06e6711f-1ad2-4674-a842-aeee5439c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_06e6711f-1ad2-4674-a842-aeee5439c91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a537d0ba-ef75-4b92-bf5b-e33cf7be368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a537d0ba-ef75-4b92-bf5b-e33cf7be368e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GrantOfRestrictedStockAwards_914f8007-2d85-4904-8828-d7bb4230459b" xlink:href="kprx-20221231.xsd#kprx_GrantOfRestrictedStockAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_kprx_GrantOfRestrictedStockAwards_914f8007-2d85-4904-8828-d7bb4230459b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:to="loc_us-gaap_ClassOfStockDomain_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:to="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_51310bc3-bd71-4fb9-ae6a-b0221e652c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_51310bc3-bd71-4fb9-ae6a-b0221e652c33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_607870b5-aafd-4713-8554-f229e18c16cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_607870b5-aafd-4713-8554-f229e18c16cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_6dbd2d36-c9d4-4881-b9ec-3284d99c6aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_6dbd2d36-c9d4-4881-b9ec-3284d99c6aa4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#BusinessPresentationandRecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="extended" id="i0aeb0acc9615401b8cc3542e8010829e_BusinessPresentationandRecentAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f1eeafc-1830-4f91-8b40-cccca218553a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f1eeafc-1830-4f91-8b40-cccca218553a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13783953-8d99-4b93-a91f-d9c5982e7fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13783953-8d99-4b93-a91f-d9c5982e7fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5a50156e-c7a5-4066-a87c-0abbf9d34ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5a50156e-c7a5-4066-a87c-0abbf9d34ae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantIssuancePlacementAgentFees_67fa010f-02fd-4efd-93c4-e1075606d180" xlink:href="kprx-20221231.xsd#kprx_WarrantIssuancePlacementAgentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_WarrantIssuancePlacementAgentFees_67fa010f-02fd-4efd-93c4-e1075606d180" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_fc9d3636-0b0b-4c73-813c-d495da53ccec" xlink:href="kprx-20221231.xsd#kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_fc9d3636-0b0b-4c73-813c-d495da53ccec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a496b4a3-9895-4c1d-b45f-e0304bfbdb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a496b4a3-9895-4c1d-b45f-e0304bfbdb40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c9ee6f4f-b8d8-46da-90d6-a99e96321fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c9ee6f4f-b8d8-46da-90d6-a99e96321fe8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_bcc2a148-1446-4830-87d3-a6b48dad93dc" xlink:href="kprx-20221231.xsd#kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_bcc2a148-1446-4830-87d3-a6b48dad93dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76e76694-ebe2-4a72-9bb8-2b063ce9f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_76e76694-ebe2-4a72-9bb8-2b063ce9f21c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a120f578-a121-4496-9b9f-12ff79ede705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a120f578-a121-4496-9b9f-12ff79ede705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_be01c63b-c658-4879-8f27-48de757fc049" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:to="loc_kprx_RegisteredDirectOfferingMember_be01c63b-c658-4879-8f27-48de757fc049" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i58a185405d6b487cb2f37b58ff73c1db_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba863552-ea6a-424e-bf21-27f8e2d4abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba863552-ea6a-424e-bf21-27f8e2d4abbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fcf006f4-13c3-4751-a67c-0c7dd31b806d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fcf006f4-13c3-4751-a67c-0c7dd31b806d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_77e2d8e1-88db-4a01-be9b-10e3456a3072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_77e2d8e1-88db-4a01-be9b-10e3456a3072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_150eaf6f-1a60-4c99-a3d3-a6b6b7794ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_Goodwill_150eaf6f-1a60-4c99-a3d3-a6b6b7794ea9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_162104c7-964a-4aaf-871f-428f70de378d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_162104c7-964a-4aaf-871f-428f70de378d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_703dc89f-89f2-4bac-b711-cd760ef3014d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_703dc89f-89f2-4bac-b711-cd760ef3014d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e0b31ac0-2ca3-4b05-a7a9-0b2bf1378cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e0b31ac0-2ca3-4b05-a7a9-0b2bf1378cc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments_15f27454-3595-4bd1-912c-3bffd7c8dea4" xlink:href="kprx-20221231.xsd#kprx_NumberOfGeographicSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_NumberOfGeographicSegments_15f27454-3595-4bd1-912c-3bffd7c8dea4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48f8f8af-42ca-4175-be3a-47ab7bb0df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_DeferredTaxLiabilities_48f8f8af-42ca-4175-be3a-47ab7bb0df60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cfd72add-6ac5-4fbc-8c51-a37d90e2077e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cfd72add-6ac5-4fbc-8c51-a37d90e2077e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fa8921df-89a9-4e8c-93a5-e0431aeca32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_IncomeTaxReceivable_fa8921df-89a9-4e8c-93a5-e0431aeca32c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb5272dc-8e08-49d9-a31a-a92696985d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb5272dc-8e08-49d9-a31a-a92696985d39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfVendors_17f444d5-239e-47f4-a41b-d2a5ce613b81" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfVendors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfVendors_17f444d5-239e-47f4-a41b-d2a5ce613b81" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfConsultants_e235e40e-c9e0-4058-a2b2-9dd7d2ddc09c" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfConsultants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfConsultants_e235e40e-c9e0-4058-a2b2-9dd7d2ddc09c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4289cd41-4242-46b7-b3ff-bdcf8f06ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4289cd41-4242-46b7-b3ff-bdcf8f06ce62" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_2236bca7-da1a-4b97-b2d5-ca7aa4f7c8ee" xlink:href="kprx-20221231.xsd#kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_2236bca7-da1a-4b97-b2d5-ca7aa4f7c8ee" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_18539d10-3d31-4f76-9b42-48745b45fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_18539d10-3d31-4f76-9b42-48745b45fb4a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfUniversities_bb4bec0a-11b3-4571-b4da-8a305d0352ad" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfUniversities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfUniversities_bb4bec0a-11b3-4571-b4da-8a305d0352ad" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35f2ab5b-c75b-437d-a991-c58fc49e228d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35f2ab5b-c75b-437d-a991-c58fc49e228d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c43eb28c-4982-4ae9-b5d0-4c2aca2490d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c43eb28c-4982-4ae9-b5d0-4c2aca2490d7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8b1182bf-fedb-4ca8-8e2f-07abfd02fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8b1182bf-fedb-4ca8-8e2f-07abfd02fe70" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45b7e073-d250-4de6-9585-f30706712174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45b7e073-d250-4de6-9585-f30706712174" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee0ca8b8-5a41-4b21-ae24-6cfb7a4e8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee0ca8b8-5a41-4b21-ae24-6cfb7a4e8eb9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7b97ad0d-583e-46cb-b8b0-dc87ae2ba398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7b97ad0d-583e-46cb-b8b0-dc87ae2ba398" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_5979f803-4ecb-46e7-985e-a715cfcc36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_5979f803-4ecb-46e7-985e-a715cfcc36a0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_453b5aa7-08ff-46a9-9a00-2bf00c4df437_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_453b5aa7-08ff-46a9-9a00-2bf00c4df437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonAcquisitionMember_7a3f7e78-1742-4668-907c-ccaa269155d8" xlink:href="kprx-20221231.xsd#kprx_BayonAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_BayonAcquisitionMember_7a3f7e78-1742-4668-907c-ccaa269155d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesAcquisitionMember_8e769fd2-8ec2-49d1-905a-c1be95b43b35" xlink:href="kprx-20221231.xsd#kprx_PanoptesAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_PanoptesAcquisitionMember_8e769fd2-8ec2-49d1-905a-c1be95b43b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeTherapeuticSIncMember_766d6685-b84e-4d5b-97c1-cda94a0ece29" xlink:href="kprx-20221231.xsd#kprx_JadeTherapeuticSIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_JadeTherapeuticSIncMember_766d6685-b84e-4d5b-97c1-cda94a0ece29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_394de163-cd2a-41ea-9217-c4cdbc4f01a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:to="loc_srt_RangeMember_394de163-cd2a-41ea-9217-c4cdbc4f01a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:to="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a2e35ed8-c333-4ad9-b8dd-0ceec99708cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:to="loc_srt_MinimumMember_a2e35ed8-c333-4ad9-b8dd-0ceec99708cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_22a0069b-3367-49cc-b2e1-bfe8a3fab71c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:to="loc_srt_MaximumMember_22a0069b-3367-49cc-b2e1-bfe8a3fab71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_82251f6f-3a8a-4db4-ba10-f21899d5e459_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:to="loc_us-gaap_ClassOfStockDomain_82251f6f-3a8a-4db4-ba10-f21899d5e459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:to="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5a26de0-a0a4-48bd-b35f-983443489126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:to="loc_us-gaap_CommonStockMember_b5a26de0-a0a4-48bd-b35f-983443489126" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96aa0bbd-e8d7-4123-9903-ed211421b2d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96aa0bbd-e8d7-4123-9903-ed211421b2d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f3790f40-238c-4f79-9634-081e4c209b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:to="loc_us-gaap_PrivatePlacementMember_f3790f40-238c-4f79-9634-081e4c209b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_82f6a138-ca2f-4148-b062-763c094e1d47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_82f6a138-ca2f-4148-b062-763c094e1d47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalStudiesServicesKIO301Member_7f0fc44f-83c0-4282-8010-7a0fe4233278" xlink:href="kprx-20221231.xsd#kprx_ClinicalStudiesServicesKIO301Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:to="loc_kprx_ClinicalStudiesServicesKIO301Member_7f0fc44f-83c0-4282-8010-7a0fe4233278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_680cca14-cd3d-4a87-b480-0aec10bc87a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:to="loc_us-gaap_RelatedPartyDomain_680cca14-cd3d-4a87-b480-0aec10bc87a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:to="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_90e46aa4-cf01-4e47-bcab-4c4d2c529512" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:to="loc_srt_AffiliatedEntityMember_90e46aa4-cf01-4e47-bcab-4c4d2c529512" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails" xlink:type="extended" id="i4f0252467a54494ab270c63e413c9d17_SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f36f560b-a8c2-44b4-bbd3-19153738867b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f36f560b-a8c2-44b4-bbd3-19153738867b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_465e9cb3-8f0c-483c-a962-04aa297a0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:to="loc_us-gaap_EmployeeStockOptionMember_465e9cb3-8f0c-483c-a962-04aa297a0d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9cccf353-9dc9-499f-99a5-b131b5e4f677_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:to="loc_us-gaap_EquityComponentDomain_9cccf353-9dc9-499f-99a5-b131b5e4f677_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:to="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_222f4c64-5e47-48b0-8b09-d000b27d1f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:to="loc_us-gaap_CommonStockMember_222f4c64-5e47-48b0-8b09-d000b27d1f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_263a335d-d5a3-4a72-b6b8-f92fc819c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:to="loc_us-gaap_PreferredStockMember_263a335d-d5a3-4a72-b6b8-f92fc819c3f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe51176a-1629-4a18-a640-bf1142e4b102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe51176a-1629-4a18-a640-bf1142e4b102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c4063e6f-45b9-4d7d-a622-cd2f4ad9aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:to="loc_us-gaap_RestrictedStockMember_c4063e6f-45b9-4d7d-a622-cd2f4ad9aabc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails" xlink:type="extended" id="i22859bdebb4844a5a41e4b9b9157a1dc_SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e02e3874-eaa1-4cff-a90b-377b2fb2b603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e02e3874-eaa1-4cff-a90b-377b2fb2b603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonAcquisitionMember_2160f6dc-48fb-405f-8fcd-425729632e7c" xlink:href="kprx-20221231.xsd#kprx_BayonAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_BayonAcquisitionMember_2160f6dc-48fb-405f-8fcd-425729632e7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesAcquisitionMember_c9f4cd12-2dc4-477c-9f18-834adc75a68f" xlink:href="kprx-20221231.xsd#kprx_PanoptesAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_PanoptesAcquisitionMember_c9f4cd12-2dc4-477c-9f18-834adc75a68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeTherapeuticSIncMember_1d99727d-f706-4591-9dd8-56031d32191a" xlink:href="kprx-20221231.xsd#kprx_JadeTherapeuticSIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_JadeTherapeuticSIncMember_1d99727d-f706-4591-9dd8-56031d32191a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:to="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioDomain_e7b7d799-cefb-4c6e-aebb-5084228b9b76_default" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:to="loc_kprx_ContingentConsiderationScenarioDomain_e7b7d799-cefb-4c6e-aebb-5084228b9b76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:to="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase1Member_6889f0a5-eda8-466e-8ccd-9dd222fcee42" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase1Member_6889f0a5-eda8-466e-8ccd-9dd222fcee42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase2Member_9aefae19-78f7-4464-9b3e-d396d75a58db" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase2Member_9aefae19-78f7-4464-9b3e-d396d75a58db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase3Member_34c125e5-3c37-47e9-82fa-ddd0269c10d2" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase3Member_34c125e5-3c37-47e9-82fa-ddd0269c10d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FdaApprovalMember_592d8617-1109-4a5e-b82f-f3e9131805d0" xlink:href="kprx-20221231.xsd#kprx_FdaApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_FdaApprovalMember_592d8617-1109-4a5e-b82f-f3e9131805d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BeginningOfPhase3Member_60d863c9-6a9f-42d4-b458-2680fdc7f741" xlink:href="kprx-20221231.xsd#kprx_BeginningOfPhase3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_BeginningOfPhase3Member_60d863c9-6a9f-42d4-b458-2680fdc7f741" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="extended" id="i6dbca4f1cccc45c2b4ab41eeb8634abb_FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:href="kprx-20221231.xsd#kprx_FairValueContingentConsiderationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:to="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8d774e5f-0fe7-4710-b1eb-b327eebb3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8d774e5f-0fe7-4710-b1eb-b327eebb3f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_76b5ed06-e719-4cae-b201-19988336065f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_76b5ed06-e719-4cae-b201-19988336065f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9d9bd95-fa58-4343-847e-dc92caae851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9d9bd95-fa58-4343-847e-dc92caae851f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_850a25fb-f97f-4e8f-bdc2-7607f51a0228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_850a25fb-f97f-4e8f-bdc2-7607f51a0228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e65380d4-f7e0-48bf-85c7-838b6516d1ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e65380d4-f7e0-48bf-85c7-838b6516d1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8487de37-c6f3-4280-9485-709a5805790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8487de37-c6f3-4280-9485-709a5805790c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details" xlink:type="extended" id="ic1162092bb8b4dc1b5ab4ff78168dd91_FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8303ae6f-2db9-4ff3-97fd-8a50b56be7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8303ae6f-2db9-4ff3-97fd-8a50b56be7ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ChangeInContingentConsiderationFairValue_46c4dcae-9630-408c-954f-42abe53dbce8" xlink:href="kprx-20221231.xsd#kprx_ChangeInContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:to="loc_kprx_ChangeInContingentConsiderationFairValue_46c4dcae-9630-408c-954f-42abe53dbce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a56071a1-9710-44b2-ae59-0d2d15d0c840_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a56071a1-9710-44b2-ae59-0d2d15d0c840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eb479c4d-662d-4806-a37f-00523f420951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eb479c4d-662d-4806-a37f-00523f420951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_2abb4ae1-89a3-4db7-bcba-8eccaeb22aec" xlink:href="kprx-20221231.xsd#kprx_MeasurementInputProbabilityOfSuccessForPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:to="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_2abb4ae1-89a3-4db7-bcba-8eccaeb22aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_b9260b64-34c4-4d15-a0c4-049b1441b580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:to="loc_us-gaap_ValuationTechniqueDomain_b9260b64-34c4-4d15-a0c4-049b1441b580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_ad513147-4e04-4b9b-b654-4833d427cea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_ad513147-4e04-4b9b-b654-4833d427cea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827ba9fa-c111-4415-acef-41ecf7258fc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_827ba9fa-c111-4415-acef-41ecf7258fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_22e28eb0-9a90-481c-94ad-3f691db45435" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_BayonMember_22e28eb0-9a90-481c-94ad-3f691db45435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGes.m.b.h.Member_186ee030-e8a8-4baf-b660-5cd53c9f8395" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGes.m.b.h.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_PanoptesPharmaGes.m.b.h.Member_186ee030-e8a8-4baf-b660-5cd53c9f8395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeMember_f227c869-1ad7-4a7c-9a8c-c7b53a2e7791" xlink:href="kprx-20221231.xsd#kprx_JadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_JadeMember_f227c869-1ad7-4a7c-9a8c-c7b53a2e7791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a13b9420-3d80-429a-ae27-faac76639327_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:to="loc_srt_RangeMember_a13b9420-3d80-429a-ae27-faac76639327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:to="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6464218c-67d7-4ea8-80fd-53609906592c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:to="loc_srt_MinimumMember_6464218c-67d7-4ea8-80fd-53609906592c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd745f2f-7fce-498c-8387-606e3fd3fe70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:to="loc_srt_MaximumMember_cd745f2f-7fce-498c-8387-606e3fd3fe70" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i2c8c9cddbf3248d98f195e187c186320_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e1d4bffe-3f47-4968-b6a8-fa20224a6172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e1d4bffe-3f47-4968-b6a8-fa20224a6172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_62bfc0d8-a60d-4696-b1b4-3c6bfe9e193a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_62bfc0d8-a60d-4696-b1b4-3c6bfe9e193a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c5c3b30-72ad-4a56-9fe5-a3e32be041c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c5c3b30-72ad-4a56-9fe5-a3e32be041c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb4ad36b-4434-46bb-b5cc-d1e23b68046b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb4ad36b-4434-46bb-b5cc-d1e23b68046b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ecdce71-f241-4164-9ba9-e80e067ba4c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ecdce71-f241-4164-9ba9-e80e067ba4c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6cc03ad0-f1b4-48da-9437-01f1a9824d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_EquipmentMember_6cc03ad0-f1b4-48da-9437-01f1a9824d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_d8e58508-ad5b-40ad-a71d-002480ca62b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_OfficeEquipmentMember_d8e58508-ad5b-40ad-a71d-002480ca62b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c263ed81-480a-4b48-9115-813c670137a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c263ed81-480a-4b48-9115-813c670137a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_303e298b-bc3d-4e77-a40d-ac806b4a9efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_303e298b-bc3d-4e77-a40d-ac806b4a9efb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails" xlink:type="extended" id="i771d16f220264f81aecc975f0b9527ab_IntangibleAssetsandInProcessRDAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30128150-c34e-474c-b1a6-959d8fbb5d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30128150-c34e-474c-b1a6-959d8fbb5d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7e97f4b2-dd19-4c35-a14e-17a93448de4a" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsExpectedMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7e97f4b2-dd19-4c35-a14e-17a93448de4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_876cc92f-50ac-4d35-803f-f57f5016928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_876cc92f-50ac-4d35-803f-f57f5016928d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66ce0eb4-07b7-4677-9114-b674cc13a8b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:to="loc_us-gaap_RelatedPartyDomain_66ce0eb4-07b7-4677-9114-b674cc13a8b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:to="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SentrXAnimalCareIncMember_868d5b84-023e-4e36-af0e-e9f4f0df0def" xlink:href="kprx-20221231.xsd#kprx_SentrXAnimalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:to="loc_kprx_SentrXAnimalCareIncMember_868d5b84-023e-4e36-af0e-e9f4f0df0def" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="extended" id="ia189825611464441b6a3f9ec5ec58d68_IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_74f3dffb-cd7b-4209-9547-9f93c8823779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_74f3dffb-cd7b-4209-9547-9f93c8823779" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23e0c2c0-5ee8-4245-8410-5eb363b0d686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23e0c2c0-5ee8-4245-8410-5eb363b0d686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37501b0b-f3ee-4141-949d-e2983f6dedde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37501b0b-f3ee-4141-949d-e2983f6dedde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3539d93d-90b0-455d-bfff-922ceaf5c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3539d93d-90b0-455d-bfff-922ceaf5c3ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_9cb0b3a0-2bbe-4511-83c9-b7b28eea48a5" xlink:href="kprx-20221231.xsd#kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_9cb0b3a0-2bbe-4511-83c9-b7b28eea48a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_dbfca62a-69f4-4b11-a30f-3d2116c5041a" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_dbfca62a-69f4-4b11-a30f-3d2116c5041a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e72bb3f-18ee-4782-802e-808d0824698c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e72bb3f-18ee-4782-802e-808d0824698c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeSecretsMember_5ab0f629-e112-46f5-b0ca-b3b02ee92971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeSecretsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:to="loc_us-gaap_TradeSecretsMember_5ab0f629-e112-46f5-b0ca-b3b02ee92971" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CapitalStockDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="extended" id="id1fb5b6cb3574b5bbc465d7d6a1e0355_CapitalStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ad4eeb7-170c-4f4f-890e-ec0aded15cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ad4eeb7-170c-4f4f-890e-ec0aded15cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_99261ec6-438e-4846-90e2-8d552bd485ff" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_99261ec6-438e-4846-90e2-8d552bd485ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant_98f2bee5-c1d4-4cc8-9276-86f95669699f" xlink:href="kprx-20221231.xsd#kprx_SharePurchasePriceOfCommonStockAndWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant_98f2bee5-c1d4-4cc8-9276-86f95669699f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68e5462c-2b93-436f-bd28-b52a7fe26897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68e5462c-2b93-436f-bd28-b52a7fe26897" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment_f2eb237c-66f3-4812-9131-bf071e177e6d" xlink:href="kprx-20221231.xsd#kprx_WarrantExercisePricePerShareSubjectToAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment_f2eb237c-66f3-4812-9131-bf071e177e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantTerm_bd60be3e-d7e7-469c-b2a0-792ad884a9e4" xlink:href="kprx-20221231.xsd#kprx_WarrantTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantTerm_bd60be3e-d7e7-469c-b2a0-792ad884a9e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_0b8d9c9a-79ff-42e9-a20f-45acbcf7fdf8" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_0b8d9c9a-79ff-42e9-a20f-45acbcf7fdf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_958edc4a-8f76-4fa3-a222-3e10bea607bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_958edc4a-8f76-4fa3-a222-3e10bea607bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a26880c5-7a4a-4f36-889f-5a3c0cc2a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a26880c5-7a4a-4f36-889f-5a3c0cc2a38b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af8306ad-117e-4737-b1d7-8cac05d41642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af8306ad-117e-4737-b1d7-8cac05d41642" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4ddea312-cc1c-4a47-b9c3-7ca4d50458f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4ddea312-cc1c-4a47-b9c3-7ca4d50458f8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bc4dc57c-6bdf-4400-a99f-5168ae4cfd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bc4dc57c-6bdf-4400-a99f-5168ae4cfd7d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_3cbb7646-3778-4827-94d4-4fa3e50b2f7b" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesFromHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_3cbb7646-3778-4827-94d4-4fa3e50b2f7b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionHoldbackSharesTerm_ce1e81f8-25bd-4baf-87a2-741f3748f5cd" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionHoldbackSharesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_BusinessAcquisitionHoldbackSharesTerm_ce1e81f8-25bd-4baf-87a2-741f3748f5cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d6ab4b44-156d-4d94-a9a3-37598b2abac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d6ab4b44-156d-4d94-a9a3-37598b2abac4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantConvertibleIntoCommonStockBasis_daaf834e-4275-4bc7-9c34-88fd5b02ef1b" xlink:href="kprx-20221231.xsd#kprx_WarrantConvertibleIntoCommonStockBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantConvertibleIntoCommonStockBasis_daaf834e-4275-4bc7-9c34-88fd5b02ef1b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsConvertibleIntoCommonStock_73dc93e0-06a5-4c60-83ff-b9b60aa200df" xlink:href="kprx-20221231.xsd#kprx_WarrantsConvertibleIntoCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantsConvertibleIntoCommonStock_73dc93e0-06a5-4c60-83ff-b9b60aa200df" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerCommonShares_7461d583-aa59-462f-a756-9ecd995c9a93" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharesIssuedPricePerCommonShares_7461d583-aa59-462f-a756-9ecd995c9a93" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_2e9ae5fe-788b-443f-a918-316a444e807f" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_2e9ae5fe-788b-443f-a918-316a444e807f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_73a7e306-9c21-4fa2-a069-755239505475" xlink:href="kprx-20221231.xsd#kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_73a7e306-9c21-4fa2-a069-755239505475" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_14a067fe-324f-4f50-b930-084fce24c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_14a067fe-324f-4f50-b930-084fce24c851" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissions_fc7a2a4f-427e-4360-af06-dc2a7718fdcf" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_UnderwritingDiscountAndCommissions_fc7a2a4f-427e-4360-af06-dc2a7718fdcf" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissionsExpenses_61141417-0117-4f2a-bee1-afb9750e4e54" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissionsExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_UnderwritingDiscountAndCommissionsExpenses_61141417-0117-4f2a-bee1-afb9750e4e54" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightExercised_55b1d98b-2958-4fb5-b8bb-eb2be4dd6260" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightExercised_55b1d98b-2958-4fb5-b8bb-eb2be4dd6260" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_1fffe80b-098b-4e3b-b6c2-c8e903360b59" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_1fffe80b-098b-4e3b-b6c2-c8e903360b59" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales_0def3b48-a26b-4e2e-bc04-3a12d72707df" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromWarrantExercisesAndWarrantSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales_0def3b48-a26b-4e2e-bc04-3a12d72707df" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_1c81842a-faec-42b5-9406-1db2c364e205" xlink:href="kprx-20221231.xsd#kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_1c81842a-faec-42b5-9406-1db2c364e205" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2519b5a0-e476-49fc-b845-027f52199baf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:to="loc_us-gaap_ClassOfStockDomain_2519b5a0-e476-49fc-b845-027f52199baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:to="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesdConvertiblePreferredStockMember_8d94844f-90c7-4c51-b3e6-ac0af9a85857" xlink:href="kprx-20221231.xsd#kprx_SeriesdConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_SeriesdConvertiblePreferredStockMember_8d94844f-90c7-4c51-b3e6-ac0af9a85857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommonSharesMember_7894bf2d-55c6-4de9-b53b-c07858d28622" xlink:href="kprx-20221231.xsd#kprx_CommonSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_CommonSharesMember_7894bf2d-55c6-4de9-b53b-c07858d28622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesEConvertiblePreferredStockMember_7bf61e10-e067-4dff-821e-34ce1340ab48" xlink:href="kprx-20221231.xsd#kprx_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_SeriesEConvertiblePreferredStockMember_7bf61e10-e067-4dff-821e-34ce1340ab48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_db1e74c5-ed77-48a2-9f05-9df25bfa425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_us-gaap_CommonStockMember_db1e74c5-ed77-48a2-9f05-9df25bfa425a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_224bd182-76c6-4b0f-b8cf-1d2e187947e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:to="loc_us-gaap_CollateralDomain_224bd182-76c6-4b0f-b8cf-1d2e187947e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:to="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_51e20274-702d-447a-94cd-eccc83846c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:to="loc_us-gaap_PreferredStockMember_51e20274-702d-447a-94cd-eccc83846c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d6b9084-a871-4ade-8e8d-72b5adf057f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:to="loc_us-gaap_CommonStockMember_4d6b9084-a871-4ade-8e8d-72b5adf057f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5698d19c-7356-478c-8fcd-ea113d34d956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5698d19c-7356-478c-8fcd-ea113d34d956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrivatePlacementWarrantsMember_2f74527d-bb40-438b-8f91-8e6107ed534a" xlink:href="kprx-20221231.xsd#kprx_PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:to="loc_kprx_PrivatePlacementWarrantsMember_2f74527d-bb40-438b-8f91-8e6107ed534a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_4e46be9f-0d33-4317-a56a-5784871d0def" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:to="loc_kprx_PublicOfferingMember_4e46be9f-0d33-4317-a56a-5784871d0def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f45840d5-a686-443e-9332-b19fedf23196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f45840d5-a686-443e-9332-b19fedf23196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGesMbhMember_fc3e7cba-9ae2-4d1b-9311-34daac22724d" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGesMbhMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:to="loc_kprx_PanoptesPharmaGesMbhMember_fc3e7cba-9ae2-4d1b-9311-34daac22724d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b240c21f-e28a-4356-9956-208703016816_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b240c21f-e28a-4356-9956-208703016816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantMember_c9e12bf9-23ef-4582-a0b7-942a5f08fc88" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassAWarrantMember_c9e12bf9-23ef-4582-a0b7-942a5f08fc88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantMember_23ddc197-a687-4dbc-945f-f1f9649aae77" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassBWarrantMember_23ddc197-a687-4dbc-945f-f1f9649aae77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantsExerciseOfOptionMember_6f9871c9-10d0-4b83-a53c-a821da565ed5" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantsExerciseOfOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassAWarrantsExerciseOfOptionMember_6f9871c9-10d0-4b83-a53c-a821da565ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantExerciseOfOptionMember_aa149efa-635f-4a2c-8c64-76736977808e" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantExerciseOfOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassBWarrantExerciseOfOptionMember_aa149efa-635f-4a2c-8c64-76736977808e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InducementWarrantMember_cebc3880-105e-494b-a34d-668ab17f2113" xlink:href="kprx-20221231.xsd#kprx_InducementWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_InducementWarrantMember_cebc3880-105e-494b-a34d-668ab17f2113" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5847b8e9-a24e-4691-b37f-97b89d339454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5847b8e9-a24e-4691-b37f-97b89d339454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ec74883c-d48e-4fe5-972e-53320cb1ed78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:to="loc_us-gaap_WarrantMember_ec74883c-d48e-4fe5-972e-53320cb1ed78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#WarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/WarrantsDetails" xlink:type="extended" id="i0c086e972f3a4cfe8d77bbd065e6b678_WarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_580bdf8f-f6c0-4d49-8459-557794e69a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_580bdf8f-f6c0-4d49-8459-557794e69a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36eac481-217f-4200-ad60-6928f2bf236c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36eac481-217f-4200-ad60-6928f2bf236c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25a96747-ac9e-483d-97b6-820345145cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25a96747-ac9e-483d-97b6-820345145cb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_05ba3f41-be9a-45b6-a5d9-fe6e82c427e6" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_05ba3f41-be9a-45b6-a5d9-fe6e82c427e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c83dc59-e3c9-4b86-bedf-d42b351afc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c83dc59-e3c9-4b86-bedf-d42b351afc8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd07a5e-b4a0-4b95-8467-8a672dcb8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_d9ef822e-63cd-48ee-afb1-a55c99b3f064" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_d9ef822e-63cd-48ee-afb1-a55c99b3f064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_5724e3cc-b9ee-4f54-8064-5dd9f8066717" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_5724e3cc-b9ee-4f54-8064-5dd9f8066717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_06eee409-1b75-435f-85c0-b5db1d08df8b" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_06eee409-1b75-435f-85c0-b5db1d08df8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_051e2fdc-9222-4c55-9976-a9647fd919f2" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_051e2fdc-9222-4c55-9976-a9647fd919f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_267791c6-29a9-44ad-b09b-c435185ad4a3" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ec2666aa-7c5d-4236-aa03-f360e366fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ec2666aa-7c5d-4236-aa03-f360e366fcf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_6ead9e6a-c7b4-4b3e-888c-603e24752040" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:to="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_6ead9e6a-c7b4-4b3e-888c-603e24752040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d628fc97-1ca1-4321-9f0f-d5f316114177_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d628fc97-1ca1-4321-9f0f-d5f316114177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6b7a1457-059f-4805-83d8-1db6281e7ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:to="loc_us-gaap_WarrantMember_6b7a1457-059f-4805-83d8-1db6281e7ec0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails" xlink:type="extended" id="i1c2b0f0345684511bda798a4d9c9333e_EquityIncentivePlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessStockSharesAuthorized_56e4dac5-65a0-4bc9-bc81-bc27a4fcabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ExcessStockSharesAuthorized_56e4dac5-65a0-4bc9-bc81-bc27a4fcabeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice_2fddc8a7-7d2a-4c2a-a7d1-bc19e55499e0" xlink:href="kprx-20221231.xsd#kprx_PercentageOfExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_PercentageOfExercisePrice_2fddc8a7-7d2a-4c2a-a7d1-bc19e55499e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6944b963-9979-4922-924a-e2ce8caebbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6944b963-9979-4922-924a-e2ce8caebbd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c4e4c27-817e-4675-a2e0-c6c55e417330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c4e4c27-817e-4675-a2e0-c6c55e417330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a5a5f41d-547a-407a-80c8-df406e73d018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a5a5f41d-547a-407a-80c8-df406e73d018" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab08cee2-ea98-4975-92e1-8570f00887aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab08cee2-ea98-4975-92e1-8570f00887aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30863577-439d-4f77-9a32-387895af0a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30863577-439d-4f77-9a32-387895af0a1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6600694b-32a0-47d6-8ecf-d637ebe2d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6600694b-32a0-47d6-8ecf-d637ebe2d14c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e89bd29c-df5c-4e19-9364-c7f5fc292ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e89bd29c-df5c-4e19-9364-c7f5fc292ee9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_292c2b86-1688-41f5-a1f2-e08772138eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_292c2b86-1688-41f5-a1f2-e08772138eff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_3fbbab94-713a-435c-8efd-f11983e35d20" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_3fbbab94-713a-435c-8efd-f11983e35d20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_efd4210e-a81f-4438-b716-458ddf014017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_efd4210e-a81f-4438-b716-458ddf014017" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_036c7da0-6e00-413b-a1e3-6db8af239699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_036c7da0-6e00-413b-a1e3-6db8af239699" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_9ced3d60-826b-44a9-976f-c8b7bf971112" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_9ced3d60-826b-44a9-976f-c8b7bf971112" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c30e4b2-cab9-42ae-a5b4-f7ab8f5fe305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c30e4b2-cab9-42ae-a5b4-f7ab8f5fe305" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54e57d84-2864-4197-b62f-98fe2c763343_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:to="loc_us-gaap_PlanNameDomain_54e57d84-2864-4197-b62f-98fe2c763343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:to="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member_15667918-f4df-4d13-bfc1-743ddfe4af3c" xlink:href="kprx-20221231.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:to="loc_kprx_EquityIncentivePlan2014Member_15667918-f4df-4d13-bfc1-743ddfe4af3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember_6c7f5d9b-de57-4cce-875e-86e3ae062fd9" xlink:href="kprx-20221231.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:to="loc_kprx_EmployeeStockPurchasePlanMember_6c7f5d9b-de57-4cce-875e-86e3ae062fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_294723e3-02d8-43a6-b2be-d0b83b8d1b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_294723e3-02d8-43a6-b2be-d0b83b8d1b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4d72e9dc-cc36-4429-980e-880e0e43122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:to="loc_us-gaap_RestrictedStockMember_4d72e9dc-cc36-4429-980e-880e0e43122a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_902015a3-c01b-4c79-9327-afd665125fde_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_902015a3-c01b-4c79-9327-afd665125fde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_5bbd9e93-904d-444e-987c-5f881725a8e2" xlink:href="kprx-20221231.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:to="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_5bbd9e93-904d-444e-987c-5f881725a8e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a63eaef9-fdbf-48e9-95b2-c2cf71b15478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:to="loc_us-gaap_VestingDomain_a63eaef9-fdbf-48e9-95b2-c2cf71b15478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:to="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73597486-30e4-4476-a1ad-2c3afc9700b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73597486-30e4-4476-a1ad-2c3afc9700b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cc84fe31-d0cc-4926-baab-b3a14a424e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cc84fe31-d0cc-4926-baab-b3a14a424e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa810a53-15c9-487c-92d9-fecf039741bc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:to="loc_srt_RangeMember_fa810a53-15c9-487c-92d9-fecf039741bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:to="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72474b0f-4c35-4b5a-b575-a8286b04296d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:to="loc_srt_MinimumMember_72474b0f-4c35-4b5a-b575-a8286b04296d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcf8b798-7627-4d13-ad65-28bfdc24e688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:to="loc_srt_MaximumMember_bcf8b798-7627-4d13-ad65-28bfdc24e688" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended" id="i971bfe06d25c4ca08fe2f3dbe50b3a87_EquityIncentivePlanRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3785b5-55fa-44c7-861f-ed000944a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3785b5-55fa-44c7-861f-ed000944a9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929fe1bf-5e45-4376-8a7e-bfa41656d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929fe1bf-5e45-4376-8a7e-bfa41656d61f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8361ae21-528c-4da1-86ab-116701930513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8361ae21-528c-4da1-86ab-116701930513" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af5278c5-361b-4113-88e1-d5b43448263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af5278c5-361b-4113-88e1-d5b43448263f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af5c9771-aafa-4873-b2d9-ba56ad4f1eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e85e73c-866c-4b18-aa4b-9d8be9130846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e85e73c-866c-4b18-aa4b-9d8be9130846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cdbdd98-68ad-4cf3-a058-bc8d80fa3dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cdbdd98-68ad-4cf3-a058-bc8d80fa3dbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89a46983-b7cd-4c16-a148-fa993d543883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89a46983-b7cd-4c16-a148-fa993d543883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f0a557d5-f771-4a3f-8228-b177d11ba8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f0a557d5-f771-4a3f-8228-b177d11ba8e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_954215ad-65df-4fe2-a674-d1b34c6c5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_72b58e19-9118-4e0f-9c27-bb5765b2fdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_72b58e19-9118-4e0f-9c27-bb5765b2fdc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:to="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c28e6261-6611-43ee-b84a-41c5d58a96ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c28e6261-6611-43ee-b84a-41c5d58a96ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8e68f5b7-c019-42a4-a160-fddec5ee5984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:to="loc_us-gaap_RestrictedStockMember_8e68f5b7-c019-42a4-a160-fddec5ee5984" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails" xlink:type="extended" id="ie8a36e112f88468ab569ea010d089120_EquityIncentivePlanStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_61d2540e-32db-4bac-bfe2-d83026b90ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_61d2540e-32db-4bac-bfe2-d83026b90ea6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30308427-19a5-4059-be55-44f05c32d670_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30308427-19a5-4059-be55-44f05c32d670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_751968e9-8a8c-4a32-a7ab-3a6eca0a441a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_751968e9-8a8c-4a32-a7ab-3a6eca0a441a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1fb1f05d-c7ba-4364-9111-ec9a01cfdbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1fb1f05d-c7ba-4364-9111-ec9a01cfdbb5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i6336ad46ca5e41b2a95529361971de13_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2d0016a3-7b2a-4890-89cd-dc40e93c87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2d0016a3-7b2a-4890-89cd-dc40e93c87cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1fe0962b-ae6c-4eab-94a9-90d86a5df68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1fe0962b-ae6c-4eab-94a9-90d86a5df68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6b3424d0-3e1f-4612-a0fb-1f10b7f8b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6b3424d0-3e1f-4612-a0fb-1f10b7f8b6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_329929f7-4764-4ea0-a58a-035675eb19c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_329929f7-4764-4ea0-a58a-035675eb19c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_a60c93a1-ef83-4b5f-9567-0aa83cbc7544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_a60c93a1-ef83-4b5f-9567-0aa83cbc7544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2b4473f8-e4c5-47f0-b2c5-73796bcd6395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:to="loc_us-gaap_ResearchMember_2b4473f8-e4c5-47f0-b2c5-73796bcd6395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_de003c63-0e71-44b5-a863-e874ba11853a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_de003c63-0e71-44b5-a863-e874ba11853a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_dfeef389-9443-4dd1-922c-ef123fe6336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_DomesticCountryMember_dfeef389-9443-4dd1-922c-ef123fe6336f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5d113801-6689-4edd-831d-3256565af865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_ForeignCountryMember_5d113801-6689-4edd-831d-3256565af865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4ffda949-0713-4c73-82dc-53e2a9b4e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4ffda949-0713-4c73-82dc-53e2a9b4e6dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:to="loc_us-gaap_TaxPeriodDomain_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:to="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_7ede0705-ea29-455b-adb1-c42d3e80dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:to="loc_us-gaap_LatestTaxYearMember_7ede0705-ea29-455b-adb1-c42d3e80dcf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i1eaa0518da004092a78499ba4c5438b7_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases_dc5e7a54-4608-4e74-9686-07eec6b9aff2" xlink:href="kprx-20221231.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_LesseeNumberOfOperatingLeases_dc5e7a54-4608-4e74-9686-07eec6b9aff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_7c46a0c2-e549-42e9-9a98-83b88137145c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_AreaOfLand_7c46a0c2-e549-42e9-9a98-83b88137145c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_eef149b7-21d5-4f52-9615-c7b61b60a056" xlink:href="kprx-20221231.xsd#kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_eef149b7-21d5-4f52-9615-c7b61b60a056" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4ebf79cf-aa82-42f3-925b-91211edaf0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4ebf79cf-aa82-42f3-925b-91211edaf0ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities_6aa9c2d1-23f7-4cd1-af92-050fe5c27c54" xlink:href="kprx-20221231.xsd#kprx_OperatingLeaseInterestOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities_6aa9c2d1-23f7-4cd1-af92-050fe5c27c54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements_640357e4-f78a-42f6-9b08-d3fd1a270675" xlink:href="kprx-20221231.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_NumberOfLicenseAgreements_640357e4-f78a-42f6-9b08-d3fd1a270675" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfRoyaltiesOnNetSales_05157c28-44e8-48b7-9b30-5b043107599e" xlink:href="kprx-20221231.xsd#kprx_PercentageOfRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PercentageOfRoyaltiesOnNetSales_05157c28-44e8-48b7-9b30-5b043107599e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ff4898c3-74a8-4c93-83f8-a5940db2ab67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ff4898c3-74a8-4c93-83f8-a5940db2ab67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8ee3f376-1a98-4123-a28c-a142a8e3ae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_ContractualObligation_8ee3f376-1a98-4123-a28c-a142a8e3ae6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DevelopmentAndCommercialMilestonesTerm_e0815bbd-03f5-4492-9029-fcfe14dad0e8" xlink:href="kprx-20221231.xsd#kprx_DevelopmentAndCommercialMilestonesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_DevelopmentAndCommercialMilestonesTerm_e0815bbd-03f5-4492-9029-fcfe14dad0e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_b960942f-91ff-44dd-b9e1-50b9c9930f59" xlink:href="kprx-20221231.xsd#kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_b960942f-91ff-44dd-b9e1-50b9c9930f59" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7f8aae75-9f7d-49e1-91fa-32b8d0c72dd9" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsExpectedMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7f8aae75-9f7d-49e1-91fa-32b8d0c72dd9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentOfAnnualFee_9fb115dc-b3c3-4992-9701-b49d380bd9ec" xlink:href="kprx-20221231.xsd#kprx_PaymentOfAnnualFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PaymentOfAnnualFee_9fb115dc-b3c3-4992-9701-b49d380bd9ec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c3574b1e-be90-4f8d-b175-581f6d5c60ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c3574b1e-be90-4f8d-b175-581f6d5c60ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_ae81e0cb-2eec-4c36-a63f-dcc0663fafc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:to="loc_us-gaap_LicensingAgreementsMember_ae81e0cb-2eec-4c36-a63f-dcc0663fafc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6502218-5168-46fd-925e-afcf8b3303d7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:to="loc_srt_ProductsAndServicesDomain_d6502218-5168-46fd-925e-afcf8b3303d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:to="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_adfb234c-2f1f-4947-8f30-1504070067f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:to="loc_us-gaap_LicenseMember_adfb234c-2f1f-4947-8f30-1504070067f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Kio101Member_ce853105-1222-42a7-9160-fc9468ab4fbc" xlink:href="kprx-20221231.xsd#kprx_Kio101Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:to="loc_kprx_Kio101Member_ce853105-1222-42a7-9160-fc9468ab4fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c41e97e5-1cb9-4d3a-8a06-e98119b85f29_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c41e97e5-1cb9-4d3a-8a06-e98119b85f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c3c95086-bf83-4da4-b604-4dcab3be3a2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:to="loc_srt_ScenarioForecastMember_c3c95086-bf83-4da4-b604-4dcab3be3a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3277b60-f942-4b78-bf23-fc7b085e56b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3277b60-f942-4b78-bf23-fc7b085e56b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MediolanumAgreementMember_3a906e7f-3264-4d22-8716-2ffc80660d29" xlink:href="kprx-20221231.xsd#kprx_MediolanumAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:to="loc_kprx_MediolanumAgreementMember_3a906e7f-3264-4d22-8716-2ffc80660d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:to="loc_us-gaap_RelatedPartyDomain_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:to="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SentrXAnimalCareIncMember_e9b21574-838b-4f63-8a90-94130c253eab" xlink:href="kprx-20221231.xsd#kprx_SentrXAnimalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:to="loc_kprx_SentrXAnimalCareIncMember_e9b21574-838b-4f63-8a90-94130c253eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioDomain_2a8f75f5-bd4c-424e-9b72-57eb3be057de_default" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:to="loc_kprx_RoyaltyScenarioDomain_2a8f75f5-bd4c-424e-9b72-57eb3be057de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:to="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ForFirst250MillionNetSalesMember_c12feff2-fccc-4b4c-9f4f-fae20b6f08cb" xlink:href="kprx-20221231.xsd#kprx_ForFirst250MillionNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_ForFirst250MillionNetSalesMember_c12feff2-fccc-4b4c-9f4f-fae20b6f08cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Between250And500MillionNetSalesMember_b5f66a10-85d3-4e1d-bb67-9d80c579abed" xlink:href="kprx-20221231.xsd#kprx_Between250And500MillionNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_Between250And500MillionNetSalesMember_b5f66a10-85d3-4e1d-bb67-9d80c579abed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NetSalesOver500MillionMember_0df4ee66-8b8c-40c1-8d6f-12ac5a88c15c" xlink:href="kprx-20221231.xsd#kprx_NetSalesOver500MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_NetSalesOver500MillionMember_0df4ee66-8b8c-40c1-8d6f-12ac5a88c15c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="extended" id="i41c8223ae29b461db677883d34bc6fe1_AcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_91b0d003-25d5-40c8-b02e-7a4055fdb642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_91b0d003-25d5-40c8-b02e-7a4055fdb642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a86ca6-0f36-43e6-93af-70630af00809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a86ca6-0f36-43e6-93af-70630af00809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2243965b-379d-48e5-b168-f34a4cbdf9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2243965b-379d-48e5-b168-f34a4cbdf9d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionEarnoutConsideration_023f8676-eac3-4b77-a817-196479d13829" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionEarnoutConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_BusinessAcquisitionEarnoutConsideration_023f8676-eac3-4b77-a817-196479d13829" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_572e4a95-d5e7-4a20-b433-f10467650a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_SharePrice_572e4a95-d5e7-4a20-b433-f10467650a9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsToAcquireBusinessesFairValue_440b9093-efbc-4786-80d0-f98c1de16b66" xlink:href="kprx-20221231.xsd#kprx_PaymentsToAcquireBusinessesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_PaymentsToAcquireBusinessesFairValue_440b9093-efbc-4786-80d0-f98c1de16b66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_515812cf-423e-41c5-8cc6-7654f13f17bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_515812cf-423e-41c5-8cc6-7654f13f17bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_e3afd67e-63fb-4bea-b581-1909b8d639a7" xlink:href="kprx-20221231.xsd#kprx_ThresholdPeriodOfVolumeWeightedAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_e3afd67e-63fb-4bea-b581-1909b8d639a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_VolumeWeightedAveragePrice_7928fe99-53e7-4120-a0ff-dc68f4b4b251" xlink:href="kprx-20221231.xsd#kprx_VolumeWeightedAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_VolumeWeightedAveragePrice_7928fe99-53e7-4120-a0ff-dc68f4b4b251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_88d129db-04a2-4f50-9b15-74facec5a95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_88d129db-04a2-4f50-9b15-74facec5a95d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_323604d2-468e-464d-87a5-028e93aeea40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_323604d2-468e-464d-87a5-028e93aeea40" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e37e4e7-43fb-44ec-90a7-88af1af9dabf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e37e4e7-43fb-44ec-90a7-88af1af9dabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_023fb245-5abd-471a-8b85-0fda552d3fb1" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:to="loc_kprx_BayonMember_023fb245-5abd-471a-8b85-0fda552d3fb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_abcf0e89-2238-4962-9134-1697fc4b4f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_abcf0e89-2238-4962-9134-1697fc4b4f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EarnOutConsiderationMember_996068e7-feb2-42f4-9219-dd0209b5a88d" xlink:href="kprx-20221231.xsd#kprx_EarnOutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:to="loc_kprx_EarnOutConsiderationMember_996068e7-feb2-42f4-9219-dd0209b5a88d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DueToCreditorMember_3e923be2-3d26-4270-9dbf-91df5f1a5904" xlink:href="kprx-20221231.xsd#kprx_DueToCreditorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:to="loc_kprx_DueToCreditorMember_3e923be2-3d26-4270-9dbf-91df5f1a5904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeDomain_adc19e5b-a938-475d-b76f-9f87d6e10818_default" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:to="loc_kprx_MilestoneTypeDomain_adc19e5b-a938-475d-b76f-9f87d6e10818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:to="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PhaseOneBMilestonesMember_8d5c6db6-ac6b-448e-bb77-3432ffd1e4e7" xlink:href="kprx-20221231.xsd#kprx_PhaseOneBMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:to="loc_kprx_PhaseOneBMilestonesMember_8d5c6db6-ac6b-448e-bb77-3432ffd1e4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RemainingMilestonesMember_4c9258ce-86e3-44a4-b477-d54905580064" xlink:href="kprx-20221231.xsd#kprx_RemainingMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:to="loc_kprx_RemainingMilestonesMember_4c9258ce-86e3-44a4-b477-d54905580064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe806c4f-d401-4e60-aba9-81cad8b6a2a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe806c4f-d401-4e60-aba9-81cad8b6a2a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember_a08ed7dd-8af1-444c-832d-90bea061cd10" xlink:href="kprx-20221231.xsd#kprx_IfMilestonePaymentsAreExercisedForSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:to="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember_a08ed7dd-8af1-444c-832d-90bea061cd10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsPurchasepriceallocationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails" xlink:type="extended" id="i3ad4f1bad62040ad9a8de507ec30527a_AcquisitionsPurchasepriceallocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2d6594b9-be45-4e2c-ba5f-94ed0550235f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2d6594b9-be45-4e2c-ba5f-94ed0550235f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_35d68679-a19f-4478-b1e5-4e8c02c0b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_35d68679-a19f-4478-b1e5-4e8c02c0b36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GoodwillAcquired_49f4821c-738c-4b81-a491-386e1a477805" xlink:href="kprx-20221231.xsd#kprx_GoodwillAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_kprx_GoodwillAcquired_49f4821c-738c-4b81-a491-386e1a477805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_12484011-80d3-47d0-892e-be24e3503b4c" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_12484011-80d3-47d0-892e-be24e3503b4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5e1bed3-0d99-4636-995b-07c8193fa1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5e1bed3-0d99-4636-995b-07c8193fa1e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b45f06a-2203-4b7a-806a-72f35285b640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b45f06a-2203-4b7a-806a-72f35285b640" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_35dca61d-ba89-4f62-9c89-708c747bd880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_35dca61d-ba89-4f62-9c89-708c747bd880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5d00ab2a-bfbf-4d5d-bf9b-ba70275ef58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5d00ab2a-bfbf-4d5d-bf9b-ba70275ef58d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_664fa1c3-b32b-4dac-8a18-a38697986811_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_664fa1c3-b32b-4dac-8a18-a38697986811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_bbc2fe0a-3975-4d8b-aa1b-c60ab3313514" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:to="loc_kprx_BayonMember_bbc2fe0a-3975-4d8b-aa1b-c60ab3313514" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsFairvalueofconsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails" xlink:type="extended" id="if87ade18192740378d9fd6226349ea40_AcquisitionsFairvalueofconsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_54ed8028-1aa7-4542-933e-0ff3d5b16977" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_54ed8028-1aa7-4542-933e-0ff3d5b16977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent_0fd8065c-1cd7-487f-b2cc-869e9a985784" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent_0fd8065c-1cd7-487f-b2cc-869e9a985784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_524a2abe-c449-475c-8676-1f91a02d0f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_524a2abe-c449-475c-8676-1f91a02d0f7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_8a7f3ce2-c448-43c1-a27a-ea51549d1e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_8a7f3ce2-c448-43c1-a27a-ea51549d1e3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_846c686c-a3f0-43d8-a4f1-3d6b49f7b40b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_846c686c-a3f0-43d8-a4f1-3d6b49f7b40b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7a2dbfe7-a029-4ca0-b423-34a1d8b41253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7a2dbfe7-a029-4ca0-b423-34a1d8b41253" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_805dc74d-338d-47c2-bbde-25dc910f6197" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:to="loc_kprx_BayonMember_805dc74d-338d-47c2-bbde-25dc910f6197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:to="loc_us-gaap_EquityComponentDomain_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:to="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4af3a967-8050-42bc-a799-9d09d1359de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:to="loc_us-gaap_CommonStockMember_4af3a967-8050-42bc-a799-9d09d1359de0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="i1fcb85654cc64bc6b9a6258aee79727a_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5aeecd78-8e71-4c32-b1ab-52ed4ddce47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5aeecd78-8e71-4c32-b1ab-52ed4ddce47a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9958f134-b7c1-44e4-a1aa-8de196628867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9958f134-b7c1-44e4-a1aa-8de196628867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d6c458f-71c4-428b-b4da-5025ddc5809a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d6c458f-71c4-428b-b4da-5025ddc5809a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2eed22a-cb0d-4525-a382-c82e37eed6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2eed22a-cb0d-4525-a382-c82e37eed6cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_607972e3-65a0-472c-b2b8-d82acff9f7ec" xlink:href="kprx-20221231.xsd#kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_607972e3-65a0-472c-b2b8-d82acff9f7ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantTerm_302f5237-654e-413a-91b2-9384665752d6" xlink:href="kprx-20221231.xsd#kprx_WarrantTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_WarrantTerm_302f5237-654e-413a-91b2-9384665752d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_7ed9660a-8627-4f3c-9fa4-ffbdb8e4993d" xlink:href="kprx-20221231.xsd#kprx_SharePurchaseAgreementSaleOfStockMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_7ed9660a-8627-4f3c-9fa4-ffbdb8e4993d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_10c58159-979a-407d-90b4-4254b80e2d2f" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromSaleOfStockSharePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_10c58159-979a-407d-90b4-4254b80e2d2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_e5c02da4-0e9a-4e5d-89fc-72302a49eb01" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_e5c02da4-0e9a-4e5d-89fc-72302a49eb01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_aeeaace8-e213-47e6-92f7-235b636ccea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_aeeaace8-e213-47e6-92f7-235b636ccea9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_76dbfe14-3379-4268-b0e8-47f22de7d544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:to="loc_us-gaap_SubsequentEventMember_76dbfe14-3379-4268-b0e8-47f22de7d544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4d66d7a3-bb69-4965-a98d-f9f6f3e3a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:to="loc_us-gaap_PrivatePlacementMember_4d66d7a3-bb69-4965-a98d-f9f6f3e3a06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_344bd15d-b91b-4838-9c99-1270756828b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:to="loc_us-gaap_ClassOfStockDomain_344bd15d-b91b-4838-9c99-1270756828b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:to="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_452dbb2e-be3d-483e-9d62-9d7c783bc431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:to="loc_us-gaap_CommonStockMember_452dbb2e-be3d-483e-9d62-9d7c783bc431" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>kprx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_kprx_RemainingMilestonesMember_90ccc03f-3b46-4593-a76d-5a433fefa5ea_terseLabel_en-US" xlink:label="lab_kprx_RemainingMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestones</link:label>
    <link:label id="lab_kprx_RemainingMilestonesMember_label_en-US" xlink:label="lab_kprx_RemainingMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestones</link:label>
    <link:label id="lab_kprx_RemainingMilestonesMember_documentation_en-US" xlink:label="lab_kprx_RemainingMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to remaining milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RemainingMilestonesMember" xlink:href="kprx-20221231.xsd#kprx_RemainingMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RemainingMilestonesMember" xlink:to="lab_kprx_RemainingMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0ab09999-4733-4b74-8ca8-00e4696ff6be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_JadeMember_c4d85439-0aa7-4b4f-9e4c-b8e1116466a2_terseLabel_en-US" xlink:label="lab_kprx_JadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade</link:label>
    <link:label id="lab_kprx_JadeMember_label_en-US" xlink:label="lab_kprx_JadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade</link:label>
    <link:label id="lab_kprx_JadeMember_documentation_en-US" xlink:label="lab_kprx_JadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Jade.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeMember" xlink:href="kprx-20221231.xsd#kprx_JadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_JadeMember" xlink:to="lab_kprx_JadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase2Member_fe9efcfa-997d-41e0-a390-5770500e877b_terseLabel_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful completion of Phase 2 $0.990 million</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase2Member_label_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 2 [Member]</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase2Member_documentation_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase2Member" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SuccessfulCompletionOfPhase2Member" xlink:to="lab_kprx_SuccessfulCompletionOfPhase2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d0b5599a-57d1-4e8d-b1fb-6dae99e10bfc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_b0315b3d-c9e6-4a20-abc7-e7c7227ef1c3_terseLabel_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CommitmentsAndContingenciesTable" xlink:to="lab_kprx_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_74a0b913-a468-43bd-90e8-eb7a430f628e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_017cce88-5564-4fb7-8e9e-b8888d1a136c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_846d3d7d-5593-4e7d-90c9-b9c9208a3b5e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c9c3aded-44fb-45a6-af47-b2ae05dc4bea_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a2ee2953-a71e-4ddd-a182-bb1d3c7e3bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0fba7d2b-c184-4b2d-95d6-931b4871b2bb_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_3e6ceac7-c71e-40fc-984c-76367c893474_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PercentageOfExercisePrice_335248fb-4c9c-4479-975b-0e11195aaba8_terseLabel_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of exercise price</link:label>
    <link:label id="lab_kprx_PercentageOfExercisePrice_label_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Exercise Price</link:label>
    <link:label id="lab_kprx_PercentageOfExercisePrice_documentation_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice" xlink:href="kprx-20221231.xsd#kprx_PercentageOfExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PercentageOfExercisePrice" xlink:to="lab_kprx_PercentageOfExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7790c7d5-29f7-4fd5-a1d4-027e47f082cf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d282a093-1ce7-44e6-831d-28a8a9b300e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4edfff2e-66d4-4528-a676-f68410ea9d35_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BeginningOfPhase3Member_09dcca84-0b78-4a9e-9c55-ba3f0452a3ce_terseLabel_en-US" xlink:label="lab_kprx_BeginningOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of Phase 3</link:label>
    <link:label id="lab_kprx_BeginningOfPhase3Member_label_en-US" xlink:label="lab_kprx_BeginningOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of Phase 3 [Member]</link:label>
    <link:label id="lab_kprx_BeginningOfPhase3Member_documentation_en-US" xlink:label="lab_kprx_BeginningOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of Phase 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BeginningOfPhase3Member" xlink:href="kprx-20221231.xsd#kprx_BeginningOfPhase3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BeginningOfPhase3Member" xlink:to="lab_kprx_BeginningOfPhase3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_784b75fb-6da7-4c62-850e-8fab9c05b691_terseLabel_en-US" xlink:label="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold period of volume weighted average price</link:label>
    <link:label id="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_label_en-US" xlink:label="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Period Of Volume Weighted Average Price</link:label>
    <link:label id="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_documentation_en-US" xlink:label="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold period of volume weighted average price to determine the fair value of share issued in a business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:href="kprx-20221231.xsd#kprx_ThresholdPeriodOfVolumeWeightedAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:to="lab_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_22dc8ed0-e569-4b92-b466-7b079351bf08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c4f7f7e9-e604-41ce-968a-059a300001bb_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_fe7e70ea-0d16-4172-9521-34f00e152f7a_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_us-gaap_SeriesDPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8e2d9934-ed56-4599-9d30-20682818c6a1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96651bec-0776-4d27-9abc-9deea4882433_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f587fa3f-61ec-4a36-a254-5a0964b51c15_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantIssuancePlacementAgentFees_5fae68d5-86ee-48a4-b7d6-c8b9df31fdf0_terseLabel_en-US" xlink:label="lab_kprx_WarrantIssuancePlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant inducement, placement agent fees</link:label>
    <link:label id="lab_kprx_WarrantIssuancePlacementAgentFees_label_en-US" xlink:label="lab_kprx_WarrantIssuancePlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issuance, Placement Agent Fees</link:label>
    <link:label id="lab_kprx_WarrantIssuancePlacementAgentFees_documentation_en-US" xlink:label="lab_kprx_WarrantIssuancePlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issuance, Placement Agent Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantIssuancePlacementAgentFees" xlink:href="kprx-20221231.xsd#kprx_WarrantIssuancePlacementAgentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantIssuancePlacementAgentFees" xlink:to="lab_kprx_WarrantIssuancePlacementAgentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_5a9922c1-c975-4d27-bdf8-9adc0d035e11_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_ee476496-eed6-4180-8582-bb44292dcd82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_95ecfa1d-8090-404c-b714-89d6d4e2b537_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_6fbc13de-3041-4c19-9f65-99f769da8982_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Preferred Stock into Common Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessAcquisitionHoldbackSharesTerm_fde6b5a4-ba86-4cc7-aa2d-8eebfe29ba37_terseLabel_en-US" xlink:label="lab_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares, term</link:label>
    <link:label id="lab_kprx_BusinessAcquisitionHoldbackSharesTerm_label_en-US" xlink:label="lab_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Holdback Shares, Term</link:label>
    <link:label id="lab_kprx_BusinessAcquisitionHoldbackSharesTerm_documentation_en-US" xlink:label="lab_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Holdback Shares, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionHoldbackSharesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:to="lab_kprx_BusinessAcquisitionHoldbackSharesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_FairValueContingentConsiderationAbstract_9f4c56a1-9489-4a94-bfd4-9d063033848e_terseLabel_en-US" xlink:label="lab_kprx_FairValueContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration:</link:label>
    <link:label id="lab_kprx_FairValueContingentConsiderationAbstract_label_en-US" xlink:label="lab_kprx_FairValueContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Contingent Consideration [Abstract]</link:label>
    <link:label id="lab_kprx_FairValueContingentConsiderationAbstract_documentation_en-US" xlink:label="lab_kprx_FairValueContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Its represent fair value contingent consideration abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueContingentConsiderationAbstract" xlink:href="kprx-20221231.xsd#kprx_FairValueContingentConsiderationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract" xlink:to="lab_kprx_FairValueContingentConsiderationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_Kio101Member_8d3434ab-5ac7-41ff-bfc3-9d2b413a7ad7_terseLabel_en-US" xlink:label="lab_kprx_Kio101Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KIO-101</link:label>
    <link:label id="lab_kprx_Kio101Member_label_en-US" xlink:label="lab_kprx_Kio101Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KIO-101 [Member]</link:label>
    <link:label id="lab_kprx_Kio101Member_documentation_en-US" xlink:label="lab_kprx_Kio101Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the KIO-101.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Kio101Member" xlink:href="kprx-20221231.xsd#kprx_Kio101Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_Kio101Member" xlink:to="lab_kprx_Kio101Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_831c55f3-1ecf-47de-8c83-4e71628c6290_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_5571b055-c747-45bc-aed5-fd6fb2873eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of preliminary purchase price allocation and estimated fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3e8eabd9-955e-4e92-a4f8-c2935757e5c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to Bayon Shareholders at Acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_4b4bb6b8-b023-48c6-9223-ccde7f7a106f_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_661722bb-6c4d-4769-8491-cd218778b3d4_terseLabel_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holders Owing More Than Ten Percentage Voting Rights</link:label>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_label_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holders Owing More Than Ten Percentage Voting Rights [Member]</link:label>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_documentation_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:href="kprx-20221231.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:to="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_adcdfb55-7d92-4266-9ad3-ffa23f450bee_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ef53989-e531-4040-bcee-6eaacf35089b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b6383231-300d-4426-9ce0-1c385b7cc9c2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ac6937a2-25d4-4a0c-87ee-8c0932303000_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_97db67ed-3024-4366-b625-a10f3a4441bc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_e047b895-a452-455e-b235-ce8a9e0c19af_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fcf45032-b35d-42ef-8db0-116cb8b06350_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares of Common Stock Issuable</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CashOutflowFromLoanForgiveness_a0b6b060-0a0d-4e19-97a3-d735ea5eea16_negatedLabel_en-US" xlink:label="lab_kprx_CashOutflowFromLoanForgiveness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan Forgiveness</link:label>
    <link:label id="lab_kprx_CashOutflowFromLoanForgiveness_label_en-US" xlink:label="lab_kprx_CashOutflowFromLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Outflow from Loan Forgiveness</link:label>
    <link:label id="lab_kprx_CashOutflowFromLoanForgiveness_documentation_en-US" xlink:label="lab_kprx_CashOutflowFromLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash outflow associated with loan forgiveness.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CashOutflowFromLoanForgiveness" xlink:href="kprx-20221231.xsd#kprx_CashOutflowFromLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CashOutflowFromLoanForgiveness" xlink:to="lab_kprx_CashOutflowFromLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bf0bb6f0-66fa-41d2-9809-cdd6d9645e5f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_04c0501d-91c9-4920-8be3-ba05d3734593_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1528a685-e54a-4251-9370-1dd5246a0ccd_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_InducementWarrantMember_2fd3376a-6af6-48dc-b556-4c2d4780f418_terseLabel_en-US" xlink:label="lab_kprx_InducementWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Warrant</link:label>
    <link:label id="lab_kprx_InducementWarrantMember_label_en-US" xlink:label="lab_kprx_InducementWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Warrant [Member]</link:label>
    <link:label id="lab_kprx_InducementWarrantMember_documentation_en-US" xlink:label="lab_kprx_InducementWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InducementWarrantMember" xlink:href="kprx-20221231.xsd#kprx_InducementWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_InducementWarrantMember" xlink:to="lab_kprx_InducementWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c85133e8-196b-4e03-b131-58960b155e30_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_59df4e12-f481-48cd-bbe2-c05f45ef2129_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_38a97a0e-cee4-46f0-af33-3a104ce77c08_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_bd968d71-3ab4-4e17-8861-517a6a0bf89f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_3f602d85-9169-46d1-89a3-08ac9b8e4415_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Loan Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_7b8a60df-bd0d-4ab0-b2c6-e7a3afbe4640_terseLabel_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember" xlink:href="kprx-20221231.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EmployeeStockPurchasePlanMember" xlink:to="lab_kprx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MediolanumAgreementMember_277ebdb4-0115-4d2d-8613-743cd304e7e3_terseLabel_en-US" xlink:label="lab_kprx_MediolanumAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mediolanum Agreement</link:label>
    <link:label id="lab_kprx_MediolanumAgreementMember_label_en-US" xlink:label="lab_kprx_MediolanumAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mediolanum Agreement [Member]</link:label>
    <link:label id="lab_kprx_MediolanumAgreementMember_documentation_en-US" xlink:label="lab_kprx_MediolanumAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Mediolanum agreement .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MediolanumAgreementMember" xlink:href="kprx-20221231.xsd#kprx_MediolanumAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MediolanumAgreementMember" xlink:to="lab_kprx_MediolanumAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PhaseOneBMilestonesMember_64616126-0e33-4e36-9ad4-02ba5ec76f35_terseLabel_en-US" xlink:label="lab_kprx_PhaseOneBMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1b milestones</link:label>
    <link:label id="lab_kprx_PhaseOneBMilestonesMember_label_en-US" xlink:label="lab_kprx_PhaseOneBMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1b milestones</link:label>
    <link:label id="lab_kprx_PhaseOneBMilestonesMember_documentation_en-US" xlink:label="lab_kprx_PhaseOneBMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Phase one b milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PhaseOneBMilestonesMember" xlink:href="kprx-20221231.xsd#kprx_PhaseOneBMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PhaseOneBMilestonesMember" xlink:to="lab_kprx_PhaseOneBMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_89d24f03-821b-4e7d-a631-5f94a0fdaae0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_1711c186-19ee-47ca-9f24-306ad7d89131_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_34eed751-6a23-4364-af3a-a23e022365c9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_588c6762-ff3e-4d3d-8e80-8b808925a695_verboseLabel_en-US" xlink:label="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Non-Income Based Tax</link:label>
    <link:label id="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_label_en-US" xlink:label="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation State Non Income Based Tax Percent</link:label>
    <link:label id="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_documentation_en-US" xlink:label="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state non-income based tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:href="kprx-20221231.xsd#kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:to="lab_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment_f6f6ca7c-53e7-47f7-95b8-3cf32658c0dc_terseLabel_en-US" xlink:label="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price, per share, subject to adjustments (in usd per share)</link:label>
    <link:label id="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment_label_en-US" xlink:label="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Exercise Price, Per Share, Subject To Adjustment</link:label>
    <link:label id="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment_documentation_en-US" xlink:label="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share in exercise price of warrant, subject to adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:href="kprx-20221231.xsd#kprx_WarrantExercisePricePerShareSubjectToAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:to="lab_kprx_WarrantExercisePricePerShareSubjectToAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_eddef8bf-344d-4849-9986-1dcc4bbb6d22_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_dd3b6b13-7ef8-4d2e-a61b-fdedf003b3a4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_aa62d822-6345-46e2-be7a-a4984fe9df15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiora Common Stock , Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_11e7d382-b5fc-4ea5-ba77-3cd4de620371_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RegisteredDirectOfferingMember_6ac79889-9178-4b78-aa3b-42e557f3fe77_terseLabel_en-US" xlink:label="lab_kprx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_kprx_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_kprx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_kprx_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_kprx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RegisteredDirectOfferingMember" xlink:to="lab_kprx_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantTerm_b1a4af85-5a68-4279-b8f4-cf12deef2055_terseLabel_en-US" xlink:label="lab_kprx_WarrantTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_kprx_WarrantTerm_label_en-US" xlink:label="lab_kprx_WarrantTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Term</link:label>
    <link:label id="lab_kprx_WarrantTerm_documentation_en-US" xlink:label="lab_kprx_WarrantTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantTerm" xlink:href="kprx-20221231.xsd#kprx_WarrantTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantTerm" xlink:to="lab_kprx_WarrantTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PrivatePlacementWarrantsMember_db82fb4d-ae56-4737-a67f-594d6f91b354_terseLabel_en-US" xlink:label="lab_kprx_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:label id="lab_kprx_PrivatePlacementWarrantsMember_label_en-US" xlink:label="lab_kprx_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:label id="lab_kprx_PrivatePlacementWarrantsMember_documentation_en-US" xlink:label="lab_kprx_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrivatePlacementWarrantsMember" xlink:href="kprx-20221231.xsd#kprx_PrivatePlacementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PrivatePlacementWarrantsMember" xlink:to="lab_kprx_PrivatePlacementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2ad2e61d-ce67-4d41-a601-f10735af270b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_9aba0dbb-31bd-4932-9681-35db07e70dd8_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from issuance that warrant becomes exercisable</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period From Issuance That Warrant Becomes Exercisable</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period From Issuance That Warrant Becomes Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:to="lab_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_d8c9e35f-0bf4-4169-9023-019312b63502_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d84d04c6-a24c-4fa3-94da-d0d42d542999_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_c5ef44d2-3a56-4d4d-a105-cd412c15db5e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9c4f26ec-324b-44cc-8dc5-33db04352547_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b17f09c9-68e0-40b1-9e69-64d77e9dd543_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NetSalesOver500MillionMember_59f04ae5-dcb1-4a16-8a4a-b0a5346db0ea_terseLabel_en-US" xlink:label="lab_kprx_NetSalesOver500MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Over 500 Million</link:label>
    <link:label id="lab_kprx_NetSalesOver500MillionMember_label_en-US" xlink:label="lab_kprx_NetSalesOver500MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Over 500 Million [Member]</link:label>
    <link:label id="lab_kprx_NetSalesOver500MillionMember_documentation_en-US" xlink:label="lab_kprx_NetSalesOver500MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for over 500 million net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NetSalesOver500MillionMember" xlink:href="kprx-20221231.xsd#kprx_NetSalesOver500MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NetSalesOver500MillionMember" xlink:to="lab_kprx_NetSalesOver500MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_71853272-0f11-47b3-90db-4d9f0ba82f6f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_8acbf72a-419f-4511-bd06-a83ffb0497c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_e8b1db8d-23fd-4a6a-ab16-a793ac9e418a_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_6e1d43f1-d6e3-44e3-9862-bb4a9cde9442_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options granted</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Values</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Values.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cc64c3e8-79bc-421f-b9b7-d0a57a322a6a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock_dafc8abc-f2e4-40bf-9b8f-6259af7ae08a_terseLabel_en-US" xlink:label="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-Balance-Sheet Risk</link:label>
    <link:label id="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock_label_en-US" xlink:label="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Of Credit Risk And Of balance sheet Risk Policy [Policy Text Block]</link:label>
    <link:label id="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents of concentration of credit risk and off-balance-sheet risk policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:to="lab_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_8500720e-fe21-4202-b0f3-16b78bda311c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_8f2b5095-b989-46b4-b447-421b5ee6de7f_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of land</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae36f0d9-039f-43bd-90c3-44409a1b8eb3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_1d6c5593-2566-455f-872b-82dcb131ac2f_terseLabel_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trials</link:label>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_label_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trials Current</link:label>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent" xlink:href="kprx-20221231.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClinicalTrialsCurrent" xlink:to="lab_kprx_ClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bc7b90ae-0bf5-41ba-8594-460b6dec4455_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_88f467dc-a2cc-46dc-8b06-572a80e198e4_terseLabel_en-US" xlink:label="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Warrant Liability</link:label>
    <link:label id="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_label_en-US" xlink:label="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Reclassification Of Warrant Liability</link:label>
    <link:label id="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_documentation_en-US" xlink:label="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Reclassification Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:href="kprx-20221231.xsd#kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:to="lab_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cef3a438-7621-4be8-9645-479741f9edda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1fc22978-8b05-4272-8c5e-e94f21646b25_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_fe303b5e-5c19-4f50-b9ca-8b6723a41c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_20b160f8-d0da-412d-837d-b0605e8033b6_periodStartLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_8d224197-7d5f-4c8e-a413-11b75966a445_periodEndLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non vested Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_05a67f82-abc3-4c1d-8f5c-be70c1baa847_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5a7ea81-efaa-490c-9f1e-43dcc1647b93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9841f6ba-107b-402c-a71a-f146b0c3b144_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f9fb3c6b-4abe-4d71-b8ff-5a150ab920c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4bf9ef9f-b2a2-4c7a-a0c9-6b4f5ae83a91_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock_72f8ab24-ccb1-48b2-8985-348253c25b04_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Policy [Policy Text Block]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:to="lab_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_FdaApprovalMember_ecabd86d-7c99-41ea-9efa-50e7a43181b6_terseLabel_en-US" xlink:label="lab_kprx_FdaApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDA approval</link:label>
    <link:label id="lab_kprx_FdaApprovalMember_label_en-US" xlink:label="lab_kprx_FdaApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDA Approval [Member]</link:label>
    <link:label id="lab_kprx_FdaApprovalMember_documentation_en-US" xlink:label="lab_kprx_FdaApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDA Approval [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FdaApprovalMember" xlink:href="kprx-20221231.xsd#kprx_FdaApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_FdaApprovalMember" xlink:to="lab_kprx_FdaApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0dc6cf49-a212-48d1-b183-8988abd1efea_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ab9dd6b-f72b-4445-acf6-322ea82d9f4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca764dcb-124e-466c-943a-54c2060f43cd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_14f3f4fb-e0af-4376-96d7-f8bde9f951f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ecefcdd0-4a47-4a4e-a755-864d958bc44a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_04ffcfee-bd06-4c94-93c9-c8404c18fd53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock, Net of Offering Costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_20e11ae1-3bb1-42f7-8c02-98003b48218d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e4c85ae-27e5-4a83-97f9-ff53e3e162db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_b1bb9f96-39a9-4b90-afb4-2fef153ac923_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d8ac7cde-9340-4e8f-be07-f593bedbde88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_d0cbc988-90a2-48fc-9925-2022d8ea88b4_terseLabel_en-US" xlink:label="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for the Basis of Presentation and Principles of Consolidation. The principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="lab_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_bb5ee185-2213-4f86-bdde-42358f9f668a_totalLabel_en-US" xlink:label="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangible Assets and In-Process R&amp;D, Net</link:label>
    <link:label id="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Including In Process Research and Development</link:label>
    <link:label id="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets including In Process research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:to="lab_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_f4dc7de6-9086-4a75-a2df-4790796609d2_terseLabel_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Right-of-Use Assets</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_label_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Right-of-Use Assets</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_documentation_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase decrease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:href="kprx-20221231.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:to="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9974d87c-8008-491b-b68a-d6da6dae29de_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_daea94e1-b080-47f6-b644-bb51634b97f0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BayonAcquisitionMember_86aa1a1f-1c58-4b54-9cc6-f45789df6296_terseLabel_en-US" xlink:label="lab_kprx_BayonAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayon acquisition</link:label>
    <link:label id="lab_kprx_BayonAcquisitionMember_label_en-US" xlink:label="lab_kprx_BayonAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayon acquisition</link:label>
    <link:label id="lab_kprx_BayonAcquisitionMember_documentation_en-US" xlink:label="lab_kprx_BayonAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Bayon acquisition .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonAcquisitionMember" xlink:href="kprx-20221231.xsd#kprx_BayonAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BayonAcquisitionMember" xlink:to="lab_kprx_BayonAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_21a6ebe7-8bf6-4162-85d3-f5ede874fea1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4ea0acd4-7545-41b8-a5ef-aadbfb03afc8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9565a887-a288-4756-9f33-add6e7621abb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_ab5a333e-6eae-48d3-af63-3285012134c8_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options outstanding</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable and outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2a197112-16f3-46e6-8261-da3806836dd1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_34de4271-5283-4f5d-a01a-f014a87982d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_91220a32-e5e4-42e4-af37-484d89e00ef0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d9eff00-5cbe-4e3d-a7c5-23fb60dd28be_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_83170e14-3523-4484-ad4c-158aed8d8f33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_af373d15-ea01-444e-8c1b-ff6d9f4711ee_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_19ddfd93-44ed-4f90-bf18-d785ada0f4d5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_23a6d9e9-b215-46d1-a0e6-ed9778999bb4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_917fd545-7446-44ff-afb4-165294bb8392_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a81d9b0a-7a22-40d0-907a-28be002cdf8f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement_53a8a35a-a705-43bb-b40d-3bb86f57196e_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Inducement</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrant Inducement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantInducement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:to="lab_kprx_StockIssuedDuringPeriodValueWarrantInducement" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_5e490ce5-d942-413d-9a7f-b62f6e98ba09_terseLabel_en-US" xlink:label="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per preferred share, five thousand Class A warrants and five thousand Class B warrants (in usd per share)</link:label>
    <link:label id="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_label_en-US" xlink:label="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Preferred Share, Five Thousand Class A Warrants And Five Thousand Class B Warrants</link:label>
    <link:label id="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_documentation_en-US" xlink:label="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Preferred Share, Five Thousand Class A Warrants And Five Thousand Class B Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:to="lab_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RoyaltyScenarioDomain_37b57d09-fa3b-4f5d-8d10-caed284bc6da_terseLabel_en-US" xlink:label="lab_kprx_RoyaltyScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario [Domain]</link:label>
    <link:label id="lab_kprx_RoyaltyScenarioDomain_label_en-US" xlink:label="lab_kprx_RoyaltyScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario [Domain]</link:label>
    <link:label id="lab_kprx_RoyaltyScenarioDomain_documentation_en-US" xlink:label="lab_kprx_RoyaltyScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioDomain" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RoyaltyScenarioDomain" xlink:to="lab_kprx_RoyaltyScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_fc720ec5-7d5c-49f8-96fa-ae7829031541_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f12214c3-0cdf-4305-b3e1-244491cd31a6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiora Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_ffca75a4-2ab0-4c0a-9c3b-add2759bca09_terseLabel_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_label_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liabilities</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_documentation_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:to="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_DevelopmentAndCommercialMilestonesTerm_330accc3-8a80-47ee-986c-78fc2cb0fe58_terseLabel_en-US" xlink:label="lab_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercial milestones term</link:label>
    <link:label id="lab_kprx_DevelopmentAndCommercialMilestonesTerm_label_en-US" xlink:label="lab_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercial Milestones Term</link:label>
    <link:label id="lab_kprx_DevelopmentAndCommercialMilestonesTerm_documentation_en-US" xlink:label="lab_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Development and commercial milestones Term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:href="kprx-20221231.xsd#kprx_DevelopmentAndCommercialMilestonesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:to="lab_kprx_DevelopmentAndCommercialMilestonesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_bee6f4ca-5232-42b4-9681-2b9cbcc18c29_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_0c86aad7-80c6-4ccb-883c-19c2ba45803e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_40684812-f9a5-4c37-a28b-53b28266f86e_terseLabel_en-US" xlink:label="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cease payments not yet paid based on prevailing financial market conditions</link:label>
    <link:label id="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_label_en-US" xlink:label="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions</link:label>
    <link:label id="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_documentation_en-US" xlink:label="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:href="kprx-20221231.xsd#kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:to="lab_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_68dad315-e3b9-48bd-b138-45e903f36c87_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RelatedPartyTransactionsPolicyTextBlock_0823bccd-86fd-4d30-9019-df4b9208ff9d_terseLabel_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsPolicyTextBlock_label_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Policy Text Block]</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:to="lab_kprx_RelatedPartyTransactionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BayonMember_9def24ba-6425-4ed2-ab75-2235d1a868d3_terseLabel_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayon</link:label>
    <link:label id="lab_kprx_BayonMember_label_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayon</link:label>
    <link:label id="lab_kprx_BayonMember_documentation_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Bayon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BayonMember" xlink:to="lab_kprx_BayonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_d6cfe3b1-e2ff-405a-b2a4-ceb78a5ca1ae_terseLabel_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration at fair value</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_label_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Arrangements Fair Value</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_documentation_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of contingent consideration recognized as part of consideration transferred in business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:to="lab_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c2cd24b6-3599-4a6a-979c-c4de632a3f12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_20e470fe-b2ce-4934-8bd0-3870d8d5a2e4_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e212bdcc-e42e-406d-bcb1-8ee1381ff34d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CommonSharesMember_6487ec9f-4286-4b24-8394-85fa49e1c870_terseLabel_en-US" xlink:label="lab_kprx_CommonSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_kprx_CommonSharesMember_label_en-US" xlink:label="lab_kprx_CommonSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares [Member]</link:label>
    <link:label id="lab_kprx_CommonSharesMember_documentation_en-US" xlink:label="lab_kprx_CommonSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommonSharesMember" xlink:href="kprx-20221231.xsd#kprx_CommonSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CommonSharesMember" xlink:to="lab_kprx_CommonSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncomeTaxesLineItems_b14b39d5-b446-4066-a36f-6dd30d33c069_terseLabel_en-US" xlink:label="lab_kprx_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_kprx_IncomeTaxesLineItems_label_en-US" xlink:label="lab_kprx_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncomeTaxes [Line Items]</link:label>
    <link:label id="lab_kprx_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_kprx_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesLineItems" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncomeTaxesLineItems" xlink:to="lab_kprx_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eb544116-3995-49d5-94fa-b24d70cb3de4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_30ed66c7-ce2b-4e53-88f7-4d53c2910a03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ForFirst250MillionNetSalesMember_041905ee-703e-4fe6-8edc-b9d5c0e5ba80_terseLabel_en-US" xlink:label="lab_kprx_ForFirst250MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For The First 250 Million Net Sales</link:label>
    <link:label id="lab_kprx_ForFirst250MillionNetSalesMember_label_en-US" xlink:label="lab_kprx_ForFirst250MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For The First 250 Million Net Sales [Member]</link:label>
    <link:label id="lab_kprx_ForFirst250MillionNetSalesMember_documentation_en-US" xlink:label="lab_kprx_ForFirst250MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for first 250 million net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ForFirst250MillionNetSalesMember" xlink:href="kprx-20221231.xsd#kprx_ForFirst250MillionNetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ForFirst250MillionNetSalesMember" xlink:to="lab_kprx_ForFirst250MillionNetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_65a4bda2-e50c-46c6-b05a-d916d34fc951_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_df1c8f95-b486-4888-aed6-162ad7981163_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9ca550fd-42c7-4c49-afea-d4aaf80dba3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_e8531d77-9b3d-4ff7-bbd1-9f3baa96f68a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_787e9062-d1ff-4511-94d6-e2bced55ef63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3372042d-d97c-432f-bc85-bcd0af8d22dc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e923f81b-be5d-4683-b2cd-871b52a7235b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8702b847-0589-4cdb-867c-ce2f5ac41ff2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_21510b52-9b9f-4136-a6ee-03623c360725_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_fa7ab6e9-b5bd-45c0-aa4d-b241d8e86af1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and Benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5b14d9e-6ed0-4c3a-bebe-9b042929b8c6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8b0b932c-dd6b-4386-9d72-f6bb4c15cfaa_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f278ae5f-d901-41e7-9465-ef1071b306f5_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_aac6d301-000c-4f85-845f-0f8bf65ad571_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent Differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_b2e37d13-a149-4dfa-97a5-25c68d179e03_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d77b9353-467a-448b-9f3d-016b36b4d9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AuditInformationAbstract_label_en-US" xlink:label="lab_kprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_kprx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_kprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AuditInformationAbstract" xlink:href="kprx-20221231.xsd#kprx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AuditInformationAbstract" xlink:to="lab_kprx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd0089fb-4401-4e2e-bea6-d5dfda6dc7d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_02bc8f51-293a-4dff-9e20-578937a3be7e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_d5e05503-73c4-4cbe-8d29-05f20ccc2352_negatedLabel_en-US" xlink:label="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_label_en-US" xlink:label="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accounts Payable and Other Liabilities</link:label>
    <link:label id="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_documentation_en-US" xlink:label="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and other payables, assumed at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:to="lab_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_86c1c6a3-d36b-46b2-9c20-ddf854823dcf_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a6f58a66-cc02-4bbf-aa95-43105177d703_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ebda379-d6e8-41cc-9a4f-5c821271dd4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5cc4d6de-1c45-4854-9c1d-a59dacbc335b_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_09a49a40-0e43-48da-964e-663b8453dbf6_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b48923d5-de1d-42c5-aae7-80bb0aa74388_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants issued to purchase the shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_25272bc5-61ed-422e-9587-71d471d7cc63_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_87b94722-d700-48db-9594-969a4350074a_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Forgiveness of Loan</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_267cb71b-6295-4a3c-bd80-c5a482d7ce6e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_52b00ba0-8738-480b-ba68-6dfc5ebc9a79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets and in-process R&amp;D</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_314317c9-8f7d-47b8-8b15-0770a3c765bf_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_73bedde5-5666-4d11-91f4-ce82fc3b7287_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_45fd00ab-cf22-4662-9257-b783f80a2272_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_000004c1-96f7-4865-bc02-6930cd2dc8df_terseLabel_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems" xlink:to="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassBWarrantExerciseOfOptionMember_579895f3-aeee-4f03-b3c5-7ff4e45ac6e5_terseLabel_en-US" xlink:label="lab_kprx_ClassBWarrantExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant, Exercise Of Option</link:label>
    <link:label id="lab_kprx_ClassBWarrantExerciseOfOptionMember_label_en-US" xlink:label="lab_kprx_ClassBWarrantExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant, Exercise Of Option [Member]</link:label>
    <link:label id="lab_kprx_ClassBWarrantExerciseOfOptionMember_documentation_en-US" xlink:label="lab_kprx_ClassBWarrantExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant, Exercise Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantExerciseOfOptionMember" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantExerciseOfOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassBWarrantExerciseOfOptionMember" xlink:to="lab_kprx_ClassBWarrantExerciseOfOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_928fec0f-fef5-4e41-83f4-3d42deb33ea5_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock from Warrant Exercises</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51a29f0b-c0a6-460b-9ffe-a4d5b2c6595a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9854b919-709f-4fbe-968e-abbee340b3d1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock, Net of Offering Costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_680098ba-0cfa-4e6c-8af7-36ee1c5fa124_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_07844500-b813-4db5-ba76-d776fc8d3c53_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6f0ecdff-8ee5-443e-a7eb-44286ffc8ef9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d8f0b7b-1259-4b91-8897-71dd4c20a15d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PublicOfferingMember_7e732954-caf7-4667-85d4-b97449104b1c_terseLabel_en-US" xlink:label="lab_kprx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_kprx_PublicOfferingMember_label_en-US" xlink:label="lab_kprx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_kprx_PublicOfferingMember_documentation_en-US" xlink:label="lab_kprx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PublicOfferingMember" xlink:to="lab_kprx_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cc37f718-a909-4250-9930-b19e50d5788a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_cb923c46-c04c-4f3d-89bc-74b7da1a1578_verboseLabel_en-US" xlink:label="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process R&amp;D</link:label>
    <link:label id="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_label_en-US" xlink:label="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Research and Development</link:label>
    <link:label id="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_documentation_en-US" xlink:label="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represented amount of intangible assets adjusted with research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:href="kprx-20221231.xsd#kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:to="lab_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_f7760d81-f1ba-47a0-b056-c191c885942c_terseLabel_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds for Research and Development</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development, Refunds, Policy [Policy Text Block]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:to="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_50b84a30-27db-466f-817e-95321cf3291c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7a90965a-eb72-4209-aab1-e01184740918_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c187bc93-8676-4d75-8cfe-d922605fdcf0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_d844218b-151d-4624-abbb-4c5d265cf3ac_terseLabel_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, designated (in shares)</link:label>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_label_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Designated Shares</link:label>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_documentation_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of designated preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares" xlink:href="kprx-20221231.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PreferredStockDesignatedShares" xlink:to="lab_kprx_PreferredStockDesignatedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c4c268d0-82bf-4f1b-9fb1-f2429d33d643_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9c4f867b-4d74-4b6e-b74d-c91464cd0dfe_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dfc54967-2b76-4f00-8da6-c22a176d0fe1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fd9844ae-c154-4688-a964-be9973041041_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process R&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b8a8d9c5-9260-4a19-a98e-424d41d133cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember_2a2a643c-13f4-4017-a888-f3a0b95e95dc_terseLabel_en-US" xlink:label="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If milestone payments are exercised for shares</link:label>
    <link:label id="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember_label_en-US" xlink:label="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">If milestone payments are exercised for shares</link:label>
    <link:label id="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember_documentation_en-US" xlink:label="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to scenario, if milestone payments are exercised for shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:href="kprx-20221231.xsd#kprx_IfMilestonePaymentsAreExercisedForSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:to="lab_kprx_IfMilestonePaymentsAreExercisedForSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_e305c211-efa4-456b-a1f9-5a7a6705356f_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_4d1163e1-f398-430d-b694-b4f1ca056728_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series C Preferred Stock into Common Stock (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion Of Series C Preferred Stock</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period for the conversion of series C convertible preferred stock into common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:to="lab_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f30f8ad9-e14c-4e42-b484-646ea795383c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_2d161838-4e35-4d2d-83f0-17c26bd37799_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_DueToCreditorMember_69860d88-de65-4d38-a8df-b5a95ebcbdfa_terseLabel_en-US" xlink:label="lab_kprx_DueToCreditorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to creditor</link:label>
    <link:label id="lab_kprx_DueToCreditorMember_label_en-US" xlink:label="lab_kprx_DueToCreditorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to creditor</link:label>
    <link:label id="lab_kprx_DueToCreditorMember_documentation_en-US" xlink:label="lab_kprx_DueToCreditorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to payables to creditor in a business acquisition transaction , as contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DueToCreditorMember" xlink:href="kprx-20221231.xsd#kprx_DueToCreditorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_DueToCreditorMember" xlink:to="lab_kprx_DueToCreditorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_cc5cc5e4-91d5-4986-a759-189f950b348a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8bb8e65f-c3e7-4550-a8e8-443e288a1f17_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9d9abd37-b3a7-4bbc-9c6e-ca9d506ca8a2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SentrXAnimalCareIncMember_0d974954-d15f-4c05-9f43-21492f5c852b_terseLabel_en-US" xlink:label="lab_kprx_SentrXAnimalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SentrX Animal Care Inc</link:label>
    <link:label id="lab_kprx_SentrXAnimalCareIncMember_label_en-US" xlink:label="lab_kprx_SentrXAnimalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SentrX Animal Care Inc</link:label>
    <link:label id="lab_kprx_SentrXAnimalCareIncMember_documentation_en-US" xlink:label="lab_kprx_SentrXAnimalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SentrX Animal Care, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SentrXAnimalCareIncMember" xlink:href="kprx-20221231.xsd#kprx_SentrXAnimalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SentrXAnimalCareIncMember" xlink:to="lab_kprx_SentrXAnimalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_f5f2821f-cb25-4acc-95b0-ded03502d444_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and In-Process R&amp;D</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_83b9f416-2338-40da-9257-f46bf047afb5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e976a640-df44-4082-97ae-e95e3c075a52_verboseLabel_en-US" xlink:label="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing costs</link:label>
    <link:label id="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e6a985a0-8805-44ae-9cc1-c2e7afeff93e_terseLabel_en-US" xlink:label="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant inducement expense</link:label>
    <link:label id="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_label_en-US" xlink:label="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Additional Paid in Capital, Warrant Issuance Costs</link:label>
    <link:label id="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_documentation_en-US" xlink:label="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Additional Paid in Capital, Warrant Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:href="kprx-20221231.xsd#kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:to="lab_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_de1b8fc8-0cd0-43c3-bc08-6e8c09c73cc0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f2c08c33-f48b-49a0-a509-81c6d4c4cb20_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d4cf7fc6-cd50-4f3a-a482-c58911fa2907_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_15893dad-8ecc-4bc4-bc60-74d52650ed03_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_cd2de509-ffe5-4fbb-b461-b5f02a7d6b16_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities_93dd0398-aa72-4c04-909e-35e991a08d6f_terseLabel_en-US" xlink:label="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest on the lease liability</link:label>
    <link:label id="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities_label_en-US" xlink:label="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Interest on Lease Liabilities</link:label>
    <link:label id="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities_documentation_en-US" xlink:label="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of interest on operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:href="kprx-20221231.xsd#kprx_OperatingLeaseInterestOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:to="lab_kprx_OperatingLeaseInterestOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d20f1ede-ba38-47d8-afb5-16ab0480c31c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fff72c4-7353-45be-bec6-33236c98a17d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1004cd14-5922-4803-bc1b-6ed4e239d822_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9478b78d-96f0-4547-aed6-67854caff612_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_145a311d-3836-4d8d-8bf8-add28b72fbc6_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SeriesdConvertiblePreferredStockMember_f3d10b3a-dda5-4d41-9f80-2db9c121e539_terseLabel_en-US" xlink:label="lab_kprx_SeriesdConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_kprx_SeriesdConvertiblePreferredStockMember_label_en-US" xlink:label="lab_kprx_SeriesdConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SeriesD Convertible Preferred Stock</link:label>
    <link:label id="lab_kprx_SeriesdConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_kprx_SeriesdConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesdConvertiblePreferredStockMember" xlink:href="kprx-20221231.xsd#kprx_SeriesdConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SeriesdConvertiblePreferredStockMember" xlink:to="lab_kprx_SeriesdConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_d711b4c4-cc27-4be1-89b1-6c574e11d462_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_us-gaap_SeriesEPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8a0f946d-c1d7-4d59-bdf4-b4f5aa3b0aa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_db31d9bc-369e-43e6-ac44-d9630adf4427_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_b61baeac-c729-4274-a686-9e700d50fe62_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Panoptes Holdback Shares</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, From Panoptes Hold Back Shares</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, From Panoptes Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:to="lab_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8ffe2432-5598-44aa-9649-d508f7f531f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ebaed9db-cdd8-4906-aa6e-933036e9b0c9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_79d70d81-c16c-4c6c-be28-1e977cbb3d07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fbd76a05-9bd5-4a5b-b5a9-ca97af6a9e04_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_3306be88-10fb-4166-9aaf-55eff0b97392_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2687fee4-7e4d-43f1-967b-a788c3068d32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b9f8c537-144e-4136-8b8c-66b7e7e29f07_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_106c4bb5-1741-43d5-89d5-2429d498a63a_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_aeab857f-fdef-46a6-8705-7d6ba291549a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share - Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fa55d49f-7662-4622-a8b7-8855b2c04b73_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e38946df-0c4c-499d-ae5f-fa99e2c812d2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_64b4b263-fd9e-4192-9936-9c8955798559_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0745399c-b8c5-4cf3-b4d2-5f211e6829f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5096fb33-761d-4e54-865a-5696f35a2f67_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant_66e56e62-7987-4058-bf41-712cf66e0379_terseLabel_en-US" xlink:label="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in usd per share)</link:label>
    <link:label id="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant_label_en-US" xlink:label="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Price Of Common Stock And Warrant</link:label>
    <link:label id="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant_documentation_en-US" xlink:label="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share amount of common Stock and warrant under private placement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:href="kprx-20221231.xsd#kprx_SharePurchasePriceOfCommonStockAndWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:to="lab_kprx_SharePurchasePriceOfCommonStockAndWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2069d707-4331-4316-8a03-4f8f0d2d2113_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d943c0e0-5c85-44cf-958c-50728c6d22fe_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_fcc111b3-00a6-47f5-8d4b-5447ab7080b2_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Term in Years</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassAWarrantMember_71bcc6b4-e7dc-4e02-8ecf-a03359f19135_terseLabel_en-US" xlink:label="lab_kprx_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:label id="lab_kprx_ClassAWarrantMember_label_en-US" xlink:label="lab_kprx_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant [Member]</link:label>
    <link:label id="lab_kprx_ClassAWarrantMember_documentation_en-US" xlink:label="lab_kprx_ClassAWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantMember" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassAWarrantMember" xlink:to="lab_kprx_ClassAWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SharesIssuedPricePerCommonShares_7ecf2e4d-3bd4-4fa4-a3e1-604108fa256a_terseLabel_en-US" xlink:label="lab_kprx_SharesIssuedPricePerCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in usd per share)</link:label>
    <link:label id="lab_kprx_SharesIssuedPricePerCommonShares_label_en-US" xlink:label="lab_kprx_SharesIssuedPricePerCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Price Per Common Shares</link:label>
    <link:label id="lab_kprx_SharesIssuedPricePerCommonShares_documentation_en-US" xlink:label="lab_kprx_SharesIssuedPricePerCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Price Per Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerCommonShares" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SharesIssuedPricePerCommonShares" xlink:to="lab_kprx_SharesIssuedPricePerCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ca364939-d645-472f-9c2d-51366e4a57a9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f19e7dd9-070c-4397-909d-c879911d0aaa_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_992a6822-be78-4db9-a021-4f5995137d92_terseLabel_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration</link:label>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_label_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contingent Consideration Fair Value</link:label>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of change in contingent consideration fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ChangeInContingentConsiderationFairValue" xlink:href="kprx-20221231.xsd#kprx_ChangeInContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ChangeInContingentConsiderationFairValue" xlink:to="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8418e919-e3dc-498c-9721-2725be22d9bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_63190c57-555a-4da9-a9d7-58a742a92ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d0684d9c-8bd2-4dde-92f5-529b397f0b7a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d35dda57-3009-4db8-b6ae-7dab2844baae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6f966105-7d6e-4c66-a691-602dab8814fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value unobservable level 3 inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f80624c9-fd24-4983-96a0-d54a6b3060a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_c7d83295-3630-459e-bff6-1c59b62337af_terseLabel_en-US" xlink:label="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director who Is also an executive at a related party</link:label>
    <link:label id="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_label_en-US" xlink:label="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Board of Directors Who Are Also Executives At A Related Party</link:label>
    <link:label id="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_documentation_en-US" xlink:label="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Board of Directors Who Are Also Executives At A Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:href="kprx-20221231.xsd#kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:to="lab_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_310dc4a2-0faf-48b0-b9cc-a01d60831f66_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_d1d17293-0674-43d7-80b7-8e4cd59e8c74_terseLabel_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses</link:label>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_label_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses [Policy Text Block]</link:label>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for accrued clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:href="kprx-20221231.xsd#kprx_AccruedClinicalExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:to="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e48b44f-8aad-4b22-a9c6-7aa126608906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_23a94595-7ce8-446c-a6fb-06ae8cfe9349_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2afacd5c-c067-4298-bdc7-05f2ac547691_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b016ca78-2f0a-49c4-9147-227419015ca3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b071edc2-5527-401c-bd9a-922fa6da6488_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0dfa2cd6-cebd-491a-afe7-cfa0ac2c767b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f91bcccc-d3cc-4a61-a552-d8a7797322b6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fc78718b-9e73-4a0b-b19d-c458a422658b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to Bayon Shareholders at Acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfGeographicSegments_c3d4ff26-ea3a-4cab-937a-31a8b4b2c01c_terseLabel_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic segments</link:label>
    <link:label id="lab_kprx_NumberOfGeographicSegments_label_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Segments</link:label>
    <link:label id="lab_kprx_NumberOfGeographicSegments_documentation_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Geographic Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments" xlink:href="kprx-20221231.xsd#kprx_NumberOfGeographicSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfGeographicSegments" xlink:to="lab_kprx_NumberOfGeographicSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b10e1eee-3753-477f-a0f9-d9ecefba799d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6c839bba-56e5-4da0-b5fa-95eddffcdf15_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8b40bdc9-e7ed-4cf0-ab7b-68205161fe70_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a217de1a-8557-4005-9efc-6075c3414478_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Credit Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_ef29f22c-a73b-4422-ba1b-352a663edc5c_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average exercise price of expired awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_14e182bb-6f20-4af7-937b-ad009b98500d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value on a recurring basis using level 3 inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent_af966f14-6341-4f1b-9c06-ce739ca481f1_terseLabel_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Consideration</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent_label_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Cash, Current</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent_documentation_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of cash recognized arising from contingent consideration in a business combination, expected to be realized within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:to="lab_kprx_BusinessCombinationContingentConsiderationCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_94ef4a5a-b9cf-4037-8d15-d7e11b3ab4b9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_0ae77231-ffca-47e5-99da-beb91df20a43_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IntangibleAssetsExpectedMilestonePayable_9339b8bf-d433-4154-a7f7-aeeb0a96d981_terseLabel_en-US" xlink:label="lab_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, expected milestone payments</link:label>
    <link:label id="lab_kprx_IntangibleAssetsExpectedMilestonePayable_label_en-US" xlink:label="lab_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Expected Milestone Payable</link:label>
    <link:label id="lab_kprx_IntangibleAssetsExpectedMilestonePayable_documentation_en-US" xlink:label="lab_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of milestone payments expected in future periods for acquisition of intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsExpectedMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:to="lab_kprx_IntangibleAssetsExpectedMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_518585e7-26cb-4252-82fb-da1f047f83eb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a988f405-127a-4f81-a845-834ede976fbb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_db8b1129-0f4c-4a19-a30c-4b0e6091e294_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_917fbb0c-1416-49d2-915e-b175b9d88498_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_7e4fc8d0-08ca-47d0-8fc7-8d2889c2d026_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares convertible (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_28082ebf-3fcc-4fd1-a2d8-af9362d26a62_terseLabel_en-US" xlink:label="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, number of fractional shares issued (in shares)</link:label>
    <link:label id="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_label_en-US" xlink:label="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity Note, Reverse Stock Split, Number Of Fractional Shares Issued</link:label>
    <link:label id="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_documentation_en-US" xlink:label="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity Note, Reverse Stock Split, Number Of Fractional Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:href="kprx-20221231.xsd#kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:to="lab_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_977f79d2-cbca-4ab0-a33f-3f31e9152b37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f964180e-ed5c-4cca-ae87-a2bb9f11e789_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8441a34d-446e-446a-81b0-82daf10d050c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_28318f4f-e9c1-4129-a443-3d9ab5444595_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8e327eb0-dd75-432b-a7b7-40cf286c1084_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_18d7e3b8-4fc3-4c99-8200-b1e2430189e0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_d76256e5-9e6c-4511-9933-f3aaf3f014a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7a8b914e-3d10-4d3e-87ec-96dfbeb7ab42_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PanoptesPharmaGes.m.b.h.Member_de459c1b-24a3-40a3-9f40-b7eefb203712_terseLabel_en-US" xlink:label="lab_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes</link:label>
    <link:label id="lab_kprx_PanoptesPharmaGes.m.b.h.Member_label_en-US" xlink:label="lab_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes</link:label>
    <link:label id="lab_kprx_PanoptesPharmaGes.m.b.h.Member_documentation_en-US" xlink:label="lab_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to acquisition of Panoptes Pharma Ges.m.b.H.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGes.m.b.h.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:to="lab_kprx_PanoptesPharmaGes.m.b.h.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfUniversities_1b51a5a0-6ac4-4e9f-80fd-ed8acd58e43e_terseLabel_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of universities with whom the company entered into related party transactions</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfUniversities_label_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Number Of Universities</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfUniversities_documentation_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Number Of Universities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfUniversities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:to="lab_kprx_RelatedPartyTransactionsNumberOfUniversities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_de53ba5d-3e47-45df-882d-fae1410d9df2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_e1452992-1e58-4b93-9091-fce2b9b64a68_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12ca5f2f-b60d-4e86-ab20-516f0b83f204_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_09a2307c-f496-4a94-96e0-eac313091d9e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_7ce30ef3-95b0-4dac-bb4d-288acd1cb96d_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_7c7edbf1-0345-4299-9a73-06decc3595bc_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_423d2296-a738-4d64-9c9a-1d1cd21c1d3c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ab1a68b-f0a3-40c0-824e-f3964dd5b7a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33c1c812-11a2-4e90-a8de-8a36065d13b7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1192c58c-7b5d-4694-86f5-1d2180d01379_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_55accd7c-8e8c-4173-ab77-266f4a943df4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, short-term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0157c6c2-2d2e-435e-af25-1f4f11b385e4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ff491e79-365a-4875-85c5-a34a53c035a8_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantConvertibleIntoCommonStockBasis_9e41fef2-50a3-495e-ab3e-99ef5d52c1d8_terseLabel_en-US" xlink:label="lab_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant convertible into common stock basis</link:label>
    <link:label id="lab_kprx_WarrantConvertibleIntoCommonStockBasis_label_en-US" xlink:label="lab_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Convertible Into Common Stock Basis</link:label>
    <link:label id="lab_kprx_WarrantConvertibleIntoCommonStockBasis_documentation_en-US" xlink:label="lab_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Convertible Into Common Stock Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:href="kprx-20221231.xsd#kprx_WarrantConvertibleIntoCommonStockBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:to="lab_kprx_WarrantConvertibleIntoCommonStockBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d50dfd79-c35f-4ed4-b8cf-8880c42136d5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other (Expense) Income, Net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b9eb2485-9328-4574-863f-453c9da971a3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Secrets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6656827d-46ec-419e-a7e0-e25d8763b7ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClinicalStudiesServicesKIO301Member_c156619a-9609-4319-b157-aba588170d99_terseLabel_en-US" xlink:label="lab_kprx_ClinicalStudiesServicesKIO301Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Studies Services KIO-301</link:label>
    <link:label id="lab_kprx_ClinicalStudiesServicesKIO301Member_label_en-US" xlink:label="lab_kprx_ClinicalStudiesServicesKIO301Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Studies Services KIO-301 [Member]</link:label>
    <link:label id="lab_kprx_ClinicalStudiesServicesKIO301Member_documentation_en-US" xlink:label="lab_kprx_ClinicalStudiesServicesKIO301Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Studies Services KIO-301</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalStudiesServicesKIO301Member" xlink:href="kprx-20221231.xsd#kprx_ClinicalStudiesServicesKIO301Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClinicalStudiesServicesKIO301Member" xlink:to="lab_kprx_ClinicalStudiesServicesKIO301Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b1962658-e93e-4879-ba04-ccdd7fd7ee0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4128f48c-7136-428f-9460-536f82019b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d22f40cc-8c56-4893-8e42-a1d6ba3ff9fa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets with Right-of-Use</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_29031072-d6e4-4d53-863b-021cbc2847a5_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Warrant Issued</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of warrants issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:to="lab_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3f5b56bb-2662-4455-81e6-d42243c70d67_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncomeTaxesTable_06461b10-bf7d-48a4-a14f-2ef5f3cbc8ee_terseLabel_en-US" xlink:label="lab_kprx_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_kprx_IncomeTaxesTable_label_en-US" xlink:label="lab_kprx_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_kprx_IncomeTaxesTable_documentation_en-US" xlink:label="lab_kprx_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesTable" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncomeTaxesTable" xlink:to="lab_kprx_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_292b5d35-9862-4693-acda-5d4db8d21ab5_terseLabel_en-US" xlink:label="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)</link:label>
    <link:label id="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_label_en-US" xlink:label="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Considered For Determination Of Public Offering Price Of Preferred Shares Issued With Warrants</link:label>
    <link:label id="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_documentation_en-US" xlink:label="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Considered For Determination Of Public Offering Price Of Preferred Shares Issued With Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:href="kprx-20221231.xsd#kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:to="lab_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_4552e112-9ba0-4416-b96e-7150723f3148_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_759b98e4-204b-49c9-8063-0d39371d4fe7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_284c90e9-e700-4876-b6b5-9f465e8ad54b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_36f2589d-d64b-4965-82b1-9b5bc4775cd2_terseLabel_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_label_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms</link:label>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_documentation_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:to="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissionsExpenses_8ffe057c-c61c-44ca-97b2-8a88fd800448_terseLabel_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting expenses</link:label>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissionsExpenses_label_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Discount And Commissions Expenses</link:label>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissionsExpenses_documentation_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Discount And Commissions Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissionsExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:to="lab_kprx_UnderwritingDiscountAndCommissionsExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e12d4b60-7f79-4d2c-9244-8a42ef0ffdfa_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_af7bad3c-43b6-4946-ac2e-86e4089790e8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b1b20fdf-dc3e-49c6-b0ba-1ad989d6a31d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_979ccfc9-d119-4144-9630-6e60c84666a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8c752b45-c36c-436d-87d4-b669bd96f7d2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Before Other Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ca16b276-8811-48dd-82fc-425fd4c72a80_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_30c9776c-3a6d-4bf6-89f0-3ab6acbdc49d_terseLabel_en-US" xlink:label="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of decreased royalty after patent expiry</link:label>
    <link:label id="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_label_en-US" xlink:label="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Decreased Royalty After Patent Expiry</link:label>
    <link:label id="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_documentation_en-US" xlink:label="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of royalty after patent expiry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:href="kprx-20221231.xsd#kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:to="lab_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_daad94e3-5449-4494-97bf-9228c9d06bb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2850f0c3-b21b-48bb-ab1e-6abaec6f24c1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_993db124-fc25-4755-a063-04d8375777d2_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2fb2052e-4d47-4234-9a0d-b091e9964451_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Versus Accrual Adjustments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f77eb3cb-e21f-4b8b-8aa5-f9e54cc66655_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f6174f78-1714-4240-b86f-3edec5cd0538_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_81b0b67a-2b57-4ecc-99c9-29a1f42fd51b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_0a494a93-d70a-418b-8eec-f99bb631f63a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bc730255-4b36-4e6b-b046-43e7b37705e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_25995752-31c8-473e-bed0-1f48e18b63b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_19e6b474-ccbc-4075-8716-b0a87f7fb703_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e06f59bf-0057-4b91-ad34-a76d9f0ff772_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3618ab43-c2c1-4d97-b807-8a583b4d8c22_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0919d451-cce2-4494-a13e-3e572f5c5836_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_2bf7256f-c342-41da-99b1-f6d49f8b6426_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_GoodwillAcquired_66ef44ba-89be-4420-8353-bf261d3c0171_terseLabel_en-US" xlink:label="lab_kprx_GoodwillAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_kprx_GoodwillAcquired_label_en-US" xlink:label="lab_kprx_GoodwillAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Acquired</link:label>
    <link:label id="lab_kprx_GoodwillAcquired_documentation_en-US" xlink:label="lab_kprx_GoodwillAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This amount is relevant to Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GoodwillAcquired" xlink:href="kprx-20221231.xsd#kprx_GoodwillAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_GoodwillAcquired" xlink:to="lab_kprx_GoodwillAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_757eb54c-155b-4080-97ce-fddafb81f606_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_142d59ad-ea6d-47d3-94df-e40cd80d5868_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_797903bc-ab6e-4671-9524-6969389f90c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11ae22e3-5e40-47cb-ad25-0ab0243bcca0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1d59cc0c-e644-4e35-81bc-675105dc35d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_45dcd7e4-540c-4556-ad9e-28973bf37aa5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dce29ded-5506-4eab-9234-4add7c12bffb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_f33e23cf-4c58-4587-a697-d17efb392fcf_verboseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f16b2b07-21a8-43ea-974e-6670fec39a1a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_6424435b-e273-43d2-a0fd-d1627fa502dc_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_98dad980-4950-4160-8007-d1999ad377cf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_2c111b13-c1b4-4f62-baec-c4c4533add3f_negatedTerseLabel_en-US" xlink:label="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Reverse Stock Split Fractional Shares (in shares)</link:label>
    <link:label id="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_label_en-US" xlink:label="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Adjustment During Period, Shares, Reverse Stock Splits</link:label>
    <link:label id="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_documentation_en-US" xlink:label="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Adjustment During Period, Shares, Reverse Stock Splits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:href="kprx-20221231.xsd#kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:to="lab_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1f26ab18-b342-47c4-9c10-8df22bd129e2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19ee2773-306e-484a-9c5d-3b61de86f30a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Shares Outstanding - Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2d222d-cf70-4f67-9fc9-648717af6b75_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_JadeTherapeuticSIncMember_00fc6d0f-16eb-4559-bf4d-4f16be92c7ac_terseLabel_en-US" xlink:label="lab_kprx_JadeTherapeuticSIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade acquisition</link:label>
    <link:label id="lab_kprx_JadeTherapeuticSIncMember_label_en-US" xlink:label="lab_kprx_JadeTherapeuticSIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade acquisition</link:label>
    <link:label id="lab_kprx_JadeTherapeuticSIncMember_documentation_en-US" xlink:label="lab_kprx_JadeTherapeuticSIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeTherapeuticSIncMember" xlink:href="kprx-20221231.xsd#kprx_JadeTherapeuticSIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_JadeTherapeuticSIncMember" xlink:to="lab_kprx_JadeTherapeuticSIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_54e45fad-b6cd-4b5b-99f1-1a32d8554318_terseLabel_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_label_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number of Operating Leases</link:label>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_documentation_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases" xlink:href="kprx-20221231.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LesseeNumberOfOperatingLeases" xlink:to="lab_kprx_LesseeNumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_3b71a028-79d5-453e-8954-741e576dc8a4_negatedLabel_en-US" xlink:label="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made for Fractional Shares Related to the Reverse Stock Split</link:label>
    <link:label id="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_label_en-US" xlink:label="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Fractional Shares Related To Reverse Stock Split</link:label>
    <link:label id="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_documentation_en-US" xlink:label="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Fractional Shares Related To Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:href="kprx-20221231.xsd#kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:to="lab_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ea58cee-a02d-43a1-9855-83ed68a91526_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsAbstract_27547a82-68c0-46bd-9666-f8ae2dce978e_terseLabel_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsAbstract_label_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsAbstract_documentation_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract" xlink:href="kprx-20221231.xsd#kprx_WarrantsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsAbstract" xlink:to="lab_kprx_WarrantsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_400b992c-d0c8-4751-b2d1-6f39ae9dbd36_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_96d8e546-8a42-4c80-ac0b-d38ce72ebef9_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cb7931c2-b129-44c1-bfd1-545d3715852a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.01 Par Value: 50,000,000 shares authorized at December&#160;31, 2022 and 2021; 1,796,472 and 316,599 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1ae3f50a-f990-448b-841c-d7bc1150d7b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_GrantOfRestrictedStockAwards_6684be4c-65b1-4e05-8dd3-759059655da5_terseLabel_en-US" xlink:label="lab_kprx_GrantOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant of Restricted Stock Awards</link:label>
    <link:label id="lab_kprx_GrantOfRestrictedStockAwards_label_en-US" xlink:label="lab_kprx_GrantOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Of Restricted Stock Awards</link:label>
    <link:label id="lab_kprx_GrantOfRestrictedStockAwards_documentation_en-US" xlink:label="lab_kprx_GrantOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount grant of restricted stock awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GrantOfRestrictedStockAwards" xlink:href="kprx-20221231.xsd#kprx_GrantOfRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_GrantOfRestrictedStockAwards" xlink:to="lab_kprx_GrantOfRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_be0d209c-77f4-433c-8faa-c07add7fffbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8df00019-7d18-4457-bb6f-416908405727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3aba0735-c1ed-405e-aeea-39a87c29d550_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Common Stock That May Potentially Be Issued in the Future</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_0328824f-f853-441a-a0a9-ed585d80226e_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Awards</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Awards [Roll Forward]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:to="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6070281f-c844-4f9a-8fc7-6d4771c9be3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_1d3e2024-a40f-4d94-b351-3b4fd5b82620_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_116d7fb7-4891-45d8-9373-765476b62013_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb4ee88e-eb86-4efe-86be-a32277596fdc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Including Restricted Cash, Beginning of Year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac103ae0-518b-4ed3-9d27-0062720b50f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Including Restricted Cash, End of Year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_41cf7fc9-bd92-490e-9cdc-8a5bcd86ff0c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_994aa323-4452-43e2-85f0-0376507398d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_c688cced-b9c4-4da9-b707-756664d480c1_negatedTerseLabel_en-US" xlink:label="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Reverse Stock Split Fractional Shares</link:label>
    <link:label id="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_label_en-US" xlink:label="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Adjusted During Period, Value, Reverse Stock Splits</link:label>
    <link:label id="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_documentation_en-US" xlink:label="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Adjusted During Period, Value, Reverse Stock Splits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:href="kprx-20221231.xsd#kprx_StockAdjustedDuringPeriodValueReverseStockSplits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:to="lab_kprx_StockAdjustedDuringPeriodValueReverseStockSplits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf3504b6-de8d-477e-ba08-102ebfec2f1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ab2e1535-7109-4ff2-8b7c-b385c33b46c9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9951a466-0140-416d-9cad-a9accdc60c3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Paycheck Protection Program Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_076c23c2-ce93-459c-b6e7-44bc839e36e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_df8351ad-d3a4-45d7-9ef7-2975241aa70e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissions_0413301c-9b46-4a5b-8d88-7e932a80ec60_terseLabel_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discount and commissions</link:label>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissions_label_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Discount And Commissions</link:label>
    <link:label id="lab_kprx_UnderwritingDiscountAndCommissions_documentation_en-US" xlink:label="lab_kprx_UnderwritingDiscountAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Discount And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissions" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_UnderwritingDiscountAndCommissions" xlink:to="lab_kprx_UnderwritingDiscountAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_13064ed0-4bfe-474a-bbbe-9d2413db1d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_551e4231-bf8c-4409-b4c7-7e8d9c5eec4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6bb3c1b6-5db3-4664-a84d-7450e96c9317_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_410ba89e-5700-4df3-8682-40b4b22a4849_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_84d54427-99d4-4325-87ee-ec84d4f165de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1db9c6bf-2c6b-40d2-8a93-858735415853_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f3e4dc6d-b748-4763-8679-05e74e7aa9e2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e47dcae1-a6fd-442a-aa68-5bcad30f8cd2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e40a6a8f-5a6c-4921-b235-d277fd76b526_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase3Member_299ca99f-ba7f-48c3-b3a9-65bfc23864a4_terseLabel_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful completion of Phase 3 $4 million</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase3Member_label_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 3 [Member]</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase3Member_documentation_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase3Member" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SuccessfulCompletionOfPhase3Member" xlink:to="lab_kprx_SuccessfulCompletionOfPhase3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_92de4674-4646-4c6c-8734-99fbb7bbf84a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales_fce248f0-e9cb-4416-b138-e54ee303f532_terseLabel_en-US" xlink:label="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercise and sale</link:label>
    <link:label id="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales_label_en-US" xlink:label="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises And Warrant Sales</link:label>
    <link:label id="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales_documentation_en-US" xlink:label="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrant Exercises And Warrant Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromWarrantExercisesAndWarrantSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:to="lab_kprx_ProceedsFromWarrantExercisesAndWarrantSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a08cf49f-e6cf-44dd-b68c-84af474b1c35_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6ae194c1-af3d-40fd-87d2-38126abb7025_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_befa654f-719c-46f9-9068-6b6b1ee54cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_40a24864-c3c3-40a4-86fd-7318662d6e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b6a0698b-f7a9-4f0b-9656-21f1748fbb77_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_05e3d296-0a2a-4872-bde7-cf2311c6651c_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible asset impairment</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2edfb752-f4be-4893-a27b-5586d10635ab_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PanoptesAcquisitionMember_5a19dd95-e2c2-4969-a999-2fb783b36955_terseLabel_en-US" xlink:label="lab_kprx_PanoptesAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes acquisition</link:label>
    <link:label id="lab_kprx_PanoptesAcquisitionMember_label_en-US" xlink:label="lab_kprx_PanoptesAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes acquisition</link:label>
    <link:label id="lab_kprx_PanoptesAcquisitionMember_documentation_en-US" xlink:label="lab_kprx_PanoptesAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Panoptes acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesAcquisitionMember" xlink:href="kprx-20221231.xsd#kprx_PanoptesAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PanoptesAcquisitionMember" xlink:to="lab_kprx_PanoptesAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_28102e53-71da-4bb4-b4df-ef5fa7a57a9c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a8744093-8dcd-43d3-a300-778f8dd9cbc1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_33338048-43bd-4bda-b549-c124ad4e3101_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_55b18e00-7aa2-46d7-b1c4-4def5b9cce09_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_7ea5738b-1515-4dac-a44c-f1806504866b_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Panoptes Holdback Shares (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_8c14d393-4ca3-4004-8bdd-7b86457c966d_verboseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Panoptes holdback shares (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares From HoldBack, Shares</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares From HoldBack, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesFromHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:to="lab_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MilestoneTypeDomain_b54fa987-4dd4-4f06-bb3c-d386c8d3c6dd_terseLabel_en-US" xlink:label="lab_kprx_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_kprx_MilestoneTypeDomain_label_en-US" xlink:label="lab_kprx_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_kprx_MilestoneTypeDomain_documentation_en-US" xlink:label="lab_kprx_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The category of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeDomain" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MilestoneTypeDomain" xlink:to="lab_kprx_MilestoneTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_67f450b7-709c-4f39-bbb8-c9116fd92305_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_488bd012-be97-4fe5-9246-5fa6c36a8922_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process R&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_7063eead-27da-4cab-996c-b04a68e57392_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d857d733-ba4b-4b04-8015-ed9ea54d6bae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6f2a6d65-ac37-4bd4-8fc6-3d4c74e0872d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Taxes, Net of Federal Benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_baf341ba-7213-4fcb-bf4b-2bffc06c2b37_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liability:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_ca51a174-2870-4093-a649-642ba79cd810_terseLabel_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_label_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and Non Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table Text Block]</link:label>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_documentation_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:href="kprx-20221231.xsd#kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62fb944f-b763-4aa1-a9aa-21d9deaa4e97_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7a03ad86-7d08-4673-9cf5-ebfc331ec3e1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2466ed07-915b-43bc-b509-31d19eaeed9f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_73f5e7c3-eb40-4595-95dc-0e1a1c306ab9_terseLabel_en-US" xlink:label="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success for payment</link:label>
    <link:label id="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_label_en-US" xlink:label="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success for payment</link:label>
    <link:label id="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_documentation_en-US" xlink:label="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Measurement input probability of success for payment .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:href="kprx-20221231.xsd#kprx_MeasurementInputProbabilityOfSuccessForPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:to="lab_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_a2a3fda1-1ba9-475f-aa0e-8493f209fb57_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ba5826c8-6a83-4268-a271-9b9e0a44bfbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future annual intangible amortization</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_b6b766f0-f6dd-46c7-830b-35494f3b4e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1f0381a4-6d4e-4f05-a727-ddebce53f370_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_7d8abebb-a06e-417c-a973-764560c9ff2b_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_45749907-4db5-40bf-ad85-70b88f0a480c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27f5af97-a61d-4523-afd5-13024f451669_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Average Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock_becea14e-e586-47f6-8338-f6d3ab7b4f78_terseLabel_en-US" xlink:label="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of business acquisition fair value consideration</link:label>
    <link:label id="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock_label_en-US" xlink:label="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Business Acquisitions, Fair Value Of Consideration [Table Text Block]</link:label>
    <link:label id="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock_documentation_en-US" xlink:label="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of Fair value of business acquisition consideration [table text Block].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:href="kprx-20221231.xsd#kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:to="lab_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_6673a840-5bf4-4839-aecb-1fc3725310b0_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:to="lab_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_122edd95-ae7b-4839-aac6-fd4d65ff8520_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a78f637c-9dfe-4988-a29f-5ec3150f6483_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bdf9b4a5-5e05-43d9-a4fd-297cd4e062d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement_b965ba0a-e896-47e1-8ef7-1edf22ac4807_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Inducement</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Inducement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantInducement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:to="lab_kprx_StockIssuedDuringPeriodSharesWarrantInducement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessStockSharesAuthorized_974120ad-90c7-4e70-a455-4ab29101b1db_terseLabel_en-US" xlink:label="lab_us-gaap_ExcessStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares that may be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ExcessStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ExcessStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessStockSharesAuthorized" xlink:to="lab_us-gaap_ExcessStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_45e972df-9202-4f8d-a272-cb4b7104d96e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dfe486e2-4a28-446b-a406-abac7c741b0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a64fe8bc-47ee-45a7-8f79-daea0e3f5d08_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RoyaltyScenarioAxis_3ef08540-655d-470c-9111-09d93d9f2a95_terseLabel_en-US" xlink:label="lab_kprx_RoyaltyScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario [Axis]</link:label>
    <link:label id="lab_kprx_RoyaltyScenarioAxis_label_en-US" xlink:label="lab_kprx_RoyaltyScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario [Axis]</link:label>
    <link:label id="lab_kprx_RoyaltyScenarioAxis_documentation_en-US" xlink:label="lab_kprx_RoyaltyScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioAxis" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RoyaltyScenarioAxis" xlink:to="lab_kprx_RoyaltyScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_707bb7a8-f513-4695-99e7-7fee43f592ab_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_748cca4d-2c35-4f09-b61b-1f52a23d270c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4efdef2f-9898-4829-8915-45d3af445de2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_cb90e0ed-9ff6-4c53-a2fe-6d9deb5f1859_terseLabel_en-US" xlink:label="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent transaction fees, equal to percentage of gross proceeds from sale</link:label>
    <link:label id="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_label_en-US" xlink:label="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Inducement, Placement Agent Transaction Fees, Equal To Gross Proceeds, Percentage</link:label>
    <link:label id="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_documentation_en-US" xlink:label="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Inducement, Placement Agent Transaction Fees, Equal To Gross Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:href="kprx-20221231.xsd#kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:to="lab_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ec97540e-f44e-418d-b1cf-4cc2ecfbb344_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase1Member_f9668d28-a27e-414a-b6a6-89c2d61bd5dc_terseLabel_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful completion of Phase 1b $0.495 million</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase1Member_label_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 1 [Member]</link:label>
    <link:label id="lab_kprx_SuccessfulCompletionOfPhase1Member_documentation_en-US" xlink:label="lab_kprx_SuccessfulCompletionOfPhase1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion of Phase 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase1Member" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SuccessfulCompletionOfPhase1Member" xlink:to="lab_kprx_SuccessfulCompletionOfPhase1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82627540-3372-47eb-b331-d88f9b03e453_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5b9b391f-b887-4294-b819-a211fc909b31_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f2a11e67-a126-4675-a25f-44beefd94f02_netLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_480c2ed0-e3ed-4a3d-84d5-c5214316299d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d519116f-c7f8-4ca9-b1dc-d1911d0b6b3a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e607bddd-8d3b-4d65-8acf-90de0fd9f207_netLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassBWarrantMember_376fb7f3-0a1d-4a2f-9d83-cd7aaea658ee_terseLabel_en-US" xlink:label="lab_kprx_ClassBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant</link:label>
    <link:label id="lab_kprx_ClassBWarrantMember_label_en-US" xlink:label="lab_kprx_ClassBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant [Member]</link:label>
    <link:label id="lab_kprx_ClassBWarrantMember_documentation_en-US" xlink:label="lab_kprx_ClassBWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantMember" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassBWarrantMember" xlink:to="lab_kprx_ClassBWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0ba19241-4010-475c-ba67-377f95dccd76_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1915bcc9-e35c-488f-9cab-8d9b39495937_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_120d6011-2eb2-499b-8b13-eefc8df641ac_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10b3ab7d-dc81-447b-99c9-4aade18b7412_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of warrant activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_fcaf46f7-c212-45ea-a703-0a78002e996f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_41505b01-cfed-41ba-8835-5be790a2a876_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0672c10f-bf9c-4cca-b4d3-7e69ba835912_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_45dae1fa-4908-498d-8254-ecbdf2c7e7f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8520ab9b-5f8c-4a77-839a-619b88f788ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_106993fa-682f-467f-9d8d-dde610dd424e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_b80651c3-7466-42cf-a73c-84a921a14014_terseLabel_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of license agreements</link:label>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_label_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_documentation_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements" xlink:href="kprx-20221231.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfLicenseAgreements" xlink:to="lab_kprx_NumberOfLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_a3653dc7-1654-46c7-b23b-d7954058d213_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_550a3d86-24f8-4708-95fc-36828d7cdc8c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bef50255-ccd9-4678-b50d-f2a0e3d2e2db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65f191fa-f461-4758-b5c9-32fc9e635326_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1ee7183b-ec13-4ef3-ad36-97d8d5187e75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c60de0ac-f129-4ca9-824d-30c6dc3954ee_negatedLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f170a525-e901-4bd8-92e1-a3e737fce40d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8cbfce3a-12cc-4cba-999f-138a102d1c62_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsConvertibleIntoCommonStock_6a24caaf-face-4f31-836a-1ac7900cea68_terseLabel_en-US" xlink:label="lab_kprx_WarrantsConvertibleIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants convertible into common stock (in shares)</link:label>
    <link:label id="lab_kprx_WarrantsConvertibleIntoCommonStock_label_en-US" xlink:label="lab_kprx_WarrantsConvertibleIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Convertible Into Common Stock</link:label>
    <link:label id="lab_kprx_WarrantsConvertibleIntoCommonStock_documentation_en-US" xlink:label="lab_kprx_WarrantsConvertibleIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Convertible Into Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsConvertibleIntoCommonStock" xlink:href="kprx-20221231.xsd#kprx_WarrantsConvertibleIntoCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsConvertibleIntoCommonStock" xlink:to="lab_kprx_WarrantsConvertibleIntoCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_41ee80ec-e8a1-42e3-a078-814bc0fed6f6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_3e09d7ee-f041-4303-88f4-606b00e48bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Preferred Stock into Common Stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EarnOutConsiderationMember_f211f6a3-846d-4941-b922-9615395a23bd_terseLabel_en-US" xlink:label="lab_kprx_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out provisions</link:label>
    <link:label id="lab_kprx_EarnOutConsiderationMember_label_en-US" xlink:label="lab_kprx_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out provisions</link:label>
    <link:label id="lab_kprx_EarnOutConsiderationMember_documentation_en-US" xlink:label="lab_kprx_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to earn-out consideration upon fulfillment of specified conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EarnOutConsiderationMember" xlink:href="kprx-20221231.xsd#kprx_EarnOutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EarnOutConsiderationMember" xlink:to="lab_kprx_EarnOutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_89ebbe7d-2b76-428f-867e-5385a5146d74_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dd03381c-963a-477e-a4be-ec7f3de8917f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued_9a8d0fe2-6833-40a4-a500-2aa0c5e333f6_terseLabel_en-US" xlink:label="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual of additional estimate of contributions</link:label>
    <link:label id="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued_label_en-US" xlink:label="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Contributions by Employer Accrued</link:label>
    <link:label id="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued_documentation_en-US" xlink:label="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents defined benefit plan contributions by employer accrued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:href="kprx-20221231.xsd#kprx_DefinedBenefitPlanContributionsByEmployerAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:to="lab_kprx_DefinedBenefitPlanContributionsByEmployerAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3f0d37c1-f836-439b-b10b-974669a16d52_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_71df0ba4-8f46-423f-b02d-8a658960954e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_571dd8cb-e6db-42e9-a50a-8f8495b12619_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_de7b28fe-b90a-4acf-929c-b953565e0d08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bac94c8b-d9f9-493f-950b-059a6c0da8d5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a8f51819-45a4-452e-9c9b-1c4bf1c22fe4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MilestoneTypeAxis_49033f12-bfb8-4731-98eb-855eef13b193_terseLabel_en-US" xlink:label="lab_kprx_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_kprx_MilestoneTypeAxis_label_en-US" xlink:label="lab_kprx_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_kprx_MilestoneTypeAxis_documentation_en-US" xlink:label="lab_kprx_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by type of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeAxis" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MilestoneTypeAxis" xlink:to="lab_kprx_MilestoneTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ddb26f54-94be-47f3-a47c-a0d413ea4f85_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b5e98745-7014-4c5c-9a68-13f69573b687_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b3533612-c9eb-4880-b92d-75d221696902_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4072cf34-0c74-4d87-a395-49c2322a047a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b6f66f68-a0ef-4748-afa7-69cb77a11ada_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b67a4326-a48b-4986-a0e1-4630dd95afbb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business, Presentation and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_2c7f907c-164c-4a7b-b1c5-aa2e7ff68e09_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4f564a8a-27e2-4e92-8abd-4c8e3ea866fc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_08ce2ccd-c137-4948-9e1f-844a789b476c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_db2d5dc2-98c0-4780-a8f0-1b891fa7a9be_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Public Offerings, Net of Offering Costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f912773a-66a5-418d-8cf6-71148104c893_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net proceeds from offerings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bc92cd9d-f1cb-4664-8587-8436773b0c25_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Shares Outstanding - Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_91afc94f-198d-464b-b398-fe0d9d3e3af4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses of acquiree from the acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_ff8cc45c-e169-46c1-a057-b7d7e4debbbc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_VolumeWeightedAveragePrice_1ff97420-9a9c-497d-9670-8a130136770a_terseLabel_en-US" xlink:label="lab_kprx_VolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volume weighted average price (in usd per share)</link:label>
    <link:label id="lab_kprx_VolumeWeightedAveragePrice_label_en-US" xlink:label="lab_kprx_VolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volume Weighted Average Price</link:label>
    <link:label id="lab_kprx_VolumeWeightedAveragePrice_documentation_en-US" xlink:label="lab_kprx_VolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the volume weighted average price to determine the fair value of share issued in a business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_VolumeWeightedAveragePrice" xlink:href="kprx-20221231.xsd#kprx_VolumeWeightedAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_VolumeWeightedAveragePrice" xlink:to="lab_kprx_VolumeWeightedAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_addfc0ee-b5dd-404f-a433-cb1dc932bd4c_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Noncash Operating and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_24c3e9a4-b6ca-4fc8-9972-21ff5b210088_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6def19be-f7d6-480f-9ec8-295f65ecb5a2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c7535f48-1917-45b0-8a18-6e8ea27ae7e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cb42c848-60a1-4e9f-8fb9-1a5ff3644f28_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_34464341-db01-4afa-bdc6-07d0a89a67b4_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_42bc2d42-4a42-4efc-be4e-12bdcf573a94_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_6fc839c9-3508-4c35-9625-2e1e1e6e807d_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Disposal of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_882c018b-6456-4fc8-86f4-2c9466a27963_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Disposal of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_854eec4d-de92-4a55-908d-f50ad9f6382b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Recognition Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AccountingPoliciesTable_ee047b03-119b-40f0-aaef-843c1889f426_terseLabel_en-US" xlink:label="lab_kprx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_kprx_AccountingPoliciesTable_label_en-US" xlink:label="lab_kprx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_kprx_AccountingPoliciesTable_documentation_en-US" xlink:label="lab_kprx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesTable" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AccountingPoliciesTable" xlink:to="lab_kprx_AccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PaymentOfAnnualFee_d570e8b2-40b3-4161-bf97-a4467830928b_terseLabel_en-US" xlink:label="lab_kprx_PaymentOfAnnualFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of annual fee</link:label>
    <link:label id="lab_kprx_PaymentOfAnnualFee_label_en-US" xlink:label="lab_kprx_PaymentOfAnnualFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of annual fee</link:label>
    <link:label id="lab_kprx_PaymentOfAnnualFee_documentation_en-US" xlink:label="lab_kprx_PaymentOfAnnualFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The details about annual fee payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentOfAnnualFee" xlink:href="kprx-20221231.xsd#kprx_PaymentOfAnnualFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PaymentOfAnnualFee" xlink:to="lab_kprx_PaymentOfAnnualFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8adca95f-d9c4-4526-bf5b-7fa8a3d9bb16_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_5a1e067b-b37d-4b16-96dc-44461f1225fc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_146e7b9f-8d69-4927-88c3-19af9030f73b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5b7aa7df-a4ee-449f-9276-a1aad9f86d54_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_376d4815-d8a9-49e7-9b98-959fd4e7c0b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Preferred Stock into Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_83c1c4b4-79fe-4f4c-8fde-744714ac0b4a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5dd34cce-b51d-4c5e-8b93-af2eceadf21c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1fb4355b-f8b5-4d90-9d3a-8fb0046a2835_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiora Common Stock , Amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_a0a83601-98aa-4462-89d0-dfc0e46f8c09_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_a8d45660-3d6e-4a41-a29f-aaa627f8785c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8a5d1127-215f-4b9a-aff2-56650c5265ca_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1b23014f-9b7b-434b-bad9-cb635b45cb3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1248cc5e-e17b-4061-a0b2-a4c11ae8b824_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_add70119-d23a-42fe-b290-d6cf92e1987e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets or liabilities that are subject to fair value methodology and estimation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:to="lab_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7f78322b-df29-4155-b065-724f07367eea_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_220dca64-bad6-4803-a981-dcc5b536164b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7c74b178-5ba4-4942-969e-05dc5e620acf_netLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_a67aa907-2208-487a-84d3-04a954233e19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_3fe71b6a-7c31-4329-8c95-12a93f62f62c_terseLabel_en-US" xlink:label="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable, anniversary of closing date</link:label>
    <link:label id="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_label_en-US" xlink:label="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable, Anniversary Of Closing Date, Period</link:label>
    <link:label id="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_documentation_en-US" xlink:label="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable, Anniversary Of Closing Date, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:href="kprx-20221231.xsd#kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:to="lab_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_6351e1f2-00c7-4ebb-9446-7a59269526ce_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_b39b94ca-440c-4c7e-95e8-65ba7c5d97ab_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_ebed6e31-6f2d-42a6-9b54-558f48a94fad_terseLabel_en-US" xlink:label="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock under share purchase agreement</link:label>
    <link:label id="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_label_en-US" xlink:label="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Stock, Share Purchase Agreement</link:label>
    <link:label id="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_documentation_en-US" xlink:label="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Stock, Share Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromSaleOfStockSharePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:to="lab_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d3f9cc91-e642-4a90-996b-471381505772_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2137ce94-5429-4df9-940d-4dedac7c909d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0613d7a3-4305-407f-abda-182d0e729607_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fbe452e7-42d9-41c5-b104-7a7e9617c8c9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ContingentConsiderationScenarioDomain_302c83bf-5354-4d6f-af5c-8636e921c2a4_terseLabel_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario [Domain]</link:label>
    <link:label id="lab_kprx_ContingentConsiderationScenarioDomain_label_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario [Domain]</link:label>
    <link:label id="lab_kprx_ContingentConsiderationScenarioDomain_documentation_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioDomain" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain" xlink:to="lab_kprx_ContingentConsiderationScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5444cff-d500-472b-80c4-9bb03b31314a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_170193fc-17fa-4517-a16c-bbf1bbb1fda4_terseLabel_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_label_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice</link:label>
    <link:label id="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_documentation_en-US" xlink:label="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:to="lab_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d508ba1a-793b-4874-a31b-8e57ae4d9df3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8f298e02-30b5-4993-bb78-fa88b99506d9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_cd58ad0b-eb48-4fa0-8dac-b1ae593f2e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_16fbfbaf-e09f-4d68-a228-c39a222668c3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_80f9208b-a73f-4b4c-b316-f33cec937161_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_48018965-a28b-446a-978c-deb3c111b915_terseLabel_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_documentation_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member" xlink:href="kprx-20221231.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EquityIncentivePlan2014Member" xlink:to="lab_kprx_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0847b210-8d74-4870-89d3-36717f10eb01_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d1177272-5af2-420e-9465-69715c435d04_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d102d855-872a-4d89-ac22-706b961aa445_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts Representing Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_b377747b-2ae4-4a95-a8c3-c0ab1e586a52_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f22a996c-1040-4ff0-9464-b6cc16e7f77d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share - Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a60e7a8f-224a-4b32-baab-c63993b1e7ee_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and In-Process R&amp;D, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7271508a-1e61-4b15-b158-cc98e7d64f51_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e515a66b-925b-4fa3-9888-cd7a09a6500a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7b6a3600-1acd-4731-9140-98a7c9a267e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds on Sale of Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_46a64325-ffcd-4005-adfd-99b51d1b7f40_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff82a950-2ee1-4e66-8591-8c31364000ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cde71aac-b867-4e2b-a37c-ec2ff70ea210_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_5841883b-7eb3-43c7-a35c-6734cb38f655_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_8ba5dad2-374f-4527-a743-cdffa52d0f23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_474c9ebb-e623-4122-be03-012dae0ded10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ce915f8b-42c7-4c6e-adc7-e06d58ccfc94_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessAcquisitionEarnoutConsideration_05d99585-655b-423e-a060-27a0f8221797_terseLabel_en-US" xlink:label="lab_kprx_BusinessAcquisitionEarnoutConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout consideration</link:label>
    <link:label id="lab_kprx_BusinessAcquisitionEarnoutConsideration_label_en-US" xlink:label="lab_kprx_BusinessAcquisitionEarnoutConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Earnout Consideration</link:label>
    <link:label id="lab_kprx_BusinessAcquisitionEarnoutConsideration_documentation_en-US" xlink:label="lab_kprx_BusinessAcquisitionEarnoutConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Earnout consideration in a business combination arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionEarnoutConsideration" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionEarnoutConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessAcquisitionEarnoutConsideration" xlink:to="lab_kprx_BusinessAcquisitionEarnoutConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_a308c977-ea34-4fa3-9838-73108e5addbd_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PanoptesPharmaGesMbhMember_7ad35d08-3cab-4744-880a-d554abc34296_terseLabel_en-US" xlink:label="lab_kprx_PanoptesPharmaGesMbhMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes Pharma Ges .m.b.h.</link:label>
    <link:label id="lab_kprx_PanoptesPharmaGesMbhMember_label_en-US" xlink:label="lab_kprx_PanoptesPharmaGesMbhMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes Pharma Ges .m.b.h. [Member]</link:label>
    <link:label id="lab_kprx_PanoptesPharmaGesMbhMember_documentation_en-US" xlink:label="lab_kprx_PanoptesPharmaGesMbhMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panoptes Pharma Ges .m.b.h.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGesMbhMember" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGesMbhMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PanoptesPharmaGesMbhMember" xlink:to="lab_kprx_PanoptesPharmaGesMbhMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ad5cb395-bb90-45a1-8aff-5fafbc8fe9a1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_66a903b9-a9c8-4205-b0f8-65bd91a59e8d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized uncertain income tax</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_685fd8e8-9990-40d2-b7a1-a15d465142d6_terseLabel_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_label_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_documentation_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsDisclosureTextBlock" xlink:href="kprx-20221231.xsd#kprx_WarrantsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsDisclosureTextBlock" xlink:to="lab_kprx_WarrantsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_093cb338-15d0-481f-ae59-085f53e6cd7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7d55b2af-85a2-4a6a-af3b-4d64a71f302e_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Expense) Income, Net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d9a944bd-ee5b-46ba-bf57-f0b7ee8ca429_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_310fba0c-1727-4807-b877-aadb021966d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6c34ee64-dad2-46b9-84e7-0e6921b136d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_438c8b41-d0ba-4524-a268-dab7d788eb86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SeriesEConvertiblePreferredStockMember_24855257-83ca-4863-a8b0-587bda08d940_terseLabel_en-US" xlink:label="lab_kprx_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_kprx_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_kprx_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_kprx_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_kprx_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesEConvertiblePreferredStockMember" xlink:href="kprx-20221231.xsd#kprx_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SeriesEConvertiblePreferredStockMember" xlink:to="lab_kprx_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e67ec3e9-d3dc-4436-9c65-9743cb1f8701_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8e3d8464-8e6f-45e6-8a92-03b00521aa82_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3793beb1-40c5-445a-a5ca-27f31bd6f507_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d7ca2459-b621-49ec-8734-231b4f458f2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_65658506-717b-49b8-a75f-c46b4830eb73_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_89d588b1-ca3b-4674-87e6-bb2f38294203_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_94f14c41-c3d5-417d-b982-04819f41b57c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_d28c2ebf-a4dd-4c65-8711-10df4b744393_terseLabel_en-US" xlink:label="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement, maximum amount</link:label>
    <link:label id="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_label_en-US" xlink:label="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Sale Of Stock, Maximum Amount</link:label>
    <link:label id="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_documentation_en-US" xlink:label="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Sale Of Stock, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:href="kprx-20221231.xsd#kprx_SharePurchaseAgreementSaleOfStockMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:to="lab_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b9ce9379-c9b3-407b-b488-7daa7ce6cf43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a24de263-2485-4010-a4dd-fe0676e000be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_296bd83d-c174-4171-ab8b-081ba2e86261_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_093c031d-650c-4b39-b791-a501c6e831e6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d03cd6b6-0498-4f33-b719-ab43d3864ce0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_e04d386c-d028-47da-8b8e-aca0ec23fc04_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Inducement, Net of Issuance Costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_f2dbfef2-8dc3-419c-bdc3-44552516c59a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant inducements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_Between250And500MillionNetSalesMember_7c41edeb-3115-4a8e-8e2d-e8e418973b7c_terseLabel_en-US" xlink:label="lab_kprx_Between250And500MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 250 And 500 Million Net Sales</link:label>
    <link:label id="lab_kprx_Between250And500MillionNetSalesMember_label_en-US" xlink:label="lab_kprx_Between250And500MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 250 And 500 Million Net Sales [Member]</link:label>
    <link:label id="lab_kprx_Between250And500MillionNetSalesMember_documentation_en-US" xlink:label="lab_kprx_Between250And500MillionNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for between 250 and 500 million net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Between250And500MillionNetSalesMember" xlink:href="kprx-20221231.xsd#kprx_Between250And500MillionNetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_Between250And500MillionNetSalesMember" xlink:to="lab_kprx_Between250And500MillionNetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4d2df768-b038-444d-a915-6233a1874582_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_03dc5eb4-3c8b-49dd-953a-2c1b13d9444a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfVendors_1260abbd-a3fd-48ed-8c72-81a5088a9ee3_terseLabel_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vendors with whom the company has entered into related party transactions</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfVendors_label_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Number Of Vendors</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfVendors_documentation_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vendors with whom the company has entered into related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfVendors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:to="lab_kprx_RelatedPartyTransactionsNumberOfVendors" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfConsultants_559f91bd-31ac-459a-bf67-46093f2960c4_terseLabel_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consultants with whom the company has entered into related party transactions</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfConsultants_label_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions, Number Of Consultants</link:label>
    <link:label id="lab_kprx_RelatedPartyTransactionsNumberOfConsultants_documentation_en-US" xlink:label="lab_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consultants with whom the company has entered into related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfConsultants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:to="lab_kprx_RelatedPartyTransactionsNumberOfConsultants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a18f7580-71e4-4378-86bd-bfb789b6dbbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e50b6a00-ddc7-431d-9f5d-f24df100d2d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Decrease) Increase in Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_52c2a14f-d210-4c93-8694-013655ae2aac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value contingent consideration measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ea1b8448-f27b-4c77-bbcf-3c98b5fa05d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ef6cb877-43f4-4a53-b04d-704db13e4dc2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PercentageOfRoyaltiesOnNetSales_8832eeb5-f0d7-4ef0-8fb4-154b65b43440_terseLabel_en-US" xlink:label="lab_kprx_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties on net sales</link:label>
    <link:label id="lab_kprx_PercentageOfRoyaltiesOnNetSales_label_en-US" xlink:label="lab_kprx_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalties On Net Sales</link:label>
    <link:label id="lab_kprx_PercentageOfRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_kprx_PercentageOfRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of royalties over net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfRoyaltiesOnNetSales" xlink:href="kprx-20221231.xsd#kprx_PercentageOfRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PercentageOfRoyaltiesOnNetSales" xlink:to="lab_kprx_PercentageOfRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_eb0128d5-e722-4b1f-9fc8-7e807c5d35ec_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_988c3497-1d50-49fc-b3ef-56ab7fceb012_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_59e85b3f-dfd6-4f24-920a-4d8fb7f1c199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_91c157f5-57b3-428a-8d0d-f02b12956d09_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bab9be67-0806-4e45-b7c7-ab21b2d806bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d89fd978-d3ba-4edc-b7f9-246d3556a795_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5b3bd04-814c-4ae9-aeea-4018254c2508_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_78820cbe-376c-4208-b525-dee373873810_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_a38eb7b6-c063-413f-b097-5802d3503b03_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_21ac925e-c307-4c48-aba4-d009e30c3ffd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AccountingPoliciesLineItems_668bc5f3-270a-41ae-890b-f397542b6711_terseLabel_en-US" xlink:label="lab_kprx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_kprx_AccountingPoliciesLineItems_label_en-US" xlink:label="lab_kprx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_kprx_AccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_kprx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesLineItems" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AccountingPoliciesLineItems" xlink:to="lab_kprx_AccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5f5cbff0-fcc8-4b5a-8483-6c9a49791368_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f553b818-a13a-4d41-8f95-4828a64e5069_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_b8cdd616-4b86-4d7f-acb6-4521863ea885_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7c5094af-bfa7-4efc-ac0d-8e18545e3c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6e83a02c-40c1-428e-b083-d7275c9b462b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeSecretsMember_d452056f-905f-4977-af77-0ac2782b1efa_terseLabel_en-US" xlink:label="lab_us-gaap_TradeSecretsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Secrets</link:label>
    <link:label id="lab_us-gaap_TradeSecretsMember_label_en-US" xlink:label="lab_us-gaap_TradeSecretsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Secrets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeSecretsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeSecretsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeSecretsMember" xlink:to="lab_us-gaap_TradeSecretsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f665fb13-0a52-43d6-a363-617f30471f27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5c48acd7-2c5c-4739-96de-5f6be5c8bf1f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_bec81ad5-2942-4223-9cc6-51239784e006_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties included in accounts payable</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7194b870-b09c-4fee-aa11-0aa4f2b4c55b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_af9de921-a647-4090-8f3a-e5189483f1a2_verboseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock from Warrant Exercises (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_c203e0bc-a6a1-436c-a1c4-493ec03526f2_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock from warrant exercises (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7fce6627-973d-4707-a793-f92898484d9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share - Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0950eace-92d9-467a-9c66-b7b0a5a9ec17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ContingentConsiderationScenarioAxis_225b367d-374e-4aaa-a414-88835883146f_terseLabel_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario [Axis]</link:label>
    <link:label id="lab_kprx_ContingentConsiderationScenarioAxis_label_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario [Axis]</link:label>
    <link:label id="lab_kprx_ContingentConsiderationScenarioAxis_documentation_en-US" xlink:label="lab_kprx_ContingentConsiderationScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioAxis" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ContingentConsiderationScenarioAxis" xlink:to="lab_kprx_ContingentConsiderationScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_131905ae-514e-463b-a172-52ab2360aa74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightExercised_ba430514-5c74-4b57-9aca-9b642a3aad32_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercised</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightExercised" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightExercised" xlink:to="lab_kprx_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PaymentsToAcquireBusinessesFairValue_0b605b99-c6e8-4962-b5b7-58d706a70894_terseLabel_en-US" xlink:label="lab_kprx_PaymentsToAcquireBusinessesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at the acquisition date</link:label>
    <link:label id="lab_kprx_PaymentsToAcquireBusinessesFairValue_label_en-US" xlink:label="lab_kprx_PaymentsToAcquireBusinessesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Businesses, Fair Value</link:label>
    <link:label id="lab_kprx_PaymentsToAcquireBusinessesFairValue_documentation_en-US" xlink:label="lab_kprx_PaymentsToAcquireBusinessesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow associated with the acquisition of business during the period at fair value. The cash portion only of the acquisition price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsToAcquireBusinessesFairValue" xlink:href="kprx-20221231.xsd#kprx_PaymentsToAcquireBusinessesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PaymentsToAcquireBusinessesFairValue" xlink:to="lab_kprx_PaymentsToAcquireBusinessesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_31d97453-da59-4854-92b1-6557937f78de_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b257ff23-79f9-42a7-b687-f3a372ecb68e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4d6e3853-a0f3-4341-b635-eb6c1af14f9f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b7dc6c30-28b4-4dfe-9810-b44d0d46e022_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creation of Right-of-Use Assets and Related Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassAWarrantsExerciseOfOptionMember_50becfc1-7905-4cd6-a082-848645fe3242_terseLabel_en-US" xlink:label="lab_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrants, Exercise of Option</link:label>
    <link:label id="lab_kprx_ClassAWarrantsExerciseOfOptionMember_label_en-US" xlink:label="lab_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrants, Exercise of Option [Member]</link:label>
    <link:label id="lab_kprx_ClassAWarrantsExerciseOfOptionMember_documentation_en-US" xlink:label="lab_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Warrants, Exercise of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantsExerciseOfOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:to="lab_kprx_ClassAWarrantsExerciseOfOptionMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>kprx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:076428bb-c7ab-454d-8d43-93f7df0e4a49,g:4a4bef31-7715-4008-abf3-14efcabcd62d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ad5595a1-3f83-4d9e-aaf3-8f3aa1349184" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentType_ad5595a1-3f83-4d9e-aaf3-8f3aa1349184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b2a34161-f5c0-468c-bba7-b77287659bf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentAnnualReport_b2a34161-f5c0-468c-bba7-b77287659bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d70f73d2-c634-4058-bb8a-0cc3f47de9cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentPeriodEndDate_d70f73d2-c634-4058-bb8a-0cc3f47de9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_db387f8e-fbaa-45d0-810a-ab0fe38472a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_CurrentFiscalYearEndDate_db387f8e-fbaa-45d0-810a-ab0fe38472a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d51d90a1-fae0-4588-a2a4-b3bde91296bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentTransitionReport_d51d90a1-fae0-4588-a2a4-b3bde91296bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_64a686e1-f819-4cef-8926-0ddbc3b77ca1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityFileNumber_64a686e1-f819-4cef-8926-0ddbc3b77ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8fc218f6-05a2-4d3b-a79a-4d4201ad0c4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityRegistrantName_8fc218f6-05a2-4d3b-a79a-4d4201ad0c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_61f03167-98c2-4b0a-89db-a0de821c76ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_61f03167-98c2-4b0a-89db-a0de821c76ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e3177408-a93d-4891-9eee-4526eb74a40d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityTaxIdentificationNumber_e3177408-a93d-4891-9eee-4526eb74a40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8757db97-b38d-4910-a12d-f7bc0d31ab77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityAddressAddressLine1_8757db97-b38d-4910-a12d-f7bc0d31ab77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0daad9d2-9f80-4417-82f1-c76d3266ccc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityAddressAddressLine2_0daad9d2-9f80-4417-82f1-c76d3266ccc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_00023576-14be-480a-a517-edca0a053e64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityAddressCityOrTown_00023576-14be-480a-a517-edca0a053e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eaa68b3e-e42c-4348-9f54-6536d13a71df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityAddressStateOrProvince_eaa68b3e-e42c-4348-9f54-6536d13a71df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_43b7aa2a-13b2-48d2-9cdb-9c05186f3c8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityAddressPostalZipCode_43b7aa2a-13b2-48d2-9cdb-9c05186f3c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_666d4618-fbac-4689-b948-9806e294fe21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_CityAreaCode_666d4618-fbac-4689-b948-9806e294fe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e5343f7c-ee3e-49c8-aab2-951af83c622c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_LocalPhoneNumber_e5343f7c-ee3e-49c8-aab2-951af83c622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cba07690-69bb-410a-a81f-fce2b695213b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_Security12bTitle_cba07690-69bb-410a-a81f-fce2b695213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b9adc4e7-f394-4db1-9712-b896d5ca5435" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_SecurityExchangeName_b9adc4e7-f394-4db1-9712-b896d5ca5435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_af3feaea-f408-42b6-a4ac-8144bddc4c02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_TradingSymbol_af3feaea-f408-42b6-a4ac-8144bddc4c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6de62354-33d6-4725-9994-e95fc566f224" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6de62354-33d6-4725-9994-e95fc566f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2f5bd385-979d-4827-b406-834b3caccb36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityVoluntaryFilers_2f5bd385-979d-4827-b406-834b3caccb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_da2d057b-cdcc-4264-9cdd-0e5fc40620cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityCurrentReportingStatus_da2d057b-cdcc-4264-9cdd-0e5fc40620cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d154be5d-d7c1-48bb-82ae-26c045cf4452" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityInteractiveDataCurrent_d154be5d-d7c1-48bb-82ae-26c045cf4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bc929df8-c283-41a4-bc79-a65efda82013" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityFilerCategory_bc929df8-c283-41a4-bc79-a65efda82013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ae9e9eb1-6dbe-4309-9826-2d54bff8f60e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntitySmallBusiness_ae9e9eb1-6dbe-4309-9826-2d54bff8f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_db746d20-ee52-476f-9b4c-8e0d7674c066" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityEmergingGrowthCompany_db746d20-ee52-476f-9b4c-8e0d7674c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_56e1cdc2-949e-40dc-a27d-ffed2cc03abc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_56e1cdc2-949e-40dc-a27d-ffed2cc03abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_636496b3-7f0b-4827-806c-410d43d98c8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityShellCompany_636496b3-7f0b-4827-806c-410d43d98c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f7a40bb5-cd73-411f-9f91-15a8905d244a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityPublicFloat_f7a40bb5-cd73-411f-9f91-15a8905d244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c7473a65-05d7-42f9-a259-77d7b1a6960f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c7473a65-05d7-42f9-a259-77d7b1a6960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cc84d962-be8a-4475-892a-24fe93925a43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_EntityCentralIndexKey_cc84d962-be8a-4475-892a-24fe93925a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bc61b8f9-4468-4995-9b30-86a7b6355e80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentFiscalYearFocus_bc61b8f9-4468-4995-9b30-86a7b6355e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d132b372-e789-4901-9f7b-b7f905b99e51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d132b372-e789-4901-9f7b-b7f905b99e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7150ad3f-f329-41ca-b8c1-0c956b08bc7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e1c15361-82f7-470f-b175-4c4875de566a" xlink:to="loc_dei_AmendmentFlag_7150ad3f-f329-41ca-b8c1-0c956b08bc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AuditInformation" xlink:type="simple" xlink:href="kprx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AuditInformationAbstract_97848af1-6a9b-4b99-ae40-3ce95a244a71" xlink:href="kprx-20221231.xsd#kprx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a8fa1a2c-2997-4967-919c-0f1392e23835" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AuditInformationAbstract_97848af1-6a9b-4b99-ae40-3ce95a244a71" xlink:to="loc_dei_AuditorFirmId_a8fa1a2c-2997-4967-919c-0f1392e23835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6e05e669-8167-43c2-89ae-faca869994d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AuditInformationAbstract_97848af1-6a9b-4b99-ae40-3ce95a244a71" xlink:to="loc_dei_AuditorName_6e05e669-8167-43c2-89ae-faca869994d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_38525538-1bb1-4b83-a8db-c4bb23115f77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AuditInformationAbstract_97848af1-6a9b-4b99-ae40-3ce95a244a71" xlink:to="loc_dei_AuditorLocation_38525538-1bb1-4b83-a8db-c4bb23115f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b10aa7f0-9d9a-4509-9f9b-b0760293dbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b10aa7f0-9d9a-4509-9f9b-b0760293dbcd" xlink:to="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1c29731-ca74-4c84-9914-3b26a888b8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1c29731-ca74-4c84-9914-3b26a888b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f247a638-29a4-4c40-9039-9d388fae2e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f247a638-29a4-4c40-9039-9d388fae2e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_81ae4c2f-8990-478e-8b21-ac982a1de569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:to="loc_us-gaap_IncomeTaxesReceivable_81ae4c2f-8990-478e-8b21-ac982a1de569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2dc2254b-8772-4658-929e-79dfb10d2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9d69fd14-5e40-461f-9f5c-49c78d2584c7" xlink:to="loc_us-gaap_AssetsCurrent_2dc2254b-8772-4658-929e-79dfb10d2dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_719e8174-d39e-4701-9667-1b760d8f0b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_719e8174-d39e-4701-9667-1b760d8f0b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_42caf814-e49e-4a1e-8ccd-f874ec733e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_42caf814-e49e-4a1e-8ccd-f874ec733e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a34a808-510f-478b-897b-e59053486201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a34a808-510f-478b-897b-e59053486201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f54c6c7-dd0f-46d3-a210-0bd6eea29847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f54c6c7-dd0f-46d3-a210-0bd6eea29847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ac189698-5535-4819-b56a-483b84db19ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ac189698-5535-4819-b56a-483b84db19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_17d7a894-d1c1-4982-a566-82612716abc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aadc680e-685a-47b0-8daa-b5008acf448a" xlink:to="loc_us-gaap_Assets_17d7a894-d1c1-4982-a566-82612716abc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b10aa7f0-9d9a-4509-9f9b-b0760293dbcd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_88d0e6cd-17e6-4135-b806-fbd2b41190db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:to="loc_us-gaap_AccountsPayableCurrent_88d0e6cd-17e6-4135-b806-fbd2b41190db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_720c3a16-aaad-4639-a1ca-478dfee20daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_720c3a16-aaad-4639-a1ca-478dfee20daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_efe20b1e-e7a7-4fb1-9b3a-b611fddb2223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_efe20b1e-e7a7-4fb1-9b3a-b611fddb2223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_57c64f4a-9ed3-4da1-a4b4-3b191088dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_57c64f4a-9ed3-4da1-a4b4-3b191088dc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8efb7692-7cfe-4b0e-b7ea-6ada449eedb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c41edb1-ba4d-4d12-85bc-af8b7c48e991" xlink:to="loc_us-gaap_LiabilitiesCurrent_8efb7692-7cfe-4b0e-b7ea-6ada449eedb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5168489e-69d0-4681-b6b6-7266921a0dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5168489e-69d0-4681-b6b6-7266921a0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_abcb2710-f1bc-4001-b12b-64382510ca2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_abcb2710-f1bc-4001-b12b-64382510ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e858a948-5baf-49db-aba2-d3e88fe3b703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e858a948-5baf-49db-aba2-d3e88fe3b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3c7ec1cb-3813-4ba2-9c81-641850aca26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8506110b-0120-4911-82bf-be1dd18d6b99" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3c7ec1cb-3813-4ba2-9c81-641850aca26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f47a2b9d-f5ca-493b-b8bf-31859a7633cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_Liabilities_f47a2b9d-f5ca-493b-b8bf-31859a7633cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4354e073-2d51-4cdb-ac60-68c75ba9e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4354e073-2d51-4cdb-ac60-68c75ba9e76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2dbd67e2-adf2-4d76-9d63-aae4112955d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_PreferredStockValue_2dbd67e2-adf2-4d76-9d63-aae4112955d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_edaaf913-45fa-4009-9385-2154f8bddb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_CommonStockValue_edaaf913-45fa-4009-9385-2154f8bddb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fb7e2e18-5345-40c8-b61a-e5cf15ff5de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fb7e2e18-5345-40c8-b61a-e5cf15ff5de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9bb85c62-d42c-4a8d-80fd-0fc28dd6cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9bb85c62-d42c-4a8d-80fd-0fc28dd6cc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04d1ad62-841a-4db4-b0b7-9959e10fc5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04d1ad62-841a-4db4-b0b7-9959e10fc5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df48b936-2055-45d0-acaa-b120fd7ca1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90e5d5a3-eb18-4cd2-a779-bf9a05d0700c" xlink:to="loc_us-gaap_StockholdersEquity_df48b936-2055-45d0-acaa-b120fd7ca1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_839f1a15-0a4e-406b-b68d-fea28fc3cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e38ac219-1731-471c-bbad-99a8ab20b4c3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_839f1a15-0a4e-406b-b68d-fea28fc3cd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bd5f7917-5be0-452d-9ec6-776feac69d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bd5f7917-5be0-452d-9ec6-776feac69d4b" xlink:to="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01f12439-01ef-43e9-bfdf-caf6d3aee937" xlink:to="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3f91991d-665c-4529-a32d-76fbd64d40be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3f91991d-665c-4529-a32d-76fbd64d40be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_f136e8f7-2192-49cd-b213-9338d12df354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_f136e8f7-2192-49cd-b213-9338d12df354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6a537aba-e4e7-463f-a9b7-39c7a354f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6a537aba-e4e7-463f-a9b7-39c7a354f0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_c6f49fd2-8499-4318-92dc-f0dd338b84b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_c6f49fd2-8499-4318-92dc-f0dd338b84b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_f4e5a781-7822-49e3-8ca5-0800947d9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6aeb526d-2b12-4f5a-be5c-06ed67c99b06" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_f4e5a781-7822-49e3-8ca5-0800947d9c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64bf3b0c-4693-4dea-8b6b-23e7dc579102" xlink:to="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5cc78a2c-04d0-4223-965a-ae75116d00db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5cc78a2c-04d0-4223-965a-ae75116d00db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ccdb12c3-b4b1-4a63-b2e0-b68d7f779a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ccdb12c3-b4b1-4a63-b2e0-b68d7f779a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares_c171d727-acb9-43d1-8884-4264ebaeec2c" xlink:href="kprx-20221231.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_kprx_PreferredStockDesignatedShares_c171d727-acb9-43d1-8884-4264ebaeec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9ba8d63d-8761-40e4-ad30-0a58850e2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9ba8d63d-8761-40e4-ad30-0a58850e2c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2c510996-bde9-4e3c-b4e8-c9d2e7faebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2c510996-bde9-4e3c-b4e8-c9d2e7faebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60daaf35-589a-4118-9329-b86ac3c6a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60daaf35-589a-4118-9329-b86ac3c6a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_87707444-d4d2-43de-82c3-f343b1566307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_87707444-d4d2-43de-82c3-f343b1566307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5b9fa54f-cb25-4ab7-924b-8ff265685978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesIssued_5b9fa54f-cb25-4ab7-924b-8ff265685978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_540cdf85-a16b-4695-a8ac-31cd4ab0b115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417c6910-c17a-4b64-93fb-39616e05cf32" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_540cdf85-a16b-4695-a8ac-31cd4ab0b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_072d47e5-a444-4392-9136-9065062dedf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_072d47e5-a444-4392-9136-9065062dedf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fb2883be-7add-4843-bc7b-c22afa4e4a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fb2883be-7add-4843-bc7b-c22afa4e4a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9e6da046-ea1f-43fd-9230-93408a853e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9e6da046-ea1f-43fd-9230-93408a853e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2032e6d2-a94c-444c-8f4b-7cc1c554a9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2032e6d2-a94c-444c-8f4b-7cc1c554a9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ee5cecd9-d2ad-4982-a97e-46792ffa260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8fcafe0d-6da0-48ef-ad5c-e5f5ffbf84f1" xlink:to="loc_us-gaap_OperatingExpenses_ee5cecd9-d2ad-4982-a97e-46792ffa260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f508d731-b4e5-4c2d-a3f9-b870976123c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_OperatingIncomeLoss_f508d731-b4e5-4c2d-a3f9-b870976123c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cd61e2a8-ca34-47ae-8cb2-de051d9b41aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cd61e2a8-ca34-47ae-8cb2-de051d9b41aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23e33e64-c33c-4171-8558-fc53a91670b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23e33e64-c33c-4171-8558-fc53a91670b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cbe03e5e-9db6-4d34-b5bb-c85d17d8fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cbe03e5e-9db6-4d34-b5bb-c85d17d8fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ea5f03cd-9dab-42b6-b38a-db742c71508f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ea5f03cd-9dab-42b6-b38a-db742c71508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6f3a0b5a-aa79-4247-9596-5556f1e7d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_InterestExpense_6f3a0b5a-aa79-4247-9596-5556f1e7d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_082d3e66-c3ad-4bfd-b39e-2868463837dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_082d3e66-c3ad-4bfd-b39e-2868463837dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_985811da-2990-462b-bc90-70182ee4ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3516aee5-3b07-4a71-bdf1-3c562bbdf31b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_985811da-2990-462b-bc90-70182ee4ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695bc661-8f51-45a9-bcd0-4385ac97cea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695bc661-8f51-45a9-bcd0-4385ac97cea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8096b8e1-ea96-4943-bc68-e4053bd1e96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8096b8e1-ea96-4943-bc68-e4053bd1e96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9da4f42a-c037-4187-b6fa-ac9eba5dc3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_NetIncomeLoss_9da4f42a-c037-4187-b6fa-ac9eba5dc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_67197ce5-16cf-4bc2-ae80-095365d51156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_EarningsPerShareBasic_67197ce5-16cf-4bc2-ae80-095365d51156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d5dca4ee-06e9-42e5-8f72-2da4a97e36e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d5dca4ee-06e9-42e5-8f72-2da4a97e36e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ea946241-48d9-47f8-8320-cbf051250266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ea946241-48d9-47f8-8320-cbf051250266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e499184-340c-4b75-aded-8f43cc5e0438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e499184-340c-4b75-aded-8f43cc5e0438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_01f3c2d3-82bb-4b52-8d7c-5b05ee393ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_42eecca5-cd7e-4eba-b17a-8ca74270fbaa" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_01f3c2d3-82bb-4b52-8d7c-5b05ee393ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db5d0c18-49a9-4863-92e6-8b3ff4b5d848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_01f3c2d3-82bb-4b52-8d7c-5b05ee393ce4" xlink:to="loc_us-gaap_NetIncomeLoss_db5d0c18-49a9-4863-92e6-8b3ff4b5d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ef4cf032-cf42-4206-a9bb-fac4f2cdae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_01f3c2d3-82bb-4b52-8d7c-5b05ee393ce4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ef4cf032-cf42-4206-a9bb-fac4f2cdae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_23bf94a4-af05-4897-8ba1-94efdf0118ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_01f3c2d3-82bb-4b52-8d7c-5b05ee393ce4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_23bf94a4-af05-4897-8ba1-94efdf0118ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aba462d8-33ce-4d72-8d09-fb927909a653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aba462d8-33ce-4d72-8d09-fb927909a653" xlink:to="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3cfb7f5f-e3fb-4e5f-bd93-2762831896f4" xlink:to="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4ecde722-1885-4d14-85a5-78b57f5d66d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_PreferredStockMember_4ecde722-1885-4d14-85a5-78b57f5d66d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f9dae68-9688-4c66-b58a-bab3f98a4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_CommonStockMember_3f9dae68-9688-4c66-b58a-bab3f98a4d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b127ea00-c932-4a20-b7e3-232ea9b8a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b127ea00-c932-4a20-b7e3-232ea9b8a7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a584a636-2d56-434a-9b0d-665abfc12312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a584a636-2d56-434a-9b0d-665abfc12312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_410ba7f0-b503-4747-ac48-505aeb3c8554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89ca3c51-1050-4eb8-819e-3d6dcbafbb7f" xlink:to="loc_us-gaap_RetainedEarningsMember_410ba7f0-b503-4747-ac48-505aeb3c8554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c66cd49f-b594-487d-b216-d45451e062bd" xlink:to="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_abac0435-6c0a-4106-a445-7796bd4d5956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_abac0435-6c0a-4106-a445-7796bd4d5956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1bbbb6ab-5dbb-4322-b347-3bd154216f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1bbbb6ab-5dbb-4322-b347-3bd154216f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_a5f92da1-71ec-4cfb-ba97-adc66fced026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_510f5d45-7f6e-49bf-98d6-85b4abc7cf90" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_a5f92da1-71ec-4cfb-ba97-adc66fced026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a134e97f-8504-4f9a-b29f-fd3ae3cb2359" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_b6bf985f-c3bf-4b0c-91d4-b8877bec4a3d" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_kprx_PublicOfferingMember_b6bf985f-c3bf-4b0c-91d4-b8877bec4a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c5395554-71c0-420e-baca-1afb7f011c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_us-gaap_PrivatePlacementMember_c5395554-71c0-420e-baca-1afb7f011c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_9256ff55-859b-4932-9456-2aeebee02a9e" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd8a3f3f-abdd-4118-a76d-0a9316c998e6" xlink:to="loc_kprx_RegisteredDirectOfferingMember_9256ff55-859b-4932-9456-2aeebee02a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f186c3-849f-456f-a3da-4d8cbf815258" xlink:to="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_89560dc8-7324-468e-a1ad-791a4500000f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_SharesOutstanding_89560dc8-7324-468e-a1ad-791a4500000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd7f2d95-b23d-4402-8f48-e53b5e976a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockholdersEquity_bd7f2d95-b23d-4402-8f48-e53b5e976a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9470ed5-5948-4d9c-b97c-c9124f5acef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9470ed5-5948-4d9c-b97c-c9124f5acef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_8e512985-d626-46db-916f-431d5cdeb8f8" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesFromHoldBackShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_8e512985-d626-46db-916f-431d5cdeb8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_a864222b-472f-438e-9899-a03da7115450" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares_a864222b-472f-438e-9899-a03da7115450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e40538e-70f6-4571-aad4-a0c439e8f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7e40538e-70f6-4571-aad4-a0c439e8f3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b02ca7dc-64a3-4642-83fd-4d5b1a328cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b02ca7dc-64a3-4642-83fd-4d5b1a328cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31225ea3-743e-4ad6-ac83-07a65195e4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31225ea3-743e-4ad6-ac83-07a65195e4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f845ee-aad2-434a-92d0-28516233a286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_01f845ee-aad2-434a-92d0-28516233a286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_245df2c2-60fc-4d51-aef8-d4d4e08fb8db" xlink:href="kprx-20221231.xsd#kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability_245df2c2-60fc-4d51-aef8-d4d4e08fb8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_d32dc7b4-e467-476e-8db8-806499b3a448" xlink:href="kprx-20221231.xsd#kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits_d32dc7b4-e467-476e-8db8-806499b3a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_01ed73f7-af52-471c-ae7e-1589a3241bf9" xlink:href="kprx-20221231.xsd#kprx_StockAdjustedDuringPeriodValueReverseStockSplits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockAdjustedDuringPeriodValueReverseStockSplits_01ed73f7-af52-471c-ae7e-1589a3241bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_8e99d8c9-7eb0-45d8-bfb6-9ac46a3c9cb9" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_8e99d8c9-7eb0-45d8-bfb6-9ac46a3c9cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_16fef984-6728-4844-94b4-4c576bbe154d" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_16fef984-6728-4844-94b4-4c576bbe154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement_8f6e9de6-93a9-43ea-bd26-cebaf8655e56" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantInducement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantInducement_8f6e9de6-93a9-43ea-bd26-cebaf8655e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement_0f97119d-2c4c-45b6-9baa-d2237a5ee742" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodValueWarrantInducement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantInducement_0f97119d-2c4c-45b6-9baa-d2237a5ee742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c208c674-c2ba-45a2-bf15-3ce5db4c28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c208c674-c2ba-45a2-bf15-3ce5db4c28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5baa9c2a-acac-4671-8923-35aa22cfc81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5baa9c2a-acac-4671-8923-35aa22cfc81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_0f2617c0-fd88-460c-b737-402890c139f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_0f2617c0-fd88-460c-b737-402890c139f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4ab9324-fc03-42ed-8d94-836e880b8685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_NetIncomeLoss_f4ab9324-fc03-42ed-8d94-836e880b8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b81e7cc3-cb89-4980-8497-76ce7cd87577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_StockholdersEquity_b81e7cc3-cb89-4980-8497-76ce7cd87577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f12a28de-a6ba-4527-afec-d53be9b80324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85a2bbb5-6adb-4eef-ac0b-2261cd51cad1" xlink:to="loc_us-gaap_SharesOutstanding_f12a28de-a6ba-4527-afec-d53be9b80324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_70f4deab-49d9-4857-a079-7a6f5e769b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_70f4deab-49d9-4857-a079-7a6f5e769b87" xlink:to="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b620b13-93fb-40b2-b099-ff530c0c1021" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_46a00ef9-35fc-4afe-a4de-ecd32bdb5129" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_kprx_PublicOfferingMember_46a00ef9-35fc-4afe-a4de-ecd32bdb5129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_eb0f4738-0519-4f64-abc3-7894bafe6be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_us-gaap_PrivatePlacementMember_eb0f4738-0519-4f64-abc3-7894bafe6be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_d3caf683-f910-4254-ba36-80249b49d803" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f268f2d-0612-4c7e-8c8e-e920686c2b12" xlink:to="loc_kprx_RegisteredDirectOfferingMember_d3caf683-f910-4254-ba36-80249b49d803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e0eefcc5-8f46-45ac-90f2-aa9c9445477a" xlink:to="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesEConvertiblePreferredStockMember_22a9c3a6-c0af-49bf-9dda-dcd4d6d32c83" xlink:href="kprx-20221231.xsd#kprx_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_09f424a3-f9d6-4ba8-8651-a98c52bc574b" xlink:to="loc_kprx_SeriesEConvertiblePreferredStockMember_22a9c3a6-c0af-49bf-9dda-dcd4d6d32c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1def0064-6b36-41a6-b37d-77c1dce83d14" xlink:to="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3395bcfb-b063-46f9-abb4-4b83e08b4091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3395bcfb-b063-46f9-abb4-4b83e08b4091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e1816130-f5da-49c3-91ad-60c8ad601c24" xlink:href="kprx-20221231.xsd#kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a0b50401-2302-4163-85bb-0249b9753841" xlink:to="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_e1816130-f5da-49c3-91ad-60c8ad601c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="kprx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e477546d-ee9b-4314-853b-e7b3e0b2d38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e477546d-ee9b-4314-853b-e7b3e0b2d38d" xlink:to="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8cd6ff2-58ff-4a0c-a199-e1c9d84ef723" xlink:to="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_51310bc3-bd71-4fb9-ae6a-b0221e652c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_51310bc3-bd71-4fb9-ae6a-b0221e652c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_607870b5-aafd-4713-8554-f229e18c16cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_607870b5-aafd-4713-8554-f229e18c16cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_6dbd2d36-c9d4-4881-b9ec-3284d99c6aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f127d4c5-5892-48a7-9262-63b18d256cc8" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_6dbd2d36-c9d4-4881-b9ec-3284d99c6aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a923ea80-03ad-4077-a304-7f27be0158e9" xlink:to="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48fe2ddb-cf3b-4a90-a3a9-0656a0f7d006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_NetIncomeLoss_48fe2ddb-cf3b-4a90-a3a9-0656a0f7d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6528ef67-0147-487a-aa9e-5a8c325c4920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6528ef67-0147-487a-aa9e-5a8c325c4920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_52676f07-f72c-45ad-b908-1c29d6a292b8" xlink:href="kprx-20221231.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_52676f07-f72c-45ad-b908-1c29d6a292b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8414c573-0118-4a8a-a587-d63512c82d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_ShareBasedCompensation_8414c573-0118-4a8a-a587-d63512c82d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_0c3af22d-7a97-4c67-af80-4093c9b910a8" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_0c3af22d-7a97-4c67-af80-4093c9b910a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18ed3d21-f4b2-4fb8-8627-eadd78d86139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18ed3d21-f4b2-4fb8-8627-eadd78d86139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0f060a1-de34-4add-a725-8c5875f79138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d0f060a1-de34-4add-a725-8c5875f79138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CashOutflowFromLoanForgiveness_7969993e-1042-4158-94e1-dc67b343aa22" xlink:href="kprx-20221231.xsd#kprx_CashOutflowFromLoanForgiveness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_kprx_CashOutflowFromLoanForgiveness_7969993e-1042-4158-94e1-dc67b343aa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f2c56129-036e-48d5-8959-81453b2ec481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f2c56129-036e-48d5-8959-81453b2ec481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_46b8d169-0415-4980-8766-493fbbf572a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_46b8d169-0415-4980-8766-493fbbf572a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_380f171b-afed-44a6-ab10-2394a715afe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f5e1df7-ab9e-402f-a9c4-e34987b9e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f5e1df7-ab9e-402f-a9c4-e34987b9e3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_95af8dad-3dca-455a-861d-e169c18bfeda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_95af8dad-3dca-455a-861d-e169c18bfeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a713e63-5ab7-4253-b93b-4e495ba752ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a713e63-5ab7-4253-b93b-4e495ba752ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_db4fb545-ffd7-4969-87c1-81ddc8c546ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_db4fb545-ffd7-4969-87c1-81ddc8c546ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_287861f5-2af4-4e7c-be34-abaa2def6fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_287861f5-2af4-4e7c-be34-abaa2def6fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eeeb7dc-f8dc-487e-9899-eb0f2ba0cb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc65f2e2-1623-42a1-8501-fd59629f0f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5eeeb7dc-f8dc-487e-9899-eb0f2ba0cb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6131e837-2eeb-4f2f-ae81-ece3acc078ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf915f84-5958-499e-902f-746e25bf6092" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6131e837-2eeb-4f2f-ae81-ece3acc078ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e69af24c-1939-47b4-bc4f-d682554a391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e69af24c-1939-47b4-bc4f-d682554a391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c2d5b38-95b6-4646-9b59-f770c0c8857b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c2d5b38-95b6-4646-9b59-f770c0c8857b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c82395a8-8cd8-43f6-b12b-76c10ac41f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c82395a8-8cd8-43f6-b12b-76c10ac41f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2818940-6807-4c0a-90ec-ff2cebae8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aeca9e46-e3af-4158-92e3-2ec5235f9b73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2818940-6807-4c0a-90ec-ff2cebae8bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9240ebe5-67b8-4ae7-8c57-5a8a436dc590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9240ebe5-67b8-4ae7-8c57-5a8a436dc590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07738fbd-3d48-4dc4-99b6-4716da22cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07738fbd-3d48-4dc4-99b6-4716da22cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1007c843-6901-4d37-b680-a45c093e0bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1007c843-6901-4d37-b680-a45c093e0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_47705bfe-9b82-4168-858a-d7594ed6f0f1" xlink:href="kprx-20221231.xsd#kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit_47705bfe-9b82-4168-858a-d7594ed6f0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8ca617b4-99e3-4a2a-8860-b2b7115c6874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_8ca617b4-99e3-4a2a-8860-b2b7115c6874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64843087-b649-45fc-926d-8e05b8cda20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec06186b-fca2-4296-9b92-9d7c3ffc1d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64843087-b649-45fc-926d-8e05b8cda20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b64a2b1-2a6c-4791-82c5-c66d3d1e14f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b64a2b1-2a6c-4791-82c5-c66d3d1e14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa379d1f-935b-48b7-bcd6-3d18fac0be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa379d1f-935b-48b7-bcd6-3d18fac0be46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef7defa2-be4c-4ac0-b8b6-b4c048c55fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef7defa2-be4c-4ac0-b8b6-b4c048c55fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6e5a0d5-b270-43b9-a9d8-695082cd7e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6e5a0d5-b270-43b9-a9d8-695082cd7e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d4667e3-c5b0-4e69-92bd-3b6ca3f01334" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_06e6711f-1ad2-4674-a842-aeee5439c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_06e6711f-1ad2-4674-a842-aeee5439c91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a537d0ba-ef75-4b92-bf5b-e33cf7be368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a537d0ba-ef75-4b92-bf5b-e33cf7be368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GrantOfRestrictedStockAwards_914f8007-2d85-4904-8828-d7bb4230459b" xlink:href="kprx-20221231.xsd#kprx_GrantOfRestrictedStockAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f136c422-60fa-43de-a5df-57179e6fde59" xlink:to="loc_kprx_GrantOfRestrictedStockAwards_914f8007-2d85-4904-8828-d7bb4230459b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements" xlink:type="simple" xlink:href="kprx-20221231.xsd#BusinessPresentationandRecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e22b77c4-7278-4d35-a436-a5aff03874ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_c6abdbd0-55be-4eeb-b800-a9ab118dfc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e22b77c4-7278-4d35-a436-a5aff03874ae" xlink:to="loc_us-gaap_NatureOfOperations_c6abdbd0-55be-4eeb-b800-a9ab118dfc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eab5e876-e25a-4f6d-93eb-2050a06c6f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de1b29cb-e49e-4ba1-a2c1-8488a0d83d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eab5e876-e25a-4f6d-93eb-2050a06c6f3d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de1b29cb-e49e-4ba1-a2c1-8488a0d83d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValue" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0e518d1-29b3-4e66-a96c-3c3d3b54f3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_02db3b20-b4e4-4799-a684-2bb9f1265ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0e518d1-29b3-4e66-a96c-3c3d3b54f3ad" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_02db3b20-b4e4-4799-a684-2bb9f1265ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6dfbeb2e-75e1-42d8-81d5-717684a29462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_04bad720-797e-450b-a5dd-8ba30dbc041d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6dfbeb2e-75e1-42d8-81d5-717684a29462" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_04bad720-797e-450b-a5dd-8ba30dbc041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AccruedExpenses" xlink:type="simple" xlink:href="kprx-20221231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_2239a956-104e-4824-bc46-dd9da1b75013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f6ce4142-9b2e-4a62-8023-253b7853eb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_2239a956-104e-4824-bc46-dd9da1b75013" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f6ce4142-9b2e-4a62-8023-253b7853eb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Debt" xlink:type="simple" xlink:href="kprx-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f5d5091f-c6c5-4c7f-9707-ec0fa8f5028c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f757394f-65c6-42cf-958b-a2f7cdd19229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f5d5091f-c6c5-4c7f-9707-ec0fa8f5028c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f757394f-65c6-42cf-958b-a2f7cdd19229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRD"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7170971c-91c1-49a9-8fa3-adcd785da39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6729d9d3-d27c-4ae6-b823-99bbc9775eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7170971c-91c1-49a9-8fa3-adcd785da39c" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6729d9d3-d27c-4ae6-b823-99bbc9775eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStock" xlink:type="simple" xlink:href="kprx-20221231.xsd#CapitalStock"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CapitalStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_642afbb6-12f4-4494-a222-6680be4d2365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_93add1db-2382-458a-821f-33bc9fec1aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_642afbb6-12f4-4494-a222-6680be4d2365" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_93add1db-2382-458a-821f-33bc9fec1aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Warrants" xlink:type="simple" xlink:href="kprx-20221231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_19a732da-8e1a-4011-a393-aefbbeafdd5e" xlink:href="kprx-20221231.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsDisclosureTextBlock_343158fc-413e-4545-97fb-490f1cfe2c09" xlink:href="kprx-20221231.xsd#kprx_WarrantsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_19a732da-8e1a-4011-a393-aefbbeafdd5e" xlink:to="loc_kprx_WarrantsDisclosureTextBlock_343158fc-413e-4545-97fb-490f1cfe2c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlan" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlan"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_a939acff-062c-48e3-8cef-427d0ed6f806" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_04dc846e-f747-44ed-86fe-047afd07d7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_a939acff-062c-48e3-8cef-427d0ed6f806" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_04dc846e-f747-44ed-86fe-047afd07d7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91671668-a752-493a-9bef-2efc1e7b651e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_573ac9c5-bb86-4953-a86c-91e4831031c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91671668-a752-493a-9bef-2efc1e7b651e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_573ac9c5-bb86-4953-a86c-91e4831031c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd5acc8a-cbb4-467f-9a3a-69addc97a7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1217e37a-1725-467a-b677-4c919552b3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd5acc8a-cbb4-467f-9a3a-69addc97a7bf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1217e37a-1725-467a-b677-4c919552b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="kprx-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_7fe80d3a-36fc-4eb8-b2f3-b0bd17db54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_b2f23083-a189-4858-ab1a-daf15dfac62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_7fe80d3a-36fc-4eb8-b2f3-b0bd17db54b5" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_b2f23083-a189-4858-ab1a-daf15dfac62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Acquisitions" xlink:type="simple" xlink:href="kprx-20221231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d4278cda-9dee-4e7f-ae85-0771ca6d4711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_edd9ef87-3132-4b9c-acd7-287933bee81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d4278cda-9dee-4e7f-ae85-0771ca6d4711" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_edd9ef87-3132-4b9c-acd7-287933bee81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="kprx-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6dc7e4e2-0f9f-495c-b3f7-feda73646d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b116703a-09b8-48c9-9324-c6c8c661c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6dc7e4e2-0f9f-495c-b3f7-feda73646d1f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b116703a-09b8-48c9-9324-c6c8c661c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bbffb1a5-23d2-47b0-b57b-f9d55a7031d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bbffb1a5-23d2-47b0-b57b-f9d55a7031d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_a54b00fd-6f08-4f2a-b154-b2bf51c7ccae" xlink:href="kprx-20221231.xsd#kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_a54b00fd-6f08-4f2a-b154-b2bf51c7ccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fbe4efa7-fb93-4b3a-81b5-ee9ff689c8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_UseOfEstimates_fbe4efa7-fb93-4b3a-81b5-ee9ff689c8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ae648a2d-34ce-4ffc-a926-4a2f11fa73a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ae648a2d-34ce-4ffc-a926-4a2f11fa73a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_66459649-54aa-462d-97f8-5ffbdde78531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_66459649-54aa-462d-97f8-5ffbdde78531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_52cf797d-19d9-4efa-af71-01f942b1a4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_52cf797d-19d9-4efa-af71-01f942b1a4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e36cc2e6-8888-4a8f-8656-9416b4f026f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e36cc2e6-8888-4a8f-8656-9416b4f026f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_08c32d0c-2cf1-4264-aa2b-f04c4267e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_08c32d0c-2cf1-4264-aa2b-f04c4267e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6e2bed28-91c0-4e79-9ed3-9ff3c5504216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6e2bed28-91c0-4e79-9ed3-9ff3c5504216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_93479609-4502-420f-a73d-0461ce23801d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_93479609-4502-420f-a73d-0461ce23801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccruedClinicalExpensesPolicyTextBlock_4b13b1f0-4e5d-4873-9c53-860a970821fa" xlink:href="kprx-20221231.xsd#kprx_AccruedClinicalExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_AccruedClinicalExpensesPolicyTextBlock_4b13b1f0-4e5d-4873-9c53-860a970821fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a89de1fa-510f-49f6-a06f-c52ef19fae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a89de1fa-510f-49f6-a06f-c52ef19fae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_63dc93b0-1964-4545-9967-93d738df76c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_63dc93b0-1964-4545-9967-93d738df76c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock_fcacc088-40a2-45e2-95b4-8e39378f9785" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock_fcacc088-40a2-45e2-95b4-8e39378f9785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_f611724a-acf1-4938-96e1-ce09985a24dc" xlink:href="kprx-20221231.xsd#kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_f611724a-acf1-4938-96e1-ce09985a24dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock_a6a8915e-542f-421f-a3f7-82945c398f0e" xlink:href="kprx-20221231.xsd#kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock_a6a8915e-542f-421f-a3f7-82945c398f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9e9d252f-33de-4d82-a446-6f8fb3c84fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9e9d252f-33de-4d82-a446-6f8fb3c84fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9c2911ea-14b6-4dc8-94a2-fb02416f6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9c2911ea-14b6-4dc8-94a2-fb02416f6fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1a022492-c8fd-4033-9467-bc4fb1496c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1a022492-c8fd-4033-9467-bc4fb1496c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsPolicyTextBlock_4e287555-5313-419c-8908-76db89cf7e50" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_kprx_RelatedPartyTransactionsPolicyTextBlock_4e287555-5313-419c-8908-76db89cf7e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9aa93cc6-2b04-4695-b84f-3290144ea2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20a4a40e-caea-47b0-9925-b2e2dd6d1489" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9aa93cc6-2b04-4695-b84f-3290144ea2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd5cd31b-db4a-4ada-84df-e23700118794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33c44e9f-dcf2-4579-9919-bc20720ded14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd5cd31b-db4a-4ada-84df-e23700118794" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33c44e9f-dcf2-4579-9919-bc20720ded14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c5d74fb9-c4b8-46ce-a730-f55d4f818e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd5cd31b-db4a-4ada-84df-e23700118794" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c5d74fb9-c4b8-46ce-a730-f55d4f818e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a2ef4b40-1f18-4240-893d-9ee86bfb3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d691d6ea-5ee2-4b81-b3cf-be89656d1b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2ef4b40-1f18-4240-893d-9ee86bfb3cdf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d691d6ea-5ee2-4b81-b3cf-be89656d1b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b7db1a6c-4acf-43ec-a291-9fef0f886301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2ef4b40-1f18-4240-893d-9ee86bfb3cdf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b7db1a6c-4acf-43ec-a291-9fef0f886301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a830aeb-4bc3-4601-9c23-590f7265692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_28dd19d0-082e-48e1-bfbd-41abd23d7c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1a830aeb-4bc3-4601-9c23-590f7265692a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_28dd19d0-082e-48e1-bfbd-41abd23d7c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_806f45e7-66f9-4cf4-930f-1fb25d58b020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c9598f5a-23fb-4f70-926d-caf3636d77a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_806f45e7-66f9-4cf4-930f-1fb25d58b020" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c9598f5a-23fb-4f70-926d-caf3636d77a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e07b17c9-e60b-4206-ad80-3a6e5a58e4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ffd7f50c-e802-440c-9010-e5f70f046b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e07b17c9-e60b-4206-ad80-3a6e5a58e4be" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ffd7f50c-e802-440c-9010-e5f70f046b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_15fb5592-73a7-460b-ac95-08180f0f4f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e07b17c9-e60b-4206-ad80-3a6e5a58e4be" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_15fb5592-73a7-460b-ac95-08180f0f4f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_6ab0d874-d0ad-4e5a-8caf-bae567f79f16" xlink:href="kprx-20221231.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f0b0ef84-7940-4d32-8035-6278605665a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_6ab0d874-d0ad-4e5a-8caf-bae567f79f16" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f0b0ef84-7940-4d32-8035-6278605665a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_cc222186-094b-4c63-812b-93921053f2dd" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_296971b9-d651-4d59-9a47-061075440c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_cc222186-094b-4c63-812b-93921053f2dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_296971b9-d651-4d59-9a47-061075440c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_91f6ab9c-2407-4561-9c7d-0c198877c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_cc222186-094b-4c63-812b-93921053f2dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_91f6ab9c-2407-4561-9c7d-0c198877c5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5983344e-1a08-4ca0-ade1-2c73daeb137d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_cc222186-094b-4c63-812b-93921053f2dd" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5983344e-1a08-4ca0-ade1-2c73daeb137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_a8b54d61-4310-4ac3-8f41-01415c26ba36" xlink:href="kprx-20221231.xsd#kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_cc222186-094b-4c63-812b-93921053f2dd" xlink:to="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_a8b54d61-4310-4ac3-8f41-01415c26ba36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_649464d3-711e-4245-b423-43c9b8204356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_74c495c6-11ed-4d0a-9d68-cfda655dfc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_649464d3-711e-4245-b423-43c9b8204356" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_74c495c6-11ed-4d0a-9d68-cfda655dfc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d263b6ec-4645-4fd6-a773-ca0b609db7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_649464d3-711e-4245-b423-43c9b8204356" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d263b6ec-4645-4fd6-a773-ca0b609db7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0436dea4-c2cd-42e4-861f-539d21b27208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_649464d3-711e-4245-b423-43c9b8204356" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0436dea4-c2cd-42e4-861f-539d21b27208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d8353c98-b800-4ce0-b864-e32e37baaff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_649464d3-711e-4245-b423-43c9b8204356" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d8353c98-b800-4ce0-b864-e32e37baaff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e528cbb1-8e4a-4127-aec6-ef2164c9d507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a6a485e1-a1a2-4598-b4c6-36fc62ece9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e528cbb1-8e4a-4127-aec6-ef2164c9d507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a6a485e1-a1a2-4598-b4c6-36fc62ece9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3e620ec0-741b-4f7c-9ba8-e31da5452291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_631612b8-f58b-4443-9358-ed68c12dbabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e620ec0-741b-4f7c-9ba8-e31da5452291" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_631612b8-f58b-4443-9358-ed68c12dbabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock_991e7567-c022-4a37-9462-dbfa91a29b09" xlink:href="kprx-20221231.xsd#kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e620ec0-741b-4f7c-9ba8-e31da5452291" xlink:to="loc_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock_991e7567-c022-4a37-9462-dbfa91a29b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#BusinessPresentationandRecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8224748-a7c3-4388-a8e0-8312e8cc2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8224748-a7c3-4388-a8e0-8312e8cc2e81" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a120f578-a121-4496-9b9f-12ff79ede705" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RegisteredDirectOfferingMember_be01c63b-c658-4879-8f27-48de757fc049" xlink:href="kprx-20221231.xsd#kprx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d1543946-7ce2-41dd-b108-ad9ebb1003c2" xlink:to="loc_kprx_RegisteredDirectOfferingMember_be01c63b-c658-4879-8f27-48de757fc049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_03b1cfc4-e4e0-4784-88c1-bcdd28721917" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f1eeafc-1830-4f91-8b40-cccca218553a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f1eeafc-1830-4f91-8b40-cccca218553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13783953-8d99-4b93-a91f-d9c5982e7fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13783953-8d99-4b93-a91f-d9c5982e7fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5a50156e-c7a5-4066-a87c-0abbf9d34ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5a50156e-c7a5-4066-a87c-0abbf9d34ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantIssuancePlacementAgentFees_67fa010f-02fd-4efd-93c4-e1075606d180" xlink:href="kprx-20221231.xsd#kprx_WarrantIssuancePlacementAgentFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_WarrantIssuancePlacementAgentFees_67fa010f-02fd-4efd-93c4-e1075606d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_fc9d3636-0b0b-4c73-813c-d495da53ccec" xlink:href="kprx-20221231.xsd#kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts_fc9d3636-0b0b-4c73-813c-d495da53ccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a496b4a3-9895-4c1d-b45f-e0304bfbdb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a496b4a3-9895-4c1d-b45f-e0304bfbdb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c9ee6f4f-b8d8-46da-90d6-a99e96321fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c9ee6f4f-b8d8-46da-90d6-a99e96321fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_bcc2a148-1446-4830-87d3-a6b48dad93dc" xlink:href="kprx-20221231.xsd#kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued_bcc2a148-1446-4830-87d3-a6b48dad93dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76e76694-ebe2-4a72-9bb8-2b063ce9f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_a7b5b58e-d693-4fa2-ab8d-5628602ba896" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_76e76694-ebe2-4a72-9bb8-2b063ce9f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d1be072-6035-4ee6-b41a-1d83f268ad87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d1be072-6035-4ee6-b41a-1d83f268ad87" xlink:to="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453b5aa7-08ff-46a9-9a00-2bf00c4df437" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonAcquisitionMember_7a3f7e78-1742-4668-907c-ccaa269155d8" xlink:href="kprx-20221231.xsd#kprx_BayonAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_BayonAcquisitionMember_7a3f7e78-1742-4668-907c-ccaa269155d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesAcquisitionMember_8e769fd2-8ec2-49d1-905a-c1be95b43b35" xlink:href="kprx-20221231.xsd#kprx_PanoptesAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_PanoptesAcquisitionMember_8e769fd2-8ec2-49d1-905a-c1be95b43b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeTherapeuticSIncMember_766d6685-b84e-4d5b-97c1-cda94a0ece29" xlink:href="kprx-20221231.xsd#kprx_JadeTherapeuticSIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7d92d06-5d77-41f0-b66f-2a54365d4f31" xlink:to="loc_kprx_JadeTherapeuticSIncMember_766d6685-b84e-4d5b-97c1-cda94a0ece29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_394de163-cd2a-41ea-9217-c4cdbc4f01a8" xlink:to="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a2e35ed8-c333-4ad9-b8dd-0ceec99708cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:to="loc_srt_MinimumMember_a2e35ed8-c333-4ad9-b8dd-0ceec99708cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_22a0069b-3367-49cc-b2e1-bfe8a3fab71c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce06f549-b63c-4e3c-b464-1a4e2b51c7a2" xlink:to="loc_srt_MaximumMember_22a0069b-3367-49cc-b2e1-bfe8a3fab71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82251f6f-3a8a-4db4-ba10-f21899d5e459" xlink:to="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5a26de0-a0a4-48bd-b35f-983443489126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_04c2c133-dc12-4bf3-8377-4d39dd070567" xlink:to="loc_us-gaap_CommonStockMember_b5a26de0-a0a4-48bd-b35f-983443489126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96aa0bbd-e8d7-4123-9903-ed211421b2d7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f3790f40-238c-4f79-9634-081e4c209b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_54f497bd-24b5-4573-a139-85938fdd58ae" xlink:to="loc_us-gaap_PrivatePlacementMember_f3790f40-238c-4f79-9634-081e4c209b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_82f6a138-ca2f-4148-b062-763c094e1d47" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalStudiesServicesKIO301Member_7f0fc44f-83c0-4282-8010-7a0fe4233278" xlink:href="kprx-20221231.xsd#kprx_ClinicalStudiesServicesKIO301Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b303637b-e519-4b9f-aa71-0462310ad855" xlink:to="loc_kprx_ClinicalStudiesServicesKIO301Member_7f0fc44f-83c0-4282-8010-7a0fe4233278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_680cca14-cd3d-4a87-b480-0aec10bc87a5" xlink:to="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_90e46aa4-cf01-4e47-bcab-4c4d2c529512" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0e03ddc3-2c06-49de-b72e-58eb6e6659f5" xlink:to="loc_srt_AffiliatedEntityMember_90e46aa4-cf01-4e47-bcab-4c4d2c529512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:href="kprx-20221231.xsd#kprx_AccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesTable_feef8e91-95d3-4e09-9e70-fc3ebf7839b1" xlink:to="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba863552-ea6a-424e-bf21-27f8e2d4abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba863552-ea6a-424e-bf21-27f8e2d4abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fcf006f4-13c3-4751-a67c-0c7dd31b806d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fcf006f4-13c3-4751-a67c-0c7dd31b806d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_77e2d8e1-88db-4a01-be9b-10e3456a3072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_77e2d8e1-88db-4a01-be9b-10e3456a3072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_150eaf6f-1a60-4c99-a3d3-a6b6b7794ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_Goodwill_150eaf6f-1a60-4c99-a3d3-a6b6b7794ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_162104c7-964a-4aaf-871f-428f70de378d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_162104c7-964a-4aaf-871f-428f70de378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_703dc89f-89f2-4bac-b711-cd760ef3014d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_703dc89f-89f2-4bac-b711-cd760ef3014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e0b31ac0-2ca3-4b05-a7a9-0b2bf1378cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e0b31ac0-2ca3-4b05-a7a9-0b2bf1378cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments_15f27454-3595-4bd1-912c-3bffd7c8dea4" xlink:href="kprx-20221231.xsd#kprx_NumberOfGeographicSegments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_NumberOfGeographicSegments_15f27454-3595-4bd1-912c-3bffd7c8dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_48f8f8af-42ca-4175-be3a-47ab7bb0df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_DeferredTaxLiabilities_48f8f8af-42ca-4175-be3a-47ab7bb0df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cfd72add-6ac5-4fbc-8c51-a37d90e2077e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cfd72add-6ac5-4fbc-8c51-a37d90e2077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fa8921df-89a9-4e8c-93a5-e0431aeca32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_IncomeTaxReceivable_fa8921df-89a9-4e8c-93a5-e0431aeca32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb5272dc-8e08-49d9-a31a-a92696985d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb5272dc-8e08-49d9-a31a-a92696985d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfVendors_17f444d5-239e-47f4-a41b-d2a5ce613b81" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfVendors"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfVendors_17f444d5-239e-47f4-a41b-d2a5ce613b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfConsultants_e235e40e-c9e0-4058-a2b2-9dd7d2ddc09c" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfConsultants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfConsultants_e235e40e-c9e0-4058-a2b2-9dd7d2ddc09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4289cd41-4242-46b7-b3ff-bdcf8f06ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4289cd41-4242-46b7-b3ff-bdcf8f06ce62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_2236bca7-da1a-4b97-b2d5-ca7aa4f7c8ee" xlink:href="kprx-20221231.xsd#kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty_2236bca7-da1a-4b97-b2d5-ca7aa4f7c8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_18539d10-3d31-4f76-9b42-48745b45fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_18539d10-3d31-4f76-9b42-48745b45fb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RelatedPartyTransactionsNumberOfUniversities_bb4bec0a-11b3-4571-b4da-8a305d0352ad" xlink:href="kprx-20221231.xsd#kprx_RelatedPartyTransactionsNumberOfUniversities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_kprx_RelatedPartyTransactionsNumberOfUniversities_bb4bec0a-11b3-4571-b4da-8a305d0352ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35f2ab5b-c75b-437d-a991-c58fc49e228d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35f2ab5b-c75b-437d-a991-c58fc49e228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c43eb28c-4982-4ae9-b5d0-4c2aca2490d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c43eb28c-4982-4ae9-b5d0-4c2aca2490d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8b1182bf-fedb-4ca8-8e2f-07abfd02fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8b1182bf-fedb-4ca8-8e2f-07abfd02fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45b7e073-d250-4de6-9585-f30706712174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_45b7e073-d250-4de6-9585-f30706712174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee0ca8b8-5a41-4b21-ae24-6cfb7a4e8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee0ca8b8-5a41-4b21-ae24-6cfb7a4e8eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7b97ad0d-583e-46cb-b8b0-dc87ae2ba398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7b97ad0d-583e-46cb-b8b0-dc87ae2ba398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_5979f803-4ecb-46e7-985e-a715cfcc36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_AccountingPoliciesLineItems_d0115c65-18a2-4247-b168-2222ffa924b2" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_5979f803-4ecb-46e7-985e-a715cfcc36a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_298ec365-12a2-4613-abad-d4923b7abc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_298ec365-12a2-4613-abad-d4923b7abc34" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_cfeeebaa-1970-43d1-b4c7-0138b51d1a0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_465e9cb3-8f0c-483c-a962-04aa297a0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b060f7e5-d50b-4452-bb33-17f03edda945" xlink:to="loc_us-gaap_EmployeeStockOptionMember_465e9cb3-8f0c-483c-a962-04aa297a0d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cccf353-9dc9-499f-99a5-b131b5e4f677" xlink:to="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_222f4c64-5e47-48b0-8b09-d000b27d1f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:to="loc_us-gaap_CommonStockMember_222f4c64-5e47-48b0-8b09-d000b27d1f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_263a335d-d5a3-4a72-b6b8-f92fc819c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f379668f-a5c7-4367-8c49-83093e356b2f" xlink:to="loc_us-gaap_PreferredStockMember_263a335d-d5a3-4a72-b6b8-f92fc819c3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fe51176a-1629-4a18-a640-bf1142e4b102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c4063e6f-45b9-4d7d-a622-cd2f4ad9aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539b4e9c-3fa4-46d4-98fc-0a8ce3327199" xlink:to="loc_us-gaap_RestrictedStockMember_c4063e6f-45b9-4d7d-a622-cd2f4ad9aabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ee0c2cb-85f0-4ddf-9f62-0905086ad393" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f36f560b-a8c2-44b4-bbd3-19153738867b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fe34f69b-10c1-46b7-ae19-7663dfe61563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f36f560b-a8c2-44b4-bbd3-19153738867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8b023c3-e8ba-4ea1-bbe8-f5611ae2619d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8b023c3-e8ba-4ea1-bbe8-f5611ae2619d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_840be1be-bbf8-4190-b3fc-e9f9e8a61a1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonAcquisitionMember_2160f6dc-48fb-405f-8fcd-425729632e7c" xlink:href="kprx-20221231.xsd#kprx_BayonAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_BayonAcquisitionMember_2160f6dc-48fb-405f-8fcd-425729632e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesAcquisitionMember_c9f4cd12-2dc4-477c-9f18-834adc75a68f" xlink:href="kprx-20221231.xsd#kprx_PanoptesAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_PanoptesAcquisitionMember_c9f4cd12-2dc4-477c-9f18-834adc75a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeTherapeuticSIncMember_1d99727d-f706-4591-9dd8-56031d32191a" xlink:href="kprx-20221231.xsd#kprx_JadeTherapeuticSIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdb3ff3-4c55-4cd6-99bb-1580eb9bf5f8" xlink:to="loc_kprx_JadeTherapeuticSIncMember_1d99727d-f706-4591-9dd8-56031d32191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:to="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:href="kprx-20221231.xsd#kprx_ContingentConsiderationScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioAxis_e7b7d799-cefb-4c6e-aebb-5084228b9b76" xlink:to="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase1Member_6889f0a5-eda8-466e-8ccd-9dd222fcee42" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase1Member_6889f0a5-eda8-466e-8ccd-9dd222fcee42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase2Member_9aefae19-78f7-4464-9b3e-d396d75a58db" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase2Member_9aefae19-78f7-4464-9b3e-d396d75a58db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SuccessfulCompletionOfPhase3Member_34c125e5-3c37-47e9-82fa-ddd0269c10d2" xlink:href="kprx-20221231.xsd#kprx_SuccessfulCompletionOfPhase3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_SuccessfulCompletionOfPhase3Member_34c125e5-3c37-47e9-82fa-ddd0269c10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FdaApprovalMember_592d8617-1109-4a5e-b82f-f3e9131805d0" xlink:href="kprx-20221231.xsd#kprx_FdaApprovalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_FdaApprovalMember_592d8617-1109-4a5e-b82f-f3e9131805d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BeginningOfPhase3Member_60d863c9-6a9f-42d4-b458-2680fdc7f741" xlink:href="kprx-20221231.xsd#kprx_BeginningOfPhase3Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ContingentConsiderationScenarioDomain_06c7db58-503d-4232-bb03-1da820657b1a" xlink:to="loc_kprx_BeginningOfPhase3Member_60d863c9-6a9f-42d4-b458-2680fdc7f741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_67e7eba9-6dcc-4ef5-8018-7da7ea64e63c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e02e3874-eaa1-4cff-a90b-377b2fb2b603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_792e2c01-2373-4856-90b2-3b6f5657a195" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e02e3874-eaa1-4cff-a90b-377b2fb2b603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7d58fb16-fe4d-4ed7-b8f4-1962bfeb40fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d58fb16-fe4d-4ed7-b8f4-1962bfeb40fe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7c971f19-1302-45dc-a9b2-b4c9ca4d2f14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_850a25fb-f97f-4e8f-bdc2-7607f51a0228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b59a332-b51b-4dd4-aa7f-db040a41b390" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_850a25fb-f97f-4e8f-bdc2-7607f51a0228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e65380d4-f7e0-48bf-85c7-838b6516d1ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8487de37-c6f3-4280-9485-709a5805790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d2fe79a-732d-4822-9f1f-e3535f46aa1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8487de37-c6f3-4280-9485-709a5805790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_719cb469-7568-4b66-8b0c-c15dfc8b59cb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:href="kprx-20221231.xsd#kprx_FairValueContingentConsiderationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bba14bfb-3895-4022-be1b-e3a9ac6f0350" xlink:to="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8d774e5f-0fe7-4710-b1eb-b327eebb3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8d774e5f-0fe7-4710-b1eb-b327eebb3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_76b5ed06-e719-4cae-b201-19988336065f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_76b5ed06-e719-4cae-b201-19988336065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9d9bd95-fa58-4343-847e-dc92caae851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_FairValueContingentConsiderationAbstract_27c06523-26ce-4260-8c7d-ca97947535a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9d9bd95-fa58-4343-847e-dc92caae851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details" xlink:type="simple" xlink:href="kprx-20221231.xsd#FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bbccbb22-2731-4c89-952d-022a2c2d5f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bbccbb22-2731-4c89-952d-022a2c2d5f63" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a56071a1-9710-44b2-ae59-0d2d15d0c840" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eb479c4d-662d-4806-a37f-00523f420951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eb479c4d-662d-4806-a37f-00523f420951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_2abb4ae1-89a3-4db7-bcba-8eccaeb22aec" xlink:href="kprx-20221231.xsd#kprx_MeasurementInputProbabilityOfSuccessForPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_80a36672-d7db-4bef-93be-5ef3a6aae6be" xlink:to="loc_kprx_MeasurementInputProbabilityOfSuccessForPaymentMember_2abb4ae1-89a3-4db7-bcba-8eccaeb22aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b9260b64-34c4-4d15-a0c4-049b1441b580" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_ad513147-4e04-4b9b-b654-4833d427cea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d05bdb0b-7e27-496c-939c-d9a8495d0e1b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_ad513147-4e04-4b9b-b654-4833d427cea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_827ba9fa-c111-4415-acef-41ecf7258fc3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_22e28eb0-9a90-481c-94ad-3f691db45435" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_BayonMember_22e28eb0-9a90-481c-94ad-3f691db45435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGes.m.b.h.Member_186ee030-e8a8-4baf-b660-5cd53c9f8395" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGes.m.b.h.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_PanoptesPharmaGes.m.b.h.Member_186ee030-e8a8-4baf-b660-5cd53c9f8395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_JadeMember_f227c869-1ad7-4a7c-9a8c-c7b53a2e7791" xlink:href="kprx-20221231.xsd#kprx_JadeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a1ea6a1-e75c-4a8f-9f77-844593dc4751" xlink:to="loc_kprx_JadeMember_f227c869-1ad7-4a7c-9a8c-c7b53a2e7791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a13b9420-3d80-429a-ae27-faac76639327" xlink:to="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6464218c-67d7-4ea8-80fd-53609906592c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:to="loc_srt_MinimumMember_6464218c-67d7-4ea8-80fd-53609906592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd745f2f-7fce-498c-8387-606e3fd3fe70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_356fee77-bfcf-4aed-adb7-b777008a4e76" xlink:to="loc_srt_MaximumMember_cd745f2f-7fce-498c-8387-606e3fd3fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5caa01e0-5d67-4976-85b6-307b3d43a450" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8303ae6f-2db9-4ff3-97fd-8a50b56be7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8303ae6f-2db9-4ff3-97fd-8a50b56be7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ChangeInContingentConsiderationFairValue_46c4dcae-9630-408c-954f-42abe53dbce8" xlink:href="kprx-20221231.xsd#kprx_ChangeInContingentConsiderationFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0970000f-c786-47fd-af21-04aeda0f3c4f" xlink:to="loc_kprx_ChangeInContingentConsiderationFairValue_46c4dcae-9630-408c-954f-42abe53dbce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4e3d7ddb-9306-45af-b112-6f13b9751c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4e3d7ddb-9306-45af-b112-6f13b9751c55" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ecdce71-f241-4164-9ba9-e80e067ba4c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6cc03ad0-f1b4-48da-9437-01f1a9824d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_EquipmentMember_6cc03ad0-f1b4-48da-9437-01f1a9824d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_d8e58508-ad5b-40ad-a71d-002480ca62b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_OfficeEquipmentMember_d8e58508-ad5b-40ad-a71d-002480ca62b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c263ed81-480a-4b48-9115-813c670137a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c263ed81-480a-4b48-9115-813c670137a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_303e298b-bc3d-4e77-a40d-ac806b4a9efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b2249fb-b990-49f0-9add-51555802af04" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_303e298b-bc3d-4e77-a40d-ac806b4a9efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_218f1de0-4ae1-4fbe-b63e-1af69585492b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e1d4bffe-3f47-4968-b6a8-fa20224a6172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e1d4bffe-3f47-4968-b6a8-fa20224a6172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_62bfc0d8-a60d-4696-b1b4-3c6bfe9e193a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_62bfc0d8-a60d-4696-b1b4-3c6bfe9e193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c5c3b30-72ad-4a56-9fe5-a3e32be041c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c5c3b30-72ad-4a56-9fe5-a3e32be041c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb4ad36b-4434-46bb-b5cc-d1e23b68046b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_888ca04c-ee5d-4d92-b111-aea621bdf412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb4ad36b-4434-46bb-b5cc-d1e23b68046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca7662ca-bc3e-4cb1-8de3-fa2546e5c408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_277a1c58-67c8-4f74-b618-5637b7633489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca7662ca-bc3e-4cb1-8de3-fa2546e5c408" xlink:to="loc_us-gaap_Depreciation_277a1c58-67c8-4f74-b618-5637b7633489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_718708ea-757a-4160-981c-bca992221ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_718708ea-757a-4160-981c-bca992221ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e023d1f7-f72c-4b22-b837-f6fb7938711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e023d1f7-f72c-4b22-b837-f6fb7938711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent_9d47433a-80b9-4dab-a0f7-844786fa80d0" xlink:href="kprx-20221231.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:to="loc_kprx_ClinicalTrialsCurrent_9d47433a-80b9-4dab-a0f7-844786fa80d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a997066-ba30-4cde-8642-572b7d53d130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a997066-ba30-4cde-8642-572b7d53d130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b915179b-536d-4e2d-bcef-cb0892a26a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f5dc80c2-c799-48a4-9360-5d52dda9da50" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b915179b-536d-4e2d-bcef-cb0892a26a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/DebtDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c7d837ac-d0cb-4351-b371-3bd9e6db83e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_076a8908-21d5-4883-ad1a-f827b89f57f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c7d837ac-d0cb-4351-b371-3bd9e6db83e5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_076a8908-21d5-4883-ad1a-f827b89f57f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef2141f5-fa15-4e7b-9465-5211e1cb4e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef2141f5-fa15-4e7b-9465-5211e1cb4e8e" xlink:to="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66ce0eb4-07b7-4677-9114-b674cc13a8b8" xlink:to="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SentrXAnimalCareIncMember_868d5b84-023e-4e36-af0e-e9f4f0df0def" xlink:href="kprx-20221231.xsd#kprx_SentrXAnimalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_09107a48-e5b4-465b-aa36-acae77c3c55a" xlink:to="loc_kprx_SentrXAnimalCareIncMember_868d5b84-023e-4e36-af0e-e9f4f0df0def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e29dd35-fa57-4c14-8310-9a0fcaa91486" xlink:to="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30128150-c34e-474c-b1a6-959d8fbb5d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30128150-c34e-474c-b1a6-959d8fbb5d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7e97f4b2-dd19-4c35-a14e-17a93448de4a" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsExpectedMilestonePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7e97f4b2-dd19-4c35-a14e-17a93448de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_876cc92f-50ac-4d35-803f-f57f5016928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_30b0f3f6-a29b-4244-8430-e47a4a4d5545" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_876cc92f-50ac-4d35-803f-f57f5016928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3691ad25-58a2-4ae7-8455-2faf41af90e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3691ad25-58a2-4ae7-8455-2faf41af90e6" xlink:to="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6e72bb3f-18ee-4782-802e-808d0824698c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeSecretsMember_5ab0f629-e112-46f5-b0ca-b3b02ee92971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeSecretsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e689ac0-56c0-4f01-9f75-02a3dfe47a91" xlink:to="loc_us-gaap_TradeSecretsMember_5ab0f629-e112-46f5-b0ca-b3b02ee92971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6b9e1ce4-43b7-4de7-a0e3-91b7c839b28e" xlink:to="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_74f3dffb-cd7b-4209-9547-9f93c8823779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_74f3dffb-cd7b-4209-9547-9f93c8823779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23e0c2c0-5ee8-4245-8410-5eb363b0d686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23e0c2c0-5ee8-4245-8410-5eb363b0d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37501b0b-f3ee-4141-949d-e2983f6dedde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37501b0b-f3ee-4141-949d-e2983f6dedde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3539d93d-90b0-455d-bfff-922ceaf5c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3539d93d-90b0-455d-bfff-922ceaf5c3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_9cb0b3a0-2bbe-4511-83c9-b7b28eea48a5" xlink:href="kprx-20221231.xsd#kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment_9cb0b3a0-2bbe-4511-83c9-b7b28eea48a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_dbfca62a-69f4-4b11-a30f-3d2116c5041a" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c3c2049-11a3-4fdc-8730-d1fb4a45f81e" xlink:to="loc_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment_dbfca62a-69f4-4b11-a30f-3d2116c5041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f7f86b0b-5b1f-4a8e-b4f7-178188f7c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f7f86b0b-5b1f-4a8e-b4f7-178188f7c3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8d855925-bd02-45c0-b1f0-1e947006ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8d855925-bd02-45c0-b1f0-1e947006ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_72dcc76a-8a8e-407e-847f-563a0533a0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_72dcc76a-8a8e-407e-847f-563a0533a0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0f8cd2a4-4d8e-432b-a755-79f7051284c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0f8cd2a4-4d8e-432b-a755-79f7051284c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26294c6e-d686-47ea-919a-7892f083969b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26294c6e-d686-47ea-919a-7892f083969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29cbea9e-04a1-47f2-910c-d1ee21e882ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29cbea9e-04a1-47f2-910c-d1ee21e882ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_270d1870-3f92-45c8-8c10-5fde1ba19c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa9f513a-3461-4704-b563-ef043c510aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_270d1870-3f92-45c8-8c10-5fde1ba19c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CapitalStockDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_83443fc2-d110-4b61-8618-922183b47831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_83443fc2-d110-4b61-8618-922183b47831" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2519b5a0-e476-49fc-b845-027f52199baf" xlink:to="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesdConvertiblePreferredStockMember_8d94844f-90c7-4c51-b3e6-ac0af9a85857" xlink:href="kprx-20221231.xsd#kprx_SeriesdConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_SeriesdConvertiblePreferredStockMember_8d94844f-90c7-4c51-b3e6-ac0af9a85857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommonSharesMember_7894bf2d-55c6-4de9-b53b-c07858d28622" xlink:href="kprx-20221231.xsd#kprx_CommonSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_CommonSharesMember_7894bf2d-55c6-4de9-b53b-c07858d28622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SeriesEConvertiblePreferredStockMember_7bf61e10-e067-4dff-821e-34ce1340ab48" xlink:href="kprx-20221231.xsd#kprx_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_kprx_SeriesEConvertiblePreferredStockMember_7bf61e10-e067-4dff-821e-34ce1340ab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_db1e74c5-ed77-48a2-9f05-9df25bfa425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_722c59c5-3038-412d-b786-1c237b2f0985" xlink:to="loc_us-gaap_CommonStockMember_db1e74c5-ed77-48a2-9f05-9df25bfa425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_224bd182-76c6-4b0f-b8cf-1d2e187947e7" xlink:to="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_51e20274-702d-447a-94cd-eccc83846c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:to="loc_us-gaap_PreferredStockMember_51e20274-702d-447a-94cd-eccc83846c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d6b9084-a871-4ade-8e8d-72b5adf057f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_550d313f-cfa4-4bc4-bb8b-e06228b1182d" xlink:to="loc_us-gaap_CommonStockMember_4d6b9084-a871-4ade-8e8d-72b5adf057f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5698d19c-7356-478c-8fcd-ea113d34d956" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrivatePlacementWarrantsMember_2f74527d-bb40-438b-8f91-8e6107ed534a" xlink:href="kprx-20221231.xsd#kprx_PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:to="loc_kprx_PrivatePlacementWarrantsMember_2f74527d-bb40-438b-8f91-8e6107ed534a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PublicOfferingMember_4e46be9f-0d33-4317-a56a-5784871d0def" xlink:href="kprx-20221231.xsd#kprx_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11924d34-f977-4481-9488-a69b162b0439" xlink:to="loc_kprx_PublicOfferingMember_4e46be9f-0d33-4317-a56a-5784871d0def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f45840d5-a686-443e-9332-b19fedf23196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesPharmaGesMbhMember_fc3e7cba-9ae2-4d1b-9311-34daac22724d" xlink:href="kprx-20221231.xsd#kprx_PanoptesPharmaGesMbhMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a6465b1-d52d-4c8f-aac6-01675b109ab7" xlink:to="loc_kprx_PanoptesPharmaGesMbhMember_fc3e7cba-9ae2-4d1b-9311-34daac22724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b240c21f-e28a-4356-9956-208703016816" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantMember_c9e12bf9-23ef-4582-a0b7-942a5f08fc88" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassAWarrantMember_c9e12bf9-23ef-4582-a0b7-942a5f08fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantMember_23ddc197-a687-4dbc-945f-f1f9649aae77" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassBWarrantMember_23ddc197-a687-4dbc-945f-f1f9649aae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassAWarrantsExerciseOfOptionMember_6f9871c9-10d0-4b83-a53c-a821da565ed5" xlink:href="kprx-20221231.xsd#kprx_ClassAWarrantsExerciseOfOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassAWarrantsExerciseOfOptionMember_6f9871c9-10d0-4b83-a53c-a821da565ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassBWarrantExerciseOfOptionMember_aa149efa-635f-4a2c-8c64-76736977808e" xlink:href="kprx-20221231.xsd#kprx_ClassBWarrantExerciseOfOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_ClassBWarrantExerciseOfOptionMember_aa149efa-635f-4a2c-8c64-76736977808e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InducementWarrantMember_cebc3880-105e-494b-a34d-668ab17f2113" xlink:href="kprx-20221231.xsd#kprx_InducementWarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4fb5fa7f-5c83-4feb-851a-3fe5f1e38789" xlink:to="loc_kprx_InducementWarrantMember_cebc3880-105e-494b-a34d-668ab17f2113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5847b8e9-a24e-4691-b37f-97b89d339454" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ec74883c-d48e-4fe5-972e-53320cb1ed78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92f3bc33-ff1f-4b20-9839-6467567993b0" xlink:to="loc_us-gaap_WarrantMember_ec74883c-d48e-4fe5-972e-53320cb1ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_828b62e7-c08c-4a76-9494-872c229d3ae4" xlink:to="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ad4eeb7-170c-4f4f-890e-ec0aded15cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ad4eeb7-170c-4f4f-890e-ec0aded15cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_99261ec6-438e-4846-90e2-8d552bd485ff" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfWarrantIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued_99261ec6-438e-4846-90e2-8d552bd485ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant_98f2bee5-c1d4-4cc8-9276-86f95669699f" xlink:href="kprx-20221231.xsd#kprx_SharePurchasePriceOfCommonStockAndWarrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharePurchasePriceOfCommonStockAndWarrant_98f2bee5-c1d4-4cc8-9276-86f95669699f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68e5462c-2b93-436f-bd28-b52a7fe26897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68e5462c-2b93-436f-bd28-b52a7fe26897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment_f2eb237c-66f3-4812-9131-bf071e177e6d" xlink:href="kprx-20221231.xsd#kprx_WarrantExercisePricePerShareSubjectToAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantExercisePricePerShareSubjectToAdjustment_f2eb237c-66f3-4812-9131-bf071e177e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantTerm_bd60be3e-d7e7-469c-b2a0-792ad884a9e4" xlink:href="kprx-20221231.xsd#kprx_WarrantTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantTerm_bd60be3e-d7e7-469c-b2a0-792ad884a9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_0b8d9c9a-79ff-42e9-a20f-45acbcf7fdf8" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock_0b8d9c9a-79ff-42e9-a20f-45acbcf7fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_958edc4a-8f76-4fa3-a222-3e10bea607bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_958edc4a-8f76-4fa3-a222-3e10bea607bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a26880c5-7a4a-4f36-889f-5a3c0cc2a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a26880c5-7a4a-4f36-889f-5a3c0cc2a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af8306ad-117e-4737-b1d7-8cac05d41642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af8306ad-117e-4737-b1d7-8cac05d41642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4ddea312-cc1c-4a47-b9c3-7ca4d50458f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4ddea312-cc1c-4a47-b9c3-7ca4d50458f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bc4dc57c-6bdf-4400-a99f-5168ae4cfd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bc4dc57c-6bdf-4400-a99f-5168ae4cfd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_3cbb7646-3778-4827-94d4-4fa3e50b2f7b" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesFromHoldBackShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares_3cbb7646-3778-4827-94d4-4fa3e50b2f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionHoldbackSharesTerm_ce1e81f8-25bd-4baf-87a2-741f3748f5cd" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionHoldbackSharesTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_BusinessAcquisitionHoldbackSharesTerm_ce1e81f8-25bd-4baf-87a2-741f3748f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d6ab4b44-156d-4d94-a9a3-37598b2abac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d6ab4b44-156d-4d94-a9a3-37598b2abac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantConvertibleIntoCommonStockBasis_daaf834e-4275-4bc7-9c34-88fd5b02ef1b" xlink:href="kprx-20221231.xsd#kprx_WarrantConvertibleIntoCommonStockBasis"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantConvertibleIntoCommonStockBasis_daaf834e-4275-4bc7-9c34-88fd5b02ef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsConvertibleIntoCommonStock_73dc93e0-06a5-4c60-83ff-b9b60aa200df" xlink:href="kprx-20221231.xsd#kprx_WarrantsConvertibleIntoCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantsConvertibleIntoCommonStock_73dc93e0-06a5-4c60-83ff-b9b60aa200df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerCommonShares_7461d583-aa59-462f-a756-9ecd995c9a93" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerCommonShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharesIssuedPricePerCommonShares_7461d583-aa59-462f-a756-9ecd995c9a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_2e9ae5fe-788b-443f-a918-316a444e807f" xlink:href="kprx-20221231.xsd#kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants_2e9ae5fe-788b-443f-a918-316a444e807f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_73a7e306-9c21-4fa2-a069-755239505475" xlink:href="kprx-20221231.xsd#kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants_73a7e306-9c21-4fa2-a069-755239505475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_14a067fe-324f-4f50-b930-084fce24c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_14a067fe-324f-4f50-b930-084fce24c851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissions_fc7a2a4f-427e-4360-af06-dc2a7718fdcf" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_UnderwritingDiscountAndCommissions_fc7a2a4f-427e-4360-af06-dc2a7718fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnderwritingDiscountAndCommissionsExpenses_61141417-0117-4f2a-bee1-afb9750e4e54" xlink:href="kprx-20221231.xsd#kprx_UnderwritingDiscountAndCommissionsExpenses"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_UnderwritingDiscountAndCommissionsExpenses_61141417-0117-4f2a-bee1-afb9750e4e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightExercised_55b1d98b-2958-4fb5-b8bb-eb2be4dd6260" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightExercised_55b1d98b-2958-4fb5-b8bb-eb2be4dd6260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_1fffe80b-098b-4e3b-b6c2-c8e903360b59" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable_1fffe80b-098b-4e3b-b6c2-c8e903360b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales_0def3b48-a26b-4e2e-bc04-3a12d72707df" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromWarrantExercisesAndWarrantSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_ProceedsFromWarrantExercisesAndWarrantSales_0def3b48-a26b-4e2e-bc04-3a12d72707df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_1c81842a-faec-42b5-9406-1db2c364e205" xlink:href="kprx-20221231.xsd#kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_deaaf36a-31e4-4647-b2e3-8e81a7149a0c" xlink:to="loc_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage_1c81842a-faec-42b5-9406-1db2c364e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#WarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_b29613dc-ff62-4776-bc58-db8d5bb30e77" xlink:href="kprx-20221231.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_b29613dc-ff62-4776-bc58-db8d5bb30e77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d628fc97-1ca1-4321-9f0f-d5f316114177" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6b7a1457-059f-4805-83d8-1db6281e7ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_fee309fe-c784-405f-9df0-47a45089ca4a" xlink:to="loc_us-gaap_WarrantMember_6b7a1457-059f-4805-83d8-1db6281e7ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b94d7691-d81e-4eda-a06c-44e34d61fa3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_580bdf8f-f6c0-4d49-8459-557794e69a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_580bdf8f-f6c0-4d49-8459-557794e69a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36eac481-217f-4200-ad60-6928f2bf236c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_36eac481-217f-4200-ad60-6928f2bf236c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25a96747-ac9e-483d-97b6-820345145cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25a96747-ac9e-483d-97b6-820345145cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_05ba3f41-be9a-45b6-a5d9-fe6e82c427e6" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_05ba3f41-be9a-45b6-a5d9-fe6e82c427e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c83dc59-e3c9-4b86-bedf-d42b351afc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c83dc59-e3c9-4b86-bedf-d42b351afc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd07a5e-b4a0-4b95-8467-8a672dcb8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_234d8386-dde2-431b-999d-bdfbfc136b8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bd07a5e-b4a0-4b95-8467-8a672dcb8eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_d9ef822e-63cd-48ee-afb1-a55c99b3f064" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_d9ef822e-63cd-48ee-afb1-a55c99b3f064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_5724e3cc-b9ee-4f54-8064-5dd9f8066717" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_5724e3cc-b9ee-4f54-8064-5dd9f8066717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_06eee409-1b75-435f-85c0-b5db1d08df8b" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice_06eee409-1b75-435f-85c0-b5db1d08df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_051e2fdc-9222-4c55-9976-a9647fd919f2" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_051e2fdc-9222-4c55-9976-a9647fd919f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_267791c6-29a9-44ad-b09b-c435185ad4a3" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_79e1aa8f-a2c6-4c9b-bf47-e8011ea8c8a9" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_267791c6-29a9-44ad-b09b-c435185ad4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:href="kprx-20221231.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80fff189-ba95-47d0-8cbe-f4202396f9e8" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ec2666aa-7c5d-4236-aa03-f360e366fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ec2666aa-7c5d-4236-aa03-f360e366fcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_6ead9e6a-c7b4-4b3e-888c-603e24752040" xlink:href="kprx-20221231.xsd#kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_f9d27a68-66ab-4326-b661-bdea28e85475" xlink:to="loc_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms_6ead9e6a-c7b4-4b3e-888c-603e24752040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8142a6ad-06a7-42dd-a339-aaa94944e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8142a6ad-06a7-42dd-a339-aaa94944e31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_caf72598-d719-4251-8c0d-5dc726650098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_caf72598-d719-4251-8c0d-5dc726650098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1dc93b79-63ff-4829-977a-98cbcf405f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1dc93b79-63ff-4829-977a-98cbcf405f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_65864f17-823d-4d28-8f75-55117ac5f5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_65864f17-823d-4d28-8f75-55117ac5f5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44797fa1-c22c-48db-ab8a-87c4b5465c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68070b7c-8f9e-409f-80b8-ebdba213dac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44797fa1-c22c-48db-ab8a-87c4b5465c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e865ca8f-b5cd-4202-beb9-928a2df55bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e865ca8f-b5cd-4202-beb9-928a2df55bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa4d02db-fe22-491d-a997-d6dcbc949c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fa4d02db-fe22-491d-a997-d6dcbc949c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d04055b9-949c-4e7b-ae8b-c6b32358b0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d04055b9-949c-4e7b-ae8b-c6b32358b0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c9bceb1-81b6-44aa-ae16-055ba467f851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c9bceb1-81b6-44aa-ae16-055ba467f851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7e00a557-c574-4c6c-97a0-dba44fee7373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7e00a557-c574-4c6c-97a0-dba44fee7373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb54fc28-4936-4a06-bbbb-95cb86cf3478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cb54fc28-4936-4a06-bbbb-95cb86cf3478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8746659-3e1d-4b74-9805-e99cf65ff7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af7613de-1661-4f51-8c72-3dd24a270f11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8746659-3e1d-4b74-9805-e99cf65ff7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_690cf872-203a-4ef3-a17f-b7d78f7a23b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_690cf872-203a-4ef3-a17f-b7d78f7a23b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b2a8efa7-b6ed-444c-b971-40d46112ebff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b2a8efa7-b6ed-444c-b971-40d46112ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60158ad0-88ea-4746-8ae8-d66baf2ca512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_97251356-3f74-4caa-bee8-13b87f0e1494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60158ad0-88ea-4746-8ae8-d66baf2ca512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_978af425-79f2-4327-ae03-ab5f31be0832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60158ad0-88ea-4746-8ae8-d66baf2ca512" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_978af425-79f2-4327-ae03-ab5f31be0832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ddbde401-90c9-4311-b24f-0b3f7855c4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60158ad0-88ea-4746-8ae8-d66baf2ca512" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ddbde401-90c9-4311-b24f-0b3f7855c4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_214d2412-b6f4-434f-950e-b6967c849824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60158ad0-88ea-4746-8ae8-d66baf2ca512" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_214d2412-b6f4-434f-950e-b6967c849824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_91451640-ac9a-442e-b2b2-591d1c8844a9" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_91451640-ac9a-442e-b2b2-591d1c8844a9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_54e57d84-2864-4197-b62f-98fe2c763343" xlink:to="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member_15667918-f4df-4d13-bfc1-743ddfe4af3c" xlink:href="kprx-20221231.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:to="loc_kprx_EquityIncentivePlan2014Member_15667918-f4df-4d13-bfc1-743ddfe4af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember_6c7f5d9b-de57-4cce-875e-86e3ae062fd9" xlink:href="kprx-20221231.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d9bdaaca-374e-4898-970e-3fb3bbff620e" xlink:to="loc_kprx_EmployeeStockPurchasePlanMember_6c7f5d9b-de57-4cce-875e-86e3ae062fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0a9955c3-a1a5-4c1e-a87e-10f80c8dafde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_294723e3-02d8-43a6-b2be-d0b83b8d1b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:to="loc_us-gaap_EmployeeStockOptionMember_294723e3-02d8-43a6-b2be-d0b83b8d1b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4d72e9dc-cc36-4429-980e-880e0e43122a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6876691a-581f-4030-929a-1e5ad83ead45" xlink:to="loc_us-gaap_RestrictedStockMember_4d72e9dc-cc36-4429-980e-880e0e43122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_902015a3-c01b-4c79-9327-afd665125fde" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_5bbd9e93-904d-444e-987c-5f881725a8e2" xlink:href="kprx-20221231.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e89ab4e9-817b-43e9-9747-e5929eaf26ae" xlink:to="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_5bbd9e93-904d-444e-987c-5f881725a8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_a63eaef9-fdbf-48e9-95b2-c2cf71b15478" xlink:to="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73597486-30e4-4476-a1ad-2c3afc9700b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73597486-30e4-4476-a1ad-2c3afc9700b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cc84fe31-d0cc-4926-baab-b3a14a424e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4a1b9309-ce18-41a6-8c60-396fd18566a9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cc84fe31-d0cc-4926-baab-b3a14a424e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fa810a53-15c9-487c-92d9-fecf039741bc" xlink:to="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72474b0f-4c35-4b5a-b575-a8286b04296d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:to="loc_srt_MinimumMember_72474b0f-4c35-4b5a-b575-a8286b04296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcf8b798-7627-4d13-ad65-28bfdc24e688" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66f97326-7005-490e-a94d-742dfe07e99f" xlink:to="loc_srt_MaximumMember_bcf8b798-7627-4d13-ad65-28bfdc24e688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_03adbacc-2dcb-4d8c-b5f7-309faf8edfba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessStockSharesAuthorized_56e4dac5-65a0-4bc9-bc81-bc27a4fcabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ExcessStockSharesAuthorized_56e4dac5-65a0-4bc9-bc81-bc27a4fcabeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice_2fddc8a7-7d2a-4c2a-a7d1-bc19e55499e0" xlink:href="kprx-20221231.xsd#kprx_PercentageOfExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_PercentageOfExercisePrice_2fddc8a7-7d2a-4c2a-a7d1-bc19e55499e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6944b963-9979-4922-924a-e2ce8caebbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6944b963-9979-4922-924a-e2ce8caebbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c4e4c27-817e-4675-a2e0-c6c55e417330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c4e4c27-817e-4675-a2e0-c6c55e417330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a5a5f41d-547a-407a-80c8-df406e73d018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a5a5f41d-547a-407a-80c8-df406e73d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab08cee2-ea98-4975-92e1-8570f00887aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab08cee2-ea98-4975-92e1-8570f00887aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30863577-439d-4f77-9a32-387895af0a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30863577-439d-4f77-9a32-387895af0a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6600694b-32a0-47d6-8ecf-d637ebe2d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6600694b-32a0-47d6-8ecf-d637ebe2d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e89bd29c-df5c-4e19-9364-c7f5fc292ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e89bd29c-df5c-4e19-9364-c7f5fc292ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_292c2b86-1688-41f5-a1f2-e08772138eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_292c2b86-1688-41f5-a1f2-e08772138eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_3fbbab94-713a-435c-8efd-f11983e35d20" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues_3fbbab94-713a-435c-8efd-f11983e35d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_efd4210e-a81f-4438-b716-458ddf014017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_efd4210e-a81f-4438-b716-458ddf014017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_036c7da0-6e00-413b-a1e3-6db8af239699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_036c7da0-6e00-413b-a1e3-6db8af239699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_9ced3d60-826b-44a9-976f-c8b7bf971112" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_9ced3d60-826b-44a9-976f-c8b7bf971112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c30e4b2-cab9-42ae-a5b4-f7ab8f5fe305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4baadf17-bff0-4693-8f9d-19b61213ef9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c30e4b2-cab9-42ae-a5b4-f7ab8f5fe305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_806f5c7f-bd77-48b4-a6af-aae0c2a6aa87" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96eb484f-5d2e-4e61-9042-0462f385ff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_806f5c7f-bd77-48b4-a6af-aae0c2a6aa87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_96eb484f-5d2e-4e61-9042-0462f385ff2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_46b5794a-a031-4079-a257-62beb144e2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_806f5c7f-bd77-48b4-a6af-aae0c2a6aa87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_46b5794a-a031-4079-a257-62beb144e2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e9f776e4-1741-4d0b-9c1d-bf97e121114a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_806f5c7f-bd77-48b4-a6af-aae0c2a6aa87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e9f776e4-1741-4d0b-9c1d-bf97e121114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_188eb2c0-5d58-4870-bfdb-95d32197badf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_806f5c7f-bd77-48b4-a6af-aae0c2a6aa87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_188eb2c0-5d58-4870-bfdb-95d32197badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_d9afcb7d-f912-4b27-b6cf-331b6191c73a" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_d9afcb7d-f912-4b27-b6cf-331b6191c73a" xlink:to="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:to="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c28e6261-6611-43ee-b84a-41c5d58a96ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8e68f5b7-c019-42a4-a160-fddec5ee5984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0afc1d2-0407-477d-befd-4ab603a56442" xlink:to="loc_us-gaap_RestrictedStockMember_8e68f5b7-c019-42a4-a160-fddec5ee5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e96346b6-4cc7-4709-9e81-7d8a82b5ab9a" xlink:to="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3785b5-55fa-44c7-861f-ed000944a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc3785b5-55fa-44c7-861f-ed000944a9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929fe1bf-5e45-4376-8a7e-bfa41656d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929fe1bf-5e45-4376-8a7e-bfa41656d61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8361ae21-528c-4da1-86ab-116701930513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8361ae21-528c-4da1-86ab-116701930513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af5278c5-361b-4113-88e1-d5b43448263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af5278c5-361b-4113-88e1-d5b43448263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af5c9771-aafa-4873-b2d9-ba56ad4f1eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0481d452-f0f4-4365-90a5-409aa28d12b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af5c9771-aafa-4873-b2d9-ba56ad4f1eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e85e73c-866c-4b18-aa4b-9d8be9130846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e85e73c-866c-4b18-aa4b-9d8be9130846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cdbdd98-68ad-4cf3-a058-bc8d80fa3dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cdbdd98-68ad-4cf3-a058-bc8d80fa3dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89a46983-b7cd-4c16-a148-fa993d543883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89a46983-b7cd-4c16-a148-fa993d543883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f0a557d5-f771-4a3f-8228-b177d11ba8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f0a557d5-f771-4a3f-8228-b177d11ba8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_954215ad-65df-4fe2-a674-d1b34c6c5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56724aa9-47cc-4e7d-97c2-bcf1e5299da3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_954215ad-65df-4fe2-a674-d1b34c6c5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0970752-6d9a-4ab6-872b-8eb51c81fdcb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_72b58e19-9118-4e0f-9c27-bb5765b2fdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c401185-56d0-4d30-a61c-a062c2833016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_72b58e19-9118-4e0f-9c27-bb5765b2fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EquityIncentivePlanStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_bc1b7544-6055-47fa-9895-886f2791f1eb" xlink:href="kprx-20221231.xsd#kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract_bc1b7544-6055-47fa-9895-886f2791f1eb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30308427-19a5-4059-be55-44f05c32d670" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_751968e9-8a8c-4a32-a7ab-3a6eca0a441a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_751968e9-8a8c-4a32-a7ab-3a6eca0a441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1fb1f05d-c7ba-4364-9111-ec9a01cfdbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10f4be3f-028c-43f8-ad15-cef3df39a873" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1fb1f05d-c7ba-4364-9111-ec9a01cfdbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c0bc8396-505a-40b9-ad7a-3f3e115c6fc0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_61d2540e-32db-4bac-bfe2-d83026b90ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_33f22855-9867-4438-a0b4-ec8aab0b97a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_61d2540e-32db-4bac-bfe2-d83026b90ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesComponentsoflossbeforeincometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd2ed689-bf47-4b2d-aaa2-1dbd297953b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_85eb7875-0b89-425c-bf63-9f20e38d8a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd2ed689-bf47-4b2d-aaa2-1dbd297953b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_85eb7875-0b89-425c-bf63-9f20e38d8a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_36fbed20-9411-42f6-81d1-ea20e2305987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd2ed689-bf47-4b2d-aaa2-1dbd297953b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_36fbed20-9411-42f6-81d1-ea20e2305987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_efe04e32-fd68-4728-b9df-cbcf78ab3739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd2ed689-bf47-4b2d-aaa2-1dbd297953b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_efe04e32-fd68-4728-b9df-cbcf78ab3739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesComponentsofincometaxbenefitexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d00678a-98d3-43c4-a5bd-49774ed25c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d00678a-98d3-43c4-a5bd-49774ed25c2c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fb0d3377-6bfe-42b5-bd1a-446f984e79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fb0d3377-6bfe-42b5-bd1a-446f984e79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_eab857cd-6a66-4527-b39b-e3da996f5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_eab857cd-6a66-4527-b39b-e3da996f5d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_528565f7-f547-4750-9308-f8442e48d2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_528565f7-f547-4750-9308-f8442e48d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_260e21be-a9a4-4a1f-a50f-b82fb90f53d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a8a7260c-7ae2-4cdb-8823-172559ecfa01" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_260e21be-a9a4-4a1f-a50f-b82fb90f53d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesReconciliationofeffectivetaxrateDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2c0d24b-f1f3-4ff0-bf1b-d92cf7f63285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2c0d24b-f1f3-4ff0-bf1b-d92cf7f63285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_be34c245-f76d-47eb-8af6-f469b39c4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_be34c245-f76d-47eb-8af6-f469b39c4ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4b229533-bf46-41ca-b57b-aa50f325e671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4b229533-bf46-41ca-b57b-aa50f325e671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5b0c793-2224-4cca-aa6e-a4ce0797b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f5b0c793-2224-4cca-aa6e-a4ce0797b5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_503fe649-7c87-4cc1-bd13-aa3090ea8905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_503fe649-7c87-4cc1-bd13-aa3090ea8905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4a6be45e-e5ec-4f97-9fee-b7f3eeec4f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4a6be45e-e5ec-4f97-9fee-b7f3eeec4f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ada0f47e-313e-489d-9a72-1f6ea994e283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ada0f47e-313e-489d-9a72-1f6ea994e283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_3a7667ac-def0-49eb-a85c-e4d2fd56b4fe" xlink:href="kprx-20221231.xsd#kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent_3a7667ac-def0-49eb-a85c-e4d2fd56b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d104ec3d-7da9-4a6a-8b73-299861638821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d104ec3d-7da9-4a6a-8b73-299861638821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8df28db3-7699-4c8a-bb0f-e1e7ec250e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5cf8728-2801-4150-9e7e-13a1fbd6216f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8df28db3-7699-4c8a-bb0f-e1e7ec250e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cbbbe604-bdf1-4b89-8a04-3d1eeff33f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbbbe604-bdf1-4b89-8a04-3d1eeff33f70" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2aa681b9-0ece-46e4-8bca-93cb2d65eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2aa681b9-0ece-46e4-8bca-93cb2d65eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f8b6bca4-524e-4921-be76-eeaf5df3c871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f8b6bca4-524e-4921-be76-eeaf5df3c871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_17582b9a-939d-4e6b-aff7-c49ccd91950a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_17582b9a-939d-4e6b-aff7-c49ccd91950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ceff0949-907e-49d1-a175-d52c9f597e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ceff0949-907e-49d1-a175-d52c9f597e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b9fb5a6f-da71-4f63-9e9b-2a2ade1a37b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b9fb5a6f-da71-4f63-9e9b-2a2ade1a37b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c79c9d25-77cf-4715-8c09-1f863f15f2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c79c9d25-77cf-4715-8c09-1f863f15f2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_65583927-e749-4889-813c-7614bc8e8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_65583927-e749-4889-813c-7614bc8e8f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c8d6f52a-77b0-44a2-92e1-392fee5a276a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c8d6f52a-77b0-44a2-92e1-392fee5a276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_67c6bf08-283b-4555-9165-f7125ca4beba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_67c6bf08-283b-4555-9165-f7125ca4beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_5bc21e6a-29ed-48ae-97fa-c0fbebe9d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_5bc21e6a-29ed-48ae-97fa-c0fbebe9d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_89967d9a-b6ad-41a2-a4be-71c7759a8ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_a10363d6-88be-4cbd-8a09-5ddff6c26f23" xlink:to="loc_us-gaap_DeferredTaxLiabilities_89967d9a-b6ad-41a2-a4be-71c7759a8ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9d1e2b5-4dc9-4d87-9ef9-6fd1435c1a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9d1e2b5-4dc9-4d87-9ef9-6fd1435c1a93" xlink:to="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a60c93a1-ef83-4b5f-9567-0aa83cbc7544" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2b4473f8-e4c5-47f0-b2c5-73796bcd6395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f3959760-3f8d-4bf2-b4eb-a73093318871" xlink:to="loc_us-gaap_ResearchMember_2b4473f8-e4c5-47f0-b2c5-73796bcd6395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de003c63-0e71-44b5-a863-e874ba11853a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_dfeef389-9443-4dd1-922c-ef123fe6336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_DomesticCountryMember_dfeef389-9443-4dd1-922c-ef123fe6336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_5d113801-6689-4edd-831d-3256565af865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_ForeignCountryMember_5d113801-6689-4edd-831d-3256565af865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4ffda949-0713-4c73-82dc-53e2a9b4e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e53a9efd-7a56-4127-8cab-f34d70acf2e3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4ffda949-0713-4c73-82dc-53e2a9b4e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_0396589b-b0f9-4f85-aeb8-dbe13e9a3d69" xlink:to="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_7ede0705-ea29-455b-adb1-c42d3e80dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_b9ff0bfb-2e9a-42e6-a155-7622b9fb37d9" xlink:to="loc_us-gaap_LatestTaxYearMember_7ede0705-ea29-455b-adb1-c42d3e80dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:href="kprx-20221231.xsd#kprx_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesTable_b1de18a5-3756-48bb-b1bc-5bb6333f10e0" xlink:to="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2d0016a3-7b2a-4890-89cd-dc40e93c87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2d0016a3-7b2a-4890-89cd-dc40e93c87cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1fe0962b-ae6c-4eab-94a9-90d86a5df68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1fe0962b-ae6c-4eab-94a9-90d86a5df68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6b3424d0-3e1f-4612-a0fb-1f10b7f8b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6b3424d0-3e1f-4612-a0fb-1f10b7f8b6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_329929f7-4764-4ea0-a58a-035675eb19c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_IncomeTaxesLineItems_2de06c7c-123f-45d6-91d0-59a57c08dc68" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_329929f7-4764-4ea0-a58a-035675eb19c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47ad15ba-836a-4b0f-a45a-59ad23bcd8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47ad15ba-836a-4b0f-a45a-59ad23bcd8d7" xlink:to="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c3574b1e-be90-4f8d-b175-581f6d5c60ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_ae81e0cb-2eec-4c36-a63f-dcc0663fafc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d7d6589e-087b-4941-8e3a-86001e37fc84" xlink:to="loc_us-gaap_LicensingAgreementsMember_ae81e0cb-2eec-4c36-a63f-dcc0663fafc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d6502218-5168-46fd-925e-afcf8b3303d7" xlink:to="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_adfb234c-2f1f-4947-8f30-1504070067f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:to="loc_us-gaap_LicenseMember_adfb234c-2f1f-4947-8f30-1504070067f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Kio101Member_ce853105-1222-42a7-9160-fc9468ab4fbc" xlink:href="kprx-20221231.xsd#kprx_Kio101Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4306e1c0-02dd-4139-b90b-d2a7d5351a33" xlink:to="loc_kprx_Kio101Member_ce853105-1222-42a7-9160-fc9468ab4fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c41e97e5-1cb9-4d3a-8a06-e98119b85f29" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c3c95086-bf83-4da4-b604-4dcab3be3a2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3d8a2e98-343f-4936-b9ae-e6b2704ed7ab" xlink:to="loc_srt_ScenarioForecastMember_c3c95086-bf83-4da4-b604-4dcab3be3a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d3277b60-f942-4b78-bf23-fc7b085e56b1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MediolanumAgreementMember_3a906e7f-3264-4d22-8716-2ffc80660d29" xlink:href="kprx-20221231.xsd#kprx_MediolanumAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cae7757-ddd8-4d71-a362-de2cbddcd572" xlink:to="loc_kprx_MediolanumAgreementMember_3a906e7f-3264-4d22-8716-2ffc80660d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6fb9eb3e-5c44-4fe0-aa1b-55d0686a1d6c" xlink:to="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SentrXAnimalCareIncMember_e9b21574-838b-4f63-8a90-94130c253eab" xlink:href="kprx-20221231.xsd#kprx_SentrXAnimalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0a5e69b3-3613-488f-b7c5-d444ca753e10" xlink:to="loc_kprx_SentrXAnimalCareIncMember_e9b21574-838b-4f63-8a90-94130c253eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:href="kprx-20221231.xsd#kprx_RoyaltyScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_RoyaltyScenarioAxis_2a8f75f5-bd4c-424e-9b72-57eb3be057de" xlink:to="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ForFirst250MillionNetSalesMember_c12feff2-fccc-4b4c-9f4f-fae20b6f08cb" xlink:href="kprx-20221231.xsd#kprx_ForFirst250MillionNetSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_ForFirst250MillionNetSalesMember_c12feff2-fccc-4b4c-9f4f-fae20b6f08cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_Between250And500MillionNetSalesMember_b5f66a10-85d3-4e1d-bb67-9d80c579abed" xlink:href="kprx-20221231.xsd#kprx_Between250And500MillionNetSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_Between250And500MillionNetSalesMember_b5f66a10-85d3-4e1d-bb67-9d80c579abed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NetSalesOver500MillionMember_0df4ee66-8b8c-40c1-8d6f-12ac5a88c15c" xlink:href="kprx-20221231.xsd#kprx_NetSalesOver500MillionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_RoyaltyScenarioDomain_e512461c-c7aa-48e5-a3d0-b213a61ce3dc" xlink:to="loc_kprx_NetSalesOver500MillionMember_0df4ee66-8b8c-40c1-8d6f-12ac5a88c15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:href="kprx-20221231.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_a5c7e994-0c44-4950-b7bf-f03d382db36a" xlink:to="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases_dc5e7a54-4608-4e74-9686-07eec6b9aff2" xlink:href="kprx-20221231.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_LesseeNumberOfOperatingLeases_dc5e7a54-4608-4e74-9686-07eec6b9aff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_7c46a0c2-e549-42e9-9a98-83b88137145c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_AreaOfLand_7c46a0c2-e549-42e9-9a98-83b88137145c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_eef149b7-21d5-4f52-9615-c7b61b60a056" xlink:href="kprx-20221231.xsd#kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions_eef149b7-21d5-4f52-9615-c7b61b60a056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4ebf79cf-aa82-42f3-925b-91211edaf0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4ebf79cf-aa82-42f3-925b-91211edaf0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities_6aa9c2d1-23f7-4cd1-af92-050fe5c27c54" xlink:href="kprx-20221231.xsd#kprx_OperatingLeaseInterestOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_OperatingLeaseInterestOnLeaseLiabilities_6aa9c2d1-23f7-4cd1-af92-050fe5c27c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements_640357e4-f78a-42f6-9b08-d3fd1a270675" xlink:href="kprx-20221231.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_NumberOfLicenseAgreements_640357e4-f78a-42f6-9b08-d3fd1a270675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfRoyaltiesOnNetSales_05157c28-44e8-48b7-9b30-5b043107599e" xlink:href="kprx-20221231.xsd#kprx_PercentageOfRoyaltiesOnNetSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PercentageOfRoyaltiesOnNetSales_05157c28-44e8-48b7-9b30-5b043107599e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ff4898c3-74a8-4c93-83f8-a5940db2ab67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ff4898c3-74a8-4c93-83f8-a5940db2ab67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8ee3f376-1a98-4123-a28c-a142a8e3ae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_us-gaap_ContractualObligation_8ee3f376-1a98-4123-a28c-a142a8e3ae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DevelopmentAndCommercialMilestonesTerm_e0815bbd-03f5-4492-9029-fcfe14dad0e8" xlink:href="kprx-20221231.xsd#kprx_DevelopmentAndCommercialMilestonesTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_DevelopmentAndCommercialMilestonesTerm_e0815bbd-03f5-4492-9029-fcfe14dad0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_b960942f-91ff-44dd-b9e1-50b9c9930f59" xlink:href="kprx-20221231.xsd#kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry_b960942f-91ff-44dd-b9e1-50b9c9930f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7f8aae75-9f7d-49e1-91fa-32b8d0c72dd9" xlink:href="kprx-20221231.xsd#kprx_IntangibleAssetsExpectedMilestonePayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_IntangibleAssetsExpectedMilestonePayable_7f8aae75-9f7d-49e1-91fa-32b8d0c72dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentOfAnnualFee_9fb115dc-b3c3-4992-9701-b49d380bd9ec" xlink:href="kprx-20221231.xsd#kprx_PaymentOfAnnualFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_63e36dd9-ff9b-4a39-b13e-b5066906e6a2" xlink:to="loc_kprx_PaymentOfAnnualFee_9fb115dc-b3c3-4992-9701-b49d380bd9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b25f265-5681-4ec3-bab1-ca1c1455c1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_7b869dad-d4cb-46b5-95de-fd563afa878a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b25f265-5681-4ec3-bab1-ca1c1455c1f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_7b869dad-d4cb-46b5-95de-fd563afa878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3705daca-f0c7-4a59-8fea-24fed070cfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b25f265-5681-4ec3-bab1-ca1c1455c1f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3705daca-f0c7-4a59-8fea-24fed070cfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8a783859-78ef-4ac2-a131-dada2cf1dd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b25f265-5681-4ec3-bab1-ca1c1455c1f9" xlink:to="loc_us-gaap_OperatingLeaseLiability_8a783859-78ef-4ac2-a131-dada2cf1dd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_c3256b5e-0155-4080-a03d-470aa99e3cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_db6495b6-eb8e-46e6-bbab-6f3f8c4725a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c3256b5e-0155-4080-a03d-470aa99e3cbc" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_db6495b6-eb8e-46e6-bbab-6f3f8c4725a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8c73a99-e2aa-41eb-8ff9-1191688ee3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c3256b5e-0155-4080-a03d-470aa99e3cbc" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_c8c73a99-e2aa-41eb-8ff9-1191688ee3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DefinedBenefitPlanContributionsByEmployerAccrued_e626fcc1-7865-4e6f-a29c-fcc499dabe61" xlink:href="kprx-20221231.xsd#kprx_DefinedBenefitPlanContributionsByEmployerAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_c3256b5e-0155-4080-a03d-470aa99e3cbc" xlink:to="loc_kprx_DefinedBenefitPlanContributionsByEmployerAccrued_e626fcc1-7865-4e6f-a29c-fcc499dabe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e1d34c76-39c7-448a-a819-96c7b1b673e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e1d34c76-39c7-448a-a819-96c7b1b673e2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e37e4e7-43fb-44ec-90a7-88af1af9dabf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_023fb245-5abd-471a-8b85-0fda552d3fb1" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83e49c1e-71ae-4845-acbf-ff916c531a36" xlink:to="loc_kprx_BayonMember_023fb245-5abd-471a-8b85-0fda552d3fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_abcf0e89-2238-4962-9134-1697fc4b4f77" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EarnOutConsiderationMember_996068e7-feb2-42f4-9219-dd0209b5a88d" xlink:href="kprx-20221231.xsd#kprx_EarnOutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:to="loc_kprx_EarnOutConsiderationMember_996068e7-feb2-42f4-9219-dd0209b5a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_DueToCreditorMember_3e923be2-3d26-4270-9dbf-91df5f1a5904" xlink:href="kprx-20221231.xsd#kprx_DueToCreditorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cdb8647b-88fe-4297-9f35-485065e425c8" xlink:to="loc_kprx_DueToCreditorMember_3e923be2-3d26-4270-9dbf-91df5f1a5904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:href="kprx-20221231.xsd#kprx_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_MilestoneTypeAxis_adc19e5b-a938-475d-b76f-9f87d6e10818" xlink:to="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PhaseOneBMilestonesMember_8d5c6db6-ac6b-448e-bb77-3432ffd1e4e7" xlink:href="kprx-20221231.xsd#kprx_PhaseOneBMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:to="loc_kprx_PhaseOneBMilestonesMember_8d5c6db6-ac6b-448e-bb77-3432ffd1e4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_RemainingMilestonesMember_4c9258ce-86e3-44a4-b477-d54905580064" xlink:href="kprx-20221231.xsd#kprx_RemainingMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_MilestoneTypeDomain_2c3d3799-a331-4a5b-8bd8-b25f81edff08" xlink:to="loc_kprx_RemainingMilestonesMember_4c9258ce-86e3-44a4-b477-d54905580064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe806c4f-d401-4e60-aba9-81cad8b6a2a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember_a08ed7dd-8af1-444c-832d-90bea061cd10" xlink:href="kprx-20221231.xsd#kprx_IfMilestonePaymentsAreExercisedForSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d6b0b2b0-795e-4e47-9bb9-f5798d9900d2" xlink:to="loc_kprx_IfMilestonePaymentsAreExercisedForSharesMember_a08ed7dd-8af1-444c-832d-90bea061cd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9bdbf4f3-fc85-4c44-8148-6bfea868a84a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_91b0d003-25d5-40c8-b02e-7a4055fdb642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_91b0d003-25d5-40c8-b02e-7a4055fdb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a86ca6-0f36-43e6-93af-70630af00809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1a86ca6-0f36-43e6-93af-70630af00809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2243965b-379d-48e5-b168-f34a4cbdf9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2243965b-379d-48e5-b168-f34a4cbdf9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessAcquisitionEarnoutConsideration_023f8676-eac3-4b77-a817-196479d13829" xlink:href="kprx-20221231.xsd#kprx_BusinessAcquisitionEarnoutConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_BusinessAcquisitionEarnoutConsideration_023f8676-eac3-4b77-a817-196479d13829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_572e4a95-d5e7-4a20-b433-f10467650a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_SharePrice_572e4a95-d5e7-4a20-b433-f10467650a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PaymentsToAcquireBusinessesFairValue_440b9093-efbc-4786-80d0-f98c1de16b66" xlink:href="kprx-20221231.xsd#kprx_PaymentsToAcquireBusinessesFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_PaymentsToAcquireBusinessesFairValue_440b9093-efbc-4786-80d0-f98c1de16b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_515812cf-423e-41c5-8cc6-7654f13f17bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_515812cf-423e-41c5-8cc6-7654f13f17bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_e3afd67e-63fb-4bea-b581-1909b8d639a7" xlink:href="kprx-20221231.xsd#kprx_ThresholdPeriodOfVolumeWeightedAveragePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice_e3afd67e-63fb-4bea-b581-1909b8d639a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_VolumeWeightedAveragePrice_7928fe99-53e7-4120-a0ff-dc68f4b4b251" xlink:href="kprx-20221231.xsd#kprx_VolumeWeightedAveragePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_kprx_VolumeWeightedAveragePrice_7928fe99-53e7-4120-a0ff-dc68f4b4b251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_88d129db-04a2-4f50-9b15-74facec5a95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_88d129db-04a2-4f50-9b15-74facec5a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_323604d2-468e-464d-87a5-028e93aeea40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d2c2741-8bf6-4c78-9213-f65b956d0a50" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_323604d2-468e-464d-87a5-028e93aeea40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsPurchasepriceallocationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f2f7a88a-afd1-4532-bfc6-907d2ac0ddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f2f7a88a-afd1-4532-bfc6-907d2ac0ddd4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_664fa1c3-b32b-4dac-8a18-a38697986811" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_bbc2fe0a-3975-4d8b-aa1b-c60ab3313514" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a03bcc50-dae0-449d-a496-52e3f8bbbc1f" xlink:to="loc_kprx_BayonMember_bbc2fe0a-3975-4d8b-aa1b-c60ab3313514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1997147-2f1e-497d-96a4-c093333bb6ff" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2d6594b9-be45-4e2c-ba5f-94ed0550235f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2d6594b9-be45-4e2c-ba5f-94ed0550235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_35d68679-a19f-4478-b1e5-4e8c02c0b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_35d68679-a19f-4478-b1e5-4e8c02c0b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_GoodwillAcquired_49f4821c-738c-4b81-a491-386e1a477805" xlink:href="kprx-20221231.xsd#kprx_GoodwillAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_kprx_GoodwillAcquired_49f4821c-738c-4b81-a491-386e1a477805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_12484011-80d3-47d0-892e-be24e3503b4c" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities_12484011-80d3-47d0-892e-be24e3503b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5e1bed3-0d99-4636-995b-07c8193fa1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a5e1bed3-0d99-4636-995b-07c8193fa1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b45f06a-2203-4b7a-806a-72f35285b640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b45f06a-2203-4b7a-806a-72f35285b640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_35dca61d-ba89-4f62-9c89-708c747bd880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_35dca61d-ba89-4f62-9c89-708c747bd880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5d00ab2a-bfbf-4d5d-bf9b-ba70275ef58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8130557f-b635-460f-8e5a-2b929b188ef3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5d00ab2a-bfbf-4d5d-bf9b-ba70275ef58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#AcquisitionsFairvalueofconsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f0f316d1-abc5-415b-84f1-57dd0a5cb741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f0f316d1-abc5-415b-84f1-57dd0a5cb741" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fc594733-b7c6-4a0d-bbca-ac6b9ded4af1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_805dc74d-338d-47c2-bbde-25dc910f6197" xlink:href="kprx-20221231.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9303d383-e095-4af0-aeda-459ee9a0c46d" xlink:to="loc_kprx_BayonMember_805dc74d-338d-47c2-bbde-25dc910f6197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61aba4af-1f46-4a8e-ba0c-f0eaf9b3675c" xlink:to="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4af3a967-8050-42bc-a799-9d09d1359de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6269db4-02ae-40de-b0b1-fdcce7b53505" xlink:to="loc_us-gaap_CommonStockMember_4af3a967-8050-42bc-a799-9d09d1359de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09be14e-a8b8-4b32-bfff-f3e8503f28c1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_54ed8028-1aa7-4542-933e-0ff3d5b16977" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue_54ed8028-1aa7-4542-933e-0ff3d5b16977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent_0fd8065c-1cd7-487f-b2cc-869e9a985784" xlink:href="kprx-20221231.xsd#kprx_BusinessCombinationContingentConsiderationCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationCashCurrent_0fd8065c-1cd7-487f-b2cc-869e9a985784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_524a2abe-c449-475c-8676-1f91a02d0f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_524a2abe-c449-475c-8676-1f91a02d0f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_8a7f3ce2-c448-43c1-a27a-ea51549d1e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_8a7f3ce2-c448-43c1-a27a-ea51549d1e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_846c686c-a3f0-43d8-a4f1-3d6b49f7b40b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_846c686c-a3f0-43d8-a4f1-3d6b49f7b40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7a2dbfe7-a029-4ca0-b423-34a1d8b41253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_452e0693-f8a2-4641-af62-8b18930a58ca" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7a2dbfe7-a029-4ca0-b423-34a1d8b41253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="kprx-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a72a66d3-03a9-4334-9f4c-05d155115f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a72a66d3-03a9-4334-9f4c-05d155115f91" xlink:to="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea54c0b7-ae4d-42c0-80b5-2b4d8ff5ea26" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_76dbfe14-3379-4268-b0e8-47f22de7d544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_024f0913-c42b-4102-9b2a-8216ed90ac1f" xlink:to="loc_us-gaap_SubsequentEventMember_76dbfe14-3379-4268-b0e8-47f22de7d544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4cea1e1f-48e7-4a4f-93d3-5bd2c1e8680e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4d66d7a3-bb69-4965-a98d-f9f6f3e3a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08a60701-1c06-49a9-b278-55e238171637" xlink:to="loc_us-gaap_PrivatePlacementMember_4d66d7a3-bb69-4965-a98d-f9f6f3e3a06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_344bd15d-b91b-4838-9c99-1270756828b3" xlink:to="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_452dbb2e-be3d-483e-9d62-9d7c783bc431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e26376ec-4761-43a6-9676-768c5259c5b6" xlink:to="loc_us-gaap_CommonStockMember_452dbb2e-be3d-483e-9d62-9d7c783bc431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_36c73f3f-457e-4592-bc3f-a0eeb29bc95b" xlink:to="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5aeecd78-8e71-4c32-b1ab-52ed4ddce47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5aeecd78-8e71-4c32-b1ab-52ed4ddce47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9958f134-b7c1-44e4-a1aa-8de196628867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9958f134-b7c1-44e4-a1aa-8de196628867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d6c458f-71c4-428b-b4da-5025ddc5809a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d6c458f-71c4-428b-b4da-5025ddc5809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2eed22a-cb0d-4525-a382-c82e37eed6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2eed22a-cb0d-4525-a382-c82e37eed6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_607972e3-65a0-472c-b2b8-d82acff9f7ec" xlink:href="kprx-20221231.xsd#kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod_607972e3-65a0-472c-b2b8-d82acff9f7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantTerm_302f5237-654e-413a-91b2-9384665752d6" xlink:href="kprx-20221231.xsd#kprx_WarrantTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_WarrantTerm_302f5237-654e-413a-91b2-9384665752d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_7ed9660a-8627-4f3c-9fa4-ffbdb8e4993d" xlink:href="kprx-20221231.xsd#kprx_SharePurchaseAgreementSaleOfStockMaximumAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount_7ed9660a-8627-4f3c-9fa4-ffbdb8e4993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_10c58159-979a-407d-90b4-4254b80e2d2f" xlink:href="kprx-20221231.xsd#kprx_ProceedsFromSaleOfStockSharePurchaseAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement_10c58159-979a-407d-90b4-4254b80e2d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_e5c02da4-0e9a-4e5d-89fc-72302a49eb01" xlink:href="kprx-20221231.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_e5c02da4-0e9a-4e5d-89fc-72302a49eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_aeeaace8-e213-47e6-92f7-235b636ccea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b3bc2642-e0f8-4192-b43a-89bad0c458d5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_aeeaace8-e213-47e6-92f7-235b636ccea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>kprx-20221231_g1.jpg
<TEXT>
begin 644 kprx-20221231_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%N&VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@.2XP+6,P,# @-SDN
M9C@T-65B,2P@,C R,B\Q,2\P,RTQ.3HR.#HT-2 @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z
M+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M
M,#(M,#94,38Z-3$Z,34K,3$Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C R,RTP,BTP-E0P-3HU,3HR,5H\+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R(#(W+C(@*$UA8VEN=&]S:"D\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP,BTP-E0Q-CHU,3HQ
M-2LQ,3HP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I4:'5M
M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$Q-CPO>&UP1TEM9SIH
M96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14),045S04%$+S=107-51VAV9$<Y
M>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04),04%!04%%028C>$$[05%%
M<T%!04%!44%"+RM)35=%;$11,3E156LY1U-5>$9!045"04%!35-%>'!B;3A#
M14%!06)7-3!C;$I(46E"65=6;V=".#1!06=!2B8C>$$[04%904U104%95TYZ
M8T4Q5%)L44%!04%!4U561$E(3E-2,$E!04%!04%!04%!04%!04%!04%08E=!
M045!04%!03!Y,4E50T%G04%!028C>$$[04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%263-">61!
M04%!5D%!04%!>B8C>$$[6D=6>EEW04%!65%!04%"<V0S4G=D04%!069!04%!
M0559;71W9$%!04%G44%!04%58VQH6E=G04%!:&=!04%!55HQ:%I79T%!06EW
M028C>$$[04%!55EL:%I79T%!06M!04%!055:1S%U6D%!04%L44%!04)W6D<Q
M:UI!04%!<U%!04%#261N5FQ:04%!03!W04%!0T=D;6QL9'=!028C>$$[03E1
M04%!06MB2%9T85%!04$O9T%!04%58E=6:&-W04%"07=!04%!:V1'5FIA04%!
M0D1!04%!04UC;%)347=!04)$=T%!06=-6C%24R8C>$$[47=!04)$=T%!06=-
M66Q24U%W04%"1'=!04%G361'5C1D04%!04%"1&(S0C5C;6QN84A19TM'37!)
M1$4U3U1G9U-'5C-B1U8P9$,Q428C>$$[65=.<EE82FM)14YV8EA":&)N:T%!
M1U)L8S)-04%!04%!04%!16Y.4U(P26=3559$3FI%-4YJ671-:31X04%!04%!
M04%!04%!04%!4R8C>$$[8S%*2%%I0DI254TR351K,DYI,'E,:D5!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M028C>$$[04%!04%!04%!04%!049H6E=I04%!04%!04%$>E5104)!04%!05)B
M35=&;&%)04%!04%!04%!04%!04%!04%!04%!0EE75F]G04%!028C>$$[04%!
M06(V24%!1&HQ04%!1&M&:%I7:4%!04%!04%!0FEM44%!=#1504%":F%71FQA
M24%!04%!04%!0U-G04%!4&A!04%T<SEK6EA.:B8C>$$[04%!04%!04%!0EI*
M4E5-9V%(4C!C1&]V3#-D,V1Y-7!:5TUU63)G04%!04%!04%!04%!04%"6DI2
M54UG84A2,&-$;W9,,V0S9'DU<"8C>$$[6E=-=5DR9T%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%:1U9Z67=!028C>$$[04%!04%!0753559$2419>$]463),5$EU35-"15I7
M6FAD5W@P249*2%%I0FIB,GAV9%A)9V,S0FA9,E5G3%-">E5K9$-!04%!04%!
M028C>$$[04%!04%!0753559$2419>$]463),5$EU35-"15I76FAD5W@P249*
M2%%I0FIB,GAV9%A)9V,S0FA9,E5G3%-">E5K9$-!04%!04%!028C>$$[04%!
M04%!04%!04%!04%!04%!04%!1U)L8S)-04%!04%!04%!3$9*;%IM5GE:5S5J
M6E-"5V%75C-A5S5N245.=F)M4G!D1VQV8FE"<"8C>$$[8FE"2E)533)-5&LR
M3FDP>4QJ14%!04%!04%!04%!04%!0WA36E=:;&-M5G59,E5G5FUL;&0R;'5:
M>4)$8C(U:V%84G!B,C1G85<T9R8C>$$[4U561$YJ135.:EET36DT>$%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%",F%75C-!04%!04%!5'!0
M-$%&1CAU04)$4"8C>$$[1D%!1#=C=T%"0DU,04%.8VYG04%!04995U9O9T%!
M04%!04)-0U99055!04%!1F-F-3(Q;%E834%!04%!04%!04%104%!04%!04%!
M028C>$$[04%!04%!04%!04%!04%+4$%!04%!;DYP6GE!04%!04%1,4I524=.
M,6-N64%!04%!04%!14%!04%!055!0V=!4$%"44%'44%E04--028C>$$[2T%!
M=$%$24%.=T$W045!05)10DM!13A!5D%"6D%&-$%9=T)O04<P06-G0C-!2'=!
M9U%#1T%)<T%K04-604IO06YW0VM!2VM!<F=#>28C>$$[04QC079!1$)!35E!
M>7=$44%.54$R=T1G04]5039W1'=!4%E!*W=%0D%18T)$445405)K0DAW16Q!
M4W-"36=%-$%4-$)2449-059)0B8C>$$[5U%&9T%78T)B9T8Q05AW0F=W1TQ!
M6DE";6=':$%A:T)S44<U06-%0GE12%)!9&M"-%%(<$%F24(K9TE$06=W0T9!
M261!:5E#3'=)-"8C>$$[06M%0U-W2E5!;#!#6G=*>$%N;T-H04M/07!G0V]G
M2W-!<EE#=U%,3$%T54,T04QR07951$%!34Q!>%E$25%-=$%Z9T11=TY003%O
M1"8C>$$[6F=.>4$S-$1I9T]7039)1')G3S9!.&-$,'=09T$K=T0K45%'0D)-
M14E!471"1'-%4T%25D)'345C45(K0DEW16UG4V]"3%E%>$%45"8C>$$[0D]%
M13A!5"M"43!&2$%5<D)4;T9345990E=C1F1W5T="6EE&<&=7,4)C548Q45AL
M0F991T)G65=":6-'3G=:24)L:T=A9UHW0F]W1R8C>$$[;E%A=D)S04<P46)J
M0G952$)W8UI">7-(4%%D4$(R14AD065'0C5K2')!92]".4E(-5%F-$-!<TE(
M=V=Y0T5925=G:'5#24E);&=I<28C>$$[0TPT23!G:FY#4'-*14%K;$-4;TI4
M=VQK0UAK2FIW;6M#8F]*>G=N;$-F<TM%46]N0VHP2U9!<'%#;T5+;4%Q=4-S
M54LS07)Z0W=S3"8C>$$[26=S-4,Q14QA475!0S5G3'-!=DE#*T5,*U%W4T1#
M;TU1=WAC1$A536IG>6Y$34%-,E%Z>D11,$Y*9S%!1%9O3F1!,D]$86M.=W<S
M928C>$$[1&9G3T5W-'5$:VM/6D$U+T1P<T]T9S=31'4T4$-1.&Q$,$506&<Y
M-D0U65!S=R]01"MW44-206U%14U165)"*T5*<U%U4D1815!54B8C>$$[17A%
M>$55.%)B4D=-16%O4GE22&]%9V-32FA*1D5M45-H0DMJ17--4S1X341%>4U4
M47A.:D4T351P0E!&12M554)H46Y&16M586A33"8C>$$[1DLP57IH5'=&4DE6
M3D)65T989U9M>%<Y1F5!5T%X66U&:VM78D)A4$9R25<Q:&(V1G@P6%%29&Q&
M-&M8<FAF4T8O8UE'>&A!1T=5628C>$$[:6AI=D=.55DK:&MG1U556F%X;5)'
M8F-:,U)O14=I;V%54G S1W T87A2<G-'>%%B3WAT:D<T;V)S:'9A2$%)8TMH
M>%-(2'-C;WAZ328C>$$[2%!59$AH,4A(6$%D;5(S1$AE=V5&:#5!2&UO96Q"
M-BM(=6MF17@X*T@R:V9L0BLO2"MO9T930D))1W=G;4-$14E006A(0T9)25A5
M:"8C>$$[;U-(3TEF<VE*>4I626]):7)Y3&1)=V]J3T-.;4DU46IW:5!W2D(X
M:U134CA*2W-K,FE52DI49VQA0U=82F-C;#EY66Y*;&-M:'EA,R8C>$$[2G5G
M;D=#9$I*,V]N<7EF8TM!,&]0>6AX2TM);S%#:T=+5&=P87EM9$MD07%!:6\Q
M2VUG<6UY<E!+=TER3FET<$LU,'(P4W=&3$1K<R8C>$$[8FEY:4Q.8W1$0S%"
M3%A9='%Y,VA,:%EU5$,V0TQR8W4W:3AK3#%O=FM3+TA,+S1W3E1"<TU+47<R
M>D53355O>&=J1S9-9DEY2VI*:B8C>$$[37!S>3%$34Y-,%EZ9GI/-$TO13!+
M>E)L3DHT,#)$551.53 Q:'I80TYF,#).>EIY3G$T,C948VM.,D$S;D1F6$]"
M43151&E-3TUG-28C>$$[0E1L0T]8.#5V1&XU3VI9-F1$<7E/=3@W3%1T<D\V
M;S<V1'=N4$=5.'!$>FI04TDY650R:%!E02M)1#5G4'%!*S1$.&A0,D4O;VHO
M:28C>$$[44-.05I%0VU13V1"2U5&<5%A>$(W:TEW46Y*0W153#-1>G!$9E50
M05)!3D52,%-+4DTU1D5K5E926G!&,VM9:5)M9$=Q,&)W4GI62"8C>$$[93!F
M05-!5DE3,&E24TYD2DA5;&I386Q*.$5O,U-N,4MX17--4S%.3&UK=FE40W!-
M8VMY-E112DY3:S)45&1X3TI5-754<F10044Y2B8C>$$[5#5.4#-606Y52$91
M=3%%1U560E)M,4AM56I&4V9&3$A5>$Y46#%/<54O6E51;%-05DYT5DM&5C%6
M8TI71#%:8U9Q;%<Y,61%5C5*6"8C>$$[-$9G=E=(,5EY,6MA5U=L6G5&;TA7
M;%IA<&QR,5<P5F)L5G9L6$168VAL>E=84V1D948S2EAH<&5B1C8Y6'<Y9EE6
M*WI9059G5C)#<28C>$$[65!X:%0R1VE99E9I4U=+8UEV0FI1,D]862MT:U%'
M4U5:3VQL4%=74UIE9&U05V%36G5H;E!7951:*VQO4#)I5V%/>'!1,FUA869&
M<28C>$$[4T=Q9F%V9')4,G5N82\Y<U8R>79B46AT64<R-6)H2G5A,C=%8G@U
M=F5'+U)C0W1W:&Y$9V-4<'AL6$AW8VMT>7!N34)C,3%Z=4A1528C>$$[9$A"
M,'I(56]D658Q-%A9*V1P=#(K2&179#=.-$58:'5E37@U2VYM2F5E9#92;G%L
M97=2-UDS=D-F0T8X9UAZ:&951CEO6#1"9FU**R8C>$$[=VXX:F8T4B\U64)(
M9TMI0D-O1G)G8S)#34E+4V=V4T16-$\V:$(R16=)5&IH565&<3193VAN2T<Q
M-&,W:#4K24)):'!I339*331M6B8C>$$[:68V2UI)<DMI>D-,;&]V.&I'3TUY
M;S!X:EII3B\T-6UJ<S903F\K96M!85%B<$17:U0K4G%*25)K;G%3-#5.3FLW
M855)2E-+;%!35B8C>$$[6#582FQJ4U=N-6-+;#-76#1*:$UM3&E:2DIM46UF
M>6%A2G)6;3!+8G(U=V-N26UC.34Q:VYD2V512C9U;G@R9FDU+S9O1VUG,DM&
M2"8C>$$[;V)A:4IQ2U=O=V%J9'%0;7!&86MX-E4T<&%M;4=Q84QP=C)N8G%F
M9W%&2V]X2VLS<6%M<4A+<5!Q=TMR9&%V<')&>7,P2S%%<F)I=28C>$$[3&$V
M:')X879I-T%!<TA7=S9R1F=S9&%Y4S=,0W-Z:7IR<E%L=$IY,44W5TMT9T<R
M96)B=W0R:3,T3&A:=4Y'-5-R;D-U:G4V=&)S=28C>$$[=39E.$EB>6)V4E<Y
M:C<T2W9O4RLO-SDV=B]806--1'-W5V9"-#A*9G=T=D1735!5>$9(17IS5DQX
M8VI'4G-B1'@P2$AV.&<Y>4QZ2B8C>$$[3W-M-7EJ:DMT.',R>3=B34YC>3%Z
M5%A.=&,T,GIR8E!.."LT,$1N475T13@P8C=34#E,0C P5%1X=%)*,4UV5E1T
M6%(Q;%A7,DYD8R8C>$$[,2M$65I.:F\R5WI:.&1P,C)V=F)G3G=&,TER9$5.
M,E<S:'IE;W0X<#,V+V=.=4,Y-%54:'I/2E0T='9J62M0<C5(4&LO3U=%-6<S
M;28C>$$[;'5C9C4V;F]-=6DX-E5B<#!/<&(V=5AR8T]V-S=)8G1%93)C-VEJ
M=71/.4$W.'IW5U!$;#A83'@O+TM-.'AN>G O43 Y34PQ55!8928C>$$[.6TS
M,BLO94LK0FXT<5!K-"MC9C96+W)N*S-F.$(O>5DO4VXY=78U3"]T>B]B9B\O
M+RLT041K1FMB,DIL04=404%!04%!9B]B04E1028C>$$[0F=114)!545"9U5&
M0F=K1T)164I#=V='0F=G3$1!;TM#=V]+1$)!341!=TU$07=11$$T4$5!.$]$
M0DU41D)15$5X=V)'>'-C2'@X9B8C>$$[2'@X9DAX.&9(=T5(0G=C3D1!,%E%
M0D%91VA54D92;V9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G061!
M14%!=T5204%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%1
M1B8C>$$[07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!05%!
M0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0B8C>$$[06=-
M4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!"571(:$UX6FDX0U)Y
M9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD528C>$$[6DA41#!U24E*;TU*
M0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%,4]4,%I85T9L85<Q>&18;#E76C)H
M<&%M='-B5S5V63-2,61N9#1E6"8C>$$[<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO*T-K-5-6;'!E66U:<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!
M24-!44E$0E%5128C>$$[0E%914-!341B445!06A%1$)#15--545&55).:$EG
M6GAG6D5Y;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-0
M4R8C>$$[3F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P,"M0
M>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1R8C>$$[,75B
M,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T1L2E=7;#5I6FUP
M=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O828C>$$[04%W1$%104-%44U2
M040X06I(-6<O;40U.'104&YM3S%T9DUE<'=7,$=P,VMC145D-4]I26E4=496
M5D1G04%#9T%Z85%H2&A'=S5$;R8C>$$[-&MP1WIU:T@O2WDO>D8O-FUJ5G8K
M:S(T+W=#83AL=U(W:#AM4$5E.5A4.'E0>D1.;$LO*THY5C5#4TU!+UAB:71#
M<C$O8CES2$)(=28C>$$[2'E8:5!E;V8X<DPO041&+S9M:E9V*VLR-"\U<G<X
M164T9DIE23DW=BM6;"]M3"\Q3D=R9CE*='@O=T$Q-#A%931F2F5).3=V*U9L
M+R8C>$$[;4PO,4Y'<F8Y2G1X+W=!,30X164T9DIE23DW=BM6;"]M3"\Q3D=R
M9CE*='@O=T$Q-#A%931F2F5).3=V*U9L+VU,+S%.1W)F.4IT>"8C>$$[+W=!
M,30X164T9DIE23DV=$0K678U:U1*=VDX>39V2DTX:4I':3-L>7I%='E!5E%(
M<5-4:G=2-V@X;#1J,W%K,VYF.$%.:4151'!S*R8C>$$[=38U1G%)8U)'>64U
M=3%N.5)I044Y371Z-4=U=W!G-%DQ9$0W13)F3D1,*UI(-6M-1TLK6G1825%6
M8VDY=5115D%Q9FHX4T)J=U(W:"8C>$$[.&MC4C<R=BM6;"]M3"\Q3D=R9CE*
M='@O>EAH-$DY=RM3.%(W,5-$.'EF>D5,:TAZ4'%P2$)Z+W9B8V1K2B]N>#1)
M.7<K4SA2-S%0+R8C>$$[04I76"M9=B]!1DY'<F8X05-B8V8X,30X164T9DIE
M23DW=CA!;%IF-6DO.$%5,&%T+W="2G1X+WI8:G=2-V@X;#1J,W4O=T-6;"]M
M3"8C>$$[+W="5%)Q,R]!16TS2"].95!"2'5(>5AI4&4W+T%*5U@K678O049.
M1W)F.$%38F-F.#$T.$5E-&9*94DY-W8X06Q:9C5I+SA!53!A="8C>$$[+W="
M2G1X+WI8:G=2-V@X;#1J,W4O=T-6;"]M3"]W0E12<3,O045M,T@O3F500DAU
M2'E8:5!E-R]!2E=8*UEV+T%&3D=R9CA!4V)C9B8C>$$[.#$T.$5E-&9*94DY
M-U!D5#!4.#A,6DIP-TQZ4G%&-6)1=$ER;'13:W1P=C--:VMC<F5J4$UJ8T4Y
M1758*WIW4$QS,T=K5&@S1#5->28C>$$[2F0W<FIY,2]Z:U9(8W)B=S8Q<48S
M23%!>&@Q9C168VE6=4):-6M7=D-";4Y+9V1+,3)X-#AF8U!K=D1*45129BMC
M:$=M=5E$<FPX;"8C>$$[>&%P1DI*13)T>&EQ>D9W=$<K<SA0.3%-4T,R=S,W
M:D1X-"LT9DIA;"M#=C S4U!Z,#%"<G4S9SAY86LR<%=::$UL;4Y1;EDK;DYB
M<B8C>$$[9$Q*-F=K-$5E;38W3%4Q,DY#5G%M54(P2'E50UAE:"]-9&PK93-L
M,U1*.5$Q6'I&9G=W,G=J37%F<$]9>6-:<$=I4FQ8;CA13$EF<R8C>$$[,6]-
M67EG5%%!*U-K4TA6:#,O2WDO=T%X9BMP;S%B+W!.=5 K83AT-$DY=RM41&E0
M93<O;%IF-6DO=T15,&%T+S!M,T@O3F500DAU2"8C>$$[>5AI4&4W+VQ:9C5I
M+W=$53!A="\P;3-(+TYE4$)(=4AY6&E093<O;%IF-6DO=T15,&%T+S!M,T@O
M3F500DAU2'E8:5!E-R]L6F8U:28C>$$[+W=$53!A="\P;3-(+TYE4$)(=4AY
M6&E093<O;%IF-6DO=T15,&%T+S!M,T@O3F500DAU2'E8:5!E;B\U9F9M1#4X
M=2]0;FQY,75V328C>$$[97!Z,C K<#)C8SA%;#5/-D]J>F]'5FQ,:T5%1VA"
M>4TT4C14<T]2-DUO>4YJ9$E0>DPO.&U,-6\O=T,R=&4O.5)$-4M(,&HS0FI,
M;28C>$$[5TXU2D-:85)*<#AF>#9J13 Q:W,P9G)226%-4G=L<%-J2C,Y.$)V
M;V]:4$AC9FMS26UI3G1R,S<S;51/>'18;&DK1D1'131T1D<S>"8C>$$[:"MF
M2E!S;F%H,WEV,2M44#!O;E5*+WE)9&MJ=')F>D)':7)+6&YJ3G-3.')C4%-!
M16IT4TYF:G)T>39B-$(T;FMP-%=$86UD34XY328C>$$[9$U76DQ!;7-#6$Q)
M.'=79S)D:T-+>$(W:%)8=T=7:2MR06]B0W)S5E1$4E5U,W9B5DQ.,6IU,G4W
M8U<X:F)Q<VA9.$=/>F)"=EDT1"8C>$$[>55C,W)32"]!2GE%<TIO23=,5TET
M470O6%IT4#%!,U9H3$902BLK479#.316:V%V-S-Q3BMV.$%+8W@O,UHV3G9Q
M554P3#@K.6%S3B8C>$$[43!/5C0T-V$U04XU84U,3TY*;%ER>6M%<U-C4'17
M+WA.>G%31S9N;&IX67AU=%-/>D-T8B]+:GIX;S%P8UAT-UI2:7AT,FU2<FQB
M:28C>$$[1&DU=#-+4V-%3')),4-P-DI79THV8C5B2$Q%<T1!:&ET=%0Q5%56
M2$(V9V)F<TA,1TQ82S(O,S(O=T1W62\U<'A61UA7:U@Y;DES9"8C>$$[,W!T
M,V)Y4$-,<%5L5FM*9V(W36]$4FHT1#)B<&="0S!6<U=M,U5S159X1EE856M%
M.&]T-%I60EI(;5!32E=#55IZ+TM..&)#,%9N,28C>$$[4B]2968V<% V35I)
M:VPO6E5G:%-#,T-G;UA59E--8D,P<W0P='!R:4M,:38K;S9P>35G,#5';CAU
M1E90;&)F-S=F.$$T368X,#1Q:B8C>$$[8E12-RLX=$QI.71.3G4W:7IT0E<V
M=5EL6C1O:%%T*SAD67EQ+T-P3S5W1U%7:7!U='DW4TLX3GEZ8T9M;$1-4V5!
M5W%U,54K>49B628C>$$[*T=/>3=T,T@Q=7AU<%ER:4LV=&)V:G=M4U)Z2$IW
M9%!S<T-O86I)96@V:DA9<G5O>$Y#95-!4TMR2U-W1&EH-&=S2R]$-UE685=E
M3B8C>$$[4E)22V\U0G%#440T:#!0,F5O>%9.3'%0>DAD86)A6%8Q0G%5*VU0
M5T=X;FQA5C1$>&9I56E::TMB3V%56'9K4G<R;F1",C)M6$XQ3R8C>$$[<T5&
M;$\X<E-I04M$4VMH<65"2E-G3D9*,SA-2DE24E5B=3,K<#-5,7!D5SAS3GIB
M=3!5.$QS07E325-R2W<T-T5%57=G<71!=&I%>B8C>$$[.$@K1FQ7;DUD=U0O
M04,K,DMQ=&A9>F%J9'@R96XR5GAE6&MX26ET<F5S<VIK07-E2TEH63=#=3)!
M:T)12%,R57-226QS-VE-:'A'428C>$$[,59O-491;39F87!V5$=W=$MS=6M8
M:U=N='%%=&Q02%IP4#A!5EAM6F=!<SE#,W!K1F%G,%)V=5!G8V5)8VQO<'8K
M5W)7+SA!>7-4>28C>$$[>%)(0B]3=&Q1;&=F*U!H4#AK64HO4V9C57@U:$YF
M4"]!2F)L=79Z0CAX3DA,5C5T5G9/15E1<U-7=4AO0E$W-69I,#5-06(V1#=M
M=28C>$$[955C4DAM>#<O1$0O05!,45 K02]T>3,X<DQV665-1U1E4V9Y:S%N
M>F,Y,W K;5AT=D9.0TDW:#)U96%,>%AK;$)W5U$Q<2]H;5!Q228C>$$[*T5!
M4S(T:GAM9WER+V]61'HS+S%D3DPO04]$=5 K<4]9;C5Q4&TS94-89CE#;V5E
M+W=$<39A6"]!34AC9CE58V9Z569.9D),=BMH528C>$$[4%!F+T%&9$Y,+S1/
M-"\V;S0O;6\K82M#6&8X05%Q2&YV+W$V85@O=V1X+S%2>"].4C@Q.$5U+S9&
M43@Y+W=$5C P=B]!24\T+W=#<28C>$$[3U U<5!M=F=L,R]1<2]N:&8S0C%4
M5$]C;C=W2&YC56]M>"\S5"]L:D0K6FI85DAG;#,O47%(;G8O<39A6"]W9'@O
M,5)W9FUO*V%F0B8C>$$[3&$O.#1Q969K-4)D5S!X95$T=%-3-492,6]F,T]0
M-7%0;79G;'(O;U9$>C,O=T)85%,O*T1U4"MQ3U U<5!M=F=L,R]!14MV-31G
M*R8C>$$[3G15,'=G+W4Y;G5/<VYW1"]D4&DR16%M4&UG-%,W+V]61'HS+W="
M6%13+RM$=5 K<4]$.#%(>E0T2EI:869L3BMF='!&3$1"-7AT128C>$$[:FQI
M.4%Q<S%W=D9/0V]O47)!0W9"67AW<#EN96XR;7)78W50=5IC12LY5F@O3$0O
M04IY0FAH:FAI.#(V8W-C56%1<4]"2DUA2T565R8C>$$[2G1A=G-O*S%8>#8T
M*TIJ-VHK4&EV0E!V45=S9FMP*V1'<V%82G!M;RM99$IM=$I74C560TUH67A)
M:4I6:W1L4'=R16\K:D--,DU'=R8C>$$[1"M0:7!X>4Q(62\K8U=F3SER270P
M*W V67E115-S1F4T<5%H-4=L669B3$)Q66YV66Y#5G8O47%(;G8O04MU;6PO
M.$%",T@O0492=R8C>$$[9FUO*V$K0U4T,% X9U!Z:#!'2F]T2#AY,DYL1SAG
M;&M32U-C0FY#1D9:=C-'+T5-94YE:#-'*RM2;&YG95E+4FIK13-M+TMJ.#EP
M<B8C>$$[3C=*=DUU;$QA>5=R,E1X;VI*5T=25E(Q3$QB0G0Q:EAV:V9&>#EX
M+TAX5'=363-Q;B]/378U:C9P9"]7-WI6=$EA8C T-&@V4WE1<28C>$$[16AJ
M5TM.46M6=6E$:6E!9$UM3E1!9#9$:6MH4"MH5B]014AX='%M;45(.3-S.7@Q
M:RM!9C=P.%=Y43%-9DYI8TID+S!+:#4W+W=#<B8C>$$[<'!F+T%!9'@O=T)5
M8T@U<5!M;G=3>4Q2=GE3+T]V4F],93)S4$TR;E(R9'%P4T<P67EY43A7:TUR
M9WAV8G-P-4]A=%5B,%@K5F%13R8C>$$[8D=E:%I$2$E)-B\O04-Q+U!454)%
M;#DU:#!E-&=H=59V571M:4EH.5I73$%T171S168T:E@T9V8Q-$)L>&IO9G@X
M5C1*355V4"MC5R8C>$$[+W=!=V)Y-VYU-3E7,'1P-VE2<%I7-3-'-W5X6FHO
M8RM*>7=A;5!M>#A+4VPO=T)#<BME1B]C2%9.335Y9G9!961X4VEB2"]D4"M7
M328C>$$[4#5M3F1594-56'!8+T]-,S5M851F2F8V8G)U;E=L-T5R<D9C4E-8
M0W5N<4E9,DMT-DY68FDU;W<S2%5B-44V;4(U9W!'2U%:5&$O;"8C>$$[;BMF
M,71!:TU8;6I387AS<DI+,%%E46-&-$MO9')5=%)63D(T1%EB6D$U369C9G@X
M5V9$3DDY5R\U>#@O3F)664QM1RLQ=E-:574W=B8C>$$[-CEC="LY1'9/1EI&
M6G!0435N:7)S04-E*U-'94$V1FEC8VEP959V*V-A+T]/:&5A3D<Q;38Q2%1P
M3&94-RLQ=4I9-&YN3'-S8S9-428C>$$[=DM*4E@U;D-D4D5G:F9K541%455R
M=E9G8C@S8F]4=DI(2"MN6F%T0VI34U8K='1X-'%J235Q,5!S;FPT5D\R8F5.
M*T%++VUF;V-)+R8C>$$[,VXK8WE06#5.3V91+T]66&%A5F)Q,F$P=DHT9W,P
M:5-R2'E0<51*-G17-$M3;UID:EAP=&U0:4(T;V4T=',V<5-H*U(K<7!P3C$U
M:"8C>$$[,4HT,FU7,# O=T)5>$HY<'5-:3=#9U V<V4P>&-9:GI84T=I9F,Y
M3G10>G8X:GIF5D9L939G;75U6#=S,C!Z.%=33DA91&=R1C9.228C>$$[27AW
M0DIB=#-Z5&Y$2GIV14--,&XX,U!*,G%A;&5A8D)*3VPW6G1W84M71FPU=55M
M;$%1-VIE2S-:-G1154DS<G1G3TM11G%*:$%**R8C>$$[95AK-5E1.35B-FIP
M.#-!4W9A,TYQ4D]S8D=0:35J:F%1,%!R<61Q;6TO5$IE0DIF14-,:R]/9CAV
M:SE&:F4S0FEM8590549L9552;R8C>$$[47!:6%5W.#$R8V9S,'=E1$IF14,P
M+VY8*UA0;S-$:E5N371S4#,Q=6)E9$I!>%9N-"]':7)7:4@Y<CE9>#A'4RM)
M1U583W R<V1U=28C>$$[<4%T2F%*6GI844MJ-&UJ05(Y9S-(8W(T-4%$;WET
M:71T*V(K9UA5>6E','5Z17)R2$PX0WE45FLT:&92=#1';6QM6E,T.5-.4GIJ
M,R8C>$$[-4Q515I--&EX-'=S6#@U9DQI-G1E-F)C,C@X371L2VE.34AT>D55
M:VQI:%9Y>&Q1<E%Z1&Y58E4T,4Q&47HT2G$Q-'=Z-TMM858K828C>$$[3"M0
M5'9,.3EQ16ES.&1N16)H,6I01GES4D1K2S-9-V)(3$U-94M12&5X;6%&=FXR
M>C@X*U=,5TPP;W O36-55DA$43(R;TIA>$5U-B8C>$$[>6-U14-2,&%Q9F%'
M-7$Q83%Z8DAS*V9F2#5/1BM:2&UH-&9.,VQ.3%E7.#!M=EAQ3$%B6D1E6%5&
M=U%J4VE6='!),EAF9V<V52M%1R8C>$$[;&-F>44K*TLO;5DK8F-V;DQ16G(R
M4SAF52].56,U9&IB;415;%%1>$YX-5%O2%=4-%=A3E=B=%5#9T$R>"]K*U@Y
M2#5,*UI(;7%T-28C>$$[,SAR;397-E=B>D9(9%)X96EL-&PY1CEA2SAM8TQ*
M8TUJ4U-)<&%O4GE6,C-">"]K*V9F2#5,*UI(;6<O.%<V1E!:=TIF6$=S>E@Q
M=28C>$$[2E97*VEU0D9-5FMM:VLT;58R;6Y#.$IV5&5K;GA!06YF1"M1;&9-
M22]-:GIA<W9.96HR-WIQ3E<X>E(R-V-40W1R9G)"3%=H.59P<"8C>$$[4&I%
M<&1I4W!#<GA(:69I>$]G;"]2*U,O;5(U;S=1=D\S;%!31U%X4RM:2DEL46\Y
M<614.4M":7EL6&-P0TEZ>F)L.7)L54=H1DM$0B8C>$$[3',K6C9X*U-2<5EJ
M=E@V=C4U.&XV:&1W,V-F*TER0V4S4DEO-7)B53)-=D=0,7%6;&XY85)J+W!5
M9S5->$E";T--03=0;4]S9FMP,28C>$$[364T<S X9S9";W9N1%,Y6G999%0Q
M<VDW4F1-=5DY5'4Q=D9-84UK-$MQ-E5"1E=65S9R>6)J46UU665P9V-204YD
M*WIF:6M*9VQ0-R8C>$$[1#AP9$@P;3=S<GE+.&UM3FY08D]I4U)W5EEX>5!X
M-4]S870Y<6-T54=P-SDX;SA5;',T2V5G-5,R3WA6,DMU>%929B]!2'1I+W=#
M328C>$$[56XO16\X;#!2,59S:6PR2W5X5E)V4#=P9BM-<U@O2GAC;$9"9DU%
M,S%V.$$U6$)D=F%+1VUI,74T;$A+;$973S5:,UEL9S1(1E9,5B8C>$$[;V%D
M8S9)5BM81B]Z4CEZ<7HO969&:S)O6$5R*U@O3S%X8U=-1C%"3DY$*RM-<D8T
M-6U49UI);45B0BM%<V9X0E@V-T5L9#AX-&HQ=R8C>$$[04Y.<$\P=&M"*U-C
M5V]Y,TAM0U!44U)E3EEQ22M,0D=).5IE459M,E9I=%%P4%$T93 V-%DS,V\P
M;DUV54QB5&9Z;G,W24ET.6]D-R8C>$$[95-"5$YC5%)Z47%':6E24E)952M,
M,5A5;#).3TYF:%=L04Y/5$1Z8S9P2V5N=V9N=6EV2F,S2&PK4C)A24I"24QK
M0DEL-2MQ4UDP5R8C>$$[<VIF0E1F:C$R=VYW+TY2>$M(;7I29GI4965(5TY+
M:3!M-S%3,W1&<WI(-EE5<S!K-&5794UZ:&EO5D964D4P=$XR3E-A67=-3U)T
M0B8C>$$[16MZ94@X-&UJ56-V3#-R0T%G5#AB=TUS-V5P=7%K=4])+V0Y.2]I
M.6AG.4AM;C%E4TLX=3)N-6=F<$=&9DTX;&QC5V%7:GAY3EIL*R8C>$$[36LU
M*W)%3DEK:7)U2%=E;D5!8U-T9#A%:D=T:VDK<69A9VPP=UI,2C%I=3)T<#%T
M<$<K>7-H-$)#9&TR1%4W6D5C:VQ*=$4P6'IL1B8C>$$[<59T9&%Z<E%U-$E9
M-6\U3%-/3S-#37=+2F)Y.&AB<$M(9$$W>6A80VAY1E5C4G5:1TYB0D%"6DUQ
M<711;T%Q4U148F,W:S5":S-I<28C>$$[4BME3$\U=F9+1W(R9'%H;'5B;3%K
M:&=J1D%795%C5EAE9S-*>3=4>4%Y06YL8EAL1GA)9D]8+TMO+WI'+W=#<DQ,
M+WE-:"\U<GIF+R8C>$$[04HW1B]/9&(K6&XS3R\U5D@K63,O5FQL+W=#4FM0
M.$%Z6&HK97AF>FPO3'HW;F8X<6HO36(O<7EY+SA!27E(+T%*<G@O4%EV-7DO
M;"8C>$$[-3EZ=BM64B]M3B\Q6EIF*U)K4"]!1%AJ*V5X9GIL+TQZ-VQR+VQ,
M*UEI27IT;S!G5E%3>#E32%E$9CA!;G<O;F-8.#5F>3@K-60O>28C>$$[<5 X
M04UB+W%Y>2\X:DEF*V$X2#4W1B]/6#AV4'5D+WEQ4#A!36(O<7EY+SAJ268K
M83AF>C),*V-V-65F8S<O;%5F-6IF.5=76"]K6B8C>$$[1"]Z6&HK97AF>FPO
M3'HW;G-N-4IE5V1C.'8V0F97,G-7:E=K.'0S-FMA37ET5E!44F$O05<W:DY4
M,FAM:D]1351E>FTV84)I1&)0-R8C>$$[>BLV6"]J3$8O=T%N1GI#:35"5G-I
M;#)+=7A6,DMQ3"]!3SES6"]'2U0O:55E4S9)-G$R4E,W1EA9<6\S;CDP=B]'
M5TPO:S1U4VEG=B8C>$$[:S=Z9&-Y,G9N=EAB:3)N;'0W:$Y3=D]-<U)+<W1:
M,T)O=UE(;V,V8D%,>%)"+VUH,4]1,4TK.4LU.5@Q1V5.-' Y475P67!'3'E)
M-R8C>$$[<WES>F-A:V=V=51W6#=H;&]G0GE!64=2-S-P;B]/4$IC95ED53E!
M0GHY54A)3V5(*S=&-E5$-7)U,5!O2'9C<E-F55AV4$\Y+W=".28C>$$[4F8X
M04EX=BMQ96%86GHY,V,W,R]!2#%&+W=!:D<O-G T-TQU-VYE+S<V:2\U1TXO
M,51X,EAD,T\Y+S,Q1B]Y36(O<6YJ<W4W=60W+R8C>$$[04PV:2]W0U)J9CA!
M5E!(6F0Q0C-V9G)S6#=Q4"LW:R\S63,X>68U1TAA:V(R<C@W,R]F55@O27AV
M*W%E1%I/-W5D-R]!3#9I+W=#4B8C>$$[:F8X05902%ID,V,W,R]F55@O27AV
M*W%E3WDW<48T.3<V4R]U;R\W>4PO9&IF-SA8+TEW>'!"=%@U,W8K*V]V*U)J
M9CE5.$=Y9#-C-R8C>$$[,R]F55@O27AV*W%E3WDW=34S=BLK;W8K4FIF.54X
M9&PS9'IV9CDY4F8X:D<O=T-Q94]Y-W%&.#DW.5-U4#-59CDR+RLW1R]L4"M2
M:"8C>$$[:E9O3C!R.#<S+V956"])>'8K<65$6D\W=60W+T%,-FDO=T-2:F8X
M05902%ID,V,W,R]F55@O27AV*W%E3WDW=34S=BLK;W8K4FIF.28C>$$[53AD
M;#-53'@W,S!L+V12+S-K6"LW1R\S-'8X06M963!G,G(X-S,O9E58+TEX=CA!
M<6YG,E1U-VYE+S<V:2\U1TXO,51X,EAD,T\Y+R8C>$$[,S%&+WE-8B]!2W T
M-TQU-VYE+S<V:2\U1TXO,51X,EAD460W,S8W1BLV:B]!3'54+V1J9GI*+VM9
M9'%2=F%V>G9F.$%F55@O04--8B8C>$$[+W%N9S)4=3=N92\W-FDO-4=.+S%4
M>#)89#-/.2]W0CE29CA!27AV*W%E3WDW<4XP,3,V86-O-'=V<7A626M9;6YQ
M<C(T1$-+46)F2B8C>$$[=FYN+T%*5%AZ0B\R,')Z+T%*4'9N5#9F*S=J+T%&
M4CEZ<6-V,4@S<$IL>E<Y3R])-BMU<D<W,2LX=$Q:<G4T:'-!,&1U=%-74'%R
M,B8C>$$[54UX<#%O0EAW>E=D<&DT>#DW;#94;5AQ,6HK660O37I7<VYL=E90
M<F%0-F%84S)S<3)--')66EDU4T=D5F%-8W9J4550=S%R46Y4;B8C>$$[2#5H
M>G5,>6%I+TU05W)R46)85G)(>6IQ8VAK=E!Q,7IA5$))6FQT,&IE4U<V:54X
M;6M596YX4E=#1C))03=69D1&,6$X5S-*6DPK6B8C>$$[=#5',7I'9DM/=&UA
M,VXY2&=)66ER2TA20S-Q:50P<6MS94LX.7=+,6]W3U!H*UE8:CAK3'%V-7,V
M;EI,24EF2D=V,T5O-4-+25<V,28C>$$[6FQ61"]U='!F:$)C9W-V3'!58VA7
M:$=)2'%&32]*3C0O=T%W4R\Q."]W0T=D9%9,1TM76&LQ:T(V-6AK-&5N079Q
M8VYE4VY*3F=#=B8C>$$[8V1-:C1F;44X6&MI=$XX=V%J9F%F3'%K=6HS1FQ,
M16PU.54P*S0R=4IK:%I21WA245-H;#0W3'8Y3TII0G1F8W1P2F(O;4(U;VUN
M428C>$$[2'ER9'A$;7%F5FE*4%=M-6-E46IE6DQE0D=H-45U6D@T3E$X2$]X
M=RM'3SE(164U5F8X04U,6&MV-4QF+T,Q-EE);4MV8VE/-TEO3"8C>$$[,S9V
M5E%,6#0O=T)Z*RLK16YW1E8U4T(X360V.%(W;6-:57I39GIJ<44K;2M6.50Q
M1S,T;31S;TAU25$T<79/3#0Q<4)486]Y,T)%4R8C>$$[;4%E<D1)86E3.$HO
M-D=!.#DO-S=S9CA!:U,O+T%&57ID9GE::3@S02].>CAN9CA!47=(;G8O9F1J
M+WE*9B]Q<&HO2FU,>E@X,U!Y9"8C>$$[+W="1$%E92\Y.3)0+TEL+RMQ;5 X
M;5EV3F9Z8R]*,R]!14U"-3<O,S-9+SAI6"\V<5DO>5II.#$O3GHX;&MV-2ME
M95I);FIA3WDT=28C>$$[<%4P:&5T0TMF-SAW:G,S2#5R*V)N-4PO05!O641Z
M,R]!3#=S9BM23"]W1%940B]*;4QZ6#@S4'ED+S!-0C4W+T%..3)0+TEL+W=$
M<28C>$$[<&HO2FU,>E@X,U!Y9"\P34(U-R]!3CDR4"]);"]W1'%P:B]*;4QZ
M6#@S4'ED+S!-0C4W+T%..3)0+TEL+W=$<7!J+TIM3'I8.#-0>28C>$$[5U-F
M;C4U-6M52S!D;%%-<F)1=C%69W<O,UHT:D-/>F-F;78U=69K=B]W0VAG4%!F
M*RLW2"]K4R\O5E1"+TIM3'I8.#-0>60O,$U"-28C>$$[-R\S,UDO.$%);"\K
M<6U0.&U9=DYF>F,O2C8W*U9F;7I64$Y(;&@Y5#%-4DQC3&-Y46=1<558:6EQ
M4G-3,B]X6G$Y6FAJ:FY1-VY-=R8C>$$[6D1/3FQM3UEJ8V]V+W9B1B]W05EP
M4#A!:55E4S9)-G$R4E,W1EA9<6\S;CDP=CA!>&QI+S5/3&MO;TPU2#@X+SAP
M<C5G+S=A5C4O>28C>$$[9F9/;S O.$%D>"]Q:C=N55IF<5!V4U1,;70V9"M2
M=&IC-FAD*UE,1S)U5%IZ6%=N*VE,<%)6-'<X9U9M5&-F149*-&YS8S%N85IQ
M328C>$$[9F4U96LU;C-056\O2FXU:'A25SA54&YH;UDW4D)$0V\P-D-1=D5R
M<E%Z=$LW;#5$1VY%=4]/-7(T,3 O2$AU8S=H4&5Q5UAK-WHY8B8C>$$[5W%W
M2'HQ4$M9>6=I85-W=$A)4D%2=V1N1'E0>7%/5$TO23 K,5=T57IJ,TQW;G98
M>BM69E P<SEP23-N3GA&0DEJ6$5%5FIB>$Q+<R8C>$$[8CAT,B]E34-Y-T]+
M.%<W0F$T3TM08W1(=E%49FPY-75J;G9*.4XX,4YP<EA):U5P2&)M6E1Z95(O
M5EE44W-O;5!.1DQH9&=G<#%/2"8C>$$[>$(Q0SA*-S(W3'E8*UI-54)I=5!/
M-WEQ2FQK6&I:>$-1<7))94QY<U<R;VAQ06]"<69O5$]08W9#93EM1W!7-S-)
M93)347A04&)4>"8C>$$[<DM/<6PK0VAT:4]L8V=/5$ES53!V>5HU>G1P3$]/
M6'I(-E=M,EA*0EDR.$5A<DUJ46AE8W)&43-0,5=D<4$P-D553S)4330Y>D52
M4"8C>$$[96AO4$EF-6=71G!);6ME8GA:.&Q0<#)*<S1P8F1:4%$Y24UR>D=7
M6F%Y05-S2VMC<2]$=F@T-&YM1C14,W,W,"M'-F=S3&%'-W50<B8C>$$[9#%&
M16E81C)55U Q6D950C5/0R]#=DYT*TDR1U9&;45"-7,P,3E5.'5A:'!K8FE.
M-S9%,GE33G5&33-W06UN:'EY>D10:&U$,TU-:R8C>$$[8FE1.&(O-D9X,78O
M04MV1G0O>4QK>F)F>7)(*V%80R]*;G9D+W="0S0V,R]!3EAI,B\U1GE9+WER
M2"MA5B]*;G9D+S!,:G)F+U8T="8C>$$[=BM28VU0.$%+<V8U<%@X;64Y,R]!
M14QJ<F8X03%E3&(O:UA*:B]+<V8U<%@X;64Y6DXO>FIR<E553'EN5C=9:$9,
M165N2C)&8U(R<"8C>$$[13E#<#!:-S$O=T0P3&IR9B]6-'1V*U)C;5 X04MS
M9C5P6#AM93DS+T%%3&IR9CA!,65,8B]K6$IJ+TMS9C5P6#AM93DS+U%U3W0O
M.28C>$$[6&DR+S5&>5DO=T%Q>"]M;&9Y6C<S9CA!475/="]W1%8T='8K4F-M
M4#AQ>"]M;&9Y6C<Q:W8O3T]U=%)Q1T]R,GAQ>7(O9'EF=$U&+R8C>$$[:FE/
M,4DY>%@X;64Y9B\P3&IR9B]!1F5,8B]K6$IJ+TMS9C5P6#AM93DS+U%U3W0O
M.5AI,B]W0U)C;5 X<7@O;6QF>5HW,W%(-6(K5"8C>$$[<FYY;#5E8E,W:313
M-6MA-&5F,4EW5D9(5E)3:"]W0EA.8G$X-'EZ-&=+,F-V1&HT23!Y<DU:=%58
M+S-T:2\T>%-F.$%%;SAL,%(Q5B8C>$$[<VEL,DMU>%92=E W<&8X06I,1B]Y
M8UA*4E%8>6@U;G-Z92]M3G$Q;4<T1S4Q:31H1#A3+T@Q3'!L<GA7<DY3=E%:
M,#)'5EEG939)*R8C>$$[-3%->&-Y4$Y#,S-L3R]T27(R67HR.#!&:3135C0U
M0T=B;49+37-59U-8:7=F-%=+54\K4VIM0F]B-V]/36AN+T%0>FIU2FHU9S%8
M,"8C>$$[;594.557<%I3,RLW0C1&8W=E,5!O2'9C:E(O55AV6$,Y+S,W1B]Y
M3&(O<7!M;#)C+V0S0SDO,S=&+WE,8B]Q<&IS=3=U1C<O04PY:28C>$$[+W=#
M4F)F.$%65$A:9#-C3#,O9G-8+TET=BMQ;4]Y-W4T6'8K+UEV*U)B9CE6361L
M,U5(4SDK=7AF=EDO-W54+T%(5S,X>68U94AA:R8C>$$[8C)R.$PS+V9S6"])
M='8X07%P9S)4=3=H92\W.6DO-49T+S%5>#)89#-#.2\S-T8O>4QB+T%+<5DW
M3'5O6&E8=G!,*SEJ+W9)=CDQ="8C>$$[+W9X9CAV1$=K1S%F:&4O-SEI+S5&
M="\Q57=B2C-D=W9F.2MX9CAI,B]W0W%M3WDW=318=BLO678K4F)F.59-9&PS
M9'=V9CA!9G-8+R8C>$$[04-,8B]Q<&IS=39H9DIE+U5R:CDW2"]D=B]U='8U
M5"]!2F5'3E=G,U-V=W9F.2MX9CAI,B]W0W%M1%I/-W5&-R]V,DPO:U<S+U94
M2"8C>$$[6F0S8TPS+V9S6"])='8X07%P:G-U-W5&-R]V,DPO:U<S+U942%ID
M,4,X4SDY2F8S<V8X06529C=R8B]F:2\U94=.24YQ+T,Y+W="*R8C>$$[>&8X
M04ET=BMQ;41:3S=U1C<O=C),+VM7,R]65$A:9#-C3#,O04@W1B]W06DR+S9Q
M63=,=3=H92\W.6DO-49T+S%5>#)89%%D3#,V-R8C>$$[1BLY:B]U-5 Y,70O
M36XK6&@R<$<Y<2]#.2\S-T8O>4QB+W%P9S)4=3=H92\W.6DO-49T+S%5>#)8
M9#-#.2\S-T8O>4QB+W%P:G-U-B8C>$$[:F1,9"MM;DM337(V<U9123)"<#9Q
M.2M:=VEK1S-Z2F1U-F9M.6-L4%,U3G(P<69V,59O>'IU>7!,8V<Q0G8Q<%5D
M4G9N4E)(-V=F,28C>$$[4#!/<U Y-2]N36LQ-3<O.4(K9&9R5G)&2S5U<E5V
M4$%P9%DS0TE'-49O;T](2W$Q;W%(;%55<'1M4&IR:6A2-D9S;F13468U2S-/
M<28C>$$[,C!V;4\T,&Q92#%+3%1U5G%,<'5-2$U33%%Y='E3:41V.%=085E(
M1$<K.61*>E!U97%2*UDO>E-A0V15.'0R3C S1&IA,SEV9D0P6"8C>$$[:SE(
M:W-O:6M63U544V1+4VAQ141X3V%F:&@S=61:-VTU4$Y(-7$O5VQ%9FMU1#9U
M=W%&9E4T>$I8:DAS>DQ'-DQX6FXX83 R.3-H:"8C>$$[,R]9='DW;6XX>B]M
M06%4439%;'AD=S(V;5A23&$W=%0O<$IL;%8P;G5N8CDP;VE72U-/:4=P3$ME
M;%$X364Y8DMV<5AM5#AY;UEY,28C>$$[=#53:&5K=$M#+U-2;6HT3S-)3'=J
M06%V055,57)55G!2:4)'4&5P2C=M4656-WI88C-1-V$V,3)X6%1D56PY47HR
M4W-R:4U#4FA'3R8C>$$[4W1)1%=-2U1V.4$V0TUG061M475T,6)5-4QM2EI*
M8E96939J=&)H;T5C,%5Y1&=61$5L9&EE=31X2$I3=WEW,3<X,')S>%A(-DYS
M,B8C>$$[:4QG46E/5TU7,&DQ551E=&-*3&1/:7 X9G!U:45S4CA583%O3$1'
M1$5'4VQP,VU,.#%,:39U6EED370W,U-F5B]W0D9M6#!"2557-28C>$$[4DI&
M0D8R<4@Y,7I:4&%L4U=89WE9=U%$2C9.;$Q9:R]N2%5*.4XX<C9N<4YV>$YX
M6E%08U%H>%9E8UAX<E5#;3%2;'5#26Q-03E71R8C>$$[43%%;#14+S!-0C4W
M+W=".3)0.$%Y2F8O04MQ6G5V-4UX96)G9FTU*U1V.$%O641Z,R]V=7@O-45V
M+S%5>"]K>D8U<BMB;C5/+W=#:"8C>$$[9U!09BLK-T@O:U,O+U942"M435AM
M=C5U9FLW+T%+1T$X.2\W-W-F*U),+SE6368U37AE82]M-2M3>5@X+U!036M4
M>'1(6F-857%A428C>$$[=E=H1E Y*UE2,F)J.#$O3GHX;"\O47=(;G8X03,S
M62\X:5@O04]Q;40K5$U8;78U=69K-R]O641Z,R]V=7@O-45V.$$Y5DUF-4UX
M928C>$$[82]M-2M4=BMH9U!09BLK-T@O:U,O=T0Q57@O:WI&-7(K8FXU3R\V
M1T$X.2\W-W-F*U),+T%05E1(*U1-6&UV-75F:W-K+U!Z>GI);R8C>$$[5F\W
M2V=:5S)H9G%R0F@O=7IX1T5D;30O3F9Z8R]*9B]!3D1!964O.3DR4"]!0TIF
M+W%P9R]K>D8U<BMB;C5/+S9'03@Y+S<W<V8X028C>$$[:U,O+T%&57@O:WI&
M-7(K8FXU4%AF>7(X,F%P-6\X<U!Q97!I2F)H8FU314-&4VDX55933FE7,RM,
M3EAR34UC8S9(8S5M1$E:>'-S>"8C>$$[>D5B;$8O.$%E,DPO04EX4V8X4VIY
M6%)(5E=Y2UA9<3=&5D<X+W5L+S1Y>&8X;D9Y555&.'4S<S%V1"MB5CE08WE1
M>%<X3W1816MR6"8C>$$[03521E5U2%EQ,W=Y5355-&<X9&EA-V1C-D])2G=!
M1"MA4'5D568W=RLY:T]Q82]:,D=J96)B9E1,>3!72%5P;&IT;U).15I41$=G
M:"8C>$$[8TI(0VAI-$UJ07)X-#=F2F=+25EZ2U5$24A:=&Q-05-R<7 O:V9P
M34]R,UAM2%1*<$AI:G9.4#E*<%EZ4C$U4T1D5#1J0C)M86I%*R8C>$$[8391
M5U0W;G!A9FLY67DX2DY1,2]73'$U:G57=4DU5G4R:4-2.&DP5G5G05ER2$8X
M3$Q2<6AX>55R5VUA:GAV24]D=TM&+SA!:VIO,28C>$$[-4Y,3RMT-G-L>$\P
M9VUM13AB<UEP6D1+.%9:635+2U=046)E,UA%6FHS0D)X;S=8=GEM,&Y7<FUE
M830Q2R]T>%!+.&I*85-,0CA-="8C>$$[5$EJ36EH;D),8F-Y869F55)Y:TI-
M3%5O4'EE,"LS5EDW9GI(<CEV0D=Z=$)"1'%$<6E&=W=$0V]:=5-H-F1A94EX
M.%DY=UAG.#)E<28C>$$[2TM"56UG<%4Y5&Q43D(V:&%P9&QR4U%L63=I,FYI
M9&PV9U!W56M6*V530C)15TU76#5:<$1D5W,Y>')M;S-%9&IY5S%T=E=:25)%
M,"8C>$$[0W<X5VI"2W4Q951C:C$U54DW-4TU4$IJ=TE5+VQ,1DA$3#E3.'EA
M>%E837EK33%R8RMH0GDK<B]!1EI8*W)20DDK4V]Q=%552EE!:R8C>$$[-"M,
M-4)E1'I:=G Y<#E4<TQA>D4P='@Y5VE32#9X8U V:S!N<'%&-7E/9G1/,4MS
M935Y<VTR65%0;7)45S%4>3=F-EES9VEA*VE.<R8C>$$[2E-/455Z14IY<'17
M;DQ,34TK1UEL,TU-:V)I43AH+S9&=79F*W(W1B]W0DDW9CA!5E1.<"]+;R]M
M+V$T9C5-.3=V.$%O5S8Y+W=#<B8C>$$[-T8O,&IT+S%5>"]L569Z9G18.&UE
M.3,O045,9&4O.$%6.6DO-E(R+S9Q62]Y<5 U=C)R*U1093<O;U<V.2\V=G-8
M+U-/,R]65$@K5B8C>$$[4B].*S%F>5HW,6LO+T]/9#=&1$I,*VY)>C9A;'%F
M5C(S;TLO-SAW:G152"M(-U9/:E!E=B]W0VAB<C,O04MV<U@O4T\S+U940B]+
M;R8C>$$[+VTO878U33DW=CA!;U<V.2]W0W(W1B\P:G0O,55X+VQ59GIF=%@X
M;64Y,R]!14QD92\X058Y:2\V4C(O-G%9+WEQ4#5V,G(K5%!E-R8C>$$[+V]7
M-CDO-G9S6"]33S,O5E1(*U92+TXK,69Y6C<Q:S,O3T]D-T=G8CE/4FUR2W8K
M.#=F='-&+S,U-S12,G%0-78R<BM44&5V+W=#:"8C>$$[8G(S+T%+=G-8+U-/
M,R]65$(O2V\O;2]A=C5-.3=V.$%O5S8Y+W=#<C=&+S!J="\Q57@O;%5F>F9T
M6#AM93DV6BM89FLR6'EJ;T1A5B8C>$$[2F1,94TP-WHK<7%'369'<6EL0U<O
M;'I8-G)0-'-U2W%C<D1J-$)42CAX;3%29CA!,W1I+S1X4V8X4VIY6%)(5E=Y
M2UA9<3=&5D<X+R8C>$$[=6PO-'EX9CAN1GE5548X:BME9BM5,3AW9CET2S@O
M-5!V;E5A9BLW:B]62#-/;WDO569E:VU83F(Q;B]N2&1'9GI"<6]74F\V5VDW
M<B8C>$$[>"\S-% U9S)A=G14-D(W,TTP9C%&-S$Y6&PO-6%:9G5J+S5O>E,S
M-4]F5'9Q.'8O04,P>2]D2"]!33!9,S5,5'9Q.'8O3%1,.3!F+R8C>$$[0412
M:F9K=$\K<GDO.'1-=C-2+S@P63,U3%1V<3AV.$%Y,'DO9$@O>E)J9FMT2T0R
M.'8Q,DPO4UI0-W54=$@O36XK4FAV8FMI=#%F-B8C>$$[=DPO>3!Y+V1(+WI2
M9W9Y5%1V<3AV+TQ43#DP9B].1TXK4S W-G9,+T%-=$UV,U(O.#!9,S5,4VAE
M5SAV<$PO<$UN.35&,FHO04XK3"8C>$$[+VM966YY45%R+U8U9BM7;5@W;R\K
M84U&*U-A9#E8;"\U85IF=6HO-6]X=GE7;F96-68X06QP;"LV4#A!-6]X=GE7
M;F96-68K5VU8-R8C>$$[;R\X06UJ1R]*855,-C-L*W!82"MK>68S8CEO+S54
M+VM966YF:V=J6E@K<GDO=T1,5$PY,&8O3D=#+TI.3RMR>2]W1$Q43#DP9B].
M1R8C>$$[3BM3,#<V=DPO=T%T378S4B]W1$Y'3BM3,#<V=DPO>3!Y+V1(+W=!
M,%DS-4Q3:&57.'9P3"]P36XY-48R:B\S-'8K4FAI9DI"0W8X028C>$$[5C5F
M*U=M6#=O+SA!;6I"9FMM;F96-68K5VU8-V\O.$%M:D<O2F%D.5AL+S5A6F9U
M:B\U;WAV>5=N9E8U9BM7;5@W;R\K84UB.&QP428C>$$[93-L*W5X9C942B]D
M>61O+S5K+WE-3C=C:U9U<B]6-68K5VU8-V\O*V%-1BM3860Y6&PO-6%:9G5J
M+S5O>'9Y5VYF5C5F*U=M6#=O+R8C>$$[*V%-8CAL<%)U;TI21VA.>$EW17-6
M5DEJ;V8S<2M#03119DI"1#5..#@O.$%+82M94"LR;&5F.$%*.3@V9E0O,V-F
M-F\K-3%/6#9J-R8C>$$[,&MY-7)E:V9K,4YC>% U:64Q=6MS<FHV:7%X6$UH
M-&]J3DUI:7)58FI7=$]61%1R;7,W4RMM4'9C=E-C>3E3,&I5+WI$,4U/*VE8
M*R8C>$$[9UA';'=&5FIA4G)U-W5#1$9(27-C<S!B4E(X>GE0>&=(86AO5%A.
M3U)%8S=C-$4Y1S=#1#@Q6E=U-U173E(P*T=A5S!M*W!#>4E35B8C>$$[<$M-
M4%566DDS2W)',&MA,7%F13=T44HT3VEJ:5<S0V9N4&(V4%I24D13-7)U3C1O
M8FPT1VME5F]Q<GIM-3-*4D9:5C5!<E)Y>&]A:B8C>$$[<&@Y1CE6.5-A851$
M*UIG,38R+U,P,FUN4DDT<&9R4#%B,41.231E45%F8E)2+V1L1$I39S5$-&%$
M67A01%<S3DEU,E=:5WE3+U8S;28C>$$[4T=:-$I69VU7,'57:6YK*W=J04E6
M9'1M,E4W;EDU2TM#=V94-"]Z1VY7,G9:9DU&;55M8FQA5$]'15%6041-6'1F
M4W1(;E8Q4BM+8R8C>$$[=UEX42MO,4]2<U!$,TU"86QO4R]M6'%-,3-F-F1R
M=')C-EDX+W=#-71P2D9,259N:F1L3$=Z6C!%;'959T@W4$MI:F1:1DUU16-W
M;R8C>$$[=#9B;$19:V9N:3AU8DQY:'$Y-6%U67)M,G1:2F]*0E%L6&I(2E<S
M<4YI374P.%%C9T(U5S$U5%536'IL+W=!<F,O36(O<3E3+W=$228C>$$[=4@O
M;6I.+RM2>&9Z6%<O;4HY-W8K5G5F;4XO,65P9BM28U O0412:BM2>&9Z5B]-
M5#<S9CAR8R]-8B]Q.5,O.&DT9BMA369Y3TPK828C>$$[=C5I9F4W+VQB;C5J
M9CE8<5@O:UA$+WI2:BM2>&9Z5B]-5#<Q<B]M,2M9:F]Y3G)-:%9G47<Y3TAC
M2&(K5$0K4WAF>E8O350W,3,O2R8C>$$[,U!Z1R]W0W(Q3"]Y3&@O-6]W9FMC
M6#@Q9GI%*SDS+TLS4'I'+W=#<C%,+WE,:"\U;W@O231V-7$O;4HY-W8X06QB
M;C5J9CA!5C9L+R8C>$$[-49W+S@P62]K8U@X,69Z12LY,R]!0W1Z.'AV*W(Q
M3"]!36DT9BMA369Y3TPK878U:69E=&8X,G9Z16-58E=:0T%19C=U2'%P<5 R
M4"8C>$$[15EF>5=,*V%V-6EF974O-5<U*UDS+U8V;"\U1G<O.$%.1T0X:FDO
M;7(K66XS=2\U5S4K63,O5C9L+S5&=R\X04Y'4#5(1B].6#AX4"8C>$$[=F0O
M>71Z.'AV*W(Q3"]Y3&@O-6]X+TDT=C5Q+VU*.3=V*U9U9FU.+S%E<&8K4F-0
M+TY'4#5(1B].6#AX4'97;C@R=GI%3&@O,'I*>28C>$$[545!*VY$,$Y#9C)0
M8D0K4WAF>E8O350W,3,O2S-0>D<O=T-R,4PO>4QH+S5O=V9K8U@X,69Z12LY
M3F9+9C5O*V9B,WI6;S%N9&%V2B8C>$$[3&)83CEB47IX;$EG1U-36E9:9&M"
M,T)Y=DYO.%%H26=B,%=E4%!->4%V<2ML334U,F%J968S4R\X6EEV*U1I-4M+
M0RM2+U!0+TMA*R8C>$$[65 X071P6&XO2CDX-FI4+T%.,T@K<5!U9%)L*V\K
M.4I-=6$S<68U0V%F86%L<4]V869E4BMR85AM;FU#-&I*2352>4]&659'-#)/
M828C>$$[=G11,4=*.#-,,&<S4'5E<DPK55@U94Q/.#AE:VE+5U)':61O<#=I
M3W%/-&M:84I);RM*;$9F169$,#)Z5"M,3'9C+V=#<EEF;%HU0R8C>$$[,"LY
M=$PR>3!O45A.:G<K<7-K,#163T1/-B]"-FY!+TA)>F)J<6-4;&ME<6E!6EAL
M8DHR2W5X5D-8;'9&8WDO5C5H>6AM9VUJ:U=P1B8C>$$[5F-O0TMJ,D]32$I"
M63=:+VQ:-4UT8C9'*T9O,#$Q8D@O4EI*6%IJ16YO<D0V855P4E%%<4\T2D\Y
M1%1*2$Q*2$%%3F4O:S$K6#$V<R8C>$$[:EA.9SAL,TI'66UV>E!-8F=Q651B
M9T9Y>')X:%!!06EG=VI.24DT07DO5#=',# K=W1R0WIJ.4LP=$EK9W0T9U-E
M36-3:$57<D5K,"8C>$$[561Z;%I.<W=H9DUE;E)A;F]L,W!S>DUK5CAN,6%2
M,'!Y0WEK25-+,4911WEE2V9$24AU67I&:6YN2"]1=6YL9B]Q-3,S+TI(+VUJ
M328C>$$[+W=$;%-F8TA'+TIX-WDW+T%+1C X<B\Y6$\K+S5)+S@P62]Y<%!U
M0R]K-#DU9"\P3' U6"]W0W)N9F8X:V8X06UJ2"M62CEW6#AN2"8C>$$[=DQV
M*VAD4$LO=T0Q8S<W+T%*22\X,%DO>7!0=4,O:S0Y-54W:B]N2&IY>$9B>7EJ
M57(P;$5:9T0V5DMG5B]K=VIT4UI024E/:VHS;"8C>$$[52\V1C X<B]!4%9Z
M=G8X06MJ+WI29R]L4V9C12]K-#DU9"\P3' U6"]W0W)N9F8X:V8X06UJ2"M6
M2CEW6#AN2'9,=BMH9%!++W=$,28C>$$[8S<W+T%*22\X,%DO>7!0=4,O:S0Y
M-60O,$QP-5@O-G5D.2]Y4B\U;W@O;%-F8T8O2G@W>7!Z+S@T.&5723!$1%5R
M,&MU:3<K;#!:=R8C>$$[<"]9.3A)-U5N,T)",&ME.'%N+U%U;FQF+W$U,S,O
M2D@O;6I"+TMK*S1*+TIX-WDW+V]85'EV.$$Y6$\K+W=#4U O3D=0.'%4-V=V
M-28C>$$[3U!E6&8Y0S9E5B\K<FYF9CAK9BMA368U56XS0F9Y8V4X=2\V1C X
M<B]W1%9Z=G8K4U X07I2:B]!0W!0=4,O:S0Y-54R+S5X-#AS0R8C>$$[-%-,
M.4I8=$=2,DHO9%9Q<%5F>68U5T@K5DHQ>4-0>6ME.'%N+U%U;FQF.$$V=60Y
M+W=!:V8K84U(.'%4-V=N.&Y(=DM,,&HX:&9,;28C>$$[;6%T6F%L1'%&-#AT
M:E!&8WAO+W!C4S!4:'=$4D%A17)K6CEP5&Q%:6AU;4]L:41D=E1C,7IL2TXU
M+V1,+W=!6EEV.$%K-'53:6=V3R8C>$$[3E<O-554*VQB,SE*9E90,&HY66PK
M=3@O6#5E=GI0<3%P=%AN6'!M9D0X>G=I<G%V2GAP949E+TY#9CA!5U!0+T%#
M-"\Y4$=3+W=!3"8C>$$[."]S4BLU5"]!36XO05!+<E!R:R\K1F94*W1E;B]P
M2#%4-GAY.5!K4'15-V-S<'HK3EAR-65D3FU0=S<Y3$Q0.44O-65F*VYN35AF
M>28C>$$[*WAT9"]O;B]!0S@O.5!/3R]L.6EU+S!4+VPU+S9E8V0O3#=&9"]O
M;B],>B]!3E!/3R]L.6EU+S!4+VPU+W=#;FY(9GDK>%9H*V]E<28C>$$[=&9R
M4'%C5S0O=T,Y3F5.4GDO:&@S.'9S6%IF+T%+2B]Y."\Y4$]$9GDK>%AF-DHO
M>3@O.5!/3R]L.6EU+W="12]W0UAN+W U>#,X=B8C>$$[<U9:3#E1-&HQ4')0
M2&MT2R]79G1C:'@O-&%M15@U9EEU>2\O0454+T%*968K;FY"=C5F67)V.$%2
M4#A!;#4O-F5C9"],-T9D+V]N+R8C>$$[04,X+SE03T\O;#EI=2\P5"]L-2\V
M96-D+TPW1E=49E504V8Q9G)0<#A4>G(Y6G!X<'9H1BM8,DQS=CA!.44O-65F
M.$%P-7=B*U@R2R8C>$$[-R]24"M8;B]!2V5C9"],-T9D+V]N+TQZ+W="4$]/
M+VPY:74O,%0O;#4O-F5C9"],-T974R]53TDY5#9Z>#5,4W8Q;C=826-F*T=P
M:"8C>$$[1BM8,DQS=B]!3D4O-65F*VYN0G8U9EER=CE%+S5E9BMN;DAF>2MX
M6&8V2B]Y."\Y4$]/+VPY:74O=T)%+W=#6&XO<#5X,SAV<U999B8C>$$[<4AQ
M<E@V>C9N1G50*SE.94Y2>2]H:#,X=G-86F8O;VXO3'HO04Y03T1F>2MX6&8V
M2B]Y."]W1%1Z:G8U9EER=CE%+S5E9CA!<#5X,R8C>$$[.'9S5F\O56%P>3EF
M-V%C95@Q:FIY-41J5W4S,G%D8V0O=T%5=7HO+S)1/3T\+WAM<$=);6<Z:6UA
M9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3<N,# \+W!D9CI0<F]D
M=6-E<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M
M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^
M,3 M2R!);6%G97,\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E
M871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R
M96%T;W)3=6)4;V]L/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.F9B9#4R-&9D+31F,V,M-#$S."TY8F8X+34V,SDT.#<Y,S0Y,#PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HP,CDP860X-2TR,6(X+30W-C M.3(P-RUC,6)B9C(P,6(X,S4\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HX8S0S8V-E9"UC,C!F+30W934M.61D,RTV,&(R,&,R
M9#@T,64\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L
M87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YU
M=6ED.F5F,V4V,V8S+60V-# M.30T,BTX-#9E+3-C8C9D-S V-F8Y-3PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HX8S0S8V-E9"UC,C!F+30W934M.61D,RTV,&(R,&,R9#@T,64\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HX8S0S8V-E9"UC,C!F+30W934M.61D,RTV
M,&(R,&,R9#@T,64\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.&,T,V-C960M8S(P9BTT-V4U+3ED9#,M-C!B,C!C,F0X
M-#%E/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(S+3 R+3 V5#$V.C0U.C,U*S$Q.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B R-RXR("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HP,CDP860X-2TR,6(X+30W-C M.3(P-RUC,6)B9C(P,6(X,S4\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C,M,#(M,#94,38Z-3$Z,34K,3$Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R(#(W+C(@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)
M0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 &
M #$  &%C<W!-4T94     $E%0R!S4D="                  #VU@ !
M -,M2% @(
M            $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M%&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M    %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M  /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')4
M4D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P
M>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#
M-C$Y-C8M,BXQ
M                  !865H@        \U$  0    $6S%A96B
M            6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z
M+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M
M &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M    3 E6 %    !7'^=M96%S          $                        "
MCP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M2_[<_VW____N "%!9&]B90!DP     $# ! # @,&  *_U  #I'$ #+%:_]L
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M5$6 E9!DA?_:  P# 0 "$0,1    O\
M
M
M
M  $#=TUU&))]*              !]S[^/A_'V
M               !]7[^?P_//!QR                          !T>7Z#
MHV\UH
M
M         $P%;S"PAYLN 40_45*5.MQK0              ,W9'3A''[@
M                                   ,I]W5T?K[/B?/(
M               &;LCIPCC]P
M
M                             %\'*^+8'COT *(?J*E*G6XUH
M       &;LCIPCC]P                                      &4^[J
MZ/U]GQ/GD                          #-V1TX1Q^X
M
M                                                 "^#E?%L#QWZ
M %$/U%2E3K<:T              #-V1TX1Q^X
M               #*?=U='Z^SXGSR                          !F[(Z
M<(X_<
M
M         !?!ROBV!X[] "B'ZBI2IUN-:              !F[(Z<(X_<
M                                   !E/NZNC]?9\3YY
M                S=D=.$<?N
M
M                              O@Y7Q; \=^@!1#]14I4ZW&M
M        S=D=.$<?N                                       RGW=
M71^OL^)\\@                          9NR.G"./W
M
M                                                  7P<KXM@>._
M0 HA^HJ4J=;C6@              9NR.G"./W
M                93[NKH_7V?$^>0                          ,W9'
M3A''[@
M
M          +X.5\6P/'?H 40_45*5.MQK0              ,W9'3A''[@
M                                    ,I]W5T?K[/B?/(
M                &;LCIPCC]P
M            MQU9.-D=?E]1[>OIG=UU%[3@_5.WX     %Z>EK'HL737
M        $K,8W44TGTH&0.CMN*U/._O=?U"Q,-!#[*M%N)JLZ/'?:L
M                                              7P<KXM@>._0 HA
M^HJ4J=;C6@              9NR.G"./W
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M/[/A6,\CID7T&UBFDVEZSV_&^>DV?VOCF/+?:L2$:':?SRCYWNK
M                                      O@Y7Q; \=^@!1#]14I4ZW&
MM               S=D=.$<?N
M    RGW=71^OL^)\\@                          9NR.G"./W
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M'COT *(?J*E*G6XUH              &;LCIPCC]P
M                   &4^[JZ/U]GQ/GD"[Q3EA]'[NO*V+W5>;(A\=^_P!4
M   !/E!Y-T+OZH2IC'@  !*S&-U%-)]*             ,W9'3A''[@
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MFE(C>YE/C.YIDVY ;"T#E&*LKIBNDNFL]US+X*9I'/I?/.+<GIKGS^*@
M                                         "^#E?%L#QWZ %$/U%2E
M3K<:T              #-V1TX1Q^X
M       #*?=U='Z^SXGSR!Z1OGVV/-R]!5/E?%[_ $#:+LVC)<]==7[?C)./
MW:;;; E7C.YT:W.NULV.)]7X^I7(SNI)(]MM7=EAZ/;G71V[_59AQ._)./W:
MJ[/"D]C>XQ+E=&.,CJOC4I9%.VUX)%?)M,            !F[(Z<(X_<
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MT?F\UF9<3OT:W6N
M %\'*^+8'COT *(?J*E*G6XUH              &;LCIPCC]P
M                           &4^[JZ/U]GQ/GD#TC?/ML>;EZ"J>5R,;J
MS[7$PU+VF#LUKLRM5842M8UG-*YL^BMAJ!RBGA:\%MFUA-899;H)O8=(H#IO
M&K*M>RSSM[ZJV86)[V2./[;/.#DZS['$^-]_,,DNT%^RC[,I'7%7D5\FTP
M          &;LCIPCC]P
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MS+\DX_;6>L2)8"SL4
M   7P<KXM@>._0 HA^HJ4J=;C6@              9NR.G"./W
M                             93[NKH_7V?$^>0/2;\]VS%))]+J]LL*
MLW8D2MU59-Z]D[C&H6UP+T]+V/0#O*LIJ8?()"=%M)I(AO\ SJ;\JRQS7\KQ
MSD=5E6O99YV]]5;,+$][)'']M-+$)!YV5]U8!Z%E#VCYZ=\5<
M  ,W9'3A''[@
M         +D-33RF];,#               EUBN\L/P.4XY[^J*N3:6 6<QD
M                                                7P<KXM@>._0
MHA^HJ4J=;C6@              9NR.G"./W ;JZ?8?5^?K17=:T  "PM Y1&
M!)-1N%J<Z&:7:    =JZOOJO;\6'8%*8+)I',:Y/2
M      ,I]W5T?K[/B?/('I&^?;8\W+T%4X%R6I9Y7BGL7T!WFL]&B@;4\]*]
MZOMRU9.(:Y;H;;%73;SZ[UK&W!5LWBXDFGGDA,DIO6S YV(7(_M?'U*3&MS3
MUM>"=PZNS1'=:WT*:(M"@!>59XLRN@            #-V1TX1Q^X
M
M                                                        "^#E
M?%L#QWZ %$/U%2E3K<:T              #-V1TX1Q^X"QS7\K[OT]E8^QH@
M  !Z%E#VC1CNBN=DM=EQNR'4@  =]Z.VWS54YIDVY 9A(GO8II/INJ=O6
M                      ,I]W5T?K[/B?/(%D>OI96XL&)@3)1+?1X[[5Z]
MY^+O#IMC8YK^5QF2+40,3>-2 Z+9V&('*8HI/I=/=M@8CRNBSK7,OBMDVFPE
MF8^B.ZUMH6MYAK3L<2MG843GQ@\ERKC=];"PHD            !F[(Z<(X_<
M
M
M    !?!ROBV!X[] "B'ZBI2IUN-:              !F[(Z<(X_<!8YK^5]W
MZ>S#.9CS5P^0?R0Q2[01#RK1W4*@L#3';Z^26/[:F[;,#E4C.YB0E.DMBUA-
M</9?14+M2#6[ZLG'?NCM@/F\:WETNQLCU]+(7I?H)?(KO/.,O^JK)E>RS<S4
M9^0>CMI-W#7UV6GK!QCD].WNISJ-5SUW@+.Q0                    !E/
MNZNC]?9\3YY                           S=D=.$<?N
M
M                                                    O@Y7Q; \
M=^@!1#]14I4ZW&M               S=D=.$<?N L<U_*^[]/9\3[^<*YF/
MS-HWZ&M#VA'SO=97ZG48C0D6H]#"A[1J.6G!YA8GO9,8[MZ*UTUSB7*Z!D[&
M[I/8YN+0U;S"FU;,#LJ5[+:7]NP"_K1UF4C+BKV]52]C>>G>]7V!X+)\L8O?
M.["I'YXU\5?8V@$JZ;W==?B=1@                     93[NKH_7V?$^>
M0                          ,W9'3A''[@
M
M                                         +X.5\6P/'?H 40_45*5
M.MQK0              ,W9'3A''[@+'-?RON_3V?$^_G 6=BP3S6.>AU0UHZ
M/;G75K["B>@6\UGH4T3:%1>TX/,+$][)M'=Q13NBN,1Y?1O+I=C<9J>>5S9]
M%;,%=RZE_;L LK5[+:7MNP"_K1UF4CKBKV]92UC^>??%76!8+)\N8O?.9#)%
MYZ5[U?8=@4I%>*>Q8                     93[NKH_7V?$^>0
M                  -I\S&Z;U?8
M[YV]?0^KL                               '[^>/O??SU+K^P
M                      !D#LZ\?]?8                           !
M> CVZM&>7[I%$/U%2E3K<:T              #-V1TX1Q^X"?*#R;N'5]_'^
M_G"69CPQ2[07LZ5L>I[9\*N+U//(W)!J=C]?EUKK"B4JD9W,4,GTML>L)KA#
M-QZYL^BMM*KYM&#(]/FK#R:AUJ0:_/2%EUI+#B4ST1WU-*VX'91KR6;C:G/R
M'T=M)JX:^NTT]8-%BZ*YG9A4D$$TUC8                     RGW=71^O
ML^)\\@>@I15GZ5[C7B%&81Z&V6Z$       #T+*'M'ST[XJX ;O:;8_JXYT7
MW6M]!BBK/\^>]:P          &;LCIPCC]P
M       S=D=.$<?N                               'V_KCO'9UXLZ>
MT                             9U[^G!71W
M       >AE7TMLGT-: HA^HJ4J=;C6@              9NR.G"./W
M                                 93[NKH_7V?$^>0/2I\\VUYJWH:I
M0._=';/;")+J=M,*(65:*5F,;KBY8[[^K,.)W[8ZS-ATEFBE_BF\CMW^KT0W
M6MEQBV\AYEFAE\BF]B8E&D]!>BK/\]J]ZOF_ALA^O\?4$DVC=X:FK$^7]<1]
M[W5X"SL: R<1G>K2[*6N+;N$^81_5K9X4O45WNW&JS= -[K(S)%J      !F
M[(Z<(X_<                                ,W9'3A''[@
M                    !]OZX[QV=>+.GM
M   &=>_IP5T=P                           'H95]+;)]#6@*(?J*E*G
M6XUH              &;LCIPCC]P
M      &4^[JZ/U]GQ/GD#TJ?/-M5QK B@KNSV+7MJ5L>J;9L+FZATBCMWVJG
MQA$EC;D&IK]3J,^B%0UHT);MK:^S25DT*[MK:Z[3]@>=7?E67V:1LKS[KTK&
M_K1UF40KKK>_I1MFTD[BKW?C2;*2V.[>.[?ZJ2J.[?3W;8$2<ITEY:F+$HGW
M37-UNH+ IWVO!+L-/V#YZ-[U?Z?/G&W_ #];SK*ZS4%@>=7?=6=7[?@
M#-V1TX1Q^X                                9NR.G"./W
M                      #[?UQWCLZ\6=/:
M     ,Z]_3@KH[@                           /0RKZ6V3Z&M 40_45*
M5.MQK0              ,W9'3A''[@
M        ,I]W5T?K[/B?/('I4^>;:H37?6HU)VF#Z&]#VCYUU]U9NEI]A:WK
M*:9LP\BB'==;]&[NOT+:(M#STKWJ_P!#JAK1\\6^:N]$BA;2\^^]*QOLTC97
MGW7I6-_6CK,HA776]_2C;-HZ7-75J.LYGN;J<^'J5Z(:)[K6POR_0>B10MI5
ML[!B>6<7OK56'$KH513^NM/8K<4JB=^>E>]7WO:4LBE_;L!P%G8H     &;L
MCIPCC]P                                S=D=.$<?N
M                   'V_KCO'9UXLZ>T
M  9U[^G!71W                            >AE7TMLGT-: HA^HJ4J=;
MC6@              9NR.G"./W
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M]M]JP!:5K695_)S&-;=CB   6G*TF=6.RX8       ,W9'3A''[@
M!94KR6[V:79:Y[#$K.6)$9IHA((K9+I=6MGA@      "PM Y1#W+-%K;L,0
M        ?;^N.\=G7BSI[0       ,F8W=;TJN<_GYXB=D^D@IFL<M.5I,JL
M=EPT       6#X)*-_-'LZSUB1'579X0        SKW]."NCN       $PD3
MWTWD.D/0>_JKH3Z*]@^/K;;59T*TPCX      &:\/(L[5S+\3Y/36+L:(?*^
M_D       >AE7TMLGT-: HA^HJ4J=;C6@              9NR.G"./W
M                                   93[NKH_7V?$^>0)OX;(H0)E'0
M,@=';/=!Y+J;M,*(.5Z*7R*;V)B4:3Y7W\S(Q+?0W2W0S+1'?PTR[03-Q'?P
MR2[02*Z#:R Z+9ZE[3"BRDNFE[BN\C'D>HGOA$EBIDVE_OCG4C:X-@.#2:$B
M81^1+0[2&27:#>_2;*6:+[N%"81_5G9X4R,2WT-TMT,L\7W<8\BU'4.[K
M   S=D=.$<?N       'I&^?;8\WGT#5%KNL9IB_)Z:QMC1      ;,:[,M^
M55.:D-HPC!V;C8ZR.H ;P:;8Z=[; ^']_(  'H64/:/GIWQ5P       S=D=
M.$<?N         'I&^?;8\W+T%4\G$<V]LNKYMI#N==7BGL7CWWNK
MN"53.K#\"E/G_P!Y5E&Y(=2         /M_7'>.SKQ9T]H       &S&NS+K
MM/V!0=N^M;N=.6% W-HW:+K>8>>E>]7@      3E0R1;SZ795QI_%+Y-)V3Y
MWU]5:        ,Z]_3@KH[@      !<)JB=P]RO0QZ[[5^B+0MI4Q+<@,D<?
MVU5>S(8      !>CI>QJCUI0B7F*[SLW7]UGK$B(       ]#*OI;9/H:T!1
M#]14I4ZW&M               S=D=.$<?N
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M8>11KN:NL9Y/2-@L#*M1UI,J_LYC,;DAU(         ^W]<=X[.O%G3V@
M    ;,:[,NNT_8% J\:SM85E--5]GA6SJOFT'DRCLKL8W7GIWO5]F"NY=MMJ
M\W^" .<QFTK6LRT\VV!3;MJ!WD*9L3'>1U?X4J[?K\ 9.QNZ_)2%E^>;?%7
M       #.O?TX*Z.X       7":HG</<KT,/\KT?I6^>K9IIVU K=E63B/+?
M:OKG9\U%;3@]RZI)[FO#R*REBQ&::(;_ +=U?<3DHTL?.]U=O^J9SBK*Z8+I
MI'8-9G' -L]7G6G:TF5?>=1B+>2Z8       >AE7TMLGT-: HA^HJ4J=;C6@
M              9NR.G"./W
M  93[NKH_7V?$^>0                          ,W9'3A''[@      !Z
MM?F2Z*[\]BW[OGFG5;$$]!>B[.\[.^JMG*ADCL0P*4PZRS0S6P^051+.A<[T
M*DE?>=1BXU4T[\Z^_*L_DV8UV9;\JJ<ZL;+"A#F4>M^55.?/2O>K[%,!E7Q_
MOYFLA\@IP6S [O-.6'Y]%ZU@.R=?W-%$-_:ZK&:T6[HKFZA4%@>>G?%7
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M;C6@              9NR.G"./W
M      93[NKH_7V?$^>0                          ,W9'3A''[@
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M6=<VJ.?1][W5PCS&/182;3=OZNSJ';UBWE5<YJ)6G!Y*H]MK \%D],FW("
M     /0RKZ6V3Z&M 40_45*5.MQK0              ,W9'3A''[@
M                               ,I]W5T?K[/B?/(
M           &;LCIPCC]P       NU4[85)6XJ] N0U-/*;ULP,6X:MG&:L/
MOT^VN#5ULF' 23Q[;V=ZXEV(,OHJRV5#K!4%D^ L[%BRDNFL>0"5TWK9@<RT
M1WXDXCNWJ]61#YV85(Y38UN=--M@=4[>O<34Y_\ )5ULF'V<*YE]-ZVH$
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M./W                                       93[NKH_7V?$^>0
M                      ,W9'3A''[@
M   !F[(Z<(X_<                               /M_7'>.SKQ9T]H
M                           SKW]."NCN
M    ]#*OI;9/H:T!1#]14I4ZW&M               S=D=.$<?N
M                              RGW=71^OL^)\\@
M          9NR.G"./W                                #-V1TX1Q^
MX                               ?;^N.\=G7BSI[0
M              !G7OZ<%='<                           !Z&5?2VR?
M0UH"B'ZBI2IUN-:              !F[(Z<(X_<
M                 !E/NZNC]?9\3YY                           S=
MD=.$<?N                                &;LCIPCC]P
M                    ^W]<=X[.O%G3V@
M  #.O?TX*Z.X                           #T,J^EMD^AK0%$/U%2E3K
M<:T              #-V1TX1Q^X
M     #*?=U='Z^SXGSR                          !F[(Z<(X_<
M                           ,W9'3A''[@
M       !]OZX[QV=>+.GM                             &=>_IP5T=P
M                           'H95]+;)]#6@*=WM?SC"K>-9@
M      6*/-%QRSTS88                                      &.MK
M@]NP<GZ_1V@                          8CWFMRYH]D
M                   ,1[S69<T>S
M'R._JZCG8V1=5G                             #$F\UF6]'LP
M                     ,3R#63"4I8XIA^Y_-$!OHJI0              +
MC?B+TA83\UW"                                      !AK>:S(>LS
M>Q8W<                          !KQ)=-L/&MR
M              ->)+IMAXUN0                              !UW)Z
M<>;/"S+H]F                             ->)+IMAXUN0
M                 (L[<@4IE1ST4P_<_FB WT54H              %QOQ%
MZ0L)^:[A                                       PUO-9D/69O8L;
MN                           UXDNFV'C6Y
M          &O$FTVP\9W(                               Z[D]./-G
MA9ET>S                             &O$FTVP\9W(
M             $6=N0*4RHYZ*8?N?S1 ;Z*J4              "XWXB](6$
M_-=P@                                      8:WFLR'K,WL6-W
M                        :\273;#QK<@
M      #7B2Z;8>-;D                               ==R>G'FSPLRZ
M/9@                            #7B2Z;8>-;D
M         "+.W(%*94<]%,/W/YH@-]%5*   !]?I[,ZQ[:ZYR?3
M"XWXB](6$_-=P@                                      8:WFLR'K
M,WL6-W                           :\273;#QK<@
M               #7B2Z;8>-;D                               ==R
M>G'FSPLRZ/9@                            #7B2Z;8>-;D
M                  "+.W(%*94<]%,/W/YH@-]%5*   !EK3;"S]Y-O2I/[
M+\]@ "7"F;"B/N:O1,A2%D0WW?6X    N-^(O2%A/S7<(
M                       &&MYK,AZS-[%C=P
M    &O$ETVP\:W(                                UXDVFV'C.Y
M                            '7<GIQYL\+,NCV8
M            UXDVFV'C.Y                            BSMR!2F5'/
M13#]S^:(#?152@   =IQ.^]1^?7JK&.VP?B]_5%Q;<$KN^F*<%EWRO=TN%,6
M%&3:T'$E%6S:B!^A?E$    7&_$7I"PGYKN$
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M                            #7B2Z;8>-;D
M      "+.W(%*94<]%,/W/YH@-]%5*    .^Z[+E"J6=8(D.JCWLJ'@?;Q^R
M<WS_ &I%[;4%&*-QK\8;;!    %QOQ%Z0L)^:[A
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M1K=:Z7R*;VD/<=>6Q:PFO\$44GTNQF+WR:ZC/S+H]F
M           ->)+IMAXUN0                           (L[<@4IE1ST
M4P_<_FB WT54H   '[NOZNI^$O3<25S5[L_$]YK=*-+7]]'U$!(G64RGD\\V
MQ]KH[>F9V+4A]F>>@   !<;\1>D+"?FNX0
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MP:RW7DMV>UN94CM*$3[P>3;RZ78X"SL:I_9\*N*59-^A[+#S+H]F
M                     ->)-IMAXSN0                           (
ML[<@4IE1ST4P_<_FB WT54H   &Q,9W$U%$V=7.].4R+7'CV_JH_L*@0+C'B
M/TA57]>T'UW)Z./EC7:X0    N,^(O2%A7S7<(
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MK>V#$[PU-6)1WN6N]Y-+L9BXGOH>99HI!]%M(9);H+2M;3&M/8<2M[55.0
M,2Y715:LR&R(Z#:1F2+43 Q3>_C^N*_4ZC%P"J9U2.N*O94(UN;#$#E$!$XC
M4S$1WV=L+)KKSZ+3]P:2UMK!BEIFM9CL!@Y6LNQQ*M%E0VXA5$Z[#U_=#>[*
MWO=4K8]$RZ:XO>4K9%2:T81.G"Y'(7H=IK+L<2K194-N(51.OX[NO&VTPLVZ
M':                             #6Z4:39&+[L
M         "+.W(%*94<]%,/W/YH@-]%5*   !R\+G/AGTOJU+M#L7&-S$#=5
M<PLWM68%ESRO=T3%R5[US)Z/Q=GSIU-XX    +C7B+TA84\UW"
M                            !A;>ZS(VLS>QXO<
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M$T"E,(4QCN$<S'['\?=P"KYMCG9X6:=%LP
M  !KG)]+L9&-T                           !%G;D"E,J.>BF'[G\T0&
M^BJE   ':\/OZIF='ZOCG<N#R7#N[UN#)!JP!/EYUMK:6(;X=3S<>LIZLH\
M   7&_$7I"PGYKN$                                      ##6\UF
M0]9F]BQNX                          #7B2Z;8>-;D
M0"SB,RH1K<[5:S-          'Y>>*A5JP?-6'WRJ1G=2@QO<   #7B3:;8>
M,[D#\O/%0JU8/FK#[Y5(SNI08WN                            .NY/3
MCS9X69='LP                            !KQ)M-L/&=R
M                !%G;D"E,J.>BF'[G\T0&^BJE   %IOR+?,)-]5?9-\MW
M6!&;:L'K_P#H^HP-[:]E5C?S#=%2KV5Y[DOJN;Q W570    N-^(O2%A/S7<
M(&N.PQ([=]J^V]7W*1&]SVOJ^P  -6-GAXBRNB031;, 1IR+4;3:S-V&P,H?
M ^_F).4Z.8N)[X #K/9\1"RK1_HXYD8T&TV P<J$V81Z;*'R$
M         8:WFLR'K,WL6-W 1N2'4R1Q[;#0?>:S:;69ND^XU\E4>VPU5V>%
MHUN==)5'MOF7$[P -5]GA:;;; E5C.Z^Y\?6"<W&C^WNLE:C&Z^[\?0TOV^O
MV'P,O)./V@           :\273;#QK<@
M   #7B2Z;8>-;D                               ==R>G'FSPLRZ/9@
M                            #7B2Z;8>-;D
M      "+.W(%*94<]%,/W/YH@-]%5*   !F71[*7VE;%@=]#50  +6GCZ_8[
MK,AT:UIPFQ[Y?NBJ1["H$    7&_$7I"PGYKN$"N-8$4C8D&JEGB^ZJX63#O
M2&\_6O\ T "F];,#N0U-/-!]YK,!9V-+K%=X (6)?']WM-L8:9=H9G8COMA<
M#*@,F\:L80&5  :S['#\_P#O*L[<M6S>K'94.NC5%/HF)1I+.%<R\
M   :2;C7Q)RG1V1Z^E@        PUO-9D/69O8L;N \W'T%5'I'>?;7C1D6H
MJB6="[\5(67YKOH2I?2I\]6U4XL^%1MR'4RQ1?=0/S:.6JZSF<WT-D($;4AU
M-3^SH5/!"I)!7-(Y<HJ6>TE;AKVQ- I57HGD7] JB[-A"F4=H1W=6WH\>?[5
MDCC^V            BIM^ T)_P!$O)@
M                          N>^&/2T^/G6VP       !UW)Z<>;/"S+H]
MF                             ->)+IMAXUN0
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MFY/I; \%DTD<?VP           $5-OP&A/\ HEY,
M                                   %SWPQZ6GQ\ZVV        .NY/
M3CS9X69='LP                            !KQ)M-L/&=R
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MHONI?(KO*;5M0.P%!9-)'']L           !%3;\!H3_ *)>3
M                                            !<]\,>EI\?.MM@
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M;?@-"?\ 1+R8
M       +GOACTM/CYUML        ==R>G'FSPLRZ/9@
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M9>VNKS;15;3&BM=-<Y_P<K+6+W7$JGG<"4WC51FTX1(#HMG<YJ.?;,Z[+
M        $5-OP&A/^B7DP
M                7/?#'I:?'SK;8        Z[D]./-GA9ET>S
M                    &O$FTVP\9W(                           $6
M=N0*4RHYZ*8?N?S1 ;Z*J4   #L6-W7"/$_HW$VXU^CL_BV7M+L:V7J2E +#
MGFFXLYQ_:];RNGJ^7CUO/4-+    "XWXB](6$_-=P@                 5
MUI]%L0Y71+Y%=Y40M2#W^J-LP                  8:WFLR'K,WL6-W
M                        14V_ :$_Z)>3
M                               !<]\,>EI\?.MM@       #KN3TX\V
M>%F71[,                             :\273;#QK<@
M              19VY I3*CGHIA^Y_-$!OHJI0   !NA!9+*S3\_UQE&EB8N
M2ONEYV,!<1\2^CH _1M1]>R>GY_9\:-V!%@   !<;\1>D+"?FNX0
M         .#E"',8[@G-QITX7(\S8F0                  ,-;S69#UF;V
M+&[@                          (J;?@-"?\ 1+R8
M                                       +GOACTM/CYUML
M==R>G'FSPLRZ/9@                            #7B2Z;8>-;D
M                     "+.W(%*94<]%,/W/YH@-]%5*    +-?E.\:RGJR
MCOH]7W;-\<>@JD/LSST!:2\D7O'W9$0^3W=?QN_JB@N*     "XWXB](6$_-
M=P@                                      8:WFLR'K,WL6-W
M                      14V_ :$_Z)>3
M                             !<]\,>EI\?.MM@       #KN3TX\V>%
MF71[,                             :\2;3;#QG<@
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M&L>QPZ_\ZC.K6RPP-I]9F6FJUF0                   $4EP0"A9^B/DT
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MI&^?;7^K\_5,RVX#+O%M[O9I-C2YMZ VD*VF.[^FV.T^LS
M      (I+@@%"S]$?)H
M              N>^&/2T^/G6VP       !US*Z<<[/"S3HMF
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M+@@%"S]$?)H
M      N>^&/2T^/G6VP       !US*Z<<[/"S3HMF
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M/?#'I:?'SK;8        Z[D]./-GA9ET>S
M   &O$FTVP\9W(                           $6=N0*4RHYZ*8?N?S1
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MZ&HV                     BIM^ T)_P!$O)@
M                                  N>^&/2T^/G6VP       !UW)Z<
M>;/"S+H]F                             ->)+IMAXUN0
M                (L[<@4IE1ST4P_<_FB WT54H   '+PN>^&/3&J\OT&Q,
M9W,0=TUS"Q>U9@6#?-MOS'TA9--WV_YML'>;;?J[^M**    %QOQ%Z0L)^:[
MA KQ3R+YCQ._]_'.2<;NEBC&Z JH6;#+,U=2Z%681Z'R5Z/)V-W3C0R199QN
MZJ99L+LA5]+*W%@Q.0W0[3^.5H:MIA1JN>NY[H1)8WY!J;758S2N!8$4THW&
MOSQA9-MRK9O3=MF!W(JFGD-,MT(F6B6^C\WNLB+E.CL[US+Q"5,8]C_OZJ_$
MZC.W>JSHTY#J+J%0V!$%*M%::K694T[;@5RJI)[49M.#X2S,?>C2[&>Z$2:H
M-:L%XRX-5,ZCAD&JKV3N+W%*HG=5RRX;<2J>=4O+=@/VOCZGOA$EKQSR+7'J
MFGF7,7O     &&MYK,AZS-[%C=P%("Y*\N_TW88BWDNF@ G,9NCU#/P*F-H0
MFQE )5LYKLP                    14V_ :$_Z)>3
M                                      !<]\,>EI\?.MM@       #
MKN3TX\V>%F71[,                             :\273;#QK<@
M                     19VY I3*CGHIA^Y_-$!OHJI0   -B8SN)I:*LVN
MCZ;IH6N/'M_51_85 @6C/)-[:&6)$XX+0A=D'R]=-43V'0     N-^(O2%A/
MS7<('Q?OYK&V-$+1E;3$                 80S,>A]==;S4Q"010R?27H*
M8L;(N/V@       #^2JS9D,M45G,P     ,-;S69#UF;V+&[@
M               (J;?@-"?]$O)@
M                       N>^&/2T^/G6VP       !UW)Z<>;/"S+H]F
M                           ->)-IMAXSN0
M     (L[<@4IE1ST4P_<_FB WT54H   '[NOZNH^$_3<2=RU[M#$M[K9*=)7
M^]'U$!8E\S7'+O2]BZD3./?$[^JIK['\^@   "XWXB](6$_-=P@
M          #X/W\ZN;+#VUU>;^SCD                8:WFLR'K,WL6-W
M                          1U6;#:POK&BP
M         !UC*Z.SXO>                     !8Y\P71*M4$^
M'7<GIQYL\+,NCV8                             UXDNFV'C6Y
M                      BSMR!2F5'/13#]S^:(#?152@   9CTFQR!K,S=
MB!R? \BU4?ED1  #:V'[_8F,[F,FUH.    !<;\1>D+"?FNX0
M                           ,-;S69#UF;V+&[@
M        ->)+IMAXUN0                               !KQ)=-L/&M
MR                               .NY/3CS9X69='LP
M               !KQ)=-L/&MR                           !%G;D"E
M,J.>BF'[G\T0&^BJE   $I]13RRCY:NWYG;UU^?2%0P\7;7 &V\,D,TM%6;6
MC]44C=?\'^G<5;?7]0SL:I)[+\]@   "XWXB](6$_-=P@
M                       8:WFLR'K,WL6-W
M    :\273;#QK<@                               #7B3:;8>,[D
M                            ==R>G'FSPLRZ/9@
M           #7B3:;8>,[D                           "+.W(%*94<]
M%,/W/YH@-]%5*   +;GC/T+5"]A^?_E=W7;R\6^BJ@?M7SH!-/1-F],SL73^
M;1RRMY9NVGK[8\Y7&/$?I"G/[<\W@   "XWXB](6$_-=P@
M                        8:WFLR'K,WL6-W
M     :\273;#QK<@                               #7B2Z;8>-;D
M                             ==R>G'FSPLRZ/9@
M            #7B2Z;8>-;D                           "+.W(%*94<
M]%,/W/YH@-]%5*   +>OBWT5'Y9$/$YWGZU(,?0-5ZB3..QD6O!\PZ38W/?#
M'I?)NJSJ@OM3SIIE.8U=0\)^FJ1?O;R^    +C?B+TA83\UW"
M                           !AK>:S(>LS>Q8W<
M        !KQ)=-L/&MR                                ->)+IMAXU
MN0                              !UW)Z<>;/"S+H]F
M                ->)+IMAXUN0                           (L[<@4
MIE1ST4P_<_FB WT54H   D,K28[<PR0@#5:7Z"..SX8.?YY_5\<_.[?GEX9J
MT.TPAO\ 5@   "XWXB](6$_-=P@
M     8:WFLR'K,WL6-W                           :\273;#QK<@
M                            #7B3:;8>,[D
M          ==R>G'FSPLRZ/9@                            #7B3:;8
M>,[D                           "+.W(%*94<]%,/W/YH@-]%5*
M         !<9\1>D+"OFNX0
M ,);[5Y)U>;V3%[P                          -;I1I=D8ON@
M                        !K=*-)LC%]V
M      .MY71C;:86;=#M                             !K=*-)LC%]V
M                           !%G;D"E,J.>BF'[G\T0&^BJE
M      N->(O2%A3S7<(                                      &%M
M[K,C:S-['B]P                          &N<GTVQD8W(
M                     USD^EV,C&Z
M  '7,KIQSL\+-.BV8                             USD^EV,C&Z
M                        BSMR!2F5'/13#]S^:(#?152@
M  7&_$7I"PGYKN$                                      ##6\UF0
M]9F]BQNX                          #7B2Z;8>-;D
M                 :\2;3;#QG<@                              #K
MN3TX\V>%F71[,                             :\2;3;#QG<@
M                    19VY I3*CGHIA^Y_-$!OHJI0              +C
M?B+TA83\UW"                                      !AK>:S(>LS>
MQ8W<                          !KQ)=-L/&MR
M             ->)+IMAXUN0                              !UW)Z<
M>;/"S+H]F                             ->)+IMAXUN0
M                (L[<@4IE1ST4]O;?FZ&.^*O               G<\ZVY
M+]25D@                                      8QVV!W3 ROM=':
M                        !A?>ZS-&BV8
M       POO=9FC1;,                               ?%[^KI>?BY.U
M.>                             ,+[W69HT6S
M         QWL\*8^D+)%,/W/YH@-]%5*              !; \=W_9N\I7D
M                                     !AK>:S(>LS>Q8W<
M                  !KQ)=-L/&MR
M ->)-IMAXSN0                              !UW)Z<>;/"S+H]F
M                          ->)-IMAXSN0
M    (L[<@4IE1ST4P_<_FB WT54H              %L#QW?]F[RE>0
M                                 &&MYK,AZS-[%C=P
M              &O$ETVP\:W(                                UXD
MNFV'C6Y                               '7<GIQYL\+,NCV8
M                      UXDNFV'C6Y
MBSMR!2F5'/13#]S^:(#?152@              6P/'=_V;O*5Y
M                             8:WFLR'K,WL6-W
M          :\273;#QK<@                               #7B2Z;8>
M-;D                               ==R>G'FSPLRZ/9@
M                 #7B2Z;8>-;D                           "+.W(
M%*94<]%,/W/YH@-]%5*              !; \=W_ &;O*5Y
M                          8:WFLR'K,WL6-W
M       :\273;#QK<@                               #7B3:;8>,[D
M                               ==R>G'FSPLRZ/9@
M              #7B3:;8>,[D                           "+.W(%*9
M4<]%,/W/YH@-]%5*              !; \=W_9N\I7D
M                     !AK>:S(>LS>Q8W<
M  !KQ)=-L/&MR                                ->)+IMAXUN0
M                          !UW)Z<>;/"S+H]F
M          ->)+IMAXUN0                           (L[<@4IE1ST4
MP_<_FB WT54H              %L#QW?]F[RE>0
M                 &&MYK,AZS-[%C=P                          &O
M$ETVP\:W(                                UXDNFV'C6Y
M                      '7<GIQYL\+,NCV8
M      UXDNFV'C6Y                            BSMR!2F5'/13#]S^
M:(#?152@              6P/'=_V;O*5Y
M             8:WFLR'K,WL6-W                           :\273;
M#QK<@                               #7B3:;8>,[D
M                  ==R>G'FSPLRZ/9@
M #7B3:;8>,[D                           "+.W(%*94<]%,/W/YH@-]
M%5*              !; \=W_ &;O*5Y
M          86WNLR-K,WL>+W                           :YR?3;&1C
M<@                               #7.3Z78R,;H
M               =<RNG'.SPLTZ+9@                            #7
M.3Z78R,;H                           "+.W(%*94<]%,/W/YH@-]%5*
M              !; \=W_9N\I7D
M     !A;>ZS(VLS>QXO<                          !KG)]-L9&-R
M                             -<Y/I=C(QN@
M          !US*Z<<[/"S3HMF                             -<Y/I=
MC(QN@                           (L[<@4IE1ST4P_<_FB WT54H
M          %L#QW?]F[RE>0
M &%M[K,C:S-['B]P                          &N<GTVQD8W(
M                         USD^EV,C&Z
M      '7,KIQSL\+-.BV8                             USD^EV,C&Z
M                            BSMR!2F5'/13#]S^:(#?152@
M      6P/'=_V;O*5Y                                       8:W
MFLR'K,WL6-W                           :\273;#QK<@
M                    #7B3:;8>,[D
M  ==R>G'FSPLRZ/9@                            #7B3:;8>,[D
M                       "+.W(%*94<]%,/W/YH@-]%5*
M !; \=W_ &;O*5Y                                       8:WFLR
M'K,WL6-W                           186[ J)7Z$>4@
M                   !_'/']\<@                              #_
M #E_CC^N.0              -H(GO?1D_,;V:             ->)+IMAXUN
M0                           (L[<@4IE1ST4P_<_FB WT54H
M      %L#QW?]F[RE>0'%RI[6M!8XI!J?E?7%A""2>QA 94   !YZ=[U?Z%E
M$6@   !YQM_U5)C'=OK/L<.V95\VD-T.T        $',SCLXT,D0 &D.YUWY
M>6]&EV/GSWK6'H,459X      $%DTCD&$TCEVJG;"[QT]@PUO-9D/69O8L;N
M H!WE6=_RC;,Z3W==$>ZJXO+4S8E$.ZZW]!2BK/CTWVKIPVS _H_/UW'I^[M
ME/6%GO!R0!#U*]%4JM&$^BU0=I_#^_FD_<%??0X^M[-)L;0%<3#$>5T>>Q>]
M87A*:L/?_1[,           "*FWX#0G_ $2\F
M                                                          #:
M:([[TB/R\]I@            #7B2Z;8>-;D
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M$[PK2[I3EA53;-A>HNUPK8-8322./[8           "*FWX#0G_1+R8
M
M                -IHCOO2(_+SVF             ->)-IMAXSN0
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M=O?56^B10MI4G+AKZS174NW[T>SJ.6E")<(MNY<XMO*;5M0.P%!9-)'']L
M         !%3;\!H3_HEY,
M                                           &TT1WWI$?EY[3
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M);D!L-P.4201_;4VK:@=@*"R:2./[8           "*FWX#0G_1+R8
M
M               -IHCOO2(_+SVF             ->)+IMAXUN0
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M8           BIM^ T)_T2\F
M                                             #::([[TB/R\]I@
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M(Z4Z/0#>ZP3^P:3YSPL@           14V_ :$_Z)>3
M
M    !M-$=]Z1'Y>>TP            !KQ)=-L/&MR
M        !%G;D"E,J.>BF'[G\T0&^BJE               M@>.[_LW>4KR
M                                      PUO-9D/69O8L;N
M                   BIM^ T)_T2\F
M                                                    #::([[TB
M/R\]I@            #7B2Z;8>-;D                           "+.W
M(%*94<]%,/W/YH@-]%5*              !; \=W_9N\I7D
M                         !AK>:S(>LS>Q8W<
M      !%3;\!H3_HEY,
M                                        &TT1WWI$?EY[3
M      &O$FTVP\9W(                           $6=N0*4RHYZ*8?N?
MS1 ;Z*J4              "V!X[O^S=Y2O( #6'98>SVMS      -!=YK-^-
M'L_Z            .I=OQJYLL(;&8&7D3'[1H)O-9OWH]F            ,)
M;[5Y)U>;V3%[P-:MCB=$[NH9KP\G,N)W@   #3;;8'!SQEC%[\\862
M          !$_<5?T,?T/\G
M                                            #::([[TB/R\]I@
M          #6Z4:39&+[L                           "+.W(%*94<]%
M,/W/YH@-]%5*              !; \=W_9N\I7D -!-YK/+T](4_ZO\ YBNG
M8? R@ -3-IA1<R333\P>3  5 K5@MM.KYOVKJ^P           (EI1I*=]L0
M2P3!9/H'O-9LSKLRVG5TVILVU KDU2ST            86WNLR-K,WL>+W >
M:MZ%J6QS )6)0HWN9+H[M@   !Y77I>FK:M73;7?/Q=+=OK[V%+6/]KX^@
M             (I+@@%"S]$?)H
M                                               VFB.^](C\O/:8
M             USD^EV,C&Z                            BSMR!2F5'
M/13#]S^:(#?152@              6P/'=_V;O*5Y "CS<M=[^:/9X8R^BWC
M5<XKJ3Z+34Q#?_1^?J$68QZ-R0:B-21:FXA4\[Y2 R;QK;;5YUIZM)E5OLJ'
M6(H%*:S-B1'7O/Q9J8?((7)?'YCXGOI58SNJS-B1'7O/Q9J8?((7)?'YCXGO
MI(8]MHG)1I+!$%D]6.RH;8K@4JK!V/#\#YN-*M&=U8/@DG@@FL;B)E6CF2B6
M^G#ALB$2THTD$\UCET&HI\* %Y5E<RJ2?0<S..V9JZEU0ZU(-P<K=E5SB%F7
MQ^(F5:.9*);Z8^)[ZJ/9L+PIF8]M6KYMJULL.N)8$4E!C>XGY@TFJ66C"<<Y
M'5:NK*9[)Z_+   &&MYK,AZS-[%C=P'FK>A:E]*GSU;0X.53VSH5;)K":Z0[
MG7:2;C7Y-Q^Z V;QJ3&.[:Q; 94!YJWH6I?2I\]6T*R%BQ#Z7'U^_P"><'9F
M-O\ Z/9_,^N(?97HI'H_M;&\ E=92Q8CB/*Z->\_%N(51.^]]'8
M (J;?@-"?]$O)@
M                                   VFB.^](C\O/:8
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MK2W<8%NVJYQMMJ\VJ[9<-VAUN9(IH-K6$L>'WI:7L8   8:WFLR'K,WL6-W
M>:MZ%J66B+[P7,ZDGM'"Y:[MDUA-:MEDPVU+6DTH77;6M[RE+(J*VG![C53S
MS:?69@\U;T+4OI4^>K:$8$DT]<:?Q7 F=C6AZWF&Z6GV%)JX:]O_ -&V;20N
M*O;*=>RVEG;T ] RB[-AGEVAU7V>%:<K29          "*FWX#0G_1+R8
M
M                  -IHCOO2(_+SVF             ->)+IMAXUN0
M                      (L[<@4IE1ST4P_<_FB WT54H
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M"?\ 1+R8
M                             -IHCOO2(_+SVF             ->)+I
MMAXUN0                           (L[<@4IE1ST4P_<_FB WT54H
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M_#9#$/*M'<RJ2>[^:/9@         "*FWX#0G_1+R8
M
M   -IHCOO2(_+SVF             ->)-IMAXSN0
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MB]^>,+)& ,[&SQA9//P_-SQJIL\+:'6YOT_GGSTKWK"^'2EC]CZ_O(^/V@
M        1QV?"ZL7KJA0                               !UC+Z.SXG
M>                               /R_?S\SM^/NX_:
M!G>/;:Z%X7],             #7B2Z;8>-;D
M   "+.W(%*94<]%,/W/YH@-]%5*              !; \=W_ &;O*5Y
M                                  8:WFLR'K,WL6-W   8SR>G0_=:
MV3R.;@         0W2W0S(Q+?            :\273;#QK<@
M                   #7B2Z;8>-;D
M ==R>G'FSPLRZ/9@                            #7B2Z;8>-;D
M                      "+.W(%*94<]%,/W/YH@-]%5*
M!; \=W_9N\I7D                                      !AK>:S(>L
MS>Q8W<                          !KQ)=-L/&MR
M               ->)-IMAXSN0                              !UW)
MZ<>;/"S+H]F                             ->)-IMAXSN0
M                  (L[<@4IE1ST4P_<_FB WT54H              %L#Q
MW?\ 9N\I7D                                      !AK>:S(>LS>Q
M8W<                          !KQ)=-L/&MR
M            ->)+IMAXUN0                              !UW)Z<>
M;/"S+H]F                             ->)+IMAXUN0
M               (L[<@4IE1ST4P_<_FB WT54H              %L#QW?]
MF[RE>0                                      &&MYK,AZS-[%C=P
M                         &O$ETVP\:W(
M        UXDNFV'C6Y                               '7<GIQYL\+,
MNCV8                             UXDNFV'C6Y
M           BSMR!2F5'/13#]S^:(#?152@              6P/'=_V;O*5
MY                                       8:WFLR'K,WL6-W
M                     :\273;#QK<@
M   #7B3:;8>,[D                               ==R>G'FSPLRZ/9@
M                            #7B3:;8>,[D
M      "+.W(%*94<]%,/W/YH@-]%5*              !; \=W_9N\I7D
M                                   !A;>ZS(VLS>QXO<
M                !KG)]-L9&-R                                -
M<Y/I=C(QN@                              !US*Z<<[/"S3HMF
M                        -<Y/I=C(QN@
M  (L[<@4IE1ST4P_<_FB WT54H              %L#QW?\ 9N\I7D
M                                !AK>:S(>LS>Q8W<
M             !KQ)=-L/&MR                                ->)+
MIMAXUN0                              !UW)Z<>;/"S+H]F
M                     ->)+IMAXUN0                           (
ML[<@4IE1ST4P_<_FB WT54H              %L#QW?]F[RE>0
M                            &%M[K,C:S-['B]P
M         &N<GTVQD8W(                                USD^EV,C
M&Z                               '7,KIQSL\+-.BV8
M                 USD^EV,C&Z                            BSMR!
M2F5'/13#]S^:(#?152@              6P/'=_V;O*5Y
M                        8>W>MR#K<SL&-W
M     :_233[ QO<                                #7V2:?8*-[@
M                             =?R>G'VRP\PZ39
M            #7V2:?8*-[@                           "+.W(%*94<
M]%,/W/YH@-]%5*              !; \=W_9N\I7D
M                   !A[=ZW(.MS.P8W<
M!K])-/L#&]P                                -?9)I]@HWN
M                        !U_)Z<?;+#S#I-D
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M^AP<\OR    'Y?OYY>.>7YY &CM@1:6FFK"%,/W/YH@-]%5*
M  !; \=W_9N\I7D                                      !A[=ZW(
M.MS.P8W<                          !K])-/L#&]P
M                 -?9)I]@HWN                               !U
M_)Z<?;+#S#I-D                             -?9)I]@HWN
M                    (L[<@4IE1ST4P_<_FB WT54H              %L
M#QW?]F[RE>0                                      &'MWK<@ZW,[
M!C=P                          &OTDT^P,;W
M             U]DFGV"C>X                               '7\GIQ
M]LL/,.DV0                             U]DFGV"C>X
M                BSMR!2F5'/13#]S^:(#?152@   =KP^_;F%R+1NP(L
M       +8'CN_P"S=Y2O(                                      #
M#6\UF0]9F]BQNX                          #7B2Z;8>-;D
M                       :\273;#QK<@
M    #KN3TX\V>%F71[,                             :\273;#QK<@
M                          19VY I3*CGHIA^Y_-$!OHJI0   ,C:S,M.
M^1+ZJ/\ LWSS_'(        "V!X[O^S=Y2O(
M              ##V[UN0=;F=@QNX                          #7Z2:
M?8&-[@                                :^R33[!1O<
M                   #K^3TX^V6'F'2;(
M   :^R33[!1O<                            19VY I3*CGHIA^Y_-$!
MOHJI0   .TXG?=$\+>F/J=/9\?OZHN+;@E=WTQ3@%@OS;;U?3TE4(L@>7[HK
M?^H*7    %L#QW?]F[RE>0
M&'MWK<@ZW,[!C=P                          &OTDT^P,;W
M                        U]DFGV"C>X
M     '7\GIQ]LL/,.DV0                             U]DFGV"C>X
M                           BSMR!2F5'/13#]S^:(#?152@   #9"+[J
M96CK)P1(=5"W>M9?E^^!9X\GWE,_1=F:2SV+CL&-W4HO>'F,    6P/'=_V;
MO*5Y                                       8:WFLR'K,WL6-W
M                        :\273;#QK<@
M      #7B2Z;8>-;D                               ==R>G'FSPLRZ
M/9@                            #7B2Z;8>-;D
M         "+.W(%*94<]%,/W/YH@-]%5*   !]['[;G/AGTM7W](U#L]$]YF
M31[*M=ZEI0"0.MY?'Y9$0      M@>.[_LW>4KR
M                  P]N];D'6YG8,;N                           U
M^DFGV!C>X                                &OLDT^P4;W
M                       Z_D]./MEAYATFR
M      &OLDT^P4;W                            $6=N0*4RHYZ*8?N?
MS1 ;Z*J4   #/T<VTY% 6G6Y]14M_?"UWX]O^J#[#H "S7Y3O#?NN9=^?ZXZ
M1GXE-CW#YM    %L#QW?]F[RE>0
M     &%M[K,C:S-['B]P                          &N<GTVQD8W(
M                             USD^EV,C&Z
M          '7,KIQSL\+-.BV8                             USD^EV
M,C&Z                            BSMR!2F5'/13#]S^:(#?152@   "
MW5XO]#Y/U6?DG59M<7T_2\6]MP0"U9Y!ORJGZ^H,     "V!X[O^S=Y2O(
M                                    #"V]UF1M9F]CQ>X
M                 #7.3Z;8R,;D
M:YR?2[&1C=                               #KF5TXYV>%FG1;,
M                         :YR?2[&1C=
M   19VY I3*CGHIA^Y_-$!OHJI0  !VO#[^J9G0.ZX&3US*Z?F]OP +<GC'T
M/_7''7,KIZCFXU6KUQ1     M@>.[_LW>4KR
M               P]N];D'6YG8,;N                           U^DF
MGV!C>X                                &OLDT^P4;W
M                    Z_D]./MEAYATFR
M   &OLDT^P4;W                            $6=N0*4RHYZ*8?N?S1
M;Z*J4   6F_(M\PDWU5]DWRW=8$9MJP>O_Z/J,#/L<VV5-1G]7R^C\/9\ZR2
MO1@   "V!X[O^S=Y2O(                                      ##6
M\UF0]9F]BQNX                          #7B2Z;8>-;D
M                     :\273;#QK<@
M  #KN3TX\V>%F71[,                             :\273;#QK<@
M                        19VY I3*CGHIA^Y_-$!OHJI0   !LA%]U,K1
MUDX(D.JA;O6LOR_? %@WS;;\Q](633=]O^;;!WFVWZN_K2B@   !; \=W_9N
M\I7D                                      !A[=ZW(.MS.P8W<
M                       !K])-/L#&]P
M      -?9)I]@HWN                               !U_)Z<?;+#S#I
M-D                             -?9)I]@HWN
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M'FSP\AZS,                               'SNWXZ]D]/<L')
M         RGJ,^R)Y>NH             :^R33[!1O<
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M:[:VM]U3.JZ\^BMQFIIYY_UYUEZ'5#6C47M.#UX)[%_0 HRS)(X_M@
M     (J;?@-"?]$O)@
M                                       VFB.^](C\O/:8
M     UXDNFV'C6Y                            BSMR!2F5'/13#]S^:
M(#?152@   "W5XO]#Y/U6?DG59M<7T_2\6]MP0 ;8PV0=UP<G4.:1WJN9T
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MF!SOPF2;=ZO.JN67#; 4%DTD<?VP           $5UO0*A%^B?DL
M
M             ;31'?>D1^7GM,             :^R33[!1O<
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M4@\PT3WLM,7W=-JVH'8"@LFDCC^V            BNMZ!4(OT3\E@
M
M             #::([[TB/R\]I@            #7V2:?8*-[@
M                 "+.W(%*94<]%,/W/YH@-]%5*   !]['[;>?BWT37;],
M4W\3OZL8[;!U[DNH M;^/K^JD>P:!      M@>.[_LW>4KR KC6!%/A_7%E6
MO98-6-GAT]K6@E["EK'ZAV]<5,FTT;DAU-JBLYG\C[^< YV-1(NJN+%\ E/V
M_C[GKA,DU!VN#3)MR W(:EGE:&Q(E=(J&?\ G9WW5OHA4+:/P_OY^[\?7GMW
MM6/H6T19]1*U(/-!$-_4AM*$>A)1-H<_ 16R;35%[3@_H+459WU/GZB^DFGJ
MZV1#KI%0S_+F+W^?U>=96MZQFD;DAU-JBLYG0*O&L[WM*61'5O\ 50OR_0:4
M;C7W,JCGNR6OR^H=O70%O*L[:%7S:FK;4"]&>@;5\^^]*Q]"RB+0
MPUO-9D/69O8L;N \W'T%5'I'>?;7J)VG!\]8639RKF7^:MZ%J7TI//=M>:YZ
M$J:^C25D[KZ?80OR[05NK!B=^6D++ ^/]_-%&Z:YM7UE,Y%]!M8")Q&=?\[&
ML[US+_/?O:L+Y=)V3E7%[J;5M0.P%!9-)'']L           !%3;\!H3_HEY
M,
M                      &TT1WWI$?EY[3             &O$ETVP\:W(
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MC5>*>1?8'!R;>%5SG9G798           BNMZ!4(OT3\E@
M
M      #::([[TB/R\]I@            #7V2:?8*-[@
M          "+.W(%*94<]%,/W/YH@-]%5*    )U?/MJ[<PN0URO3M,[G0:2
MQL6E"@+7'CV_JH_L*@0     +8'CN_[-WE*\@
M               ,/;O6Y!UN9V#&[@                          (KK>
M@5"+]$_)8
M                              VFB.^](C\O/:8             U]DF
MGV"C>X                            BSMR!2F5'/13#]S^:(#?152@
M 9>TNQL!><+=Q[LL.O'Z6IVUIX_OZJ3[!H$"X[XA](YBTFQ^3W=?1=ABTT/<
M?FL    6P/'=_P!F[RE>0                                      &
M%M[K,C:S-['B]P                          $4EP0"A9^B/DT
M
M              ;31'?>D1^7GM,             :YR?2[&1C=
M                  19VY I3*CGHIA^Y_-$!OHJI0   .Z8.3;)\<>@M<9/
MI8V;2A,GU3SJKQZTHH#/,=VV!I%J1E;3Y_U>GLPIOM8   !; \=W_9N\I7D
M                                     !AK>:S(>LS>Q8W<
M                  !%3;\!H3_HEY,
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M^*,KI$U\/D$R42WP    HBW76^><'*_+SQ85@DHDVCFW
M$4EP0"A9^B/DT
M                                  ;31'?>D1^7GM,
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M>MS?H_/.$\S'['U_?7.SXS9AY           $5UO0*A%^B?DL
M
M          ;31'?>D1^7GM,             :^R33[!1O<
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M_P#;F9.);ZJ%9T*DEC^VE\BF\HIW37-IRM9ELYK<R#":1S<+4Y]MRKIOR\
M       ,/;O6Y!UN9V#&[@/-6]"U+<)JB=B9F);[SI[\JST0Z%M*N_/8MEK%
M[X-YG'=\M)LHN))IK[E(V5V/K^QYJWH6I?2I\]6T(>I7HH4)A']6MGA=KZNR
MQ1 935OLJ'2ZQ7>0SR[07\*.LSS][SK*7>*[N+*3::VG5TVE4C.Z
M  $5UO0*A%^B?DL
M                                    ;31'?>D1^7GM,
M  :^R33[!1O<                            19VY I3*CGHIA^Y_-$!O
MHJI0   !N/"))B[;8')QSU'-Q\9[7! ^QT=DI=1SR+ZVH+DG59O/\\X-D&K
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M"E[&U VV!76GL6N>U'/JNMDP[;G59U:.PXGZ%M$6?&%(]/ S-XW<CJ6>
M      "*FWX#0G_1+R8
M                                        -IHCOO2(_+SVF
M      ->)+IMAXUN0                           (L[<@4IE1ST4P_<_
MFB WT54H   ':L/ON_\ @;U'I[-HY_//$=-FPV##T#58%IKR-?/<,'(K7^I:
M4LK>6+MJ7^R?/@    M@>.[_ +-WE*\@*XU@13I'=UV<*YEXAZE>BB1E.DML
MU=-O.DORK+_%'693:MJ!VO:QFE9"Q8A=(J&?^>]>U8^A;1%GUXIY%A77GT6]
M!&B[.QQD=64\7N\_N\ZRO7TM8]-JVH'^#GYM%5O,83)A'I'M!M:Q]BQ'T+*(
MM :S['#I#7'7OH(T79V+\GI\]J]JPO\ %'691[N2N[Q--6)W'J[/E?7S4:M.
M$6.:_E>BNZUNM6QP[0];S'5S98=<J?Q21?0;692);_HW=U40+KK?T!J-L['/
M?TY5QN^@=>%9WD*:L7..%D         8>W>MR#K<SL&-W >:MZ%J7TJ?/5M
M=;[/CS8?0E3ST0F26QZOFWG>7U5OHC4+:6N.PQ-F==F<O >:MZ%J7TJ?/5M=
M;[/B@->-9W'*GGE0NU(->]I2R,79/32)N.O+_P#1MFTD;BKVRA7LMIE6W O0
MOHBSZ]\[C'5^SXLN5Y+0         !%=;T"H1?HGY+
M
M   &TT1WWI$?EY[3             &OLDT^P4;W
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M\_0          BNMZ!4(OT3\E@
M                                              #::([[TB/R\]I@
M            #7V2:?8*-[@                           "+.W(%*94<
M]%,/W/YH@-]%5*   !VG$[[^/YS>N-3IC'A%Q;<$KN^F*< EEIRP+.'E&\L4
M[C AWNVMX"/1E2    "V!X[O^S=Y2O(  "*N3:;0#>:RRG7LL
M                       &&MYK,AZS-[%C=P  &,<GIJ(6G![GM1SX
M     46+HKJ]/2]B@           14V_ :$_Z)>3
M
M !M-$=]Z1'Y>>TP            !KQ)=-L/&MR
M     !%G;D"E,J.>BF'[G\T0&^BJE     ':<3OW!A,CT5L&*\_SSN[ 91HW
M8$6WXKJ6R[4O8D&GH"J]7);H@   !; \=W_9N\I7D
M                   !A[=ZW(.MS.P8W<
M!JO+]!B[;8(                                P[O-;F+1[(
M                        ?'[^KIN=C9*U6<              !V#'[=V8
M%*             !K[)-/L%&]P                           !%G;D"E
M,J.>BF'[G\T0&^BJE    &Z4$DUA'S9<&VD-D-<OT[3$3EQU_*C4,]VLA^_@
M0]%5+>__ #T]7U2_8- 63/+=V4FO>7F$    6P/'=_V;O*5Y
M                           8>W>MR#K<SL&-W
M        :_233[ QO<                                #7V2:?8*-[
M@                               =?R>G'VRP\PZ39
M               #7V2:?8*-[@                           "+.W(%*
M94<]%,/W/YH@-]%5*   )6*?GU@7S?;VJ<PT&&]YK(IK@@.A=B1,2OT[/]L(
M=(,)[[6;?0J15GO55(W)O#_I*FS[@\V@   "V!X[O^S=Y2O(
M                          ##6\UF0]9F]BQNX
M       #7B2Z;8>-;D                                :\273;#QK<
M@                              #KN3TX\V>%F71[,
M               :\273;#QK<@                           19VY I3
M*CGHIA^Y_-$!OHJI0  !,I1]DSL>>[6CEL^&8VVF#'59L-T+L2)CG^>;/WDV
M],]1[;50_85 ?%R.JS_Y-O2JOZ]H0    6P/'=_V;O*5Y
M                        8>W>MR#K<SL&-W
M     :_233[ QO<                                #7V2:?8*-[@
M                             =?R>G'VRP\PZ39
M            #7V2:?8*-[@                           "+.W(%*94<
M]%,/W/YH@-]%5*   !_7"3.JIO80\V7#W7 R:U/J>DXV[1A0       %L#QW
M?]F[RE>0                                      &%M[K,C:S-['B]
MP                          &N<GTVQD8W(
M          USD^EV,C&Z                               '7,KIQSL\
M+-.BV8                             USD^EV,C&Z
M             BSMR!2F5'/13#]S^:(#?152@    #+.FV&Y,'DD;MHPL
M    "V!X[O\ LW>4KR                                       PMO
M=9D;69O8\7N                           USD^FV,C&Y
M                    &N<GTNQD8W0
M  ZYE=..=GA9IT6S                             &N<GTNQD8W0
M                       $6=N0*4RHYZ*8?N?S1 ;Z*J4
M "V!X[O^S=Y2O(                                      ##V[UN0=
M;F=@QNX                          #7Z2:?8&-[@
M                :^R33[!1O<                               #K^
M3TX^V6'F'2;(                             :^R33[!1O<
M                   19VY I3*CGHIA^Y_-$!OHJI0              +8'
MCN_[-WE*\@                                      ,-;S69#UF;V+
M&[@                          ->)+IMAXUN0
M           !KQ)=-L/&MR                               .NY/3CS
M9X69='LP                            !KQ)=-L/&MR
M              !%G;D"E,J.>BF'[G\T0&^BJE               M@>.[_L
MW>4KR                                       P]N];D'6YG8,;N
M                         U^DFGV!C>X
M       &OLDT^P4;W                                Z_D]./MEAYA
MTFR                             &OLDT^P4;W
M          $6=N0*4RHYZ*8?N?S1 ;Z*J4              "V!X[O\ LW>4
MKR                                       P]N];D'6YG8,;N
M                      U^DFGV!C>X
M    &OLDT^P4;W                                Z_D]./MEAYATFR
M                             &OLDT^P4;W
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M<CBYXY>.>+ZXXN>.7YY<N7YY'%]<<OSR.+ZXY?GGBYX<N+G@#EXY< Y. <G
M.7Y?KYY>.>7CEP#EHY/XM+535A"F'[G\T0&^BJE               M@>.[_
M +-WE*\@                                      ,/;O6Y!UN9V#&[
M@                          -?I)I]@8WN
M         !K[)-/L%&]P                               .OY/3C[98
M>8=)L@                            !K[)-/L%&]P
M            !%G;D"E,J.>BF'[G\T0&^BJE               M@>.[_LW>
M4KR                                       P]N];D'6YG8,;N
M                       U^DFGV!C>X
M     &OLDT^P4;W                                Z_D]./MEAYATF
MR                             &OLDT^P4;W
M        $6=N0*4RHYZ*8?N?S1 ;Z*J4              "V!X[O^S=Y2O(
M                                     ##6\UF0]9F]BQNX
M                  #7B2Z;8>-;D
M :\273;#QK<@                              #KN3TX\V>%F71[,
M                          :\273;#QK<@
M    19VY I3*CGHIA^Y_-$!OHJI0              +8'CN_[-WE*\@
M                                 ,/;O6Y!UN9V#&[@
M              -?I)I]@8WN                                !K[)
M-/L%&]P                               .OY/3C[98>8=)L@
M                     !K[)-/L%&]P                           !
M%G;D"E,J.>BF'[G\T0&^BJE               M@>.[_ +-WE*\@
M                              ,/;O6Y!UN9V#&[@
M           -?I)I]@8WN                                !K[)-/L
M%&]P                               .OY/3C[98>8=)L@
M                  !K[)-/L%&]P                           !%G;
MD"E,J.>BF'[G\T0&^BJE               M@>.[_LW>4KR
M                          PMO=9D;69O8\7N
M       USD^FV,C&Y                                &N<GTNQD8W0
M                               ZYE=..=GA9IT6S
M              &N<GTNQD8W0                           $6=N0*4R
MHYZ*8?N?S1 ;Z*J4              "V!X[O^S=Y2O(
M                     ##6\UF0]9F]BQNX
M  #7B2Z;8>-;D                                :\273;#QK<@
M                          #KN3TX\V>%F71[,
M          :\273;#QK<@                           19VY I3*CGHI
MA^Y_-$!OHJI0              +8'CN_[-WE*\@
M                 ,+;W69&UF;V/%[@                          -<
MY/IMC(QN0                               !KG)]+L9&-T
M                      .N973CG9X6:=%LP
M     !KG)]+L9&-T                           !%G;D"E,J.>BF'[G\
MT0&^BJE               M@>.[_ +-WE*\@
M              ,/;O6Y!UN9V#&[@                          -?I)I
M]@8WN                                !K[)-/L%&]P
M                   .OY/3C[98>8=)L@
M  !K[)-/L%&]P                           !%G;D"E,J.>BF'[G\T0&
M^BJE               M@>.[_LW>4KR
M          P]N];D'6YG8,;N                           U^DFGV!C>
MX                                &OLDT^P4;W
M               Z_D]./MEAYATFR                             &O
MLDT^P4;W                            $6=N0*4RHYZ*8?N?S1 ;Z*J4
M              "V!X[O^S=Y2O(
M     ##6\UF0]9F]BQNX                          #7B2Z;8>-;D
M                             :\273;#QK<@
M          #KN3TX\V>%F71[,                             :\273;
M#QK<@                           19VY I3*CGHIA^Y_-$!OHJI0
M          +8'CN_[-WE*\@ -;-AB=RZNS,.)W@        =9[/C4#;8.\NE
MV(&*,KIZIV]>P6!E     ?P:%;S6;\:/9@  =9[/C4#;8.\NEV(
M  P]N];D'6YG8,;N UMV&)LEK\L80S,?O/3V8@R^C97798ZOV?&M&QQ-L=9F
M_N^>0 .G=O7A;,Z-FM=ECX_W\ZX;#%VGUF8!B7*Z.[=/9V3K^P
M -,)U&8W;0A0                                Q9M\#*>HSP
M                        !\KN^.K9F/W[6Y8
M        Q9M\#*>HSP             !W[79DV=#6>            (L[<@4
MIE1ST4P_<_FB WT54H              %L#QW?\ 9N\I7D!C/)Z?/XO*LMN-
M7G8ZR.J<N%R*PK!)0        -9]CAU [5@UY2F;%$,$NT%?R=1C9+79<O\
M%=[,C$M\    .F]W74]LZ%6]*KG(  &L^QPZ@=JP:\I3-B@          ##V
M[UN0=;F=@QNX#S<?054>D=Y]M?3G;8%(ZXJ]]!2B[.\WGT#5'I4^>K:KO3V+
M5NK BDANBVD9,BU%TRH9_*'&]P!H_N==33MJ!221_;87S,>V[5LXHCW56\LT
M7W>D^XU]YVF+%C3D.H\Z"_:L]&B@;4DCC^V            BNMZ!4(OT3\E@
M
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M?VP           $5-OP&A/\ HEY,
M
M                   &TT1WWI$?EY[3            $6=N0*4RHYZ*8?N?
MS1 ;Z*J4              "V!X[O^S=Y2O(#SRKXJZ][2ED9XPLD#SY+UK"]
M?2UCZS['$J]V1#I,XYN-2=K@V^*JG/G87W5OH"499E=B?1;:_5YM:RPXE< J
MF=1B2/3]MZNR7B*[S;_59WGFWQ5]YJF+$J!VK!KRE,V*-;]AB4=[EKO27<:^
M]G2UCT]K6@OHD4+:4/4KT4;DAU. L[&WJTNQL40&54#[QK._]1MF^?U>59>@
M11EF^?%>U86'X%*=;]AB6AZWF&/,CJP9F8^W^JSO/-OBK[S5,6)4#M6#7E*9
ML4           8>W>MR#K<SL&-W >;)Z$J;L/7]V1:^EEC6 2H>:MZ%J6]C2
MUD50K.A5[6E;' \TCT/4GHW4!:T5$FTNSFNS)!-%LQ62L6(_0XYCNWVJL_UQ
M,-[])LJDUHPF5N,[J7Z*;RFU;4#L!06321Q_;            176] J$7Z)^
M2P
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MTD<?VP           $5UO0*A%^B?DL
M
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M&L[K%/V!1ZN6O)CHEO9+8]MZ>UK06?N#R: V<1F_S1MF5 [5@UY2F;%
M      &&MYK,AZS-[%C=P'FX^@JH]([S[:^#LW'H"WC67H T;9OG@7S5OI4^
M>K:KJ3Z*UQI_%9"]%M(R9%J+I=0S^42-[@"#":1VC=<M=6'X'*<CX_;:&K>8
M41KJKB6B+[O23<:Z]!3%C1'2G1U"+5@\H,;W%K2LIIG/"R           !%3
M;\!H3_HEY,
M
M &TT1WWI$?EY[3            $6=N0*4RHYZ*8?N?S1 ;Z*J4
M    "V!X[O\ LW>4KR  U?V6'D;'[<M8O>,$YN-]SX^LM8O?C3(Z?H<?7>^C
MLUYS\78; RL=Y'4,B8_;@W-QOJ?'UE[%[\8Y/3\SZX_HR9C=V(,O'SEA9(&M
MFPQ,C]';DS&[AJYLL/8#!R>F]OQ\_P"N,B=';@+.Q:AUJ0>[Q3EA4>[DKRW5
M5DX[;U?>PF!E='[NO%.5T;':_+QCD]/S/KC^C)F-W8@R\?.6%D@
M ##V[UN0=;F=@QNX#6W88FR6ORQBK)Z?Z,>Y'5LKKLL=7[/C6C8XFU^LS?H?
M/( PAF8^'LO''[N.=PM3G_'^_G7#88NT^LS!@3.QL59/0-JM9F]FZ_L
M      176] J$7Z)^2P
M
M         !M-$=]Z1'Y>>TP           !%G;D"E,J.>BF'[G\T0&^BJE
M             M@>.[_LW>4KR                    @2F\:B[DFGFUAT@
ME\BN]                 PMO=9D;69O8\7N
M   BDN" 4+/T1\F@
M
M      #::([[TB/R\]I@           "+.W(%*94<]%,/W/YH@-]%5*
M         !; \=W_ &;O*5Y
M  86WNLR-K,WL>+W                           127! *%GZ(^30
M
M                                              !M-$=]Z1'Y>>TP
M           !%G;D"E,J.>BF'[G\T0&^BJE               M@>.[_ +-W
ME*\@(Q9'IY.HYN!I)N-?MQJ\WL?7]ZV;#$&R>ORP     !KQGXNON?BR$Z':
M                         ##V[UN0=;F=@QNX"-60ZG!.;C#=?3[#<G4Y
MX    AMENA_#SQE_%[Y-XYM_U<<@               "*ZWH%0B_1/R6
M
M                                               -IHCOO2(_+SVF
M            (L[<@4IE1ST4P_<_FB WT54H              %L#QW?]F[R
ME>0'G?WS5UXJFK#VVU>=YE/HJHK9U7S:P1!9/1:NBN;2M:S*1#0[0      1
M+2C2122?2VQ*PFH                         PUO-9D/69O8L;N \U;T+
M4MPFJ)V-U]/L-R=3G@   #R[O2-.W<:<L/7#88E?6=1B_P T=9F0.CM
M           BIM^ T)_T2\F
M
M              #::([[TB/R\]I@           "+.W(%*94<]%,/W/YH@-]
M%5*              !; \=W_ &;O*5Y 5O[ BF)<KHGRA$EI\VM!L:Y'3?XH
MZS/-D]"5/Z3?GNV( 9S&8FY1I.Y]/9<7J>=TX;9@ES:HY[!_,H]E[$[X5IA'
M^H=O7@;.QKL]/6#I7M]?5\LB'_(^^-]M'LI(H_MH*9I')&]!M;+M=RT
M                  ##V[UN0=;F=@QNX#S5O0M2^E3YZMH<'*E?;U?W5Z@L
M"-60ZC3G;8/ROOYB?D^EVHUF9:]K&:@>:MZ%J7TJ?/5M"N]/8MK[G8O5^WYP
MAF8TL\7W>K>RP](=SKL]X.3;:JZ;T^[6@HU)VF%=(J*?9RPLD          1
M76] J$7Z)^2P
M
M  !M-$=]Z1'Y>>TP           !%G;D"E,J.>BF'[G\T0&^BJE
M      M@>.[_ +-WE*\@,,Y>/0*O&LYEHEOYA(IO:E%HPBW55DXK/6)$KME.
MV#Y[5[5AZ)%"VE6VL&)_>^/JO%/(OZ)%"VE6JL*)Y]P<FL18\0]#"B+0KDS^
M*9AQ,BMS8,3] .C+-BSDNFB^DFGT.W>ML(023S,Q'?\ [..0
M           ,/;O6Y!UN9V#&[@/-6]"U++1%]X+F=23VEW;L L;0"5U@+'A]
MP*J9UYYU\5=<JJ2>UGK$B-S:I)]N7J,\>:MZ%J7TJ?/5M"+R2:>N?/HKK[GX
MMOVJISDK&[J>%L02][2ED4YK8@DWT.D-06U(-Z&U$6C#K*]#&Y(=3;,J^;
M        "*ZWH%0B_1/R6
M
M            -IHCOO2(_+SVF            (L[<@4IE1ST4P_<_FB WT54
MH              %L#QW?]F[RE>0 \X;T!5.3L;N]"FB+0K=6#$ZN-DPZZ54
M,_E.C6ZH1W=6GH,T59\$\UCFJ&SPH0YE'?1#H6TJU5A1//N#DUJK#B?H6T19
M]>*>185P; BOHMT':<2LITD4LFTMIFM9E -.(S!)-8W?_HVS0
M            ,-;S69#UF;V+&[@/-6]"U+Z5/GJV@-4MGA4N;>@&7<3ONLU!
M8/GTWK6%X.FK#&V>KSON_'T/-6]"U+Z5/GJVA4SM"$[?:K/@8FT:O>TI9&GN
MVP*SMB1&ZY3]@U5[,AF^.DV58FQHCZ%M$6?$I*-)#C+=#;YJJ<@
M"*FWX#0G_1+R8
M
M    -IHCOO2(_+SVF            (L[<@4IE1ST4P_<_FB WT54H
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MA%^B?DL
M                                                          ;3
M1'?>D1^7GM,            19VY I3*CGHIA^Y_-$!OHJI0
M +8'CN_[-WE*\@                                      ,/;O6Y!U
MN9V#&[@  /P_7%!V[JTOX4?9@         \]*]ZP]"VB+/            BN
MMZ!4(OT3\E@
M
M #::([[TB/R\]I@           "+.W(%*94<]%,/W/YH@-]%5*
M    !; \=W_9N\I7D                                      !AK>:
MS(>LS>Q8W<  !C_OZM><_%W&U.>         (]-]JY"]#M            -.
M)O&]*)Y&                                !B3<Z[+>FV(
M                      ^1W=74LW'R)K,T
M     8DW.NRWIMB              .Z8.3+535A            "+.W(%*94
M<]%,/W/YH@-]%5*              !; \=W_ &;O*5Y
M                      8>W>MR#K<SL&-W
M   :_233[ QO<                                #7V2:?8*-[@
M                           =?R>G'VRP\PZ39
M          #7V2:?8*-[@                           "+.W(%*94<]%
M,/W/YH@-]%5*              !; \=W_9N\I7D
M                 !A[=ZW(.MS.P8W<                          !K
M])-/L#&]P                                -?9)I]@HWN
M                      !U_)Z<?;+#S#I-D
M      -?9)I]@HWN                            (L[<@4IE1ST4P_<_
MFB WT54H              %L#QW?]F[RE>0
M             &%M[K,C:S-['B]P                          &N<GTV
MQD8W(                                USD^EV,C&Z
M                  '7,KIQSL\+-.BV8
M  USD^EV,C&Z                            BSMR!2F5'/13#]S^:(#?
M152@              6P/'=_V;O*5Y
M         8:WFLR'K,WL6-W                           :\273;#QK<
M@                               #7B2Z;8>-;D
M              ==R>G'FSPLRZ/9@                            #7B
M2Z;8>-;D                           "+.W(%*94<]%,/W/YH@-]%5*
M             !; \=W_ &;O*5Y
M      86WNLR-K,WL>+W                           :YR?3;&1C<@
M                             #7.3Z78R,;H
M           =<RNG'.SPLTZ+9@                            #7.3Z7
M8R,;H                           "+.W(%*94<]%,/W/YH@-]%5*
M          !; \=W_9N\I7D
M !A[=ZW(.MS.P8W<                          !K])-/L#&]P
M                         -?9)I]@HWN
M      !U_)Z<?;+#S#I-D                             -?9)I]@HWN
M                            (L[<@4IE1ST4P_<_FB WT54H
M      %L#QW?]F[RE>0                                      &'M
MWK<@ZW,[!C=P                          &OTDT^P,;W
M                     U]DFGV"C>X
M  '7\GIQ]LL/,.DV0                             U]DFGV"C>X
M                        BSMR!2F5'/13#]S^:(#?152@
M  6P/'=_V;O*5Y                                       8:WFLR'
MK,WL6-W                           :\273;#QK<@
M                #7B2Z;8>-;D                               ==
MR>G'FSPLRZ/9@                            #7B2Z;8>-;D
M                   "+.W(%*94<]%,/W/YH@-]%5*              !;
M\=W_ &;O*5Y                                       8>W>MR#K<S
ML&-W                           :_233[ QO<
M             #7V2:?8*-[@                               =?R>G
M'VRP\PZ39                             #7V2:?8*-[@
M                "+.W(%*94<]%3KV+Y^AEO*M               )F*.LJ
M7NE;%                                       Q_LL/M>'D?5Z>P
M                        #%6XP,JZ?/
M      &*MQK\JZ?8                               #Y7=U]4S,?(&M
MS                             !BK<:_*NGV
M        'Q>_JEFIRP@
M
M
M
M
M
M
M                      /_V@ ( 0(  04 _P#Y4L.F*(ZFIDTR1DTR1DTR
M1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR
M1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1%1AE0PY
M-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9
M-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9
M-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9
M-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9
M-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9-,D9
M-,D9-,D9-,D9-,D0489,<>-&F3ACDTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1
MDTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1
MDTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1
MDTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1DTR1
MDTR1DTR0WZ)TQG$\C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(
MVCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,
MC:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCX
MR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/
MC(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H
M^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(V
MCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C
M:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR
M-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C
M(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^
M,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VC
MXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:
M/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-
MH^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(
MVCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,
MC:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCX
MR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/
MC(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H^,C:/C(VCXR-H
M^,C:/C(VCXR-H^,C:/C(VCXKC35HL5)V4Q^TO+YWZ/0\M\Q'_?SO_M/Z]W2?
M(;*8_:7E\[]'H>6^8C_OYW_VG]>[I/D-E,?M+R^=^CT/+?,1_P!_._\ M/Z]
MW2?(;*8_:7E\[]'H>6^8C_OYW_VG]>[I/D-E,?M+R^=^CT/+?,1_W\[_ .T_
MKW=)\ALIC]I>7SOT>AY;YB/^_G?_ &G]>[I/D-E,?M+R^=^CT/+?,1_W\[_[
M3H\_'&LHRB7GU0-%\9U4Y 3:C3Y!B3/DF97M'.JJ9=Y\G<CG*MN'::,R"9><
M]7$MFIRG4M*A:3KB<D!PS 2*-U>DN(ETJND^0V4Q^TO+YWZ/0\M\Q'_?SO\
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M>A_&9G8%RU+(L8H@L,U&6SLB3*+2>="WS$?]^U>8G;:MM=36WFA2R79J<%E
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M+NAS)JNQU1O%F.XIRZGN\XXR\F73M748832ZP56";+F2IB@NOI7BILIDH6W
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MS-6(U6,E4X]+:;1E-V X4+GRLYD.)$-1I]3%*%JM26W(-CI:)9Q0%TFI"/!
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MQZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C
M['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,
M#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['H
MP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L6D6[78]&!V/1@=
MCT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!
MV/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8
M'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1
M@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]
M&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8"RBTBP+]CT8'8]&!V/1@=CT8
M'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1
M@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]
M&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=C
MT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V
M/1@=CT8'8]&!V/1@=CT8!5&HW\2O(U(,%SL>C ['HP.QZ,#L>C ['HP.QZ,#
ML>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP
M.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C
M ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ
M,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,#L>C ['HP.QZ,!,1:18I
M78]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1
M@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]
M&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=C
MT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V/1@=CT8'8]&!V
M/1@=CT8%9925**[+9>X?+[I/G^A[8PZSE._Z'.=^K_P[H$X8?<5Z $O]3CGP
MZKEY\1H?>A\\U0^E;+9>X?+[I/G^A[8PPQ<IWYSG?W0[G= G#A#@5Z $OG'/
MAA@Y>?$;"'%$YYJA]*V6R]P^7W2?/]#VQ_HY3OSG._O_ .'= G#C[RO0 E\X
MY_\ 5R\^(V/_ &3GFJ'TK9;+W#Y?=)\_T/;&/5<IW_4YSOUO^'= G#%[RO0
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M*;)R@1F.9$69Z_.DSB\WE%,HO^Y?TDJ!W#Y8C1>Y#YYJA]*V6R]P^7W2?/\
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M/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_ *8#/^F
MS_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_ *8#/^F S_I@
M,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_ *8#/^F S_I@,_Z8
M#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_ *8#/^F S_I@,_Z8#/\
MI@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_ *8#/^F S_I@#-<:=$X,_P"F
M S_I@,_Z8#/^F S_ *8#/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I
M@,_Z8#/^F S_ *8#/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z
M8#/^F S_ *8#/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^
MF S_ *8#/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F S_
M *8#/^F S_I@,_Z8#/\ I@,_Z8#/^F S_I@,_P"F S_I@,_Z8#/^F EU\IE-
MC-UUIN1-Y_TP&?\ 3 9_TP&?],!G_3 9_P!,!G_3 9_TP&?],!G_ $P&?],!
MG_3 9_TP&?\ 3 9_TP&?],!G_3 9_P!,!G_3 9_TP&?],!G_ $P&?],!G_3
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MA9KOCPB9KO@PB9;QA$3-=\.,QEO&4)K+>,@1LEYRXMR7GA% R7G,BE,MXSQ
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M]K0-.ELJ# JOSHS"WLIIW?#77L6\J&TQH/2-:I^K)4KDC8APB<IW#W'-M/\
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M08RG'SXCRXHT7GFJ'TK9;+W#Y?=)\_T/;$&$QRG</<<YW_+PW.Z!.&7A+*]
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M 8+*)A#VRB=6)90\1$LHF.$:RB1835E#C$:TA11=M(?6@6D*&*4LH< EK*)
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MRK#J:V[,0IXHS#R"Z5;ME;#3=J?-3IM-4XY%V0QVQ(FXR\9FQ52NVT+*L2F
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MT4^:V/3OUR^7^KT/G_HP_P!O._\ N/Z]T4^:V/3OUR^7^KT/G_HP_P!O._\
MN.CS71TY1)S93)D3?RV/-!QH2ILJ9+F29GM$4B2FMWDZ.BSEB+;(DS3$Z6VT
MA-D2R;-/1+Z%"CQ%Y,1B>K)<Q(,]*J*?-;'IWZY?+_5Z'S_T8?[>=_\ <='F
M5\@K?5 B+$Y*-.]-ESBP+%#1R.-M+<$$<N.5&21E)0E10Q01"!&4IA,%454.
MP&T54)0!![L"3(G&)F#97(H3!4R4C$Y*4)!0JBJAV XDJ)# 0I2A&2)HZD?A
M.$#A",FDJ)_ XD*1"$888Q8RFXM3H3:>=(Q XDJ"?!);JU/@.)YTA%(D33,U
MJIII/+;KKHBAB@B#,E01J;MBG8K(FF)\_!OHQ^,^YT9243YY..)T9<J9-QXM
MI;P@F2YDJ,%$=3/0FT54)0;"J*J'8#:*J$H.C]%/FMCT[]<OE_J]#Y_Z,/\
M;SO_ +CH\ROD%;ZILD>\VUR)28>-JA\NV2<MV+4$Q6DEUY$9Y[X=0=1'X14*
M%XS9EUF8"*8U$>6>G*[L-8&$=U&XS+I2Y:>>0>[$$$4V.9\(U$F)UK<4Q..%
MG.GG"TPF:E8E(&X:=JK-FM]:Q6I:P1P3E%!AD1-DRZU&*81F270DJKE-%S#=
M6)BQ)5"F!%0;Y LEIAEVJTZ:B+$*[ HDXD\\JFB9$G-=BS,FD#$MRHTF=/(F
M6R>-*"?O0NB***.((REBEGXY20X"QUE188&BA@E.;*NH3#[G65)./GE$XHQR
MG3)))TEV+$N:ZBL@XEMXA+45-PN$T1-(+F.SSKI6#1.)J(\L].5W8:P,([J-
MQF72ERT\]T>HI\UL>G?KE\O]7H?/_1A_MVH"&E'4K_@H@0VTJPJJ2929_L6I
M(D&51SR9)=6]A@BSL4?EG^XZ/,KY!6^J;)W_ &ULM+"'%97C+?EGOC&<('&A
MEB$F;'(G.&5 K(;,(_FFG >^/5&IC# A_&,X0GF?#$XEPHKRT'NPA881+#XB
MBZP9<46"F[(8<%HWW/#1QQP67GAA@JHO=0,GY,[\XROGW1]=/S"$E#^,9P*+
M#6(SUL_)4E!W?10R?DSO^AQF_2?P2ILV3&G.Q0+1NTO),)+5^N/3ZH$UK'S\
M&[*&7Q6Y<J4V6^?EIRFX&\84#*$V3I<XYU"4?4FIC# A_&,X0GF?#$XEPHKR
M^CU%/FMCT[]<OE_J]#Y_Z,/]NUK_ $$%S$TK/=$N RA$4P\I8ET\Z;G'DE03
MH(((YD<MMK<R$T0.$HA##%'%+;:W,@:Q8P46G;]9)HJFH206+3SD\ZGG$Z8"
MZ L&8#:2I$<"A X?BGIAO%KF&^KE9/*_]QT>97R"M]4@@CF1(#9,13W6M2S<
M:2=P3U%T),U1E_ES.O$@*DLD&>;@,DYL.#<;H9BA!A@M(IE,,E21L[&I)9M*
MF(/=@K/B*F5\GVXEQ2ID$QK)DQ.D*QS!04?A9IUKS9$Z3,:21.+8KQZ%04T7
MNH&3\F=^<97S[H^NIDR4O-XX1-D)J>C*"E$9+S2D]W?10R?DSOSC,BPQ2\")
MN(QL14":L2SJ:=3YB<EFU.<[C<DN0:\6$*X]),SX\J5BDJ#PC/P%BA X?F*\
MG$NUT>07,J:N7<$$XV2>)R R4-$XV8H088+2*93#)4D;.QJ26;2IG1ZBGS6Q
MZ=^N7R_U>A\_]&'^W:U_H(240VISW>>E2"+'_O4UF0WXE5=-*\M/*E6XCSG8
MLS)B(L2UZ4KI^*8?;1 NGIQMW*LZ<W5Z:J3W;]99WTD-KZX]?GVDDR8I:B[C
MTR>4>!V7 45#I"8H'C4AN&' KFI/*_\ <='D1Q=CE]^1$^(L85!R*:A#L3'"
MH)<.+XCZJFOJ"I@$I1F)9U;7HUG9!''*C*/,[)AGO8S'";.&3TX@Y/@4P):V
M>2L<'Q'U5-PJ"I")LZ:7:A=[&():FYSZC+!)R?!I01'!V/)G3/SIR(K]CF%0
M]VD>)GC1"=)>\^& X\5"?#''',B5W)VJ2"(X.QY,Z9^=.25@TD39[WGQ039D
M4Z8"9XVGS9#V,PPF7J<F0SITTQ-E39DB9*>\Z&6JK!E7FDGD;+RC[N/FY?;\
M>**UD@NI3SSH5<#4#J6X(E>9 HMB"..5&4>9V3#/>QF.$V<,GIW1ZBGS6QZ=
M^N7R_P!7H?/_ $8?[=K6QZJ'OR#3T/389TZ:8F,?^];QQQ5RV&$1AZ118)H:
M\44*X]H8<#RS_P"TU@SOJSM^LL[Z2&U]<>OSY;'&6T=JMW1Y9_N.FIA939C;
MY>A+,2.9G26FL1X)[1(8KR_VGATBHI\UL>G?KE\O]7:FIL]5,*B6823'XU5M
M]F$4M.FJAM;09J/[&*7,@P"4UYZF3,2)A:?SI/\ T8?[=K7^@[6/_>M?5L,<
M<,34,+D09TB<7F-)(,2Y[D/P*"H3ZJXVIY8P6G-)*-2)[M^LLLQ!$14"$].,
MM=(.XGGK\^UC4H\E*26;3)Z>C*"GC,EQR9A^"(RTH2\^.3RO_<?U[HI\UL>G
M?KE\O]7:SOJST^J?C=7T(D=,)YE463JM%^.3+QG3GOAAA@$]Q**:7FS)DZ9S
MI/\ T8?[=J6Z.S2&U#6^QHCIGXPV$Y4.)<V!\3,(5%T*!^6$Q6.)4W%\3.I+
M<A[%25E'M0Z1/F4XQ"^)F$$]RJ!DXMJ_;!@J:GDYTA[&(8#SO4#,&....*0Y
MS27)4G::/2.5_P"X_KW13YK8]._7+Y?ZNUG?5GI]4:9>094S*0B)ADLI-4_-
M<B'+2YA E.4#4PDW&])QFM59Q=D/51$*7+G*SO+%BQI)2YRL:GRVP@803VDK
MXF94F6:A2VZBR"Y]JJ4QPHO9!ANGD:6%P^ED1V^U@EX(:M),8883T)MRS<B-
M7:96*-%1%PM.DS"\U(22J@W,8VNAB24;KA+G"LPD:YLG_HP_V\[_ .X_KW13
MYK8]._7+Y?ZNUG?5GI]49OU9V118K6&..&+H]\Q!9$B''%=,QFE8.KZ&WOK+
MV^;9TF"2F&3$9HQLDES!F.4W%R(/2##%+1_JSYV,KZ=,@_,.NJ9\&BAI&8I*
MN\B\,I31(HH6M_ZAG1Q0JSNAPP6>;)_Z,/\ ;SO_ +C^O=%/FMCT[]<OE_J[
M6=]6>GU1F_5G7];#D[NLB;#U5J3$75L,,8L77AC@AM[ZR]OFV?.@G)9DO&5,
M!))8**BKK,EO81NI<CB>7TE'^K/C8ROITR/\HZZY7QB,&D6CG*[RGPS%-%[J
M!H?6'?\ 6.;)_P"C#_;SO'A'B8ZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3
MQU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)
MXZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD
M\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)X@_/CQ
MZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\
M=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>
M.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/
M'4GCJ3QU)XZD\=2>.I/'4GC&&?AA+PGQR^I/'4GCJ3QU)XZD\=2>.I/'4GCJ
M3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU
M)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZ
MD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>(OSX8^I/'4GCJ3QU)
MXZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD
M\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2
M>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3QU)XZD\=2>.I/'4GCJ3Q2))Q)1;'IWZ
MY?+_ %=K4GR"RH[C!<RI-,Q(+*;FG29ZN' >)3D))4IB4=-1ME?@CG-U"Q7U
M(J=04*9+DJSO,EC)I'59J2:,1MA>PEPM1%BA5<):R;B;2_!,GMQ$#A4BI]"+
MSHB\\R9;[A*KDI"DRFB=)EB!C'#&>@N264D1I#3,Q1K2(AE9TZ88FI)XE+;(
M:T^07573/D&%7FR?^C#_ &[6RGD)Z1V^UAV^U@N'TL]%R&?W/_ E$>TCZL1A
M3E '5% C0^3?[CH%)_NZ 1?VR/T>?)GZO/-,?E]CT[]<OE_J]#Y_Z,/]NUJ?
M1-LF3.,3)+/5YL!YNJI" )Z$<4RJ:@J*I"J)!E(F*" ?3H9305YLHT1-DS)=
MHJ\^!11SZ7C##C%$J-XZDEPEM\XK28H<88I_<_##''$HUE<U";:JL4EAN-XZ
M1.++8/J*EN6J XU5 B5!!)/J6.+,5<(3J><3Y@4&^?3X9+/5IL"BAJ"7A[;_
M ''0*3_=T B_MD?H\^3/U>>:8_+['IWZY?+_ %>A\_\ 1A_MVM3Z)N6J#<M4
M!B1&6,(9:0C(IM?5C<UM. U,-.E,EIY]EX88IJJY)Q2:?4C:E&MG^S4[!=5\
M)T<XK.(SEU7GSB,[M] E?JO3Z6&5].F_JS^YZ:>Q3CI]S*AV-KK1Z:?=1264
M5F@<-SSSC4#\A9[65 ;CCF---)XJ!Y?5.PRL*TK0S"$^4YT>;*CDS5A0A2T^
M:NJ\Z:AFXEU(F08RYGM?]QT"D_W= (O[9'Z//DS]7GFF/R^QZ=^N7R_U>A\_
M]&'^W:U/HG:RH.UE01QQS(UWW[L!)ZW:CW]WY#*^G3OU0[OHH_\ M ,[Z3*_
M5>GTL,KZ=-_5G]SR) RHF,&RCI\"7"U83SU^HLKZBZ/KH,=T&E[NV7EUNU0Q
M^L%SW=KN[Z*&3\F=^<]K_N.@4G^[H!%_;(_1Y\F?J\\TQ^7V/3OUR^7^KT/G
M_HP_V[6I]$VH9F0LHIM 5BLUM-\U+-.E3EJ!]E?3IOZH=WT4?_: 9WTG#''#
M%5+XKZ'+1%>9,;Z=@EE9OZL_N>R(Y6$U:25>)2;R&:)'7K]19DR&!4<B2H3U
M@X3,$9YCN@FG,4\\OIG;A2%%5HIA"1*;"/.FQSYKN^BAD_)G?G/:_P"XY! R
M.M#N,#C14BT&.&.&/M"LJ&>:<2$42)3>0)*O L)W99[\"$V2ZF2/%<21S\<Q
MNDH$'D$G^[DB4UNTR6XP,LHY+P,%YY6:W$8JKQ*!> H>Y DM<TI23Q7X(YR2
M+^V1^CR$O*_/,;C#%CX^Y0:ZD0@$]O$I2#R!.:B@=ES61-P@/)YI.G<BF?J\
M@0T3MF+<8361.PA4$LZF3$@G*4%%PI1=)->W*E3!V=(9)F.$XS3TB"*&*"+D
M%,?E]CT[]<OE_J]#Y_Z,/]NU/<Q]-*[9,Z<7F2G@KRX3SB53\ 2W <29,46,
M4047"=4RHWB.]FA-<1U*+A.65!+!AW*\^!-7CR9C%%C%%$XCL::7,SRD[!Y*
MV$$Y7/F#:HJF%:=)G32\W!XJV$LX=-'YT;B.QIH(*Y]-QQ>:KC"=4#BA,"BX
M3JF5"6O'$B5-F139OM?]QR!R]W\,<<,6LM&L#CQ)2RY[VB?\^]_ER2D>3HI\
M^<9F_@)JRBGP1QQ3(_QS^Y_()/\ =R1K_00EK)Q,GN\G*,)S'_O6OJWMT!NR
ML)28LR50RN_6.21?VR/T>0I_S[U^G0Q10XM-9,F9CE)2R*J;[G^W;!*2<5'2
MM&(S94X9)35F&6JMSD4S]7D#(_5<OUPL<-$YD&,#B06U]<>OS_MVU\(FHY]1
M-J,YK*9F2H/$M+DJ7(*8_+['IWZY?+_5Z'S_ -&'^WG?_<<@<O=\-8E-,JKV
M,01F48MB<:N"D@MS%9-P+"K 02&T3P>96;$OHI.(GM;B%@JS#3C2TB9BNH"O
M+(]7M)[_ "[(^87OK"&5@.MB)?1T0$SR6YY*D2B3SK)^3-?,H2"4E$XWF5D1
M*A]O*)! +H\V9$[D\G%C(2W21C@BEQS^Y_()/]W)&O\ 005*SCAATS995$8_
M]Y^:B(IP@YB*M.<R1+3#: 71YLR)W)Y.+&0ENDC%!'!' 42VPGPO$D9Q6(DR
M(XW4"0:DS'<0)Q00HSID&)$PM/V8G3>)9C_WKOUCDD7]LC]'D*?\^]?IP9I*
M;&<=IB">KR2THVVX7&DI44OLIU$I\F,O.1X6X3(PO0M#$OI)$TG(*7@JGSJZ
MFH,V:NH"K(_]<2*.G(A'?0M[U1*3U5._ 7D33,Y?FRTM Y%,_5Y R/U7+]<P
MPQQQ29>*,@MKZXNRDB28D/(GA$YT<KB4+029AB-4;J'"2<*>MS7 E0I1UNI!
M&60B>A;#%=-(9R6E)LU5.&3B*V1(<R8JS'$C8))C:13CBC&E(<M$C7%3M8]R
M"F/R^QZ=^N7R_P!7H?/_ $8?[>=_]QR!0[/[,PQ8V&,]UIY,O/G33,U F126
MS%%C%$U)4,Q9<":44#>[B6"^*80140DG'9W8#6"T4($C2=C\$U=B?\^]_EV1
M\PO?6$7NH&?CC@KN_##!89/R<<&$P^\)F,A)V2Y<R;&7:RS/P;B,;2,%>'"%
M5G]S^02?[N2-;W=A_P#!1"OMU*@4U,RJF&/_ 'K7U8CCC">>V&'PDN7,FQEV
MLLS\&XC&TC!6_P#;5L)R6Z2)QGJ4C"9+CE1F2LG%!W<2PD)Z8E''+,+SE?:Q
M_P"]=^L<DB_MD?H\A3_GUKLCX;"-CP \[I,N1%%%'$;[GAD8X_GK^&&"R6*&
MCD<EH+$P2R,TBVV\IRTL^HMXDMQJ" IIL*)*AG*SB(ECXW<2PB0)B/)F80X3
M-D$$<R-+3BK<)*BG/537(IGZO(&1^JI[I_'2E%H)T2TX3"L&U]<>OSXB]\;0
M!-$5#\*<U%,N;?$.'N;RH0,)IQESX<39(T1FLB5#A)/(B<;.;N)8<QHC.1]I
M)1.)T:.Z)IPPZ$F4FFN04Q^7V/3OUR^7^KT/G_HP_P!O._\ N.0.7N_M1>Z@
M;IJ HKO0E,PGC"5-QE[4**!2;DV5,D3)<J9-B3_GWO\ +LCYA>^L(O=0-#ZP
M[_K#)^3G1XRSCBD]J(8PE3(H&[(D)Z&:<JP:B9\\Z8@6/JT_N?R"3_=R1K_0
M=K'_ +UKZL2^<>WR;=D2$]#-.58-1,^>=,0+'U;&&.#% 65*6?>LN5":CA[:
M:^.&.&,N7,FQXX8X8[6/_>N_6.21?VR/T>0I_P ^]?IVTWW/#(^8<'^JTHSH
M6RCSEY8GXDHC$36AABCQE3ITB-K*)M3+2ITH@LO$G$8*B"5-F0[(88HXDI+*
MM\HK*QA6,<CF?J\@9'ZKE^N;&U]<>OSX_P#M!KD9)Y4<+B/%3J6HJQI4?']G
M5BPA)JJ@0B<G5,MYE&H(9J^2F$501RILO#9"W"1M#QPQPQ0RDTXJ/8Q!CCR"
MF/R^QZ=^N7R_U>A\_P#1A_MYW_W'(%M<2SB/M3%E-+M_8FNN7@7QFLC *SED
M3RFU(5S"08FJK45<,5]#2I<@QABH.E63U*2UE(DFSE:?*-*28LII=OAN'2Q!
M2<9TL?4FNKIR<6GQ0QST)R1I<$PRRC,2DXR?P3><4I/DS3+*EQ)SJDXG5*=+
M,*$U:3(FWR"3_=R1!7$LDD[6JID4V)4G2S"B5CAEF70KIRB6;SBE)\F:994N
M).=4G$Z>,RYBI@OH*K*EJK52@IJ4]4-HJY/1YDU1:"ECV^@)4!HS,.&-B)N[
M\.14VFFXSY[*,SC_ ,+\9R.+^V1^CR$G,@E''0L)RB2VF%E-F-L-92))LY8,
M232F1<J8;)1J#43P6<TDPEH:O@D&8S;,.XG'.1*E/_4(KHQ)28IS(FXG'.2D
ME=C8-I)&;/7&P:Q[29P,J#1F%^13/U>0-53(ILQ<,R#BKL0S,@FJNA0)J)P=
MM)F[:4HS$LZ85&FJ8&'"1)0.E5(J<"6XD^$C"991:)>7XU>(N8G%9TMRI"E(
MA-LPGBN+L2O%L1%^<D133[/4(HG(BI<@T:GG9_(*8_+['IWZY?+_ %>A\_\
M1A_MYW_W'0*3_=T B_MD?H\^3/U>>:8_+['IWZY?+_5Z'S_T8?[>=_\ <= I
M/]W0"+^V1^CSY,_5YYIC\OL>G?KE\O\ 5Z'S_P!&'^WG?_<= I/]W0"+^V1^
MCSY,_5YYIC\OL>G?KE\O]7H?/_1A_MYW_P!QT"D_W= (O[9'Z//DS]7GFF/R
M^RK9N<3=?;JB.W5$=NJ([=41VZHCMU1';JB.W5$=NJ([=41VZHCMU1';JB.W
M5$=NJ([=41VZHCMU1';JB.W5$=NJ([=41VZHCMU1';JB.W5$=NJ([=41VZHC
MMU1';JB*<(Q-S)6X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!
M&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"
M01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-
MPD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@
MC<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A
M((W"01N$@C<)!&X2"%-DH99-DL5!CD[A((W"01N$@C<)!&X2"-PD$;A((W"0
M1N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-P
MD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C
M<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A(
M(W+1.V-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((
MW"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2
M"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N
M$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$
M;A((W"01N$@C<)!&X2"$]EHAB;N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"
M-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$
M@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;
MA((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!
M&X2"-PD$;A((W"01N$@C<)!&X2"-PD$3F*@P24QDH9E-W"01N$@C<)!&X2"-
MPD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@
MC<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A
M((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&
MX2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((.,M$DGMPD$;A((W"01N$@C<)!&
MX2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"0
M1N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-P
MD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C<)!&X2"-PD$;A((W"01N$@C
M<)!&X2"-PD$;A((W"013\G))3]E9>\_+Z,?0.AZUCC"CE_E^=_?CO!T"2<<<
M9_0 Q\NBXXQ(_/BACC@I<\LKY[967O/R^C'T#H>M8^Y&+?+\[^__ )!T"2<?
M?/Z &?ET7'WHW/BAC[E+GEE?/;*R]Y^7T8^@=#UKW]CE_E^=_P#7>#H$D^_\
M_H 8^71??V/SXH>_M+GEE?/;*R]Y_8R94R?-56\MH>')*,?0.AZUACBCE_E^
M=_=CO!T"2<,<)_0 Q\NBX8X(_/BAACVESRROGME9>\_L4@[@FJM6"\:TA?B)
M,\B98FQML8JX6Q[*C'T#H>M8>]&+?+\[^[_D'0))P]T_H 9^71</<C<^*&'O
M4N>65\]LK+WG]B5@E3#*'$P6]*G)=)S$WL6D@J$G,8HB["-'(#Q,HQ/A6=DD
M,D@D(B53=O\ LJ,8?]@Z'K4.,2.7P]Q?G?JX[P!35"R47@.N=<QC2'86P0%L
M^<,>Q<:J93)>'O\ =^%[S,<<9$O\J0%-4+)1>6;<Z[C,3':2P0''B?F?B>\S
MW%DR5^2G>R*1K2P?Q073AA*75E&-2ILN?*]D\#I@J7+HSG,2)I-VID* OP*T
M.Q)AQAG[51&63*W[)P*4U+3R,R;.).A.4%$NE%S)5/\ ;.93.R%=/-PGB06%
M*!+(M,V>.*/L#DS\DHR)7_T;9LV7(EQ*2XX)YF)RM^)/.0*!-85I*06E2G4M
M0DEA42% +B]/+F)B4[<(&TN3E$39LN1+B4EQP3S,3E;\4@Y H):+#C"C\^*$
M..*ESRROGME9>\_LB1 ZI&)-*WE-EJS"=2-*VRI\Z1$F/O NQ=ZG.-ZG.#JH
MIJ6/LJ,8?]@Z'K4.,:.7P]Q?G?J8[P#W1.1Q0002X!A##ABJK1@BJJ3JF2I_
MYV$LN9=TR;-+NE5A.*QR-/3H'/!+2HW8JEIV)N&,BKJ1Y04DE5739U24RJ67
MA6'*;@15R!6"DI%DLO"Z5DQ$HJ$"VK;/]7(XX888(0Z)79ZQ.,X2R9)T>]+0
MU@\ISTIR8FH#+K4_<C*\I7+/+'&:>/.2.7.17--/&\<<(<#KNEPSHG6LE(Y\
M_&23(N>&)+G.M7E8IYV4HE ;F?DE61+]\T.<I 92&<8BFIA9PQQJQ1RFSZBL
M+IL@J!273A5:/'BZ<6@6W">@DO U,C*S9D\N'M,QB-R9?Y4D'8,$EU3ITHO*
MW@5%"-%5HRRDI*1=++8*SGGP(ZE,4R\E<-SG >/%TXM MN$]!)>!J9&<49Y9
M&@<\$M*C=BJ6G2)\LS)5EXFDX1N==B@0E:-7*N%5.* EN!4E2YSN,EHL/?C@
MHNN&5/ENQ1*S9,Z68E%G!',5C+J4)F"$MPK$GV&)6%6<K.-QPX8XX8838\7(
ML,J#&**;-ER99EW3)LTNZ56$XK'(T].P<^$M)0E(XI25)UP29\EU*!:<O3<(
M$5#5"R.CQNQ5+3I$^69DA2(]HDTQ/E)A-WSI<M);<B,NC'L.V73AAAA@]Y4.
M,E.FXST\B@RB:C%%#!"U8,3"RI$>T2:8GRDPF[YTN6DHA>9(;R+#C C\^*$&
M,2ESRROGME9>\_L8((YL>$]"I4WC-8W),C0ZR3(S%5&N339^UILE5=DR319(
MA@R80@=H^AE2?LJ,8?\ 8.AZU#UT8MA[B_._4_Y 8BQAD,C##X@*JPNE#K<6
MCBQ&XOSC#C(DI">6<IJ<H**>G%DTN<QP,O)W3.HCM-*APD/3&'LQ!AQA1\/^
MJ>H.GBAUR3G83Q#<2CD@R<PQ7W++ERY,N9##/>@,18PR&1#A\1L>DS\P\M8_
M#(+03L)V!N9^44;"9VB8F2I4R2R,8OSG+#--N!.3RZ86GX81O5W*$V&%'2"Z
M46=>.!A97YGY2,TDJ$UBZ,8<$-HPXX(P7IGY2.RI?5(!PS89*,RY44*>CE,5
M99AAA@A/>XP\A'C\4]'M''[I7Y,$A%QP.N?8O88F7/L6\?BG2\3N,4V6Y$-/
M+):694UMZ2I_N3W.F'< W/>8<;VCC]TK\F"0BXX'7.[IG41VFE0X2'IC#V82
M-X)K9;29@H3')-_*16A+ZB.O_P#4N8.3_J'"YST9)+:J;**I[FD2YR,T)D4:
M.EDL5A8AERI,IE8>\V#$^ M(WT2QOHEC?1+"<Y"*F:V-7_WU=3]Z*Y72J12I
M4!"!%;S+E]5-<IJ<H**>G%DTN<QP,O)W3.HCM).PA*N<]$12VJERBI&.7+FX
M.Z9U$9I)$$,AZ8P]F(4.,*/L.'"Y$N5+&7.?PPPPP;?_ +KC#WF0X2$^7C)(
M!95)RI/2TV2EE <.%R)<J6,N<^8PP^&18>HC<^*$'64N>65\]LK+WG]BW(Y<
MMPUHES\%C8\L(I-+-J>I1-BE)A<634WM-2&*DHXX>RHQ[NP.AZYA#BBEO=\-
MSO[H=XL<,(L$Z=BW%R"."9"ISX"R>R9?N)%L/B7F"D6$#S4#\A.*MS\XRXGM
M,]Q1+E_DIKWF>Z41E_DDF_\ ]0Y@B2RN#@@ER9$!-2)'XFQ'# O*:C)3"K9A
MG3G ,<,(L$N=BW5R&*&.$\H%4Z0CEIZZL.Z9U$9M2ORD5>F?E([,@@A2W$J2
MT\@TB$11.D?]4] E_P#4N]7BP@=I@Q)*R2T^:IN=W3.HC-F7^6B/&9U$EO2_
MRD4.V9U$9J2_RT7''"'!P*>*R9D%H$I)9$K_ .D$\<(WFI*,A,*MG"<8<"DF
MEE0L;;LXBGM.5(@1]D'_ %3S"JK%4J0UR,\X=</Y<ER2"Q23@E'B,I3QPACP
M<J&FR2"%.G8(+(@QQF*2:65"QMNSB*>TY4B!'>TSW%$N7^2FO>9[I3AEQ26T
MV(H(D1W*>!C%OR_RD;YAZB=C\2]'K+BB((<Z7/27>I2Y95,*Q)2$R)?^BA,_
M)(,B7[I'XS,S\DLR)7ND.DAB=36PFSS$]SS?RD1KR_RT0I%A \U _(3BK<_.
M,N)[3/<43)7Y*<]8(L2*)/E&$DPH$BLY[3/<32I7Y*8]YONEDI?Y)('CQ9/+
ME2IQSFH(()4 3HX4IU8XX0X&8]XW#_IA@IJQE6,)22622X/'BR>7*E3CG-00
M02H#/N^&0\(<$7GQ2P@Q4^>65\]LK+WG]CACCABC*C>J4A&:*8==(I.@HTRI
M3PD.,_M8<R-R-<RQ7:6G[F.P1L]TRH/948Q_[!T/6XL($8MC[R_._6PWA"LB
ME%>"%KK97&6T#1B,D2+)\A*0C9-7"XVHE$P0;<[">DHA@@J.-$.*\<$.$$#@
M0S:N9_\ 0&VJ>A/(Z9&EEEIM2U*;"V%J>$Y-*IDA6:TTR<3&[%)GHR(83C^Q
M612BO!"UUPKB7:$4R;)DRB\IPI9I6*D"^)0D[9G41B+=-3DXBTH\3&&&&&"4
MA&R:N$1"-IZ@OH&"O@4:YN9%)0Y\MP.%+-*Q5/+1$R+B232O))R/AB@<*6:5
MBLMN.63!NNLF@EHI))A4)$TT1;R3.22@66S..'$YMQRS"0C3TL\5FJ3H-XLM
M-]S3QF%E39-:ZU\;V Z039\F&;!!!+A6$8NKR8&RO2\&TFE2LPZ@J.!_=]34
M)AHO%,(("5.1BI6:I.@WBRTWW-/&865'&B'%>."'""!P(9M7,G"DD\5DM16+
MS#S7PB3"LGX<LK-DT9/HJ083030S<E>-E9)TOBU58I&E->23G*$B::(MY)GI
M!54+33B>@)<U))?C4)$TT10$N:DDMB^G&50BGEHB9%<;42B8(-N=A/240P05
M'$B'%B9##A!"<*23Q;=17*3$EM2R4]QHAQ7C@AP@@<"$;5S/_IL6F^KJIW!
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M=^39/SCW^70?H[N39YTL2=)Z03(S9\\HT_K:]@K_  L#Q.EL(I"LZ3L$$,N
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M[\=X.@23CCC/Z &/ET7''%'Y\4,<>TN>65\]LK+WGY?13Y;H>M?1R_R_._\
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ME2Y*0%9*+JI9L'9J>J[3^)N$HDMHP9GEL,(7<'><B+IK2)0ETL.PMB24R9C
MV454M;5U1SIQ5,*(7T?E+SQ_Z/\ I(U>\_+%#'W*7/+*^>V5E[S\OHI\MM><
M>,2H1EPRB6QUPX1(K)CBQ*NU0G3S:<VTXE(.-E)-XK$,,",QMBUWK#5^NJ1'
M!1)$&REDH'0BD91!JFYAM)>F.."DE-N2;E$$THFP;)L<$MT]K)87W*4Q*M!+
MFE9+TQQP4DIMR3<J03((A5+*S',J=BI'Y9V3BV%IQ&)LA&::6G&BQQMI!R&5
M*EEY/OFNE<E(:1*EKR?@@G"L^$T61T^)44)2$D292X4A0E>*7(.2#Q>1 ZL$
MM,AQ6$K!7+$VZDE);L2"I.6BFHSJ6[R9201;B>0GHW9*6"D$$MV*1S!/(H"7
MVX:B14F*6?D36PL2IL$Z4CI\2HH2D)(DREPI"A*\N/"9+$Z;!(DIQ>:YE:%%
M289:\FXH1PK-D+"8YR!1./RVPAQ2X888(=BU[^QR_P OM=./57%5UF% LU$\
MG))[)G>M7CQEI;*EPXG=JQC^0Y/PE^]X?$6/71<,(4D/>'#X9MXXQ(@?']B%
M]'Y2\_?\'_21J]Y^6*'O[2YY97SVRLO>?E]%/EMKU+10F4(W"<2MCR-P2D]G
M%HI*88]V]^Q:^DL;8M=ZPU?KIX^63B^+F6%"-4B=41%E?3GK]1D_I;39> TY
M-RTL$VVDDH@]?J,G])>PQQ1VXFF5"7NXJ">T31K&,M*FEI[44"<Z6XEI)G13
MX#:>WB,\^9W<5!/:9PS"1*X$B;1^M![?.$ODU#O@%15*I,G!PKZABM;R?"M7
MZ&]?IS7^A OWO=OO[&9O5[*#XZH0_?V0T?K0>WSA+Y,+WO['8_5Z@>G5[+:?
MO[%>GU25^EM6L,<4<O\ +[71]>4$\NI%BT\ZUE.1/E&9(F=ZSDCXDHU#/P:O
MLQQPPPAQ[8<AXK\:3W&"*W.QS6POWO#WDXXRF_.AG(X>\[#W(<G&0D!\?V(7
MT?E+SPQ^#_I(U>\_+%##'M+GEE?/;*R]Y^7T4^6VJB?*4R90XHM@[(=J--@-
MO!,DP%BJ@Z%"3)EEY+M(3BYU-<B<=D*#I326!B#!03FRI2DDZ97D@M+GFYAY
M>#5^NO>";C*159(A37"N%3I)E?3GK]1E?I;8N]FUZ_497Z4Z5!/DD#,YL*T"
MTDS()KK3\#:FHR4LJ4<*2;ENQ5)')2*6F%$J;#.;"Y(74@Q+/.Q-*Q01X3(&
MC]:#V^<)?)K47P;HC7$F&)Z03,#Y991L2SF6)"D7:OT-YRXHTMMJR?(1R9PN
M>D%^]ZD3P4"* I]AFXEI)AEGY\USK$F5!(E-'ZT'M\X2^3$^5 8DIQB:V5>%
M:28I:\I8KIQ.*0D"3T^J2OTMJUA[T8M\OM='UX+"1)5BR*J3T$[ACA%A,[UA
MSH4Z7.3'C!A+B=*'#"L.B:HP-E"B3I?X,55+PQD3Y&#IEJ*?.C5T_!3(-Y8[
M'FS5U(DRH()[I6L,,(<)YTF6B>)LH:@1E).E)4N9+FP<H>>'_1_TD:O>?EBA
MA[U+GEE?/;*R]Y^7T4^6_ 9*%CDN:STB9$7:2/(QERY<F 3)<N;!/:"1.C(M
MQ*(1A1;Z:I1E&JD%9AQ!)'3H3VZ2339@M(-R<6:DXQR4@@7*):4729*HWR:M
M.AAPAAVXMHCBH[51ODU:=##A#"#J>34)>+,2L8B*,G)V,R7+G03V@D3HR#<2
MT^,&2A8Y*F,U)CB(H"60C"<WB28:"H@DU>;*EPRI2DCD56$JTT@M&<(%3\B%
MFI,,<U'(3$]/(RDTK.DRC$K%G).,PF2*D),#=)0*0/I!!2PP9B5A$23R:?+"
M<WB28:"H@DU>;*EPRI6PZG$U&7BS$K&(@DD$W *C>)*QB&'"&':M0XQ(Y?#W
M%]I]M$5$WL5$,BK8IY&!/+Q-DA$H;#C>23L4+,2L(B*.G)WXHF8EQ1;EI8)M
M5/)&0?1T]2$MFI,$18J7)R@J(!-6G;EI8W+2P4+2R9;E#SAQ^#_I(U>\_+%"
M''%2YY97SVRLO>?E]%/ENAZU#C&CE\/<7YW><&/P?])&KWGY8H08Q*7/+*^>
MV5E[S\OHI\MT/6H>NC%L/<7YW><'_1_TD:O>?EBA!UE+GEE?/;*R]Y^7T4^6
M_#"H$(YGM9ZRF%3'*IDV7)@[62QVLEB5/DSX=F"RF8F^5+F$.**6]WPVV:H$
M)$?:R6.UDL2#14U[/%52\,>UDL23A,QCS&\\(?AOZ2-7O/RQ2P@Q4^>65\]L
MK+WGY?13Y;\"P=[/3H(3$F$D:@.E/PJ4^(JGM4X9.I_X5)IF#BC+@PE2^4N/
MZ(W$4JL#<M+!QI&B8;[DF3YHA9\_!2Y4MQ80(Q;'WE]KK^M[EI8W+2PE(Q5(
MP]DEDI2BK[EI8,LJ3U2"XHHIJ".&9!S"\XL/A?Z2-7O/RQ1BPA4^>65\]LK+
MWGY?13Y;\#S/?F3CB+U&PRSW7DAQKAM(C(SXS)(W.B+E&XN&U>-Q*JKC+15-
M9)%40ZI'9*NNE$B'!S+YC!/=TJ;-_P#4*KA.D5<W.B+E"+NAB)SG2MR<<'(0
M[,F.A<Q@1'#)5\3<Z(N4(NZ&(G.=*W)QP<A#LR8Z%S&!$<,E7Q4#$90BW%HT
ML;%!PG2BV;G1%RA)X0XE(G,X,8$1RRE28%AR%4N+>5P8X(SB+*N.QQ_1&-M=
MY/ J?2S?QR?"X3N*],F2Y,N>[C4^=+=A\M,DS8)\I8<A5+BWE<&.",XBRKC-
MFRY$LR[XYDW!UJI283.2#Y=66"R1)P<Z\8P1W+ HF)DR"5 9=\R9.P=:J5C)
M'BZ@7]@M1=1&+8^\OM=?UO9C[_<2<A[M<*I_!-(-Y2/JLA772B1#@YE^="DN
MB0?G;6YWBV/ C#.(,\[$83UU?-)1]7=N!2>W58RKR%=R%$N+!R.*/!*=18]-
M!QQ3RBZ8=1F?,D/ W(GR9TLQ*Y,\X_\ H_Z2-7O/RQ0CZJESRROGME9>\_+Z
M*?+;9DR&5+28(UMPXX88X88XM]QX8X8X/?\ 52?I:E].9'ZKJ^ALOZ7%%A!"
MDRNWE[####!X)\J83:IV,VE.'O*I?3F85D3C<V5+GRD I+GK7_J,((2#L4OI
MS,*R)QN;*ESY2 4ESUK_ -1A!"0=BU])8VQ:[UJ7TYH$2QHT%6"%/<Q\S\&2
M;6!*:=[62PX)A0JJP181P!Q_1&-M>WN^%:GO[$@[XN67-F(K244TN7F2I!F6
M?,_!DFU@2FG>UDL."84*JN,,LQ))D"9"6N2)9A)9$Z+&4\8(X5-/4DX[*_)D
M_FO0['+D($:.G)YDZBFY#1GQ2%+V"U%C CE\?>7VNOZW_P Z'_.A#[^J\244
M@TE'<% @\#<9@R2+2TT@EQEE-:P54K#!V8I\R-.,8FR&QN=XMB_[NQF1[_S7
MK]10TF0G$SD^ D3:I*%14 \D^7*B1#D1Y+<$J&>Y2Q:04DNHC+,I;+,Q3"/)
MGG'C\'_21J]Y^6*$>,*ESRROGME9>\_+Z*?+;7:>^&34@FY),K_G062:]C@V
MSWQR4^/U4GZ6I?3F1^JZOH;+^ESX8HY#,CA@4PZ9D,"(RI<4)!P]Y5+Z<R/U
M0V^\0/=[U+Z<R/U0V^\0/=[UKZ2Q]BUWK4OIS(_5#D[Q+<N*:D-9.35*'=="
M&ZZ$,,,(< X_HC&VN\Y@:/I93X%/@[XXX88X'FFF&XC917:\9HQVHVVLG)JE
M#NNA#==""FH24DC(WD<6!MHS9)5C_P!YLF6/2C;+DXA'55)/5'O+BPGD6^A&
MB6ZZ$":*F)\[V"UCU4<O_J7VNOZWM5R."BGM%1A+!ORHU=;,08S9#9)$3QW=
M="&ZZ$)$F46D[&YWBV/ ]!)(,\E$73WK]1E?I+<$4Q(9$R'8])D."<U9<4"*
MM=ZPX(X9:,QY<6$ODSSB_P"C_I(U>\_+%"+W*7/+*^>V5E[S\OHI\MM79T:N
MNR),!:0% I"?)-,W$34W4F33Y)'=4LB4,+"@O2V1^JO%)AU);[@DI$A%6.UY
M2REG$=1DO4CC+/'5!TF$XC+3B;A[RJ7TYD?JAM]X@>[WJ7TYD?JAM]X@>[WS
MY4)B02,FVNI3'C)FX&)1Z6N*7TYD?JAR=XL<,(L#9,^V%&!ZI^,!=PJZJ=V.
M/Z(W%HJCC?1+!QVFC@;[;FR)P@[XJ\\Z6(E7I*P@5E:>XYB>3A)$#9,^V%&!
MZI^,!=PJZJ==!&<=2T1T2$\E-5S[@EL?^];6E-*.8O4A^6C%C:RLK:7"JD4Q
M;.-_&>]26$" <6#OL5K'W(Q;Y?:Z_K>^B6-]$L)2R55\ YR6)!4;I#X!+"TE
MG$I1D/4GC+F.=34I\&,>,&Q+.RDY7WT2P9>LGJD4-16C<$$,N!Z_497Z44.$
M4)DH?:ZC"]4_&7,[1=A\O(EEI#A_-Q<<IX2I."FK'''-2$Z%+(\F>>/_ $?]
M)&KWGY8H8^Y2YY97SVRLO>?E]%/EMLL@1DS-N) CC.$T@1GQP0000R2A4MB)
MA C.CAAAAP$::G38H)<N5")A$E.FQ0PQPR"A0KB)1$E)F"(B2BG10PQPR"A0
MKB)1$E)F"(B2BG"=(D&(9!0J6$TH5G3(H88X9!0H5Q$TB2G3!CAACABF)L44
M,,,$.R9*ESH.R4L=DI8E2),B'9\"2_.$XB2,129$@O",<,,<,4Q-BBAAA@A$
MU/(3HX888(9)4L7BQPPBPP3$["/#### 39,F?#*($9$7L5K''!'+_+[9J>0G
MQ]DI8[)2Q(*E2NSW[Q.7;,3D^;%+ERY4.W%*2\<>R4L229,OCLGDB9F+####
M 8X88X8IB;%%####@%KO7/*%3(DR)!>'D[E)F5''*QZ#*QZ#*QZ#*QZ#*QZ#
M*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#
M*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#
M*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#
M*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#*QZ#
M*QZ"335W&(LK'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K
M'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K
M'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K
M'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K'H,K
M'H,K'H,K'H,K'H,K'H,K'H,K'H(J7/*"&13-WF9&5CT&5CT&5CT&5CT&5CT&
M5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&
M5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT&5CT"#39VD5SEBACCVESR
MROGME9>\_+Z*?+=#UKZ.7^7_ !F).!B0E(A-(Y*:;Q(VH<I_^X.@23^OT ,?
M+HOT?GQ0^I<\LKY[967O/R^BGRW0]:P]Z,6^7YW]W_(.@23A[I_0 S\NBX>Y
M&Y\4,/>I<\LKY[967O/R^BGRW0]:PQB1R_R_._NQW@Z!).&.$_H 8^71<,84
M?GQ0PQQ4N>65\]LK+WGY?13Y;H>M0]='+X>XOSOU?^0= DF#JS^@!C#WET6'
MJ(_/BA!UE+GEE?/;*R]Y^7T4^6Z'K4/71BV'N+\[]3_D'0))@ZD_H 9P]Y=%
MAZB-SXH0=92YY97SVRLO>?E]%/ENAZWAA$C%O]"_._5PWAZ!)$.$,_H 9_U+
MHF&$*-SXHPX8J?/+*^>V5E[S\OHI\MT/6NKV.7]WP_.__P!.\'0))ZOY_0 Q
M[OAT7J]C\^*'5[2YY97SVRLO>?E]%/ENAZWCA"C%O]2_._6PWAZ!)$6$4_H
M9_T+HF.$2-SXHQ88*?/+*^>V5E[S\OHI\MT/68\92.7QZQ?G?\S'M_H$E3<9
MD_H 8QZI=&CQFH_/BA-Q@4>>65\]LK+WGY?13Y;H>LX]5(+_ .I?G?K8=O\
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MQPB1N?%&+#!3YY97SVRLO>?E]%/ENAZS'C*1R^/6+\[_ )F/;_0)*FXS)_0
MQCU2Z-'C-1^?%";C H\\LKY[967O/R^BGRW0]9QZJ07_ -2_._6P[?Z!)46$
M4_H 8_T+HV/62.?%"+#!1YY97SVRLO>?E]%/ENAZUCC"CE_E^=_?CO!T"2<<
M<9_0 Q\NBXXQ(_/BACC@I<\LKY[967O/R^BGRW0]9BZJ.7Q]Y?G?K8]O] DJ
M+&*?T ,8^XNC1=9'Y\4(L<%'GEE?/;*JH2TJN3<UUC<UUC<UUC<UUC<UUC<U
MUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<U
MUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUC<UUBGTY;:4O?4\-]3PWU/#
M?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]
M3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/
M#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-
M]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU
M/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\%!W*)HA*>9^"5OJ>&^IX;Z
MGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>
M&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;
MZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ
M>&^IX;ZGAOJ>&]:EVIOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;Z
MGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>
M&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;
MZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ
M>&^IX;ZGAOJ>&^IX;ZG@1=:D7F;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;
MZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ
M>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX
M;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAOJ>&^IX;ZGAO
MJ>&^IX;ZGAOJ>&^IX;ZGA->9^.4GNY1*D-]3PWU/#?4\-]3PWU/#?4\-]3PW
MU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4
M\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3P
MWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?
M4\-]3PWU/#?4\#3K4IQO?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3P
MWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?
M4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3
MPWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/#?4\-]3PWU/!A_&Q3?_ .U'
M_]H " $!  $% /\ ^5.J?K-*.FO6[U828/5A)@]6$F#U828/5A)@]6$F#U82
M8/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A
M)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828%/BFS",
ME>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"
M3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL
M),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'J
MPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>
MK"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!
MZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),'JPDP>K"3!ZL),
M'JPDP>K"3 @\5+BZ%PUQ7!,D9]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U8
M28/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5
MA)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]
M6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F#
MU828/5A)@]6$F#U828/5A)@]6$F#U828/5A)@]6$F!X\2]7IZ0^I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6
M[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6
M[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6
M[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6
M[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6
M[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;M
MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'
MJ1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I%NW'J1;MQZD6[<>I
M%NW'J1;MQHU:A-TUY]4=G%<_NAY?4G[7=#Z&?>QS=Y.=_P#QN_KWPV7?;9Q7
M/[H>7U)^UW0^AGWL<W>3G?\ \;OZ]\-EWVV<5S^Z'E]2?M=T/H9]['-WDYW_
M /&[^O?#9=]MG%<_NAY?4G[7=#Z&?>QS=Y.=_P#QN_KWPV7?;9Q7/[H>7U)^
MUW0^AGWL<W>3G?\ \;OZ]\-EWVV<5S^Z'E]2?M=T/H9]['-WDYW_ /&[^O?#
M9=]MG%<_NAY?4G[7=#Z&?>QS=Y.=_P#QNZ/</3IAV-WR6U5(IYPEU(ZB2F;P
MC-0,;I.&/8+\IR^F(\Z8O'VFD]:-:C4;0ZY/I>Z3U5M414VTII8_JW5)8VA#
MIFV%4B95K/"PW<*FLQH]).F KT8I<OUPK!J7:>#VTT*[=*N&R[[;.*Y_=#R^
MI/VNZ'T,^]CF[R<[_P#C=T>X3?\ 9QJ0_P B TC]3ZIFG/<'Q-]AC.J;0@4)
MMJN N>=+ET%-6UJ-UW,]VT_<MJNEO?3>U3]:159MK(:>E;?J]+91;II3:AUU
MS=N/TJ-0RTQNC1K_ ,?D4OI+5&MSR3= K5R54"MUNM>+:W2*F:;]Z5'K9[=-
M*'41NN;=T.FU?-9BFA!TX;T71:=:_I@7[WF(%SMF]SUF;MM?TW+Y;S$ZY[3*
MOQLV1@G)R@KJ%.M#'5>JBWKDK+KK+0%874:;=Z]E#=IGH::K-6VC<W9-==9J
MMTGI-4>N=0N'*L.N&LHH#Z>K6!#B0%9J. <*U3EJ.N_OB5%VJJEJE"HE::P5
M>+Z*VEK>:Z;Q.(+TLK\+W[S+M;&+I[%W)1"W*O=RKG/Z"&K>FMMY,IY4Y=(M
MITP;^KOD6XS2?U$K3VULMTTIM0ZZYNW'Z5&H9:8W>C_#9=]MG%<_NAY?4G[7
M=#Z&?>QS=Y.=_P#QNZ/<)O\ LXU(?Y$-E'_B+D>'PM*MO>-WER>H+>91+0"M
M;9?$D:K#:?FI/2VA^L;I-<,'=YC1>]#B+K2<+:=0^W"B#HN5KYQ'M=FM:/8'
MPX6F,Q;N*HZF?$CW$)M;=+OB+KD'97[B'-/5FV379:-?^/RSVDX7\[7>8MOX
M;_3B6N(\U9E1Y6/7.T$XA*RVYN@3OM9N#I\HVTMO0NN%XEG48J*_-%K5?GZJ
M[-U0;0BMC-\>C:B4H<6@-7KB0[XEI\6BO6FW$-Z;.HQKWW$44KCH;ZH3PU1Z
M;:AUMR=:)>UHJV;4$T];!K@.)=U*:EOW2=U0D76):=]%KBS9;=KJ/7 VRVBV
MOU)XE+5,>50;,:V,S7KTNJ;U,K':%7K0%N_N*O8LH]0KK AQ+ZLZW -+&^]1
MT[+PW;3C3+UJZ&W4\)XJD2UPEN%<+4ZH: &I;>T^;Q^(+U3;\+(+S+M;Y[I[
MZ')3SB(Z6VG6/4RXE#5'9M2>(LMWI'<_I]:)-G#)O<U ];G7 N!L^N#T;]?V
MZ^L5UW$3ZH=PUL*EPX6F,Q;N*HZF?$CW$)M;=+OB+KD'97[B'-/5FV379='N
M&R[[;.*Y_=#R^I/VNZ'T,^]CF[R;=%C2*TY;K=.S_P#3^#4T@]!;441]1W34
MKWIJ5>]CPX='*15QU".(,I12VB^I3[ GI/56G:7G+/\ QNZ/<)O^SC4A_D0$
M,,4<538)=A?#_<- 42S.J=K*5\T5V9>!XI.%N#<USM(B@-GE+JCNNCM2M;BG
MK8U)-('A6K2,7_<9K4W?>,S4,X<<VWFQI$>*3A;@CW=<, @*^N9J]6VZFC+T
M:_\ 'YT>DM/5]3[BYUQ:[;'"DKRR4O\ >))1TA+U6[D_\7X<,Z=.%=4SBJB"
M:3U&M*?_ !QAPE_[7+K?W1\)O^\?B$94J3J_WG/2SJE6D?XI.%N%MFJ!P\%H
M55]6V\RF-^][?$S_ ,5HX2_]KEU$J5(N?X5S^.#\#$J&_P"EKEL5XDJ\^@3K
MXE:B%*ZWZ;_#J?RY<5S_ "("PSAW+S+RVC'P_FD+1.;JTL>F]/M 31:O*9MC
MM_VM=HBUPO0KGH[Z ]T]$KI>()O7I_>;?APXYMO-C2(\4G"W!'NZX8! 5]<S
M5ZMMU-&7T>X;+OMLXKG]T/+ZD_:[H?0S[V.;O)MX>3^'@4,K74:W.KO$+LYH
MU]T?[1-/V[J^\S1&RJZRY&I]VNFG>S8NW6FT76_'&S]!C5K?*%</9U=+::J!
M#0EMSK+/T(=6=\MGAVZ!UKMQU8N)7_E4M<TH+_;T:9B@5 JM705<NRLEN=L;
M>0HUHPZH%>VY<QIJ7VV?)]LUF=S]XZW6#3\N.,\/56G10U-[>:6<K_\ &[H]
MPF_[.-2'^1!N-AR/!8T7- 6LJY5CB.M5AG7+N733NNDV3WP<0UIOOJ^-C;E/
M+>=PZ+^H4S+3!PPMR+<KG:\^D<IH9:&XX5>]-J)I+5<TGZ\6$UVM\M4N/NL=
MM]FG?<KIUOO1K_Q^;>*R+MO%>=9>UJ#5[T]%>GS];[OX=?3^>]D%(M26Z8K>
MC?!';W42ZGAY:@4>JQ2E\\-3IIU4H,?UCKO4*]?4$TI_\<8<)?\ M<NM_='P
MF_[Q^(5_F!L%>-/M8[1,N<M"N.L[J%9?I8WM7WKE<Z)U)MPJ[Q,_\5HX2_\
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MI/-E#/O8YN\G._\ XW?U[X;+OMLXKG]T/+ZD_:[;PN7\EW%<_P B'"N?R/\
M$@_RQ#7C_@_X2&HZ1&W]6&E:]1O4E3DY05U#B-B9I/TA=$O^53BU/W(\+S4I
MKU.T\J^4;=EO-;!IL6F$[X;W-3'5'IKHBD7)Q%FKF[%GBH_XX-+[^1_B\H8L
M81PGW[$W@[9K!NLXCE@870:5@X::ACAJAJ;<4S6-&?E_>E/_ (XPX8?^3WB>
M/Y/>;*&?>QS=Y.=V:K,!+MQWNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8W
MNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]U
MO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[
M&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8W
MNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]U
MO8WNM[&]UO8WNM[&]UO8>N%NS53][K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO
M=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K
M>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V
M-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO
M=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K>QO=;V-[K
M>QO=;V-[K>QO=;V$IQ6]*"H_S=O#.?>]UO8WNM[&]UO8WNM[&]UO8WNM[&]U
MO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[
M&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8W
MNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]U
MO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[&]UO8WNM[
M#5EV[.%H[W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>Z
MWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]
MC>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;
MW6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>ZWL;W6]C>Z
MWL;W6]C>ZWL;W6]C>ZWL;W6]CAFV5-5J8;.*Y_=#R^I/VNV\.'6.D5#M0CB8
MJV49KS?=PV%9Z/4*O[U^:I4RK)J;#6GN\M.JIH[Z;U]SZT[+I[@W3H"ZS;8<
MU5M#C1\CUH;]K=+LM&[2"?3)IGJ4\3S7VA-?:_Z8NHQ4?36N+K@Y^'QUEB3!
M1.'$TG%M#U&2C'U2+E%W05UG6N\:OZ%NDQ(UO[];?+Q=(.BM4U^AM8J[UUT4
MM;.W?5R86CO3%@\,M=A:U06S&LIXBJ5?T<-=YB6XTG<&F=PUU>%=V:KVDWI%
MV_54J@^ZV5(TTKN;4&'H&CAUJO4GHCJ*\135ZD];M17FRAGWL<W>3;H#686>
M5DTR?.8X=\><QP[XU=;Q=/B[=2Y#5'_%]_!IR6AR[[;RM2JTEOV+7KB[&]W1
MB<6D-R;_ ,;N@58?H/0!L]Y*Y_>SGRF/VKYYX8+]D&SBN?W0\OJ3]KNA]#/O
M8YN\FWAOOXG=M,*5U*K6^*9\+]J9/YOW>Z&NHE9HVA9/H]707[6\V)Z-5\6H
M.W=1#3/KOIGO2]K17O%L70J<<,/J8OUAW!V?7'6O5THWPR6IE59I7OZ8%Y&G
MR>0D@RX%O4%T2[JM-NC(T]]%>Z74GI.NI!EOK=4?\7TJ5,G3-N7#OZF]PZ)<
MOPYVI1;<R(H8H(M#'1,NKM"N@U3>'TO,O?OP]*-J("Z/AT;VK2: "SK38O.O
MO.*7"N:CY% NILJNALG>@O2T3+S+(4.F?"]:E3_:-].D;>SI[$?;?^-W0*L/
MT'H V>\E<_O9SY3'[5\\\,%^R#9Q7/[H>7U)^UW0^AGWL<W>3;PWW\3OI1M1
M >E&U$!6RE#BH-6;2+H'2#2MTI+D-:74BN.J'H+ZUUP[XN(XA^P5FV6WB<*:
M2+J5@VHMKQ57MQJ1>+?A<Q?HZ-6Z\&*Q"R!+UB-3E+JNXZHV]5)M!JEK$ZE]
M5JI6E5.GZS^B]3+[D\5S_'>.$^_8G4W[DU1_Q?;#;MSEC=T]Y>OWJ$75NGAY
MM5J[1^WC<15;8S[<-2OAAKG[EJQW?:Z=[-YE(]5#S(=1 7-.ESOCAL+$+752
M]&[S6?U!X=(:W9%U6M2I!>5FM7*<<0+IBU(8+CI3435!O72-/NR^I.K_ *F5
M4*@Z15RZIJ^:9SW:QIC/3VO_ (W= JP_0>@#9[R5S^]G/E,?M7SSPP7[(-G%
M<_NAY?4G[7=#Z&?>QS=Y-O#??Q.^9#J(#S(=1 .1R.)Y.+6)^-PX?D:;T2S#
MJ$\6]V7E!PGW[$ZH111U+'$S_P 5H_\ ^84<+E_&C3+[D\5S_'>.$^_8G4W[
MDU1_Q?;/[.Z[WS5L(: &F%9>V-/1'X<MO7@<6#^^SA/OWV<0K_,"*Y?XQO#0
M_">:?Q4/;/F.#A$XEG&'5V[+\S?B9_XK1PE_[7+K?W1^U_\ &[H%6'Z#T ;/
M>2N?WLY\IC]J^>>&"_9!LXKG]T/+ZD_:[H?0S[V.;O)MX;[^)W;I$U[H_JI:
M4UQFB[J16ZU#T%]%&X=CW$<1!?VR[TKPN$^_8G4W[DCB9_XK1_\ \PHX7+^-
M$F;,IYO47HP<UI=)%F:2&IB^GSHLV0$M/2W"IOW)JC_B^\) YF 5J/JPZ;VI
M>L7YZ)VD?<+:E=?Q8/[[.%9>2 WM0S7@TV;VZK:GUSEL-:;/JQUR_P 8VPZZ
M-1LNN]UI-/K#5RMO1=*74J7GE9K2.G'#]:8M2W^X:KU&XF?^*T<)?^URZW]T
M?M?_ !NY V.$FWC;?I#1=5PS=^E FR:*F21GVEO=/T:K-?=<G2 MITS:=Z(.
MC-2[4P;^J#8W*T\KOOP:/N@91J_VU.\&W4_:5<_^-YZ(%J+=T;N05A^@\DTW
MN'B\P6T[TAHKGPH-TC.2ZST3JS;O4?0LTKK?-3E7O=HBU+:[O>0:;/#R7"7W
M4QO!M[\*%S_)&SWDKG][.0T5IUG!63TAH.<(>;@*7K\/;?E9VTA5S1 M086C
M=R"R'AQ+U[LV<_\ A&ZC)S=N^LLN,L7JIR*F/VKY!I&Z3_FGN3TAHJ%PCU4D
MU(O1T^;J[ WIIC6N,"]*^?6]TXJ(::M??;V]VZ5JNJJI1[A+:YN-NW.<+#=U
M2ENKJ$MM=;Y!PP7[(-G%<_NAY?4G[7=#Z&?>QS=Y-MD^OG>'8;;UMI;5:I=$
M7U3?BA-3)C(5WNN7J(WF-<:>^M1=+IL4G75<RX%L7SZW]U^H#0 >>+=CX$18
M5KEW9Z=U#A8WJI7FZ>TVLG$VZF55FE8AK+W?Z?YY=5S+@6U_6_NN<5AU#ZZU
M=MMJ<2XIC4F*M*INI=>=6BY74(U$:U:D]6*751J%12H1+BD]2HJS;GKL+@[R
M:G.O7+NS>%B@LVU+;S[##2EQ4>H^>0+K+UKH+VGL+Y];^Z_4!H -/'61N<TT
MF%4%Z*E2'[[7_P ;N0:[W\(I4T9)&>'?U7+A"]T'%$VFLVB%W7M+*_WC\6W]
MDK3[[+L['%VK57*F5WJ)^"U[4CO>LO:3F<SB>CC_ !U1_P 7WD%8?H/).'D_
MAX&G?JHW.V!U:XFZV*GM9K%^$4[R:L7\EWM]&30\IK*IY8'JE4QU"Z^ZP?\
M)[R1L]Y*Y_>SD-E?[Q^+!_8FC+:RW%3ALM4NNE?7GKYVFLVT;49N3_Q?O;\/
M?:M36YS4)XB#5<K.Y[E+>;G*]VI5 U44-FZBVA?R*F/VKY!PCGW)U]?Y<J W
M27#VM.]HJ#3UQ-&S0*_ERXLC]X_M]!+PT6*Z8=X]]ERU]-3.';O_ *\4JO9X
MI*A;+II?9R#A@OV0;.*Y_=#R^I/VNZ'T,^]CF[R<[_\ C=R#7>_A%'#N6JU
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M A+#H7:Z6CW)6SR.2<.7ACX4^A]QD$R9;VT,,<&GSO\ ESO%AT"H1+G2W+T
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M;4_U4>*SI_5^-/LEX@RP2[ L-"N&;6G7/XMAPNJ6GTZE4S:-(])Z86NPU_\
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M.'OLNMHOBNQ6>';TB51+U3-,VJVBG5W2WO6PO]LL3^&+MT(WE\FU)JHJ5%[
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M!0X6VYVAJ=I'%]2%/MRXCJEY:HNE1PW-1C+\TJ_:7)&)12W9GQPQM';Q(/\
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MC4HC;LSHX9C1YW^-D>+?H%0,[(-N;H \8X9;1MM-2CUNW/E7#L@M6?GG3?\
MN9LXBO\ >QR_ARYGOM2Z'W&'>S;>VA,_.:?._:/_ ,L.@5"%'X]R] '?,_):
M=N9WM*WOGRK*C\)6/GG3?^YFSB*_WL<OX<N9CC:GT/N,-QD+>VA,QFM/G?X^
M9XL.@5"#\PZY>@#OF8RFG;F;C/V]\^59/S"M8^>=-_[F;-?(BQC]]^[=LXW;
MMG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=L
MXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&[=LXW;MG&
M[=LXW;MG&[=LXTAJE7/-2G^;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7
M(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9
ML:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:
MN0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0
MS8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8
MU<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<
MAFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD*V5;U5I5&6W5G5HQ
M;N;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&
M;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&
MKD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD
M,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V
M-7(9L:N0S8U<AFQJY#-C5R&;&KD,W-4WQ#YL:N0S8U<AFQJY#-C5R&;&KD,V
M-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7
M(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9
ML:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:
MN0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0
MS8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(4CJYJFS
M%S-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#
M-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C
M5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R
M&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;
M&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&K
MD,V-7(9L:N0<E6=6C!NT3JWJK3:,YL:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:
MN0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0
MS8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8
MU<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<
MAFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AF
MQJY#-C5R&;&KD,V-7(5$JYJFP5,S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<
MAFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AF
MQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJ
MY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#
M-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C5R&;&KD,V-7(9L:N0S8U<AFQJY#-C
M5R&DJI5+5'+LXBO]['+^&R[D]#[C)OY-O;0BZS3YW_._^6'0*A$[\UR] '?%
MU6G;G-_.M[Y\JS._+K'SSIO_ ',V<17^]CE_#9=R>A]QD<R7;VT,<<6GSO\
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MQG]['+*LD)AJL?/.F_\ <S9Q%?[V.7\-EW)Z'W&$NTK>VA+_ "6GSOJ+IW_
M/Z26,_O8Y95E.^+K'SSIO_<S9Q%?[V.7\-EW)_"C7MV8N)]^UK+JC6!6^5QA
MBACAY2^W^Q*7-/S(=.\>9#IWBG57J3U@2MA;5)T_SER7*KEY96=;BS<((6AM
MJ1>?9Y1MV>9#IWCS(=.\4BN,M\N!E>R-:B^GP2,^9#IWBF%TUL=;C?,>HO)(
M[G?TDL9_>QRRL$DC,K5SSIO_ ',V<17^]CE_#9=R?P:H%V<JRBQENMRM=+6Y
M:7<,VKL;:?PWY5C5K?;*^',N=KY=?9'^&_;AKZRW37SL5I$& R>4ZZG\3NA/
MI1V[ZG@]*-IWBZ#AJ;@[896BSKPOFLE1PF<,%58I?;RJY(U*(V[,Z.&8T=O$
M@_RQ>E&T[QZ4;3O&G/I76^:8Q'V6G_:C3N]_4Y]*-IWBOO">TR@0[.M7R^/2
MFN+;;C07BW>8=1<[(W'_ *26,_O8Y95P[(+5GYYTW_N9LXBO]['+^&R[D_@X
MJR[2-WU3NFTGX6WP_7"FW=[S4M&N=JZ7(Z93MM+JNXJ\VJW.5,7:+6V:&.KI
M<CJ:NW7#U%M2">S]*.__ %5+5+=])6[&^R[&F^I?K!VT::*2EZ_6LU6PK99Q
M-=.:CU*E394^5J+:W-UEHNI?<Y4Q=HM;9:'Q-*.L6P5-XA[5DI6;*Z\%F>&G
M\^>(1U=#+<TF=;>E&I8:N<J8NT6MLM#XFE'6+8*F\0]JR4K-E=>"S/#3^?/$
M(ZNAEN:3.MO2C4L-7NUN==M=H6A/JN7$:GFR]?6_NOMOU9+G*F+M%K;+3N)]
M13]MB]K^:T:LV])C7KIQJ&O0:H.O+;QIZKTK7LUKS1#2SUR*":CZGLUU/XG>
M$-V\3?:P1MTO.T\;DYUWMDJ7K<W6'M99^OQFTN9-6N)IN$J_5)C\2=>-0%]T
MQJ*V:O4XU0=>6WC3U7I6O9K7FB&EGKD4$U'U.HU16-2-B5PXG5U/NHY7B0]1
MNW)\6N7/4>O%H?J4ZH%!=,VER5Q NLC6LEIAZ^;9O?K0]GLT*;-"O_$[/=[U
M.3>(YU%+<W+:9=I1"]BB?L+C#O9MO;0F?G-/;Q(/\L6PU"9C+6L:\=VLW4T&
MHQ>*F6'6=Z)5^EX^HM2/4TUB;:]-!*3]?O6?JJEZ;'$*4BO(JAMT-_YR=G%
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M]E.O[>/7C"U^U3003+3ZA79>9#IWC6I?%MEO^HTV%\FZFV-=3^)WA#=O%L?
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MA>+>[KK?7A5:L-*:%,NKG$HZ7%,#.M/J!T8U$KM4<Y-4$CAU?YAN0W#EHCM
M&E!C+:NWB*2<I0U>;V.%DIFT:$: NLDX6FYME0?\C[4@9"M4>P#A0JBHJ!>1
MMU$HBUR.O7>#4>K](+8/.8XB :4=_P#JJ75W$!T.AMLAMZ@]\-P.NO=/IW6"
M4DTZK=N+G;IV!=THUHDO::@XMQP$BU%="M!-MS2<'%U]V]'S^,+E.HN3CRY_
MI)8S^]CEE52<9BK_ #SIO_<S9Q%?[V/8M=PKC1<U;F&IZT5I3BTR+_&PM>7+
M?@*L6GW+4);NUO'UVY_A^?:\-EW)V\4;_&CPKG\<&R^"AIZY>SWA;KGT"BMP
MX<506$T%G7U_B-X3?]G G+Z$76;A+-[5[KD:BU,2EA'$6\3Q_&%PSO\ %G)7
MT(PLW2:==EMY2/H/8+] -;/4_ABCTX>$/,EX#(;2]!I.<0F1/$50B\GJS:<M
M8F<**)2VS_*!'%M_9+1+_BKXJ6&*'4>*F2YTMLUD[%SU_EC6@SJOI&GK4EGO
M-GU#;*JK):"F4*UF;![CKK>*AH0Z6#>-9_<FRKN[:JEU(9-'Z?:)C5<U[VMG
MKZ_Q&\)O^S@<6#^^RF7VVUM/XJ^$D^R7%+40>5,KQK1+G*>WB6Z!DU!852T:
MXDQ4/60UU**Z(NEW0U.XD-B6VTQOZ;/=OAU?YAN0W&2HS%O;0AQA:>WB&_YA
MQQ"6C5/J62T!=8Z&[-H"H/\ D?3Y$@U(NWH]6C0JU3[(M0&V:_VF U8]8:AV
MGS2OAN+$']<+=7M<+A06B@ZC&H1<)K87'Z;&FQ1+39HD.([M,7+E=//AB+U6
MI5:T0:[-<C6I)J=4*I.A4'HH.+K[MZ/G\87*=1>1,W _I)8S^]CEE69$R;6/
MGG3?^YFSB*_WL>Q9+CW.>?J61ZED>I9&HKJ[^/NB>W0<MCNGDGZJOK1!,OC?
M30&%37CH4S*;^RX;+N3MUZK2;@[T;'- 6T"XJR>RC;JL\/<F79U.1:7<6O3X
ME:WP^]V-5[AM7B@56KH-.KAZ;);G;&[:AJYZ+%PEW->YM+>+64D[2!T*#]E=
M3-=JU*OMY5B.AM:U7>SRP;4*T/KUER[I<H9Q7]>6]HYZ,;3TS46H;#;54V B
M:-^MQIM7 Z2-J&J51A^ZK&D71S4Y9# L?XFZQ),CT8-9[42=-NM"&7;#0ZB.
ME3?NT->$<1+8?=;?52W2XHI4VW.P#77T<7MJ+EF#9-Q.U7&)3]+=Z(Q=FI]H
M%V\W^+I70_UWK2E8EHB:[UVAC2[T3[=M-R&\^S:BM]U!$C2 URM-IVO?34XB
M;4:QTZ-.:AVFU1/5XH%5JZ#3JX>FR6YVQNVH<0AI=7U7Q78L5-.HS(U1Z*5-
MN,L X=JP^ZVQ6EMX=H=%[XZ#%-&?6RTWWNX[&>)EOF3-+?308FF/0S54T(KG
MW;=DR+:N*7N&)ZDG#@53;;$0BTXFB:+^E3?O:;J2<AN'D0FJ -*'"!J[=932
M*U#;K=279JFZ"=PR-<]8^_KKG]0!XZ0.HHJZUPN^LTM]OFI!7SA>KQJ.O6/3
M;XF=[R[-.%9=)IR4SIG3^C3"V\0';CJ47<4^H_I%\09;VF> KBD10JRWB;6A
M6N?(D&I%Y7#GUB8-=%BWCBL[A&WI&Z&],=.0R-63SQ\Y+N]/WB1[[RU'J1<5
M]0.F%FOB-\+O*-1<M!ES_22QG]['+*JE8)U7^>=-_P"YFSB*_P!['LM/S15>
M5T#%O'TJK!Z5624(IPCU@K/J9:?2K8)5W;*J2HNOAX/:\-EW)Z'W#ILU9H T
MI,1=J\[ZBZ//RY_I)8S^]CEE54>>H5?YYTW_ +F;.(K_ 'L>QM]I^5JS7OB!
MKC'DUGA:3_ 9#%%!%JA&SE<-'';H8VA$4"V1>T"K!UI:]/O8>*H:#5C[/IG[
M+ALNY/0^Y(O*-V[,^"&!H\[ZBY61N/\ TDL9_>QRRKA61/K/SSIO_<S9Q%?[
MV/8TX>JC36H>II9B<U.:0V^40K+3K1%M,TC+O[EGAKRU@IS3*B^UIVR5R?-$
M-E(J&5BKXXJR6X5YMZ4/8\-EW)Z'W&?"^'MH=3=/G?47^!W _I)8S^]CEE6?
M@LX^>=-_[F;.(K_>Q[*R74DN+L7/H?$D4WG)MP/$45:=B,\G8[7\Y]NB51UH
M/[3K+T0T!:VJ&H=8XY[#Z[V$.1DZ>6CS:)J$4PU;TNO-(5^@5:/8<-EW)VZS
M%]U7=.ZT*E'$"ZW5>6[YS'$0"U[5>UTZGW'_ (+]J\/JV&S;0;UB;[+S+N!9
M=J/6O7]JXU M5:_>B.M7^-A:JU^ZUKPW[5X?5L-FV@WK$WV7F7<?@U+]5:_>
MW[6$V7"5 6:34"I1Q)NKM7EQ><QQ$ 0.)HO!H(Z;(=0^U?4'87X;M[KZ.V44
M(AXD'4KN->%F]4:PUKMB_'?)J/6O:>"1RBY(Q**6[,^.&-H[=6G7SO#L-O>\
MYCB(!YS'$0#2*O%U![MTWV2;Q+6J6_*O><QQ$ AXD+49MT5=/K5IM#U&TOF+
M47-2-Q_Z26,_O8Y95PU(D5GYYTW_ +F;.(K_ 'L>RXCE"1$1\"7'^7,U8Z6L
MNI&F'MKRHJK-X>J&**"+6>,*;GL6O=ES6AH):/LP[+U(-:4L2*ZEOL.&R[D[
M>*-_C1X4;^._8_ZAL"E#1IO5*F59&FMWTV1MES)RBGJZ>NGD1+1+4W)IXGE"
M\&[6AUMU%>%KN0MWM\%)+H;9Z_*&JQ_D<U,K!22BJ!2>Y.W6O46RH5Y]GE(U
MYD/]B5,;HI=_E!+IY$2T2U-R:>)Y0%5+FK;J%3:5UQHI71(&LI_D#;+U/V<<
M*-_(@*Q44I)<&P+]+;:Q:"&H;:S<0R;L[>!5*ZNUZARC3*L=(JU(0XN5[+I!
MA:05(&91C33#V?[$IH@T[O/L\J\XME2ZQTBHNBTNNTM5K@LKJ^A-=)XI*Y6E
M=;;@/,AT[PG**>KI]5+I+9:%':7UJHW6Y%Y)<.I34:@#2G1&&KMXD'^6+8:-
M%B1:EMWUIE<7,%I:1FTC4CN<MLK^;#FOQL<92XB+J(YDK;H;_P Y(>#,9]0V
MSK3Z<"SI07!:8U[J/J!V<U N8MPI,]*F5>I/19NTEK[0FOJ::-%B192OZL31
ME](6$AP)@-W*VY$*MU-K+2"BB)2:Y6W*O<WD^HNL3\N?Z26,_O8Y9558GI]7
M^>=-_P"YFSB*_P!['L+/JJTGHE<:T=1/0L<F-Z=<=."FIWQA\/H$V];0&1C^
MKUJHT^O";>W2:O@MN6;?$[2/TGJ(*[YORTNM1:I5Q56]/[4#%B6E<T]-MU79
M5PF7)7)>PX;+N3MXHW^-'A]-4VP^R"S/U"NC\+3[T;:+XF)KZ_Q&Z4="+_=1
MN@+YX3:TXVP-'N\&XW3#U#[K?VN<)/\ ?_6ET<K8*W,[0GTH[=]3P:=VCU;/
MIG/#6]<#R:6NTP.'NJS>J>U5-*!_:-#JTR+NIE\=D&N=JAW&5&N;H#PGM!)3
M%NYLUNUX=ZL%K=PS+NPMYI=_E!76_M<X2?[_ .K6T]1%[6O6\\*HSW @:D6G
M95[0CJ]9/<FGW@6GZRG^0-LO4_9QPHW\B&SBEJ8)#MT].%>J:J.[3^XA/5MJ
MA:^8M+X6I#?[$U -(BNVC+*L2NF;>J;I[:O^D3Y5AZT[AA/%!;0[7PS-%G2R
ML]L:O,X@RI5>>$^M[FL#A_M2&OIVLNKGJ'D--^TG3WTB[C]9L[7'A1:+EVQ1
M2PRKU2=,76FL%H]IR79^E&T[QK;WBO739T\=,+A\VU??04SPTE5;=*\R)<<F
M1R.X>?"5H THL(VKMXD'^6+U"NC\/4*Z/P*F9)PM>8U5O1?UNVRY4%YMOB9[
MO<*#6,<.[9Q!:WI]ZE5^%UVJU?53_A-K3";&=B1=QPU-YC/=K>?S2V:&_P#.
M3LUZZ8)%4-*KA'ZFJDU/XII;,-G408>F7>]KZO'28TT/*BI'7*YJ\OB$+XT7
MA.;+Y#-=TR^#AL[QZ.599->*4:QU5ZB4,U^J5<.C4&[J=JGZ,50])B1HW7ZJ
M.H59-R;47,P9<_TDL9_>QRRJIJ"35_GG3?\ N9LXBO\ >Q[*Y*[^O5[<^3:Y
M<R8E>%:Y\/.BU8Z<)>U ;R^[%IB:)>H@^$9W-9;8SK7*&5XIK3RI5S=Q=943
MV/#9=R=O%&_QH\/II96'WOV9^GJT?A:?9=;18ZQ-?7^(WA-_V<#B.H\N-7*Z
MW]KG"3_?_5!_C@X0W9JL?Y'(XGJ5*F:8G#&F9T_2^M1=%X:WJ_>*3BD1?"S^
M(YO\H!HG6UU\M)T]:7?Y05UO[7.$G^_]4JK4THBQ:X<4O813Q9U7==6'4\MY
MX=DS.GZ16LI_D#;+U/V<<*-_(ALXI6IJ4TM/+A7J9*C1T_KYE.N+WX@/Q2<4
MB+D7/Q+=TE".'ILHNLL<MIXO(:3O\:/%GN)8*6MZ:55]?.DUDOBDXI$6AZ=6
MK8M:Q/%NNE9GU8T[60BTYL+V<5'_ "/C5CT]">I-:=1BZK6GT,4"Q3B.[-KN
M7;R2XR;&7M[:$6,33V\2#_+%Z>K1^'IZM'X%2TDF6XFBS7"O5E?#8WAS+C+#
MKQC)W62UZ:QGY]/*!:)BY?\ LZX;Q2<4B-0ZWCB%]2YA:>U+JF41L=V:&_\
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MY,_$0#2)LXU!K1T\<1*E,^Z35>MSH:S[9Z$#4OTAK;-2]!1N'[UCZ#X6W\,
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MX;[4/MWN$I/=11JH/^1\-;C1)+7_ !6WG5KU3=(2<M\78X)Z._:R:N>OX_\
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MHTJ; D @8BUX$@3< 9$@S<;?2O\ M5OF[+50RC $'@-XZE.BAA*N84-P@*S
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MBR;-R+%,W74EF&E:>B[>+F0"+P%:(,$)G-MAZF9J*&Y/$5501(!*D,6ODZP
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M9%FJ;-7T;.1=!/)D[Q4SA!T2L1I(.Z=FL2*597#+O,@+ ]<01UCUK9CXU/\
M.I:M^F/^;I=1LK1#9G-K((0@*I'P6<S?.G"K1?-XBV/9FS<5+3YNM5N/%O3
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M5$GKE !V2/NS_J?U?:_E_P!&_KM;(_H='\VMC4JLJH-)) ';-GV9L:H*N8J
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M<$]A&51VNR;4ML;%JU%R^.-.LC:0"?A(P!$$<!F;4MH  52"' W'6YNP>,.
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M0@-Y )O9F/&8]8;I/MBV-\MF?!H]6M_N)_\ )TO8"E\4^$WV SV<6HU(N%A
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MJ#(&%V32=_#/43,5DK"L*X-2J9Y-DG6U^*RLMP4&= @1=]S?]3^K[0Z7R?\
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M";VH4_CK[XL>N?L*WQ*?@+;Z#D^9I^+;Z#D^9I^+9:5)0M)0      (  %P
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M&-CNEFTF2-&@;@ %JNTU15SU"&Q 064L RL1ITR)D@BZ)-GRU4DK0K$*=Y6
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M%FDQ,:JMN;]UOV#]7*%6IRD%V( U008%^JLQB9ROXL7S892H0V:=B]0C1B(
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MY6<>\?OVRWR!\,V6LNE,L&[23:IFJVM4IT68$Z<3,JD]HMV^J:U=E2BHDLQ
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MR$[C*F+"QW)D"#PG?MEMI()2F61N#%!4]:01UR+4'1@:U*FM-QNAD$7_ !@
MPX#U'2DZ,]-L+ $$J8F& T&+X-\=5MF[7Y)-FBJ5N6(4^;J8B28(*EMR"8 B
MTC1;,U*Y&*I2:F@_&9U*@ ;L3)X ;9O/,"*)P(#OD2S=H%>W]P[#_<M/\[4Z
MM;_<3_Y.E[ 4OBGPF]J%/XZ^^+'KGV8_ZG]7[AI[0SE#!E%-26QTSQD8"Y7+
M7DC<Z_V VIEJ&+("K0.+'3%R!,1PEPUT'<OW)ZO[3^KM44:^+%@)*X6WZ;+Q
M?BF -P@0!Z.7(IZ,1;+=O$)?[]EVSMO,-5SZG$ K,=;?=S#-<8*B =!++<>J
M*%<X,PDE' DJ3OC=4W2)$P""")L<OLBH'RQ)XKTRO7P5HPD[L#LFZ4J?6;,X
M,NIG""K,/BH@%)2=!:2> Z+5<AE06/HS4T!:2=0JH+,;R;KR>N;9BIM.CR25
M$4+KHTD$D\1FCLVR]/9E+E7INQ;618!  X[+/8MELGFEP9BG2 82#!OW02#V
M";#:F6H8L@*M XL=,7($Q'"7#70=R_<GJ'*;/3E,QRJ&,2K<)DRQ4>[893:"
M<GF.5<QB5KC$&5+#W;4*VS*/*TTI$$XT6#B)C793HWK4J3B'6FH(X0 #;T[)
M,M+:,09XC@:,420PT8@#<((T$#*9=RU 7 EZ#W<!J2\#>W-P67;7UAS+5,XC
M!E568F1HQ/="C\1;B+IB5(VILME7.A0&4F,6'BLK;C 77W$ 001>,I4K<E1C
MC.U$G3^.@>I/#O73N65\D6S>VS6#579@"RD$$#&T7&-+8C>9T 97*Y@8:]/+
MHK"088* 1()!@[H)%CM=J$;.]*=\>.GQ3B@X<>+=T89X/N&E\G_6;[E?/9&A
MCRI%.&QTQQ5 -S.#<1O?894;,I<J:9J8M9%C%@CCLLS!T3PVRN4S*X<Q3HJK
M"08($$2"0>P2+5J-,34>DX WR5( ONT[]J];:='DJ;T@ <:-)Q QJ,QT;]AM
M39;*N="@,I,8L/%96W& NON( @@B\92I6Y*C'&=J).G\= ]2>'>NG<LKY(MF
M]MFL&JNS %E(((&-HN,:6Q&\SH R^S\QBIUURRHV$C$IP!3#"1(.@B1-]FJ_
M5S,<I18S&)5)ONQI4\FQ ^%._<)@C+[9JBGE01.)J84[LX*,AB-S%%\7C2%R
M&5DP99CI=CI8[V@ #<  OTE2QY//4P0C@3=^*PW5F_?!O&D@^B;-J"IEAHAZ
M3*!P"O!7K 1IW[*WUAS02@+\.(,1\5$BF#PSO:= IY'+EC1I(%&(XC WS]X0
M!H   '5I_P#QKZ+R>MYCCXC_ .K?HC1=V;(-ITN5%.<.MEEC%$\1EF8&F>"R
M93*KAR]-843E# &Y)))[)-J/[5Z1P#E.+QOYFKWMWW(.N+5/CM[Y^XLQ0HB:
MKT751<))4@"3 $D[MUJN8VE1Y.BV7*@XZ;2V-#$(S'0#?$?8':]2A&SCFJKX
M\=/BMC@X0^*^1=AG?'4R]/9E+E7INQ;618!  X[+/8MELGFUP9FFD,)!@R3I
M4D'L&S;3^K+ZK,650P1TQ:5UB%9;S$G1<08D\AM?->CY0W-!IAB+I@40 9T0
MS@:=^#DJ^QJ6+9M-J1=BZX@4J2[$,03*P=4'=  N%ERZUFI5*;8EW4)B-8:=
M$@$&Z3<9MZ+DZG*T%T''1<0+@ :T.!&@0 ! W("[2^M-4/!!*8L;-%X5CQ53
M?"DS>!&FT#18[2V4ZT<^QE@9"LWXP(!*MOF"";[C)/H]-RU,78BV7:[?Q/-3
MMW]FR[3^LF:9ZJL&"J[%I!D2YC  =Q-S05.CJ4LEL="^4.(U0'19(C #B99&
MDP)$Q.@69<C3J4<9&(I6I(3$Q++4#0)-TQNQ;CYSUM?GK4JM9\T:2U%+3F58
M801,J:I!$;D&=[[CJ?%'A#[ARR;,I<JU-G+:R+$A8X[+.@Z)ME\EG5P9I V)
M9!B78B]20;B#<>KF,EDEQYIPN%9 F'4F]B +@3>;5J&TJ?)U7K8@,2M(PJ)E
M&8:0=-_4_:_(?_N_TO'CQT^+OX<>+L89X+/L^J<+&"K:<+C08W1I!&\3!!OL
MV6V40<N3.J](I.^%K003 DA0;>E?6W,FN1."DK' "?A& JB/Q4$&Z3 PVS?[
M2IA%J"F%(96#82\D86)&D<8#3U[/MS8>:89MS)#,58:!"N!!6(&%@!A$2VBW
MHF8<I0803CH+=&ZU+7O[,[MFKUF%7:-18+ :JKIPK-YDP22!,"X1>^3S:A\O
M46&!WOO$&\$7@@$7V;-?5G,8D.@8@CQ^*P/DW WR1??A%CELW5Y*D=)QT4TZ
M;Z +QOC>NOT6>J]5JN=J@!B)"  R %W3/PFOW@LF>HM9&Y+:*"%>)##3A<:8
MTP1>)-Q%UO0]GOCRPT0]%E $P%Y:&4;L  :-VX+F?K)F,%,;F(.XG2JJODUG
M=(,"[5:R9+)*$RZ" -_?).Z2;R=_[AV'^Y:?YVIU:W^XG_R=+V I?%/A-[4*
M?QU]\6/7/LQ_U/ZOM#I?)_UF]H(ZXM4^.WOGV=J?%'A#V:V'^Y:?YVIU:W^X
MG_R=+V I?%/A-[4*?QU]\6/7/LQ_U/ZOM#I?)_UF]H(ZXM4^.WOGV=J?%'A#
MV:V'^Y:?YVIU:W^XG_R=+V I?%/A-[4*?QU]\6/7/LQ_U/ZOM#I?)_UF]H(Z
MXM4^.WOGV=J?%'A#V:V'^Y:?YVIU:W^XG_R=+V I?%/A-[4*?QU]\6/7/LQ_
MU/ZOM#I?)_UF]H(ZXM4^.WOGV=J?%'A#V:V'^Y:?YVIU<UE\X"U(;:J,.N,M
MEA[Q-O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S
M;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S
M;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6\VW;_!;S
M;=O\%O-MV_P6\VW;_!;S;=O\%O-MV_P6RFS=@BDN4JY(5&Y1 YQ&K44Q,0(4
M7<-M.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97
MNVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[
M;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM
M.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY
M7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>
M97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE
M>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[
MMM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NV
MTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3
ME>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;)Y*J,N]*MFJ2%5I*K
M,'J*I 8F%)!@$W WVJ4U]&"J["#24D02-,WVTY7F5[MM.5YE>[;3E>97NVTY
M7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>
M97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE
M>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[
MMM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NV
MTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3
ME>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5
MYE>[;3E>97NVTY7F5[MOVEAR_+>G<ECY-<.'DL6'#,XIOQ:(NMIRO,KW;:<K
MS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,
MKW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO
M=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]V
MVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:
M<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIR
MO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\
MRO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*
M]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MD*E-<N
MAS&1%5B::-B8UJR8E .JL(!A-\@G=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:
M<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIR
MO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\
MRO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*
M]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW
M;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=M
MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG
M*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<K
MS*]VVG*\RO=MIRO,KW;4Z;>C%6=1 I*"9(&F;K9S)4AETI4<U50*U)690E1E
M + PQ $$BXF^VG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\
MRO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*
M]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW
M;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=M
MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG
M*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<K
MS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVG*\RO=MIRO,
MKW;:<KS*]VVG*\RO=MIRO,KW;:<KS*]VVT<TZY=JF6H4F4BF@"ELQ2IDL)E@
M0Q4 :"0V@6TY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[
MMM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NV
MTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3
ME>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5
MYE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F
M5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97
MNVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[;3E>97NVTY7F5[MM.5YE>[
M;3E>97NV^K6<S6'EJNP:51L(@8G=YC@NN&Y?O]7-_O>K_E\K[ 9 P>C1?N>?
MK7:=S=NW1>=SVG[.4HU0'/4!A4@,WE4U5)90"= )90#>6&FU401Y5KCI&L;C
M>??/7]F,?)OB_:<8Y&#S'%PXIQ;LX(B[%-WM#V40CI.S%,L00_\ B,SK+#-A
M7X,$(94G#!#-[0*0@GRJW#2=87"\>^.O;:*A&I@9ZN,+$%E\J^JQ#,"1H)#,
M";PQT^SNUV*.Q&6HZP( 3_%T!+ LI8'B@!7AB#  Q#V9^JW^W*'AU.KF_P![
MU?\ +Y7V R!@]&B^;O/UM G3OF!,B\Q=[3]G+A=YSU#51L#GRJ7(V),+'0K8
MT@P<2Q(K""/*M<3)XQTF3)WS)ZY]F,6&ITG&+%Y/S'%P8^/NXN3XMV/X/M#V
M5JU%G9BG7;$&_P 1F=9!C? FYAA-8,V#6Q-[0*(@GRJW P>,-!D0=XR.N+;1
M7"Z1GJ^J[8W'E7N=L3XF&AFQO)DXFF3[.;7.&HT9:C>K857_ !="^HN-<8.@
M##4ABK0(Q+[,_5;_ &Y0\.IU<W^]ZO\ E\K[ 9#3/[-'6\_6T<._V/:AL[%C
MP^G4.)./SJ<2+\7XL7S$7VJQ,<JVG3QCIX=_V8_*8OVGP\GYCO<?NX>#VA[*
MCE.C%G',3Z1F>)/P.M=BQ;L^T&E,QRJZ-/&&CAWK;1PX\/IU?CSC\Z_'F_%^
M--\S-_L[M>>4GT:C&&</TNAYR+HWL5V+#%\>S7U6_P!N4/#J=7-_O>K_ )?*
M_:JF;S+!,M21G=CH55!+$\  )-G3ZO9VCFJE-0SJA.)0T@$JP!%XC1<=,?<N
M0T]&CK>?K:#O[]^]HF_VG[.+%U7TZA>@+./*I>B@,2P^" K$F  3=:K$GRK:
M;CQCI%U^_</9B,53%^T]&$\G'(:<6'#CW,.*<-^&+_:'LJ&J&-F+.-2 #Z1F
M;DE5Q)NX@6&(L,4@@>T"E,CRJZ+SQAH%]^]<;;1*EV7TZO>X*N?*O>ZD*0Q^
M$"JD&00#=[.[7!:H"<M1@*I*G_%T+JA"D*!I!8J"P4 DD*?9GZK?[<H>'4ZN
M;_>]7_+Y7[5G]BHP1\WDZ] ,= -6DU,'L8IMM3ZJ;?7T7;==::HM35)>@:F.
MF)TLRU ZQQE25)$3]EE/_P ?TZ&7;9N816-0X^5&*E4>Z&PZ4 O70>KL[ZNY
MO)H/J]F@A?,%B7(J$TY0"%047@U V)F71AD3]JR D]&BZ+O/UM!C3OB3$"X3
M?[3]G-B=(SU#61<;CRJ7HN%\3#2JX'DP,+3!K&2?*M>1!XQTB!!WQ ZP]F,.
M*ITG.'#Y/S'&QX./N8>4XM^#X7M#V5K5&C9BC77"%_Q&9U4.!,:;N*7UBRX]
M7"OM HF2/*K>!)XPT"#)WA!ZQMM%L3O.>KZSK@<^5>]UPIA8Z67 D&1A6('L
MYM<8JBSEJ-RKB5O\70NJ-@; !I!Q4Y8*LF<+>S/U6_VY0\.IU<W^]ZO^7ROV
MJO7RJX\TE%V18)Q,%)40+S)@0+SH%J>;VWL?:#9FD=5Z>S'IU!!D#E4H"H0O
MP07(!OB;[+EJ-/ZP&D@@8LE5J- WW>@SMUV8FWFMN_\ ]O;_ $UJ]'Z])M)=
MD#(.R',94T4Y85: 6'-*G+8#4A9,C$8ND=2OLVML%L="LZ2V;*DX&*XL)RAB
M8F)/7-LM_P#D3]GX/1T5?1^7G%AIND\KR(B<<^:.B-V1T%^N_P#B6Z"_7?\
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MLNI:O48*H&DDF +)6^L$9G:3B<,8A=>0E,D+AF[%4N)NN!*V?*97++0S2J2
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M@J5%2HLCBNA,JPT$:)T$B#;IG9W/)W;+0H[8V>U9V"J!60DDF  )O)-P^UY
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M+-0R[,>N2Y)[-N4V/L[#7(TX*5'K7IC)TG<]^X>EL%RRF5IK<HX3NLT;IX8
M!BV7SN9#-0HU5<A0"VJ9$ D"9 TD6IYG)K46A3HA8< '%B8DZK,(@C=F[J?L
MG;%%ZV54$*5"L<)OP,K%01),&=%T76;9GU?RZY/(O.(J%5F!W(085D<:"Q.B
M0)G);*R=.JM:D5Q8@N$D)@&$AB3>3I"W6H Y9,WMBM.NX!$@#&1(.%1B 55
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M)@"  !NGV9HK ,U5N.@ZPN-QN.[<>M;:-+ E/#GJXP)>B15<84.%)5="ZJW
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MDDQ?M..4NQ^8G!HG#\+3$[DW^T/91%)*>+9BF5B7_P 1F1C: -:[#?)A1?$
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MJR&GHT=;S];0-_?NWM,7=4_HS^$EES&V<YZ/FA2"A>6I)J@L08=2;R2)F+N
MV.TR*N;H*N,214! $ZJTE7'.]K ]:QV;LQ&I;./&)@,X&@0+E7@DDW3 D%**
M\9V"CLF++L?ZO4RQ.&F89$(I 7WL5DL0 8O()FWT7_NT?G+5\MM2ER>2<!EU
MZ;#&+C 5F(E=-T:HMFLK2$4DKN%&\)) [ NL_P"A9G_W>IE/C/\ FGMEOD#X
M9MGOBTO?J6S7+NS"G69%G0JJ8  W![YO-YME:](PZYA.T6 (ZQ!(/ ;92M Q
MBJZSNP5!_JVS?R2>$;9SY8^\+9[XU+WJEL]^F5OSC=0?*T_>-FIY@A37HE%)
M_&Q*P$_RH,;Y@:2+5=JY >D4:L$J" Z0H$02,0NNPWWP5ND\CFJ;TZP^"ZE3
MVB >KE?TFEX:V3)\MR."J'G!CF%98C$OXTS.YHMCKY\\D 2?)!;HWS5($;LC
M19LKLUEK9PWD*P=W:\ U'&JH&]= ,JEYM4SV:,UZK2=[@ X ( X +?\ V8]\
M6R?*QAY7=_&@X?Z41PVR^*?1.0U=[%C;'V8P3P1;+^B3Z3RZ88TSB$?AX+9(
MW<M-7KX=3W)T=GALV:JB?1Z19?C,0H/8!;LP=RQ?*T"^SJ2A:?E*0!D LV%G
M!!+77B846D96_P"5H_.6C:RQM*A31C)4D,K!294D$LA,P?A=BV>^+2]^I;-F
MLQ8K691.XJF !O #NZ;-24^3?+M(WX*D'L??-DR[$\C3H+A&X"Q)8]<P > #
M>MDVIF":P4]9M4CM&V2K#C,M5>PI0CPC:KM "<Q6JD?S4 @"=]BT[FB=%JF>
MS.6)K5')/E:-V\!Y30!<. 6HYZEEBK4Z@)\K1O$ZP/E-!$@\!ME,Z!Y4XT)W
MP(9>T2W;M7_2C^;IVJYC-.SUF<R3U[AP : !<!<+9;DS<Y93P@J;CV8/7 ME
MJP Q-0(/\UI'A&V7^+4_-/:C^AI^<JV6BO&=@!UR8LF0R)*!RE $7'#A);LL
M%()TG$=V_J>@2?1\PC7;F) 6!Z\!AV>M;TBF %S%(.?C E3VP 3ODDVIY/9]
M54J<C34[P>EAE& O )7>T$, 1<2<YEZ@I"==1B2!NEED#?UH/!<>H^7IU*BY
M>I&)0Q"M&C$H,&-R1=8#*4:M4G\1&;1>>*#H%JF1VG2JT_+5%"U%*G RJ3 8
M"XLS;D3/#8J=(/V>S@P=E].H7(2KGRJ7(P*D,?@D,I!@@@WVJQ(\JVF\\8Z3
M??OWG["D3HQ5?#:WH6S*'HE>K<)I4Z8<[BS38R=X-$Z!>8L=KL[ULG6,8CII
MG<0P  OXA &Z#?>W4/[K?\RULD6T>DT_=8 >[;+..(*Y!ZY4Q[Q^PHM5XHH5
M2>MB<^]:ED*!45JKA06D $[\ F.L#;SV3[^I\U9<[G:E!J35 @",Y,E6;X2*
M(A3NS,7=1*L3A8&-^#-@F>RU2BA,8E85 .$ZJ'KP"=Z;'ZQ[(J/5HD!W#.:D
MJ8UU=B6,;H8FZ\$1!SHW<5+WG[EL[/\ _%5/#/4S3;@HK[K?@MFR/QD]RF@Z
MF>^+2]^I;.?+M]U;%.&IB_\ DE"_$>3C +L.+#CW<6&<-V*+O;CE/W12_P Q
MFON.E,GRJZ+CQAH-U^]>+;1"AU7TZO<Y+./*O<[$L2P^$2S$F223?[.[7)6H
M2,M1@JQ"C_%T+Z@# ,#H 8, Q4@ @,/9GZK?[<H>'4ZN;_>]7_+Y7[6_U/\
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MJ,+C?8CBMU@%Z^Y:EM7)HM-ZE3 ZJ(!,%@T"X&XXHTW$WR2/K)MU!5J% X!
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M_P!F/?%J V<AJ9U:JLBC=*G$)T  1))( %Y-J67^M8HKG<$X!RCLDQ(QTU#
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MKG$! ::KG$!)@'2!)B=/L[M=.45<66HC"1)>,W0, S<1&(F#(!&[/LU]5O\
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M$%5.J$6)F9DZ(OTVJ[,]$Y7DL.MRN&<2*_%Y-HC%&DZ)X+?M!Z?((RJI$XX
MN)F$GK7=>R'**F=SK*#B 5VO_&8ZM/X@UANKI-EV?M3*"G0JL%!9A523=K@H
ML"^)OTWP+[4\WD!AR-<D8=(1Q? )^"PO W(.Y%LML7T16K5*V#EL0#14?=&
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M6 Q(#)+,;S)XQTVI;;V\PY#+HRA(\XQ(*B-+1#0N@S+$*#(H4,BRY$&XAU!
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M')J6%TK,BK]=?K%LRIF=G_6!6=:L\FYJ*[O,P0JU2^*&4%TPU*9(4JU?Z_\
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M7F($*&/N6.;V>_*9?DD$X66\3(A@I]SJ4<QM9Q3R5)L9U6:2MZB%#'C03(B
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M(D;I,R=TVK9G(4S1RKN2J$@Q.G0  )DA1.$728FPR60K\IF>40Q@J+< 9O9
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M[,41 &#_ !&9."X"=.*3)UM,1[0:1F/*K?O:PO[%MHN'Y0'/5SC@#%-5]:!
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M?*>8G!&'B?"G'QO@[OM#V4>3IT\>S%:4-[_XC,C&^JL/=AB7U576^"OM HK
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M-MHMB=YSU?6=<#GRKWNN%,+'2RX$@R,*Q ]G-KC%46<M1N5<2M_BZ%U1L#8
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MB5&IG.U:=82"<&*HI5;\(: (G5WXFZSUWJY0HBEC#5)@"3'DM-A2HJSU6,
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M+[\]7)?I*>$+9#_K_P#L]1OD,S[]3J)\I2]XV7(Y!<58B23<J@:68[@';)(
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MK98*-\U*4>XY/N6&U-KU$J9FGK*!=32/A$M&(C<) "Z;S! V=L\SLZDTEO\
MU'T2/Y*WQODDZ,/V,C)9L@__ $:GBV&36E4.;]"IK@"G'B 61AC%(W1$V-;,
M93,I1426:DZJ!ODE0!V;4L_>:0.%P-U&N;LCC#A M2VWL0K5K\F! ( J)I!4
MF!B63<8D77%8/HZ9.NK3$NI11PXF 6.L3.Y-O1U=6VBX.'?>JT M'XB7:=P
M:38LQEB9)WS8U,EEZ]:F#!*4V< Z8)4$ QN6SASU"M1#"E&-&28-28Q 3$B8
MT2+9NM0RF:>BU9B&6DY!&^"%@CK6:C71DK*8*L"&!WB#!!Z_W3L5<53^)*!P
MX?)\0:V/!Q]S#RG%OP?"_P"$NV_W1G/\O4^[=KC%46<M1N5<2M_BZ%U1L#8
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M]B."W)Y^L30NU% 5+M\")OOEI(W++7R[,E93(9200=\$7BW)U#0K$;M1#/\
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MET(PWB^8)D'5!Z_LU]5O]N4/#J=7-_O>K_E\K[ ;&^1S/A4?L:&1(FD7Q/\
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M0SO+#4V[ @==9M5=#.6H^33>A>,?YS29WHWNI_\ '-M,!F, 028Y11Q2I_\
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M4Y;9.TTY&F*E3%E:XP4SBAWE-5#@>&:%U&OU3#TJFR=IK5IT^48'*UP5IDL
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M24T*8>K.6KCDT(8AWE-12$8AF@$*U]QBIRVR=IIR-,5*F+*UQ@IG%#O*:J'
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M-HA)5:F=RK*I.DA?2<(/6&B[19<ME*6>I9=!"JFT*"JHW@JYH #@ MHVC_\
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M5*<IQ8XRSOWS:CM+:"9K_P">HJBD/1:?*E<#!<-!:6!]0M?R;72=R1YG:_\
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M:'LDLM-0VS%(PZ6'I.9&)[AK71NZH6_<'M H@ $FJEQT<8:>"VT:;*BLN?S
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MKNK^TLY7&5H,)64Q$H+\9ET"KO3,B^X02]+*536RZF Y7!BC="XF@'<DR1I
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M%<489C=B3';/W5DMA35HC.;;2ERTAZ:8Z0'F>54LXG%.%05U>4'%MT[^I?\
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M_P NW3OZE_Y=NG?U+_R[=._J7_EVZ=_4O_+MT[^I?^7;IW]2_P#+MT[^I?\
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MXTDC5!&8V;DZ==*CTPJ8D4+I&C"Y@ 7W@=NU3:^TP'RM-\*H>*2 &9FWP 1
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M//XP-$E*J[NEJ>&)(TP=!$'<%':"0K<5Q>C1^*WO@@,+I D?9)D,D)K/OZ%
MTLQW /P"20+*=M9]DJMNXZ5)2=X"H&)[?8M6RV1J<ME$:%>0<0@7RMQOD2+O
MM%1-G*I-( MB8+&*8T[\'M?=.SD5$J,<_EP%<PK35358X6A3H)PM G5.BU8$
M 'E7N&@:QN%PN[ ZWV%/:.:J9A:SLX(1D"ZK$" :;'0+[[=)_K.7\2W2?ZSE
M_$M0&Q,SZ2'#X_*4ZF&,.'S8$3)TZ8NT'[6,WF\SF*5'"I9FJ4E43 $EJ<"2
M0!)TD"W2?ZSE_$L?V-M NX'XU.L)NT\G@@7QP2#P6G-J&RI,"HDE"=XW J>
M@3?!,3[![%J8*>#_ .2T!CG7GDP<,8>+NSCTW8=W_A+MO]T9S_+U/NW;#!*;
M!<K1EF,,G^+H"4&%I))PG635),F,)]F?JM_MRAX=3JYO][U?\OE?M>V#7=W(
MK9>,3$QJU=$D]2+;;^JM3-U<[DJKYCRCN79ZF7J!4J%C,L:>)6@P2%O(4?8;
M1J;1&*O12HU+%N,E&DB0#O4BQ7OAHM!T6^M>S]G0-D)F6"!>*%3,UUI1N7(2
M!P=:VUJX.,4JN>O.YA<4KIWIPW;FBZVUA4C#R5+3O^D4L/9Q1'#%MEFI?'I
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MFZCME0.KR>4I5*M3>12Q[2@G<-N4SF6KTJ>^]-U&YNL!OCMBP2F"SG0 ))[
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M=$7Z=-L__P!#_P!ZV=_27\(VS-4QC6@ .L6!/@BU:KM;/9JGGY 955L*X5
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MWS2< EANF(4Z+A)W#U*VV<RI2G40)3FZ5G$S?%D* =V#O6S&<I&:!?"IW"J
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MI6GBF"=$C23(W15VA4E5XJ"Y%G\4??)+'=/4&=R#X:HN(TJPW58;H/;!O!!
M-@FW<AC8;RTZJSO@5,.'W>N;-3V#D!3)WPE-9WRM.<7?#3I&ZV=S[XZ[7;P
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MB 0M^C1:GRFR,L^"F5::V;'*-J^4,5Q!&%KEPKKG5N6*0?9&6<HD--;-CE#
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M4RK36S8Y1M7RABN((PM<N%=<ZMRQ2#[(RSE$AIK9L<H8 Q-%<83()A,*WFZ
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M4RZ@*16S1Y,B99<58AB9%SXA=<--@$V1ETQX%7#7S<HV)M=9KWL<2W,2HP"
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M3"NL9$!8IAMD99BDXIK9L8[B!,5Q$&_5C1?=-D#[)RS%:C,Q-;-#&IQPABL
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M;\,\7@CV=VO@Y/!Z-1Q8IQ1Z70CD^&8F?@XO9KZK?[<H>'4ZN;_>]7_+Y7V
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MC]ERF6RN8J4]]:;L+[Q>%(O%HSE&K2/\M&73\8#>/W(E"B)JNP51<)), 28
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M#3H&@97])I>&MLI\J_@CJOLS:8I_M&H]YJ *2/@\D^X1O AB2;BMB=FYBDU
MFX5<2L!O2BL&Z\+UK#;&WLQ2/(G$H%U-6&ABS06(^"H47@&_18>CR-GT00DW
M%B8Q.1N3  &F )@DBU78^;8(*KAZ9)@%X"LL[A8!<._!&D@%Z^R:M$99V+8:
MA92LF8!56D:8F"! OTVH)GJXS&WJSA$5=%,-=B(F1(NQ-!,PJZ3;+_HW]=K9
M[XM+WZEL[^DOX1ZE'+;>IG+9)$1<51A3#8>*ZL2",5QE@ Q)C$+[3^TX_P#N
M<OXEC7V'FRYC5#E75CO8T CKX3[LA\O74K61BK Z008(/6-J?QJ/O6I;1I"<
M!UE_&4W,.R-&\8.Y:GM#9U95S:+ :)NO."HLR"#,;HDD8@;#TW,4$R^Z4QLW
M8#*@'7DQO&U.AL*H7*+%2_&H8:"&T%C?B &$&(@R!2;)U52IB5QNA7 (9'&D
M<8^XPD:3F-L9O+T<DE[,I8W;M[J@&X ;].@Z#FZ6Q@WH%"C7IJ6TDA"Q;?UB
MV+0-.@:!E?TFEX:VRGRK^"/NG9U0U%I!<]0.-HPI%5#B:2!"Z3) @7D6JF0T
MU6O&@ZQO'7^PI]>KX;=1,]DFP9A#(.X=\$;H(N(WK;E/.IV6I5([91H_G+O,
MMSY'.*4S%,P1[Q!W01>#NBQ_=;_F6ZGH&?Q-LMC((O-,G20-U3\)=,ZRWR&.
MT<E4"UWO+TB""?Y:&[%IGBM/&G18&IGB4WA1@]LU#[UC6=P,TRZ6(:LXWE41
M )&X NC$=VW+."F42132= .DG?9H$[UP&B3U6J9DQD*!4N!I<F84;P,'$=,7
M"\R!LO9M9,GD\.%BJ8FPB $4!D"J1.(S)$"()GZ?_P!C^^M4S"9T,R(S &EA
M!@$Q/*-$[\'K6I9_+&*])I&\=P@\# D'@)LE7+5!2VC3' 72=*NMQ9"=#"Z;
MP9Q+:,WF*"Y6=*8F8CXK*H!(_E&.&W_QW8; YC!@)4SR:GC%F&FHU]VD$EC%
MP-GS.2>@M-'PG&6!F ;L*,(@[]LPV>>BXK!(P%C&'',XD7\81$[MLQGZ%7*B
MC5J%@&9P0#OQ3(GK$VJY"N5-:DV$E9*SP2 8ZX'W3L6ERJ8O_DE \G=CX@&/
M3.'X.B)W9N_XP[;_ '1G/\O4^Z_JM_MRAX=3JYO][U?\OE?8#8WR.9\*C]ER
M>7S69IT]Y:KJ-[0& T 6Q9RM5JG^6[-P?")W+NKAR>8KTE.XCLO@D6Q9RM5J
ML-UW9O")ZG+9.K4HU2(Q(Q4QO2I!BX7<%C7S51ZM8Q+.Q9C%PDDDW#1U/1*.
M9KIE8(P+4<)#3(P@Q!DS=?)GJ<MDZE2E6B,2,5,'2)4@Q;ELY4J5:T1B=BQ@
M:!+$F.H5R>8K40=.!V7P2+3G*U6J?Y;LWA$]3E,G5J4JAW49E/;4@V!SM:K6
M(T8W9X[XG?L]#+5JM.A4XRJ[*K2(.( @&1=?N76%2F2M12""#!!%X((O!!T&
MP7.YBM653(#NS@$[V(F.Q]AR>6S68IT]Y:CJ+KA<& N%N4SE6I5J;[LS'<&E
MB3H [0ZO(4\WF5H1&$57"P=(@-$&PKJS"L&Q8@3BQ3,SIF;YTS85,[6JUJ@$
M NS.0-, L20)W+,<C7K42T3@=DF)B<)$Q)B=$FS5JS,]5C)9B223I))O)X3;
M+>FQZ)RZ8YT8<0F>"-/!;+YC*H]3)4U8,%!.%B1K%1N$73%T&8F_DU!-28B+
MYWHTS;,;0VB&H9)T$*^K.&2:A!XH T$B\$G0+\SG:5U*I69E^+-Q/"1>>&WH
M^9S->IEQ&JU1V6[1JDD7;EUW4Y7+5'IU1NJQ4]L$&W)YK,YBK3WGJ.P[1)'4
MY3)U:E*H=U&93VU(-@<[6JUB-&-V>.^)W[/0RU:K3H5.,JNRJTB#B (!D77[
MEUA4IDK44@@@P01>""+P0=!L%SN8K5E4R [LX!.]B)CL?=.SZBU*=)ESU AZ
M@E$BJIQ.,22BZ6&-) .LND522&)JM>-!UC>+S<=R\]<_8#+Y7-9BG0$ZJU'5
M;]-P(%^[=U34R5:K1<B"49D)&\2I%UA4SM6K6J 0"[,Y W@6),<%O1!FLP,K
M@PX.4?!AB,.'%&&+HB(NZO*4'9'WU)![8L4?.YMD(@@UJA!'",5B[DESI)O)
M[/V+#)5ZU$-$X'9)C1.$B8W)M].SG/5/&M].SG/5/&L4?.YLH1!!K5""#I!&
M+1U ])BKC008/;%C2KYO,O3.D-5<CM%B.J:>2S%>C3)DA*C("=$D*0"8W;?3
MLYSU3QK?3LYSU3QK-6KNSUF,EF)+$[Y)DD]?[IV+1Y6EA_\ D= \G'E)P 8Y
MQ\3X,<GQK\?P?^,.V_W1G/\ +U/NOZK?[<H>'4ZN;_>]7_+Y7V V-\CF?"H^
MQ0RKX,QEU$*'G$H&@!@02!_*FZX$"Q"9$!XN)K2)X1R0GK2.O8T*S+2R9/$2
M0#O8B22W6D+-^$>PFSJBLBLN?RY#/Q1%5+VO&J-)O%TWBU8D@DU7O&CC'1P>
MS&Q:6*G@_P#DM X?ASR8$Z>+N:-.[_QAVW^Z,Y_EZGW7]5O]N4/#J=7-_O>K
M_E\K[ ;&^1S/A4?:ALZFJHS-G\N K\4S52YKCJG0;C=-QM6! !%5[AHXQT<'
MLQL6KAIX/_DM 8OASR8,:.+NZ=.Y_P 8=M_NC.?Y>I]U_5;_ &Y0\.IU<W^]
MZO\ E\K[ ;&^1S/A4?L!M&GE\63-/&&#TS*Q,X0^+1N1.Y$]5VV91-5:9 8X
MD4 G0)=E!/ )C=LU&LI6JC%6!T@@P0>$'J'*[-IFK6"EB)   W26( TQ>;S<
M+#*[13D\P5#1B5KB2 91F T&XF?M]/9V6*+6JD@%B0MP)O(!.@;@-DR^=:DS
MU$Q# 6(B8OQ*M_8/LKL^FM.G59L]0 2H81YJJ,+G"\(VAC@> 3JMH-4$!2*K
M7#0-8W"X7#<N'6'V"YW(4.4RS$@''3708-S.#I&];Z+_ -VC\Y;Z+_W:/SED
M&TZ7)&I.'61IPQ/$9HB1IC@^UAURNJ1(\K1W?^I;Z+_W:/SEL=;*52H$ZF&I
M^;+?_HOT6*L"&!@@Z0?8/8M;DJ6'_P"1T!RD^4G #@C!Q/A3RG&NP?"_XP[;
M_=&<_P O4^Z_JM_MRAX=3JYO][U?\OE?8#8WR.9\*C]@<F][Y>H5@_B-K+[I
M81P6S&1B%IU6 ^*;U_HD=2@*T+5KGE#.ZU2, Z^ *(WYLV8012S*!QO8AJN.
MO(#'XW4S&TG&M5<(OQ4$DC@):.NMLSFU,TS4PK\5-41UP)[/V_*?';P&MEOD
M#X9]E=G4S36J&SU 8&C"\U4&%I!$-H,@B#>#:J("Q5:X:!K&X=;["C\>IX;6
M^E?]JC\W;Z5_VJ/S=D.TZO*FG.'518Q1/$59F!IG@^UU,]D7P9I$I86@&)>F
MIN8$&02+Q[MOI7_:H_-V!SAIYFE-X*JAC@9  #PE6TF[1'[0R44]H"[%$,K
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M1&+!> %O'#IOLJ?6;-<IGS!9%+X5D2!AI U(_E,5!N@#06J_5^IR=11I5F8
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MS7JCJW:(-J>:HZU.G65B1HPLK*#VV7M]2C44:E%'=NM@*#^DPM1RZWM3H">
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ME;2;!E';$CG0C& 0V\K0"#H4S-Q)#;0V;FA0RSRQ 45*8W\!#KA73=) W($
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M%[MO.Y/F%[MO.Y/F%[MO.Y/F%[MO.Y/F%[MO.Y/F%[MLQLG.U,J<GFJ%2C4
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M^KG/O\W;^*?JYS[_ #=OXI^KG/O\W;^*?JYS[_-V_BGZN<^_S=OXI^KG/O\
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MU(14 4SOH\0#UB1&])W[)1K":*@LPWP-SK$D3P3;]G[/PIR:B6@$R0"  05
M (W#IW(LF3SY#I4,!H (.YQ0 0=&B=V;-LY%0T:U+C&9@RI&D";KC?UK-G,R
MN++TB  =#/IOWPH@D;I(FZ06R^S2J44,8H!)(TD3( WKIB_K+EMI%7HU#AQ0
M 03<)@ $;ANX9L*M 1EZP) W PXP'!>".O&@>U_:'R='WZG5I_NE?\P_L!4^
M,/!'M0?XI]ZPZWV"9K-TL54EI.)QH8C0& T<%O\ ]HL?V;5*U(F Q)'75]:.
MU?N[EN2KWTVXK#0P^\1NC<X1!^U&GF$2I3Y)C# ,)E;X,BS4Z"*E/ MR@ :-
MX0/M)VP7440>+?)UPG6T_=O\S[_M?J_+?U5MF?TBIX9ZI2I<ZY;#_.81'?-9
M9TBFT=>.Y-L&U*%:IF @@J2!AO@75%W9W+?1,QVS\]:IDLE1KHCJT P1+"+R
M:C&-_P!ZRUZ1BHC!AUP9%DVA0&L@#CXI$..QI/Q;/GG&K2&%?C-I[2^%:I54
MS24X%ZR[O9,GLV+P3KN3&F[>T7Q&[;Z)F.V?GK!ERN8# SI/SUJ299:BE&8G
M$ -(&B&;>OT6/Q*OOM;+@Z.5'N7CW;99/@PY[.KU*BCBF@9[#)'O^[:H1I*H
M3U\('O 6'Z/3]]>HH&[3;WK(1I-!9[Y_O19ODJWOOU*WRH\$6K?*MX1M5^1_
MK+:O_,_-I9#GD>IDL%,$+<=S#\);IC=M]$S';/SUAF,KELPE8 B9G3<;C5(]
MRS9N@&6F54:T3<(O@D>[9/E4\%NI6^5'@BU4#1RK>$;-\NW@I]B*E%F2H-U2
M0>V+!,X>6R\WSQ@. [O6:=Z189P07IE2IWU8@1UC(/8M2ZS^ UJ?Z.OAOU!7
MJ$4:#:"P)8@[H7>ZY$[EU]L.<SD/\>FEXTW-B_!9Z5 XJ"TJ84R#*AD"F1<9
M$&1=O62O6NHL"K'>!W>P8)X)M^T=G%:G**)$@3  #*2<)! &Z-\3-RYW: %-
M*9D+())W-!( &G3.Y%O(&:--0@.X3))(X),=B;%X)UW)C3=O:+XC=M]$S';/
MSU@RY7,!@9TGYZU),LM12C,3B &D#1#-O7Z/:_M#Y.C[]3JT_P!TK_F']@*G
MQAX(]J#_ !3[UAUOL$Z[^$>HN8H'#50R#_SN'01NBZQS,7J4<;XQ$+'::S#)
M)C*1.LHB9CC$;QT6.7R]-GJJ8(&Y?%YT"_?-E?.T\"L8&LIO_FDV%.F"SG0
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M.492P/XJ#>X6T]:!OV+95A2HS< JL8X2P-_6@6]&SJ*<RB$JX$72 0=Z;M$
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M$7]BZT#++RD:<9B>MAGL8NS9-HYG7"8@$!PJ P@@:8WY,DQ?8YS!R<J!$XM
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M:]"B]0LU[(I/&.Z1-OH7_9H^-;Z%_P!FCXUJ9V;1Y$*&Q:B),Q'$)F(.G?\
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M05<31I(! @=<D=B3;T')9<-44#%!"@;L%H8L=TR.S,PXVE0-.O$@@228N"N
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M'\[6[=_W(>M9/BCWON*E5J&*:U%).\ P)T6IT<G4QU%J@D86%V%A\)0-)'V
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MX;?E^<-OR_.&WY?G#;\OSAM^7YPV_+\X;9I7:LPI9DH(=A Y.FT&Z\RQ,[Q
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M"# !)T3>9@#L2*S94)E&-V)7OZSW+_1LF;HW(XT;H(N(/6/;T]2K6T8*;'M
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M[7Z8(&\3ILJ;7RQITF.D*Z$<,-.+K"/O6KU!H-..^('W[&I4!?,U:S8$&E@
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MB>O(/4=EXP0GW#;,-\((H[9/<'5HY=+W%/1PLT =>[WK5E)T40O;A?OV.>S
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M&@76IT](1T_HJ']PV*_CU%'OM_5L-H5Q-5I6G/P4!,QO8F+$\'7-FY,Q5JG
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M[^($B#UECW]WJD[BU3_VTC^KU#4K$&L1JI-['[PWSH'7@6?;F;W6;#PL=)'
MH) X;AHM1K9I0<J13)D2"H8AI&[%]W=L#EJ=-%.C"JC3UANVSF1Q%<U4S;,
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M:E4HM36BBP<18&\WP I&CA%GRE;S3K%VYN@CA! (ZUFIT,V$RK&\J7!(X4$
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M9,XF:XQ E@#O]NS5A5H^C"Y%+,($7W!"))O)D]H 6A<X%4: *M4 #> "  <
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MB< ?&,0XZP " 0UP6S4Z=*C40&YEJH >$!BK=L"WT>GSM/QK+GMK4E3+O4"
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MXRD=L19\IG:=-RR$ .H:&4B0)!OB=&];Z-E^;3N6^C9?FT[EA3I@+340 !
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MN6%6C0HI4&@JB@C<N($VRW7?^I;+?(K[UC\JOW[#Y5OO6S/R+>];-?\ 3_\
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M'2-U3N@_\WB\6'Z<OYP=0,I"9Q1JMOC\5M\;QT@Z-T$TT5^0G>QTSPC3&_\
M!._NVP(E'&=$*Q/8!<^]85<WC6E^,XPJ!_)6Z>P(.Z;#+Y<<+,=+'?/WAN#[
M Y9C%07JV\P^\=!X.&+&AF*)?*3,&<.G2C@$";KC.G0";&CL[+E:QW034(G>
M 47]<'K6_:6T?I%Y529()TLQOOON&D:3?H:A6$TG4@C@-C7R2FKE&NN!((W
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M@QU:WU*VIEZV9V56DAD4MR6(@G''%3%KJXO5]PS<3E-H 4)N#TI8<!(< ]<
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M- 68G=)F#<.MNBU2GR?)54 ,8L4@W$\5=!B>N/N+ELRZI3F).^=RRU:9!IL
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MQ=.BZU,U*QK/5#7E8(PX1^,TZ>Q%J69])P\I35HY.8Q &)QB8G3 M]*_[?\
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MS-(!-[, 5 C*;/FGOO5@GL+3('?&W[/VUESEDJZLL15HF;H<E5(!WRA4?"(
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M\NYU])[0%'95"]P1(_E/  /6%_6:R9:GQ$0*.P(]W[;FR&"D9:KK$2!J->0
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M$$$;GO&;2*=?'&B$CMX_O62G1I\GD4.G2!.DDW M N4:.M)LF7I74T4*.L!
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MA&".6J:8GS%3BS?._'P9W/9K;?[WJ^"O5H?H"?G:_P!J_P#W=EJ]<#2:=-F
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ML?+4VJUZ0 -.B%5*8_%)N ,?!4&-V#;]D9JDU&M6U0E4*U.I-V"1(D[S* =
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M76>_<U00.$@:3;+[%HF&S-3$P'_ITH@$;Q<J1\0]3-97,D^B#,NHG0%:FA8
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M^SNSBP8L*]2(T#_#U>-=HBX:+X]FMM_O>KX*]6A^@)^=K^P&:%_TP];S=/\
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MEO(5+E.$P1I,E;@1)-Q]F=M_O>KX*]6A^@)^=K^P&T/E*/O5/L%RE(Q5K3/
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MC5KRJJ"=5C>0)-]]J-6O0HO5..2R*28=@))$Z+K?1LOS:=RW)TP%IKF7  $
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M8B%P^X&CL[]J5):M*DR( RLP4XHO-Y$R9,B=-]JF0R :LQ +, <**K!IF+]
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MF.Q;D&7D\W$X9D&-.$W=<@B1PWFS5JS!:2B23H L:&R:#56W"03/61;X[(/
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M*5Z-)WWV12>V18(@ 0;@$#M6+9>E3IEM.%0L]> )ZG*UJ-%JF^44GMD3;"H
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M:7C6^C4^=I>-;Z-3YVEXULEGLSET7+T<W1=SRM,PJ5%9C :3 !N%Y^[<@ 4
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MXLTY[)C"BN?+4[E;#A8ZURMC7"3<<2P;Q)G/9.Y _GJ?%,0W&XID0=%XOOL
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MM<I#*0=!!!!O%L/IV3G!C\]3XL3BXW%B^=$7S98SV3.)&<>6IWJN+$PUKU7
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M*U,XF&'56&O;66X2=9;KQ;%Z?DL);#/+TN,-*\;C7B[3?9G?/9,(CX&)K4P
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M6?[BW1GZS_<69!LR,2D?2)TC>Y"_K6HY5MFAFI4E217" X5 D**$*#$A1<-
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M4)[;&PVIGG!J)>KYAU8@B^4154,P^#",P(U;[*<N&79= $4P=+$QB=AN%H
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MHTVIW1J+[PZ_V#]9/!'4.T\DOE1?44;H_&'"-T;HOT@R,CFS_BU&J3\-1_6
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MJ8*F8HJ^\74'M$VQ(05.Z+Q]A2^-4\!^H:=50U,Z01(/7!N-DS^SR4HLUT?
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M;MEKU//J<+]<1?V00=Z9&Y]S[17'?^R*AP1_*.M.C@C_ (2[-_3\O^=3[MR
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M=%LRGP0:9[>.?>'W/M%<2Q^QZFK!Q<8ZTX8C<C%,_!W?^$NS?T_+_G4^[<@
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M,;H!D;L3:EG4$BF2K=9H@]@B.S9*.(>D45"L-V!<IZQ$7[\BQJU6"TU$DDP
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M 22>#&U\?S=W<LM"@H6BH@ ;G_.Z=)M^U"U+T?EF>);%!G<PQ-^_9Z2QB9&
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M;@ %E96P9E-!B00=(/O@[E^_9<OF\T!E%B%#.P'65@JC@LF6S#.7IC5>;Y@
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MUB%4@^3H:Q):&/D[B) @0-42))E,6?K$+,^3H:U^[%.Z-&K%DQ9^LV%Y,TZ
MQ#5U3%(0+C>L-K&^X0H.T*Y*L23R=#6&KJF*5P$&\0=8R;A$?M"O.*9Y.AH_
M%\UHX=-^FS ;0K@LP(/)T-4:VJ)I7@R+S)U1!O,OAS]9<3R(IT#A&MJB:1D7
MB]I;5%]YEL.?K+B(CR=#5C2!-.^>&3==9B,_6 90!Y.AJD%98>3O)@B#(UC
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MKSBF>3H:/Q?-:.'3?ILP&T*X+,"#R=#5&MJB:5X,B\R=40;S+X<_67$\B*=
MX1K:HFD9%XO:6U1?>9;#GZRXB(\G0U8T@33OGADW768C/U@&4 >3H:I!66'D
M[R8(@R-8P) AHS]82B@>3H7$898>2O+09!E1B, 0L'_'UN(!YNAINUO-Z3O<
M6_1HL"<_6@(0?)T+R00&\WI!(( U3A$@@F5G/UC",#Y.A>3BACY*XK(@"%.$
M2#+2LY^L8!GR=#6F8)BG=ANB(!B^;[)BS]9L+2WDZ&N)&J8IW"XB5@WZ9BR8
ML_6;"\F:= 8AJZIBD(%QO6&UC?<(4-M"NQ#23R="\7:IBE<.$0;].BT?M"O.
M*9Y.AH_%\UHX=-VFSX<_67$\B*= X1K:HFD9%XO:6U1?>9J8<_67$TKY.AJ"
M_5$T[P9 EI-POO,OAS]8!HCR=#5OW)IWSHUILQ7/UE!4 #DZ&J1AEA-.\M!D
M&0,1@"%AO\?6O0 >3H7,,,N/)WDP20948C $")]/K1@CS=#3$8O-Z9OCB\$6
M7_'UKD(/DZ%['%#GR=Q$@@"%.$2#)E2V?K, I!')T-8G%#&*=Q61 $ X1(,M
M*8L_6(69\G0UK]V*=T:-6+4\6?K-A:6\G0UQ=JF*=P$$2L&\WW"$Q9^LV%Y,
MTZ Q#5U3%(0+C>L-K&^X1'[0KSBF>3H:/Q?-:.'3?ILRKGZP8O(/)T-47ZHF
MG!%XO,M<+[S+X<_67$\B*= X1K:HFD9%XO:6U1?>9<IGZRAB" *= X!?<)IF
M9_E2;M-GC/UAB  \G0U2(DCR=^*"#BD"3 $"&C/UA**!Y.A<1AEAY*\M!D&5
M&(P!"Q=GZPU OFZ'&$2_F])@F.+?<!=:_/UCJ%?-T.,9A_-Z1(,<6Z\&^RSG
MZQA&!\G0O)Q0Q\E<5D0!"G")!EI2<_6.$$'R=#6)F"?)W89 && 8$@R90OGZ
MS!220:= 8Q=<8IB(_DP;]-DQ9^LV%Y,TZ Q#5U3%(0+C>L-K&^X0JMGZQ8/)
M/)T-87:IBG %QO$->;[A$?M"O.*9Y.AH_%\UHX=-VFSX<_67$\B*= X1K:HF
MD9%XO:6U1?>9J8<_67$TKY.AJ"_5$T[P9 EI-POO,OAS]8!HCR=#5OW)IWSH
MUILQ7/UE!4 #DZ&J1AEA-.\M!D&0,1@"%AO\?6O0 >3H7,,,N/)WDP20948C
M $")]/K1@CS=#3$8O-Z9OCB\$67_ !]:Y"#Y.A>QQ0Y\G<1(( A3A$@R9S9.
M?<A<RRD+2H#$32IPSD4@<8D:#!"J#(D63%GZQ"S/DZ&M?NQ3NC1JQ:GBS]9L
M+2WDZ&N+M4Q3N @B5@WF^X0F+/UFPO)FG0&(:NJ8I"!<;UAM8WW"(_:%><4S
MR=#1^+YK1PZ;]-F5<_6#%Y!Y.AJB_5$TX(O%YEKA?>9?#GZRXGD13H'"-;5$
MTC(O%[2VJ+[S+E,_64,00!3H' +[A-,S/\J3=IL\9^L,0 'DZ&J1$D>3OQ00
M<4@28 @0T9^L)10/)T+B,,L/)7EH,@RHQ& (6+L_6&H%\W0XPB7\WI,$QQ;[
M@+K7Y^L=0KYNAQC,/YO2)!CBW7@WV6<_6,(P/DZ%Y.*&/DKBLB (4X1(,M*3
MGZQP@@^3H:Q,P3Y.[#( PP# D&3*%\_68*22#3H#&+KC%,1'\F#?ILF+/UFP
MO)FG0&(:NJ8I"!<;UAM8WW"%5L_6+!Y)Y.AK"[5,4X N-XAKS?<(C]H5YQ3/
M)T-'XOFM'#INTV?#GZRXGD13H'"-;5$TC(O%[2VJ+[S-3#GZRXFE?)T-07ZH
MFG>#($M)N%]YE\.?K -$>3H:M^Y-.^=&M-F*Y^LH*@ <G0U2,,L)IWEH,@R!
MB, 0L-_CZUZ #R="YAAEQY.\F"2#*C$8 @1/I]:,$>;H:8C%YO3-\<7@BR_X
M^M<A!\G0O8XH<^3N(D$ 0IPB09,J6S]9@%((Y.AK$XH8Q3N*R( @'")!EI3%
MGZQ"S/DZ&M?NQ3NC1JQ:GBS]9L+2WDZ&N+M4Q3N @B5@WF^X0F+/UFPO)FG0
M&(:NJ8I"!<;UAM8WW"(_:%><4SR=#1^+YK1PZ;]-F5<_6#%Y!Y.AJB_5$TX(
MO%YEKA?>9?#GZRXGD13H'"-;5$TC(O%[2VJ+[S+E,_64,00!3H' +[A-,S/\
MJ3=IL\9^L,0 'DZ&J1$D>3OQ00<4@28 @0T9^L)10/)T+B,,L/)7EH,@RHQ&
M (6+L_6&H%\W0XPB7\WI,$QQ;[@+K7Y^L=0KYNAQC,/YO2)!CBW7@WV6<_6,
M(P/DZ%Y.*&/DKBLB (4X1(,M*3GZQP@@^3H:Q,P3Y.[#( PP# D&3*%\_68*
M22#3H#&+KC%,1'\F#?ILF+/UFPO)FG0&(:NJ8I"!<;UAM8WW"%5L_6+!Y)Y.
MAK"[5,4X N-XAKS?<(C]H5YQ3/)T-'XOFM'#INTV?#GZRXGD13H'"-;5$TC(
MO%[2VJ+[S-3#GZRXFE?)T-07ZHFG>#($M)N%]YE\.?K -$>3H:M^Y-.^=&M-
MF*Y^LH*@ <G0U2,,L)IWEH,@R!B, 0L-_CZUZ #R="YAAEQY.\F"2#*C$8 @
M1/I]:,$>;H:8C%YO3-\<7@BR_P"/K7(0?)T+V.*'/D[B)! $*<(D&3*EL_68
M!2".3H:Q.*&,4[BLB (!PB09:4Q9^L0LSY.AK7[L4[HT:L6IXL_6;"TMY.AK
MB[5,4[@((E8-YON$)BS]9L+R9IT!B&KJF*0@7&]8;6-]PB/VA7G%,\G0T?B^
M:T<.F_39E7/U@Q>0>3H:HOU1-."+Q>9:X7WF7PY^LN)Y$4Z!PC6U1-(R+Q>T
MMJB^\RY3/UE#$$ 4Z!P"^X33,S_*DW:;/&?K#$ !Y.AJD1)'D[\4$'%($F (
M$-&?K"44#R="XC#+#R5Y:#(,J,1@"%B[/UAJ!?-T.,(E_-Z3!,<6^X"ZU^?K
M'4*^;H<8S#^;TB08XMUX-]EG/UC",#Y.A>3BACY*XK(@"%.$2#+2DY^L<((/
MDZ&L3,$^3NPR ,, P)!DRA?/UF"DD@TZ QBZXQ3$1_)@WZ;'%M"LV'$3-.A#
M"!JM%*Y1!O$-K&^X1E&].?S5-M6G0"E2BPBCDA""_"0 T'3<(C]H5YQ3/)T-
M'XOFM'#INTV?#GZRXGD13H'"-;5$TC(O%[2VJ+[S-3#GZRXFE?)T-07ZHFG>
M#($M)N%]YE\.?K -$>3H:M^Y-.^=&M-F*Y^LH*@ <G0U2,,L)IWEH,@R!B,
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M3=IL\9^L,0 'DZ&J1$D>3OQ00<4@28 @0T9^L)10/)T+B,,L/)7EH,@RHQ&
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MF,_WE+Y^WF,_WE+Y^WF,_P!Y2^?MYC/]Y2^?MYC/]Y2^?MYC/]Y2^?MYC/\
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MG<D&;<KG,G&7W\%1/Z3%A[EC6H!E*F&!W#U]!['9 L<N@-7-#2 8"]=K[^
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M4+B(PL+@0)EE TD=4Y#*F<XX@D? 4_UCN#<%^])SN9$9JH( /P5TW\+7$[P
M&_;+;V%_?6V6^13P1U*&_P H?>M0G>;PVZF6Z[_U+9?Y(?=6T=5)_9%36Q:_
M&-V'%&'=Q8--V+<_XP[-_3\O^=3[KVW^]ZO@KU:'Z GYVO[ ;0^4H^]4^PI9
MY1JK*-P3>ONR.N1OV6@3_B*("D?R1Q3UHNZX^PQU;E](0]@X3/:/4-1^*H)/
M6%YLU0#56DQ/9('W[+\NO@O:G\9_"/47Y6C[R=0_*K]^P^5;[UFI9M9R[UUD
M21<X&Z"#=.X=RWF/Z=3Q[>8_IU/'L:633 C&3>3)B-+$G[UCL_8@A 2,0B6
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M(WI<'W+)FJ0(INLB8GLP2/=^Z=HO@:/V/4&._#QCJZ(G=TS&Y_QAV;^GY?\
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M&X7]@=;[#E:U&D]4[K(I-VB\B;NJ%S--*B@R RA@#V0;%,M32FA,D*H43OP
M+<N:%'E\6+%@7%.F9B9F^=/5PU%#+O$ CW;!ER] ,-!%-)]ZV%0 HW!]B#F:
M5.H1HQ*&B=Z08M]&R_-IW+?1LOS:=RP9<M0# W'DT[G4PN 5.X;Q;'2H45<;
MH10>V!U0^9I4JC@0"RJQ WI(-OHV7YM.Y;Z-E^;3N6%.DH6F!<   .L!</NG
M:-3 ^+]D5!CG4XQ.&,/&W9QZ/@[O_&'9OZ?E_P ZGW7MO][U?!7JT/T!/SM?
MV VA\I1]ZI[%&LN*E5)DX8@G?*FZ>M'#-ABS)*[L4X]W&?>-A5I@OF!\)KR-
M_"  ![\73["9M2&8'*U1"\8^3:X:;SN7&^U,7C473IT#V8VB\-B_8]03\'C&
M[1QMW3HW/^,.S?T_+_G4^Z]M_O>KX*]6A^@)^=K^P&T/E*/O5/:AFV)90,K5
M,KQAY-KQHO&Y>+[4S>=1=.G0/9C:*2V+]CU#'P>,;]/&W-&C=_XP[-_3\O\
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M6Y)S)I.5'Q3##M21U@++^E4OZG47Y=?!>U/XS^$;<G4$HST@1O@A ;"G3 5
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MHRP'>-:?-OMZ,L!WC6GS;[>C+ =XUI\V^WHRP'>-:?-OMZ,L!WC6GS;[>C+
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M]ZN&OU"8[^</45ZP:=_T(N_SNWO[D,/?K3Q]_:V(VL']=RW]/<>O'_7?_P!
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MZXLZ4+&QZ4(B?A5*A47JJIE#EW 4@ 4W$(E]6D8BQ=6Y"WY"R+9(NIU&N1A
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M(*'2(<I3K(E.2S:C=-5[H-2$[5%:ZLEZW?:*P<OC@FR9RUWQO.V^IP[YXJ/
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M2%QCJQ=U[MCN[P#&-:S,3!LY]$\1SFCY0KM!-NZ*!FYU?;)W?5'GVJL[AA?
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M#X^S557N*+1D">L<EEZ"HM?*JUL\36(^.8U]&F9#OYGQEE8I51T9P9F"/*2
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M]*51Q==E)J!M9;E0*AD?!<50[>%DK31E6;"><@(UH^+(1R"+)R90%FY")F(
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M+'I<L5DG+!B?*U?B'DU6(BJOW*\HQIMWDXQH9M4[75F2AFATWQ6A)!-H=TT
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MH^<H=0RS:(T&0;&T&8IIMYB2U(/Y6 2D@*F"SM:MM<'PTBNQ.<#"5N6534*
M@ K&W")G-'R1:87'&%U) CWY&,2-)*NU26Z18BL8:[R;^4EK->E6:B"2_)?/
M!BRODP<H,FZA4^7M1M2]3KA;NA7H^QUVWX^5GAJ[6^5"SQ#A@_K[FPEA;"I$
M&;20-))NN5DX!-XP1$R9R<1#8;KI<._(-0L2KVB:5J2.2SY*\;+=8TXYBWL4
MA(C0L?IM.P(9BHV9H V6,3KG1A5$% (3: NM(L4U4KA59=A/UFSUR2=PT] 3
M<6X3=QTK$2K!5!['R#)RD4Z2J1RG(8 $!VBJSJ'PKCO4H2'CR,4[?'6%_AK(
M,R9%'EHO;-)QU?O%.?O . "H=I ,.: >VWG$5!<L<':2L8XKF',>JU+.Y"R-
M8LQBQ>+*E#M./C8:KX@: JV:";DI.1=) XX5%"JIE,@>6S'J)R3/Y+ODJF5J
M20F%4D8V#B45%56M>JE?8)-(&J5QFJNH=-C'MV[8%E5%1**JJASR6A3]E7Y0
M.T:YFB ^5+Y<O%3D_*\YLSGJ_$CY'[)S/%[QBX>7VN7J^3OXD>/<79W'8;L\
M5:L4S,BI*V/".2&S^<QX^DW)6J#R>ADF$C%351LR[-J1,SN.=HIN!(EUB+LB
M*9"HMI?09!OK05BHFXF(W4@_BH!62$J@(NT:VZP?,R*#$AQ*)FYI510P ( L
M7> E5QS<)2O8CPBLJBJ_Q)BA.6C8NUJ-5D';-3(%@E9*1G;<5D\0*JDT%1K%
ME5(FKT8KID5#;%F6,56R7HV1:!HPTB66HVN#6*C)0TQ'OL.G073!5-9JZ;+$
M$R3ALX35:NVZAT5TU$5#D,QB,ZZ2*%EVW,F;)HK<:)E.5PTA+*-0727DY:M/
MZ!E9GVG(I<DZW1+L6A7!53)-TDE$T$)W$,#&US3CA.RD?,K+4<=R,I+7"YP3
MM98 KMTR+(E8NGT&9@8B+IK&,(="0#F@Y(J@H"!-G_U?O[*OCOUU!SO1OE:^
M7+Q:Y7RV2EZDNU/$/Y'Y_C\6?'3@Y';0=;TV_F(<S<3;*>-?V9_ES^4R_,+S
MVU\LWR9=B=#76D!V7V=\E.0>TN;TO-Y_/;\/%P\L=W$.2<E=E]A_*'?KC>>Q
M>M[2[(\;+%(S_9?:/21_:'9_:'*Y_(0YO!Q<LF_A#).6OD3^7'Y0L9CCKQ?^
M4CY,^R-]I@++VQVKXA9 Z_\ (?(Z?ID/]+Q\WVO";+VJ[Y/?DJ^57Q _YA>-
MGCSV#XC8OI6-_?3XLT_M3M3Q/ZW\G-^1U')_&<OFGC<R:=,B2^/;HQ2Z%\=G
MR7D'9X([A!R[K-OKSXB\39*\]5;$,=NY2.":I"+)"FNFFJ1-IF+1AC_(%H(5
M$IIW'68;!B>'6X"&*L=2N6&A9@= JN?<;>21*0OL@!1 0X9>KX%QOC;3)'2_
M6(#:&;I_E+)L:P<(%02;Q-DL+""J#%T4JBHG=A7!<@<4C-S-C)F,I-6NW3\U
M:K38Y-[-V&RV.4?3D_/3,DX4=R,M-3,FNZD923?NE3*K.%U%%55#"8QA$1':
M#TS?LJ_([V+?J7>?';Y<OE!ZGQ0A+##=E^+?R/T?D]H]O<SG]>?D\KAY9^+B
M+ME/&O[,_P N?RF7YA>>VOEF^3+L3H:ZT@.R^SODIR#VES>EYO/Y[?AXN'EC
MNXAR3DKLOL/Y0[]<;SV+UO:79'C98I&?[+[1Z2/[0[/[0Y7/Y"'-X.+EDW\(
M6FRXF:P%SH^0F+%ED3%5R%\6MV->&ZP:_/LG\8LA)0%F@AD'!$7*(J)*MW"B
M:Z*P<H4G4=A;1S0L9VUPDX12L]_R[-9<C6/.3*1)RTK,-C_$@F>-1$QR"N^6
M0,?AXTC% Q3W#(EK4CEK/>K-.6ZQ+1$)#UN+6G+%).9:4680%>8QD'#M57KL
MYB-FC=%ND \)"%* !ZA,G:;,JV/&=F5(V;3*48H@]KELC&JQETH>Y5241>UV
MTQ1%#F,1)ZV6Y!S"HB*:NXX-F6;M(V,<GS#>/(V4FL>9)LF'BO7R;A3=(NXR
M;J^8&X&78<LJJ2!T$Q<@=5/EIF*W3<P^GC3EC/ CY\Q3:JVJX6V3SC8HIR(R
M'4R5<14K.-*HV=""C3DDDHN603Y*W&FMST^GM.5<NW6PY#R+=9-27L]NM$BM
M)S$J].4B2?,75'@;LV35)-NU;(E3;,VJ2:""::*9"%IV3\<6*0J5^Q_9(>WT
MZS19D@?P=B@'R,E%23<JZ2[98S9XW*84EDU$52[R*$.0QBBTB<H:,Z3?<A-V
M8-U[I4\RR^.:X_<IQ[=!-^YHS_&N0'2:JLBFJX6(C,I)&(H"294N#C-4KME^
MOXZID9CIC*16/JQCZN S4@XZ8=-';_M2X2J\E<+&Z<K,$3B59V1@@J4QVK1N
M95;C@\>Z@\'5G4^O5H=M!PM_)D*1Q3D&3:,$F;>/<7J5&GY'A[9*HM4%$U7B
M;!@Z>&,15P=5<%E5Y_'6#:/5])]4LK8["3L-7LLM>LQ$C'#-)L]CHC(SJ-J<
M57BO5#+F%Y'P3640*9,&[I$Z9U%9;ZL"T8.)/N7;%.'C<_FRF[0?M89OFF/S
M&S0EL>NJ))C,OFJC92+*N2?:%%L*2@I<:1P6RYE+4-'&MN+].J5#Z#&P2+Z-
M976^79S8GL,O9E8T[=Z[JE:84]PHX8E70*_<N6Y%15;$<H*Y.J^G3(->TX8:
MQ]:Y['5#QK XDQ%9U&D!29A_7XZ1G9+(U!MDDG.OFK$@K-F9F<<T*!446Y>
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M2=QI5H*DS].PC"72*<5^SV:;MA4&-COJ<)+M$92.JD552NF+9RJ1 )%22,=
MQT4#B>]V;'$VG8L5X@KD-@V@3S1<%HJQ-J?(34I:K'$&2$6[F*E;S8I,&3M,
MQROH]%LL4PD,0I6&%(2PP[C(3O 3# LT$HKRT:]G/ 00*]"5MH- =*,$)J5J
M-?G5%4R'.$?)$6*EQ#R0E,09CQC=,=9+B)$T6YIUG@GS&6<N!=G8MEX8@I'0
ML,5*+DWL7S [EE()&*HV553.0YI/6CG.N.L.TRU8OL&-<2TF]LEX+(&3'-I>
M0%G=6J.K<D+23BZK&P5446;JN$2K2::P.&Y#-$Q7-DC]5F&?[&M]L]X(-(-O
M'/&^>%\@FC#+D*Z-2LETJJ144\1:F-S5DD+)0I0BRA X$Q62*8"B8HGO6%,N
MT^=@0AK)/-Z/:'T:Y1KN1Z:T??\ (EQI\P8IF$U&2<2Y;*J@BJ=9BLJ+9R5)
MRFHD7%>M?(5&E\/8,P\K;%XR6R3$2%;F,I3]PI5GQS&PM#@Y0C&2>1[9]:@5
M7E5$RL!41Z9 R[@QR):;OHSE^=.^[9$T$9#DB.;/BN'R5CV=K3ETW-)V' >:
ME9Y=":CB..)5VUB).VRD,N4$U$V*:;$#B!7*1-K%CS,]&GB55O-.6E#RZQAI
M$^-LDPIS*K1,I7;-R#182;F.*51W%J+!(1ZO$FLF&XIC2"^"L6N6=*C(R0?N
M,L9&[3I6+%W;)$QT:]#VYQ$O$;%9)!P*:)&D<D[,W%8BKL6S;B7+;,=WZ D:
MI=Z+8YFHVZLRZ/3RD!9*](.(J:B'Z.\P$=1\@U42/N$Q=Y=X"(;AVKL!BF(D
M;M-/=%>C&Q,XBN,7,Q*.F6-9+!-RN*3>/CR.'2SJ#AJA(&<)D*8Z0ME $-Y1
MVN6;8#%][E\/X\?0T9>,FL*Q+N*-5I&PODHR%8S-E3:C$LW4A(N$D2)F5X@4
M63*( *A.+^%_]=__ $#_ -WS5E^BV(_SM?O5PU^H3'?SAZBO6#3O^A%W^=V]
M_N)CZ,^4_P"U&-ML-?0OQW\^.HK]XIGZQ=//]G9G:IZ@\#SK.$OU2+(-4R2T
M>27K\["3+11A-5RR1!U$ D865:*<*A2J)+)*%(L@JDNDFJ2DN,_.J-!5C'99
M%6HX[Q; 2U<I4;+3"#)M+V!9&P6.W6*5FGZ$>F3F/))PFV)QE;$1*JJ!_P!W
MCC';8%3.;[?:?2VY4"'47,O:;#'0:0(IIE,H=45'P<(% 1$?O!OV^KJC6"";
M5C'M=5+%DV2 02;M&B.F9!L@F B(@FBBF4H>S]X/4D=/>(7N+[-CKJIM_36V
M4:?+662Q@^L;EW)32]$=PUJK#<B#Z;>JR!FDJC*L2O5%%"H!SE@4MV1[_/R%
MJO-\LDW<+A9950JLE/66QR+B6FI=Z<A$TQ<OY%VHJ8"%*0!-N*4"@ !ZZ8>_
M6GC[^UL1M8/Z[EOZ>X_<5C2=^R-\JWBX^R$]\?OE\\1NL\?+),6#E^*OR+7'
MI^RNUN3O[24Y_+X]R?%PAZN>I#]G_P"7?Y;F.-V7)^5;Y,/%CY/E[POS.9\F
MV0^VNU_'/=NX6G3]-OWJ<SVF<]1/BKXC_+1DRUY%\3^W/&;Q;\9Y1>2['\8.
MQZ_VQT/.X.HZ%KS=V_E$^]ZCRZZ<[V2,CYX[,;OC>T-%I_&6048XK@K!.UUD
MKQ@L9TQ!TH#=^P<L)1N10Y$G)$U%2'00OFA2LV2QE.H+F5J.H25I,*JD/#RB
M(0$SA[(#YN<FX>(QI)4#;PW%+N]F:Q/7V]7TWXDLC9W'6> Q<ZF7-SN$(](L
M@ZKUIR'*N2/3P+MHKRG+:+9Q)'B8G3<\Y!040VE;E@6=BGM=MI&+;(>++HT=
MRV/KTVCCJFCW$E'LWT;(1<_% X5!G)L'#9V@54Z9C*-U%D%"LV6A6KM[P$>S
M3/8G6H*6>50TH04.T'A::CB!C+DCW(%4Y+89XRB'&7B76X!X\::W\Z$8Y:8X
MR8WN#@-/==F7N,L705:OU5DJ[*Q5.WL[LZA7P.G39X>4D4IJ3=F8HI.%U4DT
M@2LFIKY,/D@\8:K3*SXD^.OR@=)XHPR<1UOC)XI4GJ.T.7S.7T!.5OX>,_\
ME;0V<]/-O-5KC&-EHJ48O6_:=6N59>JH+252N<"=5%&;KTBHU2.9/C37;KI)
M.&RJ#E%%8B;.SZ&JE+WL&+Q-6QP.?)BN5(\D?G=GNTZ5(8GM,PDQ;<2?.;C/
MG47X#<*R/&'!@O/60E8)MC+ .6*YE"IZ:**XD:GCF2<5]RHD?QDF')Y^P6*T
M2,"X7:!*/S.T6"CA95BR:D540/C;+7R)_(=\GN,PQUXO_*1\IG:^ZTS]E[8[
M5\0L?]!^7.1T_3+_ .BX^;[;A+6,UX%OLUCG)-2<BM$V"&.B<JS=42@]AYJ+
M>HNHFPUZ52)RWD>^0<,W2?M54S!LVC<W:/\ '^4K2V;-&YK/C_*TWA]F^.AS
MR.'LA79BB9<3%X^3%$Q^F=-4"*E4,1(I%")(SM'P73*7I3K\^1=JO9ZM+RMZ
MS RC5R<I1E$7^5:0$'!KK('.!G[& :R:)^%1JX;*$XA=2$@Z<OG[YRN\>O7B
MZKEV\=N53+N73IRN8ZSARX6.8YSG,)CF$1$1$=F&!;+C. U%84KSZ3>TJOS-
MM?4"YT="74?R#Z @+JVK]O9*5E6P/1?%;/8AVJB=19)%9-)1,J-XP/C_ $_X
MQP?CG)=>=5:\*V"6-F^XOX.0;@A),(J3G:M4*C$%> )A*X&!</FI@(HU<(+I
ME6_AG_7?_P! _P#=\U9?HMB/\[7[U<-?J$QW\X>HKU@T[_H1=_G=O?[B8^C/
ME/\ M1C;;#7T+\=_/CJ*VN]-S=B?&F8Z@TTPY"GVM5RI1*OD*MMIUED/$3)G
M-MX.W14O&(R[1E).44G)4@632<*$*8"G, YUUF:\INC-\6Y(OJKG3+I+IT1)
M,:\P9*U>%5L2;3&5,0CY.R/$K>L^*V9MR-ZE ,%&IG2G&X239Q6G\^A7%^$Y
MC(4K%5BK3F3=)6 L;Q4_8)-\"<5#1>0,/S=GF:F^?OD4D2+/%XI!4S@B/.'F
M')M1,OZ?S3@Z;LRS$M7FM8FW;R;=8FOT<R++H5$EGDG+F4G8"RPR;MU$G>G6
M?I%CG2;A9<2$54QUIOQ(W;!:;[)J$=S<D5;L.GUB,0/(6:XV!1N4ZI(BO1**
MBQB$ 57*H)MT0,LJF4U-'5#0(#4+F.SP[A=HWR52HK-V2LDKLVPHRTM7L2V%
M<<7T&JED0518N'A&*1#B5!22=N4C*[!A&MXBFM >:[4D6O8ER63%=$PE"*7!
M<R:4 Q<QF);E:,1S1920> FHA8DXU9^1(S9L_;.E&AQB*^LL1RM!9>P9#JN$
MBF(DNK&15@9*+)E/[8I%3("8 'V0 =M(]$R/3JKD"D63)+AC8J;=J]$6NJS[
M$M3LCDK.:KTZT?Q$JU!P@10$UT5"<9"FW;P =M,<-@G"N)<*P\_AZTR<[%8E
MQQ3L<1LU)-[J=JWD)9C3H:&:R+Y!J'+(JL4ZA4_:@(![&T;A6B/B5.IPS$+5
MEK)SU@I(QN/J.@Z2:JO$V!%FO;-FFG2A6D3' LCU3DPG441:HN7"-?Q?E_"4
M1J,SIXO(OY>O6JCP6I#+,PQE.GY=FM4/D%[#86Q^J^2:IF9M4RP:AVXBLV;'
M*JNLJ;%#_!\1HNR#*%3B:7//*/2=*LBL_(*X-'4):,2V*QX5?2ZZLLHBBUM/
M.,^5!,@-ECHMN#(N+,0Y@C,GXHKN1Y&H4[-4A&.82#L=>;R@1Z=N<M8OM]<T
M*AO.<73,CDKQNEU#=(2JD3VHUZUW9*@-5&9+Y7(BUU^-3>S%E8V.,G&K==M(
MXOPU2)8C-Q0%VYQ.WGK0LY;/!(8Z+A RA&A8C30XT,T?!L]DF5CJM3I"Y:;,
M182/:;-/@[C(VN0.4=.]NE;)5YA\X6*@V,Z?Q2:SU=N1!4[CE@6I/\;R\Q9=
M.F;$)U_C9Y85DG=DI\]7EF)K-CZP/VR#=&3)&MIAHYC'QDTE7;18R:A3K-5E
ME=-&",PZ-IB_:W+AFAC2:OG5YBW%EYJ<7,73*+!YC"QEF+GD)K.5>8I;M9F0
M).-@%)1@FU$6JJG&9,=/?[>VE+]IWY0?E9^2C_[Q>#LT^)'BI\FGCUY9K36O
M%KQE\98;\F\[K.S_ .4<'(0XOLI?\#&A[SH[6[,>#/JX\ 52L4O(CW&<HQRQ
MI!TQ04ZO.L*U6;2L[8-:>2]QZL0:/M3<A5%'22PK$4 4@*!3GRM&1C-K'1L=
MDF\L8^/8MT6C%BQ:6>4;M&;-HW(F@U:M4$RD33(4I"$*     !LCK3USV"0I
MFG0S:6GZ3C]&?+2%;M4:V5R>=R)D2Z*G:N:;C%,K-QTXM7#-\[1;J/!=-6@(
M'=N,7TC037LX04&Y60#(-=TF86R)#O'!%SM7!6]PU"V^ R-.-DQ;@<BPHK-5
M4S =%0X&$1LF:_JT)J'P=E6%7=-E6D(2QQ%796P&BSIA3,MX=G'#M2D1TL)1
M!K*5]!LEP<3A$))-$4!O&(\GUU]4L@XYLTO4;?79$I0<Q<Y"NU&;Q$%4S';N
MVJAT^8W<HF.W=('(LD<Z9R&&$B2X3P SU'9/KV?(6JZ@K+B^K'R%!6V(S7?&
MU*EI#)4?7'>0DX^'[(:-#@@X4/V:06P$,B(I"G@?(F+T->.H.")V1EVQFQ-0
M,\OHNP*$:KR2;MGE"R0F&J0=B]9<@L3"NW<S%!Q-WQSK&745O3?3;ABH8'R3
M48R.0?&QWC.N8&RYB:4ED))6NSLY3:(JGCW($*X='<(.#&/,,7 HBCU**Z39
M5'+VG'(@$/;,1W23JKU^@@HV:3L>ERWM=M,<W6.HLC%6RMO&DFT*<1.#9V3B
M]MO];</?K3Q]_:V(VL']=RW]/<>O'_7?_P! _P#=\U9?HMB/\[7[U<-?J$QW
M\X>HKU@T[_H1=_G=O?[B8^C/E/\ M1C;;#7T+\=_/CJ*VO\ ]$K)?SFX5VRM
M&R,M)R$=7<=X:CJ^P>OW3IE!1[S'<)-.V,.U7540C&;J8DW+M1) I"'<N%53
M )U#&%%RV65;N6ZJ:[=P@H=%=!=$X*)+(JIB51)5)0H&*8H@)1#>'L[0%QGS
M(.IL+;IONBK@S8@B,U.,QCI!PV#B &:BJ=D<!Q%W_BSF)NW&WAK"U /F[9:=
MCFV-,0UIR*"!G4?&2Q[!<;FF5P8#.4TI1S$P7M2\!#"U'BXQ O!J[M5AD7+Y
MM3\QW##M305 R3>+IV')EYCN$:1[43&!HV>! */E  "F5=/%ECE!14X>I4%E
ME%%EELDZ>U5553F45554K\T=1110XB8ZAS"(B(B(B([:+?UINO[&VG;2;^I"
MW_V\4VRWGE=),U@R;F6UN;-)MVV]XG3<25J-85V$-N]N[[,D9.<>I>R ;Y,2
M@ " B.4\XWM^ZDK9E6]V6\3+AXOU"B2\_*.'R,<D<")IIL8AHJFT;))D(DBW
M1(FF0I"E*'J!4<*8HR/EVTB4#C7L:4FR7B932%)PN*Z\=6HV2=-VQ$&BRAE#
ME*F1-(YQ$"D,(1MVIVD.VPCVNS[5U&N+-DG"V/9II,0RK.3:/FD1>,F5J<.@
M@N9,R3I- 4#*%,4B@G3.!<13RB9 DJ_JTI"+1R)#&5!C,XHS.A(LB""A2)D<
MN&K54QA*8=[8H!NWB.VA+Z6N OG-K>WU>W_PL?\ XM/J9[^EK8_F=PWM:Z.1
MV6//<M04[5"/S)BL5D:PY&=1!79D@,452MA><8E 0XN'=OVHNG_%!5ZM5[_?
ML4:?6L=%+%9EC\3T&HS=H+!)JHE(L#%0,>13!9)/EE7:*J)*"*1SIJ;4S&K.
M1<HU?4-C_(]!LL9S?^3W3VJ5"9RG69)=N8BA#2#%_25&S=4.!1,D@L0#<"JA
M34;*,&U0:*YTP36INU<INFD=_<*+-SE&5E%UDP+U"BM.C(1O[8!.4&OLF$HE
M KR<@Y*0AIN&PEKAEH>8B7CB.E(F4CKCG!Y'R4;(,U$7;&08NT2*HK)'(HDH
M0#%$#  [*++*'666.=5554YE%555#"=1110XB8YSF$1$1$1$1VE8=@[.C&VS
M3CDZ+G&F\PHO&L?/4.P,A,GQ< +MI*)2,0^X3%()RAN YM]M>MR)$5L6&</3
M#XR:()'5=(0KZOD.N<#&%PJ#*#1*!Q ! A2DW;B@(^MF'OUIX^_M;$;6#^NY
M;^GN/7C_ *[_ /H'_N^:LOT6Q'^=K]ZN&OU"8[^</45ZP:=_T(N_SNWO]Q,?
M1GRG_:C&VV&OH7X[^?'45M?_ *)62_G-PKMF[]!\(_-15O4A?_@K_P#"P&VM
M#$2RO*GD)C$F1X] P%_ET0[97&LS"J0AO-_R4]9,04 VX/Y83AW^VW:U:?8&
MRK9=]J&R/D"*!5)1/G5;*\^ZR?47!#*AO7*I6K<UWJ![4YP,(;OO QB8EB\E
M)64>-8Z,C(YJN]D)&0>KD;,V+%FV(JY=O';E4J:2293'4.8"E 1$ VJS!\W5
M:/6.3M/[-XU7(*:[9TV@IQ%PW63, &3515()3%'V0$-VVBW]:;K^QMIVTF_J
M0M_]O%-LK8+=*E";QEF:X1]AC47?\K-3LKUJ*E8*8X0$5&19&2:S;1/<7A$T
M>8X")A,!<JX-O+)RQM>*+[9J+,)N6YFQG"U?E7+!"303,)@/'S#1)-VU5*)D
MUFRY%"&,0Q3#M@+3-,2SJ#K&0+-)O+K*QZA4))O1J16)R_7%O$.5&SU%I.2M
M>K#ADP641522>N$CJ$,0#!MC/1;H@TPXQC[2^H3/)'*G6LRQQI4Z]+34Y78U
MU+1M?D(BW9)NUD?U=XJ]>NIMNX(5(BBZ[I5802:JU[4!7J8"J2#!&O4W!&%)
M)H]>*.ES)N"^.E NLVI(..I(@!$W0)"5(G"D"@G.>@?2UQI\V6:MM"7TM<!?
M.;6]OJ^#@4PD*;5>4Q]P\)3'#36)"B;[P&,!#" ?Q[A_WO4SW]+6Q_,[AO:T
MWM%MUJU*U"3=M29\XS?JU:YD=U,)MN>0!,CSS,P)Q@ B7?O_ (MJ1GO%7/LU
M:Q[?L6:@D'\>D1?KL47FGSM9&;*B4XK=(D&08M\J=/C!%LDHH<.64RA-J5DI
MFP=*5;3O0<D7^S2()%[.1>6NG3>*JS%N7"@E KY](7A1VW2)O54+'*G HII*
MB6AXOA7"3I3!^!ZW#V<4UR*&9VZ\ST]=EHU1(@F!$R51D(5?VP@<>I'>4  H
MFGOU!:[?[4YT]1C^H++?_"5;9]^H+$G_  EI];</?K3Q]_:V(VL']=RW]/<>
MO#D;Q2YZW$/FPP-2PMV1IYFYQHB' 94ZM3LX. *!% $  F_C#V0X?;>1._=^
M++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[
M>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=
M^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1
M[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._
M=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S
M1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1.
M_=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++
MS1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1
M._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^+
M+S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>
M1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^
M++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[>1._=^++S1[
M8\>IX>OSH;I0V]O5)\M+1#HE5[1:8 6?$;%K@'/"2OE4Y@ D \SAX/:\1O(G
M?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%E
MYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(
MG?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%
MEYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O
M(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_
M%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]
MO(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N
M_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH
M]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?
MN_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EY
MH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G
M?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]HU@;"U^3*^?LV8J?+>S
M/RP<N$T1/P!B4@FX0/OW<0;_ /?#:ZU%+#=^>)56VV2N)O/EK:-^J3@YEY&$
M<].;%3HR'/*UXN 55!+OW<1MV\?(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O
M(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_
M%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]
MO(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N
M_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH
M]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?
MN_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EY
MH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G
M?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%E
MYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(
MG?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%EYH]O(G?N_%
MEYH]O(G?N_%EYH]O(G?N_%EYH]LGV0^(+\V/0*[ 3:+;Y:&BW:!YB\5JIF0Y
MP8M0!IR4YT5N(4U@-R^#A*)N,OD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD
M3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?B
MR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>W
MD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?
MBR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>
MWD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW
M?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T
M>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3O
MW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\
MT>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3
MOW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>WD3OW?BR\T>V=]0 2Q6
MR%QE:?05*:,?SCL5:]#$MR,T6Q]<EU!5R7-1L+;H$^$404YH\7++ZF&OU"8[
M^</45ZP:=_T(N_SNWO\ <2MTS7E3'&'Z<IIZR3"IVS*5XK./ZRI,OK'C]=C$
MDGK9*1$6:3>(,ECI( KS5"I'$I1 IMV)K?@W+F,<S5.-TDT2MR-HQ1?:KD2N
ML+$SS'GF4=P#V;J$M,1K6::QLPT<*-3JE7(@Z14,4"*D$UWN6;LL8TPY4'>F
M'(4 UM65+W5\>UMS.O<AXB>LX1O.6Z5B(Q:7=LHURLDV*J*RB3=0Y2B4AA#,
M%]Q#D6B95HLG3L/M8VZ8WMU?O-3D',9C.ML))NQL=8D)2'=KQ[Y Z*Y$UC&2
M5(8A@ P"'J1&,<8:G]/&1\DI?LV<S'M#S5C:WWA/L)6$&;XZG7K+(SQ.Q@2/
MU6]O_)^$>9P[AVI^H:GQYK)"I,WM.RA11>= E?<9S[ABO/U\K[EJ@QDVKV,:
M24:N)3IHR;!N94BB/-24J^3,M:E*3A;*%=@8^*2MUCRA3]-.<*_"N73I\-%G
M6N66[ZC7MG&2 +B4Z36?0CS+*&9.TDW9SKR5XT8.)#7UK.8I/VN,+9>+9'Y'
MQ]B67YC]JC<75OI]7I&+'!4%PWH&@&TE/+)MDR).XU!X9ZKB%6K:AL(7+.-R
MF-.-XN^*:QDFD/,DU^?6J<@\O3:7QLPF#VJ"\7; \50=$59)D;&W .XHE$=(
M][R/<:KC^D5O)+A]8KE=K#$52JP#$U3LC8KR:L,Z[81$4U%PN1,%%UDR<9RE
MW[Q -M,<S@G-6)<U0\!AZTQD[*XER/3LCQL+).+J=TWCY9]3IF9:QSY=J/,(
MDL8BAD_;  A[.S3,-2C/'"C62.+4\OXS6?=G-[O33NB.TQ8OS(NDXFU5U\0'
M48\%(X)J<Q%0#-W"Y31.5,I9^KF ,S-H-HQDK99L@5K3+F)A&1JK4$:U:%,G
MM9;$]_79I.DTD'"))Y1%MQ)-'94T52IN,RUO-:FL;-M7)VMCQ!O<JSJ1GH^4
M,@=1NE3@QE7JE@.$G"" '2DYQ5)W'*D 4'2*H\)V7UB^*L'UG%$,US"\OAL*
M5&2<!'*52RQ#RI9!B F'*73(6:^5>:DU'CMNS;QZ<I(**HLTD *@%$RKEW5A
M3L.9 J=<;0#"P3>8*'IRS17X%Y*.IE6BS\'F1G)5FSL8J8ZP2G092K9J=XLH
MS=@1V555:UZ+8MSK[UDPBKYOCN[9)L1[_CS&<VA(/>ENLA8X*MTK%$BK%+ 4
MT>K6HY[++%9H\M\P*X,^5TNR5/SMAJW9ML^3,"7_ "/B6K7^IO,C4V</AG)B
M%]2G<<MI0UM@&-=N$H+)15PS3;E,HCPG,19(Q\49JJJ:"MGQ#DFCY.KR+H3
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MDFRUMTB<S=W7BK0T;%-W*?$F]&).Y144;K(&VSW]+6Q_,[AO;(/Z<6S\_/\
MU*-^OW"W]B,@^I_\ 7_]']28^DQE/^R^-MFK]FJ9!VR<H.VJY0*)D7+94JR"
MI0,!BB9-4@"&\!#V-L?W'30]AYNZ2JF/=2&-ZZ>3;,64Q<Z]7[)5[KC!U*/3
M@UB;'&M;9.1B8.3IH%F6::*ZR*)E%R%Q]$Z(=1D9-=H*QRDK<\:6&@T9)5"0
M2C5G!LD79I T!6/*LJ!R.$Y(Z*S<#+)&.D43A<-.E@RS5,DYQ<7UGEC.L#3W
MS=Y%8OLM\IE;CJ[34@$B4N*1JO44'9'#]%JL]YXN$T$VRB GR#^G%L_/S_:,
M^@GA_P#I5)VUJ5"0".)E&;I>&K#53K@W-*N*)6YN_P ?>THXYR Y08MIZSUX
MSLJ9A(N=1N)P 42".I#($GIXU":@J]D;*]UM..<CXOQ[<\NPCO&CZ74=T.#4
M5I$3/'J)ZI57C.+[,>)M>0HR4(W!5$A5CX5UF:RWU7TSQ$!/6FB8?Q7=IZ$<
M9.S'D3*5 N.,X^#8P,;)N2P#9K'V5Z^*FX4&57,R P,BLS'>$P)]$JN?/%F3
M;)-;EWZ#*2OVER]0M5164*0TM-0V0L6VMW%-"#[95T%;@W[S<'WD6:@_Q;9*
MRCAO37E[+M$SS%8E>U2V8ZIDM;*S'/ZMBRBXQF(NWS\.W<Q%$7;2]2.KQS2S
M!([94JQ3BD!C%L>!\_5(U-R15VT.]D8M.083,>XCY^+:R\5(Q,W$N'<5+Q[E
MHZ O.;JJ$*L11(P@HF<H0G_I[Z>/S+C/; VIJ/9NI1OBV[MY"QP[%8B#V<H\
MXP?5:_0C)94!02?2U+G'Z"!E %,BZA#& 0#; ^L;0]/5S)]YJ%2?/*M&,I9H
MQ0S#B>T+H22L'$2<FZ:QD/>Z+86S@2QS\S(X*KR#-P=-XBBW,E16.AC5 A-K
M2*\61]-8?N-;IH.6YE"J*JY%L,9%X^0CC"F/+>'E"M%0$!(J8#%$;]DC4M98
M)_E2R2;K(=WB(.2(8]IR9(02$5CO!%!77$O;SQBA&\"KM-'E)K+R#TYN@0YI
M+_E*W."N[7DJ[6J_V=T7CX7-AN,Z_L4TX+S#J*<*TE(JF#B,8WL^R(C[.U&_
M7[A;^Q&0?4U3_K]@?F[B-M2?Z_<Q?.)8OW[_ *[_ /H'_ :]8?\ S .C[>@X
MF9Z/]E3J.E[48-WW3=1^TBAS^1S^'CX"<6[?PAOW;?:$_P"$[_Y);:1NV*9*
MB:HZ]$,7#V1@L:A-P^4R)MG"O--'8^GV?*LF]ARE4V\5)OI)97FI)M#"1,Z[
MAD];KM'C1=5J[:.DE&[EJY;J&27;N$%2D51715()3D, &*8! 0 0_?<'XLL;
MF395[)>7\:8_G7D*LU;3+2&N5TA:Y*.8EP^923)"30921SH'6;KI%5 HG3.4
M!*. K=@B\9RMLEE.Z7&N6%#+=EH,\Q9L:]!Q,FR5ADZ=C.A+MW2J[\X*F75<
M$,0  I2CO$<QY.SAE*]TS'V,['$4:+K6*'=5C[M-V62AQG7<I)3%LKUPCX>
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MZ7)X^#B/NXQ^T)_PG?\ R2VTC*8$U%XGS>LQ*V5;5ZW5R<PO8IA,S=47J$8
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M46.D'+%:':T#27#2*K%-H2UQN-,F*S[9P0J932:+:7S5*U<SY82"8Q5(U1L
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MY1C6>1J'5U$$EJ.YKD\Y29SD"BBW9M$5%%BH,C,G)%_5L^8L[]M,=*^))I"
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M1\@U<L7[%RNS>LGB"K9VS=ME3(.6KILN4BS=RW6(8AR'*!B& 0$ $/W&O/\
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MY%L$%%IO<@U_(D'<26>C7-NR9M86R*UB/@F@JN%6W4NVTR4KLRQ@!0T3D:K
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MCUR15NX07*9H\R_6<.?*_=!?.7A,?X[H6JB&A7"ZD6Z1_D^.\J2V,,$M8X_
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M0AY9^Y41;M3/'CE=P]/O4!,  G[UFM3D<(&U"/B ZXC#SA)CB@"*' )N O3
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M9(R$D9*PY8O^HS$,G+)M7<@E1[(UR]'0E]HKF;8)N>6[C48HSDS<P)/#'2*
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M*:HO!H-U7"ZLRY7D3G39(.1(LDVJ,CJH^K]KV+L,V]5*0B*W8L>YUQ5DJ>K
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M!QJG1$0$"[PT2LY%151PM@Z ETS+ <IP86!Y)3T6F *&.;E)1DDB5,=_")
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M\X.4P*4 WI,Y%=0JW%OX3)GW^P&[U(5@4"N&%'RY7T622P"*3,N ],R=E?B
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MYHZ3@2\Q)!85&Q%$RB *&$@B \ "&B-E)\WJ5\#U:92YP !^S[$=Y8(C=N
MY794FCR_X^#=O]GU;=GG/-N:T_']/:\:ZY^!Q+S\NX(IV35*I$\Q->>M4\NF
M*31HD("80,HH9-!-54D3KDU45-]CWZOW"TPXA<)XAD7#A5OD5K#RZ;IU5&'&
M1%*78S<HP2/>+ D1,CQ1$D0R'<V$T<W9,FZ#1FT02:M&C5)-NV:MFZ94D&[=
M!(I$D4$4B 4A"@!2E     -M=-XGRE=S1:IJYO:+E5,!4).V#4[CB+?NR;SG
M%)55E:G9!$#&'A4,&\=^_P!31MCHRQ33,]D?*-U3;E42$R494JS6H)99=+V5
MTRKNKJF5(WL$/RU ]D2^QI*QR]2,@_H>FC!50D4SI%05"2KN,*O$R)UTBD3
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MANC<K?\ [9V?:?E*Z;_*#?P_)YSOX_\ 1?>_C#"DLLER5\CW3,=[4() (H)
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M3**@#N*4/8#U\TEJ.6LJNZ0R3DD\<NQ,B#!DN? F3DEU9H%&RRAFJK0ZB:7
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MON#:E4\,0&1FLJURS9;_  LDO.Y DZ<JZ=PK:GXTO+1RU"-IK8IQ77;'YA0
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M1#> [-X6&U79L".:$!-LE*W62L*Z")?8302>V$\H^(W1+[5-,%.!,@ 4H 4
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MM". <&DGDSC2R@I'6 JA3E4/S5DBHHM#BM^]9K2ZA4P$U"/E :#Q<A 5,<4
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MSR$]CW17$A)* 92$0433;%ZY45V#/4%K.RW/X)B<@)J69I6)2(?7?4#;B2B
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MK[B&X!'IHL,IU;+>1[)8R23=F9%)]*5[(=EMM%?MG;OA6>-V\8R%0.(C=1J
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MGZ4DI4KJTCF,D<\6_*5%>5JDXQ?D<1KQ1%$YR\Q$Y 6;J@&FFQZ5LJ?);,Y
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M4++&T[73%#:P1<;<Y.$DY+&.1T9JTS5G3EE9RN1TDYJ-H,684+(%F$4&"RB
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M;C"D8Y-_"80'7/1E5U31-=M> ;8R:B <A&0ND1EJ'DUTS<8B*KEM0FA3AP@
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MVZAAKL*)E&B9$6IQ&-;")VR*22":3<P^R0I2$*4NX * >Q^XR\V9+=.\<57
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MPKP</,/OP)]$JN?/%F3;'WZ#U/\ ,+#;6E^JQK_;*K;:Q_UIXP_LE8]M2O\
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M+I&;LBHB8R)BD4$SL$B[@ >(/7GZRGZ?.3OS!6/5Q=]%FD_.UF[]ZP5BZ2X
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M1*)I"9EWS6,B8EB[DY22?+IM6,?',&ZCIZ^>.5C$1;M6C9(RBBAQ I"%$1$
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M9/\ [6US;!OZGL9_V*A-HO(^07!82DPNJ_1?F5]/O1Y+$M(CVN$Y^=F 6,4
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M6_\ @ZMZCAZ]<(-&;1!5T[=NE4V[9JV;IF57<.%U3$21012()CG,(%*4!$1
M VEHQG)S[;%^3LH/8YM-PX()2-.TO8C8J-4IB-"4;/(R#G)FDU\%T@70<-RV
M*8#B37%02*>676AWB8._\.NWEEUH=XF#O_#KMA2S:>[/=I>CMVU&SC@ZYY!>
MPLI8T[=0K V"UU>R/JQ!4^)E31EBC4'*B:,>V2/$3#9!055 6.;$V>:*H8U3
MR[C^K7^%145*JY8-K+$-9)2(?F(4A2R<*Y7.T=%X2B1P@<H@ @(;1ND*U2>)
M]*M%P?8;MB"TZE;&S0C,H9(EL=HR!K#4%I29EX6JNVRUMCUXRJ-WP&,@!E7:
M:RXNBQQV\I*Z\I^;HS@[MTE%0&GV(B9YS&NFS@T,#>XN<RV.',=!15!19<(8
MR;M,ARD30%0ITW..-.M1>,E9M5L[N^0K8];3N2LAR#$%R,7ENL+:/BF9TH])
MP<K9BP9L(QJ*BAT6Q%%ECJ:U/HE:COF=N6VMW]!\'_G[)/J0O_P5_P#@H#;4
MA5:@R?2=NI,5 9A@(J/15=.90,7V"/L]DCT6+<BCE^Z<TIM)E;() *BCOE 4
M##[4<_Z0)B:8LKU!9"'.M+AW:S=!]8:G::[6ZA;NQTQ6!9\2IR]28JNB@GQ)
M!,)FXC%$03VT_P"EO&SHMRF\"5>P(V*/KA"2CE+*>;9>K$"C%(Q47</+"S@:
M7#*"V G&DK) D&]45"$TXX2FETD)#$6#L>U2U.UET"MB6*#JL>%O>"X W3I,
MQG@=*%'B$I$A#VP@'$.\AJ]=*?9(\Q1$HQMBK<_%NBB0Y=X=9%RL>X+O 0_&
M)G#V/9VO.KK%N,:=@/,U)M6/(YBRQE'-*;4,HIV^X0=3DZ])T*)3;5)O,,(>
M2=S97[!FT?+&CU>I47*<>&K-K[(2$FRH.7,CT#'+N264<KEQY$HUN5CH]%=8
M.::/AK!.2;)L03'*@W;D1)PIIE(704<2F AH74F4I]P\)C$?8-$Y0-]X3% Y
M1$/XMX?[^V@Q5LL1=,FC;3*V,=,P&*5PRPO2V;M$1#_/;ND#IF#^(Q1#U)+]
M3V</SG7MJ[E*LLGT@ZT[YA@+E96[1,S@J-!ML5*T><DCMDP%8W9EBEH9514
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M26<K]G&+SN!,AU#<&XI1$0#:KJ"OU0GKL*<77"8G4B:-;"*_ <I3EYPCQ;A
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M^U/)!^"':<NGFZEE1=.!6.1'MPQ  PD8% /WK-9><D8 U"/C W!,P+I";'%
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M5183 8QC<0\7JX6-CTBP0"#NH*WTL81PHB,:3+]I2L!WPH+ 5-'Y3#M3K&4
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M:YUF2@4)I%L8Y".CQ+A\5P"1A JO+X#>P([94P%JBTSS%FQ;DJ?92SDC9\O
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MY;NVRZ:9TZAD7 EQB#**%;O'%BN=9E 3((<"C^*=TA^S;"J ^P5%\ZW" [Q
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M$#FJM$JK+M*SW6R0=2K<=SD&W7SUCDVL/#LNH<J)-D.JD'B:?&H8I"\6\P@
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MR>V#VP![(;8#>H/)210=X6Q8Z1D)LQ333Y)Q1H)5-Y+F(X=$-*.B' [@054
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MV/\ *G2X=,&[G+?<!:%NH<-.579I3JFA>)TVX(UR;J&Q><VXG".[B(',3WF
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M=O1+TL]_$UX-VGA>Z4]+C1F$+*"[=IYRF')VK8&*XKN"-CQ:A7!T4MY@()3
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MNGR3MN7784G3J'YAV_!&MB\DZG"7F'2W<(FW!O$-^[UX[2[%=>CQT/C%UO\
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M8B+APL7IP H*K?<!:3F66;E)7)LYG#8@*.$"EC'0BLW(*S<#K) '$0.8GO,
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MG3#]4K79RAT1HZ769W*.BJ^VR-;:["/D2O<@7BW75%:"P_03N1;F;MD>EDE
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MSK"2I^181IS 2+(KU*Q-F+^2A1,=,!D(_K(\BBA4CK%6WIAMFV%I:63,0IX
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M?>$=M75/64=#"P69:)98](Y3]"24M=)=Q<PHW,*@IBZ5:4QB"P 4! A$MXB
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M<V&QN<14%!A:;S!0DM(MT&$1.S$LAB;3]2I0" :JU)NSCY%599ORGBK=@Z5
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MT5X]Z0W7H<TE"RC3G)WM1R32ZM?JJ\5*F15W7+C!L;%!N5"(JKI%.O&2*1Q
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M?I\Y._,%8]7%WT6:3\[6;O6#5G^E.(OS3?\ ]QIGU+-&"YJY>,62F&9B01*
MLVEEQW:)BX1*;TQ2@9)]-PN0EP0XA'FI19P* <HV_3%?(Z3:O[!4\=0.'\AM
MT#$!S%W[%$6RITRG)-D]Q63J;91[6833 "E%I)HG* %.4/5HVFU!\@M>M0>3
M(:75AR.0!PSQSBM4ECF)MTBF50Y2+7-6#:MBJ\LJ^]P8AC"V.7:WY;G6:K-S
MJ$S-/6&N\U!1$75%H<9'T:*>;U2$,J5>V,)W@,7>F9(""4=XCM&^-P)%9_\
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M*>JUBL9M["9\T(Z3>IP9%V3@-[,S<HB3U,"?1*KGSQ9DVQX0A2D(2C5(I"%
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MG8U:K*'(F5J^NE,F:]'O054*=-([)]()K%.("!#$ =WL;.</Y+-XJ!G2G6[
M;UC.$*R4B,K0\_%V&K13TRFY1M*O)FJNX-% 1W*OI)-,0$_ (>H\DY-XUCHV
M.:N'TA(/G"+1BQ8M$3N';QX[<'30:M6J"9CJ*',4A"%$1$  1VCK)2VKF0IV
M6=7L;:6K@4'*ZAL&XEDV;X\V[2.W*9DJYQ/0 6%-4H)HN%2I&,(!Q#F_3?XW
M>(/RR4&8HWCEV!XT^+G:Q4R]J>+O;5<[8Z?E_P"@ZYKQ[_\ 2!M]H3_A._\
MDEMKGGO]J;Y;_&["]BQ#XJ?(A\FO9_;]XQU<_&'MWY7K_P!7TGB!TW2=&ES.
MKYG.+RN!3U)O_P!0C4/^>LF>IHOS,V1/V75KIEO&,PN"8BEU]^@Z=:JVB=8
MW)GZ?&TJ8I1'><.(0_R1VT:3D8\0=#7<2L<9R222I%%F$IBF3DL=N6;Q,ISG
M;+\%;(J4A^$3(*IJ ' <HCMHQPHU<F/*D5RSE*=:;Q K:/4)4*G5'(AQ<*AG
MKE.9* B7>3IQW#[8=M%]*F679TF.$X&Y/6(APJM%LFNY#)@H.D^6D9%\0MN
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M3Y\V]/\ 4<XZLYF-5RQ3^OG<(Y8Z+GOJ3:5T"$<1<H*  \D*);"MTF\NQ 3
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MIP0RB;I)$42)@"0& QSPT"R.NJSA(J/B&BCHR9W*C:-:(LD#N#I)(I'7.DB
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MO(.H:RW>8J%GI;F*R;:\;S-5)%VR5AI>1<(,:KB:F2Y9!%S")%0.9\9,I#'
MQ#B(&+M0,B9VO6>*G-XYJ#NEPC7$MGQ]!1;J+>S+F<5<2J%QQ??':\@5VZ,4
MIT5T$P3  $@FWF&D8[@W$@[A*%4*U2X=U+*MUY1S%U:&90<>XDEV;5BT6D%F
MC$AECI((IF4$1*0A=Q0@&FH>G2Y;746<C'4_*-!F$JMD>MQ\F14R\:WEUH^6
MBIF(1?*=6@REF,@R0=\2A$BBJN"K*Y2M9RGJ D8I\C(Q$9GVZ0=@JS%VWY8H
MBYJE#IN.:_9&I3D$QFTPWD6J@F'C3, % JN&M1>-8B^4E-RG)0:9E7</-U"<
M;LUV+*P4ZP0Z[*6KLNS;.3I@9NJ5)9$QD%TU4#J)&+8G]IU2V:(*\>NAHDWE
M"CMZH=!T"X(1QGE;Q17[P#.-YI10,$R#@W*+SE5=Y^.UZ"X#&Q<1Z?K86'7=
M,<4N4(:VLYV!GX2RQEO"U6%E:7D];R2==:<Z0FBRBSQ!/DN.:F/#M1],F))N
M[V*AT%U;'D/+9%DH&7MSE6XVZ<NDF63?UFM5&&6(A*3ZR: ),$1*W*0IQ.<#
M'-;L497J,+?,=7R%=5^VU*P-0=Q4S%.P*)TE2 8BS=RW6(19LY1.FY:.4TUT
M%$UDR'*:SH6+5!&PAGR#L,<LLHTY2FD;I(I)*1A7TCBY_D(6+HZ8J',,Z+D#
MG,!%2$X2E;8@TW8TA<9T9*05F7S&-4?R$G8)]PT9L75BM%AF7<A.V2>=,X]!
M$SEXX64*@@FD3A233(5U]8-&9#U$KYF=YCN>;E*R^MN-5<8EM=X=3KN6CR0S
M?$C6U!7FZE@6!ND,T+DA2DXUU! PFVCCZD,-Q5EM$(@#6!R+7W\E3<C1+,%
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M63B%[37G#-Q/08$56(1C*$?M&_4**H)I+B54K28F[9JGR-'-M_.JESR?16,
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M.7S?XN+A]C_<ET>?2FT^_.U4?X;I8<$@NTR,<AY$65E>H=)>+95<&Y(;%?\
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M(KJ 47J[F5:MQ-Q.SM4"'7!-9%0BR*Q"*I*I'*HDJDH4#IJ)J$$2G(<H@("
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MN3Q0O-HIOX^I6.X3=G1?VQE&N$SMAM$:VK:1(]X8!.Q%951+A6%-1.XXRR%
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MAW[:@<_-H]L\7PYB"ZW& ASDY;%_8(6!=#5(=<J(!R(]_8!:MU#%#\4B<3
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M2HE*O,J85QM=IEXCG?4NV ;).U.+>6=LHV9YF19M7+"Q'=(+))$*DDJD8A0
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MFORO=N^,/CGD6@=)U?C^SZ3INKYG*6YG*X2<SR-:T.[O!W_B*V<X$^K8TU9
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M''>1T3R2J60*+@_&51NZ2LRFLE,*)VN K$?/$/*I.%"N1!P KE4,!^(##O\
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M^QLM:Y?17I+E;0Y?)R;BR26G'#KZ?7DD3)G1D%IAU359%5\D=(HE5,H*A1*
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M2)KE<%5,1B(N'"Q>G "@JM]P%I.999N4E<FSF<-B HX0*6,="*S<@K-P.LD
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MDX;/#@5NN@\04(<Q54Q-T_[3VGCG]@>-?(^6K&W.\5^A[3\9.7XR\?8'9O\
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MG"<>,N]HW2U/:>%5Y" D;6P03S5C8ZSZK0[*4DY>R-$RV43N8"+C8-ZX<O"
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MG.S7*!1%)0"SJ+[4]IX9*U?I_&9)WFK&S92N]6Z19->W2+64AHCJ7KE-%/J
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MK\VO,.IL_P E6)@[8M""UEL!8&R'* -SL4THLA6;=NMT916,X<?<!9@%%LX
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ME&<04[=T0THZ(<2-P%)0!5,7>0WWAJR94UD2IUR$(5)R  X2*2,:E!-P $(
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M_P!P^WH6?XC?[A]O0L_Q&_W#[>A9_B-_N'V]"S_$;_</MZ%G^(W^X?;T+/\
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M8YHI2HLY*$PCBY"3B,;1<H!F\I..915L:?O,ZP*NL@S?S@L$$FS<!$S5BW3
MP@LHL'[DU3PEG/-D' M6Y12J=<LE@EH"+;D,0G.CZVN:2BH?B'@(91N@B8X
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M[XJM=>QEE"KIR$YJ.QX!RRZ$TF_<HS5:LV3I%NQ@, Q\(U20<IK@Y1E)<J@
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MUG;>:J-A8*]B(X O3R9,1ZW9BY0(TK0N^%6/=D&),(I*,$FOJ,/_ %:<9?\
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M6L(ZLWNEP!G#F<,ACC+$?;Y-@5@V [A\N\H0M)HB!0$5TQY:8&5 "?OVK/\
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M#(AS[*8E=7>59T]=<];/D!*_:*6,B2*3?"4MD3O\0J&<T$%2$!8'">Z9Y!N
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MG@N 2Y/XH"<:G%2,,XFKWBIC;'$ SJ],K?:WU;D[V-!, ,#1CVQ99.9GI'E
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MNB;M[57DB9$K929AUF3EI*5F>,W3(4SAHJ"3CEI@Y1<%23*5L>R:7+O'S D
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M*<@CQ!9\ ZD)B*S!29?'MNOS>U1N/JE2Y+%;FO.H<D>W5<T.!@(M_4I560Z
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M<NDB-DFR1'KK!N-'+DZ?*4/U NC*\Y14Q4SF64/O =W&?]XU9_I3B+\TW_\
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M)CEX?\@QN#>8P[).&^G7.JZ"Z9%D5D<1Y 52625*!TU4E"5\Q%$U"& 2F 1
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MS(BOLTN0BX3;!R>($P.<YC:P_P"H\4?/WBK;4C])@WS64+U)"^UDA&-A-CK
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MS05+FY^LV4\SCK)F,8BW1TI59,DDP4C']FUG6^'23<[CH+@HP5$S=4X$$AA
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M9O3%+O5,.S?#5FDS/<@Z3)IMC-8%U4U';K%LP@ZEL4/C% _&1M&,&SZ!1+P
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MU;#MA-I-.%W04NXY>IT0LX]E3L5KD6=FV3<JH^V508FGCMTMXCRTDBIAN*0
M"!_7[H2_LM@OU-:\=*MTG35OAQY/I)K)E5(62JL]!6B&< 4WL JTEX=!5,WW
MR'(!@]D VUY5-54PQ$).Z<;$Q0XC"5.2M$?FV-E50((\!3+-:@S 1#V1Y8;_
M +P?P?5NV[9BN5_Y?F25_%_H'7;?,\97J?;/:?8W1]E</XCD=H<WG>WZ?A_&
M_P"Y+H\^E-I]^=JH_P -TL)$F8J/(YR'D--6-?,'3I_/E3P;DA8K.%=HPT@A
M&NF9TP=JJ+.6!5&R"B95%#G*@IZ\_64_3YR=^8*QZN+OHLTGYVLW?O5.H%=2
M(O8+S:J]3X)%03%36F;-+-(6,2.)2G,!%'KT@"( ([A^]M36,A!*N[I:6ZD:
M1[7(&(E\SYDGHMLS5L<T^DI%Y&$85B-=O$C"DJ]0C8TKE-)!,RR@%5."6FO*
M!T@.8$SJ6^J)J'3 1X#'3*W5*F<Q?9$H&, #[&\?O[>C3DWX957W'M4L057$
M-PH$C7,NP.2%IBP3\+*LG+*'IM^K"D8DWC6Z2Y'2R]P35*<1X (B8!#>(?N+
MI]99F*NDL5XMG;+''Z"1&P3[*KHV0]"A*I63/Q,E&2U]N#1PL^?$*)B0Y4C<
M(I)K%598YOZE'K6*I:GWR<;42I5A%(&2L'')N(<5;/++2=E>.D1, KG!PDBL
MIO$J*9!!,NH_]?.7_G"L.V;]-614T)>YX#KLA3J/*N$6ZKIDVKE9\:\%2Q%3
MB4[1>!?12L&8$@1%6)8<L5#"NM^]ZL_TIQ%^:;_^XA_I,8L_LODG;,OTT,B?
M,=IU]76'_4>*/G[Q5MJ.P.O<X5KEY?+B.3F-#=N>EG96B+TBK5Q2Q0R"Y4R3
M#./F8A5%X#8RJC(3HF7*F5=$QYJUVR<B*S6*Y&/9JP6*?D6D1"0D/&MU'4A*
M2LH_5091\>R;)&4565.5-,A1$1  VCPQ>U7E<2SN5Z=",991JZZ9'3Q@Q".)
M;;PX0>D-T2%LAX!_(,6[DC?C=RS9HH4BR@AMJ3_4%F+YN[%MJ\_4]0/[:O\
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MQT)3IU=QO91;J?1LTQ'HKF7(DO(IM6X<PRZ(EVPIH<QG8FMOL..[H_RCF1G
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MUI/UG,8RPRB52&9P"6J+5S6(\U9>B)9% ^-8FD255:E7375XF)7ZC=81W&5
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M3) Z0]>?K*?I\Y._,%8]7%WT6:3\[6;OWML[Q#ARPNJHN<H'R':"$I^/TTQ
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M8Q0B!4Z^8@XT%$K)N9(YBK%*#LPJ#Q*B %W3":&JW(S-60FFLC&N$L<X)5/
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M[4&0>%Y6XR'8D^3[".Z(FV:$*F^MK8?DZXG,E+JQSI15LX%5@D:04!) A4T
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M28W0Z)*/Y1^ [3D*'Y@\PQMQ=T!UNJ?(DKV7/K2LMU./,&MO&:(4[%Y=8?\
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MX<LW+'5!!H(,G@@NH3<@K_HS5EN9LY9&0K\,B9F]$1>-#)1K8@MG8B@V$7*
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MK*?I\Y._,%8]7%WT6:3\[6;O6#5G^E.(OS3?_N0SOUW:_1?(UD_K/%[E]O\
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MMQAD!DG'JO:-D/.6,*5<6B4NV1>12CJLV2T1DTW3DV;A-5N)T !9-0IB<13
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M?X%IV&K:MF:1RTSM!<NUZ[3R3!*A-L<K0YH$*9D.@F:G<FM[GJ1<"Z X$2X
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MT!7X.+B,&-8^*B(M@D@S8L6;=,"$33(4H &VB']05/\ ^#<?PK5NKT<!R/\
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MQS;7[F3<Z=LOV''=6=.E>>LGC^<A("\5^-464$5S%B)F?E&J!#;R(LDD$DQ
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M!P&.2.2E0*(^R &-N^^.T HHF8A'6F'%J[<P_>51+;\GMC*%_P#H07;G+_\
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M[6G'>0JW$7"C7:"DZQ;*M/-$W\//0$RT58R<7(-%0$BS9TU6,4?O&#?O*(&
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MG4$RJT0O%I++B9==)=8ZASQZLYK]D)&&3>-SRK"*TP-X:3>1Y52B[:Q\L\U
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MQ%^:;_\ <AGQZN\E(Y!IA;*;I:0A#%+-,4F]&G55'D08[AJ0LHU(03MQ%5,
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MKJV/-(..4Q:*($>(2$=7-2 KY169OFKDADEEE%45B[N6(CQ;VFG;ZVK 9Z>
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M%52IUR);IMF$3"0S1-FR;))IE*!S\M/B44-O465,90XF.8PCJR4G86,EU:[
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MR%*4H;@#;/<Q-1K9:TX/;0>9:!-&0*H[@Y:M3D>RL94%  %@;3=&E)-DJ0#
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M&-PC-6>DP[XAB "BBKN ;()%$ZFX=1_UE.:&II4]#GK+.PB[PP.F:F:\T*S
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MDP;8 4G4#-'F09?)F26[0_&"J4-8[].MJ\N<#!P\,K Q39ZGP[P%%R3?[;>
M0/Z_="7]EL%^IJS>6!XV;K72DQ^,JXS65%->6L=]L<1!-6;$A2'.NY:,%G+X
MY0#<#=FJ8P@4HB&M#+CA%R2!O61,08\BUSI 5JM*8MKEXL4T5NK]]55%MEYC
MS ^\4#$W>R([OX-JW2ZR Y'_ )?F25.@[.9>-/.\97I>L[6[+[2[ X/:=-UO
M(ZCV_(XOQG^[#H\^E-I]^=JH_P +^LI^GSD[\P5CU<7?19I/SM9N]8-6?Z4X
MB_--_P#W."M4<.P*K,X7R([QU;7*6XBH43*C(J\>^>&.H4JK:%NU79MD2%*9
M0JDT<P>UXQ#4?K!G(TJC.G0L7@;'CUPT,LB-ALYV-SR*Z9.5 !%K)PD!&P;?
MB3XE1;32I1$A#B"NV6<'W!,JE9RUCNWX]F3"F54[9G:X)[#&?MRF]@KR-.[!
MP@8-QB+)%, @( .U#T43;%U&W65U"-L(75-MQE7KW8MQ5@,@RP'%LY,1"LQ,
M8_>G/R5-R383<!OO#$UZ"8-HJ$@8QA#0T8S3!)I'146U28Q[!JD'L)MF;1 B
M9"_Q%* >HM]8_P#5IL)Q[9U+4EE2[8XQTDF.2J7E5%Z5Y*7_ !M7"HK%OT'=
MGBAW,O!IHN7@O5W.YL]9/%$6;>CZF= K%_EJ,:MBRKYODFU8*ZHO3)HIOWF.
M[;BC(,HQ7>.D5%3B20(@;BX$TR 7V:)+9!QE(:>M,M+5#L66FZS:*MA^APTH
M=D-@L5?"T&;3N9LER\>FD4.D.9+VJ28FC&AU%-L9:><1QBD70<6UEK78<K@R
M:DC)N.8L^F['-+I)HI.9^TSSQS(OU2$334=NE!(0A!*0M>U_Z4:K8[S8(VN5
M^'S+4*(@Z>9#B)*AF'Q-RM4XF-3-,3Y&D.DW8/TV7,>L CFKA-(Z)G*K:,PY
MD[0^AF747$(/*PYGZY>K#CZ4F[!#1PMC.K#AIGB>X27C&@[8K.99LP?QR"@@
MH1%NR(7VMV^L#UVL#X+QKBZ8IC;">D&(A)2+>0,/>+*SKDUD*[5=](NINJR,
M<W?(-U%[!S)URJLH'31;!-%)QA'].,W?.O:=H']?NA+^RV"_4??K]Q)_P=IV
M8_K]RW_P=6VJVK[2_5E[GF6@U4E)RCC&'33\8LB4*,>/9.O6.GM %()JZ5!:
M3=H.&/MWLK&J()M>)9DBV<U_3GJDTD2.=LJ4A"#ID/,3%QM&%,OR2!$46T(R
MR)7I?&F0W-JN+ILNW23>HM(QR^(!%'";ETHJY5S?J"S[0GFCK2!@S$]PS%C+
M3JRBK WON=[?3*VXGXV3L4=/),;5.P3)JBN\:R3UA'1JJ/3A%L'"RBTDEJG_
M %^P/S=Q&U8U$Z0*ZED;2+4*A'-G^,Z54C90;/'[7GO[A)9RHS*/C\DHMGQU
M!Y,G7'A&<9$LB&.\9.#N!64Q_$?5]Q09S.N>MMP5R_:Y*.)<DGPLU6*F)6N)
MF-P77(L0S<8TL^1T5<-PJ[P$FSCZU/7U59W'232T/\FU"N6V 4IUIR)D->,[
M$IRS"B/TD9NI8QQ[#"BO'KO2HK/#,6!&_5(&<N"^N.<E")0BYT\/9,.5"S"D
M%;6,6E39BI6 5U44 A%!#<[$YR$Y GWF /9VK(B5L41K\,(E9</1E$8UL(E:
M<)C%Z8/]7N$0X=WL_N,W?H/A'YJ*MM]GM_BQ_P#D:=OL]O\ %C_\C3MGN0'3
M\7!!,(/,:LRI_*P.4#6@V0D+TN<XC\FF.PA"PP4PH!_MG4]4/^BY7XS8V2*0
M\CVS35%0F>4IJLQS@A).'NB3Q[2+B\5CDE#NB1EX7B2R(+G "O)!S()E#<D8
M-L)8:E8TL=D.3B5,FY?XDS)NU,G9 (WEYM@_ Z#8QG-1C 8P!1%,IA0B4^+B
M-O,;9;ZQWZMEI..;LM9FV3+[C?'Q^3DFKY2:.2.G^2L810%-XXL;>ZXG,Q"I
ME6>B_57.F@\:O%$&C;'>K'0BSGLNP+-FTFI%.]6C3Q*/E&X+-SR<YCRT8KR$
MO'R<CR2F7Z99HTZ@JHHMTDS$12JD#ICQ=8]%>%H^S5N85O\ &Q-EHU4:#'.&
M<TWD+UF:YQ/;&0XYOQ$4=5^M1PMY*/731>Q;M%3B4KC.X2L9.VUK!1#:TS<+
M$K0,-,V-"/;I3<K$P3F2F7$+&2$F559!HH\=G;)'*F9942B<WJ0>J[Y/?E5^
M2J\9J_YA>-GB-V]X\T[(F-_?3XLW#LOLOQPZW\G..?T_)_%\SFD^SV_Q8_\
MR-.RM'T$:%GE3L\TJG!$M4!'7#5':8.3*U>2+Q>"18X^IU'C9!%@5)P(S,5*
M-&K1%=59(Q#E4;HZOOK6YAS-OI2="\.<(6*R)7B]Y)LIE4'3%_F^QM7DG#L*
MN0B9!/ MW3ITZ3*5J\Z)%)1HNBV;(I-VS=)-!NW03(B@@@B0$TD44DP*FDDD
MF4"E*4  H!N#V-L"?1*KGSQ9DVQ]^@]3_,+#91%9,BR*Q#I*I*D*HDJDH42*
M)J)G 2G(<HB @(" @.RVNWZLBOS]SQ*WGY"T,J90H1U;+)C&/GA<+6[%URQI
M&D4D[OA=TV%4C=VR25/'L. KD6CEFWD5ST>[?5]1A,S-BJ0[P4LR6BK1Z5F<
M")(Y,^+Y;$4W:FY2J+) 9@:=%PN/L%63$X<,/J/UM5JS8&T[1*[!@=::KDQ0
M6L;CID^6?'QW@"C6@%K!).IM<52N+"]!=JFLJHX7<NE446)ZKC^CPC&M4RCU
MR%J-3KL8F9*.@JW78YM$0D0Q3.8YRM8Z-:)I)\1C&X2!O$1]G:[TRA6#Q3O-
MMNFDNL4NU=;(1GBS;)[%^'XJN6#M&)36E(_L:8=HN>>V(=PER^),!. !L3#/
MUA>@!S<\A58L=7666VEWE,/P.0P:I2!2V1";:8VRACR]N9ULRXQ=U]RR9\]J
MY#IR'!1%OCRI57"JN.=.%7ERR\(=JPLD3@FH/5BNX.4R#>LG3S8J5^M[)OUS
M5HWCTC.46W/091X*'>JK8OTTXY55D8FA1"HS=F=MDFLE=+G,NEI:W6^212,K
MR%9N;=JG00%1;HF946I5#D1*/\'U;I<BM\O]@')*G4[T/&_C\8WI>1P\[J?%
MOA]MOY?!U7^=O]C_ '8='GTIM/OSM5'^%_64_3YR=^8*QZN+OHLTGYVLW>L&
MK/\ 2G$7YIO_ -R&<F9&<)(G=X>R8V+'V:92KM;?&7I4VD5G8+ O-5M""A'(
MGX';P\BP(U0,=07* %YI:RF*;9(4Z_#$%)DX*[9I"6-;%%-H[*Y>%=-B;MR:
M@+*@<H /&;?Q#^[D)F7?-8R)B6+N3E))\NFU8Q\<P;J.GKYXY6,1%NU:-DC*
M**'$"D(41$0 -IC/M@92#W .&;"GDZ/CWZ:IV4?B;#,DUBL*55PD8$VS9S>[
MD9E)R; 3&!7JY02\PI3#_!8']?NA+^RV"_X5JWD.SZWR_P!@')+/M7QA0\;^
M/QC>K]G^*GC'U/BWP_C.T>R.#JOQ/6;_ ,3_ +L.CSZ4VGWYVJC_  OZRGZ?
M.3OS!6/5Q=]%FD_.UF[U@U9_I3B+\TW_ .Y#.Z"<9'S2BV&LGI)P\L[781<L
M=2D3A"QDD^:R<*Y91[\P\I95-XT433.)BK)" '+5RBBDV$M=A2BW04,J@@(1
MK8!115.LY.HDD/M2F%101 -XF-]\?W=WQ%DJ+>3F/LCUN4I]SA&%ALE5<3-:
MFVQV4Q$#/U&7@;''MI-DJ=!<6KM ZB)SIB82&, W5AI4PS'8J3R(ZAWET=$M
M-\NDO/'KZ+Y&$;N)W(EIMLTA'199-R9%HBX2:D5<*J GS%#F'^"-]6V3\#^,
M^H-K/T2T(9 ^5#,T+P3N,VL$RI#[Q4KV1(FDF[$;5ID7E#&BBYY&]P143J";
M^$WG&%W@6Z]+R)I2EZ59)J.FWD?:E8J;ORC9]!M$DY<[9HR,V5%8KL(X5BK^
MUZCA_%;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG
M[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[
MW<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[
MS9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N
M+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=
MRGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-
MD_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XM
MO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*
M?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3
M]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV]
M[N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]
MYLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W
M%M[W<I]YLG[BV][N4^\V3]Q;9E962IWQLTI66WM/J1XK*$@99W5D*)09]%U-
M 15^))<9NPOB& Q6H].1(>2 ""BGO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[B
MV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<
MI]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9
M/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;
MWNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RG
MWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_
M<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>
M[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>
M;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q
M;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N
M4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YL
MG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M
M[W<I]YLG[BV][N4^\V3]Q;3<@QK633O6,1)/&9'&39(&YW39FLLW*N(MT0!$
MRQ  WMR>UW^R'W]L7V^UU7(+6T6K'=)LED:P^3Y \0VGYRM1DG,(11R=I$-'
M(R+I0J @Y< *0%W*'_RA][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWF
MR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6
MWO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E
M/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)
M^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>
M]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^
M\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[
MBV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S9/W%M[W
M<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S
M9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+
M;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=R
MGWFR?N+;WNY3[S9/W%M[W<I]YLG[BVP?7(2IWQ:!O=MML/<UW^4) LBSBH?&
M5QM,6K!%,JT,=XK8X5HFL!478@U.H/ 0 %4GO=RGWFR?N+;WNY3[S9/W%M[W
M<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+;WNY3[S
M9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=RGWFR?N+
M;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D_<6WO=R
MGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO>[E/O-D
M_<6WO=RGWFR?N+;WNY3[S9/W%M[W<I]YLG[BV][N4^\V3]Q;>]W*?>;)^XMO
M>[E/O-D_<6U"RA4H')"-KQO=*M?:RL^R'(/6*5AI\XQL,*H\9':%([:DDHY(
M5$A$ 4( E$?9_A?UE/T^<G?F"L>KB[Z+-)^=K-WK!JS_ $IQ%^:;_P#<AG)L
M>&4L9'&'LF(&KR3M5@K.E6I4VF:&2?( *[)24 W(*J3VZ8GX@]D-JR0&XM )
M7X8H-#*&5,U L:V &YE3>V4%#=PB8?9'=O\ 7CK/%Y7F?L_=-XU]<OR.#Y1N
M;XO=F[NFYO%_*>?OX]WM/O?<'J0.6O*P0N]04DZ.Y5?+O LIQQ5B9'QA136
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M,(>U-]X<!M4(V3AD&V%L6-T8>;<%=S,2DC1H)-.-EW1(V&(YDV)"@DX4!FT
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MQG9_2<SI^#V>MY._VN_UZ^LI^GSD[\P5CU<7?19I/SM9N]8-6?Z4XB_--_\
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M/M]FMKY[L8#XS[?9K:^>[& ^,^WV:VOGNQ@/C/M]FMKY[L8#XS[?9K:^>[&
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MGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C
M?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V
M,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7S
MW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGVF8YO]6OKR!=_%2+)
M$76+8%5L"KIFL@F+A(ME4,J@!U XR@4PF+O#<.V-*9+_ %;.N,\K4<?TVL29
MX'$L''09Y"!KD;%/3PT>K/M%6,49RT,+=$R21DD>$HD*(;@^S6U\]V,!\9]O
MLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QG
MV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?
M&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,
M!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW
M8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?
M/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6
MU\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[
M-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]
MOLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'Q
MGV^S6U\]V,!\9]OLUM?/=C ?&?;[-;7SW8P'QGV^S6U\]V,!\9]OLUM?/=C
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+0"*F'?N__NH__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>kprx-20221231_g2.jpg
<TEXT>
begin 644 kprx-20221231_g2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M              #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M!\&B0U-C),0W\"6%I8;U%[# T.'"9/'C5/_:  P# 0 "$0,1    O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      KB?%O[,;.7E1X$O'T5^>>JU!WQIAF;2@&^VMLGY;L.OXKL#;P V!N"
MHY'MI8SB3^>GT#\9&)*!,_\ 3+YKZ$9)UAJO0=\ 2.[2QI^WU>6-7$>U0-F[
MSI"037^1H;/FO]'_ ,?E](]-W>)+S]%?GE'=C;8>N-+7*!*)N_#&/H?+H_,@
M:Y W"TAG3</1^=8>OG!]%<&57:4VOU!^9&7;%KP
M
M                                                       0P?,W
MZ43/_3+YK@                      ",[#^V=PM'YUS?:-8
M
M
M     "&#YF_2B9_Z9?-?GB_3#&?G?5^(                     '06^;.Q
M?C5+:/O);%/1]GC
M
M                               #3S.&B]P]'YTY?WUHP=Y;V><
M                #IK_ "BW3_>L+&]A)([]SJ<L
M
M                                                        >+C,
ME]I)HUR_OK1@[RWL\X                     '37^46Z=(<$;IW"T?G7-]
MHU@
M
M                   (8/F;]*)G_IE\U^7]]:,'>6]GG   D:J^:B.6T(5,
M/2-DZZ2?BR<U/.ZY6GZ5W!A$DG7SW;/Z_P"/ZB7N6NXQ+9@@ R;R?=8]R]=E
M776]"B?C.-O[:0R10D7Y5FA5BQ')O)]UCW+UV5==;T*     !TU_E%NG2'!&
MZ=PM'YUS?:-8
M
M                            "&#YF_2B9_Z9?-?E_?6C!WEO9YP  )Q*
M M089[G-E*J*?55]@9_O$8!U33OVYFRWEBO1],7=&8_,>OSVRL;:'AFO.LHQ
M;9@@]9XO1<6Q#I7/$=Z]$7Z&Y+ERI:Q=JHA(*^6DZ<NO8-U'31W+F6X'B;26
M>([UZ(OT-R6     !TU_E%NG2'!&Z=PM'YUS?:-8
M
M                                                        "&#Y
MF_2B9_Z9?-?E_?6C!WEO9YP  )Q* M2<K/UK^4]GGI0;RRY_/^EXC .J8;[P
MK7'O2\4)-^5:-K(=(+*V5[QI^[9S<!^O\_ZNBX4T]2OW?E^U1C_0$">BZBU#
MFL<M29!O^!W0]2:D3..W1<*:>I7[OR^     !TU_E%NG">7-,9ZMFJ,BS.'
M
M
M               "+K"&Z)1=WX7Y?WUHP=Y;V><  "<2@+4_3_']2R4W8E=;
M3=+1[V7#KQ& =4P7Z"JGW7.]<!NC:A&]5>RR=W/-M1^63#MT8))ZS>K*,\=[
MO-=0PAJ"E?N_+]H;)-\PL7O6&D$_BMLG&VAJZ.G:6UDEG"NH80U!2OW?E\
M   #IK_*+=.4^1T
M
M                                 !R_OK1@[RWL\X  $XE 6H(9+SK*
MZ1A/3]17:6<K@.)](4H]XY>N?X5T[7+T_2F-NKXK-.4;TJJ; S]JG,8^!L=%
M^U;]Q/I&H)M?-^5^/T+ ^;;B@#T=3]F3*EZ4JMWY>V-C':M^XGTC4$VOF_6^
M4\0     =-?Y1;ITKP?N/;S16><UV?60
M
M                                                BMP/O&5+?&#N
M7]]:,'>6]GG   VIA_?&JTPX&:.#T]LH;(O<\_U167! /1>7]I;J8L7UWB],
M3ER5YB3M<X 34T/:&1^7[? ]+QPFWU5V[,!E.^%>2V'R[:VQSU/%-30]H9'Y
M?M\#TO'";?57     #IK_*+=.D."-T[A:/SKF^T:P
M
M                                                         $,'
MS-^E$S_TR^:_+^^M&#O+>SS@                     =-?Y1;ITAP1NG<+
M1^=<WVC6
M
M                         A@^9OTHF?\ IE\U^7]]:,'>6]GG
M              Z:_P HMTZ:86VYMMH;/N:+,K4
M
M                                                       0P?,W
MZ43/_3+YK\O[ZT8.\M[/.  ![CG^H>'Z'E_9^?\ 6QL8[6!Y#R?/>K\0  !G
MZ-]?#'=YGR/W_,#WG.]?JO'Z,,]WF  >XY_J_P!_Y_OA.CY ,ZQ[K8*D/)
M'37^46Z<I\CH
M
M                             #XO,Z?VNGS.7]]:,'>6]GG   G$H"U!
MIS-XW8YR_=<9EK07=N!2FL=K"B<(]_E@ "U]CG0FOTEX\A=9S*I;LO.^"9%R
M9,*IG,YV?;7PMWN7KK)N+7TTI3H G$H"U)R<_6O1R^@&5!LA%NWT,?FCLKF?
M?5?#0  Z:_RBW3@K*NG\_P!O5)DF:PL
M
M                                               :7YFTINAIG-?+
M^^M&#O+>SS@  3B4!:@G.S[;%)G>F6_)^WS@  #,7#Z5J+(-_P!/O;6;I&:P
MFLF=43FMGJ:D=QH/)=6Y=P-O85))MJ$M*-ZT83)55<XR+S/;!S?]4[3Q'OS9
MT):=>;2]-10W'7MO3%6CMFHIW:./T RH  .FO\HMTZ0X(W3N%H_.N;[1K
M
M
M              0P?,WZ43/_ $R^:_+^^M&#O+>SS@  3B4!:@GFSM;M%7Z$
M9.    W*@TFG2SY;%6/7E [11'O6(\RW14ZV1GD;"1GL6F,BW]$[<=>>V\'J
MPSW>9$]<=>7"<2Z3B1N>N<6=?P3RYVMRN'J&DY/JFGFYD%DU-O<>:  !TU_E
M%NG2'!&Z=PM'YUS?:-8
M
M                                   "&#YF_2B9_P"F7S7Y?WUHP=Y;
MV><  "<2@+4$QU'V95.V#GW5Z7<'[7G_ %_/_7\_-_;^  /:>#TW"<2Z3IA;
MIS'+Y2ECYXCO7@+T;4,R-'67$9=%<_*_;\[I6$M/Q.7)7FM\HXD3]R5[=0PA
MJ"'.\*SPWV^;_#^O\M?XZT)0-^CF0;?V)](4V]QYH  '37^46Z=(<$;IW"T?
MG7-]HU@
M
M                       (8/F;]*)G_IE\U^7]]:,'>6]GG   F+H^RA'+
M:$*M 9+OG%W7Y_L?#ZH$M%5%(I64TC!MF!R3U;-_!]#R0M7O6 G<SS;.[\ E
M?U/R_NL3K"B+4&0[_@+T94,^V<K>^5^W\0E7W5FP,;[& 9'R(R[7@MN;%VC(
MI+AKW%'9Y\9=KP7+O$Z.(NWSK8&.="5/]C9[  '37^46Z?H5O8'J^_P/L=+G
M
M
M                #6.C+OV<O.D.7]]:,'>6]GG      V2BO;D,K29[41#O
MPZW?6LFU3SN W1M0@            =-?Y1;I^33=MY#F,/\ 3=SB
M
M
M        #$E>6#ENPZ^Y?WUHP=Y;V><     #8&-=C.<?ZLC]73?%W7\&1N7
M[:^^DZ=             Z:_RBW3I#@C=.X6C\ZYOM&L
M
M                                                           !
M#!\S?I1,_P#3+YK\O[ZT8.\M[/.     !^G^/]SC'^M@61\C*_&Z'@NCY/B^
MC\@            .FO\ *+=.D."-T[A:/SKF^T:P
M
M                                                        $,'S
M-^E$S_TR^:^+NOX/\O\                       ,G<GWQIX>VUN%H_.N;
M[1K
M
M                    5K_B9]IK'?VD^-&LE&7?K'1MW@;M:@S)ZGO<&/S(
M.N0,Y6I5N[6H,R1D8:V]\KP>\?J_?\)0MVX9TPS-I3 526R!O?J_*OY/P_?1
MO*^HP-D;KI?;O1.>HL\%[M ]5WN#)%M;&&B&3]58BKNPP)#MC8^QM"IIIUF[
M1H&TU]41L/<=/QI8BVN!DF:PO,-D5UF>S*U]W*XJ
M
M                                                        ,5P*
M>9/G,'\QPNYY?A]P#V\HB_Z_1^&/8?+P/N]7E>WE$8QC!IQ_'\_T'^_Z_G*,
M[@OBXS)?/\CK@>]ED4_Q_/\ 6O5.V_H]EG4$EFWL4^E[?$]?(H]BN!3P#]?[
M^?),VA?@XG*_C\[H@9$F4.^;X?;XV-R0#U7>X/HNSQ\9PB; ?3]OBR#,(@
M
M                                                       !C\QV
M;" P >[,6&>S[@/$&.S/8 ,"'OSW@!J8;9@                   &*X%/-
M!\D:QE,WIA(            :>&X8//FO9FTQV9[ -3#;, 'PS !LV :T&>S[
M@   !J8;9@
M                                                  @!*[YT'@4
MR=PJT%]HW=!'615EF@ %"4G^)W "D$7?0                   #%<"GF@^
M2-8RF;TPD            ./&=AP&@!SX2[&5WR^T 4@B[Z #2(H!G39 *AI9
MH-B@   #DUG64
M                                                     ! "5WSH
M/ H!D[A5H,E&HQ=J-J"*LL:G/N-'2T 1EFD!@XLHEMDI!%E,JHD;QN(=#,@#
M*<AEPZ"Y&X5]"+PF8+OY6F*HQM*="LR$           8K@4\T'R1K&4S>F$@
M           !QXSL. T .?"78RA69^)8R]:4@B[Z5>RK4;4%U\YCI(V>B.D$
M50BS04[S2HU&.A.9U.>^82+>)8H.36=90
M
M             $ )7?.@\"@&3N%6@M.DWIRCSH)E=\VA/?%NPI$F*C;(N(G(
M3.P&<FLO<%+XZCIRY"_H<RPZX9& 4D2P21>'0<.0&=6<YEAU6RM@1;%Z<
M        Q7 IYH/DC6,IF],)            #CQG8<!H <^$NQE*0ZB9SCBU
MV4(SJ.G+-.LL5O3W)0*.O\<_\L&E4XOM')I.O:0SD#YK06TB98Y*1UASE?'6
M4
M                                         !!.5CCHD@YXY9/*F)T7
MC+)R:2^X5WS7LN#$K *$I/\ $[AR23K;')K+W! "7VCG&%G,J)G3L!R6BV4"
MVV<HTO?',>)F@3ZEP8           Q7 IYH/DC6,IF],)            #CO
MG8@!&(45"Y80QEU8J8G]BIF=#,J%G15!I$4 SILE(LDR*Q1?:.9,=;8B)*FI
M$X=9T_L<VPO G-].LH
M                                                          #7
M,Y$!TUS_ $<S$ZYISVRPT34G-A+[!7?-_P T[+FIRMR<4L(D[AR23K;')K+W
M! "7VCG&%QLYJYU5B'8K1DV@+;9RC3IE'*^.K<0!GYBT            8K@4
M\T'R1K&4S>F$@           !RS2QR3N%(\E2)@2B.=2,YEI?B.=4=3\Y0YU
M:RC:;S$&ATV2D629%8HOM',F.ML1$E34_>31%@,Y19URSE0'64
M
M                               (22HF?S+?)-:5I#2$BE+TY^\CO)XB
ME.1,%QL\";_F]Q4D+;94U)W#0 GM*XQ,P:H%*<V[+S!',"6XJC%I<AR*>)N.
M7IS)X          !BN!3S0?)&L93-Z82            &O92--"2;8N3FF)7
M4(1RRB6;RIJ6RB#PI]$N1;A(!RS:0BFS)&*3V%9,MMFHA$T3Q%&$TL+GI+D5
M-2V4
M                                                    #7DV&/XD
M2IX(F-/0&)#V!ZL                  &*X%/-!\D:QE,WIA(
M     #R!Y<RN8D(@#<PD.!K(9S/4 T\-PP#$A[ ]6
M
M                                "KJ9])OCEGDV!E4K6'3R/7E+HOX@
M                  Q7 IYH/DC6,IF],)                4 2[*1;%#H
MLZD69^<Z0QS)B\L2A@X\9V' #5,I=%_$
M                                                         $;!
MJF3%F2                        ?G.70=1\HZ&VQ;5!"H4U3IJG.P+NAN
MV                  8K@4\T'R1K&4S>F$@              !H,4R3H7G'
M_.M 9@!S5RV@4_B\L2A@X\9V'  <[ NZ&[8              (V#5,F+,D
M
M      _B<SLSF2,%7,Z%I,\                       16E1$Z(!RX#H!$
MCH/YG'0.QF5ES3LN6                  &*X%/-!\D:QE,WIA(
M       4KR0XL,'(8.PB 5+S6@B--9#/((/SM=@ K+FG9<L
M!_$YG9G,D8*N9T+29X
M                         KBD!QT*P:Q'*W.O*
M    5]"&4O2G.0+3).L#6@Y:)UQ2#8KRE^,                  Q7 IYH/
MDC6,IF],)               #G[%F(FC..&=D  HXFX!7T+RQ*&#CQG8< !!
ML5Y2_&             "N*0''0K!K$<K<Z\H
M                                          !0^)2"SR <<,['@
M                   !',4ECI!$7ASCCIP%'PAK+PY9D*JYC<MX
M          &*X%/-!\D:QE,WIA(               4Z#9,M"%!@]N6J#G6&
MH!UNCG#%Y8E#!QXSL.&K9G<]:55S&Y;P             !0^)2"SR <<,['@
M
M      !3H/QER,'Y#CG'8\                       !RV3J/'Z"+$IP&/
M21<UL.A6<V8Z!)L@                  8K@4\T'R1K&4S>F$@
M     !JJ4)3I"'\RJ,5Y3;L\J6%3P9.8;0@IXE@D@G-""^H<V8Z!)L@
M        "G0?C+D8/R''..QX
M                               8$.4$=*0D6*&1FPO/@
M            @#-;"T>  "/XJ\EX<               &(*YL34G/.@@ /#1
M64ZJ4#?.\FJ,N@ 9?L:N]MM#9]             HO%K<WJ     !'\5["PF5
M>2\.              8$.4$=*0D6*&1FPO/@
M                                           TW*!AK\6<2V6
M                                        >/CDBQ+7E@@    #U\CC
MN6[#KX                   1UE!PND$UX               --R@8:ZEH0
MM@@
M           Y_!*P2KDK                           !28+J9]0
M                                      &)#5L]0;K@
M   '/X)'R<HD>
M                     !S^"5@E7)6                           "N
MR5:SI.'W@                                     ",0U5)Y0
M               <_@D?)RB1X
M                                 '/X)6"5<E8
M          ! L4[CI;&1                                     :JE
M 4B'.OH>H                     !S^"1\G*)'@
M                                                 <_@E8)5R5@
M                           B,*%!THC:@
M           'FRN25("L6>J.SD2(@                     '/X)'R<HD>
M
M        !S^"5@E7)6                             :4G-]+\Y+B
M                              #Y)1 *<)'T#I7ETD
M        '/X)'R<HD>
M                          !S^"5@E7)6
M     #&YSD2=(MR                                  PF<X\A.,#';
M4/9                       Y_!(^3E$CP
M                                           !\<Y(I[@Z"),2
M                          4TR(<Z(AF
M        A2**1T)2L^9W+CP                      //G(N,C'1=)3@
M
M    #XY4Z*T!:^-TRD\29EVDS@                             "*PY_
MQ=S)X0                              >5*'!C<Z )[@C$)$SU
M                //E2(KB%MHV9*51*^763,0
M                                          !\<J=%: M?%G8_0 0N
M%)8DS+M)G                              \J4/#"!?R,U
M                   $(Q1B+N1/(                       >?*D17$+
M;19:/Z $'Q2V);RZ.94
M                -1#;,_0#3PW#--3<H'B#'9GL^.5.BM 6OBSL?H   (7"
MDL29EVDS@                             12%"(LZ%KX_L
M                 :JE!LV?+V)[X                &HAMF?H!IX;AFFI
MN4#Q!CLSV>?*D17$+;19:/Z   $'Q2X);2Z.94
M                                  .1.=90R(#CQG8<.!>=D$F/(12N
M^2'E8XM?%G8_0     0N%)8DS+M)G                             'Y
MRIJ5E2[23I@                         QJ4E"-(OJDAH
M     .1.=90R(#CQG8<.!>=D$F/(12N^;SE;HMM%EH_H     0?%+@EM+HYE
M0                                                       Y$YU
ME#(@./&=APXYAEDZT9#X5WR: L9'Z       "%PI+$F9>!,L
M                 QR4G"*PNLDT8                       ,;E.8@Z+
MKI.2                  #D3G64,B X\9V'#CF&63K1D/A7?)G2QR?T
M   (/BEP2VEU\]X
M         <B<W#/M C>.PX<FLN.D'A: *[Y?:         *3Y+$3_
M                       PF4MB*(MQ%B@_0                     :P
ME,HC$+BQ/P                   #D3FX9]H$;QV'#DUEQT@\+0!7?+[0
M      ,?%',LG$OX
M         !R)SK*&1 <>,[#AR:SK*',/);S$Q?:         *H)N 3_
M                          \"5*2O*3:EN$V8                  !_
M,@P*D1]0N3DNH                    .1.=90R(#CQG8<.36=90YAY+>8F
M+[0        .?P;E$WQ+^
M               <B<ZRAD0''C.PX<FLZRA@(XW1;H+[0        !5!-P"?
MX                                A.*DAB<L8%E8R\
M   17%5DC<)R2V>;!                      Y$YUE#(@./&=APY-9UE#
M1QNBW07V@        <_@W*)OB7\
M                     J)ELH]$"GB7#BIJ6R@0?GDB>T         J@FX!
M/\                                 >+*ZI6Y,8DQ)8:)23^P
M     !AL@;*\IJ^2EEIHD=             !C4R4        "HF6RCT0*>)<
M.*FI;*!!^>2)[0        <_@W*)OB7\
M                              '-#.EX         "J";@$_P
M                           /QD/Q7O(N#^AOL2^$JYOZ?:       ,'D
M7A$R1#&*S,!.X6$C9@               I&$$)<M+#!^P           Q^<\
M,Z/@        !S^#<HF^)?P
M                     <T,Z7@         *H)N 3_               $>
M!H@                    #_)H81%$5AH ?H-PS;PV?,\&3SV1]X\.>.,*F
MO9JH:5&"3-1)V2S$MIE0                 \N<L@UD)""Q$3ADWQ*"?L
M       ,?G/#.CX         <_@W*)OB7\
M                                '-#.EX         "J";@$_P
M         !$41;
M    'XSF[FK)G$G@)P2< G,,M         &/SGAG1\         .?P;E$WQ+
M^                                                          #
MFAG2\         !5!-P"?X                  PR1N$Q(
M                                 *=I3C+F!:L,I           &/SG
MAG1\         .?P;E$WQ+^
M                     #FAG2\         !5!-P"?X
M'\R%PIK%5@Z_A+V
M #4,V\            !C\YX9T?         #G\&Y1-\2_@
M                                           &LYSVSI>
M J@FX!/\               :RE0 @'(135($A):S
M                              !:$)N         #2,HOG1\
M *3)ZDF^)?P
M       #QY3N(W#1$ZHQ^P         I''M"YZ               #PY#D0?
ME:TKV$B9V+SU
M  !DP]H        >$*;)',:QG4./T         %"$D&+;
M                                         !_DK8%9 N#'F#G#$C9:
MA+21^P       @^*4Q*^;1D&9>9)2P                1Y%-PEB+9P
M                                                     !_(K(%;
MPN/F"SG;$C):^+.Q^@       @A*6I,69A(:2]*26@
M                                 \^:7FZ1]X B5*8)/X3,%#4DQ+NI
MZ8JIE7\M0%I(_8     0?%*8E?+K)F(&'RC08C+VIL\
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M'LP
M "L^4NB8<A\+I197*QAH"6JRCZ?!+YALT #XY4Z*T!:^+.QB<@?+( (^C\1(
MD00E+4F++I)E0  $>Q1,)6RYZ>D!_$B)!+T?Z!H$:3$RAD('BB&TVN)&0:HF
MUP,"&2#V8                                    !BPY(YUZST!Y4Y
M1UUC*)4I*VY>Y)90   ?-*J95_+@1R>#KUD[!5&/.E<8E9+K)F(    $(1E(
MEK/C'+D)D3Q1I:=*HHL&B)*T5BCI1&2#F1%E$CQ,C'0:.4:=7(%"4LA$S
M                   !S]B/8_<;A%\LSN<VHZ2H,9E!PZ%YA<H;&E1EXO7F
M_)2V(%CUAGXO=&YQS]B[Z;& YP9T?                      8L.2.=>L]
M >5.0$==8RB4]2 $OADHH   /CE3HK0%R0Y*AUZR=@JC'@"N>3%ETDRH
M"!PV>)13XQRY"9$\4:6G2J*+!HB2M%8HZ41D@YD191(\3(QT&CE&G5R!0E+(
M1,P                                     0FE2DZ1 !S<BVV39&D)N
M\     #YI%$48C20ZRA69/.EGDS$       5OR+HO"@@4)@SF.G5*!':48#8
M(M7$P(.8(=#,YFITDP4H"V,3,                      '*>.E,;=D)90P
M.L&<>,[#@,,G+1.LH<J O,$XYHJ<NLZW1SX2U03=$;AS+#KL'*\.E,;=@Y I
MU^@                     0FE2DZ1 !S<BVV39&D)N\     #XY%>46S20
MZRA69/'%I8RH       5OR+HO"@@4)@SF.G5*!':48#8(M7$P(.8(=#,YFIT
MDP4H"V,3,                                     $5Y1I.G, <P\O1
M$IP      !H 4:2SB5DB=@\Z6VP       4\S8PM  $:Q2Y.C>#^)RAC+)TL
MS.8*#A9 .=@3[ @2.BB3,                      '*>.E,;=@Y0ATPCE)
MG4F!B8YX9T[CF.'6) *!Q-F5VRU03= YP);(**A>^-I <O$[!H
M           (KRC2=.8 YAY>B)3@      #0 HTEG$K)$[!YTMM@       I
MYFQA:  (UBER=&\'\3E#&63I9F<P4'"R <[ GV! D=%$F8
M                       /YG)".B.2]$/ASK#KH']@      #0 HTG25.:
M^>1)\RVV       "'HJ1'1B!S4SHGG*Q.L6>@*_Y7]-B#?\ +/9^(Y/QU)CE
MZG5R!0E+(1,P                      <IXZ4QMV#E8G1Q.5,7.08_*U!T
MRCFU'5? *'!+"0!EJ@FZ!SL"SF4>B>\SJ"F2=C,
M'\SDA'1')>B'PYUAUT#^P      !H 4:3I*G-?/(D^9;;       !#T5(CHQ
M YJ9T3SE8G6+/0%?\K^FQ!O^6>S\1R?CJ3'+U.KD"A*60B9@
M                         &MA0T-53:HO@FSH       - "C2=)4Q,<8,
MO]%ML        H$D61Y(LO%Q(KU%*HRX?;.DB>M.;^8B,7%N$M!',[.F("E
M3]$LH                     !RGCI3&W9'X<QTZ\9QY3L. PR<M$ZRAR.C
MI:DB!A<Y,1UBB@P6J";HUL.3P==PY;ATIC;L'(%.OT
M    :V%#0U5-JB^";.@       T *-)TE3$QQ@R_T6VP       "@219'DBR
M\7$BO44JC+A]LZ2)ZTYOYB(Q<6X2T$<SLZ8@*4!/T2R@
M                               &)"(TG-!%6>Y)&P
M                          #FE&"CTQ]$Z!)O4<J8ZK(,3'-V.G$:5'/N
M/B'F"\@3,%"DAK,R'S"]P2PG-*.@B;2 Y8AU.P
M          8D(C2<T$59[DD;
M                               -(CG.G4_!4"/.EQ\
M
M               &D1SG3J?@J!'G2X^
M                                      :1'.=.I^"H$>=+CX
M
M                      -(CG.G4_!4"/.EQ\
M                                             TB./23\ C@+?9<?
M
M                            !I$<>DGX!' 6^RX^
M                                                   :1'.=.I^"
MH$>=+CX
M                                   -(CG.G4_!4"/.EQ\
M                                                          TB
M.<Z=3\%0(\Z7'P
M                                          :1'.=.I^"H$>=+CX
M
M    !A KGEI\$0)\XF/
M                                               !A KGEI\$0)\X
MF/
M
M
M
M
M
M
M
M
M                                            !_+_ '_(X;1A.!)%
MR                                            !ZSQ^B3FIYW[GG^
ML
M                                                       ?!]'X
MT9_H'E*(NZ:Y                                             &Q<
M7[5\KYWZWW5@<H
M
M        K[:2IVF]N+-
M      F!I*R;U/SXU@
M
M           !4;VAG.MSJ2D@
M         !M3#Y!T@?EWMD
M
M               "HOM'.=;W4=)
M             #:6(=_I"_+K;0
M
M                   %1?:.<ZWNHZ2
M                 &TL0[_2%^76V@
M
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MNMM
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M0IWS5P         VEB'?Z0ORZVT
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MRC=F!2F8&D[)I&[XRS;+QMH>JAL'/N#I!R@        -I8AW^D+\NMM
M
M                     >/]'X\__6F=KHF;+P
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M_()="U-J)-8X        !M+$._TA?EUMH
M                                                          #Q
M_H_&BAJ:@;[^4="                          "HOM'.=;W4=)
M  2/5=-;*>6+QA^NRMMU8'*-3YE'J]6EJ;O$8!U31WW]E86P<<:%@/T94,C%
M837>VO9;I?.HO)M5$[K/:KHS>FOI7*-4<^CJLZ%R$UI,HFKEKR-^T(1:5R-?
MM/';F;!=FP5J2F+NC,?D_;Y[-.4;TA]NRMK-.4KUI7[OR_<ZPMIN"70M3;31
M'OU^=)4]=0PAJ#1BP8G#[=E;7&\0:6@6T54<I513ZN/J"E)!ZTF7H?-^V4.3
M[Z[VF:8M19!O_0:QXAE'D=#/$=ZT)5]U;81S5<E*_=^7[2N1;\@ET+4VHDUC
M@        &TL0[_2%^76V@
M                                               /'^C\:*&IJ!OO
MY1T(                          *B^T<YUO=1TD        !Z3R?ML#&^
MR,$R'D>0]WG&<8_U<'2#E#+'&Z'@>CY/B^C\O4^/]\U<'J:ZR?B_F_O_ #W'
M/]6;>!U1KI)^+\7T?E^_\OZRGR.AAWN<T9MX'4POW>9_+^O\R;R?=X_V^;)O
M*]^%>]R\S\'I^$Z/D^I^/Z8_Z?CS5P>I\+T?CX_V^;WG.]?H_-^^$>_ROK?A
M^GHO-^_@>CX\XQ_JX+D/*R_Q.EAON\S,G"Z?FO7Y_ =+R9JX/4PKWN7E+C^_
MPG1\GR/W_,        #:6(=_I"_+K;0
M                                                        'C_1
M^-%#4U WW\HZ$                          %1?:.<ZWNHZ2
M                                     &TL0[_2%^76V@
M
M               /'^C\:*&IJ!OOY1T(                          *B
M^T<YUO=1TD                                              -I8A
MW^D+\NMM
M                                  >/]'XT4-34#??RCH0
M                 5.MCYYK-:MHP
M               ;BP>2]&7YA[4
M                                                     \?Z/QHH
M:FH&^_E'0@                          C+M>"T$/HUD'^']_X
M                                      !9<RK>5L[&NAP
M
M                /'^C\:*&IJ!OOY1T(                          !
M!'H:IJN>MZ#UGE?#_P"                     '\'^?E/HO]
M           &0^9[)R\_6O;/QKH?TGE_<
M                                                          #Q
M_H_&BAJ:@;[^4="
M     1R3*,P3VE +>>>[E
M
M          'C_1^-%#4U WW\HZ$
M                 CDF49@GM* 6\\]W*
M
M                      /'^C\:*&IJ!OOY1T(
M                            !'),HS!/:4 MYY[N4
M
M                                  >/]'XT4-34#??RCH0
M                                        ".291F">TH!;SSW<H
M
M                                              \?Z/QHH:FH&^_E
M'0@                                                 $<DRC,$]
MI0"WGGNY0
M                                                         !X_
MT?C10U-0-]_*.A
M   !3CT92M<^XJT\)ZO/O)%^]TA<::;^]^7Z
M
M                        #Q_H_&BAJ:@;[^4="
M                              #2J2\/F#;@RI\C]/XNH9JO*TK1=L
M
M                                               >/]'XT4-34#??
MRCH0                                                 "C!J.@X
M5K*@W43PWJ[VOF_<
M
M    #Q_H_&BAJ:@;[^4="
M           :>2+BPR61"++U*VB
M
M                /'^C\:*&IJ!OOY1T(         !XGW^6(6ZJXPMWN6
M
M                /3>3]Y5Z?L'9R)]T
M                                         >/]'XT4-34#??RCH0
M       :C32.4*_HGD;6*6\(
M                                           ??\WZW+L-::G=SS;0
M
M        'C_1^-%#4U WW\HZ$         %%KZ#9/AZNZM@
M
M      ![?G^KI/\ RSV_E3C]
M                                 >/]'XT4-34#??RCH0         <
MSCZL88PYW.:
M                               !?M^<FO9/:FG@
M                                                    \?Z/QHH:
MFH&^_E'0@         YD_P!7,*XM['@
M                                                    OO\ SHUW
M*744^
M             'C_ $?C10U-0-]_*.A         !S)_JYA7%O8\
M
M             %]_YT:[E+J*?
M                                 #Q_H_&BAJ:@;[^4="         #
MF3_5S"N+>QX                 /]?XS%P^GAON\P    9,Y/NQGUO"
M,C\KVXXZOB      S5P>I\7]_P O$^_R_%]'Y >F\G[_ '?/^N/.GXP
M  /><WU^.]WF_)^G\@ ?3_'^_0^;]O%^_P PR!S/9\7T?EZ'R_MCCJ^(
M     #,G"Z>(.WS=]*ZEV@UCQ              7W_G1KN4NHI\
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M9W&)N*#M.HGM/.0         %R3#FEZN6N*%LAY<NRI+L[.P
M OO_ #HUW*744^
M                      'C_1^-%#4U WW\HZ$         ',G^KF%<6]CP
M            9YCG6M*Y&OVGCMS-EIS(=^PHWS5VT<1[\A]9S2+"WJ_C8M.$
M66LJWCX/H^3=R RF).YZ[B@N*O/<>#U[X5W+=8);P9RL_6OJI,(_M5$._NO
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M?^=&NY2ZBGP
M                   \?Z/QHH:FH&^_E'0@         YD_U<PKBWL>
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MT):42MS5WK++.$            !??^=&NY2ZBGP
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M?:V</)^WS@             7W_G1KN4NHI\
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MJU!]K9P\G[?.             !??^=&NY2ZBGP
M                                              \?Z/QHH:FH&^_E
M'0@         YD_U<PKBWL>
M      "4JHI]MY"I'7YTE3P%NC%VC*J.P,^^%Z/E            $I513[;R
M%2.OSI*G@                   +[_SHUW*744^
M                                                'C_1^-%#4U W
MW\HZ$         ',G^KF%<6]CP
M         92X_O\ 7^+TZ_27C@;EP63::3J,@            92X_O\ 7^+T
MZ_27C@                   7W_ )T:[E+J*?
M                                              #Q_H_&BAJ:@;[^
M4="         #F3_ %<PKBWL>
M                                              "^_P#.C7<I=13X
M
M        >/\ 1^-%#4U WW\HZ$         ',H^KF%<6=CP
M
M        7W_G1KN4NHI\
M                            /'^C\:*&IJ!OOY1T(         .>W]*L
M;Q\V5#@
M                          !_7^?]Z0?R[VUM%$>\
M                                                    /'^C\:*&
MIJ!OOY1T(         (?KLK>C3] LH_,_;^
M                                                       +#>9[
MEN'XCTH
M               !X_T?C10U-0-]_*.A          (X[0A-?K2-/82[W+
M                                    'AO5Y]-Y!QI 8K(0
M                             !ZKR?O+I2UC3SYWMS]/\?T
M                                                           !
MX_T?C10U-0-]_*.A
M      -0I#QJP-X55<[S==P
M
M            \?Z/QHH:FH&^_E'0@
M                  &BDIX%<BY*SN19RNL
M
M                        >/\ 1^-%#4U WW\HZ$
M                                T3E/ KGW'6EQS.=U
M
M                                     #Q_H_&BAJ:@;[^4="
M                                            1[2Z.0*VM7MO//=R
M@
M                                                 #Q_H_&BAJ:@
M;[^4="                                                 #460\
M:-Z91F(FPH9:4HNV=J^#U_I?Q_0
M
M              $2T_A\7,YB=>VW:XL6T]9=B*G[)SER_>
M                                  *AFA*:J&Z%IH270J4]+'%FH/[?
MY_H
M                                                  $;\RC/-#VK
MES\W]?Y)%#)/TO<5:B_M_G^@
M           ##_1\7+,W3DW%OO\ )T1<?Z2F@K:<
M
M                             4"=99W@0M>O>A+D71TX%83P
M                                         4]-$TO$]/HAT;,<:7
M
M                                               $?<NCE&O4%"])
M7&6G?]_X                                                 &%>
MGX=,I)PY-X1*@
M                                        ,>=/Q07:#JB/>RH;\'T?
MB                   !KCV>9L=QNF                   !ESB]*7ZE+
M(E?IRPO^@      U'FD=@!T?3VF,ZC'Y?Z_P
M                #.7 ZLV-"VE+73-B
M                                      1Y69#*-/T"REKQ)N,
M                                     !,O1EFW9,%ZC]?XO2     (
M#=&5#3IV]FKSOJ_$                                          "=
M#/EKW1,*:>^M^/Z
M                   ##O<YG.I^F^+L&R'E
M                    6 ,WW!<JPWID    "/*S(9S]/I%CSYO[?P
M                                     !:/R-?=IO(E_
M                                                     "LSJVBZ
MG>Q\]                                            #]WY_UTE_EK
MM[86,]D    4J=X9>@KT)4X
M       R;R?=TPOE3N;[?G_4
M                           "D5OG+$)5]U:
M                       !>D^?.KYAJ1LH    <[7Z:XPT?G\5
M                                     Z-GS VKM]"I(
M                                                    !1QW_E2&
M.]:Q                                             O&?/_5<SU%V
M<    .='].L6Z8SJ,
M  =%OYB[2W/@LG
M                  HX[_RI#'>M8@
M              7C/G_JN9ZB[.    '.C^G6+=,9U&
M                           .BW\Q=I;GP63@
M                                           4<=_Y4ACO6L0
M  )4Z?G\V="VGA/O<K]?\?U7,T]2N#9#R@           !(=6<RW*@TG@GT+
M4P&8.'TMJHA((];+AMSS"VG*8>Z<Q@     ?K_/^K5F/] Q/W'7D5%PU^
M     +QGS_U7,]1=G    #G1_3K%NF,ZC        L.9GN7>2OY7X_V^?0.Q
MX?!7H2IP !8&S;<.EL[C$9=KP4  "<2@+5@[O^JMU8'*)D:.LNLSJVC
M /L_A^EOK%&D(0[]JN*BX:_G[SA;^Z$%D^\]?2R.*T(3 )HZH-999P@   +J
M&$-0:73N+PHWS5VET[C         Z+?S%VEN?!9.
M                                           !1QW_ )4ACO6L0
M    )Q* M00=W_5><H]U;B&(]*4?=^Y6D#K:8;BP>30^W;6V_-<R^,"VH'O_
M %O,-1II'/L_A^FV$-D7[OS_ *W!A,EC MJ!_;\_ZY#YGLR)S/;JQ+^!)W4\
M[BFN&OL(=_E3'T?9>)NSS]/)M&MK8?((TK5@\GU2SO\ +_?^;SU]+(<[OK24
M:I)[%1<%?S:T):6\M?RN->TX/CCJ>*%:^*OD#K:8;BP>30^W;6VV$-D/V/Q_
M7:R'2"%^]:Q^+Z/R&X\&DLB-9S2)BY:[WSKJ73K9[MBK?KFA-59A'P
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M0PAJ#2Z=Q>%&^:NTNG<8        '1;^8NTMSX+)P
M                                            *.._\J0QWK6(
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M=+3=N8,W<#JV@\E7S7WTG3LGU2SR/BRH;/SG&X-+IW%X4;YJ[2Z=Q@
M  =%OYB[2W/@LG
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M5VET[C         Z+?S%VEN?!9.
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MU-\G]OSL#9NN*JIL#/V>([UK;6,M%00Z&J6>?.UN59M=T#.GGRV*M6NJ#
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MS@-T94-L;&^AM+IW%X4;YJ[2Z=Q@        =%OYB[2W/@LG
M                                                    HX[_ ,J0
MQWK6(       &<8_U=V8%*1IE.8Q@*2<@;"QGL[.Q/NQWV9#/F_M_&[,!E.D
MT^BV:.#T_P!?\?UC7J^'8&-]G5681_=2!RC$_9YWF_5^&)^SS_=\[U[\5S+M
M()_%K(N7+M@^OZJLB<SVS?4#:E:+55&Y[CO7QMU/#AWN<WW7/]?J?'Z/I_E_
M?F?5^&LDLX4BM8S32J>1?9*+=S2N>1?86,]G9V)]V.^S(9LG%NY@F0\C^/\
M7^; QOLZJS"/C+O$Z.Z\#E,>=EPS^_\ /^YVCW7U:E_          O&?/_5<
MSU%V<    .='].L6Z8SJ,       #)O)]WEO7Y_-^O\ '*G']_E_7^'Y_P"O
MYRYQNEK_ "3C_H_C_<\QWKXK['/_ (?U_GS/U_/,O#Z?C/=YO$^_R?N_/^\P
M<3I8"DG(^M^'Z95X_0Q=U_![;P>K%_7\&9.%T_->OS^ Z7DS5P>IA7O<OWW-
M]?S?U_CR?M\X]-Y/WROQNA@*2<CZ_P"'Z>[YWKQ;V/ !]+\?[R;RO=B#M\X
M?T_EL/&>UK_)./\ D_3^<Q</I>?]/XX]Z?CS5P>I\7]_R\3[_+\7T?D
M   .BW\Q=I;GP63@
M                   4<=_Y4ACO6L0                   -YJ^E<WM!6
MIYGU?A7TTG3F#9#R@                     !>,^?^JYGJ+LX    <Z/Z=
M8MTQG48                                             Z+?S%VEN
M?!9.
M       !1QW_ )4ACO6L0
M     +QGS_U7,]1=G    #G1_3K%NF,ZC
M                  '1;^8NTMSX+)P
M                                  *.._\ *D,=ZUB       !G&/\
M5&4N1[]6I=P/@^G\@ -B(QV?$^_R^1]OFDFJV< :5SN+X)D7) WBK^5:=S>-
M2657.0--IQ&?(>WS8M['@&X<(DNGDWC0   &[D!E.E\ZC'X_T_D;R5]*\=]3
MQ;50^0#"G>Y>D$_BN3.3[MZZ]EF#^_RM.)S&MPX1)-AXSVAK7*>'J3-(Z
M     +QGS_U7,]1=G    #G1_3K%NF,ZC                  GWSC;T4=Q
M5]*O3U@P*:+J*P)FVX8^+*AT?=E0X   #9*+=O#7<YGH_+^\Z^>[9KL:;I<
M                =%OYB[2W/@LG
M                                HX[_ ,J0QWK6(       $XE 6H)2
MJBG]6K7-!8&D?) $CU73:Y5AO3%0';&;XU+4@\E=5S@6"<V7%6IU11V@5D1
M"\1@'5-/#;>;+CF(-+5M-2TB-BHQVIYL[6Y14^A&3?P?K_-P[$>E*>.W,U@
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MNTMSX+)P
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MX1;\JRQ[EZ[(SK6@LEM53FHOM'.>N$IX@             Z+?S%VEN?!9.
M
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MN.O0            !T6_F+M+<^"R<
M                                "CCO_*D,=ZUB       !.)0%J"4J
MHI_5JUS06!I'R0 + V;;AU#FL<BUMV Y9XO0MH8UT136W)F<9*Y7NQKU?"+Q
M& =4T\-MYLM*Y&OVGCMS-@G$H"U,-]OFQ1W%7MS'#6FLI\?HT=]_Y4 ^I^/]
MW/\ "NG=#[$B5;G4=(_0_/\ OR7M\XWBK^56J<?Z!C^LF'5==;T+9IRC>D6E
MNP".&T84+?&*='P+:)J./"S89FC@].S?E"]O;^#U5:M<T%@:1\D
M7C/G_JN9ZB[.    '.C^G6+=,9U&            !> P'JFF;N7,EA3-5RQ^
M63#I\<YV]2OW?E^UOCO0<)%^59Y/V>>P/FVX<D\KW5@-:4/8RS#=41%TUQLA
M%^WKE*.+O_6\PKF:>I3;B%R.RGEB\*;>XLT32439_P#3_/\ ?*^SS[?0J29@
MXG2@VT!5&ITRC]NS%FC/\?ZJZ:WH3=&"2?>& 2N0BM9E2OW?E^?#.=NZWRCB
M1/W)7H             Z+?S%VEN?!9.
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MXKF78WZGBU/F4>             '1;^8NTMSX+)P
M                                           *.._\J0QWK6(
M          ^I^/\ <@5;3&.FSX6       +G6%M-TQ=TYDV@B7>^5^OYZZ2C
MB@                 7C/G_ *KF>HNS@   !SH_IUBW3&=1@
M 6?,F7Q6#UG0X                               Z+?S%VEN?!9.
M                                                           !
M1QW_ )4ACO6L0                                            +QG
MS_U7,]1=G    #G1_3K%NF,ZC
M          '1;^8NTMSX+)P
M                          *3>],MP<Z JH
M                      "]K\]-9RZTM8P    Y[7TJQO'U94.
M                                    Z1_RWVYLW$^Z
M                                                   !77TW2]/W
M;.;@                                           !Z7R?OTIOECN#
M+_$Z0    J7[*SO6EU51P
M     V\A4CZ-?S!VM_O_
M                         !XOW^7GC?2_&>H4VC@
M                          %GG)M[VL<>Z"     P7(>3SQ/IAC/ DCY
M                                           _I_*\)@+54T5%6>
M
M  !JI,(_2#WWE:/RR8>
M /U_G_5CW+UV6U<::)_;^?\ 0     TDGL6I/[SRYHA8D2
M                            &5>/T+>F*M'3PYXML
M                                                  #\?]_S%;<%
M?QZV5#?)>WS                                        #_7^?[F[@
M=26RF;%VYA<C       _-_?\QGVK!M+)W%_Q?I_(
M                    &?8YUY6J>L+(7,]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        UE-%
MR8(P01UDQ9#\3 @     @H)UP  ""@$ZX (*2=8        @-) 2)<G1-B 8
M/-*248  &EIND    1>FYQG0 $))-L""D] 3;    &@9Z(W:  /^&EYJL2/&
M7     04$ZX        -+3=(@I)U@        #YY"23C        TM-T@ ?D
M*[9O.8&)P0 #78R 9) !KB:BDI!!23K   TM-TB"DG6  !I:;I    TM-T@
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M:B? K!FTY+Z:'FEADTLYE8@W.-QB%PQV;I'D3%!9>*VQ^0LY@
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M3"9]@D?(SC=4W)(2C=0Q ;T$7)9=*T1Y$F?) @
M                                                       5VBQ*
M" XG4/N@            KXE@X          &O1 ^?6)_C*(!&R>G-_P
M  5\2P<                          1L&0#><
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M        _]H " $"  $% /\ P7ADJ>5S\TN[O. ;N\X!N[S@"7HC4M3,BF[?
M!?#=WG -W>< W=YP"/B(=M"IIS"55*)![N\X!N[S@&[O. ,<T,FD:O M6(F(
M<++=WG -W>< W=YP=$@VND*NE-N[S@&[O. ;N\X QR4<9&H-Z4ROU>WV[O.
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MWQ8F3Z/2M2^@S#MZ2WPY.:A1\+Z*F;8PHL SH(R56+AK>27EXQ6#A5+3=_\
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MX4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4 ^X4'>/N%
M/N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N%
M/N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N% /N%
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M9&^_FMV%4GU;T:G]43_X'LC??S6["J3ZMZ-3^J)_\#^Q]_?W=W<5J=-'>/\
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M:WO=OOQ>I2)\R?A-CY>=0D@?'A%0IA#/8K"$Q2\B$73M ].DN*G]4G=2F/\
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MD8,EF_Q<=.JI/JRB=)R$F2$S!+='(H)5>I-:Z74I$^9/PFQ\O.H2E_'LOY8
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M .G5U$I:*G85PE>M#*3^MI/&;[J4[JX21!X63?4I$^9/PFQ\O.M+_P!10?#
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M&]0-Z@;U WJ!O4#>H&]0-Z@;U WJ!O4#>H&]0-Z@;U WJ!O4#>H&]0-Z@;U
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M"KK'"7%.44H_[2$)1CGQNKCRC;E.U=95U]1H:>EAZ39+C'.=)PDOH)<]Z*3
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M*+50>C'?CO3HZT1'N'5M>ZSF17I0&2:M[ER=N#9-9[6925A+,H/:P+MC.O\
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MTV+ W38L#=-BP-TV+ W38L#=-BP-TV+ W38L#=-BP-TV+ W38L#=-BP-TV+
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M+U=J3C!Q8LGVE>#Q&_LRDRS>\7&^S?EG^$I+GHO5VI.,'%BR?:5X/$;_ /\
MA'8^/@4N \=VZ 3)F?'IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQ
MZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^
MQQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCT
MV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]C
MCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM
M]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''
MIM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[
M''IM]CCTV^QQZ;?8X]-OL<>FWV./3;[''IM]CCTV^QQZ;?8X]-OL<>FWV./3
M;["/OA6[E6:-VYS<NXF>V94JA/(E-7(KK+JS*5/RY&:5KY1&<*!LUD'.9C.V
M7,)2',V[CI\O60Y"&3+3B[9<R#BXO>]'R]!7%Q<&;7;+F0/.WY>@UZV.V7,@
M>=OR]!KUL=LN9 \[>IVND:D' GM-QPK6D"3;BB63PCF9LBW(L6X%;9>&!:I%
MUR,4:VZMK=&7]85C'F1L]DVG4=-*!UO5Y)YKI3QNLJVV<#"N.V.5D%[:.@3-
MYMGC9UQV"<FQRV+:NU-*8<A[3,)G:I[H%DS&QT_"NSQ<C3LT81O-!US8V%16
M>R+OWQWC^SL=.BQS&B.+M0M6M/@4BR%A)^8@,Y@7+EM'=PYE=-E?W,<QAZN^
MBPD_,0&<P+ERVCNX<RLPQZ&^BU$X$=FSFC?H>^(+Q*ZT)"ELIL/Y(I%D3;2"
M8(V;8@?*\M)J!3H0KZW!KUL=LN9 \[>IVB_<:S)>O(*C4T(C2&SDINZ];B7J
M,.FX75XWVK.C+::C3V3YLK+B#]*9-6@K9RB41\KCT0BEXOH7/U?>C.DWHB]E
M^/7AF!_7@&Y<5;-(N7$)4E=MM<Q7]3^8V],'1E^/0>O=>1;:MS\0H]DTRV[H
M_P!+&QJ\K$&:-RVBR,$[.BT9(6$R?LK^YC=\A5(":D\J7+8JO33DQX/OK!]>
MVVK<_$*/9-,MNZ/]?:0"U=*)K29<AX%*F9NV=)&PW2\18^[U,C9LVT<2'T@;
M7ML&OM_8[QY>G:T[W+4"XQ:3W 6A:!FG1?U?-CEPG=/"60>7RDPVA(:E1H1&
MCDV;G"3406HRXSJJ1(S-L@R%BTA^J0:];'9:HS72(D]S3Z^'-/KX<T^OAS3Z
M^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/
MKX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T
M^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS
M3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^'-/KX<T^OAS3Z^$
MY;CYU<B4/4[1?N-9DO7GHRV5=68B0NA45"7W I4-&PKX0YX7=D\<+NR>+;4:
M(:QO(JHN+C2^UF0:RKT&8Z:C_!46-,OQZ\,P/Z\.C+Y5U95P40E%0EMP6XW'
MN)\BVPX7=D\<+NR>+?C(1K8!AU[KR,MIKS<S]?EW*5SG1 B.K7/<A>J^ULXQ
M_/*VO9?P,6EN<WY)QOZRZL;IY74:9P[KE(428M&Y;37FYGZ_+M\JW B'$=4N
M4X:X6%DR5*JF#'*#[4:3%WG,QYZ@<MIJ-,?U=H+7G,8>D2SDTZ$B7;\D]+A\
MY;N!:EGVZT:Y%9AF,"<1+@F3_*J+MFQWGR>!_558+D>OWY8N3;>4#22/ZG!K
MUL=EKA:@V"F2:)_9S<,&W>.&#;O'#!MWCA@V[QPP;=XX8-N\<,&W>.&#;O'#
M!MWCA@V[QPP;=XX8-N\<,&W>.&#;O'#!MWCA@V[QPP;=XX8-N\<,&W>.&#;O
M'#!MWCA@V[QPP;=XX8-N\<,&W>.&#;O'#!MWCA@V[QPP;=XX8-N\<,&W>.&#
M;O'#!MWCA@V[QPP;=XX8-N\<,&W>.&#;O'#!MWCA@V[QPP;=XX8-N\<,&W>.
M&#;O'#!MWCA@V[QPP;=XX8-N\<,&W>.&#;O'#!MWCA@V[QPP;=XX8-N\7VH[
ML7'5UNIVB_<:S)>O/19(9GNC'!F0[K5+YOQ>-]JSHRVFHTO7",6CNBW>VJHY
MG6\.AIFO6+UN7=C7J1B+;)R_'KPS _KP&CHZ6GI0\(,"VS:OC085IO*_,;>F
M#HR_'H/7NO(RVFO-S/U^9ACT-C+K>B>SM[IV8P]78E3[ 66TUYN9^OS,,>AL
M9;-,F']MJ%$6JG,$YCSU Y;34:8_J[06O.8P](C9X6FYE@\,.2F2C?',;')?
M@1DE3[ 0RU G_P"N3J<&O6QV6N%J#EK?<0_=LR!YV]3M%^XU=OML/G/92<NM
M-@,-8]CW&'$NNW=25_4Z+QOM6=&6TU&N,^O"T_=MP(KT#[V6XPS![B/+GR[J
M#-K61MZ64DW/*<#B3K>C+\>O"Z):3D=-F2U/EU)HZ6/'NU7#RW7C75+IYC-D
MVBOZG\QMZ8.C+\>@]>Z\C+::\W,_7YF&/0V,NMZ)[.WNG9C#U=B5/L!9;37F
MYGZ_+GB%C6\[.8&7*E%I*ES'0C99,AI:<,:XWN59CSU Y=)]$6E%\]E@1S7:
MEFMVKJ&/DWF,/2)92N1MXQY9)#+W*!6+6%%I1O+?RCNKSRIISO[*GV AEJ!/
M_P!<G4X->MCLM<+4'+6^XA^[9D#SMZFD5DKV_4>_+-@;\LV LW!7KC&O0LI.
MR4<5*]#;/T^;,X"C4BB6)\$BN5LWYL;S,F"H"VMK:TSK0WSG.4TI]ORS8&_+
M-@'ZD42K,05&IH1&CCR(D \17T-])>1S2D-148]7CAMGK>5F<=3*A3+4_<.2
M<BW=(PW4CY#L^2(Y>KINU4XSM.J\)N#62<BSUOVV>MY69QU,J%,M3]R7\?5Y
M:9+RLE$ATX9&9D<UZ162O;]1N.\+N/&84=95E]6HY42>6*;IZC'I,=QI%R#>
M$H#?R+D&TQ>X#L.F[)D#62<BSUOPVCYO8RX4"@/U8>=3@UZV.RUPM0<M;[B'
M[MF0/.WY>@UZV.RUPM0<M;[B'[MF0/.WY>@UZV.RUPM0<M;[B'[MF1TP98"_
M^7K>B;,E7.GLM<+4'+6^XA^[78X?&<Q(EU=)54%5\NY?B&QR;KOLM<+4'+6^
MXA^[W'++2*E&<O!;_F:Q1GI(5;Z.EX&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#
M+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU
M'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X
M&6H\#+4>!EJ/ RU'@9:CP,M1X&6HJ$>K:3!H$ZH#0>!EJ/ RU'@9:CP,M1X&
M6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ
M/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU'@9:CP
M,M1X&6H\#+4>!EJ/ RU'@9:CP,M1X&6H\#+4>!EJ/ RU"&C7(=S:R$U@MT%B
M<HY')9ODMV6N%J#EK?<0^9;NOMK95/M=<+4'+6^XA\RW=?;6RJ?:ZX6H.6M]
MQ#YENZ^VME4^UUPM0<M;[B'S+=U]M;*I]KKA:@Y:WW$/F6[K[:V53[77"U!R
MUON(?,F8!WV(JORKYJS(<%--5(-^V($47YN4RTD.EB#!2:8[6G"U!RUON(?,
MEPJ(Y+-R):A(#I*'XRU<*/!#7]K;A:@Y:WW$/F7,:P?PF5D'#6,"OF/)5MF]
M232M]VMN%J#EK?<0^99[1/3\UHIY=NW^HF!0?:XX6H.6M]Q#JKAN4WS2)1T+
M^,$$"8<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%T<QK%
MT<QK%T<QK%T<QK%T)?,10W-JZ.\RXQRMH.PQPM0<M;[B'5)J3';*$;+2IEZ^
M4QG%[($LJE,AU#:.NM8TL,#L+<+4'+6^XAU2]Q)@U?6:?9$VCB*QHW"8UU29
M\V:["G"U!RUON(=4D2:UI[('LCLT&58:VU>PIPM0<M;[B'5'R\Z^R.RO[9W8
M4X6H.6M]Q#JCY>=?9'97]L[L*<+4'+6^XAU1\O.O]CP\/$Q<1QHZ2#9XH^%0
M,L\9HWWPJAG'>I&]^*O8V2+:I.MJR#T//B*--J)''W2C42LG%4KCM"[#.FG4
M6]:MSW<.:^@KBJN_22DARI#9?-LXC5*#H;EI75>$W62)63=*6H9QWJ1O>JMS
M'20;PE%13X])CL/;;DL_["]<LK^V=V%.%J#EK?<0ZH^7G7UF*_J?N-SUX?[8
M4N9 2A_B&<3[<EW1A7';]3M0X'Z2'\[F,/2)^N%36E#URWO9,2T,>9;AA+QT
M%T% GX2OO(P8-8!?%OT^WGEKOSMQGUX=-G'W)LQMZG^HV5+@D88A$%Q^1K;R
MLEW^FUY)MK8E2[O5SWC5,2NZ,N?ZN[QWN3*^\C!@U@%U7+G^D1L% R25E)&*
M<JQFFS/7+*_MG=A3A:@Y:WW$.J/EYU]9BOZG\QMZ8!EN$BL*>GN=*1.*R?<
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M"C@+W!1P%[@HX"]P4<!>X*. O<%' 7N"C@+W!1P%[@HX"]P4<!>X*. O<%'
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MQ"++8JVH(+5=NZ0,$YLWCO<FD19_V"0=%MVUKQ!THZB(V9N?#6T'*B8B:/\
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MERHNCERHNCERHNCERHNCERHNCERHNCERHNCERHNCERHNCERHNCERHNAM+#<
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M_>Q&.;,18Z84\3K%9C/T214]+V8A]#!_[,N7P]!=Z'W!QEI/P5LGWIKGS%2
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MJ>45VRJI7MJUJ2!JFB="+Q=/Z67-J4M;EI)(A#*2I#F2)))$V BJ(QV[L?\
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MQI1))J238P$DD[22=I)W_P A/I)/TYU2ZU.6TN+-83,03&)$N"X6@'=%%K[
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M."I.XTJ-A'4\KL<IUNZ?DH,PJ%-"7E(W$1BE =A=DJ"N88'3+IQ?W*P71)0
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M)\I2(!LKA6H:&AI0T/6Q)H>N1<K92;138R.*Y9(VVY76IH=Q!*L"I92^J_\
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M95Y%K1&&P]NUPS3,G75"5;:"K4H'#NMQKMS3EI0** -T40.T1J222:,[=LP
M"JMK::-:W-W=+JD;E(8GE<((+D%BL:L0H+*"Q%*L!6I&+"QU2":VO4>XS1RH
MT;KFN)6%4<!A4$$5&T$$;#U)KO6=-O[2U.FRJ'FMY8D+&6 A0SHHS$ D"M2
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M%"YI.[ELI"[5H!7;O&,\/=_X<(^TT&5C]I23C59"!R@M(P#PT,A)_G4>T/X
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M.M^]EZL/1_2/PQLU6V4+MS7$CU=1V02D9' RMBQT-*'R2UBB)'"R( S;AW3
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ME)C1214 T)I4 ]7RS6--L+N[RA<\UO#*^45(7,Z,U!4T%:"IZ^ B ! * #8
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M&SC7*B1J$15&X*J@*H'6  P[Z)865F\@ <P011%@*T#&-5S 5- :TJ<&^O\
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M[223]BZ+\8ONC"^F1][)_&;3O2![AQI7^\_^G^R[%^,7W1A?3(^]D_C-IWI
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MZPT[VYO%8]8:=[<WBL>L-.]N;Q6/6&G>W-XK!>UNM-F8#N<\J,>P,T.7VV7
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M0*D4J0.$?4UT:6\M%UAP"L!FC$Q!V@B(MG((!((7;]3.BI>6IU@+4P"6,S
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M%8,HZBVLZM=ZZZYEMXV"T7@:5R&Y-3]SVKNV\(5JP-_HG1Z.72CN9;2]F&P
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MNAR$A2%DC>@EB>E<KJ"1M&U64E6VT)(8"76M:F6'3X15F.TDG8%4#:S,=BJ
M23A[/H!HC7"J=G*)-<2LNWMFAMRN2HX.4<"A-37M4M^GNA&"-R>XCFMI O:[
M5CN"XD(KM&= <R[13MHM;T.836,O#N96'=(ZG:KKP@]@BJD$V/T6GS\^(/Q*
M=Z,=#/I?^NL_KW5?]V_0[?[!<7XQ?=&%],C[V3ZUL?0X?FU^NM4^CKGYE\7%
MWT+T_P#>-_);9)$Y">?+'G5LV6!D8=L ,Q)7;2E2,?N_4;&UTR^9:C-:SQR@
M&H#!;F5UI7:"4(J.M48BZ;_\QKU+R&=4F6)).5,P(#())5_!K$!0<G"64KVH
M95&V_P!:@4<I:6DC1B@IG"TC%-V7.5![&+OI1T^NP-54J;?E(IYR9'9FEG)C
MBD D!"A68UJ[L-H!'K7\VO/U?%ETQ_Y>SJT.>*68)%+$!,)")>UDCCV314SY
M0027)-6Q8=&;=BJ7<CS2T-*I#E$:GKJ78O3[Z-3P8M+I(U_>U_ D\TE!F(D&
M>-*[PL:,HRUIFS-2K'%QI>JQ)-8RQ,&5A4;MA'"&4[584*D @@C%]]%O\_!C
M1OQ-QWT6-'^B[3YB/&L^@O\ ]&-9_'6_>RX:QOV8Z7Y9)'2M*6MH'.4<*\J$
M-:;0\I._;A+.RC2*TB4*B( JJHV *HH !P 8BU.YMK>34H 1%*T:-+&&J&$<
MA!9 02#E(K4UQ>?CK?YY,3_2DWS-OU(_IJR]R#'D%HQ6?4;@0,1L/)!6>45_
MI95C(X5=AA.D\D:G6-09SG(!9(4=D5%/W(8J9&IW55S=RH#03JKP.I5E8 JR
MD4*L#L((V$'81L.$;2:II8N(G"5-/)KBG*Q&O M75*YJ948U(Q:?2\7Z/=8@
MZ10P)^^KQYA)*=KY8YGC5%)[A**"0M,S;6K1:7.BWZ*]K<PLC!A4;1VK=@JU
M&4C:K ,"" <7VG GR>?3BY'].*6((?M++(/M^SU6^FI_<DQ:?2\7Z/=8@Z10
MP)^^KQYA)*=KY8YGC5%)[A**"0M,S;6K1:7.BWZ*]K<PLC!A4;1VK=@JU&4C
M:K ,"" <7VG GR>?3BY'].*6((?M++(/M^SU)+J;9%&C,WL*"3_,,7&L](UY
M:V3E+N1&VJQ#JD,)'"BYE[6E"D>0BAI@(@ 0"@ V  ;@!UL'6%MK<:N8^3,_
M)IRQ38<AEIG*5 [7-38-F%TK7)V@Z-6$T5NS ,V2,Y'N9 B!B7)+ 44DA(P=
M@V1:;IFH)!80H%1$M;L*H'6'D_"=I)VDDDDDDXDBT^]27I);E7MCY/<HU<ZB
M2/.\"@*\>;8S!<P4[P,0QW+%FL[B6W4G?D7+(@]A5D"#K*H'!B;T&X^<BQHG
MO[OW+?&F_1"?-8OOHM_GX.I%Z/:]\V-6]Y#^DPXU#Z1_J8L'I;)8P-TB(4<L
M02:J**P4DH)   ) HDH ,U ,4.T' L=)')6?[S>,(NQ0DZ$E -V5<_:C@RK3
M:!BT^EXOT>ZQ_C?4XHY]1GD=+?. PACB)C9E!W2,X9<U*JB@*0'8'ELJ\MER
MYJ#-EK6E=]*[:;J]35?]V_3+?%YTIGA636([LP1NP!Y-!'&Y,8/<NY<AF[K*
M H(!;,T,RJ\3J0RD @@BA!!V$$;"#L(PEOIOX/3TU&(!0306]V$+)V0B2D*#
M7:BG:17#:I;KFU'2V,RT&TPF@G7V H64_BJ<.'Z.W+UOM,DHH)VF"4ED/9RO
MG397*H0&E1A- MVI?:G)E--X@C*M(>QF8HG95GZQQ;O<+EU*_/E,E=X#@<DG
M7[6(*2#N=GQ?='%<QI=:[>*[#>(UGEDD(X"P1&*@["P&$T?2+:*#3D3+D510
MBE"7X79MN9FJS$DL23C140 ();@ #8  D- !UL:-Z"G_ $XN-+U:)9M/DUR_
M+HW<MR;W$BAAPKF09E.QA52""1@1Q@+&H   H !L  &P #8 ,7'1JU_!:?=Z
MC:JRKL %T()7  H*!Y"0-PH*4H,1V-C&D5G$@1$445544  &X 8AU?2PL=S/
M;0W1H*?ADED3/0<)Y)&)WELQ.TU.JR;LUO&?;FB.-3].7YI<'3[QF;3#>O$!
M7=:V@<LJG[GE!&[;-SR$[\1V5E&D5I$@5$0!550* *!L  Q8:X(D&JB]$/*
M48Q-%*^1C]T R K6N7MJ4S&ND^\F_29L-]-3^Y)BT^EXOT>ZQ!TBA@3]]7CS
M"24[7RQS/&J*3W"44$A:9FVM6BTN=%OT5[6YA9&#"HVCM6[!5J,I&U6 8$$
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MBVUNY4Z5T8@DJR/$T<+QG>HC<B:X9UV!RPC1NV4HU%+:?:E4UBW?E;=FV*7
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M<BI"O12&H<K*#2A8%>C?2S2I)].MSEBY0M$54YJ)'<*DL4L=0<E ] K(K90
MC]'.AVD206MP"DK1%IW*D#,AF*110HP89RP!H0,X!(:2?4&63I%>!>6*FJQH
MM2L2'AH22["@9J 55%)L?HM/GY\0?B4[T?7VJ_[M^AV_V"XOQB^Z,+Z9'WLG
MUK8^AP_-K_%C5?\ =OTRWQ??2C_,0?P+'_E[H[5CMY5C--J^4392['<"(8Z
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MF+Z3R'R+R-HAX;EL_*B0_P#=19<O)_TJUX*;9-6UN=+;3H^Z=J[SN  !9F/
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M8'A!!!PXT2RM+,2TS\A#'%GRURYN35<V6II6M*FF\]03:QIUC=S#<TT$4IW
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M6 *D4(.XC'ECZ1I9N\P;.;6 OF&T-FY/-44V&M<+%$JK$H      W  ; !P
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M;ZQJ-C:3D5"S3Q1,1LV@.ZDC:.#A&$N[.1);610R.C!D93M#*RDA@1M!!(.
MVLWMI:*:4,TT<5:UI3.RUK0T]@];!_<U]9W>6M>1FCEI2E:Y&:E*BOLCKCJ6
M/T6GS\^!'J@B.FM: 2B2G)\GR?;Y\W:Y,M<U=E*UQ<-T!.G/=N 93!<"YD"D
M[ 2996CC+"N0%4) -*@4U2:V)65XXXJC9VLTT<;[NNC,/M[=F+KI-+"DFL&]
M:%78 F....)P$K7*69R6(H310>Y'4-WJ,\-O:K6KR.J(* DU9B * $G;N!.X
M8\ETK4]/NKG[R*XAD;X*.3_-U(],U&^L[?4I@ICBDFC25P[%%R1LP9LS JM
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MO)</](S=Y%C3_H[^NEQI?T=;?,I_!3I9JB2-/E'*P@@13L@ 1Y!3-L496"L
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MF.011J7?*ZD,*L8@<I%02":$@VVHZ_=75U?WDDDP:>625UC)R1J&D9B%*H)
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MEFF$E&84;+D8A:58,2JOTAZ"WUVUY:*9.3D*\J5459H9HEBHZ@$A,E6&Q6#
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MP:;!52I&PC"Z59L6TWRA;:-AN6W@),T@]FDLBG97,H-,1VELH2VB1411N55
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MH-=U!P#]]&URZ-[*NJL.L0.I%97)/DZP6L8]X[%FI]MV^W@1Q@"-0  -P V
M#L#%#NP;*U&6V,E]%0;@B+*RC9P HO8V8L?HM/GY\7OT1-^CMC5O1H>_;&H^
M_MOTF+%W]+R_H]KC2X!7D6O78];,L1"_;H[4^WBPDZ+:SI=MH#PYH8GC0NBL
MS,0Q-A(2Q<L3^$;:=^/\P:1S:?W;A>F_2>\T^=F,[3<B9,\CRQLM<GD\,8&9
MLQI3=L%3BT^B(OTBZQ!:VRA+>*%$11L"JJ@*H[   &#)(0L:@DDF@ &TDD[
M -I)QY!IAN-4OBP4"V0&,L30*)&*AZ\!B$@)H >MJ%@O174X-'N+=T\J?E<B
M+N+L/)<E 001RU/Z6-6'!Y5#WC8T;\3<=]%C1_HNT^8CQ/\ B7[TXOOHM_GX
M,"._[9/WS"M#PK"(P@]@A%%.$=?J7UK.H:"2SF5@=Q#1L"/:.-0MAX%].S'V
M4FC"_P SMA/I32_FK/J69X?WO%^CW6-.!W![G])F^O=:^D9^_/V HO3)^^'U
MDGTC#WDN'^D9N\BQI_T=_72XTOZ.MOF4_A6/THGS$^-*_P!Y_3+CJ7.O:D:6
M=K$7;KD[E0?TG8A%_I,,7/3;7ESVEK-Y0U>Y:=B>0B'76(+F X!&BL*-U9;?
M2[RUN;B$TD6*6.1HS6E'5&)4U!%& VBG5_\ R+^NQJGT=<_,OC4/H[^NBZJ?
M2,/>2XT[W]S^DRX*L 5(H0=Q&(.FO0_-%H[S9HR-JP2FN:!QPPR#,$!V%"T9
M[FK6?2 1F(W=RSE*URMY,X8 \(# Y3L)%"0#L_@/:SJ&@D1E8'<58$$?;!IC
M7[+67I;6UK.I4FADFMI@L2+P9I,SA>#MJ[L7W_-+716YN995@J#0O(Q,\JU/
M<K7D4WBG*+]R,/>7TL<-G&N9WD8(BJ-Y9F(50.N2!@7NEW$-S9L2!)$ZR(2-
M]&0E33AH>K>Z.BYKX)RL'7Y:*K(![_;&3UG.-?T3.5NS")+7KK+*R6\I%>%0
MT<H'!R;&AJ1B\Z9W2;6_\M 3UA1YF'LGDT##K2+U^IHWXZX[V+&D?B9/GI>K
M'T]TE66SN63E64>"N8Z!'/ HD55(/_>*U35UJDJ.B:_$@%Q!4!@PH#(B[S$Y
MVJ17+7(QS#;C46<@*+&>I.P#\$^-6]&A[]L:?]'?UTN-+^CK;YE/K67T.#O3
M]3T7Z-@^;'UW+JEUF\EMKW3Y7RBK98X+5VH*BIH#05%3PX74=$N8;FS< AD8
M&E>!AW2-L(*L P(((!!&/\%:-/'<7=Q(CW!C8,D<<;!U0LI(Y1Y K90255#F
M S+B'RU2E_?2&Y=2*%0ZJL:FNT'DT5B"!E9F!V@XF^FM3]R[ZEGTTM%)MC&+
M>8K7M'5F>)R1NSAB@.P HHWL*P313Q#75C59X"P$BR =LRJ=K1M0NK+49=A(
M96 FO;Z:(ZER9Y&#,#)+)3M1D';!*T+N1E4<-2H-WTXOE;R6)'C1R*"2>4@R
M$=<(E0U-E9%H=A&+'Z+3Y^?%[]$3?H[8U;T:'OVQJ/O[;])BQ=_2\OZ/:XD-
M@I?4K&07"*!4NJJRR(!M))1BP VLR*HWX7H5KD\=O>6[N;=I&"I)&[%S'F;8
M)$=F(!(S*RA <IP;W49X;>S&]Y'5$W$]TQ W G?N!.+C0]"N3+>0+FJ5*K*H
M-&,):A<(:9NU%00RYEJPM/HB+](NL1^\7W!A8K!F6"YOHXIBNRL125\II]RS
MH@/ 1VIV-3$-SI0@/2)C(+MNU,X82-E5ONA'DR% .T-:]V6Q?]'/*5FUV[@>
M)88B)'4\+2A32-5 ).8AC0Y5-#35O28>\;&C3T/)&.Y6O9!A-/:/N];&F:O/
M=P1Z;#IMNKR,ZA4>.%5=&).QU92I7NJB@!V8EFA97A>W9E92"K*4)!!&P@C:
M"-A&+[Z+?Y^#%OTYL4_\K<2PSHVW*+BWR!XV/!G"*_\ 2#M2N4TCU'1+B.0L
M@+Q9ARL3;,R2)W0*DTK3*VPJ2I!-WIL,\;](KJ%XHX58,Z<H"C2N!7(J*25S
M4SN H!HU+SI9>HR"\RQ05%,T2$EY!UU9\JJ=G@V.T$'"?2FE_-6?4M/I>+]'
MNL:=[^Y_29?KW6OI&?OS]@*+TR?OA]9+I/1V#RC4!>Q29,\<?:*L@)S2NB["
MPV5KMV#?AM)Z10>3Z@;V63)GCD[1EC .:)W7:5.RM=FT;L6=]T:L_*;6*RY-
MFY:".C\J[4I+*A.P@U (V[ZXBL;1<EK#&L:+72#E1%"J*L230 "I))X23C_]
M#XC_ ,??YCY63-X#N,W:>;?@NYZVWK[>K8__ *LO"9I?*/--U(^2\[V;^4[C
M_6^YPFG=)+?RFSCE$BKRFF1T<*RAJQ.C'M684)(VUI4#$6B:)%R&EP9LB9M*
M?+G=I&[:1G<U=V.UC2M!0  6O^-_\T?A>6\#_P!])R?F_P""\%R?<?ZW;9L6
MO1[HI9&;2L_*SR<M!&&<=K''EDE1R$[9V[4J24IM4XM]$.5K\UDN'7<TSTS4
M-!54 6-3055 2*D]2\TRVDY&XN+66)7^\:2-D5_]4D'[6(M'U)!'/!:SO,$=
M)%,+1E8R2A- TAB95?*X[4LHJ!U?\5^0_P#R#]]<ORO+6_@N4S9\G*\INVY<
MF;L5Q?V-HN>ZFLIXT6H&9WB95%6( J2!4D <) Q>7W26S\FM9;+DU;EH)*OR
MJ-2D4KD; 34@#9OKU5TGH[!Y1J O8I,F>./M%60$YI71=A8;*UV[!OQ9Z+KL
M/(:G$TY=,R/3//(Z]M&SH:JP.QC2M#0U'4GT75HQ)I]Q&4=>&AW,IX&4T96&
MU6 (VC%KJ A$_1BVN)"+D2P@F-HY%0M$7$H?ME5@J$9JD$KM_@S:6A,<5[<V
M@8@5*F=(5=A7>:DMMX3UL0:1IJ".QMXEC11P*HIMZY.]CO)))VG#:5H)!OX[
MB.;DRP03! X,>9J*#5@ZYBJYD%6&_&LI=5%HMY'&H!#*)HU<3964E6V&($J2
M" "#2G\"]ONBEBL^B7,O+*1-!'D:3MI$RR2HP"R%LM%RY2H&Z@LNCUO3+;0*
MK$?=2'MI'_UY"S?;ZFF1=&;7RF2WEF,@Y2&/*'6,+X62,&I4]S6E-M-F(=&T
M>+D=-@4A$S:4^4%BQ[9V9SM).UCOZV/_ -#X'_ZP?\O<@]?5_A-F3S;\+U_Z
M/7X,26&H1)-93(5=' 964[P0=A_^"-N/WO\ \O-0:SN%;,D<KR*8S_X5S'FD
M&PD*&4MP-)M)'DEI,9X10YS)ITE=@^ZN/PNRFVHI6I%:DD1]+[]8;,MF9)9U
M*"C;Q!:AH2VW,G<@ 4S+L&)I+:>6ZU.Y55ED8!%HM2 D8)RBI)[9G;^E39BS
MONC5GY3:Q67)LW+01T?E7:E)94)V$&H!&W?7%A8W:Y+J&R@C=:@Y72)5854D
M&A!%02#P$CZUE]#@[T_4]%^C8/FQ]=^2W*+);R:CIJNK %65H;0,K ["""00
M=A&&N= OYK"!V),31"X1:\$9Y2)U4< =I#_2ZT>IZG+)J6H1,&3.HCA5@:AN
M2!<L1P!Y'4';EK0C#_\ ,']Y\IGO;FX\G\GRT\HY7M.5Y<]QRO=<GVV7N5KL
MQ)8:A$DUE,A5T<!E93O!!V'_ ."-N&GT"^N+!&:O)N@N$7?4)5XI -U,\CD4
M.TU&43:]J%Q?1JU<D<8MU8;-CG/*Y&^N1T.T4(H:Q:;ID206$*Y4C0451V!U
MR:DD[222222<0:Q^\O(N1M1#D\GY:M))'S9N7BIW=*93NK7;03:)RF7EK-X,
M^6M,\9CS9:BM*URYA7=4;\7=W^\/+?*HD2G(<CER,6K7EI<U:TI04ZYQ<=&O
M*/)?*&C/*<GRF7DY4D[C/'6N6G="E:[:4Q-HGE?EG*WCSY^2Y&F:.*/+EY26
MM.2KFS"N:E-E3A]2LFDTW4I"2YA"M$[&O;M"U &K0GDVC#;<P+',,VH:S++;
MT[F.V6)JU'W333#=4=QO(-=E"UOH$!6:0 23.<\TE-V9Z  ?T$5$KMRU).(=
M;_>7D?)6:09/)^6KEDEDS9N7BI7E:9<IIEK7;0+'ORJ![0IB;1-9B$NGSK1E
MW'8:JRD;596 96&T$#!>PUF:*RKL22W65P*[C(LT2DTV5Y,;=M. 3I;K)<:C
M<0/$\\N4NJ2*5<1*%"1@@D$@%B-C,1LQ>6@O?+1=2H]>1Y+)D4K3PLF:M=_:
M^Q@Z/K =<KYXY$H)(G (S*2"""#1E(HPZQ"L,][K,TEE7N$MUC>E=W*-+*M:
M;*\EOVTX,1]'=.+BQAM^20NQD8+0@5+&II78-B@450J@ 3ZQ^\O+>6M3#D\G
MY&E9(WS9N7EKW%*91OK790R:1K<"7&GRCMD;KC<RD496'W+*0P.XC!DT75;B
MUMRQ.26%9Z TH RR0&@-:9@QI0$D@LR76O7,^I2(:Y,H@A)J2,R*SNPI39RH
M4T.8$&@2WMT5($4*JJ JJJB@50*      4 V# Z?_O/DJ75K-R'D^;S985R\
MKRZ]WR5:\GVN;<U-N(=$\K\CY*\2?/R7+5RQRQY<O*14KRM<V8TRTIMJ+?HU
MY1Y5Y.TAY3D^3S<I*\G<9Y*4S4[HUI796GU[K7TC/WY^P%%Z9/WP_P! OY)D
M\JR-DSUR9Z'+FIMRUIFIMI6FW%WTAZ2RI<=,M4DSW#KW$:CN((B=N1!2M*+L
M50"L:D_6%OZ7IW]3U)M/Z)2PP:M.5CY20L.3B<Y970J"1(JDE3390E>WRXM^
MCVFU:&%3F<@!I)&-7D:G"QW"IRJ%4$A1_H:7T.#O3]3T7Z-@^;'UVO2RPLN4
MZ/B_L).5Y:W7M(4MA*V1I1)VIC<4R5-.U!J*_P 0-:^D9^_/V HO3)^^'\7)
M?0X.]/U/1?HV#YL?Q<UKZ1G[\_8">W7PD&H3*?\ 66.0'_KT^T?XN7D<=/P$
M,$9/9Y)7/M9Z'L@_4](F2G:6O)&G 86:(UW[>TKV:UW'^+FK7T.V&74;@J>N
MO*L%/VUH3V?L!7?1>Y8!+^(215_[V$,64=EXF9CV(J;]_P#%J;4;UQ'9P1-)
M(QW*B*69C[ !.+S79P1)=W,DM/O0[$JOL*M%'8'U.]Z(7##RB"3RB$'>8WHD
MH'81PK'AK+UAL_BU>ZXS 7*0E80?NII.UB &\T8AFIN56.P"N*G:3]@*#5M.
M<QWUM*LB,.!D((V;B-E"#L(J#L.(M:L:+/W$\5:F*4#ME/74]TC?=(031LRC
M^+)Z :.]9W*M>.IV*HHR05^^8Y7DI2BA4-<SA?J=MT@TP_\ F;>2N4]RZ'8\
M;?T74E3PBM10@'$.NZ,^:UE%&4TS1N ,T<@&YUKM&X@AE)5E)_BP68@*!4D\
M&%TC1WS=&[%CE8'9/-N:7K%%%4B[!=P:24'V QJVBN*$998FJ8YD^]< C:-Z
ML*,IW&A(*BPE$&LY:O:R,!(I&\IN$J#[]!L%,ZH3E_BNTLS*D2@DL2  !M))
M.P #>3B30^@DBSZ@P*O=C;%%P?@."63A$G@UV%>4)[5IYV9YG8LS,269B:DD
MG:23M).TG:?JOEFEMREC(1RUNY/)RJ/8[B0#N) "5.PAD+(R_NN<1ZI3M[:4
MA9E--N45I(H^_CJ*4S!3VH_BLVI:[<Q6MDOW3M2IWT5=K.W65 S'@!Q)H/1@
M26O1UMDCGM9K@<*FA_!Q'[P$LX[L@$QC[ JS0LR2J00P)!!&X@C:". C"P-=
M)?6J[ENEY0T_&@I,?]:1J=;?@>6Z-#(U-N2X:,?:#12T]LX]0_GO[)CU#^>_
MLF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_G
MO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/
MY[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU
M#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8
M]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_L
MF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO
M[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y
M[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#
M^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]
M0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF/4/Y[^R8]0_GO[)CU#^>_LF
M/4/Y[^R8]0_GO[)C9H6WTW]DP4TO3[*W8CNG:28CLBAB%?9!'8."NO7TTMM6
MO)+2.$=;\'&%0D4V%@S=FI/U@)(F*R*:@@T((W$$;0<+#'?FYMEW+<J)OE&I
M+3_:8 EL=,9^N%G4>T9F]W'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>
MK].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J
M;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5
M^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-
MXW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_
M3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\
M;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?I
MWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-
MQZOT[VIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[
MVIO&X]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X
M]7Z=[4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[
M4WC<>K].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>
MK].]J;QN/5^G>U-XW'J_3O:F\;CU?IWM3>-QZOT[VIO&X]7Z=[4WC<>K].]J
M;QN#';26ED#PP0U:GLS--3V10]8C!OM9N9[J[/W<KLYIUAF)H.L!0#@'_P"\
M1?\ _]H " $# @8_ /\ ]B\:?:=+NA-M<R:E',\1L]/LI HA,8;E.6GMR"3(
MN7*&K0U(V5_R!=?V7I?Z_C_(%U_9>E_K^/\ (%U_9>E_K^-0U#0X3;Z)/?3R
M6\154,4#RNT495"RJ4C*KE5F44H"0 <:Q_\ KBT"77?*_)/),EK:W/(<EY3Y
M17RFX@R<IRD%,F;-R9S9<JU_R!=?V7I?Z_C_ "!=?V7I?Z_C_(%U_9>E_K^+
M+4/^46BR:)HL-CR<T3V]O;&2?E9&Y0+;33JPY-D7,S!NUI2@!.F:UTVLVU#H
MI;7(>YMUCCE,L8!!01RO'&^T@T=U&S?C_(%U_9>E_K^/\@77]EZ7^OX_R!=?
MV7I?Z_B31?\ E?T4GTCI6US"ZW#6-C;@1H29$Y2"[FD&84%,E#PD=32=)Z3=
M"+B[Z1VNF6L-W.--TV037,<")/*'>]1W$DJLX=T5VK5E4D@?Y NO[+TO]?Q_
MD"Z_LO2_U_'^0+K^R]+_ %_J7NG_ /-WHU-K>MS7W*0RI9V=R(X.2C7DRUS<
MP,IY17;*JE>VK6I('^0+K^R]+_7\?Y NO[+TO]?Q_D"Z_LO2_P!?Q)K7_*_2
MWTCHHUM"BV[0PP$2H")'Y."6:,9C0U#U/"!BUUS_ )EZ:^K=$8HIQ+;+##.7
M9XG6(\G/)%&<DA5JEP12HJ0!C_(%U_9>E_K^/\@77]EZ7^OX_P @77]EZ7^O
MXMM)_P"4G1B;1>D<>IQS23O965N'ME@N$>+/;W4SDM+)"^0H$.0DL"J@XBBN
M>@5R]RL2AV_=>F',P4!C4WX)J:FI )X<?Y NO[+TO]?Q_D"Z_LO2_P!?QJ&G
MZ'T&N;?6I[&>.WE.FZ:@BG>)UBD+)?,RA)"K9E5F%*@$@#J/H_\ S5Z+3:ST
MG-]+(+A+*RN (&2(1Q\I<74,E597.7)E&:H))-/\@77]EZ7^OX_R!=?V7I?Z
M_C_(%U_9>E_K^-2USH#8MIO1&XE0VULT<<)B411JP,<+R1K617:BNP.:IH20
M+G5O^;>CR:UT<DTR2&.!+>WN"ERT]NZ2Y+B:% %BCF3.'+C. %(9B/\ (%U_
M9>E_K^/\@77]EZ7^OX_R!=?V7I?Z_C2XO^3_ $>ET.YMI9S=,]I:6W+*ZQ"(
M VUQ.7R%7-'"@9ME:FEI=ZG&9=-BN8GE0 ,7B5U,B96(4YE!%"0#6A(&W'^0
M+K^R]+_7\-T/Z+=!X[?4UM)+@M=:=8)%DC:-6&:&YG?,3(M!DI0&K#97I/I.
MEQ1V^F6O2'4888D 5(XH[R9(XT4;%5$4*H&P  #^0GT4]%O^_M?](S?0-U\]
M:XZ7?\3ZK^G3_P A/HIZ+?\ ?VO4D5=1NPH=@/PC=<]G'K&\YQN/'K&\YQN/
M'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\
MYQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/
M'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\
MYQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/
M'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\
MYQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/'K&\YQN/%O)(2TC0(23O)*@D
MGV3ANE70YX$U9K9X"98Q*O)R,C,,I(VUC6AX-O7Q?])M6*G5-1O)KJ8JN53+
M<2-+(57[E2[FB\ V?R$]+N[O2XM,.F13H D[3\IR[1,22T4>7+R?9K7@IU)?
MQC>Z?]'6WH\?>#!Z-]!;/R[6E@>8Q\K!#^"0JK-GN)8H]A=13-F-=@(!I>='
MM9CY'6+"ZEMYX\R/DF@D:*5,Z,R-E=67,C,C4JK$$'^0G%'TNTG4]*DG#&(7
MEK/;&0)0,8Q,B%PI90Q6M*BM*CJ2_C&]T_Z.MO1X^\&)OH&Z^>M<=+O^)]5_
M3I_Y"?13T6_[^UZDOXQO=/U Z9J#RI ('>L94-52H&UE<4VFNRO9P-,T]Y7@
M,"/60J6JQ8':JH*;!397L]1KV^9X=%0TS+0/(W"(\P(HOW3$$ ]J 37+^[NC
MLMS.T1(EDD>-DS?>IDC2N7[IJD5V ;*X_P 3<K=^7^0\MES1\GFRYJ4Y+-EK
MP9Z]GJ&+2HP8E-'D8Y8TK]\U"2?Z*AFIMRTVX$O235.3!' 8H%KL&QI<]0":
M5H*U&P</):%JQ>XV[I8)]M*CM8Q&=E"3MV@<&_!NI0MQIH_[6.M%]^IVI[.U
M=PS5-/X*:?IT;2W<AH%'\Y)W!0-I)H -IQ<:C?W$[ZM!:2RD1E!%G1&<+1HR
MY4$ $YE+;2 M:#J#4]=F\BM&7,$H#)EI7,V8A8Q3;MS&G=*N#:Z-JS/?BNP3
M6\U* [XT5&V4J>V&P'V0JWH$EG(:)*E<K'?E-=JO3;E._:5+ $C":?IT;2W<
MAH%'\Y)W!0-I)H -IQ<:C?W$[ZM!:2RD1E!%G1&<+1HRY4$ $YE+;2 M:#ZK
M;>CQ]X,3?0-U\]:XZ7?\3ZK^G3_R$^BGHM_W]KU)?QC>Z?J#>B2=]'A?1(^^
MDQY1<YH]$B;MWW%SOY-.R1W3;E'9*@_X1Z,%8RB\G(Z;!$H%.22GW9^[;>NT
M=V25Q_\ 2/ZO%OI%MLDFDI7[U0"6;_54%OM8ATK0D5+V0%8@0#E IGE<'NF)
M.RNQF-34*5PUU>R/+<N:EG)8G[9_F&X<& Z$JZFH(V$$;B#P$8;HQKS<M,8V
MY-W[8R*!V\<E:YSEJ034LH8,2:5,5J*:;.O*1?T16C1U)).0[B?N2M=M>K';
M-(D2R.JEWJ$6IIF8@$A1O)H=F*)2XUN9>N.4E/7._DX0=V_L9VKBZU:\RBYF
MT^\)"B@%!,J@=@* -M2:5))ZB27*AK.T7E6!W%@0(U/7[8YB-Q"D'?C_  [;
M.5L;=5,@!V/(P# -UPBD4'WQ).T"@EB8K*I!!!(((V@@C:". C$EEJ9#7R@Q
M,QW\H@#1R[MA-5+$;"<XW$C"V$[I"QE$;,]<J'-E)8@$@*=Y .S%$I<:W,O7
M'*2GKG?R<(.[?V,[5Q=:M>91<S:?>$A10"@F50.P% &VI-*DD_5K;T>/O!B;
MZ!NOGK7'2[_B?5?TZ?\ D)]%/1;_ +^UZDOXQO=/U!O1).^CPFK3W;10B-4:
M-8P20I8U#EZ G-]XU*<.(M/Z-V[0VK#D^66F6$&N[;FY1]M'84J2<Q<BE3M)
MZG_TC^KQ/<L*\E:-3L%G05^"&'V\<BQ/)Q6T:J. 5S.?MDMO[ ZW5L+B/NA=
MQ ^PSA6'VU)&+.\([>.Z* ]B2-F/M\F/:_@5<DD #::[ * >P   . ;,2?1M
MY_7]349_NRT*_: E/\]?YAC4G;>+V9?M+(RC^8#J:E;D]J# P'9(E!]Q<:C&
MO<^62GX3EO\ IQ5R20 -IKL H![    X!LQ)]&WG]?\ 5K;T>/O!B3IATI@O
MKC3&TR:W"VJ1/+GDDA93EFF@3*!&U3GK4BBG;37>E>FK*FG:GK-[=Q+*%$BQ
MW-S+,BR!6=0X5P'"NZAJ@,PVG^0ET>GZ!ZE%J,5G;WBS%$E3(9'MR@/*QQUS
M!&[FN[;39U)?QC>Z?J#>B2=]'A'0E76UB((V$$,]"#P$8?HWTARR:AR14YMT
M\=.Z_&+]U2AV"1=M<I@:KZ=*289/OE&]6_II4!NN*,-AH,?_ $C^KQY-*0!<
MV[QK[X%9!_,C =<GKT&(M1H?)[BW !_IQDAA\$H?M]6QMT!*K.LC=A8CRAKV
M#EI[) WG%CI@/X5I7E(ZP5<@)]DNU/8.!I/D/+TD9L_+9.ZILR\D^[KUVX]5
M_G/[/B6[IEY65GI6M,S%J5H*TK2M!7K=23Z-O/Z_J:A9'NR(G'L NK=\N-1B
M<$%KIW^U(>4!^V&ZFH7I':22Q(/9C5V/S@Q?W49K&]W*5/77.0#[5.I)]&WG
M]?\ 5K;T>/O!_(7E_&-[I^H-Z))WT>%]$C[Z3"7EH[1W,;!E930@C<1_\4.X
M[,2:;J05-20#E .Z1P*+/'7[DFNS@[9&V$%I-+U!:2H>U8=RZ'N77L,/M@U4
MT((Q_P#2/ZO$=[:L4N8G#JPX&4U!]O@X<&RF80ZJ@#%=[PR#9G0&F>-MQV[0
M<I*N 05%J]S #L> &0$5IW([<'K@KU]I )P(8K"Y0D@$RH8E'9)DR[!3;2IX
M "2 9=7UR9&U*1:,PZV\0P@T9B2 2:"M 6"JM<2ZK<#*K=JB[\D:URK7AWDD
M\+$G96G\!9[?3[V2!U#*RP2LK [000I!!&T$;#A].E@F74#I]VO)%&$F9N6R
MKD(S5:HRBE344WX:>?3[Y($4LS-!*%50*EF)2@ &TD[ -IQ#J4E3:$&.4#?R
M;4J0.$J0' X2M,1=)NC>2>8Q#,JD?A4WHZ$FA8#816K"@&T4(M4L+B,UH6E1
MHT'7)=P 0/Z-2> $D KI=O(&U:1&"<!>5^[EIO")79["*34UZBSV^GWLD#J&
M5E@E96!V@@A2""-H(V'#Z=+!,NH'3[M>2*,),S<ME7(1FJU1E%*FHIOPT\^G
MWR0(I9F:"4*J@5+,2E  -I)V ;3]5MO1X^\&)HKJ-)8_W%=&CJ&%>6M=M""*
MXZ6QQ@+&O2;5  !0 "^G   V  ; !_(3Z.0]"-,MM-BN[>\:80@@2&-[<(6J
M3W(=J>R>I+^,;W3]0.IZ>D3SF-DI(&*T8@G8K(:[!3;3L8&IZ@D23B-4I&&"
MT4DC8S.:[37;3L=2/4]-?)<QGV0P.]6'"I&PC[8((!"0ZG;6:R1FJR1K(KJ#
MO6K2L"IV5!4[144./\,\E:>0>3\CFRR<IEIEK7E<N:G#DIV.HMS:2/%<(:JR
M,58'K@@@C[6 DKP7*@4'*Q[>#>8S&213>22:FM32F2(6D#4/;)&Q.WA_"/(-
MF\;/9J-F/*M4GDGGX"QK0=91N4=A0!_!@TVW@LC!!$L:EDE+$( H)(F K0;:
M #L#'F^G_ F\?B?3IX+$07$+QL524,%=2I*DS$5H=E017>#U.2TRX(M223&X
M#QU.\A3W)X25*D\-<&.)+.%S]TD;%A['*2.O9VJ=W6J,->ZE*\UTV]F-33@
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M9'N \WWS@N#)]MA7'DUG-:S7)R>3K%E+1D,M3E7;$,E00P6O<TKN-RJF2PE
M66.M"P&YE/WZ5)%=A!*FE:CR^XNEM;\KVS%UMW-*;&Y4&-R!LJ,Q(J QR[!J
M,=VMW?)M0\HMPRG;W*PJ(PW6+ %=A#"M2I53%I<->3C)J23O=Z;,Q%!05"C8
M"22QGGU&>&W@-BZAI'5%+&6$A06(%: FF^@)X,75U8RQS6S+%1T974TB0&C*
M2#0@@[=A%.I'!I]Y:SSB\1BL<L;M0)*":*Q- 2!7=M'7P;C4)HH(/)9!FD=4
M6I9*"K$"IH:"M=F+JZL98YK9EBHZ,KJ:1(#1E)!H00=NPBG4CMK^YGFMXA1%
M=V95W[@216AH#O"T6M  ,7%M?W=M!<M<2D))*B,08HP"%9@2"00#3:01_#MO
M1X^\&#T@Z%7KV&L-"T)E18W/)N59EI*CK0E%-<M=FP[\76NZO*9]6O;F6>>0
M@ R33.TDCD* H+NS,0H %=@ V?R$]/N^EUMIEM)IL<R1"SCGC#"8QEN4Y:XN
M"2#&N7*5I4U!V4Q+^,;W3]6MM5NHVEA@DSE5(!) .6A.S8U#]K$EQJ.CSCEY
M69YQ=2&0%S4L(AEC[6NQ:TH!O.-+%K(9]'NDDF@=J5($,C '8 2#E(( J&78
M#48U)I.Z\MF'VED8#^8#'2."7;!Y$&]@\G<;?9V _P"J/KRV]'C[P8;HET2:
MU75%M9+@FXD:./DXV16[94D.:LBT&6A%=N-0Z+:H8SJ>FWT]K,4)9#+;RM#)
MD8A2RYT.4E02*$@;OY"=M!T\TV73I;Q7:$.\3YQ&5#D<E)(!E+KW5-^RNWJ2
M_C&]T_5OW=IBJUSD+49@HHN_:=Y[ V\.X$@6'D%PDA:A9D*QC=M,M,A K7M6
M)WT!.S&D6NFL)X-%C2-V![LT1)%!K0D(@%:[&)!W'#=(^CL4E[H]_216A4R%
M6(&=75064Y@3M&PG*>V!&+FPORJ=(=6(')5!:.$"A+@'952XW[W WJX^O+;T
M>/O!B;Z!NOGK7'2[_B?5?TZ?^0GT4]%O^_M>I+^,;W3]6#H2KJ:@C801N(/
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M7A>)P/;4-3V308%U82QS6YW,C!A[%03MZX.T</V9WN;A@EO&I9F.P!0*DGL
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M=E =ZJ$!)J<6,DA)D:9R2=Y)C<DGV<67HS=^<7>DSL%GG"/'79F*9PRCKFC
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M-\?'*7#L\G78EC[9J>HLL3%95((()!!!J""-H(.T$;0<"+4;NYN(E-0))7<
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MV79/>-[APWHK]\G\9KW\2?=&-0_V']=]EV3WC>X<-Z*_?)_&:]_$GW1C4/\
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M'K8:WN4:.="0RL"K*1O!!H01P@BO\!;6SCDFN7KE1%+,: DT502: $F@W G
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M2Y&HL@&4AM^1UJ:,0"002& .X@@->">ZCU:-F1@&C,8>E4;+R6;(0149ZU#
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MM9K>8+V62-%--_W0QY#>D/&PS1R+W+K6E:;P0=C*=QX2""4T[38S)=2'8!N
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MLY*C@6M,Q70=,L+6+8 "I;M0-WX/D1OVC90#90[\3ZK=JBW$]D[,$!"@U(V
MEC39PDXN/H]_GH,7?O8?F8^K8_[;]'EQ;>A+\[+U#<77:_\ E+B6AZSF0H![
MX%:>^PLL9*R*001O!&T$=D' OX@#J"1\J -XFB!$B#K9AF"C9W2GK8:_89=5
MN5SCK\K,*1#_ &<=&(ZZOPG%3OQ']&V?]1U-0_%Q=])C4?26Q']&V?\ 4=1O
M0KWO[CJ7/IK?-18LOQS]X^++T9N_.!/;=LGDUK)_JUCK[0-3V >I<^A-\[%B
M_P#?1_,QX'T;%[J8N/H]_GH,7?O8?F8^I%Z;'\W+B6Q@?)<I+*E02"I=0RML
MVCNMA%-H--HP]M/J.H+/&Y5@;B:H930@]OO!%,>LM0_*)OCX5]2N)[AT%%,L
MCR$ [P"Q- >QU+'_ &WZ/+BV]"7YV7J&XNNU_P#*7$M#UG,A0#WP*T]]B_LZ
M_A5EC>G8967^8KMZU1U\7UK,*.MU)]L%B5/L,I!'8/4*7?:N=-(H=FV;8H]G
M\(!3K[,26*$"1)IHSV,ZA@?8[;^8];#P3 K,C%6!W@@T(^T1@(@)<F@ WDG<
M!A;&<@3-Y/%_K)E8TZ^R,XN?36^:BQ+^,;OC]?6/^V_2)?L%R>\;W#AO17[Y
M/K6Y](D[\_75EZ7#\XN+3TO^K?J#HMJK?@7)Y!F.P$[XC7@;>G]*J_=*,?O#
M3U(T6X:JT_[)]YC[ X8SUJK]S4CH[TL9([XJ%)<Y5D*]S(DAV)+6FPD5;N<P
M)4>4P:H1I_=;8E8Y-Y/*"55W?=9*#?0XFTV$B^UJ5*!E</(K#<<Z@QQ!3M*T
MSL-A##:!=SAFT^5>3E VG*2"& X2A%:<*Y@-IP-;TF\5+IE4,\=)%8#8I=,R
ML' !7NE.RA!*X\OO[D:GKL9/)0@*JJX)HSH&?+E--KL:$$JA8#+8W24R2W,;
MBFZC0R$4]O#K?DC3+I0CMM.1E)*.0-X%6#4%0&J-U"VNZ1>K$TQ!<HJS1LU.
MZ%'3*Q%">V(.^E23BW6*8:ETADFC3/5<D*NP5W[4LJ$*20"SR;:5526QI_XN
M7OH\?X9Z1,JV/;".1MJ!6KFBDWT4DG*QV $JU !@WFA7_)63DD*%6=16FQ'$
MB&@[)8T(V[-L]K<R_O#6I$HN5QG5B.U*Y*K"HJ&)?,Q&X,*+BUU.YKY*K%7I
MMHKJ4+4_HYLVS;LV5Q#KEK?+&J1!6= LJ,@)<;0ZA2,QJ:G814;,):Z%=BYA
MY(9^V#%)!L8%E&3MNZR@DJ:@@#+5_HVX_K<0ZM9^&A:M#N93L93V&4D'K5J-
MHQ$YN/)M8C  !*K*M2*H5;9*F8["M:$BA4L5(N]<U+-8*=HR+ #2IH9&D>@(
M!K0 TK0C>!T6Z,4-AE5))%%$R+2D4?"1L&9MQ H,P8D7'T>_ST&+OWL/S,?4
MB]-C^;EZH^C8O=3%Q]'O\]!B[][#\S'U(O38_FY>K_A7I8R*1'R2M(:)+'N4
M,VS)(HH Q(K0,&SX-W8ZDR:=3-VT:R46I)_""1%H!PE=E*FN[#Z1I[>6:^QV
M2JX9D8;R[+^#510CD@"QW&AJX?3]3S'1YFS5 ),3TIFRC:58 !@-NP$ T(+:
MKT=ODBY4YV$86:.IK4A Z,A)K52U :@**4QY7TGOTN)(]O)M1 >$?@59Y7-"
M.U!(.\J0:">XT.)H-,9ZHAILZY '<J3M"5.4;*TV"/TF+O'QJ7O8/=FQJ/I<
MG?'"Z)J\JQZIE574L%?E%H%EBS=UF.V@K3,48$$%O+->U;+IPJ<I18F(!&P,
M9'S&AH0L=22*4W8N[70(>0TVT9HT'"RF,-RC#>"[9MK$L:5:C$@6'OI/F9,6
M;#>+3^L?$5L;@1WP*N5!'*12A2&JA-60@M0[F&T$$;#==*-4Y2%=HB51$[_T
M<H>1V!W=KEI]\-XO[C3H5M[6**6)8@0<BJ>UK3<2I#$=<G:=YN/H]_GH,7?O
M8?F8^K8_[;]'EQ%I.LS^1ZUR >*4D!60NR\F2QRL<P)"DJU6JA-6&!?:WJ'+
M6*$&F58$/8=S(_:G9N*FE=NW8.C>@,&L05Y21=B,$[F-!050$ EAL)50M14G
M%UH$F8PNG++O(5E*H]>MF!7;NJM*U(&(=!MS_P"7M%S.!NY1QL'^HE*=8NPI
MLZD?T;9_U'4U#\7%WTF-1]);$?T;9_U'4;T*][^XZESZ:WS46++\<_>/BR]&
M;OSC_"?2!T0!61#(:))&]:QLQV!AF(%2 5( VC:;V#4S!I9HW;HK *3LI+RB
M+0@@*2IZY)K@=%NC7X=WC9I;IB"9'0 A$.S,H&8]J @WC,2S8O\ WT?S,>!]
M&Q>ZF+CZ/?YZ#%W[V'YF/J1>FQ_-RX:28,^F3@+*HWBG<NHW%EJ=AW@D5!H1
M^^-$O4BOI!5\F5LQ%-LD)*.KTI7:M=A()-3Y3TGU)9(U[;(Q6!6' ",[R-6A
MV(RDG8-QJTO1B$PZ>%"G9E5V&S,B$ H"*;]K'MBJDFN+'_;?H\N(M)UF?R/6
MN0#Q2D@*R%V7DR6.5CF!(4E6JU4)JPP+[6]0Y:Q0@TRK A[#N9'[4[-Q4TKM
MV[!T;T!@UB"O*2+L1@G<QH*"J @$L-A*J%J*DIJ40+P$%)$K3.AWCWP(#*>N
M*'83A=2TV\$.K%0II3.: T$D+%6)6AHRD5 (#,H!"ZCTDU!9;9#F"N%@1J4V
M-61RXJ1VJD5) -0:%=&T>O[HC?,SD4Y5A4"@.T1K794 L=I RBK-.&?2YP!*
MHW@@]K(HW$K4@C94$\(&#K.@WR17<O;/D <$[*LT)9'1Z$9JE:DABM22RZOT
MAOTEGBHT8<+&H.VC"/,[R,*'* 2*@G*2!1(K0,FD6Y/)@[&=C3-(PX*THJ\
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MZ?\  F\?CS?3_@3>/QYOI_P)O'X\WT_X$WC\>;Z?\";Q^/-]/^!-X_'F^G_
MF\?CS?3_ ($WC\>;Z?\  F\?CS?3_@3>/QYOI_P)O'X\WT_X$WC\>;Z?\";Q
M^/-]/^!-X_'F^G_ F\?BYNK2UT]9KJ3/(<DN^E-GX;8*U:FWMF8UH0!YOI_P
M)O'X\WT_X$WC\>;Z?\";Q^/-]/\ @3>/QYOI_P ";Q^/-]/^!-X_'F^G_ F\
M?CS?3_@3>/QYOI_P)O'X\WT_X$WC\>;Z?\";Q^/-]/\ @3>/QYOI_P ";Q^/
M-]/^!-X_'F^G_ F\?CS?3_@3>/QYOI_P)O'X\WT_X$WC\>;Z?\";Q^/-]/\
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M1:E)4VA!CE W\FU*D=<J0K@<.6G#B+I'T;EA>X:, BM%E4=RP;<'7N2&I4
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M]!78-F8[\&^Z67L2V<8JRQDJE*_=32!<J[JT0$U(#"@)GCT!WDTH/VA84]D
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M%96M*DS,0P4"M2B@E:<(<H0-N+2Z;7+*74(95;D%R9F;>%4\OFJ1N_!U[&+
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M9Y+C,HY.5ZKD45JB,!M!V$UP]S.<T\CEF-+\59B2304 J3N  ZV/_P!(8?\
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M  J23N  WG":GTH4Q6@(*P'8[\/X3[Q?Z/=G;7)3MA'& L:@  "@ &P  ;
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M1BD1"*8/415(J94HK@4""4QA+L_<,M5<*W9KO72S1 <IY23%%LJNH=!(4TZ
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M_IN@_P PM7N6EHUU8YY;M6MBFVS9!+(]C(D@@A)NDD44B%>@4B::90*4 [
M&WK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V]
M;?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y
M\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG
M)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D
M[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;N
MWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];
M?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\
M\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=V];?/GG)
MLG;NWK;Y\\Y-D[=V];?/GG)LG;NWK;Y\\Y-D[=VQ;+RKQQ(2DKCFD2,D_=JF
M6=/G[ZLQCEX\<K'$3JN'+A4QSF$=YC&$1V2HF16\FY@$9IC/D3B9)2+=!(1[
M=ZV;&%RD0YA2!)^IO+NW"(A_FVJU*@2+IP=/KD)5H5-TL+ER2)K\8UB8XCAP
M8"F<+E9M" <X@ G-O'^'_(3O$?'WA[=0NKV">*JO()"#&/&#0E$")ID0E),'
M . DQ$1$2</!_#O[&UP_&FP?A9W^YV'?)9C[Y)1&R=SRC8NYBM*RK2$3DNJ)
MV:XI-\BZ<-6W0Z]&2S\.:BR5'C%($R\.X3 (@ UZW5QYUC7K5!Q-C@9#H[MG
MT^%G&#>3BWG1'Z#5\UZ4Q=)GY:R2:I.+A.4I@$ _R$GZV/[[2[TC%';I2BM.
MM,'9TXU1V54[5-^>$?/BLSN2H'%,%!*)P(;=OW#[EP_&FP?A9W^YV'?)9C[Y
M)1&T?Y5*I^![5MI]\B&*/D' ?Y">=_Z;H/\ ,+5[EP_&FP?A9W^T/,-Y5G+Q
M7ZPWQG:;F1_CZ2@(J>&4@Y2MLFB!G5CK-KCQ8*)3"HJ%!J"@F*7<<H (&9X;
MQ5.7BP5AQC.K7,[_ "#)0$K/!*3DI9&3M KJN5FJ1X,$TH=(4RBU%0#&-O.8
M! "[2&1LDR-DQWIV@W#B+"R0:;-M:K]84# 1S$496:C)2*2CX<1$'\HLV<H)
M. !LDFJJ"_1E<1Z3+AES);NFNGD?DB^7RV4><J)YY$P(J5FEMZGCVIKOE(1<
MAB/9%1TJV.OQ(HIF!,5C?ED]V^<?"=^3/X9NHNZ6A=P?=1W+]=] ZL\&G=!U
M#TKWO*ZTZ1R^QS]_OO<=0>$J>DO"P[A!O:LB6AVI!8]J)G"?,1),SA6KYV[?
M*$$I@8QK5_(BF;F W%(#'*QF]8.M0]8*Z:*J+JQDMC?"T"@[%>,:E38V'*"M
MO"5:,GKTJ)U1:M3+G<HAP(F]ZH:$TS:[WU@MI"/"&3:Y)P7G$A%Q8KNF9C5R
M@,Z-)@1J1JJNL07?$L@F;A,EPB?9U=)IA&Y0Q W43*MD^@)O5VD$590J#<MW
MKSQ(DO5176.! <?RJ-XSD3Z7S3@G^QKF*L25.3N=YM+OHL5#1B0")4R!S'<E
M(NE!(TBH:,;@99V\<'3;MD2F.H<I0W[96RWE'*N39W.^,\%Y1R:\9T>4J<7B
MD+34*3/6J)@4HZ<H<K;)6#:.XY)LZ<]8,EGY"G4339B<I$_<89BU-9$)IYH4
MC#'LC*K]5-GN0#5SH0ODYNTK3+V.@<>L19"#KA=@]>)HD,5RW:F[)7U*T^:Z
M)><R<D+HI(UOEK 685F1FK5^=<KZC4F#IU@5%HJU%57<^1X4D%2CPC[].-9Y
M#08VG'MG<+MJ7E:KI.QK$VZ02,X4A)-!T0'=9M*+0HJF8N1,59,BAVJSE-)4
MY-JYBK$E3D[G>;2[Z+%0T8D B5,@<QW)2+I02-(J&C&X&6=O'!TV[9$ICJ'*
M4-^V5LMY1RKDV=SOC/!>4<FO&='E*G%XI"TU"DSUJB8%*.G*'*VR5@VCN.2;
M.G/6#)9^0IU$TV8G*1/]MP[Y+,??)*(VC_*I5/P/:MM/OD0Q1\@X#_(3SO\
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ME* !LTD8YVZCY"/=-WK!^R<*M'K)ZT5(NU=M'2!TUVSILNF4Z:A#%.0Y0$!
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MO#=S-^V L@'03,_K&;7M.;.1 G-1:7JB6";>H$,(\8)N%L=MS&  W"*1=_W
MW^ZDM(/7;]9%HR8(JO'*SI1)C&M$6$<R2.N<YDVC!BW3113 0(DD0I"@!2@
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M[/8VT9/"IB+9!?4(V55WAPD7=IX15;IB&_BWJILU1#<&[W@[_P"#W-(R+ W
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M--D1H9QQ$!5@X<.O<6TYZDXR6N.GQZJ^[F)M@S)/2^-@FSKJ3D&\K[HP%L=
MF'+I1PHV2'I+)95<R:3HJ_)3-D^J:KJQB&)F'P/UZ+!9^QYC&&%9=-F\<)%I
M.:*Z[NM<8N!4$>CMC,D&QE5$42(@D5)&5PM[/.!B<C9 ?(BH6=9-IQY3T[*X
M8E;=VF1+W.E:R>0)-L3@5281AE&?8%J19@D4$RPF2\\.)>^1L_E&(N.7UU5N
M.;MD4^M+:6O( J3DE*_F(\[DI.#@*0QP H%   %*?CR]88R#<G)JH.G^L8X4
MA'EAQVZ;3L O+NU(.'1)(XLBB4U%TV<-9%O']**8&Q4C* '+<6YG&N+;C&[-
MV$)E6AH.DF;B8BV*ZZD7/P;E<AT$+35CO5U&@*<*+E)=9LH=(%@72+D^UYMA
ML)Y2?1R!K)8'MRAL!WAT##JM%)E9D<FQ4ACNT2S-J9-L1VU3D%E&_&1-PH1N
M H-\MQ.=XC.F2H%,9.G29KW"YYL4.\5,Z03"MPV)86.H,9.B)?O3N203<LN$
MBA'" 'XSPYFD,[HV%L?GD$\=T=RZ3<2CIT_,";ZY7%9J=1DM9Y-JDFD1N@91
MK&MB\E$ZISN'#C(UERUDF@XNKC[3=;X)E8,BW&NTF$>3;G)V'Y!M#M96RR,8
MP<2KAA&.5R-R*"L=%NJ<"B5,PAFBYXWNE3R#3Y6,Q:G&6ND6.'M=:D5(_%-,
MCGY&$[ O'\6\.QD&JJ"P)JF%)9,Q#;C%$ VJ=7Q/GW"N3[*VS[2YEQ7L>93H
MUUG$(AK2LE-'4JM$UN=DGZ4:V=/T$U%S)@D119,HF 3E 9&U95R%1\9U@^%;
MU%$L>0;9 4R!/*.YRF+-(TLQ8Y"-CS/W2354R:(*<PY4S" "!1W9HN>-[I4\
M@T^5C,6IQEKI%CA[76I%2/Q33(Y^1A.P+Q_%O#L9!JJ@L":IA263,0VXQ1 -
MJI3\G9@R5D"J49N1M4:[<;K8;%#0!$NED14CXZ5D'35)V@U>';)KB45TV14V
MQ3@W223)MEFG9.SMAK'-ODLKY3D8ZJWO)])J%D?Q\AC6@,&#]E!V"<CY-TS?
M/F:R**I$C$552.0HB8I@#]EAWR68^^241L2I9+K3:U5U.2:S!(QVZD6B19)F
MDY0;.@5C'C%SQI)/%  ./A'C[(#V-T%5J\R)&0%:AXR @XY)195./AX9DA'1
MC)-5RHLX4(T9-B)@90YSB!=YA$=X_P"0G;6&/YFZ3"-R=1#N4-<9&#D%$%(5
M&01:E8#"5RO%2(H62/S 4!41$"[A+N'?M</QIL'X6=_MV'\WW.M2=PKV,[2%
MI=5V&<LFDF_>,8U^6%,T<2!#LTSL9M5LX'C -Y4A H@80$+=:,N>S^R,W#)U
MPG;'<<SQ>J&^OK\P?6R4<2DA.1V+VS>$Q_OAG#XR;5D5T*'1D$P,"AQ, Z+$
MJ9;G61M/V::[?,M85N$T#4DLY91^&[Y-,(J8718QK)_*Q;\8QVDY1:MB.&[Y
MN())+<9":O',H90SE+4=F&.2%4PG,$=$7N;B8@H"/W$R1+) "!_HD  _@V]K
MO6Y<.=6D].#.8,"QRE;QTH3&^H%5-\F*@"DDX$8I%7C, @4S,@CV ^S,.^2S
M'WR2B-DK_?TIU:"6G6%>(2O,&\B_Z?(MWSIN(MW3Z/3!N"<>IQ&YF\!W=@=_
M8J5Y@RNB0MSK,#;(@CY(C=\6+L44TF(\KQ!-5=-%T5H\("A"G.4I]X 80[/^
M0G-.L5W)E<&]=68MYI1FREV0,5I(CE1D10):/CS*"X(S4$!(!@#@[.[L;]KA
M^--@_"SO]N#$^&(R&E;D:!E[&5I.6*)K312.A4TCNRH/9=PW2=/CBN4"()<:
MHEXU! J*2JA&N,2Z8,KP,JM)(Q[NS6:K2<-C>,344;D7DW6256ZE+=QK))QS
M#F9/':JA2'*B150O!MH)IF'IMODJM^SIJU5HMMLT0[*NWM;]-C5:I?ZO%223
ME=LZ<-J54DVJC@%5"(R;M=%0#"W.!I'5QI+I-EU&8!U-IL,B0,[AFO2M_D:]
M9G\:T3ML'::]6&3^>AG@S:"KHQEVQ"(JN#M5C%=MUTRY@QAE!Q'0>J_70[8Q
MJ>+T9)DZLE$PRW9J1#J2N+:-<KF9G>0SZ90*0RI0!W+IH"4RC1\F3[+P[Y+,
M??)*(VC_ "J53\#VK;3[Y$,4?(. _P A/._]-T'^86KW+A^--@_"SO\ ;FDC
M'.W4?(1[IN]8/V3A5H]9/6BI%VKMHZ0.FNV=-ETRG34(8IR'* @("&PT2P:D
M,]SM(,P;11J;,Y@R%)U48MDDF@SC1KSVQ+Q L&B*12)(\GEIE* %   /<?-\
M1YFROBQ"44YTFCCC(EOHZ4BKPHDYKY.LS$81VIP-TPXE ,.Y,H?Z(;I&RVV?
MFK18Y=?I4M/V*5?3<W*.03(D#B1E9-=R^>K\I,I>-50QN$H!OW 'V9AWR68^
M^241M'^52J?@>U;:??(ABCY!P'^0GG?^FZ#_ #"U>X=57$&+E%%#F4444H%3
M.=0YQ$QSG.:)$QCF,.\1'LB.WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&WB=Q9YOJE_5&
MWB=Q9YOJE_5&WB=Q9YOJE_5&R+9LBDW;-TDT&[=!,B*""") 321123 J:222
M90*4I0 "@&X.QM'^52J?@>U;:??(ABCY!P'^0GDMAD""O<PM<I&L.XLU.C*_
M()H)PK::1=%?C-V>O&2.H:2)RP3!4! #;Q+N#?#3S(BZ3.;BH^7:)NBID<IM
MI)HB]0(X(DJLD1<B2P <"G.4#;]QA#L[5)AD""O<PM<FLN\C#4Z,K\@D@E"K
M,$717XS=GKQDCJ&D2<L$RJ@( ;>)=P;^\G-_Q;H?I*V[R<W_ !;H?I*V[R<W
M_%NA^DK9;(=&C+-%0J$_(5P[6V,XIC*"^C6T>Z75*C#S,ZT%J=.1(!#"N!Q,
M!MY0  $;1D^TLYA_ 5)JT=R+. ;LG4PNF\DF44D5DWD9"*9*'*X?D$P*.$P
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MV2FG57S#>\@:C=0(,)20+(1V(::"2T7C. EVY.EQ$,5(\!2V"Y%$#QL8JF9
MX*HI%-5,6XHI59QUCBBPK2NTZD4V&8U^L5N$8E$K:-B(>-1;LV;8F\3"!"@)
MSF,<PB8QA&_T&Q4Z!#4)3ZA89K3;EDL<R2MU-R R9+2416^OC"W=J4.[2;5)
MC,1RJPM#I+ Y*0KINW53R#HHG7CLE U28]LTNQK+\SI%2%S7A&*?VUG*-&BQ
M#IL5GN-V=B:22? BHY.V9"H?^2$3-C+Z[N(_HAU!;9\]H5D^E15UN^,,F1^#
M,!.K P:2<;CVQQU2@[WD6ZPC-ZDX11NZD;=(%HPD2%3<QK4[LJ)_Y6<2F34*
M4Z9RF(<AR@8AR& 2F*8I@$IBF*.X0'L"&V;&6GV)98UJ\NYQ7J)H,!56R$+&
MT6RVZ!B;#.DK+2,,BA#1R628N1?L6S=-LDP27(@@F5)%,1S#JRG$475?Q-I]
MNF='#$QUD"2B%5H+^Z-8= 3D(Z!:95:)M42\(*F46*4 XAW;9?SYK363RO4,
M=)SFIG,U>GS'=,<N91O-R!"HU.P1ZQ5DUJ&,LZ?2#QCQ@W4:12,<9,S5=0I8
MZ$A(YA#PT.P9Q41$13-O'QD5&1[=-HPCHY@T31:,6#%HB1)%%(A4TDR@4H
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MW #45?+-5XAWDO31&0>9<2W91@S-8*HZBK;7&5ZBV,H?DOB0=OHCI\U>,RK
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M7;%)T1%(R)FSUNU?-U(^DZJ]'=@QJ$BS21MMI>YJI]Y/$G42"0>J8\B<47F
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M5'1N+G<_I#KC_B<LO\;;'>CKPN>'#N"L60Y_PB]P7@TZV[O;K,W#HG<CW:9
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M1,0$R9E59;*OL]\Y/]1!:TB\F'>$,EQ473,P*LHTJ[Q)3'UV@7"5.O5D$I"
M2.<L:XH<R8BW6<+*)M=JOH6]IC=+1<<1S%D:XTH^:LH&>#E#3Q<ROTZ\RJ65
MYJ:*E.3N-22Y.B.G4P924K"H\2JXQJ(HM-M-'U(JI]/&>MO9S?5$PK\CH[W;
M1_Z[DW_]L"<_L,R:4<R,RJTS+M2=PA9=-DV?2=-LK<R<C3[[7TG0E2"P4JS-
M&LBTWF(511ORSCRSG <O^PAUMOC0YXO(URCM/KV5?<V/J66V/.FYR@0TD]<
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M6<="HM4<&8RJ^/V$DX)RWE@?0[!,+!;)%(#G32E;A8E7<H[(GN2*Y>'!,I2
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M1!]'0T>#UP^7(H7F-3G4QIJ#_+%_)V\'>$(K#?<C^3WX7.N.K+Y?;MW1]?\
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M< HXD)J;? FJ2)K-:B&SB1E'RA1291[59<_O4QVQ]IAQ:FUE9=@B2SY@R0#
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M%$4W5X;DCW=3R@F=0B9%3ST>]D"MB<IJ\:;^,)34M[/S*60,QX]A-[ESDS3
ME*-,@IUR/54=(L,VZ:':UC[K:^APJ.'#=!*XU]!)/GO#MQW%+"XL]J#B52K2
M22B,2MJ5P9!/G<.55(P-U'^3L*'5=ST2HB5(RCU[65WXJKGX$(- @=B+R[IM
MS#C_ #7CB7W$;6O'MDC[ P;/.4FLM$3*+14SZO6!D54H.HY^DV?M#CP+(D.
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M2NF15%S8'%CD6SA,%6KAL(\ )(())H(()D1111(5-)%),H$3223(!2)IID*
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MHN; XL<BV<)@JU<-A'@!)!!)-!!!,B***)"II(I)E B:229 *1--,A0 I0
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MPV,+>LF8^I<S*($=1L3;+G7*Y)R+95PHT3<,6$Q),W3M!1TD9(ITR&**A1*
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MC_\ ..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\
M..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?
MH@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_
M5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX_
M_..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L
M?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V
M_5VX_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX
M_P#SCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX_P#S
MCK'Z(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z
M(-OU=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU
M=N/_ ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_
M ,XZQ^B#;]7;C_\ ..L?H@V_5VX__..L?H@V_5VX_P#SCK'Z(-OU=N/_ ,XZ
MQ^B#;]7;C_\ ..L?H@VR[F^R80A<%.L8YF4Q4A782]/KZWEVY*15+=UTK(OZ
MQ5E&:PJ60R'(!%0O"D!N/>;A#[#OMRU(Y?J6,V$U3+=%56(E7W2;==IE>">-
MT8>E4Z.*[LMI?F7<)@H#-LJFV(;FN#I(E,H77!]7_'OTBK_8FD._X TX9AS#
M2:AAZIP]HM./:-.6>#@)5IFFX33F/E9",:KMV;M")>).3$.(&!%0ION"&VE'
MZW[?Z&,H[>SV\@$1^'9[]^E@R'DZZ5;'E#JD>M+6:YW6>C*Q6("-;AO6?2\Y
M,N6<;'MB;P#B54* B( '9$ VF,2^S:JB63[8H9>)6U$9"@Y)K1(QX90[7F8V
MQX]383]V>E,(&0?2Q6# JQ2B5F_1, BSU1>T5RGD3$M!L:;%Z:W9B*XF<X6^
MN**E?-X7&>)W9X^/QK5%6RR@-5)%**8LN<FLSBWR)C%#,+S4YF6FX1A<O:>5
M\:4.T9!>+0=/?W=3)M L2$),6Y=N-;J)7$/#.E2/)=TQ8&,CRN?SE$DU&,M$
MOF<I%RC-M(QLE'.47L?(Q[U$CEF^8O&QU6[MF[;JE4253,8BA# 8HB @/V)!
MZ+ZAGBAW/4U&:D,?7NQXIILD>U2]-KE3J^18N;4O$C!(OX"F3#=]8F921<F[
M;2BQ%N8FW,D4YRZ<_9QY!RVSQ#J:Q?(9:8QT/E(K6IT[*9LC9UR/D^#1QK>G
M+Q2N2,X5A?VK 8=\M'R[I\DJ#)LZ2+S?W!6JN4\>T?)=7<[^D5N_U.!N4"OQ
M;@-SH>Q,)&/5XN$-_$F._=L\>SFBNC8SG'1E#I36 IBU8/(P.H*AC&9U/'LU
M"X\$H&4]Z1:&63(  !2@  &SY[I@UGYGQ<X-S7#2#S51Z;F:*%8W-4+')3%.
M6PO)QL?QF*1-95&2713+O.#@^\1EK/!XG9ZL,51W/<#?-,BDG=IUBP(8#(J6
M#$;N.C<ILW!6W$HZ/'1DM&,RIG%1[P\)C/8B8CWT3+1CI=C)1DFT782,>];*
M&1<LWK)TFDY:.FZI1*=-0I3D, @( .V+,XWJBU[*6%G3].DYYQS9JM 7!I8<
M3V1XS2L4C"P]C8OF07.G'12F(=1,6RJKQB#0ZZ;9TY U3R)0L$Z:[;1[W6X2
MX4ZTPF),;O8:QUBR1K:8@IR*=IUS@<Q\I&/$ET3AV#)G =O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YF
ML=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YF
ML=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YF
ML=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YF
ML=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YF
ML=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F:QU\W-O5HT_^9K'7S<V]
M6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;U:-/_F:QU\W-O5HT_P#F
M:QU\W-O5HT_^9K'7S<V]6C3_ .9K'7S<V]6C3_YFL=?-S;U:-/\ YFL=?-S;
MU:-/_F:QU\W-G<3CBA4O'\6_>#(OHVD5:#JD>]D!12;"^=LX%BP;N7@MT")\
MTY3'X"%+OW  ?85@R7EN]U+&F/JJS-(6.Z7B?C*S6H9H!@(51_+R[EJR0,LJ
M8J:1!/QJJF*0@&.8"C+X=]F92C7:PN')X0NI'(U>>=0]-641004Q-B=^W1F;
M.Y7.L)6[VPILDB+I[NJGB1RJ;6G6+[1K*.0<45>2K$M;#R.63N[#J$OD5'Q;
MR78P]:H,HJW98IJZI2F1;=:)LRQZ9RF:PZZ AMJ)B=2F:J3A,<VXEI],QK,9
M#D%*[5)RTQ5V&4<PKRX/$"5:M.E62P&0-*.V23D_WI(YU1*06SYBY;O6+UNB
M[9O&BR;EJ[:N4RK-W+9PB8Z*[==$X'(<@B4Q1 0$0'[$P+I0QIG.@Y"U 8VU
M&J7O(N/*1+=U+R@P##'%XJ[E*Y3$(D]KM;L1)J>:I]3NWB4ORU.:+8$@$^VE
M_01/91:XBU08<I3;&Z%%RFHSK,;E5VA+3#QB_P 3VQ9T: LKIZT=)@,0JLTF
MP7XRI-%T2 N;]^)CG,4A"%$QSF$"E*4H;S&,8=P%*4 WB(_<VG<<:>5H_5WJ
M 9&=QRK"E3B:.%Z-)HAR3&N63V:;YK8GK)P?>:+KI'YS'05;NGD<J!3#&7[)
M,Y*5K3:UFW;Z%MUN:RV-]+%"(FN\:N4,3T5D5W(Y,LS%(%V(/D"3,B!RE0E)
M9 @@H$+=6%;-GW4.P2;JK9TRO%1SMW"2B0"*CK&%'XG]?QLES#"*2Z1WTT0A
MA3/)*D][M/4F9MI=0NIF.*\:-M.>'9B,D)B"F6Y%BE;9=NX _K>)&J3LB:;A
MNZ*\L)$UBK(1#E(#&+?;OHBT+XNP)1IZ?1"S-\3Q=BQ[I4PTBL<YD7%CMEED
M)N&CK"XCCE6<15?;)+O^2HM'029>8F"3.11G;-I4;3($3:O1F<\Z);85T\WB
M2.?D&(G\)S,^\,(@0AJ9/OS)[SIKHAN- X^U+*_D0YR?]&8\K),ZA)X%LTFI
MPI<5>S1T2+957I!B&5,A:FD*V;@<B"3YZI[X6,M$OF<I%RC-M(QLE'.47L?(
MQ[U$CEF^8O&QU6[MF[;JE4253,8BA# 8HB @/V!.5*\Y/+FG/L65PW)I\P6O
M&7"Z1LJF D*SR#.@]1IV,2H+F3%PA+/4Y<&Y^:WCW0!PC,:<="F-+]BC&$L;
MHDCBW3"M)MIE&NR2BC=NYSSJ9DNYP86%=$%1LX.+JI5YZF;DKM5C[A-!Y.]I
MQE4V1)L3-Y,^F[",S*0]+14,(+&89%R^*4;;;(8Y%!(Y:5Y&&*BX3WI2KM(W
M9?W[V?LNRTBYB:LDP3QO..K%9=/%Y7;)$033=D75GKKB^5<$* J/XSK./-R]
MPQ/-54=!7-,?M L373,^GUGS(VJ4[,,TM*"O6([D[W^FS5!%IV=E+Q<2V=-2
M]4/59Z/BFW"QZ#$N#"9)-QIMRRW:Y-9Q9).U:?LCD9T[-M43 @F=JJ515^\9
MVV'C_>\^5KKR8BD!43(JX35."?[AKI:J-,V/;Y9SM0:LLH1C%:E9?BDTDSD:
M)LLHTY:$N:S%D<_&1@Z=N8TQP#F-SAO 9JX^SPU'L[JP3YSMGA+4D5M 6H$4
MTSJBPK^8*C%$K$Y(.%=R;9"4@H- A=PK/Q'>8;7[)WVB& <R8JN&'(^>R#I:
MO]RKSV6H%MQ6$NP[N\75S+4)UOC^U*8]LED1D(H&4N],$9*K-"\E"-02']^J
MSITLDV;-DE%W#A=0B*""")!466664$J:22291,8QA "@&\>QM8,9:6DHO5WG
MEB5S'K2%>F>CX#H\J4JZ/%8<@QP+JWY['..4H>.KG-:KDYB"LLQ7()0B,O9K
MMDU3].!)E9W!Y R RDJ5I\I4:9=5L\0P+B1@9%QD*9;,2JLPD6J:YG2S<$)>
M=35WJ;1%KJ52\,NH1H@ O=0>5H^/E+/'O5$TP<^#>N 5>O8P8@<%"I*,"*3(
MMUC(.9)T0=K3C$\TCJDU*LD7\2YT^XIEHI['UR4 BB"T9FC(:J4K6<>(@8#)
M.H\J,M8$^,@FB^2?FER%D/1GHOQ?I^Q=9K8H>P/J)'6;&ND'"92I,R&C26.Q
M/;28\R5JN@Y=0=:0=O3F6.X9PS9H/+295RZ1M@M6E5K,)L8Z,LXR^<M&=J07
M=<"2%-M[-6/G<+S$RJ)SH,"+U.7='+S7#!=,-QH&@9YD?R)\\2/1F74669YF
MZPU9)57A3X*AFSHL3"1_/4'WK>RMH%3F'*B@=V?WPMGS%RW>L7K=%VS>-%DW
M+5VU<IE6;N6SA$QT5VZZ)P.0Y!$IBB @(@/V!/4R?R/^4%J#B.DL_ '@=W%V
MJ=AIA'B2Z#DFY]*"DXSZ*ZX =M7KM6>21/S48QP ;AF]/6BS'5\QIB*14!E,
MXITR+R,%'Q]>DSJHME-0NIN95KHMXMZ@95LX*Y?U>N21!Y9HU17=O@<E^TOR
M?X8+(GT:0_)RPM*S5;Q@Q4]ZKU??,I\J&OESWIJ<"[:#2KJ3=PF/ ^?(&]]+
MY,]G58([2YE0C3G&PS:WD[.:?[@Z;H 0J<;)'Z]NN+)-Z<O$HJ@$Q%F-N*1@
MVXCK;0VE'VDV(+]FO#$:86\#7,QS"[BZMZJV< T/.:?=2C<MEB<A56.*8I4X
M]ZO.1S<$"L$%(@P*"0)[2_EUB\N\?&A(W+!=W*UJ>;Z&F46Q'"L[1EWKHTM"
MMEGB*0S,*XE8,RR@)%>"L!TR_OH=66Z66OU"NL3-R/I^T3,= 0K,[QRDS:%=
M2LLY:,6YG3M<B28'4 3J'*4N\P@&Q81/VC6@\\R=^6*)$$U>Z?329Y,S@&A8
MXK N0A=F?F=CR@1 G,%3WN[?V-F5FIMC@;;6Y/I/5U@K,O'ST)(=#=N(]YT*
M6BG#M@[Z(_:*H*<M0W+63.0VXQ1 /=D8C*=^3O\ FY-H16(T]XP<Q\_DA59T
MW%=@M; Z22(QU#+E,0_2)A=!=5 W&T;NQ#@&8P#IFH5GHV 'SY-I/8RQ.]>U
M[&\+ .3D$CG45G.2+$$L: (%%<T>Y69L'ITB]"AU712 :NY0UHOXG5=FEHFW
M?DH)V;A'3G394.4H*1*W(HMY;+2[-0IR XGDV\2X34]]#%4(18&$YJ6RK6J#
MR89%#'N%Z:U9S.4K<PCDRL&$;0<8Q"K=V2&:@B5L5ZX!A!LMQ2+.D"[ME](G
MLQL1Y)PQ1K<9ZS0JN$S.YO43=JR=5!DZE\E9;8=!CL44U(JR9WIHI6'9,$UU
M$9"7>-C;]J_F;VI5U3R=:E.7,ETNXPGY)I1(Y\L8ZY6^5\KQZS&QW=XF"P"Y
MCZ^:,8IO$A#K.3:F,12NXSQ+0Z?C+'50CTXJK46A5R(J52KL:D)CD90U?@FC
M&+CF_,.8PE22*!CF$P[S"(C)0-@BHV=@IEBZC)B%F6+63B96-?(G;O8^2CGJ
M2[-\Q>-U#)JI*D.FH0PE, @(AM/9#TH+_D29K?=)?]6TR'";T]V:2/Q*\J6Q
M3TIB>B=).0B)%JN[CV#,AC*FBW:G8%-F_2GK1I2:S7 DV?=<9WT3VTCI[_%C
MWR9XJ?PC-6!X83 F0]-GGYT]YTUT2[C0./M2ROY$.<G_ $9CRLDSJ$G@6S2:
MG"EQ5[-'1(ME5>D&(94R%J:0K9N!R()/GJGOA8RT2^9RD7*,VTC&R4<Y1>Q\
MC'O42.6;YB\;'5;NV;MNJ51)5,QB*$,!BB(" _MDY4KSD\N:<^Q97#<FGS!:
M\9<+I&RJ8"0K/(,Z#U&G8Q*@N9,7"$L]3EP;GYK>/= '",QIQT*8TOV*,82Q
MNB2.+=,*TFVF4:[)**-V[G/.IF2[G!A85T05&S@XNJE7GJ9N2NU6/N$T'D[V
MG&539$FQ,WDSZ;L(S,I#TM%0P@L9AD7+XI1MMLACD4$CEI7D88J+A/>E*NTC
M=F'Q)IYQ-0<,XV@B_P"SJ=CNLQ=8A@<&3337DGJ,:W1/*S3X$BF=/G1EGCM3
M>=94YQ$P^Y/8<U"XKH^8\869,"S%+O\ 7V%AA5ETR*D:R;1)ZD=6*G(T5C'9
MR#0Z#YDJ(*(*IJ !@5U*>QVRK9H2R5:2/;873S;;^^K%^JLFPYKQBI@+/JDC
M'O.LFK@$TV3.RNVCI$"F5-/+*"5+;\DOVR6%<C70E,=,ZU*Y&>5$M&U-4!%!
M1-D@^O%3E$(* R]"E:(@H203&.EGB7$Z%Y*J*% [7,.E/-5)S/15C-V\B\JT
MEOF:M)N6X.TX&[U5^FSM%(L0-C H+"59M'7+$#@02&*8?M(NK+=++7ZA76)F
MY'T_:)F.@(5F=XY29M"NI66<M&+<SIVN1),#J )U#E*7>80#8L(G[1K0>>9.
M_+%$B":O=/II,\F9P#0L<5@7(0NS/S.QY0(@3F"I[W=O[&S*S4VQP-MK<GTG
MJZP5F7CYZ$D.ANW$>\Z%+13AVP=]$?M%4%.6H;EK)G(;<8H@'NR5:OES-E?/
M:+8QH_3[BAW'3=T;.3E3Z.-_EC+]SV,8\>D)JFZT6+)JM3"JS8O *)=IC#>!
MJ;.TW3R#Y)G/XYQN_D*EA"K1B_ =-;/.7Y(K-2[/A:[EQCW2@IN3)"I'0P*!
MPC!9.U9.8G5UG)BHVD6L',Q*C?3_ $J02*8P$BJ') =?([M ZABB\LA5&2H%
M342BFJQ.8*4KJ5RK$0=F/"=)H.!:$@RL>8[JT:)G;L6U5Q^R=,RQ$(<[46Z<
MI++14"BH3E'>$/PD%]I)]F[BC)&'<7VCG1RM#P>\=.<N6:LN1<,7,MFS.R/4
MD;CZEOFJHD>-VKB$AB)J&;/7;\HE,-=S)[3FV,<WWY%9"8::;,>2LHTP_!NR
M*@Z;)Y(O*815GR<^2/P&<1[$L7#%6(HBLK+M5!WUW'>,J95<=T"HQJ,-5:32
M*_%56IUN);B8R,;!5Z#:,8F*8IF.80202(0#&$=V\1VEJQ:H.'LU:GX]U$SM
M>L$8RF8.:BGR)F[V,EHF20<L)*/>(',15%9,Z:A!$# (#NVGLBZ-Y3\BC,KW
MI+_N7@HQ:Q:<;-(GXEN0ZQUTE"4QITI0I$2+5ITC%,$N(Y89PI]UE7+I&V"U
M:56LPFQCHRSC+YRT9VI!=UP)(4VWLU8^=PO,3*HG.@P(O4Y=T<O-<,%TPW&@
M:!GF1_(GSQ(]&9=199GF;K#5DE5>%/@J&;.BQ,)'\]0?>M[*V@5.8<J*!W9_
M?"V?,7+=ZQ>MT7;-XT63<M7;5RF59NY;.$3'17;KHG Y#D$2F*(" B _MD]3
M)_(_Y06H.(Z2S\ >!W<7:IV&F$>)+H.2;GTH*3C/HKK@!VU>NU9Y)$_-1C'
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M^DZ2<C7L@8A9MW=6U!U,QA2!9&,82!7YDSJN8!J@F!QB,)>U'I#?!604GB<
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MC$3.3]/K*4H^1*L"3@C=X[LF++G/3%<MS]DX!4JZ3&0K0I)E "H**D,"M.U
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M0,(" "._=M-Z>M%F.KYC3$4BH#*9Q3ID7D8*/CZ])G51;*:A=3<RK71;Q;U
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MMDS'5RJU.JUS*.'9BPV6RV&8<LXB"K\%$,UG3UZZ62;-6R1U53E(4Q@_66:
M/SR-.OI&V_66: /SR-.OI&V]GTWTU:F]/>H9>ESVIM:XH8-S1CC+2U31GX_
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MMV#5M@*&GZ_/PV)JE&S$)-P\ED!M(Q,O$R+91!RV7336063,0Y2F*(!^LLT
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M76[APD0R$<8NR#-F@BU:-44FS5JV2(@W;-T"%200002*5)%%%(H%(0H 4I0
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M)$U7$V58VT2F#\(Y,RQ'5N1D;A6G4>PGWM"K$^VAWKYL@=1%)P9,ZI"&,4!
M!':@Z=-/>!]?^/L-XOCG\31J=_\ "_86OJ./DYN3L3YOW0W?2G9;5)\^9F7*
MW&\?.#EYG 40(4I2O(]QCSVA2;=^T<,UU&'LK*I%OB(ND3H*G9R<9H_9R4<[
M*0XBFNW5271/N.F<IP P1EWUY6NYX^@XUPNR+DS5YEPERDJY%.UDU)R-QAAV
MK3]GG(=,YFB*A696=<A7BHD$KH!*H<C^G828/;EE2ZMX\<OY_N31F6^Y#=,
M%1",:H-15:4VAQKLYSL8-FH=-,1!1RL\=<3D^S_(> =&NJS.5 /IYP]"$O.'
MM/&7<F4X\S&*6L9*)+9J74)N%-)QX.4^>W!?FI<PO&4.(-^C^JVJ$EZS:*SI
M;T_5^R5NP1KV&GZ_/PV)JE&S$)-P\DBVD8F7B9%LH@Y;+IIK(+)F(<I3%$ ]
MS%^9K7H>U?UG#\?[0R[75_E:PZ:<T0N-65-=Y-MS]K;7=ZDJ4VJ[:LN6+E-9
M-^=T5J=)0IP4$I@$?WA9KHVH12#2P'<\29(JF<%;-:7-&K:>(+%3IF(R6I8+
MJRF*\\I\&2F/'HNY1&08JQZ '7*X1,F"A;O_ /"QR#I7DLUWR@GCKI7\-ZW)
M74C;I/'L%-QLDX=*4R>SSE1:-B(R;7:"L_;,D!3.JFF=7A4 IO<QC:_:N,<$
M1-'H=KD*]B[(.;L]RFFMI'VNY1#B2D*;#Y&ALF8J=RSFPQ%/5>C"*2#A-<L4
M9T#<3-14)9J![+.QX;L6G\,ISE@M1\)ZA9#4G6V.5Y:LT]M.-Y.[RN2LIOHJ
M<4JT7#*'C!D$B(H&26*@7GB=3[0_M!/J1:KOH'ONT]]43,WRQQ+[N _K_P"+
M/[NNJK;4O]=VU_0/@7[6?M!/J1:KOH'ONT]]43,WRQQ+[N _K_XL_NZZJMM2
M_P!=VU_0/@7[1'M!/J1:KOH'ONT]]43,WRQQ+[N _K_XL_NZZJMM2_UW;7]
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MZ9KT<[4"_P WBB+Q.MCJ&FJ>C&15M=VU*52?/F<T+]5T[@8$S0Z9E^7RP(H
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M?]-#9YD/%:,:CD"TWN"QK6K+(MD'XT=Q9(&U2+ZW1D>Z17:/9IG$P+ANT*L
MH)KNBJJD633,@JKD&XWFVVB]K/R2A[C.V&5E+*$BD\/((/$IIXZ5D$%VSTXJ
MI"10O*4'>3<.V8L&Z@9%QD^6Q:>*K,A+7!49=]<L59/AK!'M(*T.7G,=6-PR
M5KLHU<N7!U5EF;A BIC&#C/2,.\2BK?&N>LMT^.<*F$ZCR'A*SD!G"/SF$ ,
M(OXA-!;L@ _?.R&_;3UY')CY;26VK#\;,3?@>];:J?K'YQ^DZT;4O\;*[^&&
M>V'?K'P?T8Y/VO\ K1N,2B>T7FLW_),W)*\HDHTQ9BWKY."JL8NJD?H9)YW
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MO9TK]\DYLE\?1SC<K%N+8NQ:D1;F*15./8M06(1?FE"K_5$T<?SC!WN:TO\
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M7;B.<YS"!2$(4-XB/8 -L0K%24,BCJ1KY552D,*:1E<992!(JAP 2D%3@'A
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M[-=HN\X7RZ*QAYPH%57.H;%K6%R*PU=:K;?>Z/3!M:+^")4,,5^VS,3!6ZZ
MC#NY^ I+QK!/G*J**SZ5G#@H1(#MV:J[@=)_XIY9_#%%V/HVU:2,?&8U,2;9
M8YOME0!_56<)9U72T[C:_D41<$;5YT[D'*C-ZN4[1))RJV<F2;D0$'&0=,FJ
M-2EXZGGCUZTAFE;A\Y5EB#CHZR4=5K7&9"J3D(IB)S\!7:TDX%)1,#+B)!,I
MD>EVZZ$U6ZB[A N&$'W-VR)<7*O3R[50(1[#)5963J^)8:.4<HO7"LN:1?NT
MRCP$>)F3:!A?,EQ%<E)AY>7K]S<-T#NE8^MW6NR]1?S71TAZ0X3KQIDD@=-(
M#JJ$:B4A#F$"#C_4G2M2D94FD)2VU8E[;5XV#R;3+/28Q])VE@=!XVN-<:5Z
M6C>Z-T95V==TGR%4P40#E@)H"D:9,X,,R5XU,C@NB*,Y'VB2J%YBQZMEV\C8
M:]'MZLN%@Y17@,VZRCJ.<BX07313*VXYOZHFHK^<9.VQ[G7'YTSV&AS17QHQ
MRJLE'6*%=(JQ]@K,J9 >9U;8(5TNU4,4!.ES 4)N4(00I,BXR@CB/4#5V+:.
MCHY[,04'E.N=;/FY7M0=UZ>.WCLHU!68=%Z(XCC*<ATY)RUFJKEPU59WG4MK
M$ZRQC$NTG$I'K56O8.CI'HB3B15C92\V')%P29Q[IHR4%P#=-LZ!JFJ9)=$P
M JFCHDT7+,'6,4HJ&J]ZO< T58U5.GUGH(1&-\=<\B3I_&G4CDBR$D4I6RK5
M$&[<[E-PLH3*'U6KM]+.$=L[?T3B+Z':)[E-^L?0_D%E3W6'U0\9_P XJFV4
M/JM7;Z6<([9V_HG$7T.T3W*;]8^A_(+*GNIZ']<\G78E5I4F^-H>RWU\,;3,
MFT-%%*/@HJ:LYU6J=5O%9:HH(HO5W#87 MD'2+D'P&V7O.-=8<E6\2*H+329
M)VAUV^@VA4'#IT\<(Y$C,@4R$/&M8T@$!PI''!(4C*J&. B0LW@?%<F.H35)
M)/&RC/)=;M[&<FJE/-ET.L']KLD$DK186M,R-E6W<TU17D5!4 JQDU>*13L>
M*LRA+.< 9$ED9U26BFSF5?XUN8-6\:O94H5L"CJ4@9N-:-T9-%L11X3HB"R!
M%#$.BM+9PTF:EJ_1>[5<EHLT506E<RS1"/IA9RJ^?LZJRME3G*._DY$JPN62
MSP$&KHBJ1&K<2&2*M?-:.IN!RG,54G3242SKQ=+B'S@ &0:"&'*W-V_)-T?$
M8.6JA&*;MRV<$XCK-5450(GDNVZ;*++8YP[-3RKNIU667:"9HF8A"OG<=%LT
M"(UF&DWI3N&L5SG81Z2@)%5X"E33J7ECQ9\D[IMK!_HG!G\\RSMJV\O.1?E
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M:;]8MN=8[B<+L$&.3XEMW3/WUTL3*>IT^>L]50<?!.6#9>/G7#$S\L@]9<M
MYC(=(,04]H#+^)[IA6O5J*Q+6J&X8Y#L=YB9P\O#6:ZS+IRBVK>.+:P-&J-;
M&@5,YG)514(H IE "F-XT-+7QVRSZ$=LCY?M61=.,A6L84FRWR?8U^W9-=3C
MN(JL0[F9!M#MI'$,4P<22S5F8J)%G+=(R@@!E"!O,&S>VXSQEU-CYTJDDTR+
MD622I=4D04731,Y@NFIK6"TQ[<!4,JZBF#YLF*"B0GY_"D9:4A9G 607R0G
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M_%]A5[RIY,_"3+]KU;^7S)/RD>_8.K#\4\3?AB];90U ?E2]PGA)EHR4[DO
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ML*B2/,$2HFDI1H([@,!=Y0WAO#BU0)RZ:Z;E:W5UXWZ0!@,>+>T"HNX90@F
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MCE3,J'$@@*.Y8<D36G>HV&AX5D-.=J7Q[4+6Y7>6*"A0EGJ9V<JY=6>YN%G
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MW;QWJ6Q"Z=NW2JCARZ<N,@PJJ[APNJ8ZJRZRIQ,<YA$QC"(B._;1;_S&_P#
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M^PE<FX'N?<+=UH&0K"LWW.U2S\4'*N&#I^QZMN4%88@.>O&(&YH-P6+P;BG
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MENXYEKL_5LM2-#CVF.;#28B(6B&=/IM@2<O&]FQY;WJDD9[85BF.1PFD*12
M"8& QC4?3?$V).M(W3(SZH]TLDD1XI%PT6K).I&0Z*F+-*0E20\4J+= #($<
M.A(GQ)@;B+6LX8@R==+'$HV>&IEUKF2E*\[DG,A/-I%9C/522K<%6T&[1%>-
M%-:.<-W*P)J\XKH03,0S=DR;KNWCM=)JT:-4E'#ETY<*%20;MT$BG56765.!
M2$* F,80  W[1EJS9E6L8!-,QX2#.HI55YDF[1H+ W.S;6B-1L5-@H5VLB=0
MZB*4D\6;"4A%2%5,H1&I8S<95897"WTE*[LY5O4EZ6]8L5)>0@P0D852PVE%
M,59")<@D=-ZJ!TT]Y@((\(?M+_%F$(F)E[7%U.2NTB2;FVD!'LZ[%2<+#NWB
MKYYO()^L["T1(F4#',98!W;@$0NN.;.1JG9*!;;)2K"FR< [9$G*K,O8*6(T
M=E*0'34K]@H":@  ')N'<&_;%>'(J48P<EE/(5/Q^QF9(IE&$2YMT\P@DI%T
MBF=-5PDR,^Y@I$$%%>'@)[XP;/L_XHRK?[#(T)]4660(7(9ZLNRGF]IG(FI!
M)TX(""@74*JUL$P@KT%RI)F%F<X]( R(F5_<321Y \;_ "<9?:"L?DMQE^#'
MGV%*>0;(7R@HNT7Y!L>_*"];9S\O)OH]IVVH_P O.7_I"L/[$%HXKBCX3KLB
MDC?,K/V1U&R8DY:JU:IK54$TK%;W"!P'E@8&S%,X*N3EXD4ER:$-/)XEM<<?
MT!WD>ZPL.9&7E&:2$I6(!>9R;94A*9Q?[,ZL3=<K=0.:FS3W@DU:@S3/J5_W
M.?0#BO:M7:J2*D/:*?8(:TUN712;KJQ<_7Y%M+0\BD@[1<-%E&,BT35*15,Z
M9A+N,4P;P'UE?_!S /HKV]97_P ', ^BO;(V=]3F97UDQ)&+#2\>5Y7'F)Z@
MQL%C:BE(6NUK2U5H==G%(^KMRH,D.!UT-=RY=%4 5&NXN3LEUQ1):B0JK3'6
M.W20%$).GTLSABVGN:41%9&SRZSR30X@*=-L\33,&\@_L/\ D,_X?[:</+SB
M#Z0J]MBFYZ?+[X/[+9<MEK$W)=RU+M?38,:=997H/0[M7;(P;?R^/14YJ22:
MWO.'CX1, ^LK_P"#F ?17MZRO_@Y@'T5[6><E5^E2DSA;)\K).N4BATE_(VF
MDO'B_(;)HMT><X6,;A3(4A=^XH &X-G\]CLD1^4IAI!PC47B#MFFXL+(62-A
M>XCM"YG!$60R[.61D(HSL2="=N$U ,DU>N3GDH2:CWD3,0[]Y%2T5(MEF<A&
M2<>X4:/X]^S<$37:O&;I$Z:J9RE.0Y1*( (#[C;R#5'Z7X7]JONF*P2!$Z_F
M:&/;Z2@N=,I4,C4ADJM),V?$HE[^R4@KA1;L*&$T,@4@%WG$9Z[PS$6U)U#,
M#Y0B#II%(U0MQG ,,C19#E(0IW(SX$E5.Q[TDNF&\1]RDXSIS$\C:[_:8*H5
MYD0IQ!>6L,DVBV0*B0IQ3;D7<@9500X4TRF,.X $=H["&.'_ %?8+#4(/3IC
MY5,>7(KHO8@Y,B7!4A!,JD[7K:$BLHY*(<F4D4# ("8H#JP_%/$WX8O6V><2
MXISKW*X^I=A@F-:K_@QPY.=6M7E+K4LY2ZULF/9B;><R0D%E.)PY5,''P@(%
M H!ZRO\ X.8!]%>Q\79TS)W<4529C; >#\'F*JSOEX@' 1SOK.GT:OS ='!T
MI][!QRC\7OBFW!NE;!=7,A :?L8OHX+U*L!,VE+?-NRF>,L?UIZ8HIMG#AFG
MSY-V3C.P9J) !2JND#A^2;HWPY19:[4U'@GHY!->*QACR8>,6RZ2=B&&60L&
M1+NY3%(\H7I[9<IC #E^9T55%-9]'YTB*NU5!,$X:"Q%A]Q&MA(0"F,BK9J-
M8I@PK&#B-S':@ 8?>@4-P!'Q.I^AUO+%/46;)2%KHD<VIF2(]'ED2=/B1A7:
M-%L9PY?,(S*A"\2AS@+HI. J<9=M+N+$*-#)UT O%P&%4J<CDFV/G .#OGM1
M:OEH1B$$U("73B-T'\BX77,Z,JFDU,7.?EY-]'M.VS73*QJ'ZLK51RWDBL5Z
M-\$N#'O5\' 7&9BHECTR0QD[?N^B,&B:?-75564X>(YS&$1'UE?_  <P#Z*]
MJO!ZALI>$&+IDC(2M::]Q&.:GU:_E&R#-\OSZ/4:TX><]NV(7A<'5(7AWE !
M$1'["KWE3R9^$F7[7JW\OF2?E(]^RPS,EAO*JF'Q(LH&5D\>6X^-A3;3"M=<
M'"]%AQJXD0L"!V)QZ5N*\(9$=R@"796'Q5C/(.3)9  ,O%X^IECN<BB445W
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M::]%N&<8OH?$3I2FO;'.,G++&,;*Q#H$9>LT:B4-_53+14*X*LV.]ZP:I*/
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MGPM=VE]"D=3=W/<'U;OKTS/=9]8]QUSZ9_V3RN3R$O\ 6<7,][PCZEOZ1O\
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M,=%<PIQ7<J+NB@GT9JJK^UY P9D1 XUV]0JC$DDW334D:Y-ME"/:]:8CFB!
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MD7:-W<>\2%!PF7B147VB+M/5Q[>[O=YAS7<<4!B_+$#.R+%H1Y*R<K,G:/\
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MG>4]/'LZX.+P?R32,(UR\Z&8S-.P7\F%I)FQY Y9HMK8/I-!3G%8MH63%,%
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MY]R"9=0A"E.L8E<H:9#*G  ,H8B90* COW%#=]S;V=Z<C%M'A+%*4^NS@+)
M;K.#)FN$*2+=CV!4:$":=[B_P=(/_GV=,'S=%VR>MUVCQJX3*J@Y:N4C(N&Z
MZ1P$BB*R1Q*8HAN$HB [:NHLYQ%FSL>&7Z"7$H)2.9*,R2W=G @G%(HJ)12(
M"(% P\(;Q$ * >TC_P"8+^\;2]NJ+ZBWDH;$47&.JA$/2E5036J& V=QKYRD
M,"Y3+1]VL*TREN%/@63*(]DHE-M[2])(A$DDK5EA---,I2)IIDU"2I2$(0H
M4A"%    #< ;?_6G_P"3?;V?;5T@BY:N;/G!NY;.$R+(.$%I73VFL@NBH4R:
MJ*J9A*8I@$IBB("&[9)NW230003(B@@B0J2***10(FDDF0"D333(4 *4
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M[2Z[,%^HFUCD,88,0?)F_P!FI.(MG'*&;@)]S:0JF*D8R/6$@<MPK..C[@.
M^YJ1\@F8?H\L6V4OK47?Z),'[8M^M12/HDSAMII91S-JP9-\!X@*@T9-TFK5
M$IL?U\YBI-T")I)@8YA$0  WB(CMHA>QZ*39S*0N"BR"J913.[._R+DJOKK.
M#I&3.JJ,00B("81#EIE*("4-VVE&E8QH]=R3;*C0<>6;$^-;LZ;MJ9;K@YR%
M=YMQUV9_9*>R%C).:LU;."'DVB:Y(\J8G[(E'U%M*_QNK/\ C%VNNKS4Y@"G
M85@LIXUFZUD#P=7;'[RI/I1O%U)M"<%9C,K9(M)GLI(5)LZ<+"H9,70'4$Y
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MD5P8.!KD/./\<813?HB8D>$I')1#8K)11(HH2E0Q&Q8LG8D!(%E+ L<2<1S
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MM0?Q2>?W.;K[FJR\J1;=2UM7>+ZHTFC@8SMI7GZ-OF)"+;&$>%%O(24<V57
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M*0:D,Q)&H6J+EY.6J]19N$P!1ZZK:2;%#C.L7A2,8VI5QJ"@:Q6\HW#3Q,Y
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5K3<C:&35*.Y5O&IFW=G_ .A17__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>kprx-20221231_g3.jpg
<TEXT>
begin 644 kprx-20221231_g3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &3
M     0, $ ," P8  9[&  )(40 '0+3_VP"$  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,#
M P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# __" !$(!>T*(0,!$0 "$0$#$0'_Q %;
M  $  P$! 0 # 0$         " D*!P8% P0+ @$! 0 !!0$! 0
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MP
M
M
M
M
M                                                  #B2<AU-VP-
M'SS3-5:_*    9U(N<KB?6FB^JUZ,   R?4W=8-5H"IZ*[,9HS94W=/M5H
M
M
M                       "-R<X]-S635:I.BOGZ>21/@C0U5;SXTW)-S'?
MT5[Q5:O-%BDTY&Z;VFVJUW=%5T5UNQ5=1-%(T5]>F)2HKRBJ\:JWFBINV(33
M'N)M-FG)?3=N]FB0$T^K(=Q5;7-%9ZKPD3.J:;CIH
M
M
M    C<G./3<UDU6H@)Q<T7[_ &JW<M-&4:F['9.J^;602F]==-$6$Z^:K.1N
MF]T=%@\TU^15U28^\3@1:/-$>$TDTW(GI\.:+)MYH8NW33169%6J^JUDUIN\
M[-H=5G%=3?\ ]FTZJQC3IO;+*K(     CO\ ?\W./HM
M
M                     ?LQ,BO@^GWEBX
M          !&Y.<>FYJPJM9(:;UDTTPTB;B)HJ#BN^:JWD?IO="1L.JM1NB9
MES3D;IO:;:K7=T133!6*L\L7+OYHLMFC*Q3>T]3:S[17R55\TL54RAFFJ6*]
M555K+#3=X@G8Y59R,4W?RIV9U6,;5-[9+59    CE]_RX_-JX7F]S_&(K^G\
M8
M                                       'TJ9M<QGV-8&L<PTC8!E'
MYH                                   #Q!GDIN_0F+?%,QIIJMBN-Z
M;O)MT3Q<GBID=,4H17<%-$K$5U156%%8L^FBO]5?C-NFZ*_<'1CFA)!'@B,2
MKO*)CS35?%=G,T<"B>N%3*J]::(/Q-F<TUHQ59=-(   IRRSQ/YS&^]91Y^_
MY@
M                                          !?)A60_P!$W0VR^D_/
M=                                                         %=
M'O\ F?RZ^CM3\P^FR
M                                                           +
MXL*R'^DAS_L_]B)
M         '+3]LZ. ?S#.B]4T\97X@
M
M             _H5Z*V3I/U]E
M                 CJ>!  (K%.):26WD#<B\K^5]TIJ,
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M_14!E7B@                                6V8O[/\ 4.YQVP
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M@LW9KP                                #Z%,_V)^4MU]#L70
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M !O0_K-\Q;A
M  &=DO".R    ^+73_)GZ=T]#?UOA
M  $@/A^GXM=/&?KL?EB94^;]<7?1^3W=FY^,_%+Z%,\V^BU*GS?KB[Z/R>AH
MJ]A9N<B^NQZ.W7UCY;W!/N^82;\[Z_:6:_ W[?'?KL?C/*7:/ITU=R^*_'K[
M_F]I9N=%^>Y]^BN,_H_()%?!]7DKE'(OKL #M'QW^S_)?_5E#KUOA]I9N=,^
M>['_ .[YO:6;DF_.^H19]+Y/+7:.C_/=V2ZGS?$GN# Y!?#]/+_HM>-O6^M?
M+>Y+]5GM'QW_ (==/,_IM??MU2,^#ZHJ>G\?[U,]F^2_PO[?G]-;KZ'\]R5_
MF?9;_BOM9:-DXD                                !M0U%G6RK4V;@
M                                                 #.R7A'9
M#/KG..?SE-^:R_%,
M               #Z%,_/J@       #_ $?M4S^G5
M              G/XOH?U2.:]N=+^>Z
M                      ,[)>$=D    !D'VIA>(7<.!_KS
M
M                              EOY?V_TON>MI6"^%Z0
M                                       &=DO".R     %(&8^#AZW
M'@-9.1>4
M                                               !Z>U7I5U]E.W3
M3V>2*^#Z0
M!G9+PCL@     !7K[OFUI9#Y7B+U
M
M      '^B2/G_5;AB_L]K^.^
M                 ,[)>$=D
M
M
M     ,[)>$=D      !\Z[1\>_:
M
M     'J/C^C_ *
M        9V2\([(     > ]+X\Z/3NEJ+^@M3PBS[%OGW:
M
M                        !TCROMM%U)GVC+F'=5M>F=B
M                                        9V2\([(    " FQ\0PX]
M_P#*<7LN\$
M                                                   7Q\[[;V1\
M.]+^D^6^                                                   !
MG9+PCL@   !%#,<>_GR?I/QSQ_W/-
M
M           %YO/NU]KG!O47_0           4TQ769%7=R^6JWVU    R?4
MW1K!JM  9/J;NL&JU6E%7#%5T$VP  ,Q\7-#\T5WQ5P9,YU,\YI     XN4'
M4W=+-5H  5X15+R8ZF@           9V2\([(    80_T-Y+J1W/KH
M
M                                     ;A^ >JKH]$[/
M&>&+DX5-GLTPHBJCF*_EFC>JWFCIN6#3$6(G_!I4JM9 *;PT-S;J<BNP*:>M
MHJ2BNJE5O3JL53Q70?%R2ZG4=5:SM4W?,EXU5NC2FY)&8@Q$VE33EBINVCS3
M^P='1-J:;-YIA'%4KII^61EBJ=,TU;15#F*O\%[M5O/;3=E?-.@";>?^+G@C
MPD3.J::'8N3J4V1S37O%5J\T1B3#:*KPYHI#BO\ $?B)-S%\4VP     !G9+
MPCL@ /EGU "$V>XM_.O_ $VXO_Y(
M#\E*>NNLO_4N4P1V'B0 E3A_O_KU1%[+O!     '7?$]&9F#9/73L["OF7J
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MK!9I  ^0?$   !G[+TCL@ (/%/9<@35,Z/3NEL@?:_-X
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M "L JT   !Q@ZH?3 !Y4XF?N%ZQ4-V'SYF,ZQT2
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M5#C-\9T/\S[FCID_B]0\C[\J'87/PV%\2=)X].V^;
M              !_2,_+?MN3V)^\          !#2*J>(K%LDT>\/Q'[4QR^
M)G[--,45_B+HIHK1BH3DF*(XKL]4];F*?8KG(ILLFF/R?'1/XCH$Q"R*HJIM
MUFBF6*YW*?0$Z)II'BY(1$[YIC+$S5FG*Y3=U&56^B('"TQ_B9Z333%%?XBW
M6:(515\TC$F4R/+EF<TUHQ5+R8I[BNW>:*4(KN"FCY\34>JN\FB'D38O--#L
M7)XJ;#9I      &=DO".R  A45P%P9W$R^=:Z&RL=?\ /X
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M<#=#^?/5^%[]!N4/KV+FN#C#HOS'UV.Q>)Z62'L[G35SQWT)CR[<YL
M                           '],#\J>Y>U>#Z@
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M*.]_ZJT:\P;J\?\ =\V='IW2VH;DG?6.?M_FH
M         "3&*>Y_22_+;MT                       #ER?I'OT
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MD4/,WQOLWA>GVKP?4_4KIN3T=LS-/U3HX
M     #3QR;O?5EQ[T$                       !E9INV&330U%S;_ %6,
MUM-VZ>JW*M &92F[^F<H3K.JLT;174U%S9=58 S$4W?RGB3515:A9%4'4W:S
M0 !5/%<>TWN3;   SU1<OCFWE]INZM*K0      SLEX1V0    H8Z)U'B\[K
MYB
M  Z!YGV<_P#3^,       #[?SW?VZ*O,_78
M       $BL8]K^B1^9?9W6/&]$                       #)S3=MNFG.A
M%RWB:.>1-T]5NG^*_,1-BLT32F.QHQ5TW]0\VJ<8KX8G6M59 RM4W9JS%:D5
M:^ZK.86F[IIJM9*:;W;46GS12Q%SRQ;A-%$\7/2(U7U6LS%-WU)>U-O(-%VV
MM31K%S8!59J BK675:      &=DO".R     R>=C\]9F.K=%@
M
M                              =?\3TMX?YX=:V$:US(
M            90*;ML\T\P351%7-34[5:I_BOS$38K-%GLTY+Z;M\DT8PJ;U
MYTT4A17NSKL=E0,85-[2%-O.%%S8]59S24W;R:K="]-S4I5:R TWM7U5JGR*
MZX8JL%FG]$AY$S@F+EIHR0TW?'IVBU6,9E-_9G58R;4WM9-5D      9V2\(
M[(     4<= :IR=]C\]1@RWP0
M
M    /S4S<9H_9>O+BSHZ4V(>^                        !DIIO6_31S!
M-R$V_P"<)1].^>OYY5H QO4WO+%H$TZ"IMC)33>N<FB3LTR=1C.IO6W312I%
MRY2:+)IHDJC$K3?N+FC\Q'*)B.FV":?^GZ1[!%.T5S&1-*::=HN;,ZK&(RF_
MIAFU1O%S6U59      &=DO".R      ^==HK3VI@T#=B8EX+TOC
M
M                             _9HJ[]C?L6@ZESR4F(^^
M              !0#%RU*:.[H]J> /5'U0"*J?AQ/U9B6*!R1,*HF3<Q)5'X
M"+R9-HKWBJQ6:1X\YJGO2.()]@?41\]/^3ZJ/E)\8=P1QE/9D<P3S J&BO0O
M-L      9V2\([(
M
M                                                        9V2\
M([(
M
M                                            9V2\([(     #A.3
M>)7GM; XX9=CWG?KL
M                                                       ?DB>E
M>/Z$P<!RRP75>=_?^6^
M           !G9+PCL@    /A_39I&Z.TW67N/7/X*X
M
M                       '2?']"]/FG=4]-89N
M                                ,[)>$=D    /E7[6<GK;G^'6P,3
M
M                                         _+3-\O,>[K)M0;"
M                                                SLEX1V0    I
M?Z&U#4?O?5@
M                                                     'U_GNZ@
M>,.D>\8S[8
M SLEX1V0   'A_2^+*%W%S#\3Z;(
M                           Z'Y/W\\];X        .@^5]W/O5^$
M                             "R+4.P;[N8-X
M                                #.R7A'9    5T[:P"@7J/1H
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M"1^(Y!(O$L@J0WMJN8& Y9P;)_$L:U)G].?0&IO+_;\P
M                 ]?\'U:V^$^IOS4R
M                      !G9+PCL@ (7%=!< =H*<.@=2T_;\U0
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MT<&O\Y;WGQO(?(\)Z7Q<W]CSNB^1Z%2>]M6S=UQF7V?FNP)VAA
M                        &K_ASI_J/B^D
M                          !G9.$'TP >5.)G[Y>4<TZ"U)4#OO5(
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M-]4%]0Z.D9B606*:FS[G/K_!&#,\:XSD/D31UYF%5^[-9@
M                   :O.'>GNJ>)Z8
M                        $'BF0N.)V%;NWM>T)]/Z0
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MG/&WZ&.G=(W2<[[?AWG^)>I^+ZI+8?D4#=G81W;&?;K<V]KT
M                     >D^/Z-<?"/4_P"S14
M                               !\0^R?Z!S?U_/RC]P<P_/O4
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MK[#X/KZ%Y7WQ5S?&+:]%;2C'F6.2=PS)*Y=MZ_X[D'D@
M                "P?56=Z">5][
M                         4==):9JTW7K0
M                                   #\],S(U]EL,-AXB       !-7
M7680JV+AX                                 _=MUZ<.->C9)XAD(
M                                                      'G/K^?
M-9V!SS&7,L<
M                                                     _["[3G/
M<=K>C]G
M     >/^_P"2A[IS2< -I8*
M
M   !ZKX?INZYQW)99I[8@
M                    BGG&,5V[8P&..6X_\?Z+0
M
M                   Z)Y/WS!P'++(=1;!]]Y?W
M
M
M
M                     ?)/K                          'R3ZP  !\
M<^P  #Y9](_T  #XQ]D   ^2?6   /CGV   ?./W#\H  /C'V0  #Y)]8
M^2?6  !^@?E/V@  ?)/K
M                                                    C,5REV8
M                        //&?8T4G_0 "+17>7:@  JA.X$[@  9]2[PZ
M<  ?',\QHN/]@ $<"L0O*  !5T>^+!P  4"ESAUX  ^>9VC1<?G  ."E4Y>D
M  "L8^R60   H:+?3M
M                                                 !G9(3&K@Z.
M                        5*%)1H_)P@ &<PAF:N#HX /AF4DZL:>C_0 (
MS&7LM;+P@ "JTHQ-$Q/H  SRD$#5F=6 !\PRH'L#4:?E !'LRU%GQ>V  5C%
M#!H-+$P #/\ %>9JO.O  ^>95CZ1J=/V@ <.,KA987T
M
M              CV9C3Y);Z7'@                        ^.9;SB!-DT
M?  C@9ECY9;Z7'@ K#*-3\YHL)I@ H(*Y#W9J8/?@'SS+N< )A&E0_Z <%,P
MI\<MF+I@ 5M%$!_LT+$ZP 4/%:!Z\U*'30#]8S D;R5IIG/]@'&#+P? +6R[
M( %<I0N#0 6!  HV*N3U)J0.K
M                                                        B@5I
ME[8                         !EU-10  (H%:9>V  "H@[(6)@  S@%^A
MTL  &74U%   B@5IE[8  *H3V198  #.R7A'9   9=344  "-)5"7Z   JZ!
M:*  #/D7('?0
M                                          "*!6F7M@
M               &74U%   B@5IE[8  *B#LA8F  #. 7Z'2P  9=344  "*
M!6F7M@  JA/9%E@  ,[)>$=D  !EU-10  (TE4)?H  "KH%HH  ,^1<@=]
M
M                             (H%:9>V
M  9=344  "*!6F7M@  J(.R%B8  ,X!?H=+  !EU-10  (H%:9>V  "J$]D6
M6   SLEX1V0  &74U%   C250E^@  *N@6B@  SY%R!WT
M
M            '!LB\GF'J_#,C",D  @5[WF57^]Y>D7 \G  '+?7^"+^6>%/
M+7F6            #]:NFO'9>'3SUWEGI/EO@      ?I7*<>VRL.U\:YR[[
MWSW0 ()>WYM4&1^1I,P'*0 !2#E/B= OV[?L/]\  9P"_0Z6  #+J:B@  10
M*TR]L  %4)[(LL  !ELV#BM]F+^U*?QO0  &74U%   C250E^@  *N@6B@
MS"Y_BMV^-^S,/Q/1    '_"OG9.'S-P;)?=>?]8
M     _',5X;+PZ<^O\J]9\?T    "D$M6.T    C>4H
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M8?\ 2S(O'/L   \:1I
M,=7Z)<F0[SC&MQOYK=A=,Q[U@!D>_0'E>O'9^%[BOS9[ [+BON  9>NX^:Z<
MM[:QVV_G/UO*77V5@           5E;SUID![PYBTT<@[\O+Y:W8      !5
M?OS5V1GN?F?43QOT'=;S)N8 #)SWQR[63MO ]P?YO=>]YPW(0!^M>MXH?TDY
M \%Z/R;@_P U>P_0^=]8                $<,ZQG$/^CO(ML>E=BZI.$NF
MP            !P#-,=Q _I!R':/I[/]6W!G3X    @YM?!L7GZ$<I7_ /,F
MYM$_'?0                           KNW/KS'!WWRUI Y.WI?AR=O0
M  9UB>!<.=Z
M
M                                                   !Q@[.
M                                           #RA&2*OO3$J$    <
M?3V!
M
M                                        JGBNDF*[4)HIFBO9C59]
M,  "J:*\-=-[^G;7\P                                      &.JF
M]+I'J)C19-O\X   /GF9^F[\\TIU6O6@KCBJ(";OYHS94W?G&E&JUZD
M                                        &<F+GPXGQ1?;5;DT@  "
MB2+D1HF\>:*Y%48(F\FJW+Y
M             JGBN*B= <VZ0XKC!%7Q2-*>2IVQU6,<]-[8U59CHG*Q3=V9
M560                                      ,4M-[:U59JPBNNB*NMS
M'^3JZ+MIHISBO\!$6)T=U6X,155]%<AII]@7"31Y8R^TW>6)L_FCIAT$B&F^
MZ;8                                             Q2TWMK55GX)B
M,IOZ7IM5A17:;-'U":\Q6]%5J\T4QQ7<%-&.BF\-?%5K)]3=U^560
M                                         !5/%<5$Z YMT+1<X%$^
M6*H8KT'56X@1,U9B\F;8QFTWMF55D
M       #%+3>VM56?Q&(6F_J;FUEAB[)A3?9-&?V+D<4ZAIM6$33'%./FF]]
M4T.3;@A%5^E5OU)DVINZDZK67VF[6S%6S&JS.*:0
M                        !BEIO;6JK(P]TW]@M5FNF*JIXKY26$J;:IIF
MA-(RXTW;:YHS11=D8BPN:;Z9M@
M              "J>*\X<7++E,:4SMFF-L3 E5N(JL?SF:/I_HTU_-^X0,BK
M%!3>T[56[W)M@                                     #%+3>VM56:
M,8N0=B>2)\\:19MX<:;^S.JS,Z:<CU-W635:JTBOHZ)"HJEBO3+5:'BDY-J;
MNOZJS &*J/XKU?56@
M  ,4M-[:U59Y(G';3>]47U3;I:BOH2."IV;561F\BY-%%C,TY2Z;NO2JSC!I
MO[5ZK                                             YTGH"/R@ '
M/S[AZ0   ' $Y]:;FHFJT
M !E5IN]/)8S3<3-&;6F[VV8NHFC(U3=V=U6: XN>?-#4V_T#/!%SX4-$%5OU
MH,[L7(WQ.@":*S55Z$V_J
M       %&D5QXBK]I%_]5%2D5>43))3Y)/."\&:/$F3"F]\PLDFGI2(?15>-
M5;E*@                                          "N^*LP$7>[HLS
MFFVB:.^H  S^1<G BR.: ((Q5G5BY2)%=]\T:Y*K(  '(4U315=O-     &>
MJ+FA6;8                                  'F2L**[8YH
M                                                J"BNW&:/W
M                                            "D"*ZT(KU)U6J :;
MDQ9IIEBOYQH/FW2K%SC)-":9DE9,5?G-5M5GU(,1=-[;I59QITWNP(Z@?\+#
MYI@/%41$V#S33I%<PT281!M/<$6>33 6*O\ A8K-.::+DZ46 33F+IN[ *K-
MIDT                            "HV*Z&(N?41;1-,58FZ"JWDOIO6N*
M>%)U:5686Q5G5BY5G%5P$TZY*K(  %(T5W<S0    !2-%=W,T
M                           "M**L[$7+ D21F/OHNBF@ #/Y%R<"+(YH
MQ44WK!4=RF+X)M@8VJ;W7$:;:K?7$
M               5GQ5DIIO6$339A-'Z*?T3D1!"*O;$_9IJ>BOOZ/1(T+S1
M*R:1B+IO;=*K.+JF_L^JL?SQ*/HOPFCI4QX6)IGBO0W5;Y 0YBK4K5:R+4WM
M@55G)I3=J^BJ_":.KS%8\5ZU:K.9:FYQ-5LSJL
M       83:;^[*JP,-E-^1:- $VZ/HKUDU6JGHKA>G1C-L8BZ;VW2JSCTIO2
M@1_H\@6SS15W%?KD411<TB56ZLXJZ^B2<QP*)NMFBG^*^\3$58GHAT>8S]TW
M-3]5JY::                                      *IXKBHG0'-N$L5
M5U)JSBOIYH>FW2;%?SB1TQ.!%D<T8I:;VUJJR,[T7.41,_III4BOKB+T9HI"
MBO\ 8)93%ODT9>:;NNNJSG-INZ3*K0S,TW;^:K=.<5U<15)5%N<T6<32
M                                 !4%%?%TU$15(0L*FC]%/Z1S(K2B
MN=RGH4Q]X@[%4VIIOWFWZ8&(NF]MTJLXS*;^S.JQBXIO7!S3Y8JTBKFZ=!<V
MZ'HK_<-?=5K(W3>U_56<FU-WFQ<'-,HE.>Z+NM>JSF2IN155:89M6)32
M                        ,.U-_<358&,:F]^0T6S;H^BO635:A9%5#T5Z
MM*K0Q%TWMNE5G$]3?U?56<6M%^W^:.ES'S8FDB*Y<S&S.JQC*IOW.S;^0FGV
M*O$)L64P@3^-.S6JQC8IO?IIV9U6
M      !5/%><.+EH2FQR::H8J_03;U-N#"K_ *9V*;FC.JW.!%D<T8/:;]N"
MFQ.:* (N[/JK&+&F_P"I1UQ' %6O2JS3W%?"(GY96\JMHFCD,3Z@M?FC-_%W
M5%59SW4W8UFR^JSC(IO;/JK(
M  C(GNJ/'I^XC_B?\F?R*_8D"8JT93;E?-/D$_K'7$ <03V]'&4]F1^@1N3*
M!$>4]'/5(X:GU)U1'(T]?1R9/441N3*!'&4]:1S)/[1]5'N@
M                9$*;TGD>\F*QXJ[27N3;SHQ<TKS;S-Q<U*56I7H&(NF]
MMTJLXS*;^P"JQC;IOZ0)M9\(N6^31GRBY)E&C6;>;6+MT\V_B)ITBJ5"+))I
M_3*/HN;,ZK&-JF]YI.HZJS+Q
M  %4\5Q43H#FW6Y%=1T5?HIM_FC,#%RUE132KO;FB<"+(YHQ2TWMK55D8CZ;
M^EF;5!D7/B'7$=R.YS%=$5:1*K6%VCZ-R%5C!_3?WXU_/)A PX4W[RYHA#%5
M6<5:=JK5=T5:B:K0                                         $<4
M]1/>H                                            %>\5<93GHBY
MJAFU**::M8K^@65S3U% $(HJF[-,,HJF;-/ $PJBJQ^::XHJE7-/1B*<3T [
M5,?@..1,RIIK BN5$T^,B9FS3#:*O;3'-HF;DT@
M                <I3Y0D"CFR>1G^#KYSPAI%4F$>^F/<'240HBJ:\TCDZ:
M](JM,FB)L5?7F)-HK]BKL$Q+E$)XJFQ-,(HJF[-($-XJ_">IF,E%-[1G-NT2
M:/R@
M                                'G#]D^T
M                                                 0RBJ9LT@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M#RY\I/O4   >-/LGV0  #F*>G(
M
M                                                     JGBO.'%
MR2:+EIHMKF@  "L**HIJKZ9M@  5)17WE$])I  SU1<T*S;S/TW=,%5H
M
M
M                      "J>*XJ)[^B+B?RD#HJMQFBG.*_G&K&JUESIN_G
M+)YI@G%70$61S3G@BY(Y$D4173;C-/\ I$58JIVBO2?5:KHBJ6DQFDINW]3;
M@(FW.:8NQ/R#[)^4C2G8759   _X5;[<P&E_>VL(:YQC7DOM^8
M                                                        #Z=F
MY)?%?<MFTUL2ZS0^T/2?+?
M                               JGBO-W%SA<3_0.K^?/W%RJF*Y*J9U
MS'Z)$.)F7,2>4U417_TU)U6L6=-_[)='-OXR:=XJM(FF5BFO]588I\*FO^*H
MW)\0G9G58QFTWOTS9]59Q@4WNG&J*JUDIIN[):K(  CEE'B8M^[.8:JMP:_
M
M         E-B'O[/N%NG;1M1YZ
M                                  *IXKBHGKR(=Q56*JENCT:)VS'Z
M1]1%/47)6J92S%345VNS1XB)@FJNGFW\1-.D56DS3Y@I.IKTVU6\\L7+D9HK
MYB8WJM,,VL[\7)!HF?,5%Q7W!&I6JUDIIN[):K( $=<G\7^?S^D/'L9<L\(
M
M         #[OS7=RWY^]6V[Z6V.
M                                  !Y0^4= .!)_9/>'GC[Q_D^JCP*
M?2(_*G[*.-)D2CC*?:(_P>.3ZD\H<AB?N3':#](_,?A/J'E#LR(Q)D8CFB>I
M(Y(GLJ  ,&WZ(<D5/;DUZ
M                                !V#P_2_HP_F+VGVGP?4
M
M                  %9.U\%P%_H[R
M               !V_'_ %>(9!Y0       ';? ]3B7O^6
M   !J*Y(WUJ@Y"W^
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M@>45][)PZ NQL0NET3L^H[=&NHQY9X5E>J\X^/?MQ3S#'JQ-LX(
M        )W:\RW^AY^9W9@
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M><O6_%].IKD7?V2GLSG8                 >E^2_\ U!?R6[R
M
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M?S_ZKPY?H!RI?ASGMWF'K?!2]O;6(N7T9LWH?F?91+T-J:U/3^?^[\_[+Q-
M;5Q==U\PV':SS.[#0VT>2>SYW-_4^+.OTYI?87Q)TGCT[;YL
M     'I/DO?U!OR6[S
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MK%XXZ&Q_]L<W                 "<NOLK_ *(OYF=G
M                           #$C3>OBFC[1;E-    QM4WALEJL@#A"<X
M]-W5?59POTW] <V\^47-T]5C_8,Q5-W3K5:H:BY?+-L #_!F0INZ<JK0   H
M:BY^ MCFC*K3>V9U6 *%8N59Q5(Y$6T[3*K(  QM4WMDM5D       9=344
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MD                 &GWDS?&JWC[H$
M              8D:;U\4T2O1FDBY,I$3DQ]3-53Y=/?$>J(4)$ED>D.@3%:
M$53#1\=.J^JSBEIO;1:K.&6F_>1-%<,56(S3FAINZ )MUT)D8=@1ZQ%-<7)5
M33.I%%\5VRS1Z@N8FCVY2W%?*BPJ::KHK\P<<382IJ9BNW*:/0FEFJUAHIO[
MEZK RI4W9 S$-XJL8FFJB*]455G/=3=CJ3&17NJL?FBN6*M04VYSS2    !E
MU-10   !_P ,$7Z+<B59[>P$
M       #]NW5:CJ'/ZH]Q:^        M(U%GM:VU,(^!]-D
M   #JWC>A_1D_,3M3N&/^J
M     ,3=-[4]-OJ\QD[IO;,ZK&-JF]\XV:56<9%-[9S59Q94W_4($(8JNQFC
MFQ_LT0U6\X]-W5?59P>TW[>YHM\4U3*H?Q5*R:8"17LSJL8QJ;U>,57ZS1]V
M8XE%5O\ -%:$51M3?#-O/!%R[^:+8YHQZTWN[H\\>,3X$D&:$:K65VF]LSJL
M8VJ;VR6JSA<IO[H:K'^C)!3>@DG<C59]VC&93?U156<]U-V*1+Y%6T5V(S1=
MA-%C,T@    #+J:B@    1FROPOY_/Z0\>QTRCQ0
M                                                  /M_/=W#\ ]
M57$:1V4                                           !B'IO63(]/
M,5[Q7LSJL8VJ;WZ*=F=5C(-3>[^CUA"A(D:CV!-J:<_T7+/E')DZJJK6*6F]
MM:JLC#A3?L:4^_F*CXKU1S:SH1<Z&2*1+&:8(Q7;_-%?R:4XKO*FCAL3VN8T
M&S;R8TWK!IIK)BJV":*>(KL@FF,,3&]5LSJL8VJ;VR6JS4/%>?V+G1T=>+B9
MHI(BNPV:::XKL<4^/*R8K[-,?C)4J;LYIL6F@     9=344     1@RWP<5G
M=_+]8^V,$
M                   DABWM[.N%^G+8-.;"
M                                                           &
M74U%      _Q*IG<FNZ7M[:PAOG&->(^_P"0
M                                          #[WSWI*XK[ELVFMB7@
MZ!VIZ_XOI
M                            $,3EH   *@S4X
M
M                                                    ?B*+XN=E
M1;A-  '$DU.17>A-L   "KV*K0II X:F@2FY*28O)FV      /)'S$Q@B?,E
M@LT@  "N X<   "NPU1@
M
M                              %",7/,';43@1,&:8<Q5Z&8XC$Y58NZ
M2)MRI1\DG3--<<5=OF/3$6(FRZ:1BEIO:KJK7!8F3\QC/IO:7)MT3Q<USU6:
MZXJM/FB'$5<^.O3'ZT3]R8YW$]]F(,159_-$$8JZ=,5/Q7PB)E+,6031\2)_
M$23F(W1/BBQR:0    !EU-10     /\ ,JN-G^!3CN'&H=YAYOQ+U
M
M'[-,R+QW[;5M69!=/IC*/2_-6
M                  (115D:B[<5-$'XJU^U6L<]-[R2+8)IIKBO7;59@G%5
M.,5S,4]GE(9&;J+EL*GLLQ?/-O%+3>_ZG0C-O/-%SRAK[JLY7:;U^,V_TBLF
M*JE8KMIFCU96@JE0BV::,PE-W3U5:J_BJT&::%XN69J??3'(XGBY[@_:/#G,
MT_>- DVYKS2    !EU-10    !&_(_BQK=BZSK&V9X0
M                                                    $E<;^[8S
MQ]LJT36'O
M  ?@/SF-&F]R-.VFJSCMIO#9G58QFTWM8%5K+-3=AA%70YC9]59YV9$*;V@"
M;<XIIE4C%+3>].G9G58QM4WOTC9E59QF4WY-*?7$;$^*3=/-OXB:=(JZ<:E:
MK61NF]K^JLX3Z;U@**JXJTN56Y"(XLFBF*]/<VOVC+]%V[>:/TB5BFSV:0
M  ,NIJ*    !'/(OBP6]W:DC7DGP@
M                                       ?:LU;:.*MI6X:FR(
M                                               5$177K%7Y"T6:
M*E8KCZF7R-,U5K,S3=T 56\N--W[R+K9HI8BN;4QPB)_T7/31,V:<O=-W[QI
MFJM9HZ;OZIIFJM9F:;OPSL$Q]4Y-$V>S1\M-:T5>[F+[YHSJTW-'U5K(I3>Z
M0CG"='<V\]L7+>YH_?14_%?_ $MKFGYI^L2 1.Z:0    ,NIJ*    /^&%?N
M35%6VT/
M                    ZOY7T?T,OSZW)VGQ?J
M
M&74U%    %:6R?#P==UZE                           '[U$]-\R_P D
M];YP         !VGQOJXM[/R@   #M/C?5Q;V?E
M      TU\TYUJ'YASP
M                                        9=344  1).WG1P91^JM?
M9Q>BL*                        F[A/JZC>8,]YKZ5B*.5^=F-Z8P4#NG
MA_7IDYJSC)/UCKP   7PZ*RVCW=V*_ OT#_ILWXWV;3OM_&J3]TXN!=AI;*+
MP=)95&?)?A@_FWE6IZM]_%GV;K$    ;3.,MG8L^S=8@
M          3CPCU?Z!_ 6X0
M                      .?IH=BOP,3I$JM?<*((KO?F@#PAFTIN_4--%5J
M*2:=HKT@3; %-45^R+8YH&7"F[I=JM^R12I%?I2FV*_*E@$TS=1;+-
M&4\N$  *]2&Q:26WF-/M?5E0&W<<                        V^\3;3QS
M]@ZUXU['S">F">O=QI3*?+?5;H#WWA^T+C39U=&Q/%J,VWCO-/2L7<:4RGRW
MU6\\W06&ZA^8L\X[['S6OZIR&F7<F,YJ^D<'%_&A<OD]C'WP9SCR?._11"G-
M/+B/EOG78:6RCW_P7J'MZXEN)XBVIS3T[&2CK'7FB+GK,_RTLN/4&!:8N:LY
M]3\MRB3>F)WFZ/ROZEJ<Z'1&%[=N)]IU-[7QZ*.5>?65LOPM"?/V8_HW(S.]
M*8-SWT+(                       'HOGK_IH?FGO,
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MS$                        /1_/7_ $S_ ,T]Y@
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MCO9>4+JO7W&/9^66^)^C9)KCVYBX?Z?K_CN4&[YQ&/V0?%R/UOGNPTME'O\
MX+U"&^,1&TSC+9U1>VL=ZCYE^Q;7?MT9[PQ2W74F19<.G\"M/U=D$D,<^VA3
M>^(_7M5;+^.-F8M.SM8['N/-E0GS7RZ?MO8W.C!O6YKZ5BE3=&+@
M               3CPCU?Z!_ 6X0
M                           ,N=-W2C5;R>4W=?U5G'A3>Y0:B9MQ03Z0
MLKFC(C3>UNU6NG(&,VF]LRJL\N3U% @)%582JTY34O%=-45Z)ZK<.XG3Q5:_
M<,@=-[5-5:ZLC)M3=UDU6@          *TMD^'@Z[KU*
M       !^S3-UNE\HE9BOH5"[<QR.&1?#?1HG+HEY9YU5FTL?LRUK[M66T?
MMLU-D59NRO"OHT3ET2\L\ZJS:6/V9:U]VI/;&.S^P'V+#=?>SGTW_AP$GL9^
M_P!U\-WKWD?3%;*?/CED7Q38POU/0?/7 ?//(%TVF<GK5V1X=[>B\MA_E_FU
M@[.\&R/7'MS Q#TJ&-[8E:KJW(),XS]U%F\L3M]U%DG9O&^FF/<N,QUR'XK\
MM#9?S?TK%%N\<3_%(                       #33S3G6HGF'/
M                                                    (*1578J[
M^BW^:/AE-<5W830!5-%=)L5_I&DV;=?"J#$3=Y-%#L7-;]5GY9FAIN^8-&-5
MOM"*NXKL4FFBR*] <V_UREB*[KYHX FA:FYIHJM           ?\,*_<FJ*M
MMH>
M               !U?ROH_H9?GUN3M/B_4
M                                  (JIE4@      <43VM      ' T
M],1[            $<\B^+!;W=J2->2?"
M                                           !]JS5MGXKVE;CJ7(@
M
M                            (WY'\6-7L76=8^S/"
M                                                       DKC?W
M;&./ME6BZP]X
M                                         #_,JN-G^!3=N+&H?9?Y
MOQ+U
M           '[-,R+QW[;5M69!=/IC*/2_-6
M
M
M
M                                               /\'B3W(  /%'K
MC\X  /!GO   #P9[P  '_#PI[L  'CSTA^X  #P9[P   \&>\   /!GO   >
M:/W3[   /!GO   #P9[P
M
M                  $!2%1>>  "DDE&6)@ '^3,P:"SKP !X S?&G8_:  (
M/%?!?0  "F([B66   S8%ZIWH  \:9JC3N?0  (AE5QH-  !40>E+4@  9Q2
MZLD>  >>,RAIP/N
M
M             _P9>R/IJS.K  YP91SL9J5/S@ @B9S2T4O;  *5BH@T %D
M /\ AF0(O&JD[0 #PYE".BFJ0_< !#<S3ECYH!  *;RF\OG+.0 #-F0R-2I(
M0 'F3*(?7-61]@ $3S,@6"FAH  J4*2B\(M>
M
M                                 !%,S[GF2X M: !5T4WGW"_DF  "
MA<KL.]FD\]B ?$,VQ%\GF:$0 1G,\YY$MP+;@ 5G%,!](OI)J@ HW*T3LYI(
M.C@'S#-T13)PFB$_T <%,Z9STM=+BP 5VE(I^T7G$]  4EE81UDTA'5@#]8S
MB$/R9!HV/S
M
M        @\0W+J0  4WDEB?0  ,TYHF/9   RZFHH  $-R I>$  "H@[(6)@
M  S@%^ATL  &74U%   C250E^@  *H3V198  #.R7A'9   9=344
M
M                                                  "#Q#<NI  !
M3>26)]   S3FB8]D  #+J:B@  0W("EX0  *B#LA8F  #. 7Z'2P  9=344
M "-)5"7Z   JA/9%E@  ,[)>$=D  !EU-10
M
M                                 (/$-RZD  %-Y)8GT  #-.:)CV0
M ,NIJ*  !#<@*7A   J(.R%B8  ,X!?H=+  !EU-10  (TE4)?H  "J$]D66
M   SLEX1V0  &74U%
M
M            _2N4TF[XUA8GK/,I68?[X %3V<XU5GGN+ZJ=%;,_)$@ 9WMG
MX7ZSTOCOUT]L   9IS1,>R  !EU-10  (;D!2\(  %1!V0L3  /C7[>.G?&L
M-,6J\WF;BGN  #+J:B@  1I*H2_0  %4)[(LL  !DXW#K^W#S?LM7UAF@  R
MZFHH  '#<@\JIC<>OKJM$[-]?\7T@                        1FROPZS
M-JX/=EH;9_VK%T                 9V"U\F0   "*Q0*
M                                             "&6_M64@]Y\PR=U
M?FE]WYO=>@ 9Z/TYXRX7G&-WS_GKU=*33&PP!\_[/GS2?JUP[\7Z;&D'\O\
MM+HF(>^ !R$ZL?L   XR=F  !\ \P=&  !X0^@>K  (+=&ZCI=[DYJEUI_/K
MT?SNZS  '&3LP  /CGB3IP  /$'[!Z\  YWE_@9O/U!XM^[\M_2U^4G<?T/D
MO@ <9.S   IH[PYB@7T#JNV?CW?UDG*&\P                        *,
M_P!#N3H@;CU_=#PYTI.KG';H                 X4?KE@!H*/K   ^8>'
M                                                          !%
M_-,=QH]X<Q73:%VAHHY5W> !F8Z]T'5=N' -H_ _47<<9]D ?\ECW[LYDX_[
M?F[1^ ^I?1?']                 $0<]Q?')W5S->[SKMJ_P YBW.
M        /._9\^+?OSEKL7B>EL'X3Z;_ .P     %+?0>J<W75&D=<W$W1U@
M>K<V                         H+Z;TU0QT9J+8[PKTU+[ LH
M         &8\LW+6#U@
M
M                                                           /
M/'H0
M                           #YI$N*OH3$JD?N     ^,>13T= 'QCR*>
MCHYPGX9V-                                          $/T_X)6(^
MN   #@R>CH]D<>3Z(]^@
M                                                           1
MN3CMIO7_ $VZ3HKUR56NY(   '-4XA:;UQDT:.)MCFJ<0M-ZXR:+AIHS/TW?
MLE],V[$)I                                         '\_P IOZ:Y
MMTUQ7I2FW-J:0 !0U%SD435JJT/S;J\BKA"=155J3J
M
M                     (W)SCTW-9-5J!,54517TLA4J^VC8;59R+TWOT"8
M"-*55KS)75%<%$Z.)MCPY75%<%$Z.)M_IF<&FY9%--E$T@
M                          #%+3>VM56? )QV4W9V(KW5=I1IRJM9L*;N
MJJJSZP_<,5--_P#91L\JLP=BJIR*]*U5H
M
M           "-R<X]-S635:K<BJDR+GNT4Q17L>JLTM17U(]O,08BK7159]J
M0$BJL)5<S-%)E-R_2JW&*)K"5:.)MU1Q57Y%>E^JT
M                      !BEIO;6JK/&DY$Z;LP$5;17JLJLT>1<^\:TZK(
MS81<G$BDV*]?U5F"<55HQ5H[JM@
M
M     1N3B HOW:S1#M-R$T4]Q7#I.]BJQ_.\H^C?O78H5BNO"*M=E5KHJ,DE
M-Z'*=IM5GM"/EF22F]#E.D6;>)ZF]=S-%]4V[+II
M                     '\ZBCZ+_)HB$F]B:,Z,7/QFL>JSCDHO:_:K4R9I
MSA1<SLTW;2YHNPFBF:*_&FLNJUVA
M
M           \R90Z;VN*JR
M              /\F/NF]L&JL@
M
M        0TBJGB*^VS%Z,VZT8J]:5A17UF8O)FW[ \09Y*;OT)BWQ3,::0 !
M0U%R^6;8                                      %*L5Q7BKN4Q^(O
MEFV  *;(KN3FB/R:+J;@N;FB6\TB,*>4Q,8$W)S0
M
M                     ,\,7)PJ>;)B>FMN*N[&FVJU\@R)4WMO=5B-R<X]
M-S5A5:R.TWM LV^B3'%XFQJ::VXJDA,0$BJ<4TQ6BJP":?ED(HJL"FGHJ
M                                 ,4M-[:U59%.$5SCFGF\3[N8DBBL
M**[-9HR%4WMDM5FJ>*XJ)T!S;$&XJ_$<K(IJJPXJUHU6J\HJM'FB)T52@FGA
M">C'Z9VA$.8JE_-,.8JZ-,<[B?-D[YI
M
M     SPQ<@+%7 TZEYM9HHN=V--M5KNZ,=M-[4[5:^&9QZ;FLFJU$!.4RF]W
M%%E4TU@Q5ZLOGFWG=BY'I.H>;6>R+G[1<9-%;<5:Q*K0
M                   &#VF_;@IL5FBA>+G02T::*'8N:;)M?Z*((N>+-DM5
MFJ>*\X<7+0E,^9IK9BK]H^"2JF*PXJYLG2O-J@R+GQ2SV::UXJD"B\B:!FFB
MYL$JM8YZ;UBLT>;B82)T[56I3H
M                                                           &
M>&+DX5,W9C)G3=\B=V--M5KNZ,05-_:_58X8G./3<UDU6J4HKI?BNVN:;EIH
MR?4W9N33#Z*O&'Z*=F=5C&U3>]B=H1H JMR,0
M            !BEIO;6JK(QM4WN@FI6JUDIINS@1Y\@6GVALEJLU3Q7%1.@.
M;>=F+EA2G]HS,Q<N/FFL&*OC)V@56,6--^12G\2?4(YPG2;5:@=%5-D5Z_JK
M6.VF]8K-%A"*^TSO4V5S2
M                                                      *:8KK,
MBKT1=!-%045]9F.5Q/X2Q^:;9IHXDG(=3=L#1\\TJ56LM--W\!;K--7D52)F
M..1/ZIIFJM9HZ;L'$S@1Y U'56@
M  ,O=-W4)5:&:.F[[&8OOFC._3<]9,?X/AGZ43I<JM5^Q5']-P4T<U3F*IN?
M]+?YH\@F",5>XF.4Q-@$TR$15@JLF4U^*M$4VQ6/%52L5Q]38--,*XJ]8:O*
MK/[0
M                                                 ,O=-WU9-.:;
MAIH                                                    %-,5S
M&1-":0
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     (#DD#M
M
M
M                                        /Q&7(E47T K]BK/=%R5J
M.F3&AJ;8  RJ4W=5=5H  #.I%SE<3^N6133;+-
M
M
M       KX,\Q^^:J3M!5/%<5$Z YMYC*;MDTTUJQ5_@O&FBAN*[49IB>GG)X
M2)G5-/DR&D53HFFYV:,C=-[3;5:[NC#_ $W]&DVZU(JL\FB$:K0O-O/]%S@<
M3)N8OBFV
M
M                                (_E/!)8L<.JE4\5Q43H#FW3S%>8"
MF[K#JM?M&:Z+G=T:D*K65RF[Y9.TZJQC3IO?]+B9HY6F_:;>1NF]IMJM=W1C
MMIO:19MUEJJIXJ]D7U3;KW55(17JOFU8+-(
M
M                                                           %
M*Q,@G""J>*XJ)O1FWC5IOVJ31]\_?.9EO\T9=:;O[A^BG9G58QM4WOI'NS2O
M5:D"C(W3>TVU6OE&1&F][Q&G&;>8&+FD2;>'.F__ $5J_GXD9'Z;VXJJP
M
M
M                     !2L3()P@C\FBZFY]V8NLFB1**8HK_$67332/%=T
MLT18B?Q%F<TUHQ50)%S13-O.5%S9K59KJBJL**^LS%Y,VXAQ5")5-93)N8S-
MTW-4%5JAV+D\5-ALT@
M
M                                          4K$R"<(       *U(J
MK^57ES1V%    B,GI1V]
M
M                                               A4=D.X@
M
M
M                                    $?DT74W!<W-$MYI'A"N.*_!E
MR<T        5U156%%?69B\F;?L
M
M                                                      "J>*XJ
M)T!S;$&XJ_$=RF,X]-WA)L1JLU9Q78/-/"HF9TTPRBJ9<TP^BJ8<T^-.+)Z*
M>>.21,=4VD31]0R-TWM-M5KY!D2IO;;*K%6L5V"S3'>)FY-,-HJ]S,1FB;*9
MI
M
M                     '-/5^'"[^@?*TP,)R/9;P[TH*IXKSAQ<M"4SYFF
MMF*OVB5$TP=BOA)Z<OBFWFFB[W)&FBJU@>H^C;'58@<JM$4^'*D(KL5FF/:<
MZ%-S5K5:J2BK6'5:R-TWM-M5KNZ,=M-Z\::/9HSXQ<^0;#JK.2ZF]&5.E.;=
MFTT?2
M
M                         (,; Q7^=U^F'''2?+^W^G'^4?<@JGBN*B=
M<V\[,7+"E/[12_%?^T\)/A)VA56,7]-^\:;>;B+EV\T4R17LQJLUSQ5UQ%7<
M5V.33'M-5$5[)JK&-2F]LXJLY&Z;VFVJUW=&(*F_;K-'$HFM%5IKFUE?IO:M
M*K/X#,C%W9=59[6@
M
M                                    5.;CU]W7'O6G=KW*Q7[%4?TW
M!31S5.8JFY_TT*56ZIHKY-$SIFFO6*NJS&AF;>.*F]L.JLX^:;VR2JR/EF1^
MF]V-%EDTY+J;MP4T7?31/::<ZD7.5Q/X2Q^:>*IC[$^"-1]5K!I3?WEU6,Y,
M7(\Q.IFJUZ,
M
M                                            &9FF[IFJM    #@"
M:LXKO+FV
M
M
M
M
M
M
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M1(J!1JA./ON0W)A12] CTRJ2-7EA".%,F:N8YZ>IM&*%>;7:5YAG&G,J1?\
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MNAO7Y)0*=5.M=)I-HI'HOW'S<I*S\LL261B#4_N?V,&QGT&QGT2+)^X22O\
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MUU-PLI+-1UH1]2BBIXE5M'\?A6ZC(U!<(*XI9'C2%0D*I*W-4&>GR]3[A"%
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MAO4UO4ST->'4-K ]T/=;W4Q@:P,^[U[J9U!T,]9[I;Z6]#O0WJV>AWJ#H[+
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MC"C0GH$82%$J%1=CE6JP7'G7G'A3J7-U.)4:='ID?H8QK6U*B2M/H[KKS[T
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M$)98B42&;ZR[6JQTI]^XU(_SY<J+M*K:C4N)-2LO+QIJ/7(L,MDX%3]QJ?\
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MT1NUX,'YH_-#S_:8Z^UT?F,8&O->;YKN.]IYK[K@:^X\QQ]CH:W:WR8?KO\
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MPQ[\;SG::XQCKS>N&W:Z\WM-$-QCP><:\/R@QK7'FN,?:QC(8:W:W[SNL/\
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M_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/
M<1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^
M/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> X
MC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\>
M XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'
M\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!
MQ'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X
M\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B
M/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX
M#B/X\!Q'\> XC^/ <1_'@.(_CP'$?QX#B/X\!Q'\> XC^/ 261+'[4IHD*FF
M"FRWF7>5[H/*C_PN8#$7RG1\S^3FDWC2DCB@B)_A<Y<&]1.Z0B.3"^I(K(;9
M.6_09^UJR]&+B[1+\DQN+1ZWTCY]E!K3^(7/C0%034U$9!,@MGMT*NCFO_XZ
MM:]V0*O?%:6ABSYCT1L&--G: VE+E<=RYN F_)(U]LS7V_VT*V,_K#()G=%S
M%J^+39-CH17E/842#0.7YJ!BI-TG+R)-:W=LK7,%W.VP$:P_#U2I^NX3>5,.
M15IU"J9\(ZE(ORG'[<QKG:@X?\LBBK:CZ1IUB@H)@R$9H;A_]I46J?[/_P!#
M<[=M;O9NG-ZG-0JF9YQ>;X;O[GYO[QZ16:N7ZE;'G%R4VNS5A',I6I7)S$M,
MR\Y+^9"F$*CJHG'RM&/P4GE=<>=.J=I]@5H]DE'%YF&BQ*^$RH5RY6-Q%376
M"433"4E=Y:[&VIYILFQ;V;V!O7(VM(#=TG<3EA,=+YHM1LDM@LF)HR$8R4&R
M347Y6C'X/E:,?@N7Q664W<$E-N6;QP$,SE H%5/RK<_R_P!CON>.]HV#G'[9
MV;;[,2%G&0BJ6?8-K [-#G9ICN0JQ<W62XKK>["U4N9Y>K'O<PIJ;X9;"DEM
M[M,MD(=G%O=P7+LX]K@E;MQL[0JT]",>F+Y L:TE=Y85:K?.6"QRQ&.:@F9&
M4126WA/#GBHMY/%_ 3_%=;VF]^'T&6C+\D^-$A7-W5KY>(J7WF8GLY2WV!UM
M(%?31?$T\],G^0DB8XK85H652[A53^\[!QECK5@*VRDW*5"4\[ED5LMH@1$U
M5Q-U?HO3F]OYG;[;VOO0Y:R_><N3M6\Z%*NP0!(#/Q +1AQ +1AQ +1AQ +1
MAQ +1A>?=Q;TK%OY7-AG)-:0W)^8:2$U5Q-U?HN8NYV8M+QT>8A 3T]JJ<$>
MY9[)RJ=%6KEJ\G:14@TE0TD8Q=.+K'_Q)[ELG5A?#BN>^@21 %X7ZH34K,R4
MST2<G-U&;KO+UW\$RT_R$P(%95A2K_,(5UV.9%!CXQ8W49*:S?=8T=<?JNEC
M %>,:[-@CZ**[<">4WY7_)H>*0O?+CY/$/H]<H5;+%8\BQG!5?-?LERO)I74
M75@628>;Z[]Z.LW+,Y,TH+!A+I@*5=%A6-BZ/(T>K_+!EAQS+7T2LK,SLSD$
MPY6UV+XFB\73 ;:ZC?++9,56*EZ^'R^VPNC]$*%$CQ+;.70R5W&$^\'!+D/L
MS*0L!L 6O(ZM'RI.0\7"<MO?);6AU"H5;-%;3CEB<EY](=U-HMPEE:J VX3;
MJ4PLMQ?( @%T=\.:['C)8\[PO,/!Y<[-VN9*/.C)1[SQ"QG'D^$;A1*".%$H
M(X42@CA1*"%YL$-Z#IH$:MH6-=YNVFP0G(;5N;05";HMO7F'3*94:U4K&+/+
M9,'%BUT',YW]*@<;7N9XOU2TU9ALC)7R37.P($>:CRMAM\D^6:C3JA2*ARNO
MQ+>9:H5;,N5!2K.[N48+H@0(\U'E;#;Y)\LU&G5"D5 BD$]JB;#^ARU).=E
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M^E7K%%CJN6CG+E=,:9GFOE2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<>
M^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G
M'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^
M5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'
M@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5
M)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@
M/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)
MQX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/
ME2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)Q
MX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E
M2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX
M#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2
M<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#
MY4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<
M> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y
M4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<>
M ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4
MG'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<>
M^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX#Y4G'@/E2<> ^5)QX!WE2
ML=[KR8<N#BO3N:1>VVWVW*C^=F2CWGK=/=\_I#R4>\];I[OGTU2J])HT+?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DDC?DD
MC?DDC?DDAUYUYWSMR4>\];I[OGT:G*JFZ+DVZ;F("Y19M9,F=]*YS%4J]6KD
M[]XQ#6174LF4!SDWQHY&LZS)6I76S7G7DH]YZW3W?/HK]<A2.V($&ZF\1>KR
M#]]YF-G,ZH-NL\3CB5E!*WG3DH]YZW3W?/H;T+MD_LM0A>EV4JY15OO.PY9+
M)VV$_.O.O._6,Z5UR^V<63VR4CF/;K4&\,?,XBV^A+F64+^@P W&7"++>)9Y
M<9<(9^86\FY:XRX2@\Q>,PQ\/"98V,!BI*<L>.3R^9A7Q=$&21#ZA/U9%<9>
M1ZOY #7S$"O*PB=@F+TX&U0,>_T=R%5J="MWY:1=UP7=!O*RA7OU+'U::AA_
MG581/ZQDH]YZW3W?/H<QUYTS=5=-]Z&$F\Z9N7MH^L<S=\.###\+P9%[D#Q:
M)98EF>2ZBZ-(J_FRR063JJJ:S2M$M?2SF13Z8;3<9F02^=<A-9M[S;PE'=S:
M7M6='XEG,JJ*4.6Y]^"R#_9CR)Y(T*QP)50\@7,!*?3,:F5XB7[3.1S)(BF-
MU)4WR*Y]E@H!:NCA7@<P0,WWPK<3&1I5DLL>K^;+)!9.JI8-Q9.925+. N"Z
MK7,9BLB5F1I6Z\A$D,M6+64/-%=K3,<F8\Q7(K[S7'\+W/+3D$1:TO"<K650
MAEK,H<+P3SAILLR7725:SI,<X]V-OUSF:&_&[O'BFEL2\E:Z"WO+SD.J&..U
MVRI0%V5FUJ^U3UX1*TS$+D+JF1NUNXQ;BM;8A&)?(E<'>-;9-9M[S;PE'=S:
M7M6='Y<3F55%LUY4[W=;&<J]PUS64T8>LJ]PV05;+L,Y%<LQR;5+(MGO4PO8
MH<N!3R.T[F)EPR%5\N6E7!\P="3S)7EG23'HY'OXYA*B4?'+DE1O(VEV07,B
M6+4U?,&2#/%;^6K)[TD7OR0J9S^U)&[O[0<MF4&X"Z2?S77P7?*Q:3DER"S]
MR'TV2CWGK=/=\\BKUNC4"5Z<B]P$Q;+9D\\\\]YAP8,68BIEBYO^5ZE*KC'O
MU1>F^19Y:$I5[*M7>6EJ-9:KWTB/("MEP-=-&'[) 4*-6J)62W5NDJEBN'8T
M7#8[[Q+4R,+=;4+A;LC%<7:LNMIQFI6,B^"M(H)"0GJK.D;$QD442FK%CEO@
M06E^3;K8/=U=A03D43"GYO"#6G7'W/3ZHXL\@".T#H02W%;;GSO<-;.MMJ9Y
MZ;B<3T"WC'L$OQ89 5A+J[VI7&VR3_2E23*.N!\N4LRN4M!CBWJVE;KJSUP5
M\F(4;$UD!24A@C8HLA:BD]04Z/B4&T2>/:[^;02Q^VVB7;W+Y#K.*G9#<IYA
MX>KA)M +[/K',W?#@Q^8G+SUTLUMIQ,WHH>N^;[X5O+:ELO4K&ES*E#I55QH
M6>5.>JV ;E6$-3N;+/,J*N84VQNX9$<*Z+XTLR*0E99,:G+.JP8U#QV<MS[\
M%D'^S'E&7 Z5W/EQN\@81 P7G7 9O+[)63NWYD,722DI*\T$,WWPK>6U+9>I
M6-+F5*'2JKC0KJU'!+^6&Q&W[7*6;6EWE9(;X;QK8\)9;5 CXP5RY@/&2AU2
M/]]J/WR9SN:X_A>F^X_RH'\=<S=\.##H6R\6L9W-;4.E1D14FW>FWOXS^68N
M3KDB5[V(3<J&=!UUUQV;E)2H2F-*)/XQLV7,NW$UR61_,028^/\ P<89$<*Z
M+XTLR*0E99,:F$%6#&H>%'E3O=UQ'_["@Y9#WK;J"V7C=S/XLOEH!/YFKFK?
M=DLU]T%RZA593.QQN\@8Q0T^ZJ:R]XO+V%X(=V47-O?]&A\NVFMR*6+9:NAJ
M=KMS(BTIZU7$<L6O?7K L8K,LH5F-^+?)JQAH% =U%3X:BI\-14^&HJ?#45/
MAJ*GPU%3X:BI\,BM6I=:N4MT]WSR,BGNJ(;>PN"'A#;\$/67HYC=0XM'M^\P
MW77GWL<F.Y%+#D+N YC$XN&>W_F,C2\8<K%Q5M-R=S'3R_'OX9]??\^@Y;I/
M8,N3C[^^0E2=UU75.N_71/,,UFZ+9W[WB@IV?&V%.SQ;STVK^\_S#'N-H6B"
MC7&JJ9*U;YA L>5Y6C\NJE);\%0JE<P'<SVUVG6H8B+<E:YCA99PP6M\P_!,
M)KRZXP$V4U+NG&-B4.UXE104XV^/2]X_O=V3VS52[VYG)'?+0,6Z7649U+E*
M2LN>NQ$J)S.646,+1?(I-KZ66DV)QN88]^3HQ;V^2=RE[_,,W&3IN7G E8F4
MU#F+U,ZURE96+'!>^7\IJ47JVSU:T2Y<6T6PK#=JJ-I%L=J&+\O\RC_G1RW:
M>^UJ"KW,%W7%56+A<WEW]QJ08/T3*"T7W7^9C;RTOO&S)T,J7(8^L2>/*=O1
M6+,CD-DKB3R1#J8TV.V8@H%N[S')YAT.M5$N5LBFJ2/1)^K\S=\.###\+P9O
MOA6\N+\+SF1/AAV5?Z_W*I>[)G>M8-UUF/' ;?:DB_66YYKZDBM^LIP(6J&R
MU7'KRW/OP60?[,>7.A&W'SE_2%>$:7Q/2ED5LN/]RV5UZ;L1SF4I;4<K:8UJ
MY-,+KN8[&;[X5O+B_"\YD3X8=O%MM3N[Y>#EU[YD[+2+W#W56[6GDOF"+N8J
MPXS,;%N./!%;/KR;FT:NKS^\UQ_"Y6I4_7;-.5,.15IU"YC@^$=2L7F(_P"&
MCS6/NZVM>[)E-<->)W+YRWUMAAIR+]',HH49B'-V.UR)ESS=9WK6#==9CQP&
MWVI(OUEN>:^I(K?K*<6MJALM5PM<J=[NMI!W*UE',8W+78V_6B)KRN]4@UNY
M6X?_ &E1:I_L_P#-3TBHS%IMG"X(W!LH4&M/XA<^- 5!-341D$R"V>W0J[CM
M/]!PR95# IR;%,E6MWQVNWH,Q[_[)IT.163HH(Q<7:)?DF-Q:/6^D?/MY.25
M'%.5F7\'-SP\'-SP\'-SP\'-SP\'-SP\'-SP\'-SP\'-SP.Y!.*;5ZBH5<W5
MZ/X>KL1X>KL1X>KL1X>KL0=$?7\HE\4ZG5"KSUD267B$N#S)TU,/FSS#QJIO
M2E8ONYBA7*V5+=>G&[C<MT0RV:/S$:,4ZK7F8^K5[[K5>7X]_#(LOE@=G2[6
M=Y(;<LJ-1R66F4NS*[+&[C<MT0RV:/S$:,4ZK7F8^K5[[K5<1?Q&KTDPLH1]
M7[^LQ=N%QQ)QMW?4B]*WM<^8,WQ)G16#(8C"[9S;"<;O+A,_J[E%.+6,(:3V
MQ*[=%FP2JV=([M1:O[S^9*V=;;K+5+++5$@Q"6NWG7?*7>JMH2WX*F"M-:2H
M.0#F.EAKTPHG1@H5*?5JP6XU/I5)K@^A)\@%UJ((-RW[SSZ.7C^]WRY)5D9^
MY#-\:IHQY'!=TUBX82;6+PEXLV..%I03NJF3CF&/?DZ.6_)D"?6G(4?8RE7P
MVH_EHOA!&#LW3I:R-<QH4Y*GW)BWJX95K7%2LU7Q6+E<I7,H_P"=& )A"*UF
MY<Q!8H#?4<A&'55K+2S8-=K/V57,JLB^$F]0]7E+?1\G"E9+[FTZQY6U]%A<
M9Y=L&7F)9)-3$]9C]7OIL<2?((B?RM&/P?*T8_!5\>R+UJPVRFSA,;$$&O:L
MR2^_-"$OL^31)K/\?V.5$<<!%%U.!7'E=6<;6<!^.^U@W"R7%=;W86JB68KK
M>TBOE5Y'$M7Q/C=RQ>.0R&2SW&W9Q8K NDM,0*\Q+2+RSN-XG'0U8H[5#!=6
M+I[;R/=V@%E-G"8V((->U9DE]^:$6R6]$NU)!KS<.-BM\AA1_EM\;"6&%6[6
M;?EO0LM<LKC=H1U4?%!:.?52R"XU4+R1E@GEB0))2N"Y=G'M<$K:A8;[.#O9
MO;JA92ME0[(%C@0_) 2R"3:8G1%YAD\35TEPB1I>4422WHN8MY3R[!"+ L="
M!8XD\%U.!7'E=6<;6<!^.^U@W'XFTQ12+C]QP(?C?)=\N+2T'(/#M=P X\;7
MCO:9C10"S)<CGBHMY/%_ 3_%=;VF]^%QUN".W8I C_+=XZ4E4*Y&UI ;ND[B
M<L)CI?-%J-DEL%DQ-NYL1M:OD*E!Y87'12##;[;6A%JJ>HYBHMY1"]TRE@M'
M0OJ[RUV-M3S39-BWLWL#>^FR4>\];I[OGD9 Z=4*O;$AN-53ST$>MR2!"Y$<
MR84HD6D>8>,Y1J8E-^?,3(_7#=;KT2<.#&F\XTQ,%+&^.7@JU6G[*<,=+IE#
MRJ9]??\ ,$?Q#>8>AP8U\><:8F"EC?'+P5:K3]E./:ETRAY?N9&KU9>/0Y>?
MW&S[^^>A!$$5&Y=4:7(6MX)K4[@5]4VYM6.FU?WG\R5S"VVIVJ8N,CU OZ3[
M)YCX,5BRRA+?@J8*U*I*?9 .8[2*MRRD=&"9+:BDM@U:6E/S#??Q1,)XR17)
M6>W'&L<M[_#5X_O=\N2:I&0N0S?%6:+F1P7<NNHAA*&!OXA',,>_)T<M94):
M'4KMI.9IUU=J/Y:T801@[*,Z9<C7,:FR0J%R/1B_^(%S*/\ G>G&,<*W=QC
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M_M&'#_M&'#_M&'#_ +1AP_[1AP_[1AP_[1AP_P"T8</^T8</^T8</^T8</\
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M_M&'#_M&'#_M&'#_ +1AP_[1AP_[1AP_[1AP_P"T8</^T8</^T8</^T8</\
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M1A='BJMU6A!UPMV6RV\WXK,72H7$K!P_[1AP_P"T8</^T8</^T8</^T8</\
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MC:8A9$H*7(GS&Q&H!KQ>V@I=6KZ^7+Y<Z[*@/XX[0+.S!D"L#QBW_4Z0P?\
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MX@P8LQ%L5P-4";*E45K &@TR]8WB#R%%B_;'\K5AJC]-G]FRSWJJDBF+6S!
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M6N)0YVWVQ^ZNZ>@U>D54OU88B_B-<RC_ (+%-D<J]DBIYD\=-(N((EJ_O/\
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MD'!IR2#@TY)!P:<D@X-.20<&G)(.#3DD$IACR03,PG. *\$SS" 8%;5TTC%
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MD(*N]B7+&JJ>C]838M_LQ<U__'5K7NR7&6BVV7:%%(3@I& G*,+RO=!Y4?\
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M+ E35,R97!P<K.Y7AQ2N]^=/3K$V4KQKWL*.-(\"B GQ^\53]0M*&4B94H@
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MPNNJC8+$IRK4;DCPY3D$SDA=?M GT-*@7"+ !\EI&]99P":C-1$TL,)"&4)
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MS4C*?R"\D"#55'%9%B$ S"$_XDWJ5*T[P  ]^PIU_7[/'R%&U/T%6R^B9IX
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M"$H:%P2  / !(?C'*-K4=+5(.1UI#@\])WA\ A3E"TYLZL-RF%<2?"TO$B7
MCF_#"ZYA(VCL5 )+K*3C0D9769E:0!:2DN(2+5+'OXYFB',[(:4.>J%":43$
M\*1,8W"+D V3!64I(,#9VP& B8'..JDIUTCY3BY G?"0 A,S@2D'\9KNW/95
M"*7VCM4IL22S4G*"+$MNJR."2%*GS@FHN)<V?M!M;-:RLH6A8DI*A800??JU
ML+9\TH/&=<E-+30(Q+.^;0E"9C$LI3, DAG8>QFPW0,)D!>5$VJ6H_*6HS*C
MOF0D  /QG+]I=AM?_P"S4K<U)2+:EI(Y$A>Z@6MF6)0'-V\3#(W^_1NLJT2V
MYM$)>=)'&0@B;+6^,*3B4#:'%K!N'XT?ZML]&'8VT\3B0!)+;P(YY E8 20X
MD6#CJ2D21]^V7Q;N<,6Q9%OW2R+=RR+8G%D2W+(LBV+(M^XV1;NR^\+(M^^=
MG['>3BHR]SCHE,%IH%Q:3P+">;\*A$A=[Q"I1 2!,DW 0:>OVM3<\E6$AH./
MR(O!YA#DI7&=QXIML@,;.VM3<\580ES&P2;+$A]+95.=DIS,P)D'W(VYMANH
M<I"\EJ3*4*7B6%$&2W&TRXIGQIW6&!M[9#=0W1EU;<GDH2O$B4S)"W$RMLXT
M^ ?=15;>K*>D849)+BPDJ.\E).)1$YD)!D+3( F!3L[6:2X<KC50TGQK=:0@
M>-0A-33+0Y3K2"E22%)4#<4J$P0<A!E[AVNJU8*5EM3BU2)PH0DJ49)!)D 3
M( DY 3"ME>SE;Z17I:+A3S-0W)"2E)5B=:0FPK2)3G;8) RA%9[2U:*5EU12
MB:5K4HB4\*&TK60F8Q$)DF8Q$3$W*[V<?744;:\"EEEYI.*4\*2\VWB(!!5A
MGAF,4IB?_3+M?+;@J13\WS%2?KBL(",89YOE$#%CPY<4K=Q3KJDI:2"220
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M9#DF4*FD*(GCJGK\*4IGA!F4(G(8UE);V+LT!3G*>=(DIYTCC+5O#(A,Y)2
M+3,F%?\ YE;_ /JD0\RPHI565++!(OPDJ<4/ H-%)WP2,L;2]I%)G5K?33)5
M\U"$)=6!](N(*K3R$W9=Q592# :VE:J#ALDYB6THB5Q):"R1\I1-YC9^UW#-
MVJH6'5?2<:2LW<).ZS[4;6I$/;482!:>(O#/ 76^2X43XN(&P)!F$@#90%WH
MCO[P1L?_ $ND_<-QLZA29-NUY61O\VTL#Q?67;\CDBA=2)+?<J'%>'GW&P<U
MM.X*.FXK+>V*NG N&!2GF@);TB",E@.2<-T'M"R7&FG,:%)44+292,E"T!0L
M4FXR!-J00K9NRV6V*!FIITH0@!*4C&<@RDVDFTDDDDDF'_\ 5'OW-/N[+V:#
MQ7JMQPB=_--A(LRRYZ_),;\;'HQ81L]E:A98IU(=6+)BQ2S;EO@TU1QFU[9I
M&",F!"F6B)'\T&>^9G+N5KRQ-=.[3N)X"7T-$YCBO%.-H4"C-#->%C@YQI ,
MN";<Y;Y)RVPYL3;C7.T+A!E.2DJ29I4A0M2H73&0E)F"0=J;'V$PEBA;HE6"
M]2IIFM:KUK5*U2IFX7  ;;^G2?%4;E$RBF?71-4;:$20O"XXMQQ:DH4!)1*0
MD23,S2=Z0-?4>SB&-CIXV)='7)2&[Q-TN)1R?EX0G+AE9 V+7,^@[?4DE",6
M-MZ0)5S:Y)(4 "HH4)RY*ER,JC8!6ENJ)2XRLSDAY%J2J4SA4"I"B 2$J) )
M $)]CZ78ZZAAJ:6G33.U ;2I2@,#S*PSA!FI/.XL(EB 1(1M+_NA_P!Q%?\
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M:=XNS^;B"2S/AYW#PPJL896UL8*0%DVABD;-@4H6<ZYQB$@F;BS+B)*@VVV
M&T[08  N "'0 . 0G^.?_P!B*C^)I_W@BK_U=W_Z>EAOVEI&%+V&JI6ZR;0A
M;3N(.TY5*27$)4I(!F0 AR1$>EKJWT5&&?,&G>+L_FX@DLSX>=P\,*K&&5M;
M&"D!9-H8I&S8%*%G.N<8A()FXLRXB2H;5;; #:6&P +@ \T !P"-K?Q+/Z"M
MRCVFI)]#>V>E"59,;3KI6GP@.(/@5&S=G)J'O3:GFVE M*2FG64@?7.+P(PX
MN+B:+@'*5),U"']M[67S>SZ9LK6J4S*P  "TJ4HA*1E) AM>UG54?LRTX0VV
MD%SFD?*<*01SCZP-\)!DD*2F:H:V'L6@VNBE;$R2U3%;BSRG'%>E#$M64W
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M-J=JG%22E(F2?[VDW 6F0A-?[1A-37WAJ]I'TO\ U5>'B9,*K%0&VP$H2)
M2  N  N'XRS2;680\WD)$E).^A8DI)\!$[C,60K:&SRJIV*+2J7':'_$ L*?
MST@#YR4V3]^J*2E0IRI<4$I2+2I1,@!X3 >>"7-MNI'.+OPY>;;WD@WF]9$S
M8$I3^,TH6 4D2(-H(-X(@[<V.D_T=Q7'0/\ <J)LE_PU&P?-5),Y%(]^I]JJ
MU,W5XD, _)2)I6YX5&:$[R0J\*'XT'*2J2%TSJ"E23<4J$B#XH=V6N:F.6TH
M_*;5/"?")%*OSDF5DO?G3[+8L<?=2B>\";5>!(FH\ AJBI4X:9EM*$C>2D
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ML[]8]^BW%'L#V;HG*[:S;!Q\5:DI,U&00@8URF"H@I$K HW@4GM50):;)&+
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M9:>PY9I2><3X4H6JP7E(EDAWV>>4!5M.%QL&PJ;5+%+?*% D\"AO$P]M2M4
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M;0+D!U(4I WDI7B"1D3A&2?N:;9K9DY4/MM [Q<6$ ^(F&-B[);2U0TZ E(
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M?[?;)13LE2<?-MO,/-)/RRT^MPK'YLVYR,B39#5=1K2Y2/-I6A8N4A8"DJ'
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M#;E*E2Z:@><2[*9PI?#82LY,(6V$$Y"M.0F&JEYQX;:;ID@TH:<Q%Q*0,*7
MGF<!5<HK!PVE(5Q8VS[>[=4*?8JTI"5J$DJ#1<6ZI(R@*4E",,\2\2!QA(KV
MSM-*VO8J@4 $3LYN<TL@C_>ORQO*!FE-@4)-"$4["4H80D)2E( 2E*1(  6
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M8*%@*0H$$$3!!O!&4'*(P;'!:HF-HLJ2E-@#-2EM:VA+Y(0ZIL"V0 OE"/\
M46?T'8>]L:MM#NU%U"FFBI(/,H;"22B=RUJ-JA:$I !&)0*EI2 M1F2!:2!(
M3.60 %N2R#_K5=\=1NJJTE*]MU **9LY5RM<4/\ TV@0I7SCA1,8IA7_ '/]
MJ<3M6ZXM5,'+2M:B><JE3X2I+7#B6 )-F*3_ %=K_P"GJHV1^I<_?.PUM;;
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MQ]7JNPCO'U>J[".\?5ZKL([Q]7JNPCO'U>J[".\?5ZKL(*AM J.\*>IF?A9
M^$P10,UE2[DDA+:/&I:L0ZL\,*9V.VSL]@Y1]:[GK 0/"&@H9%0JKKG7'JI9
MFI:U%2B>%2B2?_9:B6&$J6\M02E*02I2B9  "TDFP 6DV"!5U2J&C6I,PV\X
MLN"=P6&FW$IF+^,5)N*09@)H_:!CFPX"6W$D+:< OP+&43$TJ"5@$$I ()]R
MMO8+*?1FB X\XK R@FT JD2I7YJ$K4 02 +856TWHE<E"9J13K67!*_"AQMO
M'P!!*U2L3.0)2H$*!M'NO3]F-M,;*F0'WU%"%$&1" E*UKD9@E*, (*2H$$0
MO:KR&*S9K8)6NG4I1;2/E+0M"%A(O44A:4BU1 M_ J*2C;6[5.*"4(0DJ4I1
M,@E*0"22;  )F!55+E!2/*$PTZXLK'TBTTXA-F\I1G80(%![0TY:6L$H6"%-
MN 2F4+%AE,329*3,8DB8^_D;5:2Q1[-<$T+J%*27$FY2$(0M>$W@J"$J%J21
M;'I^TVVG]E3 +["BM"23(!84E"T3,@"I& DA(420/NR=D[ IU/UA$S*02A((
M!6M1(2E(F+2;20!-1 )J6GMG.U(3/FDNN!1WDI4MI+>+(<2TI'SB(=V;M-I;
M%>RLI6A8DI)&^.$2((L((()!!_"AH/9ZG+JT %:R<+;8,Y%:S8)R.$6J5(X4
MF1@U5.Y053R4DEIMQ86;[$EUIM"O&I)F9 &^%T=8VMJK:64K0L%*DJ29%*DF
M1!!L(/XJ%U=6E*ET5$MUL'(X5MMA<LN%*U2WE%*A(@;FTTU83BIV.?;40)I<
M:XP*3D*AB;/YJR,ONME4=" &U433JB ..XZA+BUF5^)2C*9,DR$R!N5)H0E*
M:IEM]:1<'%S"S+(5E/.'?*R<ON6*-2L*77D()W@I03/Q3G#.SJ% ;HV&TMH2
M+DH0 E('@ @H6 4D2(-H(.0QM395  *)FM<" +DI*II0/H X?%;^!*K:52D*
M?HZ.;0(Y*G%A)6.$(Q)' LY9;E<]4A//TF!YI1O2L.)29'\]"E(EE*AO??NR
M]E5X!HGJQL+!N4D*F4'Z8&#?MLM@)2 $@6"'MG5R Y1/MJ;6DW*0L%*AXP8?
MI$*QH:>6@*WPE12#XY3^ZJVHT$FMK*IPN*'*PM' A!X$\98'_$)R[FRMMM)"
M:YY+S3A Y:6^;4V3PIQK$S.8($P$C\*4513I J*M3KKJI6J5SJT)GP)0A*1X
M"<IW*7:5,D)?K*2;LOE*;64A9_.*,*3P)&6?XJ&=OTR><:2"AUN<N<97+&F>
M0B06@W!:4D@B8*:Q&TZ>G)%K;YYIQ)WBE5AEOH*T[RC"_9+V26IZF>4/2*B1
M2@I20H--!0"E34 5K("<(PIQA9*?<L>RGM>X:=RF3@8J""6U-CDMN$ E"FQQ
M4JE@*  HI4)J55#:+-6\ <+5.>=6LC)Q>*B>^M21PY(JO:*N 2[4+F$ S"$)
M 2V@&R>%  )D,2IJ(!)]S,6$0U1>U50FBV\TV$K6Y,-/%(ESB7.2E2KU(7AD
MHG!B%RU[*J6]H[6*3S;;)*D8I6%QP<1* 98@%%9')3E#^TZY6.LJ'5N+5OK6
MHJ4?&2;,GX$;VVT@NTBD%I]L&16TH@G"38%I4E*T[Y3A) 48%8WM6F:21,H=
M):<2<H*%@$D7<7$#\DD$$_\ 2?LJI3FS%.)4^^04AS <26T)4 HH"P%J40)J
M2G#-,RK[\8VG0JP5E.ZAQ"MY:%!23XB!9EA"]J5+>SMK!(YQIXX48I6EMT\1
M2">2"0L#E)%Y>HO92H36[>=04H6W,M,E0ESBG",*E)O2E&*:@,>$7S-I/W5W
MV?\ :'&-@/N\XEQ(*BPX0$J*DB:BVL)3/""4J$PDXE$&M7M>D4T$SPH45N'@
M#:07)\&&S+*$U=.A;6QJ5!;80J6(@F:W%@$@+<(3-()"4I2)D@D_A/\ Z3]J
M5*;V4%J4P^ 5!HK.)3;B4@JP*62M*P#A4I6(83-)K%[5IG0!,(:/.N*,K $(
M!()NXV$ \HBV'-MNH+5(E :8;)F4-))(Q$6%:E*4M6\5802$C_Q7.#[GP>YX
M-V9B8][%GW&V+-RV)C\9UL<$3W)1*+/NDO>U;N3W)>XE^-"<61;NSB8BWW5_
MNIGWLSBR+=R43W9#\:'![F6Y;%GW*<3][/!$HE]RM_&E/^R!+[PE[TY>[E^-
M_@]S,>[X8E[TN'\;]WW:9^X2]YUWN;-V7N;ON,MV7W&8_&-+[G+W-E_O3D(M
M^\)[D_QJ6[EFY+<F=R?N+XD?>5/=G[B8W9^ZLBV);LQ]ULBW\:UG_L#2W^R+
M/<LBV)Q9N2]Q+W<_<2.YP19%O]C"W[QGNV_V+)#W7![FV[W?!'![B6[9_8RG
M$]R<6[EEWW">Y/\ \;V7]DF7WCP?V(Z;8FSP#653R6TSN!498E2G)*1-2C*Q
M()A#%11,;0KPGZQZI0EW&J5I2VO$VA/S4A,P)34I7&+^V/9.G31[;IVU.!MN
MQIY*1B4CF[4H7A!YLHP@JDE8((4GW%WNY;L]R?W*7W"43W)Q;_8<V7M.O*4T
M:*@H4I5R0ZA;06=X(*PHG)*>2)BZ*G;6T%!-'3,J<5;*>$6)$_E*,DI&51 %
MI_ $MRW^Q$C9;*Z>KHFDA+8J4*66TBP)2MMQI92!8D*4H)%@D  $L;:?2G9Z
M58@PRG T%9%$34I9&0N+5AMPRF9^ZLBW=GNS/W"R+=RS[O;_ /J=/__:  @!
M P(&/P#_ ,+V1$7&)HM'W,SBX_W\<7'^_CBR[[@)>X$6W1Q93_L3#PP-R60Q
M9EB:S*.*;8D;XXYB:3'!$IVQP;AW>")3MB5\<<Q-)B9NB0-L2,")J-D<4VQ)
M5D#$91>?[^*+(F;!$@;8MB8OB1-L<']B >&!N#PP!$HG 5$TF+8 G*.4(E.9
M&X8Y(B0 $%)RQ9;%N2#N2$9($"++HF8\<#<$ #<GEW1]UDX\TD\*DCXS&L,=
M8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB
M/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\
ML:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQ
MK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L
M,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQ
MUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6
M(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8C
MRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+
M&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:
MPQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#
M'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=
M8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB
M/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\
ML:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQ
MK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L
M,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQ
MUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6
M(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8C
MRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+
M&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:
MPQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#
M'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=
M8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB
M/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\L:PQUB/+&L,=8CRQK#'6(\
ML2%0P3^L3Y8FTI*AP$'XO>8/# W,2HQ9(Q"Z.",(BV^#BB0O$2RQ,[AW9BZ)
M"/%$\D3$33?N"!.Z !=$S='C@1; @$1++ 3EW1]RYZJ6$(_*> "\GP04;/0$
M(^<JU7B%P\>*/^8=6L;Q)E\%P^#\9&))(4-Z!A=*T;R^,/A/&'B(@-U0YEXY
M3:@^/)X[.$Q,7>\F<9(R1;N2%WN+;HF(R1;N61DC)$Q&3=E%ET2R1;DB1B43
M,3,2B9OBV+(R1,QAR;F')]QPB2ZM0XJ=[\Y7!^4Y,I!?J5%2S\ &\!<!P#\9
MH9>FY1[V5/"G1NWI7PE]A04TH3!']_A%X-A]^I?5:X;$IWSY!>?*1"GWR5.J
M,R?[Y-X7 6#\9_,O'_DUFW\T_.'^UP6Y!$Q=[]%%)_Y=N:4[UEZO\QM\$M[\
M:)I73-YF0&^4F[X+O!+WYNNI,G"G"GPJLF/!:?%[Q0VTDJ<-P F3XHQ*#;<Q
M\I5OFA7]^&,20AP2^2JWX%!)/B@H<!2L7@B1'A!]QZ-CYOB%4Y8KI62F-_?C
MT7'CXH,Y8;^"9^/[B13MK<(OPI*I>&0,2-^[(6DPJL=YM"$H*BDDXI 3N"2)
M\$_#+W*64RQ+4 )W3)E; J'U-%!4$\4J)F03E2++-_<4*?"$)O4HD">]8"2?
M /#*/1W5MK=E,A!)EO3FD6F^6]X1'IX6US/-XY35BD!/YLIRX9<.X&J="EN'
M(!,_^7#$U\T@[RE6^:%#\L%02EQ(^89GX" 3XA!2H$*%X-_N>?:P(:R%9(Q>
M"0-G#=O0MA<BM"BDRNF#(RX-S&PB3/SE&0\64^('X8QI#;G E1GYP3/Q3^*"
MA8(6#(@V$'A&X44P&$7J-B1X3(VG> )\4"G?*"LI"N*21(DC*!;9O;LA?"'W
M21M D9;"3:4R_-$[1E%M]@0@$K)D +23P",:N;;GD4HS\T*EX_+&-]$V9\I)
MF/'E$\DP/A]P'"E+:2+,9(/P $CQ@?%!=6D+:%Y09RX2)!4M\RD-PT].4A82
M5$J) D"!D!WQDCEL9R]"%U+BV2A"23(JG(;TT#XX"$ E1,@!:23D$<XKFT'Y
MJE&?Y 1^7PQS%4DI<OX"-\&XC_ROW/Z@^IMMJ0,E%6*VX2"3:=Z?AE;#=/5*
M*6E&5F4Y!/),V?WG!0V/^66,2> 91/@/Y)>\1I4^(LX#X%6#X%2/B]^;+&12
MRK-$O]KWB!*;28-342Y[#-:KS]%/CD!OFWP'T7"TU.RP*/C*@1\ $?\ -876
MYVV!)\12 /A!CGFT86DID)@8CPJ(GXA,@#PF)"^.<##V"4YX%2EOSE$C81!_
M5*^-,84@E1;38/'&-]EU"-]2% ?"1N2%\<X&'L$ISP*E+?G*)&PB VTE2G#<
M "2? !;'-/(6ATY""#;=81.V IYEU"29 E*A,FX"8M)WH>>=0I)6I($P1, &
MT3R3-_!P0M98>" 29X%2EOSE=N2C^H[14GG@)[Z4>#YRCOB>\G?+U2V"&UL+
M(G?*1]RS^M1^D(3^N3^BJ$TS-YO.1(RD_P![3(0FEI0.?(XHRSRK5_>TV"P6
M%QPE3BC,DWDG+ _A#^@82PT)N+4 /"?[VQC(FJP$_*6K>\%\A<!PWS94EI&\
M$@_"5 _X0$UP#C)O( "APB4@?!(3WQ'I])(U 1B!'RTRG(\,KLL[/!NBOK"#
M3 V)G?*_%O ;UYRV7K12&;;1"9CDW?)X!OW;UEL/_KE_I&$4ZI\U>KZ(O^&P
M>.$4%"0A93,D?)3< -Z<CX!*5\)-0XMRF)XP42JS?!,R"+]XPG:30&,$)7+*
M#R3XKIY9C>@HQ!+*)%1LG(Y -\[]PR[Q1LBEES@220,DA.:C\X_#E,A*:?U*
M?TE;K:5":$36?\MWG2@4H/$:3YRK3^20^&%;2='&)*4SR <H^.Z>0 [\*+#B
MVZ<'BA)*;-\D2))OWA"Z"N(6L)F"1RDW$'(93'A!MNA=.GHKT_1-WP7>+<56
MNB:&B G>Q'+_ )1^4@Y(73TCBFZ=LX9I,BHB\S%LIV"1E*W+'H%8HK"P<)-I
MF!.1.4$ WVS\,3:$F'1B WC\H?#:-X$"'WSD"4CQS)^(0YS+TFL:L(PH,A,R
M$RDDV;\%A]TEI5X"4B?C2D&7! 4N]#:E#PV#XB8<0VZM#;:Y )) LWP+YWVS
MOE=%/6O "HXASDS4/ ;#XH]/JA*D;-D[E*%N:F\Y";-^,#1_Y1LR3PG*H^')
MO#A)@+29*!F#PB&Z](^L2$K^&Q8\1^+WB!2;% PAT7*2#\(G[\J<9,*_C3[Q
M&$*NQSS05?X0RP.2I9)_R@2_2]Q_4ZM,ZC!B)RI!Y*4[Q,P"=\RG*)I::YF=
MW&G+Z4Y>;'IK"0FJPF1RS%Z%;XR#>L(WB?U2OC3!YAI*]H+2)J,Y!-LN$^ $
M<)G"J2K0@+*204SD97@@DY.'?A3;(DRI(4!O S!'@F#+@LC^IU:9U&#$3E2#
MR4IWB9@$[YE.432TUS,[N-.7TIR\V/36$A-5A,CEF+T*WQD&]81O%CZ1_1,#
M:E0G%4X<"!EO),MZ^TY!8+Y%KFVN;<:>2X)JQ E,Y9$Y3;_>1J'P@+#A3Q00
M)  Y2;;=^'*<H9P*"DW*G(S'S[_%NH9=6I32.2";!X(/\,OXCN%584I)3Q5*
MN!GOFP&67\MMH71E*N)QE)N*IG+<3*4R/ALW&?UJ/TA IV"@+#@5QB0) $9
M;;=Z%O2+CP$U$ S)R#@2-\W6D[T*J7S-Q1\0&0#@&X/X0_H& HWH;41X;$_[
M4-4\^(EO%+A42/\ 9W2A7^[=4!X" KXR8>93R4NJ \ 49?DW54S:U!A=Z0;#
M_?\ +#WTQ\4/_KE_I&'EY0V!\)_]T.C(D)'F)/QD[F)5I-,@^,!)^,1SM,M2
M')2F-[>@*49J*%?%"?U*?TE;K[N\A(^$D_[,/N'*ZKX 2!^01B3813+/C(4?
MC.XT,B@H',)^,"&5Y2V1\"O_ '[F+?<43^0?X05JO)G\,4ZA_P"L@>(J /Y#
M#"\H6H?"!Y(6A]U"'BLD@F1E( 2G?OV3,<T%#'=,ET>.9DG_  \4&LH5%3 M
M*3:0-\$7C?WA;,PFJ:M*;QO@WC^]QD8]+JTRJ<H(7,RW\'%5O6^.R$4-("C9
M[=I/Y)RN%EB1PDFR<D["V8DR  5AM/T!*TG*KX#E@&H;<;!NQ)*?C W'657!
M+J1\!5\9]XM.3?S#?Z(]^3#V0%0^$)(^(^\1E]9D@+$SO V$^(&$U"!,M*F?
MHJL)\1 \5N[;=!P<G&GX)^66XN=W/&6:F'</)PN2SA!_5I_QA/T%?%#<[N83
M^FN#@Y.-/P3\LMQ<[N>,LU,(P\GG5R^!4,#)@5\8W%?KE?HIA7TC\?N#_#+^
M(^Y9_6H_2$)6PM:%\Z!-)(,I*LF)61_3ZY6)WY*C;B'S3.\[Q-XLOO\ 2*<?
M\FLYI^;X-[X,EL#^$/Z!A&,R2X"CQF[X2 /'#5:D30 4'@MFGX9G^YW0X_Q<
M9+AGD$A+S0#XX_J$I_7\Y*Z?&Q2G;+\L:M^T_P#W(0OF^;P CE8IS/T1N/?3
M'Q0_^N7^D8<:-ZFK/$1_@2?%"UFY:4D9H3\:=PLKY090CQ\4>4^+<3]!7Q0G
M]2G])6[4(RD(/P8O+#Z3>'E_I&.:1:HLK1X^,!_@?'N(6+D(4H_!A^-4-M"]
M#=OA)/\ @ ?'N%OY2'2/$0"/\?@A;*N4A1!\1E%.A-X<"LWC'XH88^5-2O%8
M!\,S\&Z$OF;8QIM^;_[K1X+-Q+#(Q.J,@/[_ )=Z!3,$':#@OX<JO FY(W_\
MT?U(IQU;LB2;R5&P$WR M.^9PY05[;=J"1*<B+ 1(DF=LP0<F_#E-.80L@'?
M -A\8AU:N3]8?$$_^[WBM,F]+:1\  ]^2RD34V0L>*P_ DD^\44.T"$N@805
M<E8ND9V3E9;8?#9'.4KA:!ME+$GQ6@CX3'.UCI<0FV4@A/CM)EX"/*/Z<D#"
M)**;$&5TA+)OBP\-\?TRK5*HP82,J@.2I.^1($C?$Y2B276N9G?QIR^C*7G0
M**G5BJL)D,LS>M6\,HW[ -\']4KXTP?U:?\ &$_05\4(_4)_37'],JU2J,&$
MC*H#DJ3OD2!(WQ.4HDEUKF9W\:<OHREYT"BIU8JK"9#+,WK5O#*-^P#?#'TC
M^B88^@KXQN.4L_KDKQ2WP0!/Q$6^$0\^76\"05)%LSED9R";,LR)[U^ZFK96
MT&USD%%4["4VR21>-^/Z:2GG^94B<SAF0<LIRMWO%!JGU-%L$#BE1-OA2!^6
M%(JIE"$3PSE.T"\6R'!P6P&Z6QM2,6&<\-I%YMD963MW&?UJ/TA"?UR?T50%
M))"@9@C)"J*L -0$R4/G#YPX;IRN-HE,065VM&U*M\>47$?X$0/X0_H&)BPB
M/0]I80\1(XK$KX0;@>"RVU/!BIWE-IWBG%\!FD_#./2*Q?.8;>-)*!PD3/Y3
M+?$&AH#-H\I>_P#FIX-\Y;A9[A?HZFT\W*>(D<J<I22=XPXW4*02M0(PDFX9
M9@0]5!;/-J6M5ZIR))^9*<N&$537*09RWQ<1XQ,0A^E< ?1EWIWI6+QP'QB8
M,"IV@X@MH,Y)G(RMXQ($@,HEXX324QG3MF9.12KK-\ 7'+,Y)&$TC)2'%SD5
M3E8"JV0)N&] J7U-%L)(XI43;X4@?E@5#"F@@-A/&*@9@DY$FRW?A=*Z07$&
M1E.7BF ?R;G-*/%=04^,<8?$1XX6KY#@"QX[#^4&%4E4<-,LS!-R576\!&7(
M0,DS!J-GK0&UF<E3D)V\4@&8.02LWX6_5.!3Z_A,KDH%YX3XS("%5#QPEQ8\
M"1</$!"GV)I>; XQ43BF0)$&RV=F$""'M5<D%<$KE>*9GP&/3]GN(!<$S/DG
M\X$3\=E_CA5=7N)YV4IY$[X$[5$^ '(!;"JBT-W)&\D7>,WGA,)73O3K)341
M: ?FE)D1*Z>6^XRB3KK0:G>,1,O 0!^6/Z50D%[#AL,\(/**C\XS-F^9V63A
M6UJX?7J3Q1E -R1^<K+O"^7&A52^>.H^(#(!P#_WWP-GA834M #P83Q3+>(L
M)R'\J]H;0<;DE! E.0!E,S(!G9( #+OPY4RD%K) W@38/@@-*L<6V!XW#,CQ
M GX/>(RQ>"L3\ M/Y ??F4+$T$2(WP;X72JN2;#OI-H/P7\,Q[Q<+#KB$[R5
M*'Q&/^8<6OZ2BKXR=R8OCFP^]@E*6-4I;TIQ,VDQSC"U(7*4TD@RWIB4<X^M
M2W)7J))^$QSC"E(<WTD@_"+8QU"UK6!*:B5&6],SLM,3%\<V'WL$I2QJE+>E
M.)FTF XTI27!<02"/ 1; -0XMPB[$HJEX)D[@6V2E8N(,B/ 1&%]UQ:?SE*/
MQD[H:9>=0V+@E:@!EL ,K[8UA_K%^6.;?>=6WO*6HCX"90'&E*2X+B"01XQ;
M!<=45.&\DDD^$FW<"DDA0,P1>#OB,#[KJT3G)2E$3WY$FW<#C*E(<%Q!(/PB
MV FH=<<2#,!2BJ7PDQS(>=#,I8<:L,KI2G*4LEV[A9>=0G>2I0'Y#$WW%K/Y
MRB?C)]R?1W'&\5^%13.5TY$3E,QK#_6+\L2-0^0?^(KR[F-I2DKWP2#\(C"^
MZXM.\I2C\9.]N!UE2D."XI)!&2PBVZR-8?ZQ?EC6'^L7Y8+CJBIPWDDDGPDV
M[B7VC)Q"@1X1;#6TT*2'!*0G:<4@I/"4FW@ .YA8=<0G>2I0'Y"(QNJ4I9RD
MDGX3N!IQQ:FDW J) \ )D/%N?\NXXB?S5%/Q$1B?6M:M]1)/Y=S$@E*M\&1C
M X^\I.\5J(_*=P*29*$ 5#KC@%V)15+P3)W MM12L7$&1^$0/2''')78E%7Q
MDPTR\0&L4S/+*W#_ )KH30MGZMJU7TCHC\I(]XB]H."_BH_VC\0GX1[].?8$
MZML6?G)RI\.4<,QEB1O]_(!)D+OO.9M)]X::=JQ-ZE9$IRGR#*82PR)-(  '
M /[V[_OU574 ^LO4@9?SD\.^,MXMOD;_ ,9H8IDS.4Y$C?)R#\IN%L!EJU9M
M4K*H_P" &09/#,GW[%U/U=5\X"P_2&7PV'PW02\@EH?*3:GRCQ@?C*"&TE2S
M< )D^(0'*X\TSO7K/^"?',\$!BF2$H_*3ODWD^'XO?U-YE!4<HXI^%,B?'$T
MEU/@4/\ %)CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_G(T(Y;^<C0CEOYR-".6_
MG(T(Y;^<C0B:D*6?SE'XA(1AIVT('YH ^&5_]L*;BDI'"0/CCI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SA
MY8Z1O.'ECI&\X>6.D;SAY8Z1O.'ECI&\X>6.D;SAY8Z1O.'E]_BJS:#J&:5-
MZE$ > ;Y.0"9-P!,*8]G&.=(_P!Z[,)_RMB2B-XJ4@C*DP?2JUY+9^2V>:3+
M>(;PS'TI\,%;JE*6<I))^$_C'Q4%0^RH96UJ1^B1 15.(K*<9'1QI<#B9*GP
MJQ^"$TSJC2;158&W",*CO(<L2K> 4$*)L"3[^.<J?K*]8^K9!DI629-N% RJ
M-]H2";(]+VHZ52GA0+&T#>0F=G"3-1LQ*/XS4;,VZI3^R+ %F:G&1DD;2M R
MI,U)'(,A@**JE6ERF<2%)4DS!!N(/OU<VG5VJ'%;1.1<<(.%(^":CD2"9&4B
MYM/:*\=4X9G> N"4C(E(L ^&9F?QGIV-M-?_ ."O*XI-S*U?*GD0H\L7)/'L
MXT_OF1NB4C_?QQ<?[^.++ON(E$\ONB<NX)Q9]PM@P(M@R^ZB7NY1+\"+IV%3
MV92$MMR-BE _6.?YE#"#<4I21>?QH^@5:L6T:*2"2;5-GHU<)$BA5_)!)FK[
MZ/AW)&.,>+'%-L2,?FP,)F8XYCB&)&!N61(FV)Y(LB1-L$;@B:C(1Q3;$HFL
MRCB&V,.6)*-L8A:(,'%OP,1E'%NE!*C(1-!B1OB42R1(71(W1+)$HD+XXYCB
M&)&! 5EW 1$Q?$B;8X(F+XO,_P"_!'!$IVQP1,V") VQ(P"+S%AF8XYB:3]\
MU>T&S*H#>!&_C<(0DCZ)5B\"3[Q9"TF [2T#W-D3!64M3&^.=4B<[Q*\6BRV
M"[5T#W-@3)1A= %MI+2ERNMG=>;"/<G9FSUM(?#:ES<*@F22 ;4I69VB5DN&
M/Z77J:748$KFV5%,E3E:I*#.RVSQ_=2QLNG=?= F0A),AOJ-R1O3(F;!;!=<
MH%E(^8MIQ7B2AQ2CXA"F7DJ0ZDR*5 @@C(0;0> ^X13,#$^XL)2)@34H@ 3,
M@)DWD@;\"NVO3<S2E80%<XTOC$$@20M1N2;92LOW%4^QF%/N(3-4BE(2#=-2
MRE()D9 F9D9 R,)I=L-I:J%IQ!/.-K.&<ID-K5A!,Y8I3D93D8_K3=+/9G,E
MW'SK/1A.(JPES'R1.6'%DE/<#;8*EDR  F23D %YCG&:!T)LZ0H:-OYKJT*\
M-EF6"[7T+R64WJ3)Q(&^5-E8 WR3(&PVGW2JC9%*IUA!D58D(3/>!<4D*(RA
M,Y63E,0Y25*<-0TM2%"8,E))2H3!(,B")@D'(=PHV13.OX2 2!)"2;@I:I(2
M;9VJ%DS<"8-154#O- $DH*'9 2F2&E+( G.9 LF;@9;GH6R&5/5$ID"0  RJ
M4HA*1DFHB9L%I@4.UVN9JB@+"<2%\4D@&:%*%Z39.=EWN&?:*J?*-I*P%3*@
M)'G#Q4I-X6E)Q+!F+% 2PVP*BEH7>:(!!64-3!G(@.J02#*<P+I&XB81M>F=
M8F2 5":%$7A*Q-"M^Q1LD;B#[A%!LYI3M6X9)2F_PDFP 7DD@ 6D@0TG;3',
MEX*P<=M<\,L71K5*6(7RG.S+N&AV0USU4$%93B0F200"9K4E-Z@+YVQJ/[:G
M[6'*^LH\%*T@J6KG6#)(M)DEPD^  G<]+8H'>9(F,2FVU$2G,(<6E9F+I)MR
M3A5)7-+9JD&12L%)'B.0W@W$6BS<_KQIL.R<&/G%N-(XMP(2M:5D*LPR3QIC
M#.8AG9#SX80Z3QI3)P@JPI$P,2I2$S+PF0+FSIJ52$!;2C>ILW3( &))!2J0
M$R)R (]XE/,RIZD\PO\ ^(1@/B<"#/>F,OWT1A$2PB!N^. ,FX8$3@;F]..4
M(PS!B8OW#N#=\<6F43Q".+N$&#'C@;A@Q. H98GE.Z%98Q&X1.# B<"!XMP;
MH@P?# $Y1RA$IS(@"<A'*']_' D9F+(G$TF+?OFCH 9<]4*6>$-HE\$W ?#+
MWB_U_;P0-IAOG%J6+*=,IX4@W+ Y2@,6+B)LY1;V#2M>C@V+?Q$J&_@0I&&=
MDIJ5PWR ;V]2M\P3:MC$"D;^!:E8N&2T\ -T&JV"RE%.$ *<"2@O+-I44&4I
M73*0I1F5$C#+=5_".?I-P?X9K_:^XU^T"+5.-M@[V$*4H>/&F?@$._K%?I'<
M9V>QTS[J&T^%:@D>(3MX(8H-BM(-8X2E&+*0 7'G)2*C:+)@34D<E.&$O;2<
M14T)4,3?-MH(3.W I"4D$"[$5"P3!MA'M+3I K&E(2I0^6TNQ.+?*5%.$Y 2
M-Z6[1?Q;/[Q,-?QK?[MV&MF;/1CJG52&\!E4HY$I$RHY (#;02Y7KNN"GWI6
MJ.4-HG;\U$DS*E#$[M&O65U;JL2C_@!D $@D"P  "P0/]&7^X5"*6G25U#BP
ME*1>5*,@!PDF4':VTR@UZ4?6/$35B5_NF1> 38 )%?*7("23_2:1A%.#9SV-
M:B-\A"FPD\$U>$WPFG]HJ=#32C+G6L6%-MZFU%2L-TR%DB1(29R"_:;8*$IJ
M4(YQQ*)8'6Y3+B0+,8'&)'+$S:JT[J=H[1"FMA WW*>D9%*-Y,[%+\*4S,RE
MS96QBWS-$0VI+?)03,X)BPJ%ZKR">,<4XVA_&O\ [U4,;)02E#BIK4/DH2,2
MSX9"0G\H@13["]G6FD5:D32")I;;!EB(^4M:@9$SF0I2IF]MCVA<0_LYU82I
M6!"%-SD H%"4I*4WJ!!,IR-@A'M)L] 0VZO \D"0QF92Y+)BD0O)BPF]1)]%
MH$X6$D<XZ1Q&P=_?49'"D6F60 D,^S= I/\ 47DE9G(NN!(,W'"+DY$@R%X2
M+%&&OX)O]X[NTM(Z)TR%%U8R%+8Q2/ I6%)X%0SL-L_44S86L;[CET_HHE+Z
M:H7[2;00%H:7@92H3&, %3DC>4S 1O*Q&]((<8]GG$,;.;64I5@0M3DIC$><
M2H!*KT@ $"4S.8BIV%[1--+JDHFH 22XV3+$!\E:%$3*2)$I*9&']DK)4AM4
MT*/RFU#$@^&1DJ5R@1DW$[.V6V5O&TFY*$SD5+.1(GX29  D@0Q1*<2K;-8L
M(QD?6.JO*4"TI:3><@L*B5$1LWZ+_P ;.Y7[0(Y#3;8/TU*4H>8F?BBHIZ1B
MA-*AY:4%2'2HH2HA)40\ 20!,@ 3N NAW9;Z*1IAY.%1;0L**3>F:W%@ W&R
M<KB(0:I(4W3-*> -Q4DI2FS+A4L*'"D9(J*'9CB&:*F=P82VA6/#+$5J4DJM
M,Y8"F22,ML;/]JR@(KU!J<OF.H*BC?(2NU,\A4?E&/2JQ)_HM.H%S_B*O#0/
M#85RN3985),#8>RE ;%IC(X;$N+39,2LYM%R!<3-5HPR;K:96&H:<2M)WE)(
M(/PB*7VHID_6-!MRRTAMX)2M)R\593/>PJ]XB7FC)Q"@H'>(,P?AAJJ1R'6T
MK'@4 1\?WR?#N#=\<"+8GDB>3<&X4Y8D8F19!3EB66"#?N#=GPQB%T600;Q$
MC!!O@QXX$6[T&#N83?&$7#=*3=$LIBV)Y(GDW! E$A W1!@Q(7B)98F8!%\2
MRQ;N2$6WP<7WSLY/R0AX_"6I_$/>)04KHQ-E\*(R$-@N2/ <-HRBR*;9K9(1
M4ODJX4M '">#$I*O"D>X_P"K/:E*5DM<ZE*Q-#;<II)01QW%"T @RFD)&*V/
M1&=F*_I=J>D0#A/_  @@HM^;SDN&/^I_99"&ZPMEP! "4NRGC0M XJ700H8A
M:5B2BH$*"OX1S])N/ZIM"F%;[1.-)"&SA(0A,P"<0*48C,8L*UG( F<.;%VE
M1)0]@*@A92ZA2182E10@A8F#R093(-D.[.IR31J2EQN=IP*G83EPJ"DSR@3-
ML?\ 5GM2E*R6N=2E8FAMN4TDH(X[BA: 0932$C%;'HC.S%?TNU/2(!PG_A!!
M1;\WG)<,?]3^RR$-UA;+@" $I=E/&A:!Q4N@A0Q"TK$E%0(4*#]8K]VN![8^
MT80I+3"&FT%(5-S$M04$?+7(R3.Q !492!31)V<P\5TNT&GU(=2A*5):"N+-
M*W!)15*XV S%TS7LTR:1M#RFPV%!0XJ4JF"$( GCNPY)SMBIV;_3L/.(<:Q>
MD3EB!1BES G*<Y3X)Y=U//+6O")#$29#>$[AP"&=ETP,EJFM61#8Y:CX!8)W
MJ(3EAK831'I%0M)P_-:;MF?"L)"=^2K;(6UMI+3BPU-IMR12M>(3XIL60FY)
MGE.$RF SL1+:"6076VY8$.8E"02+$$I )0) 6&0GN47\6S^\3"*'9#7/50JD
M+*<2$<4(<!,UJ2+U"R<[;H=VUMM2?ZBI$W%"W"/DLM[Y)E.5BE9<*087M&L,
MD7-HGQ6T9$CARJ/RE3.\! _T9?[A4-N."8IV7'1X0 @'Q%<QP@')%'L<&3"6
MB\1OJ4I2$D_1"5 ?2-^3<%/4<;T=Y;-MLT22L \ #F$#>$KHJ]GHY#%2ZV/
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M]D1_^%L$%3DB$ -IP @&WFVDD@$RQJ*0/DDM^Q7LZ<%4IOZU8Y24*'&*B/\
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MBJ0A>T]I55 I]=P"WL*$BY"1S%B1^4S))))+NU:ERD<IV4S4$+<*I3 F MI
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MF8WII;"AXB(%=LIY3-4 1,2,P;P4J!2H6 R4")@')!K]JO*>JU #$9"0%P
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MYY0B6=!K-@$X@)\T3B"A?]6HVSE<%$XLBA<2E0(4#(@Y-T-M@J<49  3))N
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M\OO&I&U<I-*T#XD)'OR;JDBUEX3X$K!2?.P^\1NK9L=:6E0\*2"/B@<PH#G
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M *E<F0(G,_<^8I"/Z@POG&P; HR(4@G)B!L-V()F0)F#2UK+C52#+"I)29\
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MWHPJF6W1<!8";%#C8HD;"-Q+325*=40  "22;  !:23<! VG[3-(>KECBLJ
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M4Z3($DRNM._#]=LEH,;/6X%-ME"$A( %A0G$@6@V"8.6!1^T=&'D2 *VL/&
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M)"4CQ"0\O]K2>3W4A$S]RQ9/<2$6D3B8((^[R$2-\2B7]AN62)19N3$3%T3
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M@!\X W2N$O'.'.;UG"J73\J1E?9?OV>+=_J54!Z*WR9W%0R^!/Q^ PPAH_\
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M?E48>?</&4X?$ 9 >( "$-@\1Q*DGQ)*A^40V\.4MNW_ "F_X#+Q?A)*/G*
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M':KC8Y<K@PF[PP*FF(#@LMN(-X(WO_,6Q+T=/.;^,R^##/\ +"JNI <2I&'
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M(PB?HZ:"H"YRFH!*<]1"9<,[<D%AU25[1>4%.J')F!)*$SD2E,S:0"25&0!
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MX0;XPJNB8F8&_&'+N FZ)B[<F(XUACBVF,1WXF+H %\8571.V.")Q(71/)
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M?SMF7*U:J#0QJE7LDY/N]Y@ZN;XT;!'[U=B;/.2C"$-T!$B&ULFE^1(4G]D
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M#M^X*":)R%<JHX/A(MN=W)S.)>8.*CFJ0"91R_D,IYA:,VZ92@(F.LX6*4
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M.SSH,A0;) H[$THN:8D*  &P2@!=06/>9J-+RJ99D3(,$IR9D^M\&6.1,4"
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M4K:VS,#E;/;E@Z;/8R$SK=(&:JC-RVWQ*+FM4*EX[BK"U5,8!4:RR<@T4W0
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M%V["TOD5VKS+W6,O%PA+K-UV7@JP^B)&YR+&*HJ<14Z]*,(5$]X=)[DB[E'
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M!M?EZIC9QY0KNT'EFF[-,NI6U-",YZ:/*65W*F0>OBIE/PD2),DE VIH% 3
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M[1%P[>E-!VJM23J%L59F(RP0$PQ4X3V)FH9ZA(Q4DS5V#PG3%\V353-_T3D
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MN/-EC3FG@W<[E'XUZK.S>(H^<&GQ,JP:4'&4H9FYF["HH\2(L0!0;E J@G5
MR%GSQFZMXUJUOA<X6_&C6.Q7#VB$K:D% 4_'M@9NW#.W7&\29Y95Y;')55"O
M"(F2(F!4BF QCYLP=+8GY2F]3M\3DC%$E(1U$S$E8D*[8&<S4'CUB[<YY=QJ
M4TE&NS'244:*H%7 #&1,3:0?8QGB/)^8K]><98;8]6XPH]BL#V0KM,9%9-XU
M%&(CU#\(O0XQJ1JW,IQ#MFI>"D)$Q$HR_P#\'5G/X)9!]BUV3FOG*#2)21QN
M>-PEDC)_5[.G4RZA/QKB744L\RL2#I$Y*0"9R-95UP$TTDUT =(F< FXC;5R
MF3%(N*K;&<;&YJR-C4[%W2;ODA.PV!=%ZSG8K;#7&885A9FD\F69W#=T444>
M.H=L<":Y3?\ $Q@C]Z55U6,#X1LF-:M;X7.%0R6ZD<J3%HA*VI!0%/R%7WC1
MN\J-.O$F>65>6QL9),S,B)DB*"94I@*4^5<H'JUFSIEB-KH77,EGH-2EI&:O
MUM;MU$(&LQZC./DW-(P]35G)BGDI "-F+87<FY*"R_1M7KF"S9/GG;O>)$5Q
M02,N2%K,&VWDH.GU9@LLOU56:ZQW4&J &,8=AE53*+JJJGU'?_!9WC_AVLFH
MF>E6S9PXQ5@O*^08/I!!4%"8=&K6-@<MPV"4'*<7D1UNF-_9 1$/; 77+#@P
M9)T6KU#!LEE@D010Q&*L_D:_66GJ23A(B9".G3>.Q81)$RAU!0(JJ"8)\905
M?8DJ?-.EW*.%N8/(U K15CJ* UK,Q!4G)R39(YSGV$)8K_)B! V 0HAL#PZY
MK\5P;5)E XZYC\VTNOM$"I)H(5^MY(LD3!)HI(;$D4@B6J.Z0 #<#VH@ AL#
MV+YR^4K,5^J^$\GOB25_QI"V!ZQJEJ>@FP156E(]$Y04Z:WBFR3HI1*1VB@1
M-8%"% H<WGRPT'X%O]<ZG^+3F-_?#<M<U-Q4;H&DX' U=K+1V83=)18VS(,;
M*2+=( *)!0=.*6U,IM$!WD2; 'P[.9EHNLHJSJ4=A6KQ1#@ =':(X-QU-/$2
M !0'AC.3;PX"(CMW]NW8( &CSEA.22>3?V?_ "ZY DU7 J#Q++5ZQBR]*.!,
MLDHH==O8X/?(80]NH0! P ('!QD/E_RE<,2W5W!OZT[L=+E58J0=P$FJU</8
MEV8@&2=,5W+%!;<4*8"K(IJ%V'(4P5N9F9!]+3$MBS-LG*RLF[7?R4G)/X=-
MT^D)!\Z45=/7SUTJ91550QE%%#"8PB(B.J!_A+QI^\S-7L\YN2!;&,M5,:XF
MI";SB( 5!+(-HM\\LV%(Q@=',Z/C,A@,0!3+P1 X@)B;>=*ZOS',,AS,9BC8
MXJJ145TJ_6+Q,5:L-G*9'#I,KIK7(5JFKNJ&(*A#"4=FS0S%>*2-=Q/V?G,/
M>HX[+:;AV2UU;*-T![^43\"[BQ3HKJCNB4JAS;-X \.N6MBBX,W97&)S75)<
M XH@X:'PAD*PL6YBI ;?*>?KS(?;!NE$H&'9LVARL7--%(LC/X$L%8=. _TZ
MK*HY"E)6/14_)A^207NSDQ/;F\*AO 7\)M-K$FW20&TYPS%<)I5N!CK.W,:G
M7:GTE<HE* N2150;I% HB II$\.W: 3UGEUC.)6QS4I/2;@X@)EY"8?+R#U8
MPE*0HF5<N#&'8 !X?P:Y&YYFX,T$.:O!4,\7+Q=I8>T9&K]8G2[$0,H<JL+,
M.""4 '> VS8.W9KDZN:B*1I& RKDVL-7 _Z=)E;JC7Y6013_ "8_DEUZ2V,?
MVY?"F7P&_"7+M,S5S/XQQ+E*U9<OE\M4)<K$:H6)I4R5"A4ZO)UI299-6EH?
M[&#AXV;1)I%YON%=J8\%0B3+&$=;X4UJ52-70N]QO_.Y18]:42 (T]A>WBT.
MZKAMFJ=T/2 <"*,.8?;E3Z/[74]S9<F=VL60<,55BG8\B8ZM[V/G[/4ZB].R
M!*[4BUPC!BWN%/C@>"J]1<H%>,(\H.NDO$BKF1QMS+XX9M9J3I#YVVGZE(NU
MF,5>*5/,UHFV5&0=H).3,NM8ER<6KL47'0)!-NZ!%4R )F:<T7-%CE]"9_2:
MQJ\O6+;CWF$2L=B?UV*C58]K8DL(KR.',ADVMR1;=:?<J<9!J"3DJ33< <-\
MFG+'5+%ASD:Y?W0WJ\VZ2BV$>^0AXY'R6)<W%>CUG5=@7R<"Y5A*5!E.JN!Y
M%RX<[C<'"3&G?8K_ &<=4E7T=68.&I>88O$,=*6F;".8I@HSP+"H5]"1F)V?
MEG2@2%S7)Q7;ARH#)RH=9:41"-<YTY?\VX7;3*O B'&6<57O'*$JN)'"@(QJ
MMP@8=-\KPVBIMU(3#L2./X"CLUS"8HFB&=M*Y1N<_&$,"H)E,WZSJ\YD.,<-
MU7"SA'BQU@O@K(G,1,B:B8 )! N\?[Q.1%RY65<.'')KRP+KKKJ'56765PC1
MU%5EE5!,=150YA,8QA$1$=H_?1*_L;4?S1QK!/R-XP^!,'_0\DN44&VQK7[5
MFR@RKPC81XB]OB,=6* ;.'8> O!3H\D9%,?[7$4,'X#?>)REYBLS\D35JWF&
M BK9,+*\%O"U.\INZ!:)IXIL,(,8>!M#ARN  )C(I& /"(:Q_G&H12\P^Y8\
MA/YJUMVJ)UG3'&>1(UG!6:<3(GO*'0B+'#0:CG8402:"JN<2D1./LL^G[_0>
ME-^F\+;Q.B<8G2.'L\._P=NS9^/5G"JF,6NGRCA(LF$>*H,3U4)LQXPJ@(_D
MC, FB1HI@?VG$!,0]L!?8RUT_?ZI_P![>]]0\3\/"^*;"G6/ V^'HO3M[9^+
MB\3\>W7,EU#P.H_(_FDZEZ+MZ-U3\<%3ZNZ/O>VX'0]S<V^'=V:??('B7_K+
M1K''R69F^!KC6#NG[_0?]SK&?3>%MXG1/CVYA^D</9X=_@[=FS\>K.%5,8M=
M/E'"19,(\508GJH39CQA5 1_)&8!-$C13 _M.("8A[8"^QEKI^_U3_O;WOJ'
MB?AX7Q384ZQX&WP]%Z=O;/Q<7B?CVZQ?U#P.H_\ >?Y@>I>B[>C=4]0Y;ZNZ
M/O>VX'0]S<V^'=V:Y,V1W"YF;?&>5W2#0RJAFR+EW::FD[<)("84DUW23)$J
MAP #'*B0!$0(79J__P"+3)?[L\*ZR#^W%L_OY_\ <2__ ,'5G/X)9!^YY3?\
M3&"/WI575(N6$<KY*PY;W?,[CV =6K%=ZM&/;(Y@GN/,N/7D*XG*C*1$FM$N
MWD:V65;&5%%15NF<Q1,0H@ER+\Z%T5MV4';9XUPKE/($B$N_RU"*M#]8XLOT
MI,BLM/WEHW!52.>O%%EIUF8[9<1=H)F?'SMA&ON3\I67IU7JQHR156;X4OK\
M%WKG'#]455E2U>4*BJZKSE3= J!5&*FU1JFLZU'?_!9WC_AVLFL1)6B0)$P>
M::Y<,$J2*RQ46R4U=&[&5I;-?>_TG7E[K$9'I%#\#AVF8?  ZY;>;V$C7,C5
M(J"E\#9!>MFRZA:TZZY?77';I\HF95-./G5IF<;\4Y$B).4$4Q.<[E,I?8AK
MKE\OD,;*$Y?>:6W#/<=L>L4>1KL%%P,M+$50(HQ:N,;X_93 I@!^&B\VFV*"
M<A4>>0:NK91C^<I/FO&EKRA:\O/BUS:&7QJZTT1A/D@U97A]$,Z!J]!L*G$!
M);=W#?\ A[_^]A_]33K#EQ^(CXB_BEJUGK/5WQG_ !F^4'E)+1TITWIGQ>8]
MZJZ%U?P^'PG/$W][>+LV#KF\^6&@_ M_KG4_Q:<QO[X;EK.V-)!R5J[R1R].
M):"XKD$TY"5H-YK#A:*0;B;_ %E^>$L;QV00 =Q!DN.T-OARU97S1=LPR]CW
M#60H)51N=%!XPC<>0N+7:[50P[CDA9S&[LASEV "I3 /M@$1*0A3'.<P%(0H
M"8QC&'84I2AM$QC".P #\.I/%MK.=G9*_P K/+=RW-XTRXI/'EH,SQKC^58I
MG+L!0\?&L'[Q<@B *-VBH>$1 HZI?R/9B^#[?5 _PEXT_>9FKV>?&K'W>GS,
M%RXS[;\LD4W1*U(9MCGNQN(\94O&MC?:<H"4G@ VP3EV\X]>EDN#(P_--G]@
MZ* * F<Z&5K60%VXJII'4:N2;%$3[H HD<I@\ AICC.K;\C9)WE2YE>7A6)1
M,,E(-+6U:9-H4,Q,@F?B=*?LG,>]:H@(&*@[1 -@[-AB'*8AR&$IR& 2F*8H
M[#%,4=@E,40V" _@UB^TL$%566&\:YFR).+$V\-M'RU#D\2-SK#LV;JDOE!L
M0 _")C /XAU@O&<<XZ4\QIR^-Y.>W%C&282U_N]E=(Q:B [ 2?$@Z\R=G, ;
M#HO4?"(E$ U::$1=,TQBWF#OT/)QBJY5U0B+9 5&W1$F#81-T>.D74J_;D 0
M #K,EQV?C'*.*)YLY9S>,LAW2@2[1V@HV=-Y*GV.2K[U)PW5$5$52.(\P"4P
MB(#^,=<D=:AT%7#F(Y@J+DEP5+;M3BL//QRS,KG'8(%20BJ4L8VW\(!L_".N
M3/#R+CC3C^QY7R5(M$UC!U?$Q$94ZO"N';?P%/UP\FWY6YPVB7H*P#LW@WO8
M@JYFB05FJ7&)9XQ6DO,$,XW<1M7,LT4B5U3J$5?1D,SE7K% HG*"+-!-N02D
M2( :HN&L3UI];\BY'L<?5ZG7H\I>,_E)!3= ZRR@E08QS% IW#MTL8C=HT24
M76.1),Y@K_+GA"1@+1SS<P<<Z?2MX09MSR2EA59J1]CS++-G:*CA*D8^%4T5
M38QT )+O?RQD5C%ES'1^T/?T-OECFAYFTH6VS-BL+UP,U;YG*=K=JT"LR]L7
M(]FV=0@JPGUY)ID.*LE* Y.)P461.CFCDAYXL"X4<(VC%DY;(<E(C+.QIUJK
MD9(0<)8*S(U^Y6J[S#"X1WE G*QDLQDT#MP:*'3(@X026/S <O)GZLLVQ!EB
MZT>)EW!4R.9BO0\VZ2K4P[22VIH/)6OF;.%DRB)4U5#% 1V;=<S5KG/]7A]_
MF^MH+[Q$]L+#8GCV+YQONCMFQ>&Y@')=IE 3#<]L8/#L^\3EYQ<Z;="=8VP;
MB:@N6?1Q9]$7IU"@*ZLVZ(.P6O 4CA+P_P#H;-W\7WT2O[&U'\T<:P3\C>,/
M@3!_T.6Y&(9'D+%@.PU3F B&R1 $XL:>J_K]Y<F4WBBDA%8UM\R^/X# 8&H!
MLVB!@^\2K\FG/)9:S3\E5VLM,;53(&1EV?Q<9SI?0DZ]&UNYRDZ*D3&7L8DY
M6+I.3,#*>3 #E5%TL=N9W?>6G-]KY;&-G<EFE:F2JL,SXT;(O]]T8:2Q<6VC
M6&'C'8+%.BFI,OVR)?:H$(CN)D3R7S6\RUDS?3Z:Y5L#ZO&K4-@+&SB/9%9*
M)H9"D5[K?)Y>";F3<'<BTF(<50.D4RA$TE2N:RER!4V CCU&LEJ^6+WB]I'5
MG!]Q?PR;2+K+&@U&/AV3%VZK,6R,W=3S R,;)I"B5$C@$NEJ._LY.9^W-X+.
M;;%S+$4_!R,JUB['D>OT]*,4QYE[&KV11ZOG;E67$+'O7K'8Z<I2T69TNV.R
M7+O*1T-S+\N;O%/69TT;A)M\F1^0NIMJG#>*8W:TZ3K?6>P"[6P6KA>$=B_@
M !C^4/!]Y8W#F9\CYJ+HE<3=,%[NXR!>TG#^?SWE"-C7IUJ?763V1,\BVJZ@
MJNBH,XYF91!%=VVFCG,8YS\M.5#'.81,8QC6C&XF,8P[1,8PCM$1_#I]\@>)
M?^LM&L<?)9F;X&N-8:_P88\_?AS%:=_9R<S]N;P6<VV+F6(I^#D95K%V/(]?
MIZ48ICS+V-7LBCU?.W*LN(6/>O6.QTY2EHLSI=L=DN7>4CH;F7Y<W>*>LSIH
MW"3;Y,C\A=3;5.&\4QNUITG6^L]@%VM@M7"\([%_  #'\H>#[RQN',SY'S47
M1*XFZ8+W=QD"]I.'\_GO*$;&O3K4^NLGLB9Y%M5U!5=%09QS,RB"*[MMR;G.
M8QSGO-Q,<YA$QC&-BJ_B8QC#M$QC".T1'\.N3CY+,G_"VN>QG7EH-+L6N4:?
MFB2R^2 7=IIOYF@W:GT2KDF8QFH)5GB$'8::J@^.EOE;"]:<3=%<F]S79M>\
MQV$1J5+CKSDO$L*0L\WL%^:M)"0G0KN092U(4RF8JD5H0-Q%XE(SS)20$J2H
MMT#&<I^QCGF@Q1DSEDK] R=Y7]0Q&0KGE2)N#3R+O=HQ[*=;Q];PQ;(5OTB:
MJ;E5OP9!QOM3IF/N*"9,C[[/V0L6.ELRNN5+)&"T[*SEK*IC(+;<(.TQD9(G
MF5ZBWM05Q!>;2%=8(47)2%.)&YQ  --\QN8<C\MUDI$#/UFN/(K&EOR?,6I1
M]:Y,D5'*MF-HP_38@[5%P<#+&,^(<I/"4IQ\&L@5+F66D)NHXSQCY=1N,(NR
MO*HOD%^O9(N"6ZQEX.2C+8G7J^W?\1R2+6;+F7<-Q,Y2( IKU6A\MSMY%TG(
MF*XW(SG&DG8)"T/<;R#BRV.O Q:34V]D;$YKTTA! X9EDG#EZ10J^\LHF*>[
MKE-_Q,8(_>E5=4#_ !:8T_=GFK47/P$I(P<[!R+&8A)N'?.8R7AY>,<I/8V4
MBY)DJ@\CY&/>($5072.15)4A3%,!@ =7GE%YM(F#L&<(:@FKF8ZH]238MLM4
M<5&\=&9CJ!41(>*L<?(F:&DA9"FI#SP(/6H().&R:,QB*UG>6+'=A*\LN$\F
MF:"BROU%%T"9"NCII)M6MRJYUDV<VR)LX#G<63 6CEJJK'?_  6=X_X=K)IC
M+1+YY%RL6\:R,9)QSI=E(1T@R7(Y9OF+QL=)RT>-'*15$E4S%.F<H&*(" #K
M_=&^T'<8]JN7I^K)T:ZL,HFCX/$7,&P23;H-[#!V%\JQA:ID)Z\11<'BSKL7
M*<N";J$.8P%19.IC 7-'D+"E>>NE'(U"ZX\C<U-8M-0NT&$),HW;%\RDQ04_
MT8OU)%QP_ =90WMQ1SGS59?5Y@4\>E3G5#Y/CJUB/ $,JT>G50G;A5WL_8QE
M6S(1;D*A*SZD0H<#](;+E5(FE9N2ODJL!;#CNQ))Q.;,YQ8/F$7:8INL@LOC
MC&9AZ$X?5=ZJAP9F5.F#62;@9JT!9FJ=PM[.8_B$N6%ZC\2/Q>^5?QO6*\0'
M6'QE>7'47D]Y&8ZOW2^B>0#SI?2>B</BH\/B[Q^'G6E9VMN([9*Y/OM8M, X
MQ)/7*=CVD?"UYS$ND9=6XT*AN6[Q1RL!DRHI.""3:(G*/@US4\R$3E7E1;T>
MX91SCFZ,BI&\Y>2M:%4L%LM%\9Q[YBVP6[B$K"E$.RIJI)OE6Q7("4JYB;%!
MQ%S+8\32=V+%MH3EE(=RLJW966NR#-W!VZJ/UT0%1!G9ZM*/&)U2@8R/'!0H
M"8A=8US?RSYK@JMF3&+8[.,F7[('\I4TK,1N_GL/9QIS)TC/0JJ$@P%Q&O"<
M9-%0JSACTQH[.92L\P'/+F?#,[1L-2R60F-!QD^L\G6IU]5 0FXN4R'<LA52
M@(0M4@GS0SI\S(P<)NT6Y2J.4DC*EU4>6+ETL:5IP'ABPNK/:;]&+G/ Y0RJ
M#)Y"-7-9536,A+4VD0S]V@SD *"<B[?N5$=]JFV<+XYY7\43-+K]_P G>5_4
M,OD*1G(FGM/(NB6C(4IUO(5NNVR:;](A:FY2;\&/<;[HZ93[B8F4)7N8K,>1
MN7"RTF)H5]JSF+QG;\G3-I/(6F+291ZR#*TX@IL29FBJ016,9\4Y2_V2''P:
MK&>,(Y!Y>JM4(7!]0QHZCLJ6O)$)9%)V N&0K \=MV=1Q/>(P\2JSMC8J2AG
MA%C*D4 R12@4Q\G\N61Y2K35WQ//IURQ2M)>RTE57KY2,82I585].P=;EW+4
M&\B0HF78MC[X&#=V  CI+'$O((,XCF*Q+=,<M".UA;M3W"NFC\E5M3BCL1!\
MNRI\BP;$4, ++/P2)O*G3*;,4R1H=O6<]P]3SE5U13-PUAL<9Y.W$..)SD47
M'(55EE1+[4R:2Z>TNP2F-;^5_F-L[6HX"S'/H6RJ7Z6.J2#QGE@S)A!.SV1P
M&\G%4^\PT<T0=/U X$:[8-U5A3;*NG"-DSWR+9FPS 4/,<LMD%WC_)K^T1M9
M@'MLZ1.R<ECFXX^JN0$)>H3;YX5U'L3L&R3)NN)$7"B)$2:R9FOF6S1"V[,.
M34DT).2BF2$;,7$M937=P&(,(5"2>]>3BIWTATB0>*G13.H=-P\!FT;%,2W9
MORO+LZ@]SKE&&2?NE7(NXC'=/=/(NK5^.2<23ID1:)H=/:MD .JJ@55-H)SF
M3WC"%XS;AIM9*+E7"T93I%#(E@R)8[,&9',U::]6%H2S0$Q++U%G(3B4T=5@
M:O,(H$W0$WB*(;Y-2K7*3ITERY9X8P]5RP[:M7LBO3)6#</UZ1DEO&,2+.Y!
M"MN)=XVD$$$U%SQL@LHDFLN@BD<O.WR'YVP]'O<VQT9/VMC8I23?XAR!)))-
M8L<AU"]8]B;DO%OI2.8[)%J6,=HNY)$RQE45E7&W(7.KSMY_QPZR&A5%:HWL
M$>+YCCW'D5)II/IB!HRM@9Q]KR%D"XN8P&K7@1K-ZLU(9LW9F,NL(W;/!F,A
M!T%BS9T##M7DS@+^ QE6W3]:'&423<NVK>=L,C).Y:0314411=OCHD.HFF0Y
MJ':<)\WZLGS6C!-YO)=FKCUM8:C4;=)).'JF-K3AN8;UJZP,9 E>-V(22B[5
MP^5;'?HE4;KIMBI,\E\R?+Q XM)(J@O8Z,7)-MO[F(3?IE1.E2Y^CTJNLI%Y
M%[YS%&?<)-G&P@&7)M4T'V9O)=:XZQ9>-CV4PNX;0$ZUGW>&JO8B//C*NF1)
MV+$C9GEV[*3DBNW8(=&=-9*24D3I-446R#G5X^U&YTXSH>:[M2"DQMCY^DBV
MME4K-E)TBGXXK[-Z4XM<K9B<((+/SF)Q(6' $W'1R)2P#D/F*S%)]-ME[E16
M;1;95882GUED7HM:I59;K&$6<!6HLA$$@_TBZ@*.%S*.%EE#P?(?&90@\><Q
M?+W%5>$4C7X$?+PKG&D^K\6UQ?U]#HDI*4&X4YR2*>/FI3F8R*B_^F41(FXS
M'SS<\^?\+M6U2QA.U.%3H4E:9"IP,),/866F9Y]/7&KTB8E+A)]1$C(R&8Q:
MZCDSHP)J*KJIHEY@.8<\>>(;Y?RM<KM$PZP(](AZ[*S#DU8B'BC<I47#Z*KQ
M&K==8H!QEDS*?]+47C.8'J._Y-PC#T%S'(K$0?NKQS56%[;K_ /7!DTCNG4#
M2[;-H."@"FUM&"B0PI%*</O#Y7,(I,COXNTY;K4E;D2$ ^[C^EKGO&0E3"8Q
M"$W*77'VZ)AV"H)0V"(@4?OHE?V-J/YHXU@GY&\8? F#_H9^I6:,:S5;M$+*
M5VPPSX@J,I:#FV*\9+1CM,!*)VK]@Y424 !#:0XAK,O+C8TGIV-,L[EU0YMX
M00\J\9SPC+4&RIK@F1NX6?5URBF\X.\FWDD7+<1WT3 'WB*PF&.9;F Q'#+D
M226B,89DR+08Q9)!P\=HIJL*K8XEJH1%U(N%2@)! JBZA@\)S"+<^;L\9FS&
M=H5L5J?*F4+OD(S8K(7HLRMS6V<EQ1*T&2<BD!=G#Z0IN[-\VW2+ELLJW<MU
M4UV[A!0Z*Z"Z)P426153$JB2J2A0,4Q1 2B&T/#KR+8\YO-<SIW5CB%\DVO,
M3EYO6>IGB2J#N)ZA1N!(OJQTBN<BB'"X1RG,!BB CI]+2SYY*2LH\=2,G)R+
MI=[(2,@]7.Y>/GSQR=5R[>.W*IE%55#&.H<PF,(B(CH]TPKE/(^'[BI&.H52
MV8NO%FQ_9CPSY5LN^B3SU3E(F4-&/%F2)U4!5X2ADB"8HB4NPUWS/D_(>7+H
M:/:1)K=D^ZV2_6<T7'\46$::?M<G+2HQ[(5S\%'B\-/?-N@&T=-KWA[)-^Q/
M=V;5ZQ9W+&EQL5$M31C)(BVD6;:PU>1BI=!J_;B*:R95@(J0=TP"'@TRM^<<
MMY.S-;(Z%;UN/M&5[[:LB6)A76;Z1DVD"RF[?*S$DUA6LE,.W";4BI4"+NEE
M"E ZIQ,BY;+*MW+=5-=NX04.BN@NB<%$ED54Q*HDJDH4#%,40$HAM#PZ\BV/
M.;S7,Z=U8XA?)-KS$Y>;UGJ9XDJ@[B>H4;@2+ZL=(KG(HAPN$<IS 8H@(Z?2
MTL^>2DK*/'4C)R<BZ7>R$C(/5SN7CY\\<G5<NWCMRJ91550QCJ',)C"(B(ZA
MK[C.ZVW'=ZKBZSJO72BV.8J-L@7+AHX8.'$-8Z^\CYB+778NU43G06(8R2IR
M"(E,(##2>=\W9=S7)5UJZ8U^0RWDFY9(?03%\LFX>LX9W<9J97C&KQ=$AU4T
M#$(H<@"8!$ 'V(BY42TV.E6^ON@?0-JJ4W)UNR0CX$SI \B)R&=,I.-= DJ8
MO$15(?=,(;=@CIK#9MYD,]YBAV)CF9164\P9"R#&LS*K-7"AFK&VV*7:MS*+
MLD3F$A VG1((^$A1#V(C'N*.;?F;QC0*_P!8=0T?'N>LJ4NGPG6TH]FY3JBL
MUNUQL+&]934DY>.."@3C.G"BI]JAS&'U].<_^*/.'ISIS1,P\U?,CEBD/'3)
M\\IN2\Y9/O=5=OHU8',<\<UZT6B5B%W3!P *(J&1$Z1PWBB ^'45><97>WXZ
MNT$J=>$N-$LLS4;3#+J)F1.M%6"OO8^6CU3I',43(K$$2B(?@'4Q><DW.UY!
MNUA<@\G[C>+%+VRTSCL$R(@ZF+!//'\M)N023*7?66.;=* ;=@![$38J[+2<
M!8("3834%.PK]U%3,+,Q3I)]&2T3)L54'L;)QKU BR"Z)R*HJD*<A@, #IO3
M<W<SG,+F.H-)9M/M:KE3-&2,A5MM.LFKUDSFF\';K++QB,LT9R3E%)R5(%DT
MG"A"F IS .HV]XKOMTQG=X?C]47+']IG*9:HKI2)VSGJVPUQ]&R['I#=0R9^
M$L7?(82CM 1#49 9TYCL\YI@H21-,0T)EG+^0<C1$1+F;*LC2D9&W"PS+-A(
MF9KG2%=(A%12.8N]NB(:+B*.YL^9AAB<E67HQ,8,L[Y2:X\+274<K#N:<6E(
M6I.MEJSB)6.U/'@VZ(=L<R8IB01+[)J_B'FCYBL50)TVJ1X3&^;<ET>(,DQ*
ML5DF:-K%FBV9DV97"@) )-B8'-N[-X=J;O->;LNY@=HJ-U4764LDW+(#A)5F
M@NU:*)K6R:EU"*-6SE1-,0$!(FH8H; ,(#]Q8?B$SUFC"/E=U3Y5_%#E&\8U
M\I^H.L^HO*'R,G87KKJ7KIYT3I/%Z-TM;A[O%/O>OISG_P 4></3G3R,D^>?
MG%D8V1:N&,A'ON9O-;MB^8NT3MW;-XT<791!TU=(*&(HF<IB'(80$! 1#V&M
MPQ=?;IC:VL>%T*TT&TSE/L;/@O&D@CT6;KSZ.DV_"?L$%R[BH;JR*9P]L0H@
MA 9JYEN8#+\$VXG1H7*.9,BY B6_&<Q[U;@1MLL<LS2XKR):*FW2!O*MDC#[
M9,@AJ(R%BB^W3&-_K_6'4-XQ[:9REW"$ZVBWL)*=46:MOHV:C>LH62<LW'!7
M)QFKA1(^U,YBCZ^G.?\ Q1YP].=>OISG_P 4></3G4U>\CW&TY N]D= ^L5R
MNUAEK7:I]\5%)L5Y-6&==OY>5= W0(F"BZRA]PA2[=@ 'L8XS+CZ0-%W?%MV
MK5\JSW:IPTYJKRS688INR)*)&<1[E5H"3E$1W%VYSIFVE,(#RT_:)4RZ5"N7
M: >08U*N2=AC"6.TL,B2$36<KX:CF8F0=V*Y8MN+)-\X(D4Q6;&(DU@*":V_
M["M=PMS,<P6(*^N8IEX+%V9LC4"&6,1P^>$,K&5.R1+)0Q'<FY5 1(.Q1PJ;
M^TH81=6_)U[N61K8^,N9[:+Y9YNWV)X9T^>2;DSJ;L#Z0DG!G$E(.'!Q.J.^
MNNHH.TYS".JKC*^YJRU=\;T3=\B,?6_(]QLM(INX@+4GDK5)F9>P->W&QA3#
MHC='8F.[^#P>P^^(W/6:,,=9\;K+XJ,HWC'76'2>@=(Z=Y(3L/TOI'537?XF
M]O\ 1DMNWADV$L>:,LY,R[84][ASV3[Y:;],I[[2/8'W)2URLL^+O,8EJB.Q
M3PI-DB?V4R &FMCIMEGZE86/$Z%.UF8D8&99\4@IJ]%E(IRT?-^(F82FW#AM
M =@^#3FLWKG)YJ[I6WIDS/*_;.8;+MCA'9D3;Z1G,5,6]XP7,D?PE$Z8[H^$
M/8CYF&D'T3,1+YI)Q4K&.UV$E&23!=-TQD(]\U42=,GS)TD51)5,Q5$U"@8H
M@( .HB)SMS$9TS5%5YXXD8",RWEN_P"1X^#D':!6SI]$,[C8)EM&O'+8@)J*
MHE(<Y  HB(>#V(VWT"VV:C6V&7*ZA[13YZ5K-BB7)! 2N(V;A73*28KE$/ =
M)4A@_P ^HTF=,^9IS02&-O0Y,LY3O.1BQ1MC@-Z-+<)V8!B;8[5#:EN_Z0__
M ,8=O+OB7+UKK-7QX\N"-EL;6SR3".0O2-03-8&>,(SK$Z2#^5R)(L48L&Y3
M NHW<+"B!E2D*:G<FU$E4'M'Y;=^PY&79+)KMI3-EHC2I]5'524615^+RGNB
MM1W1(HC(RL@W5+OH!L^\/+//I=H<Z))UJ\PC@Y1XB8.DQC:09R65;@P(L7AG
M14EHUA"-':0[Q5&LJW$0 3 /WT2O[&U'\T<:P3\C>,/@3!_T3/-.':_UES.<
MO<1).X*,8(&4E,I8PWUI6R8W031 57U@C'(J2E?2V*&4>"Y9I$ \AOD6;.45
M6[ANJH@N@NF=)9!9(XIJHK)* 4Z:J9RB4Q3  @(;!^_F/BG4E(.8N(,\-%1K
MAXX681AI%1-:0-'LU%#-V1GRR13K"F4O%,4!-M$ _P"1%.0QB'(8#$.41*8I
MBCM*8I@V"4Q1#: A^#3Z6EGSR4E91XZD9.3D72[V0D9!ZN=R\?/GCDZKEV\=
MN53**JJ&,=0YA,81$1'[PZ?@G'S=W'0)W#>=RMD$&:CF*QIC=FZ2+/61Z;=X
M"LJX3-T2)9G,3I\FLBD)DTA562Q_A;%D$C6L>8RJL13JE#(F%4S6(AFI&R*C
MMT?\M(2CTY3.'CI43+NW2JBRIC*',8?OHE?V-J/YHXU@GY&\8? F#_H[?SG<
MDM727O[T%)S-'+[78U)!6^/A4,I*Y'QFT:<-(UU<E,*\O#E3 TR<#NFPC(&4
M0?.6#]LX9/F3A9H\9NT5&SMH[;*&1<-G+=8I%D'""Q!(<AP Q3 (" "']9L1
MAG -1<3<FLJS<VVV/4W#:DXWK2[D$'-LO,ZF@LE%138H'%)(H*/'RI. T177
M,5,6&)<<$2L=SFC-IC+F6WT4VC[+DRUIIJ@5RY324=*156@BN5&\-$@NLDP;
MF,8QUG2[IRO]],K^QM1_-'&L$_(WC#X$P?\ 22^28$28!YDW9#+JY6J$*U=0
MMY>II&(B3*M-36CF]F74#=)UJW7:3!"E3XB[A%(K899]E;#TG:<:1IS&2S5B
ME-]>L8+L=XQ4WTI*,F*$S2R*&()03GV,6J8W]@IRF(8W]9,93\?U&SWJW32X
M-H>K4Z!E;/8Y9R/A!O&0D(T?2;]<0_Z"21S?^34->.<>45Y9\5F51=K49BI&
M3>=;.R Y3&:I,"]8UG'*3I'> ',H9Y(-SAL/%"!M\(S#_+KCB#QW36!BNGP1
MZ1G$[:9G@)MW%DN5C=BM,VFQ.TTBE,Z>+*G(D0B*7#0322)]]4K^QM1_-'&L
M$_(WC#X$P?\ 3/I#+7*3B1_/21SKR%KI\.ZQ=<'[LP[0>25KQ@]I\]+.BB >
MV=N%]H !3 )?:Z6<0DSS,8Z15==((QIN4ZL^:MTMBX=!1/D'&UZ?&:_E2^%1
M8ZWY(OY3PGW^^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^
M</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_
M\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN
M^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/
M^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!
M_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+
MKKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOE
MYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G
M#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_
M "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ
M[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><
M_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"<
M/!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\
MNNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^
M7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^
M</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_
M\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN
M^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/
M^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!
M_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+
MKKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOE
MYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G
M#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_
M "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ
M[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><
M_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"<
M/!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\
MNNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^
M7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^
M</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_
M\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN
M^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/
M^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!
M_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+
MKKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOE
MYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G
M#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_
M "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ
M[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><
M_P"</!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"<
M/!_\NNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\
MNNN^7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^
M7G/^</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^
M</!_\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_
M\NNN^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN
M^7G/^</!_P#+KKOEYS_G#P?_ "ZZ[Y><_P"</!_\NNN^7G/^</!_\NNN^7G/
M^</!_P#+KHIAS'SG' # (D-D3"(%, #M$IA)R[E/NF_ .P0'_,.D7TQB:^9:
M=-E06;CD_*]N7:D4*H*A.-%45U1(>02* [O"=-UTCE#VQ3#M$58# F%,78>B
MG1$B/V^.:/7:FI+"A_HUIIY#Q[5[-NB_AXSM1941\(F$?OME?V-J/YHXU@GY
M&\8? F#_ .:)*_L;4?S1QK!/R-XP^!,'_3IKR\I'12"JG"26DGK9BDHKNF/P
MDU'2J1#J;A1'= =NP!'7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[K
MUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3
M[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT
M,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5
MNT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7G
MC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO
M7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/
MNO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0
MQ/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6
M[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>
M-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]
M>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^
MZ]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#
M$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;
MM#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYX
MU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KU
MYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[
MKUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,
M3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5N
MT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC
M5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7
MGC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/N
MO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q
M/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[
M0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-
M6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>
M>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z
M]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$
M^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M
M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU
M;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUY
MXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[K
MUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3
M[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT,3[KUYXU;M#$^Z]>>-6[0Q/NO7GC5NT
M,3[KUYXU;M#$^Z]>>-6[0Q/NO13%,!BF #%,40$IBB&T#%$/ ("'X!^^Z5_8
MVH_FCC6"?D;QA\"8/^DE<A97NU<Q_2X5/?D+#9Y-O&,"*&(H=%DV%8P*R$H\
MX8E;M&Y573E3VB29SB!1D:QRB8Q3N)T1.@GE3*Z<G$UQ8Y3[HKP&/8Y>.LDB
MS62-O)+R+Z*634+L.R.7\+L;GS'Y#BXMWQ$S5K'LJ.,ZWT0^\ ,'$71"P)99
MJ4IMG^OF=J&V )S&, #I:2FY.1F)%P(F7?RCUS(/5S"(F$RSIVJLNH(F,([3
M&'PC_6.F\QEE/(V.W:1@.FYHUVLM36(8#*FV@I R; WA,N<1_P ^^;_..UFQ
MN=F@,^55$R9%8K)T2D6PIM0$15+'WBN!$3IGJOXEI/K4I?\ ]6(>#4/3YJ17
MP3EN542:-J+D.0:#!S<DML C*GY!318P4TNLJ<J2#=ZE%2+I8VX@U4'8(_?7
M*_L;4?S1QK!/R-XP^!,'_1DEK<J2U90LC)PKCK$T8\!O-64Z*Q6IY:6=E0=D
MK539+F'C/ER"*QDSI-B+K%,0JM\S;<%I;HZC@M9IT5QXVBTB/<*;PQM4KG2'
M"+,HD A%7:QW$B[!,@N7"QBE$/ZS*]AWF7E9G(^ A%K$15L>=+F;]B1KQ")-
MEFKD <25NH\<D82J1B@+/F;<I.@'W$2L5X"[TB?BK34;3%,YNNV*$>)/XJ8B
MGZ15FKUDZ1,9-5)5,W_D,4P"4P 8! /OIE?V-J/YHXU@GY&\8? F#_HK/F:]
M'3?.VP=346H$=$:R-ZO+]NX4A*VQ.)5#(H&Z.HY>N (IT1@W66W#F(5,]MS+
MEF>4G[I<'P.7BP$!NPC6+=,K:*@81B012CH2%8)D;MD2[1 A-XYCJ&.<W]9T
M;R^9BL)QY=\AS0-XB2E%R UQ%=IEP4B4ZFZ5#:SI=A>G*G+)&.5LS5/U@'#V
M.^.4Q3 8I@ Q3%$!*8HAM Q1#P" A^ ?^4QN7.6^^_%SD)?-M$J"M@\EJ7;]
M^NS,%='DE']4WNN6B$+TES$MS<4&P+DX>PAR@8P#C3F'QWS_ /+!#4K*D">P
MUZ+NF.\>QUH9LDY)_%BE,LH/DPL42W="XCSB!4'K@FX)1WMHB ?^(GR<]B*G
M_(MK&,#S+W*MY"SU%U=JURE=J>U;LJQ9+415<7<E"M&E4H[9!DJD9,"E)$,
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M$1'7-_'2./*]1J_R\9994.G.X::D)I[:H*1DKT@TEYM5T@V:H/3,JNW,)6Q
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M78L^=;7K5R!3["[A<MYZNAR^3>)Z%8[J_;BJ**DHK#1RR\;!-5 36$K^P2G
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MXJG*/7[.WJ,S<SO\@R4_%0(Q<&\B63M KJN5FUR OU%9A(4RBU!,2E-M.40
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M?+S F;A9K_RY.U*>1V8A&CB[4[),C?*4R=+J*)$:-W]KJ[-$ZYA$$"J"H(&
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M'*"B1P*<ABAR6?(14?\ JW&N5;Y:K9\!E-<N?R$8B_=_7M8S^T"QA7E7N/\
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M-_%RD7*-S-I&'G(EQM:2T4Z()3BBJ @19)-4@E523.7EMRMF:X25QN,YER)
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M&,JJH=4QCFC+_'TFYYKNT!))R]:G<^62*N#>NR#=1%=D[CZI6ZS2J*Z>1SA
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M.[L#B+F_'MUCF%A$TD8:(SSF.+B$6_#X"49'PF1VC!-'A 5+A$:HD NZ %V
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MAXY_S*YQH[2H,7_'D:WA=*QS\U8H]+HHD8)VFY5ZGMZNH[.=8%%@C),4R)%
MA1,L)T(&H\HL_MDF,"6.RM0H.16M=*I4W$D;1\:1G<7\S)R2ELDD$5#3$<<S
MGHK@@***IK*J(%F^7RSV]E$9CCZ# T[(;17HSFPUV[TM6*=TS*S:'5<$>R=7
MGYB':.UU$3)$4.H[C^*F<HFTI5VN-*9*0)7YFA,D-,IT1&G*-@$^[*=7R$RR
MR"5F<"A[08/I(;P?DOP[&E4F+;$6/+3AG9)" 8(#P7>4,XV=N0ZZ\3%K)'=$
MIE2 &:+AZNB0J<4P2XH=+<)(*SK]\X5=O7N#LD.WCIP<RJ[ETYLM'6<.%E3B
M)E%5E3B8QA':(B(Z>?(YC?\ ^_L&J-\GN4?@NMK%_P#A:I/[V<W:F^7RSV]E
M$9CCZ# T[(;17HSFPUV[TM6*=TS*S:'5<$>R=7GYB':.UU$3)$4.H[C^*F<H
MFTI5VN-*9*0)7YFA,D-,IT1&G*-@$^[*=7R$RRR"5F<"A[08/I(;P?DOP[&E
M4F+;$6/+3AG9)" 8(#P7>4,XV=N0ZZ\3%K)'=$IE2 &:+AZNB0J<4P2XH=+<
M)(*\M#]\X5=O7MTMKMXZ<',JNY=.<?719PX65.(F4565.)C&$=HB(CKEA^3V
M_?"2$]C+&/6[](;74\Z2EEEHH5$^D)0%QI5,90,F"8&XG1WC^J2"("(; .V'
MP^'7,!?'%'JQZCCX]LN<,^:W2'E9;*,$UDGKY0M J]=/.3_7)8<HNNAS"$0H
MH4!21%5P)$C:I6'L9Q(3=YOTTC!U^/4<),VXKF25=.GCYXN(),XV+CVRSIRL
M;:"3=$YM@[-@SK3&-<C<K\PMBA47-OM4B_0K*5QLB9?^[JRRF7S=XK4\<PCU
M<3;"(KNE$RG<G17<BF@%DS+E[-G*W+66>4*@R8-KME]&!JL U,IU55JO'*86
M6+&044FH.X3>,HLJ=1=<ZKA554]XSA;[A@:S57'T<A+V",I%OO#JQA&*OVK!
M=XR:V?&M4BG)&(NRJ*D%X54R93<,BA]A!ME1O%UFJ91,>U)&UV,U438C;9LS
MZ6;Q$?$PCR782</$ )U%%5G2[9WN F4A4#\03I05"IMSE;G1;S3$;M5EK-U?
MY7PZ 3$G!O8>PJQ+.-C9%1)S&<5%X@U:)KD5$G!(9(PFURX?+SB#]X5>U3?\
M1]#^ 65-5G(5 L$C5;I3IEC/UJPQ2I4GT5+1RQ5VKE+?*HBJ3>+NJ)*D.BLF
M8R:A#D,8HV7&&5(^.C\ALHQE&Y2J; Z19BD71%%PG6LL8^.[!19*,?.4SN61
MS H5!07$<Y%=(#F<6G"F3V8!)PJA7U?L+5(Y(6ZU%\JL$%;H%0YE-YA*(HF*
MHD)C*,W::S978LBH ,?_ (/:V?N1G-5VYU.6=P-IJ<W%62N3; X)O8B=A'R$
ME%230YBG*5PR?-B*$V@(;Q0V@(>#3_!.9&T&PRC)0*">0\3+R!8JPM9Z&2(J
MGDW$+UP8SIW'-'I.EH*("X7BQ,+6034;J 9VX-@G/6,K#55G!SM$,M-[53;!
M'-#!O)MG#JG5J]QTTX2-[4RQ46!5 ]L"1/[&HFT<VF5:_<(:*72=K8PQ.2?2
MB+"NBX4.FUF[].LZY-I0IT4TP709Q;9TL"IRD=(<,#J3W)ERN3$+)6V:KA*%
M>;%17# *CBBBD9I1;ZAP+F+(I&KV61A"&C54&9BIPK0QR&,1V!4T?9NO^[KC
M7XP_B\\G/+'_ -<J!4NI_*WK[R?\^;56>L.L/)E]_P#(O'X7 _*;F^GOYPK_
M #"X]^+Z7N%ZK4S7&GE91[7UC&Q\ Y9/'/2*19;*U:<%TH!=Q<Z2AMNTI1#P
MZYDLL0V NF4"=RWF+(<5/_&IA5OTJGR=QL5D8S'53K(Z$TAQX5<JW1U&Q'1=
MNX9,% $NL89W8M'$I'5:6796Z#;*E25GJ38&3B$M,:CQ!! SX(IZ==GQ/R9'
MR")S> NL3<S/*;>:;8KQ"UM2+AG+F4*U@,A4-\]4E25QW+%2<'KELILXZ=BF
MV=IH@FL[=MW?!4*025*S\V%4@<:8GI\\RG9VKKVZHW2QY )$K-G[6N,V]'FK
M)#L8.8<EX#Y=V\17(V*H":)S'(8*]R?XHL#6P1M)LH6W,L[#NDW,4-OC&SR-
M@*$B[1**;U>N%?.'4F":AT4GIFZ(B#ALL1.M8=P[6O+#(]PZY\G:[US7Z_UC
MY/U^5M,O_P![VF5A()IT2"A'2_Y=TEQ.%N$WE#$(: RIG##'D30F5%O<,ZGO
MC%Q19.%)3,8DWC6W5=1O4_,GZ2L40WRMQ3)^$QBAX=5G). \0>7E*C\*5*HO
M)KXP,75?@V&,MU_DWT?U=<[M7993@,9MJ?BE0,@;B[I3B8IP+:L4Y0@?)B_4
MF1+%6>!ZTAIKJQ^9JW>E0ZTKTC+0KW:V=)FWF[E4GMMFW: @&K'CE^JF1',>
M)K'$Q29CID47L]+>,+JT*F!_;*@2L1<P8Q">V\ &_LD'6<DU&YTHG)#Z(RW7
MESE$O3F=XC$7,VX*'#(42(75I*M@$-[;P-HCO;0"Q\GV59]C7HZY612XX<GY
MI\DSC!MLDV81L_C]5VZ,1!JXL(,&[N*(8Y"+/0<HAO+N4"'MEEY3JM!Y.Q/;
MYY].P-9)<*C3K+C]*67=/W%:>HWB:K41(P<(N?H[!PV>+N5&PI@LD4Y3G'+7
M,SS:7:FUV[3->2CIMVR?F?P^/Z&Q>)28UIG*%037LEIN$XV:F5:LDE057:M4
M&W'4$1-;,F;@PI,H7:"J=$BY9;>2K5326852F,'YF22I2*(QY$G#X42' SM5
M<Y0,)O#8\YT/,5WL5_Q?'0TK?65P1KC>G6MF_F(N#?A4(^+B&DQ5G;5>4!=!
M)Y(2W22I\'>(<X'"G8ZI49UU<K]::_2JE#],CX[K:S6J6:04#&=82SMA%,.G
MRK])+C.5T6Z6_O**$( F#E]RGDK WDW0Z1D*.G+1._&CAB8ZLBT&SM-5UU9
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M[DQ"5E2IM>G.9(I;&P6*917P$21  W2%U<<9Y @V5EI%]K<S4K7 2*15F<M
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M+M$WA*HD<I@_$.K#>KS/R=IN%LEGDY8[%,N3O).7E7ZQEW3QVN?PF.<YM@%
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MPB4VJ:(%23;D8-TP(4H 4"@ !X-9G?2:22CVMW?"\U73J'*4Z$POE"M5U=5
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MI)B(E26,U?'(<2@ J% F]MW"[)R@H$,U97+(.+XMV*.PITS7& I2DP[*(;
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M>+2G%!,-X_!04, !L P5>M1ZR;A[3J0W0G#)CM%K(3<B[E$(Y7P;062BS-W
M_A#==%_'M  RXKCF;)CX69)+KTRD;Q@BCD!0DP:#Z=Y0EAC(B"G3!: VX0[^
M_N>V]FE_IJZ?"F3UUQ$O7,;*1<R,C&R#-8[=VQ?,WHN&KMLNF)5$5VZZ93D,
M @(& !U/8VR8S9.+>TB$XV\P8&3;'EF8'2(PO%?*41.V,5Z5(YS)@ L) I?
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M=.6FGDBW*BO)6^(=F.1!P4#@9 H <! !$/"+E<@& BSA94H&  ,!5%#'*!@
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MR33H1/[0;7H[2_@,60M;9J9.NY1:)V9BN4@@W+.MDT&%H8@H/]MSTTJ;T_\
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M_L_@$/Q[=B#[*N0).RJ$$BAX&I-"P$9OE#VZ#F8?&?R;YN<?QHI,5-GXPT6
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M"'X?NX*.E91E'OK/)JPU?:N5BIK2THC&/YA5DS(/A46)&Q:ZHAX V)[/[0E
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MV4*JW=-'21%VSE!4@B15%=%0IBF 1 Q1 0^YMV07!D3R3)D,=5V2P@(25JE
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M*O$D06?UYT;JZSQ0>U _3X)WPWI42*#N=(3*JU.8!W%3AX?Z'(.0*0^1C;1
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M\6674WE53F%L^8N7#)ZR<(NV;QHLHW=-'3=0JS=RV<(F(J@X05(!B'*(&*8
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M(.TA@$0#9^ 1U)V+&TNUAY68BAA7Z[N)C9<BL>+ML^%(J$FV<I)&Z2T(.\4
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MXIUY[PW8JI^*=2$L_4*J^E'SN1>JE(1(JCM\X4<N%"II@5-,IUE1$"E  #\
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M,<#&'NE]_F3?3/7=+[_,F^F>NZ7W^9-],]=TOO\ ,F^F>NZ7W^9-],]6+-^
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MR;Z9Z[I??YDWTSUW2^_S)OIGKNE]_F3?3/7=+[_,F^F>NZ7W^9-],]=TOO\
M,F^F>NZ7W^9-],]=TOO\R;Z9Z[I??YDWTSUW2^_S)OIGKNE]_F3?3/7=+[_,
MF^F>NZ7W^9-],]=TOO\ ,F^F>NZ7W^9-],]=TOO\R;Z9Z[I??YDWTSUW2^_S
M)OIGKNE]_F3?3/7=+[_,F^F>NZ7W^9-],]=TOO\ ,F^F>NZ7W^9-],]=TOO\
MR;Z9Z[I??YDWTSUW2^_S)OIGKNE]_F3?3/7=+[_,F^F>NZ7W^9-],]=TOO\
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M&&:,K5Z):L6T.#JR]XQW:W%@J]'"A-X62L-0JHMZ\O9F"Z)TWK=%2&51713
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M)DFJ 2UXPD5:U(;SB)<J9(J5]K-P369'$43$FX6E,&[CP;54T2E-M H;,_\
MV>]UDGJ.,<W/5X/'CU_TA-G)24>U<W[!%EWU#N$3.K!1)A["N>$93;,.2('4
M$S<0"D<J="</'>3>;:[,H->#A2F<S;G&U-D8J3F&C=LT(K($<6NZ.X2,02*!
M.L&YGJ)1.4JJ8X.Y?&[=J2>J51:R&07K4$#!+9+LQCV"^OS.4#JE>($L<@NV
M:J"HINL6Z"8&$I"[/86^RHY"6CW)^=LNO5:#FR=IJB3Q"M0SQ)9*Q8H82.P(
M]O*/(\%!M<BHN1E Q)'#9<Y5SN18Q^+U)J+F+S+KK9#SED+:#*)E;DO&-DGZ
M,:Y?@@LUI5.BV)&;$R_!XB:2KQ1)%5TLF67@^3##F-<2UCES<1SB5YX+(O=H
M7),G7F$F[:U%Z^&KO&C/=GY*+<.:I%.HYU-H),3+C(1J0/$$A%'[27(7.>ZJ
M?#G8W!&?G^6*W4+$K&*L7!H*'EY7.V16#&1DFS4R*)SIQ1.(1(HO&H&XZ$UR
MGX^P3'<J^7>7-!R-YPK'N9&393"!)5.!GL@LIV= UIE9?RFW&LXG,*.9)BZ6
M;IG<N2'(<OWR<X/[%5']Z=#TVP#F+'W,-9;BCDJ[7(TEC2IXWF*R,99"PX,4
M"O+3EFFR@OTACS\4O0@3+M+NG-M'8:)P%RJ\V66<DKD=JQ-*EH'']6:2";2.
M>NU%#2M+N^7)Y(B2Z"0+"E"N 2;F46\(I DI5.:/[3.KO.7SEOHRI!HW+PLF
M^KUOD:P9XG)A28VJO%%;'3F<\Y;)!9YR<Z%.O2D!%FV13Z.I'8\<<OE->6F5
MY<[TE9W&,JE%=(EGV.5ZF_K<B:H0C AG,D_JQTF)TXUJB955CQQ2*)T2)*8\
MP3)\G'-+<^:RD52 QP\Q?B2FUZ<A)^TT]C&55V5DD-B2R!7#O7[0^_&^3;Y:
M/6,5MOK"'$U]F#S(\Y6.JMB&:SAE["#/&V)JL\5FU<64.AYJC.@TRYV0$"LY
MJ^J*VL9>0$BISI=:D3,DSW08MI*%EV3>2B9=@\BY2.=IE6:/XZ0;J-'K)TB<
M!*JW=-E3$.4? 8IA#4Y]EY&3\E,8.A>8]E?;<R9R0N&*.(JQ7W%T;3TD[265
M*QN">(;2:%,IQ ,68?%0.!E *4&,7&-&\?&QK-M'Q[!FB1NT9,6:)&[1HU02
M J:#=L@F4A"% "E*4 #P![%+RAF^L91M,!>KN%"B&>*H6ISDPWF!@9:P])D6
M]NNU'9(QO0H94N^DX65XIBAP]T1,7EHM>$JAF"K1V&H^ZM+0CE. I<(]?J62
M;I\DQ- IU+(%W0=$20KZP*BX4:B4YB 4# )A+C3EXQWC+F?AKKE2>/7J]*72
MEXICJNS>IQK^4%69>P>:;%+-VHMX\X 9!DX/OB4-W8(B'WG<[OR>O/WNH>QD
M3"U2ML1+\T>8Z;)4RKTN+>MWDQ0*W<8]>*F,E6MND#@(%!C".ES0R;HI5)&0
M%(4TU&Z3DZ?-=SA2=4-"<SN3L:R&4(>NVB,,#RBU2L0S]EB=I981RDHNF_9N
MK&]L4@P6!$PI.46;LB*J"F[=>>+G(>S7-3FBX99M<!)Q%\N%@=Q-6?0#:'4!
M[;&L=,-9&VVN=92A'.[+++QR$8LT*@S(HGQS8'QC@C$W+CB7.3W+,9-/H;&.
M/J+6<G.\30U N<2[D+9+5R';V5>O.[+(1@%-*N1&3>)"J3CJ-ESI<N6)[[&D
MEZ5DCDEPS2;3&G*B874'9<'5F)D2(BX1<)).B-G1C(J"0W"5*4X!M*&OM0_L
MUI]62+9;Q,^15&FTTUFC2*DG4NTI&1+<Q;(J+':)97P*[;NF*_%*9 6K,X'W
MO:FQ#CV;BRQN2[PS/E_+A3H%0>IWF^MF;PL)(%#>-TNF59M&PBGMC%,K'G.7
M8!]FKWAFT&P?GDE(E&;+)>*YM2AY.&G3:S98\>VN])>FFS5R74:+*&0*^;(K
M\,QA)X!$=8LYH>5Y!YR_Y5D,RPU::T:JVR;ZKGC%A9ZT&NU/82,J]FZ;.4>1
MK[(P+Q*S:.1Z4GM23<J(*'Y9+EEH' 91M> ,/V3(8O&X-'JESF\?U^2LBSYF
M!$P9/UY9RJ==$"@"*IC$ /:ZO;VJ-GCU+'>2L:Y!MC-BBHX65J,?(/Z_(N3I
M)#O]#B'ME;/G!]TQ46[4ZAMA"&,7 ];HTK'#9<+0KS&F2ZJFNT+,5JRL9R9>
M-7TDP;FXJ3*XQBY)-FX$NZX!90HF%9%<I.:>;R?)Q"#2Y85R/B^K5^2>((.K
MK=<BT^8J=<K$4U.;I3]=R]E06<\ BAVS%%=R8 31.8,NWF?:O&-2R9GF0>4%
M)T54B4JTJE4@*U8K)' ;\DJP<S[=2,%0OA%S$+$-_HP]F_?L5:?[B?ZYY_TW
MR[?F.:O8L.9;01E.W>4.K5\/8\6="BYO>0';159DW7*B8KMO5X)$@O9AV7=!
M%HGPR&Z2NV34M_VM'-WTBTY0RS/V66P>E8FJ9''$EW+UA;,Q'C3H%2CTGI14
MB*NBF5%)K&)N%T4A05CU2?>[R,?)[C[]_5E]BQ9>SA?(#'6/:NW%:3L%@>$;
M)JN#$4,TB(IJ&^]FY^4.F*;-@T36>.U=A$DSF'9JW<_%JI\K#<LN!KG V&N=
M:M"%8J/,=-&B.#\<D=;HM']F.]:-[38$$Q=)-BBHBH8B;QF)Y+DBYDLF62H<
MMV$G4VWI.+*Y,GB"6IQ3* UM4B5ATH!9A<KVN_=.G<H5JJ^1KS<S1L<G#3<$
MO-UMG*]RN4[']2JSEU*W#,--@LCNF!(UB]!@5O8\KDN=E>3CY=?AHHMEU9"3
M="DD4JZW"+KGG_3?+M^8YJURW_:-8C*O#9!PC=:Y2KE/QC9$'<<BVGO+'#ET
M7<$!)1/R4O+1RQ%13BBHK+LR%W"I#O5OFJG8!=G@3E"Q3C&T1M9?I*+L8FZL
M(@DA6JVJ9< (>06SI+SDX@N*0](CJ^5(QC 4AQ]A#[-S[.PK^_\ -]DR2\A[
MK=:8Y25'$ O"GZTJM;EBJD9-<CI1R:IY>4453:T]B14YU"2!3'C59N;5C\@\
MT&08])3+&6%$E'(,P<J)OEZ)1%WR97S*HLGQ0.X<'!-W-.TP<N0(0C9LUS31
M*PMT:RW7$V1JE7G&\!>!.6.GS,/$K;PG2 O"?O$S;1,79L_"'X=<U7*[;UDJ
MEFR3M-=NT179X$8N9L<958V9K=N@F35UP7ZTS1'Z15G;,P<5)%Z=0I-U)R8D
MQ:;5-Q-;K5>C7DS/6"=D&L3"PL3'('=/Y.4DWRJ#-@P9MDS**JJG*0A"B(B
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MW3:)I-"M8BN5^,90L!7XN/A(.'C6Z3..B8B*:),(V,CVB)2(M63!D@1)),@
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MWQ/U&X6KRT^+7R\\HO)3(E;H/0/)SR_IG5/3_*'I?%Z>ZX7!X6X??XA:#?\
M_?KZW\A[K5;AU3_NQ=7]:>3,ZPFNKNG_ .\,]Z%TWH7"XW!6X>]O;AMFZ/W>
M;\J)NTF"F,\0Y*R"1\NFBJBR/3*9-6,KM9)R!FZB3<8W?,50!((!L-X-NI7)
M.>\C6'*%Z3SO?ZXG9;*JV5D$X.+KU%7CXP@M&S5 C5JO(+'* $#VRIA':(_T
ME<Y1XO*,XA@>K847\H\6,Q8)5YY<'&%IW)B$K*E3:].<R12V-@L4RBO@(DB
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M%UU0Z-99*'>'2!D\;M3"P$*=D2F224U3[[5J_=*I,( 8J,M6[3$M)R"DD2G
MIRI/XM\DJ4! ! #^'V>=/Y(\O_\ $1C;V+FM#W;+E_Q/"8LC(Z#Y9VMWN+S&
MEFO]TY<E6N/T"8\;RPP:!W67I*)=O'#-F,@9/CF1WEC@!L/\R.=N<5;'%4?Y
M,QO;LA8 @.8+*5!?1..B7:(F+-5PQ?C:J_$^==M5W#E([%U*++N$DNCN5%5/
M:FG_ +.'[+V8AL=EQFXFF.>N9*59,GQX9:KOV43=CQ+E_&S2=<JU.G7988[A
MNR6EY:;.";0[=L4%W#W+&!OM>LP9NS%!QZ4H3$64@NBU$GUT#MI63A85QDG*
M.6J8^D%'+/@, D*ZP;.BFX2RS-%54 MTA<ZI'4_F-P=--:/F&GI"]B(=[,/6
M#Q:MVUHT<MY"3K$7:7,2_;+LUB.'#!]'.B@51,$M^]N\O\Q#7[,["4389JO5
M.F88>EL%XDFL3,_ZO.14[0[+6+C/Q[U>&134DY*T0A'B)CJL8M-D\4(IAF\Y
M0YM[GSZ<I.4+,XB+2VRDO/O+29\T9Q:]D@&H7FV7V?HT^6"(H\KCAA8W,6Y<
MM' O69"BHDXOG-3A[GFR+B[EXJ_+(C9ICEWI];DT:MG-D])99925L5OC+_4Y
M%"(NE.N[:/>13Z+E&"B+!$ZB!S[ (_RAAG[3_F"Y0:@AENXU93$^,6^1U:VO
M,1,/4W;VVG-5>8+&,9UE,(RB**H#&BKNM";RQPW2D^SDIE)YNLY3V0*I,Y%B
MLAY:C+U?*1.9L=5=K1))B]R,S;WB?>V)N8[Q0@MI21E";BB@"804, _[P]CY
MW+-]G53[>T1M& N6?#K2W]>L*6^C'"U6=9IR%3KUC.Q-K-8FRZ#EXB<)I-N#
MCB Q8JI!'I96^S$OL6PS-]H0QS77,*8 RG9%T9J%0869:3&Q7+($H=NT"R0U
M1AT&<O#/GJ)G*[.4WY)$R3!1!2Z<U%5^UFS#E?+-!KDID.W89BG-[IV/W,=7
MH5PZL;2BQ(WJ4H%A=M(AHHLUCEZ?$HO5R;2E(Y,3?>V?)Z4>EF_$EK''V37<
M2P2BXRU@M&-9BKWQI&-$RQ\2>Q1ZZJ#MJAN)$D&#A1))!NJ@D6?^SA^R]F(;
M'9<9N)ICGKF2E63)\>&6J[]E$W8\2Y?QLTG7*M3IUV6&.X;LEI>6FS@FT.W;
M%!=P]RQ@;[7K,&;LQ0<>E*$Q%E(+HM1)]= [:5DX6%<9)RCEJF/I!1RSX# )
M"NL&SHIN$LLS155 +,^O]::TCF"PA86%%S75F*#IG'K/WS1TK!7*,BGPG?P+
M*RJ1,@@I'N#G69R$:Z3VBD"1C<RW*5RXY&N.0[KD*\1DF/,-GF]6S(,)RJ8[
MKDG=HNU.X8]O+;6T4ZNBDE%MV*223DZ9H]7HK%5=0'3*T\S^,/M:L_YTNF*:
MY+9(N6*IJ:R='P:L1#Q2TG;RU**M&4LC4V]&A672EVT:_@8XCE%N'1TBN11;
MZN#:N9E7Y8>:NM62'QE<<R4:JL[$M$3=:E:==4+W#4AQ,0#,K+)=/XL:\;%>
M-T6[M5\+<"))HI!>N4MGSY9FK^<8)U<XY[SG-@NZ^5IM.L8E2F5.E$2S"PMY
M22=>0)#"0]J6!-F0I1$Z8 CK(=BSC]H?F_G4B[E7(F%@JUE="^(L*0_CI-9\
MZG(D;?F[*S<7DDW4!NIP6[0^X4-JA@]J'^6HB,ZG1R5S"W^+<R..L6E?F8,F
MD.FX7CS7N^2"!57<744)%NJBW21+TJ6=(*H("F5)RY;-\J-\R3/*EBNT%8RE
M+4-=9GEEKSB(Z-*/F*U=A,71,YF^2@'0."BD_F$W)),CML=-RY;H@=LXRA4>
M9.S<T\) E;V&R0->RQ9N8]4T>V)((OH[XON8&KQ=RFDC-4P*NVK31P]_UI)9
MOL61.LV7P?E^LQN)N:NN13J07@8U1RC3,GL(@JAIR3HS66<N9F#G(--,5)"#
M=K.ED6Y1<H.%TRN"-.4=Y@S-N7,,.[+;LNMK$ZQ/DFY8Z<S[:-AJ$K'-YI>G
MS,.K*H1ZKQ8R!%Q4*D94XE !,;;-WQ&SV%*\)<C$E;DKFE-22=K2M:> EIDE
MG3L1'(2Y+"27 '8/06!R#D.+O[_MM9?M_P#_ %=.<;"'Q4VBLUOJ[R_S7DKK
M[RBBI"3Z;TO_ 'A:!U7T/H&YP^$YXF_O;Q=FP2SM)^W-YG9^TQ3AH\AX>[(9
MC0JCYPD[1%1.;%YS+7YFLS(VWS\%:'?(KG*":A (<3EIO+K]K54XC*.)[4<L
M?4N9NALFQI%>%9.FD>YM\=(PD/ Q^1X2ND=(!*Q[Z(B;<BDJ5VMTA51%%W 7
M"I34;8ZM:8:-L-<L$,[1?Q,W!3+-&0BI:,?-S'0=L)!BX(JDH01*<AP$!V#J
MQ8PY1<Q_$3FJ1M%.DXG(?QA9 QAT&%AYA-Y8([RMQE$3EL;=:1Y12X*3<R2^
MW=4$I?#K_P 4G_WW.=;ZLM9/Y=L1_:*9OKMVQ/7;)9[%*9&YN.9N(JSUA5[G
M"4:01A7M93M\LY=K2T\BHB5=BV(9N4YC'(<"IFH-BN'VF?7U2@;K59JTP7^^
M;SD2G75<BYU@^FXGJR4QNA&2/6,8@JCP'!R(+;^XH8""(_T'*\A@MW4V-HS5
MF5U6YQS:( MB,%-@XZ/)+)1;-9T@U;N#R-E9&,N8IS$W"E*&PQP'^C^STY1\
M9NZFTI7,#/PRN72RL 66L+R L>0F=3C4(B07=$3A"E0B)$"J)I&4,=01$?:$
MV?>=S4WO&URM>/;O7JC5W,!<J/8I>IVJ#<N,D4MBX<0]A@7C"7C%UV+I5$YT
M%B&,DH8@B)3" H<Q/_\ 63YQL/\ &O=KI/D?Y59KR!N^3!8PW6?E!_O+TG;T
M[K'_ $/00X6Y_I#[?!_X\O.-_P!BS7_.-K*O*%1.;R]\QW,7.RYYIOEK)4S9
M*C:+Y4U[?$3<OBI2RV7(F0)*":OJ^S68HJ.)?H+DAQ:K@W:N%CDGL;\U\F5E
M-2N1Y&QT/&'E3&W8V+JJM#Q+%S%C8824F:\@6>FF:[T(V-<N&+3?%8%.D.W"
M:?W+[Y=\4_\ 5V;7)A\BL)^>R7L,N3S$O.GS'<NE(R:]P;4HXN.LI9-856G.
M;/CB!>R,VRQ]6L@4N(>+N'QSK+IIN&AG"JACF4WA$1_\>7G&_P"Q9K_G&UC/
M+&0?MB.:#/5+HUC)-6'#UR:Y7)5[\P(S=MA@YD\WS07***S.JX*J/'BWI-Y,
M/R>W8(>SR[_[;A7]V$KKE!^4_)?P4KVL)?)'C;X&PWWO2EBR=@2!@<@2V^H[
MR;BM=?&EV<OE5156EIE:M='@+A+JE,)!<3L?**</=* AN$W<1\S?*AGBR2F/
M;=9)&'K$I,)MF5GB9.(0;R[C&V5XN,%E6LC5>T0Y55"K),VB#@&ZY%&C51)N
MLO\ 9\Y@:QYXEME:;C<DMHI50%E(Q"]8;C;0C'J*@!05.R3E 3$VP-X2[=77
M_"IRZ?WEB/6._E/S#\,'&K@)BE,),O8B,01 !$AAG7)!,41_LF$AQ#:'XA$/
MQZPS@FOS4;!W9YB2,N%"E9]T+6"3M="R--6&.C9MZ;:6/B9Q@Q7C5'1@,1B5
MT#@2G!+<-2^6SFTPKEF:>X/=3^)*=DO!OQ>7VKVR/I+U !A5Y"5OU4K+J1I\
M;,,VPNX:4E6CUD=HY 2E<%.IR[\Z4U@"X8!Y.>5H:18:?*Y ;*H/+TXIEC4R
M57T(APY91Z%NDKE;G+0[OJ\J\3&PC8"J.%'!TP=/OEWQ3_U=FU]G4QBU%THF
M>O\ B2,LW 45*#B/;T/.,TP9NTT_:*,C3<2V6$3^U*N@EL]L)=G+I)<NO/5R
MD4?!<UAK'UAQ53I>GUAS-UBE6&M1\Y"0=@<K\FEI7<6.-;2 )2*AY.1.=Z54
M3.5Q$5336$^8#G>Y-L@8RL+V%D9>M'ATZR9R]KTJUFH=PE-TWDQKMB9':2+-
M,_Y!VD"A0%-0#)F,0W+W@/(\U V&[8EQG 4BP2]7>RDC7'3J%34;HE@WLW%0
M4JXBVK,$T43+LVQ]Q, X90  ]GG3^2/+_P#Q$8V]C#K"9CF<HR):L%2A&KY!
M-R@61@L(LIR&>@DJ4Q.D1DQ'(.43;-J:R13!X0#3@S5,BKHJ"IFR2IA(FHN"
M9A134.&T2$.IL 1_$&N:>V<A?,7AS!]_:>0;C-<GFJ$C9N:N!;A,Y DHT8,T
MW@S-2S?H$U"OE)39U:915RUWQ<"4.!_XB?)SV(J?\BVN;+//-IES ]F:YTAF
MMDL<IC2PV1!@C9H^S66Y6BV6=G8<8XPJ];BFZ<Z[43Z&7HS8BJI0301*&IW#
MWV:')EE/G/EJRN!)[) (S==H;-L#H$D9AI%Q=?EY<E7E>$L@WDIYU6BBY( $
M17*8F_C)/GUY4,+X PHIFB(GJ!.4*;C7]R=W9>AWHL/6;%'HY]R7)M$O)-[(
MK.>/!QAB.FQ2G.B<>CG=G.8QSG^S?Q.8QC")C&,;$%($QC&':)C&$=HB/X=2
M_P#B1R?\&<<ZY+/VUS7_ '%CG6(ODPH/P4B=()D12*F-@KBXD*F0I!6/]GS%
MN3K;H  <4[@PJ";\(G'>_#X=9 (<I3D/2;64Q3 !BF*:"?@8IBCM Q3 .P0'
M\.N>Q-M^641E^7]9FU65,1L+Q2+S. ;?PE2XYD$RG. ;1*4-OX US3VSD+YB
M\.8/O[3R#<9KD\U0D;-S5P+<)G($E&C!FF\&9J6;] FH5\I*;.K3**N6N^+@
M2AP/_$3Y.>Q%3_D6US1YAYG,F84O;WF*9Q<D^^**7MC@SR[A;K#:)N<F(:7Q
M;C6 AVZJMB<=&2CTS))<<Y")(I@4!Y_/T)7?WD6_6;R'*4Y#XAR44Y# !BF*
M:F30&*8H[0,4P#L$!_#KF\()C"0N4<;&*7:.Z4QZG/@8P%_ !C 0 $?Q[ _S
M:R_^F\P?\/G^7,LY*S @E:L78CF;]DMA4Y(&\E!/<?8<LT+C?#E0<-U>D1:\
M:I+S,3)238I#H21B/1,40<*G#V.7'GGP$U0J,UE)ZME!['QY09QC_+>(IVO)
M7AX=ND0S4D??:U:(HDL@"0D>.'#U98%#.U-O(%=H4QS0UPD,G6F),KN<0T98
M*?B^68&4X9CI[XM79-NZ80V_@$0U/_\ P>\K_P ."^N;[Y3\:?!2P^QS#-Y"
M):N[7ANG2N>J!+&13/(PDSBR/<V6>+&J&(=3?L%(:2D8=(O^E*[#8&^4@A9\
M1VMZO)/>6[)*]3K#UPOQUB8[N4<2U5R*6,H<[DW4TZ:8;H;WY--B5NBGL*CL
M#V.=/Y(\O_\ $1C;V/M",39-E'6;J71I'(%#Y1\(QU'J46_=9?0R_3:G0JL-
MAI5/8W.:BRU68E'3L'SMZ[=$CP10$7:R8CA:T\V%:+COE)MT_+O<@5=A6^5U
MHS@((E$LTE#Q3B,9.IW/]=2>6*.:([[QUTI)RN1-4X%."8W?DZ^R&QU3K,?'
M!)5ID7F;OB#60JT6[BW3F(D96K=;*A3V%;9S*?1X]\_0F%9]<AS,F)FI 77D
M.83-]VY:N=O#=2W9C)]6I->B8J6IE*BT72L[8CK5S#^!K"T9%:K;ZKYNE821
MHMR.7#0&:;K?E.?KE^P_D3."4=67[YQA&K#'EOT3;(21)#V>N3XD%XJW85-X
M87CYXR:/W!X4 ?MVBZ9RE%+*=0LG+?R$U&456?5C&V0ZBP+;WT$^3;)QXSL/
M;<3<P-OAW\>1B8ZI)(E?=*+NU3]#*@+=)"1^S7^TTJ59AL\*-P;8XRM6&<5"
ML+C,,ZV%D9M)]M "2F23/(5<;*OXF3BDHQ,C\O5JK KA8$VO++"<\6;<&9#G
M) ]CE\!LL*P[B-J./C/YNBPEB<2I)?&%1G7#J?EH"+=JE=K3I4Q1.5$R26Q$
M<9S_ #.\[W*_D7 478R.<H4BFU.ML;18ZV#-V12/AG;3E#HCE!X9X=$X&)+L
M!W2C^5_Z(\P?+94JFAS4\TD_>X]' LQ8JM0:#B_#&-XI[:H_)5VRJ^HL/1R2
M,+6SDA",$7)RN'CMZ8@.%%2HL7E#SASK6["O-+RLV>ZLJ_=XW#M9K3!E3$YA
M:163A(^;2Q5B2[P<\:-;*&BG<F66B5ED$6[EQQUMA\A1GV3#C$.&N6K&,_Y%
MK\V6;&)'CC)-YCVT=+33"C04M2,D-V\&T;N2( (UM\8Z+@C@[ML99)%*B\D'
MVJZ=%N45E5_7HJIYOJ\+7*Z+<;M-OX*EW:/?T^&J%4G<=O;(08J1*ZAHN1BP
M0,X6,4S=9)P?*UX8*VZZV=^YK.),8,'R<?(WNV),S/%NE/S(.QA*E -Q(M*R
M0H+ V(HDD1-5RX;HJQF<:5E'EGY-*3;HMK-T[&%OI\#UT]K\H9R[BI)=C9,,
M9_MD8Z6C^"(DE'\:J=-5,_12"8X%)]G?]IYB^LXRYA+$D=YAW)M(22:4G)K5
M8DNZBF[U-&5E(8Y;,E#NDX:3CU&Z+ATWZM<LV\B4P*6C#SAS/95Y:8JB5Y"&
MY=ZM3:"6R6/(EVPNB_I+6(N:=26R"4\KEB08%< #U[PF2ZW 9N#D1;'E<R5W
M+'+9RYI2K=25K_+/U)C-]<F#(Z*3R/C49&XX;RI&-I9TBY!(Y)FX-E$ET3@N
M1L/M1YH.4C*<!1\5_:"8=HF2%J#-2\+(0]%DK1 J+TDGQ@U AIE[$R^-LF/H
M\LVV9 J1ZP6.*#9,[=4JG+Q1\UY\PK.<ZQGN)&.#\DTZ'02Q%CAE/W>SSV.X
M=5@^PY&.'L75K%-/E5C/Z_-.E$U0XRKP?P,Y[GIYO.7C,V!25>Q-7E)QK6H&
M+LZMJ<I-@KDDF[CN6#%#D&4>J545B];E P&#:DI^ /O-YP?V*J/[TZ'IC\N^
M5O\ JZS[',YF/$UA\E,CX]QA*V*GV/JF#G>J)ALZ8IHO.J++&3$#(;A%C!PW
M35=(=OA*/@UG;F>RYDKRMSE38OF6<UN[^1M @>K5L?T$9JHG\FJS58:H/.J)
M,.+L<1ZH./[*P*$]KIWRZ8$HT;F[G#-=K).VKF,NU8Q_4,8XGPBM$UE*JJOX
MFMQE3I:MS<VCKA-(SUH8#-4$BI-)-=50&<7S$\P.8>7WFCP?&2L1$7:/J=)I
M_D]73SDNS819[0O 89P1D&'++O!*P;/VBKN/1=/4B+EXJB!1@><O$] N=U9S
MF.+%<4,1588J4R$YME/ZUC[-C2'!\[AHZ4L;:SP;E@T,8S<'^Q-5,@<8A!>9
M#P%5,*_9[8=<.B.:-\=%?*[NMEBFX.R@F^1O.,LJ6*3)(ED$URR9*E7HYVBU
M1%F<2\<SC'O))]K TH%VA,P.HJ+QYS'T.,A8%HN\M=A>0=7LYEJU!U"L2]'4
ML6[#R"#J"K\O#) 1^Y Z91!T^^7?%/\ U=FUR8?(K"?GLE[&%?E"Y:?W80'L
MQ_V?'V<>)(C-W-.\>]2VVT6,@O:A1IH\<26=P45'$E82/?RE;A14>34K*/VL
M-! EPUB.3E<E:GRTIG;E?Y@PC&9IE_R_P55HGE LW.R6D74606N#L1GE7D/P
MNC WC+:LZ=+B4K<76\!]6^NV2I)8FYD<2E;?&;C('3E6.>QCAVK&I7*FC*%2
MF.IBRJ M9!BY!1U"O%$D5E52KMUUN7?_ &W"O[L)77*#\I^2_@I7M4GF&S"[
M>EJU0PYBUNRAH=-!>Q6ZS2M3A6E?J5;:N5VS=>7F7@[ ,HHFBW0(JX6.1%)0
MY5LX<K+WE^Y)>7UX]E4L?O[[$Q-@5O+:-?=6ND$)6UXLS'8[*>.> JF>6;0%
M?B'"S99)(15243"@8R^UAH%%RIA7(3]U&P_,IA^+8M'ITH]V5O*6"/;UB+KD
M!/I0Z;I%=S!.:]7YL6:@+I <=U%7!'-+R3YL;UJAR%S;05_6BJ7BW(D#;*UD
M.O)6#'%O1?W:F6M9G#)+02S4B\>Y;)N>N4-[?'AG)@O/,<9+AY6Q=3;F\113
M%%-C-2\*T5L,6"0G4X9HF>!RU,&\8 ,B.PPAX1;X@Y=;RC'X7P/'8O\ CRJ"
M-#H=G)>K%+O6MPMD6[M-FJTG.U]JO4+!&PQ>K'[$S=Z"P@J"X_DX"V5Q^A*U
MZT0L58H&4;&WVTE#3;%"2BW[<_\ TD'C%R10@_C*8-9TP'CW+)(WDGY=27L+
M+2(JC8PD6]D/CUA&XQ5$^1)&IN[L7RCS)*FDT18R10/&M122 $@46]GFM:<T
MF7/C0;XUB\,.:4GY XQI74JUL=Y02L!]_'=+J1Y'IY*ZS#8[%<$N#^3 F^?>
MY@+[4)#JBV4C"65K?6)7HC%_U98JU1)Z9A9#H,FV>QKWH4DR24X3A%5!3=W5
M"&((E'.]RYGLF?&;9*9EF)K-:D?(S']+ZMA'-/CY5=ET/'M4J;!YOOUS*<1P
MDJL&W= X%  UGOEVB:2?G YHK7?XJ+Y:FLE4Z+0\>XUJ46YN[7(UHRH_Q]$4
M/I=7KO!@11Z6Y:F6.X6WY!$2II.)OF5GLT\MV6*/3XMY<KKA3&5(I<TO6*TS
MBQ<S!I!K+88HUOEXZMI&.X<=3VF0=AT8YRG5;E'>7R(G MZ1E:@RK:I9BH;-
M=P[BHJ?<LS/8FPUEVZWG2U2MS))19HFN8SEHN@X:J'7X!7*_WFXIR7RT\MK?
M-E!;V:0DN8"SR3&6FHZH4N,29$:PW0JK+M[%6G%D%XX4"QN&;R)BCLTR+IK&
M<%2&.G,E9"NN K8=JVZWH]SQCD6Y*M)$P*D>I1-BQ35+O#RT6BLCO(N%Q8+K
M(JIF.V14%1%+"'*UR7XXN\=R[8GLSBUY+SI=X)2+C(UY--T(Q_995JBN[90L
M;7:VFZ)#L%W)9:=?/#D!NB1,##R2X^J[<S2M47(#RG5UH84Q,U@JQB]O"1+<
MPHI()"9%@Q3*.Z0A?!X"@'@U=?\ "IRZ?WEB/6._E/S#\,'&KE\KF(?[_7U!
MUYAE6I87?3W*Q8XIO?;Q94:A66H.;M.=,KTE/K ?H9;O'$6A2 0IU53R $(4
MQC  T#$%*^R7S7S*XP@U;"^H66<2U3+55C[2UGK989Z8?S4U 81RK6+N_2DI
M(6:3]DJS K=F1-4%E %34+!<Y_V:W,GRK04\9L,?,S,G,R<TLV47.BYD$*ID
M3$^%%)!@R*03F,T=N%# 4X%3$Q0 U>R7CRP,+71+[E3"-MJ-DC#*BQFZ]/1U
M@D8J1;E731<HE<M'!3"FJFFLD;:10A3E,4,!<OJ3UG$V^2P;5;7C*<D#K)L(
MC)%3E9.2K9Y$Z)5#IQ4P'&C'J@)K&19OU5"$,H0@:2^S^^TMJ62<#W'!3V8B
M:;>Y.F35DC4J<ZDW$@RK-EAZFQE[.OU:\=KA#3$2TE8N3BA3 %4@035=P6/>
M1['N3^=O-]U>I1=0JE5I=WH==5?* 0RC=R>TU-+(<M*$1,=5%G&5URDN5NJ"
MKMJ4"*&JMCGJK+46;GZY"S,Q2IUU%/9NHRDG&MGK^LR[R"?2<*[DH-TL9LNH
MT<+MCJ)"*9S$$!'V.=/Y(\O_ /$1C;V,0?IO#_\ P^>QD#F4:8PMV1.0KF57
MFT)AW3FZ+@U:8VV="S%J/3)%1*-B;WC>TE,,,A).FK>>A%3)$=D7.Y.S6M,=
MF2\6R=2C^FDQM7\+Y.;75RYX!U>J$7]JKE:QT60XA02WE)]-IOF >-N;3AST
M*5?E8R)@(+ACNY0'+>[LDV5R&>ZJ_JZ[M%*!6Z# /SR4^M'K1RQDVRL J,HB
MV1D'?!>F3M_+CS1R4K@#)]?RQ<+#+SCG&%]LB=W&1)$1Z;>>"AU2R62+N%6/
M&JQJS619I)(M&:.XL*ACHIPEGY><%Y 0Y-\*YHK\G.\S.0HT]2:W[)<Q VJG
MP=7QM6GBX/9& A499_UL\."BZ3PS9)9)E^3Z;"8JHD>O,76Y_9P8YCJG"M2[
M[N=L2&!:U(P\ R+^ SV<?LDVB.T0+Q5B[1 -HAD["G,O9;A2<BUG+UOO5?KD
M;C^UV5W>8Z>KM78#"0[F'CG$3"V:,F*TX1<)3CF):@"R!BKF_+ C]F_G_&@3
M1*-E9UENVU]O9(T(BP,6SV"QXFXC)J/3</6R$I%OD%6RXMW#EH=1(3MUUT3)
MJGQ%\F%!^"D3I#]-UK_^WG%:OW[%6G^XG^N>?]-\NWYCFK60.91IC"W9$Y"N
M95>;0F'=.;HN#5IC;9T+,6H],D5$HV)O>-[24PPR$DZ:MYZ$5,D1V1<[D[-:
MTQV9+Q;)U*/Z:3&U?PODYM=7+G@'5ZH1?VJN5K'19#B%!+>4GTVF^8!XVYM.
M%\RQ:.5V^<O&/T;6V0PQ8+?*(23/+=#>,-]*R18JQ\'(&=,WC8XNE6[1:&$'
M22+1^\50="GS^?H2N_O(M^LV_)'DGX&S.N;[Y3\:?!2PZG>8CF,8S\#A3()G
M]HC;M'P<A,I'J62L,^1)[,PCHY!:1F&%1OB;AC)(M$EWA$V:QD45C\(BN5,8
M\MUBN5I>8H@:]97]HFJ-,U.JVF'GG;F/4<U4T^5E9 /"2"*:+M*5C8I4XN"&
M:E<IE6.C_EKFNP+>A/%6V;JF<<=1+=_L0=O;?C?+4).R445!5=4ZBZM;KLH]
M]J=4>&S,;:8HB?V>2K"T+_WE<(6!RY=I&(9%.[E.AW^8Q]5Z<F@R;[ZYCRLC
M194B9-PQUCI !/P"!OLS:-+$,G*4R#M=3DDS*@N8DA7<;XCAWA#+@8X+&*X9
MF 3@([WX=HZG_P#X/>5_X<%]<WWRGXT^"EA]CG(M\RH0C5GRW9>BFI52E,FY
MG+32I>JUI@H!@,4"2-CFFK<1$#; 4V[!_ /-7D!RU<)0EKR]2JK%.E$P(W=/
MJ/3WDG+E;J".\J9NG?&H'\&Z F  $1W@#V.=/Y(\O_\ $1C;V.9UU:8=K,J4
M3)/,[>ZP1X7BH1UKCI3J>-F ;FVI+.HUM/+J-Q. \%SPUB;%$R&+S;Y$J*[A
MI::-RTYRMM<?-# 1Q'3=?QG9I2+E$CF 0*:,>-2.-OA'8GX/#K+=A^SPY1N7
MW-]%MN5$8;(%^RC8:_$6E&V5"HPCYC3T&\CS'X=>*0$)#W$CUN?JUPD+B5<@
M5R8P'22L-2G?LY.3=Y!VB#EJ[,M#76GF*ZBIM@XC9%N8JO/*JD8J[1R<H@8I
MBCM\("'@US(_[^\?!\O-(CLHIY.CWUIR/CB?@8Z'>4^N5R<FEY:D6VTQC!63
MD89BS1:J*D=NG)4TT4CG4(!Y>D<G/*KS,<XD_''2:,7=1JSVJP,^_?N$&\,6
M+;H0MUR*W92BQE$B'>UMHY%9,"$;J ;>+R Y5RWRHY%Y,+HE?^6.FCC'))K)
MY3SD$US/.;EUXMIQOBZ45BYQ&;7C2?\ =RJ6R..4K@^P4TN0/]"6+]Y%0]CG
MZ.)2B<L'7RE-L#>*4^2+:)B@;\(%,) $0_'L#_-KFB<.FR2Z\4\P6_CE5"[3
MLWJG,1B>+.Y0'_H*FCY)=$1_^(J8/QZY?5D$$D57]CS:[>J)D IW3DF:KXQ(
MNN8 VJ*E9LD4@$?#N)E#\ !KD(GX[=9S2$/D0R4FB4I791B+KCI[&?E1 1,5
MB[>*J)@.T"F4,/XQUR28:IE6B,@R,?CW%<GB_&=O<-$*==LD90SU;*Z:#G%7
MDU6FC:!N;RCPT5(*+24>F#=$PF<H%#BE_P##LY.>V]3_ )Z=<H.><[\EV'L7
M2?+;D>H2K"UX@R?B:+52@&>1*M;WCV?;SW,WD:5E2UM6$57:),2)J?ZPN7AK
M&4* 8@ Q2F )S#I@ P 8 ,3E_*<AM@[?;$.4! ?Q"&WV.9!NR*5L@[?YR,Y2
M2 "D6,[Q_%2CDQP_&9>0#C&'\9_#KDR_3?*M\*IG[S^<']BJC^].AZ;9^S%D
M'F&K5Q6R5=J::-QI;,;P]9",K98<6*Y6=IQ-<I0'ZHR!^*;IHIFV%W2%V#M[
MX.<;YP,*?R]ZYN()F==1I"X">1+51R9,[E1M''B&:!W!TDT4CKG21 3B4A"B
M;;L  \&N9W]"<Y/[K3:YH#@4H'-G6 *8VP-XQ24",$I1-^$2E$XB ?BVC_GU
MSG).4B+)EPY).2D4*!B@NSEHAXU5 !_Z;=T@10H_B,4!T,[99F.A*[6,P9FD
MY6:FW[6+AH&"C4(.6E)*3DGJJ#*.BX]$5G"ZZQR)(I@8YS 4!$)#&O+5BS.7
M.%;(XKT5'N*ZP,;379F/';N B9253<VZ7;MY$J1#O&T I''06!9NY<%W2GY2
MY[-'(IE[D=E\<O+LC5E,IJ7([_(I)B>QT\<N()>WX>Q,L"5*=1"0J @#\I3R
M91,*(B'%??+OBG_J[-KDP^16$_/9+V(3 -\D;'$T[+$KR]4VQ251=QC"S,HR
M3Q=7077A7DS$3\6V?D @;AEV3E,/QD'7?!SC?.!A3^7O649_!MSS7:W65HJL
M1=C2RM8*18$6;:HNIM[''@T:9C>C+HN%U)U8%N,9T!P*0"%((")N>[F.MX)/
M\CO8"MG4DG)SN'O%S5D"WW2ZKI+*F$YS/9>D,Q54$!.;P!M #& =7^ET,A(N
MMY+M^1FUKC&A",F[]#)7+<?-LRD9)N4$MPN1R-W^P2CQ#H ([##O!R[_ .VX
M5_=A*ZY0?E/R7\%*]K[+S'#==4M>M%/M%WE6V\J5%:9H>-<,P-?7$FP$%56S
M'(TF4!\)TP6'\ '';B'&U6;-VE;H.,:)38)NT#8W2B:W6(N(8@EX3"8IF[0H
M[PB8QA':(B(B.LEV.69H+RF,LBX@N%7<G02468RTI>HO'KQ1!8Y14;\>OW=Z
MF82" F VZ/@'43B"=3Z[MSS#F6JS03K =PH>RX1RO<W.&&B0@ KM2,UZ5$1P
MBF)Q!N0VPHE-PM9;J=_F.A-N3.UWF<G#+NTEEH;$MDB9/*3:36;K'059()SC
M2SD(50>$(,QW3^ Q$_M;N<F\PIG>7.92[V:V8C$YTU7[*6PW,+9RDHRMCT,J
M"#"WV&31JY1]J4$8\Z1"MR!OFD\XV*42=VKDUQCDC&DR@JJ5TJXEL8PYG&'H
M@K=XZ,?>F*I,UR/2!4Y$E'(G NXF&Z7/G-I8$#R5_P"9#)DC'0DG) <ZLQ6L
M9DDB'DNDJJ()%Z]R799M%WPQ(!S1Z8G.(E*5/_P[.3GMO4_YZ=723^T+P?B[
M!.2V-W%C2:]BJ6C9>'F*-U#$N F9%>,R_F1)*2Z_6>(;AGS4W"2*/ V""A^>
M?]"<NWY]FK7-7_ANSE^["T:YG_EW@OW?Q.N?E84R"LG P*1%1(45")JY)M9E
M4R'V;Q2*F1()@ =AA(7;^ -.&;QN@[:.T%6SIJY237;.6RZ9DEV[A!4ITED%
MDCB4Y# )3%$0$-FN?S#->453H[*LS)TF@*J&1.IC+,ZU5JJB@+&!=55M$6YZ
M4AC )@!0VT0$WA^\Y:S9"Y2>62^61P3A.+#<\"XKM$XNGQEW/#6EINJ/GZI.
MD.5%-AE!#?4,;\)A$6E7H=2K-)K3 H%8UVHP,56X)D4J::)2M(F&:LF#8I44
M2% ")EV%* ?@ -14/G'#6*<RQ$$]6DH.+RMCRHY$CH:1<(=%7D(IC;X>8;1S
MU9L/#.JB4BAD_:B(AX-+XJMV.Z+:<7N8J.@7.-['4H"<H+B#AS,SQ$,O3Y./
M=5Y6*BSQ[<6S<S<44!03$A2[A=C:CXBQS1,5TIFZ>/FE0QQ4*_1ZNU>R*PN)
M!XVK]8CXN)0=/G BHLH5$#JG'>,(CX=+4C+^-Z%E6EN7C.0<5')-/KUYJZ[^
M/4%5@^6@+/'2D4J\8JB)D53)"=(P[2B ZQ;6N4_&R2.-^7[(YK=:L'XBK*$1
M'LZ<K79V.;62N4&J-&K%TSI4A*+J+MV;0RB#>2<.]T$DG!PIK'(=GG^66P5R
MK5R"<XWDL79$ME?AU(Q@,6:*I4QBVKW=FZK,2E')@T,\+'KBU51 404*J1*#
M^S\^SOQ1D+F-NEXO]5LLUDIW2']6J=/BJQ,*@TDXDUJ0CYZ!(Z74+UG-S+6%
MCHV(7.F918[E4C7 W*-FJFXZSW7<3T"F0<TQR'28"[4V:N4#'B:3L4?6[?$R
M#)% DV]=FCS*H]);ME"E$PGWA&%I- JE;H]-K;(D;7:E3X*+K-8@8Y(QC)Q\
M+ PK5E%1;),QQ$J2"2:8"([ \.FT1FG#V+,O1+(_%9QF4,?5*_Q[13?(KQ&S
M*UQ$LV0/Q$RFVD* [Q0'\(:<M\+82Q'B!N\X_2T,78VIM 1==*.U4<])2J<-
M$D7Z0=B@93> =\42".W<+L]F:O.(^7W"&+;M96CR/L5PQSBBATBTS["1D6TQ
M(,9JP5F!C):5:/I9DBZ62764(JX2(H8!.4I@TSSG+8'PS*9LCSLU8_,,CB^D
M/<IL5(Z/ZHCU&>07,&K;6QV,5_JJ(D=E%)O^3+L)X/8>Q$U&L)>)DFZC21BY
M1FWD(Y^T6*)%FKUD[35;.FZI1V&(<IBF#\(:"W5CE#Y7ZY;"JNURV>!P#BB(
ML)5GX*%?+!-1]3;R0*O2K'!4W%VJ 8=[;M'V"W[)O+%R\Y%O1"M2DNE[PMC>
MW6TA63A5XS*6QV"M2$P4K1VN=5( 6_)J',8NPPB.E<77_&M O.,UFL4Q6QW<
M*=7;-1564$LT<PC-6HS4<]@%&L.X8(*-4Q;B1N=%,R8%$A1"&K%8AHJN5JN1
M4= UZO0,<SB(.!@XAFC'Q,-#1,>BW81<5%L&Z:#=N@F1%!$A2$*4I0 %,H6G
ME@Y>++DM9Z225R)8,*XVF;TK(I")DY!2VR-:<SYWJ9C")51<"H CX!U!L,X8
M0Q#F5C6%7B]:996QK3,AM*\M(IMD9!:#;VZ%F$8E5\BR1(L9N"8JE2(!MH%+
ML9QL:S:Q\='M6[%@P8MTFC)BR:)$0:LV;5 B:#9JV03*1-,A2D(0H    :#/
MBN!\,JYU Z2H9I4Q?2#Y:!1&NDJ"*@9&-!C<0.E4TRQ91Z9M+'%!L'Y$-S3A
MF\;H.VCM!5LZ:N4DUVSELNF9)=NX05*=)9!9(XE.0P"4Q1$!#9J=1P7@[#^%
MT;0>.5LR6)L:4O'*=B4ARO21*DZ2GPL.67/%EDG(-A< H* .%-S=WS;7L1-1
MK"7B9)NHTD8N49MY".?M%BB19J]9.TU6SINJ4=AB'*8I@_"&@MU8Y0^5^N6P
MJKM<MG@< XHB+"59^"A7RP34?4V\D"KTJQP5-Q=J@&'>V[1]B?GL,X'PSB.<
MMA$TK3,XQQ?2*%+65-%RL\13GY&JP<4\F2)/'"BI0<G4 JAS&#VQA$7T5*L6
M<G%R;-S'R4;(-D7K"08/43MGC%\S<D4;NV;MNH9-5)0IB*$,)3 ("(:F(W!N
M%L389CK"Z;/I]ABC'-/QVRG'K))1!F\F&M0AH="3=-$%CD246*<Z9#"!1 !'
M3* S7B+&&8(*-=&?1T+E*@U3($2P>G*0IWC*.MD3+LVKHY4R@*B9"G$"AX?
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M:5@)QFDY5(B^8KMW:2:JA2* 4YP%KD'"?*]2*]>(YPD\AK79):ZY/G:X_1V
ME(U61RI:+JYJDDF " .8TS5<"F,&_L,8!O\ =^6_$?Q<VC**#=M>I/R^R=;^
MO$6DD\EVY.A7RZ6B.C.'(OU5-K-%N([^Z(B4"E"VX*SK4O+G%5YZA\J:MU]9
MJSUIY,V:&N,'_P!^4Z9K]C9="L=?9N?]6>(\3@\-3?2.<AJY@[ M/\A,75)>
M<<UZK^4%HM'5ZUDG9&RS1^NKG-V*Q.^FS<LX7V+NU03XFXF!4RE*%"L/,UB/
MXRYC&*$JWH[SR^R=3>I$9MW&/I0G1\?W2J-9+I3J&;&VO".!)P]A!*!C 91%
M9,BJ*I#I*I*D*HFJFH42'34(<!*<ARB(" @(" Z<W"[<HE%1G7JKAP\5H=BR
M-B2.=N72@*N7;J Q/=*5 .'BZH;YUCM14,<QC";:8PB^9<N6"<=XG4E6;2/F
M9JN0B9[9.L&!$"LV,_=)0\A;IUFW.@"I4G;U8G2#'6V<510YH?G4G\1]/YF8
M%>'<Q.2O+[)S7HBT!7O)6)/Y&LKHVH"_1('\AL5BC@I_;.!E/;^Q8N<VKXDZ
MLYE+6>;4G\D>7N37O3SV*+2AID?(^0N;NA->F1J!4_R,6F">S>)NG$3:CZ/S
M+8AK.5:_#/'#^"ZW/*Q,[77;Q-%%^M6[=69&$MM=-(I-DBN08OFX.2HI@J!^
M&3=7L7+IRZTB@6I=)RW"YN5[%>+RT9ODS)/F$9>,B3=LML1&ODC;J[9J\106
M*  <A@*79]YMPPGF>L>66,;\R9QUMK/75AKO6S-A*L)IHCUS5):#L#'A2<8@
MKO-G:)S;FZ(B03%$F'N72B_%WCE.>EK,2N^4]QMN[-S@-0E'O6]YL-FG1Z4#
M-/\ )BZX)-WVA"[1VZNF',LU[RKQQD*%7KMPKG6TY!=;P[DZ2BS/K>M2<//1
M^^=$H\1JZ05#9X#!X=6?EAQ'C7R2P;<D+DVLE(\LK_/=9(Y BNI;<3RELUJF
M;>SZWC!X6UO()"W_ +2(IG]MJT4WEAQG\65;N<\A9K+'>6>0+IUE-MH]**0>
M],R%:[8_9[C! J?#;JI(CLWA()A$=73#F6:]Y5XXR%"KUVX5SK:<@NMX=R=)
M19GUO6I.'GH_?.B4>(U=(*AL\!@\.G6"<$XW9T[$SZ2GY9_2Y">M=Z8/GEH0
M1:V#ISO(4]:Y5XSE&S<J:K91P9MN;2@F &-M6O[GD^I24ZN]3D#L(ZW93B*2
M5=)N1L5-'&D3?&6.6[(4TP$S9.**V.IM4,03F$PX\PWE; ]1DL78EFF]@QI2
M:FO/XMA*1(MFCMBD6N(XKF*6I'18MGJ@'8$.#%4VZ<Z)CIIF*?#W,71?C$QR
MI/1-F/7?*>XU+>FX,'01;WK>C6&LSH=%!XI^3!UP3[WMR&V!LI>',35[R4QQ
MCV%0KM/KG6TY.]40[8ZJB+/K>RR<Q/2&X=8P\1TZ75';X3#X/8A><VU8>ZTY
ME*[(5F5A\D?&#E)CT-_3XMO#5Q?R/CKNSH3CJZ-:II[JL6<BV[O*@<XB8?87
MQ]G/&%(RM3%W";T*_>:]'3[%K((D.FA)QO3D%%HJ5;IJF*FZ;'1<)E.8"G !
M':VMD5R@U9W*-'"SI)K9[]F*[5DZBXF$Y7-+N>19ZG/6Y=\=Q%9@HDGX-PI=
M@;(NM5:$B*U7(-DA&PL! 1K*'A8>.:D!)K'Q<5'(MF,>R;)E J:229$R%#8
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M7.4>+RC.(8'JV%%_*/%C,6"5>>7!QA:=R8A*RI4VO3G,D4MC8+%,HKX")(@
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M6QS4K!94*Q)RC=BSLE7G(2L1TK8G->EG$8C+0<K%LY%H_3?+*;Y4#-U5.8S
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MEFJ5+5*M6N%GG;F.5>5(M@!E:#=0R"22+TDI&1:@F=)&;@X("ITKI^FLA?\
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MVSY?P3AK*UEJ!=VI6').,*1>9RKEZ8E(;M=EK/!RC^$+T]$B^QLHE^6(4_\
M: !^ZDX"I3!W&"\+O92H8Y;M%Q-&V651< VM61C@4=UR>QO6H(L#B.Z2);-S
M%*FHLXW_ .I&B9KQG)#&VZAS:$JR YE.A2K(Q3M9FNRZ21R'<PECB%UV3Q,#
M%,9NN;=,4^Z8,<YQH*X*5O(=<:3*30SA)RZ@Y0HG9S]9DE4 !(9:L3K9PP=;
MH 7CMS"7VH@(_P!6&29B!D3QMZR@=MAVC.4%#).VDC=&K_R@E6JJ1@7:NH:D
M1\HX;.";!1>E0\("(#][F.[[D[%]KI]*RO!,+'CZTRC 0A+'&R3(LBS*B^0.
MLDRDEH\Y7 ,G(H/!;&*L"7".0YO^0VXV&L8VN_H4.NR5IM[Z#CS'C(")C(Y[
M*'!])N#(,"RK]K'+@P8%4,^D54S)M453@)?\C9AY3IY\8[==N&9\=)+J^U0<
M('BZSD&*;F5VB/2TEHAZBW3, %X+Q;=$3J&_JMH]?R(A,-(R\,YAPA98UKUD
MSAE(AQ&H'"5CT!ZS,U6+([>(V3<*%$NSA" [P-K)2K'#VB"=A^0DX1^W?M1.
M!2F.@J= YA;ND=X 414 BJ9O 8H#X/9Y=,)(.5"-*S1++E&3:D,((NG=VGQJ
ML*LX#>$IUXY"A/@2\ "0KL_X0.&S_(M>SKS4RE@I>.;*S;S%'QC7CDC+G<(1
MXB#B.LMCF7*#GR5KLFB<BK1LBB=^^;GXO$:$%(R[C'=DKW*VO,,E"QT@R=8O
MFN966BW<0BFW492]A3JN6'T5))<7=<$<NTEU5RFXH&5(?=F66#FV*HNX+,57
M""^$3NL,Y KQ$&R;$)E#%#^-K[11BAPB"<[VN+M#JB)S?E%!.:^X*A\FP.5F
ME058F"Q0C9PR=1YI)H1\%<M#%0%F+*V0Z*I"O$F;IXW()R@*B:_&;(>SS8?L
MGB;^^+UKFG^4)#X+U_\ H9CGOLEHR:WRX,-)V*!JK&7JJ&/R1*.6B8^BNM(M
M>FO+&Y6?Q"1WN\E+HAM62]J7=.0WLI-VZ2BZZZA$4442&55655,!$TDDR 8Z
MBBAS !2@ B(CL#36U<U6(,>9(S9E,&4Q(5C*%.K5V88RA"ME'4-3HR*L["48
MM;7T<ZCF9<(D*J"I@:@(IM145YC:=0JK6Z148.S5UO"U:HP<96JY#H+T.IO%
MD8N#AFK*,CTEG;E14Q4DB 910QA#>,(C[/+E3K[5:W=ZC.6:Q-YJK6Z#C++7
M)A!"AVQXBC*0<RU>QD@DB[;)JE*JD<"J)E, ;Q0$.597#V&\58H5L,GF1.P*
M8UQY4:*I.)Q;7&)HPDP>KP\6:3)'&?KB@"^^"(KJ;FS?-MB*[7XQ]-3T_)L(
M6$AXQLJ]DI:7E723&-C(]F@4Z[M\_>+D222(43J*' H (CJP9OYZ*+C#(M[5
MB&MGORE_I]9R*SJ+AX@V)!8EQY"V%.4A)"RC(J@V.[; 120D5SAQ^A))&)B^
MU(X?Q7C/'ELSKBR BL/T6AU.NT:,HRE[A6",#,0L)#1T79W\G'+GZU=NT#F?
MJK*%W2-@1;I5.T8GP%A7&%E<Y]I<,XL./,64:E3B\0ZI62G;J*6EJW!1K]6-
M<NF""BB!E!2.HBF82B)"B"3=NDHNNNH1%%%$AE55E53 1-)),@&.HHH<P 4H
M (B([ U$9@YYI*6CB/&*%@;8+AY52L!#1!"=,4^-JVH'1EF+APQVF<1L6LP<
M1P  K/@6XK=%6A/X3E/E'+!PN"RS;!<GS &3<( DT615O<?C[)0+;@H!^2&1
M,7?WC &\8XC-ON7SXO82RH)=8*S> )4U$L]5ZR;H"U7FL2OD&L2QB5EN& )O
M8!#=4(JDBHBH*^D*Y<#A;,=6=1VMC?*D8P690]I:-3 9:-DF1UG?D];8U%0A
MG<>==8 *8%$55DA!3[AIC;$L*/1&HMGEVO4FDNG4:! ++<(\M//R%V'=+ 4X
M,V"0F>/E"&!(FX151-*C.L'XQR_88^(>O9[).6\<TV[6ZP3YV ]+D&[BPQ,M
MY-Q0+)AT2.9'*@U3 -HJK"JNKJC82QG'@^MEYETX]NLN"H1T-'(D.[FK'-+(
MIJJ-H6OQ2"SMR<I3'X20E(4RABD-4GO,I56.?LM6-N[<-B6^J,,C6FZKLF:R
M$BK6\63<@7'-4JS-=Z=-LM(BF/&.F55^X713.G8,>XRPXRP3EIE7UG<7&0%-
MKV#\A1K!BZ=D&RP490)&6QC=1:&>B9RBY"35*W43,NB0$DCHSN&KRNG,-"M4
M+#1KDT:JM(Z[4N16<HQDXV;JF4,S>).&BS1\UWU.C/6ZI"J*I\-52NXZQM5Y
M>YW>V22,37ZW!-3.Y"1>KB(["E 2I-VK=(IE7#A8R;=L@0ZJQR)D,<"V'F4I
M=!SOFFUL$!FXVXUR&NF.L?M5 27&NU>$L+%]&2LNBL78[F5D>(H8O#:E11XA
MG',/3,?5*L46GPDG0TX:J4V!BJQ6HA-YBFB2+LD9!0C1C%L".I!XJNH"21 .
MLJ<YMIC&$?8Q=BN5:*.:.R>+WO)@D _#"A4X49"48KG(0YD$[+(':0Y5-@;B
MLB0=H;-NL<\GM5,W0KF*&D9D>]-FJ:::)+O/PCEG2X8B! *5J2M4.54<$ @
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MI9O)%VK-'B#)MEF;=RH62L\G%LQ(W<2+<AQ ^PAUTRCL$Y0$M=Q7S1\NF2[
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M==V\=KI-6C1JDHX<NG+A0J2#=N@D4ZJRZRIP*0A0$QC"  &W71<J)IU^VT_
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M$R&!T[MM6YP^:V)YE1;R+YCF1>:J!H<MM?D=)J3;NMQU<CK\HW=-W(I.4R7
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M"N]AJ-H<S]RO&!<5VRU3CEODBZ,6[B8L,]5'\O)KH,6J2)#KK',5),I $"E
M RY>\2\K'+CBZ[QMNQ&VCKECK!^,J3:F#:2R176,BW96&M5B,EVJ#]BN=%<B
M:Q2JI',0P"41#6$LJT-R5AD^T,[QBC&,H84=L';KQG7+H*V1$BZ:R:S^L5>,
MDI%H0R:A#NVJ0*%X8G$*GSC<V..H#F,SCS&*SV0T0S0P1R)7:W59N5EF\8Y<
M5VSGEX*V6V[([9Q_+RJ#IVFH\231X*B*RSF[\VW*QC&L\O&;^7DL/D=13#D<
M7'M=L53@'T8E-[*Q5$V$#7;'5F)>N6,I&M6CH7#,Y5SGXP*HY_R7?WQ97*=%
M@XK#>49D (4\_;*3DC%KMG9'9$RD3)*V:FS\3(/P(4B0OW*PID(F)"A5.:WF
M;C%>8-_'S]MH6(,59&Z3,8JQ/6ZO<Y68E4V=/>/W4+9E;1;YJ0D7#9\W-%D.
M\5'HAUU5G!ZOS6<O.**3@+(V/LHT^NS!,1UV-Q_7;'6;*E(M6JBU9JR,3!L+
M- 6-HR<M9)JW2<BD9P1851,B=#E9S%=W1Y"YW+#]74MLJJ83KS=EA$5*W.3[
MD1*38ZGI.'5>*@ ;I5%Q OM0#^DHG^):L?O18_TCK).9K,6*9&X[>NUN.!N]
MN%VET2)FZDJ,&HY:GDG@"LGQE3G2:,R'!1RLBE[?4M6T95UBC"2RKINRQ=4)
M-T@,U&*^T*&1+ AT1W<W"J8 )VQB(19!V"1J!P%4W]1J=KPG?I.O$6<HK3M2
M=J*R5%MJ20I@9M9ZJLL6/?B=%/A%=$!%^W(8W1W")AWM(U&12:XTSY'L%7,M
MCA\^%9A8F[, %U-X^EW)$1FF94_RJ[ X!(,B[XF*L@F+HWWUH$<.$$#.EP;-
M2K*II&<N1356!N@!S%%9<443GW"[3;I##LV /L8%YAJ53ZY2<TY(OMLJMY7K
M3%E#?&3"LZ^WF36BS1[-%)&4L=<D00;C);H.ED9$$W)UBIM@1^QZE,@]/<W4
M<&Y"+?G[\W&=GN\ACKE8<3O6"X"8#OW<LU>'..T=XQ#CJL.VJI%VSJO0KELN
MD8#)K(+QK95%5,P> Q%$S (#^,!U]G5^A,/_ /$?-:^SJ_0F'_\ B/FO8Y#?
MT+E;X5XRUF#F#MD<_F('$5"L%V>0L6)22,XI$,CJL(-DN=-5%JXFI$46I5U"
MBD@*O$4]H4PZL/,EF_G3MW*]RPFN4S7*'B+ W6<22>/!+LSR+9.+B+%7T#1$
M%('(1"9LKJPRJKU!P1-L@WX2NL99FQ?DK.M^R#><T1&/K:OD^PT>2K[M&3H=
MZM4M-1D;7L?5V;9R3J;K*0DZ3)O@(@JH4_%4$%0^Q?R,@DJ>MU? $3291?A"
M*+>;OF"L!SL"D*X%V$5>,,<20@0QA$P(")0#=-MQ!DVI.FKVLW_&='MT(NS4
M35;C'3];C9)ND4R0F*4[8KCAG)_:3.02F ! 0#FOQG6V[AY9+_RWYMI]=9M"
M+*N'E@L.-K)%PC1)% !6<&<R;E(G#* BH!MW\>LZQO,OAM#(^;L8Y38N4G*F
M4,MTIZTQ?;*I$(5QH6!H.0JI'.4&EMK4X91THT.XWW)4SJB4J1">J;]._,Q]
M<NK34.6#&)<8UZZSC:R69AY8Y N9I.99L"1C9V+W(-KMD@T*DQ3 @)(*I(_A
M,)-X1$=<RWRA<VGYM*Z^SJ_0F'_^(^:]CE,_VWEX_-9_7(;^A<K?"O&7L<F7
MZ;Y5OA5,ZD?LLN0:^-^7V,I[=PVS)F\3'C;:MU?7VM@N;^)GT4'-AK4!6$)1
MJP8$A$VDQ(30"87R3!7?3D;'S-\Z'-UGF^1\2\>(69.P56 0Z>8CV1F%19Y
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MT5 RZSJ6==<7B?K4"GT1 P&W#.BJ*?@(4P^#7+3AC,%;\D,EX_H:\-;JWUQ
MS_5$D>R3K\K;KBKRDU /]K1XF??:NED_;;-[> 0#^CHG^):L?O18_P!$)C"!
M2E 3&,80 I2@&T1$1\   :E8NJS*CK".('<E4,;(-G&_%V!X@N#>SY#*5-0Z
M#D;1(-0*Q5\ ]4MVWM2*'5 ?ZD:3F/&TF,7;J---Y9@8XJ"RD6X;49.#ED$S
MIF=PL[&JJM':0&*)T%C 4Q3;#!CS-]%./D]?X!&5(R46(NZA)5!5:/L%<?JI
MD3(>0KLZS<LES%*!3J("8OM1 ?ZIZ)_B6K'[T6/]%D63@WZC"[9/4;8?I;A
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ML/*>$=IE&AF1B$+X$E3CX0GL<6^(M# I4Q=)LEQ3DHTZH")$)>'=%0E8EP8
M$0(X13,8/"&T/#JY,%@."=8Q[C*#:"94% ,W<5TED,)"<,G )TJPJAN[3[3
M)MOMMTO^4:YDZ3;IMW][@;5GK(<N#<B;M>*1;OEH-L5=<J:QF,51H5L9),Q^
M"5PLX5)L!8PFO69\AR"[VQW:<=R(-CN%'#2 B 4,G!U>(WRDX4-6XHJ3-L7=
M 132 Q]IS&,/L/Z[77Z=/QW3TV+[(^1WS%9^V@VS]8Y&$+"L"'0),6R8(@L=
MLV.L@B1%!5554H%(10,8\P]R?VW(K5!HI*EGKCFJQ6>+44;%7*G,Q'+VUC8F
MM*/D5B+IMWS5-<43IF+M(8#&>YH^SJRH1=T/6:D/4GML&VX\GWC$ZCM6H(S4
MR7RRHMG12=)I$&7=/" 4J!7": **/-8.KE@C7D//0',1C.$FXB00.UD(J7BL
MDPC&2C7S94"J-WC%X@=)4A@ Q#E$!\(:QDWR3E:)PYB+$UNF<@Y/N#]=DT>H
M5TE<=1I6\6_F0)7HI15RX#BO7QQ2;$]L"*YA!/3;!>.K&-RRB]&1AXN;E[SG
MVKV"=E"K.Q*>OR,SY*8NL4HB4@E:),6:Z3I-,A@27WA.>NKU><DK9AC)1)16
MBS,T5N:Q0DE"]#-,5.T+L&K..=O6R+]%=J[21;E>(','"*=!3:_KM=?IT_'=
M/38OLCY'?,5G[:#;/UCD80L*P(= DQ;)@B"QVS8ZR")$4%5552@4A% QCS#W
M)_;<BM4&BDJ6>N.:K%9XM11L5<J<S$<O;6-B:TH^16(NFW?-4UQ1.F8NTA@,
M9[FC[.K*A%W0]9J0]2>VP;;CR?>,3J.U:@C-3)?+*BV=%)TFD09=T\(!2H%<
M)H HH\UC#%F18!XBD\S72L?WJKR!G\3())N+U&5RSP#XS19G)QKQ,IUVZHI*
M)+HG =TQ3@ A@]OA2&?8.Q&U9Y"DL_S3&XV>TR;EA%EJBE-8UDV1IJV)Q<]*
M+.Y%,[DXBR;-4CKJ(K'2(BLXF*;9,>3-CK&2<'UZX3-)YD)[(606-2D\Q4V)
MRH]4I<+D">9*3),:ISJG";P8G241,9%$AD]I9UQR+OWTWC1Y>Y!K:[%+$R(E
M*R]\CH2!%X+U'(\;#2"0M8)ZP*4&+1O'[#;2E%85C#EWR0[X/)J_>2_KJ=Y/
M5<MU)_\ +3_U7\Z.%_\ )'^H?_K/R6WV1YP<V1;)##6+G;YSCYG8@3;Q5MO4
M"?BN;8],] K56GXZ.@HH94XE15ETR%$XE9NDC<N-9I$BX'E_Q0]S5&T)J G2
M;7&>)@G*:$QDMZU,!3&/(F+T>**KM,WC4RG J*SIR08WY"Z!_?UXUDZWY3OM
MMJU+Q](0U=;0U -#L[1,3DRQ=R(O%YFQ0=BB8Z*CF[=, 3*R<+.3JF#>0!,!
M5ON"VUG\L(FOD@Y: GED$FLDY@K+#,YN.0FF: F0;S#%-X*"W#V)K"F"Q"D*
MH!"ZDOD+O_\ ?U'UB+_#M"?O*R9J.BHAJY?2TF^:1\6R9)G5>/)%XX3;,FK1
M)/:HHY<.5"D3*7VPG$ #PZRW'7MTF[L#V!Q!!F,JL45I.Z)9#H3I55!1,IRJ
MKI.(YP[-N[ ,DB?P@ Z2_2N;_P"\)+6/L'Q%NJU(D[_,A$L[#<%W:,2W.FW6
M>*-T2,FSA9],O&[8Z3!IM1!X],FAQ4Q4 X,:SS<9CD<BY#<LRA)Q$Q9+X1^R
M7>)M%V\DECWE^;C;:K%J(M#BU&6=.TU <J[5E1!'A/\ -/V<]O4CYEJ@]-78
M5*V62PT:SRD8Q;N7E+L+3(IW=]HMN<D.B9$SQTB5J9T'2&G!53505A5F#Q.7
M1?GBU8LS97IY))-P+0[ 6FYQ^F%= *?#W=_?]KLVZ)GC[0V_J5LB,6QGYJAH
M6IM2ZA1F#I1NJA"W2VI[LQ.6EYQ"-%&L6X:%3=*F;MU'BHI*Z#%>(+WY!7V1
M<':Q$K'7;.E7?O7RB+ILW80[S/J,E1IQPHY$#HH()JKN%"$*03%/NGL/*QAR
MXM\^33>WQE,KCJM1ZC*0>667,W2"H2B"ZIHI*Q0#UST204;NE62*J9Q441.1
M=%"#R?\ :)Y=2E)N02 7U9;V:;J])+*$8*NWM:JL?3DD<HY!DXTAMXRS!1$Z
MW#*)6A"B('FZKR:Y2?8_R7"QSEXU0AYO)SMZH" (@>6D\=Y[X=CLU;:*/T2.
M%8APQ(FH)"F<$,)BFN.%,G,D&UGJ+Q$@/6)E5H:?AW[=-]"V."=K)(G=Q,Q'
MKD4((E*HD??15*19)1,M?PVPMT'06<BMBVPV6ZV$AEHVLU2JI-9JP2PM2KM"
MO7*#!J8$4CKMD3*&#BKHI =4K+#DSE5GE;(*CQO&'NEPO6:*W /Y19!NGNL+
MM2B4;#96"[A7:D8':Y2G,*8K'$H@".>,#R]DL.("2C"'NU:LRK>2GL?.I98K
M2(FT9MJV8EE:I)2:B;(P+H@Z9NED %1P183(16(L9(MFJIVRLS:[9*D<C7Z3
M5F:B2;Z>F#-4U%U1,NNFW:-B!Q'3Q9-/:0@G53A:[S=9'E+K>YF+0=F0LMFR
M2G,*%.H9,9N/Q_@,B$_ 0+MP@JFW/(F=I&W#E!PJ<AC!.WKD$RZI5)Z*!))L
MP1L5FMM.923A@DJPBKU5,@)+Y6JHRQF1SI.3N2'1%5<X-714B()W'%&2856O
M7>BS3F"L$4J<BQ4G2 $41<M'*0F0?1DDS63<M'*8F2<M5DU2")#@(_Y1J]F3
M,J12NV*$G2'02166*>(DVT@4R*+D0;JJE%OM*53VAA\!O!M^_IMC>&>+M9'F
M"R[4:))@W6%NJ:FUEO)Y$GAXI2"H9!>8JT4T62*8G%1=G*813$Y#\MF#6;5!
MH[I&*:SY3 W2!%-U>[$U\JL@R()^$Q>L[O./U]AA,8 4 !$1#;J;Y:).>7JY
M,IXZA8V.L2*72 A;'"<J$K:ZI).VH;#O(MK9X%F9X@0Q#KM043*<AC 8+%]D
MGSO'6J[N!NLG5\*S\\\55;56[/W2#AKC9&3<@FW=X]R0#H9.K/BB"9G;XB2?
M$1D&X-M?:O?IOF]_XR*OJ)BLX\P6$,,RD^S7D(*-ROE>AX[?S3!JL5LZ?1+.
MWST.XDF;9P<$U%42G(0X@41 ?!KUZ>3G^)S"GIOJ*KU>YU.4N>GYZ28PT'!P
MW,;AZ4F)F8E'23&,BHJ,8W)=[(R4B]7(B@@B0ZJRIRD(43" :><NU/S4EA('
MUS@+A/2+JFK7..NT?5&,T\AZ),-V]GK3B%BG5S6BY-203Z<HW/%DW6JN]L#$
M?+G1SMW</B^GQL"[G4(=K JVZR"07=KNC^+:+.DFDE;[&X<R"Y!7<&(=P)15
M4W=\<4GFRQHWDO,G62T4YP)UT5F>@Y"&W%9F+_K(0QFA&HO _P! +@&F_P#E
M 0UR7GMQG1+$IRXXUZ.K*E,X7ZE&N-@IRZY"KIJ+('JO03E**A%#)" ")3;=
MF0.8[[6.]0ULQK0;8_@L18GH,\H6L9!IT=(.G$"$4RBI99YB[%!DCI+*1RBP
M6:5=G7%\= X&<//M%8N%BHN"AXVM\Q;")A(2/:Q,+#QC/FFHS=A%1$4Q2091
ML7'M4R(MVZ)")(I$*0A0* !]QEI'E/D*E&<PHT^2/B]Q=62;V#4L*9 .5H4'
M3MG%M9EZU*HE'.'_ !8UO(&1.\3.V!4-<[G.EST2Y,S<Z5HY?LS6MHQGI?RS
MAL3ST]5)M)[//YQ1T\97O*QD7PGZS 56$,YV=7"JJBD_&]_XJ\D?NWPW[$)@
M7 JCR>YRN9-+R4Q3!UU$TI/TB(G7Q:V:_IQC4%G2EC?2CGJ^KMQ(/3)<#K%*
MJ1BLBIR]I7KH<YS*YJYG8^\YYMO%)).VTG\5F1%8/'C&:,*JSZ*I:<FX%PN"
MB@/YAV\<@<R)FY$L1?)A0?@I$^QE7-1@&>P!]G#5DZ!1G!53KPCS*B+V;@8Y
MV4I$TT%57-X6M$NT<D,;BIU]B.\=/= /8Y<?LA>7Y\5>>N%SJ5MS,\:CTAM&
M2TJV=/:M%3R3=5)SU/C^BG>7"70$1*=N=BJ3\HAL#&F#L<1_5M(Q938.EUYN
M;=%RLSA62;8\C(JE*7I4O,.BJ.WBXAON':ZBAMIC".N?;DK8;T9CO*K"?O%-
M@2.BI-&3EFI#9BQVT:-..5NY2B,8Y(EFH"0AW!2I%V[I2J[/Z6:G%LI6]NK-
M2TC+*H)PT,9-%21>+/#I)F,?>,1,RP@ CX1 -=[%R_4L)_Y^N]BY?J6$_P#/
MUWL7+]2PG_GZ[V+E^I83_P _7>Q<OU+"?^?JAL8*TR]G);V,^[<J2S-DS,S-
M#N(I%,B ,Q$%"K!(")M[\&Z&S36,B6#V4DGRQ&S*/CFJ[U\\<*#L30:M&Q%7
M#A90? 4I"B8?Q!IG-Y7>_%A6U>&MU1PT9"\/D!V&W.@;QF%?XA/!O.SG<)&_
MM-1T=KCJJMH^0<M@:2=F?&&2M$NEOIJG3?3+@O'*V471(H+9 $6@*% Q4@$
MU<GZPG%.SX]QE.- ,D"8%;MZZ2MF A^(?CDZ57E1WMA-AA$NSVN\;_*-+K=0
M*1S(6?DNF\<1J:&Q?BV1IC69H+A#=1#:97RA9*$,0/; ?:4?; .C%,42F*(E
M,4P"!BF =@E, [! 0$/"'LL,KQ\8V6F;(VS/E^Q /M3RCRIS%EKD4U<.$R"L
M" 0-%:D H;>&8YQ*&TP[;%<K3)N9JS6R<E;)89=X?B.Y2;FWR\E*2#D__27=
MO7)U#?BVFUF7$/3W)JG;,2*7T\88YU&B5GI=LK$(S?(I&,)&R[B'N3I-8Y
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M09[Q&R9UC[Q@(43CL$>=7[1?G%QG+XRROGNUN*EB&D6MQ"/K'4L4D?-W2P.
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M^8K(<6@C95VZK=^RQ[7#J$>(T2"?)E$B[Q1<J:LP[2.9%RY2321,=%N19?\
MJS=8VS-62RK(O'<5VR1PMV5PI,NL1,O7=1G%&SH\:\$44^,D<BK1X0@)N45D
MO::E[&C$.\K8104<.6.4ZC&.%PAHQ,3'#XPZ^W%V]ICE!/9Q')S+11Q,4$W8
MJ"9(G]1J=4PG09.PD1<HHSMM=IJQM%J22HIB9S9[4LB:/8"1%3BE:D%9^X(4
MW1VZQ@W=)6^26;9-SW(L5&TMD9^Q!&/K3=V0I7<'CR)7%4T,Q,0.&N_4$TB]
M 3@)D4%.BD_JU.FH0JB:A3$43.4#D.0X"4Y#D, E,4Q1V" ^ 0T^G4J.ZPU=
M'O$56LV'%F-7:O'1S<0J\K35V$A2W1E%Q,=PJ@Q:O7(J&$[C>W3%=+X=S=C*
M]QA53';L[PPL6/IWHYC&$B! BFEYAW;I$!*43G<-$U  Q@ @[$] BPPM"69,
M3*E%W!Y8Q2W;E!,$]TXELEQK[K=6WQW=B0F#<'> OM=[U<?I?P-]:.O5Q^E_
M WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5
MQ^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]
M:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I
M?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CK
MU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#
M?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'
MZ7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUH
MZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_
M WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5
MQ^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]
M:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I
M?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CK
MU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#
M?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'
MZ7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUH
MZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_
M WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5
MQ^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]
M:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I
M?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CK
MU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#
M?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'
MZ7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUH
MZ]7'Z7\#?6CKU<?I?P-]:.O5Q^E_ WUHZ]7'Z7\#?6CI)!;E\;,$E!$#O'>7
M<(G;H !3& RI6&1WKL0,(; W$CCM$-O@VB#=2_6_#^,8LW"%V5:?F;A84@4
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M,BJ=1J$WA$$^O4#J,# 4-Y9P=KM'83[JNX$@7G_\+;[[P5/_ +KR7@G&Z/\
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M-O"">U]%KJD3,;:"2VXILVD#4-9H%XE(0E@BV$U$/D1$4GD;)M4GC)P3;L$
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M=,$D@$0 3F#:.K3?K)AVY+35KF7DP]V(-C)-^DJ#T=BVWW@F*RCFA4VZ!?\
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M-8)^1O&'P)@_N_\ Z9;_ .BC_7?=_P!,TKX61.LV?H:C_GUF^[P!_P#/5_\
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M6CUNBNB HS>%2.**JFX?=^ZQ=\LD/\(P^[S1^QKG\[9ZN/R-V'X;8\^[Q/\
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M?3"%@N=7E)FIF4=(L8R)B>8_#LC)R+UP<$V[-@P9W)9T[=+J"!2)ID,<PCL
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M/8S^,VMTRMREFK4=Y9Y I?5LVYR:6*7>],Q[:ZF_>;[!<R?#<*JHAMW@(!@
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MAYY,N1F4\;9(EJ>29B(V9D6#%%64@7#&QO(21<HM 5,R=G<I-P7(DF$5R?\
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M.I9<M;3+$I:(FNIXG@:;.N63FI-(5Y(GFB7"^T5)L@LE.H@@*!W)C&*?> @
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M,(>'2=8P#S*T*Z6QP9P5E39).PT"ZRG1"[[D\-3<D0E1L\TD@G[<QVC18@$
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M;-%/05K66KTE5<;X[!V)1<U"[9#:+KO),2/&I.-*TNML)-ZW(HWV'>LTP53
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M -.:C+\W]2>2K5PFU5=U6C9=O=8,HJIPRF;7:D8]L-,>-P-_:61?G2(7VQC
M7PZ2OV#,HT?*]/57,T-/4:Q1M@9M'Q"@=2.DRL5U5XF42(8!.U=$1<$ 0$Q
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MVW9';./Y>50=.TU'B2:/!4166<W?FVY6,8UGEXS?R\EA\CJ*8<CBX]KMBJ<
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M3$JA$E"14!"LTH^'@XUC#Q+!#>X+&,C&J3)@S1WS'/PFS5 A"[1$=A?"(_\
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M+9$L4N'F.K#88\Y7\/7[Q=Y6.F\RRX&1+PEHW&U)J+ TD<JAC [CG3<"@HB
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M3;#]FLPQGS)X$RF]*H?'N1;)6(CH\8Q7F%:J2]Q%OO>*7'E136\@HV3E("=
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<'$R\C*24G)3#M9N]5*H,@DFKM50$?_PT_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>kprx-20221231_g4.jpg
<TEXT>
begin 644 kprx-20221231_g4.jpg
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M .R'_P *<^(?B[0KO5OAQJ&D>,H=>T/Q9#:*'O(8+E(HGANH4.]H'0G8I?<
MR!P#W3X,_MD_L\_'_P"-_P 3?V=/A5XWEU'Q?\'[W3[3X@:8^E7,"Z;+>QS2
M6RK++&L<^Y8)3F)G"[><9&8OV3/VWOV5/VZ?!VL>/_V3/C1IGC71]!UZ;1M6
MO=-BFC6"]B56:/$R(S*5=66108W!RC,.:^)O^"0/_*:/_@I%_P!CAX$_](=5
MKHO^">/[>/[/^G?\$TOVC/VQOV=OV$/#7PPTSX2^*O&UUJ?@7PQJL4<7B2]T
M?3TNY+IYXK*,0/< +%S%+Y2HN-X 4 'Z&45^;/A__@M7^WM\>?V8M(_;%_9
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M(VQ(TF6QMH ^D*^,9/\ @X9_X(O12-%)^W]X/#*2&'V6^X/_ (#U]G5^1/\
MP:8_ GX(?$3_ ()5W/B'X@?!OPKKNH?\+5UR+[=K'AZVNIMBI:X7?(C-@9.!
MG R: /TE_9D_;8_9'_;-T&Y\1_LK?M%^$?'EM9;?[03P[K,4\]GN^[Y\(/F0
MYP<;U7/:O4:_(K_@OA^Q]\/O^"<W@[P]_P %I/\ @G]X&TKX;?$;X6>+M-7Q
MG:>%;1+#3O%FBWES';2VM[;0A8W+2R0J7"AF21]VYEB:/[A_;.^#?QT_X*%?
MLE>&O"/[+W[4UY\(]'\=-I]]XM\1:;I/G:M<^'+BW,DMI93>8HM+B0/&/.PQ
M W#N00#TCX+?MD_LN_M&?$OQM\'_ (%?&[0O%?B/X<W4%MXVT[1;DS?V3-*9
M0D<D@'EEMT,JD*S%6C96P016S\??VBO@5^RQ\-+SXQ_M&?%C0O!GABP94N=:
M\0:@EO#YC9V1*6.9)&P=L:@LV. :_,?_ ((&_LU?"7]CS_@JY^W3^S/\#-$F
MT_PIX/7P!9:1;7-V\\I7^SKQWDDD<Y=WD=Y&/ W.< # 'VC^U]_P3(^&O[;W
M[5WP@^/OQ\\72ZUX1^$7]H7=C\*;_2HY]*U;5+A L=]=;F_>&':A2-D897KA
MG5@#0_9)_P""M7_!./\ ;J\8W'P[_94_:S\,^*_$%M$\K:"@GL[V6-/OR107
M<<4DR+U+1JP P2<$5]%5^0O[:'BG]E'_ (*"_P#!3/\ 99\.?\$O/[ \3?$;
MX2?%>V\0_%+Q[X"TY4LO#WA.!U%W97M[&JQ2M.5:*.W#.<^8N%\T[OUZH *C
MLKVSU&SBU#3[N*>WGB62">&0,DB,,JRL.""""".M>$_MY^+/$NO^%- _9&^&
M6MW%AXL^,VHRZ(-1L9-L^C:#'&)-:U16'*-%:'R(I/X;N]LQ_%6=^PL'^ FL
M^*?^"?FM7$OE?#,07OPUENIF=[OP7>-)_9\8=R2[6,L5QIIY+".TM9'.9QD
M^BZY'XX?'[X(_LT?#VZ^*_[0?Q9\/^"_#=DP6XUKQ+JL5G;ASG;&&D8!G;!V
MHN68\ $UUU?CY\*?@WX5_P""WG_!<+X[>*/VM['_ (27X/?LFZG;^$O ?PUU
M%RVF7FM.\R75Y<PYVSXEL[@LK##JULC;DB*L ?8GPI_X+Y_\$>?C5\0(/A?X
M!_;S\'/K-U<""UBU:.[TR">4G"HEQ>0Q0NQ.  '.XD 9)KZ_!# ,I!!'!%>(
M?&K_ ()J?L ?M#?"Z7X,_%S]CSX?:EX=>#R8;*#PS!9R6:^MM/;+'-:L.SPN
MC#L:X#]N;_@H%\-/^":'AGX9?LX_!OX":K\0OB+XX=?#_P '_@]X3NH[62[A
MM(45FDN)=R6=I!'L#3,&P.<%4D9 #ZNHKX$T'_@K]^TU\ ?CIX#^#_\ P5,_
MX)^/\%M'^*.NQZ'X)^(GA[XB6OB/1QJ\O,.GWQBBC:S=^BR'<K')P$21TZ+]
MK/\ X+ >)OV<_P#@H7;_ /!.CX=_L5^*/B=XNUSX2Q>+O"3>%]>AA-]>R:A-
M:?8KD3Q+#86R1P23O?R3%5"A!$S,NX ^V:\J^'?[;W[*?Q9_:7\9?L=_#KXT
M:9JOQ*^']C%>>+_"EO%,)M/AD\O:^]D$4N#+$'$;L8S(H<*6 /S=^S%_P5D^
M/^J_MT:5_P $]?\ @H)^PZWP7\<>,_#MUK?PVU'2O'=OXATSQ!!;*\EQ;^=#
M%'Y4\<<<KD'.1&<A-T?F;/[+7Q__ &?_ !G_ ,%C?VFOV>/!G['/AKPOXZ\!
M>'?#$WBCXNV-Q$VH>+8KZPM[F.&:-;9'B$(=$R9I?,\I"0N%"@'V;17S1_P2
MA_X*)_\ #SW]EN?]I7_A3_\ P@_D>,=3T+^Q?^$@_M/=]D=5\[SOL\&-^[.S
M9\N/O&N5_9T_X*O?\+^\.?M8>(/^%"?V3_PR_P"-O$/A[R?^$I\__A)?[+BG
MD\_/V5/L?F^3C9B;9NSN;'(!]@T5^;'PJ_X+6_M[_M<_LS:)^U-^PY_P1VUW
MQ?X;DT3[;KUUXC^)]GI"SW49/VFRTA9+<S:F(RK)]I\J)'D1D1'88KVWX:?\
M%H?V1O&__!+0_P#!6#Q'<:EH/@>TTR5]9T:XC274+748[C[*VFHH(669[G;'
M&<JKB1'.Q2=H!]=55NM;T:QU*UT:]U>UAO+X2?8;26X59;C8 7V*3E]H()P#
M@'FO@[X6_P#!33_@JQX[L?#WQDUC_@B1KEM\,O$MQ:M;-I_Q<TV;Q/:6%PRB
M.]ETN6*(<JRLT!E1XP268!2:^;O^"@G[7/[;>D_\'!/[/_AWP3_P3VU3Q)>^
M!?"?C-OA_P"'U^)VC6C>,[.\M3#/J4<TK^78*B6H;R;@K*WEX Y% 'Z;_M1?
MMO?LI_L60^%;C]J+XT:9X.3QKXACT/PPVHQ3/]MO7Z)^Z1_+09&Z5]L:;EW,
MN1GU6O@3_@HK^UGX.\#?!G]F/QI^W%_P31T#7/$OQ"^/&A^'+;P1XL\36%^_
M@74[IYQ'J$=U#;W$-T\:Q*VR,H&\P N-M>P>%O\ @HUY_P#P5.\2_P#!,3XE
M?!L^&[V'X>6_C#X>>,#XA^T1>++(NL5U&+<V\?V:6&7S5VB27>L$C_(!B@#Z
M;HKYJ_:"_P""AP^$G_!03X-?\$\OAY\(#XO\3?$W3-1UOQ+?_P!O_8X_".A6
MBG%_*GV>4W'FR)-%''F(%X\%QN%>??';_@H%_P %+!\7?%_P_P#V,?\ @D'X
MA\::#X'OGM+[QC\0?'MIX5@UV9!N9=)AGCD>[A8'Y+G*QD@C% 'U=\:_C'\/
M?V>/A!XF^._Q:UMM-\+^#]#N=8\0:@EI+.;:SMXVEED$<2L[X12=JJ6., $T
MGP1^,WP[_:*^#_AGX\?"/7&U/POXPT2VU?P_J#VDL!N;2>,212&.55=,JP.U
ME##N!7PO\;?^"@'P[_X*4_\ !OQ^T#^TAX"\):GX;N5^%7B[1O%/A/62&NM"
MU:UL95N+.1@ 'QN1U;"DI(A*HV47WC_@C!_RB6_9P_[(SX?_ /2&*@#U;4?V
ML/V=M(_:8L/V.-2^*>GQ?$W5/#;:_8>$&27[3-IH>1#<@A-FW=#(.6S\AXKO
MKZ]M=-LIM1OIA'!;Q-)-(W1449)_ "OR+_:_^/7P2_9O_P"#K7X<?$[]H'XM
M>'/!/AR+]E9[>77?%.L0V-HDLFH:L$C,LS*H9B, 9R:^U?'7_!7[_@E3>^"-
M9LK/_@HY\$I9IM*N$BBC^)FF%G8Q,  !-R2: /9OV:OVHO@#^V'\*[;XW?LT
M?$VQ\7>%+RZFMK;6M.218I)86V2(!(JME6X/%=]7XD?\$8_VW?&7_!.K_@V@
MT_\ :[\+?L_2_$BR\*_$+4V\3:);>(O[-GM=,EU+R9;V-OL\_FF)GC)C(0;"
M[%U"'/ZL_&#]M?X(_"/]B'6/V^KG7DU#P)IW@#_A+;&ZMY IU&T>V$]M'$3Q
MOGWQ1H#_ !2** /7J*_/OXI?\%S_ !!\ ?@/^RY\:/C;^Q'KUI>_M)W$Z+X.
M\,^(VU34]$#0+-81PQ?8HC?W%RLULODD6_E/,07.PDYOQ$_X+1_M>_LD?$[P
M9J?_  46_P""8EW\*/A#X]\30:#I_P 1+#XH6.NRZ#=SEO(&IVUM&%A5@"S%
M9"$57VF5EVT ?HM17R9^VI_P4W\0? O]HWPY^PU^R9^S5?\ QH^-_B309-?D
M\*6WB&'2-.T#1DD\HZAJ5_*CK A?Y4C",SD ?*7C#UOV4?\ @I7\5_&?[5+?
ML(_MS_LH2?!OXJ7OAJ3Q!X.6P\6PZYHOBO3HGV7#6EW''$4GB/+V[IO" OG&
M* /KRBOS3'_!>OX]?&'XG_%S]F7]BC_@FGKOQ/\ BI\*?BSKGA;4-&MO'$%G
MID6D:?,((]9N[^Y@BCMI+J43)%8CS&/V>4^:0N#[+^TA_P %4_''[/7A7X-?
M"B']D'5O%/[2?QHT..\T?X#Z+XGMQ_9,B6ZRWIOM4=/)@MK9B\9N-A#M&Y4;
M59E /L>BOB_X(_\ !3K]H'0/VJ_"7[''_!1;]B]/@]XD^)-K>2?#'Q-H/CF'
MQ!H>OW%K'YMQ8-,D,+VETL9#*CJ1)CY2"5#<IXG_ ."R/[0?BW]LKXU_L$_L
MF?\ !.O5?B)X]^$NH:5'%J4GCVWTW1KBRN[,7#W=Y=3P 63H[)%';IY[S_.P
M*+&Y !]]U6UK6M)\-Z-=^(M?U*&SL+"UDN;V[N9 D<$**6>1F/ 55!))Z 5^
M<GPH_P""Y?[3O[1=SJG[./[/W_!,76M4_:+\%:I?6?Q7^'>M^/K33]&\(1V[
M1I%=/J[Q%+M;EI/W$<4>Y_*F;<$19)/<_P#@FW_P4KM?^"A'A7XG?#[XL?L\
MWOPV^)OPCUTZ!\4OAKJ^IQ:C':R2)(8I(KE$5+BWF$4P!V@'RVQO0J[@'LW[
M)W[8G[-7[<OPE7XY_LI?%>R\8^%6U*?3SJME;3P[+J$@21/'/''(C#<K?,HR
MKJPRK GTNOA7_@D9^V;\#/B%_P $D!^V)^SI^P2_PZ\.6DNO7T7P>^%5LFJW
MEW/:W$J2"U2*WMOM-Q.8QM38#DJF2 *X'XI_\%K/V\_V5_"VD_M-_ML_\$BM
M4^'GP*O]8M++6/%$/Q0LM2USPY!=2K%!=WNF10@HK,ZAHMX9&8(6WE58 _2B
MBHK&]L]2LH=1T^ZCGM[B)9()HG#+(C#*L".H(((-2T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXA\1>"/V?_"6E7'BSP]9:#XD2PT2&.#4=,LXGAMK.6%5\IH8XI&C5-N-AV]
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M+QCX9U(#[;H?B/3([NVE*G*MLD! =3RK##*>00>: /S5_P"#FKXF_#O]H/\
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M2 GA'2)!&]S%GHEW<QK(R]I;>3UK#_9X_;+_ &U?^"H.E?%?]H'PM^WQX/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2U_M(G:+(WJH;5;C=\OE&4/N^7&[BOI.@ HHHH **** "BBB@ HHHH ****
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M3:33OKZ-=$^Y^75>R?\ !/\ _P"3N?"7_;__ .D%S7V1_P ._P#]D;_HDO\
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M"3!'!5RK$-M8$'&#Q7A_[)_[-O[9_P %_&NHZ_\ M)_\%'M=^,VDW6EFWL=
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M$&O!_!__  2K_P"":?P^^)D7QC\$?L&?"72O$UO<BYM-7L? =C');3AMPFB
MBVQ2 G.] &]Z /F70/&_P\TW_@XHO?'GQPUZPM[;Q7^S#IG_  H/5==<003Q
M?V@\FIP6;38 NSO1W1<2^2W(V9KQCX[:KX6\9_M?_P#!2/QK^SEJ%E>^!4_8
MUFL?B-J.AR*]A=>,4TS43&#)'F.2XCL<I)@EE)VOAN*_4+]H#]EW]F_]JWPG
M#X%_:7^!/A/QYI%M<>?:6'BO08+Y+:;&/,B\U6,3XXW+@X)&<&CP'^RU^S5\
M+?@S>?LZ?#;X!^#]!\!:C9W-KJ/@[2/#MM;Z;=PW$9CN$EMT0)*)4)5]P)<$
M[LT ?F%^W'X)\':!_P &>_AP:#X5TZQ^R? 3X>:Q:FRLTB,.HR2Z/-)=KL V
MSO++([2#YF:1R22QS[ZUXH_X.5M#U"^N%4?\,&W,DTLC  ?\5? 2Q/0#O7V5
MXC_9V^ GC#X)1_LU>*_@SX8U+X>1:5:Z9%X(OM$@ETI+*V\O[/;"U93$(HO*
MBV)MPOEK@# KYV^#/[%?[3&J_P#!4GQ;_P %!OVEM1^'UEI-M\)Y?AK\._"?
M@J[O+QYM(?6/[1-[J,EU!"L=R0D:&&$21@,WSG;E@#Z2^#/QP^#G[1?P^M/B
MQ\!?BAH7C'PQ?R31V6O^&]3CO+2=XI&BD598R5)5T92,\$&ORO\ ^"<?_!/_
M ."7[7O[7G[;?C#XH>,?B5IMUI7[4NL6=M%X(^*>LZ! \9CC?,D5A<Q)(^6/
MSL"V,#. *_5#X,_ _P"#G[.OP^M/A/\  7X7Z#X.\,V$DTEEH'AO2XK.T@>6
M1I9&6*(!06=F8G'))J3P!\&?A)\*=4\0ZY\,OAGH7A^]\6ZR^K^*;K1M+BMI
M-7U!P ]U<M&H,TS  %VRQQUH _,9OV._A7^Q_P#\'#7[-6@?"WQ-XYU*#6OA
M-XRN+M_''Q U/7Y$=(=H$3ZA/*T*X)RJ$ G!(R*\[_:L\0?&K]@;]H'X\?\
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M.<R")-Q.T8 /3J*** "BBB@ KXW_ ."M?_-/_P#N*_\ MG7V17&_%O\ 9_\
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MPTL/B;IV@6MIJ?CC1O"-K'>S72VR13SI/Y2R!I"&W2?*[ACNZFNR_:*_8O\
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M6E^98GN'BC6Y:-1)N?=N8?MUX5N9[WPQIMY=2EY9;"%Y';JS% 2?SKQK0_\
M@F%_P3F\-:SXE\0Z%^PQ\*+:]\86T]OXFN(_ ECNU"&?_71/F+_5R'ET&%<\
ML">:]Q@@AM8$MK:)8XXT"QHBX"J!@ #L* 'T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKPO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)H ]THHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\@O?V]/V3]
M.O9M/O/BMLF@E:.5/["OSM93@C(@P>147_#P#]D;_HK7_E!O_P#XQ7>LJS1K
M^!/_ ,!E_D<GU_ K_E['_P "7^9[)17C?_#P#]D;_HK7_E!O_P#XQ1_P\ _9
M&_Z*U_Y0;_\ ^,4_[)S3_GQ/_P !E_D'U_ _\_8_^!+_ #/9**\;_P"'@'[(
MW_16O_*#?_\ QBC_ (> ?LC?]%:_\H-__P#&*/[)S3_GQ/\ \!E_D'U_ _\
M/V/_ ($O\SV2BO&_^'@'[(W_ $5K_P H-_\ _&*/^'@'[(W_ $5K_P H-_\
M_&*/[)S3_GQ/_P !E_D'U_ _\_8_^!+_ #/9**\;_P"'@'[(W_16O_*#?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KPO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_
M .2)ZM_V/>L_^E)H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH _(+QK_R.6K?]A.?_ -&-696GXU_Y'+5O^PG/_P"C&K,K]YI_
MPUZ'Y3/XV%%%%62%%%% !139)8X8S+-(J*HRS,< "G @C(- !136FB218GE4
M,^=BEN6QUQZTZ@ HHHH **** "OT:_X)Q?\ )K6F?]A.]_\ 1QK\Y:_1K_@G
M%_R:UIG_ &$[W_T<:^4XR_Y%*_QK\F>_PY_R,'_A?YH]VHHHK\N/N0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7(=-T;1M CNM1OKAL+%$D0)/J3V"C))( !) KPO_ (*D^.S?_LS>,?@%X=\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_
M^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2: /=**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R"\:_P#(Y:M_V$Y_
M_1C5F5I^-?\ D<M6_P"PG/\ ^C&K,K]YI_PUZ'Y3/XV%%%%62%%%% !1110
M4444 %%%% !1110 5^C7_!.+_DUK3/\ L)WO_HXU^<M?HU_P3B_Y-:TS_L)W
MO_HXU\IQE_R*5_C7Y,]_AS_D8/\ PO\ -'NU%%%?EQ]R%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG)[T >_T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%U_P2L:Z-?:3;7&D"*+RU%J\2M%A?X1L*X';I6M4&F6VG6>FV]IH\$,5I%
MB6L=LH$:1@ *$"\!0,8 XQ4] 'DW[6O[,OB_]J#PA:^#?#/[5/Q ^%]N@N(]
M4E\!)I9?5(9HPAAF_M"RN@% R1Y81LL<D\8\]_88_P""9>@?L/\ PED_9Y@_
M::^(?Q'^'*^&FT+3? GQ#BT>;3["T=F,BI]EL())-ZNZ,)7D4JQ&*^FZ* /@
M^W_X(&_!0^&+;X!:Q^UW\<=2^ MEJ:7EK\ ;[Q= VA>6DPF33WG%N+V6P5P"
MMLUQ@;5^8XK[KL+"QTJQATS3+**VMK:)8K>W@C")$BC"HJCA5    X %2T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?#/C_P 7^(WU+5-0CT/QA=):65Y<3\W"W$=NEJZ<!Q,5 "G;0!^GW@/PG:^
MO ^C>!;&[EN(-%TFWL(9[@YDD2&)8PS?[1"Y/N:U:Q_AWXGN?&WP_P!"\9WN
ME/8S:OHUK>S6,GWK=I8ED,9SW4MC\*V* "BBB@ HHHH **** "O"_P#@GO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU9E?O-/^&O0_*9_&PHHHJR0HHHH **** "BBB@ HHHH **** "OT:_X)Q?\
M)K6F?]A.]_\ 1QK\Y:_1K_@G%_R:UIG_ &$[W_T<:^4XR_Y%*_QK\F>_PY_R
M,'_A?YH]VHHHK\N/N0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(8]A9=P( /U/^'^BV?AKP'HGAS3M$DTRWT_2+:V@TZ682-:HD2JL1<$ABH
M4L"<XS6O65X&U;3]>\$Z/KFDZ^VJVM[I5O/;:HZ!6O(WC5EF(  !<$-@ =>@
MK5H **** "BBB@ HHHH *\+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW
M_8]ZS_Z4F@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#\@O&O_ ".6K?\ 83G_ /1C5F5I^-?^1RU;_L)S_P#HQJS*_>:?\->A
M^4S^-A1115DA1110 4444 %%%% !1110 4444 %?HU_P3B_Y-:TS_L)WO_HX
MU^<M?HU_P3B_Y-:TS_L)WO\ Z.-?*<9?\BE?XU^3/?X<_P"1@_\ "_S1[M11
M17Y<?<A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI4FE?:<F+S.-JX !^K>BZ-I7AS1K3P]H5A':V-A:QV]G:PKA(8D4*B*.P"@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCW:BBBORX^Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;>"V^!^JQ6T"1J/'6L *B@  7! Z>P _"O=Z\+_X)[_\D3U;_L>]9_\ 2DT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTSQ+_P (3_;?]I:@;7R/[2^S>7A"^[/EOGIC&!]:\+_X>U_]4 _\NO\ ^Y:
M/LBBOC?_ (>U_P#5 /\ RZ__ +EH_P"'M?\ U0#_ ,NO_P"Y: /LBBOC?_A[
M7_U0#_RZ_P#[EH_X>U_]4 _\NO\ ^Y: /LBBOC?_ (>U_P#5 /\ RZ__ +EH
M_P"'M?\ U0#_ ,NO_P"Y: /LBBOC?_A[7_U0#_RZ_P#[EH_X>U_]4 _\NO\
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MDU[I7A?_  3W_P"2)ZM_V/>L_P#I2: /=**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_E!O_\ XQ7YIT4?ZEY7_//[X_\ R(?ZRX[^6/W/_,_2S_AX!^R-_P!%:_\
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M->Z5X7_P3W_Y(GJW_8]ZS_Z4F@#W2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\@O&O_ ".6K?\ 83G_ /1C5F5I^-?^1RU;_L)S
M_P#HQJS*_>:?\->A^4S^-A1115DA1110 4444 %%%% !1110 4444 %?HU_P
M3B_Y-:TS_L)WO_HXU^<M?HU_P3B_Y-:TS_L)WO\ Z.-?*<9?\BE?XU^3/?X<
M_P"1@_\ "_S1[M1117Y<?<A1110 4444 %%%% !1110 4444 %%%% !1110
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M'_Y.7\$_]A^'^= 'ZET444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]CWK/_I2: /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_!W2=??2/AO\0+[5V:?QP8&:.ZOX+,P+Y%DLJF.*4R.TNUCM0J5 !]'4444
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M)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DT >Z4444 %%%% !1110
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M!_Q7\</B6GC'X,11M\/OC99^)%7Q;870A$,LS73QLDRSH DT4D;)(@4$956
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M[3^4E>KDG_(WH?XD<&9_\B^K_A9^>5%%%?LY^;!1110 4444 %%%% !1110
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MFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\
MHO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@HA_^
M)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1
M_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\
MB: .%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\
M,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?
MY_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@HA_^)H_X5=\,
M_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_
M]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;
MG_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\ HG>A
M?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_
M (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?
M^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:
M[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B
M]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XF
MC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_
M .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")
MH X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS
M_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G
M_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_
M .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W
M^?\ ^)KNO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?
M]D?_ *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_
MX*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G_P#B:/\
MAN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X
M*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KN
MO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+U
MH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/
M^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\
MZ+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@
M#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_
M *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_
M .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\
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M%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\
MHG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\
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M_6;_ (5=\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B:/]=,T_DA]TO\
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M-_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \31_KIFG\D/NE_\
M)!_JU@?YI?>O\C\F?[%/_0P:#_X4EE_\=H_L4_\ 0P:#_P"%)9?_ !VOUF_X
M5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XFC_ %TS3^2'W2_^2#_5
MK _S2^]?Y'Y,_P!BG_H8-!_\*2R_^.T?V*?^A@T'_P *2R_^.U^LW_"KOAG_
M -$[T+_P40__ !-'_"KOAG_T3O0O_!1#_P#$T?ZZ9I_)#[I?_)!_JU@?YI?>
MO\C\L/A[#8Z'X^T/6M4\3Z#%:V>L6T]S+_PD-FVR-)59C@2DG !X S7Z*_\
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M_P"R/_T7K0?^_P __P 37=?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
M!1#_ /$T <+_ ,-S_LC_ /1>M!_[_/\ _$T?\-S_ +(__1>M!_[_ #__ !-=
MU_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \30!PO\ PW/^R/\
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M'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\ $UW7_"KOAG_T3O0O_!1#_P#$T?\
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M[5&K?L5VOC1X_B5HWA&#Q1=>'+G3+F+S=(EF\A;N&9XQ#.@E(C;RW8JQP0*
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MG^SC\3+3SM!\;^&KS1M3 4%HX[B)H_,3/1T+!U/4,JD<B@#XC_;^EM?V_?\
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MMH? 3XW>-=*T[2_VCOBBWB?P9JVA32W$^D^5%9O9S7$;I&!)'=V:.T:.0R#
M<%LCUK]FR^_X+*3^*/"?@W]I_P )? 33= T+]WXU\9^'/$.JZC?^*$2%E1K.
MQ>VMH]/=Y-CN\LTP7D+&V> #X>_9M_;TO_\ @G9_P33_ &DOCCX7T;2K_P 3
MZK^W%XQ\->#H/$$SQZ<FIWVJQ11SW;1_.+>%!+,X7#,(MH*EMP].^$?_  4P
M^*OPP_:=^$/@+5/^"BO@7]I30OBCXNC\+>*=#\.?#E=%O_"MW<02O;:E:O;R
M.);(3QK!*MQN=1+&P<G(KIM _P"",OQ9\2?L-_&#]G#QO\4-%\.^,_$7[3.L
M_%GX6>+=#,E[%HMX=2BO=,DN$DCCRP\MHY44, LK;68@5[K\"=?_ ."QWB7X
MC^'=,_:-^&_[/GA/PIICM_PF.K^%?$FL:Q>Z]B)@HL+>6WM4L%:3:Q:>2<JH
MP$?.0 >+?\'$E_JGC'X-_ +]DR]URZTSPA\<_P!IWPIX+^(=U:7#0M<:--)+
M++9[U(*&5X8^<](R#P37W=X7^&?PZ\$?#VS^$OA#P+I&F>%[#3!IUEX=LM/C
MCLH;0)L$"P@;!'MXVXQ@UY/_ ,%%_P!A+P!_P46_9=U7]G3QMXEOO#UX;ZVU
M;PEXMTD9N_#VLVK^9:W\(R,LC95EW*621U#*2&'SUH"?\').@^&XO@W?V_[+
M.L7D,'V1/C%=ZCK,<DD8 47DNE1P!3=;<L8T=83)QPG4 Z?]KW]H?X_Z=^UW
M\+O^"4G[ .I>%?AUJ^L> +SQ7XE\::AX72_M_"?AFRE2RMX=/TX/%#)-+.1$
MH<B.)$SL;(VY'P=_:O\ VQ?V<_VU]?\ ^">7[8GQ1T#XCW6K_"&\\>_"[XH:
M3X431;BX%K,8+O3;ZRCDDA\R,E)4DCVJT8.X%FPNE^T'^PG^V;I7QF^#W[=?
M[.GQ:\'^,/C=\.OA_/X,\?P^.K*31]*\?:5.8YIF#6*3'39UNHS/&$C>/,FU
ML*O*?!/]B3]KGXL_M>>)/^"@/[<4G@;1/%*?"NY\!_#/X>>!=6N=1L="LKB8
MSW-Y=WT\$+7%U+(%3]W$J)$,?,QX /FCX??M@?\ !97XI?\ !("Q_P""N-I^
MU9\-=(D\-^ ;KQ-/\,HOA>+BW\2VFGO+]J:]OFN$DMYIE@E98[6-$C^1=S$E
MQ?\ V^O%W[5O[1_[=W_!/[XF?!']H3P]X)TSXFVVM:]X-T[5?AVVK-X>O6\*
MM<3S7+"_@&H+)!=-"D8$'E-E]TF=H][^#'_!-SX]_#[_ ((&WG_!,/7-<\,/
M\0[CX.Z]X62_MM0G;2A>WHO!$QF, E\H>>FYO*R,'"G SC?M$_\ !/O]LG3?
M!W[&7Q3_ &;K?P'K_P 0?V7M+^P:QX8\4:[<V.FZRESH,6EW30W<=O(ZE&CW
MINB&Y6R0"NQ@"']J[]I/_@I;X#_;C^"G_!/KX#?%7P+>:_\ $'X.ZO>>*?'>
MN>#_ ";+3]0L[BV$FLQ6"SO(V(O.2.R\\H9+B,NY1&-6/B_\>O\ @H5\.OB;
M\$?^"6/@?]I'PMKOQI\=:+KOB/X@?'75/A['#;:3H%G<,(I;71HIQ$]U(98;
M<!Y#&#$[L#Y@V>B2?L@?M/\ CW_@HO\  S]N/XH2>";)?!7P:UGP]X[TS0-5
MNI5_MB^>W?-CYUNIEM@8W^:0HX&WY3R:F_;N_8P_:$\:?M+?##]OS]BS7O"D
M?Q/^&6G:EHE]X9\=37$&D^*M!O@AFLY+FW226UFBD02PR"-UWDAP5H Y?]G[
M]I3]L/\ 9T_X*(:7_P $ZOVU/BSH/Q/LOB!X O?%/PS^)6E>$DT.]^T64RI>
MZ7>VD,KPMMC=98YH]O *L&+?)D?\&TO_ "AW^'?_ &,WB_\ ]2;4ZZ?]G;]C
M_P#:[^*G[>=M_P %%/V]H_ WA_4_"?@6Y\*_#'X;_#_6+G5+?2X[N99;W4+N
M^N(+<S7,@18E2.(1K'URW-=?_P $?OV._BG^P5^P)X3_ &8/C/J>BWGB+0]8
MUZZO+CP]=RSVC)>ZS>7L01Y8XV)$5P@;*##!@,@ D ^FZ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $DCCE79+&K#(.&&1D'(I:** "BBB@ HHHH **** $,<
M;.LC1J67.UB.1GKBEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFRS0P)YD\JHN
MX+N=L#). /Q) _&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^+'_!?
M_P#X(H?\$ZOV7O\ @FC\9_VR_@E\(=:TCXB:==Z9?6>MMX^UFX2.>\UZR@N&
M^SS730D-'<3#!3"[LJ 0,?M/7P-_P= ?\H+OCI_UQ\._^I)I= &S_P $]_\
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M)Z5^SI\>)/BOIFMR:=??L_I\-M_C6%4@CG-X]FEP8([,Q2Q,+A[A8SYBC.6
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M^GZ<I,MS%%I[W-Y&B+R[R6\4R[0"7+;<$G%>M_#KX5?!']I;_@E[I6N>.O\
M@O?XKL/@MXB^&4&E>(-%U"U\#V=KIED]DL,VF2$Z4LL$D0S#M#"560;3NP:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>kprx-20221231_g5.jpg
<TEXT>
begin 644 kprx-20221231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#YI_: _X*(?\ "B_BYJ_PK_X5!_:G]E_9
M_P#3_P#A(/(\WS;>.;[GV=]N/,V_>.<9XSBN-_X>U_\ 5 /_ "Z__N6O&_\
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M,^+'[7/QUT?PK!KFDV,=K<ZO.S7&J7CVZ.R001JTMQ)R6*QHQ .2 *J^#/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$SP'\%_AIK_Q>^*7B&'2/#7AC1KG5->U2>-W2ULX(VDED*H&9MJ*QVJ"QQ@
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M+^V'_P %S_CE\*/AA=V.I^!?$O[&_P#PBGQXOM!=);0Z[=ZG)'8).R':;]+
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M?@3^S3X(C^&O[//P<\,>!_#\<IE&C^%-#@L+<RD -(R0JH9S@9<Y8XY)KL*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW\5]QZ!H&B>%-!LO"_AG2;>PTW3;2.UT^PLX1'%;01J$CC15X554!0!P  *
M+=17UA8ZI:2:?J=E%<6\J[98)XPZ./0J>"*EHH PO^%7?#/_ *)WH7_@HA_^
M)KRG_@GU)))\$M4$CE@GC?6$3)SM47! 4>@   ':O<Z\+_X)[_\ )$]6_P"Q
M[UG_ -*30![I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%?+'_  5F^//QR^$7PA^'?PO_ &<O'=KX/\6?&CXR:)\/++QS=:>EW_PC
M45]'<S37T<,GR2SB*T>*)'^4RS)7C7[)G@OXY_#_ .#W[;/[-.J?MS_$S7M0
M\!^))++PG\4O'WB".^U71#<>#M+U S*[1K%%%%<W4KK&B*J+WW9<@'Z&45X;
M_P $SOVA/&O[5_\ P3[^#O[1OQ(MUC\0^+_A]INH:ZR1"-)KQH%$TRH  JR.
M&D51P X KW*@ HHHH **** "BBB@ KPO_@GO_P D3U;_ +'O6?\ TI->Z5X7
M_P $]_\ DB>K?]CWK/\ Z4F@#W2BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7PI_P57_Y*[X;_ .Q;_P#;B2ON
MNOA3_@JO_P E=\-_]BW_ .W$E?2\)_\ (ZAZ2_(\7/\ _D6R]5^9\M4445^K
MGP(4444 %%%% !1110 4444 %%%% !7T1_P3&_Y.2E_[%NZ_]&0U\[U]$?\
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MLI\S[0X'FLJK&ORR/C"_X(!W5K8_\$7/@#?7US'###X"WS32N%5%%Q.2Q)X
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MMW7_ *,AKRL\_P"117_PL[\K_P"1C2]4?H11117XP?I(4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?"G_  57_P"2N^&_^Q;_ /;B2ONNOA3_ (*K_P#)7?#?_8M_^W$E?2\)_P#(
MZAZ2_(\7/_\ D6R]5^9\M4445^KGP(4444 %%%% !1110 4444 %%%% !7T1
M_P $QO\ DY*7_L6[K_T9#7SO7T1_P3&_Y.2E_P"Q;NO_ $9#7E9Y_P BBO\
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MC6N@_ 34].LY)GCC\;ZLBF>4NV$F"#)/4X49]3D]Z /?Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:* "BBB@ KPO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\
MZ4F@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'Z$4445^,'Z2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^%/^"J__ "5W
MPW_V+?\ [<25]UU\*?\ !5?_ )*[X;_[%O\ ]N)*^EX3_P"1U#TE^1XN?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17XP?I(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_!/?_DB>K?]CWK/_I2: /=**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^%/^"J__ "5WPW_V+?\ [<25]UU\*?\ !5?_ )*[X;_[%O\
M]N)*^EX3_P"1U#TE^1XN?_\ (MEZK\SY:HHHK]7/@0HHHH **** "BBB@ HH
MHH **** "OHC_@F-_P G)2_]BW=?^C(:^=Z^B/\ @F-_R<E+_P!BW=?^C(:\
MK//^117_ ,+._*_^1C2]4?H11117XP?I(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4_$>B0>)?#U_P"'
M+JZN((M0LI;:2>TE\N6-9$*ED;^%@#D'L<&@#Y _X+>^,?CYH?[-_P /OA]\
M#?C+JWPWM/B-\<O#7@[Q]\1]!?R[WPUH.H22QRW4,W'V:1K@6EN)LC:;@<C.
M:\[7_@V[_9L=0^H?MX?M;7<YYENKCXY2F25N[-BW R?8"O*OA%_P1%_X)>?M
MN:?\0? WPY_;Y_:>\;:9X)\77/A'QO:WGQ:N9;$:G;K&\UMF>T\JY";U!*;U
M# C/%:_[37_!%'_@GQ^QO\$-7_:%^/\ _P %!?VM-#\'^'C;+JVJ0_%^]NA:
M+/<1V\;M'!:N^P22IN8+A1DG !- 'Z0_ GX0:+\ /@WX:^"GASQ+KNLV'A?2
M(=.M-5\3:D;S4+I(UVB2XG(!ED/=L#)KK*XO]G+X;^$/@_\  ;PA\,O 'C?5
M?$NAZ+X?MK;2/$&N:Q_:%WJ-L(QY<\MS@>>SJ0WF?Q9S7:4 %%%<Q\;OB!?_
M  F^#'B[XJ:5X9GUJZ\,^&-0U6VT:V)$E_);VTDRVZ8!^9R@0<'ENE '3T5^
M1>M_M&?\%'?!'_!*33O^"VT__!2FWU75+CPY8^++KX/R>"=(3PA-:7-S&AT"
M-TB^WI<)YGD"?[2TIF0J1R<?K)X1URX\3>%-,\27>C7&G2ZAI\-S+I]V,2VK
M21JQB?\ VE)VGW!H T***S_%?BOPYX&\.7?BWQ;J\-AIMA"9;R\G.$B3IN..
MW- &A7A?_!/?_DB>K?\ 8]ZS_P"E)K=_X;G_ &1_^B]:#_W^?_XFN9_X)R:M
MIVM? C5+_2KM)X9/'&KLDB'@AI]ZG\593^- 'OM%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?"G_!5?\ Y*[X;_[%O_VXDK[KKX4_X*K_
M /)7?#?_ &+?_MQ)7TO"?_(ZAZ2_(\7/_P#D6R]5^9\M4445^KGP(4444 %%
M%% !1110 4444 %%%% !7T1_P3&_Y.2E_P"Q;NO_ $9#7SO7T1_P3&_Y.2E_
M[%NZ_P#1D->5GG_(HK_X6=^5_P#(QI>J/T(HHHK\8/TD**** "BBB@ HHHH
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M\%M\#]5BMH$C4>.M8 5%   N"!T]@!^%>[UX7_P3W_Y(GJW_ &/>L_\ I2:
M/=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^%/\ @JO_
M ,E=\-_]BW_[<25]UU\*?\%5_P#DKOAO_L6__;B2OI>$_P#D=0])?D>+G_\
MR+9>J_,^6J***_5SX$**** "BBB@ HHHH **** "BBB@ KZ(_P""8W_)R4O_
M &+=U_Z,AKYWKZ(_X)C?\G)2_P#8MW7_ *,AKRL\_P"117_PL[\K_P"1C2]4
M?H11117XP?I(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOX'_ )^Q_P# E_F>R45XW_P\ _9&_P"BM?\ E!O_ /XQ1_P\ _9&_P"BM?\
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M_0BBBBOQ@_20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /F+_@JK^S=\=_CW\%O!?CO]EW3]*U3XC?!
MSXIZ3\0O"'AO7+L6]IX@GLDN()=.DF/$!FMKNX5)#PLGEDE1EA\)?#7]K#_@
MK-JOCO\ :,\+_!G_ ((V_$CP_P"-_CQXOM;S2-;\>ZG;VGA[PHJ>'=-TB6XG
MO" MZ(Y+.295B \Q"@'S$K71? ;4?^"WW_!4OP=XB_X*&_LP_P#!1+P]\(_!
MEQXJUBV^#/PCG^&UIJ5EK&G:?>S6:OJ5[*?-B:>6WD5V59=O+((QM4)\-O\
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M5P_QK_TF1]#PU_OTO\+_ #1[#1117YD?;A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\*?\%5_^2N^&_P#L6_\ VXDK[KKX4_X*K_\ )7?#?_8M_P#MQ)7TO"?_ ".H
M>DOR/%S_ /Y%LO5?F?+5%%%?JY\"%%%% !1110 4444 %%%% !1110 5]$?\
M$QO^3DI?^Q;NO_1D-?.]?1'_  3&_P"3DI?^Q;NO_1D->5GG_(HK_P"%G?E?
M_(QI>J/T(HHHK\8/TD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\C/V4/^"<__  <G_L2? 71?V8_V
M>_VNOV8;7P?X;GOFT:#5M)U2YN$6ZO9[R3?(;#+'S;B3'H,#M2_LM_\ !/+_
M (.7_P!CWX00? _X+_M>_LN0:#;ZOJ6I1QZAH^J3R_:+Z]FO;@ESIX)!FGD(
M'88':OTJ_:9_:H^%_P"RCX>\,:]\3$U2X?QEX\TCP?X:TW1;+[1<WVJ:C/Y4
M,:H64;54232,3\L4,C ,0%/A/[;W_!93X'_L3_'JW_9P?X!_%GXG^)K7PH?%
M/C"U^%'A%=5'A70_,:,7U]F5"BEE8[1DA!N.-R!P#Z-_9[TWXXZ/\$/"VE_M
M,>(="U;X@0:+ GB_4_#,+QZ?<WX7][);JZHRQELX!4'':NQKG_A-\5/ /QR^
M%_A[XS?"OQ'#K'AKQ5HMMJV@ZI;@A+JTN(EEBD 8 KE6!VD @\$ @BN@H *X
MW]HCX(^$?VE_@%XU_9V\?/.NB>.O"FH:!JLEJP$L=O=V[P.Z$Y =5<E3V(%=
ME10!^;U]^RE_P6[U[]D'_AV5JFO_  'MO!\GA$>"K[X[0:GJ;ZK-X<^S_8V=
M-%-N(UU%K7Y23<^4')8-T-?>OP&^#?A#]G7X'^#OV?\ X?),NA>!_"VGZ!HP
MN7#2_9;.W2WB+L -S%(U)..3DUUE% !1110 5X7_ ,$]_P#DB>K?]CWK/_I2
M:]TKPO\ X)[_ /)$]6_['O6?_2DT >Z4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$QO^3DI?^Q;NO_1D->5GG_(HK_X6=^5_\C&EZH_0BBBBOQ@_20HHHH ****
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M>+M4T:&Y\1>#O[8CU#^Q[MES);?:8@$GV'C>HP>U=?0 4444 %%%% !1110
M5X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DT >Z4444
M%%%% !1110 4444 %%> ?\% _C;\3O@AX#T'6OA?XF_LRYO=7>"YE^Q03[XQ
M$S 8F1@.1U !KY2_X> ?M<_]%:_\H-A_\8KZ'+^&L=F6%5>E**3ONW?3T3/(
MQF=87!5W2G&3:[)?YH_2RBOS3_X> ?M<_P#16O\ R@V'_P 8H_X> ?M<_P#1
M6O\ R@V'_P 8KN_U+S3^>'WR_P#D3E_UEP/\LON7^9^EE%?FG_P\ _:Y_P"B
MM?\ E!L/_C%'_#P#]KG_ **U_P"4&P_^,4?ZEYI_/#[Y?_(A_K+@?Y9?<O\
M,_2RBOS3_P"'@'[7/_16O_*#8?\ QBC_ (> ?M<_]%:_\H-A_P#&*/\ 4O-/
MYX??+_Y$/]9<#_++[E_F?I917YI_\/ /VN?^BM?^4&P_^,4?\/ /VN?^BM?^
M4&P_^,4?ZEYI_/#[Y?\ R(?ZRX'^67W+_,_2RBOS3_X> ?M<_P#16O\ R@V'
M_P 8H_X> ?M<_P#16O\ R@V'_P 8H_U+S3^>'WR_^1#_ %EP/\LON7^9^EE%
M?FG_ ,/ /VN?^BM?^4&P_P#C%'_#P#]KG_HK7_E!L/\ XQ1_J7FG\\/OE_\
M(A_K+@?Y9?<O\S]+**^!_P!G7]M3]IGQW\<O"_@[Q7\2OM6FZCJ\4%Y;?V-9
M)YD9/(W)"&'U!!K[XKP\TRG$935C3K--M7TO^J1Z>!Q]',*;G3323MK;]&PH
MHHKS#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!LW^J;_=-?CC7['3?ZIO]TU^.-??\
M#[8C_MS_ -N/D^*/^7/_ &]_[:%%%%?>GR84444 %%%% !1110 4444 %%%%
M !7Z7_L"?\FD^$?]R]_]+KBOS0K]+_V!/^32?"/^Y>_^EUQ7R'&G_(KA_C7_
M *3(^AX:_P!^E_A?YH]AHHHK\R/MPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^%/\
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M &G/B/\ #R_D.O\ C3X=WOC10?%GV.SBB2+49HD22_/V>T@A S&2(D 9<9H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KX4_X*K_\E=\-_P#8M_\ MQ)7W77PI_P57_Y*[X;_ .Q;_P#;
MB2OI>$_^1U#TE^1XN?\ _(MEZK\SY:HHHK]7/@0HHHH **** "BBB@ HHHH
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MQ\ ^(+GP_P#\'-7BKQ+X8M8[C3_%%]X?\+:')#:+Y69XI;B"Z/V=Q&V2259
M0W'!H ^]?V+-(_9QT+]DCX;Z5^R#/;2_"^+P9I__  @<UJ\K++IA@4P.3+^\
M+LI!;S,2;BV\!LUZ=7GO[)O[-W@+]C[]FKP1^R_\,+J]N-!\#>';;2=-NM2E
M5[BX2),&:1E 4N[;G.T!<L< # KT*@ HHKS+]LS0_P!J#Q/^RYXV\-?L7>)/
M#VC?%#4-%>V\'ZQXI>1;*QN)&56G<QQR,'2,R-'\CKYBIN4KD4 ?"G_!4#_@
MJ!^TU9?'?0OA;^P=XCM],\'?#7XP^$O#_P <_'YL8+F.\U#5-3MK8>&+,S1N
MAE2"9Y[N1!NA)@CW([,I_3BOQ&_;!^ W_!2;]C?_ ()U?"_]G'4_V<?@3IWA
MK1?C;X+G_MW2_BGK&H:IKGB"37;>47E\TVE1!VN;L[IYMQ9%<[$(54K]D_@[
M>_%[4?AEH]]\>_#WA_2O&$MKG7M.\*ZG->Z?!-N/RP3SQ122+MV\M&IR3QWH
M Z:L_P 5^*_#G@;PY=^+?%NKPV&FV$)EO+R<X2).FXX[<UH5%?6%CJEI)I^I
MV45Q;RKME@GC#HX]"IX(H \M_P"&Y_V1_P#HO6@_]_G_ /B:YG_@G)JVG:U\
M"-4O]*NTGAD\<:NR2(>"&GWJ?Q5E/XU[!_PJ[X9_]$[T+_P40_\ Q->2_P#!
M/&W@MO@?JL5M D:CQUK "HH  %P0.GL /PH ]WHHHH **** "BBB@ HHHH ^
M5O\ @JU_R2_PO_V'W_\ 1#5\,5]S_P#!5K_DE_A?_L/O_P"B&KX8K]8X3_Y$
ML/67YGP&?_\ (REZ+\@HHHKZ0\8**** "BBB@ HHHH **** "BBB@#T;]D;_
M ).8\%?]A^'^9K]2J_+7]D;_ ).8\%?]A^'^9K]2J_-^-?\ ?J7^']6?9\,_
M[K/_ !?H@HHHKXL^E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]7LDN;6\@<;7BEBD!61&!(*L""*^)/'O_!%7_@D?^R#X0\9_M?\ PI_X)_\
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MI?X?U9]GPS_NL_\ %^B"BBBOBSZ4**** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 5\*?\ !5?_ )*[X;_[%O\ ]N)*^ZZ^%/\
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M^E)KW2O"_P#@GO\ \D3U;_L>]9_]*30![I1110 4444 %%%% !1110!\K?\
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M&OO^!]L1_P!N?^W'R?%'_+G_ +>_]M"BBBOO3Y,**** "BBB@ HHHH ****
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M//\ D45_\+._*_\ D8TO5'Z$4445^,'Z2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^/WA+_@XU_X*
M">-_VG-3_8T'_!'_ $30/B/92[(/"/CWX^6?A^ZU-2S*C68U&RA6]#A2R^0T
MFY?F&5YKO?!GB[_@IY\./'<GQ2^'G_!KS\&M!\32NSR^(]%^-GA6UOW9LAB;
MB*S60DY.3NYS7VY^W'^QO^Q;^V+\&[WPQ^VW\,O#>L^&]+MI;H:WKDJVDVA@
M+E[F"^#))9D 9+HZC PV1D5^<'_!-S]KS]JSP]^W=9?LC_\ !/GXW>+?VM?V
M8=/OQ:>*OB)\0-),(\!(" 8+3Q$S*NM%%Y$7E-N4(L1"[I  ?J[\#_$_Q1\:
M?"'PYXL^-GPPB\%>+M0TF&?Q%X2@UJ/4DTF[9<R6XNH@$G"GCS% !ZBNJHHH
M **** "BBB@ HHHH *\+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?
M]CWK/_I2: /=**** "BBB@ HHHH **** /E;_@JU_P DO\+_ /8??_T0U?#%
M?<__  5:_P"27^%_^P^__HAJ^&*_6.$_^1+#UE^9\!G_ /R,I>B_(****^D/
M&"BBB@ HHHH **** "BBB@ HHHH ]&_9&_Y.8\%?]A^'^9K]2J_+7]D;_DYC
MP5_V'X?YFOU*K\WXU_WZE_A_5GV?#/\ NL_\7Z(****^+/I0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ;-_JF_W37XXU^QTW^J;_=-?CC7W_ ^V(_[<_P#;CY/BC_ES
M_P!O?^VA1117WI\F%%%% !1110 4444 %%%% !1110 5^E_[ G_)I/A'_<O?
M_2ZXK\T*_2_]@3_DTGPC_N7O_I=<5\AQI_R*X?XU_P"DR/H>&O\ ?I?X7^:/
M8:***_,C[<^$/^#AW_DQS1/^RE6'_I%?U^*U?M3_ ,'#O_)CFB?]E*L/_2*_
MK\5J_??#K_DFU_CE^A^6\6_\C=_X4%%%%?=GS(4444 %%%% !1110 4444 %
M%%% 'I/[&?\ R>!\*?\ LI6A?^G""OZ3Z_FP_8S_ .3P/A3_ -E*T+_TX05_
M2?7XSXH_[[AO\,OS1^A<%?[M6]5^04445^6GVP4444 %%%% !1110 4444 %
M%%% !1110 4444 %?"G_  57_P"2N^&_^Q;_ /;B2ONNOA3_ (*K_P#)7?#?
M_8M_^W$E?2\)_P#(ZAZ2_(\7/_\ D6R]5^9\M4445^KGP(4444 %%%% !111
M0 4444 %%%% !7T1_P $QO\ DY*7_L6[K_T9#7SO7T1_P3&_Y.2E_P"Q;NO_
M $9#7E9Y_P BBO\ X6=^5_\ (QI>J/T(HHHK\8/TD**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\+_C
MO^R+_P '!_[:/QXF\<?\% OV(='^*'PZTZ^$_ACX)Z)\>+#PYX8B9')CDO8H
M&DGU%U^4@S2C!W#E&V#ZY\ ?M$?\%R_A1X-T_P"'7PO_ ."%?PI\.:!I%N+?
M2]$T/X]:7:6EI$.B1110*B+[ #K7Z+T4 <K\$/$/Q5\6?"'PYXE^.7P[M?"7
MC"^TF&;Q)X9L=72_ATR[9<R0)<H LRJ> X !KJJ** "BBB@ HHHH **** "O
M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4F@#W2BBB@ H
MHHH **** "BBB@#Y6_X*M?\ )+_"_P#V'W_]$-7PQ7W/_P %6O\ DE_A?_L/
MO_Z(:OABOUCA/_D2P]9?F? 9_P#\C*7HOR"BBBOI#Q@HHHH **** "BBB@ H
MHHH **** /1OV1O^3F/!7_8?A_F:_4JORU_9&_Y.8\%?]A^'^9K]2J_-^-?]
M^I?X?U9]GPS_ +K/_%^B"BBBOBSZ4**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &S?ZIO
M]TU^.-?L=-_JF_W37XXU]_P/MB/^W/\ VX^3XH_Y<_\ ;W_MH4445]Z?)A11
M10 4444 %%%% !1110 4444 %?I?^P)_R:3X1_W+W_TNN*_-"OTO_8$_Y-)\
M(_[E[_Z77%?(<:?\BN'^-?\ I,CZ'AK_ 'Z7^%_FCV&BBBOS(^W/A#_@X=_Y
M,<T3_LI5A_Z17]?BM7[4_P#!P[_R8YHG_92K#_TBOZ_%:OWWPZ_Y)M?XY?H?
MEO%O_(W?^%!1117W9\R%%%% !1110 4444 %%%% !1110!Z3^QG_ ,G@?"G_
M +*5H7_IP@K^D^OYL/V,_P#D\#X4_P#92M"_].$%?TGU^,^*/^^X;_#+\T?H
M7!7^[5O5?D%%%%?EI]L%%%% !1110 4444 %%%% !1110 4444 %%%% !7PI
M_P %5_\ DKOAO_L6_P#VXDK[KKX4_P""J_\ R5WPW_V+?_MQ)7TO"?\ R.H>
MDOR/%S__ )%LO5?F?+5%%%?JY\"%%%% !1110 4444 %%%% !1110 5]$?\
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M8_X[_P# JV_^*H ]THKPO_AK#XV?]&/^._\ P*MO_BJ/^&L/C9_T8_X[_P#
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MU3_AD7XV?]$>\=_^$];?_)E'_#(OQL_Z(]X[_P#">MO_ ),H_P!:,B_Y_?\
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M_P"*H_X:P^-G_1C_ ([_ / JV_\ BJ /=**\+_X:P^-G_1C_ ([_ / JV_\
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MY]_C'_,\KHKU3_AD7XV?]$>\=_\ A/6W_P F4?\ #(OQL_Z(]X[_ /">MO\
MY,H_UHR+_G]_Y++_ .1#^P\T_P"??XQ_S/*Z*]4_X9%^-G_1'O'?_A/6W_R9
M1_PR+\;/^B/>._\ PGK;_P"3*/\ 6C(O^?W_ )++_P"1#^P\T_Y]_C'_ #/*
MZ*]4_P"&1?C9_P!$>\=_^$];?_)E'_#(OQL_Z(]X[_\ ">MO_DRC_6C(O^?W
M_DLO_D0_L/-/^??XQ_S/*Z*]4_X9%^-G_1'O'?\ X3UM_P#)E'_#(OQL_P"B
M/>.__">MO_DRC_6C(O\ G]_Y++_Y$/[#S3_GW^,?\SRNOTO_ &!/^32?"/\
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M?+QW_P"$%;?_ "SH_P"'*OQL_P"?+QW_ .$%;?\ RSH_U[X4_P"@C_R2I_\
M(A_JSGG_ #Z_\FC_ /)'Q/17VQ_PY5^-G_/EX[_\(*V_^6='_#E7XV?\^7CO
M_P (*V_^6='^O?"G_01_Y)4_^1#_ %9SS_GU_P"31_\ DCXGHK[8_P"'*OQL
M_P"?+QW_ .$%;?\ RSH_X<J_&S_GR\=_^$%;?_+.C_7OA3_H(_\ )*G_ ,B'
M^K.>?\^O_)H__)'Q/17VQ_PY5^-G_/EX[_\ ""MO_EG1_P .5?C9_P ^7CO_
M ,(*V_\ EG1_KWPI_P!!'_DE3_Y$/]6<\_Y]?^31_P#DCXGHK[8_X<J_&S_G
MR\=_^$%;?_+.C_ARK\;/^?+QW_X05M_\LZ/]>^%/^@C_ ,DJ?_(A_JSGG_/K
M_P FC_\ )'SA^QG_ ,G@?"G_ +*5H7_IP@K^D^OQC^#/_!)CXV?"/XP>%/BO
M_P (WX[U#_A&/$MCJWV#_A"K:+[3]FN$F\K?_:+;-VS;NVMC.<'I7Z4?\-8?
M&S_HQ_QW_P"!5M_\57YGQ[G669UBJ,\'4YU&+3TDMW_>2/LN&,NQF74:D<1'
ME;:MJGT\FSW2BO"_^&L/C9_T8_X[_P# JV_^*H_X:P^-G_1C_CO_ ,"K;_XJ
MO@3Z@]THKPO_ (:P^-G_ $8_X[_\"K;_ .*H_P"&L/C9_P!&/^.__ JV_P#B
MJ /=**\+_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJ@#
MW2BO"_\ AK#XV?\ 1C_CO_P*MO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*H ]TH
MKPO_ (:P^-G_ $8_X[_\"K;_ .*H_P"&L/C9_P!&/^.__ JV_P#BJ /=**\+
M_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJ@#W2BO"_\
MAK#XV?\ 1C_CO_P*MO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*H ]THKPO_ (:P
M^-G_ $8_X[_\"K;_ .*H_P"&L/C9_P!&/^.__ JV_P#BJ /=*^%/^"J__)7?
M#?\ V+?_ +<25[O_ ,-8?&S_ *,?\=_^!5M_\57A/[5GAKXV?M-^+M-\5?\
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MV?\ 1'O'?_A/6W_R91_K1D7_ #^_\EE_\B']AYI_S[_&/^9Y77T1_P $QO\
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M$%;?_+.C_7OA3_H(_P#)*G_R(?ZLYY_SZ_\ )H__ "1\3T5]L?\ #E7XV?\
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M?5Q2ZGO\-Y-F6 S!U:]/ECRM;Q>MUV;/MJBO"_\ AK#XV?\ 1C_CO_P*MO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,B^&'AR_^"OAKX8:=KNLV_A\.;N+43=V.A,9;2]N;J-?(NIT57CB94E7RR
M?JE17Q[_ ,$0?V9/BY^SA^Q!IK_M!Q>-8?&_BC6-0U/4K+Q[XSOM7U&RL&O;
MC^S+><7%Q+';31V+6ZR1P!%W@[P7#&OL*@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS)X]U?4=/T7QYX9N]$U2]TB2-;J""XC,;O$9$= X!)!96&>H-%% 'GW[1O\
MP3K^$7[3/[#6F?L#^-/&'B2R\*Z79>'[:#5M+GMUU!ETB>UFMRS20M'EVM(P
M^(QD,VW;P1\._M5?!.UE_P""D?Q<^-'[7WP&_:GL/[3L]&TSX4>./V5[36VM
MK_0X+;<R7\FA,9_MJW<MP"+I0@1(A'P"SE% 'U3_ ,$>/!/[6_@WX'^,F_:<
M\2?$:[T34?B%>W7PDT_XQZI'>^+=/\-&*%84U29"3YK2K/(L<C-)&CJKMGY5
M^N*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>kprx-20221231_g6.jpg
<TEXT>
begin 644 kprx-20221231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBO"/^"@NN?MPVWPCT7P5^P%X=TX>,_%OC"QT?4?&>LQV\]KX*TF3>UWK36LT
MB?;'B5 J0#=N>525*J00#W>BOSQTSQU^W3_P3Z_X**_ 3]FSXP_MLZC\>O!/
M[0']OZ=<V?BGP?ING:KX=U#3; 7OVZUDT^.,2VSY"/%("(@<@DFJ7P;\9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPYT*1O,_LRV$<I-UJ,V UW=*/F8&*/;$OS8'_!#CXS?"7]E/X'?%S]A[X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_Y2">/_P#L1-*_
M]&-7NE>%^ ?^4@GC_P#[$32O_1C5[I0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^TY\2=+\7?%_XN>-I_%OQ)UG0;9X=-ANGAB@AL+)9 '^RV\$*1HS@.WS$XR
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M^C&KW2O"_ /_ "D$\?\ _8B:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:-O<-IFD3N1=B.1;*!HT,#R0QV^=P"R,?T#_ ."-WA#]A3PO^Q78:A_P3_\
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MY6:XA@G>)=NXY6)SD 8YR #X5_X(N?#/X??!G]M']MSX4_"CP;IWA[PWX?\
MBMX?LM%T32;58;>SMTT&$+&B+P /S)R3DDFO'/B[\1_VR/\ @II_P4CU[XA?
M K]D#2/B?\%?V3_&=SHWA70?%GQ$3P]INO>/+4 7>H/_ *+<F[DM"WE6Z,B0
MHS^<906:,^X?L%_LT?\ !5#]GG]L3XM_&KXM?"#X(_\ "-_'+QY8:YXG_L+X
MGZI<7F@Q6]BMH4MHY-(C2[8A WSO$.<9XS5WPW^RU_P4V_8-^*OQ4LOV#/#?
MP?\ '_PY^*WQ U#QM8:;\1O$FH:/?^$M:U'8UZA:VM9TO;%I4\U%7RY4WLG(
M 8@'T!_P3W_;G\+_ +??P/O_ (FZ=\/-6\&>(O"_BW4/"?Q \#ZY*DEUX=UZ
MQ95NK)Y(_DE"[XW610 RR*2%.5'NE?.G_!,[]B3Q1^Q)\%?$FF_%3XAVGBSX
MB?$KXA:KX\^)OB#3+)K:RN-;U%D,R6D3$M';1I%%$@;DA"Q"[MJ_1= !7B6J
M>!?V])=3N9=(^._@B&T:=S:Q2^%Y&9(RQVJ3NY(& 37MM% 'S%^S;I7Q:TG]
MN#QU:_%[Q9I>KZHO@C3S/=:58&WB93+^[ 4DX( ;/KD>E?3M>%^ ?^4@GC__
M +$32O\ T8U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_F?I9_P\ _9&_Z*U_Y0;_\ ^,4?\/ /V1O^BM?^4&__ /C%?FG11_J7E?\
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M_DYGQK_V'I?Z5YQ7[C@/]QI?X8_DC\OQ?^]U/\3_ #"BBBNLYPHHHH ****
M"BBB@ HHHH **** /U*_9$_Y-F\%?]@&+^M>C5YS^R)_R;-X*_[ ,7]:]&K\
M.Q_^_5?\4OS9^H83_=*?^%?D%%%%<AT!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %><?MBV^OW?[(WQ3M?"OQ:A\ ZI)\.
M=;73O'5Q<M#'X=G-A,(]1:1?FC6!L3%ARHCR.17H]?FQ^VG_ ,%F--_8'^//
M[0WP'_;RN)O#7A_4_#-M??LV:U=> ;K4-(U]9-%"7-A-+;0RB24:BL@=)@JA
M)!DA"N0#*_X)W?\ !Q1_P3:@_8^\#>"/VK?VV=/T[XF>%- M=#\=3^(9;F]?
M5-2M8EBFU"*[ACDCNH;AE,RR*Q.),,%8$#[F_9-_;@_92_;H\(:GX]_9+^-6
ME^-]'T;4O[/U._TJ.94M[GRUD\L^:B'.QU;@$<U^:G[.7_!?_P#X-^+S]GOP
M'>?M&:IX&M/B%+X,TM_'=K9? :],,.LFTB-ZD9BT]HR@N/- V,RX P2,&OO?
M_@G!^VA_P3__ &V/AGKWCG_@GK?Z7<>'-(UT6&N-I?@R?14%[Y*28,4UO"9#
MY;I\X!';/&* /HJBBB@ HHHH **** "BBB@#POP#_P I!/'_ /V(FE?^C&KW
M2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%_P30_Y.9C_[ -W_ .R5Y>=_\BBO_A?Y'=EG_(PI?XD?H=1117XN?I04444
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M & 8OZUZ-7X=C_\ ?JO^*7YL_4,)_NE/_"OR"BBBN0Z HHHH **** "BBB@
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M+?[.G_!/3]CC]NS5?V![7P]X<^%&H6\7QY\-:E\,$;5+>PNM'O='U'4KVV:
MW%X+?46ANR[*[/&/. (Q7TK_ ,$,/BQ\.?B]X>^.WB;]EGPO=6/[/T_QDFNO
M@K<SZ!+ID5Q;SZ?9RZG]D@E2-ULQJ1NVB!1=HE:,!?+V)Y[\(O$W_!R_^U7\
M+_#_ .T9X2^(7[+'PWT/QKH]MK.@>$-0T;6+^\L;&YC6:!;F8!D:;RW0ML.W
M)Z*<J/L#]A/PK_P4#\)?#[5[#_@H7\2/AKXE\1-JP.@7'PRTFYL[2"P$2#RY
M5N "9/,#G(XVD"@#W&BBB@ HHHH **** "BBB@#POP#_ ,I!/'__ &(FE?\
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M1117(= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP_\ "/7Y= \:^,_$WQ*A\.VM[KD**]SI.FJUM,9YH=RH\LACC5SMY!5CE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5A?%+_ ))EXC_[ -Y_Z)>MVL+XI?\ ),O$?_8!O/\ T2]:T?XT?5$5
M/X;]#\C****_=S\J"BBB@ HHHH **** "BBB@ HHHH *WOA;_P E-\.?]AZS
M_P#1R5@UO?"W_DIOAS_L/6?_ *.2LZW\&7HRZ7\6/JC]<J***_!S]5"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#\MOVN_\ DYGQK_V'I?Z5YQ7H_P"UW_R<SXU_[#TO
M]*\XK]QP'^XTO\,?R1^7XO\ WNI_B?YA11176<X4444 %%%% !1110 4444
M%%%% 'ZE?LB?\FS>"O\ L Q?UKT:O.?V1/\ DV;P5_V 8OZUZ-7X=C_]^J_X
MI?FS]0PG^Z4_\*_(****Y#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^&O\ @HG_ ,$X_P!J3Q-^TOH?_!23_@F+\8M"
M\%_''0_#IT#Q'H?BZW>30/'.C"3S4L[T1 LDB-]R4#)P@WQ^6CK]RU\4?M(?
M\%W_ -E']E_XW^(O@'XZ^!WQRU/5O#-ZMM?7_AGX5W-]83.8UDS#.C 2+AP,
MCN".U 'C>M_%C_@Z@^.&ER?";1?V3/@'\&KB^C^SWGQ/NO&']J+9J1AKBTM8
MYYV$@ZJ)HI!D<CN/KK_@F?\ \$_O!7_!-W]F&V^ WAWQE?\ BK6]1UBZU_QW
MXUU8$7?B/7;LJ;J^E!9BN[8B*I9B$C3<SMN=OF3P]_P<^_L!^+M'A\1>%/@A
M^T%J>GW&[R+[3_A!<S0R;6*MM=)"IPP(.#P01VKZG_8 _P""A'P6_P""D7PA
MO/CC\ _"7C73O#UMJC6,%WXR\,OIOVYU16:2VW,PFB!;:74X#*R]0: /=:YO
MXN^!=>^)GPWU;P)X8^*.N^"K_4K<1VWBGPRML;_3F#*WF0BZAFAW8!7YXW&&
M/&<$=)10!\=?LP?\$C=0_9:_: U[]H7PQ_P4*^-VMW_C+Q%;ZUX^TG7?^$>:
MS\2W$, @C%R(=*CD11&%7$+Q'CKFK/QB_P""0_A/Q9\;O%_QT_9T_:]^,'P,
MU#XD2)+\2=-^%VMV<-EK]PJ>7]N\JZM9Q:7K)A6N8"C-C<06)8_7E% 'G/[*
M'[*GP4_8J^ VA?LX_L_^&6TOPUH$3^2MQ<-/<74\CM)-=7$S?---+(S.[GJ6
MP   !Z-110 4444 >%^ ?^4@GC__ +$32O\ T8U>Z5X7X!_Y2">/_P#L1-*_
M]&-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 5\_?\%+_P#DV:3_
M +#UI_[/7T#7S]_P4O\ ^39I/^P]:?\ L]>IDG_(WH?XE^9PYG_R+ZO^%GYX
M4445^T'YJ%%%% !1110 4444 %%%% !1110 5]!?\$T/^3F8_P#L W?_ +)7
MS[7T%_P30_Y.9C_[ -W_ .R5Y>=_\BBO_A?Y'=EG_(PI?XD?H=1117XN?I04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5A?%+_DF7B/\ [ -Y_P"B7K=K"^*7_),O$?\ V ;S
M_P!$O6M'^-'U1%3^&_0_(RBBBOW<_*@HHHH **** "BBB@ HHHH **** "M[
MX6_\E-\.?]AZS_\ 1R5@UO?"W_DIOAS_ +#UG_Z.2LZW\&7HRZ7\6/JC]<J*
M**_!S]5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\MOVN_^3F?&O_8>E_I7G%>C_M=_
M\G,^-?\ L/2_TKSBOW' ?[C2_P ,?R1^7XO_ 'NI_B?YA11176<X4444 %%%
M% !1110 4444 %%%% 'ZE?LB?\FS>"O^P#%_6O1J\Y_9$_Y-F\%?]@&+^M>C
M5^'8_P#WZK_BE^;/U#"?[I3_ ,*_(****Y#H"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\Y_;!^'/Q"^,/[)7Q1^$GPDU
M[^RO%?BGX=ZWI'AG4_/,7V34+FPFAMY=XY3;*Z-N'(QGM7HU<1^TS\;M)_9G
M_9P^('[1VOZ//J-CX \$ZKXCO-/MG"R7,5C:2W+Q*2" S"(J"1@$YH _.']E
M3_@X4_X)\_L:_LS>!_V4OVT/#/CCX)_$OX<^$-/\.:U\.]7^'>H2,;BSMTMR
M]I);0O%+!*T>Z-RR[@X/^T?</^"'VL_%#XC^%/CC^T3JGPB\0_#_ .''Q.^-
M=_XD^$GA#Q58&TO8M-FMK=;B^-N2?LZ7=TDMR(QP7DE<;A('?YFN_P!H?_@X
M?^(.M? 'Q9<?'']G;P3:_M&W%Q)X.T6/P9=WR>&U_L6XUB"&YN)=S/+);6[(
M=A8>9D#Y:^SO^"4/Q@_:Z^(?A'XG?#W]NOXL>&O$/Q/^'?Q)GT#7=/\ "_AD
M:=;:=!]EM[FTDC;S&-U%<VUQ#=)*4C($QC*;HF- 'UA1110 4444 %%%% !1
M110!X7X!_P"4@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*_P#1C5[I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?/W_  4O_P"39I/^P]:?^SU]
M U\_?\%+_P#DV:3_ +#UI_[/7J9)_P C>A_B7YG#F?\ R+ZO^%GYX4445^T'
MYJ%%%% !1110 4444 %%%% !1110 5]!?\$T/^3F8_\ L W?_LE?/M?07_!-
M#_DYF/\ [ -W_P"R5Y>=_P#(HK_X7^1W99_R,*7^)'Z'4445^+GZ4%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %87Q2_Y)EXC_P"P#>?^B7K=K"^*7_),O$?_ & ;S_T2]:T?
MXT?5$5/X;]#\C****_=S\J"BBB@ HHHH **** "BBB@ HHHH *WOA;_R4WPY
M_P!AZS_]')6#6]\+?^2F^'/^P]9_^CDK.M_!EZ,NE_%CZH_7*BBBOP<_50HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH _+;]KO_DYGQK_ -AZ7^E><5Z/^UW_ ,G,^-?^
MP]+_ $KSBOW' ?[C2_PQ_)'Y?B_][J?XG^84445UG.%%%% !1110 4444 %%
M%% !1110!^I7[(G_ ";-X*_[ ,7]:]&KSG]D3_DV;P5_V 8OZUZ-7X=C_P#?
MJO\ BE^;/U#"?[I3_P *_(****Y#H"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *RO'7@GPM\2_!.L?#GQSHT6HZ)X@TJXT
MW6-/GSLNK6>-HI8FQSAD9E/L:U:\U_;-\%?$SXE?L?\ Q6^'7P6U![3QCK_P
MVUW3?"=U'/Y30ZG/I\\5JX?(V$3,AW=L9H ^(/"6@_\ !.K]ISX,^&/^".7[
M)?\ P4MU34/BU\!C%K_P\\<Z<BZMJ7AFXTN=H89&F2%+&[C@BN_L+VV_+0,4
M;D,X]W_X),?L\>#_ (/^ _B/\1E_;3D_:!\=^.OB1>2?$[XEMIMO8+-JVGHF
MG&P2SMV:.T2V2V$8C#'@Y4[#&!^?O[)W_!3G_@ES\"/C=^RW!=>/-%^$5M\)
MOV?/&7AGXG>$M?T:;3KWP]XB,OAI9+6YA,0>>XEEL[MPZAVF,;L3NW ?97_!
M$/5;WXN+^T/^V/X4\%ZIX=^&WQI^.-SXC^&=CJ]@]I+J5BFGV=I-K A<!HTO
M)X'E&X!FV[B.02 ?=5%%% !7S9^T3_P5K_8<_9B^*NI?!/X@_$+7M2\3Z!91
M7OBO2_!7@35_$#>';61=Z3:@VG6TRV@*?.%D(<IA@NT@GZ3K\G/@#^TI^T/^
MRY^V/^V!IG[!O[%VL_M.^&-9^*MQK^L^*O#_ (AMM$.@^)_L<,5[X=FFU *M
M^+=HT*FT,K1"4HT99J /T^^#WQB^%W[0/PQT7XS_  5\=:=XF\*^(K%;O1=<
MTFX$D%U"21E3V(8%64X965E8 @@=+7Q-_P &^>D^ M%_X)H^'[+P;\0K?7=0
MD\6:_=>,K.UTJ?3X_#VNW&I37%[HXM+A5EMQ:O*(MKJI;'F !9%%?;- !117
MB6J>!?V])=3N9=(^._@B&T:=S:Q2^%Y&9(RQVJ3NY(& 30!!X!_Y2">/_P#L
M1-*_]&-7NE?,7[-NE?%K2?VX/'5K\7O%FEZOJB^"-/,]UI5@;>)E,O[L!23@
M@!L^N1Z5].T %%%% !1110 4444 %%%% !1110 4444 %%%% !7S]_P4O_Y-
MFD_[#UI_[/7T#7S]_P %+_\ DV:3_L/6G_L]>IDG_(WH?XE^9PYG_P B^K_A
M9^>%%%%?M!^:A1110 4444 %%%% !1110 4444 %?07_  30_P"3F8_^P#=_
M^R5\^U]!?\$T/^3F8_\ L W?_LE>7G?_ "**_P#A?Y'=EG_(PI?XD?H=1117
MXN?I04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5A?%+_DF7B/_L WG_HEZW:POBE_R3+Q'_V
M;S_T2]:T?XT?5$5/X;]#\C****_=S\J"BBB@ HHHH **** "BBB@ HHHH *W
MOA;_ ,E-\.?]AZS_ /1R5@UO?"W_ )*;X<_[#UG_ .CDK.M_!EZ,NE_%CZH_
M7*BBBOP<_50HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;]KO\ Y.9\:_\ 8>E_I7G%
M>C_M=_\ )S/C7_L/2_TKSBOW' ?[C2_PQ_)'Y?B_][J?XG^84445UG.%%%%
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MHN[!;:6(7=M'TE110 4444 >%^ ?^4@GC_\ [$32O_1C5[I7A?@'_E()X_\
M^Q$TK_T8U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S]_P4O\
M^39I/^P]:?\ L]?0-?/W_!2__DV:3_L/6G_L]>IDG_(WH?XE^9PYG_R+ZO\
MA9^>%%%%?M!^:A1110 4444 %%%% !1110 4444 %?07_!-#_DYF/_L W?\
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MMM1OK.W*JL=G<WL4TD10!&4;E&TC(!]F4444 %%%% !1110 4444 >%^ ?\
ME()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\ T8U>Z4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7S]_P %+_\ DV:3_L/6G_L]?0-?/W_!2_\
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MB?3/@[X"6WUO]IC5O!'A+5]8O-8 (EMO#2?V7;S/;V[8$MY<-L4*HB#B0,C
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M -Y_Z)>M:/\ &CZHBI_#?H?D91117[N?E04444 %%%% !1110 4444 %%%%
M!6]\+?\ DIOAS_L/6?\ Z.2L&M[X6_\ )3?#G_8>L_\ T<E9UOX,O1ETOXL?
M5'ZY4445^#GZJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;?M=_P#)S/C7_L/2_P!*
M\XKT?]KO_DYGQK_V'I?Z5YQ7[C@/]QI?X8_DC\OQ?^]U/\3_ #"BBBNLYPHH
MHH **** "BBB@ HHHH **** /U*_9$_Y-F\%?]@&+^M>C5YS^R)_R;-X*_[
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M)7EYW_R**_\ A?Y'=EG_ ",*7^)'Z'4445^+GZ4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M87Q2_P"29>(_^P#>?^B7K=K"^*7_ "3+Q'_V ;S_ -$O6M'^-'U1%3^&_0_(
MRBBBOW<_*@HHHH **** "BBB@ HHHH **** "M[X6_\ )3?#G_8>L_\ T<E8
M-;WPM_Y*;X<_[#UG_P"CDK.M_!EZ,NE_%CZH_7*BBBOP<_50HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _+;]KO_ ).9\:_]AZ7^E><5Z/\ M=_\G,^-?^P]+_2O.*_<
M<!_N-+_#'\D?E^+_ -[J?XG^84445UG.%%%% !1110 4444 %%%% !1110!^
MI7[(G_)LW@K_ + ,7]:]&KSG]D3_ )-F\%?]@&+^M>C5^'8__?JO^*7YL_4,
M)_NE/_"OR"BBBN0Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "JFOZ!HGBK0KWPOXETJWO].U*TDM=0L;N(/%<02*4>-U/
M#*RD@@\$$U;KXL_:^_X*^^/?V4_V@-;^!>A_\$HOVI/B?;:/':M'XU^&OPRE
MU'1K_P ZVCG(@N%.',9D,3^CQN.U 'C6I?\ !O)\8? ?Q0T/Q#^R7_P5R^+'
MPX\)>%=)U+1_!WA6ZT6VUJX\-:5J$EO)=:?I]_/*DD$!-I;B,,CO&(5PQ.XM
M[_\ \$BM!_9!^$?@'XF_LJ?LH_\ "87MY\+_ (HWVE_$_P 4^.I%GU+Q+XFD
MCBFNM2FN Q-RTBM&-Y5.$"A0!D^,_P#$0-\5/^D$O[;_ /X9>?\ ^*K5_P""
M"3?%_P 6ZS^U'\>_BO\ LR_$7X5Q?$OX_7/B+P_X>^)GA6XTG4#9RV%L WES
M*-X#*RED++E2,\4 ?H51110 445\B?\ !5']MWXH_ _PQ:?LO?L<QVM_\=_'
MVB7U[H+7$2S6_A'1+6,M>^([U""HBA \N%'&)[EXXPK@.M 'UW17@7_!*_XQ
M_$G]H3_@G%\%/CA\8O$SZUXI\5?#G3-2U_5GMHH3=W4L"M)(4A5(UR23A5 '
M8"O?: "BBO+;_P#;8_92TN^GTS4/CEH<5Q;3-%/$\K91U)#*?EZ@@B@#G? /
M_*03Q_\ ]B)I7_HQJ]TKYL^ 7Q/\ ?%/]NGQWXD^'GBJUU:QF\#Z<L5U:,2K
M&.4AQR!T++GZU])T %%%% !1110 4444 %%%% !1110 4444 %%%% !7S]_P
M4O\ ^39I/^P]:?\ L]?0-?/W_!2__DV:3_L/6G_L]>IDG_(WH?XE^9PYG_R+
MZO\ A9^>%%%%?M!^:A1110 4444 %%%% !1110 4444 %?07_!-#_DYF/_L
MW?\ [)7S[7T%_P $T/\ DYF/_L W?_LE>7G?_(HK_P"%_D=V6?\ (PI?XD?H
M=1117XN?I04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5A?%+_ ))EXC_[ -Y_Z)>MVL+XI?\
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M6<X4444 %%%% !1110 4444 %%%% 'ZE?LB?\FS>"O\ L Q?UKT:O.?V1/\
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M44 %%%% !1110 4444 %?07_  30_P"3F8_^P#=_^R5\^U]!?\$T/^3F8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUS4M3>]^SFZM+6]O]-BF=F+16U[/.JC)*^81G@8_,?Q]JG_!J;XI^)TWQ%\
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M1E^5RCKE7&-R,I(4DJ/;* "BBB@#POP#_P I!/'_ /V(FE?^C&KW2O"_ /\
MRD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^?O^"E__ ";-)_V'K3_V>OH&OG[_ (*7_P#)LTG_ &'K3_V>O4R3_D;T/\2_
M,X<S_P"1?5_PL_/"BBBOV@_-0HHHH **** "BBB@ HHHH **** "OH+_ ()H
M?\G,Q_\ 8!N__9*^?:^@O^":'_)S,?\ V ;O_P!DKR\[_P"117_PO\CNRS_D
M84O\2/T.HHHK\7/TH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K"^*7_ "3+Q'_V ;S_ -$O6[6%\4O^29>(_P#L
M WG_ *)>M:/\:/JB*G\-^A^1E%%%?NY^5!1110 4444 %%%% !1110 4444
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MHNN:1<B6WNX6Z,K#N""I4X*LI4@$$#HJ "BBB@#POP#_ ,I!/'__ &(FE?\
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M1117(= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_X0'_@H)_T7_P "?^$I)_\ %4?\(#_P4$_Z+_X$_P#"4D_^*KW2B@#PO_A
M?^"@G_1?_ G_ (2DG_Q5'_" _P#!03_HO_@3_P )23_XJO=** /"_P#A ?\
M@H)_T7_P)_X2DG_Q5'_" _\ !03_ *+_ .!/_"4D_P#BJ]THH \+_P"$!_X*
M"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4D_\ BJ]THH \+_X0'_@H
M)_T7_P "?^$I)_\ %5SWQ,_9N_;(^,/AD^#OB-\8O FHZ:9TF-M_PCUS#\ZY
MVG=%(K<9/&<5]*T5<)SI34X-IK9K1HF48SBXR5TSXG_X=@_$O_H9? G_ (!:
MG_\ )-'_  [!^)?_ $,O@3_P"U/_ .2:^V**[?[6S3_G_/\ \"E_F<WU# _\
M^H_^ K_(^)_^'8/Q+_Z&7P)_X!:G_P#)-'_#L'XE_P#0R^!/_ +4_P#Y)K[8
MHH_M;-/^?\__  *7^8?4,#_SZC_X"O\ (^)_^'8/Q+_Z&7P)_P" 6I__ "31
M_P .P?B7_P!#+X$_\ M3_P#DFOMBBC^ULT_Y_P __ I?YA]0P/\ SZC_ . K
M_(_/#XI_L0^//AMXS\%>$[O5?!\S^+M;;3X)+>UU )$PC+[I-UP25X_AP:[?
M_AV#\2_^AE\"?^ 6I_\ R37O/[1_@7Q=XL^+'PDUOPYH,]W::'XPDNM6GA *
MVL)@90[<],\5Z_1_:V:?\_Y_^!2_S#ZA@?\ GU'_ ,!7^1\3_P##L'XE_P#0
MR^!/_ +4_P#Y)H_X=@_$O_H9? G_ (!:G_\ )-?;%%']K9I_S_G_ .!2_P P
M^H8'_GU'_P !7^1\3_\ #L'XE_\ 0R^!/_ +4_\ Y)H_X=@_$O\ Z&7P)_X!
M:G_\DU]L44?VMFG_ #_G_P"!2_S#ZA@?^?4?_ 5_D?$__#L'XE_]#+X$_P#
M+4__ ))KH/AG^PI^T/\ ![Q,/&/PY^(7@33M2$#PBY_LF^F^1L;AMEG9><#G
M&:^N**B>99C5@X3K3:>Z<FT_Q*C@L'"2E&G%->2_R/"_^$!_X*"?]%_\"?\
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MZQ*&4^X((H_M;-/^?\__  *7^8?4,#_SZC_X"O\ (^/_ /AV#\2_^AE\"?\
M@%J?_P DT?\ #L'XE_\ 0R^!/_ +4_\ Y)K[8HH_M;-/^?\ /_P*7^8?4,#_
M ,^H_P#@*_R/B?\ X=@_$O\ Z&7P)_X!:G_\DT?\.P?B7_T,O@3_ , M3_\
MDFOMBBC^ULT_Y_S_ / I?YA]0P/_ #ZC_P" K_(^)_\ AV#\2_\ H9? G_@%
MJ?\ \DU/I?\ P34^+.BZG;:SIGBOP)%<VDZ36\GV#4FV.K!E.#<D'! X/%?:
M-%)YKFC5G7G_ .!2_P P6 P*=U2C_P" K_(\+_X0'_@H)_T7_P "?^$I)_\
M%4?\(#_P4$_Z+_X$_P#"4D_^*KW2BN ZSPO_ (0'_@H)_P!%_P# G_A*2?\
MQ5'_  @/_!03_HO_ ($_\)23_P"*KW2B@#PO_A ?^"@G_1?_  )_X2DG_P 5
M1_P@/_!03_HO_@3_ ,)23_XJO=** /"_^$!_X*"?]%_\"?\ A*2?_%4?\(#_
M ,%!/^B_^!/_  E)/_BJ]THH \+_ .$!_P""@G_1?_ G_A*2?_%4?\(#_P %
M!/\ HO\ X$_\)23_ .*KW2B@#PO_ (0'_@H)_P!%_P# G_A*2?\ Q5'_  @/
M_!03_HO_ ($_\)23_P"*KW2B@#PO_A ?^"@G_1?_  )_X2DG_P 51_P@/_!0
M3_HO_@3_ ,)23_XJO=** /"_^$!_X*"?]%_\"?\ A*2?_%4?\(#_ ,%!/^B_
M^!/_  E)/_BJ]THH \+_ .$!_P""@G_1?_ G_A*2?_%4?\(#_P %!/\ HO\
MX$_\)23_ .*KW2B@#PO_ (0'_@H)_P!%_P# G_A*2?\ Q5'_  @/_!03_HO_
M ($_\)23_P"*KW2B@#PO_A ?^"@G_1?_  )_X2DG_P 51_P@/_!03_HO_@3_
M ,)23_XJO=** /"_^$!_X*"?]%_\"?\ A*2?_%4?\(#_ ,%!/^B_^!/_  E)
M/_BJ]THH \+_ .$!_P""@G_1?_ G_A*2?_%4?\(#_P %!/\ HO\ X$_\)23_
M .*KW2B@#PO_ (0'_@H)_P!%_P# G_A*2?\ Q5'_  @/_!03_HO_ ($_\)23
M_P"*KW2B@#PO_A ?^"@G_1?_  )_X2DG_P 51_P@/_!03_HO_@3_ ,)23_XJ
MO=** /"_^$!_X*"?]%_\"?\ A*2?_%4?\(#_ ,%!/^B_^!/_  E)/_BJ]THH
M \+_ .$!_P""@G_1?_ G_A*2?_%4?\(#_P %!/\ HO\ X$_\)23_ .*KW2B@
M#XX\7_\ !.[XV>//$U[XQ\5^-? EWJ6HSF:\N?[-U"/S'/4[4N H^@ %9W_#
ML'XE_P#0R^!/_ +4_P#Y)K[8HKNCFF90BHQKS27]Z7^9RO X*3NZ4;_X5_D?
M$_\ P[!^)?\ T,O@3_P"U/\ ^2:/^'8/Q+_Z&7P)_P" 6I__ "37VQ15?VMF
MG_/^?_@4O\Q?4,#_ ,^H_P#@*_R/B?\ X=@_$O\ Z&7P)_X!:G_\DT?\.P?B
M7_T,O@3_ , M3_\ DFOMBBC^ULT_Y_S_ / I?YA]0P/_ #ZC_P" K_(^)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +-X>\$^'[?2M-#* \PC0!YY,<&65]\KM_$\C'O6SK/P=^$_B+XF:-\9]?\
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M6M6T>,-*TS;;0Q^4I,KO)D+G>Q;KS0!^>'@?X._L\_\ !.W_ (+2_!+X2_\
M!._Q5)JL?QG\,Z];_'#PG?>)9/$=QI^E:=9"?3M4-]=R3W=DOV@F(1M-Y,W"
MJ@89K]5*\N_9Q_8C_8^_9!2_'[+O[,W@CP%)J@ U.Y\+^'+>TFNU!RJRRHH>
M10>0K$@=@*]1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>kprx-20221231_g7.jpg
<TEXT>
begin 644 kprx-20221231_g7.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M      #VU@ !     -,M2% @(
M                            $6-P<G0   %0    ,V1E<V,   &$
M;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M  -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E
M8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (
M#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#
M;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M    $G-21T(@245#-C$Y-C8M,BXQ
M                                  !865H@        \U$  0    $6
MS%A96B                      6%E:(        &^B   X]0   Y!865H@
M        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M   6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z
M+R]W=W<N:65C+F-H
M                 &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #
M7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M               "CP    )S:6<@     $-25"!C=7)V        !      %
M  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '(
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M6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP;
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M P,# P,# P/_P@ 1" &C"B0# 1$  A$! Q$!_\0!4P !  (# 0$! 0$!
M      @)!@<*!00# @$+ 0$  @(# 0$              0(#!P4&" 0)$
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MD+#AX_3U-A?_V@ , P$  A$#$0   ._@
M
M
M                                                    Y_(R:?B=
MS3%_LXP !1+&2W*<>Z  #"2I6+W030    :_Y+XZZMF]-UMRGQ
M
M      ;'XO[+%M9=SV#QOV  "-9!8ML/1
M                                      .5"N;IZMBY0ZY;5)I6W%IL
M3$>XF5DUB#%J\EK^YQP1BTTIK R+_DC(RPB:PLBWAGTF#&VT='UL8 \G-CY=
M/6NB.:[U+I/ ^1^4
M                                #-?@^GI#\O;JZG/(N^?:P90 (N$6
MBT@
M        Y4*YHN)O,G']A2#%]CIZUK8>4"N78R-[3%=46[,[8>4JN7\$[H1T
M!VQ\S]<F5&P)BP!%-<7FC->@J<8'YS'$G[T\P4@[\U<
M
M !=/HG9O<#X&]1_M60!XQ407(
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MOB\\[8 'C%1!<@
M   >*>T                          :%-] X,/T/\FU0;BZ
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MK-'@                      "TG4?>^^7\ZO6P \8J(+D
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MNU+.]=8W?Z#VE%'N'7]#]BXFUS3VP.,CW+YIZ@/)N].3OV+Y_
M            &Z."Y+_IC?E7[? 'C%1!<@
M    <:U<_4%;#'V+5<1:5\UCG%K")K7;%LAF-71,JYB1:*SHM99-8]IK*BUZ
M4X["YCE]KDV26R32G6+W$S3DHKFLPFEYLTIJB\TIK#F+8 7#33E+KFZ +8\'
M.A"<8 KL*%3IC)-                     YV2V,]0   H<+62RD_YO/ZC^
M*8S]JX0                      =RO@#U/S@>H-+6X:8V'RG^P-!=M/@ST
M]H+L?$\UGJ7244.X\!U+^1M\5(;FUYDGS9X@=UZYNS@>4Z"O-NW^0SVGYU[-
M/#7I;C(]R^:>N'QEZ&Y??6>BI$=9YFT#4W>N<OT[ID=97CCT#2EOC6-OVE-C
M<LGKK0TL.G<_TR>5=X9_QOV<@OM3SIV3>'_27$![Y\NVJZ@[]89K3N',]ZJT
MC*SI_/R@ZGSH$)>^=7T;V#B^JWR!OVCK?^K(+[ ZKFGP_3VG^$_35>NRNG^M
MAR12[AU^-/:N$K2VGTCP/IQ=RO@#U/PU>_\ RQ+CIG8>D?R[NK/N-^OC"]S^
M:>U;PCZ;XJ?=WF3M3\)>FXA]TZY0=Z+U+T.>:-Q<YWIS3/1OYBW/R;^QO/P
M                      D#UOE_^E;^67MH >,5$%R
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MFD      #G9.@T]D    %:NT^D\ OZ-^1?EO
M          G7K[M6F><XV/79>'&VN&Y"Y;1VRJ#_ $5J4       ?O6>D3R]
MNGFT]1Z5       OR\Z[:J*W/KO078^)L:UAW.&_>.M:MY?X0
M           /VJ[Y?SJ];6AZE[V /&*B"Y  &KD\?=<O:K;#6I%JD8OU,VQ
M      #EKKEL!FN_D5.1?4R>@F<<R)J                      !@:::8O
M>E.,        "NPY\@"Q8Z"#^@ "G.+TV1>S::X"6KJ\J\9;+E8JI^ B0G:1
M,!$N9K 2+;((W)N,G'&1.BHF,BW:E;       .=DZ#3V0    #F9]5Z/Y._8
MOG[\Y
M                       ?U#JX\?;_ .G3RAO( #QBH@N0 !J-/#93/U\V
MPT*QDVRCU#5Y=I-*A8O)V8KWBUWTTB(G5QZD3^LQ^Y'R)O<FDH9KR65S1"3<
MS-(Y1;5Y 2+=%UL4)8M+28K9BUI4U@#$R+1&I;Z$7#36EB+VK32$46U>;_/A
M.D.V+[P         53Q?VT6>S4   825*Q>Z":  #E.KFV@C8\Q6I%Y'*W.S
M2JF+V7335J;E)H !78<^0 +ERXD  IQB_C%8,7EY-;.%:-(R38FNY4;_ $4
MQDO-G'"&+6736C&+_:GQ3HKMBI@B_/)7)TOVQWV3C      '.R=!I[(
M*@=U:YY=?6NB:Y-G]+^2\
M                                     ?32;%-9]RZAO)>]KB]([(
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M/G3">^      #"_N^;6W*_"
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M($:DT/UR7B6QPQBT0T]&,X_B*9(OL4G7-=GHS, UJ5X@    K%.G$R$
M 'S7KY^7&
M                        !['SYO\ 0   "ATL4)G &"&#)WH@
M                  ?P<NU<OV$VYK<I-*8XOJ).OXFUR:4XQ>8LU_U-C<TY
M;JY?8+G9I7I%KUII!=..IW&B#J=91/\ 9T_VQ4@QDN^G&*08R6RS2K"+>2FW
MR:4XQ>]"<8 %=ASY  E>=+![( !K%-'T7J>B]A"NRIBUA6'*=K(Q5-J<TY1J
MYK;YI#=-N4TI3B^K8FUR:["18;-0      .=DZ#3V0     5^;2Z/4QO'6,6
MNZ=;^')0
M                       #+/A^J<FM^XW&:#VM('JW.  #R"H(N4 !'E.A
M8F1TQZ1N! CVG=Z,!3GR-:)YT:Y.F"V+3B9'(TNG/4>,G&3WSW$9&:,3()$=
M$R)1_0                    ,$.>:N66DUN@F@BPG]#>R,M*EXO R+6H32
MPN:P,BVT)B1Z*AXO*A$JIK7C%ILS'[FZ$  5V'/D ;>.G@V4  "!D6TLFN&+
M?>0$6Z-IQT+Q>5:.FVV+G)C):^K+2:\B%<U@$UA]%M$'55;%63%[UIQ@
M  <[)T&GL@    %'_HW3U46[M9@
M                                            #W?FS=#OE3>TX]<=
MQ  \8J(+D  0>BU:$7IT6V8CM/MAIGB\7TQ0BVTT7TVQTK5R5G+6$*R,F-G(
MKXBVC4Y^;E1KLQ)/A'I&\T:M3T<VQ2:0              !6=%IHS&(GD'I&
MDHG9\QA43,^:UKQ:>TQ%^)T\FS2:1Q3*1',Y7+OJ8J1B_:O;!S"UR]/5L0T8
MFEF+P BW1%..$:UM$TYDZY;C)I7;%O01TF6Q@ 5V'/D#)#IG)*@  &L$TB1?
M1\3T]6Q<!-/H[FKX-N('-;7)6^OT 3CIIB_T'0I./)CGWB]MTUV6BQ6:@
M   <[)T&GL@    KIVQT/GX]1Z.                    S[C/MP'D_B
MS[C/MP'D_B           W'P'*Z<Y_B@    /9^?+]F.^-?9\X
M          V_P/*Z@Y[B@             !E_P 'U=47BOTGLSA^0 'C%1!<
M@ "#T6K0B^HC7IU7VQ<Y\9+<%>=V+^^FZF<<,%H7Q;_$=*5L=1\7VLBIR+Y2
M7[3CKI6B/$QT3T'SCS$KU6SU%UDT              $>4\IM<O1G..LQ;4<3
M^9;+-*1HR:P)]JQ+6^ T4GI#G%%5:*\3U#VQ<UU<FZ)8>>>:NB= I@Q%NL:V
M&:DUYEZY;[YI2I%_S,!.JNV+E/KEW2=(]L0 %=ASY'ZG0^3\    *A8O;U-
M     !47%[<II_0      !SLG0:>R   ?R?T#EV]F><HU]OZ^
M !_4+VO-6Y\*Y'Y*^]I=&E%TSL=76YM<@   7Y>8MV4&^G=)@  7Y>8MV4&^
MG=)@ ;#XK[KSO-VY:1_16G]3<YQF3_']%VWG7;^N.6^#%OM^:I+>>L    )#
M]5YV6'1^S6':J[W$KO/6)!=6YR@?T_I+Q?HP@  3'Z!VO<G <M6IM[7P
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M5R?4= %L>(Q.TICD>KEZ<9Q_88:4PQ?$4W&32 T3YB>E:V( "NPY\BZ@MX
M                  !SLERAZH  !0H6PDW/L^?D/]W>6OYD
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M^R*=]]ZJ              $UM>=OZ1_(^_@!XQ407(
M            _ JYB]C<TA%%L\,KF)0HXIZY_M1U.6Q1ZB9G3&O8F5\UY?:Y
M>H*V(4+1DM&FF_T>X1I3)Y T@FN*+"UR:5GQ>T*:>&5XQ:8LQ7?%KDYH !78
M07+^C_0                    5E$<@   5;DOBY3E/BYFO<_E\
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M[-POZUFJ#=^LKD- [7I:]":D              $O.B=IZ8?'_H0 >,5$%R
M                               !JY/EFY4  :L3M-            C^
M;I/7                         !%HE*?S+DF]R^8->\K\(
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M
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M,<>             !_ITS>/?0TMNC=G 'C%1!<@
M                                                        #%OM
M^;F3]A^>([]KX(                                           #.N
M-^WX<F/$_N^8                                 6L:3V7>+YPW$ !X
MQ407(
M                       & <I\-$GI;3%?^T.D?Q,
M
M9)\GT6_Z&VG;KHG:/ZQ( $1B/99Z
M                                               :;Y_B8I]WZUXG
MT80
M                  -@<7]TO^A]JRSX?I  $:R&):N?6
M
M
M
M
M
M
M                  "N8EV;>                          ,'*["TL
M                %:Q-LV<                  ?P5'%N@
M        !"PR,E@
M                          ?&<K9-4O;
M *8BKLZNS)@                 >8<J!8 7A                  $!3G@
M.I4D(                    #F:,F.C\
M                                            TV4+DA"\$_<
M                    %.I"0O<)$@                 T<4,$IBZ\_L
M               %=A3V7A$U0                   #!RAT]HO;,E
M
M      *B"<))8                          UH50EU(
M    *;RQ,WZ                  #GR.@T           U$:#)L@ BP>L21
M     !789D3A
M                       !403A)+                          &M"J
M$NI                  !3>6)F_0                  <^1T&@
M   Q(YGBWXL0 --'-4="!*H     %=AF1.$
M                                              %1!.$DL
M                   :T*H2ZD                  %-Y8F;]
M         !SY'0:          ?$<Y9,4M\ ,..9LN1+!      "NPS(G"
M                        #\#]P #51BX               /D/A
M                 !6<2W-]                          &!%<9:R
M               "KHF^;F   /(/Y              !3*7-          %8
MI_!?6?Z#SSG"-BEK(      (4&3DL                            11(
M4EQQ*4 K8(R
M        'UGW
M            $ #;!T?GH@_PH7-9DC           #US^@
M         #1Q!@ME+=C[0
M
M                   "OXIJ.F4S$ J&(:G1L?:
M               :Z/9,L
M
M                    !%<Y[#I4-S@%>13X=,1EP
M                                                          !Q
M=5SSJ5_$Z8;8@ !S35RZ7+^YI,::@                    1N3037)G9T#
MVQ[%0 !_)SU1DWJBZ*:             "A^,FH"Z::290  (?Q:K=:_><?H@
M            $"XM4+%]A3'0E./V@  :L36W%K=YH     !323G)7@ H<+A#
M;X    *ZHM)Z8TI$Y),>\85$S5FH I)C)=M.,>&<Z<9)Y(M6F@
M                                                       Y-JYN
MLFV'F/KEF_-:RHMN4MDFE8*W1W./E-KEZH;8N6VN7JCMB
M      K<B\>TVQS3E<KELSFGAFZ"UN:5HQ:9,Q'V)HFC)UFVP@
M  #DVKFZK;8>/6N;J+MBJ'B]BJLSIK#F+3VFM&\7W>8V6^S0
M"A:,EA"NT9CGTKDD[,;X1[Q8I-8OQ,])KRSURY6=-ML0              $.
MXM3XMK^)^4^\NHFE-T7NYMCJXB^WD5O1>Z6<<L9C0L3MJ8YN*Y>LVV$
M
M<FU<W63;#RAURV#3742<J*R8M9--;^9Q\H-<O3I;'SLUR=.%L0
M          %;D7CVFZ><?(37-=Y-.=6,EB<TS<M(5FE-8)Q:LI;HAG&
M        .3:N;K)MAYQ(R331"Y.-1.>3&HHGI_MB''S7-T%SCGW-0
M     *%HR6$*SAFO(37-<3-*.XO(Q&WIB_::4BQ?5D3!-/:5;"
M     .0FN;>",5/$3\I9U-*J(O\  ;41&-;>BO6K;$*J8MIY-V\T
M                                                         '+9
M7+G!,V:^0:13.M%'$7ZR[8<D*78O!J+='=L>S$                     5
MN1?G'C),U6;DUH\C)D9V#6P\1-<W>%;!%5/#=3/?C./I*MC
M'%17/=?..HN+[B1NY&\)4M1?J=G%.2:\L-<NS2<<UMNF@            %"T
M9($Q;)46>S6@>,FY4=(\X^8.,G:+;#II.GHGGZB_67;$               .
M/6N:[V<<?UH?1,RIK$:+6*S6DJ+V.36(D6V2B]6V./T3R'5S="%L?0!.,
M                                                          #5
M*=*DKT:)3YA)I&ID[91I5.ZD>":<3(%%746M%FH
M     CZFM2+76S0               1?3YI*U&+&,I]HYO*Y.GVV(8R:H3OU
M                 KHBW\EC,U
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MGHC)-6:]#DXQ"2+5&1>;DUMRF@
M                          Y4*YI_36JV+:N3,]6;<UH)KEW?->S&V$<U
M-<L>DR\5MTM2A:N2#RURLTBA$QC3B"?:1]";=9I7]$REF+M9INI
M   &HT\NU<O2-;%S^5RRSFMMTTK!B\#XG=!D,QM,C9$^"26F,=)'H@E%IU36
M!,6L0FL2(M7XG>J.J^V+GGC)\Q=I-.(>F?H*MCA7$VK36&\6B,;V.F2V(  <
MFU<W63;#1]&35T3=/;'6;%L6(C1:X::4_1>=TU@C%K2II51%[PII2%%[+YK
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M1-\DXZD8O.V:U(Q>&\6^)'1M;'(Y
M                      '*A7->W..8\UY0ZYID369RM-,9)C3642+89I7[
M%H;)K>B][\XZ((R9@=$EL7%S7-U'SCH+C)T)3BI)C)UF6Q<[$7TO$]55L0
M          U&GC]KFZ(9QU-1?[$7UVQ\A5,_4W;#2?%_A3U(6Q<8E<ULTTW>
MB,"=!1/5K;%R25S6GS3\RKF+[I1K\ZK;8A &+491?*4W(3CK^6BM%O%++YK7
MS$]5ML0  XJZY[ E<I1%];H>MBH6KDQ1/1#;%RWUS6W32K*+6_S2(T6^4^DL
M]FGM%!T9)$HULGP#HIMBJ B_0O..#<6Y7(RV-*]#EL=5<6JMB^U3P"V.:?:B
MU&:@ 4+1DUG$VMS2C>,GV(LDFO.C7+VPWP<Q-<GPIO+G'0Y&2:,UW*C5:8AQ
M/5K;%Q@USW,SCPI, XM9?-:^8GJMMB%5<7K#BWTEGTUJEBWC)\4OUG'1G%^J
MVV( #E0KFV*BQ&:UE1:S.:0I6\F)G+-=0)Q8E"B!2<Y))(K>BV()ZB;8>.FN
M:QJ:U[Q>YF<=9\7ONG'4/%]1'51;%7A%Z68O=]..DZ,G5S;#PJUSV%HB&GI9
MG%2?%]US'Q1/@FR9CYC"XF[RV.ABN3%TWXSCK@6OJG&
M                                    !7[%I\37ZBO.+6&36LJ+926&
M36L"+V?S2IF+ZL+D9I0[&2P57^32::KHO&I/3E.*NU:=2M@LUJRB_P!Q:3-
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MR+4,1?:Q6NM+Y7I1MCW:@
M                      #SRJZ+SQFN\$ "+B91H
M                      &K$[30 !K\ST_L
M          TNGGMKDD3,7XSC $ 8MNJ8DH@        "DF,EVTXP
M
M                                  *2(O3S%^@^<=2L7OAFFVYCB%IG
MN$FG1];%Z@!RUUR]2EL0 %5L6L2F-@(%&\9+R)Q@
M
M
M         ###F0KFZ2;8J;(O>'./#$\0M,_19;%65%]MHSL@@F/Z9P(WFCY"
M*21(]&'IV6C7Q6#%^QVV&:LU
M
M                                                      '*[7-U
M16P@:C3SW5R=-ML7*'7-U>6P\.=<]STTAG$^<GJ\MAXA*Y[CYIK(B[%O4.KN
MV+EKKD^Q/5';"
M
M                                           *PHM4K%[]9I+*:C$4
M\QM<FSB<$UMRFE4T7@]$Y?*$D6D4B\>V.IN+Y(2>1A9:]-*M(OHY,_E9ES4
M
M
M                                   5\1:P>:@
M
M
M
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M7CV#K,=9&>..!@CZNLP6(ZS/K(&8P/V8^PNSU)%AZ9]N!@C'69X&0(\00,\
M6/L./69D,.HC&(A!]A&0Q(=AXD#["[/M?:^T"[.H%A[;3ZMRE14":K)3]3P9
M>9EYL'T,QQP94"FK$@$QEU!KBI5G!ZV'L[ 18%""+KP'876(1@"/$H>R(1='
M\\ 18 ^PNPQ$#["[/M1# 8 OB/L(NK ?:!=A=@(NO 8#K+V NPP8P,P1CK,S
M(R+^768ZR/KQ[!UF.O$S&!@CQ*$%B8/$@9X%@8+$^@^T%V_S,R!=A'@"Z_8\
M"Z,"Z,,.C NG AV]& P&'1V$6 ZC/V[1S29RX]L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%
M:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-L%:-;-9I,3]>18
M=)%@#(8&#+$8&"(8&"+ 8&, 98]!EB,#Z<#(8 RQ!EB1=F'6,#!$,.L8&0(A
MAU@BP&!@B!D,#!D,#/V"'LB$707:7:?9]DBZL 7Q L01#[0(0B$1=A]GU@18
M=!]O=+H[3[#!#L/V/'KQZP9X>AV#$$>(,\!CTD>(,\/<,&7F9A^$U0\)JAX3
M5#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>
M$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ
M'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)
MJAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/
M":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35
M#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$
MU0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'
MA-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)J
MAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35#PFJ'A-4/"
M:H>$U0\)JAX35#PFJ'A-4/":H>$U0\)JAX35?P3@8P!ECT$769# Q_+ R!$,
M.LP1#K(&6(P,8 BP!%@#+$'V8&"QQ!EB?1AU@B,@18=!$9>QD#ZS(Q%V?RQ(
M8D#+'H($0/L+L/K!=I]A=GMJ6I9.9[!**<I&3PY63DZ>#Z&=9+);,89Y2-.3
M*%2H^=I;.]:6'JB/K&)>^, 1=)]0QZ>HQ@"+#HQ(8X]&)#$CZ,2]D/L+L^T9
M SQ+^0+H,P18=&& ,^HC(AB6/\B[/;*<TWR]'E_0]K-'I9AIJ@(3.2NJ]6?8
M7818@RP,&>!8$.P_M NPB('U# AV$1#L,^TR+ BQ!=1GUG@0QZB(@75[@Q+H
M[1B,1B0QP&)=&)=&)#$NC'H/K.+L(\.B'T"('U&?81=0/K/ @0+V,NS[0,L/
M0,P1D0(\1V#'$8=6! NT^PNSVNE*4@G<V]TZ*=R699OIZ*=R699OL\M4\DF\
MQ]7JM7I=#D:*8:"997NJ;J:32+4>W326Z2<2^?R;4)^;^J/L+LA$71%V$.T_
MM'V0]A=I]!]9%V'U@^T^R'L^U_/J'4#(@79[<8+ ?RA[(A$,!_,\ ?47U07:
M0,NHNPNLP7;%V&6)$8A!X8_5!=@+K,^L=T%VEV@NW[7L6'7ZXRQ]M0DGADB5
M]K,R(M5.5+4Q1:BCLZEN6A<M494DJ$IIK+%3ZFBWYI].BWYI]&>3+^CR:0IY
M05.U";DQIZ2"8:_2RO19ZF6M1IKN3U>9"F934I/*'U*VGD2>35'I$6EDZ^TW
MC*B'0T\-1KEA3&=Z34Y6MTGIU0_(M%ORMZJH=0MF1H*>K)7Y.KI:JD] C<U1
MYTB]*K*CF<AT>ACBS-%Z5,U--E!.NBLWYKEW]O\ 4U<D$,R3U/9[%/TO[=6N
M3PEZS $6 ,L>GND"+ &6(P($6 P(8#NET8$"(B&&/018##KPQ'=(8#NE[AQ(
MP0(P9B+H/#$L ?81D,2$/0?49=@^U%V R$(P(8$.P=HQ(&> Q(%UF?4>) @7
M;[]EVF\9,"(B+VO.RBS\F23>:4W4LEJ>DYP<RRM7JI8II6H](J$JDEY*IY.M
M35&?SF;%4I Q)Z<Y*@DJ75ZYS<V<2*J2?T5.E;GJN3K%>SZ8S[(D564[!1;\
MTJV85'UD[F\JJ@D-*B5*2JD.<NI[(E>FY75'4*%8KV?3&?9$BJRG8*+?FGHJ
M*OHTM!D)>K,VTZ97R@DT^JG(U'J\A$IQ7SO2)S13*7205JF6;D2BEDJRI<D>
MA<S1=9>MF*<JK*=)3E89RKE:K5\V3U1])IJL*#6KQ?3+1S0TC5N#+ITN=;/\
MT5NU<4$N3^BAETB7&=EZ>I4544,4,_S=?5119F7G2B2P:*KBM/2*=8()05<F
M.OEJ;E6KJ4MY?G3Q>T\G,<ST>7+-I%W4*;*G05#D"=HR<1)/.WLJW5ZN:U!I
MU,=9/M%I$_+]54FH>;,E%4=!:B7SV>R5,Z/65*J%'GS>H=.M7H-;IYEH@E(-
MKJB]&LU>GT&EVH7509I,M-5)#Y2,56G5LHS%BJY<M-<F:LY6DIBM-<I=.OI6
MIY7K4\C:A:?7*V85'UD[F\JJ@D-*B5*2JD*OJ!/==/32E6Y=ES?15%GB;1$C
M4L[U",E,]DTI%9OS7+O[>%0NY_-9_J$S5F3:>GJTB5TOS%BJY<M-<F:LY6DI
M>M=:I,E3J]4SY4?T&KJ=BU&DS9E)Z(ZJ,B]NJIIBU")_@/ NC A@0PQZ3P!=
MF!=&&'1VGT&.WIPP]# A@71@73@701>_I'F0Y,Z]MG*<D:@RU?232:"748G6
MLUFAJ'^I0FM4,@IBN9K4#72"DIF:+HM^:5.1&FZ)QQ09-'((=2K!1;\TJ2I.
M@D^O4L\J1KY#1,S_ *+(<C*U%8,Z**#*HY!#J58*+?FE8I9;3B;IY'5"E\Z4
M?_RZNBM65EP3]5YD>:@:)?VE;290SK0; U2%9=!J/Z/3*896O1O0K*@RI+YV
MK4E3IAHZ(&?CU9D96IJX-#E3W7U&_HU8PED"J)8K17&"+OZ:.',TRXR<O45*
MW7H4+Q+D@]9(E+D:M);S)Q.LZHNK5FKUE63,T/2_\BUQ(ONU+G9N52"BV3E0
MIJJ'Y%HWFY>2DM15'.F&MJ'KUOK-!)Y3_7J:(Q;P(.&>9TTJM-ZR%%ITLD95
M4K-3LX1=3Y_HTG*=5(D\$%F$GZ@]%4LW-RD11?*RH4RH<K*SY!1#,C+7)K]8
MQ1OJ5M;O[G+O[>I*DZ"3Z]2SRI&OD-&8XX$_1J#+SU2)I_;*(_W#HK-^:Y=_
M;\Z*.')I_I5/KIO_ $:L8I^A)VEILFOUC%&^I6J= J/0J'1U5G,HU>FU.1K-
M/1DRS)S[=4S-ARD1]$)&9'(YC!-Y/[7-,[79$ND]6)U)LY359T\XEM,$IJ4W
M)ZKY.JEJQEM2I<J]8A53E(*:+!73!;2*DOY,HM^:5-^6Z&C/*84P6^;5?^L%
M1W)CTZOE<VS4"NIZO-6M)71+^S)K]8QGE,*8+?-JO_6"H[DQZ=7]%5$K,8)C
MH:URH]%I=+-JIJU<D1(ZB7]IZ)])=(H95I,]54HFT%:TZ>3*E\LE4H5%J=4D
MJFZFID:E@HKEQY4T4OZQA?2&;I=49%;)&>F0ZTGJLUPK-+H]2G4/,X9LE%WJ
M(-)4??2E@I%#-JFS17IC5:*FR'J;*$W(*@32<J(58_(U+_R+7'\+)E!3ZG"+
M6&>@-6K%OK%G(T-HM7,:7T^7LO1^D7BAFJOE2?,BINCIXLI!EQU46<J.8PZ*
MIB*2*ZUJ$*8UDBU44OSM3J-"*E4_UFNU4@K%'HLB:UHTL>3)-&HU2CDTHII3
M&9*JJV5/);3!)ZA-RA-?K&*.?FZMN@U)YD@JQ*M;FRN;9J!74]7FK6DKHE_9
MIKH9M3%7:JM<G+2)[73I0)E"JC)0LV22HTZLE8K-^:])61,9&ED=49 H)K.9
M?.*:*Z.MDB+3(-33U3Z9-?K&*.?F[5U7U$EGRW6>4O3S^\D:?T4ET63*?;JS
MS,M/(OHBHTHX<W2^V:R7Z"8Y>BDTGET0U6CTFNR=%+);+8=;)9-,H_!Z3PVD
MT6CE^3HI))9;FYN5EY^7H93*I6-7H]'K\G12R6RV'3RF5:35:V52N9EIM'H]
M%DZ*6RZ6P94DDN3K!J]'H]?DZ*62V6PZ>4RK2:KISTZG]5FY>7EY,&?I\C59
M.AEDMED'3F9>7FP;+IGOY>7EY,&LT&AF.5HI=+Y;!II9+='GYLDDN=K 9$9&
MFT[%G0PPP0B;2W3SB64HR9Y*-7J4](-;G[)I8:71Z3190B3\ABU&METOF65J
MY;+M?D:72:70Y&NE4KFA965E:?*UTHE,S.'0Z*'2Z*7Z"6Y6HD,CUF?J-#HM
M7IJ@R'5:]'H^J,O3LH5E1\M6RY!)[/3*<ULMETR@T4JE<M]#6R>43$]')Y1+
MC&JT6CU^5HI+)Y;&,J227)U@T<EDTNSL[)R=1E:*32B6Q:V52N9EIM'H]%DZ
M*6RZ6P9N5E9^7I4_(=#FC5R22S#-@RX,J :V1R699NR:6&F3T@T6?'!!F09:
M;3N3FC*DDER=8-')9-+L[62_03'+T4JE<M*K<,ZU^1()/D2"3^VF9$50U&2D
M4GT12Z8:N5:Y(JS0*R6_PSK)-)YC%HI9+9;#_ E4%[EZ/(^B23SF8R'7)6J<
MEG<)&41?0WK=?H9;IUC5P\^"***.+Z)I2JE%(RT]8E=DP[Z52-]*I&^E4C?2
MJ1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD
M;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^
ME4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5
M(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-
M]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2
MJ1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD
M;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^
ME4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5
M(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-
M]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2J1OI5(WTJD;Z52-]*I&^E4C?2
MJ1OI5(WTJD;Z52-]*I&^E4C6U866KAU\SF,TSO\ Z^5UF>!C'TS,\>L@1X^[
M#&(Q]1B"/VW$AWB';Z9G@.\7MIG@,3&/J2/'W 9X=!G@"ZP?4"Z_1QZ^G$$>
M/T"E\0B'7A@8[2+K+^8+HA]V'V%V NH\1B,>L$>/018 ^WVPOB!]0Q'>(8]&
M/1AUGV%V>UQ=A=@(8@CQ&/6"Z^CM,O<!]D/8?69"(=A8@CQ&((Q]HSPZ#Z^C
M[7T"%\0,8X#K$/874"Z"[1#[L/L+L'VL2(&8,&?4740,\ 1>VE\0B[/Y&9 N
MLB!=9]!D8+K]LB["[ 7;B0_F?49]!F",B!&7N$NHRZS/J/M,QB8ZR!8X'B8/
MM+KZ3/ $7T"X'CA$"+ &6(P,$6 /MZ#(8'[M/L(\"Q!%@"/ 'U]!=H/J&/7W
MB]M[#Q(=H,8D(>P^HRZB&.!F9 NSVN+L(R&.((L"(\!_,^L%TX$"]PQ NP^R
M$&0[P[1C@,<1]HRP!=8,\ 1C$OX_Q+IQ+U.'7[W+W#@0P+T>T_<Q]A=1?1A$
M,"'89]N! @7Q&> (L.CM/ O=)8F/K#^?L!8^@9X#ZP+$8]?26/J3,\?K#$\"
M[/7]>/H8F,3!GAZ'7CZ@^HNL=8_G[ 6/H&> ^L"!'CTGV%Z@SP'U@1^D1X^Q
M'V%B8Z^D^S^1=G\=1#$@769]N((L!UXEV]!D,3('V#[7\\,"(BP(NOM,\ ?9
M@"ZC/VR$8D/M8]8(^KK,8F#/ ^L8F8Q,@9CK!G@/K#'J^L"/$$?41F8Q,C!C
M$NCKQZQUC'JQZNLQB>/I?:!]F.!#'K,QB9#'JQ,8X#$QCU8F,1B9@C&)C$8]
M>.!XF"Z^@CPZ(L06(Q,$8QZ\>O$R].+L(RP'VB/K/LQZNLP1@SZ^L8F8Q,@9
MGCU@S'6#,=9#'JQZNLQB>(,8D#Q!8@\1UD#/JQZNLP1^E%T?:Q,QB9 SZOK
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M'!"6)Q1D1EW8RAC[H[T! XC,XXBB..,HB@B*$X.N(\R$Q$4)P"&,H8>@XR.
MCP..*&(1QE$1'@<44,1>PD6)YG;"?=@CA&5\6!G%]W&#@B(H8NZ0S.R*/$LL
MC[T6!Q0D4)1F9P0'A%&6$7ML]7,ME<4P6$_F!YF9F9L7T,Z?6ZS1G*Z@3C1G
M)E#+)[E>L+$CB.(SP/$R,NDB,^C \!@8BA/N=@[L701&8[!@8P/ B,QAAT8&
M71@?NPCP'WA&(HS,NB$CB,H3,SZN@N] ?WA"*(XN@H8C!PF71]W&#ABA!$9C
MN1$"+$S+ _88/BC^/_B@B$,/=C+X\!$74((2(11'$9=0*/O@H,8XX8XC.&(X
M"ZHLSXO;%@LH]1']#VGU&?I,Y)JG+GN1ZN#XH_Q,R(X3AB..$00]Z(\R+$\(
MX/\ B+MS#,HXXHB* N\9YD6/QQQ1F1D?WD.7\,.9$<4<1P'$?>@A+NP%%F8]
MTBS(HXR.(^\?MY01&,#(S(R,H3,%"9@H(C(H3B!PQ%T%!$8,C(=R(=R+H*$S
M(0_5@ROBCA[Q#-Z2PQCC/&$SB@A+&*.(^\9F8A^I 4<1'F%UYG67L)'@>87U
MO^(9<7>(^WHRX,1%!'$<4!PD9%F$4!0&<1][O1"(S[D!8Q1GC%[6NY[%+=![
MIU,LF6BR_3U,LF6BR_9];))E+]'ZO(T^?JLW4Z35Z+,]U2^2S*:9/MVAUNHE
M^KE4QR9M+_50?%'^)F]N5T91X11$9&1=W+(L<J$C,\WXLSX<OL,C(X,88HR,
MHLLNZ67\$/Q9OQ?\18GEXQF,(C.&*,CS"(HO;H<,8^_CB9Q9OQ90R@<1F9F9
M00'%A 7>B,LTSC(^Y&9D4,1E%F%A%%]6 1?AY7Q0Q=V+,AP&:(3S.[CFB/'O
M$6(BP@AA/NG]Z8C(CAB^ 1?A_P#%[$<1'!ZZ&(H2]L5,Q.9SWVLB,SR)=)47
M*,JHDMUL:HCDD<S2,ET.MD?J:D?V/TZD?V/T97HOZC,9K-Y2B<F<S$IM,QI-
M+GZ[4Y4E3:/T.\K3PG.M>C)O*/4IJ6%-YS4.:'GS%*9WATAO.&5I4\MI;J,B
M/3:CTT1^:*D?WSU212/]:&J5J=3^9D+F13>)1P2?+FGI(&3Z*::G50PP:GTE
MI)=!*9;T4Y_L.L_[?J4!-8M%-U;*RE,\]NIK,3/U9'@9Q&9Q1'$(8CAZ2S8B
M!Q'$(8CA!YD1B*(XC+,B(N\>/WL0,S,RS(B$4<40*,X2(\#BB.(^\?=*(X3^
M]B&)X_>Q SQ]O(L3(HX3S,"/,A,S@A,BRNT^V'O%!%]X999X1101$9PF19O8
M(<(X8SQB!]>7E?$?;!$,T=Z(AWHAUQ&1=PCAB$,)Q#N18Q_5@A^O 4$1GF&0
MBZLOW[J\[P^D,S,_:\N,\O,F<OT*QDLR1,^EQ:*/(R-;)==)]1))[/TKKI9+
M<E#RJ6Z T8JRF\NS)3,IVGDQ!!+YHAYMJ5?(,N0S%.I65:.5YLT04WBJ1_8Y
M!I$=IY9+]<B%!G*62_T*:9:7E<T3\YUR'R92G4K*M'*\V:(*;Q5(_L?0CTI#
M/(LV>('09LZ2DIF,J0TSD^1F*:<)^6:B<:G1ZR9"FVC@S9@N==F:Q0="8T27
MCTVCG"$U^H6">RY#KI"GM!-T=J,Y!2G3)9*:+4:$E @8HU>E]-*8!3/3E%K)
MOJ8M9-$QEQYR,)#J@SE4&E0LG@CRYA,HM2@) 6?)$\JI2@-'I=9.=?IT8F=7
MERQ*JZ70Z+41ZW^C)9)2^1ZI(S6;U'*$Y]E[ R#3Z?0I)8:/3RK4Y\VU>0C4
MCEZ.4(Y59.KE<KF4ZU&G1B1ARI>D5AD:K39NCU(GT7] 1_1I]/FZK/\ Z(ET
MEH='G(=31J.19L@F$*=D6L3>FG2!CSUJF]+)LY*ZZ2:[33=1)'-TT@TB.T\L
ME^N1"@SE+)?Z%-$^DY7I964^0&KCE^I2$LG*FF<FEF2H]?*YCKQ3G^PZS_MB
M1I:4Z"594Z04QS5<FRD&KA3LBUB;TTZ0,>>MTUII-FR1/R.52/\ JE/YN63G
MY>CF-3,B$_;T+GGDJ7^ ^_$,<04<1#O1$91'#T&1F4)1D<1XQ%'$0,S,'$9]
M!?5@Z(#($9PGT'$<721F1_>1C[R,$9D._'T$9D._$8(L3S(L3]^S. \R6^VR
MZ<3.4QI]?ZC5:NH\MT^GU*1_)@T"(S#TB8T"3TLV7WYCJ1_8Y(9E.:E0PQ9E
M1(CR9 *D?V.3HW53'2266(W2S6I?]QFN;F9-/<N$HLRHD1Y,@%2/[&G9XFI=
M+YNHDEJY;)__ (]/Q3:..*52*"'+5=2_^^FIC*);JMJD,*<ZK)_J"UTF9I5%
MT2%):Z=Y>GDR)TFIJ9_U)!FYF0@!JHY7I$?_ %&G8GBKD>MD IC%#W<^&*#.
M3&9'DHS;=4!+3PU5IYI)<W3S_8N72W+2&1(<C3H+J4ZW_-%,3/OR7+@S*@U(
MS(SG*(_-%18(\R?Y*'R])IDCI$SIM5,-?_2EHHTS$J3EF7H4'+Z==W.GB@UZ
M,@F\N4B(E.HGVOR)I-PJH#FR2Z$-!!&I:D1QG.I1F1Y4UJ9! >EG/Z=BHO7(
M*9_]'6?]N3HW53'2266(W2S6HT,,4VJ-%'E2,:'_ +U3/^IT4Y_L.L_[>44,
M68K,^2:67_U&G85BIED\T$Y_3L5%ZY!)%7)]5*-2A)=,,C.R<W3YU1B[DM]N
M1<!YBF_@DC,@9F?I8F?\(F1&4ST<4OF/M>AR]-FZR8(*6S'+DB"S9=K5M/LF
M<S%!YF1K$[K$9K)%IU/(XU5H4\G](FIHOOS'4C^QR7^\U.&4>D6R9@0?]/.H
MF9#G)[7:#+5:7E:6R$WK:E_W&<_IV,H](MDS @_Z>=1,R'.3W0AI[HXM'JJ:
MZ_Q.?GZ!"R!,&9J*I?\ W^B53+42C7Y^5(EYH(J;3C[S7I1.R*42?)R)^BLE
M%0R:*I,<.9H9-^G82DTE\[DF;369EG*=-RN0Z44YUD.3.%/HCT$^2V5%J$=N
MWG@DTIT"*T*?G>1J5DIT5,)S-4GH9=)P@OS0M_S13'X\R8'*EBI$]E*S3R!,
MZ=.3-3ZG(T:W5J5U:ASTK*-"GM=-BQ6*BEB<FL<*%3FN+1GJ44I5 E],J3T=
M.X<B'5Y>3DZD(Q6:?2Y$UIW#J<W0TWSX<R9ZB3R-13J3Z%;:.1(3,EFM6T^R
MIS,)S^G8J+^7Z::K(*":H+7Z>#7:#+5:7E:6R$WK:E_W'0:K0+5/Y%-9@>?-
MM-+93.U1),Q4:"?R3.D.M%.?[#GTZG>;GS1$3:4Z&7:N7+200TUFAYRIDLKD
MF=.?T[%1?R_IT'DS*5)E.1I4LK!0*RI6L+,U_MU.-$>=-/HBJ+)S@S_;-/J]
M7I(M3,ICK(1D:C/TN9J=;K=:>FF4QT</B-1]_J-3J-7F:F9S+6Y<$<>5'JM?
MKM<,C4ZC2YFIUNLUL6;K]=J,C3:[6Z(\[4ZC4YFIUFLUL4<SF69IAD:G4:7,
MU.MUFMBS=?KM1D=.5.)MD01QQYD65FYN1F:G6ZS6Q=,$<>7%_7)UW8XX\R+3
MZO5:2/4ZS5ZR+.UNLU&5!,YEEZ8=@*<S@LN****(:#6YLNUJ\S)9,-/D3>;:
M;*_KT\&?J,_4Q@IM-8<G3:O5Z./3ZW6:7-S]1GZK-TNOUVB&9F9F;F::8:_1
M$>IU,6?J=7J];F9,UF>GRLK4ZG(SDE-<C2*%0H?5S>82%'1R#5JJ;Y4ZG&FU
MFLT<6IU^NUOH::8S#1EJ9C,-80R-3J-+'J9E,=9"(YG,LS3#4S*8ZS+R\S,R
M8]3,9AK(=-KM;HCSM3J-3F:G6:S6Q01QY<6?-IKJ<L:>9S+29<4<4<0TTSF6
MCR_Z]/!GS>;:G*ABB@BCG,XS,L1S.99FF&IF4QUF7I]7JM''J=?KM:$ <MTN
M;-IAFS68^V]H2,G.32;Z(M9I-/K]*H)#JY#K/X9T\RF.CAU.MUNL/^!$0E8]
M3F_1),)=HYII9ZAIE+#,C(_H;TVDU.MS4Z@"RHB(H2^B;7R.43,9U.Y!F'NW
MD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&
M-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=
MO(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R
M,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&
M[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNW
MD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&
M-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=
MO(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R
M,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&
M[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-V\C&[>1C=O(QNW
MD8W;R,;MY&-V\C&[>1C=O(QNWD8W;R,;MY&-,@D[ISTNBTFAR_\ Z^5]6&#O
MP@X2,O2AAA*$C@B.*'NG[KA+$SRR(?=X@R,O3++ZHH#(O;"RXC+[J(&1P^G#
M"<0/*B+VV&'O']W"#RSP],BQ..'N^X(8>\9E@<,/>.(NZ<)8G$7=/T"@+N=/
MW> B@.'Z!8OPQE'UX0E$44!F1%#'$7=BP(H!F=&;[L@^/,^,C,A']: H#,C@
MP+N?5$4/=!'@<47>.#X/;(OPQ"??(B,S^ZB!0F9GU H3,AWB*" S[V9AWO:\
MKXH_B(S(\PB,BR^J*#ND<&$)%B<1=TP6$$.9[@A/"+-+"*#ZL.9UEE%U]<47
MW9"*$X3++ZHH#(B_"AA.('@1PGW3,\3+\+Z!(OPQEE@"A[P(X,<SXHB[Y9A]
M8S.N$BQ/-[?=<'QYGQCLRBABB*"' LL^N"'Z\1]Z(0PG$<<1$7MD7X8ROBQ/
MO0PQD<9]W,S"ZX_JP]$,<(B+NG[7E?%'\0CZLLH8C!%AEP?6ARRP,SQ/+AQ.
M*&.(XX8C]PQ?6RX_JPP_6R_AR\O##NP#&&(XRA.*$X82A+'+C^J71##WCCB(
M_H%*.#N][+$49Q""(H1WH2$<11'EF90]O1#'@7?@(&9F?NN#XX\LXHONR(1Q
M=X10]\H"*$$>!QF10B$N\9PF4/W47MID9Y?W<8ZLLLOK(H(L<WXH,(H8CQB'
M=*.&'+BQC,CB]KROBBRXC,H"A$47>BBA[QE@4$)]T\P\"!&9#O1#,,R+W!E'
MB49XQ99X19I]<$1$?W0,BA,X2S <!0D7X4,11$9'"<,/>.*$S(\N(B_CTB,Q
MW8N@B,QW8NC \!@>'09&70<7U?>Q%B<9XG[@[T0[T71V S,P9F8^&#H[ 9F?
MN. B.*,^]%]&&5V_>1XGA'!"9EEEF1#,(B.+\."#O".+O=!'W("S(AUF8P/#
M P9&0P,^CM!D9 B,P1&8,C+H,C+VHNV(LN$8Y0(B^[]@C.$_0AA[Q_[1"(H2
M'=^IT%AC&<)GZB&"$X<,H%# <4181>O(H.YZ!0$1'!#A##WCZ3*#N>H@(CB/
M[LC,\O R+[OUY88QG"9],$/>'^T(B(CBA[O3#@446&/IY<)1#'*$4!8>@76(
MB[I^PPD1Q1?=PF9Y?3#\1D7WF81%%_'65V_=QXQ8000ECE_=X".(HC^K]W'U
M0]$,98=R&(9981GV_P#%CA 41QQ11Q%%'$?=P."&$XS. L(CC,1?6@RRZS/$
M_:2[<TC,^[$"_"[I?=EVQPX1&67"#AA,H(2BA/[LB*&&$N[!$4,)8']V8@A[
MP_V@4.,7^T(H>Z<<)%%%#!"?=@BA&69$9Y<1#L,^YW,(#,ONS/NX1G"7WAE!
M"9PPG#Z1?A#+^/NE%F'U'W2[D,&)=R"(%#]8X(2,H>\?=RQW#[QPP$#AP/N0
MPB*$B'<A(C@+ H2. H".$H8#$1=TR[8X3B!D9#+*$1% .Y 0BAP!PD4'W9=T
MH((@98'Z.5\44,7>,C('^%%"100D1Q'#C&?W<(B@+"& C@/N8=V"$'##$4,,
M)0G]V90PEA_MF4,)8%]W$90X1G"7WAE!"9PPG",LR,CRXB$/=QC. CA*$P19
M<0AA^N4)'&99<(BA+#T<KM/M+JRBAAA(H8(Q#!C%_M"'N]Z,X,1"7>,_NR,B
MA[\1$44,)'!# 1P'W#(R@A!PP80PE@7W<1PP_7P@A!PPG!"6)QX%%!\>81G$
M9&0AA(R_VS'=[L<7XL98QF67"#AA,BA(X("(SCA[L1PD4 @(CB/M[I?=]R'N
MD67$#+ _XMRNTXHN@OPH(L!'#W3B_#@B(A'#W3!P1$661]Z$R^]B(RB,C+*B
M_#AZSB,R.,XC.(XC@(XS&7CB?;EGUQ?4A]J+MS(HH3..(R+\+_B+M_Y8_BRA
ME_ 7;F&1&4<)&4> [L,1%^$,OX>] #B(QF?'F]N5TE'$0S,#A/\ "AA[P+N$
M<7XA_BYGQP_A^E">&7][$(#QCA_$/M_XLSJA+J,_Q<SXH<"R_P#;!QEWL((S
M@APCC^*#XH^YWBB@A!?A%^$7;F_$"BBA!1%F%E=O\^Y@#P^[/\*+\.#XX_B]
M'*^**.(HCBBB!_A1?AP?'#^(?;!\!?A0?%&</>*.$@4?4<,)EF?",2++[T [
MW>C/\7,^.'\/H*.(AF88YO;##B4/<[Q?BP_B1_%_Q>CE=O?('$<1YO;!\1Q=
MV/ZD9D6$>9\91PD7>^MC!$"A[N9'\</X9?A%U"*&&(XCA*'$BR^] (8N]''\
M668A+N$(/CCCB*(XXC(_PA%\47XO_+'\64,OM+ZL!_6AS#ZRCA$!XQGV_P#%
M%^'#\69\7\6PQ'#T]\^Z#C,R.,SA'?/N@HXH0>9$8+J'WL0[QF1QF<,!$<1G
MFXF9]R&(X0>;$8AB.'H@+&*,^]%[47;F1%$8*(ONX(B(L8(3CBQB,\N('%"1
M01$4(**&(O\ ;(0G!AWH("@B[H_V@4>$7^T8B.'&.(CBS(BB."(BZ((B(?[0
MCB[P**$X2B@(8P0@XB.,XB^\C,CBAB(H/2(R^[&69%%WL,R*& S,X>X1PQ0D
M4$)E%C'F&1Q01$0[D ^IWNY!C%'C&901B+ND#[D8,H"(C+[LC+[LNW,,CB+
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MY<FQ!D]Y=D3BZ!-KN<L^=[7-M]8$[9MNVURO#VWZ#HN_HODY56SY;-_;N_\
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M(U7(WE*B8(I7X5_M-Y_O%?"O]IO/]XKX5_M-Y_O%'57R]![/8&1TF3/))QW
M G-*][L0T8*F& T[&I/T+O\ KMZU-_ Q_P#3L3ZJOVY[*YA?&\;K7M+2FX4.
M!VBAK7.I=9J8Q!/&AP:^>!KY+5Z+HEQ:W;285K#Y_P!9@ON9GNAB<[2YSB)+
MB0;Y<6-!'_>!=(K4^M6A;9IGB<=QSNC>P?V@U_-K5^O&ZN$DL]LPR$7-WA,
M&S @3@ MD#@@ &X *^%?[3>?[Q45C9M#+2&-L;&A4:QC0UK0JE T 8DG8_\
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M"5'-+HY$:6H]"",H<2TXXX$8J+;4>KAEL[6%L;=TH,7'\YSE<X[;B3]T"]Y
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M6)]CU<[$9@LKQNM9@@/Y3R-T-<*&2U;/./QYTD).[E(Z,']%@KHX&-9&-IH
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M#"YSHI8^20 [&-X1#E0M(;RF(L5Y#U,L;7M_1< X?@/U%]_H?_415<?\0?\
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M_JD"^0;7UB?5I]0OW+Q^M7Z.]]!:787[OP6FGI9F,YS@W>W=T4@P ^V/A<2
M]I;Z0E2QW,.=S5CEC/%SL4$.8Y"F@.:Y"""1MJ!$Z8VMR?Q9P&!=Z0$Q^17
MD'1I GAU;(([V2%PB?M->6G(Y0#@"A4 ^0U'8:YNA/KEYBRRA[R&YW<1'%K7
M-#251K4;I;C4-]KO6?M.K6!^:/VFXDS*QS6\21@84<0<3@BC$"IM5:KB=J_5
ML3RT2+D:YN@/Z<MS/48@0@%JC,,S5J+6=[?.NK1[PTK+)/&N)#'MF#7-S '%
MH&CE!R5;ZX@&5DS%+=.5P):]J[>5P(!P4!4%2ZJU5+<7FL;H-##*]TO1!I.9
M[>D):W H7..4;8)1':\GUE++%'QWM9<ROR Z2Z-X:PM"XAN8#2F4+3GWP;_,
MK=X9(0$#@0K7H-!<A! P5I( ! !^5OD\N:]LG1E[$+Y)!R@UQP8QA!5P(/%)
M+@ROYJR\%Z& .? Z:28N:,2,LK0%15Z-^<_BJ4JX_P"'O_?04=1_+ENZ"P !
M%P $>"%),KQD8APZ-HZ3 XN:4K^=S:R?<6\9&?+/+,&@D %\<S0TM)0*T.1<
M4&-,UD]H9=M<8Y6C0'M )+=M'-<UP!T*BE%.M")KBXC$]S%%"^1[XVNZ8B,A
MA) #$P#0"1Q00#5KK/7;[QNK#*'R SM8S* <# V0("4!9T8WQMT?E;Y/+FO;
M)T9>Q"^20<H-<<&,805<"#Q22X,K^:LO!>A@#GP.FDF+FC$C+*T!45>C?G/X
MJE*N/^'O_?0;+-7:L#7:XF9F5V+8F*@<6[;G$'*#@$)<"$!&LI=8R02/;F$;
MKB6)R(HXD3>C:3N$M(T. K_EGYU4DR!G2. #XW.3(2YO%?&Y1QM(!#LQ:$J3
M6^KKPQZFAM$F@Z21H>CW$NR-!C>K7 ',A1@TX 3R_+=_[);LD >WIYHLSBU0
M4B:X'#!3C5O9:WFZ?64;2'R9W/S$N<0<SP'% 0,1M)HV+35D91EQ,YSM\1!J
M [V:0.\K14$[0!<71=*\[95Q:P>0, PT D[I)V(M4?*MJ[HIF*;AH#D*D%I<
MX='"@_&>I<H+"T@T_7;]922]&"]T;+B5Q 0EQZ-S6Q$-"DM:OYH*5(+X-_FE
MLX->0$#VN!+'H, 3E<' 8*U0@*">03W#]6PF,]!TCA$[-;,PR+D +G*3EP*N
MTU!K>1UW%J^61A1D[8&",N!*1=(UQ;E.!+7.<-MU-^5OE9N;6SBUKW@!Q:YZ
M98XP>+F0@N<5#53 @D'6(UDXW*%W1>U2$K^3E+>@\@S9=RIM1Z]:&ZZMVDYD
MR%X:<KPYN ;(QQ"AH ()XHRE:L+$'BR32//^C:UH_>FK.Q:$Z*VC:?*&#,?.
M5/GJ:XF*0QW-NYQQ*!L<))0*2@&T%HD7I) T"&=3O!8@/20-^HF:@@D;JRW;
MT9E>$:T%Q+GO(4!1R&*7N 5 20.AU9%T\UM;!L<9=E+^C8C6YD*$HFC3N4ZZ
MDF=JVV7BL+GVR)@@:QKITQTR:=TH$CU5\TS.N=7/(+BYYD5CB1TL<CN/Q2JM
M<B@(6CBD07&K9YK>9U\QI=&]S'%IBF*$M()!(!144 [50P:KF=:ZO@C#'3F1
M\9E>T8N=*T.E>XHAR#*/QR25,<.N[B2ZM7\8A\CIF2,5'9'OX['#:Y)!0N:6
MG$ZWD>!8"#I<WYF7.OHVO-4EK\NR/M+!F*,>8Q&U>*Z65O'+G)R6KH.5B!QJ
M>RUY.V^U+/D#GYW2F)PE:]IS2-9(,Q;EQS,Q3!V6KDL +_;Y$"HIZ&! J%%W
M4*;E2LB#M56+'%H!+H0$.T\-,TBH..P=&=K*"14+M<W+KRQE*\:1\K'@)G:U
MT@$D;V@A, %*@.&84[YCQ=8BV$S0-+FN:'-&X"Y0-P$U+>:MNS::OC>@RR/A
MC:47(#&#(\@$$EV;2%(XH U=K*X;.V1JL>_]LUP!0ELC@)%!TAZ$!"@!!-QK
MSYW$39HW*QD9:2YI#0QJL+FESWE 0X@#$H :DN]67'L6JVO0%LCH6 C'*',!
ME>4(S'%JD<G0(GZ\F]NU5(Y#F>Z5KMLM;(\"5CP%+<PRG\EP;A%K"T.:VFC:
M]IWG $+N''$;1PV!>7R/B?/).X'$(Q71M_1!#&H<,H0KLR7MTX,MHF.>XG::
MT*3Z-K;J6S^67.M-7,TY79,C3@UTDH!?F<A1L>^C3E+J_FT]ZZZLFEN<]*^=
MC5* /;,T.:"J%S  I'&!2A?,:([MCLDK-IKT56KB6N&+=S%I)+2:UA:ZNDN+
MJ1]U<PQ0O>^1C297!I9&21Q .* @ T\507ZXEUA*96@O="RYD#@F) 8T"$H!
MR6.(.@ DI4^K-:.#M90,#FR( 7L/%5P&&9CD4@#,'!0H),#?F:\;=S2,<8RU
M[W!K00#@YC TG G*,4Q-65_=:USZL9)$]T?M-R5C!!+,A8&%6X92<NTJ4=1_
M+ENZ"P !%P $>"%),KQD8APZ-HZ3 XN:4K^=S:R?<6\9&?+/+,&@D %\<S0T
MM)0*T.1<4&-,UD]H9=M<8Y6C0'M )+=M'-<UP!T*BE%)^5_DY1*V0QE[0TOD
MD'*:PNXK&,0ASMXNS!H4_P P@UDZ:=H7HO:9)#NIDF;T+O(IW M6]R9XM7WL
M<<WM# ][#(T9<CN(Q^5Y#7*T. XPQ ):VXC^6[SV26-C2\]++%F!) "Q-<2A
M7 X#:IUI\PW/M=\9W.#^DDE1A:P!N:4-=@0XHB!5&).Q%_ Q_O):@_N6?JC8
M/RK\E!)6O+'2  N<YO+REW%9&Q""_22"00$4ZUBUB^=\;<QC;/+*Y!B?V<K.
MC<B<D9B=#05QD;>-:S6MN0'AN#7M<N5[0="H0X8@$+@' #6%KJZ2XNI'W5S#
M%"][Y&-)E<&ED9)'$ XH" #3Q5!?KB76$IE:"]T++F0."8D!C0(2@')8X@Z
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M-VNC)4:,4J_&UT,?ZSJ%M.T.@DO;)K@=!:YEN"#O$%-BY;J:>*#79N[HL?*
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M(&C1L,L;OB_M9;<KM..9K><\- \NS=]&HS&)I(_),K%].@[Q3;J>9H'2NO7
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M@D$@%-"@':IT,S6OA>TM<UP!#@0A!!P((P(.!%._EEM;V^=,W11LCS953-D
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MH+2_<G'Z&GZA/M.U]=ALX?:%%(?H:?JM_P"LT_4I]0IV-.RM)],_1796M/\
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MBYS6N/XI+F,XPVP 4T'$$#^9W\MJ^#.UB1ND+E<J8.B8$PQQ\VP+BTM\EHX
MB24Y&D';:#QG#;5K2$&E4!SLDLI'?DMD>#_EQ-'X:]FUM!)!*=&88.33E<%:
MX#=:3]#V75,+I7C%QP#6#=<XH!MH%4H<H)PKI0^S+T!R"1^;':4Q!BC;XR88
M$X4ZQUI"^&Z;M.VQNM(5KFG:<TD%#C3+2RC?+<O*-:T$DG> ]).@#$X5TLCK
M2%_Y#Y'%VA=,<;V;W*TC<0EL>MH3&UW)>"',=O!P4+NM*.&E$V!8ZK9FDTN<
M<&,'Y3W(4&Y@2=#03A45KK%\+Y)6%XZ,N(0%,<S&%5W ?+L^SW&8:MA;GE(P
M*:&M!VBYW^2'$:*N=7:ND=-9PREK7.120!F!3 Y7*U0 '(J!4KV;5,$D\HTY
M1@U=&9Q1K0=UQ%9WR64;OR72/)_R(G#\-&XN[?/:-!)DB.=H VW <9HVU<T!
M#I50*=K'5\MJR!LIC21T@<K0TDHV-X1'#;73A3K9R9VO+=Y04]'FKK[#GR]Q
M2B>P)_3E[FNEUE;N%MA^T80]F.Z6KEQPXP:IT*$/U,[M6R6[! 6!W2N>%SYD
M3*Q_Y)54VM-=?8<^7N*Z^PY\O<5):R$&2-[F%-"M)!10"BC# >3ZB&^AGLA#
M-$R1H+Y5 >T. *0D*AQ0D+MFNOL.?+W%&XNK?/:-TOB(>T;Y XS1MJYH"'2J
M@?4OL=:R/:UL)>UK2 7D$ C,0>2#F08G=0&I]57/60O1?RFG%KAO.:0?/]T7
M:GNG+=V2!JZ70GD^7(06G<;D&G[T=PP%8;8-A;O90K_]8YWW/_\ ;(/U8Z;8
M6O%A'&DD11&S;.^XZ&MVSN $AGRS\N(W6)C0)B8FG3(X[<KRI:N[G(0-#FO>
M27EX))Q)).))H_Q,?^=3]=:R8'V-L\-8PXM?*@=QAH+6 @Y=!+@J@$&357R[
M)T-I"XM=*T N>YI0Y200U@(0%N+D7-E*4)HM8W;GC:?(Z1N[BV0N:=&YO:":
MFU5KN)GMT8&<##2H;-$JEK@5!T@' JU^6I]4W&,D+T7\IIQ:[^TTAWGV8VZC
MN+:77<C&JUKFN?TS^6][%S)&%#<P0Y6#0ZA>B_N'R9E+7O+HSCB#&3D .CB@
M$#014&O',#;J,Q/:=L-F #F>12T^5M3_ #;?-_:O9(0Y,6PQ+F3])S7$Z%#6
MTZ]9=SP1YE;'$]S&-"X AI ?HQ+U7%<"E3ZOUR&NO6'HWN0<I%CF T!VZB E
MKL TI3-07,K+>0RN8YSMHM)!:T;;RA#02 2@6K7Y.U.T/OII6AZ$$M48OF?M
MO(Y+!H"8-;E!L_X8_KG9N?F!$NYVO>#OKT,(.]GXW]KS5!JN _MIY$+CB@Q<
M]QW<K07'=2H=5:DB9[=(#D!QT)GFE1"YQ* # $X!&LRT9I=8W;7G:9(Z-N[@
MV,M:-.YO: *CU5\Q2=-:3.#6RN #F.<4&8@ .824)=BU5S90E,UUJU@987+R
MU[!R62H7<4: UX!(;H!:Y$! $G\;)^[BJ3^(=^N:-Q832P3^T1C-&]S'(<RC
M,T@H=L+0>-97R@KC/*1AN@N((WB"#MU_R[\R9)7S-+8Y"UHSX%8Y&IE=F:N4
MIB>*[,7 T'V035ER"^,?D$$9V>1I((_-<!M+]1K+]*#^J6KZWMK^\C@9<.#6
MMGD:UHW T.  W@*^)7_O$OKT[6FKH#<0%[@YW2Q9B\8N4.D#R[$'$*5!"K1:
MX(X4^'4\!FDC:'.XS&@ E KGN:U3M!5*%!@:DL+QH;=1.RO:'-<CAI&9I<TD
M:"A*' XBA<V-E(8"%#G%D8(.VWI',S#?"T&:VMI(<Q0$A6$C::]I+''>#B4Q
MT$;+;FUD?%<,U; 6N8XM<#ECQ#@01YC7Q*_]XE]>H]5?,4G36DS@ULK@ YCG
M%!F( #F$E"78M5<V4)4>NM6L$=C<.+7L 1K)4)&4: '@$H, 6E," /\ F)EN
M3J=">DSQZ \QDY,_28/!')W]&-?S"WLW^R9<V9SHXU:BY@V1[7$)B" AVEIM
MK91OEN':&L:7./D 4UT_L+\B*G219D_0Z3.N]E7>IUK?120W+=+7M+2/,=H[
M1T':J7^30=-T.7/QXV)GS9>6]JKE=H5$QTBG-U9:2R!CBTNP:T."J,[RUBA,
M0JZ-T4'ZVM9(HW% Y6O8NYG87-!WB5T[AJVUI%RH96N.^W0X?VFD@^6K+7T"
M%LK#$XC;3CQGS@O\P'F^Z%MBD5P3"[?S\G_6!A\W]!,2:TG_ !\U8:/IXTAT
M40-'T #HH@:/I@[M<;16&CZ0_H!>SE5?=S.QWY'':P^Y]O9ZUEZ#5\FKX ]^
M9K,HR,*YG@M&*!2$J5GR3T%S.6N+'ND:\2R##CR,&4D: T96K@<JEU32ZR+S
MK R.Z3/@[.J$$;1!P1 B(  *9^D/ZZ/\3'_G4RY@PE,=R]?SFOE _ T4IT['
M1M/$DMI 1N@97#\+140B'[26SC)WW=)*T?@:-->!_P!=;][3+?7$/0S2-S-&
M=CU"HJL<X#'=(.PV)"-61.!F?H ;^0#^6]$&X%<<!47RM8%I+'!\N70W*$CC
MW-O,1M(S=(H"/!=7M_RR"[]8[&L6?BED)\X,G":UAT>!]K><-TE2?25JP>\D
MO-R"2<2254DU9_PQ_7.SJ^V'%Z1EJTC=)B,A&'YS5\U2/=RF64CAY<\3?ZG&
MC&\G)';QAHW 5<?PD["C33[F;K1';2+^<7Q@[ND.(\]2?QLG[N*I/XAWZYH_
MQ,?^=L6D\)25ES$1Y0]M6LY3I6W@:/(Z.0G\+&[$CM30=,(2W/QXV)F7+RWM
M5<IT*B8[5>!_UUOWM>!_UUOWM>!_UUOWM"QUM%T5T6!V7,QW%)(!5CG#:."K
ML:R_2@_JEJXN]9:UZ&_DE)D9[3;,RN.D97L+AY"2:-YJ+6/M-^)&@,]H@DXI
M53EC8'8;JH-NI-23E(+MJLW!*P$_Y3,PWRUH3&I71A+6Z_;,W 7$YV^9X) V
MFEM3_,5R +F=IE .V.1 SR.)S>23>J?6VM!TL=LCR'8A\TA<6EPT$#*YR?E9
M5PP,MM\O65W%J^)Y:UXM72&3+@7*^-[<I.+<H'%0KBE76I?G2RF8[* 'OA=$
M) Y<0'-#1)&0""P#2" ",9;*3&2&5S#Y6.+3^$;'_MD'ZL>PHP(I]U.G3!MO
M(/TG/C!_ ]U6[M8AIL&,G?('8C*RXE>5&V!E4C;T5/;6-O;,L)&N8,X>Z3*X
M$*2)&MS(53*0#AQJ=\S7$8=?RP"5QVR)".AB!_%:2YF;\XDD% ![0)HA#F7H
MNB9D3<5.D3_2+OT->LC#=8Q0OD8FEKHUZ6-=):[*X-!3'(ZM9_\ EO\ QZFU
M1\O]'9V5K,^/!C'.<YCG-<3G:YH!<I #0=LDDD5=:OUZQCYF(R1  'L>"6.3
M0UX+7:, 6AP0X">PDQ?!,^,^5CBT_P!5:NN9.L:VU=Y3T3F$[6E2?\5^Z-I,
MSELN8B/*'M(_H($K0:0UQC2C10-<4J:5Y2E85H[! W:0G&E&(K,[ 4K31\M)
M6)XM*PUO4@.-([10!.%("5_QWJRBN,<:S J*!I&G&D=7&-$_BUQ3C]WKZW<$
MRW<H'DSN(/D(0C>^Y_\ [9!^K'71W!+M3SD"1NG*= D:-T:'#\9N&)#4_P";
M-1@/DR!TH8A$D:*)FII+0F9.4Q':6G,S](?UT?XF/_.J;Y?G(Z>%SG!OY44F
MGRH\NS;SFU+JVY:1&'$QN.A\9/%<#H.&#DT.!&UL3?,ETTMA=&8X5PS*07O&
M\,H:#H)+OR:FO;1P-O"6QQN&*B/\;?!?F<-XBO'?ZFW[JF7&N)NFFC;E:<C&
M(%5$8UH..Z":Z"!66+"#+*1@T;@W7G\5OG* 4WY9^6&M&L<N)P=T>88R2'\:
M5VEH. "$@-#6ETLKBZ5Q))))))*DDG$DG$DXDT_5,1_^J9!+ BC!X5T?F(+/
MP[BT8Y 6R-)!!P((P((W0:N]<W/$AG>T-)P&2$.+G>3,X@G=:=RKK6(Y,]P]
MXW@YQ('F""M7_P 0/ZC5G_#']<[-A<MQ$4=J7'3B&="2OZ3M.^E075P0VTD6
M)Y.TU^ =Y&O#2=X&HOF2T:7PMC$<R8Y0"2QYWCF+2= 1N[L1:NMFDQEP,CMI
MD8(S.)VL,&[KB ,34.H8B.GN'M<6C:BCQ"^5^4-73E=N5)_&R?NXJD_B'?KF
MC_$Q_P"=L0W&0_R^UD;)(XCBJTYF,W"7. P_)S'0*MM10N5T*RR;SG !@.^&
MYB=YPV)&ZFGZ$3%N?B1O7*N7EL<B9CH15QVJ\=_J;?NJ\=_J;?NJ\=_J;?NJ
M%]K:7I;H,#<V5C>*"2 C&M&V<478UE^E!_5+6L/XEVQ%?6QRW$,C7M.^T@CS
M88C;%:OUC98/,L;ETEL<I:V9JII9I._&:M?E:R1L,;1(]HV@!DB9YAF<GZ)W
M*UA9$_MB(GC?:,[7>@N;Z:NM6F[+613.R PP=62L94Q*586E5/EKQW^IM^ZI
M]S<.S3R/+G'=<XDDX88DD['_ +9!^K'L1:NMVDQ9@9';3(P>,XGR8-"XN( J
M'4$) GF>'N:-J*-44;[TR_H&I/X"^_6N-AK[+C$65NY!CU1C,@_L97+^CL/N
M+WB,=;W$F.'%=GR<\(6[N8;M:S_\M_X]:R_C[C]Z^K^_<"()'Q,:=HE@>7>5
M,[?2:OKJ$K%)=RN:=T%[D/G&-:NLI.M<+9I&^(G/=N8 A/1M_=&RMFZ7W<3?
M3(W'S:?Z"!*0G#8/EKST*&R=@U^-^"LH6@!HH4?+0\M"O-2"AQL=@4-@JJT6
MA<:%"O/0K*[12M*_8$%:/K<VU]P/;VC]A>1AX.UG8 QX\J!KC^E]S_Y)#<YM
M9^PQ1Y.CE'':U@<,QC#,"#CF0[1V#J;7[W#52$QO1S^C.VPAH<XL=I" Y7+@
MA5OM?RS<"35\KLQ9DD9T3E4@9V-5ATM12,6H@!)L-57/2W?3L=EZ.5N S*5>
MQHV]U:CUCJZ0QW<94$>@@@X$$8$' BFV?SA9@/"<8,Z2-< 7-_ZR,[S<Q11F
M. /M-O&)90G%++J0'$?BS?LSOKM*,50NU7J.)UKJYS<KG%.D<W1E :K8VD8$
M-+B1@' *#LMU7JV\Z*W8U%$,^8DC%Y/0XO)Q)(WD0 4Z:X>Z2=Y)<YQU@7.)
MTDG;).)J?^0DC6X:#&GM>)4*/VH+$(553>(-.FC;TMA* )8U14T.:=I[5*;1
M!(.T1_--9QY+XE2'1SM<2@*O$*QO.T<Q<J%5!4_R#Y9B=!JTMR.<0&$L_P"S
M8P+E:=!)Q(P0!5C]I\/G;GT\E1FT8Z%T8[E1W]D[)=Q.S-<E\4.ZC@0?."*9
M<:XFZ::-N5IR7C$"JB,:T''=!-7'\B^$9_V7+Y*#_M./I7E8[%Y\L/(]IA#V
M-7:$BR1..\)<PW@T(=QT4H+9&N((.D$%"#O@TW56O(W76KFC*UP(,C6Z,I#C
MED:!@T$M(&&8M0#VFYC$4I56AEU&F)_%A_9X[VT@VDJ>R^4A%$8R26]&6%VT
M)"#E>]JX*2' (TY5;4__ #$2Z_)4.'(<S\4Q_F)@!I!4.XRT^RUO<]%=&Z>\
M-Z.5W%+(P"K&.&EIP5<-%/G:5B,Q<#CH+B533H\]>P:UN>EM,P=EZ.Z;B%0J
MQC3M[J4'M +@50B^(PWC@?(<#MX5_+?DVT$0 0/<QK&-)&+FQA2]V^]%<%(<
M-+[JZ>Z2XD<7.<XJ23B23]1>MUS/T)F=%DXDCURB3-R&.1,PTHJX;=27]Z[/
M=RN+G.2^"DZ2C0 /, *__GU+['X3I79-/(S'+RN-R4TX[N-7$M\0W5<$SW,<
M=IH:'2_V6G$'\HOW*N-:RJLTA(&XT8,;_98 /-4>M+ CIF8$'DO:>4QPW#Z0
M0'#$"F2?,T#HKMC4XS9"1BN5LL'&+5Q&8-&GBA<9;7Y3LVS3RM+22QP8X$:)
M'R_MGMQY"(4.+5!)<@"G0- \F]L6^I-;W.:/V2*.5G1W Q:QH(S,C&APTM=C
MM%*__GTZS^4+,%Y7$LZ.-<0'._ZQYWG!N! S#0'ZPUC(9+N0J2?P  8  8 #
M "GZAN+C+K8VETP1]'*>-(Z8L&8,+.,'MQS(%Q(0I1U7K)CIM3N<2,J9XR>4
M@) <UVDM)&*D'$@_S$Q-%SB[H^CN47<Z,#H/-R?)0U/JB-T.J 1F+D#I,O)&
M4*&L!"AJDD@*B)6L_P#RW_CU=,^9[;H=9V]Q+&7I,DG1O+ XF!"XD-&#V\70
M'$(IU'\F1ED986=(&=&UC2H/1M*/+S^4X!%S<9VBVU6P$MEE&;>8.,\^9H/G
M05:ZDA(2!AD>!M.>@8-XAK5\CQ]T6WC@MO9QND.YF(+&#RJ2X?H'^@@Q%<H5
MIPHTFW0&WL*2CJP*NHK2G11(T4H*4C<365V!%:5-&AY:0E#6!5U%IVZ55-84
M%*$5IPK,*54-8%30&W06B12JE(3C2@J?L!<--*M*:4"L:1*QI4I#6%8BD&FL
M!6-8\FEVJ5-A0,*T?:WP0!=8PGI(M]P'&9Y'MP&@9LI. HL>"'@H0<""-((V
MB/Z"MU@CGVKFEDK!I<PXX*0,S2 0N^% )JXUK'$(&3R9L@*I@ 23@KG$%SB@
M&8E !LQZQU<\QW494':(VVN&VTC @Z10M=96,L>L&!62L>UW1OVT4-+F.3C,
M)"X8AP#A]@ ) !.DJ@W\%/H!-1_*_P L3F64M;&\ADC$9RI'*]C5,CL$"X.=
MHP7Z^^_G,_0]-T.3B2/7)TN;D,<B9FZ45<%0U>WMJ[-;37<SV%"%:^1SFE"
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M $5@!2U@":%<8+0(T&O-1H[ ( -:!Z*4T-@^2CL&AL8@>BD0)0V"$'HI$";
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M>D<-<MGI'#7+9Z1PURV>D<-<MGI'#7+9Z1PURV>D</V!!2'3]V.,,:1,*QV
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M+9N:>1P &^?Z@-).T,:;>:W#9[TZ%:'$N&*1,. 3\IVC ES5 H11V)]F"#K
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M#YC@"*M)[QD4#&P0R22-:UCG#HQF#GH#QB<25).C%#3=71VC!&3E$CH6%I7
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M<YQ W!F)04'QDM>-!!0CSBNBN;FXDB.TZ1[AN:"2-!V.BM;B>*([3)'-'H!
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M*'3.4J@F(8 @Z%CJJSMUN=E>%8059K<:YEIB3=&*90Q&[-HFHJ*:"*9E55!
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M+O <D43YG-*)EFKI%9LY;+*-W#=PF=%=NNB<R:R*R*A2J)+)*%$IBF !*("
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M!U0&.V;4V# %SOW)M^ (PJABF,8@AQ%0T^8 JLMCG3\S=L%)YU,IL(ZRY!)
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M)1=%0IB%$!V5R'IPRQ5\K55HZ18R;J".^:2D$_<-2/6\?9:S.,HJSUB16:*
MH5O(,VRQB[Q O<'=EIECBOU='VD,95'4QD\[>K9?;NV$')0%4<RDZS?RL8GA
M-O/3-?M<<#U]$*!+/4WBB:ZBAC.B[.=+5KR[#5G.#'';[+#ZJ3\1:8>)8X\B
MXY[+R5G?7^0@F^.6;./BHUPY735ER.$D$#G,F!2B(!0$]8%-+.C*+1'3W%-R
MNTI72T .)U1R4[H*..0BS<L>!]UKT)3N<*H\1=[&5BGS.3BY-FVD(V2CW*+U
MA(,'J)'+-\Q>-CJ-W;-VW4*HDJF8Q%"& Q1$! =GF-\UZGZ?7;W&.'#.:JU=
M@+[DR7KK]J1NHO'6AMBZI7/Q7DB$=$'HT@+9<V\=Q!X3;HZ]XXU'8:LU6E#+
M)M9!&_UV/737;'Y;AG(1,N^CYB(?HCN$S=VW07*4Q3"7A,41_AI7_4VH_FCC
M:"_J:+_,4/X.=K-89I+9=QRZ/D#$YS&224D9I@T50F:<==02%(WN4(=1LD!C
MIHEDB,UE3<"(@+N/D&CE@_8.5V3YB]05:O&3QJJ9!RT=MERD6;N6ZQ#$43.4
M#$, @( (?\A8K*Q(^1L-&F(E[4<FU&.633=SU4D#H.TUHPKIPW8%GH.79-W;
M0ZQBE$"*("<A%U#;9:SK$4..QHQR;:5;*2FQC]641CG"S-FV?O7<DJ@T%],V
M%^V5DI!4J2*2C]VL*:9""4H?<J^7\1V5U5[O4WG26#U'\JT>M50Y4A"S3 X@
MA*P4NU$R+IJJ D53,/N& I@CZ+F'3'<ZME6"9J/:;DNIVBO30T2UN$D22"L6
ME)-(.0FJ?.&:I@^BG*J(+)E)N5*X00=$_B#=!5T@R267224>.BN3MFB:BA2'
M=."LV[MX9! HB<X))*J"4!X2&-N :?HET69/=7R;D(>OT"\3#6CY"IZ;6K%,
MK8\DV%P\O-2JJ;R2R/:!.BHW;)J!T61=\7) B13_ ,/J>_XB\E_-W\XGS*^)
MW_4V_P!MZX\4OG:\8?(:JV;J_J_QF8_^-<CF\_\ )\? IP:DLBTJ3ZZIM^SY
MF*ZU*8Z'(1W6U9M60[%.P,GU?+-&$JPZ?%/TE>2Y01<)<?"HF0X"4-K)DVTX
MK/DME9Z0[IG/C9-K%V:KIN)./EU'D&J_:.6+@DBM%I(.DC&0,*6XQ5?>F34R
M%F6^NP=VW(UHD[/+BF)^C-#/EO\ ,XF/*H)CI14)'$19M$Q$>6V03+O[G\H(
MMFR*KARX530;MT$SK+KKK'!-)%%),#**JJJ& I2E 1,([@[NT:QM\>#3,N67
M+2_93*?A%Q"+*-!1JU$,<$TQ *?#+&Z20>8!99X]X%#)"GN^\G?ZFE/S%?;/
M_P#LJ_WD?>Y?E8I\\C)2,Q=D"0C9*/<K,G\>_95.6<LWS%XV.FX:/&CA,JB2
MJ9BG3.4#%$! !V7TS:M,N94R97]13!61P;>,R7"W7=_'9&J_36[FKPMGN3^2
M=%KESCH]VW(DFX,W3G(]%!),%WBPCMD#*D<^8%RO:$C8]PC$.E$3JO<A6)LN
MDA.]!.<#O(VCQ9'$PZ+NY:G1$VYC%,X((ZT#9[S9F',3VJ3F"T*^&6\C7._K
MU@99KEX9MO"$N$Q*F@RR*L8WZ2FW!(%1;I\8#RR[OXA[,_\ Q"6S\^Q'MA^E
M8,S+7L9O,=Y">6FQ5V[25HB:;;FSY@T:1\VY>5*%L4D-HHRK14\6D=IR%.L'
M'$L@<I#C:\IR4XOEK(> ,)8ZI+.UVE-8R^0,G.QJ&*(2Y6ALDX,Y7),W2:1E
M))(BP*'2%8H*E'\H&GCV@VH/VFV88>!N=FKN8CZ9:SXT+8]N>. E^LF=:L$3
M Y$I.-:NSN,400.R:UF21:LW"?$(K@9-*:]F<ZS7<,/Z7<#XXC;=D"'I#A1L
MZO;U:DU2W3TDNQ6'JZ:GUW62F$&T-)D<1\8S:N'2+95154CI; V(K=E&XTT]
MSG+NW>Y9L,#8I^.?3[&&8O(F,7K55IT2Q@$QA2KIMR,P,#EPNH8YA4[G\GY&
MKT,VZ9,3U#M\-$L^<W;]+DI2OR#%BVZ0[50:H<]TN0O&H<B9=^\Q@ !';+&-
M]3>.?FTNEFU S-WA(;QOHERZ;5W>.<<0+>3ZQQ_:+7%-N9*P+M+DK+IN Y7$
M*8$,0QOXFQ^DNL?V59?O$L9W^1..*[*^#H+UR)E"T6>=J;NL$S;]Z5>E5C@#
MY/<)45-S@G#^7!4BB9RJ)J%*=-0A@.0Y#@!BG(8HB4Q3%'> AW!#[ZI9!B;T
M]PMJ,QO$'A*CDQE%#.14W7V\@YG8RJ7*)1D(B2Z+%SCMPM&R+%VDXBU'SA04
M7A1*@ VO)DQ6-9VF"EG:'L$_)/G64F<+ F29MUG$I:W3*GZ@:J1LR*"0/I$K
M^ CG:?&<JQ#B#G).N?3L,O3;M9HMIBB'BGRY%9_%>5K19XJCV$H2B*2#9Y(4
MR,EUYB)>II FZ C14Z*0J*(IXDSIG;"6.L_YHU$TJ-RM9+%F>IPV2XV(@+UR
M[+482MUNY-YR B5V]=<M5GD@1OUF\>N'',7Y I-TLFYET]XAB,7V[+,+$0%I
M9UM[)MJDUC8I\M(F;U>H'>*0%40E'@H*.D6"*#8QFB0IIICS15U[+YY8(9!Q
M!@G--AN;/"L]SG5&M65+ED/)T%6+A;(,3]6V-K4*S S#=-D\(H@HK)E,8IDR
MJ)J.,9Z1L:X[T\KZI,HML?7);#%$JF,D%JB6HS,E=7*B5.AHINO,V"-B&4*H
ML<H+C&.UR%4+PE#:H8XNLWAG+]^4J,0WR;D7*&D[.V0['8;DM&F\99&!EK3@
MJ2<T^+ZS>+D8(1(L^0V30XC*+I\\V<,$Z"<@RUZT1:@,7/\ (D16WD-D.#C<
M?9#JK&,E7+>)C\AQ,+8!;Q!SR,<DZ<-2BNP>M$%%W!V::A]4N:?:IY+.VPQA
M*:L>*=-.'9FI97N%8E658N4U7(U21C<7T^QBVBXIA$.)B19/3-B/YJ;(83.4
M6ZJ6UDF]']GQUB#5=CP\-:\+2N"]-F8<(KSD]#339VO79E:+Q'1J@;K!BHL=
MM(O5D74>]1;JIN (F=%7$F:+X/,NM[9:=W]L><LZ/6MA86E*$EYWE'*7E=?O
MHP[WA+[P.D;B")=PC@'+>0,!4#.V4,YX<H62;Q<\\5F$RJ\(]NM<C+ 2$KD7
M;V,I UB(KJ#LC)H9DU1>';H@*ZRIS&,.6M-F!V[JKX6RIB.3>KT-)VZ6AH4)
M'&4#F%%DS3=N7)U6L%9XQT2-$X\QFR>G;D'E\7%K1^@@G[L=-.V"M/N2'MA9
MX^R-B:G-[DE6)12%E9B K-'RA=W5<&22*99K'6,]9(Q=F3X5BM5U!2.FJ!%"
MYZ@J=I>P_C>;QUA7(%SHN0J52HB(R1#62B5*9LT$\D;^@DG<[6U4?QY4WC>4
MD':;QN8Q%-X@0Q,B&I[V4E<GX>B-3-$PRJ7BD)0LQ#5%>YX[C695!.HOU98K
M6FU9HB(@FBDDD4 (4I0L%]RIC+"^H74[*Y*O1LOHYLKU8RI;ZRV3E6IJX9M6
MKXSF#1,5+1KA)Z>52;<Q](/'*:CI0R7)0R+A;$^,J3EK315,0R-_GJK#V&<E
M,<XXR8QBZN$@>!=P$RV92D;&V>40:&CG*[Z-:/)-= J1#M44VW\-*_ZFU'\T
M<;07]31?YBA_"6#5EI<K/3[:X25E<S8F@VP ]M2Z)5%GN1:6P3'<[LZJ)0&5
MC$" I)&)TI IWIERNE$%TU$5D5#I+(JD,FJDJF82*)J)G #D4(<! 0$ $!#<
M/^1X"E 3&,(%*4H")C&$=P  !W1$1VJFKC5%7%F%F9*-Y[#&(YUERG5>< 7F
M1N1+U&O$N8UL#<PE7AHU0I58]0"/%@*Z*B1O][._U-*?F*^V?_\ 95_O(^]S
M;]$>2?U-F=CZA\/-W3+4EHYU197RY0IF#!8ECDJ;$5O%\W=(",%FBLX>2\4,
M(UG8HG"=4KR,,@@!3/%.+&F=VIV#>Z'9^)V7H%@($1KN5JRU9HVIJBVXU#LX
MV9!PA+1Z1C'.2-D6X&,8P&'9K3TS^,.AGV>IUE)]0.D'KE^N#28;)S+ GO.0
MZ^<F_P "2/ Q3<EY5*TLNBH4ZQ /[7/_ !(U/]<M1>V2_9[>SLR>RT]8WT_,
MIAKJ'U%D*/C O88E^%?L,3!3;%-W,0R$397 1,>UB18RSN19O'*KQ-DD/*-J
MYI^O^]Z\L/T:4@5\Y8GSDSN"[D:>^E"12[V)0N>0<OOXV+;.'C<',C#246_9
M&5*NH@X9HN0VK.?_ &<5.IU^ROF"HT*S8_B,B347#-:] W1-H-@DS%FWL/7I
M*UT1-V?C8OGC9J99JL.YR=,C)U+9N?>UURB[U%QT,K:&V#J:YOL'A^5L$<B+
M].J,I&&NU<I@%>F*9 A34(&"R_ 10@(F%0F=]5N8H-K9<R:2H')J.16$&P1K
MS;(CVC49.\UB;"/CT#,:X>T,7:;20%NB1JW=MG*Z2"* D1(GK7MOM3<DZ88B
M_6&UH8PQ?A-K<&-43B*C8Y:K.TI>NT/*N+HRN-6EA@%FC8KU*?DW;),'3I=0
MZWY74%7M:>;*!E[(]/@<EGQ/E7&326@[._HC"A+/8"9N<CU14TTKJREQ53)T
M5B"[<&I5%7[]53GA=+?FG*>1\O6UKJ6O\"UM&4+Q9K_8FT&SH&)WK.&0F[7*
M2TDC%-'DBX53;E5!%-5=0Q2@8YA'V9$;B/,.4\61U^SI;XB],,<9!MM(972)
M;67!*#:,MC6LR\8A8XYNA+NR$0>%63(1TL % %#\6D^\X=RCDG&;P=0XFLWS
M<W:Q4U2V0,16'4P>N6$(&2CTIZ%=*M??LW@+-3B/OB"&_;&VL;,WM"LE:4ZS
M;;'5\HUG1WAZ.NS:NP.(W+^)L,#CZ]R]>RIC1NYM,S5D$D)8S^,F%&[ARMQB
M.\[4E']EC[.N;AJ-FF8B6UESEG&709/"8S@'L$E;"Q4<J[93+>!*PIBR<A(O
M.A.)!<\BQ:1PI.3F$\]JCPY[4K*>J*UXQKSN\7S!V5F-XG:O/5R#01F+;%56
M+OV2\H0MC72CT70D(FPK\DJU2$&*R+LZ*08HU(0T:A /[E%O&%RJ[=PJZ2JU
M\K<@Y@K;"-UUR)KK1Q)5D9=DHH **L%T#F]\8=K?D*XR:$+4:)5Y^Y6J9<CN
M;1-;K$4[FYR3<"'N(,(QBJJ?_P""0=LEYLQ]JVNN@+1U4;Y(U'&S#&*UE8VV
M1=1<<9TW9+)4>VT"<O4BVC99F>??/["A$DD'7#'M3=&,@WT'XAU5:A(K5CBN
M-S6I)X/S?(PR\!E4KKKC';"WTW)#1Y+3C^4,W;I1SUB]<R$LZ4%=P51ZH!2(
MH88L^$<MY.PY9934M!0,G8<5WVU8]G)&#6Q=E.05AG\M4I6(?O(I5_'MUS-U
M%#(F603.)>(A1 ^KAGJWRS"8OI^(\ U&[:4 =6=[C')MGE,FQ*#;(<P9+($=
M7D;"T=7%HX.=W7Y-PLK#H"#A,> 4=/65Z1[935/A.H7K&->G:WB6JM\M+5O'
ML.L@9)E5X12(U25*,&-C$40(D"$8R2*7<!4B@&[;4'I,A_:+YRJ6:*+C4MAL
M6L2-0OPY0R!&#3L0RP5N:2:YRC;65@#*U,V?Y>T/4^5$(_DN'@(C=[5G74?>
MM<F77V1W\;B6U9;-9V<K/7.\PS8M7I4D-DR7D2>&GT]M5I&9=E;RJ1U6B:Z:
M!$53@H-?U+9L]JAE33':\CUR/NU*POBEK=(JOP<%/H+3=<BK;$8]R3BBNUQW
MT!PTYB0L9U\B@J)'BIW*2B0YJ]F5[0"8B+EGW$->)>\6YEBVB#%++>.=\6<>
MDF914.QEG2,/-LWK)X+9!^JB1XB_*+QHJHIKGT8Z9LKVYU,Y:>MZ;CN1R+;[
M)9<5Z6ZY!155M-WRG6Z9)K3,% R+.MD>LF2;1FF1>3D4 $JBO*(;5)J]UA>T
M S;K:J\;0(EY&42\DMD)'0%K-8#-HZ*IB-LS#DB#:2-[LT\PB$#-V,<FU3,4
M>$R?Y,K'5KD#VA5UT-XJR ZFY+#.,,#L;BP5+5F\H,6U=/XFF9&Q4^4@7:C-
MP+%Y-S,Q)NB)@N":;==$PU?V:GM <G-=0%9S)47%BTQZCET%B3DFZC64DX"L
M6&6<-22DP>2/!/FJY)=9Y*LI4&X%=N63QN8M4P/HYOL]*SN3\"UZITS$URN\
MY\R$+9+3 7%>5RG)T)[*^)BDO18V)4FNDJ,7"JG0.$470#T96\ZM8'VMF9<G
MY6QC 3>5+EAML_R'%8W5BX"/>R]L0J#.5OLQ1K"6,AVZJ[2*=4N,9.!)P$(B
M<$P-"ZN\S*0U4EJ%!Y"1SG(13=5O 1[O$J3U_8[0T9 =PJT9R=2;MY91L41*
MW4<'23WD(41R)F''.JBT^SZT95.YRE1QVAC,+"VO4Y(1;?IK=)56G6>B6&[/
MV\=(LRSSUQ9&4*B\5!./9J&1<$24I6:=8\#K"T@/J=,/@M>465D#.L'>4G!!
MBXZ+5F)BU31&L@L^%151_8YQB#%JHDF@S6%$Q\E^SV]G9D]EIZQOI^93#74/
MJ+(4?&!>PQ+\*_88F"FV*;N8AD(FRN B8]K$BQEG<BS>.57B;)(>4;5S3]?]
M[UY8?HTI KYRQ/G)G<%W(T]]*$BEWL2A<\@Y??QL6V</&X.9&&DHM^R,J5=1
M!PS1<AMH IF@R784R_\ M)G$,2HY/LB,?QT*'L#JA5QM6V[J682$1"V9Q9\C
M(M)&3,W74A4&"YT2%<*H.$(K*&%?:\6C,^3&IV3V:Q7J+:Y(?8;E2&5;NIR"
M17LEXS,U4:N/RS=NNA7H9SRQ**2[ P@=&-)-K,',R1@S++N(IJX91CB3*W3!
M^M&LG;N0=M&"KL#F12577433$"F4.("8?XIK!_U*J/[TZ'MHW^C!S^N%G_@<
M@4NOVJ2HD];Z3:ZO"7>&*!YBFR]@@G\3&VJ*(*B('DJ\\=D=H!QDWJHE[H>[
MMG.M9TS57LGKY0O<+8ZU7:7)6F5J=62AVLVA+6;I5MAJ_($MV0#RS?K5)-L=
M%,L4VW.%S&,8OWWL_<"X.U.YOTYQ>>E6%!G9+%&1;Y5&"+^YY:K5,:VF6K=0
MMU2;V=Y MY@5$TEG")U"$%(%D@-Q M8L;^W$U(6J[Q)>E5ZOY'^>2/I,F^+[
MTK>PNG6H;*39-@)#"(\R DR[P#\B/NAFGV?&O-C'HZI\&$FG<7<V3"(B!O$3
M4Y&.AK+$S3:#(UKTC/,NLVTG&R46@DUF(98ZPIE%N*[K6AI,Q][1?5!I>I=!
M2ME^KQ*;D'*\[5XIA77.-(0*M#4.$R_C>*A6;I6Y&< J@N!$S(B7DF%03DMN
MHS 7M3<L:IOFTAE[M=L;9@96E^L_J=80>OYX];K^3<AYPK<TJSB!5<.6I5(E
MTX;IFY"BCI)LF>LYVDH&-J]]BK'-8VRI 09G1J^PR!66D1)/'%?!\Y>/T(:<
M@+#'2*""ZRRS0KSD&56%+G*>TW@<N9IRSE.#H.1:@QHL-D?(UPN\32V3F_YV
M9N6=3CK-,R;.N-7#.(:)'39D1(=-JB40$J9 *:8(1A<-0.0TG4+@W%(*F6=3
M<V;@;*VRPLVAP?H4FL++D.X,0"J/W0I,D3$.L99&9U':\=0&=;_G7-133K#"
MENRC>'.-\(5B95&4)$AB\TTG1XR]21URF<H)L"I5]!--BU(@H#L5?O6/TEUC
M^RK+][$Z?\F2@ JF0C'&-CD'!ORR:9=R%'?N5A$I3I)EX8HQC !B@#0OONCD
M-][DG1UGYA>L(FH[>#+#YEO$!)-L?6V4DX=K+NVY&J4<-@A8, >E2CII5!6*
MDS(K*%621Z.HYS8PKVHC"N=;QD'&%]H-(QMB:^5;*[FP6&V5F0K[-&S#2I&>
MCJU5VYY/GOG,DHV(=HDH1 %W IH'REAU[49EGFO*-F?ZK:1CYRU41LHD@Y6C
M/Z_7%8I0O/+8+KC['YU&;,>!<KB5034*14#IAB+!V<\WXXP'F73S28S%EA@,
MRVV&QK%S->H_+K=/G:S9;BY@Z_+JN:XV:I.X\CCK)F\;N.8AR 2<*Y(P!I\O
M$IDVP8MJD;;;%=ZW6Y1[B=VV?R9HI6,@\@I)FB9&48.#(F$1!-H\(L/05W8M
MW96WM<_I<J?[S]1>P6?&41)6"YZ=L@1V7E8"';G>2TQ1TH.;KEX+&-$MRZKR
M"93"$R?@$R@M(Q<I"'4,0-J%;<B:D\.89RRTK$#'Y5HF8L@U;%\E&7IO'I(6
M!6!7NK^O1]KKTA((*.6;N-.N0&RR95RH. 403O> M.]_E<D6?'M,;7B8L\54
MK ACQ[%GEFT*^:PUL?,VR#Q_$O9!H"HG22;. =%Z(LY%)P"&LS%.IYQ(4/3I
MK*FS9-Q?EM]&/G561.>VV>TT<[]>/:/%RQ$23(,U795X0H SDVB*KA)-FITA
M)Q<IC5=B3(Z@-W*L94,&W.MYCNDTZ;E0$L<WAZ-+2C>&<.A<E!-67<1K,1 W
M$L4$SB5[DVH*OUZGD.QZ?;M65Y2*D(.17@+1-1LU$+O8B5;M)*-<+,'J9C(K
M)D4(([A#;0[_ (5,$?NWKNW^Q;_^EK;6C]!!/W8Z:=M*?T1I_N.SOMJK_P -
MV<OW86C:VR$?'*S#]CG_ "Z\91""I$%I5VUI^/EVT<BNH4Z:*KY8A4BG, @4
M3;Q 0VSGDSVF^7LU:3M4UGSU=)Z9I6$L7OJOCZ*@G23)).N1-8KV#LQC'RD7
M/IO^M5)1*/E%GFXRPKJBNX7D,*Z!<Q5>1R?>UV"4Y)9';Y!K66\IO(]NY6CX
MV/?Y9J%%">(P;IK+$B*ZV2:(G%5?HH*G44-_#2O^IM1_-'&T%_4T7^8H?PLS
MD&I*!A#.<B*CQW<ZW%I.ZM<9 =QS*WRG$78(/7[L0,!Y-BLT?"H?FN!><!4A
M?K3&');)53:*&!*\X;(ZR%"N&Y>(3.W$1&-$[I!MDRAO.I(Q;1(HCW#"'=V<
M1\DS=1[]FJ=!VR?-UFCMJNF.XZ+ALN1-9!4@]P2F* A_D:08L&KE\]=*%2;-
M&:"KETX5-_120;HE.JJH;\!2@(CM'F@\,SN.JH\.@9:^9A;/<>5ULS7 #$D&
MK*79^-EA:'(.\IHN-?%'\(@'=VA\AWI5/.N;HX4'K&T6.)2:TVF2) 36*O2:
M:LL_0+*,')=Z,J_4<O"'(55L5D83$^_FD44SJJJQ,BFDDF4QU%%#LUBD33(4
M!,<YS"    (B([9Z:&5(#E='&+A% 1_**(-3W])PJ4ONB1%1XD!A_ *@?S_>
MYM^B/)/ZFS.TR0Y2G(?4AE IBF #%,4U8QT!BF*.\#%, [A ?=VUAX@T[QLD
MEA;7QCA2<T[%BP5.GCB\RMC91<HO5V297)$;'CAE/SD4R;()F770>0+A4P\D
MJ84C'TY'MT,PWXQ<FYN?)F,JJ%VGVC<&E7*LH0IRLZ)7D6L7RR"*!WB#IR3<
M+DV_VN?^)&I_KEJ+V]IS@N\ZIM9&EG*]9RQ9;7&L=+F<4\,OLDUV-ROD)C8Y
M2X@O6;$[MK.$5M,*ZB%DQ*DFA,KJ[S@N0VTU2;_[1_VM%XIMD9'C;%4KAK B
M[-6)Z.5,4RD?-0,UBA[%2C)0Q $R2Z2B8B ;P[FVG_"V+*I;LW6Y_(-\(Z=*
M):[)&-9ZV32JRSYQ.76S1D!&1Q(N'>S3<JQ&;!N9PL[;MDRMR'.X086#(FOG
M3QI%EW*!I!7'^ -*E>SK'QZC_EB2!F+%FVPD<'7A&Z!1,JQ573.[77("SA%-
M!8VLZKVEI'6F#L.=#0-C823)LYB;'$RV/6D?+M'\<<%6:\=+LW"A%4! R9DU
M!*.\H[6>V>RUURY/TOA+O5)XN \FMV^6<"24VIPH&0Y,RVDW$"U%F4I0?/8B
MS2903X.;PB04==..,_4VLUK4/I3AKQC7)+V@\\:9;ADJID&(C)N+;JOY3HDR
M::HDLB^2;+JL5!32<-N4FX!LAD9DBY04=L-5>0>F-B*%%=L#K&>'%6QEDM_&
M0C@A1$AA#A-PF !WE'=[)UL"R0N2Y_NBYF_,)SRH'MNGI,JPI;^8"1E""4#;
MMPB A^#;3!].\[^[^6V@/ZDBOS%#;5;B#(N?=2VF26RK275AQ9?M-65D\07N
MXKJTC%=P95(;2Z@[ ,Q3W52@Y91=B@F C(PB11$.C'(#Z*E?:>>V!DXN39N8
M^2C9#6FB]82#!ZB=L\8OF;G%ZC=VS=MU#)JI*%,10AA*8! 1#9GI^P[.W^Q4
MYG:+%;22F2I>!FK.K)V55LJ^24=UJLU"(*R1Z*0J*:;%,0#>)C',(F'6O'5O
MGC*J::LM. 2;$,HNXCV%1DI";9I)$*8ZIWD*U<) 4H"8W'N#NCMC%C!&:C*5
MO).8X6Y@W,052V5>\R%B:E? 41$CKQ/GHD0 VX>2*8^X(;>S/9](0Z7\_P!;
M'/1>:GTGHW66(TND<CBYO(YOO>/=P\7<W[]L%?XJZ]^Z++^V3_ZETS?O8Q7M
MHL^@BH__ #;C;6C]!!/W8Z:=L$6M@T>.ZY4M1+1"SBUXQ(Q\8J#;VL._> 4J
MA&[<73$[4JYR"0B[I-/?Q*E*:A9)HOM5O;!2%+OU.K5QJ;UEK?04:.:[9(=G
M+PZJ!FN-#M^ 6#M/N$$2E]P/<V8:NCZB]9&?,SQ]/F*.E-ZDLPUO)X*P$PRZ
MO%NZD"8X@;0Y+&M3&!HD:2%L@)Q'E".[=[03Z([_ /VSITVSBI7FKIZ%7LF*
M+7.MF95%%1KL;D:O-I%T=!(>)5K&&D$W:X[A*DB@=4VXJ8F#3+ENF>TK]JE4
M8JR8DJC5]2L9:QF]>Q_1;17&!*S<J13:XVQX])7:S4[7#O&+!B94YVK1!-,Q
MA, B.&]2UUU::^<_Y%P3.$G<?EU#Y\K>4(=BH455#QIQD,7LY]O#.'"G-5;L
MY!H550H"<1#> Z4_HC3_ ''9WVU5_P"&[.7[L+1MKH@JLDNO-.CZHW#=JVWB
MY>-HS%])E)1BW( @99=]%,ET2)EWF4,<"  B( .*X*NNF2TY0;_F&M7QNV41
M%TTLLCD.<NL>6033,*I%UJ9:XHY!4 !,B)=WO0#[GM.<%WG5-K(TLY7K.6++
M:XUCI<SBGAE]DFNQN5\A,;'*7$%ZS8G=M9PBMIA740LF)4DT)E=7><%R&VFJ
M3?\ VC_M:+Q3;(R/&V*I7#6!%V:L3T<J8IE(^:@9K%#V*E&2AB )DETE$Q$
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M.X\]'=OLVX"]3N//1W;[-N O4[CST=V^S;@+U.X\]'=OLVX"]3N//1W;[-N
MO4[CST=V^S;@+U.X\]'=OLVX"]3N//1W;[-N O4[CST=V^S;@+U.X\]'=OLV
MX"]3N//1W;[-N O4[CST=V^S;@+U.X\]'=OLVX"]3N//1W;[-N O4[CST=V^
MS;@+U.X\]'=OLVX"]3N//1W;[-N O4[CST=V^S;@+U.X\]'=OLVX"]3N//1W
M;[-N O4[CST=V^S;@+U.X\]'=A)1,?TFE$%($!)4JI!5PHH%$1*B)8=@S 4B
MB.\"^X _P4AG#%D8:1Q;8'KHZO\ FZJT$TCK _3</Z%:"-3 M&MD9$J8QKD1
M*4W APG,L11/:MTXT;::E>+(Y3CVT+(,$Y2*4DCD.IR&4_&J&!9MP$'<JY;,
MQ'<.\@=S?]W(E,BEF;>4MM%MM8C5Y!19)@@_GH"0BF:SY5LW=N$V:;AV4RID
MTE3@0!$I##N 7^!\S6''=FM[K+=QOJ<CC&6LLS6PA[##U./9-CO+54J7)A))
M+02PJD!F*12F()5#")@+4)/)&,\?Y!DL?3Z%KH,A=Z97+6^I%I:G14;66H.Y
MZ-?KUJ?;J-DS)O&1D'!#)E$#@)0W;:Z+EEFSXNL,7J;RW"7VA(8[FK9+/XB'
MC9_*\JNVMR5EI-2;L)([>]-"D(R5?I"=-8!4 "D%2"UFZ0<[26D[6#!-VC:5
MN,8C)!6\B)QT:2$CE["X@7*$O!S*<"0L<Z=%0DVDE%HD:.6)R_E02QUK8]IS
M28;"BZJ3>RPVG*O PLEOK[D#&G(&74@,0Z?6SI)\1DW;I#).)AJD#A94[50"
M&;NL,X.JF5;)4,E:;3P"^(LL7Q](W.;E.J:\RK4NVR',(J-)B0>VIM&M7KF3
M:@1RC)M$EB)BES$#L,9>T)]I!&S>G%BWCV5AQWIR;]6WC+$"U*@@]IMVRV3$
MV'+FR@YQHERI)PLXG7,B@=5,X$.L+@FN_3;9<GMZI1=364;D_P 5VS!-DG6E
M_H>+)F(4@(%N_>6JJ-4(2X-(<J:+A)LI*(< G*1V8P@H'S*8=]J/CN2P DKU
M.PLN0HN3/FB(JBRY(\2Q,E*8?R3:HQY$P+=(S)JTO#5%!8!206;$_+#9*(QM
M;_*F2,HSY;?F7)\XP*Q5M\V1F=FSBV,6H[DEFE9A4W3HR";IR[<K.7SI=57\
ML"262[C[*C6ACC#V)\MS+V8F<:Y<C':S:IM^EF<PL$PBGF+<UU&XE@"/G3=C
M*+,8F3;,@30,=<3*K&P'FNS:J66H'5K7LZ5"]YNRCFB1L]2J8XLK+I*38XWP
MQ4*M7;FSKS6"D4CJ)('28-7Z[A5<19%X&Q<.8^P?:<5U69Q[DJ2N4TYRM-VZ
M#C'48\J[Z$20BUJC1[RZ6?E=.2F,55%!,$P$0.(^]&+8+&(99E',FBIDA,9,
MRC9LDB<R8G*0PD$Q!W"( .[\ ;4',./\ES.G;5AB K4N.LWUEN]576CHR16F
MXFOV(L1*0<V@6'FW"KB+E&+M-Y$KN5C@FY(<4=AQ5F;VI6+JMB%5(D<ZLN)Z
M^Z'*KF+3,6,$'<A!87PQ:'ZKF"=.%7!%K@;I#HB9%5#B;I*6--/]>N5ZR!$X
MV@SP[6W9'FS3UKEN>_>22HN70)HMV<:R5>F;Q[) A46+!)% O%R^,S^(EF36
M2BI5DZC9..?()N63^/?(*-7K)XV6*=)PU=-E3)J$, E.0P@(;AVO\U[*K6Y0
ML4X=R;,O)F3QMF=D_>IU5/FIC$1C6/DL7YOJES>13595NE,K,H>3*T2214,N
M(G5VPUERUZK([4#K#B,U52X9=RCF9Y9*10VF)H$KIZCC3"M'I-=MT34V43-B
M1P5 &3%O).5UW(F8]QL;&V(<(V;&-6LM.S7%9(DWV5)FU0D&O!L:+>ZPJU8.
M:E2[P_5E3/[0W.4BC9)$42*"*H& I#W+2?C6=HD'D6PQ^'VC*:O,G8(RE)*8
M_N]*LLR9U(P%7LTX0CEC7%R-1)''$ZQTP."91,8NGO -\D:Y+7'$^-8.FV*2
MJ+N3?UE[)QA5077A7DS$0$HY8'$X<!EV390?PD#;4'[0N8M.*W.%\KXU+3:[
M6(V;MRV4&4F%.Q#7A7FH5U1V=4;,.FT!X;B0FW*G*51'@XC'*G?<"YEKY;)C
MO(L,,1.,2J@V?-%47"$A$3D*^X%1CI^NS#-!\P< 4W)=-TS"4Q0$HN\7:#/:
M/XQ+@--^^>5FMYVK8+2E4:NG2KQ.*AX:=PQG^$B4A6=JG=&BG,4U>.1,Y%HF
M=8Q"9#U#ZGM9&4=4F>LF5E"E2:+V2FHW%U?J\=+(R<4@RK\I)OUIN9CUD%#,
MW/+C6<:E(.T$&0F4.Z5U1:^K+:\3OL/9MHMGK%5K<%.6]SDN/?S3_%#IJM8(
M=_18RKM&::=%=@H9M,NS@91'<0P&.*=JQ]>X&.M-*N]>F*I;*W+(](C)VNS[
M!>+F(E^CO*)VK]@Z43/N$#;C;P$!W#M;VOLM-?=9H&%[I..YL,4Y]C5)1E43
MNP*4Q6*;[&.;*G/3)4FJ")Y=&&@W[ELFFFN*G) ZD1K UV:ZKQJ!S!78&=@Z
MOC>@/)6M88@D;A&BE:&[UB9K7(Z:@3R#@%6D8PKU?:$<QS1VL582IMFV%/:(
MQ=KQ.WPIC>BDK$Y5Y"<MZ64G3\N.,E5 5HJ$;T5U4UV?65R:GXEIM _(35-P
M<92$/FO%]><QK.?R1B3(]"@WDRLZ;P[68N%.F:]&.95PQ9R+U"-0>R)#+G1;
MKJE2 PD3.8 *,MI[SE,XUN-DE<J7>Z++XZD;#8*DXK]H@ZK%(QSM6WU"G/U7
M@FA%P<(BR,ARSEW'/O,!;MEGV1FL2O8 JV2)$'<_AC+:<@\I<&DLC)G4;,P&
MA9:K%R90;MZ*<&25KI'\4T<*$*_44(*B\5K!U]:U[-J#S=6ZM-5"F4#'"S^G
MX5JT;9FK<EB,YC8^+I,99&[Y=,AR,4J[$-.D,V[MP5TLFW*T@M9ND'.TEI.U
M@P3=HVE;C&(R05O(B<=&DA(Y>PN(%RA+P<RG D+'.G14)-I)1:)&CEB<OY4$
ML=:V/:<TF&PHNJDWLL-IRKP,+);Z^Y QIR!EU(#$.GULZ2?$9-VZ0R3B8:I
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M->>V^IXZI3M[(5*/.FBXM3F:=LZQ#5H72J3A*/:STY-MFB[HR2I6B"QUA34
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MYJ"R/7HR\9'L\[E')5::5^UVENK-RD376M%M-65D>@*RA4G;V84E'+]ZW.Y
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MD<I?D<_D<''RS\._?PCNW;% ^ C%()@XS%RF!S%+O]\)2#CD@&, >X F#?\
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M+I%4,T>D3*FZ173#@V+89N3U'9%B 7%4:+<LH5UC53)B_;O.C&>8^Q[1+OR
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M!7NK^O1]KKTA((*.6;N-.N0&RR95RH. 403O> M.]_E<D6?'M,;7B8L\54K
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MB&H;50IQL'L:VFXRJO5GB,7%Q$H!"P8R+&,$LG.6.;(NFHBS*;@1*J4JB1E
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M @(#N$!#N@("'= 0':@*G$3J&RO5A,H<>(YA/0[\8XB<=YA$Y@WC_..V6O\
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MSA6Y$XE&#?Q706R\?9[$\=KN%7")SF6X1$$-XF,8=H3Z&].O]K8QV 0$0$!
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MYA'^,5FC24GU7 M+[!V:R*I<SI[N$B&$RFXC8L2E$B;Z1</4D@5.8I4$C'5
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MD3\H2AQ JQ$W<98FI]G:UZ8)5TJI-G;[U%X*Q1,\69%*89(*D<%86<68**F
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M:J:J:I8K*>:KO3'$?0WGC%&Q-?<2"L2+^-(1S'3$[.V&-KY6#6&=E%QRBH&
MRB*9C*@4#$&*A*8]ZQHF.F\C'1LHGW&L].R:S<9V89#PE.M&@2/;MVQS;RJ
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M RLC"3,:N1U'2T0^<QLG'ND_^C<LG[)5%TU7)O[ATSE,'X!V:/+S<[7<W;!
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M(.[!:IV9LT](<CI\W8)1[,R[WHK5%DUZ7)2*[EXYZ,S;)HI\9S<"292AN*4
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MTC$524(/= Q1 0V-$2&8LIOXDY$$CQ;S(-M=1QDVQTU6R9F2\N=L8C=1$AB
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M4Z:A# !B'(8! 0$-X#_D<;U^F5R;M,VY[J,7 QKN4>"F!BE.N=%HDJ9%LEQ
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M\CX _P!JO^[?;"'T:5/^RF_\CE^DO._ZMY(_B\Y=[C*(0]=KS)1](/%S% 1
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M8,H6&PMHVA!>\NROC$JV?JMNK[%!WAK#.>C-VBS_ (7SB4;E*')XBBH'$!0
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M-Z)JW"/4CD)>)IF?_P 953-P"O5X=R'Y00WIO'1.2/$FFX((         &X
M .X   =P  /NR$U-/VD5$1+)S(R<D_73:LF#!FB==T[=N%C%20;MT2"8YC"
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MW;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[88;P-;/T!MVPPW@:V?H#;MAAO
MUL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[88;P-;/T!MVPPW@:V?H#;
MMAAO UL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[88;P-;/T!MVPPW@:
MV?H#;MAAO UL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[88;P-;/T!MV
MPPW@:V?H#;MAAO UL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[88;P-;
M/T!MVPPW@:V?H#;MAAO UL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MGZ V[8
M8;P-;/T!MVPPW@:V?H#;MAAO UL_0&W;##>!K9^@-NV&&\#6S] ;=L,-X&MG
MZ V[88;P-;/T!MVPPW@:V?H#;MAAO UL_0&UIJ-!R/'S]G>RM4<L8UI'6!JN
MJ2.L<<^=*D7?1+1N06[= Q^ZH ^][F\=P;,X>QN_G2IR'+2ZIM+Q;K]BV+N#
M@A[;P.9!+A(4"D3>$?()D#A3(3W=FK"O6(M?MZY2E-2;6*$3.J+B&XR<2<5E
M(Z?*)@,)09K*K F'$HDG[GWC>_PMZKU<9HU6)KPQ\I'23IR9:.>2KD[@%6A@
M2!)0L@  'N@)1V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_'V[6*;X%F_P ?;M8I
MO@6;_'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_ !]NUBF^!9O\?;M8IO@6;_'V
M[6*;X%F_Q]NUBF^!9O\ 'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_'V[6*;X%F
M_P ?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_ !]NUBF^!9O\?;M8
MIO@6;_'V[6*;X%F_Q]NUBF^!9O\ 'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_'
MV[6*;X%F_P ?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_ !]NUBF^
M!9O\?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\ 'V[6*;X%F_Q]NUBF^!9O\?;M
M8IO@6;_'V[6*;X%F_P ?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\?;M8IO@6;_
M !]NUBF^!9O\?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\ 'V[6*;X%F_Q]NUBF
M^!9O\?;M8IO@6;_'V[6*;X%F_P ?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\?;
MM8IO@6;_ !]NUBF^!9O\?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\ 'V[6*;X%
MF_Q]NUBF^!9O\?;M8IO@6;_'V[6*;X%F_P ?;M8IO@6;_'V[6*;X%F_Q]NUB
MF^!9O\?;M8IO@6;_ !]NUBF^!9O\?;M8IO@6;_'V[6*;X%F_Q]NUBF^!9O\
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M[;(;S'?>DVW;9#>8[[TFV[;(;S'?>DVRM C<C,LAS<6E_P!9U(N"5B6$!('
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M>1MV_P#[*O[R-NW_ /95_>1MV_\ [*O[R-NW_P#95_>1MV__ +*O[R-NW_\
M95_>1MV__LJ_O(V[?_V5?WD;=O\ ^RK^\C;M_P#V5?WD;=O_ .RK^\C;M_\
MV5?WD;=O_P"RK^\C;M__ &5?WD;=O_[*O[R-NW_]E7]Y&W;_ /LJ_O(V[?\
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M;"HF558AU$RGCZI/(Y\PPVDE46Z-QROCVKDIZ#IRNFW11D'F-\AY'EXU(3J
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MBN?RMCNSX_9Y#;PBMB<U1&UQB\-(RC2(0G*TNY>%C':Q$3)OVRB*ARJE/Q$
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M 0V1H.2]3.GW'EZ<&;%0I=YS/CBI6U<SQP9FS*C7)^R1\PH9T[(*28%1'C4
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M<$JYLR<VQE/8#9/[WBV$R!;([$]IM"6,,_.Y";DL?,W\?4I)PO,0C9P15:/
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MI(\2I3K)IJ&+D[7;A%8V/;PEIBS%>H9N=*)LRF/<K8ZKMG9R3'D3T4ZB)YO
M7&OJ&;"]8BB]: DHHAPJ"GMD_6;:LI=::E*[3<XRL/DCQ(QTQZ&_I][F(:N+
M^)\=46="<=71K5-/A5BSD6X>)4#G$3#CA?2ZMBG!T/3HMU!9+U:YB@*@@3,^
M18R0D3R*=2JR.,[K L(%G'':LU^J*DJ@2226 [Y >)LC7_9R>T\+2+U9,IQI
MW^*,WTN*KT WD7#EI8I*OO$BU.NU&"L%/M#B =0[?CA8J58R;<I7!#@902_?
M:9?HP;_]GW,_W,T_ZZX6_>G6-M'NH3$$#0K'=(K!NDZL-XS),789BKG86>E0
M3)^LLRK%II\J9XBD0!1,5Z4A3?TB'#N;8!R]9VL4QLN5,*8KR186,"@\:P;.
M<O%%@;/+-89M(/I1^WBF[^44(W(NY<+$1 H'54, G'(GLZW57Q8GA.HXL8W>
M-M#>$MI,IKRSG%U%NRC=]-J7=6I*1P2MG<)@1.$24Z.1,O,$X&4/%:*]'6!)
M75?K$EV#9[)U5BI(#4\>E?Q![$S;SS6"(><L,RE7"DDWK4B\4RCHMPFY7D"B
M!T2QF1?:.>SLH45@!],Q4/+733[8VCJ3J/3UUFG2I5TQS1G&M@X>.ET$V+:4
M6KZ+MP'1RN^8N04\E:Y=-DC4L@QD;A1_E?&;JQLY9W6)=1!,G+8V2*BY:O3B
M"K!X"K5^R*[:.VKM%1%02*)F*&-4- ^C*@9NS?'4IK,ZE[C87;NHX#QY='\W
M)-X[']3"W95HJLI/.JRP2DED5;2LNT(]2*";C@5,7!UVU8XRBY76QF&%:QT?
MIBQ3*-R-'V0@!/KQ%M+-Y[)(QM*K[AZT:JO&SJ=6</72*+8J_,,9)SGS*'LO
ML8&T[Q2#ZQSE;@9B4C\R1509INW3A65:)9ANEN@EXMDS45=O'5"*DDD7FG;I
M$,7:=]HFT<SR>+:M"KA9:<9!H-YB<B(24=74\5J->DDCSV21M$RR:M5Q6*S5
M;O4'AE"-CB<K+43I]]FEB.2TQ3B[B5K+&R6A<^4+!5FCD2G7@W4IF3'LU8NG
M(;@:2+&D*M'0@)T$ER=P$-4F=\2WK2*WA("YSN3J/FAJXBYB@,\>+RC>V2SH
MCN.B9Y2N(]3.56BSV+C7SEN0%.AE*=,5+=(>RVT"5:\82IDL[B#9+U!2'51;
M2LW!GN*S=.<M88I<+.)E=D56AFLO/OD&RJ2JHI ?<&5L2:R]'MPTMY>PG!PL
M]:+@0BRN#+;&RXK(INZO8Y1\]3;N%5F+M5)%G)6!@+1FL<TB"B8I#?,9>R+T
M<0.HBI8OFC0ECSQE>06C\=S[M$K\3]1E4O>*("%CI,L>=:*7?V07TDVW*=7H
MB8I1JVB7VEVF)KI9S_D5 Q\4VZJO7+S%>19(SAX@U@&!5YVZM&IY!9@HV8R+
M&Q33)[(!T4W1E12!;3#[/^OU;%;S#>:L:Q]RM-EF82W.,F,)-VCF111"OS+*
M\1]6:L"FQXRX2N89TH *K[SCQ)\L=-$[B*&R9B%[A>&LE8B*/ V9QG*UY?MS
M:7;TJH1LJ%H<UHL'.V-FV9G D X>I$<"=/GJ%*@HYU(9?]FOB&L:9(YP26FF
M/6$XXR?7*J[4.@V\:CQ69YVQU-5FJ8G2Y*2HS5J@'=5;H@<HACC4AC%*18UJ
M_P <\,M!3/1^NJQ8822>0=EK4MT511 [J(FH]9,BI! CE#EKD "*EVR14*Z]
M2C;!:J%<*W!2*ZAT46$Q.5Z1C(QZLJFBY.DDU>NB*&,":@E N\"F]P<W:)M9
MK>2T]9+;YUL%E4N%G@)%6'"8)7:U3)BA7=S%-)!_6Y*MOZ:95HZ7(,6ND].'
M-1,0#.6MSQ9?J5DNGOCG28VO']J@KE6GBB9$U%$VL[77\E%N#ID6(8P$5$0
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MR1I^Q-=[I/\ SS:@HCKFT6:DPTO-R?54%E>+A8[ILB[44Y+1L@W3XN%-,A0
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M:/;A:O)FHR[*,&:JIV.6Q;/H5<C=9U#D-(ZL)6,3XFV]-,ZK%PDF;<843@'
M.3EM/<=8[;G6UT*P1C[,=V<-'][E')(M5Y%5NO(13*.B:I60L3=%<K-D@#AP
MJ1$7CEV=N@=/4MP<CQQ_XBT.O^+AZQZB^;>I^+?3-_Y?D=:=<<KC[G,YN[N\
M6VKSQMZ+U=XFU+J_I6[A\:/G.H_B?R=_=Z5XT]$Y>[N\7_>W[:4,$Y[?3T$]
M1B[!;:%=H5-J>PTB3@<GY-C:),L&T@F9G(QRU!DBL7#54"E<1[HP$.DL"2Z3
MN]WRQ84]HQI5Q2P(XMDX_),8UU'5O'T,H@U/,2;WA=-'146BY#N'JHW9\BFF
MJLYW(I&7'4;J.QJ21;T_*FB_.TXPCY=--.6A9!E1K?!6.NR8('5;'D:W98EX
MP741.=!51L8Z1C)F*8<+?ZZYI_>G9]LGY4H?MD-4>#J=>[;(V&NXCJ+3+!ZS
MCZ,>B04*W"FAM4=1BS,&(%$"<B,9)]WN)%VRCHFU@ZF\HZQVN49R:E7N8+R:
M?87ZO-UQK+^I-J^XN5\RP[;N*'9JTG)L#*/5&9G"AB*-13,J552/T[98PYKS
MTQXHB%C06(<M5^4IF;JOCR"9*/CPE*E(V21;RA*]#LC-6;=2=?" $2381 E,
M5JEJTU"46O25+6-C6ZTJ[T66?I3#NEWFON*Z\DH0DZW91S:>8+1,RQ?-'A&[
M<RS5XGS$4%@413TC"0Q3 $-E0HB40, &)G?*1#EWAO#B(<H@(?@$-VWLOOHP
MJOZ_9[VTHI.FZ#E(F*F3DJ;A)-9,KEEA;.+QFX*10IB@NT=H$52/_234(4Q1
M P .V1,5V87!:WDRBVW']@,T.";L(2YP$A7)46JA@,5-P#"24X#" @!MP[93
MTW8+T;6CVF.FS$N<\A4_'V>-.#/)3*'6FG"["PSL:G,0&)LEH3<6F>1Z6809
M$(@Z?F*C(O&8LSGR)[4K7)C1A@"2D<<#C+"^$BARK$PBG+&,BAF)B/5=NY>$
M814*V>(BG+\F4?R,@LMT9JU1;E5UHU7%&J(NDK,3BBNI:I9&E<&T;/;F>K*=
M(PDJVI<35LAOXR(B%7U$5(]2DT#&<I,HQ1L7\FX4VG:K8?;1%D8"S0TG7YR/
M-[.73>W*_AYEDO'23,R[2WMW2!73)R<@G24(H7BWE, @ [7+3D.4U<P=7Z@Z
M7;@N"E,+0B"%IO,<XZK0KI;5<A028BV$14%^H*IU#&X2!N*&A])JW0;)'TM8
M2<F3;I)HIF<O<?P;QXX,1,I2BN[=KG55/_244.8QA$PB.VF'VE>'F_1LHZ0L
MGU9E9)%$I]SBE25I8SE+<S0$()G,+ 9$1Z =#C*19*SKE4*<@^]]F)H7P;+N
ME*/J20J6J_-70':O-KV-UH1^Z8Q4RX:IH'2EZQ5V%J679N.2 R:<?O*504C%
MB*Y 1[6)@H"+CX6%BF*14&49$Q31)C'1[-$OO46K)F@1-,H=PI"@&VL_Z%9O
M\]C=L*YQSUI\\>\HVV4RHVL-H^=?-]7ZP1K>6+I6H4G4M,R57:ZTZ%"1+=#>
M@T2%3E\:@F4,8PDS#ITP/\W>1DX&6K)+%\Z&9K;PPDX+491EU1><B6:"'I0L
MT_R@M><3A]X<N\=^L3YP/*#YHYSQ"ZR_Z?R!P1U#U7S_ 'W9ETO@Y?\ ]&X]
MWO>+93G<')X#\WF\/+Y?"/'S.+WO!P[]^_N;MO;W(U<W_FF)5'RF/"H /5P$
M5K69BNC,A$-P\5:1A-_=W@F">_;)OT$:POWG93VA>H^E=!^<9UXU=&YG#XN_
M\9DSP]*Y?_T7QAZOW\7O>+AW[:)_%CHO5O\ P\8ZZ3T/E\KQBZF2\;^/E>]Z
M5XV=-Y^_WW/X^+WV_;V>JU;,0N7DLQY 4H!FX;Y8J!/FP,[,U H"<2!9PA=W
M<_Z3AW?AVTLZY\?H&3O^C_/];D#OVYUVBS:N6N4AY6-?N7S98ARI1N1:7"MT
M0X#'(,HH8AB;SE4]FIAFHG+-X6PAAJ,U_7]J<$W+)1:WL8*S8R9S;<BAVK\S
M4[>LAN$#-Q;610!%0#F('M1<(7-1*$PMD_%<WKYQZCQ)M(QLSJK*9N=ZBH%+
MB1;QI>CV";:@F5$Z8-ZNF!3$!,I5-1.MC(#8HY$UG9_MMK6D3$74.ZJM3EYH
MO.0=.S&7Y3C(UELA3  B!R-TA,8Q@ "6.=C?;FZO*['34]+RS"OL6>9A903*
M1D'#QK#LQ0U>,4!:QB"Q4$^!%$G 0-Q"![T(G$.2<TVO41=Z3DG&;"?S/>"2
MZ=JO;E[?IZ7;R$P2>M=XERKL6,BDR)SY5X;E-B[C%+N(71F<ABG(?2EIW,0Y
M1 Q3%-B&GB4Q3!O Q3 .\!#W=LW?X>XG_L^XBV]H)]$=_P#[9TZ;:UU[0=F2
M%'2KGQ!QTTQ")*.7>,+,TC&Z)CF(/3W,HNBFU @@H+DR8$'CX=J>>3*X!DXR
M]EU:NBN0Q4S0Y9ULW7,S,8A04;^,"#X!,43!S0.&_> @'_*V@47.-JRM58C'
M%HD;9!N,4SE1@Y%U(R44,.NC*K6^C7ELNR(V'B(5%%!0%.Z)Q#WNS-@B8YD6
M35NT2,J)3*&3;)$1(902%(43B4@;Q  #?^ /N47VBDG:\LH9LQ_ DKT-5V,[
M3TL6.61*=9Z2"LG".*(ZMJSKJJUN%.)*;1)T@B9N'@ R9]KAK0PC=,T8HMV0
MU90]^Q)3K#1F^![<E.@1S-,Y2F26.9.P(,Y"P)EE@(TF6W1)$.)J*"(BB.8]
M>]7M>67^8,W0,]7K76YZ=I[K&L>RL4A3Y%ZK7H>/HD7:&CI)>DM 2,YF'9"D
M45 Q3"8@I[.]>F*KMFO".79MPJYNM4Q78J)$XDR">3(F6V)W&FSV-[([?-[R
MJ@DYE4V[]J1622)() C(!TH=IK(5]QU.8\RC8U3.;!DO"\^E2K#//E%R+KRL
MY#OXNQ4.:G'1@,"\@[AEGS@%!%58X@021&26]<R/FZUUN2),U=;/-J@K/#5^
M6;F:'8R#>JU"H4.K2[B,6;&4;=:,WY45EA5 .8FW.C9\?WROQ=KI5T@92L6N
MLS34CR)G8";9K1\K%2#53WJS5ZS7.0P=P=P[P$!W#MX\&3SZK6.L2O?F<4RH
MS#&_1@;E0&(ZT2J*>7NKC*%%83>-72^880!8$]Q K.L'&L?9*#<*CAEM@N"Q
MK5%:G$8:94YDT,P:NDJNA4/&!*>28\"7-3ER-S@D4QT#*"<Y\PZ^JU:\L/LP
MYMKDQ6+56YV<J#G&D>PFG-+=.EJ_#L*+&6AH\34HK0$S.9EV0"J+;R&$Q!3R
M3?M/[$OC-*S]8HEJM(Q#.=-0,?7 [^.L=J2C9)L^C%%7*X-8<JKA!4C;K;G%
M JB9#EQ_-3.2L(3=B&N1"%HF<V:M[UA#(\E9!C&;N8<6#'3C,&-HV%<%=NS)
MB6,BDHPIB&(@=7@,<=.R7L@[!<)?$5+J5@L>IZ7C9VW67%-=K#AI-LI>OQMG
MMYUIZPPTVV>1C,@.G,DT"<79G;K"L@J+>&C]1./#RM@JZ#AM4<B5:5=5;(57
M:NE!5<,6$^Q Z4E$*JG,IU?)MW\>18XK%0*MN4!G:9]IFW.)8]ZQD&=9S%D"
M!7JA7,?TDZ17D7C6CXU5FF2SE9)1=H_6=-''1B)J)&0.X26Q=AW)\ID+'%'P
M_-$F*3&X0>TBGIL$V]=/5F,$5G8:%<HAK7HR(,5-LU:-6H(@F0I3 0O!LS8(
MF.9%DU;M$C*B4RADVR1$2&4$A2%$XE(&\0  W_@#;4/(VQC$3<EEJJ/\#T6M
M3*::R$Y;\HQDC#E7204 2JKU&N)R,^ =P?\ 1.XI@.)1VPY19:-289%R P-F
M7*Q@2!-UXY9!:LW[:)?;R@<'=1J"$7#*AO,7G1YS%'<?^-Y1K$"UZ=.6/'5V
M@89CSVS7IDK+UF3CXYKTEXLW9M^D/'!"<:JA$R;]YC%* B&6,;ZF\<_-I=+-
MJ!F;O"0WC?1+ETVKN\<XX@6\GUCC^T6N*;<R5@7:7)673<!RN(4P(8AC;:8M
M9M=QGUAIKQYB8U9N&2/'/'[3J>;&B9PA@9>)[ZUMK[(?Z2N$<GS&L6NC_G'%
MQ\*:IB82]H'H#L-<B-46$(8D-)5.?DHV$"\QL$M,/:VK OYY(*DXF7#:P2$-
M),YI=FPD(MRD0SE$$#%6MF,-9#O"^BS#*M9L+&QTW LBQ?92SL]&%6ZDJ,K8
MXW)N782L8_GY10J,VHE,1RJ[0IVQF*Z"YCIS^BO6MC0]6=W^:RY&W.G(6NH6
M)XE6;F_34B9>-LE'G+3!-)=L)"NV:J;@ZS1TBF<Q ,4 VF,)Z-(_!&M;34I-
M3,MCV-R9)PE;E*(G,NTGSU5:*L65,.R]?>OW21SJQ[">G87GN%72::3APL(4
M/7?[6"TT<DMB#JJ1PMIEQZZ:2=9J$[&K-Y^%6EEH=_+UQA%UBQJB\.BA)3CZ
M8DVR0NGPLFR2+GV;6:<*XP\=,9X"R+4IW+5E\=<>5WQ3BHS,U#M;YUU-;+;!
M3\[R("%<N.",:O%#<K@*45#$(;;)VKGV2-BH$]5\WO5YW+.EO)#^-C(F3G'$
MD^GEF$4$^^K];?U<)N1=N8]0DY7Y6#!ZHS;+*,U5=U2BLR6C!?L[<905ABY2
MU2.'5H"V7BPMJ^_:RS<T6RCLB9J5E>M7+@K=:/=6&#BW+5HJ5XDJF8$'M:U
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M7#E*M7<C#QSA!-4KU)X@/0W6+-<.B+*$=B+6QAADQC6TG85BL:]D:#B$Y$C
MCYXA#2\:QM#=A+/(\Y7D>O%3,:[Z ^Y+9,I@'%:^&M)>G85DB1SC4(C/4Q])
MF3*8L0O) QC\NYJ*S5>I/#2)CMJ6DJD#801(DIP-U,O:6[)D^9U3:CYW3%ES
M':%\GAAJM(Y"NMKK%E9UR*4?SLJV8H),S2;:,3DI=^"SHB .GBQ#J*<.3]&5
MJQ;U7J4L5-SC%0^-_'?'3[IC^X7N8F:XAXX1UN>4)OUC&NDU.)64(1'BX51(
M<!*&%<'9ZI_B)E&I2F5'-AJ_C!5[1U>C9,L72RPI^NJ9-V*NN^FPDLW7W(.U
M13YG H!5"F*'L]-3.,,9>,V$<&_-_P#.E=O'3'L+XK]298L5FE/^K=AMD3;I
MOHL(_27_ -','?'Q\!.)0!*&U$UF:"=5[JC9*HE-9T=?"E]DSQN.9"";R+V1
M?EAB-H:7K4R2QN7I3R,?8H]<%ED4UDY!+H[1N@YPE,8;TQ:98^PQI*].Z@8*
MW5!*S$CG!48>6?)+5_-.9GT*_E&;E5V=S#U5J\:\!C,C-5@1)LWP97Y4]TLM
MFD'=JRY?5VIXU2Z7"4CFL6Z&/8E<+K0];AXMFDSCVH+&,1,AECF%PNL<V<-.
M^C*EX(R!@_*ER5GZYGB]V"BG5J!R-%X>+MC:N2UXKME86M:OLF*<FR=UNRQ)
M'2).C$5)S55,.>TBT;FQ-E+4:3#E)H>H'&SF8C(*I62[0U69TRW/ZVC?I:A1
MS[&=MBTTU0:'E(J7C5F0*(***J$%+,$7K L&)\$,VE"FI'&>D#3W)1;)3+^5
MX#HTO2DLQY F+GD&!:5-&78)JLF"5H58K2G)</"LBM$E1I>BZM8PZRU+Q..L
M$P4AC7QUQXSZ/*TW*M1LED:^.+^VM:"KU;"Q:ZW&25,FMP<"1CJ&*4<':.Z3
MBWKK4;3Z;IXBK'CKQWQU&]7/Z*O'GM2'C=+6YA17?594##Q(2:I%]WY$5-X;
M:5L3Y'AO%V_XWT_8FI%T@.L8J7ZFM%9I,-$3<9UK!/I2%D>A2+11/G-'*[=3
MAXDU#E$##_QL?-E_]6/YL/%WYS/'3'ORQ\P?B5T/Q,\;/G!\IO\ -N9U3RO_
M (SBY7Y3[[ %3TP8R^<ZP4G)]AL5GC_'3'M+ZLAWU4/&M7G2LA6RILGO->CP
M<MNHJJ7W1*!>[M#M').6X:Q<>V73XB'Y:R#1%)4G&F8Q#<)RB&\HB _@'[F4
M=6/LDK!CVU4[-L@>:R=I3R6\CXJ*<RCB5//.(Z*/8)>N5N2K9)MR\78.$IRN
M3$(W>J,&RJS914YJ5CK7^7#VCO3!6+2SL=SHF'Y>%G)V_*Q M3-7#1I!Y'S#
MTZ240?.$60RLZVC8Y<AGAX]PJBU(KB?&GLTLRU[3;9< +UH]5J<K#-7U?OU0
MI%>&$@<<2<_*,K E&L@23(H<'K!ZUE'!$R/#I$$ZX3>E',6(]+FGG%5S8(5O
M(N9X.R5M5_<*RV?QS:4;+MH#+^6YUN6R-TS.U46%<A><B51N91J10$#._9Z5
M^S/_ !:>Z?;_ (8=7I9F4CY:?R7#60+5?$X@'2J;<SJXVMY*),!7532*8J J
M*%*)C1>C;%U#TR06$J]DQ>R1NH&X6&IV=!M!2MB83-GB(6/C[BI<UJO8557:
MAR/Z2$TESURH.FP@V$B8K$(FL)""J1)0RJ9%!*'&1-4Z2)E2%-O #"0@F#N\
M(>YM<Z'I9S@WT]9HD%8=]6,BNH@\FW2ZHDD)-Q7W#E!-T\K[.Q@V*U<2+=J^
M6;MSJ 5LMQB7:4TZ36'M+D PLD'*4Z<U3LK'06$^M&RD8\3?S8,HG+$BG&.W
MC=R+(BL?CQ%=!42*)I)" N MVA&[V'QV#,D+D)3-=NAVZC!J_M^2X)M7I"2J
M#9^"B[)"IPL5&MHU98H*K+1I'1TTCJBBG*Z7=.>.]-FHG :MFD96EY%OEF@T
M(*BI624=&DG\=#O<KXMR+$&7/PRDC&FC; S0=+*=#,X.=;F:%=8F9;Z;4Y9H
M^<D[!J<O458:A5\>X218 _2JN/\ %%*L$G5[)(4*+:S"O*/&1)W#MZ9RZ<-T
M%%_?Z?M:,%C#IVFBD8Z)!6C)7CKCQMU9*ABK+-;%KXG/+:WOSW_35F8H\;>*
M53_+\?%RR*&)ES,&9Y!_&XPI%)F']O6B4C+S3I@]1"(0AX)$JS;FS\_(2*+%
M@4RJ)!>.$P.HF7><K.[:%=4F,-/>FG,4W)Y*Q=CS4$M!6Z]JTV=.0:I;Y*)2
MT^9HJE9>VRMI-'*R<:^:=)-N65;)"8H;:>(K7O>,'ZG\&9_R9!XZ/-8]@*O&
MR409X]BFDP%55JN.,-6%O9(QK-$=IIR<-(,'W1CMR*)&."Q<8:Y-#^2XO#>M
M7#;5I'M'LXN9E6L@P,461+'(.GH14XS961G'RSR.,5^Q=1DU&.@8OQ2;IE.
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M:S:U8<URMPD\BXK<9!2@ZW..:+1(56EORU+ ^5& RK5A"MWQA4?(+<E\GO0
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-CE Y3B50O_=J_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>kprx-20221231_g8.jpg
<TEXT>
begin 644 kprx-20221231_g8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M6 4H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_B<?\)K]K^S_ &>RGNO]5]BCW[O)V??&-V><8/XP5]3?\$5?^4F?PT_[C/\
MZ9KZOH\XX+X:PN48BM2H6E&$VGS3T:BVGK*V_<\C+^(LXKX^E3G5O&4HI^['
M9M)]#]\J**^5?V#OVR]<\6_L?^+/VBOVJ_B-:+;>&O&&KVUUJ\UG#;I#9V[H
M(DV0HH=LMM4 %W9@!DD"OP8_3SZJHKY]_8P^(W[37[1>J:M^TE\2WD\+?#[6
MXPGPY\ 2Z= +N2SSE=3O)BID624<I$K! K9PPVL<G]@O]ISX@?%;1_C=XB^.
M/C*":P\!_%S7-)TZZ>SAMTL=*M%1E5C$B[PBEB7;+'N30!],45\7?#'XF?\
M!0#_ (*$V-S\8/@3\7M)^"7PPFO9H/"-W<>$(=:UC6X8G:-KF6.X810QLRD
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M#;WD]NAR()RN)H@>X24.F>^VNZH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU'7M1AU;P'IVHV>G:? 8_L]PEY%Y;F3*ELJ.1M(YZYKTB@#XG^*FI:C\-O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>,_!&C>%O#5AXXT1]*U+Q=>6C(SZS)9/^\C1$C,4;R %XY5QR'50#]'****
M/+_BMX4_:SU?Q<]Y\'_BOX7TC13 @2RU;0GN)A(!\[%P1P3T%<#?^,OVN/A)
M\6? 7AWXJ_%+PUK&F>+/$!L'M])\.&)P!&7)+L_R\#J :^CJ\+_:P_Y+9\#_
M /L>Y?\ TF:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KPO]K#_DMGP/_P"Q[E_])FKW2O"_
MVL/^2V? _P#['N7_ -)FH ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+_:P_Y+9\#_\ L>Y?
M_29J]TKPO]K#_DMGP/\ ^Q[E_P#29J /=**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXM^/O_  ;\_P#!*C]I
M/XP>(_C]\8_@+K%]XE\4:B^H:[?V_P 1M<M(YIV W.(H;Q(XP<9PJ@>PKYH_
MX-[OV*/V<[3]K#X[?\%"/V4O!E_X=^$<U[-\.O@U:7'B&^U!=9L;2>)M3UKS
M+R:5G2>[MXUA(("I%(I7.20#]::*** "O"_VL/\ DMGP/_['N7_TF:NX^(/[
M3WP ^%7B-O"7Q$^*FEZ1J20I*UG=R,'"-RK< \&O$_C7^T3\$?BY\=_@Q8?#
M7XD:;K$UGXX9KF.S=B8P\!12<@=6(% 'U11110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[6'_);/@?\ ]CW+_P"D
MS5[I7A?[6'_);/@?_P!CW+_Z3-0![I1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445'>WEOI]G+?WDFR*")I
M)7P3M51DG Y/ H2;8;$E%>-_\/ /V1O^BM?^4&__ /C%'_#P#]D;_HK7_E!O
M_P#XQ7H?V3FG_/B?_@,O\CD^OX'_ )^Q_P# E_F>R45XW_P\ _9&_P"BM?\
ME!O_ /XQ1_P\ _9&_P"BM?\ E!O_ /XQ1_9.:?\ /B?_ (#+_(/K^!_Y^Q_\
M"7^9[)17C?\ P\ _9&_Z*U_Y0;__ .,4?\/ /V1O^BM?^4&__P#C%']DYI_S
MXG_X#+_(/K^!_P"?L?\ P)?YGLE%>-_\/ /V1O\ HK7_ )0;_P#^,4?\/ /V
M1O\ HK7_ )0;_P#^,4?V3FG_ #XG_P" R_R#Z_@?^?L?_ E_F>R45XW_ ,/
M/V1O^BM?^4&__P#C%'_#P#]D;_HK7_E!O_\ XQ1_9.:?\^)_^ R_R#Z_@?\
MG['_ ,"7^9[)17C?_#P#]D;_ **U_P"4&_\ _C%'_#P#]D;_ **U_P"4&_\
M_C%']DYI_P ^)_\ @,O\@^OX'_G['_P)?YGLE%>-_P##P#]D;_HK7_E!O_\
MXQ4ME^WK^R?J%Y%I]G\5M\T\JQQ)_85^-S,< 9,&!R:7]E9HO^7$_P#P&7^0
M?7\"_P#E['_P)?YGK]%%%<!UA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[6'_ "6SX'_]
MCW+_ .DS5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,O^10U7_L&S
M_P#HMJTJS?&7_(H:K_V#9_\ T6U73_B+U)G\#/R!HHHK]Y/RD**** "BBB@
MHHHH **** "BBB@ K3\&?\CAI/\ V$X/_1BUF5I^#/\ D<-)_P"PG!_Z,6IJ
M? _0J'QH_7VBBBOP4_5@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \S_ &P_VM?@S^PU^SAXI_:A^/GB#^S_
M  WX6T\W$XCP9[R8G;#:0*2-\TLA6-%R 689( )$7[&?QN^+?[1_[.7AOXX?
M&G]GR?X7:OXEM/ML/@J^US[?=V-HYS ;EO(A$4SIAVAVDQ[@K'<&5?S3_:FT
M?]M7_@KY_P %:M<^&'[/*^ +/X3?LA:Q:;A\3K2[O-*U7QI-!Y@NGL;22-KU
M[52R1H\B1QE"[;Q,8F^K/V ?V]_VI?%_[8'Q#_X)M_\ !0#X?^#M-^*W@?PQ
M:^*M#\3_  Z>Y&B^*?#\\JP?:HX;IFFMY8YGCC=68@LS;0 @+ 'VC1110 5X
M7^UA_P EL^!__8]R_P#I,U=)\5O"G[6>K^+GO/@_\5_"^D:*8$"66K:$]Q,)
M /G8N".">@KQ7XI^&OVF]&^/?P;D^-'Q+\.:S;OXW(LH](T9K9HV$)+EB2<@
MID#T/- 'UU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5F^,O^10U7_L&S_\ HMJTJS?&7_(H:K_V#9__ $6U
M73_B+U)G\#/R!HHHK]Y/RD**** "BBB@ HHHH **** "BBB@ K3\&?\ (X:3
M_P!A.#_T8M9E:?@S_D<-)_["<'_HQ:FI\#]"H?&C]?:***_!3]6"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#X'\>_LB_P#!0[]C']L_XG_M7?\ !.3P_P##KQ_X3^-L]EJ7COX9>/M=N-(N
M--URV@\C[?87D44J-',GS2QR@'?C;Q]WK?\ @G_^PM^TWX8_:L^(/_!2']OS
MQ;X3NOBUX\\.6GAC1O"W@$SOH_A+P[;RB86<<]P%DN9I9@DLKE0H=3MR&P/L
MNB@ HHHH *\+_:P_Y+9\#_\ L>Y?_29J]TKPO]K#_DMGP/\ ^Q[E_P#29J /
M=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LWQE_R*&J_P#8-G_]%M6E6;XR_P"10U7_ +!L_P#Z+:KI_P 1
M>I,_@9^0-%%%?O)^4A1110 4444 %%%% !1110 4444 %:?@S_D<-)_["<'_
M *,6LRM/P9_R.&D_]A.#_P!&+4U/@?H5#XT?K[1117X*?JP4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^>?VT/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW>@:;X!\!^*;<6^L1:/I%D;9;[4( 28)K@[&$3'='M<<J49@#[[HHHH \O\
MBM\>?B5\/O%S^'/"_P"S+XH\4VBP)(-6TF>%869ARF'.<CO7BOQ3^-/Q ^(W
MQ[^#=IXK_9Z\1^$H[;QN6BGU>:)EN"T)4A=A/*@[CGL*^NJ\+_:P_P"2V? _
M_L>Y?_29J /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LWQE_R*&J_]@V?_P!%M6E6;XR_Y%#5?^P;/_Z+
M:KI_Q%ZDS^!GY T445^\GY2%%%% !1110 4444 %%%% !1110 5I^#/^1PTG
M_L)P?^C%K,K3\&?\CAI/_83@_P#1BU-3X'Z%0^-'Z^T445^"GZL%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%K,K3\&?\CAI/_83@_\ 1BU-3X'Z%0^-'Z^T445^"GZL%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KPO]K#_DMGP/_P"Q[E_])FKW2O"_VL/^2V? _P#[
M'N7_ -)FH ]THHHH **** "BBB@ HHHH **** "BO*_VEOVV/V8_V/WT:/\
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M\^_Z!*O_ (+E_D']JY7_ ,_X?^!1_P SZFHKY9_X?5?\$S/^CE?_ "S=9_\
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MC;SC(SZE7G5\/7PM5TJT'&2W333775/7;4ZZ56E7@ITY*47U3NOO05F^,O\
MD4-5_P"P;/\ ^BVK2K-\9?\ (H:K_P!@V?\ ]%M44_XB]2I_ S\@:***_>3\
MI"BBB@ HHHH **** "BBB@ HHHH *T_!G_(X:3_V$X/_ $8M9E:?@S_D<-)_
M["<'_HQ:FI\#]"H?&C]?:***_!3]6"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !6GX,_P"1PTG_ +"<'_HQ:S*T_!G_ ".&D_\
M83@_]&+4U/@?H5#XT?K[1117X*?JP4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?$/[27B#_@JG^U)^VYX@_9
M9_9+\>3?L^_"[P#X=L+S7?C1JOPWBUFY\5ZG>(9%L=)2^ M7AAC&V:5=SQRC
M:<94&#_@FC^U-^V1#^V7\:_^":O[;WQ'T3XC^(OA5I>C:[X=^*>A>'8]);6M
M,U&-F$=[9PDPV]Q&P4 1X##=UVAF^C?&7C?X?_M5^'/B3^SG\!?VIV\/^,O#
M,D.E>)M7\%75K/JOA2[E431[HYDD1'9%8#>A&-^,,IQ\2_\ !)G1/%/[%O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "U&OU&K\N?^#:C_ (\?C+_UV\/_ ,M1K]1J_G7CK_DJL1_VY_Z1$_6N&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\+_:P_Y+9\#_\ L>Y?_29J]TKPO]K#_DMGP/\ ^Q[E_P#2
M9J /=**** "BBB@ HHHH **** "BBB@#\KO^#E?_ (_?@S_UR\0?STVORXK]
M1_\ @Y7_ ./WX,_]<O$'\]-K\N*_HO@7_DE</_V__P"ER/R3B;_D>5?^W?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_I$3]:X9_P"1'2_[>_\ 2F%9OC+_ )%#5?\ L&S_ /HMJTJS?&7_ "*&J_\
M8-G_ /1;5\I3_B+U/<G\#/R!HHHK]Y/RD**** "BBB@ HHHH **** "BBB@
MK3\&?\CAI/\ V$X/_1BUF5I^#/\ D<-)_P"PG!_Z,6IJ? _0J'QH_7VBBBOP
M4_5@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[6'_
M "6SX'_]CW+_ .DS5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 4444 %%%%
M!1110 4444 ?E=_P<K_\?OP9_P"N7B#^>FU^7%?J/_P<K_\ '[\&?^N7B#^>
MFU^7%?T7P+_R2N'_ .W_ /TN1^2<3?\ (\J_]N_^DH****^M/""BBB@ HHHH
M **** "BBB@ HHHH _5+_@VH_P"/'XR_]=O#_P#+4:_4:ORY_P"#:C_CQ^,O
M_7;P_P#RU&OU&K^=>.O^2JQ'_;G_ *1$_6N&?^1'2_[>_P#2F%9OC+_D4-5_
M[!L__HMJTJS?&7_(H:K_ -@V?_T6U?*4_P"(O4]R?P,_(&BBBOWD_*0HHHH
M**** "BBB@ HHHH **** "M/P9_R.&D_]A.#_P!&+696GX,_Y'#2?^PG!_Z,
M6IJ? _0J'QH_7VBBBOP4_5@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^2V? __ +'N7_TF:NX^(/[3WP ^%7B-O"7Q$^*FEZ1J20I*UG=R,'"-RK<
M\&O$_C7^T3\$?BY\=_@Q8?#7XD:;K$UGXX9KF.S=B8P\!12<@=6(% 'U1111
M0 4444 %%%% !1110 4444 ?E=_P<K_\?OP9_P"N7B#^>FU^7%?J/_P<K_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_X*8^/? WA?]@[
MXU:)XF\::3IU[?\ P=\3+8VE]J,4,MP3I=RH$:.P+DL0. >3BO./^"$/CCP5
MK?\ P2?^ 'A;1O%^EW>IV'PKTW[=IUKJ$<D]OA #YD:L63!('(')KV?]HO\
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MAG_D1TO^WO\ TIA6;XR_Y%#5?^P;/_Z+:M*LWQE_R*&J_P#8-G_]%M7RE/\
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M:N)P]!VJ34?5I?F>R45XW_P\ _9&_P"BM?\ E!O_ /XQ1_P\ _9&_P"BM?\
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M9?\ (H:K_P!@V?\ ]%M7RE/^(O4]R?P,_(&BBBOWD_*0HHHH **** "BBB@
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M9&_Z*U_Y0;__ .,5^:=%'^I>5_SS^^/_ ,B'^LN._EC]S_S/TL_X> ?LC?\
M16O_ "@W_P#\8H_X> ?LC?\ 16O_ "@W_P#\8K\TZ*/]2\K_ )Y_?'_Y$/\
M67'?RQ^Y_P"9^EG_  \ _9&_Z*U_Y0;_ /\ C%'_  \ _9&_Z*U_Y0;_ /\
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MWO\ !/\ Z&WQW_X65S_C0![I17A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\
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MW_X65S_C0![I17A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M]L?SMT5_1)_P[W^"?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^-'_$4_\
MJ#_\J?\ V@?ZD_\ 41_Y)_\ ;'\[=%?T2?\ #O?X)_\ 0V^._P#PLKG_ !H_
MX=[_  3_ .AM\=_^%E<_XT?\13_Z@_\ RI_]H'^I/_41_P"2?_;'\[=?L3_P
M;C_\FP^.O^Q]_P#;*WKZ;_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PL
MKG_&O$XAX[_M[+)83ZOR7:=^>^SOMRK\STLJX9_LS&*O[7FLFK<MM_/F9[I1
M7A?_  [W^"?_ $-OCO\ \+*Y_P :\K_9!_9#^''Q6^&.H>(_%/BKQ@+B#Q5J
M5E&+/Q3<1)Y4,Y1,@'EL=3WK\^/JCZ5_:._Y-[\=?]B=J?\ Z2R5^45?HY_P
M[W^"?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^-?1Y)Q!_8]*</9\W,[[V
M_1GC9GE/]HU(RY^6RMM?]4?G'17Z.?\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_
M  3_ .AM\=_^%E<_XU[?^O'_ %#_ /D__P!J>9_JO_T^_P#)?_MC\XZ*_1S_
M (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO_P +*Y_QH_UX_P"H?_R?_P"U
M#_5?_I]_Y+_]L?G'17Z.?\.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65
MS_C1_KQ_U#_^3_\ VH?ZK_\ 3[_R7_[8_..BOT<_X=[_  3_ .AM\=_^%E<_
MXT?\.]_@G_T-OCO_ ,+*Y_QH_P!>/^H?_P G_P#M0_U7_P"GW_DO_P!L?G'1
M7Z.?\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C1_KQ_U#_\ D_\
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M5S_C1_P[W^"?_0V^._\ PLKG_&NO_7/(?^A12_\ )?\ Y48?ZNYI_P!!\_\
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M17Z.?\.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C1_KQ_U#_^3_\
MVH?ZK_\ 3[_R7_[8_..O5?V(O^3J?!W_ %_R_P#HB6OL?_AWO\$_^AM\=_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>??LU_!G4_@9X"O?"&JZU!?R77B&^U%9K>-E55GE+A,'N <&O0:* "
MBBD=TC4O(X4#J2<"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *X[]H+X9WWQE^"_B+X7Z9J<5E<:WIS6T5U
M.A9(R2#D@<D<5V-% &?X2T:7PYX4TSP]/,LCV&GPV[R(,!RD:J2/8XK0HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _'WXW?L0_LR_\% _^#F;XA_!7]K?P!=^*?#&
MD?LPZ=K6G:5#XFU'3%AODU*T@6;?87$+M^[GE7:6*G=DC(!'7?MR?\$L;?\
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M/OQN_8A_9E_X*!_\',WQ#^"O[6_@"[\4^&-(_9AT[6M.TJ'Q-J.F+#?)J5I
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MO)68SV=M<>3&A5V7)9@S,[L?T>K\S?\ @B!XC\,:/^W!^U9^S]^QUXVO=?\
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M/O@&R^%?P+^&&@^#_#6G BQT+PWI45E:PDG+,(XE5=S'EFQEB2223FNGHHH
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252077360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-8869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,117,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,919,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252082272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EISNERAMPER LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332256185616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 5,964,556<span></span>
</td>
<td class="nump">$ 7,854,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="nump">343,069<span></span>
</td>
<td class="nump">606,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax Receivables</a></td>
<td class="nump">1,373,041<span></span>
</td>
<td class="nump">529,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">7,680,666<span></span>
</td>
<td class="nump">8,990,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">55,177<span></span>
</td>
<td class="nump">73,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted Cash</a></td>
<td class="nump">49,260<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets and In-Process R&amp;D, Net</a></td>
<td class="nump">10,743,164<span></span>
</td>
<td class="nump">10,768,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease Assets with Right-of-Use</a></td>
<td class="nump">116,992<span></span>
</td>
<td class="nump">209,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">42,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">18,678,259<span></span>
</td>
<td class="nump">20,130,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">1,008,262<span></span>
</td>
<td class="nump">160,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">1,835,934<span></span>
</td>
<td class="nump">1,330,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease Liabilities</a></td>
<td class="nump">105,782<span></span>
</td>
<td class="nump">118,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent Consideration, short-term</a></td>
<td class="nump">322,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,272,363<span></span>
</td>
<td class="nump">1,609,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">3,309,175<span></span>
</td>
<td class="nump">3,048,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Tax Liability</a></td>
<td class="nump">689,121<span></span>
</td>
<td class="nump">802,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-Current Operating Lease Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">3,998,296<span></span>
</td>
<td class="nump">3,941,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">7,270,659<span></span>
</td>
<td class="nump">5,551,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.01 Par Value: 50,000,000 shares authorized at December&#160;31, 2022 and 2021; 1,796,472 and 316,599 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">17,986<span></span>
</td>
<td class="nump">3,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-In Capital</a></td>
<td class="nump">146,035,314<span></span>
</td>
<td class="nump">135,541,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(134,462,959)<span></span>
</td>
<td class="num">(120,879,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="num">(182,741)<span></span>
</td>
<td class="num">(86,431)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">11,407,600<span></span>
</td>
<td class="nump">14,579,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 18,678,259<span></span>
</td>
<td class="nump">$ 20,130,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251884528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,796,472<span></span>
</td>
<td class="nump">316,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,796,472<span></span>
</td>
<td class="nump">316,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock, designated (in shares)</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock, designated (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock, designated (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock, designated (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock, designated (in shares)</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of designated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332256220896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">$ 3,448,925<span></span>
</td>
<td class="nump">$ 5,350,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">8,277,993<span></span>
</td>
<td class="nump">5,323,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,037,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="nump">582,605<span></span>
</td>
<td class="num">(475,956)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">12,309,523<span></span>
</td>
<td class="nump">14,235,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss Before Other Income</a></td>
<td class="num">(12,309,523)<span></span>
</td>
<td class="num">(14,235,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Expense) Income, Net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value of Warrant Liability</a></td>
<td class="num">(1,425,102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on Forgiveness of Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">278,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on Disposal of Fixed Assets</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest Income</a></td>
<td class="nump">56,891<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">(8,599)<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign Currency Loss</a></td>
<td class="num">(14,498)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Expense) Income, Net</a></td>
<td class="num">(1,387,097)<span></span>
</td>
<td class="nump">272,480<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Tax Benefit</a></td>
<td class="num">(13,696,620)<span></span>
</td>
<td class="num">(13,963,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">113,010<span></span>
</td>
<td class="nump">192,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (13,583,610)<span></span>
</td>
<td class="num">$ (13,770,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per Common Share - Basic (in usd per share)</a></td>
<td class="num">$ (18.55)<span></span>
</td>
<td class="num">$ (57.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per Common Share - Diluted (in usd per share)</a></td>
<td class="num">$ (18.55)<span></span>
</td>
<td class="num">$ (57.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding - Basic (in shares)</a></td>
<td class="nump">732,303<span></span>
</td>
<td class="nump">241,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding - Diluted (in shares)</a></td>
<td class="nump">732,303<span></span>
</td>
<td class="nump">241,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (13,583,610)<span></span>
</td>
<td class="num">$ (13,770,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="num">(96,310)<span></span>
</td>
<td class="num">(85,629)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive Loss</a></td>
<td class="num">$ (13,679,920)<span></span>
</td>
<td class="num">$ (13,856,314)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332248024096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Registered Direct Offering</div></th>
<th class="th"><div>Series E Preferred Stock</div></th>
<th class="th"><div>Series C Preferred Stock</div></th>
<th class="th"><div>Series D Preferred Stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series E Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series C Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series D Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series E Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series C Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series D Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series E Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series C Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series D Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,729,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,837,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (802)<span></span>
</td>
<td class="num">$ (107,108,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-Based Compensation</a></td>
<td class="nump">842,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Stock, Net of Offering Costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="nump">116,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Stock, Net of Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,988,861<span></span>
</td>
<td class="nump">$ 9,756,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,988,478<span></span>
</td>
<td class="nump">$ 9,755,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,092)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,312<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (172)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of Shares of Common Stock from Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of Shares of Common Stock from Warrant Exercises</a></td>
<td class="nump">50,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued to Bayon Shareholders at Acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued to Bayon Shareholders at Acquisition</a></td>
<td class="nump">67,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(85,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,770,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,770,685)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">14,579,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,541,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,431)<span></span>
</td>
<td class="num">(120,879,349)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-Based Compensation</a></td>
<td class="nump">462,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares', window );">Issuance of Panoptes Holdback Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares', window );">Issuance of Panoptes Holdback Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Stock, Net of Offering Costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Stock, Net of Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,462,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,456,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability', window );">Reclassification of Warrant Liability</a></td>
<td class="nump">3,674,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,674,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits', window );">Cancellation of Reverse Stock Split Fractional Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockAdjustedDuringPeriodValueReverseStockSplits', window );">Cancellation of Reverse Stock Split Fractional Shares</a></td>
<td class="num">(15,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of Shares of Common Stock from Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of Shares of Common Stock from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesWarrantInducement', window );">Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodValueWarrantInducement', window );">Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360</a></td>
<td class="nump">2,738,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,732,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(96,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,583,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,583,610)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 11,407,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,035,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (182,741)<span></span>
</td>
<td class="num">$ (134,462,959)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,796,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Reclassification Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockAdjustedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Adjusted During Period, Value, Reverse Stock Splits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockAdjustedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Adjustment During Period, Shares, Reverse Stock Splits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares From HoldBack, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesFromHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesWarrantInducement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Inducement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesWarrantInducement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, From Panoptes Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodValueWarrantInducement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Inducement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodValueWarrantInducement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251943664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts', window );">Closing costs</a></td>
<td class="nump">$ 381,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">505,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 136,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 993,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid in Capital, Warrant Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kprx_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kprx_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kprx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332178282368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (13,583,610)<span></span>
</td>
<td class="num">$ (13,770,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization of Intangible Assets</a></td>
<td class="nump">41,609<span></span>
</td>
<td class="nump">45,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncreaseDecreaseInRightOfUseAssets', window );">Reduction of Right-of-Use Assets</a></td>
<td class="nump">92,419<span></span>
</td>
<td class="nump">181,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-Based Compensation</a></td>
<td class="nump">462,450<span></span>
</td>
<td class="nump">842,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="nump">582,605<span></span>
</td>
<td class="num">(505,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value of Warrant Liability</a></td>
<td class="nump">1,425,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred Taxes</a></td>
<td class="num">(113,010)<span></span>
</td>
<td class="num">(192,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CashOutflowFromLoanForgiveness', window );">Paycheck Protection Program Loan Forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(278,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,037,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on Disposal of Assets</a></td>
<td class="num">(4,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="nump">275,161<span></span>
</td>
<td class="num">(156,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Tax Receivables</a></td>
<td class="num">(872,736)<span></span>
</td>
<td class="num">(441,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other Assets</a></td>
<td class="num">(22,465)<span></span>
</td>
<td class="nump">14,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">782,463<span></span>
</td>
<td class="num">(310,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating Lease Liabilities</a></td>
<td class="num">(103,629)<span></span>
</td>
<td class="num">(181,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">609,719<span></span>
</td>
<td class="nump">40,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(10,428,133)<span></span>
</td>
<td class="num">(10,675,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of Property and Equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(63,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, Net of Cash Acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on Sale of Equipment</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="num">(157,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Public Offerings, Net of Offering Costs</a></td>
<td class="nump">5,377,719<span></span>
</td>
<td class="nump">17,745,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Warrant Inducement, Net of Issuance Costs</a></td>
<td class="nump">2,738,831<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of Warrants</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="nump">50,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit', window );">Payments Made for Fractional Shares Related to the Reverse Stock Split</a></td>
<td class="num">(15,629)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of Loan Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(212,282)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">8,620,921<span></span>
</td>
<td class="nump">17,582,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="num">(85,037)<span></span>
</td>
<td class="num">(81,503)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash</a></td>
<td class="num">(1,885,874)<span></span>
</td>
<td class="nump">6,669,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Including Restricted Cash, Beginning of Year</a></td>
<td class="nump">7,899,690<span></span>
</td>
<td class="nump">1,230,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Including Restricted Cash, End of Year</a></td>
<td class="nump">6,013,816<span></span>
</td>
<td class="nump">7,899,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Operating and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Creation of Right-of-Use Assets and Related Lease Liabilities</a></td>
<td class="nump">55,415<span></span>
</td>
<td class="nump">313,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_GrantOfRestrictedStockAwards', window );">Grant of Restricted Stock Awards</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Operating and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Preferred Stock into Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Operating and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Preferred Stock into Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Operating and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Preferred Stock into Common Stock</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CashOutflowFromLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow associated with loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CashOutflowFromLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_GrantOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount grant of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_GrantOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IncreaseDecreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents increase decrease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IncreaseDecreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Fractional Shares Related To Reverse Stock Split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332257805808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Presentation and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business, Presentation and Recent Accounting Pronouncements</a></td>
<td class="text">Business, Presentation and Recent Accounting Pronouncements<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (&#8220;Kiora&#8221; or the &#8220;Company&#8221;) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company&#8217;s certificate of incorporation to change its name to &#8220;Kiora Pharmaceuticals, Inc.&#8221; effective November 8, 2021 (the &#8220;Name Change&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company's lead product is KIO-301 with an initial focus on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#8220;photoswitch&#8221; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes&#8217; ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. The Company initiated a Phase 1b clinical trial in the third quarter of 2022. On March 17, 2022, the Company was granted Orphan Drug Designation from the U.S. FDA for the Active Pharmaceutical Ingredient (&#8220;API&#8221;) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (&#8220;Bayon&#8221;) transaction which closed October 21, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 is a product that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (&#8220;OPRA+&#8221;). KIO-101 is a next-generation, non-steroidal, immune-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (&#8220;DHODH&#8221;) with what the Company believes to be best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In the fourth quarter of 2021, the Company reported top-line safety and tolerability from a phase 1b proof-of-concept (&#8220;POC&#8221;) study evaluating KIO-101 in patients with ocular surface inflammation. The Company expects to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma Ges.m.b.H &#8220;Panoptes&#8221; in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, the Company is developing KIO-201, for patients with Persistent Corneal Epithelial Defects ("PCED"), which is an orphan disease and as such, the Company is currently seeing orphan drug designation. The Company is also evaluating KIO-201 in patients recovering from surgical wounds, such as those undergoing photorefractive keratectomy ("PRK") surgery for corneal wound repair after refractive surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. The Company is currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. The Company is in planning stages of a Phase 3b trial for patients recovering from the laser vision correction procedure PRK and plans to initiate the study before the end of 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">course of business. At December&#160;31, 2022, Kiora had unrestricted Cash and Cash Equivalents of $6.0 million, and an Accumulated Deficit of $134.5 million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at December&#160;31, 2022, the Company anticipates having sufficient cash to fund planned operations into July 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $2.7 million in a warrant inducement transaction that closed on November&#160;22, 2022, net of placement agent fees of $0.3 million and expense of $0.1&#160;million, additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company&#8217;s recurring losses from operations have caused management to determine there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Reverse Stock Split</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;23, 2022, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#8217;s stockholders at the Company&#8217;s 2022 Annual Meeting of Stockholders held on September&#160;23, 2022, and by the Company&#8217;s board of directors. The Amendment became effective on September&#160;27, 2022.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The reverse stock split affected all shares of the Company&#8217;s common stock outstanding immediately prior to the effective time of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, and restricted stock awards, and, in the case of stock options, a proportionate increase in the exercise price of all such stock options. In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plans immediately prior to the effective time of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#8217;s Amended and Restated Certificate of Incorporation, which remained at 50,000,000 shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share). As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock as of September&#160;27, 2022 decreased from 43,163,123 (pre-split) shares to 1,079,045 (post-split) shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are presented reflecting the split. The Company&#8217;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on September&#160;27, 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252923440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, Jade Therapeutics, Inc. (&#8220;Jade&#8221;), Kiora Pharmaceuticals GmbH (&#8220;Kiora GmbH&#8221;) (formerly known as Panoptes Pharma Ges.m.b.H or &#8220;Panoptes&#8221;) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon Therapeutics, Inc. ("Bayon") (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (&#8220;Kiora Pty&#8221;) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as &#8220;the Company&#8221;. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company&#8217;s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&amp;D), stock-based compensation, assumptions used to value warrants including warrant modifications and </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operations of Kiora GmbH are conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets and a component of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less. At December&#160;31, 2022 and 2021, the Company has classified $49.3 thousand and $45.0 thousand as restricted cash, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December&#160;31, 2022. There is no assurance that management&#8217;s estimates and assumptions will not change in future periods.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company expenses research and development (&#8220;R&amp;D&#8221;) expenditures as incurred. R&amp;D expenses are comprised of costs incurred in performing R&amp;D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2022, the Company had no goodwill. In 2021, this consisted of the goodwill of the Company&#8217;s subsidiaries Jade and Kiora GmbH and Bayon. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company had no goodwill as of December 31, 2022, and accordingly did not need to perform an impairment analysis. As of December&#160;31, 2021, the Company performed qualitative and quantitative impairment evaluations on its goodwill. As a result, goodwill as of December&#160;31, 2021 was reduced to zero after taking an impairment loss of $4.0&#160;million. The fair value is determined using the income approach with a reconciliation to the Company&#8217;s market capitalization. The impairment is reported on the Consolidated Statements of Operations and Comprehensive Loss. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Process Research and Development</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets. At December&#160;31, 2022 and 2021, there is $10.6 million respectively of in-process R&amp;D as part of intangible assets and in-process R&amp;D, net on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As part of the Company&#8217;s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment and Geographical Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic areas.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">between the financial statement carrying, or &#8220;book&#8221;, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s net deferred income tax assets were subject to a full valuation allowance. As of December&#160;31, 2022 and 2021, the Company has a net deferred tax liability of $0.7 million and $0.8 million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December&#160;31, 2022, the Company had no unrecognized uncertain income tax positions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company classifies warrants to purchase shares of its common stock as a liability on its Consolidated Balance Sheets when the warrant is a free-standing financial instrument that may require the Company to transfer cash consideration upon exercise and that cash transfer event would be out of the Company&#8217;s control. Such a &#8220;warrant liability&#8221; is initially recorded at fair value on date of grant using the Black-Scholes model, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in the fair value of the warrant are recognized as a component of other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company will adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant or meeting the requirements to be reclassified to equity.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For warrants that do not meet the criteria of a liability warrant and are classified on the Company&#8217;s Consolidated Balance Sheets as equity instruments, the Company uses the Black-Scholes model to measure the value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferred stock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refunds for Research and Development</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora, through its Kiora GmbH and Kiora Pty Ltd. subsidiaries, is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp; development expenses. The Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. As of December&#160;31, 2022 and 2021, the Company has a research &amp; development tax receivable of $1.3 million and $0.5 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance-Sheet Risk</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Comprehensive loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company&#8217;s only component of other comprehensive loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees and non-employees at grant date, based on the estimated fair value of the award. Compensation cost for employee awards is recognized as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company&#8217;s policy is to record forfeitures as they occur.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share &#8211; Basic and Diluted</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 30,000 shares for year ended December&#160;31, 2022 and 375 shares for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December&#160;31, 2022 and 2021, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. All shares of Common Stock that may potentially be issued in the future are as follows:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common Stock Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,597,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,932</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Shares of Common Stock Issuable</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,712,409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,313</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Transactions</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. The Company incurred expenses of approximately $0.1 million for services to the related party vendor Ora, Inc. who is providing the Company with clinical study services for KIO-301. One of the Company&#8217;s directors is an executive at Ora, Inc. $0.1 million of this amount was included in accounts payable at December 31, 2022 and was subsequently paid. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendors, six consultants and two public universities, all of whom also are stockholders of the Company. Additionally, on January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. Steven J. Boyd and Keith Maher, each of whom were members of the Company&#8217;s board of directors through August 3, 2021, </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company&#8217;s CEO, Brian M. Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December&#160;31, 2021 are not material to the accompanying Consolidated Financial Statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Each period the Company revalues its contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Milestone Achievement Condition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Contingent Consideration Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 1b</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning of Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Changes in the fair value of contingent consideration are included within &#8220;Operating Expenses&#8221; in the Company's Consolidated Statements of Operations and Comprehensive Loss. Below are the status of each transaction's contingent consideration:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Bayon</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company recorded contingent consideration at fair value of $0.9 million as a result of the Bayon acquisition which closed on October 21, 2021. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.3 million. As of December&#160;31, 2022, the Company had contingent consideration at fair value of $1.1 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Panoptes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: The Panoptes transaction closed December 18, 2020. As of December&#160;31, 2021, the Company recorded contingent consideration of $1.6 million. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.1 million. The estimated fair value of contingent consideration as of December&#160;31, 2022 was $1.7 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Jade</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company had a fair value of contingent consideration of $0.6 million. During the year ended December&#160;31, 2022, the contingent consideration was increased by $0.2 million for a change in fair value. As of December&#160;31, 2022, the Company had fair value of contingent consideration of $0.7 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">At December&#160;31, 2022 and 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332266592608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or 2 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:59.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,048,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Contingent Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,631,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,048,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets as discussed in Note 14. Acquisitions. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 67%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12% - 72%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 36%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 36%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table resulted is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The changes in contingent consideration of $0.6 million as of December&#160;31, 2022, was primarily driven by higher estimated probabilities of success and an increased discount factor and was recorded as a change in fair value of contingent consideration within the Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252720432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Useful <br/>Life <br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less Accumulated Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation expense was $16,596 and $20,296 for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252866368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payroll and Benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,312,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">282,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,835,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,330,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332266592608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2020, the Company received loan funds (the &#8220;Loan&#8221;) from the Paycheck Protection Program (&#8220;PPP&#8221;) of $0.3 million. In April 2021, the Company was notified by the Small Business Administration (&#8220;SBA&#8221;) that this Loan was forgiven in full.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has no additional indebtedness at December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252719104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and In-Process R&amp;D<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and In-Process R&amp;D</a></td>
<td class="text">Intangible Assets and In-Process R&amp;DIntangible assets at December&#160;31, 2022 consist of the rights to trade-secrets and know-how related to the manufacturing of KIO-201. During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (&#8220;SentrX&#8221;) with respect to certain rights relating to the manufacturing of KIO-201. The intangible assets were recorded at $0.3 million, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $4.8 million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company&#8217;s intangible assets are amortized on a straight-line basis over the estimated useful lives. Additionally, in-process R&amp;D as of December&#160;31, 2022 and 2021 consists of projects acquired from the acquisitions of Jade, Bayon and Panoptes that have not reached technological feasibility and which have no alternative future use. Once the <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">R&amp;D process is complete, the Company will amortize the R&amp;D asset over its remaining useful life. The Company periodically evaluates these assets for impairment.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets and in-process R&amp;D at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated Useful <br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade Secrets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(106,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible Assets, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Intangible Assets and In-Process R&amp;D, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,743,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,768,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization expense on intangible assets was $25 thousand for each of the years ended December&#160;31, 2022 and 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected future amortization expense is as follows for the years ending December 31,:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332256114128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text">Capital Stock<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. The total net proceeds from the private placement were approximately $8.0 million. The warrants have an exercise price of $209.00 per share, subject to adjustments as provided under the terms of the warrants and will be exercisable on the six-month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;27, 2021, a holder elected to convert 4,092 shares of Series C Preferred stock that were issued in a public offering on April 17, 2018 into 21,313 shares of Common Stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On August&#160;11, 2021, the Company completed a registered direct offering priced at-the-market under Nasdaq Rules for 116,721 shares of Common Stock with a purchase price of $92.10 per share. The Company also completed a concurrent private placement of unregistered warrants to purchase up to an aggregate of 58,361 shares of Common Stock at an exercise price of $89.60 per share that are exercisable immediately upon issuance and will expire five and one-half years following the date of issuance. In addition, the Company issued to the placement agent warrants to purchase up to 5,836 shares of Common Stock at an exercise price of $115.124 per share, which expire five years following the date of issuance. The total net proceeds to the Company from the offering were approximately $9.8 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;17, 2021, holders elected to convert 39 shares of Series D Preferred stock that were issued in connection with the Panoptes acquisition into 273 shares of Common Stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On June&#160;18, 2022, in connection with the Company&#8217;s acquisition of Panoptes Pharma Ges.m.b.H in December 2020 (&#8220;Panoptes Acquisition&#8221;), the Company issued an aggregate of 10,087 shares of common stock to former shareholders of Panoptes, which had been held back for a period of eighteen months following the closing of the Panoptes acquisition to satisfy post-closing adjustment and indemnification obligations pursuant to the terms of the Share Purchase Agreement between the Company and the former shareholders of Panoptes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;22, 2022, the Company entered into an underwriting agreement to issue and sell stock and warrants in a public offering (the &#8220;Public Offering&#8221;). On July&#160;25, 2022, the underwriter fully exercised the over-allotment option granted by the Company to purchase stock and warrants (the &#8220;Option&#8221;). On July&#160;26, 2022, the Public Offering closed, and the Company issued and sold (i) 592,392 shares of common stock (the &#8220;Common Shares&#8221;) (including 98,138 Common Shares sold pursuant to the exercise of the Option), (ii) 1,280 shares of Series E Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;) convertible into up to 160,000 shares of common stock, (iii) 30,095,697 Class A Warrants (including 3,925,525 Class A Warrants sold pursuant to the exercise of the Option), and (iv) <span id="ie8d26f95c153412dbc0bee56ba637c99_16848"/>30,095,697 Class B Warrants (including 3,925,525 Class B Warrants sold pursuant to the exercise of the Option) (the &#8220;Class B Warrants&#8221; and together with the Class A Warrants, the &#8220;Warrants&#8221;). Upon exercise, the warrants will convert on a 40 for 1 basis into a total of 1,504,785 common shares. The public offering price of $8.00 per Common Share, Class A Warrant and Class B Warrant or $1,000 per Preferred Share, 5,000 Class A Warrants and 5,000 Class B Warrants resulted in net proceeds to the Company, of approximately $5.3 million net of underwriting discount and commissions of $0.4&#160;million and expense of $0.3&#160;million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Each Warrant is exercisable at a price per share of common stock of $8.00. The Class A Warrants will expire on September&#160;23, 2023 and the Class B Warrants will expire on September&#160;23, 2027. The exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During August 2022, all holders of the Series E Preferred Shares issued in the Public Offering, elected to convert their Series E Preferred Shares into 160,000 shares of Common Stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November&#160;17, 2022, the Company entered into warrant exercise inducement offer letters with some of the Class A Warrant holders who agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of common stock originally issued in the Public Offering in exchange for the Company's agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) on substantially the same terms as the Class A Warrants to purchase up to 654,609 shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of common stock of $5.97. Each Inducement Warrant will initially be exercisable six months following its date of issuance, and will expire on the eighteen month anniversary of their initial exercise date. The Company received aggregate gross proceeds of approximately $3.1 million from the exercise of the Class A Warrants by the selling stockholders and the sale of the Inducement Warrants. The Company paid its placement agent in connection with the inducement transactions a fee equal to 8% of gross proceeds from the exercise of the Class A Warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252900768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">WarrantsAt December&#160;31, 2022 and 2021, the following warrants were outstanding:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Remaining <br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,168</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,476</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,452)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,932</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.42</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,159,395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(719,609)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,112)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">900.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,597,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.07</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of shares to be issued upon exercise of such warrants will be reduced based on the exercise price and the market value of the shares at the time of exercise. The outstanding warrants expire from 2023 through 2027.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252825344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Plan</a></td>
<td class="text">Equity Incentive Plan<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In 2005, the Company approved the 2005 Equity Incentive Plan (the &#8220;2005 Plan&#8221;). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. During 2010, the maximum number of shares of Common Stock that may be issued pursuant to the 2005 Plan was increased to 59,414 shares. The Board of Directors (the &#8220;Board&#8221;) is responsible for administration of the 2005 Plan. The Company&#8217;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company&#8217;s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company&#8217;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), no further grants were made under the 2005 Plan. General terms of the 2014 Plan remain the same as that of the 2005 plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s Board adopted the 2014 Plan and the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), and the Company&#8217;s Stockholders approved the 2014 Plan and the ESPP Plan in February 2015. As of December&#160;31, 2022, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP was 220,733 and 284 shares, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In January 2022, the number of shares of common stock issuable under the 2014 Plan automatically increased by 583 shares pursuant to the terms of the 2014 Plan. Additionally, in September 2022, the number of shares of common stock issuable under the 2014 Plan was increased by 200,000 shares, as approved by the Company&#8217;s Stockholders. These additional shares are included in the total of 220,733 shares issuable under the 2014 Plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following is a summary of stock option activity for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Contractual Life<br/>(In Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,249</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">840.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,654</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(825)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,046.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,124)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,087</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">847.31&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,641</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.49&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">842.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,830)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">446.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.59</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,939</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442.52&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.59</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of options to purchase 78,641 and 8,654 shares of its Common Stock, respectively. All option grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. For the years ended December&#160;31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Average Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the years ended December&#160;31, 2022 and 2021 was $27.08 and $145.63 respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following is a summary of restricted stock activity for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Remaining <br/>Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,173)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.79</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the years ended December&#160;31, 2022 and 2021, 127 and 149 shares of restricted stock, which had not vested, were forfeited and returned to the Company, respectively. During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of 30,000 and 0 restricted shares of Common Stock, respectively. All grants of restricted shares were pursuant to the 2014 Plan. These vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">343,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">842,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The fair value of options granted for the years ended December&#160;31, 2022 and 2021 was approximately $0.6 million and $1.2 million, respectively. As of December&#160;31, 2022 and 2021, there was approximately $0.9 million and $1.0 million of total unrecognized compensation expense related to unvested stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted average period of 2.5 and 2.3 years, respectively. The aggregate intrinsic value of stock options outstanding at December&#160;31, 2022 and 2021 was $0.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, there were 101,850 shares of Common Stock available for grant under the 2014 Plan and 191 shares available under the Company&#8217;s ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252905552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of loss before income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,563,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,639,818)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,133,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,323,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,696,620)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,963,288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of income tax (benefit) expense are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(117,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(168,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Taxes</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113,010)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(192,603)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income Tax Benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113,010)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(192,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States Federal Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Taxes, Net of Federal Benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent Differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in Valuation Allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Non-Income Based Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective Tax Rate Expense </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s deferred tax assets and liabilities consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net Deferred Tax Liability:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Operating Loss Carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,809,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,689,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credit Carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,925,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,853,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,606,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,640,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">782,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">835,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash Versus Accrual Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Tax Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,461,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,146,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,593,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,298,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,867,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,848,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process Research and Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,556,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,649,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(689,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(802,131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022, the Company has federal and state net operating loss carryforwards of approximately $80.5 million and $52.6 million, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December&#160;31, 2017 totaling $46.1 million, and state NOL carryforwards as of December&#160;31, 2022 totaling $52.6 million will expire at various dates through 2042. Federal NOL carryforwards generated during the years ended December&#160;31, 2018 and forward totaling $34.4 million will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $10.7 million as of December&#160;31, 2022, which can be carried forward indefinitely. As of December&#160;31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $2.5 million and $0.5 million, respectively, to offset future income taxes, which expire at various times through 2042. The federal and state net operating loss and research tax credit carryforwards may be subject to the limitations provided in the Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383. Approximately $0.6 million of the federal net operating loss attributable to Jade is subject to a Section 382 limitation. Jade&#8217;s carryover of its research and development credits will be subject to the Section 383 limitation.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company files United States federal income tax returns and income tax returns in the Commonwealth of Massachusetts, California, North Carolina and Utah, as well as foreign tax returns for its subsidiaries in Austria and Australia. The Company filed all foreign tax returns for its former French subsidiary EyeGate Pharma S.A.S., which was dissolved December&#160;31, 2021. The Company is not under examination by any jurisdiction for any tax year.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has recorded a valuation allowance against its United States and foreign deferred tax assets in each of the years ended December&#160;31, 2022, and 2021 because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $1.3 million and $3.0 million during the years ended December&#160;31, 2022 and 2021, respectively, primarily as a result of the increase in net operating losses and credits, adjustments for accrual to cash basis items, and capitalized research and development expenses. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company will recognize interest and penalties related to income taxes in income tax expense. The Company has not, as yet, conducted a study of R&amp;D credit carryforwards, which are fully reserved for. This study may result in an adjustment to the Company&#8217;s R&amp;D credit carryforwards and related </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">valuation allowance, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The net operating loss and tax credit carryforwards are subject to review by the Internal Revenue Service in accordance with the provisions of Section 382 of the Internal Revenue Code. Under this Internal Revenue Code section, substantial changes in the Company&#8217;s ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset the Company&#8217;s taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the Company&#8217;s net operating loss carryforwards before they expire. The closing of the Company&#8217;s initial public offering, alone or together with transactions that have occurred or that may occur in the future, may trigger an ownership change pursuant to Section 382, which could limit the amount of research and development tax credit and net operating loss carryforwards that could be utilized annually in the future to offset the Company&#8217;s taxable income, if any. Any such limitation as the result of the Company&#8217;s additional sales of common stock by the Company could have a material adverse effect on the Company&#8217;s results of operations in future years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252916128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company is a party to three real property operating leases for the rental of office or lab space. In February 2022, the Company entered into a lease for an office facility in Encinitas, California with a term through October&#160;31, 2023, which is now used for its corporate headquarters. The Company recorded a right-of-use (ROU) asset and lease liability upon lease commencement in May 2022. The Company also has office and laboratory space of approximately 3,540 square feet in Salt Lake City, Utah with a term through November&#160;30, 2023. The Company has office space in Vienna, Austria of approximately 1,555 square feet with a term through October&#160;31, 2023 as a result of the Panoptes acquisition effective December 18, 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional ROU assets and lease liabilities were recorded upon the new lease agreements or extensions that were effective as of December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease assets and liabilities are recognized at the lease commencement date at the present value of lease payments to be paid. Operating lease assets represent the Company&#8217;s right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments. To determine the present value of lease payments to be paid, the Company estimated incremental secured borrowing rates corresponding to the maturities of the leases. The Company estimated a rate of 10% based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company recognizes expense for its leases on a straight-line basis over the lease term. Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $0.1 million and $0.2 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Future annual minimum lease payments were as follows as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company is a party to seven license agreements as described below. These license agreements require the Company to pay or receive royalties or fees to or from the licensor based on revenue or milestones related to the licensed technology.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals GmbH) entered into a patent and know-how assignment agreement with 4SC Discovery GmbH (&#8220;4SC&#8221;) transferring to it all patent rights and know-how to the compound KIO-101. The Company is responsible for paying royalties of 3.25% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals, GmbH) entered into an out-license agreement with 4SC granting 4SC the exclusive worldwide right to commercialize the compound KIO-101 for rheumatoid arthritis and inflammatory bowel disease, including Crohn&#8217;s Disease and Ulcerative Colitis. The Company is eligible to receive milestone payments totaling up to &#8364;155 million, upon and subject to the achievement of certain specified developmental and commercial milestones. We have not received any milestones from 4SC. In addition, the Company is eligible to receive royalties of 3.25% on net sales of KIO-101.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;12, 2013, the Company (through its subsidiary, Jade Therapeutics, Inc.) entered into an agreement with Lineage Cell Therapeutics, Inc. (&#8220;Lineage&#8221;), formerly known as BioTime, Inc. granting to the Company the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (&#8220;modified HA&#8221;) for ophthalmic treatments in humans. The agreement requires the Company to pay an annual fee of $30,000 and a royalty of 6% on net sales of KIO-201 to Lineage based on revenue relating to any product incorporating the modified HA technology. The agreement expires when patent protection for the modified HA technology lapses in August 2027.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On November&#160;17, 2014, the Company (through its subsidiary Kiora Pharmaceuticals GmbH) entered into an intellectual property and know-how licensing agreement with Laboratoires Leurquin Mediolanum S.A.S. (&#8220;Mediolanum&#8221;) for the commercialization of KIO-101 in specific territories. Under the Mediolanum agreement, the Company out-licensed rights to commercialize KIO-101 for uveitis, dry eye and viral conjunctivitis in Italy, and France. This agreement was amended on December 10, 2015 to also include Belgium and The Netherlands. Under the Mediolanum agreement, Mediolanum is obligated to pay up to approximately &#8364;20.0&#160;million in development and commercial milestones and a 7% royalty on net sales of KIO-101 in the territories through the longer of the expiration of the valid patents covering KIO-101 or 10 years from the first commercial sale. The royalty is reduced to 5% after patent expiry.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September&#160;26, 2018, the Company entered into an intellectual property licensing agreement (the &#8220;SentrX Agreement&#8221;) with SentrX, a veterinary medical device company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, the Company in-licensed the rights to trade secrets and know-how related to the manufacturing of KIO-201. The SentrX Agreement enables the Company to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use. Under the SentrX Agreement, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified developmental and commercial milestones. The term of the agreement is until the product is no longer in the commercial marketplace.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May&#160;1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with the University of California (&#8220;UC&#8221;) granting to the Company the exclusive rights to its pipeline of photoswitch molecules. The agreement requires the Company to pay an annual fee to UC of $5,000, as well as payments to UC upon the achievement of certain development milestone and royalties based on KIO-301 revenue. The Company is obligated to pay royalties on net sales of two percent (2%) of the first $250 million of net sales, one and a quarter percent (1.25%) of net sales between $250 million and $500 million, and one half of one percent (0.5%) of net sales over $500 million. The agreement expires on the date of the last-to-expire patent included in the licensed patent portfolio which is January 2030.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On May 1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with Photoswitch Therapeutics, Inc. (&#8220;Photoswitch&#8221;) granting to the Company access to certain patent applications and IP rights with last-to-expire patent terms of January 2030. The agreement calls for payments to Photoswitch upon the achievement of certain development and upon first commercial sale of the product.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The continued spread of the COVID-19 pandemic could adversely impact the Company&#8217;s clinical studies. In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, and business shutdowns. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which could negatively affect the Company&#8217;s ability to raise additional capital on attractive terms or at all. The extent to which COVID-19 may impact the Company&#8217;s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, and the effectiveness of actions to contain and treat COVID-19. The Company cannot presently predict the scope and severity of any potential disruptions to its business, including to ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to the Company&#8217;s ability to conduct its business in the manner and on the timelines presently planned, which could have a material adverse impact on its business, results of operation, and financial condition. As of the date of this report, there have been no material adverse effects to the Company&#8217;s ongoing business operations from COVID-19.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252906368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As a result of the 401(k) plan compliance review for the year ended December&#160;31, 2021, the Company contributed approximately $29.2 thousand to eligible participants during the third quarter of 2022. As of December&#160;31, 2022, the Company has accrued an additional estimate of $8.5 thousand for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252981120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayon Therapeutics, Inc. Acquisition</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Effective October 21, 2021, the Company acquired all of the capital stock of Bayon, a privately held ophthalmic specialty pharmaceutical company focused on developing light sensitive small molecules. With the Bayon acquisition, Bayon became a wholly-owned subsidiary of Kiora. The assets acquired and liabilities assumed have been recorded at fair value on the date of the acquisition. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill, which is not expected to be deductible for tax purposes.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the terms of the Bayon acquisition agreement, in consideration for 100% of the outstanding equity interests in Bayon, the Company paid cash in the amount of $0.1 million to certain sellers and creditors and issued 845 shares of Kiora common stock. The former stockholders of Bayon are also eligible to receive up to $7.1 million in additional cash or stock payments based on clinical trial and FDA approval milestones for Bayon&#8217;s product candidates, as set forth in the Purchase Agreement. If milestone payments are exercised for shares, shares will be issued at a price of $80.40 per share for the Phase 1b milestones. The remaining </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">milestones will be calculated at a $132.00 per share. The cash or stock earn-out payments were recorded as contingent consideration and fair valued at $1.0 million at the acquisition date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The fair value of the shares issued in the Bayon acquisition was approximately $0.1 million based on the average closing price of the Company&#8217;s Common Stock for five trading days immediately preceding the closing date, or $80.40 per share.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayon</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">406,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(265,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">_____________________________</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets include cash and receivables of $3.9 thousand and $1.4 thousand, respectively.</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration at fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,007,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Fair Value of Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss in the Consolidated Statement of Operations for the twelve months ended December 31, 2021 includes net losses of Bayon of $0.1 million from the date of acquisition. The acquired intangible assets, which consist solely of in-process research and development, will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the intangible assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company recognized approximately $0.1 million of acquisition-related costs for the Bayon acquisition that were expensed in the year ended December 31, 2021 as a component of general and administrative expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252916128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;3, 2023, the Company completed a private placement with Lincoln Park for 52,798 shares of common stock and warrants to purchase up to 105,596 shares of common stock. The total net proceeds from the private placement were approximately $0.2 million. The warrants have an exercise price of $3.538 per share, subject to adjustments as provided under the terms of the warrants, and will be exercisable on the six-month anniversary of the closing date. The warrants are exercisable for five years from the issuance date.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;3, 2023, the Company entered into a purchase agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $10.0 million of common stock (subject to certain limitations), from time to time and at the Company's sole discretion over the term of the </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">purchase agreement. On February&#160;22, 2023, the Company completed its first issuance under this agreement for a total of 20,000 shares sold to Lincoln Park for proceeds of $0.1 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On February&#160;10, 2023, a holder exercised Inducement Warrants resulting in the issuance of 50,000 shares of common stock and proceeds of $0.3 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332178149728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, Jade Therapeutics, Inc. (&#8220;Jade&#8221;), Kiora Pharmaceuticals GmbH (&#8220;Kiora GmbH&#8221;) (formerly known as Panoptes Pharma Ges.m.b.H or &#8220;Panoptes&#8221;) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon Therapeutics, Inc. ("Bayon") (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (&#8220;Kiora Pty&#8221;) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as &#8220;the Company&#8221;. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company&#8217;s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&amp;D), stock-based compensation, assumptions used to value warrants including warrant modifications and </span></div>inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operations of Kiora GmbH are conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets and a component of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash and Cash Equivalents and Restricted CashThe Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December&#160;31, 2022. There is no assurance that management&#8217;s estimates and assumptions will not change in future periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company expenses research and development (&#8220;R&amp;D&#8221;) expenditures as incurred. R&amp;D expenses are comprised of costs incurred in performing R&amp;D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillGoodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2022, the Company had no goodwill. In 2021, this consisted of the goodwill of the Company&#8217;s subsidiaries Jade and Kiora GmbH and Bayon. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company had no goodwill as of December 31, 2022, and accordingly did not need to perform an impairment analysis. As of December&#160;31, 2021, the Company performed qualitative and quantitative impairment evaluations on its goodwill. As a result, goodwill as of December&#160;31, 2021 was reduced to zero after taking an impairment loss of $4.0&#160;million. The fair value is determined using the income approach with a reconciliation to the Company&#8217;s market capitalization. The impairment is reported on the Consolidated Statements of Operations and Comprehensive Loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text">In-Process Research and DevelopmentThe Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets. At December&#160;31, 2022 and 2021, there is $10.6 million respectively of in-process R&amp;D as part of intangible assets and in-process R&amp;D, net on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccruedClinicalExpensesPolicyTextBlock', window );">Accrued Clinical Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As part of the Company&#8217;s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segment and Geographical Information</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segment and Geographical Information</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic areas.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">between the financial statement carrying, or &#8220;book&#8221;, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s net deferred income tax assets were subject to a full valuation allowance. As of December&#160;31, 2022 and 2021, the Company has a net deferred tax liability of $0.7 million and $0.8 million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December&#160;31, 2022, the Company had no unrecognized uncertain income tax positions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company classifies warrants to purchase shares of its common stock as a liability on its Consolidated Balance Sheets when the warrant is a free-standing financial instrument that may require the Company to transfer cash consideration upon exercise and that cash transfer event would be out of the Company&#8217;s control. Such a &#8220;warrant liability&#8221; is initially recorded at fair value on date of grant using the Black-Scholes model, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in the fair value of the warrant are recognized as a component of other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company will adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant or meeting the requirements to be reclassified to equity.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For warrants that do not meet the criteria of a liability warrant and are classified on the Company&#8217;s Consolidated Balance Sheets as equity instruments, the Company uses the Black-Scholes model to measure the value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferred stock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock', window );">Refunds for Research and Development</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refunds for Research and Development</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora, through its Kiora GmbH and Kiora Pty Ltd. subsidiaries, is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp; development expenses. The Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. As of December&#160;31, 2022 and 2021, the Company has a research &amp; development tax receivable of $1.3 million and $0.5 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock', window );">Concentration of Credit Risk and Off-Balance-Sheet Risk</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-Balance-Sheet Risk</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Comprehensive loss is defined as the change in stockholders&#8217; equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company&#8217;s only component of other comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees and non-employees at grant date, based on the estimated fair value of the award. Compensation cost for employee awards is recognized as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company&#8217;s policy is to record forfeitures as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share - Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share &#8211; Basic and Diluted</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 30,000 shares for year ended December&#160;31, 2022 and 375 shares for the year ended December&#160;31, 2021.</span></div>Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December&#160;31, 2022 and 2021, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RelatedPartyTransactionsPolicyTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Transactions</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2022, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. The Company incurred expenses of approximately $0.1 million for services to the related party vendor Ora, Inc. who is providing the Company with clinical study services for KIO-301. One of the Company&#8217;s directors is an executive at Ora, Inc. $0.1 million of this amount was included in accounts payable at December 31, 2022 and was subsequently paid. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">During the year ended December&#160;31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendors, six consultants and two public universities, all of whom also are stockholders of the Company. Additionally, on January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. Steven J. Boyd and Keith Maher, each of whom were members of the Company&#8217;s board of directors through August 3, 2021, </span></div>are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company&#8217;s CEO, Brian M. Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December&#160;31, 2021 are not material to the accompanying Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Each period the Company revalues its contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Milestone Achievement Condition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Contingent Consideration Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 1b</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning of Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Changes in the fair value of contingent consideration are included within &#8220;Operating Expenses&#8221; in the Company's Consolidated Statements of Operations and Comprehensive Loss. Below are the status of each transaction's contingent consideration:</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Bayon</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company recorded contingent consideration at fair value of $0.9 million as a result of the Bayon acquisition which closed on October 21, 2021. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.3 million. As of December&#160;31, 2022, the Company had contingent consideration at fair value of $1.1 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Panoptes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: The Panoptes transaction closed December 18, 2020. As of December&#160;31, 2021, the Company recorded contingent consideration of $1.6 million. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.1 million. The estimated fair value of contingent consideration as of December&#160;31, 2022 was $1.7 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Jade</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">: As of December&#160;31, 2021, the Company had a fair value of contingent consideration of $0.6 million. During the year ended December&#160;31, 2022, the contingent consideration was increased by $0.2 million for a change in fair value. As of December&#160;31, 2022, the Company had fair value of contingent consideration of $0.7 million.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">At December&#160;31, 2022 and 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AccruedClinicalExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AccruedClinicalExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the Basis of Presentation and Principles of Consolidation. The principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of concentration of credit risk and off-balance-sheet risk policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252927680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Shares of Common Stock That May Potentially Be Issued in the Future</a></td>
<td class="text">All shares of Common Stock that may potentially be issued in the future are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common Stock Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,597,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,932</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Shares of Common Stock Issuable</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,712,409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,313</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text">Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Milestone Achievement Condition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Contingent Consideration Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 1b</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Successful completion of Phase 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning of Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">FDA approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252914816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value on a recurring basis using level 3 inputs</a></td>
<td class="text">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:59.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,048,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Contingent Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,631,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,048,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of fair value unobservable level 3 inputs</a></td>
<td class="text">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028 </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 - 2028</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Bayon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 67%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12% - 72%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Panoptes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 36%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17% - 36%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Jade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of Success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252841280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Useful <br/>Life <br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less Accumulated Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Property and Equipment, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332256114128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payroll and Benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,312,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">282,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,835,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,330,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251966832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and In-Process R&amp;D (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets and in-process R&amp;D</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets and in-process R&amp;D at December&#160;31, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated Useful <br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade Secrets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(106,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible Assets, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Intangible Assets and In-Process R&amp;D, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,743,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,768,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future annual intangible amortization</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expected future amortization expense is as follows for the years ending December 31,:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252720432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text">At December&#160;31, 2022 and 2021, the following warrants were outstanding:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted <br/>Average <br/>Remaining <br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,168</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,476</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(260)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,452)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,932</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.42</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,159,395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(719,609)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,112)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">900.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,597,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.07</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332261207760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text">The following is a summary of stock option activity for the years ended December&#160;31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average <br/>Contractual Life<br/>(In Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,249</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">840.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,654</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(825)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,046.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,124)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,087</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">847.31&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,641</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.49&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">842.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,830)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">446.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.59</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,939</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442.52&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and Expected to Vest at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,751</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.59</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text">For the years ended December&#160;31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Average Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following is a summary of restricted stock activity for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average <br/>Remaining <br/>Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,173)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Awarded</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Released</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.79</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">343,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">842,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250398368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of loss before income taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of loss before income taxes are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,563,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,639,818)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,133,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,323,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,696,620)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,963,288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The components of income tax (benefit) expense are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred Taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(117,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(168,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Taxes</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113,010)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(192,603)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income Tax Benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113,010)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(192,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">United States Federal Income Tax Rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Taxes, Net of Federal Benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Permanent Differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in Valuation Allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State Non-Income Based Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective Tax Rate Expense </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company&#8217;s deferred tax assets and liabilities consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net Deferred Tax Liability:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Operating Loss Carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,809,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,689,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and Development Credit Carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,925,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,853,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,606,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,640,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-Based Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">782,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">835,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash Versus Accrual Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total Deferred Tax Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,461,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,146,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,593,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,298,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,867,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,848,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">In-Process Research and Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,556,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,649,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net Deferred Tax Liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(689,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(802,131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252866368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Future annual minimum lease payments were as follows as of December&#160;31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251868128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of preliminary purchase price allocation and estimated fair value</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayon</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-Process R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">406,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(265,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">_____________________________</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Assets include cash and receivables of $3.9 thousand and $1.4 thousand, respectively.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock', window );">Summary of business acquisition fair value consideration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration at fair value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,007,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Fair Value of Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of Fair value of business acquisition consideration [table text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251210288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Presentation and Recent Accounting Pronouncements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,964,556<span></span>
</td>
<td class="nump">$ 7,854,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134,462,959)<span></span>
</td>
<td class="num">(120,879,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant inducements</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,738,831<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantIssuancePlacementAgentFees', window );">Warrant inducement, placement agent fees</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts', window );">Warrant inducement expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued', window );">Reverse stock split, number of fractional shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,045<span></span>
</td>
<td class="nump">1,796,472<span></span>
</td>
<td class="nump">316,599<span></span>
</td>
<td class="nump">43,163,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid in Capital, Warrant Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Note, Reverse Stock Split, Number Of Fractional Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantIssuancePlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Issuance, Placement Agent Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantIssuancePlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251026448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>consultant </div>
<div>director </div>
<div>vendor </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>consultant </div>
<div>university </div>
<div>vendor </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,260<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Tangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss on goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,037,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">In-process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Business segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfGeographicSegments', window );">Geographic segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,121<span></span>
</td>
<td class="nump">802,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized uncertain income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RelatedPartyTransactionsNumberOfVendors', window );">Number of vendors with whom the company has entered into related party transactions | vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RelatedPartyTransactionsNumberOfConsultants', window );">Number of consultants with whom the company has entered into related party transactions | consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty', window );">Director who Is also an executive at a related party | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RelatedPartyTransactionsNumberOfUniversities', window );">Number of universities with whom the company entered into related party transactions | university</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">116,721<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,605<span></span>
</td>
<td class="num">$ (475,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption', window );">Other assets or liabilities that are subject to fair value methodology and estimation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=kprx_ClinicalStudiesServicesKIO301Member', window );">Clinical Studies Services KIO-301 | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember', window );">Bayon acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember', window );">Panoptes acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember', window );">Jade acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Board of Directors Who Are Also Executives At A Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfGeographicSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Geographic Segments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfGeographicSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RelatedPartyTransactionsNumberOfConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consultants with whom the company has entered into related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RelatedPartyTransactionsNumberOfConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RelatedPartyTransactionsNumberOfUniversities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Number Of Universities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RelatedPartyTransactionsNumberOfUniversities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RelatedPartyTransactionsNumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vendors with whom the company has entered into related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RelatedPartyTransactionsNumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=kprx_ClinicalStudiesServicesKIO301Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=kprx_ClinicalStudiesServicesKIO301Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332254677552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total Shares of Common Stock Issuable</a></td>
<td class="nump">1,712,409<span></span>
</td>
<td class="nump">182,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total Shares of Common Stock Issuable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total Shares of Common Stock Issuable</a></td>
<td class="nump">1,597,606<span></span>
</td>
<td class="nump">168,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total Shares of Common Stock Issuable</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total Shares of Common Stock Issuable</a></td>
<td class="nump">84,751<span></span>
</td>
<td class="nump">12,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332256156672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 322,385<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember', window );">Bayon acquisition | Successful completion of Phase 1b $0.495 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember', window );">Bayon acquisition | Successful completion of Phase 2 $0.990 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember', window );">Bayon acquisition | Successful completion of Phase 3 $4 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember', window );">Bayon acquisition | FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember', window );">Panoptes acquisition | FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember', window );">Panoptes acquisition | Beginning of Phase 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember', window );">Jade acquisition | FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ContingentConsiderationScenarioAxis=kprx_SuccessfulCompletionOfPhase3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ContingentConsiderationScenarioAxis=kprx_FdaApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ContingentConsiderationScenarioAxis=kprx_FdaApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ContingentConsiderationScenarioAxis=kprx_BeginningOfPhase3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ContingentConsiderationScenarioAxis=kprx_BeginningOfPhase3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_JadeTherapeuticSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250981040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_FairValueContingentConsiderationAbstract', window );"><strong>Contingent Consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current</a></td>
<td class="nump">$ 322,385<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent</a></td>
<td class="nump">3,309,175<span></span>
</td>
<td class="nump">3,048,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_FairValueContingentConsiderationAbstract', window );"><strong>Contingent Consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current</a></td>
<td class="nump">322,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent</a></td>
<td class="nump">3,309,175<span></span>
</td>
<td class="nump">3,048,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Total Contingent Consideration</a></td>
<td class="nump">$ 3,631,560<span></span>
</td>
<td class="nump">$ 3,048,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_FairValueContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Its represent fair value contingent consideration abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_FairValueContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251862304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ChangeInContingentConsiderationFairValue', window );">Changes in contingent consideration</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Payment discount rate | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.147<span></span>
</td>
<td class="nump">0.131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember', window );">Probability of Success for payment | Discounted cash flow | Bayon | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.17<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember', window );">Probability of Success for payment | Discounted cash flow | Bayon | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember', window );">Probability of Success for payment | Discounted cash flow | Panoptes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.17<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember', window );">Probability of Success for payment | Discounted cash flow | Panoptes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.36<span></span>
</td>
<td class="nump">0.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember', window );">Probability of Success for payment | Discounted cash flow | Jade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.56<span></span>
</td>
<td class="nump">0.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ChangeInContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in contingent consideration fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ChangeInContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=kprx_MeasurementInputProbabilityOfSuccessForPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesPharmaGes.m.b.h.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesPharmaGes.m.b.h.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_JadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_JadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251201728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment, Gross</a></td>
<td class="nump">$ 172,496<span></span>
</td>
<td class="nump">$ 187,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated Depreciation</a></td>
<td class="nump">117,319<span></span>
</td>
<td class="nump">113,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and Equipment, Net</a></td>
<td class="nump">$ 55,177<span></span>
</td>
<td class="nump">73,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment, Gross</a></td>
<td class="nump">$ 88,399<span></span>
</td>
<td class="nump">88,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment, Gross</a></td>
<td class="nump">$ 3,409<span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment, Gross</a></td>
<td class="nump">$ 58,119<span></span>
</td>
<td class="nump">72,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment, Gross</a></td>
<td class="nump">$ 22,569<span></span>
</td>
<td class="nump">$ 22,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252073952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 16,596<span></span>
</td>
<td class="nump">$ 20,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250450544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and Benefits</a></td>
<td class="nump">$ 1,312,443<span></span>
</td>
<td class="nump">$ 937,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional Fees</a></td>
<td class="nump">282,721<span></span>
</td>
<td class="nump">194,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClinicalTrialsCurrent', window );">Clinical Trials</a></td>
<td class="nump">57,020<span></span>
</td>
<td class="nump">168,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">183,750<span></span>
</td>
<td class="nump">28,961<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 1,835,934<span></span>
</td>
<td class="nump">$ 1,330,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252825344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Paycheck Protection Program Loan</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252053824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and In-Process R&amp;D - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 26, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets and In-Process R&amp;D, Net</a></td>
<td class="nump">$ 10,743,164<span></span>
</td>
<td class="nump">$ 10,768,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember', window );">SentrX Animal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets and In-Process R&amp;D, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IntangibleAssetsExpectedMilestonePayable', window );">Intangible assets, expected milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 4,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IntangibleAssetsExpectedMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments expected in future periods for acquisition of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IntangibleAssetsExpectedMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332254045104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and In-Process R&amp;D -Intangible assets and in-process R&amp;D (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 143,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeSecretsMember', window );">Trade Secrets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Trade Secrets</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="num">(106,250)<span></span>
</td>
<td class="num">(81,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">143,750<span></span>
</td>
<td class="nump">168,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment', window );">In-Process R&amp;D</a></td>
<td class="nump">10,599,414<span></span>
</td>
<td class="nump">10,599,414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment', window );">Total Intangible Assets and In-Process R&amp;D, Net</a></td>
<td class="nump">$ 10,743,164<span></span>
</td>
<td class="nump">$ 10,768,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represented amount of intangible assets adjusted with research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets including In Process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeSecretsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeSecretsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332254649216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and In-Process R&amp;D - Future Annual Intangible Amortization (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 143,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332248377136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Jun. 18, 2022</div></th>
<th class="th"><div>Sep. 17, 2021</div></th>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Jul. 27, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">116,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_SharePurchasePriceOfCommonStockAndWarrant', window );">Purchase price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantExercisePricePerShareSubjectToAdjustment', window );">Warrants, exercise price, per share, subject to adjustments (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Total net proceeds from offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,377,719<span></span>
</td>
<td class="nump">$ 17,745,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ProceedsFromWarrantExercisesAndWarrantSales', window );">Proceeds from warrant exercise and sale</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage', window );">Placement agent transaction fees, equal to percentage of gross proceeds from sale</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassAWarrantMember', window );">Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="nump">654,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_InducementWarrantMember', window );">Inducement Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 5.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiration term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable', window );">Period from issuance that warrant becomes exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesPharmaGesMbhMember', window );">Panoptes Pharma Ges .m.b.h.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares', window );">Issuance of Panoptes holdback shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessAcquisitionHoldbackSharesTerm', window );">Holdback shares, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_SharesIssuedPricePerCommonShares', window );">Public offering price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants', window );">Shares issued, price per preferred share, five thousand Class A warrants and five thousand Class B warrants (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_UnderwritingDiscountAndCommissions', window );">Underwriting discount and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_UnderwritingDiscountAndCommissionsExpenses', window );">Underwriting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering | Class A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,095,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants', window );">Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering | Class B Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,095,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants', window );">Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering | Class A Warrants, Exercise of Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,925,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember', window );">Public Offering | Class B Warrant, Exercise Of Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,925,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock', window );">Conversion of Series C Preferred Stock into Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock', window );">Conversion of Series C Preferred Stock into Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kprx_SeriesdConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kprx_CommonSharesMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kprx_CommonSharesMember', window );">Common Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantConvertibleIntoCommonStockBasis', window );">Warrant convertible into common stock basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsConvertibleIntoCommonStock', window );">Warrants convertible into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,504,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=kprx_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares convertible (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Inducement Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="nump">654,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessAcquisitionHoldbackSharesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Holdback Shares, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessAcquisitionHoldbackSharesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightNumberOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightNumberOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period From Issuance That Warrant Becomes Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Considered For Determination Of Public Offering Price Of Preferred Shares Issued With Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ProceedsFromWarrantExercisesAndWarrantSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises And Warrant Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ProceedsFromWarrantExercisesAndWarrantSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_SharePurchasePriceOfCommonStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of common Stock and warrant under private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_SharePurchasePriceOfCommonStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_SharesIssuedPricePerCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Price Per Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_SharesIssuedPricePerCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Preferred Share, Five Thousand Class A Warrants And Five Thousand Class B Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period for the conversion of series C convertible preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesFromHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares From HoldBack, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesFromHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_UnderwritingDiscountAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting Discount And Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_UnderwritingDiscountAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_UnderwritingDiscountAndCommissionsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting Discount And Commissions Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_UnderwritingDiscountAndCommissionsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantConvertibleIntoCommonStockBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Convertible Into Common Stock Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantConvertibleIntoCommonStockBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantExercisePricePerShareSubjectToAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share in exercise price of warrant, subject to adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantExercisePricePerShareSubjectToAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Inducement, Placement Agent Transaction Fees, Equal To Gross Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsConvertibleIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Convertible Into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsConvertibleIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_InducementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_InducementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesPharmaGesMbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesPharmaGesMbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kprx_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kprx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassAWarrantsExerciseOfOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassAWarrantsExerciseOfOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassBWarrantExerciseOfOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_ClassBWarrantExerciseOfOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kprx_SeriesdConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kprx_SeriesdConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kprx_CommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kprx_CommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=kprx_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=kprx_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332255775712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward', window );"><strong>Number of Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at beginning of year (in shares)</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at end of year (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward', window );"><strong>Number of Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at beginning of year (in shares)</a></td>
<td class="nump">168,932<span></span>
</td>
<td class="nump">68,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">2,159,395<span></span>
</td>
<td class="nump">102,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised (in shares)</a></td>
<td class="num">(719,609)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(11,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at end of year (in shares)</a></td>
<td class="nump">1,597,606<span></span>
</td>
<td class="nump">168,932<span></span>
</td>
<td class="nump">68,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 199.65<span></span>
</td>
<td class="nump">$ 336.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Issued (in usd per share)</a></td>
<td class="nump">7.38<span></span>
</td>
<td class="nump">135.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice', window );">Exercised (in usd per share)</a></td>
<td class="nump">5.06<span></span>
</td>
<td class="nump">192.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">900.00<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share)</a></td>
<td class="nump">$ 21.22<span></span>
</td>
<td class="nump">$ 199.65<span></span>
</td>
<td class="nump">$ 336.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms', window );">Issued</a></td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
<td class="text">4 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of expired awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332252030912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">12,954<span></span>
</td>
<td class="nump">6,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">78,641<span></span>
</td>
<td class="nump">8,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(6,830)<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year (in shares)</a></td>
<td class="nump">84,751<span></span>
</td>
<td class="nump">12,954<span></span>
</td>
<td class="nump">6,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year (in shares)</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of year (in shares)</a></td>
<td class="nump">84,751<span></span>
</td>
<td class="nump">12,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 426.25<span></span>
</td>
<td class="nump">$ 840.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">8.49<span></span>
</td>
<td class="nump">164.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">842.57<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">446.34<span></span>
</td>
<td class="nump">259.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share)</a></td>
<td class="nump">36.92<span></span>
</td>
<td class="nump">426.25<span></span>
</td>
<td class="nump">$ 840.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year (in usd per share)</a></td>
<td class="nump">442.52<span></span>
</td>
<td class="nump">847.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at end of year (in usd per share)</a></td>
<td class="nump">$ 36.92<span></span>
</td>
<td class="nump">$ 426.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">9 years 7 months 2 days<span></span>
</td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of year</a></td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
<td class="text">3 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of year</a></td>
<td class="text">9 years 7 months 2 days<span></span>
</td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332249637920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Maximum number of shares that may be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,641<span></span>
</td>
<td class="nump">8,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.08<span></span>
</td>
<td class="nump">$ 145.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues', window );">Fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember', window );">Holders Owing More Than Ten Percentage Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember', window );">Holders Owing More Than Ten Percentage Voting Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfExercisePrice', window );">Percentage of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember', window );">Holders Owing More Than Ten Percentage Voting Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member', window );">2014 Plan | Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Maximum number of shares that may be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares of common stock issuable (in shares)</a></td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PercentageOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PercentageOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332178242256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Weighted-Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Average Volatility</a></td>
<td class="nump">140.00%<span></span>
</td>
<td class="nump">140.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250973904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Restricted Stock Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at beginning of year (in shares)</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at end of year (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at beginning of year (in shares)</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Outstanding at end of year (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 261.47<span></span>
</td>
<td class="nump">$ 283.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in usd per share)</a></td>
<td class="nump">6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in usd per share)</a></td>
<td class="nump">261.45<span></span>
</td>
<td class="nump">292.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">261.51<span></span>
</td>
<td class="nump">264.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Outstanding at end of year (in usd per share)</a></td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="nump">$ 261.47<span></span>
</td>
<td class="nump">$ 283.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Recognition Period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested Outstanding</a></td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="text">1 year 1 month 2 days<span></span>
</td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250889744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Stock-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">$ 462,450<span></span>
</td>
<td class="nump">$ 842,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">343,475<span></span>
</td>
<td class="nump">246,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">$ 118,975<span></span>
</td>
<td class="nump">$ 596,089<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332254539120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes -Components of loss before income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (10,563,302)<span></span>
</td>
<td class="num">$ (10,639,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(3,133,318)<span></span>
</td>
<td class="num">(3,323,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Tax Benefit</a></td>
<td class="num">$ (13,696,620)<span></span>
</td>
<td class="num">$ (13,963,288)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251875488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of income tax (benefit) expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 4,954<span></span>
</td>
<td class="num">$ (24,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(117,964)<span></span>
</td>
<td class="num">(168,517)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total Deferred Taxes</a></td>
<td class="num">(113,010)<span></span>
</td>
<td class="num">(192,603)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="num">$ (113,010)<span></span>
</td>
<td class="num">$ (192,603)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251185184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">United States Federal Income Tax Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes, Net of Federal Benefit</a></td>
<td class="num">(2.59%)<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent Differences</a></td>
<td class="num">(9.24%)<span></span>
</td>
<td class="nump">0.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill Impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(6.07%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="num">(9.53%)<span></span>
</td>
<td class="num">(21.33%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and Development Credits</a></td>
<td class="nump">0.58%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax Rate Differential</a></td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent', window );">State Non-Income Based Tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.26%)<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Tax Rate Expense</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state non-income based tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332251184928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Net Deferred Tax Liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
<td class="nump">$ 22,809,667<span></span>
</td>
<td class="nump">$ 20,689,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development Credit Carryforwards</a></td>
<td class="nump">2,925,890<span></span>
</td>
<td class="nump">2,853,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized Research and Development</a></td>
<td class="nump">4,606,902<span></span>
</td>
<td class="nump">5,640,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-Based Compensation</a></td>
<td class="nump">782,355<span></span>
</td>
<td class="nump">835,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Cash Versus Accrual Adjustments</a></td>
<td class="nump">336,360<span></span>
</td>
<td class="nump">128,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">31,461,174<span></span>
</td>
<td class="nump">30,146,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(29,593,286)<span></span>
</td>
<td class="num">(28,298,339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net Deferred Tax Asset</a></td>
<td class="nump">1,867,888<span></span>
</td>
<td class="nump">1,848,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and Amortization</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-Process Research and Development</a></td>
<td class="num">(2,556,532)<span></span>
</td>
<td class="num">(2,649,616)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net Deferred Tax Liability</a></td>
<td class="num">$ (689,121)<span></span>
</td>
<td class="num">$ (802,131)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332249621024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 80,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized uncertain income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,400,000<span></span>
</td>
<td class="nump">$ 46,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332249857904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 12, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>operatingLease </div>
<div>licenseAgreement</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeNumberOfOperatingLeases', window );">Number of operating leases | operatingLease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions', window );">Cease payments not yet paid based on prevailing financial market conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_OperatingLeaseInterestOnLeaseLiabilities', window );">Imputed interest on the lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfLicenseAgreements', window );">Number of license agreements | licenseAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PaymentOfAnnualFee', window );">Payment of annual fee</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RoyaltyScenarioAxis=kprx_ForFirst250MillionNetSalesMember', window );">For The First 250 Million Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RoyaltyScenarioAxis=kprx_Between250And500MillionNetSalesMember', window );">Between 250 And 500 Million Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_RoyaltyScenarioAxis=kprx_NetSalesOver500MillionMember', window );">Net Sales Over 500 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember', window );">SentrX Animal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IntangibleAssetsExpectedMilestonePayable', window );">Intangible assets, expected milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 4,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,540<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">&#8364; 155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=kprx_Kio101Member', window );">KIO-101 | Mediolanum Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_DevelopmentAndCommercialMilestonesTerm', window );">Development and commercial milestones term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry', window );">Percentage of decreased royalty after patent expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_DevelopmentAndCommercialMilestonesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Development and commercial milestones Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_DevelopmentAndCommercialMilestonesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IntangibleAssetsExpectedMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments expected in future periods for acquisition of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IntangibleAssetsExpectedMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LesseeNumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LesseeNumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_OperatingLeaseInterestOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_OperatingLeaseInterestOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PaymentOfAnnualFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The details about annual fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PaymentOfAnnualFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty after patent expiry.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties over net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RoyaltyScenarioAxis=kprx_ForFirst250MillionNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RoyaltyScenarioAxis=kprx_ForFirst250MillionNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RoyaltyScenarioAxis=kprx_Between250And500MillionNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RoyaltyScenarioAxis=kprx_Between250And500MillionNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_RoyaltyScenarioAxis=kprx_NetSalesOver500MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_RoyaltyScenarioAxis=kprx_NetSalesOver500MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=kprx_SentrXAnimalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kprx_Kio101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kprx_Kio101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kprx_MediolanumAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kprx_MediolanumAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332179642416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Lease Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">$ 105,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts Representing Interest</a></td>
<td class="num">(1,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease Liabilities</a></td>
<td class="nump">$ 103,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332179641552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contributions</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_DefinedBenefitPlanContributionsByEmployerAccrued', window );">Accrual of additional estimate of contributions</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_DefinedBenefitPlanContributionsByEmployerAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents defined benefit plan contributions by employer accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_DefinedBenefitPlanContributionsByEmployerAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332249577888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details) - Bayon<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 21, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of equity interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration paid</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued as consideration (in shares) | shares</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of shares issued</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice', window );">Threshold period of volume weighted average price | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_VolumeWeightedAveragePrice', window );">Volume weighted average price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 80.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net losses of acquiree from the acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Phase 1b milestones | If milestone payments are exercised for shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in usd per share) | $ / shares</a></td>
<td class="nump">80.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Remaining milestones | If milestone payments are exercised for shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 132.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Earn-out provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessAcquisitionEarnoutConsideration', window );">Earnout consideration</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Due to creditor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PaymentsToAcquireBusinessesFairValue', window );">Fair value at the acquisition date</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessAcquisitionEarnoutConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Earnout consideration in a business combination arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessAcquisitionEarnoutConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PaymentsToAcquireBusinessesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period at fair value. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PaymentsToAcquireBusinessesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ThresholdPeriodOfVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of volume weighted average price to determine the fair value of share issued in a business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ThresholdPeriodOfVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_VolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the volume weighted average price to determine the fair value of share issued in a business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_VolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_MilestoneTypeAxis=kprx_PhaseOneBMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_MilestoneTypeAxis=kprx_PhaseOneBMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kprx_IfMilestonePaymentsAreExercisedForSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kprx_IfMilestonePaymentsAreExercisedForSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_MilestoneTypeAxis=kprx_RemainingMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_MilestoneTypeAxis=kprx_RemainingMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=kprx_EarnOutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=kprx_EarnOutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=kprx_DueToCreditorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=kprx_DueToCreditorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332248331552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Purchase price allocation (Details) - Bayon<br></strong></div></th>
<th class="th">
<div>Oct. 21, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current Assets</a></td>
<td class="nump">$ 5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">In-Process R&amp;D</a></td>
<td class="nump">1,063,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_GoodwillAcquired', window );">Goodwill</a></td>
<td class="nump">406,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities', window );">Accounts Payable</a></td>
<td class="num">(36,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred Tax Liability</a></td>
<td class="num">(265,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Consideration</a></td>
<td class="nump">1,172,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and other payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_GoodwillAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount is relevant to Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_GoodwillAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332250921424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Fair value of consideration (Details) - Bayon<br></strong></div></th>
<th class="th">
<div>Oct. 21, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue', window );">Contingent consideration at fair value</a></td>
<td class="nump">$ 1,007,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessCombinationContingentConsiderationCashCurrent', window );">Cash Consideration</a></td>
<td class="nump">$ 97,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Kiora Common Stock (in shares) | shares</a></td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Kiora Common Stock , Amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Consideration</a></td>
<td class="nump">$ 1,172,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Kiora Common Stock (in shares) | shares</a></td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Kiora Common Stock , Price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 80.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Kiora Common Stock , Amount</a></td>
<td class="nump">$ 67,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessCombinationContingentConsiderationArrangementsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessCombinationContingentConsiderationArrangementsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessCombinationContingentConsiderationCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash recognized arising from contingent consideration in a business combination, expected to be realized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessCombinationContingentConsiderationCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140332254786992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Sep. 17, 2021</div></th>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">116,721<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 50,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of shares of common stock from warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount', window );">Purchase agreement, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement', window );">Proceeds from sale of stock under share purchase agreement</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from the private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod', window );">Warrants exercisable, anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ProceedsFromSaleOfStockSharePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Stock, Share Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ProceedsFromSaleOfStockSharePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_SharePurchaseAgreementSaleOfStockMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Sale Of Stock, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_SharePurchaseAgreementSaleOfStockMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercisable, Anniversary Of Closing Date, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>kprx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kprx="http://www.eyegatepharma.com/20221231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kprx-20221231.xsd" xlink:type="simple"/>
    <context id="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d290f7be9574bcebf7238844379effd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c689070f3d244078fb089421b239bab_I20230320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="ia02f437734fd4e36ae0a425508221c0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i746a7934f1634bada7a8c67124affa16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ac3e47fbb9a40e6b33136687271985e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id89f9ff5bb924034b3dbe3c193c9f394_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b6f1204652347fdb415623b23490c21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec1b90f6e26145af8ecb19e5f10688ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideebc6d462dd43b39f1bc22f874315c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2257b859754445a88c5a21dc111b650_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic684d7ddcbac43d0820e53df9cc25544_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ee011cd1891496fa9edd4ad779a10f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i830b531b6bc24dd2a949f55a286c6888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeed21e0a98842d1987142fe74d1f345_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i320d385ba935451a894515e3831f68bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24398d9d387448899d7d6f67b0d18e73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22387114e3e7474dab945dd9d9406081_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id89f9810f6e54da3941651bc0c466491_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id16e66ce7c40470481151ae6a1bdec32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibae2553f4c6147269d9f2446ff9cecb5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife6098f944e849dd8e3b695e81997494_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bbd708d2acc4d68a5639a37269bcebc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb69a13a02f74a679635fb5e795a3515_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a9bdcba91c8451886d8aabf630b77e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icced56a3f28a49989883d98b093dc865_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d2e47ef018340cb8ebed40d2781bd4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07337b2a24d34ea8bce4d5b0b5d79397_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id85228c389d248878079223a2e81bf4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6321cfacdde541d6bcb432afea175641_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3616262e1e274a0f808b0eec4ef7eea2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8af2f5766874a71b1cf8cc1ee00516a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6800052e1e5a4f7ca848d35a11c2a8c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32ec6781878b4a5aa00aba09602df9ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib39304336073457096a0aab8825b9dfa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic73daca2444e47508725f0b023021fae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4129640388714f6cb33e9916567cc679_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b19d9d48e644670b62130a82a554097_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eb9245348984b9c8801dc1000c6f9d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cf8b4d600b847b3b4b65b1860728288_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i602889283bfb43d69fbac7a5f9edd564_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i447a4d73b07c4e98b072bfab8d19e602_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib88c374fff9b4b1e86655b1b374c77e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if598f7f07da9469aa774b84729f5f86f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08d1531c5c8a44fba658fb9b271b9635_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b9abe9e1f4348a593e3702b5ad4bcdd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="ie73652b7324f410eb0a236c5ab74f270_I20220927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2022-09-27</instant>
        </period>
    </context>
    <context id="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-09-27</startDate>
            <endDate>2022-09-27</endDate>
        </period>
    </context>
    <context id="iab476c35d5854b3288e7c65fae86f033_I20220926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="ic6dde5f6b02b4d3a8d35d27b3c627622_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fe5ad0fbdd64d0f90e7fbe407e4018e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7816963ef37e49fc9b2b1b915da2a22f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7564a47a7da94e13b7282837ea444347_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4915e719780444bb5d06f84de1f000a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ce5880d70044e6b8f03f31c86c7583d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e93985e88d14fc2822a56282e1b4674_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib210e42a94504411b696b6898cff71fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kprx:ClinicalStudiesServicesKIO301Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f1302ad90ae4297bfaa1b3b75847254_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kprx:ClinicalStudiesServicesKIO301Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id831adc4181743088eae7312ce945c05_D20210106-20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-06</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="ia86727de4c5a4926a0e5747099589716_I20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="i3c22c28aff144ee595d728f32589250e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf6d43f133f747a0ab9dc998896d995e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0ecf2b2ec16422cbacb311f726e1ec3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:SuccessfulCompletionOfPhase3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia50f44856f9c4fb8b1538310decf01f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i888435cf3f784a9ba1bf3f83b65808c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:BeginningOfPhase3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaaed018232ee4376af66b1bb3f267c0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide0c249357514cff9aace25f8d87b162_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:ContingentConsiderationScenarioAxis">kprx:FdaApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i799e66b122254b9fb460f1351862d609_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64bb67e607cc4f0c9c84c43c78f4efea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieef5b9cdc86b4a77beddae9c62c61595_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23180588e9524c849bdffc35ee9bd8aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04d2cd5eafe44865832330aec4043e6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42e744283a104e7aab5283d862fa0714_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fb04f42eb4c42bcb708df3c9ab9d6cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ddd33b6700f4b608668df77f0df0cf9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i85a6ef5429de4056adb997f7e9262826_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeTherapeuticSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i087a5072b67a4c169cb7911c09453420_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c178a39c69548fda2705ef06500514f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92ee76833e9c428f9fd3ad7f7192e706_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0e51232f4a14c209d9c5df6ff177065_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ea89645f1894b4fba9d2c548706de5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a9cbc32704e41d09a92d143608ba5eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2411b19d85894c33a481ac01c23e03de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd7b63c35c834b628a7731a06aee8457_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie954ef05d7134b6f9d9dd90ee01b1211_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i834e6138cf4c45329319e7013dad7d7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ebe6a805c674f3d9d16186d17a8debc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGes.m.b.h.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb5e4b8cf2b145ab8c2f3941f240109c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8c79b49342e4aae897b21feea0ee57d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:JadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:MeasurementInputProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id87329af756f41a9bd8bee769f08e565_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75764a07c6654ad08928cf4027c83f17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f21e2cac0424fd79527f4ae97483cb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibaf5f9545aff4296b09d8d3d1ded4f0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59768bc60bf14b3495f61e99faa48435_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifafd19d03e684311a9182b00ff277098_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c2af17f178f4edbb10c214f6d710e09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7c18db8d117144d1bf9d77fdd49e90ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4dc53dd0efce433fadbcbca72c48963e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8140c0eecc74d328848491bed2731d0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied744319bcce42c2947e7cb3c0d9b546_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96515979ddcd4f16b4c0312d1f057eae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">kprx:SentrXAnimalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ia067078212ed44749f27634d5c3506d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b8a4fc1832247a586bd7f78fc809839_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a1e806369794ad2856ea6dbcb0161ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeSecretsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2021-01-06</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="i2eb912acb7a84e7f899a898ef68025da_I20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="if363cd03c440489cae184e83db725dbe_D20210106-20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-06</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="ibbef246b73ec4853aedf59d7fa6d83ce_D20210727-20210727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="i20ff746adaba4d52862cc8fe8045f21a_D20210727-20210727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="i231e710e53a94b32bd4380968717a154_I20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="iea08751701bc47a9bdc29cf167c3a9b4_I20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="i94882f0f19bc4f1a9ba8053af45015f0_D20210917-20210917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesdConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesPharmaGesMbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-18</startDate>
            <endDate>2022-06-18</endDate>
        </period>
    </context>
    <context id="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="idd47b9b3e10d46d29b71583d4dafc1d5_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="i19ded37b921e452b99960ea388a4e60d_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="i45c59bdff9d148dda84d10448e82d282_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">kprx:CommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="ic8f91e8319c64ff39768af4b6a7f2366_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="i487e6598d77f4f0b96574b8f7d9e0080_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantsExerciseOfOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="i55104f5329234e7f8ec5172aa858ce3c_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="ib036afd5d8a7483089c4510b19eba804_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassBWarrantExerciseOfOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="i1bde319e174f4eaf85b6f29075e81c13_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="i62af4e98e26040bb88a1fcc90172c191_D20221117-20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="ia811bfae64784023b2eb006045403cbe_I20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="i8e97479594434d06b760d7fa074563be_I20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="i58366d417e1645fab574b8a7fe469157_D20221117-20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:InducementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85689dc882234a148ea4e1af5e916f2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95e7fecaf8fd4207806af45324ae8f90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id5e36c5ec60743bb983183d644c22f6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d6b9d5d260c46978aec252087242f31_I20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2010-12-31</instant>
        </period>
    </context>
    <context id="i3330bdda247340909ef880086af2dc10_D20100101-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i1c9bdfc674f144df89195e7f413c9078_D20100101-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i3ba894cd6b144b8f9075e713823ec483_D20100101-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="ide7b6258bd17457592b81acc9062273f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id38a833f22f24032be3a7e78950e921a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i795d0aceb7c54c7293c21cba1406d938_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i1c1283a1942d49d3a4dbd18de8e7917c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4c4ef98046ac4ad4bfb9fb4488c8e276_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55c57edb8428421a821f6bc68bf101ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99a48c50139c4eb598eca8ffd0d33853_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40cc4e02cb1e43849c0b6c2e74f65db2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1b08f940273a487b92ac968165f4687b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60ca6dd2eaac461ca903428aa88ce1da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc96ca35437b4369949f0a093fabcb10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45d74368d0d343e6a4e730cc009f7c82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cea2dd17233476fbcf15949d7520ede_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i50cfa066a22f4226b954687d13a1302a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7aa3ab539c714dae87e11ec896cca4d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie678dc82cc1b44fdaea24b535ce33f39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i350f7b5583cf4743990fb1864cba9f04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13faae7dbf404c9ca4a7ad27545e7d7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7386b4156e64f10a54ecf9bdd879e97_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i53772301813341239fac34a54517b47d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6091ba41f5734ea4ba9b5aadee940665_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1316295f29124fd8882adbcf2ad44e82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92bb8ffea2e14d55ab953dcb6895cbc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a467fc4202c4b38b702366fd2de3793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13150472ec5a4562a80ec73c18d52b3b_I20231130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="ic4a8d3ef8ffa49ccb26b949764fa8fee_I20231031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="i48105e35cedb4703a776e5dc694b2952_I20130702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-07-02</instant>
        </period>
    </context>
    <context id="if26ec064aa5b44919c5571e6926241b3_D20130702-20130702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-02</startDate>
            <endDate>2013-07-02</endDate>
        </period>
    </context>
    <context id="i076a9cb935ea4b94bb35bfd4c2edad1e_D20130912-20130912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-12</startDate>
            <endDate>2013-09-12</endDate>
        </period>
    </context>
    <context id="ia857601644d14861b27f01abd39ba087_I20130912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-12</instant>
        </period>
    </context>
    <context id="i33078441568940d896f1f0dc9f50a202_I20141117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:Kio101Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:MediolanumAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:Kio101Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:MediolanumAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-17</startDate>
            <endDate>2014-11-17</endDate>
        </period>
    </context>
    <context id="i9dcf2ad2cdd04f2e8c2e583db3d2594b_I20180926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">kprx:SentrXAnimalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-26</instant>
        </period>
    </context>
    <context id="i7bfb95e5fdd6415fa8eab70b36245efa_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="icdd19ae6f91940c681c6752beffda62a_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:ForFirst250MillionNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="ic0bef4b71f5f45e382bf6c1ac713c7c7_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:Between250And500MillionNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="if750165f4c9d4109955ee668d01b093e_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:RoyaltyScenarioAxis">kprx:NetSalesOver500MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="icf18c208a9d143518246d68a22a96f9b_I20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-21</startDate>
            <endDate>2021-10-21</endDate>
        </period>
    </context>
    <context id="i0e569234706a4ea9b4ffdd899380ebbb_D20211021-20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">kprx:EarnOutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-21</startDate>
            <endDate>2021-10-21</endDate>
        </period>
    </context>
    <context id="i30888c172c61432abf146a3c8dd8bcc5_I20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:IfMilestonePaymentsAreExercisedForSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:MilestoneTypeAxis">kprx:PhaseOneBMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="i1fef671ae73846238e24d7b9e5c28b89_I20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kprx:IfMilestonePaymentsAreExercisedForSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kprx:MilestoneTypeAxis">kprx:RemainingMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="id863c423f1fb4e25825a1e8a560df47a_D20211021-20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">kprx:DueToCreditorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-21</startDate>
            <endDate>2021-10-21</endDate>
        </period>
    </context>
    <context id="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-21</startDate>
            <endDate>2021-10-21</endDate>
        </period>
    </context>
    <context id="id6e223d2316642d58da08e015cef85be_I20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-03</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="i7604460adc254f1e9a1bf2330d64d148_I20230203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="i370500edd4064c70bf772759a785cc00_D20230203-20230203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-03</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-10</startDate>
            <endDate>2023-02-10</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>kprx:segment</measure>
    </unit>
    <unit id="vendor">
        <measure>kprx:vendor</measure>
    </unit>
    <unit id="consultant">
        <measure>kprx:consultant</measure>
    </unit>
    <unit id="director">
        <measure>kprx:director</measure>
    </unit>
    <unit id="university">
        <measure>kprx:university</measure>
    </unit>
    <unit id="operatinglease">
        <measure>kprx:operatingLease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="licenseagreement">
        <measure>kprx:licenseAgreement</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="day">
        <measure>kprx:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-31">0001372514</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-32">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-34">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927"
      decimals="3"
      id="f-373"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i231e710e53a94b32bd4380968717a154_I20210811"
      id="f-587">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <kprx:WarrantConvertibleIntoCommonStockBasis
      contextRef="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726"
      decimals="3"
      id="f-588"
      unitRef="number">0.025</kprx:WarrantConvertibleIntoCommonStockBasis>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i350f7b5583cf4743990fb1864cba9f04_D20220101-20221231"
      decimals="2"
      id="f-716"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i13faae7dbf404c9ca4a7ad27545e7d7a_D20220101-20221231"
      decimals="4"
      id="f-717"
      unitRef="number">0.0067</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231"
      decimals="2"
      id="f-718"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231"
      decimals="4"
      id="f-719"
      unitRef="number">0.0067</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-4">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-6">001-36672</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-7">KIORA PHARMACEUTICALS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-9">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-10">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-11">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-12">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-14">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-15">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-16">788-8869</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-17">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-18">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7d290f7be9574bcebf7238844379effd_I20220630"
      decimals="0"
      id="f-29"
      unitRef="usd">6117599</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0c689070f3d244078fb089421b239bab_I20230320"
      decimals="INF"
      id="f-30"
      unitRef="shares">1919270</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-35">274</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-36">EISNERAMPER LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-37">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-38"
      unitRef="usd">5964556</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-39"
      unitRef="usd">7854690</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-40"
      unitRef="usd">343069</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-41"
      unitRef="usd">606520</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-42"
      unitRef="usd">1373041</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-43"
      unitRef="usd">529560</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-44"
      unitRef="usd">7680666</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-45"
      unitRef="usd">8990770</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-46"
      unitRef="usd">55177</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-47"
      unitRef="usd">73999</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-48"
      unitRef="usd">49260</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-49"
      unitRef="usd">45000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-50"
      unitRef="usd">10743164</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-51"
      unitRef="usd">10768164</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-52"
      unitRef="usd">116992</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-53"
      unitRef="usd">209411</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-54"
      unitRef="usd">33000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-55"
      unitRef="usd">42964</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-56"
      unitRef="usd">18678259</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-57"
      unitRef="usd">20130308</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-58"
      unitRef="usd">1008262</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-59"
      unitRef="usd">160621</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-60"
      unitRef="usd">1835934</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-61"
      unitRef="usd">1330141</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-62"
      unitRef="usd">105782</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-63"
      unitRef="usd">118846</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-64"
      unitRef="usd">322385</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-65"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-66"
      unitRef="usd">3272363</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-67"
      unitRef="usd">1609608</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-68"
      unitRef="usd">3309175</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-69"
      unitRef="usd">3048955</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-70"
      unitRef="usd">689121</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-71"
      unitRef="usd">802131</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-72"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-73"
      unitRef="usd">90566</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-74"
      unitRef="usd">3998296</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-75"
      unitRef="usd">3941652</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-76"
      unitRef="usd">7270659</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-77"
      unitRef="usd">5551260</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      id="f-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      id="f-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="2"
      id="f-80"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="2"
      id="f-81"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-82"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-83"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <kprx:PreferredStockDesignatedShares
      contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231"
      decimals="INF"
      id="f-84"
      unitRef="shares">3750</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231"
      decimals="INF"
      id="f-85"
      unitRef="shares">3750</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231"
      decimals="INF"
      id="f-86"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0ac3e47fbb9a40e6b33136687271985e_I20221231"
      decimals="INF"
      id="f-87"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231"
      decimals="INF"
      id="f-88"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i89d2b2aba45c4b03b01ff8d8cfeb0bce_I20211231"
      decimals="INF"
      id="f-89"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares
      contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231"
      decimals="INF"
      id="f-90"
      unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="i6b6f1204652347fdb415623b23490c21_I20211231"
      decimals="INF"
      id="f-91"
      unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231"
      decimals="INF"
      id="f-92"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6b6f1204652347fdb415623b23490c21_I20211231"
      decimals="INF"
      id="f-93"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id89f9ff5bb924034b3dbe3c193c9f394_I20221231"
      decimals="INF"
      id="f-94"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6b6f1204652347fdb415623b23490c21_I20211231"
      decimals="INF"
      id="f-95"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares
      contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231"
      decimals="INF"
      id="f-96"
      unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231"
      decimals="INF"
      id="f-97"
      unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231"
      decimals="INF"
      id="f-98"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231"
      decimals="INF"
      id="f-99"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ideebc6d462dd43b39f1bc22f874315c9_I20211231"
      decimals="INF"
      id="f-100"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iec1b90f6e26145af8ecb19e5f10688ad_I20221231"
      decimals="INF"
      id="f-101"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <kprx:PreferredStockDesignatedShares
      contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231"
      decimals="INF"
      id="f-102"
      unitRef="shares">20000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="ic2257b859754445a88c5a21dc111b650_I20211231"
      decimals="INF"
      id="f-103"
      unitRef="shares">20000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231"
      decimals="INF"
      id="f-104"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib9d8bd6c0e064df7990f4bd2804c739f_I20221231"
      decimals="INF"
      id="f-105"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic2257b859754445a88c5a21dc111b650_I20211231"
      decimals="INF"
      id="f-106"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic2257b859754445a88c5a21dc111b650_I20211231"
      decimals="INF"
      id="f-107"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares
      contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231"
      decimals="INF"
      id="f-108"
      unitRef="shares">1280</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231"
      decimals="INF"
      id="f-109"
      unitRef="shares">1280</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231"
      decimals="INF"
      id="f-110"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231"
      decimals="INF"
      id="f-111"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9ee011cd1891496fa9edd4ad779a10f4_I20221231"
      decimals="INF"
      id="f-112"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic684d7ddcbac43d0820e53df9cc25544_I20211231"
      decimals="INF"
      id="f-113"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-114"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-115"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-118"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-119"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-120"
      unitRef="shares">1796472</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-121"
      unitRef="shares">1796472</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-122"
      unitRef="shares">316599</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-123"
      unitRef="shares">316599</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-124"
      unitRef="usd">17986</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-125"
      unitRef="usd">3166</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-126"
      unitRef="usd">146035314</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-127"
      unitRef="usd">135541662</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-128"
      unitRef="usd">-134462959</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-129"
      unitRef="usd">-120879349</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-130"
      unitRef="usd">-182741</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-131"
      unitRef="usd">-86431</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-132"
      unitRef="usd">11407600</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-133"
      unitRef="usd">14579048</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-134"
      unitRef="usd">18678259</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-135"
      unitRef="usd">20130308</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-136"
      unitRef="usd">3448925</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-137"
      unitRef="usd">5350264</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-138"
      unitRef="usd">8277993</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-139"
      unitRef="usd">5323649</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-140"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-141"
      unitRef="usd">4037811</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-142"
      unitRef="usd">582605</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-143"
      unitRef="usd">-475956</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-144"
      unitRef="usd">12309523</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-145"
      unitRef="usd">14235768</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-146"
      unitRef="usd">-12309523</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-147"
      unitRef="usd">-14235768</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-148"
      unitRef="usd">1425102</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-149"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-150"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-151"
      unitRef="usd">278190</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-152"
      unitRef="usd">4211</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-153"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-154"
      unitRef="usd">56891</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-155"
      unitRef="usd">1141</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-156"
      unitRef="usd">8599</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-157"
      unitRef="usd">6851</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-158"
      unitRef="usd">-14498</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-159"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-160"
      unitRef="usd">-1387097</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-161"
      unitRef="usd">272480</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-162"
      unitRef="usd">-13696620</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-163"
      unitRef="usd">-13963288</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-164"
      unitRef="usd">-113010</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-165"
      unitRef="usd">-192603</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-166"
      unitRef="usd">-13583610</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-167"
      unitRef="usd">-13770685</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-18.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-18.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-57.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-57.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-172"
      unitRef="shares">732303</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-173"
      unitRef="shares">732303</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-174"
      unitRef="shares">241099</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-175"
      unitRef="shares">241099</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-176"
      unitRef="usd">-13583610</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-177"
      unitRef="usd">-13770685</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-178"
      unitRef="usd">-96310</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-179"
      unitRef="usd">-85629</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-180"
      unitRef="usd">-13679920</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-181"
      unitRef="usd">-13856314</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231"
      decimals="0"
      id="f-182"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231"
      decimals="0"
      id="f-183"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231"
      decimals="0"
      id="f-184"
      unitRef="shares">316599</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231"
      decimals="0"
      id="f-185"
      unitRef="usd">3166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231"
      decimals="0"
      id="f-186"
      unitRef="usd">135541662</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i320d385ba935451a894515e3831f68bb_I20211231"
      decimals="0"
      id="f-187"
      unitRef="usd">-86431</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24398d9d387448899d7d6f67b0d18e73_I20211231"
      decimals="0"
      id="f-188"
      unitRef="usd">-120879349</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-189"
      unitRef="usd">14579048</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"
      decimals="0"
      id="f-190"
      unitRef="usd">462450</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-191"
      unitRef="usd">462450</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <kprx:StockIssuedDuringPeriodSharesFromHoldBackShares
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-192"
      unitRef="shares">10087</kprx:StockIssuedDuringPeriodSharesFromHoldBackShares>
    <kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-193"
      unitRef="usd">100</kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares>
    <kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares
      contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"
      decimals="0"
      id="f-194"
      unitRef="usd">-100</kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares>
    <kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-195"
      unitRef="usd">0</kprx:StockIssuedDuringPeriodValueFromPanoptesHoldBackShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231"
      decimals="0"
      id="f-196"
      unitRef="usd">505020</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id89f9810f6e54da3941651bc0c466491_D20220101-20221231"
      decimals="0"
      id="f-197"
      unitRef="shares">592392</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id89f9810f6e54da3941651bc0c466491_D20220101-20221231"
      decimals="0"
      id="f-198"
      unitRef="usd">5924</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id16e66ce7c40470481151ae6a1bdec32_D20220101-20221231"
      decimals="0"
      id="f-199"
      unitRef="usd">2456914</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231"
      decimals="0"
      id="f-200"
      unitRef="usd">2462838</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ibae2553f4c6147269d9f2446ff9cecb5_D20220101-20221231"
      decimals="0"
      id="f-201"
      unitRef="usd">136401</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231"
      decimals="0"
      id="f-202"
      unitRef="shares">1280</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231"
      decimals="0"
      id="f-203"
      unitRef="usd">13</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"
      decimals="0"
      id="f-204"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231"
      decimals="0"
      id="f-205"
      unitRef="usd">665178</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231"
      decimals="0"
      id="f-206"
      unitRef="usd">665191</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231"
      decimals="0"
      id="f-207"
      unitRef="shares">-1280</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i017542f6e80a4d47b24b9e6e90fc6b5f_D20220101-20221231"
      decimals="0"
      id="f-208"
      unitRef="usd">-13</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"
      decimals="0"
      id="f-209"
      unitRef="shares">160000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"
      decimals="0"
      id="f-210"
      unitRef="usd">1600</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231"
      decimals="0"
      id="f-211"
      unitRef="usd">-1587</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231"
      decimals="0"
      id="f-212"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"
      decimals="0"
      id="f-213"
      unitRef="usd">3674791</kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-214"
      unitRef="usd">3674791</kprx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <kprx:StockAdjustmentDuringPeriodSharesReverseStockSplits
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-215"
      unitRef="shares">2215</kprx:StockAdjustmentDuringPeriodSharesReverseStockSplits>
    <kprx:StockAdjustedDuringPeriodValueReverseStockSplits
      contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"
      decimals="0"
      id="f-216"
      unitRef="usd">15629</kprx:StockAdjustedDuringPeriodValueReverseStockSplits>
    <kprx:StockAdjustedDuringPeriodValueReverseStockSplits
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-217"
      unitRef="usd">15629</kprx:StockAdjustedDuringPeriodValueReverseStockSplits>
    <kprx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"
      decimals="0"
      id="f-218"
      unitRef="shares">65000</kprx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia745ea4a45fd43af88816690b71e5c19_D20220101-20221231"
      decimals="0"
      id="f-219"
      unitRef="usd">650</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ife6098f944e849dd8e3b695e81997494_D20220101-20221231"
      decimals="0"
      id="f-220"
      unitRef="usd">519350</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231"
      decimals="0"
      id="f-221"
      unitRef="usd">520000</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-222"
      unitRef="usd">381360</kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts>
    <kprx:StockIssuedDuringPeriodSharesWarrantInducement
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-223"
      unitRef="shares">654609</kprx:StockIssuedDuringPeriodSharesWarrantInducement>
    <kprx:StockIssuedDuringPeriodValueWarrantInducement
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-224"
      unitRef="usd">6546</kprx:StockIssuedDuringPeriodValueWarrantInducement>
    <kprx:StockIssuedDuringPeriodValueWarrantInducement
      contextRef="i22387114e3e7474dab945dd9d9406081_D20220101-20221231"
      decimals="0"
      id="f-225"
      unitRef="usd">2732285</kprx:StockIssuedDuringPeriodValueWarrantInducement>
    <kprx:StockIssuedDuringPeriodValueWarrantInducement
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-226"
      unitRef="usd">2738831</kprx:StockIssuedDuringPeriodValueWarrantInducement>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i6bbd708d2acc4d68a5639a37269bcebc_D20220101-20221231"
      decimals="0"
      id="f-227"
      unitRef="usd">96310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-228"
      unitRef="usd">96310</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icb69a13a02f74a679635fb5e795a3515_D20220101-20221231"
      decimals="0"
      id="f-229"
      unitRef="usd">-13583610</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-230"
      unitRef="usd">-13583610</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231"
      decimals="0"
      id="f-231"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4cbe2e89165b41bdba6042bc7fd5f817_I20221231"
      decimals="0"
      id="f-232"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4a9bdcba91c8451886d8aabf630b77e7_I20221231"
      decimals="0"
      id="f-233"
      unitRef="shares">1796472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4a9bdcba91c8451886d8aabf630b77e7_I20221231"
      decimals="0"
      id="f-234"
      unitRef="usd">17986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icced56a3f28a49989883d98b093dc865_I20221231"
      decimals="0"
      id="f-235"
      unitRef="usd">146035314</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d2e47ef018340cb8ebed40d2781bd4c_I20221231"
      decimals="0"
      id="f-236"
      unitRef="usd">-182741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07337b2a24d34ea8bce4d5b0b5d79397_I20221231"
      decimals="0"
      id="f-237"
      unitRef="usd">-134462959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-238"
      unitRef="usd">11407600</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id85228c389d248878079223a2e81bf4a_I20201231"
      decimals="0"
      id="f-239"
      unitRef="shares">4138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id85228c389d248878079223a2e81bf4a_I20201231"
      decimals="0"
      id="f-240"
      unitRef="usd">41</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6321cfacdde541d6bcb432afea175641_I20201231"
      decimals="0"
      id="f-241"
      unitRef="shares">138910</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6321cfacdde541d6bcb432afea175641_I20201231"
      decimals="0"
      id="f-242"
      unitRef="usd">1389</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3616262e1e274a0f808b0eec4ef7eea2_I20201231"
      decimals="0"
      id="f-243"
      unitRef="usd">116837777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8af2f5766874a71b1cf8cc1ee00516a_I20201231"
      decimals="0"
      id="f-244"
      unitRef="usd">-802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6800052e1e5a4f7ca848d35a11c2a8c8_I20201231"
      decimals="0"
      id="f-245"
      unitRef="usd">-107108664</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231"
      decimals="0"
      id="f-246"
      unitRef="usd">9729741</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231"
      decimals="0"
      id="f-247"
      unitRef="usd">842475</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-248"
      unitRef="usd">842475</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231"
      decimals="0"
      id="f-249"
      unitRef="usd">11142</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231"
      decimals="0"
      id="f-250"
      unitRef="shares">38278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic3cfcbf1e6934b989ce7e497a2341077_D20210101-20211231"
      decimals="0"
      id="f-251"
      unitRef="usd">383</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic73daca2444e47508725f0b023021fae_D20210101-20211231"
      decimals="0"
      id="f-252"
      unitRef="usd">7988478</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie2c61e254cb14b8f9fa472b86f43fbfd_D20210101-20211231"
      decimals="0"
      id="f-253"
      unitRef="usd">7988861</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231"
      decimals="0"
      id="f-254"
      unitRef="usd">993666</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4129640388714f6cb33e9916567cc679_D20210101-20211231"
      decimals="0"
      id="f-255"
      unitRef="shares">116721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4129640388714f6cb33e9916567cc679_D20210101-20211231"
      decimals="0"
      id="f-256"
      unitRef="usd">1167</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1b19d9d48e644670b62130a82a554097_D20210101-20211231"
      decimals="0"
      id="f-257"
      unitRef="usd">9755181</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0c14eca1dcd244c292c6a0b1d9d43ecd_D20210101-20211231"
      decimals="0"
      id="f-258"
      unitRef="usd">9756348</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <kprx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"
      decimals="0"
      id="f-259"
      unitRef="shares">260</kprx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"
      decimals="0"
      id="f-260"
      unitRef="usd">3</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231"
      decimals="0"
      id="f-261"
      unitRef="usd">49998</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-262"
      unitRef="usd">50001</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231"
      decimals="0"
      id="f-263"
      unitRef="shares">-4092</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id5d8db7a8a8e4dee81112f78f157d6c3_D20210101-20211231"
      decimals="0"
      id="f-264"
      unitRef="usd">-41</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231"
      decimals="0"
      id="f-265"
      unitRef="shares">21312</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2f26c8efca2c4c1980770d97555b64b3_D20210101-20211231"
      decimals="0"
      id="f-266"
      unitRef="usd">213</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3eb9245348984b9c8801dc1000c6f9d8_D20210101-20211231"
      decimals="0"
      id="f-267"
      unitRef="usd">-172</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231"
      decimals="0"
      id="f-268"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3cf8b4d600b847b3b4b65b1860728288_D20210101-20211231"
      decimals="0"
      id="f-269"
      unitRef="shares">-39</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231"
      decimals="0"
      id="f-270"
      unitRef="shares">273</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iad6e5f59e1304fbea0849446003cb633_D20210101-20211231"
      decimals="0"
      id="f-271"
      unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i602889283bfb43d69fbac7a5f9edd564_D20210101-20211231"
      decimals="0"
      id="f-272"
      unitRef="usd">-3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231"
      decimals="0"
      id="f-273"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"
      decimals="0"
      id="f-274"
      unitRef="shares">845</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"
      decimals="0"
      id="f-275"
      unitRef="usd">8</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib39304336073457096a0aab8825b9dfa_D20210101-20211231"
      decimals="0"
      id="f-276"
      unitRef="usd">67928</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-277"
      unitRef="usd">67936</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i447a4d73b07c4e98b072bfab8d19e602_D20210101-20211231"
      decimals="0"
      id="f-278"
      unitRef="usd">85629</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-279"
      unitRef="usd">85629</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib88c374fff9b4b1e86655b1b374c77e5_D20210101-20211231"
      decimals="0"
      id="f-280"
      unitRef="usd">-13770685</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-281"
      unitRef="usd">-13770685</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231"
      decimals="0"
      id="f-282"
      unitRef="shares">7</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i830b531b6bc24dd2a949f55a286c6888_I20211231"
      decimals="0"
      id="f-283"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231"
      decimals="0"
      id="f-284"
      unitRef="shares">316599</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifeed21e0a98842d1987142fe74d1f345_I20211231"
      decimals="0"
      id="f-285"
      unitRef="usd">3166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c84c323907d4b5ab9e3b3e3f8ced120_I20211231"
      decimals="0"
      id="f-286"
      unitRef="usd">135541662</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i320d385ba935451a894515e3831f68bb_I20211231"
      decimals="0"
      id="f-287"
      unitRef="usd">-86431</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24398d9d387448899d7d6f67b0d18e73_I20211231"
      decimals="0"
      id="f-288"
      unitRef="usd">-120879349</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-289"
      unitRef="usd">14579048</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-290"
      unitRef="usd">-13583610</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-291"
      unitRef="usd">-13770685</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-292"
      unitRef="usd">41609</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-293"
      unitRef="usd">45296</us-gaap:DepreciationDepletionAndAmortization>
    <kprx:IncreaseDecreaseInRightOfUseAssets
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-294"
      unitRef="usd">92419</kprx:IncreaseDecreaseInRightOfUseAssets>
    <kprx:IncreaseDecreaseInRightOfUseAssets
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-295"
      unitRef="usd">181977</kprx:IncreaseDecreaseInRightOfUseAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-296"
      unitRef="usd">462450</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-297"
      unitRef="usd">842475</us-gaap:ShareBasedCompensation>
    <kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-298"
      unitRef="usd">582605</kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities>
    <kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-299"
      unitRef="usd">-505675</kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-300"
      unitRef="usd">1425102</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-301"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-302"
      unitRef="usd">-113010</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-303"
      unitRef="usd">-192603</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <kprx:CashOutflowFromLoanForgiveness
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-304"
      unitRef="usd">0</kprx:CashOutflowFromLoanForgiveness>
    <kprx:CashOutflowFromLoanForgiveness
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-305"
      unitRef="usd">278190</kprx:CashOutflowFromLoanForgiveness>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-306"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-307"
      unitRef="usd">4037811</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-308"
      unitRef="usd">4211</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-309"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-310"
      unitRef="usd">-275161</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-311"
      unitRef="usd">156951</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-312"
      unitRef="usd">872736</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-313"
      unitRef="usd">441196</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-314"
      unitRef="usd">22465</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-315"
      unitRef="usd">-14111</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-316"
      unitRef="usd">782463</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-317"
      unitRef="usd">-310665</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-318"
      unitRef="usd">-103629</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-319"
      unitRef="usd">-181977</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-320"
      unitRef="usd">609719</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-321"
      unitRef="usd">40882</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-322"
      unitRef="usd">-10428133</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-323"
      unitRef="usd">-10675390</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-324"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-325"
      unitRef="usd">63865</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-326"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-327"
      unitRef="usd">93155</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-328"
      unitRef="usd">6375</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-329"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-330"
      unitRef="usd">6375</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-331"
      unitRef="usd">-157020</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-332"
      unitRef="usd">5377719</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-333"
      unitRef="usd">17745207</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-334"
      unitRef="usd">2738831</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-335"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-336"
      unitRef="usd">520000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-337"
      unitRef="usd">50001</us-gaap:ProceedsFromWarrantExercises>
    <kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-338"
      unitRef="usd">15629</kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit>
    <kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-339"
      unitRef="usd">0</kprx:PaymentsForFractionalSharesRelatedToReverseStockSplit>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-340"
      unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-341"
      unitRef="usd">212282</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-342"
      unitRef="usd">8620921</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-343"
      unitRef="usd">17582926</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-344"
      unitRef="usd">-85037</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-345"
      unitRef="usd">-81503</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-346"
      unitRef="usd">-1885874</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-347"
      unitRef="usd">6669013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-348"
      unitRef="usd">7899690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231"
      decimals="0"
      id="f-349"
      unitRef="usd">1230677</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-350"
      unitRef="usd">6013816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-351"
      unitRef="usd">7899690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="if598f7f07da9469aa774b84729f5f86f_D20220101-20221231"
      decimals="0"
      id="f-352"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i6b30f6f883f34e4d9a995713644c66c1_D20210101-20211231"
      decimals="0"
      id="f-353"
      unitRef="usd">213</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i08d1531c5c8a44fba658fb9b271b9635_D20220101-20221231"
      decimals="0"
      id="f-354"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ie25dbe09b9db46c48e07301ad2c5b4cf_D20210101-20211231"
      decimals="0"
      id="f-355"
      unitRef="usd">3</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i60299ef641884ab08c36676b1c35a6d8_D20220101-20221231"
      decimals="0"
      id="f-356"
      unitRef="usd">1600</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i5b9abe9e1f4348a593e3702b5ad4bcdd_D20210101-20211231"
      decimals="0"
      id="f-357"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-358"
      unitRef="usd">55415</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-359"
      unitRef="usd">313312</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <kprx:GrantOfRestrictedStockAwards
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-360"
      unitRef="usd">300</kprx:GrantOfRestrictedStockAwards>
    <kprx:GrantOfRestrictedStockAwards
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-361"
      unitRef="usd">0</kprx:GrantOfRestrictedStockAwards>
    <us-gaap:NatureOfOperations
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-362">Business, Presentation and Recent Accounting Pronouncements&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (&#x201c;Kiora&#x201d; or the &#x201c;Company&#x201d;) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company&#x2019;s certificate of incorporation to change its name to &#x201c;Kiora Pharmaceuticals, Inc.&#x201d; effective November 8, 2021 (the &#x201c;Name Change&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company's lead product is KIO-301 with an initial focus on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#x201c;photoswitch&#x201d; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes&#x2019; ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. The Company initiated a Phase 1b clinical trial in the third quarter of 2022. On March 17, 2022, the Company was granted Orphan Drug Designation from the U.S. FDA for the Active Pharmaceutical Ingredient (&#x201c;API&#x201d;) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (&#x201c;Bayon&#x201d;) transaction which closed October 21, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;KIO-101 is a product that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (&#x201c;OPRA+&#x201d;). KIO-101 is a next-generation, non-steroidal, immune-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (&#x201c;DHODH&#x201d;) with what the Company believes to be best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In the fourth quarter of 2021, the Company reported top-line safety and tolerability from a phase 1b proof-of-concept (&#x201c;POC&#x201d;) study evaluating KIO-101 in patients with ocular surface inflammation. The Company expects to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma Ges.m.b.H &#x201c;Panoptes&#x201d; in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In addition, the Company is developing KIO-201, for patients with Persistent Corneal Epithelial Defects ("PCED"), which is an orphan disease and as such, the Company is currently seeing orphan drug designation. The Company is also evaluating KIO-201 in patients recovering from surgical wounds, such as those undergoing photorefractive keratectomy ("PRK") surgery for corneal wound repair after refractive surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. The Company is currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. The Company is in planning stages of a Phase 3b trial for patients recovering from the laser vision correction procedure PRK and plans to initiate the study before the end of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The accompanying Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;course of business. At December&#160;31, 2022, Kiora had unrestricted Cash and Cash Equivalents of $6.0 million, and an Accumulated Deficit of $134.5 million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at December&#160;31, 2022, the Company anticipates having sufficient cash to fund planned operations into July 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $2.7 million in a warrant inducement transaction that closed on November&#160;22, 2022, net of placement agent fees of $0.3 million and expense of $0.1&#160;million, additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company&#x2019;s recurring losses from operations have caused management to determine there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On September&#160;23, 2022, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#x201c;Amendment&#x201d;) with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#x2019;s stockholders at the Company&#x2019;s 2022 Annual Meeting of Stockholders held on September&#160;23, 2022, and by the Company&#x2019;s board of directors. The Amendment became effective on September&#160;27, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The reverse stock split affected all shares of the Company&#x2019;s common stock outstanding immediately prior to the effective time of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, and restricted stock awards, and, in the case of stock options, a proportionate increase in the exercise price of all such stock options. In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plans immediately prior to the effective time of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#x2019;s Amended and Restated Certificate of Incorporation, which remained at 50,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#x2019;s percentage ownership of the Company&#x2019;s common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share). As a result of the reverse stock split, the number of the Company&#x2019;s outstanding shares of common stock as of September&#160;27, 2022 decreased from 43,163,123 (pre-split) shares to 1,079,045 (post-split) shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are presented reflecting the split. The Company&#x2019;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on September&#160;27, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption of Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) to clarify an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-363"
      unitRef="usd">6000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-364"
      unitRef="usd">-134500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122"
      decimals="-5"
      id="f-365"
      unitRef="usd">2700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <kprx:WarrantIssuancePlacementAgentFees
      contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122"
      decimals="-5"
      id="f-366"
      unitRef="usd">300000</kprx:WarrantIssuancePlacementAgentFees>
    <kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts
      contextRef="i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122"
      decimals="-5"
      id="f-367"
      unitRef="usd">100000</kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie73652b7324f410eb0a236c5ab74f270_I20220927"
      decimals="INF"
      id="f-368"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <kprx:StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued
      contextRef="i8f26b8c3f8bc4f6fa8129481f27ece92_D20220927-20220927"
      decimals="INF"
      id="f-369"
      unitRef="shares">0</kprx:StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iab476c35d5854b3288e7c65fae86f033_I20220926"
      decimals="0"
      id="f-370"
      unitRef="shares">43163123</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie73652b7324f410eb0a236c5ab74f270_I20220927"
      decimals="0"
      id="f-371"
      unitRef="shares">1079045</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-372">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption of Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) to clarify an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-374">Summary of Significant Accounting Policies &lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, Jade Therapeutics, Inc. (&#x201c;Jade&#x201d;), Kiora Pharmaceuticals GmbH (&#x201c;Kiora GmbH&#x201d;) (formerly known as Panoptes Pharma Ges.m.b.H or &#x201c;Panoptes&#x201d;) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon Therapeutics, Inc. ("Bayon") (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (&#x201c;Kiora Pty&#x201d;) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as &#x201c;the Company&#x201d;. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company&#x2019;s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&amp;amp;D), stock-based compensation, assumptions used to value warrants including warrant modifications and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Operations of Kiora GmbH are conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets and a component of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less. At December&#160;31, 2022 and 2021, the Company has classified $49.3 thousand and $45.0 thousand as restricted cash, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December&#160;31, 2022. There is no assurance that management&#x2019;s estimates and assumptions will not change in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company expenses research and development (&#x201c;R&amp;amp;D&#x201d;) expenditures as incurred. R&amp;amp;D expenses are comprised of costs incurred in performing R&amp;amp;D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Goodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2022, the Company had no goodwill. In 2021, this consisted of the goodwill of the Company&#x2019;s subsidiaries Jade and Kiora GmbH and Bayon. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company had no goodwill as of December 31, 2022, and accordingly did not need to perform an impairment analysis. As of December&#160;31, 2021, the Company performed qualitative and quantitative impairment evaluations on its goodwill. As a result, goodwill as of December&#160;31, 2021 was reduced to zero after taking an impairment loss of $4.0&#160;million. The fair value is determined using the income approach with a reconciliation to the Company&#x2019;s market capitalization. The impairment is reported on the Consolidated Statements of Operations and Comprehensive Loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-Process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company records in-process R&amp;amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;amp;D process has been completed. Once the R&amp;amp;D process is complete, the Company amortizes the R&amp;amp;D asset over its remaining useful life. The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets. At December&#160;31, 2022 and 2021, there is $10.6 million respectively of in-process R&amp;amp;D as part of intangible assets and in-process R&amp;amp;D, net on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Clinical Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As part of the Company&#x2019;s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;between the financial statement carrying, or &#x201c;book&#x201d;, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December&#160;31, 2022 and 2021, all of the Company&#x2019;s net deferred income tax assets were subject to a full valuation allowance. As of December&#160;31, 2022 and 2021, the Company has a net deferred tax liability of $0.7 million and $0.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December&#160;31, 2022, the Company had no unrecognized uncertain income tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company classifies warrants to purchase shares of its common stock as a liability on its Consolidated Balance Sheets when the warrant is a free-standing financial instrument that may require the Company to transfer cash consideration upon exercise and that cash transfer event would be out of the Company&#x2019;s control. Such a &#x201c;warrant liability&#x201d; is initially recorded at fair value on date of grant using the Black-Scholes model, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in the fair value of the warrant are recognized as a component of other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company will adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant or meeting the requirements to be reclassified to equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;For warrants that do not meet the criteria of a liability warrant and are classified on the Company&#x2019;s Consolidated Balance Sheets as equity instruments, the Company uses the Black-Scholes model to measure the value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferred stock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Refunds for Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Kiora, through its Kiora GmbH and Kiora Pty Ltd. subsidiaries, is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp;amp; development expenses. The Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. As of December&#160;31, 2022 and 2021, the Company has a research &amp;amp; development tax receivable of $1.3 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-Balance-Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Comprehensive loss is defined as the change in stockholders&#x2019; equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company&#x2019;s only component of other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees and non-employees at grant date, based on the estimated fair value of the award. Compensation cost for employee awards is recognized as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company&#x2019;s policy is to record forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share &#x2013; Basic and Diluted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 30,000 shares for year ended December&#160;31, 2022 and 375 shares for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December&#160;31, 2022 and 2021, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. All shares of Common Stock that may potentially be issued in the future are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,597,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,932&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Shares of Common Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,712,409&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,313&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the year ended December&#160;31, 2022, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. The Company incurred expenses of approximately $0.1 million for services to the related party vendor Ora, Inc. who is providing the Company with clinical study services for KIO-301. One of the Company&#x2019;s directors is an executive at Ora, Inc. $0.1 million of this amount was included in accounts payable at December 31, 2022 and was subsequently paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the year ended December&#160;31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendors, six consultants and two public universities, all of whom also are stockholders of the Company. Additionally, on January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. Steven J. Boyd and Keith Maher, each of whom were members of the Company&#x2019;s board of directors through August 3, 2021, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company&#x2019;s CEO, Brian M. Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December&#160;31, 2021 are not material to the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Each period the Company revalues its contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Milestone Achievement Condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 1b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Changes in the fair value of contingent consideration are included within &#x201c;Operating Expenses&#x201d; in the Company's Consolidated Statements of Operations and Comprehensive Loss. Below are the status of each transaction's contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Bayon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: As of December&#160;31, 2021, the Company recorded contingent consideration at fair value of $0.9 million as a result of the Bayon acquisition which closed on October 21, 2021. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.3 million. As of December&#160;31, 2022, the Company had contingent consideration at fair value of $1.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Panoptes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: The Panoptes transaction closed December 18, 2020. As of December&#160;31, 2021, the Company recorded contingent consideration of $1.6 million. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.1 million. The estimated fair value of contingent consideration as of December&#160;31, 2022 was $1.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Jade&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: As of December&#160;31, 2021, the Company had a fair value of contingent consideration of $0.6 million. During the year ended December&#160;31, 2022, the contingent consideration was increased by $0.2 million for a change in fair value. As of December&#160;31, 2022, the Company had fair value of contingent consideration of $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;At December&#160;31, 2022 and 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <kprx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-375">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, Jade Therapeutics, Inc. (&#x201c;Jade&#x201d;), Kiora Pharmaceuticals GmbH (&#x201c;Kiora GmbH&#x201d;) (formerly known as Panoptes Pharma Ges.m.b.H or &#x201c;Panoptes&#x201d;) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon Therapeutics, Inc. ("Bayon") (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (&#x201c;Kiora Pty&#x201d;) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as &#x201c;the Company&#x201d;. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</kprx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-376">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company&#x2019;s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&amp;amp;D), stock-based compensation, assumptions used to value warrants including warrant modifications and &lt;/span&gt;&lt;/div&gt;inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-377">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Operations of Kiora GmbH are conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets and a component of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-378">Cash and Cash Equivalents and Restricted CashThe Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-2"
      id="f-379"
      unitRef="usd">49300</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="-2"
      id="f-380"
      unitRef="usd">45000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-381">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic6dde5f6b02b4d3a8d35d27b3c627622_D20220101-20221231"
      id="f-382">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6fe5ad0fbdd64d0f90e7fbe407e4018e_D20220101-20221231"
      id="f-383">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-384">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December&#160;31, 2022. There is no assurance that management&#x2019;s estimates and assumptions will not change in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-385"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-386">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company expenses research and development (&#x201c;R&amp;amp;D&#x201d;) expenditures as incurred. R&amp;amp;D expenses are comprised of costs incurred in performing R&amp;amp;D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-387">GoodwillGoodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2022, the Company had no goodwill. In 2021, this consisted of the goodwill of the Company&#x2019;s subsidiaries Jade and Kiora GmbH and Bayon. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company had no goodwill as of December 31, 2022, and accordingly did not need to perform an impairment analysis. As of December&#160;31, 2021, the Company performed qualitative and quantitative impairment evaluations on its goodwill. As a result, goodwill as of December&#160;31, 2021 was reduced to zero after taking an impairment loss of $4.0&#160;million. The fair value is determined using the income approach with a reconciliation to the Company&#x2019;s market capitalization. The impairment is reported on the Consolidated Statements of Operations and Comprehensive Loss.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-388"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-389"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-390"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-5"
      id="f-391"
      unitRef="usd">4000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-392">In-Process Research and DevelopmentThe Company records in-process R&amp;amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;amp;D process has been completed. Once the R&amp;amp;D process is complete, the Company amortizes the R&amp;amp;D asset over its remaining useful life. The Company performed an annual evaluation of it's indefinite-lived intangible assets for impairment as of August 31, 2022 with a quantitative analysis. As of December&#160;31, 2022 the Company also performed a qualitative update analysis for impairment and based on this analysis, the fair value of these products was greater than their carrying value. The Company considered the development timelines for its program and noted no qualitative factors that would indicate potential impairment of its indefinite-lived intangible assets. At December&#160;31, 2022 and 2021, there is $10.6 million respectively of in-process R&amp;amp;D as part of intangible assets and in-process R&amp;amp;D, net on the Consolidated Balance Sheets.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="-5"
      id="f-393"
      unitRef="usd">10600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-394"
      unitRef="usd">10600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <kprx:AccruedClinicalExpensesPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-395">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Clinical Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As part of the Company&#x2019;s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/div&gt;</kprx:AccruedClinicalExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-396">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic areas.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-397"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <kprx:NumberOfGeographicSegments
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-398"
      unitRef="segment">3</kprx:NumberOfGeographicSegments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-399">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;between the financial statement carrying, or &#x201c;book&#x201d;, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December&#160;31, 2022 and 2021, all of the Company&#x2019;s net deferred income tax assets were subject to a full valuation allowance. As of December&#160;31, 2022 and 2021, the Company has a net deferred tax liability of $0.7 million and $0.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December&#160;31, 2022, the Company had no unrecognized uncertain income tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-400"
      unitRef="usd">700000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="-5"
      id="f-401"
      unitRef="usd">800000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-402"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <kprx:ClassOfWarrantOrRightPolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-403">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company classifies warrants to purchase shares of its common stock as a liability on its Consolidated Balance Sheets when the warrant is a free-standing financial instrument that may require the Company to transfer cash consideration upon exercise and that cash transfer event would be out of the Company&#x2019;s control. Such a &#x201c;warrant liability&#x201d; is initially recorded at fair value on date of grant using the Black-Scholes model, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in the fair value of the warrant are recognized as a component of other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company will adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant or meeting the requirements to be reclassified to equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;For warrants that do not meet the criteria of a liability warrant and are classified on the Company&#x2019;s Consolidated Balance Sheets as equity instruments, the Company uses the Black-Scholes model to measure the value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferred stock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.&lt;/span&gt;&lt;/div&gt;</kprx:ClassOfWarrantOrRightPolicyPolicyTextBlock>
    <kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-404">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Refunds for Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Kiora, through its Kiora GmbH and Kiora Pty Ltd. subsidiaries, is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the incurred research &amp;amp; development expenses. The Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. As of December&#160;31, 2022 and 2021, the Company has a research &amp;amp; development tax receivable of $1.3 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxReceivable
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-405"
      unitRef="usd">1300000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="-5"
      id="f-406"
      unitRef="usd">500000</us-gaap:IncomeTaxReceivable>
    <kprx:ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-407">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-Balance-Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/div&gt;</kprx:ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-408">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Comprehensive loss is defined as the change in stockholders&#x2019; equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company&#x2019;s only component of other comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-409">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees and non-employees at grant date, based on the estimated fair value of the award. Compensation cost for employee awards is recognized as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company&#x2019;s policy is to record forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-410">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share &#x2013; Basic and Diluted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 30,000 shares for year ended December&#160;31, 2022 and 375 shares for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December&#160;31, 2022 and 2021, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-411"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-412"
      unitRef="shares">375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-413">All shares of Common Stock that may potentially be issued in the future are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,597,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,932&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Shares of Common Stock Issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,712,409&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,313&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5011e3018e2a4c66aa1729e56a83e48e_D20220101-20221231"
      decimals="0"
      id="f-414"
      unitRef="shares">1597606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d9ec2e03db74a7d8f857ca7e9160adb_D20210101-20211231"
      decimals="0"
      id="f-415"
      unitRef="shares">168932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7816963ef37e49fc9b2b1b915da2a22f_D20220101-20221231"
      decimals="0"
      id="f-416"
      unitRef="shares">84751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7564a47a7da94e13b7282837ea444347_D20210101-20211231"
      decimals="0"
      id="f-417"
      unitRef="shares">12954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="0"
      id="f-418"
      unitRef="shares">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="0"
      id="f-419"
      unitRef="shares">375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ce5880d70044e6b8f03f31c86c7583d_D20220101-20221231"
      decimals="0"
      id="f-420"
      unitRef="shares">52</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1e93985e88d14fc2822a56282e1b4674_D20210101-20211231"
      decimals="0"
      id="f-421"
      unitRef="shares">52</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-422"
      unitRef="shares">1712409</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-423"
      unitRef="shares">182313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <kprx:RelatedPartyTransactionsPolicyTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-424">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the year ended December&#160;31, 2022, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. The Company incurred expenses of approximately $0.1 million for services to the related party vendor Ora, Inc. who is providing the Company with clinical study services for KIO-301. One of the Company&#x2019;s directors is an executive at Ora, Inc. $0.1 million of this amount was included in accounts payable at December 31, 2022 and was subsequently paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the year ended December&#160;31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendors, six consultants and two public universities, all of whom also are stockholders of the Company. Additionally, on January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. Steven J. Boyd and Keith Maher, each of whom were members of the Company&#x2019;s board of directors through August 3, 2021, &lt;/span&gt;&lt;/div&gt;are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company&#x2019;s CEO, Brian M. Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December&#160;31, 2021 are not material to the accompanying Consolidated Financial Statements.</kprx:RelatedPartyTransactionsPolicyTextBlock>
    <kprx:RelatedPartyTransactionsNumberOfVendors
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-425"
      unitRef="vendor">1</kprx:RelatedPartyTransactionsNumberOfVendors>
    <kprx:RelatedPartyTransactionsNumberOfConsultants
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-426"
      unitRef="consultant">6</kprx:RelatedPartyTransactionsNumberOfConsultants>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib210e42a94504411b696b6898cff71fe_D20220101-20221231"
      decimals="-5"
      id="f-427"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <kprx:NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-428"
      unitRef="director">1</kprx:NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i4f1302ad90ae4297bfaa1b3b75847254_I20221231"
      decimals="-5"
      id="f-429"
      unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrent>
    <kprx:RelatedPartyTransactionsNumberOfVendors
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-430"
      unitRef="vendor">1</kprx:RelatedPartyTransactionsNumberOfVendors>
    <kprx:RelatedPartyTransactionsNumberOfConsultants
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-431"
      unitRef="consultant">6</kprx:RelatedPartyTransactionsNumberOfConsultants>
    <kprx:RelatedPartyTransactionsNumberOfUniversities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-432"
      unitRef="university">2</kprx:RelatedPartyTransactionsNumberOfUniversities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id831adc4181743088eae7312ce945c05_D20210106-20210106"
      decimals="0"
      id="f-433"
      unitRef="shares">38278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia86727de4c5a4926a0e5747099589716_I20210106"
      decimals="0"
      id="f-434"
      unitRef="shares">38278</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ia86727de4c5a4926a0e5747099589716_I20210106"
      decimals="2"
      id="f-435"
      unitRef="usdPerShare">209.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id831adc4181743088eae7312ce945c05_D20210106-20210106"
      decimals="-5"
      id="f-436"
      unitRef="usd">8000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-437">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Each period the Company revalues its contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Milestone Achievement Condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 1b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Changes in the fair value of contingent consideration are included within &#x201c;Operating Expenses&#x201d; in the Company's Consolidated Statements of Operations and Comprehensive Loss. Below are the status of each transaction's contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Bayon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: As of December&#160;31, 2021, the Company recorded contingent consideration at fair value of $0.9 million as a result of the Bayon acquisition which closed on October 21, 2021. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.3 million. As of December&#160;31, 2022, the Company had contingent consideration at fair value of $1.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Panoptes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: The Panoptes transaction closed December 18, 2020. As of December&#160;31, 2021, the Company recorded contingent consideration of $1.6 million. During the year ended December&#160;31, 2022, the Company recorded an increase in estimated fair value of $0.1 million. The estimated fair value of contingent consideration as of December&#160;31, 2022 was $1.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"&gt;Jade&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;: As of December&#160;31, 2021, the Company had a fair value of contingent consideration of $0.6 million. During the year ended December&#160;31, 2022, the contingent consideration was increased by $0.2 million for a change in fair value. As of December&#160;31, 2022, the Company had fair value of contingent consideration of $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;At December&#160;31, 2022 and 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-438">Below is the list of obligations for each relevant transaction are as of December&#160;31, 2022 as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Milestone Achievement Condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 1b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Successful completion of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning of Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;FDA approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3c22c28aff144ee595d728f32589250e_I20221231"
      decimals="-5"
      id="f-439"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ibf6d43f133f747a0ab9dc998896d995e_I20221231"
      decimals="-5"
      id="f-440"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if0ecf2b2ec16422cbacb311f726e1ec3_I20221231"
      decimals="-5"
      id="f-441"
      unitRef="usd">4000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia50f44856f9c4fb8b1538310decf01f4_I20221231"
      decimals="-5"
      id="f-442"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i888435cf3f784a9ba1bf3f83b65808c1_I20221231"
      decimals="-5"
      id="f-443"
      unitRef="usd">4800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iaaed018232ee4376af66b1bb3f267c0f_I20221231"
      decimals="-5"
      id="f-444"
      unitRef="usd">4800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ide0c249357514cff9aace25f8d87b162_I20221231"
      decimals="-5"
      id="f-445"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i799e66b122254b9fb460f1351862d609_I20211231"
      decimals="-5"
      id="f-446"
      unitRef="usd">900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i64bb67e607cc4f0c9c84c43c78f4efea_D20220101-20221231"
      decimals="-5"
      id="f-447"
      unitRef="usd">300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieef5b9cdc86b4a77beddae9c62c61595_I20221231"
      decimals="-5"
      id="f-448"
      unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i23180588e9524c849bdffc35ee9bd8aa_I20211231"
      decimals="-5"
      id="f-449"
      unitRef="usd">1600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i04d2cd5eafe44865832330aec4043e6e_D20220101-20221231"
      decimals="-5"
      id="f-450"
      unitRef="usd">100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i42e744283a104e7aab5283d862fa0714_I20221231"
      decimals="-5"
      id="f-451"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5fb04f42eb4c42bcb708df3c9ab9d6cf_I20211231"
      decimals="-5"
      id="f-452"
      unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9ddd33b6700f4b608668df77f0df0cf9_D20220101-20221231"
      decimals="-5"
      id="f-453"
      unitRef="usd">200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i85a6ef5429de4056adb997f7e9262826_I20221231"
      decimals="-5"
      id="f-454"
      unitRef="usd">700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-455"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-456"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-457">Fair Value&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or 2 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;322,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,309,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,048,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,631,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,048,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets as discussed in Note 14. Acquisitions. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 - 2028 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 - 2028 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 - 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12% - 72%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table resulted is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The changes in contingent consideration of $0.6 million as of December&#160;31, 2022, was primarily driven by higher estimated probabilities of success and an increased discount factor and was recorded as a change in fair value of contingent consideration within the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-458">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;322,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,309,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,048,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,631,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,048,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231"
      decimals="0"
      id="f-459"
      unitRef="usd">322385</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i087a5072b67a4c169cb7911c09453420_I20211231"
      decimals="0"
      id="f-460"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231"
      decimals="0"
      id="f-461"
      unitRef="usd">3309175</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i087a5072b67a4c169cb7911c09453420_I20211231"
      decimals="0"
      id="f-462"
      unitRef="usd">3048955</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icbde01e8a3c345a9bdcfaa39b08e940a_I20221231"
      decimals="0"
      id="f-463"
      unitRef="usd">3631560</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i087a5072b67a4c169cb7911c09453420_I20211231"
      decimals="0"
      id="f-464"
      unitRef="usd">3048955</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-465">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 - 2028 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 - 2028 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 - 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12% - 72%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17% - 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Jade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of Success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3c178a39c69548fda2705ef06500514f_I20221231"
      decimals="3"
      id="f-466"
      unitRef="number">0.147</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i92ee76833e9c428f9fd3ad7f7192e706_I20211231"
      decimals="3"
      id="f-467"
      unitRef="number">0.131</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id0e51232f4a14c209d9c5df6ff177065_I20221231"
      decimals="2"
      id="f-468"
      unitRef="number">0.17</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4ea89645f1894b4fba9d2c548706de5a_I20221231"
      decimals="2"
      id="f-469"
      unitRef="number">0.67</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0a9cbc32704e41d09a92d143608ba5eb_I20211231"
      decimals="2"
      id="f-470"
      unitRef="number">0.12</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2411b19d85894c33a481ac01c23e03de_I20211231"
      decimals="2"
      id="f-471"
      unitRef="number">0.72</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icd7b63c35c834b628a7731a06aee8457_I20221231"
      decimals="2"
      id="f-472"
      unitRef="number">0.17</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie954ef05d7134b6f9d9dd90ee01b1211_I20221231"
      decimals="2"
      id="f-473"
      unitRef="number">0.36</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i834e6138cf4c45329319e7013dad7d7d_I20211231"
      decimals="2"
      id="f-474"
      unitRef="number">0.17</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i1ebe6a805c674f3d9d16186d17a8debc_I20211231"
      decimals="2"
      id="f-475"
      unitRef="number">0.36</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibb5e4b8cf2b145ab8c2f3941f240109c_I20221231"
      decimals="2"
      id="f-476"
      unitRef="number">0.56</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie8c79b49342e4aae897b21feea0ee57d_I20211231"
      decimals="2"
      id="f-477"
      unitRef="number">0.47</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <kprx:ChangeInContingentConsiderationFairValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-478"
      unitRef="usd">600000</kprx:ChangeInContingentConsiderationFairValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-479">Property and Equipment&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Property and equipment at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Useful &lt;br/&gt;Life &lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Property and Equipment, Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Depreciation expense was $16,596 and $20,296 for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-480">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Property and equipment at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Useful &lt;br/&gt;Life &lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Property and Equipment, Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;172,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id87329af756f41a9bd8bee769f08e565_D20220101-20221231"
      id="f-481">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i75764a07c6654ad08928cf4027c83f17_I20221231"
      decimals="0"
      id="f-482"
      unitRef="usd">88399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5f21e2cac0424fd79527f4ae97483cb8_I20211231"
      decimals="0"
      id="f-483"
      unitRef="usd">88399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibaf5f9545aff4296b09d8d3d1ded4f0a_D20220101-20221231"
      id="f-484">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i59768bc60bf14b3495f61e99faa48435_I20221231"
      decimals="0"
      id="f-485"
      unitRef="usd">3409</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifafd19d03e684311a9182b00ff277098_I20211231"
      decimals="0"
      id="f-486"
      unitRef="usd">3614</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1c2af17f178f4edbb10c214f6d710e09_D20220101-20221231"
      id="f-487">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c18db8d117144d1bf9d77fdd49e90ab_I20221231"
      decimals="0"
      id="f-488"
      unitRef="usd">58119</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4dc53dd0efce433fadbcbca72c48963e_I20211231"
      decimals="0"
      id="f-489"
      unitRef="usd">72549</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if8140c0eecc74d328848491bed2731d0_D20220101-20221231"
      id="f-490">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied744319bcce42c2947e7cb3c0d9b546_I20221231"
      decimals="0"
      id="f-491"
      unitRef="usd">22569</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96515979ddcd4f16b4c0312d1f057eae_I20211231"
      decimals="0"
      id="f-492"
      unitRef="usd">22569</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-493"
      unitRef="usd">172496</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-494"
      unitRef="usd">187131</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-495"
      unitRef="usd">117319</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-496"
      unitRef="usd">113132</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-497"
      unitRef="usd">55177</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-498"
      unitRef="usd">73999</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-499"
      unitRef="usd">16596</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-500"
      unitRef="usd">20296</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-501">Accrued Expenses&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payroll and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,312,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;937,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;282,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Clinical Trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,835,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,330,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-502">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payroll and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,312,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;937,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;282,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Clinical Trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,835,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,330,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-503"
      unitRef="usd">1312443</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-504"
      unitRef="usd">937970</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-505"
      unitRef="usd">282721</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-506"
      unitRef="usd">194425</us-gaap:AccruedProfessionalFeesCurrent>
    <kprx:ClinicalTrialsCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-507"
      unitRef="usd">57020</kprx:ClinicalTrialsCurrent>
    <kprx:ClinicalTrialsCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-508"
      unitRef="usd">168785</kprx:ClinicalTrialsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-509"
      unitRef="usd">183750</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-510"
      unitRef="usd">28961</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-511"
      unitRef="usd">1835934</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-512"
      unitRef="usd">1330141</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-513">Debt&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In May 2020, the Company received loan funds (the &#x201c;Loan&#x201d;) from the Paycheck Protection Program (&#x201c;PPP&#x201d;) of $0.3 million. In April 2021, the Company was notified by the Small Business Administration (&#x201c;SBA&#x201d;) that this Loan was forgiven in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company has no additional indebtedness at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531"
      decimals="-5"
      id="f-514"
      unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-515">Intangible Assets and In-Process R&amp;amp;DIntangible assets at December&#160;31, 2022 consist of the rights to trade-secrets and know-how related to the manufacturing of KIO-201. During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (&#x201c;SentrX&#x201d;) with respect to certain rights relating to the manufacturing of KIO-201. The intangible assets were recorded at $0.3 million, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $4.8 million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company&#x2019;s intangible assets are amortized on a straight-line basis over the estimated useful lives. Additionally, in-process R&amp;amp;D as of December&#160;31, 2022 and 2021 consists of projects acquired from the acquisitions of Jade, Bayon and Panoptes that have not reached technological feasibility and which have no alternative future use. Once the &lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;R&amp;amp;D process is complete, the Company will amortize the R&amp;amp;D asset over its remaining useful life. The Company periodically evaluates these assets for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Intangible assets and in-process R&amp;amp;D at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Estimated Useful &lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade Secrets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;In-Process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Intangible Assets and In-Process R&amp;amp;D, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,743,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,768,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Amortization expense on intangible assets was $25 thousand for each of the years ended December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected future amortization expense is as follows for the years ending December 31,:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930"
      decimals="-5"
      id="f-516"
      unitRef="usd">300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <kprx:IntangibleAssetsExpectedMilestonePayable
      contextRef="ia934dda6cbdb4ccca31609f13d8f8e10_I20180930"
      decimals="-5"
      id="f-517"
      unitRef="usd">4800000</kprx:IntangibleAssetsExpectedMilestonePayable>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-518">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Intangible assets and in-process R&amp;amp;D at December&#160;31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Estimated Useful &lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Trade Secrets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;In-Process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Intangible Assets and In-Process R&amp;amp;D, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,743,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,768,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia067078212ed44749f27634d5c3506d2_D20220101-20221231"
      id="f-519">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231"
      decimals="0"
      id="f-520"
      unitRef="usd">250000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"
      decimals="0"
      id="f-521"
      unitRef="usd">250000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231"
      decimals="0"
      id="f-522"
      unitRef="usd">106250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"
      decimals="0"
      id="f-523"
      unitRef="usd">81250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231"
      decimals="0"
      id="f-524"
      unitRef="usd">143750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"
      decimals="0"
      id="f-525"
      unitRef="usd">168750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment
      contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231"
      decimals="0"
      id="f-526"
      unitRef="usd">10599414</kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment>
    <kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment
      contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"
      decimals="0"
      id="f-527"
      unitRef="usd">10599414</kprx:FiniteLivedIntangibleAssetsResearchAndDevelopment>
    <kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment
      contextRef="i8b8a4fc1832247a586bd7f78fc809839_I20221231"
      decimals="0"
      id="f-528"
      unitRef="usd">10743164</kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment>
    <kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment
      contextRef="i4a1e806369794ad2856ea6dbcb0161ca_I20211231"
      decimals="0"
      id="f-529"
      unitRef="usd">10768164</kprx:IntangibleAssetsNetIncludingInProcessResearchAndDevelopment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="-3"
      id="f-530"
      unitRef="usd">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-3"
      id="f-531"
      unitRef="usd">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-532">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Expected future amortization expense is as follows for the years ending December 31,:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-533"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-534"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-535"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-536"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-537"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-538"
      unitRef="usd">18750</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-539"
      unitRef="usd">143750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-540">Capital Stock&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On January&#160;6, 2021, the Company completed a private placement of 38,278 shares of Common Stock and warrants to purchase up to 38,278 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $209.00. The total net proceeds from the private placement were approximately $8.0 million. The warrants have an exercise price of $209.00 per share, subject to adjustments as provided under the terms of the warrants and will be exercisable on the six-month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On July&#160;27, 2021, a holder elected to convert 4,092 shares of Series C Preferred stock that were issued in a public offering on April 17, 2018 into 21,313 shares of Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On August&#160;11, 2021, the Company completed a registered direct offering priced at-the-market under Nasdaq Rules for 116,721 shares of Common Stock with a purchase price of $92.10 per share. The Company also completed a concurrent private placement of unregistered warrants to purchase up to an aggregate of 58,361 shares of Common Stock at an exercise price of $89.60 per share that are exercisable immediately upon issuance and will expire five and one-half years following the date of issuance. In addition, the Company issued to the placement agent warrants to purchase up to 5,836 shares of Common Stock at an exercise price of $115.124 per share, which expire five years following the date of issuance. The total net proceeds to the Company from the offering were approximately $9.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On September&#160;17, 2021, holders elected to convert 39 shares of Series D Preferred stock that were issued in connection with the Panoptes acquisition into 273 shares of Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On June&#160;18, 2022, in connection with the Company&#x2019;s acquisition of Panoptes Pharma Ges.m.b.H in December 2020 (&#x201c;Panoptes Acquisition&#x201d;), the Company issued an aggregate of 10,087 shares of common stock to former shareholders of Panoptes, which had been held back for a period of eighteen months following the closing of the Panoptes acquisition to satisfy post-closing adjustment and indemnification obligations pursuant to the terms of the Share Purchase Agreement between the Company and the former shareholders of Panoptes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On July&#160;22, 2022, the Company entered into an underwriting agreement to issue and sell stock and warrants in a public offering (the &#x201c;Public Offering&#x201d;). On July&#160;25, 2022, the underwriter fully exercised the over-allotment option granted by the Company to purchase stock and warrants (the &#x201c;Option&#x201d;). On July&#160;26, 2022, the Public Offering closed, and the Company issued and sold (i) 592,392 shares of common stock (the &#x201c;Common Shares&#x201d;) (including 98,138 Common Shares sold pursuant to the exercise of the Option), (ii) 1,280 shares of Series E Convertible Preferred Stock (the &#x201c;Preferred Shares&#x201d;) convertible into up to 160,000 shares of common stock, (iii) 30,095,697 Class A Warrants (including 3,925,525 Class A Warrants sold pursuant to the exercise of the Option), and (iv) &lt;span id="ie8d26f95c153412dbc0bee56ba637c99_16848"/&gt;30,095,697 Class B Warrants (including 3,925,525 Class B Warrants sold pursuant to the exercise of the Option) (the &#x201c;Class B Warrants&#x201d; and together with the Class A Warrants, the &#x201c;Warrants&#x201d;). Upon exercise, the warrants will convert on a 40 for 1 basis into a total of 1,504,785 common shares. The public offering price of $8.00 per Common Share, Class A Warrant and Class B Warrant or $1,000 per Preferred Share, 5,000 Class A Warrants and 5,000 Class B Warrants resulted in net proceeds to the Company, of approximately $5.3 million net of underwriting discount and commissions of $0.4&#160;million and expense of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Each Warrant is exercisable at a price per share of common stock of $8.00. The Class A Warrants will expire on September&#160;23, 2023 and the Class B Warrants will expire on September&#160;23, 2027. The exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During August 2022, all holders of the Series E Preferred Shares issued in the Public Offering, elected to convert their Series E Preferred Shares into 160,000 shares of Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On November&#160;17, 2022, the Company entered into warrant exercise inducement offer letters with some of the Class A Warrant holders who agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of common stock originally issued in the Public Offering in exchange for the Company's agreement to issue new warrants (the &#x201c;Inducement Warrants&#x201d;) on substantially the same terms as the Class A Warrants to purchase up to 654,609 shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of common stock of $5.97. Each Inducement Warrant will initially be exercisable six months following its date of issuance, and will expire on the eighteen month anniversary of their initial exercise date. The Company received aggregate gross proceeds of approximately $3.1 million from the exercise of the Class A Warrants by the selling stockholders and the sale of the Inducement Warrants. The Company paid its placement agent in connection with the inducement transactions a fee equal to 8% of gross proceeds from the exercise of the Class A Warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"
      decimals="0"
      id="f-541"
      unitRef="shares">38278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <kprx:ClassOfWarrantOrRightNumberOfWarrantIssued
      contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"
      decimals="0"
      id="f-542"
      unitRef="shares">38278</kprx:ClassOfWarrantOrRightNumberOfWarrantIssued>
    <kprx:SharePurchasePriceOfCommonStockAndWarrant
      contextRef="i2eb912acb7a84e7f899a898ef68025da_I20210106"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">209.00</kprx:SharePurchasePriceOfCommonStockAndWarrant>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"
      decimals="-5"
      id="f-544"
      unitRef="usd">8000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <kprx:WarrantExercisePricePerShareSubjectToAdjustment
      contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">209.00</kprx:WarrantExercisePricePerShareSubjectToAdjustment>
    <kprx:WarrantTerm
      contextRef="if363cd03c440489cae184e83db725dbe_D20210106-20210106"
      id="f-546">P6M</kprx:WarrantTerm>
    <kprx:WarrantTerm
      contextRef="idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106"
      id="f-547">P5Y</kprx:WarrantTerm>
    <kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock
      contextRef="ibbef246b73ec4853aedf59d7fa6d83ce_D20210727-20210727"
      decimals="0"
      id="f-548"
      unitRef="shares">4092</kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock>
    <kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock
      contextRef="i20ff746adaba4d52862cc8fe8045f21a_D20210727-20210727"
      decimals="0"
      id="f-549"
      unitRef="shares">21313</kprx:StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811"
      decimals="0"
      id="f-550"
      unitRef="shares">116721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i231e710e53a94b32bd4380968717a154_I20210811"
      decimals="2"
      id="f-551"
      unitRef="usdPerShare">92.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811"
      decimals="0"
      id="f-552"
      unitRef="shares">58361</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">89.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i231e710e53a94b32bd4380968717a154_I20210811"
      decimals="0"
      id="f-554"
      unitRef="shares">5836</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i231e710e53a94b32bd4380968717a154_I20210811"
      decimals="3"
      id="f-555"
      unitRef="usdPerShare">115.124</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iea08751701bc47a9bdc29cf167c3a9b4_I20210811"
      id="f-556">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55b863baa3d94cbeaa979ddc84bd38b5_D20210811-20210811"
      decimals="-5"
      id="f-557"
      unitRef="usd">9800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i94882f0f19bc4f1a9ba8053af45015f0_D20210917-20210917"
      decimals="0"
      id="f-558"
      unitRef="shares">39</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917"
      decimals="0"
      id="f-559"
      unitRef="shares">273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <kprx:StockIssuedDuringPeriodSharesFromHoldBackShares
      contextRef="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618"
      decimals="0"
      id="f-560"
      unitRef="shares">10087</kprx:StockIssuedDuringPeriodSharesFromHoldBackShares>
    <kprx:BusinessAcquisitionHoldbackSharesTerm
      contextRef="ibb2b7778e1d04d039f67b19c83579237_D20220618-20220618"
      id="f-561">P18M</kprx:BusinessAcquisitionHoldbackSharesTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibcc4b1bc13d6443abfeddc9d34019b8c_D20220726-20220726"
      decimals="0"
      id="f-562"
      unitRef="shares">592392</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idd47b9b3e10d46d29b71583d4dafc1d5_I20220726"
      decimals="0"
      id="f-563"
      unitRef="shares">98138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i19ded37b921e452b99960ea388a4e60d_I20220726"
      decimals="0"
      id="f-564"
      unitRef="shares">1280</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726"
      decimals="-3"
      id="f-565"
      unitRef="shares">160000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic8f91e8319c64ff39768af4b6a7f2366_I20220726"
      decimals="0"
      id="f-566"
      unitRef="shares">30095697</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i487e6598d77f4f0b96574b8f7d9e0080_I20220726"
      decimals="0"
      id="f-567"
      unitRef="shares">3925525</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i55104f5329234e7f8ec5172aa858ce3c_I20220726"
      decimals="INF"
      id="f-568"
      unitRef="shares">30095697</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib036afd5d8a7483089c4510b19eba804_I20220726"
      decimals="0"
      id="f-569"
      unitRef="shares">3925525</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <kprx:WarrantsConvertibleIntoCommonStock
      contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726"
      decimals="0"
      id="f-570"
      unitRef="shares">1504785</kprx:WarrantsConvertibleIntoCommonStock>
    <kprx:SharesIssuedPricePerCommonShares
      contextRef="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">8.00</kprx:SharesIssuedPricePerCommonShares>
    <kprx:SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants
      contextRef="ibe54bb58b9444c3d97bfe9914bad3eda_I20220726"
      decimals="INF"
      id="f-572"
      unitRef="usdPerShare">1000</kprx:SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants>
    <kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants
      contextRef="ic8f91e8319c64ff39768af4b6a7f2366_I20220726"
      decimals="INF"
      id="f-573"
      unitRef="shares">5000</kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants>
    <kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants
      contextRef="i55104f5329234e7f8ec5172aa858ce3c_I20220726"
      decimals="INF"
      id="f-574"
      unitRef="shares">5000</kprx:NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726"
      decimals="-5"
      id="f-575"
      unitRef="usd">5300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <kprx:UnderwritingDiscountAndCommissions
      contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726"
      decimals="-5"
      id="f-576"
      unitRef="usd">400000</kprx:UnderwritingDiscountAndCommissions>
    <kprx:UnderwritingDiscountAndCommissionsExpenses
      contextRef="ib5b3e2bd94e5461995b9685349bf3c57_D20220726-20220726"
      decimals="-5"
      id="f-577"
      unitRef="usd">300000</kprx:UnderwritingDiscountAndCommissionsExpenses>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1bde319e174f4eaf85b6f29075e81c13_I20220726"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i45c59bdff9d148dda84d10448e82d282_I20220726"
      decimals="-3"
      id="f-579"
      unitRef="shares">160000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <kprx:ClassOfWarrantOrRightExercised
      contextRef="i62af4e98e26040bb88a1fcc90172c191_D20221117-20221117"
      decimals="0"
      id="f-580"
      unitRef="shares">654609</kprx:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia811bfae64784023b2eb006045403cbe_I20221117"
      decimals="INF"
      id="f-581"
      unitRef="shares">654609</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8e97479594434d06b760d7fa074563be_I20221117"
      decimals="2"
      id="f-582"
      unitRef="usdPerShare">5.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <kprx:ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable
      contextRef="i58366d417e1645fab574b8a7fe469157_D20221117-20221117"
      id="f-583">P6M</kprx:ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i8e97479594434d06b760d7fa074563be_I20221117"
      id="f-584">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <kprx:ProceedsFromWarrantExercisesAndWarrantSales
      contextRef="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117"
      decimals="-5"
      id="f-585"
      unitRef="usd">3100000</kprx:ProceedsFromWarrantExercisesAndWarrantSales>
    <kprx:WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage
      contextRef="i443979b44cce4acca29f5f3c7aa8035e_D20221117-20221117"
      decimals="INF"
      id="f-586"
      unitRef="number">0.08</kprx:WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage>
    <kprx:WarrantsDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-589">WarrantsAt December&#160;31, 2022 and 2021, the following warrants were outstanding:&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,159,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(719,609)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,112)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;900.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,597,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of shares to be issued upon exercise of such warrants will be reduced based on the exercise price and the market value of the shares at the time of exercise. The outstanding warrants expire from 2023 through 2027.&lt;/span&gt;&lt;/div&gt;</kprx:WarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-590">At December&#160;31, 2022 and 2021, the following warrants were outstanding:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,159,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(719,609)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,112)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;900.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,597,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231"
      decimals="0"
      id="f-591"
      unitRef="shares">68168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
      contextRef="iaacd49bfe5be4b5d9514ebfe4347a506_I20201231"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">336.40</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i85689dc882234a148ea4e1af5e916f2a_D20200101-20201231"
      id="f-593">P2Y5M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="0"
      id="f-594"
      unitRef="shares">102476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">135.65</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice>
    <kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      id="f-596">P4Y8M4D</kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="0"
      id="f-597"
      unitRef="shares">260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">192.00</kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="0"
      id="f-599"
      unitRef="shares">1452</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      decimals="2"
      id="f-600"
      unitRef="usdPerShare">2100</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i95e7fecaf8fd4207806af45324ae8f90_I20211231"
      decimals="0"
      id="f-601"
      unitRef="shares">168932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
      contextRef="i95e7fecaf8fd4207806af45324ae8f90_I20211231"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">199.65</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ife27382c2ad34b07b84d4501e12697b7_D20210101-20211231"
      id="f-603">P3Y5M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="0"
      id="f-604"
      unitRef="shares">2159395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">7.38</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice>
    <kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      id="f-606">P2Y6M18D</kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="0"
      id="f-607"
      unitRef="shares">719609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">5.06</kprx:Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="0"
      id="f-609"
      unitRef="shares">11112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      decimals="2"
      id="f-610"
      unitRef="usdPerShare">900.00</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id5e36c5ec60743bb983183d644c22f6d_I20221231"
      decimals="0"
      id="f-611"
      unitRef="shares">1597606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
      contextRef="id5e36c5ec60743bb983183d644c22f6d_I20221231"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">21.22</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231"
      id="f-613">P3Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-614">Equity Incentive Plan&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In 2005, the Company approved the 2005 Equity Incentive Plan (the &#x201c;2005 Plan&#x201d;). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. During 2010, the maximum number of shares of Common Stock that may be issued pursuant to the 2005 Plan was increased to 59,414 shares. The Board of Directors (the &#x201c;Board&#x201d;) is responsible for administration of the 2005 Plan. The Company&#x2019;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company&#x2019;s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company&#x2019;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;), no further grants were made under the 2005 Plan. General terms of the 2014 Plan remain the same as that of the 2005 plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company&#x2019;s Board adopted the 2014 Plan and the Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), and the Company&#x2019;s Stockholders approved the 2014 Plan and the ESPP Plan in February 2015. As of December&#160;31, 2022, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP was 220,733 and 284 shares, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;In January 2022, the number of shares of common stock issuable under the 2014 Plan automatically increased by 583 shares pursuant to the terms of the 2014 Plan. Additionally, in September 2022, the number of shares of common stock issuable under the 2014 Plan was increased by 200,000 shares, as approved by the Company&#x2019;s Stockholders. These additional shares are included in the total of 220,733 shares issuable under the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The following is a summary of stock option activity for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Contractual Life&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;840.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,046.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;259.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;426.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;847.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and Expected to Vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;426.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;842.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,939&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;442.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and Expected to Vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of options to purchase 78,641 and 8,654 shares of its Common Stock, respectively. All option grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. For the years ended December&#160;31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Average Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the years ended December&#160;31, 2022 and 2021 was $27.08 and $145.63 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The following is a summary of restricted stock activity for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average &lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;292.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;During the years ended December&#160;31, 2022 and 2021, 127 and 149 shares of restricted stock, which had not vested, were forfeited and returned to the Company, respectively. During the years ended December&#160;31, 2022 and 2021, the Board approved the grant of 30,000 and 0 restricted shares of Common Stock, respectively. All grants of restricted shares were pursuant to the 2014 Plan. These vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;343,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Stock-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;462,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;842,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The fair value of options granted for the years ended December&#160;31, 2022 and 2021 was approximately $0.6 million and $1.2 million, respectively. As of December&#160;31, 2022 and 2021, there was approximately $0.9 million and $1.0 million of total unrecognized compensation expense related to unvested stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted average period of 2.5 and 2.3 years, respectively. The aggregate intrinsic value of stock options outstanding at December&#160;31, 2022 and 2021 was $0.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As of December&#160;31, 2022, there were 101,850 shares of Common Stock available for grant under the 2014 Plan and 191 shares available under the Company&#x2019;s ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="i5d6b9d5d260c46978aec252087242f31_I20101231"
      decimals="INF"
      id="f-615"
      unitRef="shares">59414</us-gaap:ExcessStockSharesAuthorized>
    <kprx:PercentageOfExercisePrice
      contextRef="i3330bdda247340909ef880086af2dc10_D20100101-20101231"
      decimals="2"
      id="f-616"
      unitRef="number">1.10</kprx:PercentageOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1c9bdfc674f144df89195e7f413c9078_D20100101-20101231"
      id="f-617">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3ba894cd6b144b8f9075e713823ec483_D20100101-20101231"
      id="f-618">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ide7b6258bd17457592b81acc9062273f_I20221231"
      decimals="INF"
      id="f-619"
      unitRef="shares">220733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id38a833f22f24032be3a7e78950e921a_I20221231"
      decimals="INF"
      id="f-620"
      unitRef="shares">284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i795d0aceb7c54c7293c21cba1406d938_D20210101-20210131"
      decimals="INF"
      id="f-621"
      unitRef="shares">583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="i1c1283a1942d49d3a4dbd18de8e7917c_I20220930"
      decimals="INF"
      id="f-622"
      unitRef="shares">200000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4c4ef98046ac4ad4bfb9fb4488c8e276_I20221231"
      decimals="INF"
      id="f-623"
      unitRef="shares">220733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-624">The following is a summary of stock option activity for the years ended December&#160;31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average &lt;br/&gt;Contractual Life&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;840.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,046.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;259.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;426.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;847.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and Expected to Vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;426.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;842.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,939&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;442.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and Expected to Vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231"
      decimals="INF"
      id="f-625"
      unitRef="shares">6249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i32ec6781878b4a5aa00aba09602df9ab_I20201231"
      decimals="2"
      id="f-626"
      unitRef="usdPerShare">840.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i55c57edb8428421a821f6bc68bf101ed_D20200101-20201231"
      id="f-627">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-628"
      unitRef="shares">8654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-629"
      unitRef="usdPerShare">164.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-630"
      unitRef="shares">825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">1046</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-632"
      unitRef="shares">1124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-633"
      unitRef="usdPerShare">259.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-634"
      unitRef="shares">12954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="2"
      id="f-635"
      unitRef="usdPerShare">426.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      id="f-636">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-637"
      unitRef="shares">5087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="2"
      id="f-638"
      unitRef="usdPerShare">847.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      id="f-639">P3Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-640"
      unitRef="shares">12954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="2"
      id="f-641"
      unitRef="usdPerShare">426.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      id="f-642">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-643"
      unitRef="shares">78641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-644"
      unitRef="usdPerShare">8.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-645"
      unitRef="shares">14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-646"
      unitRef="usdPerShare">842.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-647"
      unitRef="shares">6830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">446.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-649"
      unitRef="shares">84751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="2"
      id="f-650"
      unitRef="usdPerShare">36.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-651">P9Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-652"
      unitRef="shares">4939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="2"
      id="f-653"
      unitRef="usdPerShare">442.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-654">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-655"
      unitRef="shares">84751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="2"
      id="f-656"
      unitRef="usdPerShare">36.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-657">P9Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-658"
      unitRef="shares">78641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="INF"
      id="f-659"
      unitRef="shares">8654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i99a48c50139c4eb598eca8ffd0d33853_D20220101-20221231"
      id="f-660">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i40cc4e02cb1e43849c0b6c2e74f65db2_D20220101-20221231"
      id="f-661">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-662">For the years ended December&#160;31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Average Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-663"
      unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-664"
      unitRef="number">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-665">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      id="f-666">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-667"
      unitRef="number">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-668"
      unitRef="number">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-669"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-670"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-671"
      unitRef="usdPerShare">27.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="2"
      id="f-672"
      unitRef="usdPerShare">145.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-673">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The following is a summary of restricted stock activity for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average &lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;292.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;261.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-vested Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1b08f940273a487b92ac968165f4687b_I20201231"
      decimals="INF"
      id="f-674"
      unitRef="shares">1697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1b08f940273a487b92ac968165f4687b_I20201231"
      decimals="2"
      id="f-675"
      unitRef="usdPerShare">283.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i60ca6dd2eaac461ca903428aa88ce1da_D20200101-20201231"
      id="f-676">P1Y7M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="INF"
      id="f-677"
      unitRef="shares">1173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="2"
      id="f-678"
      unitRef="usdPerShare">292.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="INF"
      id="f-679"
      unitRef="shares">149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="2"
      id="f-680"
      unitRef="usdPerShare">264.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibc96ca35437b4369949f0a093fabcb10_I20211231"
      decimals="INF"
      id="f-681"
      unitRef="shares">375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibc96ca35437b4369949f0a093fabcb10_I20211231"
      decimals="2"
      id="f-682"
      unitRef="usdPerShare">261.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      id="f-683">P1Y1M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="INF"
      id="f-684"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="2"
      id="f-685"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="INF"
      id="f-686"
      unitRef="shares">248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="2"
      id="f-687"
      unitRef="usdPerShare">261.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="INF"
      id="f-688"
      unitRef="shares">127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="2"
      id="f-689"
      unitRef="usdPerShare">261.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i45d74368d0d343e6a4e730cc009f7c82_I20221231"
      decimals="INF"
      id="f-690"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i45d74368d0d343e6a4e730cc009f7c82_I20221231"
      decimals="2"
      id="f-691"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      id="f-692">P2Y9M14D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="INF"
      id="f-693"
      unitRef="shares">127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="INF"
      id="f-694"
      unitRef="shares">149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id4915e719780444bb5d06f84de1f000a_D20220101-20221231"
      decimals="INF"
      id="f-695"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i63cde2c6ba9b4ce79ebc1a367ad5b308_D20210101-20211231"
      decimals="INF"
      id="f-696"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iddcdb30cd8d549d5ad95f8f150dd303a_D20220101-20221231"
      id="f-697">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i66c68281b3014e56a22e50e935a398ae_D20220101-20221231"
      id="f-698">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-699">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;343,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Stock-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;462,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;842,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i1cea2dd17233476fbcf15949d7520ede_D20220101-20221231"
      decimals="0"
      id="f-700"
      unitRef="usd">343475</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i50cfa066a22f4226b954687d13a1302a_D20210101-20211231"
      decimals="0"
      id="f-701"
      unitRef="usd">246386</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i7aa3ab539c714dae87e11ec896cca4d3_D20220101-20221231"
      decimals="0"
      id="f-702"
      unitRef="usd">118975</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="ie678dc82cc1b44fdaea24b535ce33f39_D20210101-20211231"
      decimals="0"
      id="f-703"
      unitRef="usd">596089</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-704"
      unitRef="usd">462450</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-705"
      unitRef="usd">842475</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="-5"
      id="f-706"
      unitRef="usd">600000</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-5"
      id="f-707"
      unitRef="usd">1200000</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-708"
      unitRef="usd">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="-5"
      id="f-709"
      unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-710">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      id="f-711">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-712"
      unitRef="usd">0</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-713"
      unitRef="usd">0</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ide7b6258bd17457592b81acc9062273f_I20221231"
      decimals="INF"
      id="f-714"
      unitRef="shares">101850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id38a833f22f24032be3a7e78950e921a_I20221231"
      decimals="INF"
      id="f-715"
      unitRef="shares">191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-720">Income Taxes&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The components of loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,563,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,639,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,133,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,323,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,696,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,963,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The components of income tax (benefit) expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(117,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(168,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Deferred Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(192,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(192,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States Federal Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State Taxes, Net of Federal Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent Differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State Non-Income Based Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective Tax Rate Expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net Deferred Tax Liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Operating Loss Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,809,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,689,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development Credit Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,925,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,853,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,640,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;782,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;835,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash Versus Accrual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,461,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,146,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29,593,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,298,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Deferred Tax Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,867,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,848,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;In-Process Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,556,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,649,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(689,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(802,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As of December&#160;31, 2022, the Company has federal and state net operating loss carryforwards of approximately $80.5 million and $52.6 million, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December&#160;31, 2017 totaling $46.1 million, and state NOL carryforwards as of December&#160;31, 2022 totaling $52.6 million will expire at various dates through 2042. Federal NOL carryforwards generated during the years ended December&#160;31, 2018 and forward totaling $34.4 million will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $10.7 million as of December&#160;31, 2022, which can be carried forward indefinitely. As of December&#160;31, 2022, the Company also has federal and state research and development tax credit carryforwards of approximately $2.5 million and $0.5 million, respectively, to offset future income taxes, which expire at various times through 2042. The federal and state net operating loss and research tax credit carryforwards may be subject to the limitations provided in the Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383. Approximately $0.6 million of the federal net operating loss attributable to Jade is subject to a Section 382 limitation. Jade&#x2019;s carryover of its research and development credits will be subject to the Section 383 limitation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company files United States federal income tax returns and income tax returns in the Commonwealth of Massachusetts, California, North Carolina and Utah, as well as foreign tax returns for its subsidiaries in Austria and Australia. The Company filed all foreign tax returns for its former French subsidiary EyeGate Pharma S.A.S., which was dissolved December&#160;31, 2021. The Company is not under examination by any jurisdiction for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company has recorded a valuation allowance against its United States and foreign deferred tax assets in each of the years ended December&#160;31, 2022, and 2021 because the Company&#x2019;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $1.3 million and $3.0 million during the years ended December&#160;31, 2022 and 2021, respectively, primarily as a result of the increase in net operating losses and credits, adjustments for accrual to cash basis items, and capitalized research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As of December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company will recognize interest and penalties related to income taxes in income tax expense. The Company has not, as yet, conducted a study of R&amp;amp;D credit carryforwards, which are fully reserved for. This study may result in an adjustment to the Company&#x2019;s R&amp;amp;D credit carryforwards and related &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;valuation allowance, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The net operating loss and tax credit carryforwards are subject to review by the Internal Revenue Service in accordance with the provisions of Section 382 of the Internal Revenue Code. Under this Internal Revenue Code section, substantial changes in the Company&#x2019;s ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset the Company&#x2019;s taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the Company&#x2019;s net operating loss carryforwards before they expire. The closing of the Company&#x2019;s initial public offering, alone or together with transactions that have occurred or that may occur in the future, may trigger an ownership change pursuant to Section 382, which could limit the amount of research and development tax credit and net operating loss carryforwards that could be utilized annually in the future to offset the Company&#x2019;s taxable income, if any. Any such limitation as the result of the Company&#x2019;s additional sales of common stock by the Company could have a material adverse effect on the Company&#x2019;s results of operations in future years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-721">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The components of loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,563,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,639,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,133,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,323,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Loss Before Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,696,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,963,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-722"
      unitRef="usd">-10563302</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-723"
      unitRef="usd">-10639818</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-724"
      unitRef="usd">-3133318</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-725"
      unitRef="usd">-3323470</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-726"
      unitRef="usd">-13696620</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-727"
      unitRef="usd">-13963288</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-728">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The components of income tax (benefit) expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(117,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(168,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Deferred Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(192,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(192,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-729"
      unitRef="usd">4954</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-730"
      unitRef="usd">-24086</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-731"
      unitRef="usd">-117964</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-732"
      unitRef="usd">-168517</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-733"
      unitRef="usd">-113010</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-734"
      unitRef="usd">-192603</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="0"
      id="f-735"
      unitRef="usd">-113010</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="0"
      id="f-736"
      unitRef="usd">-192603</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-737">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States Federal Income Tax Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State Taxes, Net of Federal Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Permanent Differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State Non-Income Based Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective Tax Rate Expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-738"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-739"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-740"
      unitRef="number">-0.0259</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-741"
      unitRef="number">0.0335</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-742"
      unitRef="number">-0.0924</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-743"
      unitRef="number">0.0072</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-744"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-745"
      unitRef="number">0.0607</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-746"
      unitRef="number">-0.0953</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-747"
      unitRef="number">-0.2133</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-748"
      unitRef="number">0.0058</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-749"
      unitRef="number">0.0109</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-750"
      unitRef="number">0.0289</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-751"
      unitRef="number">0.0100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-752"
      unitRef="number">0</kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent>
    <kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-753"
      unitRef="number">0.0001</kprx:EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-754"
      unitRef="number">-0.0026</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-755"
      unitRef="number">0.0161</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="4"
      id="f-756"
      unitRef="number">0.0284</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="4"
      id="f-757"
      unitRef="number">0.0138</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-758">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net Deferred Tax Liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Operating Loss Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,809,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,689,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and Development Credit Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,925,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,853,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,640,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;782,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;835,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash Versus Accrual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,461,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,146,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29,593,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,298,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Deferred Tax Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,867,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,848,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;In-Process Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,556,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,649,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(689,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(802,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-759"
      unitRef="usd">22809667</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-760"
      unitRef="usd">20689134</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-761"
      unitRef="usd">2925890</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-762"
      unitRef="usd">2853598</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-763"
      unitRef="usd">4606902</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-764"
      unitRef="usd">5640428</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-765"
      unitRef="usd">782355</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-766"
      unitRef="usd">835432</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-767"
      unitRef="usd">336360</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-768"
      unitRef="usd">128188</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-769"
      unitRef="usd">31461174</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-770"
      unitRef="usd">30146780</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-771"
      unitRef="usd">29593286</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-772"
      unitRef="usd">28298339</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-773"
      unitRef="usd">1867888</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-774"
      unitRef="usd">1848441</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-775"
      unitRef="usd">477</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-776"
      unitRef="usd">956</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-777"
      unitRef="usd">2556532</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-778"
      unitRef="usd">2649616</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-779"
      unitRef="usd">689121</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="0"
      id="f-780"
      unitRef="usd">802131</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-5"
      id="f-781"
      unitRef="usd">80500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231"
      decimals="-5"
      id="f-782"
      unitRef="usd">52600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id7386b4156e64f10a54ecf9bdd879e97_I20171231"
      decimals="-5"
      id="f-783"
      unitRef="usd">46100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1d97a256341d4e518d4ae9a853fe5ac6_I20221231"
      decimals="-5"
      id="f-784"
      unitRef="usd">52600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i53772301813341239fac34a54517b47d_I20181231"
      decimals="-5"
      id="f-785"
      unitRef="usd">34400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6091ba41f5734ea4ba9b5aadee940665_I20221231"
      decimals="-5"
      id="f-786"
      unitRef="usd">10700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1316295f29124fd8882adbcf2ad44e82_I20221231"
      decimals="-5"
      id="f-787"
      unitRef="usd">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i92bb8ffea2e14d55ab953dcb6895cbc3_I20221231"
      decimals="-5"
      id="f-788"
      unitRef="usd">500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3a467fc4202c4b38b702366fd2de3793_I20221231"
      decimals="-5"
      id="f-789"
      unitRef="usd">600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="-5"
      id="f-790"
      unitRef="usd">1300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-5"
      id="f-791"
      unitRef="usd">3000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="INF"
      id="f-792"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i746a7934f1634bada7a8c67124affa16_I20211231"
      decimals="INF"
      id="f-793"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-794">Commitments and Contingencies&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company is a party to three real property operating leases for the rental of office or lab space. In February 2022, the Company entered into a lease for an office facility in Encinitas, California with a term through October&#160;31, 2023, which is now used for its corporate headquarters. The Company recorded a right-of-use (ROU) asset and lease liability upon lease commencement in May 2022. The Company also has office and laboratory space of approximately 3,540 square feet in Salt Lake City, Utah with a term through November&#160;30, 2023. The Company has office space in Vienna, Austria of approximately 1,555 square feet with a term through October&#160;31, 2023 as a result of the Panoptes acquisition effective December 18, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Additional ROU assets and lease liabilities were recorded upon the new lease agreements or extensions that were effective as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Operating lease assets and liabilities are recognized at the lease commencement date at the present value of lease payments to be paid. Operating lease assets represent the Company&#x2019;s right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments. To determine the present value of lease payments to be paid, the Company estimated incremental secured borrowing rates corresponding to the maturities of the leases. The Company estimated a rate of 10% based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company recognizes expense for its leases on a straight-line basis over the lease term. Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $0.1 million and $0.2 million for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Future annual minimum lease payments were as follows as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Amounts Representing Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company is a party to seven license agreements as described below. These license agreements require the Company to pay or receive royalties or fees to or from the licensor based on revenue or milestones related to the licensed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals GmbH) entered into a patent and know-how assignment agreement with 4SC Discovery GmbH (&#x201c;4SC&#x201d;) transferring to it all patent rights and know-how to the compound KIO-101. The Company is responsible for paying royalties of 3.25% on net sales of KIO-101.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On July&#160;2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals, GmbH) entered into an out-license agreement with 4SC granting 4SC the exclusive worldwide right to commercialize the compound KIO-101 for rheumatoid arthritis and inflammatory bowel disease, including Crohn&#x2019;s Disease and Ulcerative Colitis. The Company is eligible to receive milestone payments totaling up to &#x20ac;155 million, upon and subject to the achievement of certain specified developmental and commercial milestones. We have not received any milestones from 4SC. In addition, the Company is eligible to receive royalties of 3.25% on net sales of KIO-101.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On September&#160;12, 2013, the Company (through its subsidiary, Jade Therapeutics, Inc.) entered into an agreement with Lineage Cell Therapeutics, Inc. (&#x201c;Lineage&#x201d;), formerly known as BioTime, Inc. granting to the Company the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (&#x201c;modified HA&#x201d;) for ophthalmic treatments in humans. The agreement requires the Company to pay an annual fee of $30,000 and a royalty of 6% on net sales of KIO-201 to Lineage based on revenue relating to any product incorporating the modified HA technology. The agreement expires when patent protection for the modified HA technology lapses in August 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On November&#160;17, 2014, the Company (through its subsidiary Kiora Pharmaceuticals GmbH) entered into an intellectual property and know-how licensing agreement with Laboratoires Leurquin Mediolanum S.A.S. (&#x201c;Mediolanum&#x201d;) for the commercialization of KIO-101 in specific territories. Under the Mediolanum agreement, the Company out-licensed rights to commercialize KIO-101 for uveitis, dry eye and viral conjunctivitis in Italy, and France. This agreement was amended on December 10, 2015 to also include Belgium and The Netherlands. Under the Mediolanum agreement, Mediolanum is obligated to pay up to approximately &#x20ac;20.0&#160;million in development and commercial milestones and a 7% royalty on net sales of KIO-101 in the territories through the longer of the expiration of the valid patents covering KIO-101 or 10 years from the first commercial sale. The royalty is reduced to 5% after patent expiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On September&#160;26, 2018, the Company entered into an intellectual property licensing agreement (the &#x201c;SentrX Agreement&#x201d;) with SentrX, a veterinary medical device company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, the Company in-licensed the rights to trade secrets and know-how related to the manufacturing of KIO-201. The SentrX Agreement enables the Company to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use. Under the SentrX Agreement, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified developmental and commercial milestones. The term of the agreement is until the product is no longer in the commercial marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On May&#160;1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with the University of California (&#x201c;UC&#x201d;) granting to the Company the exclusive rights to its pipeline of photoswitch molecules. The agreement requires the Company to pay an annual fee to UC of $5,000, as well as payments to UC upon the achievement of certain development milestone and royalties based on KIO-301 revenue. The Company is obligated to pay royalties on net sales of two percent (2%) of the first $250 million of net sales, one and a quarter percent (1.25%) of net sales between $250 million and $500 million, and one half of one percent (0.5%) of net sales over $500 million. The agreement expires on the date of the last-to-expire patent included in the licensed patent portfolio which is January 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On May 1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with Photoswitch Therapeutics, Inc. (&#x201c;Photoswitch&#x201d;) granting to the Company access to certain patent applications and IP rights with last-to-expire patent terms of January 2030. The agreement calls for payments to Photoswitch upon the achievement of certain development and upon first commercial sale of the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The continued spread of the COVID-19 pandemic could adversely impact the Company&#x2019;s clinical studies. In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, and business shutdowns. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which could negatively affect the Company&#x2019;s ability to raise additional capital on attractive terms or at all. The extent to which COVID-19 may impact the Company&#x2019;s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, and the effectiveness of actions to contain and treat COVID-19. The Company cannot presently predict the scope and severity of any potential disruptions to its business, including to ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to the Company&#x2019;s ability to conduct its business in the manner and on the timelines presently planned, which could have a material adverse impact on its business, results of operation, and financial condition. As of the date of this report, there have been no material adverse effects to the Company&#x2019;s ongoing business operations from COVID-19.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <kprx:LesseeNumberOfOperatingLeases
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-795"
      unitRef="operatinglease">3</kprx:LesseeNumberOfOperatingLeases>
    <us-gaap:AreaOfLand
      contextRef="i13150472ec5a4562a80ec73c18d52b3b_I20231130"
      decimals="-1"
      id="f-796"
      unitRef="sqft">3540</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="ic4a8d3ef8ffa49ccb26b949764fa8fee_I20231031"
      decimals="0"
      id="f-797"
      unitRef="sqft">1555</us-gaap:AreaOfLand>
    <kprx:CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="2"
      id="f-798"
      unitRef="number">0.10</kprx:CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="-5"
      id="f-799"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <kprx:OperatingLeaseInterestOnLeaseLiabilities
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-5"
      id="f-800"
      unitRef="usd">200000</kprx:OperatingLeaseInterestOnLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-801">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Future annual minimum lease payments were as follows as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Amounts Representing Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-802"
      unitRef="usd">105523</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-803"
      unitRef="usd">1830</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="0"
      id="f-804"
      unitRef="usd">103693</us-gaap:OperatingLeaseLiability>
    <kprx:NumberOfLicenseAgreements
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-805"
      unitRef="licenseagreement">7</kprx:NumberOfLicenseAgreements>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="i48105e35cedb4703a776e5dc694b2952_I20130702"
      decimals="4"
      id="f-806"
      unitRef="number">0.0325</kprx:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if26ec064aa5b44919c5571e6926241b3_D20130702-20130702"
      decimals="-6"
      id="f-807"
      unitRef="eur">155000000</us-gaap:CostOfGoodsAndServicesSold>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="i48105e35cedb4703a776e5dc694b2952_I20130702"
      decimals="4"
      id="f-808"
      unitRef="number">0.0325</kprx:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i076a9cb935ea4b94bb35bfd4c2edad1e_D20130912-20130912"
      decimals="0"
      id="f-809"
      unitRef="usd">30000</us-gaap:CostOfGoodsAndServicesSold>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="ia857601644d14861b27f01abd39ba087_I20130912"
      decimals="2"
      id="f-810"
      unitRef="number">0.06</kprx:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:ContractualObligation
      contextRef="i33078441568940d896f1f0dc9f50a202_I20141117"
      decimals="-5"
      id="f-811"
      unitRef="eur">20000000</us-gaap:ContractualObligation>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="i33078441568940d896f1f0dc9f50a202_I20141117"
      decimals="2"
      id="f-812"
      unitRef="number">0.07</kprx:PercentageOfRoyaltiesOnNetSales>
    <kprx:DevelopmentAndCommercialMilestonesTerm
      contextRef="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117"
      id="f-813">P10Y</kprx:DevelopmentAndCommercialMilestonesTerm>
    <kprx:PercentageOfDecreasedRoyaltyAfterPatentExpiry
      contextRef="ic14523d10d0646099a34dc8d5a38f68d_D20141117-20141117"
      decimals="2"
      id="f-814"
      unitRef="number">0.05</kprx:PercentageOfDecreasedRoyaltyAfterPatentExpiry>
    <kprx:IntangibleAssetsExpectedMilestonePayable
      contextRef="i9dcf2ad2cdd04f2e8c2e583db3d2594b_I20180926"
      decimals="-4"
      id="f-815"
      unitRef="usd">4750000</kprx:IntangibleAssetsExpectedMilestonePayable>
    <kprx:PaymentOfAnnualFee
      contextRef="i7bfb95e5fdd6415fa8eab70b36245efa_D20200501-20200501"
      decimals="0"
      id="f-816"
      unitRef="usd">5000</kprx:PaymentOfAnnualFee>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="icdd19ae6f91940c681c6752beffda62a_I20200501"
      decimals="2"
      id="f-817"
      unitRef="number">0.02</kprx:PercentageOfRoyaltiesOnNetSales>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="ic0bef4b71f5f45e382bf6c1ac713c7c7_I20200501"
      decimals="4"
      id="f-818"
      unitRef="number">0.0125</kprx:PercentageOfRoyaltiesOnNetSales>
    <kprx:PercentageOfRoyaltiesOnNetSales
      contextRef="if750165f4c9d4109955ee668d01b093e_I20200501"
      decimals="3"
      id="f-819"
      unitRef="number">0.005</kprx:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-820">Employee Benefit Plans&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;As a result of the 401(k) plan compliance review for the year ended December&#160;31, 2021, the Company contributed approximately $29.2 thousand to eligible participants during the third quarter of 2022. As of December&#160;31, 2022, the Company has accrued an additional estimate of $8.5 thousand for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      decimals="INF"
      id="f-821"
      unitRef="number">0</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i08d1ba10070c423f8eb7d756c8b134e9_D20210101-20211231"
      decimals="-2"
      id="f-822"
      unitRef="usd">29200</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <kprx:DefinedBenefitPlanContributionsByEmployerAccrued
      contextRef="ia02f437734fd4e36ae0a425508221c0b_I20221231"
      decimals="-2"
      id="f-823"
      unitRef="usd">8500</kprx:DefinedBenefitPlanContributionsByEmployerAccrued>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-824">Acquisitions&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bayon Therapeutics, Inc. Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Effective October 21, 2021, the Company acquired all of the capital stock of Bayon, a privately held ophthalmic specialty pharmaceutical company focused on developing light sensitive small molecules. With the Bayon acquisition, Bayon became a wholly-owned subsidiary of Kiora. The assets acquired and liabilities assumed have been recorded at fair value on the date of the acquisition. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill, which is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Under the terms of the Bayon acquisition agreement, in consideration for 100% of the outstanding equity interests in Bayon, the Company paid cash in the amount of $0.1 million to certain sellers and creditors and issued 845 shares of Kiora common stock. The former stockholders of Bayon are also eligible to receive up to $7.1 million in additional cash or stock payments based on clinical trial and FDA approval milestones for Bayon&#x2019;s product candidates, as set forth in the Purchase Agreement. If milestone payments are exercised for shares, shares will be issued at a price of $80.40 per share for the Phase 1b milestones. The remaining &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;milestones will be calculated at a $132.00 per share. The cash or stock earn-out payments were recorded as contingent consideration and fair valued at $1.0 million at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The fair value of the shares issued in the Bayon acquisition was approximately $0.1 million based on the average closing price of the Company&#x2019;s Common Stock for five trading days immediately preceding the closing date, or $80.40 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-Process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(265,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Assets include cash and receivables of $3.9 thousand and $1.4 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Common &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,007,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kiora Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Fair Value of Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Net loss in the Consolidated Statement of Operations for the twelve months ended December 31, 2021 includes net losses of Bayon of $0.1 million from the date of acquisition. The acquired intangible assets, which consist solely of in-process research and development, will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the intangible assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company recognized approximately $0.1 million of acquisition-related costs for the Bayon acquisition that were expensed in the year ended December 31, 2021 as a component of general and administrative expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="2"
      id="f-825"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="-5"
      id="f-826"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="0"
      id="f-827"
      unitRef="shares">845</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <kprx:BusinessAcquisitionEarnoutConsideration
      contextRef="i0e569234706a4ea9b4ffdd899380ebbb_D20211021-20211021"
      decimals="-5"
      id="f-828"
      unitRef="usd">7100000</kprx:BusinessAcquisitionEarnoutConsideration>
    <us-gaap:SharePrice
      contextRef="i30888c172c61432abf146a3c8dd8bcc5_I20211021"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">80.40</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i1fef671ae73846238e24d7b9e5c28b89_I20211021"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">132.00</us-gaap:SharePrice>
    <kprx:PaymentsToAcquireBusinessesFairValue
      contextRef="id863c423f1fb4e25825a1e8a560df47a_D20211021-20211021"
      decimals="-5"
      id="f-831"
      unitRef="usd">1000000</kprx:PaymentsToAcquireBusinessesFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="-5"
      id="f-832"
      unitRef="usd">100000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <kprx:ThresholdPeriodOfVolumeWeightedAveragePrice
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="INF"
      id="f-833"
      unitRef="day">5</kprx:ThresholdPeriodOfVolumeWeightedAveragePrice>
    <kprx:VolumeWeightedAveragePrice
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="2"
      id="f-834"
      unitRef="usdPerShare">80.40</kprx:VolumeWeightedAveragePrice>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-835">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-Process R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(265,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current Assets include cash and receivables of $3.9 thousand and $1.4 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-836"
      unitRef="usd">5290</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-837"
      unitRef="usd">1063000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <kprx:GoodwillAcquired
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-838"
      unitRef="usd">406599</kprx:GoodwillAcquired>
    <kprx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-839"
      unitRef="usd">36525</kprx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-840"
      unitRef="usd">265808</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="0"
      id="f-841"
      unitRef="usd">1172556</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="-2"
      id="f-842"
      unitRef="usd">3900</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="-2"
      id="f-843"
      unitRef="usd">1400</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <kprx:SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-844">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Common &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,007,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kiora Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Fair Value of Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</kprx:SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock>
    <kprx:BusinessCombinationContingentConsiderationArrangementsFairValue
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="0"
      id="f-845"
      unitRef="usd">1007556</kprx:BusinessCombinationContingentConsiderationArrangementsFairValue>
    <kprx:BusinessCombinationContingentConsiderationCashCurrent
      contextRef="icf18c208a9d143518246d68a22a96f9b_I20211021"
      decimals="0"
      id="f-846"
      unitRef="usd">97066</kprx:BusinessCombinationContingentConsiderationCashCurrent>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021"
      decimals="0"
      id="f-847"
      unitRef="shares">845</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="id6e223d2316642d58da08e015cef85be_I20211021"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">80.40</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i1d84b2a8fb4c4319b8a61fe4c507a6a3_D20211021-20211021"
      decimals="0"
      id="f-849"
      unitRef="usd">67934</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021"
      decimals="0"
      id="f-850"
      unitRef="usd">1172556</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231"
      decimals="-5"
      id="f-851"
      unitRef="usd">100000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ifa136cd31a2c49c7b462bce78672d93a_D20210101-20211231"
      decimals="-5"
      id="f-852"
      unitRef="usd">100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231"
      id="f-853">Subsequent Events&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On February&#160;3, 2023, the Company completed a private placement with Lincoln Park for 52,798 shares of common stock and warrants to purchase up to 105,596 shares of common stock. The total net proceeds from the private placement were approximately $0.2 million. The warrants have an exercise price of $3.538 per share, subject to adjustments as provided under the terms of the warrants, and will be exercisable on the six-month anniversary of the closing date. The warrants are exercisable for five years from the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On February&#160;3, 2023, the Company entered into a purchase agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $10.0 million of common stock (subject to certain limitations), from time to time and at the Company's sole discretion over the term of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;purchase agreement. On February&#160;22, 2023, the Company completed its first issuance under this agreement for a total of 20,000 shares sold to Lincoln Park for proceeds of $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;On February&#160;10, 2023, a holder exercised Inducement Warrants resulting in the issuance of 50,000 shares of common stock and proceeds of $0.3 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203"
      decimals="INF"
      id="f-854"
      unitRef="shares">52798</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7604460adc254f1e9a1bf2330d64d148_I20230203"
      decimals="0"
      id="f-855"
      unitRef="shares">105596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203"
      decimals="-5"
      id="f-856"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7604460adc254f1e9a1bf2330d64d148_I20230203"
      decimals="3"
      id="f-857"
      unitRef="usdPerShare">3.538</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <kprx:WarrantsExercisableAnniversaryOfClosingDatePeriod
      contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203"
      id="f-858">P6M</kprx:WarrantsExercisableAnniversaryOfClosingDatePeriod>
    <kprx:WarrantTerm
      contextRef="ibee08fbef8d24449a8913329c77e0ed1_D20230203-20230203"
      id="f-859">P5Y</kprx:WarrantTerm>
    <kprx:SharePurchaseAgreementSaleOfStockMaximumAmount
      contextRef="i370500edd4064c70bf772759a785cc00_D20230203-20230203"
      decimals="-5"
      id="f-860"
      unitRef="usd">10000000</kprx:SharePurchaseAgreementSaleOfStockMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222"
      decimals="INF"
      id="f-861"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <kprx:ProceedsFromSaleOfStockSharePurchaseAgreement
      contextRef="ie8b61edcdffb4787bea39a76783a56a8_D20230222-20230222"
      decimals="-5"
      id="f-862"
      unitRef="usd">100000</kprx:ProceedsFromSaleOfStockSharePurchaseAgreement>
    <kprx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210"
      decimals="INF"
      id="f-863"
      unitRef="shares">50000</kprx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210"
      decimals="-5"
      id="f-864"
      unitRef="usd">300000</us-gaap:ProceedsFromWarrantExercises>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKL8$"_0'TJ0%5S6&=([TH!?Q08>]_V>:Q-+IFH90?C@ATA\,VH-!;RBEI31
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MI@KD]SM*Q?..>B-:O &?_0]02P,$%     @ .#AW5F,7ZG;*!0  $Q<  !@
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M3\O+-:,1RPL#^'W)N7R_*5Y0GX/W_P502P,$%     @ .#AW5KBD4C.$$@
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MB7<#9/7$ &4[0!$':"<&J-L!JCB@=&) ?CL@+PQ0BB<&%+8#"N* PHD!VG:
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M1P;LDIA%8CT2ZY.836(.B0U(;$AB(Q(;D]B$Q*8DIJ?G],SU!Z0=U1]R;E^
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M+J7TRA86P((E-2##T#'$ WS3>.!SHPK*^L0RF&^9KH6=K0?=),1,O6]4K$,
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M5H=539)9R91$ *QHU[!1=/##S4=:F;213!0S1ME2B ,<,88,;-LC]1",,N&
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MX^S.0>(.-SJ*]$0NA%79% FHQ,JQ.<1*O2!X?)U[U!DY0)F?9YKVQVF]]X^
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M"JKUQ?-G)UF6G$6!L$G/7D8E@%K#/B62PS@&: = 2#'$_F\Y?L2I?(3U&IG
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MCYMN6);X:R$L">!\:8SO-N1@^V?E\F]02P,$%     @ .#AW5A17,;,L"
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M5'"%":YFGB(3[VKD4*A8Y\ISVB%QFRHSW#CLK]_;_ZBSN^.WI=JV_6Z#:#K
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M>*6-!+]!$=12GV#5C%8D'(/N,A+HY+)4X2,Q!8P.Y3$$'V6Y]1KCZ&&%K^L
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MZ/ %D9Q>:9@^Q]O2UC$;<GKI[#8(NJGX%96RA'[&-DE76 S[&$0FAS*<PQV
MC 79&"BW[/HK@7BE4!R& O#KX/B#!$3@!2=K!B.@>&&RZ4TH[L#O+;(A\JN@
M<X<]\[MHCN-21$\(8A7531RRAGCUE;8?=*7BQ [3T6$=?WX=O#-GO:><_8F(
ML- V4&0FW=)^!HR:8EN* C9NG34Z RZ ]Z1T9?, AN_/.BJBT+!U@7JWK#"^
M06,8>TO IT#$F CGWE Q#?A]>8 L&K(HF)^\>0]MQVPV"U5D=/^67CS:[WGX
MF&0E/]Q($9P4HAUI7;0E5'10I,9.CU]2$=?O=I0RQIM!.<-[V11(D)& (;.)
MIU"IKM@O#,U;30D>ICIKURAY*=4_9N1V;=?\,0/WY(N ^Q69R7#I5-)Q63OL
MY4=I(Y LU_([.(]=)^_]K6H=7(JN%04G$&50_%Q-SZ97/=[[-R/D1+;M "I3
M]9>8M^>@C.I)L*YUFFCF([49/'^P:*?DV%B#=)&G['@C,H9<WUXKXN&)R&%2
MM0T\?:T=[(2J];?64.7'"0#Z78 0MZ&X?H,@I7.-#P7EAMYBU+A6H:C$]OJF
ME#OJ^2ECD5K[D"Z4>*7*M:;]0";![6?$)<@!7[]@YX.G5),OP:*I#*(("[EA
MW(_'3('V>-95Q-C9@/-O9_P8F8_O]\&YGY!)(FD]<&/7ZG-]9LT:&XNE/\>5
M'#8#Z./ 12'$J.]"B43 3-(MV3/6[UVIN-+.-T.]2:D0PDE;+GI  <%"R"=R
M!0U3*+,:VYU<LGC$?GMRUW'5;>&U+Z(>D)@8*%=XX/[15^5=N'#8A;< F[BF
M7A=-(0!:P>$(<W(7'<-D76:037*A3[U?NY(9]2I^*&##Q4Y&37JDPQ',=E7:
M2=2FCZVN9^/X0I4*+*-Q=FJW'-TIS7O%8C<8F3QX:G=]6)IZW9OYHW4>#"]1
M?JU0''/OCZ #,.+I4BD=(2R3-=(:?$&A/EZ:L6S$F]=GA]IPAT>'$.F0D<;O
M92O9I1$:PEF/CD/N-F)\\J?+NWLGT\?_T\KN0PC>*@5D#V#L =VH+N.Y2\RH
M=)J:HCK&_E RGV/4)1\$OPLGGJ$%GOVE+NP2CGK;Y']8J=$2'PU,[;P.%<7@
MU#BEK8]]S_5E!5B/?M*VUK7B\Q%(KPO;6(^ELP+5 'BA+=5?*(WP\.,Y%TBG
M5!]-J&+<4-&)O\,C+@SJCMQN@<*0YGO8$1#Z:KNKHR@RCT&WL9ZZT:K<R#>#
MBGTG+S0;C  :F (7]Q\F7 72OK<X[9,1WG13)R*I)T4\C^_%S*DE>#@:+Y:J
MV2A49R.)? )T.IOU 41/2#(JV17?6%#L);FSZ0VQ?-HU%'%;:1BMG\<C/LYU
MTC>'C3T,0U*RB>D_3]'2\6JJ*ZUK5F@1;7]?\0/H*]R>',_^+V%T.8#U'?W.
M8-@?1I3,,N5#A181F@Y1ZAHF8=8-^>3B,@4<Z[+?JD19C+>QK<:^PIY+GTX\
MNN 9;NYKHHATX_%[ZX\$@DB44W'^[I>+UX?S[UBGC*_CZ(0[7+NGT=T@V"A7
MU&MEMBT1!#E1&%5Q&N;+]A_29V AKA%\T^9</X\:[TXVW>:$"Y: 0CJGHMH;
MCA)K KR)::)2TG,9L53D02Q=LD5"W-,>G WI8+P+%-&M'YZ+4 0S#"BP43'
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M<VAE971S+W-H965T,C$N>&ULG5;;;MM&$/V5 1L$*>"2$B6GKB,)L)P4S4,
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M_DU9WO2 O)O&8\5[<6O+A:XD.RK^?;WPP8$1__F1SU'B[,<2*4O>^EIFZG*
M-/#*/:C!U:N?)B?)NQ?LG?7VSEZ2_G_C\?=OBQNY >V_%LK)6C5!9WXH/E:
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M9?.AOOY5RX8>X7QY73KZ-[OF9Q\]/LGRUC7U3@8#!3M3\?_JLS B&?!T?F3
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M)+/\-Q/XEZ;>T]\I6-5-4^_H1[PEK2T^ -^OZ[KQO^ "X2]7//\O4$L#!!0
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M8&P'G6I'8;LQLG;C)Y&&AIE;%O3K 955('DNJ6ET&TO0_QY9_0U02P,$%
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M -0N@/8+I>S.<0?TOY3%7U!+ P04    "  X.'=60,,P'Z("  "I!0  &0
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M-H^A""DO0] Q!59P%J;YXXBSH$BB ^"4BH0_%S$C@"!/8S*;9&')H S3\KF
M&?"@3-P&<6>=01ZR_*4![[2\IW_2H7_27^Z?];;RQ*;RA*'"]Y5N=K71?N2W
M+VJ)P,O.A-1P)YJ5]P=%M=AVVMSM+"R$@2EB!Y0E22<-0=(WIUG3Q.GT<BOC
M-M"MGS6BNCVD*!71-'SLP:ZTK)S >U6C.T?LHK<^-/TV$X<[,G'4.^Z+\%J:
MV\.W&I%8TJ)V>W?M'&$A9Z\A#@OZ'7;W;SE#*M-HDY$X&H:#R+;E/ZM&6-DX
M9HEY]+K_&:0NB'-J2BA\E=C40)^BUWM*(1M*(?OE4G"A4)*<M9[P]M'I?MC]
M=/JDH?^!4@__2ZG#P@?5'=[U#?@LN\9!5CJV8D42LH0V-<O@FBY+=,/I"3-/
MB#!+%F;L!R;E)2T3[T;\!>:(#?/4&<OBD.=DC*CQ="VT"SZ)@HC8.@OSXI$#
MC!<'O7CZ@WF6]\M$&;]NGFV-O.K-L##?1S+Y4%GYRP[IPZEWOE(MW9F-\$V)
M]VZ,NPIL+_KN"X:K.JNL:)XUZ L-VV6C'I HPA541PG[OD(E*[NJ6;D]D#W;
MB,HAB>[!Y?&<2$$ULO9T=&/IC^[BUKA@/RZIWCQK>%QBK[X3B$2^4EGW5[\=
MN]"3"\4B-%&@4[W .WH7+!VR.P)X$O"^4'@6) 6=?-B1J<;+GM9T_Y745\)?
MV^*X"$H23LN,#MX2/OFTW/BTG/FTG#].R^4F+71<92S@:>1/:N;M[:J%\:,[
M=8MZ[E\.AE*]ZFQ_O1Y6A\?):7\G_R[>OVS>"SV7E*L&9Z0:A3F=,+I_+?03
MJY;^ACY5EN[[?KB@!Q9J)T#?9TK9[<09&)YLDW\!4$L#!!0    ( #@X=U;@
MWXZ9J04  +4-   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)U7VV[;
M.!#]E8%[@0VPMD1=3*6) >?2W0*]!$G:Q6*Q#[1$Q]Q*HI:DX[A?OT/*5IRM
MXP9]L46*/)R9<V:&.EXI_<TLA+!P7Y6U.>DMK&V.1B.3+T3%S5 UHL8W<Z4K
M;G&H;T>FT8(7?E-5CF@0I*.*R[HW.?9SEWIRK):VE+6XU&"65<7U^E24:G72
M"WO;B2MYN[!N8C0Y;OBMN!;V2W.I<33J4 I9B=I(58,6\Y/>-#PZ';OU?L%7
M*59FYQF<)S.EOKG!^^*D%SB#1"ERZQ X_MV),U&6#@C-^'>#V>N.=!MWG[?H
M[[SOZ,N,&W&FRC]D81<G/=:#0LSYLK17:O6[V/B3.+Q<E<;_PJI=FT0]R)?&
MJFJS&2VH9-W^\_M-''8VL.")#72S@7J[VX.\E>?<\LFQ5BO0;C6BN0?OJM^-
MQLG:D7)M-;Z5N,].WM>YJ@3<\'MAH'_#9Z4P@^.116BW8)1O8$Y;&/H$3$CA
MHZKMPL!%78CB,< (;>H,HUO#3NE!Q'.1#R$*"=" T@-X4>=HY/&BGSH*Y]+D
MI3)++>"OZ<Q8C=+X>Y_/+6*\']&ERY%I>"Y.>I@/1N@[T9N\?A&FP=L#]L:=
MO?$A],DUIE^Q+ 6H.:#EC:I%;8T;H>D&9@(34H!LO;*.OGT>'#[C9B&>B0T<
M)[B!N2HQC<T1_"FX;KD&9$I4,Z$[MMQ/".>XV5B9PTOHAP%)THA$ 1ULAFF4
M$1:R 6!N8>;4T(](&.$2-X?/$8U(/ X&<*,L+^&#L^NTM>N19!U:1-(L)2D-
M!IMAAF=1Q@8':$@Z&I)?I.$A/"#NL48:L8^ P^@_$K"#VI^)6LRE'6SQ?X4$
M,1=:XWL?K2-X)PJA,9XO(299$KMXT9@$+!W M>568/C",<8O1A+"E)$D'&\I
M> SE(XVA#L)-U#-*TB :[+"#?'G[GUIZ@)VT8R=]-CMB/A>^Q._&4#N?M,A5
MG<M2<M<(]K%T^!3'4B$17HLZ%Y@>=B5$#1:G'P[=G#1W[0:#)-OWC59WTC<P
ME.[CC,*YW6S;I%E=^'V\4DNGB$)8H;'L(^)L#;QIRK6L;]LE.)"Y*]A@D+JE
M57H-7X;7PP?'O5YJ7JZ_N_VN 3]',U]JZ3SP>C"=8G9XO7+8-!P& ;SJ_EOY
M>&T0^(2W":1DNW<KA#X=)MD HF&4P"7ZQ9WLL1QO0XL=*!M2U%XP'%/X3:EB
M)4L\NFJXU)5;^_H%HR%]"_UT&* RSQ:\OG6$PU=>+CV],'7)P1U1"):@(OMH
M8H3_5UBCN<X7/LCGX@[CT7C0,U2UQ& 'PX0!NI,]>+FUS4IT@PY9!M[=UME/
MJGZS"<LI7@Q\9G06!L,@A,](E(9^,*288.$P#>&B$TQWQL4FNQ$^QD"BL0Q>
M'4B.<9<<XV<G1[%-7J<-;HRPK=8P)V:8&%;N;Q^'#W!Y<8;5B]=K[_7XK7G.
M05CQ\$YGO$*<D-MRAK)^CCB=LG8K$7S8 *^/_+O/#2K.NASQ+>.,:[W&_%IQ
M7;B:12EA04;2=.P&V(98AFTG_IDV_H=#2483PK( GU@2D21CN**16":E2[4G
MT6(L?"G) @H)2>. Q)2AEE3^[4TK(!=-U$(KY#&C)$H28%%"XHCB"68!7X4V
M2P/3/-=+E.2T^ ?OB)7O'E&4DB@-(*2,A(SM*=LP;0G!D,9I2,)Q#%% PC@E
M8Q;L3R&:H7>NFZ8ND1BA&2-1A$G\ Q$>&T+"TC%A>#P^Q8S$L6M">#_*V^KK
M0S*ME+;R>SO1C\>8R?TL25WS>'.I%18"\W0,^Y0D24J2B#J+,(Q(9YCN,:A3
MAFLZGF@:^@;$ HJDAWL;T&CG*ET)?>L_&)QDL1RWM^INMOLFF;97\8?E[0?-
M1ZYO96V@%'/<BB4-[P*Z_4AH!U8U_F(^4Q:O^?YQ@=]50KL%^'ZNE-T.W '=
ME]KD/U!+ P04    "  X.'=695@2-HL"  "<!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6R=5-MNVS ,_17"&X86".I;TG598B!)5ZQ BQ7M+@_#
M'F2;283JXDERT_[]*#GQ,B#-PUXLDB8/#RF1DXTVCW:-Z.!9"F6GT=JY9AS'
MMEJC9/9,-ZCHSU(;R1RI9A7;QB"K0Y 4<98DY[%D7$7%)-CN3#'1K1-<X9T!
MVTK)S,L<A=Y,HS3:&>[Y:NV\(2XF#5OA [IOS9TA+>Y1:BY16:X5&%Q.HUDZ
MG@^]?W#XSG%C]V3PE91:/WKENIY&B2>$ BOG$1@=3[A (3P0T?B]Q8SZE#YP
M7]ZA7X7:J9:265QH\8/7;CV-+B*H<<E:X>[UYC-NZQEYO$H+&[ZPZ7Q'6015
M:YV6VV!B(+GJ3O:\[<->P$7R2D"V#<@"[RY18'G)'"LF1F_ >&]"\T(H-403
M.:[\I3PX0W\YQ;EBH:7DCKKL+#!5PT(KQ]4*5<71PLE75@JTIY/842X?$5=;
MW'F'F[V"FV9P2U!K"Y]4C?6_ #&1[)EF.Z;S["CB)59GD*<#R)(L.X*7]Y7G
M 2__K\HON:V$MJU!^#DKK3/T?'X=:D.79'@XB1^IL6U8A=.(9L:B><*H>/<F
M/4\^'BEAV)<P/(9>/-"(UJU T$MZ$ZXUW'GNI FDEPHWG)5<!.,AZD?!#U._
M:IUO"5.J9<*_1RY;N<W6L)>NFQOT+A:66M#,6R\2);H_E"6:_@['\*5!PWS3
MX<8C6&_.(4U&@Q&=-VCM&&92MQ[T'@.+<$=PK1SEL Y.TL%%GIQV\?OUPEO"
MR0?G'W(XU.AX;V(DFE78"Q8JGZL;GM[:KYY9-W%_W;N]=<O,BBM+35A2:'+V
M?A2!Z79!ISC=A/DKM:-I#N*:UB<:[T#_EUJ[G>(3] NY^ -02P,$%     @
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M8:^>],60)I=#@JT& JLQ:%L?=SRK^XN-)8FB*J?P%I%,[ABG_ZAOA1N:EC>
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MQLR@(@-*"Z$TZAR:BH/."&JP&Z]6'H[=>>A^N[WP4ET6,7?<UW=:?17'^ 6
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M@'S$7Y0<Q-$UT%16C'W2-V_7$\?3&9&(A%)#8/6Q)P\DBC22RN-S">I4<^K
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M1Y3NN1Z@OM\P)I]O]$E_]69G^@U02P,$%     @ .#AW5J#Y\=6\ @  APD
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M8XVD>'PO0:WJFKIQ>_L%_6,^O!KFB0J8LOCO*)3+L36P4 ASFL7R"]O\#N5
M/8T7L%CDOVA3U'JNA8),2):4S8I!$J7%/_U1"K'5@/T##:1L(+L-WH$&MVQP
M\T$+9OE8MU32R8BS#>*Z6J'IC5R;O%M-$Z7Z-CY*KLY&JD].9EP]$5P^(YJ&
MZ.Y[%JW4/9+HW2U(&L7B/?J OC[>HG<_OQ_94EU/=]E!B7U38),#V)B@3RR5
M2X'NTA#")H"MB%9LR0O;&V)$O(7@$KGX A&'D!9"T[>W8P,=MQ+/S?'<5\2[
M0+.8*M6:&O[SH,K1O81$_-LF7H'MM6-K^UZ)%0U@;"E_"N!KL":__(1]Y]>V
MP3L":\C@53)X)O3)GTS2&+4_21?H-\Z$:)N_ .WEH/IMLY[@/O&&_LA>;T_6
M4C;H8Q=790W.O8ISS\CY 81 UT&0)5E,)83H%I0R043URZ6-;0'G;]/ ?1</
M=]BVE;G8)>UL_8JM_S\4_@-D&V-_3[A>#_?[.X3]/<)]=S@<MO/M5WS[9G7I
M$^-4,OY<\VRC:$0YU@(=@34&'E0##\[X)AAT*4-'8 T9AI4,0^-]OQ,R2G([
M90+F68SB: YM$YMA7/0,E+>]-*;&QA.GPT[]L73.\:8K4;>M.!BXP]UW1UGF
M'RQKLM[ZQ&,CZ\_S>12 V8EFB&.?P:[0F@.3>F!R1C>6X%U)T1%:4XHZH6#C
ME__MCGP%QV!)<^>I$];A Y\E?>#]7.%ZSIXEO3U+NC[V#CBR#A_8G#Y*1W[,
M>!K)C+??$"/$T8]A1VC-@>O\@OUS.M*8CHZ6HB.TIA1U-,+F;/1V1YIQ>@9'
MGB,*X3H+86/&.-F1@_W .L![";LL:R16TO,.?27KZ(+-H>,!J( EBT-TGZPX
M6X.FVTZTHQ!2SG..2$/J2$.<,SJ3&//2L5)TA=:4HLY)Q)R3WNS,5W#(86>:
M.T^=L Y&Q)@V3G5FB;KM3$)Z_JXS7RTK6-M;JU4)\$6^B"=0P+)4%@M7U=%J
MH? Z7QZSZ_)BE?$3Y8LH%2B&N6IU+OOJVKQ8N"MV)%OE:U]/3$J6Y)M+H"%P
M7:#.SQF3+SOZ M7RZ>0_4$L#!!0    ( #@X=U8%ZBG&7P(  +T%   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U4R6[;,!#]%4(MB@1(+4M>VKJR
M "\IFD, (T;:0]$#+8TM(A2ID/22O^^0E%4[M=T>>I&XS'N<]\B99"O5DRX
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M71<@^Z"BX^T&) X/J8[+\& 8^?U0<0<5GX2Z%]H\L,,.TT<9'Y^^ 0F')#C
M[*DCQ/.#0U!WIR':C]$W*A>L4HA#;I3>16PL9-O@VXD6==,CYT*;CML,"_--
M!&D+S/U<"/T\L6VW^\HF?P%02P,$%     @ .#AW5J%;GY<Q @  JP0  !D
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M^@:RJGLY?=O0ZZOG9>@Z';_E!G[??ME7M3(PZ!X%AK4)Z]NQ)S(<P<!2UY\
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M<]M16?'<=>83R3)CJQ9,*I-FAFMEU('K +6_9$SN)OJ TOH/_P!02P,$%
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M];::E?6>U'163/)UO1Q@]5XPR1>+ZCUFEB];$VZWV[D%CF_D'K1V )I=HYI
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M*<_+]V_J"=[RU<^;S;[[/U!+ P04    "  X.'=6*]Y9C<X$  !>&@  &0
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MYX3MB#'[Z0?H6;^HU!D2+!P(K*6<4ROGZ-!G7VEVLR-<D C\OA5<X"R*LQ7
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M9GJ^)9GX9973%'-Q2M<&VU*"HS(I30QDFJZ1XCC3YM/RVB.=3_,=3^*,/%+
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MW3ZTFTEFVV?%OH"GMD0E <W?KV0[-AAA".ML'H)M[CW2.9:OCB^3+1??Y1)
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MXEE^N 0:@S !^OLYY^KEQ Q0_;8P^Q=02P,$%     @ .#AW5O<<"G@I P
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M$':&9]!A!QU>A+Z#-%"9;>N=N6('J$4[J"P:+6'UN'X_@D:>G(*E.$I2KQ>
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MKQ<JKF_P;%.M+WN7<9XEU;</+%RQO-Q _'R=97QWH]S!?KGH^?\!4$L#!!0
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M33..KJA:,6QL' JD#,[>HS[5M/C&,+)V77(I#?9<MRQQ*H*R&_![(:79&?:
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M6HLD?XR 86J;#OA]+H1^?3$35%?[T_\ 4$L#!!0    ( #@X=U:.-+-LS@(
M '$'   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;'V576^;,!B%_XK%
MIJJ5U@).(*%-D/*A=94Z+4K;[6+:A0-O@E6#J6V2YM_/AI1EBL--8AN?\YS7
MQF:TX^)59@ *O>>LD&,G4ZJ\=5V99) 3><-+*/23-1<Y4;HK-JXL!9"T%N7,
MQ9X7NCFAA1./ZK&%B$>\4HP6L!!(5GE.Q'X*C._&CN]\#"SI)E-FP(U')=G
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M')Z0KWMA@ ,[>="2!YWD.:Q!;W"*GLD[>J1D11E5>QM_<,K'83#TAO8 PS;
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M+W]9?NV<W.,7G--M17W^"U!+ P04    "  X.'=6I7\.<>X!  "0)@  $P
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M[YU;_W'\^"P[V_1O^6S\(]KB!5!+ 0(4 Q0    ( #@X=U8'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ .#AW5@Z/Z&SM    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ .#AW5IE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  X.'=6
M>P-(2Q0'  ! +@  &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ .#AW5D&__= X @  M04  !@
M     ("!5@\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M #@X=U;9+1%BF08  #X;   8              " @<01  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  X.'=6;F^;"QP$   -%P  &
M            @(&3&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ .#AW5F,7ZG;*!0  $Q<  !@              ("!Y1P  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #@X=U:XI%(SA!(  *,?
M 0 8              " @>4B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  X.'=61 LU^R@#  #?"P  &               @(&?-0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ .#AW5H/UAYWF
M"   <BH  !@              ("!_3@  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( #@X=U:D0V#S^Q(  'TS   8              "
M@1E"  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  X.'=6
MKZU[234;  !Q5   &0              @(%*50  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( #@X=U:Z$\0O:@4  !0-   9
M      " @;9P  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ .#AW5BZ<#H'W @  M08  !D              ("!5W8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  X.'=63"+9)Y$"  "E!0
M&0              @(&%>0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( #@X=U8WIU"*L (  -4%   9              " @4U\  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ .#AW5D5"-)IC
M!0  N P  !D              ("!-'\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  X.'=6%%<QLRP(  "4%P  &0
M@('.A   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #@X
M=U8?-L)3=P,  +D'   9              " @3&-  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ .#AW5J9Z"0UM"0  51P  !D
M         ("!WY   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  X.'=6EHF70?<*  #)'   &0              @(&#F@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #@X=U:->WPCQ@T   (F
M   9              " @;&E  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ .#AW5D4_8 ]T P  &@@  !D              ("!KK,
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  X.'=6>(ML
MRD('  #:$   &0              @(%9MP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( #@X=U:M\X=EW ,  #L)   9
M  " @=*^  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M.#AW5J[0;RU7'0  Q6(  !D              ("!Y<(  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  X.'=6]9N[JZ8#  ";"   &0
M            @(%SX   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( #@X=U:1>SE]I0,  !,)   9              " @5#D  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ .#AW5K6;+E?? @
M7@8  !D              ("!+.@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  X.'=60,,P'Z("  "I!0  &0              @(%"
MZP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #@X=U9D
M 934/P,  /('   9              " @1ON  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ .#AW5I+>J8K" @  (P8  !D
M     ("!D?$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #@X=U;B.E-WD00  !,6   9              "
M@6@& 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ .#AW
M5@KXEC^/"@  &U\  !D              ("!, L! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  X.'=6+WP+OKH#  "!$0  &0
M        @('V%0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( #@X=U:U;8?*(@0  .49   9              " @><9 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ .#AW5J#Y\=6\ @  APD
M !D              ("!0!X! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  X.'=6R*)E9"8$  #5&   &0              @($S(0$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #@X=U:4IB(N
M#@0  $H5   9              " @9 E 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ .#AW5@7J*<9? @  O04  !D
M ("!U2D! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  X
M.'=6%5)\S:@"  !Q!P  &0              @(%K+ $ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #@X=U:A6Y^7,0(  *L$   9
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M970T."YX;6Q02P$"% ,4    "  X.'=6*]Y9C<X$  !>&@  &0
M    @('P2P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M #@X=U;)4I.X[@0   T:   9              " @?50 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ .#AW5NNUO0'G"0  A6L  !D
M             ("!&E8! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  X.'=6[[I?L+ "  "W!P  &0              @($X8 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #@X=U9!56<#E 0
M &<8   9              " @1]C 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ .#AW5O<<"G@I P  K0L  !D              ("!
MZF<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  X.'=6
MD4 ;K*T"   '!P  &0              @(%*:P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( #@X=U8:MMN1K (  (4'   9
M      " @2YN 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ .#AW5N!W]@6X P  +0P  !D              ("!$7$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  X.'=65=*H0\H#   1#
M&0              @($ =0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( #@X=U8XT#0WL00  #4A   9              " @0%Y 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ .#AW5C;XOV@%
M"@  .GH  !D              ("!Z7T! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  X.'=6<3\SFT8"  !&!0  &0
M@($EB $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #@X
M=U:%/!3;G0(  ','   9              " @:** 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ .#AW5G?\:U3(!   YA<  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( #@X=U9_R+GO+@4  $DK   /
M  "  <*D 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  X.'=6'M^97AP"
M   ])P  &@              @ $=J@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  X.'=6I7\.<>X!  "0)@  $P
M@ %QK $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  "0K@$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>389</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Business, Presentation and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements</Role>
      <ShortName>Business, Presentation and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets and In-Process R&amp;D</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD</Role>
      <ShortName>Intangible Assets and In-Process R&amp;D</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlan</Role>
      <ShortName>Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/FairValue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/PropertyandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Intangible Assets and In-Process R&amp;D (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables</Role>
      <ShortName>Intangible Assets and In-Process R&amp;D (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/Warrants</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanTables</Role>
      <ShortName>Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/EquityIncentivePlan</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/Acquisitions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails</Role>
      <ShortName>Business, Presentation and Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details</Role>
      <ShortName>Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details</Role>
      <ShortName>Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/AccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/Debt</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Intangible Assets and In-Process R&amp;D - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets and In-Process R&amp;D - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Intangible Assets and In-Process R&amp;D -Intangible assets and in-process R&amp;D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails</Role>
      <ShortName>Intangible Assets and In-Process R&amp;D -Intangible assets and in-process R&amp;D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Intangible Assets and In-Process R&amp;D - Future Annual Intangible Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails</Role>
      <ShortName>Intangible Assets and In-Process R&amp;D - Future Annual Intangible Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Capital Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CapitalStockDetails</Role>
      <ShortName>Capital Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/CapitalStock</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/WarrantsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanDetails</Role>
      <ShortName>Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/EquityIncentivePlanTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Equity Incentive Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Equity Incentive Plan - Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plan - Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Equity Incentive Plan - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails</Role>
      <ShortName>Equity Incentive Plan - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Equity Incentive Plan - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plan - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes -Components of loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails</Role>
      <ShortName>Income Taxes -Components of loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Components of income tax (benefit) expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails</Role>
      <ShortName>Income Taxes - Components of income tax (benefit) expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Acquisitions - Purchase price allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails</Role>
      <ShortName>Acquisitions - Purchase price allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Acquisitions - Fair value of consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails</Role>
      <ShortName>Acquisitions - Fair value of consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="kprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/SubsequentEvents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. kprx-20221231.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. kprx-20221231.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: kprx:WarrantConvertibleIntoCommonStockBasis, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WarrantsAndRightsOutstandingTerm -  kprx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="kprx-20221231.htm">kprx-20221231.htm</File>
    <File>ex231-20221231xkprx.htm</File>
    <File>ex311-20221231xkprx.htm</File>
    <File>ex312-20221231xkprx.htm</File>
    <File>ex321-20221231xkprx.htm</File>
    <File>ex322-20221231xkprx.htm</File>
    <File>kprx-20221231.xsd</File>
    <File>kprx-20221231_cal.xml</File>
    <File>kprx-20221231_def.xml</File>
    <File>kprx-20221231_lab.xml</File>
    <File>kprx-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>kprx-20221231_g1.jpg</File>
    <File>kprx-20221231_g2.jpg</File>
    <File>kprx-20221231_g3.jpg</File>
    <File>kprx-20221231_g4.jpg</File>
    <File>kprx-20221231_g5.jpg</File>
    <File>kprx-20221231_g6.jpg</File>
    <File>kprx-20221231_g7.jpg</File>
    <File>kprx-20221231_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="689">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kprx-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 31,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 689,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 219,
   "dts": {
    "calculationLink": {
     "local": [
      "kprx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kprx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "kprx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 611,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://www.eyegatepharma.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 84,
   "keyStandard": 305,
   "memberCustom": 39,
   "memberStandard": 39,
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.eyegatepharma.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.eyegatepharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.eyegatepharma.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.eyegatepharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible Assets and In-Process R&D",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD",
     "shortName": "Intangible Assets and In-Process R&D",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Capital Stock",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.eyegatepharma.com/role/CapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kprx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.eyegatepharma.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kprx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Incentive Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlan",
     "shortName": "Equity Incentive Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.eyegatepharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.eyegatepharma.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.eyegatepharma.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.eyegatepharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.eyegatepharma.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.eyegatepharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.eyegatepharma.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Intangible Assets and In-Process R&D (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables",
     "shortName": "Intangible Assets and In-Process R&D (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Warrants (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.eyegatepharma.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Equity Incentive Plan (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanTables",
     "shortName": "Equity Incentive Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.eyegatepharma.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
     "shortName": "Business, Presentation and Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i992e4d73631943b797fa8dfb4cbb426f_D20221122-20221122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails",
     "shortName": "Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i3c22c28aff144ee595d728f32589250e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details",
     "shortName": "Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "icbde01e8a3c345a9bdcfaa39b08e940a_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "kprx:ChangeInContingentConsiderationFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
     "shortName": "Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "kprx:ChangeInContingentConsiderationFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Property and Equipment - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.eyegatepharma.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Debt (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.eyegatepharma.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i18585e02dd354f79bb924f1f70829ffe_D20200501-20200531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Intangible Assets and In-Process R&D - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails",
     "shortName": "Intangible Assets and In-Process R&D - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Intangible Assets and In-Process R&D -Intangible assets and in-process R&D (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails",
     "shortName": "Intangible Assets and In-Process R&D -Intangible assets and in-process R&D (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia067078212ed44749f27634d5c3506d2_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Intangible Assets and In-Process R&D - Future Annual Intangible Amortization (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails",
     "shortName": "Intangible Assets and In-Process R&D - Future Annual Intangible Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Capital Stock (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.eyegatepharma.com/role/CapitalStockDetails",
     "shortName": "Capital Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "idfeb2656a64546ea8755b33f2212fb9c_D20210106-20210106",
      "decimals": "0",
      "lang": "en-US",
      "name": "kprx:ClassOfWarrantOrRightNumberOfWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i746a7934f1634bada7a8c67124affa16_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Warrants (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.eyegatepharma.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i99c4f9ba30df4f2587cfc85bd7c1e743_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i746a7934f1634bada7a8c67124affa16_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Equity Incentive Plan (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails",
     "shortName": "Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i5d6b9d5d260c46978aec252087242f31_I20101231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Equity Incentive Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
     "shortName": "Equity Incentive Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i5d6b9d5d260c46978aec252087242f31_I20101231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Equity Incentive Plan - Weighted-Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails",
     "shortName": "Equity Incentive Plan - Weighted-Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i746a7934f1634bada7a8c67124affa16_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Equity Incentive Plan - Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
     "shortName": "Equity Incentive Plan - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "id4915e719780444bb5d06f84de1f000a_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Equity Incentive Plan - Stock-based Compensation (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails",
     "shortName": "Equity Incentive Plan - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes -Components of loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails",
     "shortName": "Income Taxes -Components of loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Components of income tax (benefit) expense (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails",
     "shortName": "Income Taxes - Components of income tax (benefit) expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails",
     "shortName": "Income Taxes - Reconciliation of effective tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "id85228c389d248878079223a2e81bf4a_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "id85228c389d248878079223a2e81bf4a_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "kprx:LesseeNumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operatinglease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "kprx:LesseeNumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operatinglease",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia02f437734fd4e36ae0a425508221c0b_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "icf18c208a9d143518246d68a22a96f9b_I20211021",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Acquisitions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "icf18c208a9d143518246d68a22a96f9b_I20211021",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "icf18c208a9d143518246d68a22a96f9b_I20211021",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Acquisitions - Purchase price allocation (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
     "shortName": "Acquisitions - Purchase price allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "icf18c208a9d143518246d68a22a96f9b_I20211021",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "kprx:SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "kprx:BusinessCombinationContingentConsiderationArrangementsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Acquisitions - Fair value of consideration (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
     "shortName": "Acquisitions - Fair value of consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "kprx:SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ia7d097f6b22b4cfcb1a0f0208f4d56f8_D20211021-20211021",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "kprx:BusinessCombinationContingentConsiderationArrangementsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "i02af99cfa76b4d6e8328ac069ccca569_D20210917-20210917",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ic191541ff4494af189a3acbb5f124ce0_D20230210-20230210",
      "decimals": "INF",
      "lang": "en-US",
      "name": "kprx:StockIssuedDuringPeriodSharesWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "kprx:AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ief4ad0685f5341e794ef340d5506b6be_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Business, Presentation and Recent Accounting Pronouncements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements",
     "shortName": "Business, Presentation and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20221231.htm",
      "contextRef": "ib4b1039f1ed8450a95ccb53f7cccc245_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 83,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "kprx_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_AccruedClinicalExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued clinical expenses.",
        "label": "Accrued Clinical Expenses [Policy Text Block]",
        "terseLabel": "Accrued Clinical Expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Additional Paid in Capital, Warrant Issuance Costs",
        "label": "Adjustment To Additional Paid in Capital, Warrant Issuance Costs",
        "terseLabel": "Warrant inducement expense",
        "verboseLabel": "Closing costs"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Reclassification Of Warrant Liability",
        "label": "Adjustments To Additional Paid In Capital, Reclassification Of Warrant Liability",
        "terseLabel": "Reclassification of Warrant Liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "kprx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the Basis of Presentation and Principles of Consolidation. The principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements",
        "label": "Basis of Presentation and Principles of Consolidation [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_BayonAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Bayon acquisition .",
        "label": "Bayon acquisition",
        "terseLabel": "Bayon acquisition"
       }
      }
     },
     "localname": "BayonAcquisitionMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_BayonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bayon.",
        "label": "Bayon",
        "terseLabel": "Bayon"
       }
      }
     },
     "localname": "BayonMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_BeginningOfPhase3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beginning of Phase 3 [Member]",
        "label": "Beginning of Phase 3 [Member]",
        "terseLabel": "Beginning of Phase 3"
       }
      }
     },
     "localname": "BeginningOfPhase3Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_Between250And500MillionNetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for between 250 and 500 million net sales.",
        "label": "Between 250 And 500 Million Net Sales [Member]",
        "terseLabel": "Between 250 And 500 Million Net Sales"
       }
      }
     },
     "localname": "Between250And500MillionNetSalesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_BusinessAcquisitionEarnoutConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Earnout consideration in a business combination arrangement.",
        "label": "Business Acquisition, Earnout Consideration",
        "terseLabel": "Earnout consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionEarnoutConsideration",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_BusinessAcquisitionHoldbackSharesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Holdback Shares, Term",
        "label": "Business Acquisition, Holdback Shares, Term",
        "terseLabel": "Holdback shares, term"
       }
      }
     },
     "localname": "BusinessAcquisitionHoldbackSharesTerm",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liabilities",
        "terseLabel": "Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_BusinessCombinationContingentConsiderationArrangementsFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in business combination.",
        "label": "Business Combination Contingent Consideration Arrangements Fair Value",
        "terseLabel": "Contingent consideration at fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsFairValue",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_BusinessCombinationContingentConsiderationCashCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash recognized arising from contingent consideration in a business combination, expected to be realized within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Cash, Current",
        "terseLabel": "Cash Consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationCashCurrent",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and other payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accounts Payable and Other Liabilities",
        "negatedLabel": "Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_CashOutflowFromLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow associated with loan forgiveness.",
        "label": "Cash Outflow from Loan Forgiveness",
        "negatedLabel": "Paycheck Protection Program Loan Forgiveness"
       }
      }
     },
     "localname": "CashOutflowFromLoanForgiveness",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions",
        "label": "Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions",
        "terseLabel": "Cease payments not yet paid based on prevailing financial market conditions"
       }
      }
     },
     "localname": "CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_ChangeInContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in contingent consideration fair value.",
        "label": "Change in Contingent Consideration Fair Value",
        "terseLabel": "Changes in contingent consideration"
       }
      }
     },
     "localname": "ChangeInContingentConsiderationFairValue",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_ClassAWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrant",
        "label": "Class A Warrant [Member]",
        "terseLabel": "Class A Warrant"
       }
      }
     },
     "localname": "ClassAWarrantMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ClassAWarrantsExerciseOfOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrants, Exercise of Option",
        "label": "Class A Warrants, Exercise of Option [Member]",
        "terseLabel": "Class A Warrants, Exercise of Option"
       }
      }
     },
     "localname": "ClassAWarrantsExerciseOfOptionMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ClassBWarrantExerciseOfOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Warrant, Exercise Of Option",
        "label": "Class B Warrant, Exercise Of Option [Member]",
        "terseLabel": "Class B Warrant, Exercise Of Option"
       }
      }
     },
     "localname": "ClassBWarrantExerciseOfOptionMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ClassBWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Warrant",
        "label": "Class B Warrant [Member]",
        "terseLabel": "Class B Warrant"
       }
      }
     },
     "localname": "ClassBWarrantMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercised",
        "label": "Class Of Warrant Or Right, Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Awards",
        "label": "Class Of Warrant Or Right, Number Of Awards [Roll Forward]",
        "terseLabel": "Number of Awards"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfAwardsRollForward",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_ClassOfWarrantOrRightNumberOfWarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued during the period.",
        "label": "Class Of Warrant Or Right Number Of Warrant Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantIssued",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period From Issuance That Warrant Becomes Exercisable",
        "label": "Class Of Warrant Or Right, Period From Issuance That Warrant Becomes Exercisable",
        "terseLabel": "Period from issuance that warrant becomes exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodFromIssuanceThatWarrantBecomesExercisable",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kprx_ClassOfWarrantOrRightPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Policy",
        "label": "Class Of Warrant Or Right, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPolicyPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Term in Years"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_ClinicalStudiesServicesKIO301Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Studies Services KIO-301",
        "label": "Clinical Studies Services KIO-301 [Member]",
        "terseLabel": "Clinical Studies Services KIO-301"
       }
      }
     },
     "localname": "ClinicalStudiesServicesKIO301Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ClinicalTrialsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials.",
        "label": "Clinical Trials Current",
        "terseLabel": "Clinical Trials"
       }
      }
     },
     "localname": "ClinicalTrialsCurrent",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_CommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares",
        "label": "Common Shares [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonSharesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of concentration of credit risk and off-balance-sheet risk policy.",
        "label": "Concentration Of Credit Risk And Of balance sheet Risk Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-Balance-Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAndOfBalanceSheetRiskPolicyPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_ContingentConsiderationScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Scenario",
        "label": "Contingent Consideration Scenario [Axis]",
        "terseLabel": "Contingent Consideration Scenario [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationScenarioAxis",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_ContingentConsiderationScenarioDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Scenario [Domain]",
        "label": "Contingent Consideration Scenario [Domain]",
        "terseLabel": "Contingent Consideration Scenario [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationScenarioDomain",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_DefinedBenefitPlanContributionsByEmployerAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents defined benefit plan contributions by employer accrued.",
        "label": "Defined Benefit Plan Contributions by Employer Accrued",
        "terseLabel": "Accrual of additional estimate of contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployerAccrued",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_DevelopmentAndCommercialMilestonesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Development and commercial milestones Term.",
        "label": "Development And Commercial Milestones Term",
        "terseLabel": "Development and commercial milestones term"
       }
      }
     },
     "localname": "DevelopmentAndCommercialMilestonesTerm",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kprx_DueToCreditorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to payables to creditor in a business acquisition transaction , as contingent consideration.",
        "label": "Due to creditor",
        "terseLabel": "Due to creditor"
       }
      }
     },
     "localname": "DueToCreditorMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_EarnOutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to earn-out consideration upon fulfillment of specified conditions.",
        "label": "Earn-out provisions",
        "terseLabel": "Earn-out provisions"
       }
      }
     },
     "localname": "EarnOutConsiderationMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state non-income based tax.",
        "label": "Effective Income Tax Rate Reconciliation State Non Income Based Tax Percent",
        "verboseLabel": "State Non-Income Based Tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs",
        "label": "Employee and Non Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2014",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_FairValueContingentConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represent fair value contingent consideration abstract.",
        "label": "Fair Value Contingent Consideration [Abstract]",
        "terseLabel": "Contingent Consideration:"
       }
      }
     },
     "localname": "FairValueContingentConsiderationAbstract",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_FdaApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FDA Approval [Member]",
        "label": "FDA Approval [Member]",
        "terseLabel": "FDA approval"
       }
      }
     },
     "localname": "FdaApprovalMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_FiniteLivedIntangibleAssetsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails": {
       "order": 2.0,
       "parentTag": "kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represented amount of intangible assets adjusted with research and development.",
        "label": "Finite Lived Intangible Assets Research and Development",
        "verboseLabel": "In-Process R&amp;D"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsResearchAndDevelopment",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_ForFirst250MillionNetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for first 250 million net sales.",
        "label": "For The First 250 Million Net Sales [Member]",
        "terseLabel": "For The First 250 Million Net Sales"
       }
      }
     },
     "localname": "ForFirst250MillionNetSalesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_GoodwillAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount is relevant to Goodwill",
        "label": "Goodwill Acquired",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquired",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_GrantOfRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount grant of restricted stock awards.",
        "label": "Grant Of Restricted Stock Awards",
        "terseLabel": "Grant of Restricted Stock Awards"
       }
      }
     },
     "localname": "GrantOfRestrictedStockAwards",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Holders Owing More Than Ten Percentage Voting Rights [Member]",
        "terseLabel": "Holders Owing More Than Ten Percentage Voting Rights"
       }
      }
     },
     "localname": "HoldersOwingMoreThanTenPercentageVotingRightsMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_IfMilestonePaymentsAreExercisedForSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to scenario, if milestone payments are exercised for shares.",
        "label": "If milestone payments are exercised for shares",
        "terseLabel": "If milestone payments are exercised for shares"
       }
      }
     },
     "localname": "IfMilestonePaymentsAreExercisedForSharesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes",
        "label": "IncomeTaxes [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_IncreaseDecreaseInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase decrease right-of-use assets.",
        "label": "Increase Decrease in Right-of-Use Assets",
        "terseLabel": "Reduction of Right-of-Use Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssets",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_InducementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Warrant",
        "label": "Inducement Warrant [Member]",
        "terseLabel": "Inducement Warrant"
       }
      }
     },
     "localname": "InducementWarrantMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_IntangibleAssetsExpectedMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments expected in future periods for acquisition of intangible assets.",
        "label": "Intangible Assets Expected Milestone Payable",
        "terseLabel": "Intangible assets, expected milestone payments"
       }
      }
     },
     "localname": "IntangibleAssetsExpectedMilestonePayable",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets including In Process research and development.",
        "label": "Intangible Assets Net Including In Process Research and Development",
        "totalLabel": "Total Intangible Assets and In-Process R&amp;D, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingInProcessResearchAndDevelopment",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_JadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jade.",
        "label": "Jade",
        "terseLabel": "Jade"
       }
      }
     },
     "localname": "JadeMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_JadeTherapeuticSIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jade acquisition",
        "label": "Jade acquisition",
        "terseLabel": "Jade acquisition"
       }
      }
     },
     "localname": "JadeTherapeuticSIncMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_Kio101Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the KIO-101.",
        "label": "KIO-101 [Member]",
        "terseLabel": "KIO-101"
       }
      }
     },
     "localname": "Kio101Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_LesseeNumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Number of Operating Leases",
        "label": "Lessee, Number of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "localname": "LesseeNumberOfOperatingLeases",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_MeasurementInputProbabilityOfSuccessForPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Measurement input probability of success for payment .",
        "label": "Probability of Success for payment",
        "terseLabel": "Probability of Success for payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessForPaymentMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_MediolanumAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Mediolanum agreement .",
        "label": "Mediolanum Agreement [Member]",
        "terseLabel": "Mediolanum Agreement"
       }
      }
     },
     "localname": "MediolanumAgreementMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of milestones.",
        "label": "Milestone Type [Axis]",
        "terseLabel": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The category of milestones.",
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_NetSalesOver500MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for over 500 million net sales.",
        "label": "Net Sales Over 500 Million [Member]",
        "terseLabel": "Net Sales Over 500 Million"
       }
      }
     },
     "localname": "NetSalesOver500MillionMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Board of Directors Who Are Also Executives At A Related Party",
        "label": "Number Of Board of Directors Who Are Also Executives At A Related Party",
        "terseLabel": "Director who Is also an executive at a related party"
       }
      }
     },
     "localname": "NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_NumberOfGeographicSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Geographic Segments",
        "label": "Number Of Geographic Segments",
        "terseLabel": "Geographic segments"
       }
      }
     },
     "localname": "NumberOfGeographicSegments",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of License Agreements",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Considered For Determination Of Public Offering Price Of Preferred Shares Issued With Warrants",
        "label": "Number Of Warrants Considered For Determination Of Public Offering Price Of Preferred Shares Issued With Warrants",
        "terseLabel": "Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsConsideredForDeterminationOfPublicOfferingPriceOfPreferredSharesIssuedWithWarrants",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_OperatingLeaseInterestOnLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest on operating lease liabilities.",
        "label": "Operating Lease, Interest on Lease Liabilities",
        "terseLabel": "Imputed interest on the lease liability"
       }
      }
     },
     "localname": "OperatingLeaseInterestOnLeaseLiabilities",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_PanoptesAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Panoptes acquisition.",
        "label": "Panoptes acquisition",
        "terseLabel": "Panoptes acquisition"
       }
      }
     },
     "localname": "PanoptesAcquisitionMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_PanoptesPharmaGes.m.b.h.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to acquisition of Panoptes Pharma Ges.m.b.H.",
        "label": "Panoptes",
        "terseLabel": "Panoptes"
       }
      }
     },
     "localname": "PanoptesPharmaGes.m.b.h.Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_PanoptesPharmaGesMbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Panoptes Pharma Ges .m.b.h.",
        "label": "Panoptes Pharma Ges .m.b.h. [Member]",
        "terseLabel": "Panoptes Pharma Ges .m.b.h."
       }
      }
     },
     "localname": "PanoptesPharmaGesMbhMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_PaymentOfAnnualFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The details about annual fee payment.",
        "label": "Payment of annual fee",
        "terseLabel": "Payment of annual fee"
       }
      }
     },
     "localname": "PaymentOfAnnualFee",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_PaymentsForFractionalSharesRelatedToReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Fractional Shares Related To Reverse Stock Split",
        "label": "Payments For Fractional Shares Related To Reverse Stock Split",
        "negatedLabel": "Payments Made for Fractional Shares Related to the Reverse Stock Split"
       }
      }
     },
     "localname": "PaymentsForFractionalSharesRelatedToReverseStockSplit",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_PaymentsToAcquireBusinessesFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period at fair value. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses, Fair Value",
        "terseLabel": "Fair value at the acquisition date"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesFairValue",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_PercentageOfDecreasedRoyaltyAfterPatentExpiry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty after patent expiry.",
        "label": "Percentage Of Decreased Royalty After Patent Expiry",
        "terseLabel": "Percentage of decreased royalty after patent expiry"
       }
      }
     },
     "localname": "PercentageOfDecreasedRoyaltyAfterPatentExpiry",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_PercentageOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of exercise price.",
        "label": "Percentage of Exercise Price",
        "terseLabel": "Percentage of exercise price"
       }
      }
     },
     "localname": "PercentageOfExercisePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_PercentageOfRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalties over net sales.",
        "label": "Percentage Of Royalties On Net Sales",
        "terseLabel": "Percentage of royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_PhaseOneBMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Phase one b milestones.",
        "label": "Phase 1b milestones",
        "terseLabel": "Phase 1b milestones"
       }
      }
     },
     "localname": "PhaseOneBMilestonesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_PreferredStockDesignatedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of designated preferred stock.",
        "label": "Preferred Stock Designated Shares",
        "terseLabel": "Preferred stock, designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockDesignatedShares",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Warrants.",
        "label": "Private Placement Warrants",
        "terseLabel": "Private Placement Warrants"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ProceedsFromSaleOfStockSharePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale of Stock, Share Purchase Agreement",
        "label": "Proceeds From Sale of Stock, Share Purchase Agreement",
        "terseLabel": "Proceeds from sale of stock under share purchase agreement"
       }
      }
     },
     "localname": "ProceedsFromSaleOfStockSharePurchaseAgreement",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_ProceedsFromWarrantExercisesAndWarrantSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Warrant Exercises And Warrant Sales",
        "label": "Proceeds From Warrant Exercises And Warrant Sales",
        "terseLabel": "Proceeds from warrant exercise and sale"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercisesAndWarrantSales",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_RelatedPartyTransactionsNumberOfConsultants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consultants with whom the company has entered into related party transactions.",
        "label": "Related Party Transactions, Number Of Consultants",
        "terseLabel": "Number of consultants with whom the company has entered into related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsNumberOfConsultants",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_RelatedPartyTransactionsNumberOfUniversities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transactions, Number Of Universities",
        "label": "Related Party Transactions, Number Of Universities",
        "terseLabel": "Number of universities with whom the company entered into related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsNumberOfUniversities",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_RelatedPartyTransactionsNumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vendors with whom the company has entered into related party transactions.",
        "label": "Related Party Transactions, Number Of Vendors",
        "terseLabel": "Number of vendors with whom the company has entered into related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsNumberOfVendors",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_RelatedPartyTransactionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions [Policy Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_RemainingMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to remaining milestones.",
        "label": "Remaining milestones",
        "terseLabel": "Remaining milestones"
       }
      }
     },
     "localname": "RemainingMilestonesMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise.",
        "label": "Research and Development, Refunds, Policy [Policy Text Block]",
        "terseLabel": "Refunds for Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentRefundsPolicyPolicyTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_RoyaltyScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Scenario",
        "label": "Royalty Scenario [Axis]",
        "terseLabel": "Royalty Scenario [Axis]"
       }
      }
     },
     "localname": "RoyaltyScenarioAxis",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "kprx_RoyaltyScenarioDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Scenario [Domain]",
        "label": "Royalty Scenario [Domain]",
        "terseLabel": "Royalty Scenario [Domain]"
       }
      }
     },
     "localname": "RoyaltyScenarioDomain",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SentrXAnimalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SentrX Animal Care, Inc. [Member]",
        "label": "SentrX Animal Care Inc",
        "terseLabel": "SentrX Animal Care Inc"
       }
      }
     },
     "localname": "SentrXAnimalCareIncMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SeriesdConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "SeriesD Convertible Preferred Stock",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesdConvertiblePreferredStockMember",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of expired awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Exercise Price",
        "terseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price",
        "verboseLabel": "Issued (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non vested Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Values.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Values",
        "terseLabel": "Fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable and outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_ShareBasedCompensationOptionAndIncentivePlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan",
        "label": "Equity Incentive Plan",
        "terseLabel": "Equity Incentive Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlanAbstract",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "kprx_SharePurchaseAgreementSaleOfStockMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Sale Of Stock, Maximum Amount",
        "label": "Share Purchase Agreement, Sale Of Stock, Maximum Amount",
        "terseLabel": "Purchase agreement, maximum amount"
       }
      }
     },
     "localname": "SharePurchaseAgreementSaleOfStockMaximumAmount",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_SharePurchasePriceOfCommonStockAndWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of common Stock and warrant under private placement.",
        "label": "Share Purchase Price Of Common Stock And Warrant",
        "terseLabel": "Purchase price (in usd per share)"
       }
      }
     },
     "localname": "SharePurchasePriceOfCommonStockAndWarrant",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsexercisedweightedaverageexerciseprice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaverageremainingcontractualterms",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kprx_SharesIssuedPricePerCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued Price Per Common Shares",
        "label": "Shares Issued Price Per Common Shares",
        "terseLabel": "Public offering price (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerCommonShares",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Price Per Preferred Share, Five Thousand Class A Warrants And Five Thousand Class B Warrants",
        "label": "Shares Issued, Price Per Preferred Share, Five Thousand Class A Warrants And Five Thousand Class B Warrants",
        "terseLabel": "Shares issued, price per preferred share, five thousand Class A warrants and five thousand Class B warrants (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerPreferredShareFiveThousandClassAWarrantsAndFiveThousandClassBWarrants",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_StockAdjustedDuringPeriodValueReverseStockSplits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Adjusted During Period, Value, Reverse Stock Splits",
        "label": "Stock Adjusted During Period, Value, Reverse Stock Splits",
        "negatedTerseLabel": "Cancellation of Reverse Stock Split Fractional Shares"
       }
      }
     },
     "localname": "StockAdjustedDuringPeriodValueReverseStockSplits",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_StockAdjustmentDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Adjustment During Period, Shares, Reverse Stock Splits",
        "label": "Stock Adjustment During Period, Shares, Reverse Stock Splits",
        "negatedTerseLabel": "Cancellation of Reverse Stock Split Fractional Shares (in shares)"
       }
      }
     },
     "localname": "StockAdjustmentDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued during the period for the conversion of series C convertible preferred stock into common stock.",
        "label": "Stock Issued During Period, Shares, Conversion Of Series C Preferred Stock",
        "terseLabel": "Conversion of Series C Preferred Stock into Common Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfSeriesCPreferredStock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_StockIssuedDuringPeriodSharesFromHoldBackShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares From HoldBack, Shares",
        "label": "Stock Issued During Period, Shares From HoldBack, Shares",
        "terseLabel": "Issuance of Panoptes Holdback Shares (in shares)",
        "verboseLabel": "Issuance of Panoptes holdback shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFromHoldBackShares",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_StockIssuedDuringPeriodSharesWarrantInducement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrant Inducement",
        "label": "Stock Issued During Period, Shares, Warrant Inducement",
        "terseLabel": "Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantInducement",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Issuance of shares of common stock from warrant exercises (in shares)",
        "verboseLabel": "Issuance of Shares of Common Stock from Warrant Exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_StockIssuedDuringPeriodValueFromPanoptesHoldBackShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, From Panoptes Hold Back Shares",
        "label": "Stock Issued During Period, Value, From Panoptes Hold Back Shares",
        "terseLabel": "Issuance of Panoptes Holdback Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFromPanoptesHoldBackShares",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_StockIssuedDuringPeriodValueWarrantInducement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrant Inducement",
        "label": "Stock Issued During Period, Value, Warrant Inducement",
        "terseLabel": "Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantInducement",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issuance of Shares of Common Stock from Warrant Exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Note, Reverse Stock Split, Number Of Fractional Shares Issued",
        "label": "Stockholders Equity Note, Reverse Stock Split, Number Of Fractional Shares Issued",
        "terseLabel": "Reverse stock split, number of fractional shares issued (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_SuccessfulCompletionOfPhase1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Successful Completion of Phase 1 [Member]",
        "label": "Successful Completion of Phase 1 [Member]",
        "terseLabel": "Successful completion of Phase 1b $0.495 million"
       }
      }
     },
     "localname": "SuccessfulCompletionOfPhase1Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SuccessfulCompletionOfPhase2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Successful Completion of Phase 2 [Member]",
        "label": "Successful Completion of Phase 2 [Member]",
        "terseLabel": "Successful completion of Phase 2 $0.990 million"
       }
      }
     },
     "localname": "SuccessfulCompletionOfPhase2Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SuccessfulCompletionOfPhase3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Successful Completion of Phase 3 [Member]",
        "label": "Successful Completion of Phase 3 [Member]",
        "terseLabel": "Successful completion of Phase 3 $4 million"
       }
      }
     },
     "localname": "SuccessfulCompletionOfPhase3Member",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kprx_SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of Fair value of business acquisition consideration [table text Block].",
        "label": "Summary of Business Acquisitions, Fair Value Of Consideration [Table Text Block]",
        "terseLabel": "Summary of business acquisition fair value consideration"
       }
      }
     },
     "localname": "SummaryOfBusinessAcquisitionsFairValueOfConsiderationTableTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_ThresholdPeriodOfVolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of volume weighted average price to determine the fair value of share issued in a business acquisition.",
        "label": "Threshold Period Of Volume Weighted Average Price",
        "terseLabel": "Threshold period of volume weighted average price"
       }
      }
     },
     "localname": "ThresholdPeriodOfVolumeWeightedAveragePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "kprx_UnderwritingDiscountAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Discount And Commissions",
        "label": "Underwriting Discount And Commissions",
        "terseLabel": "Underwriting discount and commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountAndCommissions",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_UnderwritingDiscountAndCommissionsExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Discount And Commissions Expenses",
        "label": "Underwriting Discount And Commissions Expenses",
        "terseLabel": "Underwriting expenses"
       }
      }
     },
     "localname": "UnderwritingDiscountAndCommissionsExpenses",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_VolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the volume weighted average price to determine the fair value of share issued in a business acquisition.",
        "label": "Volume Weighted Average Price",
        "terseLabel": "Volume weighted average price (in usd per share)"
       }
      }
     },
     "localname": "VolumeWeightedAveragePrice",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_WarrantConvertibleIntoCommonStockBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Convertible Into Common Stock Basis",
        "label": "Warrant Convertible Into Common Stock Basis",
        "terseLabel": "Warrant convertible into common stock basis"
       }
      }
     },
     "localname": "WarrantConvertibleIntoCommonStockBasis",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_WarrantExercisePricePerShareSubjectToAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share in exercise price of warrant, subject to adjustments.",
        "label": "Warrant, Exercise Price, Per Share, Subject To Adjustment",
        "terseLabel": "Warrants, exercise price, per share, subject to adjustments (in usd per share)"
       }
      }
     },
     "localname": "WarrantExercisePricePerShareSubjectToAdjustment",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "kprx_WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Inducement, Placement Agent Transaction Fees, Equal To Gross Proceeds, Percentage",
        "label": "Warrant Inducement, Placement Agent Transaction Fees, Equal To Gross Proceeds, Percentage",
        "terseLabel": "Placement agent transaction fees, equal to percentage of gross proceeds from sale"
       }
      }
     },
     "localname": "WarrantInducementPlacementAgentTransactionFeesEqualToGrossProceedsPercentage",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "kprx_WarrantIssuancePlacementAgentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issuance, Placement Agent Fees",
        "label": "Warrant Issuance, Placement Agent Fees",
        "terseLabel": "Warrant inducement, placement agent fees"
       }
      }
     },
     "localname": "WarrantIssuancePlacementAgentFees",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kprx_WarrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Term",
        "label": "Warrant Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantTerm",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "kprx_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "kprx_WarrantsConvertibleIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Convertible Into Common Stock",
        "label": "Warrants Convertible Into Common Stock",
        "terseLabel": "Warrants convertible into common stock (in shares)"
       }
      }
     },
     "localname": "WarrantsConvertibleIntoCommonStock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "kprx_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for warrants.",
        "label": "Warrants Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kprx_WarrantsExercisableAnniversaryOfClosingDatePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercisable, Anniversary Of Closing Date, Period",
        "label": "Warrants Exercisable, Anniversary Of Closing Date, Period",
        "terseLabel": "Warrants exercisable, anniversary of closing date"
       }
      }
     },
     "localname": "WarrantsExercisableAnniversaryOfClosingDatePeriod",
     "nsuri": "http://www.eyegatepharma.com/20221231",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r492",
      "r565",
      "r607",
      "r608",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r338",
      "r455",
      "r480",
      "r493",
      "r494",
      "r504",
      "r512",
      "r518",
      "r561",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r338",
      "r455",
      "r480",
      "r493",
      "r494",
      "r504",
      "r512",
      "r518",
      "r561",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r261",
      "r456",
      "r505",
      "r517",
      "r556",
      "r557",
      "r563",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r261",
      "r456",
      "r505",
      "r517",
      "r556",
      "r557",
      "r563",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r329",
      "r338",
      "r365",
      "r366",
      "r367",
      "r454",
      "r455",
      "r480",
      "r493",
      "r494",
      "r504",
      "r512",
      "r518",
      "r555",
      "r561",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r329",
      "r338",
      "r365",
      "r366",
      "r367",
      "r454",
      "r455",
      "r480",
      "r493",
      "r494",
      "r504",
      "r512",
      "r518",
      "r555",
      "r561",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r339",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r225",
      "r339",
      "r529",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r225",
      "r339",
      "r529",
      "r530",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r551",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total Accrued Expenses",
        "verboseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional Fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71",
      "r183"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r191",
      "r476",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r26",
      "r144",
      "r445",
      "r481",
      "r482",
      "r535",
      "r536",
      "r537",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r545",
      "r546",
      "r547",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r110",
      "r111",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r85",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r43",
      "r59",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total Shares of Common Stock Issuable"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r159",
      "r167",
      "r187",
      "r208",
      "r249",
      "r257",
      "r259",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r410",
      "r412",
      "r426",
      "r516",
      "r559",
      "r560",
      "r611"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r179",
      "r192",
      "r208",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r410",
      "r412",
      "r426",
      "r516",
      "r559",
      "r560",
      "r611"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r405",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r405",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares issued as consideration (in shares)",
        "verboseLabel": "Kiora Common Stock (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of equity interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Kiora Common Stock , Price per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r134",
      "r135",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of shares issued",
        "verboseLabel": "Kiora Common Stock , Amount"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r409",
      "r539"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in Fair Value of Contingent Consideration",
        "verboseLabel": "Increase (decrease) in contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r133",
      "r136",
      "r408"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "totalLabel": "Total Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "netLabel": "Current",
        "terseLabel": "Contingent Consideration, short-term",
        "verboseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent Consideration",
        "verboseLabel": "Noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Net losses of acquiree from the acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "In-Process R&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "In-process R&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r181",
      "r496"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "netLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r46",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r45",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Including Restricted Cash, End of Year",
        "periodStartLabel": "Cash, Including Restricted Cash, Beginning of Year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r154"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r208",
      "r228",
      "r229",
      "r231",
      "r233",
      "r237",
      "r238",
      "r263",
      "r285",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r309",
      "r310",
      "r313",
      "r317",
      "r325",
      "r426",
      "r495",
      "r528",
      "r541",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued to purchase the shares (in shares)",
        "verboseLabel": "Warrants to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r162",
      "r171"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and Contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r279",
      "r280",
      "r488",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r545",
      "r546",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock, $0.01 Par Value: 50,000,000 shares authorized at December\u00a031, 2022 and 2021; 1,796,472 and 316,599 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "verboseLabel": "Net Deferred Tax Liability:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r141",
      "r145",
      "r194",
      "r196",
      "r202",
      "r472",
      "r477"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Other Comprehensive Loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of Preferred Stock into Common Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r6",
      "r7",
      "r86",
      "r89",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Number of shares convertible (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r30",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r206",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r543",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Total Deferred Taxes"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r43",
      "r123",
      "r390",
      "r396",
      "r397",
      "r543"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred Taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r543",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsofincometaxbenefitexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Capitalized Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r595"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net Deferred Tax Asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r119",
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and Development Credit Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "verboseLabel": "Cash Versus Accrual Adjustments"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r115",
      "r595"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net Deferred Tax Liability",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "negatedLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r121",
      "r596"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesDeferredtaxassetsandliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r328",
      "r330",
      "r337",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r43",
      "r247"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and Amortization of Intangible Assets"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r14",
      "r287",
      "r288",
      "r289",
      "r293",
      "r294",
      "r295",
      "r447",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties included in accounts payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r203",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r226",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r416",
      "r417",
      "r473",
      "r478",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net Loss per Common Share - Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r203",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r228",
      "r231",
      "r232",
      "r233",
      "r235",
      "r416",
      "r417",
      "r473",
      "r478",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net Loss per Common Share - Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share - Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate Changes on Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Tax Rate Expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r210",
      "r380",
      "r399"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "United States Federal Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r399",
      "r593"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "verboseLabel": "Tax Rate Differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Permanent Differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "negatedLabel": "Goodwill Impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State Taxes, Net of Federal Benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r593",
      "r599"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "verboseLabel": "Research and Development Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesReconciliationofeffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Payroll and Benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r177",
      "r198",
      "r199",
      "r200",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r236",
      "r264",
      "r327",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r445",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Maximum number of shares that may be issued (in shares)"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r43",
      "r80"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in Fair Value of Warrant Liability",
        "terseLabel": "Change in Fair Value of Warrant Liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r418",
      "r419",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value on a recurring basis using level 3 inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r303",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r419",
      "r451",
      "r452",
      "r453",
      "r502",
      "r503",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r418",
      "r419",
      "r421",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r303",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r419",
      "r453",
      "r502",
      "r503",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of fair value unobservable level 3 inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r303",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r451",
      "r452",
      "r453",
      "r502",
      "r503",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueLiabilitiesMeasuredAtFairValueRecurringBasisUsingLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r185",
      "r273"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r270",
      "r272",
      "r273",
      "r275",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r64",
      "r458"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Trade Secrets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r64",
      "r457"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails": {
       "order": 1.0,
       "parentTag": "kprx_IntangibleAssetsNetIncludingInProcessResearchAndDevelopment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDFutureAnnualIntangibleAmortizationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign Currency Loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain on Disposal of Assets",
        "terseLabel": "Gain on Disposal of Fixed Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r43",
      "r77",
      "r78"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "verboseLabel": "Gain on Forgiveness of Loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r184",
      "r265",
      "r471",
      "r501",
      "r516",
      "r553",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r268",
      "r269",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r43",
      "r266",
      "r267",
      "r268",
      "r501"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "netLabel": "Impairment loss on goodwill",
        "terseLabel": "Goodwill Impairment",
        "verboseLabel": "Goodwill Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r209",
      "r398"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r157",
      "r163",
      "r174",
      "r249",
      "r256",
      "r258",
      "r260",
      "r474",
      "r499"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss Before Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r209",
      "r398"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesComponentsoflossbeforeincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r381",
      "r383",
      "r389",
      "r394",
      "r400",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r211",
      "r223",
      "r224",
      "r248",
      "r379",
      "r395",
      "r401",
      "r479"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r375",
      "r376",
      "r383",
      "r384",
      "r388",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r166",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Tax receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r161",
      "r172",
      "r533"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "verboseLabel": "Tax Receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).",
        "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option",
        "terseLabel": "Other assets or liabilities that are subject to fair value methodology and estimation"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Tax Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r539",
      "r605"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating Lease Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r271",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r61",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets and In-Process R&amp;D"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRD"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible Assets and In-Process R&amp;D, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r155",
      "r165",
      "r201",
      "r246",
      "r440"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r32",
      "r245"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest Income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amounts Representing Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r208",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r411",
      "r412",
      "r413",
      "r426",
      "r498",
      "r559",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r160",
      "r169",
      "r516",
      "r542",
      "r552",
      "r604"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r180",
      "r208",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r411",
      "r412",
      "r413",
      "r426",
      "r516",
      "r559",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r208",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r411",
      "r412",
      "r413",
      "r426",
      "r559",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Non-Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Payment discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r239",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Business, Presentation and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r44",
      "r164",
      "r173",
      "r178",
      "r193",
      "r195",
      "r200",
      "r208",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r230",
      "r249",
      "r256",
      "r258",
      "r260",
      "r263",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r417",
      "r426",
      "r499",
      "r559"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Supplemental Disclosures of Noncash Operating and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other (Expense) Income, Net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other (Expense) Income, Net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r249",
      "r256",
      "r258",
      "r260",
      "r499"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Loss Before Other Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-Current Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease Assets with Right-of-Use"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r81",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r141",
      "r142",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r35",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, Net of Cash Acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of Property and Equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]",
        "terseLabel": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Public Offerings, Net of Offering Costs",
        "verboseLabel": "Total net proceeds from offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "verboseLabel": "Proceeds from Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from the private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from warrant inducements",
        "verboseLabel": "Proceeds from Warrant Inducement, Net of Issuance Costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds on Sale of Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of Warrants",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r70",
      "r182"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total Property and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r170",
      "r475",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total Property and Equipment, Net",
        "verboseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r336",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r176",
      "r446",
      "r447",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r336",
      "r446",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedTerseLabel": "Repayment of Loan Payable"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r113",
      "r175",
      "r619"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r45",
      "r50",
      "r487"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "netLabel": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r93",
      "r168",
      "r484",
      "r486",
      "r516"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r177",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r264",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r443",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Creation of Right-of-Use Assets and Related Lease Liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Shares of Common Stock That May Potentially Be Issued in the Future"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/AcquisitionsPurchasepriceallocationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesObligationsforEachRelevantTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Summary of preliminary purchase price allocation and estimated fair value"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets and in-process R&amp;D"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r188",
      "r189",
      "r190",
      "r237",
      "r309",
      "r310",
      "r311",
      "r313",
      "r317",
      "r323",
      "r325",
      "r504",
      "r528",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrant activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future annual intangible amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Business Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r531",
      "r532",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r531",
      "r532",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r531",
      "r532",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r531",
      "r532",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [
      "r531",
      "r532",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E preferred stock.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Recognition Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Expired (in shares)",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Awards forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "netLabel": "Awards granted (in shares)",
        "terseLabel": "Issued (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awarded (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested Outstanding at end of year (in shares)",
        "periodStartLabel": "Non-vested Outstanding at beginning of year (in shares)",
        "terseLabel": "Unvested restricted common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested Outstanding at end of year (in usd per share)",
        "periodStartLabel": "Non-vested Outstanding at beginning of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested Outstanding",
        "verboseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Exercised (in shares)",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Released (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected Average Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of shares of common stock issuable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares issuable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable at end of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at end of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of year (in shares)",
        "periodStartLabel": "Outstanding at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and expected to vest at end of year (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Vested and expected to vest at end of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "verboseLabel": "Total Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and expected to vest at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r96",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plan"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r51",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r208",
      "r228",
      "r229",
      "r231",
      "r233",
      "r237",
      "r238",
      "r263",
      "r285",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r309",
      "r310",
      "r313",
      "r317",
      "r325",
      "r426",
      "r495",
      "r528",
      "r541",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r85",
      "r177",
      "r198",
      "r199",
      "r200",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r236",
      "r264",
      "r327",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r445",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsFairvalueofconsiderationDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesNetLossperShareBasicandDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r236",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/EquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r7",
      "r8",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued to Bayon Shareholders at Acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r85",
      "r86",
      "r93",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Preferred Stock into Common Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r85",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Stock, Net of Offering Costs (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r21",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Shares issued to Bayon Shareholders at Acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Preferred Stock into Common Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Stock, Net of Offering Costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r57",
      "r516",
      "r542",
      "r552",
      "r604"
     ],
     "calculation": {
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r207",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r327",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/SubsequentEventsDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Tangible asset impairment"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeSecretsMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information generally known to only a limited number of the entity's employees, such as a formula, pattern, machine, technology, and production process that may give an entity a competitive advantage.",
        "label": "Trade Secrets [Member]",
        "terseLabel": "Trade Secrets"
       }
      }
     },
     "localname": "TradeSecretsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IntangibleAssetsandInProcessRDIntangibleassetsandinprocessRDDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r374",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized uncertain income tax"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r240",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted cash flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueEstimatetoMeasureContingentConsiderationUnobservableLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/EquityIncentivePlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r227",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted Average Shares Outstanding - Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted Average Shares Outstanding - Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001372514-23-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-23-000050-xbrl.zip
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M@%,C(== "49H75642&4D#I0G-.G"?L=PN\7$E,E[5N).DV5<...\Q-#K1N-
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M)@3)93!$*FC.,*Z,-G$V02&R-9M-WB,<Y.*.LUFC4JHO36C+SO'BK6=4$Q:
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M\>L6#RUI*SR9+Q@B M#' +Q@QAH\13APJW!Y.K-ATW7@[5V"==&!RCG'.8!
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MXG?"-W==#EXBREVBC\IYQX$NC'J1,J.4RHC77$HM?$;<YA.E 2UOOQ6T;(R
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M":U3(X2BRJ9I3GVF6,8$-<WFS<@=O75EDT<DR=+&S M$^=+&S NWWFZ-<*9
M_*2ZI#.*NA2,YB_?_O'AUIJ"Y)E6UBB>HKL,ZL'PU 0G+/-..^I;7@#'K==]
MV/+"M;R@ .W=D!<6;[U3,<\TSPC-A,"C13)J6!X(U<9Q9?#,PU;3KR'9MIK^
M"YI^D3ON5"*$Y%+@^K%4@CBILD #<5:%E&@ -9$[Q#K7C<0$KL.PCY5I3B*-
M%_:8_>Y=4?;U<#*8<<#],4!\XZ]%20F]5^*+E54/M52DC#M*'-CZC"BEN7 6
MW#G-9<ADW%+6$+^WY8)UX((E:R)N7&CSXJUWV4WGXJ(LL\X1$9B7  /P<#G#
M'4L!'#1Q#:+6MUC]!X\'8[LCF*TI1HIK'=?>P(PL7EDZV&PXKOZQ/RP&NO]:
M5_Y@:.\YV '*?24UV7/<*)SZ-#B7@8H'9]YKDQ/# <6G/G2[6M)V5PM^6,,M
MH^F--Y(LW7H')@?FIDK[+(#G(XC-)+59GC+C0W Z8TT1C0>9KMLR>638#^54
M]\?3Y>60>.5=6;TKJGK,4O)[T>_#(^_]&,]LN-]C%"]0YBX6BP 1A,EI2 .P
M,)?,A,Q2;7/*;6[SC:7,SWY\[OT0"+,_="G94/*$'&8>MS!:Y00%0)&FWF>X
M!8@:HKC?6/)T=#@\\]6<.AM"%1LHF&DB-1XNR5,JF<A<)C5C&N"^,NV^./A_
MW:ARLY.A?];3>Z8%Q:5=M@I:Z-P1E8?,,&:$#=9030(06P;ATBRTI8"0%KTM
M4;X&#BZ0Y2L9LXNWWN6@>I]F>.)>3G!'HU9& "H QUEQ2;PQYKNBX(U?]1JF
ML #7;#B&3S5TOHKYFC]/Y_NOFJHPNAH>3I9O>HI<Q(F4TN+92!GH9*9-H"+3
M')QO)XVUZ?KKY"]YW <!+*2OQ^70'^EI7'C;KWQW?IX#&+K:@X ?@)&;E81N
M5!>X]@@+TAT._<^S&^X7L:W.'M'@0Y93[7,N1<:X]$RXW"B?6B:-5%L^W"0^
M_. 'NAAB.=)-XT,G,VX%XX$&(SQ+)4LU]5*G&5;&;[<K;(95O:FI>S/Q'\LF
M9[#\6KKY%I1='_!T>GIUD@1<N'6TDSHI#-,2N- *3I61.@,=*6Q*<@T&>H/X
M<)87TU3:PVTRH!!0!7[C<71;)OR*#LL\8]PQ3K-,,)=*IXGTA*;6XX&@?OUM
MZ7?&,O=BR8*F/+..4\VL4#8W *N,];G,<N84WZ2-[^L@QX^P)]9X3\  @- Z
M)H106BK*.0-:YIYXUQQERPDCO-=]6%<*?N%DYEEIUJHX@XDZZFN[DM#HXJO]
MOR:H3,[@C\MU5B[<<,^<Q'N$]0B_"2==N/4N-1(R(D1&M+,L%8%ZI:D)C'/B
MLIB-TR36;AEH31EH*;EWB2?NDG&3DY2 &G&"9,+FQ(0\9WFJ="Y3+(ZV8=IE
MA12Z/4QYI$.6'U^Q>&DRZIUU 1R57.;&:PX<E.62@\NL9<=$C/6Z#ULF6G<F
M8C?)#+UXZUW2'*BBJ: A ,81.E"I--?6F#10)JR?:2)$QNV'[X2)5D).2FY,
MSOFM-R7GB^+SR\K7Y:2ROFZ^GGKM8N==<?;J1_BCR_"TE%K"=0@.L&RFA+!:
M\CQPG?.4R?]!]V/^3#V>]H%\@V+8._5X<M%+D8[&/YP7;GSZDA+RUYWE^W1U
M K>:<CPN!R\I@UO;G\;EZ&4VPOTK]4@/N_MMV2^KEW\!+B A_!!@.+V@!T5_
M^O+_[%>%[O^?W5H/ZUX-PVXOU\6__4L%[<9OYVV?"/FA#[Y)UT?*TK_^@#/3
M<]Z6S8+;R\D0Y@/O@C[HQ^U <EKY\-/.7[Y.C7SGU4=M^CXIPX\O]&9U/-FX
M'N-:+:YOQ(Z_0$;M9.&R1,S9FD:V'D<RM5=-64$'>C#DOA[5_F7WX0=7U*.^
MG@)BC&.(#_VP+#4H7V>^&A=6]WNZ7YP,7\;A-9?GHK='&O$;@Y"/7??F]O)>
MO/1B["Y?4W)/D>LODSTZN_8BMEUU-[0SSIOQN@1&A7/TTP[?N3#P=BAP9^+*
M"4X,TOV'D7:N&)Z\)$DS9_.7O(@S\>5Y!O71$+J9%#PIQ%?7*Q1XWXV9C(H+
M7)9?XC*<L3_>'WQ\^R8Y_KC_\>WQ,H,L=/EQ^WC\]O4?'PX^'KP]3O;?OTG>
M_N/UW_;?__(V>7WX^^\'Q\<'A^^O[?@R'][C=,L;C>3/_>._';S_Y>/A^]WD
MS=[KO8215*BO]?Y+G/*P,IKF>^#*?8N(<K;'.+^1B*Y+L^)!% K9@YE/ZK)?
MN.0OF<-_KU8JZ]O8C=3=@@@^D )D-Q+)=X<??D]^!'0Y+(?O)P-HQ"8M"/V
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M\58Y&4>4B1S5,M:H/(?W7.HC@*$SWV2;^,^XU;'1^!$E1 (W?4 <-,7HMO.
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MY*NSPFZS.#=+P69?5[#;&.XVAGL;EE)=$/?OVQCN%H"LD[:CLQ/[MO4N-PV
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MJCP'D]QZ0S/  :*'YZC447*NIL=,RA9D%WH)'L3XM*Q]U\*6;"LB&U)AT0=
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M+H0]RR'.6]WI$[2JS><BM@%LLY?\V= 'YWHRBG=\[?6[,>2**[63D]/8@[H
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MWKBU\^V&\6F:C+I)'$TM L.CEW!E**#VY^=,"D%/..WB&^UB7KYN44B*T;B
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ME7HON12NIHT [H3L]EE C]Z<^@UMCP.%@EM,BRF_G3G2%9@"=A2L*R*T\PR
M,?T?N2';5TW]Q9;9;Z8<#_)!;60C%R-K1Y#X;G@OF2JQ9UX0\@@Y&<D93XIE
MK^-3I+2IM B[=W0>4J!N*2JBWO)<+\<'1V.H])2Z"YJ%Z57])1,9^I<@EM7A
MH$(:W,#GGO)D[Y>7KX$3^)41<EACF$D\";&O-MG<C&1KIK2-D/K<:/68VZS8
M42LXLZK:!B371M0G^N#Q8^-!-'T=+L 0O>P" $.T,-;*A Q0/1H@O4R"LT/.
M:<Q+-^*A1OOV'\_8KX4R0O*,&[=3;HHD &) [P6N8^<8@Y@>?+/86EF4"(>3
M+NG\>VR:?M*.F[X=YRV5G1.'0:F0S]'(Q;T9CQ_M;K!CNIB1R;9/X9E?:&V+
M@\]VL.GG$%$;D'ERI6#6E\1)V7>H+;N=6V"'(</DGY0WGU_B9& Z1N=Z:3A-
MU(/DDR"K=G'[L#&F,#'(4=-8D@X"R9X'<]0"2#)?%RML#0K5I3,U EP]!SDX
M;;4Z!'OF,<*]J,T6@()Y4[<MD1#I(ZB5LYRI;@$C94? )HAW^-8OF#4[&5PH
M\MM?KQ7?)3Q1JI0LSMKNUV=G:3R9)C9CD_$T67E.6!.EB4$TO*WNP"QFM3O:
M+G!B" 14=F-9!"AV_GY=L^&6ER9_P_=%^_.(P,W.ON4BV1!XT;4(Q3U=>G!M
MG3MD9:S7@D,$PMAN1Q+&ZZPHJ5\9AU<>UY7<TEH3/LTWJO&9DE>+VI]1V<K-
MIY(XAOR"3.HHW>VE2EXV,0LV>G#O0X/J34&_Q_<=].O)D;FDAZ7@:9('5,C)
MWH^G#ZR\R+S>$FH(?0^+H5A+ 8;X@ X3*9[08NH;X<1BYYL\;!8DNUHA,L%1
MZ!P3;X9G[F8$_JE&3XI.$V/<^<:2L_['9;$J#+I>N3J(0<5;%O<./Y[Z4@CW
MQYTN^+GA2J1#*P2FC-8"<WT@XLSO'+F9C8!R_&"#ZB'/.S!(%:O>=TX"=R2%
M92&,7O U<F>0.ZZ%#"E?W#DQK_>S!8SZ!9-(8RP$38F2HG)/#P94F15 ^N&,
M!G7J\HEX42S82PESCHH'(+,[G=W!DD"%F-I1)-TIPN,'R8NSB*9;(0J!#($(
M%)0NFGCC.E]7HAM!7I5(Q:E#>*L#DD@QFGIMJ,6L5S C_]I][\?3^^Q(R1#F
M[ZFF%/?_MDM,J8NKF#\[$(?+#CO+,W)LS,+U"].M?+BXJ*>UBD FE86*#I5%
MRNNQ!W4,VKD;1 DXN_FF=/ PDS@4FVCMA/4U<R<OH9+IVAS(L*T@;.%9V1=$
M%JBD>O0* )Y*)$G8/+X1Q'"[X,/,9#,&&\*2]TI#,LN[3FYF=@ ?\/2.9]E%
MS?'F8"'K%F!>/S338L^2E(8SET183@EZPQ0B^A_%BOR ?N$IVW76F!:J';=A
M%"YQ+S/ ;"Y(;N285DV*K5L)U,23ES"Y>73+19VSZ\$,,7CVAA7G+XFA;_11
M?+_$$O/3#A\T;&O%EA8L7+!",W$J5U:V>PPB:;1\.>2&EJ4_!F"JHYO9"H'N
MF&!-M>\DJ]R1IL"L*X0?N/=A:(%5-00@:KL$"O'F"[,T3 _X14X"9TB ]*AU
MG*I>A"UZH.H]1[M]I=ACYWW^"[;9$,6RXUJT)"Y$A1X^XBQ[#J5YV-7ELLJG
M+CNAGO2QRTEVP42[F'K^6K8KP923)@3HEXJ+NL-[QQN<^JF(DMUKX'E_/1\<
MD=DY+ Z'H>KVP.PNH#8.)1V2><^\>V6#PGN\0Z^E#=*U+B4\SJ;M9A(Z'F,2
M>A?R"2GE-(0=2*)[WNX"9+PJM< =9Y4WT46U8-(-CV\.-Q;]E-C N.-MF5%R
M(+JP6Z[,9,B;T(/!A6O/N@X<_8TD1"FE[OG\1M<PYX6O7XIR\:'G/A5'KUO,
MCZ?BZ%0<G8JC?]+BZ*#D.48OZ8\M1.[5>4.5U+.B&^&F>W(=,YTYU$9RZ/=$
M(8E2>'0\G=]4&^GQ9S?Q>(GS.J-.67*JJ65+<TW21ZHRJD%5(-"$<4*)6N;+
M?*7-N^0+M#(XW)U:?WW#03K!49PML"3VR_RL^_ID?)SX3\Z/<3?]>O_HZ1^?
MT[URY(AF]O%'!V/&0W/T$(#1O_SW<YFW9T@WG+9M#K/T8:/]Y/AS'>VCHT\]
MVL<'#Q_BQ6'ZB\J%=SYHLGH!]9DE!AT3O/8ZL+&OORHHLC7\H&,Z[C>UC]/,
MWM7,'NT4- RQ\U9+G E+MJEXQC@Z]_*#\X-T5'+:Z.".*:N*#*[PWW,:G-GX
M1Q1;Z9'3I"T5@N">JW&A; 44ZLI441C2LJ7B>HO3>EJ-=[$:1],&04*36MJ!
MINH;:UFH')ZM8I5+(YSJ\Q;;5?X <U,5S'G>D.9HMUESBXIU\$: Z8J)D8=H
MM0;#:'+*G;AM,.^I6M]&!-N@X<[87QS(B'*14%Z:USQBH;Q:K$$:>^-,T^1_
MW-[_^ Z)KT7RJFZZL[HL:D\P\,PRI4\^R1W:BE=]T_:Y.MW%/":I)^]>:SS8
M2L^(NG?CJ\FDNL4"/? >><])&S9^6^67"23%!7YI1 ;0QUV3!K6S :9OP4:/
MBC]!!C)HJO UN[P$ 47/%H)*:_<I!'QN+/*K8DV=6A^8TSX:7^;NE8J5L\C-
M_+_^\F[=O-^'%,#1\<G1_W]^=/"O]?E?4-S8]5&<YSS^ZN'Z_3?Q4XQTG-$S
M\,>2O7O\^'#]'GF^SWQ&GNF98*;E\\<(C;^+N)I?)[=AL\=V?$F[_#3XE,^]
M3TE\DP\^_Q'9(79L+<LI69;[6SZ*B!*A<E,0HH@%7ICB>S?-C)= AD#B_BI[
M3X  __'&X"KPZQ?/'AWN$V(.(W=X<))4/Q\DWRI<A7 ]@%9?ULT[AKWGA,>X
M!)--6>074F-=Y5DE> -2H-AWI[V8?SX1$F(0'Y"MX.[R @^/'KE;/QC0KNM0
M@-"M8=(YP3TJ?)9\2M*XC"E1YYNN?D>\AHK6>/&/?<BEO/C^E_WS-/D_W_WP
M/>T)TFQL8^TZ0HH @4U](=QQH)P32F]ZP!>D:] U/0V@&_D2=3_S#/+ ##EZ
MNSQBQJRE^[DG [',)JE*R(-%;][TA*M2-CT)U105%[UUX.:C5@-1I8PJ@Q%1
M*W1%C)[/5 Z[=G,^F<IA4SEL*H?]2<MA>W$GGTK2>+&O46$;?P*-9NP\M-;]
MSQ 0BW;+@64B5P@'GU%5"*@ZH1=49DY)E4QT'S>84N"/B#!Z[O$N(_C@Z]G,
M8H8N\FQ,5A@,UT2GB%3J!HQF;HD(3TOHX'KUXN2G-#G]Z2W-[M]/?R)VS"#
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MB*ZN]__4-)M[]*!KR]].  #H",9DWAY/[DZ\@*!.DRJ[$-;!E-BU5WG7;$!
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M"<P>.^(P$GRTQKJ\<M >'^HYB_>R5>2=IZ7RF3[Y:S OXZ>:+Q:$V4MT75.
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MEC$'_',.:B6ZH6!+! -;SM(PORMS\E'1@!U8$=[":.3.#!0K?5.R7>0""Q/
MA4;A\Z*9]RN5.PL/ZH\^G6O38-<RU<  @1=0_JD5A=@IN76EBF70U^0VO)T&
MP6>F4*FY%?CCLU+_>TW3_EI()=S$8LU][P?ME=1G:%Q^R84VQW1*"B_"A_?(
M?':69FJ<^Z,:YSY#'I8W!7L"8:IN,]MLD<$;C'\'\L'WBJ?\CZ.3@\>)>]I2
M$^<8\4V>(1FY("D0)JW^S_]U]/CPFR SAQ\^O?4/CVCFW&^= QI^C)-%&.!
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MG-"V/8Y1M24RPW+9,JL SI!RY4ZJQF3KT=LQ!"9A;"<@W%WZQ)*?8;/;]BR
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M8!C5O;+YB6_<7$VAR=W-#6LE+"T3R*KV@H;4W<BL^M=S!NV.#"; J0).OYH
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ML&HF'K3NF1=X);9S6FW@K>JT5+X&8;.L?C*_U/&DB*RR^.#\LDU=K\12+N_
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M@^@<F7E17MU6G?\;Z@6A#T@1U%/]0%0>H*/[QKM-"@W&1[*+VCZ(!X0"X4@
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M6;OQ.BJ]8U51JXJ/CU7%8U7Q6%4\MKBR/7CCTW]J?*D$X4QX0./WJL!J!6U
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M Q5@'%!$EYAA3?=<>= -($'4@'6 ;;"> K:*;YQN6[E,;5MU(%^:*$L98WK
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M%Z8%_I>7P3*2[G>:KQ']0F.J55*^)ZX @@A)L,;QH!%5WN09F6<2Q:U#YWZ
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M0N\=UX"%6'MF#:37+(+OCW/TR>:H@\ [QS%)E%1B%3&>O>.,?+H9T= P=O]
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M.X^#6XC,$#<&&H_MFG*/;^>[83"@R& $^D"N0)D@%_RO) OESDO?RZA5,J]
M@HM&I C16$W7)=1/G=6EMN<S$@FI3RX(@T9</)U*V'%,1>2W8$703+=69 4,
MYL+$IFAK2:7EO[@O(Y2"TX#5A@Y<<3N,G[?N$>Z.D\G&BY_,Q041$C?]SHDI
MU6V$L]B;UM5X7JQX!ON\WCV;FNW(._/)1RP[B'M(LS&/]ZH.2[9HH]FG-4N.
M5G!TAOM-<J_=Q#R&29-9I)423YTII1M:!9V']M=,Q.>$R'AC9.DKHA->640
MM1RW91!$GZ[\Q5Q1N@JA^MF:*JMRQ/A2K,\/^ZX$6X4GXS55]#Q@=,++H1(
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M-[[9U3@5*?9$NP8;Z.[*N>?-1::DE#XA87SP*&;U2<R)(S&]RWE@W7%QMXA
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MD>S!&&QSSJ+1F:&,APN0&E%;8=.7!UTY?ETE+_)%P]0*C]/DT8-'CU+3)TG
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M>_1<9_\4^$+7O<,>EY)6T8KJ<W@N>HW;AZJ_PSF-6A#U^"TA73\8EAF'@GO
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M(3UV1)!QORTWH&Z*W<[718TV.;!0(#"NFXDE,R!WFR2CZW+.95'=(O2O<1,
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M<Q*08;E+!?.X.C_V.,BI.Z% \O.2*#0XXQ/9;OH_YE4YOKJK^@154P1/DJ(
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MTI]P!HLF5MQL?7+*2,1*[YD^49RMD0_1@VF++";:*#.'MST6@6^R@$\>'(O
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M8FR:?%TJP$B=V\LBOQ(/1PAZN1^(XYU+3VY T^8!;>X8[Y6B8N!68Y1EW,U
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MH&M-U<R#GZ'^IFF](5UZ70#4AEBM G^])7-,Z:(%[R1Z6SU+BM2U5+WDT@]
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M9;H2W@VNOPBGF'DT@*X$13A=7H5YV)<( ZV2CP^CB-R78NX3Y.YC^S!V9=7
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MG/B3[( A@R,8[IK?:*P'I05*+K.4+ESQ&H,11>T4>8SJU66BXYR6%]X4HIK
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MOKN4=Y>=^NZROKNL[RZ?X^ZR9K5:/X\=DRJSD&+UH&2X@2,&V3'@[Y',8P/
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MQ[#R8,K1J##^K[<"EL=46 J%X_E^*7<R6PU8HS$'L$7'1:1^*#-4;W=8;%I
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MR2'.=O/2]ZG^,2+S^2K"42-6U5UC[D^?Z=;I,W7Z3)T^LZ.E_W^68GJ:=EJ
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MO B_C7_^ASOR<;I^DD8AL@C<XG%I@ 8:!2F!Z^36Q$'_3A$&+ M55 $XE@N
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MLTJ_(JUFJ)JL;C53K58S%5DH:QT!JF9A.QT?[#V]CXKD1\(AD6-.D@&%-/#
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M0']-/1[,B5MA)/B@0] K%^HI5BX 5F7[J&D$,\L(BRRQL 0$AC0?O(#N ;G
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M1G[P8<!C_!K$T\/1&SHSXSVG_>:3W6W][7WAO9\>?,9Z=D7.6!_/V+?!T:\
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M*OLN+^2]YC:UZE$BK+Q+5[JUHK'APCB2^+0RR%<?XETA)(K,B&*$("VXU[A
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M%O-#+(2O]1"U1XC:KA&U1M2-(&IEZK%J1*T1M8"H]B)$M5=$5%4X*OJ\=&I
M?8V ^KQ86C? W 4\@M]UNGW"(Z</?RA%$PM7KJ+[]A(04H$\MNKLI@(A=QJ)
M5IFE.PW\U1E>H,2),8$_^",^],&S!1T%D4<-15L-14X-1:\?BA;VA4#3:&TD
MDHT:N+#,6@V'9''$<T/1>ETE>$@U#KV@C]FJBH]9)_"]3NQL*LJC8HFIA>.F
M$E/,5"D9<F?^S(U+=1N+4=.Q5F=V/$O]V27\Z6L<39\Z$R5W<FM&V6H@964J
M0.IHW [ YD*3LV6UK3:;G,U^LQR-.P%8$4CW6QA=&]_@_P^2!'9(=/Y8#*3$
M/;ODKOC$#:-9ZB<B0\?XU4\:T\:P\8T^U3K;-[X$B1>!/-P:OTZ'WYXE'F>W
MZ\8A%<'4RI2/U)A:8VH!4YT"IMYSH_$P#&W4(%J#Z H@6IEJD]J%WR'<[+=[
M;=%WSK$Z?:M\%\-L+O=;GG8I['F'__X9E@3PJP&.?.Q/G[$G0XV2VX^2O1HE
M:Y3<-I2T['[7Z1%*.LU^OUS]<C]&JH(V:W68/(@#S_A'P_CBAH$_29ZKY*Z&
MR@K<3=>MQG< =NQFJ]]WVJ+WGMTMP\Y^%";9)$4"A"6PPSYB?_6K%<":,4#$
MI3$8705)%"?/T39K,(N#2=TWJS(VFEV9$I+:1ML=L+2:3>')VG:G:;5*8'D\
M!@0QOOMIBKT =9"4C-#=U6'R=Y"O)'&-\RCQW"=&1ZUPI4;([3?-;*LVS78!
M;1;U$\S11F,OS3PFC%H$/:JUWSK@@[_Z%DU&F#08NM-GRQFL^Q!6"H?J2HK7
MC$.K=!^TFBH-S\MB,)_Q\E*RL=]7U,7Q_/EKT 6 ]!TQ8((WI/%/8]^=!:D[
M,;["-)_#>:S;%U8)E.J:BAJ4UB^MJ$%IQT#I!6):E2FP**:XU9EN-;CJX"KS
MW58U\YP:46M$?1I$K6@A1HVH-:+JB-IZN+E:@^MN@.OSX:IM->K[A=>,22VK
MV>Z" H*?^W;[_<]9?+.'Z5B8G7OCW]C62,;TLF$2C (WQJ@>@$X)4YZV]H S
M-F0/W1HNMA8NG(;U_VJ\J A>P/%V+#SME(M_@V<_3_2BGC/<#G&&?.JDTO'P
MPN$:&2?9<!)XQL#SHBRDC+"O03RM3]RSGSC'JD]<E4Z<8RT^<;BFJN<HG#M0
M>*$7S$ Q^C>^EU%CJ6@,G_!C8^M[R"^=YBR+DPS-!3 '3K,)6!*6X^Y9[;?^
M.U+J5GO$_S+)?!AA >3(T+]UYGNT1$[3EE;(F1L/W=!/]HYO)OXM8!(!%Y)0
MUGCT$GADUWA4)3RRU\2C<1"Z\"/\1&QCN04@X:D^Y*_^D-M@=-2GO$*GW'ZT
MU5$%HV/Q+"MA+RT>N@Z*5L_XT3AK[#<4/%I.NWDOAO:;G1I#MQ-#[1I#*X6A
MJUE*E4";A5-YH(U7 ].K B;,XCT\.ML&:'J^2?_OY]/OQF&8I-00\DOD97C-
MVBBLP0[)W#!*TVCZ[&)WMO_M9<7N!>9-DG?NWD1A-+TU#FY2/TRH\[MWZ4_=
M6A1?2!3W!]]K412BN.].O&S"!L[W(/R)F4RU8+Z08'XY^%H+IA#,+SX8JD$M
MER^]/RB7WP>?:[D4<OG='2*!4BV3+RR3)Z<'M4P*F3R)?<SIJ+7XB^^0U6SM
MG%3N(TVQ<>)>^.!EISY&P_!NX8N;NL;78.(;;['4?S3R1\9UD%X&G+-\&.*3
M#!+ID9#4=_.2^CYUAQ-?QH?@/W).4S>^",(]GN\'!T8J?H-9^I9=7*E_9TD:
MC&^?=5G^WU__8G6:'^?_^Y4R'S&1$9>C48R W3E#(0M[N/$?G,[".?*O LKJ
M^K"''WK>62^=]OEED!A>(:*:7+J3B1%&J3'TC1&FOX\,*IF <>$BT<_61V,<
M451R%B6^Z+\L8I$]%67,J](/;KQ+-P1A%*%&J^^T3 .>$&'RZ'4 R)ADPW_#
M(V3BZB1PA\$D2&_Y:6YJ)/P"$\86BU$&^B#AB_"/Y6FJ00B?<$-*E\70*L5I
MRP/-Q^?@\%:81E5DY3DJ;#98$+2B:"\3[/TH' >XA!A33V/?38FC)?;_D_F)
MJ.0 << 4:)BL2K 6%P8-H_#]*0@3#A4^-@U2^G8X$LG2"7= \B>W!*1EB2&>
M3RDU^]%T&B1H'31JJ5G:S&$+A <&[()*]'0A*(H*P*;,M+\&?%&",?0]-TLH
M)][@KXX#?[3D26^#=X8+7T:PE3)&$O,V@+]<1]D$'PA?GL[\-,!E!2G#Y@3C
M#+!O#/"+2<'PNU&0>!, XE$M5LO*_9;M]?-+'0::1Y2FA5LMI"B!?07[;(C5
M8U*6QG$T+8J:?JUWF/I3H].TWKKOWK;?H52>^A<R:GBV]UL#&W,#X*F*$31N
M0"&2VDO=GSX!X#B+PR"Y!!F;B3H3U) "#>5 DL4CSF;P)H&HJ&KQ*W@QN0K^
MU7*JD5>^/.+][H;@*I"*!*BBRW,T?PAYPL1-H_C6F$U@E/!+-XYQ-XM>K-K&
M8/3W-X'C>);E-1UW/!ZU^FZGWVIY;L_ICAVWZ[3MWK^L?O/-O9O?+_H/=FMC
M9K-56JSNPL4Z/#_XW; Z#4.KD#K+IC"DVQ7%EUP>;0J+A??9?($V3.HH"OWE
MIT]\M(5R.R_4U\$HO807X>+HWQ*S;>9?<8=)-,G2Y5]9:YT\'UW89UVF3J^4
M!*']=PTQM]I*S"_C/'IPX>\-P2;]N>>.86(?W,FU>YN\>5]<(5@+?3L>O)++
MUVW#N3#M%;.-7F@$(AOG+_=O6_?-IW.,<* >!$< .TLE"_)BRH?GN21V"5H=
M?3GX7^/\V-@_/CH[_G[X97!^\,7X>G@T.-H_''PWSL[A%[\?')V?+3W]+SN!
MWPZ/3P?&R;?!Z>^#_8,?YX?[@^]GIG%XM+^JM5 6?OPW1E!I+Q56Q2 0>S"5
MB3M+_ _RAX]@0X.&N_T04 QLC[[TL?C\!=J<EHS_G)_01I-/J0B:BC>+/S?H
M3S*X6/A;WVITN[VE?VXVK*5_N^NQG4;3ME=ZZG,3D[Q0NN/+I@.N $"6U4-"
M"B[07K,F=$D"WV9W]+D18[$U^W7O'@NZEJ\[Y,N^.]6S!H&7WB3;XLKP:!(P
M^\QG=T+IDF>7O@_^-Y/1?/$]9FT6'=:+Z=#5F&4E!TVQC8HNN%5KB1J 5I*4
M=JTEMGR36B4M<9;"_V!TCAO3S7Q^.L=B]Z/I+/8O,4?ERC>^1TE"%[D8NOVG
M[\:)<1!B3D#EE4JKBDJE56&ETJJ52HU7JTI*IU8J6[Y)W3N5RED:>3\ON46-
MX)4S#OZ38;;.J]0FW2IJDVZ%M4FWUB8U4*TJ*=U:FVSW)CG-.[7)OIM<&E\G
MT?7K]$5P]I4<=%6U!XZ]UAXU,*TF*?U:>VSY)CF8M91ROF)!C7Q5K"FY0JG/
M?2U2*XF4U;SKX"\M<:HSY$2&W-<]:S,I<KTZ16YG4N0>L1,;SCA#$3X].#D^
M/3>.OQJ8/'=R /\Y.C=.#WX]/#L_.#WX8IS\^/S]<-\8[.\?_S@Z/SSZU?AZ
M>/I[=9-_S[FV[G/DQB/*'0ABWTNCF.^&]*@>_+6ZT_PM -$V3K!2QO7\C%1X
M8AJ'H??03,(GD$QZS@=L Q1X*\CJ\2P(B?".*W47F3Y&=7?L3Y_K7]QL%*3<
M\)Q8\*8P@EO,;/-TNV\H\F 2SH,!0;YCQXVW^#!1P;K/3Q0UK.^6I-#8TO.%
M?\J&[*3BN9(K'TA2B&-$Q:M6KW#5.HD2&%"R('#N4^"<W^1A*&2L0B&^ZUW*
M8IQ;"HG 3Z&!J8"C^:&%9"2_Q8Q6WQ/58E3^&G-UK$M?SXMYI03ELY#KTMAD
M98J]D@08QB;?N9K4'<)QRF+8-SI:)JW.HF4Q9LSE8(S=()[ 5@6A@>7'JF8/
M_CR#)4_*CY#6GMQ#(7YKB5V235B\L.2J)&+XJ[5$1A0U1O$4[VJH8%4CFQ1\
ME%CH=>&'\*8)2!#\W2=.2<$1\",,5 B/QC68PB)X[HO*3.7@_-<(%QPL)\^/
MP^KB]GD9IQ<>G[RT$0[2S(VI_#K)IO@%*NW7S\9U "<+B]"",/.)T]2XB(0*
MP,7:$6P:)%35FR4)'SV,@!B69$=8M,QF81DO8>7@-&<$_JA\X+!206D)0D+_
M@ES7 HZ4/D=[%+N"I0$Y.ZF.>11EP]1PAU&6$A))P@888[U_>46E:KR&!92X
M*5B4BP8X[R4L*NB1%&UNK 4'NR4R1G[BQ<%0W_D=6;;S92IX%%&9/(CT)!OY
M5*7LCA#R^,\DHE-\D%"9LGH:/-0L!8#R5=U^AF*(]?WI;:VSUM%9G]TD8"-#
M.".5UEO)$D'#0R@LKQF 7Z"ST"AX56=ZJH[YCAS08S"82TL34&3>OT$KF7I0
M1D5?M;QF"Y<=R^*I]21:Y.0&)CNRHN#[$O +.@_=(!\'\510.%#%EV*8$:5?
M4MEK)6#'5Z!)" <YRO.V8*^_,]X*]^]D?W#\.?>#D74^]HG-(8@U,J6\\(S>
M+1P=:8;(]Z,_!$.(1^26JU$2&<38'Z$G@?1-DA1BXEXGRL-Q9S.8"L428\4Q
M$2LJBV0!F]024@GU2)K;(T(]+XU.?R+G2SC*/-RX_#PL6V8TR$:PUVJIBO-_
MW:?G_#)*]"40$LP&P;7/K!4H&&#.HM_+,H?KB4(<#8GH)_;=) I)!M$QB6E]
MV;"]OO21HFQY; "/S3CVR;Y0 0&42/D14SUC! 8Q(F4<(_-9#%^#@>S,/FEP
MD9 MIX,-NHC,[$9T2K!Q?G@!FI7^*+8.HR)BZT0X),!;K]!E?S&.)@:Q'N;;
M%%,)+<#BCBPR.(W@7M/RY+!AXFJ6P5T(/@R,;G_H_'"_D=47U1C"^<"-E%E;
M@@X0'R*L ?S4O$'@C\<<H S18%AB6=5[6]I;0GZ8+P8@\7P(>RN,P"G'F!^O
M<875WK&NZ<C-4ZC-T<G(\T=9S(D@+D8T.* =!\G/9"G\2OE:'#*Y$YI-77&4
MAT Q$3*$A2>/DD]#V1&!/$.ITU9$[9E_ R\)8;U,//"ND1(_&#J/IN%?(0V>
MYXL8"$<  9ZF:+^R92?([,0SE^[=CJRR=B@H-)2O\I4[R=Q4K>#",'Z6"+)*
M< E"XGB% P';$4PI>C]U1SXRM^5>+'61NO8G$_S?TBL0@/':8Z8S6]]QNG9D
MA_[$V/8D\*^$T:D9[' Z4-[A#&@6YE"%4;3+ISH2M4XD:A\=00^$;4#6X.\<
M/ZVNYD/CV)-S8@M7QH0]<&^S$,F9B5UT$EV3+9>'C ,RLE2TDR+^<,A!:P71
M*#>7E_HO["BYI3=%<3D64/BS\/_YZ?@7)(KTA0/NIA^,M]8[<2_-VIK1*<'G
MZOA.+Q?S8=5]QP4'4Z/:[P #KZ+)E?"-*2(1T%6EAZ30X#>0ZA%\T@'Z%8+*
M<.+?&/_.1A>,3AN%BA6/W,OX7?G6:8B]1-Y&D<_>F3N!?Z,"KLD"[UOCKWOV
M\E3(.JEQYY,:7UJ]T+6Z>ZO;&](57W*1[/[T0[Z[O;Z,)CX[0B*, .!@HM&H
MH8HP$)= "FDM4QA#^%G)F2X'D\C1+'D FDJA;N7.ZY$(!AIX% ^]%8IGNSWA
MI1;/LE2EO1-TM<#E/07KVXUAKK@G7\#LG$0S<G0/IS,WB.G'0>A.;L',W.HE
MN"^4M2A%JISD@#?D>S.Q,K&^,B-M93!8P$E4[@P^?$/N#Q@,OUC-1L> ,4_0
M!-\-@P 32^;2"^S5$TM$."3A &PN<N3ELVV1^/!'?XH&6YBA9486V/6E'_H8
MPX/_B"/,5SCDYGM![&53[@>+OQB1I9FG!WEN'%.&$?JDOC1BUMA\_\;S_1$/
M&_/X^$$[LNGG\QOH<_H@;]'RC12K)P(QZ640CXS_9&Z,QB'UC+;MW5O#/$A=
M6C;AF9 S!3I.*<;'"B^?SB!6L9O13LHPW@RY%/+6%AZ3VV#-0"#!=.;.+JY,
M EIRMR"$'K=L=RX0%LEO+D1:5%!>H>91092_*=B$2\*(E#V "9TSOK'G&*44
M?O@47P.-5)@7M@4D']US7\]Y)QMQJ/5]2C*/C@=?T7J7^!PP4W[ZJ8H4XP,-
M-"9?-MQ8/0/KST*#&L*C>1VP&D3!>5MHN<M;%4I2T"1'Q6 6!*"EIEDN79G(
MB!5CD&*V2)1W!AD#UM!9'!H34>QA7,(G8)$N1&X";0S87'+QM0B9*C_QQV.D
MG(9'+;UW$W<",D=.1K7E3>YT/NUU)<S8D9T:C$84\V*C. ^AJH47@4W\2\8W
MZ;#\8Y_RF[ !&27]B(@GO'=D)#\Q7QY7\V<87</F7VCV0/50"19(Y@W@&@@<
M4>NR6"Q)=/.[*K&D\J:1:UY"T9Z0%E ^@P(BXE9KA<#(C@@I: 9.#Z&[PU*"
MB+;60D[!FP1I05$5F1H)IVHL3.IXJ(I!*]C4#(L2^$M<P0?NG&$,^U7<$7D'
MA)*;+4VP$2UAERXZ[,I%[$YW1>H/0\,5Z$SY-5D:,,(B2 APP?:H GN3=!D8
M)T4TIJ*[TDWZO-Y<F%ONIY?1""9]P;2*0LCINB\W=C(%EMCZ=.ISB N,Y8_E
MMQ;-9;:CBK871W6%X\H9DN!*49HMC+'T?2$K\)!\"--H)!H>NC.,;?+)Q8P$
MCVSW:.1//I;Q6@#]I8^3(QO2 PEV/7(!/-F+T9UX*B58)4$(8[$T\U<5^?U#
MB1ZLQI_4?"TUOLONN%L]T[LOS432(!:I<GGJ?='>&&]W\'.N"!SB]FLG =;G
M6JQ/H7OP+U:CI8*\N^'K/S;(JRUUOI2(06*!X0B"[<[/_D<VN<W+E]4W21$M
MV2;\FWJ2=!#UA#VM^) R&_!ME)2=7L91=L%Y[R/IAJA'4>XPC& "L"/\VDC4
MU^,@SK"0F02,PI:[(0HO%?8A, ;@AX_J2HY4 .D>EC@,VY5%@O\")K^;WEE\
M16P*>:U\.7A$!2-XW7CIQCZ3+O"HKCC/A'\6O7JE@.4@(B8(ZX(E-3Z_#=3]
M),@7QKUR@PFW%\O&L$ !6:L9Z.V8#0)\=6+JS<TQAUT5+N9E3\I=(2>:0EP@
MWVZ5?;GY"-.5KLO20I?W?-$?%$[RZWC2"\:3_#J@5 >4MA.$ZH#2RPOI$P:4
MV-P4E4N:#0&;E*1QMDNKO'T!C#IS]%XG>,^I,T?KS-&MU9XKA2#G HUSUC58
MY(KZK%A1!UN,!'EL,\(?.6V1[,L\\!B$L^R%RXG4UO'K/_UM&+__=)]5M"6;
M^#YY;QP$2>C'@RDLO?']^\DZ]MS+>Y'$'P9?O^+LGH67&<(; 4,/+#2[:;66
M!X%?>$)_"VX^A%%XE!%O'MDX,*!31)I@V!I:3:<_MOQ1K]5NNOVVYPW;SKCK
MP?_9K?:_OF#DJFDUK3W\P;(=ZXT1NE,8],@//@QX%8[@%V^(?WF\YW3>?#HX
M/#LZ.!W\?G)PRIM?&,%R,7[U"_4]XIH8M5B XX>)#T,QC2/_VO@'!GYNJ[)>
MO^,UWE__8G6:'VV' NA.;8'=;X&U-D)CCKU2:[MM1^RVYQ+9^>I7E(G?#H]/
M!\;)M\'I[X/]@Q_GA_N#[V>F<7BTOY+.>X$1[Q\?G1U_/_PR.#_X8GP>?!\<
M[1\89]\.#L[/'AA9PG_#%%*.O4MTBD$"]I#_V)TE_@?YP\=1D,PF[NV'(*2A
MT9<^%I^/YZ[<[0.7C/^<'\E&DX^E: PCWBS^W* _R7XCA;]UK4;?6?[G9L-:
M^K>['FO9C69O^5?O>NS=?VLU.T\S6&>EQZ[8?*>)75NTYZF/]E=I\<('H;SM
MO..;.1Z]^TZ'U8(IZ]?>ZCAL8A7RCXJC02=GEAK$8&[@=#Y68'W0@"NLRT/G
MN ,+9:TC0$/7^WD11Z X]\2X/,_W05.OV1?I^6<Z.#O3=<<=^[ELBIN1EOL6
M\#'/6'.$:^_UF/YO^_=Z7V0S#B@)],.#-KTTUP=MRU,_8T.'U<#_;3?:"[:2
M_AT0G>>'/3!EK'FCYRFW=\Z*Y^W%\A^,"M(/V$7ZRIVP'5[<Z'76H6EL@3@O
MGN\OCYJ7/I\8G_KR$Q)AFJ^QRQ>B61APD"9+1F^*41NW:8];3K?KM, ?\YV.
MZS?=EMUN-Y&&UFL._W68!VO LPNF[B3Y^YNFC-QDR=Z%Z\X^H*0,PA'^CR8O
M@W1?E%EBRB1X@1AC=E-X[4WZ(<RF>Z.(_$5\*IPJ6#*?GBU"/[TWG]IFO],R
MV^V.C/C(.7WBJ,IC=DZ>S#5V<).*ISX\E3\\W5;'[?;AZ%@=IS5T1V[7[7F=
MKF6WW/'8M3IT>*R7.3S]-Y^Z9J_=,CO]YA8=G@W91%53J2?8925 CNR9'R8B
MG^68>"Z+QM126\I>;XT6(D;U3MB&U)-8?K'Z<-9HZ7G%Q?JO>;Y:S3>?G)9C
M-CO]QYZN.R3\J533JH;S;@K=AF#]"83.>O.IT^R8;?O1D+Y!H=M1+^G<O3%.
M?<\'?3V<^ \#[E5-O>J=H0T!]R&5D<%2^TF^UNN>&OO-)\MTN@#6+6N+3*%-
M![!V4] V!-8;$30''%:[;[8[K]#BWC[/\SS"<M;-F<^K732\DF.S(7Q^E#73
M0A>UTVN:G<ZCXSMK[6&%S.N=$LH-8?FCA++]YE//[/>;9K>[*2/[:87R%=PH
M+HN98,UQR@G*&!B;<4W;D9_6QO;31$EXP4\F;IB"OZK6'%9\W6/4 5.H;5K=
M[A990K7!O44@O4EAZX(AX0!H/SH45YO=]XO*J9^D<4 \D7AC40>LGP**\T5>
M?#ET%(7>P^R;WIM/K;YI/]Y%K</66R9Z&P+FIQ.]/HA>VX1%VB+1>[76\V&8
MNN%%@,G8[ ^1&:TW+?BK.YU]_%+;TT\8O)9;P#L "WUP(PAY?HVBT74PF:QY
MAMK--Y\L\$U;CFEU6EMD[M2V]19!^%,(GL6"U^EMF>"]6CO[F G7P@OCN^\F
M"L6)(.(4/[<7C?=^)'YM@#\%=JO5I\6G]3X>PVK3+JQ[=O "TNJ @VIOD>53
M&]U;A-@;%3<'ZT[Z9LMZ]&UW;6BO@-.4Q?>(Z\?7:\YL"HOSO*D'.Y_MUIM/
MCK,)Y[,VFK=,RC8%P9N0LO:;3RT;:Q:V2,I>K87,"2"+D?<)[]6W8_*KUUVL
M-^-J8\%&TUK6/?P=,/-[9J?;,^WVIK+"*Y'04A^VG3QL&TW76?>P=='),2VG
M:3K-7B4.VROP@!:7@W\_''P^_'YX?GAP9@R.OAAGY\?[OWT[_O[EX/1,T,$9
M!__SX_#\GQNB!W!@!T91AG<;]Q%!;,FI6BR/&S7^=W )7X%E>S?!@FPJ$_B;
M85FHU.Z^( M$I=9I1^NO!I['K6M/W%LLUJC)*5Y=??VFO#DA*4)0'I88WNYA
M%5FS"<Y=Y]'7.-L70ZQ/2^5/RZ;<L8V<ECZ<ED[3[-C;5'&YH^03L*,Q=H:3
MY!-UQL 3:1E<9<UD?]C1Z6"*E]ESVB:<Y2VZP*WS!;8+I#<C;!;5QCM-TWI\
M;?SV90M4#:G+.5_:_M:I!4^?YJ5Z^#[P,&&>5[-M=GNOT$'8<7E[DCROQ\J;
M@WF%/;/7VB9ZQ!TULK%7 0P?H[;P8Q*,1+MDTT@NHSC=PZZZM>']%!C^&9O=
M^TFR'TV'04B+GF]&82\>>]XPA\RV3:?7WB)3J;;+MPC?-R6+X^#&'^W]UX^C
M!6+8QFN 'AR,CULDAJ_@=GL5FJ$-6>0[1>NR(9Q_O+/; ?PV[2X@>,?9D,6T
M'?E9&[3==THR-X3ZCY?,+H9A.LT^_/]')S,]BV2^VM2+HRC<VW3ZQ8-:V&S)
M:=J.Q(Q7MH([&MY<YB/7L<TM\8L?7/C2Z:%IY8 "L[J/=H[KX.>6">3+.<</
M%\@^"F2SU3/[[6T2R!V-CG[QQSYLX\A UG2UNW4\]"EP7ZZUHK36S-CUR?6Z
MS3>?.CW ]<=G\M1!SRT3N WA^H8%SGKSJ=>T3<O9)H';48M=]X;KY(3M2$Y8
M9A/==6?0M3=V9U!;YULF;4^;FO!@"[SKO/G4;YKMQW/[;Y_YO:VW5$N"EW57
MC!>[J7KX\<%D [/?[YEVO^Z.40OG4UQ6/5PXVR2<+<OLM#?%:;=E]U752D^H
MTQ*V >S7/44=;(!D=YMPBC;5NF [(+[.1]@6B%]7)+O8<[W=MC;1(> Y$Q'D
M*.3*VR1P6WE3O0F"@F<<X:O5G/O1=!JDV'*&N?'5790'Y\9X>Q2EOF'9[S9!
MVO(JP&D=?7F3!!_"8/+W-VF,K>M+_>[SA<?V$OJR+T"D'@KB2D"T4=6T:[N[
MCNK9X.[V5]O=;4/YK7[&*T#LQ;EY9VGD_;R,)J"^$D4L]I\L^/_LO6MSHTBV
M*/I7".V)>[KC8#?O1_4<1;ALU[3/5)=\RNX],9\F$DAL=DN@ 515GE]_U\I,
M$'I:V$A&<NX=4VU;(LE<N=[/\NEEZ7E'0\>2WQU-C[ H^5:M/2'Y0Y*>\8\^
M:.<:AOW$NF>XR =_NA3W\]GE' )>AL9&;%9Y&8RT5.4OVR3&+<WO'DE..[&C
MC=6!@&(O;"NW)!_E=R4I:?3?9#RC\W<OBQ!/VR[G-NSZ9:96=[O6!T,,\JX(
MOY4_*+"HPE;[H&P\9X%O*3HYXLV73]L/R4Y47,S*QRP'5(M:FIB>L>6^UI[C
M90BV]W.8;"(.4.7:KO*K]\C/II#ZA0HIE2L:TDE <\ZY3%U5\"S,'L'+^;7E
ME6LD-*GEQD'@$TNC3F":NNDXGFNXNN_9]%E0_3G-?RS!Z8H6P.$0I^_$*]O!
MR6I[WYX?&8%! F+9H15H9J#I<>Q%7AC30 M"^BS>[N$0S.'MVKO<<U2_2KD#
MK@Q7?J$>^AJW8?QH5A8E(!A(H34'==K>UE[W>E,4,Z3,E6VZ!T>J%VW3Z]4V
MM]\\F&([H/?NC"YA0&&L+)N_> >FUY9:(L^/_3BV 0,-2P-19T8!-4/=-T,_
M-GWK#9B>OTTI67L()W!B4,HLQS9,H*8HL'3;,<P ?O.UT-#?@.GY>B7A7L3U
M/A[\'E]"HGYK=>35-_6B;9IMM[E7:&[E)'YKB;]7D&[?J]T7KM=6U:.A'OA:
M[%##T2V;Q!X- ]VG=JQKCN>1Z"VX7FOE(:(T")W(<HPHLLS ]&,]" TC]ES+
MU.W0?PNNY[;@>N+25YG?96OF]UI(O(BKM-9/7HUU+Z=4_^#(]>*]ZEIK^;]7
MP&ZZ?UW3^\+^VM)+X$=>$#FA1C7'BF+7!^!9061XFA6Z<-5OP/YTK;4N >AH
MNX%G^ZYM67#MGA?:Q-"C4-?UP+&U-^!_NL;F1[Z6 5X=_$)?1@"M=96][O,9
MKF(?'+]>!M36>L!>]_D,4$'>N[U@@6TUP-#QK,B-HC @H65&FF=HU#:CV ]#
MPP8XO@GS:*U1^)1JNAY&NN?KEN_$Q*<@KDGDNC[1@;3>A)%C^W(52/I%') 4
M%1.\;LL$7WVE+Z)7O;6V\NI+>]D^]5[M<SM?T=LK _N\_&<V:QY<#U16^%\=
MMXV2;[)&M]LLY4648.'$W:L'8=-];#DHB\![E'/\2@23/2V/+7<$\_P LUZ1
M.-)1"@;?2,O\"UW?9J/L/=GEA7MVCRAII''$5V9:Z'IKHZ*SE)$N3P%&A=VW
MA)'] 6I!X6P'*:.U/;*_8U3&2,L3L+DJKN^HEKM:(+EZU7A]?:'3%YZXM;FS
MOQ.\!O7 $#)U1[7]U8J\?3B]X?$IA=6^T?'3*^R?T^UNT9']T\"1-;KI#G@!
M%I#NJK[7IVX6LG]*CPR@5V,82S'49;N40Z#'!>P/84O&H"DGT=E-JER2:5*2
ML>Q)N)?AB#6\$=PWJ0!V:QH!HTVW'%4S;=74Y73$4\.VKJ8C=H1MF D$F&9C
MGY/7#WT^8L?4X?AR&,XFLS$+HUW1. F3\CWT%OSI$!P9XY/_9W"V3"Q?:4E@
M0]$UR5. 5=&X G$#K>D&1Z6;EFHYANJOZ6RR4E(O=>6CP;X7<^C#81_&[@U-
M]5Q?-:V>8-_I*M(-ACTJ'VFN@!TTS>DC38OD&U4^9\6[F#?^EAR\<0?L"A9N
M@#=EQFOX0LM1?$]^M"4H$P>2>X;JKID0O3LQ25V[;VC8-2O?-QIB7W!'M=:T
M!7\3+#Q9'9QW%-S<:T.1'08/ZSQI7@6_@M:T@Y/)==727-59$WKL8U\WV6KP
M*%PM'> F]E&P5!O4=<V2PP][P/H;[2-9I'*S*'AACU^1U60"^*-L%HPIOYI7
MT%\_P/>7-X''<?.A[KOP7J11!UP)X[V>ZKB>:KR^.6^'U_W&1I.D<$GA;][4
MN!L*MUF9HVYJJOGZH<L]H'"FE?Q2$GA=E4.T,:'8@4L6?\'=.(NT%E*XOKP;
M=-*U9[.);6SM2*ER$8;9!-[XA,E3V'ZW4,I,*1\IFQ:+P&)NQD])2M(P838J
M_(%U&CU?S)UJG%N\Q6+YTUG!XH(?<CHFF'/UZ_<D*A]ACYC0W'RJRKN>/T("
MV,&LW/S((H"Q-6F_(/SIS%Y*,&O\B^= NDA,,]1![)I FI'E$\>WK)!XIAN;
MQ#5MP_L7RX023SW6#5FGY(&>!3DE?YZ1&$[V@8R_DZ=B\,LBB  8S?MX,2@W
M RZ..P8<OS5@(QD?3?H!B)[F^"W8!'GC'2B/.;+8_WK^VEQ0[I$S*%G,&ETC
MT?SU%S)<AQ*-FS@4RJ[T>V4E!G^_&7V]4&Y_N_CZ^\7E]1_W-Y<7G^]4Y>;+
MY69Z?]L=7XZ^W(T^WUQ=W%]?*7?W\)_?K[_<WRFC3\KH]OKKQ?T-?$&Y^'*E
M7(Y^O_UZ_=OUE[N;_[Y6/H_N[C8>Z>6<9?C7(/]E^,*%J^[*#&UJOL@D& !Q
M3*8%_5#]\&N4%-,Q>?J0I PH[*%?%]>W5P<:LGWSC^?,X%SC#$$8V.+-XN-S
M]M&2..:?N?JY;V[^6#O7-WZV;5G=.->\S8]N6W;[9Y;F[&>SYD[+/N/$>-:A
MYJ]\=8W6SK'Q[3M'_Y.27+D&OADMU)^VZ13<IH/RKGI>'T&%YO8NG:8[F7-Q
MY(#27]=J^NTC0OY.)YU/?KW^,:5I08M7]5M_T:WOW>Y=!D6?.[&?& 0[\J=O
M&:[\YJ?^2@L00>$C<ZA?T6]TG$W1<CW5T9R[0:6%%RFP EW#%FXT\BQ;([X=
MAH%MQFX(_V=8]K^N4'!INJ:?[>0PKB[D(HT:UR'X6VM?DH.U&Y;EJ;YA'\4\
M1#FL<[_HJGF1'A"P9EPMM PS]FC@1J[MA%Z@FQ;U&;KJ%;H^[_WL%EW9E#?3
MUE3#Z:J(HF<1URVYFSV5$'^C*6A98R8@+J))DB9%F3,OY7%GP/=>$@C  V4M
M@OVEQ.4-AIYJN*[J^V:/:OG>90)\[_EZU\CG,\YNF*JS)O7]Z M)>\V_LRSZ
MGHS'RLUD2I+\M<K]"=).YXQ;0'P.<,PO;M%URM+ZV'7J7::W]Y]1[X!LS_-G
M2Q\,+54S7=735_/8C[Z@M,_\^?*1I ]425+E$UP@;XY514/9A-*2I1DD$>5A
M5JEU[Y5Y?YP5L)VBN,PF09(RB,]O8N$B+O(<;X[E>?!+O$DO)@#U<A1O>*3*
M%7K26Q.H 0J49ZB.]FH_CM3=#X'";2J>7B\3-I0^]16939 VKJWZ]FI3&5D&
MVR46\L3YU3B9=.^_D7BIKZ*ZB=:T@PG@AFIJOFH;K_;C2)_^">!HUR;%ZW'4
M9J53AFFKKM-Q"G._'?G]DP!SWH]VH?*1PE52T1*!%S^?:MEL]WK:ZX7!!CVM
MOJ1Y.7IKFG.VRH76:E4_1,([J:(](I.B"U1UMXJ'GJ'J"=@&&[+GF SX20CY
MGX4T4)4OM'Q9&MW.@OI%*6:[:H?=[_ =.R'_0= O4-:EURN5U>_===.U?8C@
M9]"_B/YG5I3HCQG%XA;:,UIL>*=:AJWJVFJ;2-GNKE]H]X867PNLVQZX]#L+
M7/;/N]=G_OTW JP;<.93EC\DWRCZ?)%]?\[(R^)%IQM_[3S8#Y O4 NFQ2B]
M_H&:\2PI'CD)7=&@;$$^MHS[GRS>=1[W;X=WSRL+MCX8&JZGZOZK&W')!("7
M\.ZKI)AF!1DCX_Z$;$*Y@-LM7Q:K.5W=9Q\,'.EHE/(+8&T51C&'?>O0IFU@
M(HWQ^B0:J7/W#._VP<!WQ;OM6H,IE>XW09X;K/>E1?F:.,KI*CQ=\^F;]!OE
MIBD'=P7]UAS:&@QM1_7\/N4Y2AV[CRRZ,Y3#>+BJK^E3+A7K0_!G$>)X#XKT
M6_JN*WB_L$;(=K! ;=V 2^FI/EXDZYXGOP[)W,$0A+_]FF;]4DMN@RR?LAQ^
M397+69[3-'PZ@=$K?63%&](U!/0KX-_G<!Z^G<K^Y!EA+QA\87LLC</R7Y/"
M(77H$]>A7XR VWT>W04:^Z=3]X^'BS*"S0E#,H?TS3G]ERS-%G/S7J@B.3A7
M2S4]5]5\M^_9>3*1]+C$07=8RL*5AFIYQS$WZ 322-<C4[.L@-^H K(<_I+2
M^(53<D^FB*<7@F&>J/TISR:\F',&T!.9W%DJ-##^/;@[6ES_*',"T$]2DC_=
ME'12 -WB;O-L/&:4^S)'J(/SODS5\1W5,5;IMK79T _9(NO6^E:DT">4-QG*
M^XZI&EX'EG+/I-2Q6# =2:8C<]3V1_P X(6B)\#?FHZP[AD("7;0HRP'&23H
MAY&Q9]S#^*V/S5?ZU#CQ0!8%2)I#HLT76JZ-$.Q1<^J'A'KI"+=>#6D[(K,(
M$.WE):R.P[0ZVP-C9HU ZIE6=]@9BY($3XP$]R:>7T>"+B-!U]54QUMMBM8S
M$CQ9PZJ2UPJ8ULIE-ID +MT]DIPJ9\I'4B0AGRR1X(S":#\NV9/@*.U.?&P<
MY9;F#"FZ%>[&1LYR3?(4@%54[Q7XMXZ->-M-E;?>.:.A=?OV<1#TN;W*^=Y)
MR$[RCO?-.UZIE73!.USM1;SC8#O?Q#M<?3"TW7-]M2=$WWG'R491_\%^P9I/
MV IYH%R'*I31K"Q*T*"P@=L."E4;F#1N:GD@>/^GM6TDNX+!;<^9[M5MB<OZ
M,L/!G:.8WUGCR@0!MC-L7*.GQQ,XMW+*U@<T!T/7Q%YUJ^[4-7]X.89WW"OJ
MU*FDZUR?_5*)U=/C=48E]F!H6+JJK2F(V4XE0DA6&%9AA,W'9K_I5-!-)/2:
MY=]BBR>@AVQK"GB93:8Y?:1ID7RCS+WSJHZ ?>G[]UZ[^[6.J>T::N['\5H;
MRD=M#A]%?,SM*C[6OUP-233'3S3]C&BY746T^I=DLKMT/'"ZR4IU*BM0&[,D
M467>#5,6K!ZL%3XJH OZ9R.9=V,MX44:-2YN?F] CZ/X!;6MKC<8^HYJ=I';
MT:,,CO>.M?OKBM\/K/4'0\]6'>,U+33Z5P_;9]-JU5)^8<"$;WW%^]!P3&CG
MKKT047D'L<PNH'+D/&MODG8-NZH8#_PVGB$$;[.<L::RS)-@5A*X@?NLF\(8
M3^.U8*ZO^J^J!>L<8WIN8$J&(1G&FR@Y;\TP=,8P/!OU<NL4& ;3CWYA0(+_
M1LFWX5_AGVKC$Y(_)&FU/]T 1!%_PDTYBU0;4H1J-RBI:Q5.LG4^)"6\(]R.
MI88-6'I'J5+=0J?[V/K6BQ P$=[VA#D27[*2%DJ9*:"0L[G9>&D$$RL^)2E)
M0WB;<E?"'YA5?U[CS#+PQ1LL5#JKYKP?<HJ:^C?ZZ_<D*A]A?QK&6!M/B;O2
MYH^0 '8P*S<_TH-;W@K=3V?.(I":_^(YD#H3TPQU/=1,$L>1Y1/'MZR0>*8;
MF\0U;</[EVZX@^JIQSHT.24/]"S(*?GSC,1PL@]D_)T\%8-?%D$$P&C>QXM!
MN1EP<=PQX/BM 3/+>,'Q!^ _-,=OP2;(&^] ><Q14OS7\]<&EW:/[*D:2,]=
M862X#B4:-W$HE%V)81J($W^_&7V]4&Y_N_CZ^\7E]1_W-Y<7G^]4Y>;+Y69Z
M?]L=7XZ^W(T^WUQ=W%]?*7?W\)_?K[_<WRFC3_#;Z/+OOXT^7UU_O6,=K]Q?
ME>O_]\?-_3][>I9_4I(7RC4@6Z1<T9!B5@0ODC1U54$3A26PH>JQ\03;*1E_
MQTP&AI@UYV7B&HXV)M."?JA^^#5*BNF8/'U(4K95]M"OB^LC3UGV0B,(^<=S
M=G.N<98C/!KBS>+C<_;1DN[!/S.M<]?S-GZLG>L;/]NV[,M7W?Z985GO>J_V
MN6X81[+78X*K>T1[]<YMQY%[W0<.^+OAP/HD-L/=DL3V;-3#7_GJ&O\'%YG[
M-/F]G3*Q;D%'HWD.4O2NS,(_=\B_.JWS5[6$71T>OIIGWY?#7T< B O8(2KP
M9/S7(/]E>$N2Z.PF93]?DBD:Y^\;/&$XF\S&:.,SF+!0'(=.TU_%_K*U]?1[
M!-85C9-P2R^D]P 3UMR608/QFL=L#)9$(6PM]O?K?\^61Q]OR+&V7B.>&C&#
M78NH^@A/GOF^2[YP)X/"CQE4%Y-LEG9%?:< $(D[;XH[!_SJ!@9J'(J!=GM$
M^3[YOA-ZWQ%VJ]F-:7XD8Y*&5"%E[9M6A%M:?U&%T_,'WWL&P6XG;U<KZ9E:
M8)MZX 2A846107S+CVV;&)X3.I[G_>MFIQ+)-460JV%]8S!<'3/0Q64<7>7&
M;C=Y1)4;KT3-U=R6KO"R8>AQXZ[%[!EOR[S=#K,?EF&W/C'H=%K?OD,N&U,:
M&3K5B.]YEA'ION?JEA%3UXKTV+3LEW/9EIE5UF!HZL[:V8N2$4M&O(81=X6Z
MSS#B'7#7!MQ5=<>1O%C2I:1+,_2LT#1,7W,C*[!)X%,S,*D9>R&-=$,['%VR
M"G!;M2U==9QUG<8D=4KJ/ 7J;).;;QI:9'IV0'S3MFR=>#[\:U/3,_78\8)@
M(WEN2,GO@$[=P=!S5,OLR41D22R26 2Q&);I>Y$/!.-:EN?Y?N1&3NRX@1;I
M'G7--R 6''EL:*KG^JIIG=:@>DDQ_:28%@3C6@YQ?=.*=<>T A(1EWBAX^J&
M1>*8Z,[AE#^?C0:W@4PT:W7HV3O2_5X0YCS.-FIR#;F&7.,H6Q>^I1!?SZ^9
M!#K[2 H:L5Z4-"U8#=NIA&@W22D15.K>XUZO<10#!G=3C); ]0Z4B7<><I-4
M(ZFF!U1SE,CPZAFMAF%Z+CQ%3>I:KA61P+?L*/(CW](<S=/;SAAH]%:\S^8E
M+EC=<I.*NA86V Y0"V@J 5\IV*1%4M([FG]+0GH+1\^BKS3,'E*VRG^3\8RV
M-5E];3"T'$.U;#E?^"AP5S R>3?R;N3=[(?G=SU7IG<\7^\CSY<N0[F&7$.N
M(5V&;<3:35',6&E'%BNW),VFV ?NMVP<X9&4W>L*I2/DY/0@Z0B1[L/VZO#:
MC'U;TW5J:KI'#6*%CD.([AH^M1WBF=3RZ*X:\9_3_ >/LR/?HM'5+ <P<:V6
M\ZI/>39!]O410'LGMM)2NS4&0UU3->\PU57'S2->;2L= C.8D8.(40FX9019
MQ0$3<:!/UHW$MDZ:/+_>';N4)-<QWEGK\>Z8$^1.$>6DHT[>C;R;HW"BOHI!
M[US<[-N;BYNE2U2N(=>0:YS8&H=VB3;ZG(LESO#[;!(,6R-)(YJ6'\[\;1,+
M]NM!;39?56(0+,KM+!@GH3**8XIR1U5PJ#1\L_H#/%*4!?[E+RV$(XTM$FF.
M9\>V:>G4]2T:FY86V;;F!$ZPL]7<*L(XEZ'5D=G>6_M7G,'0UFQ56S.]:FD^
MPDEZSJ2_6?J;I;]YO_[FR/-CW].UV*&V%1'3MW3'UH-0"RW'L?S667=;7<Y?
MZ'?V47M.Z (G] W5]#?7^4OVT)E%>2"D8$;ERW'" YQ0?6-U4-OI,*1WBGZZ
M0QTGI&YH:9:K69ZNVSJA#M$#0 ?3Z ?Z^8,A)G8YJK]F5J!$P1ZBH/1WRKN1
M=[-7UMVUN;T/UFUH&F/=CJ%ZYFKO .F$EFO(->0:)[:&=$*O.J'O8 5:*-?*
MTBBT?3JD T(-VS9C*W1TRS4</_)CP[*<./9#&@;[*7GIQB$-N\*6BXYJ::N]
MW-Z#0[J=:TW37=LR8H=Z&K$BRPT,*_"I0WTM#IW CGOA6H,WPYVJAK<EQ"#5
MXZ[4XP.AQ+)ZO'KIF+5I]DCUE9[\5[,;XEHV)1:Q[#BR3!)[GJ<[CJ\%KD[M
M4/?WQ6Y6D<L:#"4WD8Z0T[N;5NWK'<WW8M^RJ&?Y4>11,W!\FWJZ[[N6;_7#
M$6(/AHYCJ[K;)S>(1$#)'.3=R+MY&\;M:(;OT]BQ=,^S2*!YH>DXKA/HH6D3
M)_+ZP;@=P;C]54-<^J_E&G(-N<:)K7&R?24NLQ3V4*!8VN:23M(R6\B:/NU>
M$YM+5??D:]TVTF&3%V1^=:.8_UPFP9C>T1"^6B8OD.ON)F?L2EVK5/5>7^-\
M:*QA2M\.2+.*%]Y:?^U)%#N?!+OJL:NV>R:%LS<<3=76E-]++M6Y07H@9-F5
M-[7#%5U#@>;(!B''@99MA.?K/=S[$9XM$113&E1[30NCDQ"N)X2;TK\J[T;>
MS<GXOEMR\FT]16 CLJ>(7$.N(==X-VN<HCO<T$!<?:7AF!1%$L,N2N$4_P?)
M<Y*6RN>$!,DX*9].V_<M^U[(OA=2VY66B+P;>3<]M!*[&M3&^DWN4KZTK!*,
M8J$0U/I :Z^?.1B:JN-:JMNK#"J)H))YR+N1=W,"C83?B+%;_63LTA<HUY!K
MR#7Z[ OD0DQ;XQ1<[M?P]E+M$GL8C,>UA_ KQ6 2%;FR=U.0'4K%]LE83F>3
M>M')ZZPG@<0MT[Z[GXDU5UM7,RD%DV'?8RRF?;:1C9W'X#\ROUO2[>G=S6'G
MBZTGW36I)AW0K3,8ZK;J&+Y,$^PY#DK^(.]&WLU^>7?W$\?VR;O=?O%NZ0J4
M:\@UY!I]=@7V*BUPM6TKL\;73Q&K4@6O?] \3 KI]'NG2HY,%91>QIY5:V^;
MK\M9FF!>1<6\HM:ZKC<8.K:LS#ZNRNQG!R^OP8O5J_?QZF6=]:DA65>-1%^"
M9.V8CZ$-AK;NJZ;$PN/ 0NF.DW<C[^8H*JH/P+UUX-[&^JX^,F]2KB'7D&N<
MV!IR)-:J;W6S1_4FC68AQ<RH>A)6_>#+)F'MI]Q@8[6!.,BK)F 9QF!H>KIJ
M.EL\+"<\ 4OZFZ6_6?J;]^MO[CZI]1E_\YRSMV:')CH=+=715I,K)(_HW)H\
M!&8TK<E7((8%B*':EM,C6U+B8.^J__>+@RS9WC4-U?!6$^XE'O80#Z774]Z-
MO)OC*?+?+_]V./_V5,^4M?QR#;F&7./DUSC9!-Y/60Z_ILKE+,]I&CXI]R =
M"E'!/_?>RG3==ZG62/>I=)]*JI%4TP^J.4IDD%;[L=U-FY);)P@B5_,B@X2A
M%3D>L1W3)Z9K.'X0TB!L.YIC5#[2_#*;3'/Z2-,B^49OTC";4*&F55H:4]+X
M[B[2J*&RS36V+[0<Q??DQVV6LP_*,D^"64F",;W/OF0I'B//QG#\AQLX4$Z+
M]IX =S#T'=74=YB+*7%:\AMY-[TI\3].?N/UB]](CZ-<0ZXAUY >QS;B#I-4
M/V>%[ #P/G4@Z1R1+D5)-9)J^D$U$ADD,DADD,APTLC0QL$4!HY/=)-H1NQ:
MQ'%]Q[3CP*:N;Q/3UG=P,!5PR/\S.%OV-(':SUU+J/NW]OSX@Z%NJK9GJDY?
MO#\2X7KBT=P'PIE:_Q"N;^[&(,LCFI^5V?0#'JG(QDFD($;UQK$B=RAW*'?X
M+G=X N[3]<K<1S)FM?VD5*YH2"<!S1535Q44CJ_QFPCX\@-], '$438+QG01
MQGW0.=;#I5TQKQ4&U*">KSMV8.E!%!!'LXP@=./(CCW=_=?-3N%37J\[FI5%
M25($T#I50A\,W8.4X79WQ6N5RW[@_U_:JEXM3GU,:+VJ27>%TU@\])B- 6C%
M];]G*],^X^0'C<[^0_-L';(;#=_#!I3ON3.B%2/LA>4HN?LR)1 _B,* ^'H(
M-J7N>4[D$1+$CJD%KDM?P=U;6I$F6)&JZSNJY1I2!$@1L'<1T!'B/R,"=L!\
M"S#?57UOM=.$% .2Y"7)=T;R<-[(=H@9&QZQ?-_S/<^,?"_0?#,*/<<^',G;
M0/*6HVJFK9JZ)>E>TKVD^SU&ZNS(H)9+8TWW3$L+ X\&-+*TR' ],/ZL<"/A
M;XB7=, !<!RG9ZBNM=H7HG7$1-*AI,.CH$/--4TW,(AA1:9%B1>$U(KL0 OL
MR/5-?[/.O3\ZQ-&*IJ5:CJ'Z=@?S%24M2EH\!ET8LU8LTW5-*XXL:CJ$:L0R
M;%OS@ !#+3B<+NP!!>JJI;FJLV7HT[M7A5F4[A=6)#84#9H;W;@G)'](TNK]
MF.CPJ_@3BP(:B\094BPKZP8S=:T"*UOG _:I3L+M@#9L /0=I1U>[GP;6U^J
M7(1A-H'7/<%]*%^RDA9*F2GE(W8 3UFDE)0T4CXE*4E#>)UR5\(?L&JO.%]L
MC]V OGB%9<,>IEG!6G=_R"G6_7VCOWY/HO(1-J@AA3:>$I>ES1\A >Q@5FY^
M9/LU.X>XY:W@_73F+O40;_S[6.?C3,D#/0MR2OX\(S'L\0,9?R=/Q>"7Q</"
ML9J0?3%0-H,@CCL& 8<_<+LL9T6?'X!5T!R_!9L@;[P#Y3%'WO]?B6F&.C!Y
MD\3 _'WB^)85$L]T8Y.XIFUX_P*MZ!XY#>^G#V@$Z/_77\APW>4V;N)0R+<B
M_0S$B;_?C+Y>*+>_77S]_>+R^H_[F\N+SW>J<O/E<C/EONV.+T=?[D:?;ZXN
M[J^OE+M[^,_OUU_N[Y31)_AM=/GWWT:?KZZ_WK$HH?NK<OW__KBY_V=/S_)/
M2O)"N09DB^IL"RY+1<J%KI TPA^TC2=X7HIA^AY#S)J',KD+1QN3:4$_5#_\
M&B7%=$R>/B0IVRI[Z-?%]9&G+(E<!D+^\9S=G&N<Y8@4&?%F\?$Y^VA)3>"?
MF=:YZWD;/];.]8V?;5OVY:MN_\RPK'>]5_M<-XPCV>LQP=4]HKUZY[;CR+WN
M P?\W7!@?>:VX6[)W'XVZ<-?^>H:AP47F6]OP]^"CD;S'*0HLZUWR'PXK?,W
MQS=U<7CX:IY]7ZX;.0) 7$35#*B_!ODO0QP$=7:3LI_%.*CW#9XPG$UF8[36
M&4Q8>QX.G6:/'O:7'7LHO!]@7=$X"9-=6M6>+DSNLU*05M.)*6PM]G?NT%P
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M35',6"D$Z^PT+[57XCR;*+=Y\HV45+D=DY U/5,5G$$/WQW%,;PO?8"'BK+
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MM+/I8_E(QA,@LR@IT'57G"NC%/31;XP]*C9CC, >^19O%S91L%+9<^4G-&A
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MCV*+K<%A#8:Z:9VO%@A5 #EO:/B@]L]87?DX*]!OBJ!*Z0,/H+"&=O$X^U[
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MER_.*:T] IR4SRI2QA+U/"G!8D :'%=Q*E99#:L0S-A4:]_"SYS!\.C),E=
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MQ>5)6<S[.@+]J,"9X;$MO;[P\RH1=4,?2.5OD^"WQ3:7[$]U_NJZQD ;&_T
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M^R+O A969W95YZ@'8J/T>*0D4A5@KVF1Y;21%<4VHM:UKEB,2_-O28@K5:,
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M+[B&%IW_!T&DE>ZU+T$C?SL:B5;%=?GE?(X><ZS,)R755?S5=+BJ_]%B=(&
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M42;@>-HG-Z4RVXFUJ(]I7J@6^>/2T;XHUL[/L,K9UQ6%YT"'L.B6U+B[6E@
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MQVG$G9=[E1W,;P=)=N(0N*)KA7%H7%$ANISR;6!%'=%U!*\=4Q/QKHW$'@!
MN8OWLEB\V8(V!  ]>83(.9_"*K@3;P CLU0"J-9QP48V1Z[$!GU76T?W&8!8
MSGW'KHW-^39%!WJ]FZ@5<>OF4AW U1ZWM#NX*5V9%1*4OA<H&RDNB4^H(X47
M^*'4GK5G<R6H+<MS\@5^N5UZ::M1RSE"QT08=PAO"$3A7KKYWZ@VVIQ)QV;8
M<YFD/G*%[S$!V25!'4*Q75X?W9LVKLQ]NS8,B7!]-GYID"+6=*TWVI3KV-#?
MP9IO.D5_@N?G>-9\MB=5#;J+M$'O$%MT$-O9I-<SF;X7Y^V-JN3Q3/H.*HE!
M)6W*.\)IDDK6Y*<WT*0_&GJ\99%;U8LT"8*2)!31T@Y&4TAII<NO O5_5G.
M]4KFQ$W3\6[+R@8)6,@[+D$=QZT+([-653ARW-0:A-8@G+2O4MD@T!H]E"89
MA+,;'G[,M5+VM>KI#QR\6@G]Y=+.VI0"=C*:,5WZ,W5*JX<RST.9K -FAN3
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M8)&&N 3MV6_/?A.]I4.>?1&??1WFG\?9/S.ZPGRQ(*,K' W+9EP/RV%X20J
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M%N0H:("I8D3JF\U!-G>8[3G(4=S&+@9\Y0.1\R4)[@(.WZ)[5%0.47@HQNU
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MJ9NH[XU<&>4%2<?E(O YQYA0B2A7DBHD0T<)Y(8XQB"VTP2L79J W9L^YYR
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M-:>OZM(;*_G'I0SU(M_)P7?Y&EW\//^T^KF2CQ?P_5M+9;D,PK!F&<0;H$_
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MY1BN2M2E.],0GD>8U7RC79Z!W<:U.^D,+">0@;5W(@4YX3C92/[LH^1J?DI
M!7(40X)QFU+J>4Y@NR&G@4*A7IT\((CDVC,QW]%?-?_*J79F[(Y^J(-4KML
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M4.-O?5\M$<U@,/+-3_=A F;R?RJ()7 ]BB;+R B%.'EHL,EH(@?Q77MI\-,
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M$")I$'A2ZC?[GD\9L4D(?>H' ^8J-+7!J&%?>CING?15M 23R]F!\[(AF%Q
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M7^N-2AV_FV+?CR /5^SZV:LA^/9/C8$:=Q:K6^LMD:HO/%$:*$UN!%"M\%A
M0W?P"&X9%O.$LL9;$+<$$U _'41H4Q]QH)F6;H2:&D) 9*N>QPPS#-S08H8;
MV6Y(EI]H==X0K46GU@0XNA%=G>''^@B_\&PQ3.F%989=T@WQC/;UA*IN*#NI
MZTQ:%&=YT>84)*8P8A65*:N"^ WAQESG*./L18QM. C4C,#H%*RTNL"JW14=
MV5L\T-4H/^'X@A%^HI)?99V)'XX\+]@+.'1;#$C8=!5WG<4<,Y(_XV.D[;N&
M7V3_W23X:PM(EE1\.D&X6;S %"=HQA>@P^%L4%_AK<R@#A]84>FPO+KK4D:H
M/]$.MQYP1TF6 &]>2?^L8SGZ2^I%T4EC+NL[*F0R05<+ )F,]]./O41RLS!Y
M^T6ZED)P^N\'2F/I<AAD(/P'8E6 [Q?QC"YT@1U-L^JJYASX"O84L"7$/@7-
M=^B]6D ;*>_>7)S'"=UZP)MEU05J_/ZH \)JOQ:_0J$1WG';3$3YF[W32CO!
M[H<T1D /PE U(YV[$#=9KA'Z1JA;$$V)01RJI]L="]S-3+P'79'00L6D>[R;
M@P2J->D56^'![&R1<7;WU'G>G-(78> 6E=%JI!,.2(!A29PE$;_@#?C*\DG[
MV'XR74I;SO$&_U%KOH],9I%%_5=]4$'D"F3H0Q'>FVG!5WQ-8L29B47<W (K
MJ(*$KTWY8[L$2J.8<+7+>,GIJAX\?3E+BS2'5P<SB!Q!99=S_H#4!OSRZ^M=
M$QR.'_F>Q:TH#&UP#"/F<N8[JF_8NFGQB%'M4E4M4;ND'T83',*R"Y5Q&5W0
MJM[Q+66RR6IH-ICVT:1&!^2^?4,6]ES?V%TCEVV/NE%P!(U:)UWK% +:  /\
M0YE*&"3C!\%**W';<V2+NQ2!M@(RMCMZ7&&H>8S;D:>!JQ[8KA;8CJ7[/(I"
M9NN,VO(&Q_%P5QT'KPQ=JU_J(13D9_X?W5+;XRGJ34^4BK!,D5 <>Q- A;V:
MOJ-%5@2<:+BZ']F!Q@)',P(G<,8)\."<MH:W@4=SVK]T=JKXO+CC/.G2@JYW
M6JK:'36&-)FQ>418*VA9]Z-(Y,!F;:!&X(6F!DZX97%N@_>M:K[J&7R<(L:#
M*>*-SZGI$X1N';<WORZ')F4UE/?)*91C>0'6YUR.KY$NO,PTU%-C:G^O2L"E
M61&E\*H&'N:?X%8)Q!JCCUUQZK3<LM/2/75:GCHM3YV6IT[+9^JT?$CGY(N-
M9I2G#&2N6H'%AHIQZVOWQC0LP%MF5)&03G754;9<@EV60)OH[;R_JD(>6LNX
M:<>0EUSDCL'N.0R(E)M7[5^UO]_>W"Z./ZZ-OC^:*ZT\$1EH;QL]O[A.W=>7
M?[Y_<ZYYQQO]$P)PU4JMY$OP,<(:6E;N#A@"3.*"<O8(%BO!81'I%M@U&(>!
M"N!=E+!$;'&JSW5:=.IGBP%;B)HF7,\6!K)R@UYN(M,Z"\YRRFD*M/$8@<H7
M F^<*G=)D:4B?=/=Q6V<E7F[.0Q#)1([C*"*C '3X@J*3$PRDY!!?IGC-T!1
MS,HB3.^P#:*S:"K/T0RN4+G%-HP:?Q'?>C-/?<P4]!",)%KX#+LL>")FFLS3
M.WQ^[R_!'TG2Q:H+:YSP&R8@6A0FD'E'(8 EH"(F&AEB7+<P@>4D(X(S*JC.
MAED3J2 R! D#-2!4 ^&N41).+*'>/2(T;SCYFG(T*R;D2TY1604*W-(2G5$M
M,^!*V%>#&B\&+R5R MD2<9TH4TN*#J@3Q2$G.'N!J"UR-F'9+4NE94%^L[ $
MP# 9HM5R$4S=T=Q.1@NI()9J8#G: J9]*RQKP635RJA1IJ9)-V\A5RWO@,]7
MU>(%=P;I4D3MV"Z>R=P7M4VD2'!DEC#.LW)9OQ?M5475-B=C@W=RDU8Y[>4<
MWHO-0 /1J]&D:V;&PTX)M;L^+@*5JE\K&*X9CM- 0R<-'TIJY>N&Y;0X48[Q
MZ>RE8OD%KCN3T;NH0L8+2MSE;2**[74E8AUPM>1/]'(ZQ!N#K!:'WXAJC3)6
M31CN!M!4VL-HF'@JDVV*/J8GDG0=A/9:$E4'6-.DA:1-!<>:Q0Z(H^UJ1X"C
M;3P%CC8"CXGA>$GX%DQ*NN)<#N2Z G[+AYA30U1JS]0TU?1<RW CT](9SN#F
M>FB83/,];MI]C*KJ/8I\D4)OV@<^^[X7'Y\OT@:@A??RBE1R;ADI@1J:KS-M
M\USDE*N_R.7<TFI$@*EJ/_]59U;7#,K %>!AB&$I.=VOJ.MVS9,+%/._A.-$
MHX!)6F4;3:LNM:SS?_*],946:YYKEP[QM=UP!<RLF$,OY["V4^$X)@%=<D9I
MN9:]JPG67EN]-!J>SK%&_ VAQKI6:X&%W"?%FQR9C?=&K/!U:_5(&2DRV4?<
M-:C+SN>"RI<1?7CO%+U6LE771L?H"=JB4NX0L0VKMQ%5[XB+@1=#$&,I."1X
M-!XHIJ$T<I+-MD3I#8VL"8LN\-[#8A^*UZBOX;Z6 6@S6O[[JN+#[2IM1L-I
M^MDKW1L#;2QF:9F30YDVJ@8O2<9!O$37M#T^%9R/+*QK/7!  A1]T]3._K#.
M>JZC&'=8!P85^.RN)<W]$"W.]5[[UI9TOQ!KWYG\QMDK=Z2JTE!?='VTU;D<
MD!R6? S:>[-42"AAGM&M@'!OU?$P)\\\ B?/?'0G[W?I6(,(^'* ^88A*:X^
M&)("[I43<1XYD0>>E>'XGL:YQIS -0)==Z.^>W?1@+WOX]3=_[K>U7?-AZ^:
M1N@$MJF%OFL#B1S+=(S(\C1S(R;JBTNH_<Y60(>1+&J+J,=K7=_6H/5RA("B
MCUI'&A> &6?T/Z7"J1(W8H@3_))(-:&NM/A6V,X9AXBX=9F'/%%J1UUV<MMU
M]V"4!J5LQ)!I&8*LIJM'.78PTF+S!:ZCU3/SKZI_1QQ7:[K!1/X*I],O,#"_
MFZ7S^>H<IWB%[5L)V/Z'67>9A98 ]_6^^TCW>5ZB'FTB[6;(2*%$#/QJB>H^
MK':W5E?EM0*9VJ$4=)D%,P+<S6@L2X7FW7YH).<3%(.%4BZ@6DFNW*1IB%FO
MS@@5,1D\D(E*'S-@A/A=W;:FZ8AEMDP1$/YXF;L)9>IRPRB+M"\FQ(D 1 ]E
MRH/HL6/G2J2Y@:ZZS LUG"4%"MP.;9?I.O/LR//E5&[X_]'6G;Z5:.F9=O?&
MGRF6:2HD1_&M#/V0D:#"PA;R,8C[)B6),Q8I@X?M9I0TE@]&BDC!;BL$'$H@
M1M/+C%DSU6XG7\T)5<^);%_7?3.( E]C:J0"\2(SM.S(%?XRTNI\C&C#NQH5
ME.F75%*D(B//_\"+BKLVB>KV/8CNK8I8CGW76=X"_4_EOV+0%GS#4/H<E"%V
MWQR2-H.[AR,,]98.NV:B][3,RPS_B[T#%1+)-2U/?#K2M*<[X,N:8V-KZ.]J
MS=J9^B<TG[BC*GX#>CE$\E66A'+P5-,8:U3>O1E9Y9;MZ8;IJ#8S.?-\$QS5
MT/4\PU6Y[_M;\QH%"&/49%D"HO2ZK3]VYC?W[)6SB=_BI%L\ 0E,)0&;,FG=
MS%@GWHLZ4_[NS84(<&^[%XI0T1'=ZT1PU70<H&I  Y93$R:.?X O%[7H7U4&
MJ^XRGRKOH[%6<CQ1_@W+KM4(+\$BDXI5J$ #!DD*#!9_*C-XCV(!W4ALVK_R
MI+JN&VB.'MB@C'7F1YII,R-PX>3](+"V5,;TZ"M<R!C_>\#_ZG1L(M:2RRW6
M =<544KS!UW@&5^ $D$5?.I;VZMOS3OUK9WZUDY]:Z>^M>?J6WM VN,%1D\M
MUZ"RRF#X@E+<H"/+O(]!UB(>V8[&N&.XIJT;+M?-T/$];@6ZZ[O>(0RRH6*Q
M5I^.86/4%EG.&N\X4!P\N'-PX7JS;MH!M3CW&^I/ZP2*E+.M0W2BT"[>:>C:
M!I4,M,@WN6Y!U,8T[C++5L/(=-ANWNF&,.@=K/%/7.*NKJFAX=6($9+6MQ^*
M?GJ#TAY'G$'X,IIVD;ZJ]%&E$SS,*A"BPMZ5I(-'QB-9YTZD\J4"\^/A:%AX
MD8157+@SY^CW!-%UO$+\<PLKN@'1G*=T8;GV_\>:55Z+D/*:Q'=CKB9DJ\.2
MN(_;^05\G!R#6-!\<1IBBF9>+OB_B*& ?F);4F?MA.1I&&>O(G#H1ZI%&:.L
M#6P.&'*!5[(%JRTQ3@ZK*EU%2A3'":J[?33W \G5K:]MHLUP_^;] =:33HB[
M#F8\+.?\,AI) ^2_KUK_&M9S#.NH1\2)M UVHQ!WB0%MY0(62<,J11,UG\<+
M<<F_E\W&-I:@,9C4(%(/&=TNP[TN%;]6$4N[5*7@V^GW+4V3?>3#Z8RI8[J/
M,T9.?Z8Q<B]X-AQQX+,.A"-N?KIQ(Z_+C& O!#Y#M?,#O-^>6ELL8"3SA5)Z
M;DQ'! M=#9$4^5G[I1?;'70BV?<X*><[GX6S7^5N;:&EY6E_KH>BOP^QHSZ*
M68UG4I7NP,%N#8BZ$%9-BI;XYJYH"@:A*>C>.M"QTRB^IV'!]\GY5992C?_S
M?[#%\K<W:\=_?4]3\XY;\OJP0Y=XM>++C"5_R):*G:41(:PGJFV,XIOL*)&G
MJ7M;,&!U4GM)V\@N3]+6!/ 5;9O&DQVEP3U[9:KVQ/*\ UFGDPW:Q!X702 F
MP4JTM!_" NTRM_400G%(^]/^C3P[>73P=3)&K6_L+'V('@["-P)T=)K\>E 6
M?,-%3EWYPK[5 V!7/X1%>D+I>PP'L#HY.+@'2)JIGKW2;6OBJNX#1.UDXK;@
MMR\(5*ITBEJ[ZK+3B.3'(,A+5$Y/5XK=1DFMJ\1J.ZL;+-)/-$>?6-9PF,9^
M0>:+&:'\=$6N_]WT?X?N9WC:.I)G[5M&\MRIIZ[_>(]ZSY:*$JAWP*+&8Q<5
ME ,60/8JP-0C.JBYB6!NJ6E>H)?O>$-C/\=L>)'YH$EQV!>B8\!7;D'_]4>C
M;G']UM1Q=-DP\]!<OR4HUV.G4[MX\+GA@9VIA3,HIN9Z:A&*S5+<))SWARX,
M]7C3V-Z^B+JU(I7E]\=I\: X_IKZ&5;C[1UU ]UEU#7;N+EANX=I#MH]CJ9Q
MP-*FAFX^3N/ ^C_=]-C-G[GV=N;I^U[L=@?VG;1DN%NU9,@V06KH%K?9UF9@
M#DV"^QHU'KFI?COZ4.<=-=,1=0[HP5A3?8L5K/.V]*F[T=MB:UHXOGN&OJ#K
MML_:9/2$[NW:GOOV5?LM)/KAG0TO,95!S=#Z(*S?AP?6"L<6>>D'9,=>&"5?
M8G?,@0[TU-OV@_:V'2J)N:[.V>CH3E!TD64,?DN7D7:\>=1*:EK4.:,ZATAJ
MGGK9'F:+,:>TL<9RH/V^%!E[B'7M[7(OZWIL/1?[V= #]A*<#N?%-(EM;R=0
MK<ATY<[6P3Y[Y3D3U3Y4O>O4T+*)A0243_O>Y2$"CV.4F5'4)BUT35]G;@1>
MEFEHGN\R6XNX&5BJPVQFO!C4)G,-:M-CA)$/;FEZ(;R_<VQQU!'$FGO H<UU
MW0AU0[-M4P\M-V2JRU7-"GCD6C[?']]N(ZB#Z:Z[!/Q\[<+/D&7Y'EV-Q]*9
M3P9UT.)2[^R5[4P\8U@M/76U/U;+'R86E#^K>^,'#TZWJ!@<[3-.#9&GALCO
MNB'24K_CAL@!EOO1(2Q]XH4R3YO!6WCN2#!6C]&I9CI>MJ9022S-XH[/;[D"
M@6@QRWM3#)1JS$?5#9<3F B^B[<P9G?LAHN89MA!:&A,#TPO<'S3UOV .Z[M
MZ*%GL/OF>VR#RG25I>^0Q=\G@M,ELBPP3GZ9?8#U7T:RZXM?P]YXRX%^ _2Z
M"(J2;7DYM8%HLK1[()IH\M<Z&!4!F5Y#D-<W9R5V2S,@#80Z)Y% C")X"##B
M4MZ,QJEJ+ M$PV)K)-]$P,_)H7ML@=.%_A^\I4R*6$Q7%#"3*P(X:@W\A ??
M9&PA4&=I(@8'IIHJ7W$(:.H7$FTUXS>(:9=FJQH65T!=#[9!#X)/$%V&+F1)
M#%N6XZBVN.#G\_AV;/^TI6;E6+@&Z<H8RL$YR@0"8,5RA#J.D6H@<<J<1^5<
MF<<1GRJ';CQ^6M"@"CH\J]L9'P"/]A2"V!*LSYQ@#U^G^;:]IBW1N@_]K"M,
MYYEX%^P7X=<K73>$-2IFK!#XA(CFG^0-!-+(4)=&'=+H&!2'-)&:]88GH%H%
M.C0+%\#*R)QBFJ)X\E9#8$9Y<>T\CS%PS>U'R>B.Z3J.ISJJ:AMG]TK$LP^5
ML1Y]J,QUZ>?\[Q*.].TM(3\.&E$MHS^HA5NNXQM<]>")IA&XKF-&(?>8JII,
M92'O-ZXV[U#$2_88)G/_.WNC#!U$^K,,57<TTW0]5]4#WW<T(PI"WXO,(T-/
MNTR4=]S/<.:UQ*\EL33ZP\BDM6J&J>!@IZ UX_L#F/YTGBA7++L'^' T3>US
M#NZZSR,WU$T39,SU-,/009,Z7 4WFS@.B*X:Y]4/]\S)HU* R)^\H?E@ @91
M9*$_\3OZ:.?KDQ8<L*5/'&]X>[(U7J ]6(#4V!W#O@,QX[1&H!,C W:CDV.K
MIFD#8P:Z98)\>DSS(]TPU- V0\UT*=DY(,\@PGD]9^BW_4LLZS+[C"Q1)^IY
M  3#OOW7;#[GX>\K^;U<?G%WJM'$#VMB><.09PW9A ]74#X%'65RRWB8-X[?
M"".B\=G?AC^0!T>&?\@UOX,E4P(/O./+Z$JL^ZI:]L[VFT: C S*D_9;4*[F
M.#'_-ZGG'#QL?L%^_&=LQ7]OY0HIXUY_6#.=-L98#MZ;L8P1::R1.''\M?]O
M&@6>@C^!6E9.?Z"1$K=Q2-[[Z&R>BHIB '*%.RU)*6#AA8NST9KNPU>MJG5%
MB+?-:R^2),;AR70IY+5 4\5@2^BX(9QK6&8UG&M%.O?L51Y_.Z=HM6\X8;OU
M"^KY6BW0UAZ/M>9HL&IHTQ-0Y L<U79[]01@+7FB R^A42FQ%-)CQXG>SJI3
MZ[B(#W'T;6V7ZO%30\L^P6\AC5I3[SN6G\9GXM^''5-74[AZMYRWB[.NX-LW
M>XS5-!S54H%90E.US<!1_<AQ=,?RF.."MZJJ6VMK<<.*2GURN?7<F&N&F+KD
M27P4 X%%G_NN*MO&I)^Z":N\[S3\W-)9U3PGQ+ M1,KIEXDD:;R@*43T7XJ7
MBC:9_V].N0TEC/,@XT31>GP;ZKE*M$\37G:7L7?GAGJ:\'*:\'*:\'+?BC^=
M)KP\SH27[RP7,71 ILK D\%YW9L2%)BNCN(L+QIGKO+MX[SEVE"B7,:7(/B[
M1>'<]6V-AT$81;[IN([/F0&.A^VX!K-LYE:^AZZ?5S\\2[;"ULY>Z>HHOF<5
M=H,5)E=MD+^I ^X=_;('TJ8_.*850K>\L7%W;6>W[)Y,^/<4 6AJ)3=,$9,M
M6Y,/WR=A*7,H5; II[ECP">S^+4\[2PN@>9IEJE%$81Z)HLTUV,& TUE19IN
M!KQVU37UO/IATV"3C;+2"Y9W!P+%_+VU66;&,GS[BLL#:;,YZ22)4=%BYU*1
M;:* &-L*R"EPV#)PT-8'#MO7G#2OJ30](-R@ SF%&R\LW-BM@*B;.SJ5C^:M
M'F3%#Y5#;2NO_OK]'Y\NOGS]_'9]V/'BS?Q5*QM7T-!>ZGD1^6U@L&LN#)!F
MD)'2K)_#7ZJD3U/F4=Y^ T<JN>'*14 5>% MYD0^\(:J[_ *3.V%Y1R<;5:B
MTT .=<:7:4:O][F2 QE$/PEZX3Z?L7FD^*NF*49\@9Z<\1+3CO1 5A:S%,<U
MA?MZ7,<V <ETIIYW>+@=8VM O)T6:TY=[3EP]IYK?A!64GY5/F+WEPPZ9?Y\
M9W"7E]MH_/OJUQT@AU[N/OXS_T_E=WA,HGR<*M<%Z+Y=0&CV .'9INM]'_26
M%T+/*PAP8H3U(X/Q>A;S",P#F KJO[J,HCB T'&,QCU'7[.$2GY"NH]^]:22
MCD64OR>5])'/XSQGRI<4@NJ31GH(.1OM\R<VKC0*"AS5=W&"*:DA@;O0GKOZ
MD0\.FP[UG",(,;8,)9I8 >,(G_.D"A=\/D_OJC"AF>2ZA' !+U?@.&812<B7
MM4(2-%$R.QFP)0OD -:DGMV,?1QXER,$%BYX^.LQA1>>-U6]O:(+ ^(2;[M!
MJ+O%"*:[[U]NB"[4J;?G,-BG7ZRN3W5ON\4^DM_Q='KW&M[+BC+;!LCP":!)
MG_ 2;UQLF$?UG6X:'<R'>O7W>QE/[=4\Z_N.7@/<$UO_ %*Q533\HQ&%HE!E
M$(!N@^QPJ#!$3.!XPM#T!4K!$V<@?K[*XB2(EVP^E(!'1;T>TZDO--=T5!FL
MEY(0^0$TYJXIC!^ )#^@$7F!(O!\-D2P?2RO><N)LICW.9F4DTG9SJ1<L7(.
M/CE+^/KYM=^I]GP39SPHTE/H\?16XSFBT,=F]*?3."<M>TSBAEKVOWB2\&*F
M_,%6V5;XA=^5PCDIVA])T3X%KS_.5U\N34<@#4^VX C/D3SNC-UBY?[+Z@<L
MD)TLP0]D"1Z?TT\^]TG/KM.S;]@MB,H_L*,(KTW\:"KGI&I_)%7[),Q^TK8G
M;;M.VUYD.#EJQI9QEOYH*N>D:G\D5?OXG'[2LR<]NT[/OLUBPI?!MOX?3=^<
M].R/I&<?G].?2N>LO4=U@G.1]Z.\'A!<YW_]-%S!?V;%8O[J_P-02P,$%
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ME12&LRP,0&L(XA9-\S@,J+UP\S'X(R!KL!.U9KR0@73RS[.3'[,1=FS#J$5
M\+?=#[ U>%YCE]:T3%E:Z?1?9*<_XF#$+%HT\7T\KZ?Q@D ZQ9?9*0:R%DWK
MD/?<79"Y@[N48D;Y>SUT^5MN\JW+I%]KPB6LI%"\RT*Q96B$'(75&;J=B*DQ
M^1-:K?_:;Q%</;0F##E3YIG?ZODN24(I%#]EH8C(#4'?HOG^BGP?U74Q-D32
M>7Z?G>>8M$53#+L(]C)TP2<BCWCLH'K'147TTHG_D)WXD(NQ86, GQ:AP ?N
MK? ,/=?<TR3II+.><Y)#:D.0MVBR>]YJ19CP]?F*UO.$]XC=VJYN%1\9&.<Y
M_S;!32RT*7XM0F>P6CO>"\8WV.5L&1B">K 4,I#BD7-T8S9&Q$>8I#8!T36Y
M4::"6UU'*T$HG?B<DYLD;]%T3X,YQ7\$? "#Q]IAU1RQ=-ISSNV6A1'R:-7<
MJP0M7S$>JAP7/<]YS.IQ4>/'^*\V'4*I 3!#W,]]#60CQE)<<^YW'5Q#(6U"
M=1/";@!<EE:*3<X?WP;!VSCW1<'L!C!4L)$BDO/<BR/C;40G$^9N $PQ!RDF
M.:<^&RYO(QK54=D&X"@QE&)5$ I0"_:V$<,X*M@ K0RI#)>+7%0@9M#&>2\(
M+3: H)R+%(U\3* H3-E&:!)QQT8V+$LMA2(7)4C&+MN(0$7PL0$B<FY2A'(!
MA<J 9ALA2P:V&FW+<N124'+1@B23-F+0*/^PCQDBSG=(=(P%27'-10MVR'<T
M?HS$MDD/U((W7<L2 I&3*&=KH@U[$"?5B5R4HD8$B1N&C>QDZ=Z;;I2"]8#9
MG4?I&OM3#C:^010:6GWB! Q;KZ<D:G*EVI*+H-32%MX) WIA\&X8HA]@@Z K
MPN1$G7G3GE(41W.'+$1/*7_9!LA<3K"#'WG;&??W*#)?U]+4$B_5I5SDIY8N
M)?IB\,X8T!LC[HZ1Z$\KU6D3K+XC:$X< E7]]QC!1%M=MGG*%_G ]_G,PDM(
M/_/-P.(./V+GHHD.[4NF5'%R8:A$8+UC)*0;L7BCRY*--ET0QH<:HA.&Z(5Q
MT6Y]&5!&^"*.F1?-W<;_8OPO2BSLBZY^=KTYQ?XCN )[4)G=Q<JTYC(7)$MI
M3=P!@WFQUFQ=3V:D.F$D>]%JM2DZC&FB!U5\I,#FXFUEISIO (F)V)M[4INY
M%$K%TI4WQZ/BZ*X)DB4LI'A):UU:"0A4HS1!(4DGG?K"&IA63G?UV>;>K-T.
M8J1@-JZB>;.$ZIJP?8KBI\1=QT_WKQ)J\J2ZD0O0J>M&HB7:MB1N9YT]GG]3
ME@QXMP'CL]UUW0#>Z$W+E><S\N]7LB'J,J5*DXO3U3 H83>,L!\IPD1/6JDR
MR7J\)O 7T4NAS(7)4F5]K<0A3F]I@D&65CK_N6C3-KFFA5-?D!?3!(4*-C)
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M$38A]!L?"W]?0UV:+C$6/]:;EKWPUF6>'$3IR(XL]\B?P!XALU.88+"U7/O
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M4AWT,]71&F/2:@R)KQ9)AE#0\KN.X.<3/@!J+OF^X=,/_P]02P,$%     @
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MBR*&,AX7(*O!"2Z4S5Y21Z1K8/3)$.XH_35INITFG53S3<974"3NM*^0F92
M:\OIS)*7FL4<I$L>LN+4HK^)H4_FCUCN.TTWW8Y5*<,V]CAZ%X<8I;Z*I\-Y
M' V"5+YX&YFT 1FHE&!>!LZ@9BZ-MB9K\KVK]5#Z9.:(*4 Q^83U4?,X'$,Y
MC-,QVM?90<YG)VVJH;R&.LS#^<"&(*+3A@EE<*Q6)@QMHV=!!>-+P0GHH"[J
M(51]*G(AY@>Q2"A/.%W@6.PIH2H[G<)G&,^&7V"9Z3J:S%I^Z[A^C-\&@OO
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M6Z)I/ALHXY..UC/O_&(/4;(HH)6<RZ!Y3C)6ZNJ/>P$]LD?9CZ@IZ 32:0(
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MT<?&YL"U%IQYTSK)B=8"3%O'D@PE%W!2DI_?O@]/OUJ [$<'D<FG8_/UO?F
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M XG>H0H94 "V*6:-EKZRGB2CG(2D,\TKJ;B;RFL^Y?8GRY8]::0'\_@#?%G
M/L\+E.\]NH:O(,P&-GK-2LC*.;3QI.>>6*LI"3P8QE34UM0N'?,8GI.E3W5E
M]+#GVEX4 RUQ3J2V3(;2$5D*T3JN$[& 3+<1EU":#^8_G3R)>E)4#[NQKW-N
M2IF^_A:; YL?D/#GHP*^_%>"4E_]97D:/@#*91CQ<6A"H*-T_XT[WQR@YXF/
M1F"$>QW18G.,6!X5B5HGD1@PF6M/63T,X]D[]X=6;0^QR4[@W\-D.$X/4R3B
MY77"9_*NF.:B&V0OC$LL$R=4(-(&?$ICTNB3,)M]I %D[<)4^QWAL^?X$1.B
M!T.QV[,+V93RLYP@RE*6/J+=8M&E#C)2::-2V=>>EG_L"7A_ZNK!UNP&/FI0
MGB:%EK%!L8G@B'?)HI.N*"X8"25ZQ%Q[@F4^'D6\XNW>RRC=&'L-D6[,RLR$
MCI)SHFGV*)D$Q*N4B3+,.- Y@:I=1Z(UN&?_Q/6CAAY.:<\+"T^;XYKSHM1-
MF91%O6%(;$ U:/0I,V$^H?NAC23>2DX\ "@I7'2L=M;^5E '\-OZ4>CJ1%U5
M&SWL7JR4&#L/,Q1>\2B7-LJ;\613GKA7PB0:/,$%11%97-B0T7H!(6(V 82V
MM3,_.L ]58KM2X,5]T*:@.I?2[2]1,*6"^?\^?C=3])TX-#=LY0:PI,M!\RI
M)-9R2Y()07)!I7(KR6H;(MF/W>74&%%7K#TXV2N]4KSC KREA J?B*3&$(\8
MB,D<N4>9LE#;8#F:OJ-=;)$.8CR:OJ,;VV=DBVYOSIPHFS,Z)S02S\H9$A;1
MS)<X455/SSGVGD([*;AU3Z%=!+V?;C)M$/VP/85V4M?VMC)/D?6>6, X3HY1
M(3(T1Z3UIFQ;X$(H K.)*QUC[829H^\I5%OY.XBXC^:Q30N<EVO[WB@F&"V]
M#$,RK-16=.@):4]"L>Q *QY%]>E_,YRC:#6TD[96I_]*HNZA4\<<VJNUT#0U
MUM"@B/<YE<RLTI5=29(Y=\!L9#K6/@#U")P384%W4?<V%[Q>#RV%Q)/0!"<Y
MB4.VC 0'D0AN97(N:E]]6^$1."?"@NZBWA@(J-]N;'E$"C%/<5ULZCK[$FR/
M^-NB_ 6ZSN\GXQ&^G/?(G;Z"F1]>3N_#;=>)K-/]:C4IJS?HE?YEU$.@/D:G
MF9*4!1NC4)*#I8Q:?-H'G>[<<1Y8UR/]UEWV)JB ?@Y)V@E<JSPG/MA$E.96
M4QZ\=;7WRQ]'5&,3[&RTNEET-GOI)Y/O*..F^O2 9@;@<R3,"HK#+DD105(2
M\8_G#"=J43U4WP;8 ;9SZO%CW69J757T8"U]@'E8][6?C!#3%)_&ZZOK)HGP
M%8H_#F<#)HP53N'ZC3-V">8*XAW+)+FHG.5@<JIM-&U'=5),J:R$_1]&45Y1
MIC20:+PBDFI-O#614!]"=DE(7[T6Y;$=1NF1'A6%7WNS90%BB>K]I9^OWF>E
M;<8;*-FB)GNT S*AO/@!@#^<*-4N&35*4YV8I=O,IW:W.@F=]R#5VF=(;FO]
M?AJ?I32<'UEX[X?I[6A1&FIE "_'4^1I1A] :/0%:*"!R&AP,F,BDB2=2EZ)
M&"&V8L(3 9P./_:A@1Z2 9OA7XPO\6K38A'-OO\ZGMTYU7*;U/"AN ALX*73
MH33#=M;AS!99(D&J3( **D,."0VEZGLVNV$\"5+M14%]9/S=GM:=GY@ZNYY=
MC"?#_X$TB Y 9YD)#MX2J5,I()!P:70.G!:<9:@>[M\,YZ1H4DOLM9O-K*?O
M@\-SOUX7R9WGU>-V9:[$$808N6?2$B:E)K)X9=8D-+>1Z:7HLA.IW3)5!<Y)
M$.= VNDE"W*%^N?7L^G,CTKV_<!H,%H[M,("<"*]X<2%8 D/5(L(+G-6^Y3U
M8WA.@CK5!=]#'YK;89]/YLS^.^"$F.;I6 !WA/'B^\,O+[\V3\J@(K"8BRDO
M@1)I;$FEBJR<VDC<&LX<J][TM"+^O:4^]6@%'4J=1Y-$M4ZV3;Z 9YQF92S!
M%XQ(.3]AF@GC.1L'"0RM'>?9".9@250'H\=&GG914Q][K[=P?O57^/(3NJ+3
M^7*^V&]L@["GE*SMZ Z4HE5'G:LDZ4<7AV%-8N7D MI])I9UGB5T-QE%X,E!
MP%=4Q-K%V0_%EFTI78<BRRXJJ$B2QH/X )^'.'5.(+T:3IJ#XADF:/\M<@U*
MRFK4(I"H2^5P:QRQF9O2EQ",,CE2Z5HY;H_?YP!F=66UC/N1Z<;=R?KY&Q^O
MKZZ0^^/\<?AY-,S#Z._E$8POA[$4QK@)C;X=Y3%>H!'8T[,X*MRU5BY';0&L
M9'0HZYE5DJI4W&H3 \\"+6J+4XB(+(5!A?MWV8%X<*=;RS_1IJR-(LPV15"D
MP2=!HR^(?W+VCLO0KJ7P(S?IONF^<LIW)4>@'.>YGDQ*:5WT5+10BA/PVI?A
M  GHSA)NL@6>9-GCJ[[YWA;=_J;"JFI_N/W>BSIZR-;86(+YMRGDZ\MWPPR#
M'#.E.DO"1$37URA&O"[;P=&D)%BP5%<O\K\=UHE0I;8">K"C/_G1YR'ZELVI
MS=N&S2]Q!?D,TX$QR%,+#/W,%$K*/SJ;X )A%(14V@MJ:MO0CR,Z$694%'L/
MU4&7#;P'3%'P69=CX9H2&9TC7LSCYSH8XR3XVF<CE_<^$44_290]''K=T).=
M:<ZHC(8X+7&%\CX3:UC&0=IL: )A;.WI?SV2$U-W!S'WD$JQS*A^.;X*PU%C
M5Y>NVVB+_P^DMPE1HE'NE]/1=-G_ U>L.WW5\+/KJW*B?[:8NW":HB)%ZW P
M+J.D@H^DU(DD,1E-(0O*9&WV]#24$Z'?,2BZC[J@BUW>FP(2'^=;%],!T""8
MCY3PZ-%Z"E01;[PC-/"02Q9LC+5S?C:".1$.U1%V[6R-):J_POCSQ'^Y&,8;
M6$QE;J221*B25A02(X[Q2$0H'6BC3;!Z0&N##[_Y'L]<M34EV$.:Q*O%4;!/
M_MO=/I[29OQ?:1O#2]]R9E1I (NOC \F!)JRKOULKT?RS+5?4<P]I$/\-IK<
MK%"([ 6,4+ZEPAXRC_N4B/91E7/!L?330.=8F.0H<(H^4F7M;X!R(NJO(>B'
M^G<5^BR/KP !E?-]PZ_-/G?VUG&6BKF!RXL$&XD37A&@$A<@P-6'UTZ-6@/C
M1/3>5<!K@D[=3]V7I*P7?@H)+=4O,)KZN6 GI5)869->?+_]RJ+G05,\:ID5
M,9U-KN=%[&<7,/ETX4?G7\HE2O2UR9A(\^5N$(/BAJ=8ZHV7!L&IN-W,$Y29
M=MI9E43UZD[[&MR)$/0XR;"&]EWWHV^;+=S9DITN[;+_A%$:3] 8,UE*F13A
MP@&NPED2+UD@B7L503,1;+OV*2UO^,Q9U)MLUQ"@V^FW;2!?XNOKRUES2@^X
M4" ID.A*IA=5EG@>2G.&9!)/*5+7+JU\AYO^"$1XJHS7D*%S2'8#UM??RAP(
MS?G-NT/XQW!V<?>?#"2W+B;)BGQ*S=92K%WD3$**:-%3C82NO3?3$?(S9]@A
M%+>&>$\.!]\+ [P8XPIZGN=Y/#@W_N-B?#:!L\OI^/4WB->S(:Z<9[.S>\ Y
M%SI$;TCRN&K*X! XQ]D4W_)>9A,M;$V+Z0KBF7-HKSI80Y[.L=A7UU!:C-T@
M*H6]%ND.S"KA$J-$)%%*>9F23%@8;HU4Y:1?D+7KA&Q&\\QY4EG<:YC0+1Z[
M;:'];31L#G_.VS,'&: T968L""*5823(Y(GU@JI$A>(^5;%F[M[UF1.@7RFO
MX4/G,&Z3<CH_>/?JNF2%SOO/S ]@_0J_-Q]-!T)E[H,*))K28T:85(Y[,A*5
MS5$ZX+SZEG,[9,^<,#VJ80U;.L=]%V7E%I4'SB=- ?DEKS_BZC=I6/W27UZ6
M!G/+^B6++TX'40H(W$9TXTM/2P^.!&0YD9'[Z+ET--4^^=81\HGP:Y^*6T.\
MS@'GNP>$WT^&$?#Y:-X;V,"8Y2&3#"7K*GI++/!,J/$A)\HSF.H%)#:!.1&R
MU!'VFA2W&LFQ:\HD(<:ON.+>U- 9H"5E@!I!$E?(T01H9"FK2!;44&T89]7;
MT[9#=B($Z4$-:]C2.4UV36+-RW$C#FCZZ$R'J<F6*,<SEFU- "BR.EBB?/'U
M V?$ Y=$QQR,EV AU-YZ> +,$^%1WPI:0ZK.:;;M,=_9#)F^;-KIO!W->S@U
M(<U'A\D&)CCC$TU$60%$ZAA*ISU*4K0&!QR\<+6+V^QI:#\<>?='A#6$[QSQ
M?MB*](T?3IK*IK=%RJ;GHT5VXKVLQ%('=0CI;';S3WX;(:R;W^9;?@/EC,N6
MHO\+.#JIP1!G%1!O4#LY1J%];1NN_U&=",V/3/UK&-XMM/Y0;O.R#1D@6T#?
MVJE4D%%''%JW)$?TA'*IU!K:[>ANN$'?553ZBV_5D-BQU$%93N)-4O5TKH!R
MQ%XJ$93WAM"F:XKV.!9/*4'?A](H4Y:B=J!B Y1]UT"II^(-ZV474?=PEFX=
MK'F&/2P.WK<!V%,ADZW@#E/'I(HJ6]"CNQX.0A@PR?%$-5')&")9IB1HG0GW
M2@JMDLR"G091MI0P.0Q/=A%_[?HE+_SW!9XYM$6-#>-%-F L8:9)'L!EUE$3
M28S><^V84LFV,B;67W__]4HJ:V%<5X05C^4WD-[[T?C+#*8/45DPVN7$B87(
M2W(B+HU4>1)9 *>"%$&H5HK=>(N3TFT=0=9^:/\?G^#3!7K>7^!Z-HP?T>59
MDD[KA$Q3Z'%+]+V3"L296([0>2<]A0B\7;VAC;<X*?76$63%L_'3R6SPH01<
MFF5'.)F :8%WY>70#'CB.#,DRIA"E)DRWRJDAE>]LR;C;[?K\;T;/GO3_>GB
MZT.'"RJU@;&+.=Y&F_6?U>W&=@?AKZJO@^0JSK6K<")0G95T.+F(B(S$'T%J
M29B7P(-BT?A6J;"'5N &([B^_G816&6]_1TE=75]M0#B.0@%R9(H!,XE/KE2
M"SX1&@&B<X;:&"IH[MY-][=0=A+[N(;,*MJO#1#_[0X0SM'5TBX0(32N[B[B
M<#@P$C)8M+%],.U*F&]3WMV;/D/E/5EF?=1-W=C=V7*N6"E0([S%:24%28)G
MN*IS9IU+"J2J?E+N6%K>]Q:IK"/N'NH!K>GJV@;1#]OX?B=U;>]]_A19[Z?Q
M/9611X;K2HJLE'K)@EA1?+<D7$K44*5[RJL\WL;WE96_BXC[4/IM<XQEW5[E
MN4Y B:>^]%T.B02A,G%62"FD=8S7[FO[ ,11-+;>23.;>XX\0:Q]M+;?6/7;
M:>]I0#A@4XG*<$&<HX) XHQ)S@*OGCM]-(T9^EOJJXB[CT9ZVPN"MT'X1X.%
MIZAS]YKY3]'%81HL*)FE,XB4RZ#*@2-!/!..6.6$S2DIZVN7Z'EV#19Z)LLN
M*NBET?/]/.W%PI>%<31+2K@HYSRRP6E4"TFH98 K+'5!M0KJ[)0TOP[)479?
MV$EG#]+E.PN\E[;P:X\I+FSGK'%XED3/,SX TI) -2=&BTB=!)9D;5OC$3@G
M8VW4$GD/U3HW0+OQ?+>#Z\G4>!388:R,:FIL1X\..NAA]7@<9!!4:&$" <5<
M*720B?>&$2HU%XSZ9%7M[G$'(,@6P^(P_-A%]+4S*%[BN\/H+S_.KA/.E!]A
M\G488?I_WIX+RI8I )GF*&5&YSS24D2;$TL9)<;3#)(+P4V['*@6-]N_"5%1
M-^,>!;L_.V+ZXOO=3QKR:TMC]$R2F$0BTEM#@K244 ^1T5 .M.QI=EB#[M2M
MC*X*J5@<>AW2Q9/2!M$>+(TC-"\ZZ^\1FG00?L\FQC+&"U2D% 7AD>J2'@@D
M& Y$60@:M%8N]SES')\QL0<V["+SRNDF9SD/+X<%T&N<'$O[W6:E<Q2D]AX'
MF"G#6;$<68J^%"*0B4?%G6(U,H;6W_VP-L53=#*N*M"CZ_WX*S1]6KXLBE.\
M\-/RQ?1J>'F-X^R]"62[V^^W&^031++2%E)FRA67&J<**9WT@1L:M0#)1'2)
MF99M(=L!Z;9,G.$=4[G@\"O<EK!Y_2U>7N-X2FV*4IKX>M8<J#[/K_UDA BG
MRV(F[VY.0F80,NNF4U=D\]*.'M!.-UJ+E$$SI47EQ:46]JY+;4<<\U/L@RQT
M5IH&XFU)WI=EJSV@W<H<4\((:[6I'3JN GS_4_I!.+NZUN]?Z7ULE,<+2-<E
M;M]Q.'.'2Y:Z(CP&8E4NM6I2)BYK3JBCBEKMDW"UYX"Z(^C[//E1,?B RC^6
MD^OSV@EO<>G^!NG3N*G6-9G.J^O/?S8^0<P $+S'Q]+@T$0J]26C(90)&Q1+
MS-/:A1O;(=MWN.48J#/N784]>../H?R$UUAX)FU0]A2X:8?P,,&</G2\ XTZ
M*NAP= I4TVQ D:30Q)!2<;0N!%H7)E,!J1P;K!WP.22-M@2!CH=%N^BE!_:\
M1O]]_!V@R=680UZ$,J16X&(0Q&8:B;0B$N_*1"R]Y\[@R&GMFH\;P>S?K^A#
M>^,^1-^')[!, 9\/MRS:XU$I2C7/Y8HQ9J$$<2DZ(IW#!=IY10(3+"A $]14
M3YM]#- ?=D]%A?701GT%TS*_LP6HGJR;M8 .?-*FN^)6)Y=J4N]CT5D+KJ3O
M:6TS\0J76%D.!MHH';&".@%"Z<#S\Z5"VV,W>V+"+L+>R^F;4B1/1BV)*ILF
MLA3DQ/\<2932P$UBN7K;E",X?5-!.5L/X.PBV1ZLB?>31<?=>YBT\$*HA'93
M::+M#=I-.EB2'<_1,A=%]>WG=3A.0>&=Y=O#X]TTIBQF<C-[95",&8U>E.8X
M>WEFB=>2DI!+\C_(P&CM%FWW /QA(7902 ^GKK>V.IUNZG5Z.XQ1>G_I1^5P
MP?(1:C&FO@YO]3">P]BC'6BR:SO;?>FXCT-A?8Q-"1<D>OU$Y'),5B=)G,V1
M4&\CE)13YO;>HOEH>+O%>#YRVNZBVEZR_Z:SR3#.[EL(45(M0&<B54 II=+Y
M2G->RBGE4DS'^U"[N_Q:( <XG'9P'3](%>RJH*-+)3L/E\//C5RG>3QY[6/I
M_0I?\;MW<_G[SBC;"<5^$\N>+J"5_#+.K7(A00C22NE+$Q><XEQP3!G/4FR9
M7[83GNKUGM_=)#$8QX%'R@@7!AT7JS1QZ*42$4IR3!F2J^T8/H;G !V3EHU-
M@7(0UD@"WC,B8T;O$$5!A#'H#08>-*V=0/-TM$=1=?5I+*K00^DI*NLU@VN-
M<'!1N_/;W*/4!@P$[XA.L=1RRZH<=++$)&\ ;2;0HK8-L"O&?65A]4:G7I5R
M++E3F^K26TD#L  DA&R)9(Z6'N^1@,L.K-?,L]HA_2/I^K$?];?L"+*+&@[2
MX*$-P#\Z@NRLRIT[/3Q%#X<A3$@(+.-D')7"'PEG9!<"8<I20.LWJ]Q7,[_G
MT1&D9Y[L(/X]=03A3-.,<R8NSSD0254FZ'\G(KDRW&G!P<1M7N4SZPBRDQ9:
M= 39183[ZP@27<:A,4YXBI)(8R)Q&1=$*Z1/T2BO;6ZEV&?5$>3)NJTCR/UU
M!&').<--(MF4 YBJ'-%/R1*%OA)+@C/'?"OU/JN.($]6;QU!5DSSFE?56.\@
M?XPP\I/AN%F1P 23C',D0IE=H@;B 8>LJ)6<6QRTT:T4W>)F)VWM]R+Q/3/B
MIC'.=H3K[?ZG<>,0%GT_ZMJ!"QUD7;VL42ND5$>3@L*IBY:R"UR4I&HJ"$O>
M<JJ5"2V7A .R88/9?BQDV$7$M4GP\3I&G!GS]679?[N$><[+^PL_A64%)FVM
MR]0K HBG]*8#8B-:HKB@E6RV""!Y*P9LO]>>NTKWH)YQ?[*M;>4_ H\O*VAX
MG(*:8ZLV&R)+:Q$7!*Z^PNF$1JJR*715/?_!5/\4V>[QJ1?+=EHR,JY $1$%
MPC/@B.79DY02Y=I%1E/GIU[\8*I_BFQKVX)ODC_[\F4R_NHO%VB4X\EJ9@AC
MM*3H*" !X9 LP#'!+%6)MM+T@TN?EF*[2:YBZN8\; 2?AZ.2F+K"+4T1DHCH
MQ'B7<7A)DB!QM%Q;FE,TV4C62IL;;G!:.JTAQ8W]$>KG^[SQP\E_^LMK6.YV
M#V'Z=_#3ZPFDL]G-IQ]*5O,$1U4J$TU_0^?W\SOX"I>B0Y)/K5O7RNSI110K
MZ3PZA>AE9A'_2!5YD#Y(!A"0&_@R#&J!Z+9#<W.?L^D49M.S45H#YWQT@P*_
M\.MX-+D'ZMW-_GH(GLF ?HZP3A&)'"!E\X* \,Y'G:E0*\M!Y]V<J@/HMCHN
MD6R8=\["=#;Q<3;@)N*\P@7."!%P@M 4#7>32/3..&F44-ZT6S1;WG'_@=/#
MT>K^LMN'2GI(^.F0JF23,1)4)C1#L0<9)8%!($%P@[--$%G6[EKR'+++>E1_
MO32S7737X^[\#LCQ(8T+\$8'!:47.IA2N3MZ-& Y980Y9ZT0&@7:5TK0DP#_
MP;TN&NRAGL 3P ^\2RXD7 2R1XM:"BF(11^8I.AX]!ZLZBT/;0>8?U!M=VWU
M<#RQAA$RW]W#YR,&J1TQ2N- @M;EY'4DD:F4HPW*M6OKO6>[=J^)MX<W^0ZK
M]V-)X;T9_8OOB[&6J[Z9P+^N813GY;!,=(9EG/29H)Q(E4I=HL!+32R'7FOB
MF=4N"=4"UJ$V^P_$ETVLK:2W'@S&&XCK "[":6T@]I0!W +>87* JZMV$W4J
MZ^5 %)+XG'A1XK *9WR9DBP]@3))@4KJ)0O"]19%VC=UMF0%'P-S=E''GA@S
MO9F+%S%WJZCG"LV%[!"9!)M)2+$T#Z,F*^91W[73R-O@.F#@K99"6Q"FDS9Z
MB*;=>6AN7OYMB-[))%Y\;X+G\\P<K82E./AL@)9R2IG84K7'"ANT8CHQ7_O0
M7#MD?]A!E;770_!B[7/P$.\R9:\%V#T:11N!'MP\JJ;Q-M-6577M:^7;")KC
M0@_&>6($3P@:/6:764:/60F52S.CZJ&Q(^!6>_OI.*BUBY;ZI-3;T9?KV72^
MD[Q<M:4U"80A49?S#-Q2XJ15Q%#GE:7*.-K;>O@0SG&83I44N8DR';6PQVHQ
M-Y!?3V?#*_S";+P0TX8H\&^C<9C"Y&NQ!^HED'2_>_4<DLH"64DCB8QI3AT/
MP0:9(@O*!YFSL4S;E!P;5,11:6IYW&B<I['<P= \ _CQ>!2;1GSW"C909RC^
MR20:JXDT.1&?>6D/["%YFD64O2UJ%<=Q@*VR.Y-8@VQ@!16^E*'BJ92A*F?6
M7)&G]8H&I0.8ZNY.!=@'7 8.Q>,*.V^=E%_[K,#+BU*/[>TFT#?R'D@=<8KS
M0)P6:(51&XE3LJ10XA652"%"RS[H+>_X Y.K/\WT:;5VE]H\/J&B]Y2AJ:^2
M-D0ZH]'>#YH(:H)(4GC97YYBI3'L?5OWT(P]"C(<RR;OZ@1_4S/5*TT-\PRG
M=T9+[TE./"A':.*)J42CE;69O0G+P<.8!R'(N =%]3"EKL.U\&S;(.LI6+D9
MU6$BDW6TUX(2'42_7W)8ZH76AI-D4B R0"9.X'.I( NO/=J8H7:Z\;Y)L26D
MN&].["+Q/7#AU7#:E)S]X&>P"%E!D,:A@4BT;D)A5!,O3":4*BZRY-0IUC,G
M'J+:OVU?2X=;J-%1 ;6]NU5X[R?CL/!"S_/B/.N;\611?7M9H,J'@*8>(]:5
MKB8I&!)B\,1"1"\C<.ZA78VOI]S]V3-C/W+O82XI5MG<KH)X,1K^ZWH^<0;'
M-0U:$B%+/2N<+(FG^(I*%YB4+"A;VV9=C^0/B[6.DGK8;W^(:MFXLP6NGJS5
M39@.8ZO6T-M6*G00^E[FDP6^1%5(@09B@!?^ZXBSJHLD.6^E0UL,6.U\_?V2
M88N-ND\N["+K_7!@82!!>NFG%V\NQ[\O5C^?%!.LM,X#BL,/+I"@E2Q]>7%2
MY":"K]V2H#VZ_5LE=32ZG28UU-'CF=L'!7>Y"=YE3R)C#-VX\I!$-,LD@Y@-
M5S;'OMHU'$FI\Z,R1VJHJ8>S92TJ@[8 ^$<I])U5N7N)ZR?HX2"ET)UG@"X?
M(V!4)-+;TA;2&&*E5$ZD*$WU,,HS*X7>*T]V$7\OI=!ONOP"MQ H<=Z57$2&
MJZ_TB8BL'4M!*BE6K)3'ZI\?;^7DG>3]H.CY$X355Z7S]TUFV%]A^J>K/X4_
M7?QI6<;9:@ J* %;RC,&G]&\T;@&QJ1$=-F*U0986\J=K[_/2:FVHDC[*'R^
M@)$Y&J=6.\)\,J4G,Y+.VTBB"4IX#L:X=F72;J]Y4EI\HJ@J1HVFD]G@0\EM
MF6_,,!&<Y)2(9'&2X,X37SR;['TT6@LGN&FSL.)5[RRJ^-OM@GKOAC^TW?YT
MT6^LA==!_TM7LP6,76SQ-DRH_V!OM[0["']5?1TD5W'J784CE,Z LP8).:+A
MYR$1W^QB&&,HM5[":N^!XU3@!@NXOOYV$5AEO?T=)75U?;6LBBFUY RG?FW*
M2@"X@)=RF$0)39VC6CG>*OUXB^;NW71_JVHGL8]KR*RB==L \=_N (G)2)5Y
M)B:7PD$.(5EA#=%4@\A)9#"M=NBV*>_N39^A\IXLLXU/7OV#/.\G8S0I9M_]
M*+U&<^]+V1WN<#+GL<O5.FK3&O)J1^5HHXLIA2RXM,G9S)P"9DU$1T)P.GCL
MPMVB/<LKE^;BL[,[EW]WDP-KK8V>RD@ 5"(R.4Y"B6MX-+HY"RE+QML\4SN$
M>[:CZAKEVGB'WZ:0KR_?#3,,@"49<@9TTF6SO6#1B\.I+?L"6'K-S-X&?@MK
M_QY898ZL1KQJJZ*'+9B-$/\Z&4^G \UQ J;)$J\ICEX[C:,/DHBH0P8'S F_
M+Z(TB'X<CNRN@!Y"YF<Q7E]=7^**D%[!EPG$N6^*K^>=$1#PV=5X,AO^3_/^
MQL$,:%11!$&)X3Z56ON:N R*> &"!Z"2Q=KESFIA/SG*'42I/20D;03V*\P&
M.4B?A Y$2B'QP0F!!!4C20RX"-I2?&M?,Q?B.3D251-^#SO#MZT#-Z*<1]?0
ML\LLE7H3)2-3YM+C5PL@S&?ME%72\=HD:8MM7X?+>J9)+ZHXEB-@&X?TXOO-
MD00.,44PC&0N<5RLZ1/E'0%+@6H3O(RU,VM;P#I\4\^:=&@[-3U1+3W859M'
M?YN7W@9B3]DK+> =)G^ENFK;4J>C7@Y$(1G0A7095U]7]N9=+KOT*1'%E%*6
M<I]I;:O[8-39DM%R#,S911T],.8&TC*V'2,5/E&2BT<I;?+$26$(99EY9[E,
MHG::Y0J$([**GZJF<3T9]Q#>.<]Y&&$55+* 2RBUQ">%-CI%Y\T;E@BE7%H:
MT:H+M=/<U@(Y/?5WEW<?M3NN)RC7ZPG@@-\,OY57T^4."4>C*EE63BQZ(H.T
MQ#&FB&4B:D.9,+YZT=Z-:$Z/#I4DWT/LY!WX*5R,+]/;J](3<UYI;[GY1@5P
M9W'$L;1C+-MP7E+D;+14HV?O(-?VBA^!<WJLJ"7[C9&3^EN6;T<S/_H\1,]L
M7IC8C]+;$A@L1UP_O#I+J;F-OWP[RF/\A_-PXI-W-#O<K=:&9ZT!K^R'&ISV
MF<X<AZMEMLQ#C,ZH3(-3W/@PZ'#?CC&S&4KA?MQ'T$"SR)IX[G#9XE(2*TOJ
MIS1>>IF4DK4/:SU$T76B6Q7HKS![_2U>7J?AZ/-?Q^/T^_#R$D?*N&6*DB@D
M$&ED)(%Y39QRR>805!*U"_.UP;7_J:\C"U9GNNK"KYU O@KP];<O$&>0_CZ\
MA.EL/(+W_ON\G#HXDTL]D92:1FU"$<\0+C/>"8EV/4B_;5K;Z8[/5O?]R;6/
M_<T[^USG>17UP!KTWQS/1%$?"?IJ:)]1D4E6)BO*M.,VU=ZU?!31LV5%#P+O
MP2J^&>P\"$W1%$L%0_;*(#D9#E2P8NG1'+UW3-I6J:Y/60#WN@E46<D=Q'@L
M6SL?H-D??^_1#_@T\:.ICT7PTQ??[W[21 VUCD A2$)-P.%I--G1DY,D:%S*
M(A/>AMH^='MT!]OHZ4"!\5Y4T<-J<A?/PD]L@ZBG39R': ZS9].7_AZA20?A
M[X<6U#&*\Z@EH$I86*M O!<XV4:/+G\44:G:>77[HL.6?9C#L6$7F=<^NO@1
M9\+)?YV-AE?^\J6?P-M17#:;T#:I8'&07*#W P50ID# 99EIPO]#;N58;+S%
M_FW&KL(?5Y?<'MMT/![!N?W4+S\=CKXL/^TM9M;NMOL)GCU!!"M1-,^LLUQI
MG RT+$63M!?9053X?YNTW1)%:P>@>C@-G=O(J72$L5+Y+Z=(K$&+.K&2+B=5
MMJQVW=;ZX;0WA17P;O@5THJ0[^2T&YE%RCF0F$SQ':@KM>IQ]LY.1&NY,,;5
MWE5J@>LHG.==6/!@.ZFV\'O8<=Z,<3K/:,?)FD8>*5$ MCB6Z.)+5GX-0HM
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MP(6)1.LL2J,*3AP3C(1,#0-F#.C4:LK8\<;/F0Z]"[KVUL\"ZR>87 U"TC2
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M+B6S)HM,,*Z6*81<&V,]=U!4+K17<0FU.#]8)7,NJ$*1J=-]]<5ACF]>'Z*
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M@D-9<[J:DV$-D,OCP:'2?DX!=] IL%)28#[EFQO:P>I-9TC;U6P\PFFMVSY
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MA&)T]-IDNMRU]E:\A.=0?\R:SUY-W__'N-YS[FIX+?YJ@GG@>629,0E"U]*
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M5TK]=MM/8/]6AW_P\VUQ?*_A]%Z[['V]WNZH<I,FU6*XA_O((G<]2/Q[XHH
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MP7\P]B()@+R(9[H$YH$&+S#^Z\8&?0;6 I>$TMEH%7#G# 9@7QP#7 ,> 3)
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MZ<YGIM8N:71!T!4GDU O9U8V;F8"A9E03W=VJ,CJ+7#U.UZ6.71<\W[GEU&
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M-PK*YXN!@!3UF&9"7>,@36H"NH%U_N$%\[3"!#>_U@M<[OR'-EQ?&/PM\%=
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M"/,&9AEF!Q8 BPJ+#TL!RP3+"RL&JPBK#6L.ZP3K"QL,&P6; IL/6PW;"CL
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M\W [<>=S+_)0\1CR/.$9YL7E5>*]S]O&!\]WC<^/KY;O@)^;WX6_F']=@$G
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M-9CH$^?9K<XU+]6I9HC/5,-'_*D.32>NQCR+6'2*X@&KY;;I/6 XT(,X:=[
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M<+%1HXR@E[V%YXS>/?9#^@XSL5P\^(@WC"N:Q8\6<ST D0.>HS<A!I OU8Q
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M5/#%>29WH)I8.7VOCL)(A&OB9T1_ @2B*6MVTA*>(A.W\]!$&]0#-H+6YWX
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M5F_CU')Q&2M/O<_?BY KBJE,/"0UBZ-#[+.E>*3SM#3/EBU/Z"YV19DZ'P#
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MHR='!M.)2PS/B,K!&OMU6U]C<OP$N7#A!HFM7(?,A+>>@W0_^M5G_$M0%WL
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M.T#VVY3=(9(,4U 6Z5HS KX!8*HC>ELJ8$5PA_+:9&A#'_9E"84MZCLG_O[
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MQULW<,B&F\47Y$,&J$_$9]=Y8M(_LJ3H4M6T$ZF@AE7A/OG")T6>E3RX7_-
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M/C*[0%\6].1\D;W^6J;% V;!R3 /_J%WPQ,IX3L#RN9&402WM*35[-&'#I2
M^F3W JI(0GK4^, 'A:DY2GBEK96]VM8SXVCV,\ENUXX[G[Y2U877-K"T2[&N
M8LLLWTM$7PX!FOKB\29I)]3)W"DWNS!5(#O[ ;PDYUY=;N4FIM;.@9)D4!3/
M+:V=-:7>%Z_>B448#:C)X10&J[=XIMT*\2K<35ME'9[(+.NE5I- ZG6&PF X
MC[OYQ/F6=8[-M80E-D<+GLSX0'JG1Z^@A^GR UU]/(_3YB27=>6QD.F\N'M
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M0#[&Z'P4G9JT3&Z()BV42[)S/!07,PJC)/ .4-=E_@-C<XKC]X^%QH1KP^Q
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MZF'W[K99Y"\YP0?QTQN5O-'3%6H<J[..6Y']I7$[B/[URY24$;MLR.0;*)\
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M\R=4F'G/83**IH!]1H"P\GI6X9<7Z?VS<O>]7^U]>F1-5I.Z>PI8?_SR3*8
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M($!*HS&A\(9 5L6NN<"B_ID#[H]^+Z][H%T<7E IZ!O=(DE^;K"++RSN5^4
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M:K!@H>CXYN$?!Z+2>NH'+L=6:20^+_4OPP<= TR5#(326FH-;B+JZ^JM5&%
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MDU$8P;TD3L/WU:WO_I?)*Y--:(3"=8??]K#EKO1&)#U@]EL,@>[-/YLW>NQ
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M"N)Y,-+.7A(%E'<9/N,M3U?L<$#IFZ+.\>Q_G28 "'GEG@SY'6.:YO ]ELF
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M&5]6O4,S81X0Q0RJ! J*<748)/ILE%#ST:JO&*(=N3G0!TZV@G^$(D=_U7\
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M?;J2FV+AO!A75O.MID'ZU1G$"O0<J?T?DZ3PL$6;7"/A69IQ^,63?"XCOH2
MO-"SP(>G(XY7&HK6[#-1&XJE1% T7 4B%ST#IMXI&"6VD^<81JK\T%UVPP**
M ]F&G[)S$K_%(SL_-N3%^C"+52Z[LB5[V9^N?LN@P=T[[CDV.R58%C!+\XCG
MJO!I?(+I)"O0M"Q:( .76!CG(@!^_@)H4I96= =.9T ?T;U)NS?MZL2354:P
MI\IJ[MVQX64[&75G]O*UO\X_Y D-FM<O_#5H^>T?BG@'/'31R"5*PXB4"4-%
MXO2IX__*/R<IF[:83DOH=?!V_19CXO1%'+*O.\6"[(PDW1=09N%Z_X5Q8VN^
ME*EYZ&2C7HDR5VI.SMLRGPOG9J<_5*<M;XW[K5L^^<*FZ('IQJ.ENM?'1IF5
M/EB@ATNSS,Q5<,Z>?PO'"S]S41!GZJ7L\"V=%4B!%5-:CD<=X$VV.3D3]:K\
M*-[H_OA4+O"W,/&8US)]GG.UJEL?G@T!]%Y]Z;_"H@.]6&$8 SH_[Z_!Y5AH
MBG$K5!1*.Z#5QJ^)#[]0:HD38C$5-@W2$+V9,:X;Y>MYL""C"5@V1N?K^F2.
M6[LT+PQXU!O-"M 1;*]M'AV8PT][WC(0.^F_ZZ3(,(?\=R79K3M7,[HO8##]
M6*3<%S,!-C4"R<I\%"=.5MZW:<& 1KT+,Q!MBGMAV(U-Q0,G]\![<GR/Q46I
MRIYGO-6/HZI2; >*@"Q+YRP<XCZR(@@!;Y21;ZR] Z0TH5?ET;+G3C=:EM;S
MF,?.K5WUZPU^M)VA)5MLN1[VC16HK&3^RG0NFC $\+*S50CQ,9V0=W#9.KXK
M@UE)9LMYG_P NU0H>W9S.<[!G&-0W50WH*>Q8B:A\Z9&YRMW*&#S?*!I6*/_
M^?R>SX8$3=&KK@_' )&29],IM@Z,)#-,J#XAW!$F#2H,5B]]FV?TAEMR$SA+
MN>^_0+Q0IO7]II@2@JEKR<BW5@@.#G5BN!5JD=Q4T\'..8QYV='!;9>P95><
MO9R6HZET,57M;6GZLXTR/25&2YZRXJZ;*3L&Z/QKXT]N(-@2)%/H91^!G%5[
M17UV:G(^IU"'2HEY,3*6%52\_\PGBK6!ORSX>:";%,U1_/O^[2\6<H92 .?5
M"/!$-'0$"?4FVUUZ=_\JSX#KD.,,#HS@Y;QT1^S56PJK(SGWTO<-2'$A!%%&
MXY++G+T%=S-RTC[A("U?9[CC9T?EW:_IQ^8./T&_5^CD!]*B[,W7;\V3C_83
MJXB+K??LN;8&"K/M[SL)8ZE,J9 U@ZJEJSY\0U-9LTH^U?!0DN(L+/G5FFG8
MPD#SA-JK.'LV=9;/,50.#>./]CU=5K0FVEQG7GD.5+J^JE^&RJG3$C6@$ZH5
M'<[;V J.7.3HSTC]6N=3^14=,3T6+>8+BDMRH\(#4J-:$DZE?%!UD4HM/7?6
M\FH+B#Q#0B&P)YJA^V@Q]" >DG9WQ9K:;C:<JJ&<_/O9,BF?QT2H'RYK7@PL
M9T^4SZO@_;JE:1 8/?%0!\&]XHO&DY,\K00$&5VQTE)G+JD;"6M-!+6CZ!F-
M7.>1/:77H,$T?TN:P,M3^5VH@J=C,79]ED;ZM_@F9M?X/)';)6)1;?%6UP/]
M=-W'GZ'6O9J-?>4D'IDLJ-[_";58YANZV!ZXB76E:"V&']A;H'A"_;K7K>?1
M3//=Y#0$SQ2,7-S\"4QH8G%H)F? ++G77JOV%;^BI? K;:P6M#?Q+EQ#G7$<
M17'0[&[A^6B9N:*M&?.WF&O;.3FAM[AE8W@2@!5FDXZ#L2_B!],4M7OA<9#$
MA@O,XZ)%TQ9C5A;+0)%,:<C,-FK:8V#KJ-\HF3W1I"SWT)S*&XL*2D)X0USP
MU_1CRMH;Z\EX+8.,@+F%<ZQJ^86N].YKZH\J>^U_Q9F3?$=H]?PHUV_([TMY
MI&P=DA%GCZ7>Y4U"&1K((B=0/:[<ZE9XOY<_N\FA>:G[-D(C/W_6'^./8?EN
M3K&XADJ2QU6X,K6WS2A[R9532GS7.THG$O_[&?D?+'#?D1M/N?5^BEX:5YV-
MQ7#?#N67LD9ZI@^200=TW13%%TY&'FE?+WLM^9/K=JSX:VH;Z_:1$@UNGL$'
ME@4&KOH*IJS&ER(D0!(5T?5MD3!NVK$5IZN/X382! M <L.FN5!5<^2&WAVQ
MXPV=J![G5N\X\.826P%7(V86L&KIRYT\?97+SR2_WB2C^,U2'$7)LKLH#V1)
M.Z>/%MC0:2%E$85FYS3I$^$8MBD'N@_'609MG>4[.?*N:X%@&<,>+RI]4O#9
M_FTA<6YM5:[[6;/I0#S^_*GWRPZ@,^5QV =/V9@S++48>^-0F<H2@IB7$%O5
M@+VFK 97H.6<[(>+5=L4V=Z6']E XG'AJ/>N:[FB4H$)"@+Q$85LV6HJ_MUG
MP[/I8$][[6'.QU%+Q)FQ,REEZ=[J'I]!>-X#,POQHM^?C\IG2A\&Y J:,QGW
MO3ES54A\HL_&2,8MK&7?AD"WT++T&FJQ'O):\:35ZL38->=$CE+U.%/@L3T7
M3>>R)=?VV]Z?W/% J?$%J'$.%H2Z%W++,S#.E5?UMU4P_X=5()9R,;8!S<D:
M47SOJ8-8VBA#I95!&BPE9"Y3)*]_W_[(=]IM5J [1*J6Y.PP^]'TI[.#7@%M
MPV^FQ"TI'9'1W*8W4P"?M.%M]D3>=8/".^0//S:?K.J0JMMFA[GHKPN:X8T[
MG@[A]L7_SG3Z)EN/W>/7!B41H!GU>_R7&:),^Z7Y;B1:4NG"R,3[5X3ZNIS2
M^[.,,*M0SQ[[FZJWG,;O,+9:T8V\#NS?.OM'\^J;[ CWOVUZ9Y="_I ?Y:.4
MCR6UF^15<\[[CUQU02I(L$&7XHNR^LKGBL#]!(U,8[Y%,:[KQ>GJYN^]QW+%
M8=GWGQ</R4O#B<IQ8W&LU4W+<5:,H=M*360:/,-6_0N *;6T:LNSN!1(&;*7
MRBU 71<;4+"SW&3VSJ7XMU<1)]Z[TFY:P*D9SJAXY3<:&+UF8\@V234UM-6P
MT"S8,1\;K.+IW]JX4>;415T9(>^VE_K5H>@^O6P+R=.BL;K'P%Z76(/X7!4J
M G9]*"Y/J*0,U4& OY,=B-^_:GW@T 4M_-W/@JI8\S<=Q]5'F);#E&/V,SY1
M/-_H'I=]76E^"]1_.XZ3MCB=,BKQI)]PXZSTF4N:Q=D\XEOL)._3A]=PH2^:
M]*55)L8I4>A<<K&!O@ M%D8-V@#=<LGK'.;F0Q7<E0;+PW<-<$)PG^]/I<Q&
M^Z+3AE->"0C83#"7FDK+<.Y?H9#M.H-I7(%3IJ'IW[FDX&'1F0$AI'0C-RE8
M(!Z(KSKD2<&L .;4X<B^.#TXV&P4TB611F'Q6G>9RQ\)!F6A\)JU!N&GT/*!
M<J)>+H615$LZQFFH-,%'[_$B3I& /AS('PR=ANP*NEDSS[C#US"D:.-Z6MD>
M9E%#1%DL?Z*+6QJ:ZAVP6&(H$B*8R?:B((BB<MP%Z@'A#TH.*-%%W!=0.C^1
MNFC,G>6!').%1T/F:<Y,^.M1!,YQ@$2T+6NUW 7E,85Z]*;04JW?MFP 9^SO
M'YF\O>_%!^\V$-[%10M&5(@9S>2F,-N$<JI=9"L5@Z;9>W-1C@KT*=9; W>I
MOV[<'Q?"$A3TL'-%5O/IVKD*QT_4VT\1/Y8_8E_/W53,F+3:IIMD96*!E=?N
MCRTK1[]5%:X0@ZM.HO/G-:![Z;!=MKNU^I@7]S#[_M+*$P[FV6,+@ZZF-]/U
MVNN6DS^BYPT_N&8X^ZJT!JSEAW/V&:Y>&8O3!@$+Y+9>RZU9Z2W8;9JY5/)5
MIKEVO[TD]DVLIH#)O,2H^1'CC_L63^[6Y60GFG\SDJ8MFQ2TJ<N@21=38A[)
MT\Z;NB\\X"NMP&,_2%.F]^$YI[G[N1E<OP&M^8)7V 'HB?V"O\BD!O)91>N:
MJ<<[PW+N;GA77=F,+V6''T7;D"/M0K84ZS+7FI/ !S%.5W*;0[)JE81&>MGF
M(?@G)9+SD/]K9^+#+=O!@JPYEST.[!%V53;<>5Z^]M!3ZF$*,Q=5_5HD5JY,
M-]UL3)B0#? C'>N#:;MM!RWC.Q"6D[3"_,,!@K(+K=SV0QZI@5J,9Y3S'Z!6
M+R:8I1JG8_3']2N#JH),5ZEM%//&>#@>P00T;!8F"+3A%K].^=]U"_TNNXQ#
M+*Y&T9I,5D$^AT,9+VI;Y#;TI78NB%S(<2M026FAH>AOYB+@/(UU\9Q)SD1!
MT)0;BORZ:*][X6V/C>4%F"U1X30VW:LI/R3[1N<R7&G%E^*['8GS(64YF.<.
M32R!1]/K*'G**)Q3S*7PK**0&Z8D%XOOCGB%O6E8<8!TPM*; (TOT)Z?<OTT
MN_V)X_*:9RB[D_IS7.A(B(7YJ+%CI9M 3FL\M:B$WR"V7>VBBK'R@0W4%E8&
M'WXC=DF*UA*C8[.406R;TFJK@4[97HR6YL$0"O^&X/GZRPO'KK8*7]G"KPE>
M!?> A@N_>;@?N13MO.?:><\QGP@9+[MUQZ;"0#6_*0TA*:RA[Y\?-D_.,L:3
M:QQ)O<45<GT]=9DM1&4_NS;93E#*J]2)VPG+IW,.K-1S9JP0,X<+*MF.<U:&
M6!=L%**7B:.FXYC+6,0%SN+=A;%FLR__YL)(SU'\N]W'[)R #*+XVXG'D)K&
MQ;>A48OMAAYCZ2H!OO?T7HCQ:./DPTJ[+S><*S>CF3>^IU=WY'K]J,OBR>/:
MI#<Y^69#(&!_MB+XBU^\Y!&+VV?-1GZWC)2XW,U1TUZ_=6"1N#X1L9ZV=L[V
MQ*EA<4BDYS>#S=)!:?GA5\%'$X0%GL+G5,U?A,E!8[G;=;Z_R?A=0 E[''S5
MWD A6 4WTT_7#>C;>U64<QDI6A:EU2>FRF/<TF/4KV71!(YGX@ "D6N7\<I%
MFL%=AM0@WA4L,]N1,]C<26;HN(I_UW%."YDL_3O/.6N)$M3BKI?;^,0M$"N]
M[O1=ZD2Y7YY$KX1]^IBA:2+?M"J]FJ%R% %&"<\NA;],(=8 E8KBYA,Y9A-[
M2.)+SGW X^P['X: JL[6^T>:-E/B'*;TD,P8Z<IM81G6]2ZX\CRN;3Q=IH/-
MI[).>'S!<]E:3!-=[ZV2DZT1X_5K.U3AT/[=Q-+5G<LT?GUZF2"1MQ.?ESS6
M<BIFWV?D4UZ(F<3[B@C2AY^WC@^.O+)\'/)A\!.<$G1.@A#.]UBJ'#I!Z2F-
M+9+@-@GZ)-JYK.GP:G 2,R<IY1*(U:] @JB5>2@O")6TI3&_G,7665':3M59
MA=E2/RM\*Q>_VU!T+ =E6777;8!73FDA6[;4)!@XV/;:<P@P&*J1,;,IG8$Y
M<)DX'G"_Y;G1?4D!8B-<X52FMROGK:AQ(8[;,@A"7*JN.6$OY\,[=%48QPPK
M'<-!=CJ=$*I,00ZW-&T22/>L+M \LIIC/EKD&T=[X/Z'86EFY$+QNTCMW:YR
MQDK*93;DP5O3*%N'C>GNDFIO/Y^]VZ_39#D' A@U0>-F7^PKY.C0"PE5_NW=
M0<N*C6^I16)?S>"Y9O#T92Y _;LTHGWWHX[76YI$OZ_4>,1])2-EI @V_ZRM
M+V4PNTXL^F7^A? L+1D&*LW65:M+L7)YJ_<7=FMGN4=>A?-IW&6O5W0Q.;G^
MW/-8N:)+M$#H2X$IEC5M"%LB9$FOKS(#$E+^-;4P]'3&GZS*=#>H*6E*&U57
MYW2+DI@4:&$Y#6L1RHK/6ZT 12F!1E4NL/Y'XCGK9[1TEA7H2/K5(5GWD"S_
MO=3B/.$PB\)!E'\[(719G1.\<T;^FSU4*J:/BU"9RG& S7;^W3@@\^YWX\#(
M^H9H5&ZC4ND'_]CY: =)L9R1ZP6GUW)FRLOZ+PI0H>K??'Q!N/73?NK^]B[J
M\U!0"_,R,U?V0W-=WXF4W*M";J\-./^G_$BNM10[9OM7H>;_U ]*7)=>EFM(
MY00@/NR_HDMN'.NQ\^42>CU_,,*YK%9"FR+H[V59RS-5?K>ZQS@NII)M@J)9
M>JC*E/OJKADNR-QG.A#(*!+2: 7U>*W0I09P]TBXN'7AR',!BK= +:DZ8S[O
MUGR*.8]AAI.R&*RO80('\-Y)!8Q+'>2_?^;0Y%VP6!WH.'U]V JD\#%K8 KW
M7=U#SC-/>/]*W:/B+%OLUI=M _!D==(8W61>;5-M<KX4TXW&ERDDTQ\I )/:
M[V?$YM*1^\D 'NYXFZEG)F"8E_DH>1K5[]$34U8Y&N#BK/@SK_2=O&<(MBEV
M%R5?Z$B5OO7=TJ.0$[C^RD4WL=!>+BZL,QCQE:)^)^]9E&297_WI7Q;X@6N$
M@+R>-R0+//C(RN]B0?/3<<5C/8=D(T\Y_[L [^%6G7VNRV%2Q6.]\%&?+JY[
MOUQF?*UNIB)(B>[G4<3HO.1 *%_8F]"#WJ.CB!1="U+D*$]P#ZKGK!I@(([E
M]Z.(>..%LYQN><*^8(>VZ*,#* _9K)]AFS\<COQ/F@M%CQ+IME[NML\M8'3M
M8OISF.WE;F_4)]YYXIP$^!'GA&GN*&YS&Q.D@2KG4Q/LCY/_D_^)CP:B1W1&
MM4?I[<87TJTBKK,2#\Y3PS]#EN]2^SG>T,U$>/S)*>9E)N(%YX!R.;%&$>DP
M"*A%JC$["5G,1)#Z($3_0Q_[ZP%'&4*<20=>\"3\T2G<XQW([CH?;3C[[YY#
M?7G\9C].B61IO1+)L\DP6V>4*'9&>(NDP!5<Z67/C+' 0L;X["A+19S0=3%D
M&75(LBA79EH!6ZUGE^MB96VUNSE(=:J*M84EBO40S]&0SJY22'&4[TGJU RS
M=TR3,'X\)5K?/\KU]+%(@C##%@%D#42K:!N)9,V>(0C9&-MJH70;HE@N-L1,
MWO&DX2B3*'H&K"H^+V"KW4%E;?:%0Z*8UAHF&TVJ0R2*.EXD999$F*PGO4B1
MO0;>I0P-H6A$Z\O<<67B_DD5$J%:AWR.=#W-R$00ANC6(=F8K<WF&>\+Z+#[
M"GPKM-.,%C42\:?V%DFFLH;)X%G1*B=.B=QE14/AI#I$HC2="$+72(1![;3B
M1*Q'_+-%7>F/2;HRT?+;:L?\H@I^VJ?XJI.M5J=V'3*1;M'%H)J5$J&?\/__
ML1#G4N=H'KWU83JO]&]ZL"47Q9D3N,GM"$+DK-H^9VJJBM[)V&IS5!4[TQJ)
M7(N=A &8V6"">"\"MY/3&#=,L^DNHN\757!R@A!$LR[F=KLK,U6X*_,])@(O
M (B&^B>X,DD(5Q5U"]IIQDF]U'I_OB&*UOP7PS!4%<,1XB+7:-E@)\1%LCI(
M=130^H@NM/Z7G+H8CJR&F".,CQBR)IY>1J)8"]&(L(%_1%P*)8XD',[^6A;.
M)N)LJQU/'4]5ZTP"^6@D,(&CX0/A; XR58!9%+$3*FM&?SP0X>!_!#)>"C)D
MHY-->S1^D13HQU*UAJ-90=@$D&8%6 7H..T#V']$',HKJB?+3#CI]F[2K+ Q
M.G43 7!N2MX;(9(#)@%FB)=HAMOH=' 0468@=H<PHFJ>/0( X1" J8D'<]X3
M"2#!ETTDSO,(,:J:>1)B1C8ZT;Q3.MLA!-"%)L:;X\36HXD(U&35Q+/)$1F
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M17JO:C3G"EST7'@K_$:EWR<YH!MIBJTP#FMDMB][!;WKG>KOW #J4LZ2Z%"
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MFTSXH.2X[/L)E[Y_NZI^73Q]K)*ETHSA#FM;?^9SXW\"<EH-XA[FJ[;YR\K
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MT;$'JT\P!"=DG=-G%O*QPC&A4;+^Z>P7O)S+[RN5=%#[S$<Z\AYMC)&(/1'
MCYEU+^G,WVZCA>7=/)G<N/Z#K& Y[,3'+JC4QE+]UZ%'Z^HGO?Y8>(("=',S
M95"*]($\^YQJ?+S,K63(H&0LK3+9XX'N?M$VM"9YJKK@Y.E7ZWNZDOE#DDEO
M[H07\SS$&J9+*L+ZM)"&+#>7U.A"EG4EBIY%]KI%^!].77+/2?(/M*? 83"F
M1:KR2@E<2/"-_0;ZH:F3DTE;E2-[K^LKYJAC%VF\@S$EJ!S*#OIX3;/5*\@G
M<Y&VJI[=%\I<-?I:IMB.VE2EVZ2L"?P@$YXV_Q9XHWW4R^1<>20N5"[O&$.B
MO4:)^MQ7!J>^Y/CU5 J4WH31:<(3(>K25=_USG/=_5= -.)U*()BXQ32.$%9
M$>OW32,+I]DG[Z0JPY+$A4RZ>O-XZE;]7*O5\0GKT@;.^85!O0LGHORL3.S5
MO9@M])2J!9D<TI%#]CL* JDX&]J;.P&P"L\62'/?!^\9O'!4]\5J] ,6FF?"
MU2Y^8]@N$$'/:-_Y1?/W.O8:R1["E$8E88:OPE8O9!.6[G0B]?!-/P_*DV"'
MW<@I%+T[=L=L$CP=>?+DR["M ,QFU\F0 PTA  W-10&3SB'.]?>.A?^!G'Z+
MZ-.H#HE^5*)&ZVU-%]3%[%<#=CD^'?QX6=LV^ G;;_P767E72[N>RS8&) [L
MH<O89IUD"$V2>LN!F; [(K6ZUHF$4S 1XC[8Z-,MKV_'DS8NQZUJ[J&FDASW
MYZ86G@?@=[YOY12%YXRU=+Y"]9M29UW,$I>;/19&'^]T4]N=<SUSU[>/WVA^
M9 3S-BH-5JRC*[25!'+D"#.AX_NB:YZ<E<,OU_4%^@TVM>43,336E-A)M^S;
M8T[(2%"P<2S"':%AH;<I[?TF0#^4?E)L98]#?/E*;J<CP;^?3_BHU9(3M'I!
MD]PS7Y.N3WE &'+\B!0_U.R,,<8DOC<I$EN4BCIU]$L ['Y!ZN[->W'W'<+!
MTXT)\N!A:'N1?;Z+WSM5VF[J@;2W5JF2U)6'%PL%4E3%92P\'!]=L5U-KN+&
M08<J1'NUGY:E:Q\+L_'VJ$NW<HYWRPCM/7T]?7^N;*&)-A*P5*+S>S:_9Z?U
MN*H[QK]!?&AW77WE]YK705M;<^=JRNE^W0^?:H.6Q^307P@F&5.%X<?9Y:1>
M&<?E7O+]!LO<BI]&9^"O<IIAJC1'F;$0PH;L^9-Q7G?U0ZC6@OHU)C11=$7,
M(U;-ZH[[F7-?&0,2K\U/J""W=[U/%CQ.<KDM@AKV4Y64<GD&']E[]87F!]FQ
MP^W+[M#XBN53% Q]M^#^(<(KIVP_X7;Z3NN+5,\C-*/?09@ABW8*[A4%1;F)
M#\<13>'\TQ''@CU+_JZ*8V4,=Y*%RJLGP^4L\U89"H500I_W8NX/8[^Q)VR\
MI\@WTM>UE T*9E\X/'R6P0 E?[A_--)9]YPW.]S,&-H)>H.C7'Q,ST5XJ9F5
M*6B4MZ69[C&R*(%-,$H G9S8(51N%["2]$)=7?2,X)OWL"'1*^BJY,BI,3:&
MPCM](4>A%.=F[TN<3FMJEI>1;K"X=(<Z\04J6:%VHO/BH]/SQ\>V-C87>PCV
M>AIF' +0ZY <<J9#I0-'ZM@<TJRL/Z3I//Y.E7[8!F*8K+CV-T]V(P'P9/1^
M?SR9N+*=R;$E32$WJ,.9Z\JWY<HD9T9DG'R3C2Z5""/A3 A-:*>/[@G*THG$
MHILIX+VCDH_GGV4D3UKKARF[O=)(LWV/S++J?Q".X"6F Z_/Q+5LM<9><T@
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MC=;DVJVT EMDSQ[/Q*]%4)SWQ[32_L[4[MX$=WUO>?ZYOC+H( \[UN;K1Y'
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MAP#VZ)#UF6NQLY>G)3SEUKN(R /L,0#HI<< ';0<BWW"!7YT+DV=B#H1CDZ
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MO'TSDG@PSU$7H_3N[Z&>_YM;P16M%/O_ZU3\.[=7F-K;A,_PUN3/QO"N7;B
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M$,A,'YIPP/:QO49!07.)<(=]R1MV64\,/?9=I6E^BXDE *'R4&TMFWB"XP?
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M&D\4I&Q*?TDY^BO7\;%W][Q*R/2R<-QZ)+$RD=Y!LII#2M3,?!\JY4TK5^L
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M?E4=4C6R05_$*03&%VE*%"&07V:"<LD"6+/AIGO[5%P3UCJX*^C?XM3-HDQ
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M_Y.$0I*?H@?4RCOW";!5/#^MPP$5C@'*KT5%$F@L6:8I!P'=H:@R;P"A2CZ
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MP.5HX3.KF' _ECBTL7\-K[.3R,>[9.8D\B\7]XQ8-J$U;LD8B0S7]M\L"!\
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M\6^_VY]'#EJ=6I1?GA5D-0SJ1YN,R[^'*MR8K-6A;OPRTBG#$ZQTY@;-ZMG
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M"\EX%&,UQ-]"M*\/295&_Y^XX_O3,!Z2&<!H,+7#D^["PLS(#,AKZ(91Z06
M&:,=;[7<+Y\'LO]AE/[[;'='*"2OI>Z,@^TAEJTNJT(\R('3GK'6V),#MH]
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M!G\AE,)7GK'C;*T']QRS!T_BC@?<SFW&8X>-BO:D\_V>_:L2&1@='MKHW[D
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M2EIJ]L@YH.2=YSOZ+F@SX?TJ'3\MX65"F>Q5LQCL<=>D K6TXH\9!"&=LZN
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ML<'3!89XAC0:(IC5LZE5G3#9HRZ_&\9!,DL1#8L5-;T^Q@FBE.VJ2LSP8MQ
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M^6+<:[;%Q:HF$N\ZB9'PVS]873_Q,=.+S9)H^%%1A>)'S]+,/JS4UF#%GWQ
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MGF12S 3<;\.I7=2TW_'F(\3O($3U0#DMF3:%D:P=B]OGXV?5H1!.9<KX<
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M)O SI*;B!D6O\[:BV;>IB>U*Z6)$%2"8(=T4>/1A\G'NTZ>832AFGVS#OO!
M+(&+7K<YN]-4LB*3R%["V)NKB"4P[KAT)9J6A?(%M^;1L'\1+8TR-=6CBE@Z
MHBNCO^)=N:P$3B)2EO .8*>-O*)Y50_?UILI5( 0[4SX5T[B"GZ=A)H[MMP/
MB6J:;[1Y"(+H$ZN2,EGZ-?O"B1['3[XIJ2]N8+O'JIN/U<@Q%1UOPF;94=[J
M5'<:UUKVXB$S'>.X0GHV4>Z1 >&A89D2#1GMSRV[5=$1]2"6?1ZK$'#>'JW2
M.(P,=S]:<#M"CG:D,\GB15140_9IM_@E/',:EEF"IPNU@N!!B43OM?SG]9T#
MG%WVU;;2P/0[(+/P,OR'>/MUC8T@2@T<"\9E.H8M,A^3R,^Z)Q+/<"BP>A"0
M"!$$(T!'&!(U6(>4@C@RS*+^>#>S7VK,>B>>?M@C_.VD:](+S-$ JR;\*MF8
MNR8LHBY4\#9L GD*CJ!< $+<^6_/5V3Z_),JB:F9*C4%1O\6-=S5])*"^MWF
M8[([ (MAO>=7;41/CZ#C8T*#'W2.Z7DL(+ARY'+RUSU\"=BC=U'KWPRGWJX4
M>Y' EJC>T\X:O1I5XC^,BI(:)IR!&\9,+A/T4TKL!>\N<QF)0E:F*3R'Y.6R
M>!H$QM+Y8#A_)NTCG%G%%V-V-L/8%F>W<#\PB'XGT)U#LQ?,X"?K(HY4*B$-
M5 J)6+AD2I@_3+.'/!H-X[C$_/J]K)P97S&DO>;7%@WYF'(DD-TM(6<" T6K
M2>Y'D>=.8N?[&HA'KO7XG-0YQ1*:)9HE*I2-C['ZF0!@0MQTFLC(.G@%][!'
M*O\8(2D*I,"236=?93?X+4%WN+'U00 C)+8;$CML-;B]IUW8.L"A:!"FQ@#Y
MP'A1GNT[JFO:C^'P!3^2M<P@]MB)4HZMZHM."3I@ R,BE+"<!(.3,\#T8=@:
MDU>13YM_:@W% EGGYC1I;@)M^D45X NC?HV^ W1^=IR<_0=)ZXK%4V4-[$/C
M\\^_EC@?.64;I3AF#<4H]<$M7Q4J\;NU!$^+*/3>VQ6:&GYFA2>:_M4!2Q^:
MX2.(N<$JM5O'^8A/%52A-P"8J4P#?%BOJ"*CG^A(A5^&DA!&5R%;* B"P%CR
M7R.PY%'.A%_?PW(=K%SPQ90/'40)GA[,Q\JR%:_R%T6V$L3Z/)\$?5\#^MH$
M"K4^#)8?I<]_[&FVG18+:JZA4TD4X1$2Y@BOEZ_1.SV:WN=^3%A0BA7QG GW
MP%C@Q_S,"_$938*6QUC$"(-TJL=#&Y3:;GEP*I?V53J#(Z)3:>Z,(?W' 6EL
MV :3,/HH?4<AE^P71RRK.(7<UEFYO):1I;AKQ-A*+2K/5\B<-03?%SALOT^W
M*R),L');H3ZF"7$7-=QQ,G).&V*F9%F%T<=KA=._UL9=PE&+FZ#]6I;294>@
MMR=-G:2-0G0Z\-&MVLAG>P(\@3$XL83$85@>%L&B]S  .\$F^)Q:3(H[G=^2
M0:ALC$P9WXLC;K K5<4-N?#.X@?"0.U"28.JM3-'NX>U.YFUF5XY^X_CR093
MQ@[Q#[5V-[ Y9YGP. .Y6&S5O]E-9T1R.2#_!&#L#NL#O7NU4/#SOM"X4/EK
MC3P;$A9(1KQR^0='GA70UY+PMH)"G(X.V\%;*W"][O>N1[Z&',3\]!^+_=8R
MJNVJ1^A"Y0D+7$+N -%8R**3<=HGG]<B!48)/MVZ4R;2#\5L!D5C17?;ES/?
M(7<,P6U@D2+<Q74LK6)U%@QCE262\.?Z_C]\6?B;2N) 2H3S0UZ*%+%\,,CD
M/.T;83TLA9,EG%!X2+=4[+_00@>?;S7V[H#/H_\1>?0:<?M(DKK.=>K!F5=9
M3B%KD/9TAC3A# >9M7*_7/8-@M$".W>G1ELU&5OO@.!S*W?*0 7)AF>W',=E
M88O/T&01I.U1R2*WIK7@0EPEEF?)ZO/-O9MU])>DW]4+PJ?#J_-I2B^;O?1Q
M3K.2-&RP&:.U!S4![8(@10NYB['DGIDMSU2'R<+V PJ?P;_*?REAQFL<?"%>
M*A\98T50.=C5Y0OWU)_< 2[HE0G':_"?H_3SP<V2RH.\^#'=ZMG(+FDA[R2G
M'P>S=7**I:S>:$3.+O^JZ.[>$XMX]G<E,<0'@B#F,EGE?:+])X8C4<(#9M@6
M=!+KGVLLXC!DC7EP18/QIQ(4=D2"\KKF7O!8XAZ$W3^I#OGX0A>K_M[*I<B_
M>,N:!W^RASO@@<A_',S_2D9F.N!O1B>K U,^8*MJ75](BNP]^+D2B)8<7Y?]
MN+^7N-!1]^=L^P;!*'[9T- OZ5B-2&M"DW.)SNPL_83^W6YYN7-H:=\[34A0
MM+"4RM0>FQ!408$9$_F_TMV[I]T^(4U7*$P#FXB,T/L *+$BZ'7G;^P%-2?O
M!>_P] )P,OP\A!Q0X I@?TO)_=+"K9U[;"CGLG/P9]_DWQ!GUW3DS1P3U=P!
MYT^O_%.>RC_(0MKFPG%RJ>L3[0>VO1UU%0MQ3F:"XG<J]R\>\"AM>1)'@8]*
M<5C+,+OV8V^>V!YME28]X4#4K( 9HWF'M]KV7LN>[MZ^N/?NS=X-_;^6Y&.]
M68=</W?MT[O3M_\>;8Q=>6.WJ/"]H\:%V7<%W4#:\OU@(6+IZM*YU^7F1F1=
M]/5MYO\,_/\X<$!&I/H+_=OXOM5_7AW_>PVLI/ECMV_L1N',,E4,SALG_[R:
M_O,.')NCT[T7VB[]R_B?0IU_\H'U/*H)G:-I3K-<GIC(3H>U3I;'?.X#&3',
M&O\^+.<G%VJ7FRO)AE)4(>C@;"QBSOII/JDJPNH.$<1E;^/4$](M")68O)0D
M9E4>B^MQZM&FBFFITG1?=0=;G;PA0FJ.ZOCKA4RG>G-TFR1"$*YTXN&"&<-V
M[%N_/M7H>!MO"T=@W@Y_K]GDR.(52ZQ=<^>S]C*#T??VTH@XM3_CN:@>Z5W#
MG4$FYY-T$5:+Z6:/6ZTIONA7M*'I1Q72]LTW&F;<K%/=])!BEI3*5-LDZ.GY
M*'0J/ QCB&&17[\Y?/_QG0+2$-FIAYV>)2M-IF&%3AF;*)6?1R4PTN+1>"$Z
ME:J&],0XV?O4UMT:C+V5&N/&$K@\T(Y$YNQ1,J'"R"1?!5SO-;J&9?GUY4CM
M^#R;^6\S0D$/AOJ-D P$[DL@@P/"&3O4=MI]K=#KH-XBT90@(,DM IIY\,/I
MD]Z^IET2MD@I/#U&>BH8C[0 R0<UQ4J:W[3Q476? 5.Y,VCBV9.WQ(2V[M5:
MTJ;^I?YLMIZBK1/A8[F>>S3*'"P;XKZQJ,V]'\VUZ'N&03@K=1JP86$O][>I
M13,.C0SZTV':+*LJF0.0^7IKURFCEXI 7KJ^MB@E* OJT.^N1"I@%6N29M;F
M:,V%P:ZVB!4[0I8;&4SH-I]4^3!4&,0(Z6PXC(WJ$KRB4NZ)# M7:.3\/@AT
M"A!^R9\=J+/'BGFN:[VB;1%>)W%I\FV6Z?G6NT",GF8DW%UYR2[V+"*BVM9C
MB"I4&#_7Y:\FO&SHLE-3\V/'[ZE;U=_HICP2\K*RI.5P!5^/VY<\W]R=+C5.
M^\N @@0L8?R6BH_5"SD6:[)X"N$T(808\=8._TJ9&]&:S%JEDJ2L:>>C(J7A
M0*>9UT+!'6 XXI>V^W36\_ZCTMB&C/.D+;Z7*JE\_5QF;K@9=$)]/W$6%<_G
M<V9OZ!:4V'R+J"C20378]W]=<BLZS$C'/V,H$0!3VTSZ'G_1$J1,JBSC#-%&
M?E!+\JZ[+BMKP 9[X9+Z+J[\Q<P0OQO\\UUMN7&-=1IQRS\N?8K[[I-<OK#\
MO57\8S[[_YYP'<K\*XC5OT[YA7T#'K'+=AC7>L4/$ ]>@9.;G"CZK2I7Y$AO
M162/#)]KH1RVC65T:90E.@=E_+"4%QE5C)^*U<4:H7 Y*$H(^UP?=34&P[%\
M?C0OACFCSS2)033I6'DVH=3FV$%,QY!HW?(D(U3*''L_!2V32_?H]VA]%89"
M'A@_/XI2@3;81@*7OH;._V2@F%?O#2.)Y=2O(GV)*YY8<M=Y6A446@F:[$/3
M&I;>+=TZMO63MZI0X]TGC!C=<<O#%NA%)Z2O'Y*\0\F"BF3K(0CJH,\/5680
MX?$"-!Q'DP9U/M7I9WB8:N(2EAZ;Q@P3#41VE&3 ]YXYQFO0L)7(D>G_4B_Z
M"Y!T]0=C',[]SM3Y.9OL1B74IUBA!2=5=B?N(2MY1>C$1H6$S75NZ;*Q;G *
MQ'\CD1JL0K_$T)T1IJCBP.Q.9HX5A 30Q*+KB#+?%V<XGI\,ZLDTS]"^)==2
M#R-W:U^V?[RL\V-!!_W#WS#1J%2:JX3*(G.@1'U[50IV(U-I%"Z#9R\I)I<@
M!B>FMQ Z@]G':#%7>,M85TE2;5UZZY6$*+4*_++EZPF68QS<TU>1_-_WS80G
M(Y:I_SUAG]X#/%*W#_6BLD?RL9+)B1F8+T5IS$3[-H5<UEA$78(#E_X"S^WC
MNP$Y%YGSN/O1NM>'WW/L'0.TUN[9U3\X,GJ3C?S/RD"ND1J=QB^SOKW4^.:\
M[9F]]32[CNL0(L\Q/=/)#Q$/(P=%A@20L7JA?8@-\SG5*UCR/>]'Q?7X$E<^
M&#3.K:K,$YA&M>(YHNIHXWY70KQ3,+KLYF\XTO/U4ZCEFPR5@Z7'"^U<@LB]
M^F(9IJA&M]+96579R=X>+^IF+PK8)#NU$#%S=60A7>?O (.JV;'M@"(&>"ZX
M59VL/&*D%]' 96J?7Y-0R!$?$3SRM9.:"MJW<.F<HYVO,U1=HXMO45V*%>Y_
M&1(8D0TQGI B1A23/O3^^:OXOI\JO?[/PG>H9]SF(K5SWT.ML$A]UGH['1"B
M7 *E*7E[("IOXF\![YA)6-5Z,8ZEJT7D*H=+\TN2U,%-"=E0][2;=>CH)?*$
M?EFD_"?];X]WVN$[^6>IW!KKO*U<;]20MR]TT?WYVEO K.F H%]BI/I>$M0E
M!-RI7]"4U;^OAQ%N25A"_Y6\O1\[TW&3K9#N/,,=A*&7&J'.%@HB(T2(VMEM
M;@TZIG (LXLK:9:U%5J(=T^7;GF<.SQS&L!.I#0(CH,G8 BX"K:\KIXY,S2I
M4SD<4A6&VO'K=2;I)@. &,AXY_$3NYQH%X4HE+;)H30%  "M '8G42>W^?-*
MT*0RUNLX5%R5%<9JW>OR>D.4EB(9-$YK_AIJ1BEGPJP2!)"ZR%<;.I&2L9>X
M_ *F>@1M1IRVK=,L8V&2-BSW,UU['=9T^LEM1B8%5?(X>0T1S(LBSME#=1R$
M93/,RO(6;D&Y69H*G$'D(,2]_"+U$"X';^+/X>2J&@81B]':(TY-*G+<NF3J
M9#3!U:Z</D<;\DG5BXRR/KVW+7_U!WR<_/%T7[26]"L5\F1AY<G8]'5^]_U1
MIZ>+M7> A$ZI\6WO';"Y^PI#=3T'KZU$YWK_>_3]IAO\%;(<1/U/8HV,XO6%
M?ZS>ME!99E+SS](!3  P :@!'LQEG?BA;2;?X^DKKPO!UF+R/V"8Z.K<;>$Q
M@[H::P7W@\#IO]&<XQO2UVO3;Q*0:[PZ=T#[WKV)Y.Y7NM>QW^GU;XGN@,>J
M2-ESK1]#:<4GU,M43XNF?]=E2N4X"<$0V >].WKT!9<(4!+ TI\S<_ N&4=9
MOT1A)XDO;^PD&X(E[MB.IO%1M>1AYF$R=<,U9WM8N51\TN!L?I[_H]GGXT_-
M7TNJMF_V?OL7:_[.>;;R2O+YEL,7UQ:J $E7E9?[J\57^<C$.V#Z=*F"]>K<
MQSGI<_'$USKJ5XG_>^]/QX#.,<Y"QU\U0T;>Y-\UKV",[HXYC&UG!X<:49(/
M#V9[;H<USNK^D][_RO(3]FN"2X(&C^''CJE-\A+IHQ?LR8W&!K$7HF9%W94C
MDP6]>$9E)4.^=1%@T>G$'CLT/4=NN7X9CG>;'BP)8[POCR>1/* OUFF\)W.D
MTJI8I80$<;QL$#NBZ0K^+[:74ARW3L58CC*/7]N3'%^)XU@H)%1M!30 6G(Q
MK<GP2.3[1%NK06I;'"RTZ%KMC._U_H,J&-\V](@RDKNM,"*(GU10Y-\>1[6W
M_FM:LUSG SEVPP-PW-AM]3E5&SXE^Z2>EX^N6.>L>*]5[^0DB]VUJ%'] !JC
MAGBH7&N:@6*"UB2#Z::3VG&ER*7NS63\]NY\MAP9,D-[$2@MNQQ@S-09MCNC
M0.KGFI.U8$,%:X)SE[^*=F4>3=F.;1K?-XT$NL"P8%S1D*_[<W\_O6?H$6EA
M;0R)&%Q;J3 @\QE:PM8HF_K%B ;+^B[$3.^M&:M,HCO+8HV]QQR3A:[VTNJC
MXF"6P7?HH1ZN?,PDL1+"-H7EC(G._!BKZ=/I3X5JE(J&TEB+5/_8.>Y3G!Z1
MX5^A3X'7?YV;P#7'P! Q@WBIUD"5%>D[H.-V-)1A/*!.QH476X)+R+RYDPB]
MG.CWU+D\HP@#J9Y<F4V&4DH/(>-M-6KCVM/2*XA2 #H'H>:1"Z\\N!6YDPKB
MS?+2'IU0 C0("B1TI<7[*VVU,UA=_>,C P>R8B6)SQK@Z/7 7J>#5#KG4+VL
M=LX3<X*W9:;',2M>IJ\9<U&:>M)SZFM+Y,VLL"7JV]P#JF+9\=N'R#'JSP1\
M]O=I6TZL0X[HS%EO[6Y2+UWS/!HIU7F>$:YK>GDXYUFKM0?= 6]N,K&_V.Y-
MX'@KE>"8;?+/:OL19_*\8-5RM%TT&;()Q!0B<06OLZ!]!@JIA:/'^/KY5B.Z
MAZ_[[7RYWWW1Q^>8*2B3&0 26:#)C!Z!:^>2;4^51Y!?,8Y1;E3=DPNK! WP
M)4<)63"Q4;J38!2KAX7&\]=#XNLS3R1>?3OB:"KI&]2QCXSL+NCMBHSE\Y_]
MB7-[!QPY\=M8!AJ]N0QOYVJRXWXWRH_@D.-?Q AB4E\54Q;%:W;R(9C*%;#F
MU\X*#7!+SQV3%$2QZHOA+'*G#8>-;.LFN)&0D#::C&0TKA%BG]K(YPLF>Q6V
MUV%E2_21/,\)+3I$WT^M691Z'"PDD+U-![LB3E#J.!+/H?"3/:(3?DQLGF;'
M$$#Z]MZFT,BQ\<Z#JSN@J=:NVB72>U_S\5HCRH>W([C_TY<2F@I:M;&:O&?A
M;I$X;DN.-XI<I*63!!A!G*]0&0!R7'VG?<;S\4Q!'=DG4@0?Z5OZ$T':Y(XK
M+'O!&:H/IE[)':U :W(C )W[I,JI7<[G51/EV0T\F^H!,_NLLG_;U1TF\YL:
M@NPG4(;[^[FT=Q<*T&4",# ,? RC)E$(N2+^K[V+<_Y[9+K1& 5)3)"W-"9&
MT6?I]CN@TJG>@:H03*+W-N2/CP]7FN2.RQC1IA]8C=\MS?'I;J-3*++UDI*-
M"&D'8>.\Y8H=V&-Q%;^8S=/IQ!3  -(ZR/@SK%OF*F&Y@(2I;*U *F>=5:@E
M&K^'1&THRN[P=_'AD0[_;E8%.TTRF'NG*^IIMJ04[,.8[@BW9I E+8!09K"Q
M%OU^@66/_&""2UQ,$-0F&@Q.H"$AWMKN+E<W:P2[3;N'UT8EST)#J",2GG^R
M3BFHI4!%R>M:\GM16&+R()BZP C@T/CR=+IB-PN)I$D&U0[$T.3= ?T?Z$5T
MQ*-U>-8OGGS#95:"!!.'N&B*V$#'&%Z$E_M3A9P4A\WXV.DGP.ML.([564 D
MRM;0S!%S+#>")SK0&:/,Z7[55!8E A]*+9)\SQK[H>V$)Z:] MF@-V,A!?1]
MEUM8=C(:Y'1K^\HR$[]VUQKRG'Y:9=,FDRF+0Y.AF:&;Q\^K%DK_K-VN5#=X
M,(0<'M$5Q=MBY.<?<AE*,@,.!Y7&$<K@,8 500NTR/><DMJ[C"^0(8P9:PT/
M:Y#<0N+J::XQ_<H'Z?2)TQ*R[-HM^FSZC EE_*#%DB*7E3T6:_&+F=TB4D0)
MJ6 @],4-T^ [9;8("O5T+4PO<Y^KOR/0$9VI_S+6/-$J^K)?Y?WDJ#:D41/P
MAF)!3"/(B+FA2H)>N@.SC^(,I]G%9<3$%"U*%8Z#FBX7O^[,!(#K73>3NT6,
M7JE'S>@*-%0GBENFA(5X1890HSV:Y(Q>>I%0F.#< 07+ZDFN3ZU2+V.QD88@
M+"Y"AY"W,3*^=/+;^P>U2#8C%0# !0@06&X8ER$_G37V7_>H;MX!92L>TW\5
M9TMVM=_S>!#C(X"N!F@TVEY)XCVDBZC:D7S@J_Z,1"H).7,X?J7$E2O!/]J;
MJLWS68.?K#J'5(;\U'(B7F4PJ*4H$AI;>Y[3M_C"MO1;YB\[BR8V7EP*+DQ?
M@_5V'E),KP764X(KMG_)N!MKS//UCNEF[@#YIUG%5JF C3B,[)[58-VE/[XE
MRJ($]= F6 \QWHP+,;&A 2L7Z_"I/BOHSR0O6 O&6^L>9O5::;&[%6GX_6V1
M4* QU'&$G 1'3^E1S)'23/9E\\U!B[D4_(E+;0HAE E3&D)?6+O^2YN)-SGM
MB[9*2@33B5_VC+CN<82(!#_->R+#G8;3MUF@XP&<>J$'C7M_(8%&CS?WBUO3
MA@*>_=J?F_@SJ78@U@+J'9<J"0GF#@NY+Y,M/W6,E"0K[\"W>D/K+M^-_K<V
MJ=LN16M-HP\QH5KJY&];NNRS<7 AC >L8</O!J;T(+#G-'-':<XL2A.Y+@ V
MZE!8WN0"UTD:9LN%Q4E:#(],PFV&HD]GE#EEJO!]4Q'/#VBETA=OPO]KY/IW
M0>&*B*?-%>-GJL>(8L'V0TI?*Y@U?2>1Q";1@IWG&*[*#.6S\&0BJ)OJ9Q,W
M@V_+;MK^7-;*#.^5&-V9/CM\]2I.\12:S:\N8AS!17U5[(903;'8+<9-V>C
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MROL!]0T.J^[/'C:XDJR!:.>"8.T,&Q="3=V+ M*O3-.,-'33R')1^H\)\G<
M#="#N&!D%Q><<N+" "$CP[!@T:LKC/KH%O,DM?<<J4U6%#^:TR-9<#F,/? 0
M3)-"QH+:330H;<?G3VFS51#@ _@'P#GS"Q]39"?B>R+74NZSAO\74O+OGP4Z
MHGLE^U@6K*6F[.3UA9:&('783&EQ_Q8QG^%(4XU9CA7-R.\!ZG5[1^3%.'S%
M6GJCL7>HI=#.98#'&=JP6WT2R(X0Q27!R7_']"%&OGJI5<;\.]IG;&%$V.1G
MEC0G_^R*+]^H>W >QK@J]V<4VS,Q0;Q'#'@<ZM=+.EZ1Y$ P;B9#^T#) R[E
M]3:!M@#*?#R)2@F6794<PQHQ@3U[7(Z1)QP0BI1L[((/6'DS'K2:!C\%=:2-
ME*<Y<FOH!YM/_;?149GJ\=!44IG]?&50<J]=W&CU^:4MC]YN"]6L/$(:*VY8
M*MJV^F5A5WJQ$IB,D/X*!KG$J_R/%U?BD2GU&/Z9(XR?8Y$%7J5U-&<K$NSQ
M,DYOQ$J_L9=6NV>I#G]!()Y3C9U$7<A +#+61R???QHI%F[DB+L&8+FJ#PI,
MSO.#_>+ ,5I0OHD(++=@(1*!#%]N:1,\_WN^&$A>K%>>;H8^7V<9AG7'F,%Z
M^E8VSWNO9.)[C2.:K71CD=7H9^(48&UKJON<G"Y\U.;N  QD)I#*Z:%K'7,H
ME_TT+FA/@_ABJLDV(-%I>4$X1,_'@H =1,)?:V*M:B6:,0Y^QIE.\V)J.*\R
MP3(8(1<,"VG&HY(P+5$8.R\.\-L]46<3<U]?F@CS>[)6>/IFUK7)7"KQ8SR'
MO)B3UV=*:5'!$'?Z%<M4>H%W' [OT^L2K:EP-ZI'NB8D18:V!#G#^=6C2O'
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M'7H>B-)->VU4H^.=_&NF'I73%(:X^7F<:8*F&9520$YIW1ZP;PB #;7F8A\
M'!D>THBGH$#YA3CP!J8W!?6(R_L8\_3%16ED,086#3LW%/DJ@<900R]*'44
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M;9)?F;,U=IS)!P2;P:M]1*'S<)NA[<M4UG+"Y_YC.:-=(]NE.DURLRQ@M5Z
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MZ73%?VY)M(I-^MGA-J99%)6)Y8MP-@.%P_(NISBLQ;%*O>3B7\(SFNR2,]_
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M!X()/$1BGSL-TC+1"ZS*FM6OQHTWWSQ27)SY#1D@GXS2WP1D6A5XNXYUQ#P
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M'=:_1\C-Y!<36BE1M!'6C+KV]4\7CZ6, 7CR(C!2<\_4T\C!BH-@AI,;'8?
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M&_GUPW##R+)URL*-#+.NM1<;@9.[8[M9N\(Q&)K* HI.07$:O<P:"?I+"@<
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M+DM]H^9H-'<;HBVYZ ZW\26B^PUF^3C(Z/&3)6UNI.J7L<09ZYDLOE+<FF*
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M2G">6L/7]L0[/+A^K[O$&)V0#/-RPJBW]9!KAS'_<HYW020 9A( WP-@\5.
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M1[+\V,Q=6^._-]T9CARZ4A[;:]D<EE?9.FJ5CJ:)2@JZ[7%(#%8,9HI9O7!
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ML473I5B0Z%^AG^7PJ<5RG<4:0'M] GMTD*FQGH!<FBMW0SJ/!@ T#X!3#00
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M$S2H'I9/].R \7,DLF1] "@7M=$Q-0!EN5MTPF?!._Z.Z<;M7&]'_0OAPA-
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M_K=KOXX+V*Z<E^L\%E\G+BA_8!=7KBIM42]HD532,L&RW)";PLRK8\V333C
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MU"W.\<8LRRH'J]D43K+5BZ"!LK/$"IET54H?9B8$?:4ZGAUD&@Z&@N0FP3$
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M0.LSW4J,1=-&7?0T6J9VSF *0* L/%(?'VN399@63V:IV%M^,.RDP.8%.P*
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MAGO4YZZ=$1_NI1[X!8CK#ORL>^W[$]/N\/_][0V7W<8W(4\@W3NN-VBF]<B
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M:8-]$IS18!;9@,S(N0=YBXQF6XZTM<?ZYV4S%;#UH\J2!J#"9-!6K3^%C3?
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M0MB3M[]4:=&HK!NCC.)A4*$1"A_(GQNO-O1<)TRQ\8O-U,,^EK?>=EO M^T
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M[VS#ISU4'M;>_;'P.!AP-VGB90$MC.^XF;:+NHT.<6OG[>P(K\KUAC;CSE\
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MO>$93_ ]-I:S6N0SL1/?< [!]5OV.J)+QX/GE!T".Q8L'._A&*V-G1FJ(R1
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MZ0I)EH2,.TYEB:: )$M@(^_'_TV-2"L?OV3L.RMC*$=\)A8E3O+Z'0J,9 O
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MGTJ%-XCV[6T:&I,7R8V*8%("5/#P,D3=_K+,6JKO""*_0B[5/1?9;R#KZ"%
MIC-R6+.:_21#4JW[V:VPFS]P>#KP&N!;,1JL$!@Y@IIDI@*[?N)XW3/R]L2]
MJI[(\"_2TW&6C\AMOA+(6+OD:4RAGTK=Q+Z.@TU3XP_L I7>M<\U.51P?P])
M./AC9,#QF#S;P$.$*WJ6 3M>*&%JLZN2 Q_G3W,KIYA/K,?+RF<RC &<^ R&
M<6#7E>:A%M]X)[%(&+(T9ZBV5$KM(:SKEI%#BW(Z7TI1;E&Z/%%I/1<4O4S4
ME =8Q9X7>W$-6$1? \H: CY_M'QYF3*'K[3IY?V=>.AE/;TE[3M],MS2BN<
M-JUO_DVWRHZ],L-F4[F945AC;#WC&!BW8"'.1ZKIV0N%>)^QZ7[=]VGD:#E7
M[38!B9^)G<5C$F#WX'"=^<:_F=53 R\M0QFY=&SW7J1$/LG:)+D="RFF6HA4
MI5UIC^'B_HCGO=>]%QJT!,V2H/YH:8I[@K\_CC TBGH.4ZAD<3\Q0P*WF[R=
M>J4OZO>,C*8FEI[;)+CKJK<Q#.FE9RIC%L$BJ&4@D0^TFB1GL<*O:S')1.NV
MF4024\4+(S2I\$FPHFTT5?;_-"?S[.-.NY$7MSS8G?U _S5#E)9MUO,^FL2H
MH!JSXM&QJ7P18;":SG?%=PL?1W_2FA4'3HCYV F FTN+.)_E"UNN\:,+?-ZD
M57"0PH(@H9#01Y"82)9O*KD57HEVI76/[3?BI)Y(_LIE#464</?&"XU>?D=)
M:SAP.%T#<O/1A3*TKZ"&.+C=\HX63Q4^'KEXYPPRV=_\=EDJ.[XP<G!C5@V<
MY]*Z8T]]BW)*DHJ'AZ;?PT6LDAI9M5-92I\, EB P*0>^8L'?Q]@0J/X($V[
M^ PJU-%H#Y$$9N],B%QK#%((_%?5[/CV.L9T:$:[XQBGKZP@Z'CT3F@^IZ_K
M:41M$"958+^7O(;[M[*W"%7%,Y[5;N)\PAN/.6"$>?-;<MI_9EX45QG#(&/V
MR:CK.W*4/41)+!$8*4ZU_^6C(I+\YJ:[K% JKL%=M?*IL798TW!WNA=_NNMI
M0^E,"<]CQ[J:901NQBE ;/32<L%GY6X-NC:<IWR@7(<]/0^,=$>S9X=@260:
M8TR3I:73GLZ4F=0)[A-%AYYA>+^>F$W-76ABZ]+YUQOUT_0JG%!3?4L]L<DF
MQ7+)O08<;BWP[= SZL",]N"$\.0J%;^T AZNK*+U[?A*C;T+NP<Y 3E8.HD$
M!&A57APZ/I;=&JQG@+:+MH6_:T[O\JE[9WI-$?B'Z+%@LK4%V?)W+./8<,J;
ME?75K/Y1?/RWQ5;PRM:7)+_@OA=KG1V@$\KX"OPK$'^>:9C4(%536E2. #+)
M=&.W4*?6=S^+J9 I%BU43^0*Y8F4D:W;X*[OC]ZZ+DNM+R@4($J063)FZ<7,
M3*B:GE"J+K%4T#(6^'WAA61# K(P^&A*WH!RFE54::W8HUPH,2X>G!3=330J
M^J>%I0>FAJQIK]0JZNJX:DJHQGV,Q@,2:>=-(4*QYW8S-7<()OT=@G9:>>"0
MCK?5R>7O8.)8+G6-OHY\=8%]$AZ]MOX#:'OO>Y_T"H,%/>+1YS$GHLMI[D :
MC#ZH3%0]3TBO") J80RS^<C;*6_&23[Z.3/,OHWG,T?1CSW%>U3B(1XX0EAO
ML@OV5)N<&YT$CK4?I%EE51_G^R [G=ZXXAVL-.S_;0IB-WJ@O.E7$\DO/1K]
MTU94',>A]S*?41*AZ(/#@EAO]R>"@U:_1T_6?GH-*.VL?W&8O'$%-N$H9SH[
M+I W^CA[L.M'CM-G+T3%0LD\+B4!$*DQ&B\PV>E2H)=)GR6;P9X<;5>V_"8'
M7OC -6:LKL42!ZX[9P()_R1BMPW2Z%V-$K^MZ__I3P-<#5/G.]> 3Y4/3Y\T
M/<H31 RG"6U/Y1W5$[:BFL.FT<VO,SZ,V?H^195Y<.0@'H,]<#&TC[#+C?9)
MDS6C17T>Y*HG0Z"N+$4&?C8*$K,8%G(UI\JZV#UVK?8LZ/2<&X)8@ILY2 W&
M_J++TQIQ=_;.?)[%B/1TOI%97S&RFJ(+)(3]#+P4\+3E[V (CE2Q^ZU^OIZ)
M21?M1VR+,Q1_0G4$$6!^D/Z>'9J+-R2]=Z?^$UUWKH*U*IV?=LZ8PQ.VVDG=
M!4&U[J*(PBT5SK=.Y@S-K]T6F3YP!6%Q8,R\/<)SB5W SNB;V^^ 9NO1/-A\
MBXK#7O,VD\E9(*/-PAT:9WM#;R\NIV[FQM;9BDJ>^1?Z+I=%#QT,"^3-JTO1
MN\'QWWJ4<K$"#5/?VZ*196W'XR^<0YRY-L>Y)\ T<KI2'7(7-+-SSD6HAR:^
M6NI:.E(--!92[ $@A31;_=TA#6[UX.A%(QDIXZ7T]*HL!-8N486F--83"^I9
MWAT(*(><__8MU1F&K8KT@9Q$9674H/93YEAKBSK&A(S,%_]A3>=.VCD&SB<
MRM?/'V,*B+/O$LR#5A\!=QM#$>34T17N'T3CNM;<%]_Z1-0QOF'7N'7 M<DY
MI,,JP8I/M:;#W=>"WW7C (?UBW1HW^L3T8OB%]KA2;V,NN4+2I]&2GSM:OO
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M=KM.'\V27P-T([>(7TIW<YG(C:8#,[.2W6;>O4W13&M]^,9@[B4]S34 /YT
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MQAHW@.^!0::P>I )2CP/>V6"L_Y^QZ0GG%4-1R\\ZYCK"B[?[H[M%BE;U_@
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M^!LWZ2B)+N!.]"W@B3)4KD$% @ F:0?A[8BYM+Q1CSUE".L'QB3B=Z'G"<'
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MY_V?2XL3)2BL+6^DQ:YL(74[X&GWS79?S^X^S1Q_/G;%I9PF3MIP9QK.4MN
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M4+)+6(Z>?VUD9C.^^*-)-K(Q"',-Z3-0H#EJS[: +VJX(PX]4,MZXD*AQM!
M[PLB@^9V$V_/4KD&C&SSB]6QNFWQ6>$;?#TA-) DY$&&J->I^!Z>/0\R)#SZ
M)L&J1LCH1O!SN93 <N?##.LC"9>RXMB*])ICR)5NYM+19XIT,WWHZ'_L]U:U
MG55S,UP(O!&']U-EZ2OE&%=E0]HYL2;>B9V3.KJ->Q6B$G^$%: -\$?<9PCB
M#':\L71QC,)@AJ\!J1'3?9M+Q)<B^O(=OJY$^H#S;@PX'&'A6JD$YGN\%SE^
MN[#Y9BNUJD-6E9\JZ4 IAVK_>=>@)C&#@M F&B8>=I=R'(P:0L0PC$M<^+/6
M>*58I?JFZ[=03^@-&42TE/P8']QVR21A-!AFKE]Q&?5D#8FSE!AG'*THTB!T
M@+N81]Z)IC+AMR4%QPMYO$T*YLR>8&]NN$A2]9)4[MB]B\A[Z=$>90;<XKYF
M/I6QL$4TEQAR*TP.7RP48P B<OP1W7FRN_V=Q<]T](I\OZVT.ZY<]8Z@9)"8
M%-]*/,_,MPET0'.G7K6>+@0CX8XL1Q.F03*M5RQ4DT5R2?8&>T;GU%^<?!)7
MD[!#Y?*T55\C_$S,36>'#;$@?_[PZ[RU?67+V!3/ =_;6:Y0L72;)V(S(Y[L
MV&9T'BJ1)'ZX E4I6N6#"9#U&6!6?=CD^?<^<-&%4Q1Y^7Z-]AKX>_2:A,R:
MJ6"*X2;CRZ65-N(7'(/?GB)&_"OBCW(.;SA^I+VOLW$LRWG#Y;W;+5[R"F/J
M<4,*NH>;8CQ$2K+SFYV4(FT<#]T8$C!QE2'/)#"OJ[V*#$Q0!0VSDQ()PA)6
MF^90%7<:C4@_A<G]  E#BJWR!!BLV.4-.S^4Q7S0[@)2BB#XG]NAB >57I-N
M]2I[4#""-U&>R7%P>9+^4D6PF#^&]EY0KYYSLR#BJZD^*:L",Z<,MOWFV(.O
M*ZFA3=9+BR$5>C<F) ]C%/B1DM697[MR"K+*=DS(2/M8WX;*NEPX3X3/]KS[
M;'[MBE$2$1<IQRJIK!);_E+ILZ]IN")UC++Y5B66/"J3,T/-3/HNXX7 NY])
MGU5_3I/)*&B(]"#GWIVU$\?TQ\3+$M$-Z!Y3[U,EUE?$65X5"J=57Y_2E-5&
M<&<F[O6GA31=;U 3:PQA?E4W26U,UI,DW!>'4#M H'^"+.]T3E7HU0!VZ!P?
M>%M,$&JB7%Q1II-C/V]VD=BB=^/.[/\='4X- BSPLZ.4><_<Y9M1?.*Y<XI4
M/&G%]4QR"=!L!<?=?2U+;1@40ZO5<HDVB23\N DA;A66+*B_N[TX2MY*V4+.
MZ\+71#XSISNZH43H0J5:T>/;\.KHING8/MJD]5J1 36'L]'PKE9]M#.);V/M
M;/R/S;\4DDX-%F<94RRNG_BS'!?"2_:#9UEU-W<Z4'50.O23E]<@;]:/'%,'
M],_MR_1]>)T<.SVP_+P,F'5&*&<6A,8-1'8,=V32,.]EYR>W*RP?ZS>20VE(
M\0]RV>W+(EZH%XF*2=X5T>9AF#![XB-;IM&QPOS0-:B7I+2@OE&):M!MXIG(
M@_@>.F_9_,]#_[2NX/7I2GMZ0=;8._(8-LIW%;+#P2:1?>@N\\Y'$C<]+.&?
MJ$@\W0KP1A6Q+!WY25J7,[==5)5.[_UW[S%Z2O#W:-T!S*A%PPQ(*YIV&Y\@
MY-O!Y>88ODZ/7Z(R4#2"-_4ISDE18/K\-^;.VA]F -%:E/X0B-;U!'9]C'P9
MZ]XE"B!:!;4RY"TE-'B=9H!HA>RBH5<6'&R1)B^[R$\5BT&4NLB6-[*]+_U:
MWBW?''RAG&U<IOG@BA5#J3,=O+;W'KF6$$::3I&U,O^63%..4?&&Z(RFB\C,
M:PE5AU(1\0;Z\&BX;\(0O3K)/T7K M7?^HSGZDP#4]<,"0DP=1G8NX-5W$1)
M(X,E\1P"2(_H\"KO"SXN,C::B#O3249[=QQ\W7*N4NCHO5K;/^],J\FWN1CG
M[&#[3=W)T8T(M2<U@F'N)]@G3 Z;_DM3TL_[C>YQ'AI"-UNZZS"<E0G\(%)K
M0A"-$-'B2LUVJHQ.$WU,_W3."D&L$[V@-"4M?O!0Z#^ 7)0U;G$7E(^(0Y?W
MB7(QQ:;0BPHB%</@$DN.YBL+1X[85Y/"2^9^$\^')RG%%G'K9U$A4"VFTSEA
M"G-E^930/2@LK;;@\$Y@X/!VOI$1E#4^*':..<BKD0_.BF[=7;\L%@VO[1-U
MI8Y-0XC>SEV:I1+=$IW1<$^@SRJ$QD**V1$DL!O0?Y(]_]!DGP!NHI"K8IIM
M%W18B4^RP9G),L:7TI]C[8][3+N%VG1*=/03=7J?>>7Z7O]ZY:7&EN,AGNW@
M%L3D63';OOU2S]&]^BUXV4]0N^D7WYZ?H'X7B8JP]^%2(K0ZFZ:>K O92\3\
ML8>5OB)ZM2TL-#<2DEJ:GQ'#C15R;4V+' ,/J_'O+N:[LK)$=G+QL.D\=)5L
MY#:]F'C-P@I>=HR7FK'R2-1G5$0E;UF2AR?>_N=_:!P1.=[TUL/Z&(L$KM9;
MEXN<P&/]7,SRQ/-!&P+DD?6B_7$)_8>+[3-8SLS#+\1@7DX(!ES''7M_D<5]
M"Z$OF+TY?GCGKBKZ*:OP@-1BD9-S-#RN;\SE,]+7H53^R<:'QC0!&15,E! S
M1;UH=T-$IZ54.<C 1/=6'Z.#MC:E"RF!0[YU"M;H()K?99(B#"$Q/M*%"E@)
M0)7QU(N.).&0<8L-(\V/T^FM1J2QV_UMD:9'#_CK#O&L."1[LX]A-)^?Q AT
MTS++S$"1;DI_+[3*W]X1.W'P:/[C1]C;EL=NTTZ"=8=53)FFP*NMDR#7&7O
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M9!5N\_PU3G3_LJ'_3]G02V?I.GJ6KM9 NJI]\?L/%)MPO?\X7:99UF+!J+B
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MB* (8_A' "UUS#VW*I$4<*^]M2,GX<"?5]W.+<JX\!MFQE9G069>1B',08
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MT!,2>F4W?4?P;!>TV+1O.T*1G"/_4\Y([]<)P3M\4;/.$._^U6>\R8KR>)L
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M2:;'GLLXJ&8%9X2MB(QOM"T]N76^ZA8?TMO4MY#Q^28[55]P+AT9[ "&51&
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M!4O@J-2W.CY)"PHUHE&DH7-?2)3/9&1YNB>U$)&C&!O:V3\1/E!5*X6GF,4
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M4]!O29]@%@H8A=A;$@81;&NNY^QC!&^N@CUMB5"GV\=>DVH%#&T;:H2:@Z)
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MD1M43^7.P<M5LL%UD]%*41EZ/92XP*H*7%>EKRV,FT1M/*FDW5>]RY5)[(G
MSA*6)MN,):"33FH3KQMO.Y@X+9DYFY>7#Y]3A*AW)*$XV;6.(K4_OSR\>6D9
MUZ#;KQT&?,6Y9%!-D"<>MF6U'2Q%C:HF#:Y[$MW28I(T3Z]6PI^#MF(FR.CM
ML0%CF7Z&R:L<(X-:;J#X,;?>@;*@&_4M"B&L$06V[\&K_C-UO %.Y/D 2'T!
M+Z>/0G$=YOHPFV9&C?2"*SXSIK%$R"0$-L.5X+[3[7(9K15*5W;PYG_&*Q\
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M(W3L+)''87'7\.+W(L0,/^,_^\LHSSIC);X8[ !VM5DQ3R6D0M-]8L*EY&>
MI9QEFJB1_:>454)T:MV.N- !"C][[W:N:S-V]2,<KS2 ?;Q+/K<^7O:+0GOG
MA$O&X[E6S4?_W8FC8A]1]OZC4P\E[EH'\@;J).KJS7LKGU-[A']T04 O%Y1E
M5<B@Q<F?O&0D,E9.5,#]5&-<(M"&?4!=Z"#/-VM09(A<@_(I0:ZR,8I?RAP<
MT:1@FFM(+C8%KYLTV8^?5-\E DP_IFSVK/0)E(/KLW\,ZC*,WZTQH_)D\J>/
M$J@+!F]E2N\S*=R9=\FQVF M(4WF;&ZWLW=!'6R+8Y O3V LS7&(D:A%VMH=
MW6/.V"6&U[?.8+%@6\?H4M&:*IR1DG%[C3S^PTB;64+NSA4BE(\)KRF<X7 ?
M_=J<6=L9[P' _[AI^-HUPRPWC;F_;LHT4!)##SV"B]6,--VS,)>R0/H^]X>)
MK::TC5_P@G!IY989;@YJ"BITBDSQ<JBO#Q=!*JR4-@Q>+*+;#5Z+'POQ9BG:
M,?SV=2^T=0RB!X*2;)1IV7L(7"]-"KSQ/Z,Z%[8H&>T(TV*5!V=B6G5.'350
M;3= EU\<\-@AS"*N+^R?(ZLV3A)V 2&D9("H63HWSX+IRB&%A 5%FNYAJ?'.
M$8UL DX&'CGNOYZ8]8;_@[WWC(JJ_]8$3T&1@^1<@H @F2(5%**@1"4GB4J0
M DJH0B0)"D64+$$0+($BYYQSSD%R+**@Y& @"$+K^^^>Z7M[[LSJU;-Z[H=9
MY^,^ZZQ]SMG[V>G9ZU>LTV&N/F$W=_9>[![NQG-60<58\#(Q-VR-^TQS&$I0
M$><K$<M?09K*?N*[<'\COH,I_6AAB4DD/D^W!NM/4D+*4TF/*+6,,+)]"=>9
MK1;.-G[@G*7([=D52!*D5)ZW_MZ6-^7/]1OG&YGFL\_V-_VL-RBYI-T6XBD?
M[.L*ZN/Q(%Y=XEED-K&?I-9/9CXH9(F> Z.?M#I],KU;ZO1I$-9Z LQC=4MY
M6!(T6&RU^>$\;M3GWE/Y=F].O96L6UGB9OSK1!O0M]E$DLX,_@\G2__6OTJA
M?_9\I;I<X$;(9J73Q0+SC><\[,-=!%G[6[&PT-LT6^HJ_+HK*+(8VP"EJ+U_
MT8+VB396)G*@2J>:LADPS\\!YS*?!N4LFF6I@HZP&G$P9F5TH'R,D)UE;#L>
MQH+G4>(@WJ'< 03#G^FZL)=35ZGOH5_W_HW$)]2V:[DMTZ4S3T!.@G9("5GY
MD/V^4>^>'9N"S 0WA? (+MIFK]3RL&KJ1B^J?\89YP$YHP6#@^((;E5AH1O&
M4F%<L:W</25V_6!\94$3X'#]\G<\W]!P0CX/F00H#(QV"&1/L;8K"J R<UUT
M44_MBY[!R_^'D>Z?1N$)Q<_\TX>3#]JNJT970OH#&-S[3T#RB9F)!L5:)FE?
M8PFK*N=J,XILW// FQ^=2<J<-PT3TL0S( E*CHM=7<470(R48H1K,E>7K(JN
M,IV;SY>[1"&VMS-*GI>,4J:,8O# HJWO94S->B6K[6;OF5()MOJ!?R>]=8V,
M+H%_P("44B,->PR*1W&)QK=M9JBO_T8@,Y.SK+T+")P"PTCUR6FE*5ED=Q5Q
M+]:+/Z1ML-7>JN2;S.PW"J3J@=^AP+"A1I79@X\S UQ<M^ASH'_,4?=T[X#B
MT6G$ 19Q1W?6SJ*C[CG<UA)W3'7\0^N]6H+0B]O!*;\=;I:N4#2[IP9[ZYD:
M'UK%P,9P[&^!":] 9+)J*Z&%9WNSSE/:N>I_."0ZT4MGM7N612!-V03S<.;G
M2:\$\&S<HKR+_>O?ND;9I /\E(5\CI$_MCZ8*RL#7/$=JH7"J!1G@JW*J?EJ
M@G KFJPVYTLFGB.5KT'JM3<K*RJ547VYT#;&YED9Y ]=@Q$!;BMBJBP;GLC<
M-R%<LYFA[KRT'5*S_]XM^,PP'TJL/'6 <>V5VHR1RG=*%^,L:9OG-4,_XW\=
M%SZN\-8>S]LH2PHB/A2+@1^:>P RK!R+0-(0H.[.[S40RJ]8]_.@HL6"-J&
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M,23P]=&?A&B(EF!#+UWU\/RKQHXB:VJ%W^.YM$2T[Z2)A8KA87 >9$GW]&Y
M1\I-$=U-0$/!2DR&TC$<Z0?![,;P1D\>4!BS)N9TY)!V:$3*YM@]>H5>@+YQ
M;4S;HK=+-SI$!)\B6,W$,%Z#)[71 7,V"3%H9*W#XKR-E[#CE'XU0SM8B20(
MPF01;ZS9S*/!S*[L (X8"'/@T=ZJU=BX M*_U["65[GNB\<8ZSV]?EUW4]S-
M+-NB4FC"JC8?K$U#M;8W>.KU7[D5_P-L/5G@5.OUY(PB.1(;@Z-JI.E4UQ])
MSL(\]C87KJ>":%@PZ;Z"% U=79P!3J9APIIQ;O'6OQ3NOO9.#L;?:EE56$
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M<(.8[S;0!JE3**WS>'_ =$A?J'/RX I(\K,2?&6]\A9Y[9_YR['M69K?/M/
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M-?BT_#S_Q7<%.)Y5"I8G%OI0/I!F.S9Q)'2S=F16&D-Z4V=LUCFP$2T='MM
M^4=_6$]___#<>FW?NCOG0KYE]/M\GZVL5R'XI2!,IF#-&:\_0P.U))PGTB+4
MJUJ2@G!? 5X+M^S,7"=+]8*U,Y8**8!]2B&"33:%E#Y*=;[JA^']=^X5#[A\
MY'7D,S:DY7-)0W@L'WBWD/]T\,6DI93N$C]3F[CV9'CB"HB=.T['1DIN3GF-
MO0G%.S927RPRY6:&-D@YL"DDG=)NOF)I^HJ^5G]G]/M$X-:;"/HO>4>9J^X'
MH?BW#M)2S]FUHTBT*N)#7K.]9Q(_8HY@MEZ*R)S#!UE%F^4DI4$-(F C%Z]8
M\<?/G"]/"E=*__7WK@"D&8,2<J3=D(HW'J"F0U743 \:XDK4]<? 45PTZ@HM
MM?CZ8DY-!3^8SJ6:_7R($Y#U2]H\"9.K5V*C#J#C% DUV)QUU&C='$:E?*#B
ML9O>3VV^?^"VOT;-@LU],7_=^]ZUHS?A2OS]>LVX)!0A,0 %T^\1Y$3S.([A
MMFIT:7"_I(7>!63JH?3)P&@:=1XE^.N4/AJ::+/L=8Q:3'XW.$![%9 23@+4
MC^W_G>(#>TPL[\62<G6C+JC9Y*%.B?@Y^\2YJHC$ITW6>?042:,,Z0:GV;C#
MUPE^Q3K&>2/Z-@24LI3PXE]U53*7J27H9[I#T/FJYT19X%N"A/?9!]DB;JAC
MJ),#.9'_S6Y2?R[\LCEP/"LGGT@L?,$AZ,[VQ=&$Q&W-A+EO NE-G+'9Y,!&
M=7EV;..2._IC[8_9B*^M[:]UYNR:I_XQFSQ^6:]BWC-!6$VEM?.0>"W@LLS_
MQVQ(]*KP4A"^@U?FMVX82TR6&(2I9N"+1;A0'%K<9W_?GN.63?7#0:7K]XJW
MH93*F]QL#/$$T&O_UFJ."]QV.*3,,D(DP )<]'RKA&YXX1\RJ-&!<+$>XQ&A
M_&59MG1%[2T*?M6(HJF".P,]/=H<';=V!:?(Y0'SMY4*#J]^YAO^JIB33)/+
MINHW9F2/7]^F%QJ0$N6*L]4D:RU\**?C&"DM4*B8'@X%;%1\UCS?F$VUY'L;
MBYJ&;;R\%6:'XK]E'\'Q/,=YW*_0SP\5_]O\_!Q1*5WX+0[:*$O.&A#S;DH)
MKL%%9O.0_;/:?*7JW=\NRU> =EKSR>\\Q*2HA.N4*H2EFFV+>3ECQX"6+<+C
M9^=<I)?H#]ENO\M<)BF7@Y]RK]H388)1PEZRQ%OXG;:;W^['#FAUW8O:A[(D
M':PV>()JA70DD.)X1HOS: *LS*=YAD]97'%C(3S/N]OHZQ3IFQN/"X3>=0Y.
MN8K1N[ ONHKXIE4,ZG$.WB'E].U_>*1+/1J=*Y8DT;.AE_V6!%B43_$"M^CT
M/>W'J.8M?5;R6!5RVR=DVMA"L.6S!V3>_8$$KID0>,(O@U-!+]ZWC[))A>*M
MFW'+F4KG@@Q^K+,GN&L[9L$B4QF!E4$ZC<<-514O"\*)^5NR%7$V&&+691IN
M[G').%^ST@CKQ 7!QV&+4&A+D2BJO-75>- LEDH#PQ4UZCNCXCIU'5M9GF"3
MA2'>Y-[ICA=/[J =%2>N-@4%A4W!EE\?RP453<60B7_)NA:AJ_.$5/[\/9LT
M1G,[C,O!NJ5QK$&>Z\!=LBN'=81>PKTI ?+L!UJQX:#,8LFR*:B$J8N$#Z#C
M1GSG6T&@%\]-AW2C3>KT8!'KV(:V^03DTLNM0IF-=0)G+0GX0-%S7O]P&ZIU
M*A,8?:-[ONYPS>V.XB_V;C'\GJ3^MSG12%/D%"TMTX8-N$>H3=PMBOO<8+BT
M4U<'-*IFU;<M8]5>@%)JZ56S<KQ-,,4N:58X8:;<;J.<:-)@J]Q%47MGPKAV
MS<!V7M\YJ<CSP:U=&_YE3JNI@IBJ23H-/*'6A]2!#W+2T'"78]-2R4:RS!"^
MP:12DRF<YN.A'?E>!G'L >U,]>T-*/D.M$FERX.4&U^M%%YH$='B>\B>6R05
MBW[ ^)*<[^>T5#L'"&0#BW!<EK%,J]% BK!U]0-X%IE$TPD)E5^D7+-.PXG0
MKQ]XNU;Y%0F5')J&,%*'WH^RH'EB;8)2B_4AXM>KVE<K-R3??\D/(^:A29*0
M4N=UF("+-A<:W7#,XXVO(\9**R1(N2)M&59W*Q_;>]"K46J]ASXN+U1,:DZ>
M]HR^90U;XBE%/\P1S=<H60T@W:517KB5[4*;F"6^U9E7J]&RQWPN'^/$@BG6
M/X.WW,.ELJXMM^Y.__=!['*Z7BOM0;;3H(,AT=O'>P JWF51AGI2X(9\E!'_
MKYMO&F7D(I>,L,(9#R>$=$$M]^(&9$U G<<LF_(\Z'RN\\1AIX:SIKY?;<A4
ME4!#49H/")4G@6=*+#GP(U3<IU_=3ZXOWDS[&=ZBX#\O%WX6T"#W(/IHNDOS
M=:F4[14P0W4%_-A:G#V_G)1T8*B70V:2CH]'%7#1\RMBT/AJ*&U>+=I"]-CV
M.O';^Y&>J]\_6M+*-R!@\&".^/@<K>4^ \X)*+_6!4%'BC@!"* "T-3I5L0\
M63^+W_?I&3XM?,,PM'.''8>1@G#-59Q+Q!3VIR"X$E8QC>\A-C9N!$1K+4^#
M0"#'4=&6GI ^W)2Y2TR/USV1HQFN0PH^@[N)1LA('*F;LRVPPX0])0[@]RYQ
M32(:)4VA4R>P"FQL19H.C0=^+ P5D8H5[T:<<5EV^F(\&;Y*I$OLX1C=;60I
M6!3VHGV$<W!2$051(H4W4-B1*'!@/5+SS"/W\4?KG/MTFFM-]^)A#@2K[L$<
MQ^9Q@THWZ^$1.(N;21&?B.I?]4^XZ&5''UX_@U%/-?/PQ"LE<JM*OF1?LR1K
M5!98P2H(ACHBMK8>DX6Q4?6LD3;LR;^!)L,< $?;ICMGH\+(#0G_BDQ-H?)H
M)AH2'Z=<OFS5C(J4&U'W0UU"(_97HR#ZT1K]$WP'ZS<NZ\-NWR9HIP$PB@0K
M ![RX.5N2V'=M8N?L-3AB;G*+S/WQL7\"-9:/J5]*@@/R%<QC U=)7%+"FL:
M M6+4QD-C3'D<P>(6J'Y-;=&T8"YY)/; CEF033&:$H3X&DR'UCY23U:?6##
M9=T^<ON+WT=2O>G64I2I*MN ]7M-2 ?U$7XW:M#NVV!/FU_6V&]SCL2>C!>,
M^FN*"#UF18J746<$.[E:S20*6HXSDF!U.C'!^W1*=?M;#<*FD2"TZMR[*.]*
M^E?T%S%BJ&8\G5C9CXN" @A0.,$GU6ZS=%3Y13W@W:#2BFG$'3^'X$>,#P1Q
M\%Y2<1"_\A("V%4OFM--5H79/&HM.A'[X93< ..)8L=%A"K8+DQ,%IJKDCOY
M*&(10FA!ZCG;DX8$CK<"#RVU?["?V_A FQ$9RW%YBCLT;/)/%R3?#9$_B\.5
M/'\"CP1A^R0T%8$ALQ3*9M*^QM@P_SB [RDR$%CT>SSIRFJ78XPS%6:),0U?
MI(01G^@G#@T62VH-$)A >>B50JU$:>L1PPA- _9Y#3C _O406[S%+L^7&O&*
M24+'W)*_C.I$JYGC:?)W;B7RGJ>.4VWJ40LWD7V.DW;@? EC3ZJ.R[9M79Q4
M^-/>'NAO\YMBW;KR]^#A/T1SIA@S_?>M]ZO0EHA2RX!Q/=Z4]BM _H.VOXT,
MWR/(S=N>=9Q;MT@":6\SS]?<=]1?KWP9OM'/86%G!(3!: )(;<A6)&V3AK23
M_F5<>*8?'UNTB$V60/ NEV?Y$E(TB<@$AV:VT%EU.!F;C=5B VFC,E9FP"AW
MLV"(+*2[(&NKF^-9E4,EHI)/(&J/-P6@^GZJ-?TC*B5>1Z6%@I6_N"1^EO@\
M9RE:0O,LEBO85D)J>X57=0_K4"V>C,&L/%LI!PA9M/=^4>7;2SZ@=BWAJAI7
M[F3$KOM[4OT"X0T^#@0-UF",ID)7A*U.:C2[>:12[E.7TU\!6S7D<6=QO%P3
M,[:':@V>1-$VT;J41=K<"2R@%A-&VDXFY$^!(,%3E 15VX%E%GH^@?S,?C"8
M%S,AK-469C26L>(VYQB5G!2L>^?ZRMO?0D1#3Y$&MCC)!/YBJ:[Y\ZAH [N)
MC9U-[,#(-W\?U5T:6-B$G59Q8KM6;<)HSQ:HOWL!XB/BS<_(#P2V.2</((BD
M^W4?R9;&^@<D-P6^' 4D"88?(>PT!@2:YRS?6*QBFN-\HL+N(1Q[N*1HW&@;
MZYZBT,O''Z>(QT)P*6L%--?;HZ<*G1IF#'-F,4NM%-3MT?TR\2Y,PO;'QB9T
M7HKG^VK6JJ<U]N+S&GJK]"=%R"FKJDD-OA6B**I8I8*:U1N1AT'FGTN45I@T
M<_R$"Z98%6DVYWM TR*P0RJP]D^+#7$*'"V<-P;<3N+I.UGI/BKC76Z55TG,
M4K3,2SW'M]K(*(C8"K=[# !1_:VT\D%/&IMMW\U5G7FOQ,)64U:(]GR3N-#T
M.0/8)\*.X[990ND<XA,113P'9LU*N(GH4_^37:0AT7?I9S)@-A,@X_LK,NS*
M,HY]-U<N@4RIBJ"D2 UD2])<@1!@S=IF<0]-NP)T]"KL!H2Z8GC;)"%E_ $[
MHOJQ,;SQN#BW^ -J@"B*[_.D.\6LA(Z#3TU&@J@-A1HAE ?/-><:Y6L6VZ&Z
MSM7UNR9ASXRHS2S8+X3U?9GB79]%F733NF$5LIT$^OWYG''O*/W&D1@PDX3Z
M2<AAK,VNM6*<)Z;&5EY3A12]U>0_3SP<+ZKWF->?#Y2TYW^;V=3U7:0_;PHX
M/BO-RP40=H1=S\Q[W![G<W^QPB"/6B9GC[UL-A02HX::4Q;4C:R^$;1EHC(E
M 8K%]3'O^_R)P92SSPRGZ<G6!<F>1?6&\T;T+3;.%=>>+Y4&-)MQXOB_/ON=
M9Y##ETD#+/.MB#Q(,=SP*+;V,KEFU$849BOKR(L1A7(SE/..F$7KIRBLE?16
M//2?U[/+_!DHIN4 #=2/%GE,%VD2VQJ<A1(80\K[V164J,E8=_2 ]*'$)G7D
M$7Q$XUE1,'?3BF['IP))WL6\A+GD_CY2CY4Q(#KEL/"SH4'#92,52 ;G<NUX
MI=_QQ4/CH9)G,F8I?%;7^,$%\20&@7LO,TFV0GY_@NDL+;:Z>;S._3)!<7NC
M(%*HQU&U'O5LQ+\ C8>+:"JQ13P?%V5S\UD:<DWBW'P>L7+6W]G]&754]0JR
M("_&<N/.:K7'J1+S(M_KU4EO.>%2@023D/5MJ8$ M#'!FOJN66E6L?0#:UM2
M:Q_M9,12Q=A@4@F1M$&3ULJAJD#*L(Q%B040+B:?M5^^>C=0)=_I=GEP%]2E
MO$F'H/CWBQ:BD"?".*J)AMY7:6>$B@V36UND6[\9K^VS,UYXARL<7Q:_=_RB
M*IBC(NY+'O T:DWS6(S#%FEU5/\<LJ-5L;*UWKZWC%[/]&(XS\Q[XG 'DJ84
M[@\.#'0%),,.8,]1,NLU[H+5._M %M5!5+/']3Z9XFH93&=2,;RQ83@L;"D.
M3,7CT<G7]>LF]Z.R)M]!Z8EF]FF&?*!J\D]D)2$*P-$($LZ9>87M]"FHV7T&
M\^-EAF =I)DU.B[N#AOC)PP_7"H5(3[-.\;Z;GH4"\'GQW*[;=W:6%I-""B4
M!5L*4E1H1U;[,6&OC_(-/5N.S3%*]F0M[: ^!<IO,Z/F\B8)8P65V&-I#\S%
M[U S[ VJ+5=LY)WA;P5BL.>TX?:N@XF#46S:.Y!QW^/#.DLK@7U#TUT#\'SJ
MP.#+@=HJQ[#@)U]94ZL<^-II")-Y+&LUEDXS73S<%D3>C8OG[3;&'H"<.M%_
M//FO7A>CW:K8>P)CT5L.*PVROK>JG9[T1;=(5\3C)FWW>Y>V$>R^R9 ?8LO5
M9JU1QO)3D*5L#_X'UKOEA ?SV0;I!8NS>HLG(KK0*X#<-#7WV_OK7+F8FNN3
M^R;<  TI8 $L$4QN[?-,7(:_V0;5E=Q-UWY]Z)R88Q][LW\G\LXA'_S+8+\B
MCD'UF$9T5Z62%=\Z]I[Q/,1=[371&_/"!R%'6<V5=Z=3B^$,!X*3[Q<I?0Q>
MY^U..4F--*8,#@G_Q,7!IS5+'D)4C  B?=[#M<Z7<*U?GD[G-L4RF>\W@N^Q
M/2VC""(#8EWC;*2ZL';?!:%VHU6++OR4.J#0$Y@37::K],AGAU3BL87 ]LFA
M+]2A>3Y?:??IG:HE;X>)ZEA8G_A#9V0>/R ",F!E_IXV(DDC&Y>1=:5XR0+Y
M36'XM-#I3P:?O=_FHA-#D4::X587C.!^]J[DW<>R/9/MGUW7Y*>Q!L.33=DT
MBO)9*7ISO-35:4Y[G+>Z1VC0X/UR#C8&!]J,5>17-TSS=]"!5J"O@NJ=;U>
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M3!IOD\PQ:Z;V<IOW9T?(];U@K?P/]O*XA]=9[,?J#[5"G@C6.5*<],MG_2D
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M84L "K2H@*ZR#X$YR77<J!*+RW I*9]J\:5:W]Y/+6)OKYR9C4RX=;?-]B6
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M-MZ!R5QBN08M?<,FZH\-OS?"#!P0'T[8[ANZ0AW&J][=D@\B$*N0C[,8*]"
MQ:DWQ3=H5;9F3U]\-G?<19YL/,50KQ1K)03_(BXZT.#WVWN9?@6<O_GN=MGV
MJN)\&%'Z,3LZKT!Y[;D+N9L0J,$Y)$Z:?]G8=A]J?>#3Q=&LRB\6:L,>F7M?
M]918]8@6>M<N83!3/*=8G88,B-?7C&+C<E=@*F0,H23%<]%FNBEQ"Y]:3!8=
MB=!P:0*\/?&PY'.&_ $V]QCE'B[5)&[50-S(5L7&K3A##=XMWJV[W^N1CAKA
MC5/C9,0$*?MT(HD(WO)T;9WO1*G!.C+;AC]# _?9*5<+ILA':&GI2..>KM4=
M4%T!%:7?Q%:PAID?-=VF8[D>4AS=.N6%@.>)Z*A//<]WU>J1+_%1JNL/%>^2
MF6NRU 7PNQZ2\KR65%:Y?^/-M^ >6>K8F=KL;U%]MMT!,(0MP^9*6-3B<OW.
MM &E@!1D3?F:VWRF$0*Q,?]-XY2L]>2Z<SE19+5Y7XPTVS>N(<=0R6:DO7;&
M>><N9U$JZ;9K:;%EB<KR[=N$;L=2L8AY[ -SL7#TJ7/ST2,E?"/I8BB;\%WM
M)R/4Z7U/*1]%>5R8XCD'EN6Q[Y<4A.Y\B:L^5*Y?E<RLY']%@30L80_*_WN6
M1-G(!I(I*S>Z@OS"^G6O:AQU8(ZP?A'E!K0(QN(K?O[9Y9#V^%JRR49TP85M
M9A5O+Q'688__A592]TD]FX9\I\K" N:Q<4"U(#:2->KB1AC8H^'8.=8B52,Y
M$498U [QBJCJDT]\M?BP@R+D# ::4TA_G:90!6F&:+(LPEU$DP#V7^?K6*N<
MR 2>2-:P/2A/J<M*!"0%Z]A?"7CB-O-@M5 7=9C_I%1^Y]?0>D_FX);#<2^B
M8\OLU*Z7KB[Q6?[,_G6UH:.PDIHGZV\6S56>4[_)<^F^L/6]-59/WWD=_^PR
M]0KXD'X"N9^IU_S9*=.&2@[YR/\OF50Q;(*&QV<.C^D"3^>[:8O=T&V#%K(A
ME/W9R_\= V>R*434G*:3[;G6&//0YFK%[A50-&>6+%)ZCU5(2T;5(:R-DZ5+
M=@<@ %&YF$O#W?(F%5%V!9CK-"R%'FVU8UO?JRZ>B?H\TS<<;%;$O%&=%AP"
M"_#?P_YX':Q3,,7!-SI(QY R;*L?W[O6+[7@ 5KD[I-)-<O09T!&ZU(:#L_<
M#S,_":-J =4XN[+"]XNQA528 J6\T8=57! L@AVF9XZ<H<+AD0VKREK@ BH;
M%!_+HLO_26'\A_IZF7=F=_+AGV.H#&('=V0IM/>F4R !MB7"S%X@M.I@7GY*
M%">1O>JMIOBZ#-&F6+=O/]X52TA99RGT3O_=+)+QG<T1F!8!X8KH<>+RYY&B
M8VY/'.<>%'_H$H5VMWAU4>TMB&6YE>5AGLO.UTDAT2[H_84K8&YW[N.@=48Y
MWRV6.&(,V;AGL7'.\Z.&2< B8S,M@"B/(WY%]+&[X9!UM+C\5Y7W(N4"B87^
MSYL<;,3"IG2IQN?5&_:X:[RTKC/F/*IPW$RMJ\WBZM1EL5NZS;ZR?WTCKT7C
M4!)*O"$)^(K+:':%C$C3*7&1.4!=_'-D132=,0R/=2EIZ]C#-98^7Z_.]Q8;
MJY=N_R);)K[5JNS8ZGON=Z[0S"[WB%&8TI:<H@M5$+@_5^E^FJFXR+M)6+I/
M)B,M@P1G4*^8[##]%_;>.BKN;5D7[<;=G4 Z:" X#4T@0)/@[L&"!@V>1@*$
MX-X$=W<(!&W<W8.[NVL") 2X8>VUU]Y[G7W>&^?=<\?;YY[S)V/,V=1O2LVJ
MK[ZJ*G00.J5YPTA3 IV0Y'X$98AV)GOUW!5BVV@I+'L'H+O%1!A$B!!]0^4/
ML]$P*<-D1KB8#0YE?N*FL685/K&Y?C9Q!\ <(.WP!TL&=X0N)E.%0R50HF
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MJ%MR=_R77^^OB820ZP.51A2ZA3V7&7G-UYF =OHGXNS4D\TZCT\3Y"7BCZR
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M+Z;T-J,^%Y>36B36/XA5!2X_5O>@ R2K#1^,4G/R<M5+0 AD?:^*\1B7IJ@
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MF7BATAD@"5*67NC\_.L':FU4FR>**-21-1T() ^"-.IWM-%]./-UF95H^'*
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M,3YBU)U$&".*Z>:.*"CT<87O0(0;K YBH.A:*"XV$X!(./$?\79[L\Z#A?K
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M$ _/E<@/3V>H36@FH#-,Q('9#EJ62Y"FX$ZJ/!PS%=DL,TT(:54D(Q@]\NU
MZ6JB!TOG!F'[+9G76;G+O A#0/(,O4,(?&RCF,PX][OBHL9+@Q. 1<EYHK1_
M[)U,-2FG^I?67WNG3MLYHY(W&!ON[T \!8I-PXRN%0QDC.TVH&"(1$)9S#,S
M<:1WGCAS&BLO2L@I4.4T,R):V1&:.G\7_NV9.Y-JE";I@U8&-KME/*6ZB3L
MN?*35"Q.DQGR'DQO:\8WWH+VQ>[A2G6V:BS*@G A/Z<V'Z%7MO^!C^N9<4RL
M]P:.@*.GD,[G]N<Q=#844Y[0[OO^ME[#X,*Z0,/E!W12N,G<"0(6&5&&"0<
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MT5%5]]-.).J1KXS>+$V]<6A$A\K=?,8AU^1Y5-FO8O([E?>7WFGK"+@EHFX
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MY2^$_(60_R8($9%_M].'/A1MK"-BG=U#L17DR@ZHC1]V62-(?;8H$$K^+JG
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MZIG+0(*B3!=[EOVO+W49HG:)=1[S7_%'=\(-#PMXJ3V? N3XW:L$(A:@%$&
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MZMUP'W.2(D,9#27,L'5I4FX::!T;J8A,S*FL/DN18>0LLM6$-#XF^(A*L'1
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MA)-7RIH=,C;,]*]SW;%"KH<Z=85/[S!/HA&@;R#;#,(P52+8S7T U\:$&?;
M4N_N/&Z%#U3SQ%WS*3K@/XZC_Z],YSHIT)YQ'\M2UW,=]K_EHOO@.'EK1VW
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M;E1::9\Y3X4D#S3.#!/V;9QIKLRLW(1 W;P.ZJ,5XP%RG'.W?2GSLMEZ$;2
M4_DRN.F\M/A)W'V.6#B>47HEZX$/V?/J'P!8?_R:IS _FH*P#AIV^(.S&0OG
M,0^\,SNCP\WG_>,?CCB7DM6NZ1OXMHHY XZE+%$5%W:GMZK;"TR* +>OI@<Q
M;B60!Y';H><1X<>XMKOH;B1Z3YUO/]9XK_**>1N3VJ*4/^(Z3.U=JA[^. @'
M:\D7DAWQL7&B[P< 2<!FJW37-!<JR>A4U=)Z5&^?5_+UF.4):.!H@&1B95CZ
MBK^VL'^#-]N^.$98?=XHYN>0(S?S987Z1B1]'_SR;/K92_0'MWN!7MMFPWRX
M]_?R6*J>%1[A+8LHK;?BJ7&9L4B$4!X029^ZL_=H9NO>XY.^*]7I.@PQ_*1%
M:@0KX;,I]6562UV:-)@$. XN.G_N,<PV*]@F!EKSKP$Z?+-]<F#+P];N'S,O
MVXM_(TF,/Z6]/*,VQPYWT22#K+#B,BW.<U9GN#P  M_<>35\VZ]&GUT?[VB9
MJ5S5"=SY7+SWG%E4J%I[)K73*B$2Q45[:Z=.;6L2!XL8%87QD./-/(UBO4.F
MV:7)EZ**\H<ZLL39Y&98$O;C8)T(_);07GDH*3>:1-C[8=?YG])Y.AV;AF2N
MO6@+"-O.IYV":JX=B/W(^?P7/@=)8YOI 6I*6 #4Z2#=*%![M?MBE?&']C'Z
M"./G[FYUK[=>W"W",BQ4;&"'@UO-T8J#WS:;G>L\/G+E1:EP?CH#C'+1Y7F+
M3F-1'>FU?/IX6$_N3NF6=6MG%V0TB,F9&WY%_P>]X1Y 7_I$OA-Z_!$YAVI
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MDG.?_M'5_Y6)![,P Q;YK<^T8IGQ)A, $MMD ^M1'3YK#1WK0-]\MO<MT66
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MAQXD(_:CO!9(9Z#=)$/UGKS0%QBR;O_2:.E/$WX^MUC$5@ 8#0NQ4! ]\BD
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M<9%IM8#OR\[\TTTE!#?\>+&6;S^59M3\P=NB]#R LPN_=#L;<^IZ>@\/)A-
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MLH8+E4KN"R#YQ4#S0._W*JJ9L:R=$B&$U.'4'TIPP\$NA_E.:DC FG*'AM\
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MJH7]U($F$7M_:U_;/QO_'S0:Y\:^LK5$EU35$X*CAI22W0BI=C"\,)G1 UX
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M7IHA61<IMWOGZ:JX.SWX%\#0"YY5?+0 +=KRX[&,6KX\-4HV03BRTAQRI%@
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M-_U0#DJD10Y;Y5UD^%'EDAC*_/3KO"'FS28<O%0E/$9[#!!#%NZFS2;.T8+
MS!0GAR4I"Q-XG)/?#GD9&ZE3( 3PY2H*4D<3\)'RO-/*:Y#99O%S85=<PE^
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MY$UWOP/@,]0B:AER@MM@8N^JGW_,_574J!"MVWN NJ90+^JN-\2P,TZV,,4
M.>ECKZNTIT 6E+2P+>;1Q!AF=2%=HUUGANUKOQK@+PNCQT+^")88:BGSR5/H
M=OS\U>"V^F=.)0-JMS;HH*JL%2)<&Q8R2JC>K? 74)623AU3]?U7)6VANR_]
M?O"OH7HSC7$(6$EQ^>NM5(PF@1UIGOV"G6%B9?G+V8E]DC>TRJZ,C':RE+<,
M^]HTXOTO87UZ%>I7ZRWMO=C@G2IIG8+Z<=UG&U,>>DH'6,9BKHM78A!28 ;\
M(M:7L.K!<]2$@NX3)<W*V'()ZK&9)! 7)*RUAMK+U< *NUW/V!QM_&2T?KFW
MR8+YP/^ODPUJPX.ME)/I$Q2:=,G[.)/:XR5VGB@YPU[&E@&U%IS7]R]*%OTY
MPZL^'[ZQ9'U;O+.'_J?BJ7$<6_8C)B:6+I<C;M'OR0FV37 :%(CBEHE)_T#N
M",?#E[/"X&!:E!O"'&;"T"THG=BR]HIC*13NF#?>QVF!H6(>0*-"3N!-OGD2
M^(_$.[2-M=J908E08@9I(=3VXR1$5I?.%X)HM*]G2SKE19,<9MD?LB#+3R8:
M#UZDUY3;LQPCZ=\@9I"I\D:Z"BWQ9A7'G/X$K4ZI3^6;VZB3G#MSX8O1]\98
ME1%U43/+#>T?OLWS-$N^'S(\1$ 4(B+P1S=9'$5"8<ZQ:"H+-8Q7]U3#J6RH
M=C4/F T/E6M?P;V:J^B)H0L3_"%G]BEO4R8.IY!'F?[AA?)BOU:760_YE]_T
M 3OIB&*:7K-#A5FBW>A?OPOPK-VXE:C;,D3@'MTF$EC; DJ:>>/#BM8])UY?
MQT2?D30YY1M6IFG(J%^U;-EJ22:_(8M)^-3\RUT*@SHI-:_T>;8@Z%B97(D,
M@]3I60/+B*A>%]1^57O9[7:<PVOA$ZFW!VD@/0\Q]P<#!O28D ],"UY'5\,<
M@87CA)PI^]8HM5C&O#\V(A7J'_N'9DP8"&8PY7>;]U[Z/2+Y^[T$H#8@@T"R
ME&$C>-B DM<K -Z<QI/KRX#2FSG@3;69LAG9F\B2TI(1HVE*H,%HR,?KYI*D
M5,-,(R?CKLL:8S 3/.5@FSWH/4#:NZCAQ>HIBQ&RDY-#&T+J7EMEJM)4>>>C
M:OU6T9T>JQ10L%(Y$DGWW93L$1&F(Z7<G<\D8S!@WF=P\- DV2IY^J!ZS]CB
M*VUYE1R?LWYX>B_U$[:_:5&$MNZ5AJ+(IL;J>&R'))E;[Z>"?D'&34N_AU #
M203UH;1"Y^LP8:FT@"0/K$3_A%X6KHS:CIQ/=K1G\L:U!8D)6ZJR21&&JNJE
M+!<T&_6,PBS1)'3J0 ]G*)D ((+7XC.[$=TF.\]J.FX]DGMP.+=,TFFUUS35
M4'Y#5 @[RE!=.6#34)N(NTZ$G&8$H0=L4N:I!BNZF60+0ELL4V%.- +S[-D5
MKM'&M>.*FBH#'VOD_3X8++N<M R3LNVVQBRY7/3$@_T6P8H94S;"C7!.DX#-
M\0)@TJ93GI;1<V;>"AT+]H-#E/87:I,2Y[&J<= 6R;DI^0>H$&1>3>F30B#1
M^]$5D?V8\\K0B4E=M(\0?.59(6E[-J!Q2X@WT;CG[5.'IRQ\^:,"\0IRDJ4'
M2:6E3)"2Q]>#+4UIC_XX4G,#AO^<K^EA:(>Z966O_K L[/Z/+$6HW^>#@$_^
M_6)_;.BFAS>X]E^OE1S.'@H]#%UOO.;= 5HD?EHQE0MX[1B:=< P?W33MQW^
M:O %Y0O>0&]"M7&+G-5PSL"SU./FD.WY\W1:7CWAQYSU5VSA3@'A3C[=#S&2
M?73F+9Z[!)G9 TI_S,-TFG/WFRC_Z,EH_F9]6XTQN4&/VJ.0._L+8/X."LM[
M<=,7NN,ZY-:/_)JY V]"O":2/:),+9:^>Y&P.H!(?;SYV:I]H;5X)=OP4+@#
M6_0)IYX\*A87<EY@T=C?J"#KH40[C@?C.$9)Q=#UUF^<S2;T0>!]MX;#@AO=
MJI_S*UG&\5VK\RLAU39S<;)C%%'D)/F!] ZT3SGBS2+BN-%ZW=9E#CARR.--
M]P,8U[/S"#(YQ3C+IDCO ;$%-K]!XXAUZI[PK!8W5QQ<<JR"X35>7B8D@049
MDILC@/R##PY9RN9T2EY*Y5+CEJRH2]OJP?;TJEN'I,I"YO6"D!99(.M+46%@
M;QVUFO@E0@@E80$FARKBI5@3$Z^_T-QI:1K[:K-3%UA"/V ^H!-20L;,*["5
ML[<S]LB8N?ZJ?^KX]OC@>U>PX]X>WYHVS9^IOP"^<*Z<(\KB]7N'>Z%SK;B>
M><R6WU('-4QW.>)51]?W%S^#NH)M>Q-\M-3/!S[>*PZ:>[Y*7K[+L0M:LX&5
MG _,G;#^5FS]K8B8/6">_KQWF!F.:^K6E5>//9.>D=ML#Q.$CKVFZ+2UI*VG
M>?C-<97,S/[$(8H:!PL\P5*NWNE5[EK^SB>60W?53$6$U]'=*S-&KW7G^_FR
M>:KMC&:EVJ3ZE)CL<)1CJI*F#_[7;#GT[K[J"";9#X)$5SU)UU>GTY(>S2^)
M\5Z8)9OZC+ =F>HZ$)$?"69X74!#SH]8'5+G/#)>X.'J1>#4:A953Z%L1P/L
M5=?:)G23F.ZZW5)<FG/4&0X-LL 7 0MD8$);8HZ&[ .ZH7*6_-ZTYWD.%ZRV
M="4"V]*I6?GH/.!X?-+M=P^R+99+(8^F7-K('.M)[CHF/U)*)G_]PVJ;3LB4
M3+'(8<HWUN,I?9<&Y*Y[YHP89PV+$+TFPIN<1V*^=NU35*HD&SPY6UY&?=.Y
M85:[INW0O-?_W8%TLG^FGN6L1YMJ X<@]\TAB]HUI4$0;:O=$MM&NUNBOMLT
M4JTTRKD\#]<T0!M-P86/^,VXQGQQ<R9B L?Y%L"),S8.5A/G/N%;LQ4+VJPF
MRX8H0?F^<RIFC'*V)4[0"%?N^) &6&V]J=(6FMS/W__!A>Z4%[]TFKUJE//+
M1XY5HV(34B;4J)(PU!!\A,(&C6MA@VEUL-R3E$I#F7K;T\_">H0@ZP45S]]Z
MN]Q]B*'1DXDI8@F$HYU55)7@>IN'O>%^-+HG^L-2D7:38;P[SK-PH )L1/(I
MI (KKS/=.P1!$Z82WZ%>OH1-"MUSHP(%V1(;X4"]3*#'5\O/*Y9N2@Q:.J3P
MI)Y;3KX,F5)*\9H&SMJ6"PG7KA="@YH,A(XH8=\@]D1<F4\O82!'71-/%,9<
M=*+,X0;9[K[O?4M!&V-[G&>^[36M"'OS&9(M=VK I<*>9:*;8YW,#%\=W]R9
MCF(R3T-G;K1C[Q%4I?A%\)WJ0*J]_X!%X6KQ1WX'0Y&+[5ZD8:[^)N=NHI%<
MTV:W!QAL..P3U0UJJM&,MER(HT$O=Y_[*XZ^D\@D-EET?J*6&_XZ#58$'UND
MM8/[-N4W,]6OY>6A13C)R<QR(B8X9RQM=45[;][8>IHVN7_(?55(%N')^:W/
M6ZE4K[Z2$^#Q1YLEXI+X+O!RLP,I7 V*+[=D\P[CF!8916+&:FN,"XLG3=M(
MW@J>PU^59\G(IQ6:M-IP<N<9)T9E37!:\:26\K4EDRVI[T)SK&5-6E?8BCYJ
MRT%&NB";?O5**&R=-XQ,XQ-@D'JE3V$<@(B^' 6*'^KZJA<3G\Y*=G&U3/G3
ME6DJCRS8J;]5#6WTE>SX*^ S1MFZG,!1Q!OW8V(=\^8/Z^JC$HW64R$-&E(9
M+:+)@LF4R=PZ%Q(_5UT&F)SP.YR !Y4'%FR$$@8ZR&I]IF W=&UAIBS\*[P.
M4<<&)%>C6I7(,H :MI]6O8V",+D@1ET:RQ9L&;9ZK4R@Y"1)R%K?QUF7?Y](
M/VR?:,SG?@L;)=U_</7]OI]/NZ-I\LBK)#H].N /\=9@V.[&^=U? (7L0ZJ4
MYI#SCZ<V#3($^:JEHTM2+UGS+V\_<3\?^5CK2/+M9H+F.WX_1)ZYDJ>I -;2
MURQW2D;G;C]^;WEB.V;R=)^ELCU_QS7+5U"<[U8!(50TB5:1G(AV.(%1?,F,
M?3J]P*)&E)A1^3SX+T#WI/=7F->&N0<CR&+]Y%2*39"ED4P(25QH-]_</*UN
MFY# -/&J7+7R=9]2)I?B*F#C^=!DA]MW[M?<^V/=8IZDY*:@](Q.)9&0M7DP
MUU2%_0:W36$I!HLNT::4-:XA#U^,R)^ZL_XN/,9(<8>DD6[(IAF'63]"1SBZ
MR(LI_85H-P%S7Q71AH:[#9D1PM8]W\IA ^B;D6X=CVDWCL@TQ[?")G&XH\>Q
MTO<D%!NAWW@OMB!]YI?!>UY=1#^JSJDT880_JG" ,DOP"(D\KU7:A/1C /X"
M,OMVOIY?/LW64U$26=A.J6M07Q*B2D4],W_GI]XP3Y9D@*L"JSJ9\J ? J=^
M[!K2?5XMDW*O_5LWM6.<$3DE_)CJV8:>M^7Z"["_ZJRKF#V;:KK&0P0L!,X5
M#H("MXI5]?"-Z[!$7A16PDQ?LNOKHC:$Z>+NT-SI3U3+A3#VK#<J&AD/)$BY
M,9AH_P*\G]^H_^J7[5RW_4/[KQ,:ZY3*T,VK=5"6<^6%S+XXU<[!H+#(X=;)
MLWW]=69IK[=I&SKI:[$1 :_4[+'+'TJ&D37$$H/Q:V[PVT3IR.B6325(.+\>
M,[VHLPWG2E%_(+1W4>LQH#GM);FBAHR:6-HR&'7D0T@,JN6T,R_CS]MTT7L!
MZ=:[6%SW;(%\-[#,=["OGKI*K-I<M1+N=]&@ K7+!/Q^4[5G5N0L3!THA\HD
M-L)RA+< WQF?>DNT3XJ2:\)FVJ7O1CYVC124;B5/&&;7"1+:??)G9HH<J1SC
M'!DGD6C4%X*L8MMJ_0JOEAG^I3PZW\#&RF)'*Y#4?)#H!'1(;)#-BXZ#.B4A
M9!H8_)\1XVY!(ZKU:WV\=5(S['^ _SNCZ'\!7L> 70T&"=2FZ5S-=PRXB;KE
M-)X)E<O^3]7CZ83O-3J]Z@3YJ-ER+B(3#&4N+:!..3:FH9>'3ZLM+;1E*<6Z
MI<\OC3.O7<M(MW'&M!'Q-*6XMW/^2XO:- <[.,"?E!5,A$6F-&*,%APKN=SU
MM_T-#:T/Z$]GD N*_DZ[QZ&]?^Z[\O@Z59:7DL_3WJ^0;F":7S8YG.1-YW,S
M+:HC'X;J2U-NCSG'[ME.GSN^$DA#.;SEVF6T!>3)7D3]L?J"1I1Y'GL;I%H#
M)8LYXTAU2Q>:8O <Z9:_J<0"CZ>JC<H6)G0H"K@"3TG"BO<FO<!8C$(68*H>
M=\XO*'+DYIZX ! J&Q3_QKW&%'E^SLE]^F0KJ9\?=]V[!:\-ZDAT-M[FEI6/
M6_F(2?4E<4*O/C?A4C+PW$*[9[;=G,NR?:!=98^3LDWMV7YO<]TU"<+968/T
MSG!BW%G UB/.[P,[J8+%6@\42C'"P5$$_U:LY+ 6>T:Z[4YUM[Z46=P>R7&J
M3[C+EI4:BE=I=)7<[6!/RX?-920W+ %X$KUB_F^(C>HOP-+EQ3'+[N_4_Q^K
M#*JE-#S6OFV5Y#S6:,E(\]NZIFPP$.(SE79JIA/UV[+!I6??:,S34@1$9+W'
MH%6<MLY3%9=,-6S7.- D78%=7:#R,T=UC^V#1Z^Y&^U)(J3W\<:5!1LII0Q&
M*GLID;FIY&(_?O[@VT=5B_:.\J$"$:[M'J;=(HIL)PX*Y9KV-!TF"U"Z3DE]
M"R80][>OS"D,,PNF%[,&:IO.AE&5LPOO4MCGN4;"9AT*.LB?BDF=>L$OB+/2
MD&"H^DFR(S<, --31<NAP9B)7P/<O,6*DLGW\ _$GI=JBYA3)#6+U8Q!U$WK
MO9^J@GMSZ\RFDS2II331/%]NS'CU\0@4$'%D,>\^=HUI?2,E>"9"DO1]KLE1
M&HN(YQ.B(UK.KP(+6.4B>K]$KADOH3).;%,U+)V1-4R=3K4EN*R1 !,QR_<O
MQKNF=N3#7EOML*2*@GUZ-Z+.!SE_+2"5K8='A12#&LPHYFN;2LYTG1$NO#0>
M^)#J_1)X-Q[$&YE)MVXI9[)E6H'R49C7XD/18AOH.IQV*:'4JM])>"B*:!J)
M_>O?4.LVKDBT)]W50-!KIGR!R8S&5/5Q/V2E@?ZP:>[F$EQA7"&+98)(@I0<
MSA51;I/XU5B?;^'82H%F7'H[W>DMS2'-I4IUV]N_ !9SY^NG7+D09;7A;C=D
M:5*-2=)$LB.[VH0+F[E10VBL<L['5>$7/&Z60F9LPZJ&1T)9CT,(1[3@NS8)
M205!>###VFTMN254:>*]@4JUW&27X%CVO_Y1P42(,PX2CF:3=K\;OBIJD/3;
MG ^@P\E'%%O@U>Y)[$$WC!.EW"J%#K$6(4G.S9@)Y!-*ZR/IPJ]H@A"&UUJF
M.M_/J)Q)]]TR\7VYVS2K J;'1(S5NM.X# (IRC\P,S21N )IDVQ5^:.:7;/]
M:L?&<2Z%1I4O0(:\%AMLFGZNG^Z.B?F)FTW8Z/"=8)4^6E.;ABR-(ZT>[)-N
MZ, O>#15V\FV>;4;**$O-]\S*-1OHA/J:N._?!4@7@R-AI+([ H&Y@3AQNVN
M]SY)LF'S6-#V,ZJ@)95(VJ<4)DG+LS7A)?7IJMR6D4ZCYSTEI"EC<L3+J 8I
MK,D1;>NN'Q98";Z]?/UB'_UI+B<E?ZB9;R_5$/9N0%V(/&4:(59!,KT8DQP#
M8W$P2B S$4H U&KQ_Y>^___ %.3/GNV7V:R_@':J#3?1&WYTN PHZ7$O[]?(
MPNQ=@*-+<>DWZ3,)C5O5EN?Z;&W![&?7[S)?DEF+FK<HT2MA*%- RPNYR9!L
M+>IDR4Q(C<K\RLJNV9G:3]"4 !-R%XFO%.\UC+AT6Q9PA=SYK4QHL=.V;!#Y
M83$A=D?2<*\"&V]$,S$W,O(O(#!-<,/*8,:S<_WMRVX=YD7SR74WP4_.&%S5
M^IS^8)4/0]A/B!G[:.]^]508,Q48"E[XZXUDVD7( R]H6*OM:)ER<1.BG,KS
MU!EFMU_HJ6@'Q5[RM]HV(MT?13MT:R9-[)JCSVAS?/0UYN@_FJ*>CT6?="+'
MJ"N10O7JMV R[B<SQF2==F\>'F*1UZ$MD$T^"A,H?GW6;3::9<_4Q>)D3&F!
MDO_ HK8N(I8+ .FJPH@ A)S\UZX0FX8B1;]90U%!7;^97UW]/KP>]FA%3[*-
M1.?L-8VUHVO.&Y</OEZP2SX,O!J_\HI'%5?*.OX%Y(1G'TELY7 <FAU\'$G/
M//SZ[%JR!+CVHJ/W-?K51I>IWZ/8XZGOJVK?1>VD =:'-KM)2_"5;*>TPY7G
M:##XH)=QE!#==(=6G/E\"J+HV]JX5_J]73'96/C5+B6]6$JP=_^-(KCF*EM>
M6:(1_X.4A5T3%:^CIOQ\Q-9O'%YV6I@BC(,- E;U(QIPTFNU:\XZ?99GFE;&
M[BR K)26+F=^(AS?@GET#-S=$ZQ$8'H^'^'[ZN!*NK*Q=+.3R)M:A#;Y+.A;
MER,N%<,ZSQN-O*UAGNAF77C?Z]3$->G4X<T6E%LD+GU 1J;H;):-793TQJ(#
MENP6G\R72C]I>[;@M(]T^D&B>[ZC/ :>'<&,E2\LP'E>5 K5RDNI\*>05VBU
M+S/M??->I57SCL,T*CO80*0,F_!3D*F+1&1*-^MFI,%!!_4^9SQU4(Y91-!5
M=>=U&=5AM<1XZB4AIK;_6D[7)*6\8=.2"?=Y/53JC51KK='[DP7'^"R8N@MD
M+;<\,W9)3222!U@]H"FC*FV-7."18?MY]CUR/JB"H%#%;)\CR:"XHDTR=.:U
MG);A'P;AOP!$FYCOPG3?DFN*K7UY%56_Y[J_*\+^M/8ENU[W^R(#W8(FU=HE
MUCP9D16/'C4)-R2A+M@&.#-;ALSJ/Z?J@YC1$8;F-AJDLX4%.O9J(9@3+X3Q
M!-V'2R2[9HO /Y\/M4A;?XBZ7E8PQ.L0>B]ITYW%'>)4W@6KV\_C(/_!S19.
M#:0K#OM@TZ;ZOLNB5%U6N,V8<]?>N,4%;"#W<^-E:.)#?&CQO@#:DO^A,K0Z
M8.!,\S&G0\IHF#?\4YCY@=^CT%_ EZ[[@8V8]I252,]6XV.VQ<*D.3%<VW*?
M^BU=SE?Q^<DAR;4%ST.@+#[;*@/R'\75?D/U!=S6Q<6=_@(8#WDT'*9I\V?3
MO[=M,SK\_.([MGL>&V"3F$-*F9Y)IAF6MV" 6V<@2,)%QJ(Z,_?-0BBG"O1P
M3^G27]S SQ,R15!AQ,&EK$MY;YA!Y.5:'SGS-&ST27T^QZXN*FZ"-,%"517D
M<__[F*<OY';OM#O@:@.AV9NC5=AH6[\[&9MF6W@LD'M$_$^LQ6&W[$L\!UNK
M7Y^(MR$?IMMO,8Y5%"Q4OK\H9>)K0-W=J1M"W[VB''&[8UZO+0+#P7;SND(5
M0>]__@5H_T3C[!?F6/H;]O%898MY=@U&9WC@J@DD91:A#+@%L8,PK'DB([WN
MZR*21+VB3A">NR7_40)=_PJ97BVA<0!%0P0.N.[:S>N44 ?<&\[+)B^(A1S%
MM@FWR/FI4GJ5];1TU<;UL#/5AF*X(FH$"/V7'?JJOTQ?>:@.((\U>S1JE-0$
MFP3L&BS)S4C<!1&"N/=2K,,-9S(\#NYCVU6 #\K5?C6T,9F.Y#777XPH=R53
M8GG(C5%:=EOL5KR>Y+)6F:%X(XK@ P)9<<>\NH&P>S(8RRQEDKR^!(OT[A%=
M@:[0GY)I"9#'5"O)TE%[8J<G<,O&]<:79;),E[U8;3)/;?49KY#'EE+1R7(8
MS+8(N&L_' /5]*]^4-UZ9^K9XD*\N0DS/ >]M1'$'#-I%,.FS3J%L_23)"53
MQ3R!3I06^,E-<N=!(/0ZGYA$G^6>?[ND=-IAURMO#5 ?YVEUXYS4,&I^&>L]
M<D-39R=O8-P5I,Q%M&= !@\X9.5Y9TVSS9+_B<&UG<WTCGW<;L1/DQVWZH,O
M, N34C W^]!IV!><E1&$5QN;*+%4 F,5<WMLK:*AL^$YXU7AD;<_IR9$Q?R3
M9'N:889/U7GSM"^2P)H1N8"W&4\V5&\TT[60!_C@3+8N6YOJ+=0<14_];Y+%
M\S3U&9=^T-R#$DK'*Y(,:P6LX)U1O=4'"%B@$\,;ZLK!_SB[>Z99>&[(CB8[
M]Z859=L^#6@X8,]=*"O+'QN0K_490XZ 8K77(R+>T"KOFK+N&9QZ32DL9;?X
M+N.KCNZ?@@CA+JCA56*'_E:'?+\R4R4TQMBMEB:'KI)I^>&0Z,/KG&]9RA7"
M-<EC@SE-IK7?3#,FA0GL06$6^4LO,BP_6KN%H0[RJQW<]7EIXCU86AW0W*CZ
MNF;%!T;B\O-H3H,]9]]9SILB[K'ZAZ@N$7\\I^$.'@;RMWP]+1,LR6;:$K,(
MK+'GV:"774)\O,.24<(<>TF7*K!:_5:#&-M<52GZX+Y2E1H/GV7^SA41;MH9
M;[^I-/6K'@M%OQ@D[%7M2D.@7>US P>-0Q^6E=>ID/,11&J:D#?*?T-U[T%4
M-9M5G Q[HU!K.^13:_8L5AR(CT@HQLDX543BTS3CTUF[/./3=I#"8?44.";=
MN54[NFML_8!0=Z&_QW#<*#=TUZ9T=:9D!-BZM '#UMK/QJZ3'?U^36$!<ACF
M>+WOF$T.#[2KF37*MG$5DWDGZQ;M9S=.LVY=D8L>A;!;M!F/U^K7+]DC%I1Q
MIT!BN8.N/KOY5/,N]TM'+T=R\@O-1Q8XWP6G\-KG=A\ 6Q'!26;M>1EL^U9D
M658%NA3(NE$[M'9X9T?6H/-.%B.B!)[^YRI(2N0G;*]FO";=TJ1!M(FBS_XJ
MF_:[IU3]^5_ (1U=C,3 Q.MO@F5?05)FK0P$O[J^8>LU:XRE>Q=6T#57T@O*
M:S6!AMI-VNHOHDV#^;U/AVED%C=C=574>'F(Y<@B2O5+>)25A5WI:>GAGKRV
M^ZN=X H*7E.30]HVA^D*'V"T88..9B5$B*R2&?]?Y@QH61M>^:ZR<>7["3L[
M_]*250YMB_58HEDS+PYDL=,HKW$Y*DC1YQ&GEVCWFKYN,ZO]9B'JA$N_D?):
M]1/DC82\?+<)8$QT"VCMEDAX]8%2R@C;TVOQY0 FJY:8IEGDV+ORUG]XGIZ<
M\"DQ+=#U5QNP[%L --9BP=Y4@01-;&3O]C099*TY&13@_;&=BWA^2/=I"^*&
MEOW#\"X1'$(LYTF5SK'RVJ"%4+)58]']=HTDBVYD1J%7MV!8WF JX'*]UN\^
M=;/<MM,O<JQ%!>3('$?"UJ4-$%X,T&YR'#-M+*WO&J@/C<5V3Y@.'%VL<R9
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MQ3XL@78&/D&,;RZ72]8PG_MV6<%-@0L(MMRX>'*-]7A.[B5QY1M=P<@*QTA
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M6>4V,*D_Y-2]-XJ<A;/G$F$L#T2NM#^QK,:H8_I <RN.9:T&3+?D//$%?AX
MZ?"UNJA*G*I&$(O+92!8O"KQ\69"<.97:$+7'!K:V&_:W[^6;.\?:(J.U&3C
M:K?49_3ZEH5^+IJ(#_S]WO8) 1,CNBM\^U9X9WX9?2T5=]>V/>>^W*"^^,]N
M@:'[XJ=+C7:!^G@=QQE88]=34WBC !:+WW\!R2[*;T;,?XNZ,NPT.Y1FA#/
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M_&]=YNUO/<LB8?<"E\"+%86_;J#[YM*'_ZZBXL5SGOV/_/?:.R8^ECOLGO\
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M1*G3TA-6Y^UW[ZI_V.=P=[J+?6@94R55#\^$W#MX\M$RZ^,B##(@15E%S,P
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M)$;Z9M=V+'\4&I;3,77,"B';KBRFM;T<2Q9,1S]$'.ZM?1Z=Z.+!L&^Z,VJ
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MXNR/R#>N)5W[0,>G\EQ[R?0B<\.1;/W@R9=5Y.=EF-)%V2 ]Z8W2L34"_'\
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M1-,:!K@BO+/&)*;9)::9H92C="<@A-3PJ$#"%='C<T7JFU1*AE/MFO8$6=-
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MX8C(9/\I']OI6^Y%Z0_(0WO3\O9PTK>TP_1\)-%6GNGT+*WZ<7'1#<6"TLJ
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MLIKN?$?F:!DP+)%[Q+YXCV5#9A]TPRR=D9_;W1MH&3Q[*>Y-4&F_!30_KQ!
M[J)##V49&4#G$KLG<CD V[XEN];:T+KZGC?]&R%H&7^&6\!T0$BD*XF6!U"U
M +Q[9'0=,V1ZCK^ ,K'2VDT2DQ-2C<5+BX[S5Y_Q\G@H5=.?QR*5DCL()-5Y
M&Q[Z]6LQ*]>,'!@C$QBY>KP+H9/:4K*M,-ELM5DA@C=8OD<OA>V"MU4Z%QG9
MVMC-4=[AI\&&K*\X2[SK."L +M;$>DY*.M/IW'/*7Y[4]?00[0R9R*ITT'\<
M2RJN_<6YYBM'+@K';M- "K5K^:YQSIRI;+"K05;=AU=@I<9MHWKV+0!=13GK
MD&:ADM2>(J;77;?!J5?"Q_*!%#IRC9WCNH[:O&X',?QU9#K#61-&>D-A*\-8
M7^ )TY1P@!>NUDB4:C5^+N"CHE$#F @\9=.JW!S>M/HM5R0KOS _RRN#!)Z;
M.\'*>2TM+[5WH$2@3;ND)Q.FC$3WJOW'"NYMI(IDQ^?H,%I+VK%ZYJ*]X&W+
ML]+QW.%8(63GGHG3V*+^B D$TCL<X.R\*<D!!$+1#>\A'.GH]S;6>_*A'KWZ
MO.QI/.G=!<R(/19$0I_=JEZ48F2LRE2,[]6-4N,MGR>ZF']!_1<"NE[B;$;K
M!CU^P)0JQ,PZ)%>UKO._]RS\[PG#-FGWV53 =>41DM:IHB#90J?$2,:5T0\=
M6B>WT/4_'9E #VY<'>+(0PJ:6B*'$WETD$=ZTA9+7BM1(G_G'3TRF$>50QXX
M'.RL%U[PR9C2U/TYX"NMF=G,A"5>B7%B3%OI>GHB*3.3WKQHY'8U4KJ]/5D'
M+6S6!!*[_JQD@=J#EX*;PVM_TM22%' /]DPC;/E2=^/LP%C56:$@"K:#M;"!
M\L.//5"/6)B^V-X>58:4FC_G&6Q)JY29I?N=BHCXVZW&R4BD0F27 L8SR^;9
MB#7(<+7S=&/+DG-)D(?(1^UB'D*6F&1KI61[4&:3/VB(M^[%Z<[ULHFXLB6>
M8\!U5OA&&%C?5N;3/>.Q!,M$JKMPM"27>UQP\E;DJ5%7FU08Q1R4-%5]\%@$
MMOICI5!<+$2G,@3ZL2''.Y9Z0C'R0?C0-R(,PB"9JONNAGSU S0C%]/2RMX#
MR06'^20>TP%Y 6!![Q367*M<GQK#9.Z[O%Y-90;:R/R(T()POY&TS%:4.KX]
MPQ:7;AD-K6NQLTUATC%Q/8(,KP81L)J?;>2[8Z516EQ\G!-H]3)I71+=CDXT
M'(?>OFS:T%&'6RO'84C<DT1 ).%>7LUHG49:*7_V84+!<%"<OF9R3 <0D&6J
M];UE0J_G].,E,!ENON'P;6)"(/#97IVB+SJ]=D1&5JXSU8H!H2V"'%NN@!!R
M@1/I!7O$L[39LL#^849=J5'O11&VTEYF@F4Y2"82-+V618LUWOP52_3NG<\B
MAT\$/M.1!.5A/!8$GDVD1-' ^@O3RB6Z8W9Z,&1&CN7V YFPT!T3_E4MS142
M3C7WSXN*)Z3A&WU?(0](?8>M>?X0Y[>S10O36AVP6YJJ&$/+^^C\;WL G/.+
MW?YW3ZC_4WE-_]$(X^G-7T -!3U4@K*-?PO\QIE4[9YY]O93E8.9_&3&BK;?
MJ,M$,Z%NH  0?:%O*4C2.&LDM?"(5NUT^H29^3B%"/3F#.<4T1@M<<\ULVCB
MV<,;R#90R7/5.)!\6,MXT;D"EC]*3*7;+.D97L!C0;DE/[$]$QCW\.^-C7(>
MH!0KHS0-A:MLGK(RO,.-FEV[V[JJ8+/(YU&,JV5?NS1]SXK&:<A^G']AW2IJ
MY&E8P"NK;I*9NY'=B^=R>/)%C4^V0BM'#$S/.L\ZAID>HRZFRU)8P_TSU^F!
MZDMP/MM:G0;88+AVC9W801R(RU,GX+?]G6>")+F5E]!(&H;@49LVS%'AHELK
MU4NU&[[7<8N!G=%J&M+Z3 KRTY==W]%EIYGQTMV@4AW*K0VDI"NA?N+<IA')
MFN#5J/;0?34R!8R'LY?+Q\,#YB==:TG%"TC:J>J\)OQ'J&F%B.#"=@8YPLS*
MHYS7ZZ\P=+M ZNJ2M5F$&3SDE34@_D;"$EB="DK7P=31M+P '!]4H&94_]Q-
M$=]AMI_&&U1W(;59:E4<1E&&[&58VA+KALJN[J;K'ESNT=9M] CR%I>;\:=\
M]FA,E$5FXT:XZXLZKAEYO^?6L2*EVFHDD(OTY".I3<67HR>/K*C./\IJDT!D
MSDD,FAU=S+RHMX[3MUHQ.3;76YG<DI(E:#K\!=1ZS4N[@400^#'^"$T<W*6.
M%#UAG8-.<AI-N]0LXF+Z@X1!1Z51@^H2)8&3J]GW7T]B5)<W;/>]9'4DB/9(
M1I!>P<3F8^O-!/95DS(/ZS,WN2#J0W<S;-F)VE+'5NO[M+;[?^;B(K)/8!C1
M/R!EY\Y<E84EQ6(&2^3U,G7 WG\TYL$@GYK[W,'4>>-=ZN1$[YUH=F5.YZ:A
M(7D^KV2"2_ QJJ)B*;%-7H&V_DY&HE,V+3S+<UT,W&O\Q]96 XE'-9 JQJ1=
M UL7,^O)#G20$;-9V#<:V#];O?D#\5Y 'V>_MX>]F,T42*'3K%!,"A9/"6K4
M.XZH0JT-YC>ZUAB_P'(>[7N_<*M6\%ZE?M5D ->N7OZIX'"ZRWX85*T@V_A8
M/ZG+YA7(B8Z,5<(Z4LLNVAT:KO5JD\W(G/+V)]@DP[\DZB/<8[4A+K<-H3C1
M=V)6OK[O4E603IT-LX>I<TRPJB(!3%X5GOI0#%;+*/5E-N"U7Z5"G*3O#+^)
MY7/(]>]W<G<:559D$7E4LL6X;^6<%8U@+>X;$FX?4:1HQH9_FB5<JA^P>4ON
M2$[&>:297"0L!%]I+A!*5#UUL)^XU?7 @&*AF!.SO>H>ZIS%^&C4:Q(Z\<?R
M]A4CN&?3E>2EXA5.H6HO"RWO7D8228-(9E6G/8,.;W8"TC#3]HAT"UG1&LT]
M^@##Z4(+I'@XA=G6]KN@0[^*HTR\I-&BR-VI<V/IX;0WDSV?A\ED+ Q.[+6]
MO\J@UQ=)S)HO-GU;*'P]Z$4\9X9/O=]+!*,M,^&L-*X,R=COK^5(Y%8QV/])
M2"=XF,90").+3Y.M-LC.#;K UE]X$T'K=I"E\FH?TS^EBEV+P%C5NKS_A>.V
M+)NGMB]3[S#ZDQ*!LB(\<Z\"$ZTTGW;B\'2C=3IWQ75"-3 #A)W3I)N :C,]
M>K<-GO<OR O//,^[P_5T'_!R;%\Z$'7:1IB8 )ED )DDWR?XQ+Q%,A64UG9(
M:Y->5&YXQ03M4 FMIJ7]ONU35DE3I;9,8VOCA<^K8]O5=N6$_,3\CYN=\VY$
M04O4L88.9/H\/>FU3QE'CPJJ2; +2$Z8A,O"54-\>]<'2IKX@@P_"Y64*$G:
MT'%L??!GD&'VB_+FP?=ZIHWDFEA_@:M-1UW30SDGAF^3!--A^X%BV?(R ]\$
M4?QWXO%_LH["9D83;/OM)H69A2'D2<#Q=4_NH@Z3PF*O.TZ%5G:M>?R6;1UK
M#!>53BBGVF.R=$I+)VZO$;6/M4U93DM#^3CCHEC@^A=-8B%#>]]M"D]?#ZP'
MQ;MX5H04(U@G)C*2)Q+@1LBE(MQV*#^K/+UPER#F.O7)I/(.@@^#)"IC]\XD
M2$,G!_933>*N"V"PX<%81917E-6_,NJ4Q],#WX@5%964;L.N.!JP6%\YJIYM
MUG;V1N1P+.55SDYY4M'5T9@N^J:8I($O<4RJ[6ZX5MR.$<]?/@C[J88D?S>"
M1D>Y]::YI+UH)%]7=G(/<UBE#.G&[F3+IGO4$@'E\/(LC2QNVL4_*))A1HVF
MZ[&C)O(<O<]LD=5RYLF.O_G3M1)M,%%]J:6?37;/H,5*3Z<3G\A-%VX70YY3
MYT"OY;<,/-*8[.30@ZCV*$CO?BA6KPFJ^S3E 88B.RW;2Z\X%859I(C(^0T/
M&_3R>:NGA^9%2K(1?JC_H28WF0/[%2(I$)/YJ';9AR=GT*MW[WZD-5JI(KIL
MR5C2SE)'!&8ICY_NP!?RG1+-9.25CW5GGU"8UJ"K2DWPUZXXFKRK9A-S68\K
MFT[S-KB(+ )B67,,G7^I]J#D(<(7-)1!8C,$H68M.F+9LANNL'@)Y:A32>['
M8THWYL34CO5ZR19*2!@\3Z]^QI*=N5/:CXK/9RWBQRMP),94+0EM)4@@7F?&
M552J)?) @-2(9/NU&.\Y%YI,<1(5&U:.Z.J$Y6N9$M)?I=GMUB4.P%0=SJ@.
M6?7(NIM9(1-&X55?;7=>>VOQ;7+$*#4>E34T%E33I/:DI9J.Q*7AW"FGO1(E
MT%^NK1+4KX^ABX!.Y!# //EC:P5F-VGD'8RNYTS<N8JLS8>_I.E6J%%YU$-6
M>>:6Y3!@/3*:PH1%X/=7V0VM^FQ\0#7_!J/&K]JJ8X1QA)A+TZ2\;M5(Y9=$
M'L^G([Y<%$)>L.G:4TC)TT)08U U]M1QU7%&"6&I8(#H7\!L2="V[Z/O]5_
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MFM]MG"4OO*"J@AE7F*3P3 <7[6ANE00='+).:.)\$W@>#2<ZLV3HZ78DKML
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MW$@9(-]A=$$$__.P[RAV($L//?4F:C-P>I"3IC)\S,)U6?I,)6PZNOA#$Q^
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M17YA3$T>O:#G!2BW>5K<K"ZA8:\*:_ZOE%O3/7@BYAVK??[\C>Q8Q-E .LF
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M:HCHU!Q\U2+*Z25;JL=HYG"2@KGZ6A:> M+5$K"*3][A10HEWP#A<JG"=S\
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MEU7SZ>@=QV4NA^H4"-N1=GYT]\OXZRY0QW\TQ6(1E:A%)LPNH3HF!-;EI:;
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M4+&:6V?JH$J58F23M6.E%0GSIDK8^R/9%P'YO, !?Y?RJU R\1^ T;A 2VQ
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MW[/]3]7TO $DX4:O_&9_BM-T/6 Y(5W^_ED0%TNYJ*#4>7-/$3ZJ?B1WF1-
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M8&OOE7_+*)K/P_!8%OHF.Y2A(D_!H8Y'-9WGIO]X6TELASE<3JM3AE]_ME3
MY)2_BP\,GZ><[?Y#JJ;:'QB=+.E_0;S6$]UJ8U((EI ;K!<W+?(EL;3!MUVJ
M3=ZG'!&L IT&)VDSD2EE52S*E@H-3K]/BFGL"BO(XC<E@Q10\-)P$+1VOH$O
M@(9HESUI_QRB.>HC]/F\6E0T#8$F\;H9'#]-D0JL=G,'"IR%-2K<R0#" E%
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M)TPU,$LF0RU46_XC5T=]^8/Z@LA?Y9[)3ZL-%#^MA-1'$==]ZQ)BY)/K?A]
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MUG!T)K3(NEW /WT)A%_7].-DA1PJ2P6I4;QXE$W@ZZ@;X+!>?5EVI,H0AQ+
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M_<4ALT2FOZ$\*+&,NQQOH*<B2Z$^0\"T(<V"!^KY%H[ZLB@?G@@.*I+,:OW
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M2T3W",3,^U1%(LYD,NJM2S.;$N!7UZ[\R<&ETO8+NO%W V_O#L^%*^Z;_^$
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MLR;6!A2F?UW=-#I.9GE@3HR=TFYDTE/"M/*:4CZ^ .A&EVG09\9+!0H]]R1
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M('[4J_*$8'UM?%SL"J'5M$8Q2ZWQ+B-GL)IKDD-M]W57W'*S9;U"(':+^1N
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M=>],J.G<OF%CEL>X*+50Q'!0[RLL]1VEE="_X/!SBT:YD^<I)"+SEE.4TI0
M"/3_<NVNI273[[Y.-37%DJFHH4NB"1RWZR)#*N+/;M7EX&FB:W@@.TL<3Z7:
M#*0:UY12$D[,2?%5/QHY2(Z2QQ<.QTN4[#]=L/?@VL*Z_LDC6XWXKU K4)[>
MZP-1=, ]DJ<'"\$FU>MDO<5PQ[3 4<-6S1"S80;Q#+0MAL=?3#VE]9<<E%7M
M6.DY:#Q,?,0.G\A!<UU=%MV15V7_5_$X4<P-6+%$2^ADQ0UKM]LO@Z(C1-7A
M1RQ!C]2WC<5^/MO/I9]TO>7GON9E@1%ISGB2)%O_PSCT%Y$2/,N]5'\G)HLH
M@S]Q-&\<XM\()/,1BWL[2B7A&WUSIL2&(XS+;3:=\^RGD0*(H5FWVQ>BX@1T
MJP><^A1(2+?MV<T;MM\RDX)SL8\J[$W 7.2.B#60W^G[NH12@E,]*?6=X2 #
MY)34+W:R90S?V[VA14E+8],-X[KI38>LR>0]^<&R:$IUF&!*J;*S3\L^[CM"
M,_(.3__B#[LD.<]&\T)"SGTK9$.@4'NS+)B8RT#J5_\=[2SP6NCJIAJ ]480
MZT735O)2C_G:6PV-ZE>=O5II7,L3^GLPH3^6^]2QWQ83 XYC[CIUC>VG>,)I
MW*^BOZ^I@.'K-R_?[PVO?8@UM'VWJE.]'*0':D[,_U4=U^A57KXWU\ OW&Y/
MHAD3_:3H^?$ ?H%E;(_=.D.C JJKJ^9-K*N+7>E9T9;'!MH6GN+]]WI@ QMJ
M]_K6V#7$Z+K-)=L7S5;V=C]=^H9 ?$<XEZ 2DQ:.@?%VM<EH_/DJTJW.-;XP
M*;IY7<516<66^+AXFR5>$(BGW!^O!=) 4;6:'!I"7%NQFDFLK@-R9LA3R7?.
M0M<" '#V>)J2>43.5;Z,94+=Q5;A#/HY-D>\QT\_;.U8HR "ZE^C1:MY(%R8
M#)H9W*J4H\-7G<ZFGJ_R56214XUUK?B\\@ 55W7CZ23ZULS $T?F*QH\D]E.
M_[K//?+*+K<1ZO L59O"6-8I[XAX[WC2*M:H(#7==S]YU)#ZD27> #^I. _O
M1$_(+XH=/<[Y6>=U^SZDLN![5H,3M?:UW\WSNLA8<;\!LFU0 ?$?L% ^8OSJ
MNJ=2V#RV*Q!LY6GE,.-)3PO=(7&SY/%/@/<YW)9'LD15-:5KC6GS98V!,6EI
M:8$41O>"Q>T'ZA-/G-\V_S*O.? *3K=-\$"-##.L-9/:C:KI6/!NAA;KH@F<
MCC4^(0(MM!"0?I/K/ ^W&)$/.&6DVZJU&ADQY#M89_$0/.8D*SN9R46MJHM'
MLW5^]<$^[&SJ8KH:[L1>^%DA_0X<1ZS#B]KB84LFG/-H\I>,+)#>"]23V(_9
M.].J5^:3H"\U/.8.G_P]^XA1K,W_'L.>UEA)+K%]R1F+W)=03(99'Y&-1><#
M\0D1ZCO#:.3AWX_UGHDCEB1TPO+34DW( [GKGMTLI%_UHR5GL(ZZX2\EVPXW
MWT+I[[4--L; *MZ49;KI7]^Q)EIMV^26]V/J JYQ:89:.%:KN,IO.^BY%$]<
MDD,#09$^P=XSCH&F1!K<Z';#FT V CZB$=)]!I+%2"^$ ZS22^@3<>M/0=*:
MIREE!Q#4GQ>"/X<73@&<\_ZKGS]@MY]8Y?F(*0MXSB60TP\J@DF(;/[F:'%J
M.GB7DL*H.\Z#DZ44-:&(W1<L[9](*:RV$Q7%)/I-V)92LZA%GYZV?P6/[/P]
MSQ*ON>"[(XOT_*Y\<O\8/''#]DGER9KS3*W82-K/!_2_,K%RC#[EQSZ*_S_B
MN+O@\'XA5\+/!H9K_/SL@KBQ[M.25."I/?X C$]%Q4"B" =S249:, $*;&C!
M_LRDQ8*#"G O*_@X)"^BW&'*8:*\').QZ-3J/(JM8=20S3H+5L\J*"DIR*KJ
MS<C-S\WPK8_3* 2579-HP5AL*4?H,4(FR467)B3[UG8PSJ]@F=6SJGH=4A*\
MH$Z^*5-,(OGH?MU2CYYE(EQCOI^4XWO=<N(NJST]F>::KQ9/#&"SC,"^J=O2
M'_<BJ>%\G3W%D^_9 N@W#_<N/VZ<T%0*P$]S4-\ 2.VWZ%\M29C^Q+1(S0,&
M<B\"NUAR/]M_DIS".NB'#Q1]H:4-DL?%Y$B2)F): O&I,! ZT:K=_8#H3V65
M)G2;$1(*$UG0(N'L/?Q6D2G+E-/KH:#'\%8$RM,3">__'^R]551<W1OF6;@3
MW-T++[QP*QR":W!W*)P0@DOAA4-!T,+=+2&X)[A#\$" ! @D6#+?USW=TSWS
MG[7FMF=FG9MS]:ZU+\[>S^_LYWU>1 X67Z02?T9A*S>+/8M=AH)PLUI?!%;"
M?]0!WS#L3OD!J9/@-*K/UC=D1FP//"D;)+W?4@P!TT@=Y<2NO A.P)W2^B;
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M%>!RQ"&)>87N!E^SJ[_G;^9L;#]C??P+>-?ZLN:%.,4ZYC6>EBM_R$(E<$J
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MF\.+QMLGX[1(_@ >CE3A*[:K-&53HI[N$MJ*EC-6_#RY1.8ZB%Y7Y7@ 5$U
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MS@EB)U-[DIJR)Y-7:<JYHL]!C:R9"0 TV$;727KI(P_/S.C[LAWUVR?&VMX
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MK]=\=^5,OU)EH,!9+WAUW!]B"2ITL059K@E?!H'=J]2\'QS2_8.!,:^Z;+>
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M"<S,#_U>0>'/@ .JUM\Q)'<X9 RA34KV&Y.85JGV2ZD*!!U.]!8:]E&E^!!
M#8:F2G$A[D&J>-#]%T4[\!O6GE)>J**8ZY5*)+=%UV=&J**'U3NY26:KZE:1
MJ+(^]X@J$3,@PXZF[]_\(7^):J^6V9B9'>+KHC! !<8L%RY,K::G-!,[EN5!
M$:_T@Q&NTQS\3)A-T/%AH0Q1X4C=YJ!#-TNWC58]6ZRNO*,==5X*2[63QMB,
MK,Y$+./\DO$I3$^ZLGD8UH7N6GTD:<BJ.2+ S;PG>8J@NR<Z>QVQB?X3=#EJ
M[1FZJOD3?/\^;4CMI0\-2V[\W-Y%5U[;U)/Q;[D;^<>?OQJVJ,L7Y:1M;S,O
M>#520H^G9.C(NURH:5QY/DOJ0"&-9:KC<&92?.HRR_?EUR-"6RAE,LS-#- N
M03?6-4E*>IB<"'?E%N0(H!M$,7X=L@GPHVM'\@T95R2BVK?7/2?#:"%:5$MV
MD0N&"R6?@"(@_"7%E+A[4G  G*>#<M<_P'\AQ9*>,9N-+JF9%V=]E/0=&;.[
M,U39T_,!,6L!593QK-!R'K&\,:1U@9H@_$O&:D%MQ?F7E(_<VN*&1E_U2I^N
MK3[I\NF+RX0XV^'?Y;'$/*51.PJ/'E_@"PEO;H&//E=3-CNR*OXT_[2EUOGT
M";1Q=_\[!,<2[?W[U\IY$A@+"TPOK[TA?E#"'"Z*R5-!+OW%*#,B\/C;4@XC
MQZ+!#PZ>Q-"J=6\C\&&<O6/1N,^,MR''Q\C]*4V7T("F#]]_?%JG>B]Q=KOQ
MBNWN[4E':GY.1W?\QM/'9T#+9T^OGQ(M2\^ ZI\A2\U&'R6$UK,C4N+/3_&/
MA>H_'_A#/C6RA5]7!?HC!EAK:=ZM/0-8W3O=^WMR.[90BOX\&@KWM(56%7GG
M">[%N3H6-?E,=^:">OYMRD,4]6I&H\?W-R_?7U\B&F8]?JA.0OWX9KIDP\V_
MRH?3&CSNN^K/1MD_H_.+[KW_PB#G;D',M6%4XJ:G"DQL+$9(-<15YG?P3(6#
MO/OME8AC6U>W+2Y3W3P7A_C3U[_+4.Y#!,J66$T8BVB8<=!B$H.JXIE17F)\
M$D[)/B- +'"1] (:';SJ0_OC=?USI\)<Y'3?,/4PA-._)%,@;"^%LNMESMD=
MIR0EQO" SX+? "NXWPVXQA^B&&DXU_3#>C +>U['Y)^ID:\-[#OR50;:'8C)
M[9CCWCY  I\!#519AT0-; _>ET^:6Y=-X (6<8E80R,G^8U>B?$.]Z<=M1\S
M-&^^H559+#4IS2('%AVM,6XH4"$*E$Y&W5(4U@]YO#!*G%>DFNM!4*ADF/5N
M..C;DI?X8V5UYQH>: ]_H:A,3/Z2(OE1WSXU4GF@'2*E[)99_.<'Y%>_U^CN
M4GA)!*CW:TVN'LA,#!F8XD^24)O*+=XM9M1+2ZN/GM9BLC?G#B;@3XE.O?KC
M>8O884WTR6,^."BFF2%%IG:LI$+T8NSN<\7WW2AO*#WW'CE=H5A+[6JA91*8
M8?>GERP__(\^31$GZ%"4)#(QFM#%E$;[UN5+C50P7RMR3_G$5K9K=(?3*6Q=
M0YM"GP'^V-(1M]?';$!_W#?/ *J.U-JHS^"&)\\=6#-3W\G'VTT?I;$"I.QG
MP*C#_[8@*WW<R*9R_NE4YLDZWVV[G"G!CLZ-?D*[MCX67/Q:BD;%!=XDII@R
M8)$*K2:PLF!=B!0A@.!KR^[0:HCG5^6%V;>$QCB;\US*XD^JWD).D/?LWVX%
M]K;?_P?R'\@_"&+?69:CDFU:O[(X(K2XQH[#1U][6,DL#;=4Y>#=(![B:V6D
ME.-&>0G2+*VB) W*3.QS&$1D;ZTH&[4?(6'7%]4$JPB*E@\,(TCU;Q)P\':(
MC#MR)V*JT\9?]_?\DY;Y'\C_"DC*3T';E-$728'6T05L"P$O8HS%G+\/'M*8
MWAOIV+UE/.MZ^O!BY.[;3X=_]C+^ _GG0\!A;U6S+?+<TVW\\\I:<GN8<)66
M4WEVA$7:3F)*4-<6IV$1HDPF]U)Z,E3K22?.Q;",?]+;_P?RCX=L>!N?JRG'
MD86R%_9XYKMFNGK6O8L^Z D6%-,/<W:'[9C0IO:YX&Q&!*[%*<UD\0^:U57%
MVL@WK%&=*.H*:39&5 ^3,UI.L7E;1<ITIIBPU'N6*@*%>(:YZ21[0OY!R_P/
MY+\;HG:4N6B5!;1:[C;"@D7(<(Z/"[6.OR3<(4J.]V.N);]838X/8JL8,A+
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MQ<%?+65+NN)BJ9&BHU55[]6;_#KAOZ@7B2J3Y0=6NDEW%2+26^H*L3!D"OK
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M$DQV1)L9KJ@"R2>P>U _-# &.E670NG6\6(\+799C96SQNT=HW8Q1YGOX,\
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M:JF3*-(P4M7NJI 1(]!T1$S/VT)^Y)>,3Q19[,9S4>QBQ'A16MG).??]A;I
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MZM2\QB/>H_AMP[%OCWS0]8O4!FI1K.%/A+P<SX":<S%)G^5[<2:N[ 2NG*%
MXVE^D/?H1GC:9(/#]^STM/@JK9%/3?V6?!28I7&F \EWCU:84_A7ZIV":*?H
M+AJ@\DIZV;Y2PFNW7T9V%#]E<5HB&@QIYW,@Q.[7FV6:CNLU5N=9\"UA(TU\
M>G59(,:_Y+ 1\/$ &_KUNXR;;LOI&/.9XR/G=^5A$P)"BCT@>(JY=[/J0M/0
M@0W1B-;$Z%0W1%.E3S,+2C1-D9#1>M2+9)*?"&7M_E!XP2U@MS25?.*H/:WJ
M4K;53 SKU&'4[9,MSY<3(BRE)P:<0JI3CWB@,JG8,JF2PSPJ%!-FF4+OHDVH
M]NB^/0R3.TZGJ2R#'";;+MX7D\Q"ZC2.S^:X'WIZCW%J8F0>K^)T&]OXW?,"
MO'"C9W@^8;TB9)K6DJ6]1>(UK%VY:M4]>XP0CL#KX^\T!AXRR** MM;@J=FU
MB]63O29[#?BV3)S3%U<JL@N0\^JHU+&,6D+-R33A7&N;V*I9H4F/'Z'8(5UD
M-DF9]JU@EF\]ATSL8VO"6L0Z4K "KX.A8E0:C8^_J]H2"G0+-.'>(S?S,9EL
MJ!CCG)K&4EV4)5@2QK4*>JR>H9KJT0BOX1SXV$<YN9A V8U4F4\.E;GVVY;^
M^NWG8=L;1DUP@F*?WH TGB4JGX5*C E9E?5XY125\BWSE'Q:ZJ51JB:YG!9+
M30&%3==KWP:;L)9Y-BT?7WYL\?I/8!F[@[G??B!M=@Y5*J;71H/%+;%^ [.A
MXU_@^ IBDE,9; (]'"0BKTQGZ(:X<3A?1G:.:T@I?!,DMF2LX;]H_D0JS#:D
MKSC9XMM#B.^>)&)7;,G+<(F\='<,92+; +&Z3=]M!Q8AT=[(Z=-;47#@*@7<
M?!^?Y!7$)4:!SVE5;']O8GX7AO6AG/?:CZHEA:UXI684S<TK)B4]E+EVI40Q
MQ(G.(H=5J3+Y39=J)X^%9<I+Y4*9=P]7@)*+WENC>MU=JIC8IC%MA*Q<1)#$
M @TOR>DZLHK/ '3L\M&TDP(S)Y+U"(?O.!,[@: ?8K!FI@XZ,PB3O3OB23%W
M*%<3B&ONJZQ* :OK6?4M[S&:M\,M!A.6,@J[WV^WY$WTT/)X,@>\6CZX43$M
M)="SH.;7W[=J@3'#.,WA$*5C0=[ZF>B026[$,# 6F7* ^UAV8%YN"K\*W3V6
M>E3UZNL>O(1SE9M+E;8C3+AESJ&85E5G5E*<9+A-):O[T'77]4ZS<TB[XYSB
MHKP#7'706C67$:[NO.T>ZYXN91&/2C<!U"22E(2@67?I:.C!JJ+.8M-0RS);
MQ-0I)\;(^&H5?)>P?5_4:H\OXRE<X(<:R"= DZW!,(+$ 5R@695^77>C?-)D
MRXI+NI@MZJ?<+-P*Z,YQ9K4V[&LY=Q+4WM5@2F/OD/,0NSC;80H_/882T4@V
MAGJF,;GB2%<NMT^AF6VI5C7S8W(8(14W&?KO9K%H9JWX)NV=3(<<4UM;BRGI
M?$!9 =UN+=D/(>H%NW--_4D6+"ZQ&<^/R?7V<^:(G]4O9IYTWRF<TS'QW0;E
MQADC,L'T?$)=EI5'[:WCJL:U7M?&=*A"%0XM:@OB[>,5&!SAD94C:2CXNL&:
MF5N6H.X1K(_*0Q9KWV<V_")YW>EL'[&!Z-O=,T=FF\#?5FTV#B35(XJGYN-C
M9$4IA+7(LA XO-YQB2@LGC?TXA!'3G7;K/=D&JAW?L)'@#\D]D869DB>AR[0
M-X'Z&\DY*'Q_AU3-N.UB!&H>XOP;NK =1W[T5=RR7<T+-N!9/=Q]$"(LZ*6G
M5*D\/B&8<K44QQN-10R1]:#(O'#6K%1?"]%5+>=\J+Z78YG*0\("D>\HC7,N
MD$7?80DL8:TJ\B@N+F1I,D97$W/CLV"+1O,)7I;%HY9HU8]VIC?J7=W=?B8^
M8VX/):8:5YE6ZK2E(*->YC[0L%P&6G U Q&:/Z=="AK/.I)].*-^/Y"YWY-I
M041'B3F#ESW^8/^:C'N86 /Y\8K8,[FX"CNQL@!_DCB6)2,FD&E"D(EVIDIJ
MYK[SAV%:TWZZ'O)AS8HP%LXH36^VNUG%HCRY*?AE<!?F-@H4KI2_\$-I\9*]
MB<G!*Z5J,0-+(+V 0K^4+[QT3$^-Q5AV,4;CJL$^:BUSI%:27?$0NG3"+7I*
MF$[*IKS^FNS"M?_MB 3+]D>N!);,:OW\3Z,JXXG-E*\M%/3X9*&VHVI8]O8I
M\>Y^@6@0]=)#%<RBI[@W,CV]5,^ R+JF\%R7$<YE,89==K4JP_J)[2KA=,'J
M\3N7A&.5VL4S]EV+#/LE@U'*0@O2+@G25&$O]$C[R8?$J<]M;_A;3+S0X@LW
MQ@QY(8,RE)J@K[;+[0L$24V8F16($HFH+J<B5G0ZQ$@1%J;;Z@*V.)0UQ^34
MJPQQ/-F-.#F)$T3-;P0CIV'M(3RZZ*@LFG$:8P@A4< $/*2<G2S77TY,,B/5
M,;8/V,'2U*O:GGO![@;ZMNF,&H+5C[G.E'@:DY YCTF>1 U8JNJ%U9J^OAX?
M7D40B_68UR5J8-QH:W:WUDKSA/3D+%]>PU%-#C]I7R^12,M'$EJ8B(+BU),)
M$T@G*&HIW=B4T@-VNTEV:.<*?WD)O%[43!9>9V,ZS $E8QBDF;'RE$E!M&E3
M3X3(%&Z:@C\MW)()ON)KSS_ SD/7#Y1!#Q9R;.DB;1_[F%6G3R%;W93LLW;G
MBFIC,72)@*]!#+]7[[FPYM9V*76/$$O[[F7EP^/:UFFO3IRSS,+-87'-]Y22
M&Z9G=8V[7EDIY5PMRTUA6;0Q)V#+1YERM$&P2O''4.JX!KGCJ0LV[1G3&MK!
M31!<1AZM.-6Q=_)AH!?HV-'9;Z8:'RZQ05H[:RY/@V1*X9!@.S=B'N^+(DMK
M"L;?+ Q0K5G:/FIY8LW4W-\\B-<>TUWIDP>>/*-)LCF=ZSWD_:97WH/OWU#K
MB,? HW,;%9R\[X'. C;=^9MO7Z"CA[.-=9N.5UMB6VHM.IBE_M:R$^K6UUAM
M=0W4R\M+H->6KM$J7U5_\X7[@FQ =<G.&:P 1X$LLP#??-YH4HR%$)FC>Y<S
MVSX#-*L*9P1YJE4RVV1Y37D3HX3LWBFH P  G/Y6XG*$W=<HEA&Q!6$!8ZZK
M=5&9%J&Q;SZD77#D"U[H==$]VI5GEQYLF:7VT5*7>QG41<8=F]86-MBL@40=
M$2(XDX0=VQTIFMFI&O!6O7@FC=]]4H]2*8!VO&1?=G.CJ!LV"A,"%XO_17AI
MIS:W^B7Z%^'E$6-"+:@8H<]H,V1Y?'?)U_^QH^)J_W(5G=]J'L5(U/-<:[/=
M;KW;"NZ%^U)K2)$(7R'8/'< A442 @$(E@<8_R!PXG(9.#?6AXR2(U\VRXON
M'F)WY6V?YJ.7Q["#I609MELT=I%X2]<5(T"=<2+:PA.U5I[V)6_8_1^<)DR6
M-'Q\.PJ#^U*$?[LH'<<Q5K\@>8,]Y@V)(I/'#.IVW3M=C_A=)SSY^XN >&GY
MB7%[;&1X@@\;&_ 65KCP2E"\.WY7W+UI"#W&JDZ#-X+[)PH+1-[J\PW3\?XY
M&>(QZPA*( $K:80*Z2]%#-X'-WET^JF4#VP=O 6Q"E$?FL<_:6%BH9/4A38*
MD-#0F%>GP(IH7A!$1G_*)Z-/"9 P2='52FK2*\>-TO(#WLKF=6NN@T>= 0ZF
M(QUCNMY;6<3$]%^P+8LLI->:EF?+M6[+R1C/J*6..>%G^"R938=2FZ8G>&&>
M,9;S:?/U:GI?J42%MZRYZ^[R&(NK06JSJ16P6P$PX_3PA$USIH=%@G[GU1!=
MV+AQR122^UAT8+U5Z@((L[2^!'3.&W_K;C3>E <9@P)A6=K7^'SI4UK-GDYB
MM\C^C''Z6G6+WE0LRSQ6;7'WS4Q6;QE87)(:RT)O-$U!'A.>$$H,HI83,N9O
MCJ*L\3G% )XPQWTA HP.6G;MVS!5M)EBL_6VN.B(U7:OB,A8DVT2EUL7?*YF
M?G<M0S?&(]46TK.QA_'";>1HK219WL0PQ%2 8/C@<A2*^:F'1-+: J.6E-:\
MH4L=.*M>B#Y9,[WXB9>/8U^74VN86R-G.=+M,ZDF[*602+A9NN(R0[SK)SY!
MJ^/KT#,!GRREP%=US&?J*OM$V2YJY1HJY6#O\EA3JM]+.:8XIOOUY0E"68?D
M%OP50'S9+M)3?SH)Y!?7^$_-B"QCPC%)];V&N%+$^<&3E%#+A![DT[&A!<=-
M;C-?:FEX,B,A :?TO$%":D8XX8MFU@&E3KWB G_A>:H!NJNK4P*+Y1+F#9XB
M5>&WL;P0_=Y>4</1ZE:+XG;^ZI-TV+C33(IJ7HB0:B[:P1&"5I+S!M6KPH\Z
M-P2+OQP4.MNL[U%8/-LG*G,VRU7;^4('5*8=>R;+DY'? NF-3.RWB>9-*9-'
M98O1Z4V9SR+N4=2> 2$N3VS:US_ED*Z>QMD\Y<W^HOSY-RC^#0_U]U&WV ]-
MVV^G=B5/0LH8#[%(T!*@!:\[K/%]"1=;?XBK]'L!,[5&!K'7B0[]L\X=.F0S
M%LEC;O"3KQ/_,^[)#<^]S\"$IY&:<BHR2/_V%JA#*/14P0;\6KK'A7C355GZ
MUF)S;"U_]A8U\^PS.GZO@++:=\_WE-FV:;0D3;H/O5/1N66$3D:C;)E%H2KF
ME>:D T @Z,)JG&F<6!Z.-4/0)$.II(E) '6M,RNM+B,$1&'SD$1 =JAG#B,#
M]JG:/-3TY&6P4+)LTG6_QFM^I4]M6S :GF+>&B@LYTRS53'# A AHT,Z(H."
M2.+N;?Z<6T#-*O%H@JNX)\,W2+G<-)AT_B[S1YD@;;%-3W"UI,K0![OH"22W
MB0G,&J8ILWF8=G%S.>&(;]JT&MTF2](=HUGE\!&SO-L,##A[>)Z:$^)C5V;7
M17 T*IM=U8S!,,],-1F&2XL<FF,:2; X',QI1W64<BW"A!^W7]O(GM="IC15
M1]6J7,T'*3/'AP-?)<1;TH:$(9CJP5+'JFJSVWR20+1L^M Q9SR7*N;F*OG!
M05A&?*Q%=CV1WD"HS7@3(1*S6ZYDSQ10=-2IEND9$.SU#"!S@OV?XMN<;VOJ
M9-[:%+5/B%CY)3MX9W81B =S-!"#1)U[S<>Z&)OCDO(:A#*#Y(ZU DN,56)E
M(FSH;[N&$"!IK,J,_6SYK/5V.8Q4B'$Q=-834ZKM9)<E@GK=8ZLN6AWVZC7J
M1WQIN,%V12"@% %F0P:O(FDZA['M%^SY1O@S %__#,.0]&"-D;\;_B'&HVG@
MT-GB(@H00YYKOV24W$]Z_G(JNQT.\V!PF>4M%=$:^N3ZJ99$[$5B7?=;_JOL
MRZZDI'=50W".UB4C8<,PWNT0U?>CPZ4F/$/J9E 0QO=OM@>R18^.F;;:E??-
M^;.MSJM\)\3S$HVTKY:E ;]^1=5QU2YC.3K/=)<:C5AYR&E?VI=(KM#=H5%%
M4VW]^ IF+2M;'C$J378BL=.Y/CQ(%E%1V/3%)/W6K9UYSLMO]T&F&^?$E5%N
MTZ8SF, R/#[$?D)$>I.-CSU5D]&ECR5)!XN5E;4HONA;*M:%LF%]NC!KF'3=
M?0Y$;?U:.\K[QR_'+A3"[$/C"=59J+*P+1D^/ODX8>W^9)BF+%$D$SBH$-11
M41_S#+A6#/D@=IWLWE7"-NZ&*S?EX?55M%R]CC_I38++,LG,6)Q#77'%4583
M1=B'87W_&M1#(BS>^(LT/9U0SR5R&OJ+9P#WZFNM*]]W(4$U9KY+@WR-^6^B
M2O*K)$#V*5;G7=3-;Q(9)X85CF)9LN1X0MT91* YN?RWP+FG#A7^&BW?=37K
M#>$W65\PSPK6\&CLB@"!OX=6,E;LPCJ$K8U@G(=\(B5L'NT:A6_P'I'BAW%O
M GPITV +%X><"XI",0)L#[>WBE2,] [O4; #(%N?M^5TJ ]TR]N??B4>;F^R
M?Q/"V82=,VA,N1/VN+<.=27* 7L9;+;EL>I;RJ80BX:&6-P$"SW<3)NZAK2(
M2/6=N-63%SCF3/%%>=C#&1?O6=714:N7<EH2DOYDB7?YK-LA99)]ORX2,$E_
MB6.?I\Y)3EU)_?B>77UR/:8QGI=YF+S5J /*VF-U0>PD,RZL<E2I0.[#)'W#
M?GYG-4#N.HY_=:VD6:#<D^YZ2:*PIFH\V>EK.YC/1(+85YSLBN>X'9*V65WK
M.\'<TU[-[*!@02G.>R?HZDL2HB&]C7CM;C2HU6STHT*S:7+X@X59_;8>YM3!
M-9YK=E0>DACK$#=IV&Y2RXEMJ7F=Y$FE?Q:=D@ZUA6>2YX_?/)5M89$!&,!+
MLBD/]05H_4U^MP98D1&:1,!#1!:M!/R6&2*O[Q?43SB-F]C2>9Z4BDJ>+M6E
MDED_[_M5#&G*A5,^#%(FTK"7UZ4B%,U::IZKJCK2:E,N(.85:SN7AMFK9!=%
MVK=LY\)Q<$B1MYB&[<8X(Y#D$U/K1GF *A).B!'+69WRDH*>,:M*:;/LS=0A
M]".JZ*(E$/:*>X&;)WZS?H#S9P;#ENS]+&5I81F(.9,F=SW$:EB&9O L![J8
MI,C')V#5C,I7>Q0SV0031S_>;DCD4F&ZL>W5$]PKI'HYCLB);0E#7N*)%7%<
MQ0W=43!7*BL^9MPO$VY>X'5QMX_380/KW(^$T.XKDF';)M>\R"WN58[ U03:
MO'=D!,$-BO,I9NY355;0>,S)7RG%FGE(>908&%ZZ+.X3G:L#3:R3Y/TYTA_*
M\. @0!"ZXX:;*E+J*8^Q>%Y(F\$7PHTO$71LUJ/N.7&>&DJM[EZ(C<FN]=?R
M,<YSEH1Z,2B;Q)]8/'+H@RO_Q 22/39Z/=WJZ>4(^L,S[)S$UY7GA?S>O^PC
M?*Q%7:P>1YNK4')&JOBUME0CPP_>N<@I+;PV@E:+QY?;<9%(<X#H:!>RS"(Z
MI@8WF#$^^!_[*"I5S]04%B6Z5O=JM"!.G:B'4MU+6_K#I2>$'ZZQM#Z 9"=:
M-Y9_=^=$H;=_X<$UDMP ,= MI\2 ;I%7CF[+3?%IPW]5>TMW1=V6HI*XU5X3
MP'/-2)48C-E>-NBVM?=9M:Z2%/)$2U?6$J<N<J%*965C>06?.[J\F)8@\I\2
M#/_JA\^#]UB:JU5KE=78@L$\SHA+Z#XB+?Y%7PF:]<KB'%B97)59S5@D.8R'
MA[!!@_9AZN&)L93J@>!FPQ=1?+H8T1 $<Y_?XO@0=B@ $YE9EVO KB%.\Y0U
MIRG//K]-R0V>N@Q==)28T::S'B\8$XFN677]%1RP_T.3\UXXQT)SP\.DUT$)
M@X&0?*RJ8@B1B3>&2H6M)HY[CNYS<GIL_2'I$7D:A@!MU0V[Z_TERD.&;8T.
M&97PA/+9455RW(HT>UP69? :3 I4[%93YG_NZ=_;MC"?8-BWQ9A'>N(C83?2
MGH/+V:2;GWD.&OHQR*.B=S$ >X<"G^[O[0EU(?X35&P/40]ZMBO@&BKVWPQ=
MHFSX_1SB8O.Y)]U@*J>U:=%/AE,]>ACI"CU&0EC,LH:ELE!$U]3^LMZ(M*\)
MY6)Y;QO].SQ_G=+MJ<#=.Z&>T.*[*\K7;]9KTQ19JCBGP^+LIS^"W>[T.U2!
MCBIAS+XH-A]_3WJ+'@@.E2]<)L(QPPR,P3N(3?":(?G52X\QYBS*Q E. E1<
MAAZ%L<C(%84DDNN<TFSF4DDZ3!0 3LM*N46V8+(!R7R>@O8!-;-%UHQQ^0YO
MC?F94'6YB1[S8TSOD9\7*]-0L<,2>$(30Q)-[,T+0\\W@BHEFG5-E^O%1E,?
M$GPR>=.JA&##P<GI,<X[<I@AL@WMDEKQ\:(XXST)=G/G_%(6GMK1/V7(7TOC
MVQP!9WZ\?+%8XT5KOU65)@ ;:SL;ZPT.C7K'?2)&7V14#01ZJ#!RQZ'1VY9/
MBCP#B-=!Y$<B$,A1TI0RE"\QSY@-:!)S=X;AYY-#?.A-X%DLMC1O+'Z.LUHT
MS8#%O)B;=RU/OW"Q>E$SK)1%[&78V=_4)-6E'EG=+2MRF\Q"*5D!EI1?XXYH
M:3W)1F.9,>OU$T6SZSAA:CO%E=:>C3\7(K\J3K,YNT$QI3\VVD@@V2^<8&PA
MP6IGVX%="BJB:(SB_>#HTU9H;H+GU. JCLZ1"=%^U%B4M+G]L8Y[-^-Y,/TE
MP1*&)10'LZGJS,''&48\B$TK_="=I^5'I;)DS!ZJ+R<M5<8[_,(I*Z)5G=#_
M<>(N.0V>IR,E0WL,]RZQ0LF:*D(7O7BIS;%L,[&O$]3:8M<5--G^QB3*EGV[
M>X29J!Q.E/=.A1: 2'=AX?_>P]73_<H TGZDK%D:+5,;YID!^#W*6XVL?IXD
M.TE%7H$ &3YXM;=[=9WB.E)5YW;=9*DD[$KU0(ZK9Y9.GK%I$3F2B4;3HQ5R
ML"0:;U?<TIJ3!-?G"3R"ZC&9[,&*F^9&,E9#Y<#>S:^R![]>,HP9_+E":,!=
M.<)Y-6D;@.KJ/DXOF*UMT0%)L"@ENG?W3L585 F4&IPK8%L[+5^"^M)<,Y4,
M&"KG,2O'$?VV2%*CNB/\41-3I53E2_:ZT-4VE?:)2OGHR]H(A<BF0P>5 \\J
MBUS?8Z_W\;D;G"3!'U?(/UK\(M/:U'%*5#-H\<P)-28L4S7A549K&]6M42%"
M<6F7:+$MSD@Z9JLV<.S@Q6G78;)B;0T-)NC8)"[V(<J#+&:FJE^$(5+QD88Q
MYVZ>+]SI*UU86-JUG3/=O#+VX$\0OSP+=\SCF)#A*PTV7%[FZ52 )?9\ P#\
M**3@A>3N>/!*[S%T;;%OG-W,F9X*\G*M%_FUQX?Y63EFA)G5T:R!5"<\L7\N
M_=:!:A9N@7+-;]E&J#,:P?GT4&?/4Z.GF&;A#@^Q3\.NWIV_ZG]5/QE)O(QI
M[#5B0E/^V&+@=-[U.N;\VS,@:?#:V\OQ0<(EHQ3L?Q-<\R[_SOO1?R>#5"OC
M^(NP6O]H?\];])O=C\[73!5;K\,6%GYI7UB2'H/'MNHO09N<RWRE9FSRYJSY
MKT85X9=N<J_.S<I3,@@XQG!DM38JSU]RM"G'WZ%H"I^*?5B; V.>XLU?, R6
M)?!YS3K[&_I_=;<,QH2*Z^!L37?J=5,U-JBTN.B+Q6;H+)D^ VJ@O,^ WFDU
M!\<UTW2-WA(.3JLATFZ%I[:LSI1"J"S^!=J>!.;5CQM;\82[,>JQ@,]+T_L+
MR-I6=17?)[XJ13-JQEAU4(8AW\&U5$R?E$YNI9"_!PF'\>7V]&&;"-6D65?U
M'>?&>6FN88%&R,5YT$I;%"4/[(..)WF![E"O:-U2+:V<6$TR&:<=1-%G@(?0
M,Z!2KN@9(&XQJRF=B"IXPLZ6'9JA\*Y3.&]2<?\$BAW0A^A(9*J)^ E_NW>S
MPXGJ!XDM=92ZE!&'J8\L^NM>ZQ9W[Z@JAH\_K'FYEM7?/EK?\[\3=/\V)G]\
M%4&T;#3\$'MBF^2XR]2KQ/1D]UDU8HT;K?5!,B!N0\CS$6IWMM1P"Q'\@GOB
MK)<"&I!GNIYR>=+R]X7\_/F^H1% $20X9WU_4OJVT.17J\R/X(IG0'_G;^*:
MMV.4"4\?>?^DO(G?%V=NTSX] ZYZD$*> :T>-+]>_DP^^W*N6K&;5YWP^?_]
M,/=_XPM_([=>:I'#RN[R'D[.M#*3(@AJL;4<]8R*"55R4H&]2PX0PDK,0!8.
M]:F2S<5$F!#\Q?,:5+KQL5'K=@F79LQAC@=ARN@GD6QSA4H%_;KXL,6%0ZJ?
M7N@B@$6V-)N)&0&J?F^SX2!UAV7<AI9"5[8< 4I$P[Z=8=-*!T=U*)3#<6$<
M;MHX-68UDZP_MTC#N=O!GAW'72MV+6Z5*M/BIO5?U#7P/62+1N3GB_.=M$)Y
MRXS7!KR"AG>RDA$QY+WCYS\((<I:/P,R!?&/0[-2>0WWL@M1U"':+,B8U@&D
MA8B4C3N2" 0 ]!_9QS_XCIVN>JX_-!;\QMA]LGRO0+-Z$_JQ>8UKJ>MW?1O.
MK^+P#3=Q.X*Y.M\LHMM<?@M_ \FTMJTZ7DO#6P%,BY?B3>7VO"S\>NJTE3&>
MU^IZDVGJ=L&33"R&/SKXF3XTT0#W2VID?@2,"LR.)G4K2)CYX62#]0-9"[D8
MQ[N+2Q2)=C'")A0Z7"V59%].+OXXBKD2IX9ZO^-)VO>E(I7S%&41*U+RBS_X
M*1A=_3@CT7)'\+G*%?DT43DD7'(@4X2J97=A9?2+:/A#7P&D^G26Q&*3&B^,
M!5U)0*&43A(3EMJ(OP=++>K$A 4Y EZ\_QE;\NXFH<+L@BSA$L,E]NI.P$OC
MJC;6I#[+M"U08PMKW*:K<Z3Y>ET"G%.YGU.J4 G( V7XR$]RMHH.]>]^]]@@
M/T4(HSSVVPY@%$]SG"6\M @C^VB^R*JWQ'+1%CWB<,7H/Q>?XIO[?[#V5E%Q
M=0NS*,'=W6F\<7=W:;1Q">[N'H*[-TX"#31NC5OPQB&XD^">!!)(@B1W?__#
MN?L_]YZQ_X>SGN88ZV6M.><8LZI&S2HJ"H?/8NU"?DFYJ_^C[^KJRDDYO$R-
MK=EM&%6B#1<IF=KPEUV%(J-=QU'LRX547&>VHG155/D0K"N4!"A^9=@6>.*"
MZ!()#0+C]SI3V!8&[<8D!X6D[ R*C+''ID6]U/#*DI4*6< #:FR?O!\ZY(J<
M&9Y=/-%_2K]XAR:*#C26_V[RW+<<,[',.1W8!JG.3(O%6I\T4$'L]+*,<M@L
MD[ =P=.$.LBLO!<@L>,I.^LV2"*=&"+(=+K%UK6'A6EG'*635O2$8\96P$--
M7=*+LW'M !/.!HACBE$3>C$MKHU$3'U=;QF>L7+B1[BEIOCTZD!4I.:#"U2&
M.GU2;-3<U-]US2_)0-.UK9[U*+VO)$?@5-0=%7INSEUA/_#8V?JB4P)*[7?0
MQ:=_*$^2.28L)=7+**8P,[JR<[*HL!:7J13(]//;FKW[5']2)FEY(_X'G$2;
M0:$SHE!@($#A(3_:KF',!SZ6=+,]+;]@KO)$<-P4G!<J65+I*E.D(%@UMR^7
MDHMW*$H&UDAZAI4TAZ<:=&<+<Q0X:J=#3<^0C6BEE:\H8SBS)C@3;_ZL)W[G
M/OJ+E(Y7Z5ZT<E6\& H;Q&/?T?MFYDQQ+)V.1R:TW&._O=06C&>I#;=G7Y(R
MH@]3!@Y4X^OPDF#BXZ_DAEN4S(0XTQJ?J_;TI;!@=ZE\WB+"$#R)84D;L;60
M]D<$F =F3, !X(G .&A%BUPM]\I+]^0^+%].S_"3>,Z3:_L]6F*4UU6_8519
M,=J?U!H&_035!4$#/\.N24%]TUE*(V*/NYNLTR,JV,6=[Y2DSU:541@M;?<-
MI[,:L['\"7&4R,Q-2?,7"X5B,GNTM*W:>^7&=(&3,6ZL?*>+(/<)=<<2YF(O
MGJ#?@#[Y,/0V%W7LIC4]U*F8Y!KMOTCS.%,$LRK!$P1*F=STS,?6PS_"_B*]
M>W?W;/,7R>TO4LY?I,>SHT?/CK67T+(/47?&FR07[I:_R^9*7$G^#+WY*E<\
MJ#'THBA"\/N*S3/BXJV^LM\IS<TK[9F\>-<CB;B8'C9#PHO S]%(M)K6 AQ?
M#Y&C/X5+96_+=7JIW_QYS56VS< N'EYU]BU*Z$X.-#)Y_>5I?[*N/#:1"T%"
M87 B3CA.]D19&8,F6Q4M[:C^FO;Y+3\2YO>>X"^B-P1!DPPF3])ZH=(+LKRS
MUU]_$P0S='V^MGZ?^*OG7^A S#/T1<'I_<T'V7OAML>8=[_'"W9 [VNYI;X'
M6]V+="\APRR.>:<1F$4&[ZO(-E&CDZ"&I09<^#:UR+0 >4+^M\K*(GNSQR$C
M.\7!5W)+@3+I'YV\YO]U&.UF=#?\13H/&?H=_J(M&SS0O,7;7'L2AP] >6?6
M1NY)I4/L?4I5"%#^#45B10NU^(E9$,5Y@R^;>\(N_,# P$#@^%RN^;W7TGHC
MMJMO\2XR@^<OTN20A\@/OLDWLI(I.PQ1L:M_D?A;7Q#!(/(E G)#/(<[EN7A
M^T8/E&H\]5).&AWU#V](I^,43PFY(/D!6RS9))27,#V2>$M<U8M"KM9RAVT.
ME>(L19%6+!KNG 98@U]FJQ+I&6=JC_PH_>(7P>![^O>RGA=/YCXZ7M$*QP'M
M)OA $_0F:OJ==,_AM\ED ; I<>U)>R[:(0(1GL][3UZBS9I0[-)81X2$.5!U
M)=$3'VIQ'(*9I4^][C*.B+B5['J-2(RJ,V/U;0:<3&_#ZJL%>?NF$E-8$= Z
M@W9REDY5JS:$4HRK?=T6E(R,:EJU[Y IQ8\2LU\"'3]'O[VK@4P,=P\*Q2%,
M@?FAS\G=NR)>_RRJNZFEI1F(,^0[B"A+-V^LF"HR_]!GR.:^]%7!"#M@68I]
M&:O1, F3</S5WK7'&<%Q>T@MU7*9U["WZ0)A8U[2S,?OMT'4'88KG+VJRRUL
M;LV?E^35_%JJ<K7E=8>9+J5S<T/6)44E&A*7B0E* 4NIY#Q$4HG>]%(^ 1_=
MUNJQ"B\Y_$GCF)25Y9'47*Y8>1J*L(/,UJX]JQO>*LQ<TJ ?FHEZ9XK>,'=S
M%@'/2#Z^L@49Q+CT@.LH1U^-2PR!_HB%Q-Y-*Q16AIQLT@O_ZMV>T!ZL._SJ
M:2)E7W/R%ZG\JOCV7Z!&G2:R0N[@7R@MQ\+]7?A+W0>+9Z_1!VZEPYJIQ.D6
MYX>7(SK+9]N;3Y"KOT@FRR%O5P+*J"T76HH6^+C>ZAIX_T722U?Z$S;]#I;Z
M7<A!=RO0'6:!$,*)L>,,_'DN&5C?E;R.M%OT&.$)M,M3"QU+4GK.WE'-S<XD
M#!#9U9RDFF;)J=)W(BZ$Z6C1]3K="I:>>0RA>:3D)1Z0,-:[(?G00J5<)K%%
M_.QGLBW;\VK,O0FY7.ZQ].K6:)-\?6J=FPV+.# +0B5]=V4W@Y8B@8X%SAH9
M)&][9>R81AM4X.Z]N(4<DKKYV=D1BCO1M&QVM[!N(FV #1%=!]5+:!W#.:6<
M)^&?\KJ_2-^\Y.+=]JPS4++_(A6<:NBVW)!;"W\?< SSRH2'&_X3"K%S+T/!
M7/M0^H=OXG^W XZL.",=",/IE02_L#J8=A38*=GL9BGRF#J<ZN?6F:%!! Q\
M2@+HRT35S P)D[-FV?_#%>6>#ZZ(7U=M%$47'F <J*?DSY"_2"S#L'.WA]/K
MWIN^8\(K"J??/1S99:K2?F_!ZC-DBE9M7@:(+XZNHA3)Z KC[08$A1_O&J7M
M+CMC9PJ#'H@RLEP9G6""GB=$+GUNC!5%TW ,#B)1SQ/O+1+ 9XTOD+9/1G[D
M+!^V=F&_+B54=D)^>\A@Y1Q:=\K/CRBOFZDF&J$M$VF(A-96<H-DA*:*"P9P
M'#6L01#-<(J/N+_F#*W0&LEQ4ZDPO%SI4SM[V;G4*=QI+QCBL MA==7^;."
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M8%EPT"FN?@52I'3ZBW2/N2IWUEC4%;K"'8MH\Q*$,(U'^MG>L5OET1WB/=&
MT#TO.3%Y&RA+JFC0-H!VV'2H"P9)F#?OA/V;*6GH^2LM;AK-MAWVQ_LC/M#/
MD@50I&OZ60L*--1)I+!>#IST4*N\M<XR4)0Y\N.8=RPELUBY\;^(#%&VS\J3
MHK0<T8%;QK?'P!R6M>A,JDX$L>]8T5 *Y[*=@K*BWRYSY V3TGK#BE>O<$TL
MTMPS.8F_9]=P C<79 -#+9/+ODXQHE^3>Q?D'&E 4_W!*I@/RGS60QP_<"WT
MO9P@VNX:]1^Y\$ CX]N#.C&V5O%>7F8DNLF4F\<ITJR<D9DV2#+I_V?.^ &F
M,2[&@GM9F7=N_!SHXJ5#;[?V5!VEV,NO'#?,"JQD8*E!^HM$U(V_Q47DEM\M
M">/M;.65G3+DSP:6MI,&.B%TJ=R04Z8^!WID@>921MN-K\H"MONS/%BD<W4*
ML4(<F]/YF+%#?@JJ./(57D">0L3<L+'KWM,O:B(^Y6;QLTAW):1A:&$F\@CY
M4D1A+*LF<>5+9RI7;9Y 70TP5233??/OK#HH._*ZQ3)SW=95AQ1@&X=I6#+9
M7+*&C@P# <HE$"$*E(MW/-]=7^>XD6!*%.6[E/5SSD;$)@;1S'UGNR02R7*6
M\"^,N@%PT(["6E^-:R,S)WR(__7U;%+?PO[KQ[#WI^0,/0OG/_3_B4G+([Z^
M0GW_7S%I[#A+H+F'P?^*23OI#=R 7RP)Y%T2'9R2-UM;!(2XMU8?=UC4N>6?
MKX_,>AS5!J^*L>\S_:[WS4,*F1\*>>R5>LS4?2_ZXR^2_H)D>U&Z";?AX^]=
MYGQ)WO!+4'4 IAJ17TPTRC0V:VO3LC?O..JP#8A"HZ#>;7>BS\7>@KNF05SB
MY:S5J\T/X0_0I@L*L2.6XUI%8]+GM'3U<CIIKU,20#.(I Q@I4*N9W.P%LA/
MCE@P .J7F%%.BY^IRV1F9X:]I6V/F#BRK]_:$?.$ ).!16DJF#8"RO+R0?^F
M,Z^VOMB%J4:_*XAMG<VY>0<4=CB6]D5L/&BR,YZ)&BVGB$_WMNA(>Q' P&Y(
ME]1@_+](.R(^;9LFOLU#%Z+W35D"R0@*/?%105'/I@%*4>*NK"GQ9RLEZ;AW
M0;D^7(FML(B]HXGHX9$4:2>N(E')XD+XH'Q2&? '&];BN;:,8 -+]K+'8";E
ML#SA35)Y;93_L2:+]K""P"]-5Q"'2S>=-0?E$%L9,!X695:OV^YDX<[QHXFD
M8J,!HN;O>=E*;EB8).FU-?M;(L#H0MN!4'\L6'"[>-5#$#=0 -*0/#)LL!OK
M[.73+!%T0(6A[[VA/LM8]GC<[W2I 1&BM#=GS.67,-*_LW]*Q'UWU:TZ3R]L
M]<_]FM4'8J^3AOQ+*M:='@6+7C*5 "/&O&/^5RDVA(2O\*J_>[P#3Q)M.EKY
MG[G[A?K>'\)7*.O !053;N-;TU&^'&7@^POE?:C35X5/VKW&C%FG* 41K!1T
M5S2:/Z\Z(9_53#A7!Q7MM$"P*/GIVC;349/RF\7J:FML#<KA',S:*.*D+[LH
M7>8K;:4":3V:;:X>$Z)8]/RNK_+J<7"K]<<F#($P3S)A&W. @ET5/ DQ+2[I
M6F20)3KSB+L19Y1)]E$WJXJ%>GY>25,F:S043-.>"%<V/SPBSHGJ)-Y?%RD^
M'[#).>\(T&GP:V( GO2G9?,TX6(YI^G(B,USA:PPF<"=E'*,9H6D'*D_T2^_
M!ED434D0HJ81F NK0!'(??I(*%B6#D78:?>O0>"?$%A^=6GA9=O$8WCM8-0C
M>=:E:PV.PE21RL5[+"*O0&T-*C$=$A1!!VB</0GY?$>$@[UHV^T<%53UAK+5
MX2V-L--:GSSXH\=6GPH3IAYR7C42@8UH>K,S2/VS-H]M4=I-;0AW>Z'OJ401
M).&R5.#&9;,_/H7JZGRA$UK[?9DIYQ3FY^M+*B\,SD!;W-05XS$J7)S9)AXW
M,TC-,6JJ%IS%SZ'3.+[(75%-9*FKI(VU]<&*.=RSQN<U^^GRD/UFW3CO?$-S
M@;A^? M(@:=T")R'#G+LIL8F;4UA-81SFA:AHBJE4V"Q500_,=(H6@O<=+6'
M5YL5UK!;]!@Z0YO(W%'=8 (&67&MBE*1), ))<)A(STSY7'Y8(*V9W;C+U*2
M__CL.!Z&/-_\8[/3W=KG??AY3' _Z.WX%ZDCBJO^+Y+1?_?980<%H'QX#W 0
MNH>W6Y7QD4W&^BE:@>R$N@^?;;+\)Z=\,C78IQWJ9^]R3@(Y_U-$X!?=S$"L
M9(ZMH')@T:Q+0R.)AN'XH,0K9HV-JCD#+>/JWPHC:Y/-6U.$RN4UF$D$KNOO
MW)0(X:>#AA/7P1";JH-?=+PXC(ERW'J"<7^1@"+\)P"98*I<NBLJPZ?((LU-
MU][74@.9$:[HU7._>8R.>B?TBYOTP['2F'SC:/O)G=T\Y_=%?6).K!3% >.?
M.9E<"O??FY0;N'M,,UC7&C+:79$5BF(E)5.-CRAV.E+1;\+X,Y$U"/O'U;XF
M/>9CL_YI>158;0$H&]FZ#"K,%UK;017Z$4^1G4MXYR)A"YB84=T-6-.>8/C9
MY>_0S/KNFQ\!;7_0:4L2'$Q4?]B_H+" 5W2BR::?E>Z1,DU[7KZVC+=\5AC/
MR )6SR/[4Y%\XI>@V5B&04CQ?&9[^T<'H-+VNQ:DNJZ7^19QS;XCSDGF]4(I
MO-=N)%@&3RH)R5BX8S.NW.+8<E)I5\WIM<=;;(?M.A/9+[.M:9%HJ%O(\,XR
MQI+'NZC!B?"M(;#CE%8RX5 //C[7WQ1Z_CZ+_9IX75 >'^/M<?O16#WYJ^6Z
MU>LW.NV,.UGEV5C_(O:_2FD1VI, =#42=_Q;V[E VLK$V70M-*(,;G!2&/>6
M+ZC)PE&[2UP+7;)#HQ:\RX%'CDZPZ0MGPK1&R2.]9[E72Q;$KV@T0S8F/T$]
M9 !LWPX,BJ?S$5C(YNM3/BZPU<Z3S086D](D5^$:D*JEU>,?X(A2+^1Q<$/2
MON!E>\J!6ZMZBR7(FTF")H[4/ I<V8GXJ&^)>9>^B^P,N/1B0X%9)R@8:2X6
M(KIT!-L\#"'1L^Q+N@87)7>A'U\<$MC>A%^?/5?Z@W:L3/WQ9JQDQ@]FS W&
M?X4))J?Z&[%-J,S@'[Y6EQJR/&K\*"AR=B?4B^P;ZBZ<UB^:TU!'[U@@Y3(!
MIH>0&CY;KU]+Q/)0:6Z8]CFH]0KJ/YB6U"TL5$C^Z31KX%Z*K8]D2Z;/4["_
M;%H K[K5#[>M$H$U69F $ID2G]I?#!:U)CW:2BUH=5TG]?2T1OCA6TT<_5'K
M!RE?_;!GBQ57/R?HBVD .++Y4:.'[=]1HV5O&)6R@".45.BHA'KU.]R5S1B#
M,318#"3/- A)DM45D[N_<&"T/<6X[UEFU@%.D9W7J5.QMX.>;2@W)EV>[,-3
M!.SQ/:3#U5)@N1[@N42/0+OH9(4IAIW$!OVYT(67]Y?Y8=92CFF'FX?A.I(Q
M,=98\?GSKBH[#]VX)N%9QI;+Y#6H@LE]&D3*R=$LZ"BTWSYR9_0U'@ J#ZDY
MSJ?+9M(KS0'3*#V2&H#L#4GUZ%)-15+0D*^\3*9^)XFA:4QW;L61D=D<RL]*
M)@+W!BD?><""VX;DU6:)4<2"."87;&O;1?(DKP%6IXFVY9K0_6*NI ;\+>90
MKWH\X-2(XG0LZ"1LQ^OXK;&I?,X8&4O;D27/#\GV %PYRG1$_IX_0%KE^5S6
MK<N@2UUS'RZG!3 LOZWRS%_XHJ Y1L&MC;?NC5\:AD_,=Y14,5>Q**<P!9$\
MN<QVSS 'S.MW*ZEMNOO?>HGY%VJ-SG0',C"N'NK1HQGR^Y*BRF2]V@JG\VP.
M&7'I\[O9J5]@G/8Y;:SM'Q4^0J4Z"5,%1U)O4>"M&;%02WCM,?E58,LK)[&D
MT:M5VKL^%^4UL#.GG*HMD+.T".GQK?A4QCDQN=_>&C6&DLFNGNK69"F2B<U+
ML IBP_R!CJ(Y$]2Q"#++!H4\"0IC[(6IRZ+<XQ0[9AXTWGGC7$@=XEAO0N/9
M/[^%F',.%8R$>!4L@.6Q)BN1X=^?"X8Y/'*=H].D^1.HGS'9N9^4/PT/OYZ<
MYKDFE<L,27-\(K<E;0R5))MUSNH5X@)-.6B!<=9=8"6NV"NA]L1U1@4:-OHV
MD524\^=T]AA2^>!<75<K-=N!V%IWGGV["N?JWI3IK@%O(2,6*[@QM;7***Y;
M3W$1KQFJY2@+&-\9H5TE,#PNGD39KR?(%C3HG%*Z+U$K53TJ,MX5$8E&?LES
M/5LT8:E9X3OQ<])]BFRGDK1&)8 $=1A)G6W?MLJ^1XP8_X##"'N-EVX5WK21
MYT]AG."(07^H$>1IVF&NX)2F[IB1@PES1%6N8@HF9:1VHR_CM;!2*4T+E./X
MZ$3<X!"V&U%$)GC;=+*>F9]2E*1R5V:.6UTX):CPB3A.'5K_N8$KK\F9\Q)9
ME?-.4("HZ.$"PZ9!(.A3/D=J<35^28;[@VJU!"K"DW]?I3[&]DA[& VY(:&3
M(MV.+R]OMX85O0@23""F5^HU'\3=2'J%*GE=W0"_WI&0M'&ZA+!F"V19B>A)
M)E-VL3^4&6Q!L6^O*J"@$VRIL(J/ 3@Q1(A0BPFRIV&A]-,\/7[MV%B_U 4C
MJ[.CSG->%!H*HHO'3=/ /8$)7KV$KO:RM^_CX B+T35;1]=0&6^6LL :2447
M>*JT@JQ6AIO]6">#=F&.UU>[BH]6%O1*LPYF'%3A_A OT8O9JB*'3^ON1I2.
M27%5C]/E6/S*FKM5G.-G*+3KU_J02_[NN<"(^,#77:N-> J[X#G#5HXR5G5T
MP/QNMVF<67N>3DE^AB$H@!3D,.57O!"?"B9J38B(;9WDAJ=+:+K25*5H<%*:
M+(OW_E$DY\THK/7'/>]%*1U64=<AAG0QK@0)QR,"'*K(BB(0(FIWQ$%8/_&H
MV@+M.DR=K*9TMMC+A#(52"1"#ARQ8["J=$ASM>,#[V-5'6246XK*3J7>>1G
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M16RV+>$L$%V(U+0D1)>/N3:$1RNG9_\H-3D=\?/UP.0QNCY;DB$^ES-U3KM
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MCO2,/949.17_> MMHCQ#=L2ADU4O?YN&.-^NYH (3*N?4. M.#3A"!-RKDB
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MUPEPP*C+D1F-=8NXB:')S&&@G5S@!&^7=UP1HO#WN*\9:5+J(8)MET+[TNN
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MU1,J5+243YQXF=]+X^-I#F^A@6EPEJ(DP'A PHD!J3*=WET3CX9(W6] A=6
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MC22S]"GK>!E\,8\;<5K4RB"K:Y2>Q):5CRDE^)FV#IYM_B[>9,5*E<"V7*>
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M8FW*?,^*DDES='*HK\X/7G2C5;K7E.23YX>N91RKYP7"BDYD)NNN;0)@GDA
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M4S1>SJ5V*WFUG#>(3S;JYPO6(1F'H69-1@,ZK L9'E^BJU?_(FV8R"H?/YV
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M3CBETA*5_=VH#DF7XG19DQ8J@T-PC=Q7K.M* ?4Z:5) G0XZTAX<YBM ][!
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M!<I=))<0>0XR<_)*S#KQQSLCPHQV-!I6",[E5>:_ZDK9)8(GG<F/807?+3C
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MFMAZ)TDKD(RAI.T?-S>?]ESRO*>^%+NWBI1'Z"8%)[<V2 @OQ2<TG[0(,2D
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M"ZUQ4^EWP0UOSI_%Y[UD#+[";7J,#LCM?*2U(WOQ,+^D\R'@.AXMA>:T#*
MKVW6 IE_L7$6.\[ZREG&!AMWN[;"\DP8?!(BM2BY=S"_^52G%3#W+2L:D\N5
M[]J ]\"D/4_Q+K?0F5 #*? G\-*R?.I@CSVEQ"V.K66AW,=EKZ0CIONC^/->
MK%IQ_)* 58YE"*?,3.0'@D"8O)F?$@MCG!6&)#Z0[&B%>"A6V'$"8&4F0U5?
MJ],?_?'<W^(S,G[&S9D6WO>$]#3>CHI/64.N?F:A;_#J#GNM%\LZ+@1SG]SQ
MI)FM7G_8;[T>O\:AX."@'<#6VU^=GG<P.BEA.,CF;%G(:R/Z8$W?&#]MVV"T
M1:]"O-72W6/%D%#&453%BMJ!O22:9IY92?"S-OB B[62J-[8N)@'2_1N%NH;
M0&8N*UV2"VUV/D<RCM+O5<R?4=EK&DN0U+AR^J894=>/,()K8NB-&=JIT"JT
MLJ[7E,&<$R'@>Y4&V_2SECH!"<\)Q#U@>^S:E/-NV>2XS>@[XAY_P[A\=Y-/
MZ,?$ W0>8 <WYNL'1?.?<[_P&!JIPB?F.V1$.PV,TF#0TRDP$4'?]X5;/IP"
MD)\=1/;B!]BE]X'FW"(?#HUL&?\,D*@>YG#!\-59X#C7L+.(&O:M'?@=]3-;
MNM,NG0:^_4.J':LDX.U%C+!6%G;BI!P=/D$^R-NFCK1>\:$*60-&4!O,?GZ?
M8_I\=X3/$V8 WT%KJXJCN? *#Y!O^=?5;X[+N/>.$ZB%T(;[.,+2-XZB1(@(
MO,/)%HW?\<.,]5AG@;<G/1_ FZ_G2@.LOJ?*M.[\6[RI^2DI?^=[HINTSO*+
M,;XRGLOU'14BA@UX1AJ _U XV<?<+?QN/9^0%SC.8-C4:JO^J;;BA*Z1M6"G
M&LHF+K/+/\2S*7UX*)93,#L0VWH)#:\J[0=(*]9B?^P@C4MM47MCK*B\3/>3
M1B?G^G/(<TBG\]:VG++=-1D]R8\5T*F77B*2EFLF3RVZ&#M5#0=04L;)8H=%
MKE"9)DV#3P0$53&9E.9/^MOW-@X-'B(..H@6Q,O"0]A;44/$C:[2_M;MW H5
MKLVT!)_*57*&"=Z)"G)K[_2WEU,6G "#<%MDT.*+1T;B-&#T27&!F:PMLPL5
MG;D0FZ3;+^-0BF1KJ#7F0K_V)R-F3P?B"P!OQE*G"@>D50GX?TYZ3)/\_9'G
MYYRRF'(W"Q/%1)]H&12Q(*2P*#@XVHYX[@[@<,C2:[[\DN#^  #ZF-G]-FV,
MYVJIY9B:>H"(=7GL0V7>H>I(]KMBH01:E4#/4AX'$UE9OU0 )+!+N,[I^"8]
M$J,8"/LB2KTAI?'%B';+^Z@YYU.B=Y&PC-<\\'\JV]LX\@L_\0%>X9SPF"4K
MWMT63)R50I.OX,"D?=.>OB;']^ZDH#2.$D/H&\S^FET)?G=.F/ @*:/6:^KL
M3M&)$J/<(_&S<T*7WUA\1S+^/Y*&?#]>*6A=$[?)TKP <^]KY:OXW/(E&6@8
M9UY[SG5]3%K64\Y $R9#B-P>2H5VC9U0@]9<EF."0,58&.I\9UXS+\3R;30F
M%IYY4T"2&4?\@W&-.=?WRG:W;%*\A+IN_V("SI,LL60+M5)_W?#J1WR^W\D
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M L0_@F+ &I C8XX@7,;^1?PO>U#FQ08OZ:0R4SCUY;!-0FI9O<U+='-Q-9?
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MI5,LEPN5)<NZB_T+-R_^'I^V SV%4S^3PR1-[9XW=Y%N+K6..0=E1).(&-&
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MX_\$2#^;J OJP),>-11N>]^8-9RT\]K46(HT4<&&'*S:(YJCL2JE2>,^\@2
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M98/(SJ9F^Y1HS4[W%MF462F)C2F ),Z'HI:ME*WY:WMN*"YW;2%/YQJ17)'
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M4F^N^W^[7N\VYJOEJX)$VS?L9M44V]4(0(.Y'O(E$8QTI211\E>"=*0 4A(
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M,5"RK+C *AWT'N=4)\NDOT+%>)?X4)XUK;!.RA,Y6\S5[K "UM#\M-Q?FG]
M]RH:BKV8B-IV^55 NW)NA#$V8:^I7CRC*77K*]QUA7$\F&V0X8!7 (=JP]/$
ME^4"TT?NYA2F]+I@B#_TA$NLW[Z"N9\/G+O>9NP>I/L[>NM.9L;6Y5 3][[<
M,56//M:T_3NFV'VP";T*J1[G-'6BMA1HN_V\(I;)0\06F74T[W\WNH_0$C>D
MM)B<(+"GULY6ITK=F#D=/#GN&A>>@)G1:Z:_2M?P4:6W;"APB6;9W5ZD,3^@
M2FLLD36/$>GSCTV)]4VM9D#ZHAH<T!*IEYZN2X6FGN,NA>*Q)<OG[3K"O]E'
M;L.^_VZRY>NSBBN:S"([SX??JRY<;ILMZQE>0'QII^B\W,I<#5?*?K@O3,0M
M;>^<(X Y](W?ML7VVGDQ@V5"J+;-HA195;%R/&&$.P*[Y6!,D, *='IDI-U7
MVRR^5>^\F'M4Z6I%H8('I"TV8TL?>TBRHT?"O,>(6O^M2\,\RJ#!JC'3RG=>
M"J)Q7)[+Z)Q5D8WT6C-$)=JUU:YV>_KY%!2HY9Y/X6/)X]X1^[H'._#9^R2T
MV>(T<YS#".9R7 TW'./5KP"\;?JZ1!.@JMOCQ+N8=:(&#IR]S_A6\4 QD7C#
M6?G6QDCZ H,P!VRB+3:;6]7 )\"69?L%YN)1>D^N(R^Q1&K7&Y0-0;=^)RS+
M#/Z.V\9"!!HXE:[ SM06MN2H:Q23*"RM7,.LW]U0BFSK@"V2KUSMH(PWVH.K
M;8]?@K/MK*JE5IX *0Y-@9#LYZ$#!YG8?NB*[TFC:A0*2%7;7ET;0[]&31IW
MZCICY6B":[KA]52/98VB+DX,]I!ZZ;'?897.^7^^;1%(I8<Z-HB\X>7(A+H;
MYNF]:Z)Q.2JMK?K0<B+@;\#RT&B]U.-C+^';;&[?* ?BSR+O3]<RMVUX%\L>
MIOSPLJU;I *+L:JEIJ)>W?2DB2&VBJ%2/%ID4ZV-;=MQYMR_B, %M$<<4"%
MK"U :=8K?Z0PQ=NMIYSF5I/DMVS IBP2_,?TV.F,K,=.Q"@C<'+!WKUXP%<'
M)%*#DP2<#*I7'RWXB-+#<:FJ*$L2.PU?-=R%%E@4\5@Q?&@I7-K6:C#<JFC3
MKK'9OR&W"[U,"9T@]<2BD3&NT<06F[$&;,C=-*=\(J@2\2++"8)[9\=VH&8S
M3FBIDSIZ#]7O)GR'*2X4E"W+28;^SI%+E>"KG'C*+9M;))V0B/&%J<$5B>OU
M&H4@$G14PCW%7Y-AD[A=T( EF6E464F0 (7,5/%)\9%D UQ()?&[EX#Q6QLS
MY=LR$[1]BDTZ@]846J:)6+9YMB'#JV/5 -JA[8);X[R61L^X!P3M;Y9]"4@3
MQ-@GS(N=] XAN9WG3.R$UKX)<GA'PU&E#W?@\:P[DDHVZ(&]0GT]2!<=LIO3
MA5* =7E&OLQUO/YG+_[B0=\#?B[)FX;:7CS](Y#)[^GFO#KVNG^5ND&X3:79
M%N)9*E@W>7<J9K,[T<(W"1.8^EHT.24%IX"Y'U(42W@CX%*>??8FV)^-HPOK
M4(A(^V5UPQE.84T,G&=;<F-#2&9DNE#G2*!0J?YP/"BC4VM__!<MCRH!-_<5
M.,.:;D"M$[H0:OT2JYZ>;1LND,C8J_:]E4>H26^"+/@W,V0< 8+-' %=%!'E
M^P:NI%-MI;TNQR9\:($-!40M;ULZ[(7&^)(?H9=[C=W$BO',+%)=:EP/:+8V
MUN, 07^^\DA9L66F;T< (;)9!9Y(^*N2X*(@C79)S1C'1.!W1H_4P:NN*]4K
M1V;@6_A;O0&7TB_'I$\ Z?=GOUZ?O9YX?>\EZDK^"F:KDZ-RAPYC+Y1Y*^<L
MD;Z6;)85 QE^^]+'K_:=1@>^F3W]N^>1&EEW9=QTQ88IHHD-.R [=Q_ 7+-F
MXVWW<J_LVF=-P,?Y='<3^V].52'R/@]NW1HHK^LT61O!C=,%L]'XUWP?+L/_
M7&\'?- <_/;B+['50?-!Z<.G]L$[[<:=X(%FT=MGD_P#;J=Y!][!8S=6U/V2
M05JS>_\,/GT9[]\(__&;<_YHH4AG4!;*O-MG9;Y\Z)#RB>6 4EU(=;I+&P7:
M94C:LH>YYA/H*V>"*D;)#7P,1#-T7[5BKC;_#T/6>^U-(;V#PW<PCX+JDYG*
M@C;]QX!(34UV.[!Z$S#)P6*!IP3F]4XRN'(4\IQKLQI*#7)B.([TE.@_;*84
M3W)?F5OE76V:5U]368?:\+RP\3)/@E"D+\!; '5K5>YM8*CH!1".M_=@]#HH
M9>SG'X(?EG5R[S6[J#-S8FNK=-/Q53WZNO!1RMGF98#*^(E+&FPH0B=1<?5T
MOAW1S:>7R6H^:]>?,J+2R+'L1]S@V%78L6X<[9Y3V-ST!SD&I5@ .Z9OYA,8
M7./I0#_;J"95BZHU2XSWODH-_FCB+/4M)*K^Q_$KK58R&77M)4=\ME\0''*P
M6ET KG>=]>/O_]W!3*D<7]+1TNR%_<226T 639<&1G.]@8=!;'-^IE\"WU;K
M,A8=GD@P2U_L5O3@]UD33\<Y$UJ"!Q$NQU_*EF(B>HUP_A)XV1IX"L.2\C55
M:=>SV^K[H=,/C6=,_"8R7FNX'"-WNZ,1%-+_A-^'[:WBVOH^V!\^ 4!?-LS^
M6CT6!>U'_#>:\:VZS#+"!L@0DV$I590@/$Q6I9JOR@XF@VQ@QR)X*NUS0V%$
MD7.5D<Q]RB'(M&\G_Z/AW0HIVBOUXS3GX9E;^@Y]?L5+?D\C*=/]&#\]8:B&
MK[[B2S")\-L[XL=6N32@+S&()E>42M$2=7.'T4@R/+I[</#HV&#^QA">:+%R
M(@P%0/L-4_AF^F=/*$XZ-;*:!5=G$KXU"IX99 P;4,BCA94AMOF5 X1Z1,,8
M&$P?SRL?OG@+,WXIX(_A/JA9,=:^ F]7TLT.F6IS&U8XR+XU-/M@''6>5(%]
M.XPM2=U 62=)J[@K;+5D#_Y'=A_-P>XFT&J>98K>VT\SED:XL=-R\MVJS?]L
M(JRH:YI)9OMEABJLYV+01\SJS@2,7>D4OX3@X+*TXADCI'2G,&G:9J#?.";0
M@]0$_WF[)Q1E &[&09ZC=S\;G@"D@1.Y:P5\>RZFG53;=BF\_;\(9HE8\9^Q
M<DTT97)RDB.WS#L%:>4/R:F# 0E?_IOYHIRXI82V ZZ4&4^W*1/ID*GF-$<G
M78 XNRTCDX1]:M47DN&L .RB%K9:8!+HXJNX<1S8\9#3ER3.\^!K92R!\5@9
M7H\4VQ9QFSP#-Y-IV SFN<;OF-5PL_=G(4VU3P#!-XC5,>*Z=P)7+YU#F^U^
M6:3/G#<Y[?]Y7]Z?>1X:_I\D_03PM6 *Y^FXO^[4^T=?S;F44)@!?:<R,=6-
M2/-79F?1;L*?]$B[^AA5?D!XDS4*%354,^+#2EM5>T #!N)>_4]NL2<)F17D
MV YUU#+O5_C9@< <=3K4/NV*>H&NEIX:\6&4O-:P)^/][Q<[FSBG2FINX^8>
M+G95QOR&0: QX<>N^,/]]5O=UCE+9(H=_7OB3SS [4U<C3*"DH LS)S  W6/
MP'W>;SP3.0SP(YD/%CE<0]JE*>V38OJOM9S+_G'1+F)]T5#I>QGZD,</1SZ/
M5OVOO4AIG^&?]GD=*=![?UK/_I!SRW]  C<8J'50=)VF 5+WV#4F@5L?7?&Z
M<=CJY:E]$U6#CU?EUV:G7E_CY9@I'^CSUAS.FA8IU_17V3E+.V21Y345NP'[
M1TC4H%*T;"V1I+8^?WN?ZRW+L%U+.5',B$0/;M'/+2^(O]7ZLPM?)U_9UBIW
MSU#ZYRU&2>T\-.*O5E>@E%VEJW[";S!\MW"8Q<=O2ACS?>,-_7K,6,LW2J8/
MT,!C6I0!.9^U)I5OA7I2/$943RS 6.7;EGK8F#:GP3?T_T7967]%X79K?T"0
M$.FA01IF"!FZ)(?N@:%1J:&'#@$!Z>[N'&"&&KJ4[E"Z55I2 4$1U/,]/YSG
MK/.>9[WK??^&^UKWWI^U][XND&OCNZ24;%[:.(7X;&%$0KH!X"] $TJC?T36
MY,%[]^2M\W_;8X?TM/UZFE97LASP=NKL3\YPW&Q%T^VG^+,0XS\%">M7G?YW
MC/!;*[6G(ZO/7YCTH#^?+F\RZY&U'4N&3FV=>KI?[QK_!>3<:?VCI.F,OX#E
M8.,OP?9!?P$;=Z$E?P&+/G\!]WW_HVB8'@>%HF^5QXN*UBR+QP_OH_>20Q/O
MWX_ZA6I,'_U\5MR1T;?^]?KDW^Q$=-1=#"?:5S/.O*-GI %W<Y^=P??BTOCL
MN:V7[?8KJQ !,PMLVMOEI1G)YB_W:?$UA+.PI_F6/6/31 #F]HCQ)A&**DF
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M_04@&NE[+2Z*!8@$QRXB]G_U;3"3R434?#&_\G??I_KJ1AJ4E=ME>X,8A?B
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M$FKQ*6VM%Q$U7,*$:H+IRP$F :B'^95=\:7BP5G &\EFG0JFN.'R"@,L,QR
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M2[;P3(-*Y3/[J!VKI$;:U0,[22IK?&#F;J[BC<]0M8)/!O\F5$1EU@ZF.-A
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M/9-1%]%M7^K<UWR K7(,^]GV@BLZ4M@>/&A])]'ZXMM!V5] BE4-W0^9+P0
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M1+_8R%.I+&D60VW#8H:_T:_6J[[,;$B8)EG0TR%(>TAXD4,X%8S-^ZYMNRO
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M2GB=%]/03=E9M%S$&F:+4F&Y#XE@!Y]K<NB*IAF26Z),"5@@Y9/1:T"C7TV
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MJ!> P"7F93'<"*]S'S_GQF@HX*R%9$95[&O>$E+8NQ'XKPCB6" %JUD:A&1
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MB(_0)HGU\,W9[;T6AZ65A'6]IDJ^CDCO896.J<^DY<$G$:H<I&.!=/K\("[
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M)!;.)H09ZS%F51CH5O#?EI::.+Q7@5U#2$O"B?0QWW._M)MAAB#C;JB3Y45
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M<Q(XLYX,5 69F&D0>G;'.Q<GU3=7,Q "G3-M-:6;DR=0039L4KD<WM!DCT3
M6^J_4$36>Q3>[Y;^,.4'3N/&003JPW>W]N\LE6>-'"-P177D[-6/VQ2[D6\N
MA6! QZKHY^5[+PP(5\@+A?$+'",T:]7U:G>8>1'4*(6*-Q;:[Q"TK"C#,GWU
MWRA2-M!ZPU/7*G'B%__BJ7NJ+@AND=\\M5-<5?J&IV+=H BN"*HX8B'%H<$>
MG4TES.# (!0,HG23*O9B,,ELM-+J%_MHHJ/I0VL@&:V?K(:M]NUK55R2)!V[
MECP%5W6#UP%YR>W'X#!97B%S_\;Y1YEJTHN2U>3+)FY"Q)7.M/IH@<!<O%O_
MQ:-Y?Q,V/VLVNMB9'[<Q66K7+U'@9096BU;KYX:]U'+B3JHX"REX665^Z\05
M D^21=5I/-JTIUR#O2^%#Z\EX>\%H4\=IPMU)T#<V71%LO<JT&;5^Q.%3$\S
M59(3$['=["20_L5EMP?.N[%W>58OF:5=[^UZY!US3(38P=MHWWK"M<I2/*\,
MWD$8)V'APEE6P6%AIERSG";=%E)/"G^:50=<F]EN=3^>7+%$A>@[3W4).=E>
M,C&G&'O^ M0%S:OY2RM@:!+",<:45)<F>3/A2%J'HQI6-J52Z$0NZ0/V?G&X
M##_?>:<C5VN?KQG88<CA50#VCXNMULQ5/U.%!U.FA.@8$HU=H9ET/X2.R#&#
M+PMW)?,3!&R>SC\6;[90(XJ?FYA1-IJ4Z_MZBE Y%82:#08SVS?@1>A7!-.:
MJ"?2QG&I:&AH   R>8M7%$LSS#_R=@QXC>O%W#Q3-2,<J8).3$?N\U[> ]9D
M8@:S^8K!8J*HJ#2$Q/"7BJ1?@+#./9+4#*<E]^7"T[1J&]1#KK5@S+1I=]TD
M>XQP_9KL,UHG/MA>)\1E>7M;/T$N6G/?=J'3[2NT</S")##DX"&_E6/6FGBV
MR&9+6N"2LZ>P:OW/JD4(T<#2J8 AVR%(147KBR8\3"OSM[9K=4),6)4C_D/;
MK5>%VS<UD?R'MDO;D!R_?:/M@D9;W_B:U(.)TVXTX_MQ.BO9OS2C#:.9^XLG
MA;\UXZLB^^0;S4B %>J?@#YEVT^#'7<Q.N/KC*.OTC(_YHE5V5KSB:PQ9.DJ
M-*P)4V4;+&:[;DO;)+T 6$D3.P;0#O"<J$O,?HL=8C383R,PK)^1>&51OALJ
M^:2@MLC(5ITKX/$C<Q-\SP8U=!!@7W\<(!:5Z,,6,<KPS="P4I]ITM$W[,,R
M7A!:ERD[EZE/*#BY\Z<NUW&1HL8QF$C(USJ.&AD0I>ZXW76O:='4MN^^ES66
MN$WJ:4K6)/ZS9]FZ=+D"[<'"?&U%ZV]=AGRHT_"?.::GFR47%*M4GK //^A:
M/J8DJI]0VG\>">P@AWPEZ=DK-739 $(LJCW1Q=P/KMNG_?I,*!T(<!K). UF
M='L@J;8:FE7-(SFH[$,"W(TV!W;,25M7>K[Q !182!I(^!9 M9;:)Q7+Y%XH
M4ZN<EI,:LG4=%,N@D^LZQ_C,L^))28=_TL!Q;6&J>HZ*B@;!9T/A0I&/AN/!
MKA%O&Z?NM:DMU9_?"S'<RS\!NKT:'^>:2,^P&_R20TY+:;S[%"46>^^1T')G
M(1S6,@^5M'Z&H[33FYLT:1&!$<:1C6M<WW/. R] A3<R=3,O1'H\$KKD51YH
M!5X5KMY;HB'7LI.^#<2P\^6;[=,;W.L&T6U(^BSUP8MT+HK[/&NACSXR JQA
MXF];I%HBVF^_?K%R7!0[TIGTN3=5C4*'@LCW ?=AP)+ ?8V9LP*<+\.?J23E
M-Z0=;04IE+^Z3X!L.[*.5W=D/'5Z(^M&(O1.4Z<EK1@FI,D=%C3&C>N^.P H
MW-P5GV&_M.E;.)L_FC(___1UM5?ZSC#];E@7(O9Q?- 5V/J6/]8;JQXTT.?5
M0,;[AI1<X1HO'K,Q:R/D!,TR9M\:],H@E TG'#8\3D7/)'<4QY!L@AO/6TG?
M+.LK*@MVW?\%,.I"G)M&$(T\O]_YP0[M%RV7/Q?R2J_#X#T_]=>W&Y,A=<]Q
M=^[>V@@7698=*-8[[/7C6Z_^0I,4\=EGK]?L-7: :.EY7[XG\HTAW\>M?YOZ
MMZF_9VHM8#^%Z7"4>;,5.>5C+&@Y1SRFJ-O: 4S#1H3L%^P30H#"7)* 3X;G
M&(0(Z<@,@D%-(UN5XO^'/_^WJ?_G3'D\(FV)K,9<G)G%:L9\2TJT%2<PM!9*
M"0B+Z2Y9T)/&,V0=8N(C=O3#XHH*)9>I6Q?/*U]N@QU)G9PGZ5;+#XO3N? [
M"+;,MQX^T1AW223\,H$S(6-LU:4:RVOB-Z FJU&%._7_TN_^V]1_!U.KCL-D
MJ1^W.8^NZLV>]66'S1'WEYI+W&7=$!2/K]96P%!G</'IV1=XNNE)AS)6S)?U
M\,/,EA2#(_[;_>C_)5/>/DF"<KM0(>]PW1^&X[#/;1VDCNM4Q5OKHVQ6R<%B
M![?%=/K]:+>NB]S\@UCD+!.CXY($[+$SWC?]G3SB+T! Q(R\Y\1*9;IX1\"/
MZ@W[,$@>#V,G+MF>[WRKEU)F5L2;XR[W96R![8TJ4P@WDWI.Q0.I8V(.+NB%
M01%D5]>7:JS5)>IQ"ZRPVX#'IFWK*_+ @(B5J!;Q[D4@YZLF6J"!^&&#2EAO
M..MN_71PBE"C=:>_=-_]E,,V%E=!D<IL\)C:/=?C1"H"_0ULUD'OK07L[EPN
M6@6/K.#GINWYI:?R"Y[ETWD9;OAQL]C3&G:]O+0G(/=ZM[:7L"SNA* "2N_4
M8M8X(P1Q;4N6GC#T<EZS%<^+?$:J>J%US"*YJ-8U:</)X1>@V,R+5*A8W72K
M\I04CX[N,5SX,?#8WA>-T#*!,#[$7GX\_U@I8L6Z<^7V21OC0R_OR(:(/!G&
M2VD"9#4*Q!BUH-T1L="8J@=\]W:-:U-OJ*1O"(9/L2[KN[FOH X"3Y]2F>];
M28Z=^IT"ELRMW?6WQ[W1PRK:6C/[]0]@QWF,4U5Y7^^[>:8\:2FB/(2,\]%^
MP1>;%!S;)#?3/0G45$B;T'^7>::Z]T#=V,D2F=R&Z53,C6ZS>:N$-MDT-6R1
MYXQ)5M>EK0<JN7'1XI3?,OTV(-*95)_M=;K:=U?[Z7I].'5D;+H]$Q=K$INS
MG+PB3N%8X,+U1S'7ONRERDKF3OP=A!<QZ.?E_7&)MWN,D+O'G??,D$?YV LF
M.0_05)]H7@8TIIPCM66\K\<A*E?:Y2H/4SS9RS]4EXF79#-NVY@B76\[9+!L
M4CU_=;=L3">'6Y9Q;95QE5F=%A:2G9 DB2AEX.7:P%H$%^_\?&?^4#/BXJ.5
MYX;E+P!ZVN''DY9? *)9G2S+WY7;R3CPE?U?E=NZUEP;@ CBK\KM5O0$' [X
MCN$Z\['"DG0BM-B.TI]*J!2+\[*GD=H&Z2U2?'LV@#7<N_ICS/!GY>+AS+/;
M2^UN9Y-<8RN*/[50"ZL]JB1 O>>WO/?=%0P\I)-K/M1L@5,4X*#:G/NX%D&U
M1%24+&/H#@L^\)S1I<>8:E;5#FTH%255 ^X<Z)OO<%GY2W/Y^A!RP+M-WD"A
MP>3Z6_#N*HZR4%B/-#<VN-ZP9G!T!7U9*^,^/CPPH-:FJ0SD%D^!9]$W6$KX
M:F1SJ0"J!/"G;]\8OONYL.Y;6C,YEAN!W[)+)RG?X^>%7,Z"C,IMO G7V0ZE
MR5C8<UO\Q)%!^M 8,H1*B=-;7DBOQ?2E;/$'YS@R\J7L_,O-KMH-NF0UPSGF
M'@@M67+ B)>%'R5:I([ETTF,L;^N%)8BG\4^MMK^O8-GY?MN$QJ08N=71:\&
MU!OK\K0;"0\"TH-;G[EK().FU:GE'8SW01HH'*(IBH#XIY,C.TF32\@JQ\J9
M2>=;HGM)DL#6V+L]BVY6FK(IK4JIJG#.<(&);@3?'%1XE=C-,F6SC*E<=SJ'
M?2II)JSLG4*'H"2U0*-X)_@T-\Q6UT18;72P\J5Q62NXK W659LA?M<"Z*D[
MRFQ#6A7>)D=ZWU@BF5LO7:<-[$HGP"]B2EV"4F4+>(:PK)S1%4?&HF#TN(NW
MIBSN#2^1-38]XA%"+*^"X*U0JW B%0,":K,()MW(K\Q/B-,L=SPMFG0124+O
MUN&E2@R-E#F!57;J!W(1CSDXN-\"197D*FT]\L)Q$3K:3RVHS739%?-J4,=F
M2P86UW511D7J. ZXTS#V'U;,?<USEN%^HM)"=ESWLZ"N[]+@(7)2%5=*>OPN
M\,OUUMS@M8$)U"!?GK_[YQEJSZ4?$B,Z0G6UQ=7G(3G>1M"'[@4\$EDZ3)!%
M"?URP2PB=- +*'Q9^:+!B[HV:$%RW"-Z5HTHG4'0UV02REBI;]EC0&!H(ZFF
MZ<3B^*CU@;W%4<%Z66CS_$O6*F%Z"!F/V+F:/,^#TQ[CQ,*X>^G,VUNZAST_
M+31O24H53WKL3J4K9>9 "KMKY>IA=5)>O$H1V>\!X*J"B$I:?6Y0KW@H8[^Y
M\K/J_:J GL\%US;$/]=D=@9V23=J=-? I,O*R]R1]Z\%[YVN/N2WW?-B7SXQ
MVLAMPAEA/9.)2'W?>=;FGG'/VR".\S5O?/6''SBQ]EE9_B %/L,TUK/!EWK=
M^J,@[: BU/EK'*=1+Q;36T^?27QWZC0)H*[R;A"1C%4KHS(ZDXK0PSY>2&9F
M1^NL\&6%%<C#0E-HYTJ$WA^*'25<XAG] L0&7 N:GWP\C>A?)>"M6?15'_MY
MF_$5\O'HY$F$S?95;W<QF\77WA^//SO,'RX@C?H581S;#_].ZO?GKN$WF<8)
MD5GE_?7PE\"R9)1>!_>;QT_K=K5'!Z($FU@]1@Y>@;-&ZDCRA,TVG5#8)00B
MVH,M,A[+&JSFUEU6N<YX>6X9AYD\UU8ZKA?&>)/X*PVM$IAJ/'[6G(IKVR'>
MJ/SEW%GFA*ZP+C/78X%$[8(]&D37':%98__]--UL;#=A(UGEBUX(;)N.RG>K
M1U=DV]D&58$J2O_6']F$_:K,GK6VLE5WODVSPN=!*L ,^;PH:2C]Z.S$UQ9=
M3NX\W1>C$Q!CCZ[L-DD>?VA%'[]WX=A47!'N 3;PXW'T2O-EP\1)0"=W6!=V
M?-4P"(-E4"I>2<:NP$5VHD9=FJSTMEX.[#OSW8H44>O6$29C"(83G5;2%C:/
M<;^=7) <&?/D3FL00F1-$:)AKI],.4H\%C8DW>?AT37CQOQ(,I@ME^N<)KC]
M30/M=;Q]V'FO0AHF Z@35+JT0<='^OXHEZ<67WN,NJ#( M,:MM*%D ZL37W(
M$U@X*FWEH=LH,S[?;*$'P_J!#M%4]?*)1T5</D*=<6TGMM6D\,8<^)]W$R:G
M%QR_$W&Z);]RY.64LK7\J5$*[;QZWT:+KD*37BS^H?N4A4!LF]5F%HUMQ0"Y
M+R=U,;*+Q([V#F<S+GOVZKHXZ:UQ_C6GQJQ"XC8B1$"N^0S(.;,+R<VOY<)A
MUV(57J/0S*V2IF$J%A.[A%>$O+0XB@DTIB-VJLC]<3*?'"AC7M \ECF[42>3
M+CO\@:Y.5T@IMI+3%:RK+;1W1!M^CD0W@?"_#)\R+"B)R*2=.VJNV^UB&@W&
MK A8I/WK7??R"D<+K4.V02ZZ\D&V)-7'?2EPY[1GU+5HU@1IVV@MI)-+]1W!
MS,Z3DF1Q=4$V19L6+9G\N'S'<HQZ84.J5_NR46*5+-%P&. [B^XAF?J&P9T&
M*;AV+:,<BCJGYZ[0+#7,%0:6#GM;6.09O*Y=HKH#PT]CJ:Y,\.KR1M13>Y!A
M_["KO>/YPK"4:<'OXBI@R0?50D0OCS\'S!IZ5QNPG*!EMV9FQ4.RA"!PKR N
MUB419GD4V7:+?_+XP&X(Y24;6FL!QS,9E0^E)E_O"'<;8A)H[7*]W,.H\-08
MN&SU:ISG2GB_W-VOQ/.JG]:R])()"YLB"XEDVZ&FHLDTU<]$)!:D1*Z>R#Q@
MXV/?E\ZTDF1,1L$+*C@Y%?4<T%5P+1.%A/A]?L=*\T.6E;H<O$T9P3BK5^\P
MXX;8--<=BZ:ME06W_0OEDH_.4D$7W5,-SY\06MKB1]OHE;Y4K-ZRU%:7:41M
MXTN0=$\1;G%Z1,$>YVIDWQ/?4\4CAS))ZZON9H\M+/-L&VBOV,_=YDFW,ZQQ
M:+3C9&+KM1(446A!CW'MSB8-[<'.U*NKPMF31VF7(Y*]NH$-/U._[AZT+G?>
MT I8P?!W&Z?+(!T$POMXA@L1WIKZ=4TVA='+K+!EZ=K&#9L/N_IDBHKR_<1;
M&J))ZL;WHEAA[>?52=X)%F/K*4-?.F/C+<880.:7AUW53P^ZV P:+2^FUH)?
M. 69#Q,09R>8G.5"=;(S;<E7GPS2Y5XRVK.",J3.W6L41FC[HE!YT#KGNEXQ
M_=4#G_DY)-6^D?""XY X+R<5;:)0/+1@G$; GCHZ9,X:.=K\Z?CT0#@=U=<T
M\GKWH HL2M?JO X3OG!EM/"FL\K'U149ZTG"IMA(LJ629-17$2?+^U :5.^(
MKGH4GS_.,=PV\B+D2,!-;%"O8?5;(? SR<SYR<(#[P74KLX0")ZLLG\!*%AW
M>QCML>JYWNF:-:5_CC?5<=K^09^Z7&9<4+T(%U1('N-: _>Z7XJR)2F3HQ(!
M&,5=A^55Q@14!0I[XO^(NVB$/2^*=#0H%1YN^I!^.[;/HEX4.5);$O-.V=RT
MMB=HE*"E3MJY%4]RL=O$#'E8E!=<]J8'A2]8"1,RGFOA\_T%P.'<<1Q5_BEF
MK<^^BWCWI+A-$DC,)@:1P=#NL1W(D;\)B&HIH;)3\Y2O=R6Q/'U2HX>C.7:B
MQQU;.W$:M*L)_= :TM5@B]K+/+/!2MZ",H4:3 =-E$MT6GYKY]I^KR @5W#?
M*;1&V'SWRWQ3M_WYINF0BQ??\Y"B95P$[J; V06:<[]'UY^*4TZ@F*<OOF8&
M!GO;R%A=A>@W2!P)[6DWRRS87,G,)^JK3W=I(-4V%L@=>A^0S*BA8B)ROILF
M+9IF[[M<)&.649C=.+1G^331*\4\LS,<@T;KC:L8K7-3"A[Z@^6\!6[[PZQO
M4$;7B8C$?<$<.O[M?M0X9=9:UJX.&L^49]0NQX)=)U8 ^A31XI)B1C5Q+.KR
M@EXJ)O!A)>WPZIJ;B+E.[PVX]":0U&H8J^)J@\&MF%J^O^I)3HQ# &.RW3/O
MCR1'ZJ1\=2DL\K(=@QAZ@H\"+X!GQ\G3UN)C2]\J783#);AT)!F"HN]J\)Y1
MB5O184@J/M4Z"YO^L")]T[P#]+0B@HDIUS93@PM#R8II:YV+4V2SP-/Z)\+\
M>-H4C/V[Y)!GW=02NI,NWA J/[3V4G56O;.N-$8*FEFW9NY,3=CA8>](8N%]
MD5%(*+(U#.D>2$I9EO6LBQ:N:EZ&=O/4EJ@/?<AN,:D/3#LUPV"_9:$;$GH7
MNN]4@T7TT_JX;LUDFN.I?C$D*$23]LOF_LI=\S@A$1R5)U5S7B6+O@V\7$@+
MJ'\L$][F?IQOIM0 > Y3H?.,\0-G3 *(M*B:\V)RU\,SZWTURDO,[7'6N$B-
M:?-+D4S2]*V&W'PVRV4GRHM#C6TX^(IK$=J7 7%,]GP.D=[,_J_UQG'%.M<.
MQJ&A5*/(DKTC+2JHO(XFGL=CDF%NIU LT78(#]XZB^1%<#NQW?R'?WUTXI8D
M7@@M*1)"V 8EU.S$XG%!P(*6?4VN"!V+]\5#"1G5U_ZW^/!:\9D.J?WF*CMN
M;.A-'_Z5YBTWF3$U[UHV_>BKON*EX4N$ZR "3S&_R4('5SN8%@1!Z4.A7S8,
MY8X&0, N&</NJ.:=N2]V,Y.Y/-02H>)[L5J)O)F,%5\O")/,#"643F4KWMCR
M6/A Q^6^<6;Y7QS[HR\_QA;/NGC3S U*+>6W6CKGPG8_)P/8AG/3?0:P\<@*
M'IXLIO:_DS3=X-QGD4_7?253N2&Z0H,"Q:!B:U3Z6_28Q,U&M,G-J3"$1'$D
M_>\2\6??6L=IK* WGSRZ0),>4O?3%'SU_,0[13Y67BQ'9:!0.6400T]YCB&B
MS>QS1^%N\Y.$Z"/+YI$:U)[SE6;9OFOUKL>YO"Q=JMQ9O,80;BQMM2C:*L#-
M=RF!3SZ5>[ 2$8XXA=.E"$'W-&#X<Z8_C?@9>R8:J19?9&@C)SX["Z!G3HB$
M#,:YM-PC.#R1"L:/9C[>T\40$ A*/FJ'O0U16S[N/ 3Q/N4LAIN>#%D:2[SA
MCH4GLA)R/WC5@,\Y%\@DPMYAWE$3&AV:>G;1,6DN$^?$H2:;*^]ZNE*@0V>C
M/G7+N]!.PDYJ,:PVIRP -)7V:2.!LD"/W8FP9OY%O>5CF>P6G>X"9';K[*R1
MMJ0#_>3FR'F,RV(7OFJ],Q8DKHX78:_&X-Q4$*%H6"/X1'\<45F](W\R_KQL
ML=C.[>YZ^ALS<HW@"G9.<U".N&Y@/[?*'9Y<KL4\_+2PD"37O@[GIT94$M\E
M@J\E<>A-4FP/<&B9T[)YQY0HR<;IK*HYE3CM94KS'9?J# ]X&[I;WWS,T4CC
M$0PJ"7E%Y+"9K%O0<&3\XES%$!P QQV5Q4HVWM!=STQP7:N_SM#I=6*QZ71/
M)F?(&I/(#+P,?;>L3VQ!P3KZVK;+0/7:G8=5C? ]E9A(KJ3M8JQ2RZOF7+JM
MCNUT H8N[=HXK\^RR.%K1&^'1I\QL>)(E"_5C09>/T>?JWJROT:(L35Z*-IO
MKT$.;.^F;_=J@L9VZ> X"0>\=X"/0F"FGDA>'<X<-0]Q XUE&FV&D^/R%U[&
M0>LPE6\Q33!T;NU8Y@NZ+W)/4QE7E,'<PC':DHZCR*"!. ,)VC*LSL2'QF:_
M %]D.88Z?)NTL"9^ :8^\M:\O$H190Y_)?%,5FOM5MVZ7?3@^;?2E*RE^X8/
M&79^ ;82M![K^BA?GYL]C/^[C:[?D^UO2U2[&X!VJ8>P8U2YN,<Y#W#09H#G
MDU"FRCXJG/M*C@[?AU@\)EY M#,?#7R)<TA\M*V2I9Y1/\QNID'J3YN\&$5R
MEM%R[?0]F3W%2](PR71<9M.H1D$2-]EEEVHB//@<MG^U4XE'IT+!G5-5CK+)
M9M)8H']!1$A$S&_\J8\A%DVUU!>NF>S'PL ZBDO\%C(/U6^E%Z3YE 7QV##[
MCB I9,+[DA^R=R _O@8@?9)T'EQPK-?GHSOI/M3IPE31<"X(&AGN#K?*C(_@
M5YUR;?U !G7BW417(U=(!+)^ 6;$)0_270]8NZNMZVZ+Y,B->S946BJF0:V)
MZX(T.:-J0#V=)S^28MZJ:/.)J5+J\HH5TY4]$ ZHF<GS7+OJDQ2V9N#>.O0)
M(98A3^UH=G&(&^^XYX48-]QPK'1^ =_J>.[[(K1AP59GVGZF(!E?H,_&^<PU
M*54ZGG&TG+J$GDS31<"-/#-BAT]>5:^1U_%=$:IE(WJ0!UQHR$=#BRLD]QR#
MBI&>SLKZ%*[VV)HOR!K#1^0_+N?Y#(SRRB<KE?7C1#+1X=&1)Z.XH[ =&0&Z
MTL6RL0+&C+NL2T6?YNDP'R6Z-*98B47YJM@8#:]\(ZT</Y9.*)JX93"(U;8F
MR"6>ITEBFB\F]HIA1:?![M_%I/7Y;.=%FT-R:L!H12XL%\O281;F']RU3E0X
M7191  MC@\3"N4E!@4;Y7A>A8,;>:..W+ .C&ZQSZIJUK>7/G"O6K(BWGF]3
MHY:E$&0#I6_0'HX;6>47I61#5YL^,?,=&V?B'44P+KV%7(_IN5PW5(V9&CN3
M]B7?8'T"B0!( -.W%.I');#X?HQQ!?A(8/5#&N4Z-S$QCZDE'W:2L79< #_P
M3;[C$^%;0BV0T+E\FNZPO4.8:<$!U8: *%$]&8>=Y%NV)-;8.-:EP"NZECU^
MZA8_*U&GRH'6Y,Z>9@/)7@OM[>Y*&ZSNN>1E?P.(3;5)_KC,R[?.F\<;HJL!
M6U:+5>&G_!F'7)RB=%^6Z8TA@?3<KI$F:%R9#]R3O-3Z*DG1A \<9CT^Q,K6
M?AR':$54Z7<\!&]+#E9D6R:U"QKML9JRV#I9R1KT2-:-T[NG(0PH@S%<A"PJ
MZCLR3]#25<%)4=E*SA*\#DQ,!&B%3KE@!/>J5KNO,_-(4'>D"6\1=Q;4@ JL
M@T6,N_V?$Z9/NHRZ3WH:?E"OF#<2]P7F[#;D)GU9)FT7[JP4"WG[G7V2N#M5
MH $$3JYCTV#E;7/)@^ATGXM;@=;+RC@A=\:&@\_$&^U]-UF3<AS?=KE%ZIHM
MI#(*F/ \,BT[4#FJG\J J'/'M'PYF'*?;J_.'6YXO4=C&OR=+Y\=H]X!APK$
MAW#O!#GS"(K8HF FF;636G2#9&,IE;S=7UL9,->BB59W.90=L K%'5MYA.B2
MK*1*GN#<QA%RG5[*J[%!:CTU0:"Y$4=RWOOH>+$RDB<4G]Q&'Z^G9I]X47S+
MH(WXL?.D@^=3@>R,"XD/_L,[GEK?\"DV6#S7S\WC>SP%C?UK[ZQN-N@S&?2/
MRUT.QYM6FA]3<'"VOO"<5.WPX^/>QS+ 3#WE"60U<4_TX9>9!8HW+*V;'.E/
M==HO$^D$<6OO96E/]NMP]T;F.+ +D6'J9@EC:K!]=V2N7V<% [)9\'70$$\*
M&7,;2V)DLXVT<&Z]<>-^E@\WC/C$O)LJ(/_>1!]WFQ;98E ^UGK.J%5;#M1_
M;4B7<[OG.,N90=61V+.B51<K&\9G*I8S*D;(2.#_G<7 0<D*VH#9_AP^)[E4
MO/MQ0&-VF7%@RM'&I36R\Q6]:GVG?D7+CSH:IFX:T#WJ4<KHIW'42=IJ.7%<
M*B@N%6)H3OG3*I"Z_PWF;P(X[GM'_]!"4\QMMY> LX4.V%_7I4S?882J)B>H
MJ:9A61;>U]2$M6Z?$^=,*S$;&ZJ$%EO/@ :?#HYI=+0XUHOG3*]A(H\I]-LQ
MDCIN2YNF)J7ANN;@=D$FI]$FC_8!'9$?"_;)3<RY:/5GO)_1)\JJ]6[3'#)V
MR!4C2ITIK316E#-K1] :O(2!K)@[D')/7J-&()&0D'P6)&?#;'(!N[5TO5\U
MZAAMG80>%'1HO27YM<Y)4UW:?1$=UIS3.]"+4.7-U"=,U@&JGY('&N4P/=,J
M50 K[H-=ZK]:$)62T1:-&)1;/^3<*5C?99[L\9DO,91KT_!&N,<VFA"JK&-S
M4'7XF#P1;-#'+=SERN(AG)BX9;+<,MR013]TJS*0<X6G:NI#$N\\;3+"/0FJ
M36C,3_Z?!>Q/FN+DL%4=! N%\U 1^PRX@<W7LE(7B:.Y"GR!;&BB(/QRF_9\
MGK=R=@NG1 4>E5^D.X$MC(RRV(YB:;6=M2K[_>JZ,&OAU**<=_Y74+&YF:$Q
MUJ[,3ZY+^&?7GR87%CA!'$?]&Y'Z8#O1;P]''M9L_P*(KC_L/_/!<O@VN?M.
M@I&YR<O]N"?35VK]&9A]Z9*/A]M5I,7:S=88<G?_T(/]9SB[KIZB!%DNN!$W
M6311ZKOQ5\E9QLL0>$_B$\L#)B.[5MQ/60J:A0$=28Q/U5=!<%=MJPYWI/.U
MC3CQ*!19$+M&89+P\XG<U,^/TK<ZEL2+Y^$*%C/Q%@AC^>]*G^0K]-YAX0!X
MJ8 V!;<C4*^XGJI'KC<J5&F[IL2<[-L'X 1.T=__KIH/=J5P)V):8TP:>)!%
M*?*N[_;3Z>=@N,(O0/[6K9!0H]G]+Z,[[.R'%T$/,>$_GDT??/@%8)K9V3KO
M[#WP;G.X,&5Q2B3(2RG);G7CO\],%$5K]_SLWI+S]*<, 7*.9/?EX+2?'@1^
M>OT_!CT?3C<NRE7JK;W<O[%^MVIB3SZ,(IMU4N\8="&9B]F,Z_=T5KIO&A^P
M.&/#,W^\  _5.I'#%%1#2(V@HY7"2I8TV4L'IK&,>M<CXJG;^H(9#6?ZV0B<
M.+EHI<*@U"#"<1G@9ZII"\F/'V"26-8V,/F?SQN4*R1]?!H@=Y!"+XSS1^3*
MIQY]&,O(534&-XB\?)E6U(/P+0^?GV'J]/:%'D;DK3/O[AY%0.=*9'YL-C9U
MBM^V&;R.B"A]G/(+D#O<&??5EO5V:PC!ZZGM[8-KY,ONC2\/TI5#&1@N+OQ>
MGWTKTM[9"WXLS!"IQ2!:=]RGI56_[W?MQX.<//"]ZK-E^5'*UAZ\_/'K<Q'G
M5^25A=/'SVU;'T*&IZ\VTS/R,5OGX;9*RB]#Z\KF3F>T?P%4!K^[_TW*]_#L
MWFO)*ZQ)OHO8SI<7_;%CLI6K/X6_3"V&=8U^^=G;\N5;TV@PLI_JYYF"TC=3
MC\^'GI77HJ>@;Q%[[Z;I,BP8'M![W%:TZETAL_J9LR,Z(_L+L.G1;VE,-=67
M4L\O'@-71[%\O,]7W+O_EG'Y8Q4-E0GA/A^LQ#.8%J"=;MNI3TI@625-0CDQ
MW09T7VBGU01V6=!'%%9Q&'.^.+NV"7*>5$^I'&J"^<;I8N[[\Z8Z;GPAKN#C
M@#U#<E:XKX84O5F\G)P:YP4G\D"?/DG;WSW4=J2-@[4QAE<(.8A2+2H .2\$
MU GJ/'K7[(*D,3YPWV7ESPDIE?%-F@KYN<'#?7UVBO2>'"'O7_=Z0293^*@2
M:HY_ 02,#-$)[8XO.@7Y1/I96/DIL8M/^PIV=3BOQGB<BG'@KELJWZQWC9!"
MRYU4/^1F7BM</8827'XO%SWK)+GDB.P/X+]FJW&]W;39]0M 8+Z^EMXA;@$-
M)=W[8;XS9%?Q>-KR=(;WJ+L"G%=![>#0@!F<DTA/)3&A-W$UHE:X!5I\?4YJ
M\(SJ]N?O=;\ MVSN<3]\]]GTY[W.5F.ICA3CT0Z]!P6^]-H?-D1#927RV#$.
MQ%K)TWN"D%8?7JJT5.VD#H-)9EY?R2R)6G2UTJN4R#I79<'E[4/^':K)]WP-
M30$3QL&A[F+->Z$O!:&^IT^'Z64CC*&W7"/J+'R65 SWS.]I+[UXT-#4D/J!
MNO'+X5TITWTOZ*$:)BK.VVHE<U(VU=[",.6.'13\J0PLJWPUB7U48$%*5<61
M(YI[%_'$^FCN9^27FAU9O["/?(\DM)[Y,36RY:]%R@7=S;$-_!89NO.UN,)S
M[FBN5-E+V,:+X](J]79'Y^W-PV01]T;5R=&1G>_GG2UN"/>EA=6=+3LT1D_M
ME1=T"NA&V2K6Q)0%T2],1E:75;KAF?2@JQ_HUZX>$G=+[2QE$T6G$A4]T$<:
M2WL?<A)@I6OO5:E4*$]@I?6^2W]!+%"8J&7M,%K?)?9CWT2XG[]3(OX7X$@U
MY%#T%T"ILL50G79/7F5$7H/4E':PKQH4&\98C?4*F^.AC\,O@,E.QN,^6"<J
M,AO_:T.YS]^<(:^CN>2'K6</=#O&3_HPDA^^34QVUEB1#]=<VUG=5W0;#6>>
MHVT?^91T)S7P6U"\!9^ZXGUA21P!;JJ&S<9ZU!C? L3W.4?T"X-'T7YA:]>B
MF"7-3$GA2 \"JK,[EZVU-G!(D0V!%'SOR73(6T4EYL:G0/,RH(D$^V3#N9M>
M9^$RWXKRP IV:4F:8O9TR/WL*HL^:]\N<U$4]Q,KD55B<$R"\_%'X RKB$/0
M?JCF<<@$Q]*]LNN?+!X5K^;1]2KFEW@\)%+_@[JW_FKSV]I^@VO1X.Y."0X%
MB@0+00()#J5HT>)>2G'7X-#BKL&M@@0(TN(.Q8NU>&FAY7SW,\ZSSQGCO.-]
MG_WC6?_"O=:\/G/.^YIS3TP@;O*ZBO5S=[3X'C9QN;;W@A4%<(/HS5"%]"5S
M@?,K?C],@&\YRHH1/9M$5N][H@3O[ML5Y@%@Y^T*E\F4D[\G[.%] #B]KI,I
MW:PU2TVX#@P:NXWR#B5R%5KS!K)8K9 *R[%<8^8*>KZ+#2=O H&I9N\$$:M^
M%-3=-&\SI"397(6.N12BZM[++4X"?YG/=7]!%7,PT?J5B^ONT-/,EB[FP!/Z
M^8F3/_>CE'MX:09QG37W2/9,=NN,>R0> ._>"]PFKVXHC#U/2O]A@7:-=;AY
MEL)"MT?'_/==T>U[)_[\UM\2!ZGYX\8K(W^,[<A/W5-O];Q35 7DYC>W3G+'
MZ-6M\A4%LJP,*[_H"9CL>GXYR4R3#X_/QC,$?KQ7]OZ^08.$ADN)(V[M)Y9J
MB2L\;#4Z^(L1X"/B\+180J:XU9\O-YYVC6W.!8?^ZJPZ=1X)(NZD]"RS*BX_
MIL6T78(W!S\K0]L02866D>K*6JU.NL8@S1_T,C_XWX3C\N<7S)SL?MEB6%4;
MZ0I;NV_BWJ%V^UIZ\[G*[2-\#IQ1(Q>K:Y]!@] URRWO6<!P_RG==[*<,FV?
M@<WT":CNKGD?7@88"]N%J%!()OO;U'A/]84TK$,MOIL[CXK!I)1K:DDXL__=
MWSY-]T+D%F(V=$LM6JZCE<Q=O3ZM'5_0C-EZ(^X-^Z#<2#+J$*-76S?2/KIS
MJN\%%DL/OO]^-H5*R/V&'ORH!]6\4?\&9Q5_;.C@$AY=()%Q'I'6Y\HSQ,M'
M'5!?R'Y:T$;E.[V*,/)<GG4BRH(SRUAQL?"DF7&]B?..0PY34%!B78N3>8UG
MT\Z[^235O6R@S<O!5A&'+K\Q\AB.P)=W?"TEP8X2SI5DO[16\LP@"J\N47Y^
MB<B@]!D0*MR_=LV< 4CD8HJDLYP@LT:U\KZ9!IS3(X7<+.ZL8@*+V@;43*\9
M(G[$>$^&H/O<T[^R(K[[O5\HC#C-Y?MJX#_2(63H.3N]]H4]3*JLG/;QKZI'
M_T]@A>Z]>FS3E,GT)R*'*Y7GX*]1*\]L7=6XGHEP!B5+3MH%#8KF TS**-6B
M6KN%A;KJJV!XWIS 35"X)VZA8HY)#K\/@\-'<\RPC?Q]@2U#!6IJ]&NK24Z\
M1MVES=8B#D7Y5MA5Q&JEROVS!<KK-YKC*Q(5I9;>HL)H,RQ-PU:_^&X3-?'L
M9^,.V>)3F_8'4PM'.W9%7JST^P1ZD6W=SB.G5<P_&8>^C\=XSR?D**!X*"7=
M0T"+._/"!1]LB$FU[='GD[)18$CO[D<<KPF.*F1^K^#EK5=[+,'JB@^UP30*
M;A9+T%BL(%A= CEFTU&3 \AI<7RF"B=2)G5OJZFBS]&2"TDYI',K>^$RKR;<
M\_+"MT_$OWGL"+P!MI).&?F^J/OT*B+S(E<M:I=RYBUMOKIQAZ 259E,AX09
MA8J&C$ NLCZ %CN-4@++U)R7I10&4E$#AO/=#"A51CYMDN+Z@T-P6LHV1_/T
M[Z.1LP:+<7]&*YD3G R[/OOCSY\/;M'7GY_?/$.,[WD_ )!^S,EW?ZI8?[C^
M!X!A#R7/%3HT.W^OW]!7;\X)%^-N[O"T7Y/(3/+E-IB>_2*>_.4U\\F;2<<_
M**&JKD.DOPFLQS'G@RG([_E568]UJ9?OLY>LC.5VE+,)-R$5G .&2@RIT'SM
M4=Q6/AIGB;2(_$JC$%\F#2=%3KNU)F>7^8+G;3OW%5(QJUK\:U-QVZJ&_2*:
MXW$,EU=X7=6/F"4\U$=;9L'QM?DB<\._-6=UG<A7O]O3OS C/+A<B<:,RIOE
ME[9\FSZ$']%<.^'NBL>3Y!*IEJ=#F<N8L0SW10R.N03MB8^35<N#S!X]M>15
M<&HW;YC:9+_<2Q1]DF6H&SS93RM05&>L.\]=6]TMILT \"A06VB/K%@9K//W
M')E'7Y/F)#_OBAE._P;R*!I5-A5H .QR5VQG;ZL,N(#X_;Q;:M.2A[XSR+CL
M,U$>'Q/L_>HK2=Y!5PAD@'P8!PM86N:(TI,]*GZR/:L/O!M>#7[![HUIC$HH
M]SX'&30P79)FO&PSNGYM0]K-N"D+%*0="[H=/4SZ$-B@79[AW2;83A;U=YWE
M66K!1BG5RV3^^V,T [C;/:$TEN31N\<R=G<Z!YD#F%UITB+I3.>4HV;G7D5]
MQO9,%[\5I2S;MK*<3%'S:L<Z)=,X7H<9^\2L:C8=2^=+A_R.@:=5#+T'UK-'
MRG\_^/+\R?X45O9C\3OW/\S:=C)R?9?] /AZM&HLY5[)>'03>ITL%%VS2^I'
MRZWWDG>GZ\!CCX-'4/NE%HJN1V?D>V39YIR.IB@1^W//R58G4)?3,>ZG;NOA
MM/,>W%J%L=SE0B*/RRWB)5/>% WTSU^U@K!%C81V ;9^#8/HP-(8N3SV4L>#
M=O0'D\8L;\5, 8N)<D1P  C<@LQW8N_5=RFR(]NN62VH"YW6<X"_G,C7!49C
MYQFG:/F40[UXFG[7BUC J$AW82V=<<:@J*%)9[OPA8/O[;\'-6B.I&X,0:]_
M:0A*;B<B"(WB&41+6R90A8XOAJ@[(5MU :3Z@G.QW"3':)'<MD]FSGDFC'H*
M'H%!XOW6Y<,>9B,9 K6G&=O+V[8BVUX;\6U>-0JK18V0KI@JHQ_I68SC/%4F
MA^/TM:"EF=5L-W_'R5&'-3FW?*^R<0^\(T/!6*OWJ0TKNP&(9S"Y'W+??DB;
MFQIA-27.!]98]EJ7&E>?(&T<<ANV):6?0KC1Z@'V&Y\#C,\^BF;_+RI(Y(@>
M1-XHWBSMXVHQ!SKJF&<3%ARY$,&2=2OK(RY*WQ@GN]0";VY.T<7G?&3#B1IH
M@D=L^.>.*35ML\CCG(X&"#(J&V!>X5NCI_18*/E2%IKH6SR!,&\:*HXT&H46
MB6+'&E31Q_-<P:X#G =%0?J2$N9-[N\R;1="Q%9J9C0.^5P,X,&<-Z8N;L*M
MZEA$00Y[FTB[0N&TK)* +LE%C-E.T9&,G%)TZ]Z7!.\%#>FW:*+6*X&N&>GG
M)4AWT/: !#GS4__XI'5GF>-TG/IE()T1[;$1&7S/XX<7GKP:XWX@XQU>^0GE
M[;I #9.#\=&,7#7+\3?Y\K6K;IX@@=HR.%OYMV$A>RO!+,XW]0I/\O=11<3=
M>(;&=S&F,'=8$&4YD^B4QO3SY#Y[TM"+=D?_R3JOX (_;HLG@0XY4/.T(3?H
ML6+X&1A=]+Y)&*2#'/UE_,LWL+5[8O=OU#6R#@+UG35ML^,.8?1+9VF@)I^3
MMG=4!!?&T9N+2_]O@!0ZDJ74I/!VQ.@7^MAWC %/,)NE6O^@0$JW_:#!^B[^
M<?N+E;4YN_FCXMZ8T@V!U4Y*X?QB(4;%&9N,%^55\Z9U%53:DE-[KTA<W>JZ
MY CQQ(]I.G0\EFKK;;;%>//ML=A<#&.^$IZ\;BIB'C9:]4_5=7^=M-.TM' .
M3?'L<2X1I&\2UC:W,M4;R6@Q=@N*:Q491N='BW,FS#,GJQ79O2A_YBIF(O@J
M0^Q P?>/[23]@B.Q0SR2$Y)HQC]2(_R.$N)!'7.&M<%D3WZD:!#V^A'J?;Y[
MRDRLX3%%).95^6G2MZNU-]:^R&'I*;"1O$[M<M*X(>\U<$JM)\5L,(P=3],M
MMO*/KDWW'1E[IWZ=%$C=ZGS+0J'@Q7H4S/L[Z0<1QIO^%RE9T>JUCV$ B8!H
MCP@2_D^K?K+/WN$<MAH8WR-1JE$*UB;Z+':_S<D6^43X4O>=.]>*GK)G2B41
M'%*E>C@I6YO*>O#M4W/8/ZYG8@+#EBT:7K5$%N;C+AT=\H&+7+:T"4>6SGLE
MV51GGY,1TGX0X-SI*%^M+TWTR>!R:O3^_]G[?CW@TPO<*A=V41PT4RP1FN;L
M@NBS3')Z40UJ)!I_MHR**DD=!1NI.\C%DE'1!P!=#DG\S!+\EN##I?>6-Z5:
M"\.TQU[I$I<&%%O2%\B 6!36SP]>F1^JKWY=OM2_%KVEDYVWL&B9OQ$SA30;
MJ!"<3TW+6:J;NEZPJS60VS>-\A94BLZ2<9M 2]EMB>+LYZA&-\\0>VIG]'@O
M>E+*/7V"%$?8SQ).7)==WJPH<\+VZT@$J\D.0/H?G\%\%JC:I#OM0J,IJ)K_
MX5 #WW5X-J*PG'L6)ZZ)^GD31MJLX"8A#-1;KJ>RV85K^M_-V&N*.=ZW^@0F
M\]'6+/1Y+Y8#!(86?++,1;"XX<QK>8.5D?T?.0TT>!$>M,<=%/:WP\K)EBUV
ME9;'R=Q.W_R +.HF(-&R8V/9,9<)(T[O@DR:W;B?I.]Z:J3ADY]JY%J;!5IN
MDJB5:RD-NU6[BW,#:R[3*9SX9&HT6\^^"2(R)"*[(^TBZO2MTHV_>J>5IX.-
MY!*>@SZ6JJD;NEX3R0G#B.33QTU*P9 O;>,IY8"-H3^_MR0OM/O:,^1!9T6<
MHZ-:X\3,7Y*<^M6IY*^6^!H:?V7?OU@.G<_&BT,IYILKRG#06#2VFV+D$LO@
MF%_>('4UXBE:LP =SZ(P0Z4&\Y:$[8R,.>M@=V>[%(<]1LIU'Q:51>J$E[8?
M1MNLI!@G)\6L7Z%@E!A )V(ZJ3=-_M'$\@2ZH?UII/OO^<G)4V<+9\].A=R9
M,GUWG]"MJ_HITSY][3EO\.3*)8O(;#Y'Z?0ARJ5[/K2T5EZ[BNODY@% ^_0^
M^8F=@H],B39Q&^+WG6'%>Y2ZBVY_I2H1"?B87B7;V3(@0K"A<M[&Z6,5-(A7
MN9HNME#W[@:3[X>ISPH!C]-H9N5%2@''.8"[<%55_'$RO[A:HJFY$Z@Y1$P^
M"L:IZ)B>HH;$+?.N<1!VX,J2'$'R&#KN#9J0;X/>FSH#G4JL/MA9O-:68=+#
M4*9K&+ -*G"LLU1?L)3;)WSZK<?R?%W*J1??Q%Q1O"URS,4.XZ^0BC3+ZZ[K
M:IMO7"S@'@IU/<<25(^U+=N%L M*@CJ1FV9OWQ=7[(#R/"90;F _%,-D$/I%
M^T!Z]S=/W]^M%Y&Y]T(:0K1/,<8"^:-2CIGX^S[H\T'W&ME6>8/+]<;!5V7X
MRK%!\;6W%_X,;6*?QQ?EG?GH2"O P4GO+(AK;JD\4)9E%$&%JCRB>4LVYM9N
M-2(Q]MZSXRJH4^]$[,RKIH86C-C>&T9'K0\,TZN,Q0<U!( Y0@*=</CV4_PB
MR>O7P\'UN3VVPG8X.BCMV6^W":J--X;"M5F#<3*M9I@/@OL*VYY?G\3H(MEV
MV-T3_2A3[82_S-5W(IP]&H;7\H8U5\PT^A"^AJKN2.[)!)[6[;SNKH3(18%P
M0@_9!P#=6;+%V&VO$.:_^L3-YZTAC4/[@9CKD<0^13K-E;ZGF(!KY@W]W^_9
MW/_GH+_^J(#[D%SG%_&H/5Y-/5T27H)[IJ.;Z/HHB5?6VYH/8?PD/X^;/DUL
M'8B6_/1B'E DHQOHRJ$4QV5NQP\<9#:J%@EV:B)B/_^@#X^)UTD[_>U@9>BQ
M!;-],X%MLWE4QI%_=1CA0W)SP-FPL2>LGGI!TD:CVV)662KJWG[HER''2%$#
M0'YDS\5Z/?9H]3%35',CSV#+5'>1#JE9BL#2K\P4[PHKCQ!SI*0JB8\)._.:
M.BM7..$=QY%,Y?Z)?K($BTIYK_--NV4-N&Y7<-5Y0=<:Y22]0;9.\Y@^J5?#
M4 ^F/6:(EZD]$"407B5&PDC+,0*'(M23K"ZK5ZQEJA>_S<O^%/>8?\V]E>S=
MPD9'-AU$,%[D,)7/(UY;."(6'Z4YIP_:D!RN*GAK!5'%-Q.N<1U8VAA.GT76
M<0\3#V4$Q ?/CH.XA>+4.[CPWGSAGTC.P(T*SY-Q<]%P&K[](3HSR3YC.D_Z
M#M+PK'8?F;H?2<2E;+[#4QJCDB8:!EEKM UUW*+8>$*;'@,*>S($1XT^R191
MHS>L@S-V.W#+*?_5:J;1&LTM3@LFI"[L%,JMP@J,"B"HGO[^<A;]:"+5U/-*
M]**1IWA7!MIE),YSR&Q1=W'4L:4U8/"5ZCM_W*M3I'.T6 K'X"2M[H".U'#7
M0EYJ06WF\!??4RF*FH$A7M_U?\0L 1#^9@Y:*7W.3^B6_%)J6\$N5Z@ABV;U
MHX,@C0F[:J<EPJVK/LD*Q6N5 $DX27]*:82U X[\B;'Z;&YSPA3;/&[&55N?
MZ 9+.C0][;TVP2]&I<*J5=4JOQWC &6CE<4*,G0? +MT?D\X[-?8XL2E[EBZ
M'2_9-AX'SN1X=,&*1B!<,JQ'10[-JJ.ZQI8M^1X%0WICOJ29I32&<?P&8CHF
MPEZ@S.O#VY&SUF8C*"-F4%<-THY(*H>V6>SF./ P<(_YE/:04!P*IT^H(2&<
M3-"QK\D*-FM\/'8N\\DQ:E2VYF0RK^2'$S"R]E,.Z_(?2/O*C%WK?<KS]^6H
MY88@ $ZNNTC3BT9DVW*F&Q_BZ*!H5/8QW=H^M"^S['VZZ4RV?%OFK!#[M9IP
M=]3=/'S YZ58W$GP!MU0UV>*1>36OO+V;Q;S-\15.-T$NSN)M>K@%AF20R<=
M_*L_T9:UKR^0LJG5%7\_E_T1-?WA\MZ)MV$A1/_VK?5*/3* KW47V#(*+X2R
M7++F*4%*FZMSA/LXF3FZYXDA#9;II?WAAM4WV;^I0.NZZV8OSN/-VXZZMFK3
MOK/3)%*Z.3J!+?*Z+H8*6=$SB FZF'-CVB;HV,W<$"WO2!:SSR,AB9E.NY49
MF.]MG*-^^6_>>*[/\!@39![1\( !X(VFHDVA5$%Z[5MM\QZS 'I#;PBBW1$R
ME$FL7.43F2\LMZ=#O\2<Z DUP3_T.O<>ZR'.4:\WJ?$]ZK/3,I_7JR)ALJQ?
M?)[+#:<?^J0\V.%$1TD_AOV&2J5'NSQ/&5 !6(57?>JOE$OJ>36.1JO@PQ3.
MUA/5BAA_)@X!9%ABVY2+ !X4=(7]?]$K22,,WL<:Z* =7GTCUAEW!FQ5P9ZL
MA0)ZM#8=O%K(%].P7"4Z,/356H#>;\9<LU;K6[J/]%,>"Z%?73&((:X!LQ"<
M;E[W$LI$H,I';2%!U)!-86"G&%NA('8HSO"'@-:.?,GERH#YPNLBYP =ZB<T
MK0R\"VN!B\9?HYJ,ST[P\BGIJE<.A*75$J9V<N5,ZUG;5&A(Y@5]9V;)B#IE
MN0K\'P\$_JUS%Q>B&8>+0.M./MO;#(\!*GQ8F"11IZL"77A@*HXH@*;_E+BU
MR"SOV_-&37]M<-$N,3[="'"U%5D%W)_DW5ZT:AC1J]>.?M5:++Y-]NBD9DBI
M+"$&/C(7FF<4,'%TS(!=A>/3V'T@;97?#Q9)CD*ZK"VDP+76M,FI7.C+3J'L
M'(Y#YJ:S*4(H CZ_6&:;>P?-0K(B%<3[0Y=A6Y%;;QJQW'=)-Y4L6UVOP*Y!
M390[S)^LW*H;-W $#&J[L6EZMNL<ANUM3]/%3PSA)O;QMPFYY(S<;.\-OP?/
M$MBL*<:8C[$@["ULDYP@(^Z;M5U2>,C@9%4J%AE-4_J2(4&LJ+6,EP\ ]MZ:
M91+>K_<JZ4U+I^,RN7_/0]#(7K^!I._R,(:NG_!CD0A:51?47M*L[P:GOTZQ
M?1%%+5)%]4V$>;==?-*[)GWTT^BBB'R;!6-&%T9$;;T#IT/I)G>O /\8KTX1
MS1?36&W[%%OF4AC%BJ,^KO,._I:<$)-QO9LX?2;5%Z_>PP5A8]@@KX_HX?SM
M/\34:F57Q+T(&LV;XC3 HF3;DL,H!IKU<I(WWT =V_U1N_7UF8=R%;JEY2*O
MMK;JP<XR_&H)CVCH?W[-/Z(86'=?:S4V%'(2QF2%,8BW!7O"=@PSI%I46MNQ
M>I5A& "S(!,R^Q*0BA5V%MR(XC6=J2SP#E,.+@S6?RE'CK]#TC"\ GN4[@0L
MJ)/*:.*3W))%N\]J=[%XX1I!*_B(( #6<K\0N:T^1#X[QRZ^.2^YL!TF13TV
M$2E.X.+,_VT\"CS(:XB]K,8KQ*U:,RZ6$[9%L:+:&2GV77B09MF9,C?KS=#M
M[XJ4$ON*X1X1?$-5T1)*LN'=N#:/?,MK:O$^%+#/(AQ DL=RJ*:KASH7:7BY
MBTD1,Q:UX*:]P>@*5)H8;@#K&*<L7+6S#WLA6BQ^\3T<",%P3QR"ZN#KFQ*3
MWH_\30IG_K>$!<)RB[NBBX6!8]FI9@S6>3,UYT0R%W.@L/,HO*A=LMBK-T12
MP$.Z:>]S1N=!2E1Z4T$AT.,\*E+04'2YYY\/&U?J)(#AZ,,E<#3XDMYR-DV9
MG.'$0@.<[ MU"P$3XZK7\8I0J]<9CZ;) ..1%?PA +;NR)"WOK^B)%PQ&/+\
MA?6]"9C:F*CK9/F<6WUFH-1W VK!H1+V.FYH-P404Y/!7H@+L=IX8_[X 8#:
M(+M-[BPV3GP G'1&ON=R9Y-X5-+/.@0%*SGST0@Q5+H)#T#$M2.CUD%IJ:$+
M&9F5^GGR6K7<M8Z"\=4&(# NX)6F)VTN?X@P]5]-*Y*G]!A;GA^0/;J&X*YE
M('.KSZR"6W[->=H:<:41_@X0E]'\_'O*58M:F]CFEV6!_-"A]J ;BPFU5&T0
M$<R.<S5HEO].G>0$27 ;.9_<<J K8P.=?1Z3=&(:M-8:V[*OD9<0<U2H=)*[
MK!/M[W!,/]6^4N=-)6>X7^US=DX/?H7=]NP!X-#'<L[T4KF![@&P_)(@5&.%
M*C75!9'/(X@:EL6L*Q7@T)C4F>P8@I*0H3QAE&7TN94"N?M4Y1$"E=A<78KO
MMN0[L_Z)RG-_/\KQ/D5O-+_E]U:P"SX8GOI\'I*WPR?Q2_])>Z?O^\7RS=L?
M_U,;T>]Y4):-ZF&5<+I#NKGUT@. LH%DVP%E=EG! IF<,*BG3-TQG=(J4A&O
M S^FS1B/S['B69"/50ANS?^3EAZCN^.#:4Z8Q0ETEDG?@Y>>UH>V3BI_EDH*
M[ '85O8D%:5SQ=&/5F,-"'O3,'8_QP35%(ASKHKN';3XS/H="+6+4R4:?"W=
M?GX,'^BG@7/0::,NQMIE.R7VM!SP]$TO=WB6,5K%/T@<I.LT!X"5^:&9"9)'
M$(DX@=4>C@H6BFV-KP+\V#6)?3%W@\;0FOIXHT95BAHY  $1,#T90M0%X #0
MLN/OW!G<?%3Z&'Q>%\3Z.?_H]<7/,>%>DZBWHA<*+X(_.)U?]4VM[(=)!#P-
MX+J?_+OZ9\DWZ*IR]L?4O.;ML__#$+CSHQ\\7&G.T:B"BG(.4L-)D'8_HQ^"
M%4S_G3$-E:RE\L2+Q@@ K]CP_G-6QX^@-:TUX2!#6,:11$,"T95XS(3,7X68
M"8+^--\]9[-_%3C?%_!"U^_IKY#=G/ZL(7VZ(%9)1;4V6?E&)W>?IW0?TGO3
M_X8] /Z3,KZ6<_YT#;#.#,7'R4:C/2<L6R W(/T\6+A+!5>GSO>MN*N6>OZ,
MAH!ANF2:AG#Z: LS W66RK5 2W#UY/E2C_'?!=@?/?9VTOB@G(S4&+/6@ O!
MX9W@Z %50=D4*QKN-07='J%:HW0NYK%JO/J-0Z/TA6"_*6S.643+8!=75\W1
MR7U(D*ESW*+VG2:I?5D1+TJ3_"+.DPW6:#+WW2!I&&E&0D)<[E8W&J*8?M6>
MH$W@L3(,-C[T]-=1:$VS_^0W?Y@G:'PZ+5\;3\V?R^HP*;')O!OJ/S#- [4>
M;>=CATU+I7 D629ETB:)BQB7B;!G:LR*W!86KVN4EB3E\@OREA#=W4#G*J'Q
M'5,P+SC<K3^&-VZ 56_IO*TB@K-C+6W"C7H^+H D_6I&4U;T3[<*9Z'R@ UV
M_@,@74S72!B^!9KLKQ!U;S2/J/H$D4>&D*YX\5%J&34%H!-'LLI*D2-FOD \
M@#(AS]KSZUDYK<=2,A8J*:QCJ;0MQA8TIQE8O',U[<C\IE:%2=^4_>U1%:M2
M-?:/0"MQH"77AUQS3(7WWA:B:9#?Y*4649^O$;I#3,X_5]:?J-N2(%[U$K'V
MG&)'9I/-V ?_B,Y@DV\9TH6F@C@V7>@4-KQB$F+6,1MUZ/5(3SII7V2QMYC+
MVM)>B=5/C%86^ AAS7E]%S'W ,BSZA=] /S$JWD B/<^LW;6%[FOE4$++:Q:
M \_)>:?O*%V]?1(6XS^E'R(OQ_S?"+W4#!'S)/)^S<B]HY_XLX8P7L3\:@:D
M7X3^\/+B44U%-[EI%ZRN/*CZ>;2!";)'XS$EJ2V3_QDEN=._?Q":W')FG!B>
MM"\:];?0^$73_X$T:W;+Q<FY=!UM6P]CK#?!?2Q"C=S.GX+"">U$;2N%=W=8
MI=*3TUW6KT(CZ0A[;7\EMFEME:$]5HO +%*^$='R+A1HCE$;"DHLK.M4XW-K
MT++\NR4"[M' BNG,83+-I)<6@2,KK&*7"O;[KWEW;_2^YZSZA3P J/^#)P)V
M_$:+3HF8>RO;9*7-/A3K,#9Z>P4KLZ#T\,VBI(L':WP<K>Z6LW78!8-E/^J]
MDC["J1'J9LZ*/YKI<("4$K\1/9^XP_Z]F-Q,P\IK8IKS+0Y+BP?XDPC"SO.H
MG6P_.[%.44T?IB=VA55&W#O$)9@+SR"V=ZXPWIR]@8F#DRXSNJ#$\:NU.835
MG,0">,F.W,&]*;D>$K(E1ZY"$\$5@LJ#GB,OYT3/J4"JH@Y#3U[VGW* GR;.
MS:;DV'++)7GYX;\4MF22,8A1=I<3AS;[+8CC;=,0<1&8553OB7_GQPGZ*'WI
M%8N?Z[ES@Y?:UC'B]GUQ")I6>9(SD7NXH-PF'N93GC N%Y'60OH<ZGU.@Z^=
MIEA#<O<7]0!0.7P R%\]:M?__>?-K]ZXZ\4G[_4<5;O*A*4RUS,&J4B2RHE6
M#?EHA2=>2'F/C8ZJYQ9>J4BE&^4J;\EI>D4T5G<AOM9811M8-0U_]N5+=GON
MV<DP]U3*BY7K)2@V\([SZ>N?#+U7;(3W<XB.*_ #8/-[U?VU^[?X!\"'=?U?
M1RN_/T,",W<;WNM9=^R?O4O-DSY?=84;%4+ZPA12?;I895K'[(.9\A(]38IN
MOSS%#GW:;P<E>GO$JF3KNK<#LY::?Q(V;7+ZC.9<^EGWI]?C;6,]IUFI:@Z-
MK3[W>=L*&_HB>I(IWDS3U ^ USWO+N=;][NTWZK/THPV& ISGSH>.V-HHC8K
MY@%-#C4.(7@IYLZ)$=W\M9$,77ZRJ^7<9F('-/9M!T6(S+%@MW3OI-GZT*2"
M;G.6J4@AWEJ(@S .C]1,_KN7;K6BQ'OQ/<935ND:,R^(/K4.\7>'T"\QK'C]
MU:P;7!.4.-$?BDKB7I5\VR8WRX9N"XQ'[,EZ5-,X3A'Z9@G .1)8FX\V)- "
MUB9_G^7Q/  20HK\^230)@WWMMO'P4KS6W]U>ZOV+UXO>-X]^Q][AK>%),"@
M)P6LN1?V(BV8&FX28<M78<!J_YM==H"@*JW?%?4>G#]>*RIH:'C]="S/=X?_
ML@!4=5^9G$V$\RXV4V4BZ:UVZXMUB4*T27G?O%..Z1! 0/XJ_".V#;4+-2QU
MS@W18@UJT5M,]R\EDD[O[?$PA;XBKEG#FA9P:A)/G^C/J'ZR>$/HM:;F.BOK
M&%/[>?%"5!;EK(Y<J['4?A_T.&=[TGY"8JS'N]3&@AMNV*RI/0VGLW&6P@7J
M) ;GQ6HPB(2-F0A*]=L2C0Z3]OI7.Q8^ CWA(_,2&BJHM>;O6F4"0DJ=:TL_
M&XI^%7OS2GV4V=_R59J?<G4AIGQRA^;J9_B7K_S">5BF2$;=[1,/0P]*&(^5
M(H#22CV@IOGKB0D\8>)WL1_9C#4$WU!]%H+/_UPP3BXJ(,U2G4' +'[,/\*$
M4$7"<_(SN(2Y\1#E*D4@<O%>I*1O!)ZW,-H=U]B0*AF98D2;P*X9IZ5I(L4N
MM$>3]]YE-T;; 8F@2>S-YE2P6'%>/7;YZ%05SBI2WZ$<68J!B8NH]-56:%=,
MC6@1Z!V;K)@/"R#I:';I:T8Y$Z2X=I -D_^Q4=7DRMWX\ZN<RH,>]"R^H%]*
MF(YGZX8["2?$UO@G/1O3KM=X[]:3YTP27X\2^<DM+G\6HVS!0P5P\?W<"[:Q
MMZK(.47&A+^?MK,8#S[73L!0H1-)S^QW&2<;*45+(3V3>D%,-&-R"CP&%7(8
M-[/"=A*_7RH8XR?&ALEY;8'=AK5^275Y^&%D#*Q#Y<H+=0V_93NT>88RP5-5
MY%01=G&YEELA>DZ2UK$UV9;<<@2L?(DM)T<3ASE036A>]YA4"ZJL"S.U(9[;
MW(54E[ZH-$! J],JU<YQGKC_;KHZ%XKW_4$N>-INOBEB.D@R9F$^U!W$?))I
M1@=SN<_&Z/%OV?)_%^Q2ITV$<98ZD;Q!F 42\RV8)8>&U>OT(.;:'M6QV26(
MI&@T%J"3N"O.\34&06>!&Y@^H9@1*A95J(3I>!$-C4YNQ.GYE"O:N[]=!0/_
MQM1O"![BU /&-FN6_D&1KU*J]S 8*VRIK-K1ZRW/N'"_=%-99LX)L^V?>0!X
M^OXFH; U[<8MXVGJX-4U\KX.R'"1#J4Y\GLE0_C6$&K1=?C)UU";IE T@0\Y
MQBA1*E%E>_.#>T5"ZC&#32#4NS:IL#1BNA[%6Q-ADYVWE"ZG=2C[2XFSVBZ^
MH!* RQLT_7BAI&)QGDG#N51#?1OZRS0R-BDZKW7>HST$%ZF;=2IO[4.]$J(2
MA1/)$+Q3F3@B6.:%B$BVRAI@K/H3]O%^?<C=.+)IONS"O\P[4F8&R,A=-^+F
M*O5[%2]I>/WWU?[3&'4M0PP!%*.(2EZ#B.;O<7ZCQ$,(07=B!$5KZ:>FF:.&
M740:Y698&"*7_"S\W'F.#<RCM1?T<Q-R7MC63W\&K3RFEB-;&Q' \!JIFE_,
ML,349>N2.+27I+OZCED&;%?88M'I+>2/7NM(_*28:2>2J2UAH;-YXYOIMVB5
MS^UR]IWT1-%KRI ?4H7;2ZJ8R5HF7:>FQ4-:9PY?.<34?DQ>+SKR.H#2BK-G
ME!931Q&ZW\6@6G((-(P_D)849H&T&DD#%] TF+1T$)2&<AO[+,?_SVKDOV6F
MWX20^] ?4A]1PWM=8\$RK@Z$#G%5[@:OKTJ(KJ%QTFBTX5$?F<&@@/"*TC_!
M!_[+?.05.;O-OJ472TWD!BI T7'.%/IQ=]Z6&[DJ3'MJ-H.L4V)DUO ;SO(<
M^1KD83K<?YP!T_9;[BTL9#GP@)1*MRP(EW:L$X%P9[QJ^2R#RE TQ"I'?NNT
MK&5'>6EP1AE$<$O]-)(?G]1#*7IO^1J^BZS;'PE,25EODV*WE.A95T?+CES+
MH.(G5JP8>7#790VJ!0AWUXKWTW8N"&)J06:M"+V=O*>9$5G^OX1?QQ= I3TN
MWE=<<62Y2SUO^2SAG7]J0R]G_P%<P]SEOU0KQ=4R[DLLW,^8Q3[)@"^%:&E,
MK9[ZE$_I;H\7>&3MX]'XS-=,>ARYBX.--K-CX :0P:#U;5;7Q5LWLFK".N9Y
MAL4H(<@)6DF5=5:LUEE990^"B#_>W3%=*NQ5EY8FW)M.WJM?.^H\G"J[^-U%
M=[6#>/HS[+-U?:,S1 2OJ<>J:U&T.:-<\#G7ML.*/VWTJPC.JL>MS ?M914F
MO!=Q^30@+$HR:L<_LI^5$&>'.UR#IBXL:N&@LD.&DOJ3'!N4LNX0Z<[WN<,J
MM!C^5T-3Y=>3C]K64SR5K%3SXH0#LR/#1B5S3._HE@O,BKHF3&Z%"& V'3-5
M[NG\$&.A44E9S0_.8P)XX&Y7>@R9ZNSF/$]2O?_1>_'0;3)]D9T^\9\&<F0'
M0F1_X XG\^;;!G3R463RGMN*@R^NBX:UFKCG0<&(@DNM"(:_3L<$TLH\^R4Y
M7 )S-W)L1(MG45>6(2Y)H?67U,H?OX#.E 18,<5V+(,(8RWTU@YV')#GJJST
M_C5YX?4C2K%HU477? U;CT2]7D4S:>X2$Y?KK&7=W<1+DT:MR*BTP/4RHD>3
MI&1K68/V! )#AGNNUS+V"K\EG8"*5,K:[2E.M\,E [%!8!^(IB><U,"EBQ&F
MISA&3I%IWU9V_<XV;H+IM6)Z WN>DOR')RJNANU=<A3.-/DOC*L^%RY8:,M9
ML3-4NA0/5POF+3IFJL"V+4)CS7U<#()9:\W/;.7P8SI (ZVX29767HJ"Q@=B
MM#%P$S,S/SM'83V>3*$@M6H"+4H.TMAM_&F9:V-G74N?JKB#QTOPBW4T$T-R
MXQR(6F3I0SIDZVT]I:G5W!ODRS%#*IZHNKCW/A'"AV.SG*,F1Z]--T!J[ L'
M14_,AL.N4UM.\36\L:5FI7WTO,@0G\YALC?/KU3OF76JD]_40$Z(2XA)I!$*
M/M50&9G5KI^\RCPR9#T5N@+TB]KUK40]:\?P+,LD8;\@= K7+@5.-;RHXU]B
MA"?W(=)E@Z^3ZO"##7,FU_:F<MCKIVB9AEZ?=GGK9T(Y]^^J#GYLGM[*A+S\
MG\]8D?@:PL]-T?V:?KUE=9&XDMC_=7+6P=EIQ3069T3!J)-'IG]$-):\3JE:
MSBI0V@A[$_R%*[M4W+'PNY<^X=<Q#7M(Y+Q;&JX<T3A,3MR\.E&MU"=M^+%S
MM1&PSW+HS!I9O)DGX#8?%)+A4<V.!XJ(382I$[Y8O'>\MW"^&X[O;<.-IB9.
M(\ "D9S"9SWDTVU>W"6_+8;VI\V:0AZ3>&'0))%Q!_>H+(H@L^@T.S(;WHLW
M=I&KS &%2Y>F].M5JJM<2N@>9".)'UPW(8^:95(L<I1"B"B!^/6XQ[&N_;.<
MX'A^[4L@@6>"_61P3^DD=7&'\U8AFBM78"2W[:]G7$+#]B&ND?+]<,J*X_?A
ME2CV\"QN/4Y;9"7(CZ..J!+O"30 'C4H::+C(4=N]U[^//_;80FD\LI:9;'.
M:W+"+M,K/5^,0G/U>]M:!:1[^P@QUBN9SI@&]/:G *546-/TV-J^693PC\$&
MQ $*/%^N+%<KW \WS$]J-^K,OTJ0=U-5Y5C_M8>BHLV88)37U;-C?)5PMJ$J
MTJ(BR80KB O S<35;VFG7DH:3_>=#ZKL=W)4[^')-GZ37M_2=3-H[+G+5-T;
M%UWOKY4'@.H9J#NJ>L=AS0NF@":+[FJ('LDYU"E)1U@M?_)3C99A>A36($7'
M>Q\<E9C>JHU2D3C'\7<WT(H@0D;QF#P #))IPX(__JW .71-5G)K-5[2O-J1
M"3U>\?<#=VID.%;YC9N+U)AMS5O-VE>X+LCSTL3F)\/&:5;Z/32GFVBT]!)J
M:I6E+^@K 101E;-"9]>0+&L!)(MWNW6*,R4!P2/&-XS-20E)MAFD2RV.Z^+I
MDK,<$,.8KX]J%JM.#)B49.<4.2 GS>QY;XL'5BV[5$R?8[Y^FH#(PU4*LN*>
M/5??68U[ *0QV74M$Z0456AC@B)J@":\.T+\PR*\[5D%:D13'LA4=Z%"0& @
MU >($P70Z*R(.N#11C1N-O-F'1X6^P(ACZ:40XQ\@@OM1S=',T)UK/:FC:V>
M@Y :<A3PC_E@3M\UB^3CEGEY%NQN&GC-(J=%Y7(4E%L"O(QRRW!&%OM<S&[#
MU%["'* .9+QR25QU/'S/[7CF&S].NWF2:(E[' 9JWYBI9L_7SZF.4V!&M,LG
M[Z+D1N.!M-]IM,!&"-4"^ .@:8FMH"NYF;5^;3ZK;6LLU$ZOF/W7!1G;PM)Z
MR_K*EO-KC>:+H:%D)_M8%/=>"YE Y%>ZOD8N]N;HYXGWO7A5S(6_6AV]39MD
M^E21"X+0!IE$?N:4/[2R,R/T6QA!+E:!4>DT3T N_S"JCOM-[CCXO9, #?]D
M?9)]H4\YZ\CH2+]RBME[V_.6>;?3@@Y,%C@+BN:,$J/_!Z>5NIVX6"%4]-&#
MRV+HW%9U(3F+>'[#RJ$98T(PA_#XA"J('-WKHK6,TZ4<"V42Y=UC1;&W.@&D
M;I\3D*9).+K&.G:LM6J@W48G5X7^&MH##:F RK(DO5&*ENN_R:/"7 177]4]
MVWEGJ>3:<6?\842I*W31G77Y:%T-?6+.?CH"4@_Z;J@BN6B17TV#"*I%Z@[9
MX#"%G=_X#^2?56BR4*0=GL4\\_\8H_5-1S/].A*X8B+.M^^SUJ)G*!*@@1UA
M,R7'+A8?AQ7I8_2+]<L'R7!>^?&!TN@G* <(MDB)\(\-8*4L9XBM_4OY#%M.
M;E?!-/+6#^XR?RQE7XQ-/"W%+-CNTLMXH5?49 ]BQ=RV\G2N]BR9VBL-LU--
M35@&EE _@J*QJSZXI$C6=L!<E K.NLV!0X(BUE-E&O5-/$]E3Y3E<'/;M=J]
M_TS_]"3IU)0^'>QUU6O_BRHLG,+KU93I^XR];9B8CN)BP@]N-5U^%,2I.NTJ
MP]?2@ER@)M^U4\<H+V?&+8!U/-.5V/Z[RK02BF'4&T]&T?J4Z9@Z=SHP[BCT
M@X-_,&B+"\\Q7E"9D;#!R^P33=M:X0W4*I_6*E;&4['B3S-G-,P[>XU5U_T_
MTF/TEGE[8F%!KJI2,90W#-$I59TT#OL,PKNK0P'$O9T%/U)KWKS6DS)Z  2<
M7!\=(R8RHK1[NJ)-=R>* <AG$V:NTR#M</(6=%O9G!;L[JL=X+3A5SFF6K6U
M\NM29\PNA8%D.7(#&L (\^8DX"QW!AY[$6/CXQ 6!! %?-4O1?@<)(J[QX%X
M\#D5B6+GB4\_\)L;@)]H_,H4-DAB6Q'VUB?#WO,?#J[N2 'O@\S0Q1&X-T1]
M?E)OGY,,VPW?6M\YU0)*-8GP/A'2N=<2^":$VT\-/Y'(CO'J(P7$T0>0;["H
MNS1Q@GAZ/D4)9>7VN%4DP[*#%[D<S4B,XGL'=!3PUA\[.EA6*[J(SAM <0M,
M5U-*P@]/JW2?#:I*I'9G7/S MMYGZ%2GDWX17SNQMQ+CG%FYF7MH/H \]+6H
M]P,,:S\ A ,3X&\40=8B3>L0BV-$GIN^0WJPI]E:9"',-JM,3:LWX&_6Y:%@
MH8)/K%!=OX-E;0D2-,7IH[5S[,JEC7AI9J(AN2KI]<\=<[J^4R0@486BA#H2
M. ]KBC3>&X27:G)&;6_ L  LQ35MF'M%PPJ3! <"RP:3LGRPRJ=!C6*->B[.
M,OKR2&EALTYHN:[DZ+^<MSAN/T%2C,NN>N3N!'DOJ#64:Y]$9C?H::):LO
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M8P6[X3)%@7,R*D:AO[O(;3S):G$-Y?3995?>FQFH_EZA!N%9VW6@1Q/D/3[
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M,;'X6P#?$8)8WMAMVR=BU2JJH ARQE*XD;I)R?RR4!+).,/44(WB4<9,<%A
M0)LE2')^4;%KIU8GI(_Q252WF8^,5::[OPDCA9)1>CBNLRK9J>B#C56=\K+
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MW&+Y@#99;+FL.17TX;OG"WZCE" *C\>)VK+HU"6R-\5(G39:[K)>]7$?D+)
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MY52Y*8S@\=E!<Y)19 NC>GQ4K^5J8)&=!5RWL/J91CX(-,NN7R)&,%CR+9Q
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MZC Z%)34:!FPV\&(BF# H JP[7C/A;. ,P1$%0" (#2*,'4QG#;05&GL;JN
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MKOE\&2F71*+2M^*U'A-J]N-E/PKF(*3)MK-6FP]EY*P2BY!1,.@O#;;OFI[
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ME8:;!5"R'1R6>PP$>K%R* CZ3C+K@QF^'9>[J8@/%.M(I(W@415L-P>*&T2
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MH@J52!S$%/,$E4T&)B8"@45DMM$V)S<-!%IMQRZFL.E*M38]_[[ 9&!!8%X
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MZ-VW_G+E+V_^U8I?W?AKY-?7WQ.]Y[I[X7NO_0W\FVOOB]YWW?VQ^V]X(/[
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M)KQ/ /:T8,4AB5\(^R:XO,,RQW6PX+>R":V/DC#TF1*\"IK2N.;XA7F0PO3
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MHMU/Y@-T11,3M-ZC1%77712Q+"$@RLA \5#L/\89@ZN)F1(K<+D,]C^D8?I
ML'Z5<P _/4JN7K?AFUY&4B;D8RCKSG, PX>RC+;Q&*DZH@V<(+&29I*"3Y"
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MAH"-F6L1NTLW)K'_ R8$9TC_X!"!CY>(74%@6UT":6_9K@4C7QX/Q=#BP4:
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MDF@O7? 3QNE-X./I:X.[GSC.U<>QU*6^BTK7DW03&1 <H6HHB?S#L 31'E,
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MIC^'](#[$L<(M:*\L>T;T_@<0KYH^%@7<&V(W,S"!&:+]0'FDY6G.G<EGA6
M==7$:_ $]CZ,_%[MMX2X:,;+1ABT^V"FZ\U:@K/&;ZF0"DI''<X+[E!?'+2
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M;F[**+S6-]<=,:8.>W,7:!+C_T&>+S.*B^)[YM=G)W^_R ;!T<PVG'2XETT
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MCZW/[IQ,\%:^> Y/S2WXP:?&2!*49SP;<#&OSC 5HBOOF$-C,-X-+)00)6=
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M89^'(=? I.0_&GXO*@Z>B+IZ?!4E4C3OJ_'\KX'MM!#^= KRO7W/D[]XH9)
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M>%,7N$415HD?5<<19_^9M90PO^.1>F;ML=KTF,RHYS30;EXR?J<^81&TT"*
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M '_8C[\EW+Q6;9%Y(!Z/] NNM&\J]WEV]<XN4G+&^L<UAM?UJ\*_OCDR"^+
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M_?B%!<KFC.4#VK[JPM*.,MT>0G]M"IL+'*Q>4O;TS#5KZ9.3J:'&O[QCOX
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MR,0*"N>[+4P#0"KDN_RCHGCWF@X=-4,CIPUC]$EF)<32&HV7]*/-+:\^)G\
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M^.K(P$+45$H,ND9D&QA$=>7USE/_;[\VE.62+U/IBBK*^KR78_C-O7@>.OI
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M>G&;3)= JXVJ-[9%H((?TQZKF%;>D8?H7BGN[-+U-/25&US31+L_T"OA$40
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M_107,G1:G&G\._/_E)_1)=L=?-C"L%@ZR-FV(HF <)1F36"N/0$X3!'L#\K
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M6$8?5R-Q''=H;U@@XN/DF_&Z %M%Q>/N4M/-QF'I^TQ_EL 4T+7^O+U^2*H
MRTB8Y(?7]Z1SS0H]T/&\7\%#$]ORHOT*]RK8O/BJ5UXWBEL.R2?"W%FHIX[G
MW3#[<21;_-VXN4/==[?>W$*EJ.[UW*FF/]'\HJS.)Z?]^CM/S\=HN0-4PP#S
MU4P759]UL*"*JUGZ52^^I-\N@N6P%*BCA']7+S_T@,>P]NDIE3&IH_? _KF\
MJQV>4EM]L.S]X"0RJ?^]^2I;K#Y!(P!$P,_LN,$Q'.G"^/Z.DY,36Q!K=<3&
MVI,GC-Q%54_8CY'L4E4F9<QMY'E-10-C?_"=^C^QH$5K@QO%MV)OQ*8&(8/C
MERT8<,1'5?:UJAZ&?H*]X:L_U#F,-I4*G&J3TC:SC=RM1^<+GC]7[@M-,>X?
MK"/:8LRA^/6;WFM0()^M\0[+-YBG]DI[S,=CT#?G"BV2;N8G2^_MD6)%V/RW
MHZAW?.GISWL&>JH.V=8OU9L_9V!B\B& Q%.(K$9N_,:NQ9(0J"$"IV,T?6F1
M80]U_Q@<2LEA*Y^D-<>A(YHWG"99!6"*+[_AE $\S1_UW>,^0EY=VMU ]M/5
M/3/D*7XO&/CAC RY=1<Z(4N:>:Y9</ R:Y@BN)\>+<>4!W9^+BK9H;B,']HX
M5#HC#%ILL(<J&YF)@ ^ST<2594JZMZS,CNNH%@HAS#OZD3:,-,L^/LK2IPI*
M"EH*,_I:6!T2ROBL&2O?G8[E12RD@/).A='2HP:>*]=QB495E+ P]Y@&(I2#
M$H_T;%W&9N T6_DI1Y;4<S0DBEO&].2#,-EUG/BATZXQ2U?]R@&4HXW%EC]6
M2!241P-@&J"\<<; ATQ_]T'6@^-2B[^99 UT\FI# 543YV[%N28,$O5DH]@@
MF"LUR,D3/[#3+\YB1WV'4XKX.KR]7F=2E#NNMS[K\"W23Q*DCGWOH2[7-T.-
M^F/$R&Q;1>I@+-,!R]*M[HM"F.-W?)DLLDW0X;;L_/YY=E_6%TB^.2OY"&N$
M$DM>U?8 Y"Y(0PCAI_-2*9M5I^WWF<H,@:T^RNVM![WYLRH*KE+_HHQ'N*4J
M/HFO.B_N..^/$DUF5U7_-M2J,;Z*#AW[C)\2FE]=_G]0K+:C:IBH@M=<&7+8
M1.1V;9RE>>=BP:^'R_3?I%$Q)K)1MIB-ITU24%G>+>=R0/&'*F<RNA4LG-/.
M.Z+X,TJSL'?B/FXHHN\$&M)Q\*P8#Y1]QYBP5"/:22'O*%.T"/$I=02FS\*8
M]7'26ZKH2B8<73#TTT<(,'CE!T^F.^FUB(S9QU=IR33:DEW91%F][?2-LAID
ME;@XW")?_1<ISU?9^@P:*/'9$FHZ7U"+<C>/=K^C(G\!$O=]?[YQZ4KHULCK
M='N%DY74;+9-N7TN(/<_8R-+ZT/Q9X=%K9GN\43_I_R7*@@\O$=PB@: DO5.
MWQP4!K,$-J!VAQEO:]1R&*FS$/J:A\1].8ZYL0A3%^M$)^[4\A>Z,Q'OHGVO
M?\2,L7DJ ;\+V<UL*+ZN7^0',S\*%62\^!/_2R?QC;. K<-%+KV)Z(E:Y*V9
M9M\36# ^[U>?M_C; NEQDMF5AS<:B833'U3^<Y=XA_-'F-L>0;/11%WFKDN1
MHPYK&_6B6!KW8(BQ=;TH-RP:[F4A(<(:@('_H];<@)@$[%WNBQ3]5=]*LI(6
M1'XG! ;)RLZA3._-9EQX(7Y"[^IL5M[O'P=8Z$XD7R_C=&<6MWC(R'LV*+KT
M-@=G,TX1G=I_W8ER>\6O4\RSOBST'6?_S?^I_'^^DL'( Q[[Q\:L2O9/*K9N
MS8<_H!PI0"R82OZ2OB#P?(YTOF$'</<YV%IIEFS4/TS*JC<*1_?R"":N;!6!
M3X9UR<3*S,6\[]5%K2NA)D)4D1H<)'9B<@E_9[S(]Y(9IDO(/J#'\RR1EZ/X
MY?8PO)ND7JBYIJFTB35^GY+#7FFXX9I.8O0R)P/JI'''_[G\OW5Y*6*_##%[
M$!MQU7$W0G=:FJ/8NHB&#ZV4</8>R7&A8^Z9]Y'2D#&0F?J9*J=9O,LZ;WL,
M>+ED:?$S-B4E-C1FL(Y5Q-(N-\GX6"=M.<#NX+70HKOE,AK+YDN(&)\=<D'%
M3\H*UFTC_CII&?OMKD\J6+AXJ9FI]S[QYB@-C!"P@<[D*M(MC+'AS)),94&#
M;0@9TQ1=!M?]8-[LP-ENV.LUH2O%SJ&*\E3*?2./Z^Z@9CT%;%AZ2]ZR+_MF
MEI3T>>KS+1Y0+K_$L?UZR$X==B-DI>8S:0,\8/(G@<[M$M:A7MNVP(D9NDI!
MV@>&V^S%IC+&4X 8I1ZC'W-_$XYQE--B./^5Q[>"!UUZ^\T)Z_'UG:8/>39[
M4B3,2EXVB$V7L);/>$UG?-LAPC5TX93CS78U3BB3=,E=4TF%ZZD%P9?+#)[4
M#YOLS[G=YX9F\<@505R<09!F.TJ846;9"F"L'B8/5M;!;K#-3'%ZXRPKGTO;
MA*-<_#39XUDQ8JBCL_FG1OC^0XW(JOJ8F&"ZC=]);(LK<*:2#%'\ )1JTF>X
M6W9Z8%"/[+;P$+[I44/J*7V7*KP'Z>UAERU505:6SXPU0'JSZ T<3<=-'^%?
MTS&@OY>/)/!XT?(2H[X927TU%.;1XEIAES119GOZ5O(EN7JL(G4X=KX'V1#K
M:[-W=*YUK[:^J"QZ ,R^417GEQ54%5Q[D(THV?,YO<J&74VUEX78+64P:A.Q
MH]AP$2VN1*#CSR%:S^E^H,5<ZF3X06(S+X&N@1ZJW3>?/>L[')#5L;NH6KAA
M!V;620O4&9@K/P''-*@=.N\R'&*FH1*Z@3M&A'>7_9ZOZ#30L>Z'#XJ7?(;T
MQ\Q2C>[OMQ2=H-'US("0&P-?D66AV#S""0VR\H87;FI)?TT&8^UX?:X=*:EH
MR41Z)JNH:ZQO;_!>'UQN8_@58H5L_SWB:6X\G,@*J8Y-&6Q*0G<KOF022F-;
M@BQ,^#DH^-(?-$)6![]&*%BQ*AW%1,O-[H-2H*&X[QVV8O7Y2K76H! $1_<U
M+]U/CO'RS5RYA879L:#K=F"VB=7&JP!Z@4$SG-#L4*HPT:+FD);W0I%\;!=Q
MJ=0Q/I"IMEU8&/J0?0:62V ZY\!H;A##\MB"B^SL5ZB74"V72\X9T,F;Q; A
MEL\3EOO+HWW,T-6N5,4)LH!;,?*Q8M-6W5-;?+'TDL<5QQUQ!"&F><'0G-(1
M!ON2WT"E<H]*L(,__1FG-W:68+3SG:ESRDJ3O)EOLU8OMPWNCSNS6RS$=7@K
MXH'::&%\22000^>-Q=3E\JB60T0I+=V>S9XI_0PPQA8+9_2]W?PI93.3EK,X
MYPPZ=)Z+S9BIGJ1WH Y+)W9):*>E[8)Y?TW'@RI*/0REFV"TG_/J0J%%NXLO
M)2?_*,3^V+2?=W:^$U_" 9ND5I+;RC[R][Z5Q_HO=:^8HFCB^_(KRN0_SA81
M8V3OXQR&(- <#L\(ZF8#8(O*5WG-1!*TS99*8PBFB^2<D:_K//BL1MGU@Z6V
M$ :6Q\*&U'IW.X-6N(\VFJ-N&']Z8(R\H+7K$[#Q)YS.AT8DD^DRQ1?W\^ +
MX'.1=%Y]-5D&E]T.1RUM^\GHQ S%J<>V,1E)<"ZJJP5RMKR[?D71LT^6F6!&
M%Z0\K@+:QAAF*Z1H'(N9=#Z@L-3%6"9\I@=.V1\?MWAW&3,8<23X:R7[2F/6
M^:@]20@C&VJ<MTB(EUD5XG+PK(/OZZ16Y(S5@93(29[2V[S)68KFS>,13+;<
M7U)4=('D',Y*7RTS#YMQL^-9C-6CAV^"]=35>AM2%*Q0*1(KY:7"7UH"O?!L
M:K;L4M2;&\M47"7]!,T71>RO\U65/(BFV(YR!FE?2V,T( WF;H$E6QO2@[.[
M=JJET6Z<72V2IOG;!(<?X2#;HFVCW[\*#$Q>R8ZA5+PK;88Y%#[""6-9B'DE
M#A5/4Z6E?QI%SE^=.6(=.O9#4_Z\1C&Z-?]-#EJD-_;R<P)#M+)E$8FKQ<=3
MA4!WV15['!3/,7(GO-MO#?7#ZX"Q^8F,H,.K%PTO!A:7-S@W^B*JFE:<C)OQ
MOF?EVM?9HV!_F;#>L/TT$N&3^>6C3T)W[WK%9 3Q6]B#AI$;L\N=R3:,,@U!
M>3':>^:>JTRJ )-&M%'OO5*L,YLWF[U \/''_A8KC8M4W-I1)HGG2XW?S60&
M5M,G&@ @0[^JI _//F:_4T]8BJ+I>9_\J00Z0IKBIQ#UH03FE,I#+OPC97<.
MZ2B_03TTF.<5V%Z^>X1C-#O;IV55^5<E=H.S9;VEXPAK^9*+@S_V^-G)1_I,
M(ZVS!:M%%>'X_U5 46YS:.#G,N0E4C)H:3#>NC13(-$4P'3KG3)6AM[/0<Y)
M_#9W>GBHJ)6PQB3G>L2B/FS1QE1@M;N\C?122*$[10F&+DC._"&LK(+5)9U
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M/>%^#?-PGA,UH<]R\]"NB3O%3'":C806I_1,4 'D)5+N*P[ >Z=LNFWQ^"L
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MEQ?Y?W#W0'+&<BEAT'E<! 1!=0$:TU+R#;E_'J%\V+#7GSHJ/4[;;;U>0\@
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M3>AY[KCG2:V325@,>N7L8HIC'12]Y96=$8K;$B/GG3$2EIN[N+]9-V41LWL
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M8I/J(3G4L=>^>H#C,4.6?[Y@7+?;+ELC,S:FP3@7HEX"5O#>B)K,W*;XX3?
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MDIR]ATP>.Y)?UE?R5N<0F:V)/H@[(7^Y#(*M",S05+J)(\0B?:KTV[RBE;\
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M\;T%X9>UZ K,52_DC%$)?FIYO(($X6\]>T/,.J]I8<>;":[KSU@FP2=E7'=
M7*E4'V,B7^P/<N@MH>XG_?CZ^D1P/"R^':I?+OGE^>141GM2G\]I7\[=[,:P
M_&E]_N"+BOZZ5'$MIY<CV$68SF1J&V;-0:A?9VK;^4'Z+4TY- N%L!^F\61Z
MY/-X5%)S!WIZWN0#PQF$VH7L4A&J-QU ]&]]87$;3,0-KS70Q.8VG:@J_->
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MKN("X-VW;*/C7E/.F+:8$M5O$>G*TLC98!/]?(UD[:.R;I=Y#5;^,PV.9P]
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M)@J=,T\%!4*J7%P_"X174Y4W]U:WMS*6K(&/[P<+M4H]DZ=UW6'/E/=U@$E
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M<LC\0H'"4MDNOST]LBDK9M';B:&ARE':'XP#P35))KV$^3L@(,1S"K/"C!-
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M&U<<"&>PU#YN>V?\MH<RV!!6Q^UW_+"G#>^+R$&*VBU*Z[<T-U+H#F#RETI
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M%PZ,A-V1=K.+A,=;$Q.KQQ?2UCR_V+_O_ID211_X:62?M%;VI&P0^2]!'D&
MJT%P_V&$RN*C&A()&YT#>#:(SK[*!F>#31XX:$@.FOT$->+;\<S%9:$+T[X#
M['#YR,G[<+=QNZQ26\>+>-G+#V'LVJ1T14@^,5M'MOR%,,%_?6OHJ4CEKM97
M>9)7JQZ-&VD_YRA)NA^F7>?C_(B54"WE$;#*]5P7)P ZG$F;)8^>E%]/27_G
M[%E@TI Q!?J-:,8(&X-B5!"8&-D*KQT)D@VB10D?*%P[>%+GS,F"<LT$"ZT,
MDX1WMB33HJS2HE<&TTJ6T.-:V?7E,1DEFTRPC9<P"N?2)SAQC< R_&3DQC"B
M6,;VE]__"K]<S.?1%_LMOB;\J<0GC<]NA1<BY[^.#/0.C+'>J%E7:+:7UG#
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M6\+#3?BP67N>;;9E%6D83S>4M$O;I[/S!X!\JVMY]:Q Z%(Z((N/C\6E^[S
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M2_F;]J+8:NPJ\,=Q\-FMT&N2'T?*&>EUD21[2*#-B9(AF0C%U_ FC+?TO&B
M2!.]!%'R$TOG>JDU.%9XOII&:NLBLS-=4=6#*4$Q]\$-OUD;U6O!^3WVP3M
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M/;B0>-*]:Q^!7VJ/B,S,G84  3/Y^EB+9U,V6HT]/>/W99:^C%\IJYE.)RT
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M?BY?.5 $+33D)6)LY#@OZ^%?C/VJ#_) >.7!XOCXFOU$('7DQEN<A1RU.CO
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MT\QOL%5)*@1X)FL2Z*N5>PWG7(O.K;[ZE..MG2E9AY+WQ!J/I[LTV$X2=N_
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MJ&-<A+8;==GC\W:UWKW4/.9;LT!MN6A@D3"@< ">]N[Z<,"3*HA"=?+>R1T
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M58X$!TMT/_GY:A9Q$[C@[,X_T=GB*L 6N:+718*\<;2<_R9&(O_U!1<I!,"
M%EYMP*W2# KA==(-EZR++@IDVB^;,0HNB:ORUNOW*T5*J< 4I$_=0=YW7G0N
M-AS[".K^K)G#G[8T\K/AJ5*&*='NU&#H+Y*+;ORM<3%XIK#,I/$-L(67M,0-
M>\KW^KZGY$<[NAVQ8$E'3>U\G!>.?^R'1K5L7.%2K7_'B-<18V>T-A&*7C)8
M'LI7&J*SA'#"6^"N:G5%2!)A:&@)@!)M""!"W DG^V6Q9D)GPY>0;54$2\(/
M&CDE23<!=MU973V'27H??,]E5&=2(/H-R)RTS'ZC<EJ1:<328P3UBIV..L_\
MUP]1YY\S<]O[<!/J1N.0KYT,:#:23,V18)*I1YCJ?^O8HRF:A9K@=W3!XU4/
MGA)8I7^\P5XE:]J5A@]C#3=8@A48Q;$HG0;1^L/$D;,B;53S[#JO4JUC-#)W
ME#GWB!\-S0+BRH/W^8I@9O$F4"@3Q(D O,\:F>=;O&5Y+50L>4^F.$1^3SI<
M0Z]Y]WNL?@"^#3NGS*2'S$-J@JT.6B,#0_/C<C2MEJR#EP0@^,/2>7S" J-;
M@F+:3=N2:#66V0/S2_/P6\$ >H-&-L37:AI4)S%)RIT@/)&KL6F.VX)+;Y=G
M^Q<^):Z6*M'1(X"!P&PWO6B[H@GA .3G,T%6QZQ/G0\&W?S4LN4JSF'<2NQ#
M<UXPI 2^>JPQTU !0M**=DNEG'<!"'-?#$<&O3^![6[V;8>"ZN*%'K=?B$8Y
M:?J\'+D)P06X'D'KD8$9R476GS -BXOMIWI; 9RJS9;3/22D_"0)IJK:3)N0
MGX:.96?1%\+U[QDDGU]]@54[M-D;9H+F/T<*#SW[JO(;\&C^L8&8S OT^G?7
M#H;.;&\3J%]VULH3"B$K8 *^KXD12SIP#RM?LOYXVW)&^?IMET\JR^YNV,OS
MY_^ZD Y ?[:!4IF5#D(%@&9P8^8V5J1#K7>]7H*\^CB#R=_B+)GX]8JXYD$J
M/5S;-K;47=;R?*C.&P,PJ3%J$531O=USZNS:(#Q2U2N>26JL1T0+RR"G)-2B
M*%DE,V%"+#U:;0.).-8VJEHEG:&:[:<.Y%FFI2;0-]3L3/KX\O*NE[%Q+Q>3
MXV =$0V=Y"_BKNA?U _P78!CE"__U$,-T</O\)KMNT4&\$D6+TDOYO8<DRE_
MCIJ!A$DFJ>C7>"@K(+ND%)0>Z#G2CJN4]&"O,K\/,IJ)<Q^L2.G)A<U$,8U,
M:<NJ#PXNWGV=2?@* ZZ)AC&[\L"8 6@P1)8K:]GFP2@6D<@'Q8/4WJ(3)@_H
MK J9*0R.TLURO,":2U %J&?;A *AMK<ZGUF.U Y];]=7+\H:733YC>X*F8X%
M%U5W-J=8X<.4)<KY"QC7*^!)>8>(O("J/S<&M=CV)A4"F-YQ-).1 <5HGQ>Y
M*N5YP;LL5>.,BY5 :,+[:(C4K!QQO #&$ZO=MF=>JJ3A%LX:["1B]?8D)T-]
MS>@P\/5X=<D4#KDJ\(SD9Y 'D8[>S'!UEA7L* U!C7R?9:0DB]6<TF[X$-FI
M<--#E__>J2S)6#T!DM@$XFKDD:8Z5$/>BL+[2KI@PVHH)O,,OJRZ5IR3N5+_
M!FAYEW=%:5.1:)0JQ90#=O6II87J*9A8$9_@VO2ZTI($9JK5KH(. "_0(1'B
M97O4\4D"B+DC48<R(!_!0W6'0&]@MF0V-I.E[-5#$?1747855JM2P2:06$?@
MU5U%>ZQCD"^J-?==9[R55$DM7<+V=, E=18?PYZB*,N,[9"WJX!_(JS*7X>(
M8Y9CX5%3I+!=3]3@F0\L^I?N1^UE&>A-+2C%#=PG2%7%YM+RW[']XJ&:(4R=
MWCO4UEJ7*&XW!YK!E[[U$"?),?( 2+($1TF\:.:/?;;A3/8I1('KR)WK3S,'
M<<^7@1*E%A"L;[<$566],80=ANH 5JJ+QLT=U.E1A4CPJJ,KA?,FHC6X'^?1
M[VNR"\D.YPNTDOSL, P##0RBI.#N[XTH0CXHU,27BPGK]^Q]S.^7];E:%//7
M5;(S]FXX9F"\S4% I/T2UFR3S:.FI&V"Z.0J;5GP_JZO3=TT6&'% G<_*X.,
MPIFU(+*D>4C5^.!S$?>IC7%*)G;559Y\BZV&826"K1+AZMT.>MOE>Y]2:\#R
M,8-U=\PB'0=)Q50B-(-N9Y]V*1"G5H_[AK2>HD=U3FMSQ)'3BP4B5/F9)_SS
M7T03B<%<3FE=6;G,9JIJC&\."HZ1!-PV;[KCRF[]@);JQ;BSA["Y.K[ 3:@2
M5 _:6XVA5W6B4-/QYB9@-DL8'61:R\ST02^LQ]$LC@!M0DMQG[CLI/R>F0P/
M5$F"-UA6^P/HXHB*7\LEMC-HK=.88JT]&A/Q>?=HWL)\('(%R4:Q2O3''-)>
M):H">;%+UIPY?3P;F87*[)G?&39%6[M;:D&9I5D%RF([)P8ALM!00U^Q!F\%
M OKMBO0L \M.4J%M/'A,6^9U:X1=1B7$^R>V/II-A40FQ._CQ)9S&FYLXS5"
MOZVJ<='DBH-S[^IY\IGG+;E[S3/]G(\V1U+YOD@]/NM3[6;ETI-=:=DY]G7+
MR)K0S_/]A)4C.0P S<F<Y9C,EX$D$FH&ZPB.J%[A%*HH4D%F1S5^XNHWS6<%
M.W J08P'2K3G0"$2Y:>-SO0'BHP'RK%93$PDECY:IA MZZ1:@+L:$S%#@%V$
MMP&O>T*Y#+IC\U46VS-;-!-D$<[^T'Q),^MP7VC*M^IL2X&804P+L$,=^H$Y
M%=,Z4C5278K>-").H+J9,AA;6ZHD+;QBQ&G41 :]S(C(D&,OZ>]1X&A='YWX
M#GDB;T4=<D\M[(5AD/#J4IBIMYB82M!WGZS[)_8/4!.HZ-G"E*Y:Z\6R(N=D
M.U-!P1VYF8GLKI;3A,8<61*$M7ETSZZ\PYYOGH]L5H5["?Y^P&] 'RK!#&G1
M9GM,+0V.IX[L".7#OEAML2-S;(4SU7\@\_ZU;N2UUL,2?GMF8AV+%M'U:1:_
M*0V^P$,!7E4!8FRE!#748N>6]?KU]75W\WDRE&1!;F^T-2DMF4A(/;%A[0U3
M1K_"?@@H:WP_.<Q]D3'V.'ELE6>KR_-G5?IOP(9FSFW!:_!2=('+_WAU68??
M@(F#">[L]]K3&P61A*?IH($V"#=A]!:%U#';;T!Y?,NT*&:^3 .2B>=.05F?
M/HG)*GJ",2-8-2^+Q<;W( 1R9^^9I8\)Q-[4\7V&%E UP&^#>U8BJYG8U?9?
M%#BU[%NGN#RER[)$Q85!\FK-ZPFV9U7EYN-M,>+EY?I,C3>T?%O:OW0!6=56
M3#=22VB ,=7^H8]$D:K^?**HYO46GE5<:>EJO496+E&J8<D2W6:1TP<#?XO[
M"8/4PWK,=:X6 ->C:C:^2 XDGTWTL46OA(L$2%^-1217$FU9O44B7!#?MM6M
MS\ ^EEJ2TB^.J@_1^^Y[ZCMA[2+;8/<^:\V@HOG,[NTD--5PVN*3Q3>11XV3
M@R$BXT.L4S*9;[.0 ./!X[&LE0))0!9NAO/HPCC_D(\S&F?L_<YHGF9]WNBP
MGNSXARMZSDH6(PTG554Y+H):<'N)K+XX9:P22Y0-]_;OF"OC;,4%?097D>2E
M[9B1Y!X"WHV6[5FPR+U#/;?*)D3HT-5R_*!H.,4 *)A HJ&!]8S=\,,Z)MV6
M<5(G=X)<8A'[GE=5=RP#!/YO_-E[K8LO4,7]*@Y"?5(1W\)=_D6UM4:7:S3'
M(&YMA19L\:[LAV6R53O2(ZA)@U$OJ"Y#LVC[<BQJQ:/UGO6\Y^TY@QR>'JN*
M1U3>K[-:FAGTQ:==G 7@ '1?K30I".XA?%8@I$%(M#:<?2K\#AZ<I:]62M J
MO(Z'I3\H6S*5=L^PQ4@MEMHKN#MT5KP;X]1EJB<3BNYLVHN+,SYV-LU]:&O=
M,E.C\GD2MG5$LU$@%E" ]&4Q_X*76XR:EQ5I=:^G>=GF_0I;L8=I ]JE[+?]
M!ORP7,GUYFT,_%D4Z.G81B<I%R=B'J[X+HYI@_$<=<](3W&>B#F<,[%:]OPE
M:O07(P!(OX+ZP+UT3$VPIMO#QISCNQN4,;$TI=R+-KHPIGP5_HGFI^UHG3[W
M]&&( A>C4V_K>)$1C&L>D)KWU%L-CT5:<M[977V2D86]#^;'>FP-[$3]2L^0
ME3,OD,CG+$SS[.T22T.:E?10C#]=IS &>6M7>N95R?\3UCMXL"&!=ML]1W^7
M;0./**C&ME(-M5MF%5X22X]-2@NI5UQ6*"J7V[0Q,YP6QV>KSM3S.Q#_4;*D
M($D4!PC:%G]@KJ51.W,E8#NF/(W6[.WZZ9@\'DWS!@@-J?VR=,[+%D7Q@C&4
M3@(?@T]C'"4_60M7VXJUTZP^$*HRU!'%ALHM'H#RI%GF7J\D- JS*6F]VX=.
MZF<G(T>X^XLF,>&SZG2Q*C/B^\,/,SF8ZE,O2IT]PFOL5D=ET(9 /8(L9KVJ
M!C8F([J2FG@D@\&J$U?F+O.7E?40G1'11Y$HQ;$Z#3#- AL;XCXE93,HL)SY
M6K*I3;C1UE(/K>."JH6XOP4S;\]+:Q7@5%7Y_4Q=;[](?E(<\W=<XCW4KPI1
MZ&R?[_%^&)MZ!E*7($^5[?[*USK!X%1")M!.NA@CIW*;UUU5"W%X'+.1XGLX
MH=';V2G[-[?*+EJD]V9MQY$#SX_E2+9<V5NKQZ"5;Z-41UE6Y^68$75MGV\J
M#K'F9N<1W12RW6Y:1JY!AEIOVATH>L5M3,]CC;[:C(C$T:NJQ_L[9S)H,Y6
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M:Q/5O>N8%E_6=,1/6-%%B,OW5PW&RN 6IRC\@E2RO\T$DD-@MY_9,*S &Z,
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M6=K5CO\:Z> OC/++&7&O]?UAS5?IF'#'&$X:DXVGJ*O_/@+KJY[IX;:$R\C
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MP+5::Q@@E]BNKDT)@C\:R<V*=!BKTW<'/0< @QUGSD:2T?ST<>^K.Y6))9R
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MEVV?#DYM_KEY*6)T(7U^"S Q"A;ZX/*CXH;_V85L\<@]4":$.5P>ARZ<8)%
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M'%JHR\UA-HOJBOZ(TZ3J"4-YLOF)N]@^(I*!Z;ET]]1^&V-<V!MQ ["$(U5
M2\&K.QAF'[4]\_OM:M4X!IXTA0^I2AL&*](#2#;B6J9*H_JRD'GA(X@C_[X6
M&'<UI<7GDJ4'(R;)VQF5\%_X/$;GR/0S%ESS&4%5V.OH$6X1%[8HIR>J)(5_
M6SPQVPNPF4'O@9 PI6ZC9^*<I4F59'!X40DIN;8[.9!? T"OPN&._2XL9,HI
MS8$<<.2D/DPBW6R5=A>7\P1>B0/J:IX4\PE<!; WOPV][G5,6CCX_6R/RM_/
M]K@_I5=KP'H D=;?;>9:0U9:$%+L+B:,IK)50XAMGMA2*!52#&YD>'693+L]
MVUG3=&E[3!S)VO0,JKCPQ#RVT"!J<%'9$;EXGX]:#V9:R+,XYB;X; 1L7YY_
MLV,UZ ;QF[=-5CPP=U*=]F/&V$BG$.+<0S-R&KMV^M$_S>:W__EH+*OX]1M'
MEX6EN<:XE_N*VQ"*F5(\X:)&0E9M0FL/U8?K"(?F=R_=*L17F*(5R)<$N%@P
M1;6]VCP*FRZL*!.7NU0)52I\$Z!]V^8< 1N8J*[&+>"ET*9$Z2-G$666<WY4
MF<-[,A_A@H'(<,)OM%]8UM1UG_!@.?H]=2085R:=T>F>*629@\X4"+3H?7*A
M7=205E;H0;Q'1[2[7_^H6&:;A0%X-4 98@!6!V-*&*=>!-*G5&_=X<($ZZ1:
MQ/GI\P\^185[@#N,'^]%/8,YEDMG 5*ZGP ^(W"*1D@!CA+W-) D\!/5[^:]
MN I"2@(-2!5HK&D-$?SQ*T&K5%":"@ZY L'\[RNSAS0I4Y:'3'39'1$K^=23
M8IZHXXBSU9SH6X!FUM8V;%WI:6*D=@E*R6ABMDH24N;C36_<D;7+G[E)J93(
M1X8E+NKLYW.V.LLK<_)6A)U/YM[%0/?:LB1R:JG5%CK^I39.9_$6H))#"B+F
M";-L:Y<M]\$UWJ\RC?AN?.<64)U742O8^'7KI)*>>Q /2N\PN*?[1,Y>O@2@
MV5.G5N$H("R7A6 6RB3)4:$+56.-U_F$ZZ31$3CB)=)3M*2I8Q8ZI5(GB&WY
MSI'&-@#:#M)<KH3/:[P\O^M>/Z64B"!JO[\M*K8?\'7^FZG].8)E26/8EE/N
M!8S#0V&X)R!^1G/X0-J#K2P2017&X-CO#^_58QC&BB15))3IKDHS0' [(U"V
M^="B^?2E=)W&KM]/FH6//1NL[7O=\E8M#=X S(A>2YLM3Y0#DT$L2#<(2/PX
MVE(,DG)I\!+[[V<JC0S9#LJ#:/>T/XJ/JCBXE]G%+= P?LY(55YD)5\T39RC
M:"M.;A<"W&W29,[BJK6>97<O%%$>.BMND-2A<2Z< +XIK*L4%:N?%<UJ33=L
M,[74B:>L^88BPN+2IHVZ\Q HC_!=9[3\]KEV$+3IR8+=C??2<R5B<2Y8QX3$
M4*4E:\=D?@0FG$1CI?SRX5!2V$'PIL U3=O4?@+J_3U*:"\5L_<@$0\&B+$<
MT9\8&VWK&_7!#/816V7*F<6S9.JSHVP=.<5JK_B2VZL%#J/+K)*-K)CWYZD4
M?5V[BF=C4.M49R8.$@;G;C#Q0B@#468P4+':%D$4+2W\FJ]91<Q&0R5TG\+H
MQ:(?($-:]L<3Q7>F+MC?+AZ->50,H&9"M\AE;P'"D^9*HVA]9A\TCUE3F\:2
MU)+ZII "-A&K>'=7](]NTE'3Q=UWT@.\;)\X]5*?D#=R,Y=)K5]*"AE/24ON
M#JOVH$P. &Z_3"+7')BDA<SQHKHO0/Z@O#GV_J R%+W(LQ14'^>&^*J&H M4
MTDNS)W"%BF2&@AE_W]/EF1<EBG<+6%,^%EI_6633=KWN0F'66K)Y+&X2[^E?
MV6SG]FR<;1I%G<NL9I!*,QP]"DZ28TOKX_P:CBI?[9C\\'KI93 M@;+S^]*$
MANAV<CG$G31D\HP#\I$)?R6X6<X0E;=JT9$%F=20N)X82%U-_5$WQI"PW#:;
M6?Y=?G[8]SX% 9OHOK@(&SK&@C[TLZUT>-)F0<0="=53H7MUE]G)E/BV'X_Q
MQO&?<Z?KU.DZF9VHZ1@/)XU/#M;X8+98 /P'E#*O56P"DAC1ZOH9ASB!'>Z*
M\I3,J0%9BS)[D*9IS]QX,AKKN&7MAKK58I1N0WORLHK#"Q[%0F6Z^C>.0B!\
MX= B[#0%+?>J4OUJU7P>%^-R--P'?+:)=O[^PGB'A%O$L(&GWHZ?8VK3D3?4
MYD'SIG=E"1DA#@4-=DLXEHD)JXH7*ZZ^#E1E&0_W4$T@:\6WH4B1B%.#>$K?
M::Y86WLRAR[Z6;)CN5HFSMON)Y+K94_EB9*Q''TCNIYL2N4!(%52^RK4M16V
M!V1R+QI*[/]LBN48"P;LR/063GH5:3RJ+V4!J;%IS:S*%-B-%C +K\"'5"AZ
M_#MJDR[JJL.RNR6YA$MU[Q]XSJW6S_O<QY_VEASU53GKPO?B6A[V(\!$*!!0
MR^:MB5']L:#'R'+Q^*(]Y9WS?P,?\2$'5[ 9]E'$<!^5[;"2R7 -:;<&WDKF
M2@I/8]N;LWDZAL;>71T%>7L=C4!@V!+&4C/II<("8C,6:;/P4(@6)YHSIIE?
M<WD*(+_XA'&V[67IUIO/^F,^6^RU3G,C)CX>>'&31CR6\A1;?E^ E+B04%_-
MB?U10!E(Z5NB?\J(Z6_+9B>!9?7D[(:0$2F(OW!H.=IWB7Z.3T.."*\K >&H
M?4<N@<%[W8';++F>2/B25(F?V4Y6WHE5D<X014MJZ.C*EG//_*=GTD=+GB5:
M.ND,]R=W[>QEW)6Z2;O%&7.:3F9^5GK @X7YS]0=[^<_'F\2/50Q<[@%)&1_
M2+GCY4CYW%]*QL'DDZR.[MQ0CMLJ'-^*Q,-S'WS0VRC$EE.PF8Y,C^,MRM-K
MS$C\45VG7(X9)C4H$]>CLUS[X7FU9"F@D/*5[=OCR6:FV2_#M0#[F@UA0,@A
M-^CN!8KW+C9GCSU\T^$L3$E;@TY)>[37/9.8TM";1"*OIE[(F#*<0)0YJ3!<
M/)QT0@DCO'8VUT\-1=^GX]X,L8&75:IN6X@S_&V/,7@*G-;I:UICPTI/A:!K
MM65Z.6,)E([N4LWKJ32I-_Z<*L@\@9%6KNNNDI^79\9(-KUG_5Z_$H5_(4"?
MQ>1<?&FN<^+\[)OEEYWSGSM"[&G@I,NV%2LNFGF4_<R(X&5Y-1GALCB1WBRC
MZDS\)^*P,+R8%XLRT2 H:3<A_HL^U&>FJ&0,Y^-)O^6Z2QOJQ6^\Y+\I6Y0L
ML$?\_$%54/)&TW;$-5$<1&M<FNJ=,[&_2GM,4H*; ^O=EZ3SSWO.?#='L:!5
M<"T(UNKE(NU@1K\O_H"_T9L!%J9/^[;)2+L1!)0#Y*4";<NOW_D'VD^M0&9L
M'?:'. HNY5RQ0IUIE-N;[$_\Y8UC^.Z0;FXZ5S]@RZQ$8GEF,4BF?0;<B85"
M\=<8A@?V,T8#P:^5=X5\4Y+45KL.QA(^E=)W_AFZH--_-)Z74-V_T,I-IWH3
M=VWUY9QH!2(:_[8K'KA$E\F+9UF*WN3+*LW3VR@)?E1^"VAN.6)[->!OGZ-3
M?3[ /]VC.]<W,'EX/&%U)6:]#WH-0?!##3-\:</SW!2A)!)4[(5;-)O?_*5F
M,Q?,9\J_3=L$9#W>[U3.IKH 0RFG%X$\\(6"A+;0%6]MU)VVTG0H53ADR!!*
MP#SQJ^<)EI6!/6K^2RNH$AADT2:TR0!#9=\%=A=:)A'DM74T>9:L?AH9X:R\
MP Z7N:$VC')P"<B4><$-J'D\:X988&L;(*D:134UJ,9_'SXEW"<>FW\0\%NF
MI5@CBB'>.P[JU;SDJ>BG;TBUV&6VCY?MJN>]W!L;>B8BB)-,]!EUYV<I[$=>
M:YP8HT5G /YR5"%6*#!),0?6+UD5,IM.EU+:].!#G1?CHD-6D9&;V1X1A51_
MHKUO!-*%AG\SF[VTH#3]??I<K]3H2L<RE1>9J0,[J3XES E9!= \UC7_>M?+
M$W-.(61K*_;[J=IQO (J?I9Y$$6-$+Q!1%9'(@:P3HEM.VI486)X'^WV!TU@
MW7PI5$"Q8<C$[<VKPGMS@\;*-MHD\T[YV0[\C'&VEBK@PU^2-O8TA(7JCZS8
M-0&?)[U(ZQ_$BJXUM$<+7)^$B-S'GZP/K$Q(*5G[6MB;]Q0F<;#GG5AJ93E3
M8LC;<Y!7(\?A/L^E:^3-8\#S2!@/AXXQQOZ,1A\B30!FC*&:BPRFDJXKO 4H
M?O'LV<]X[D1-MV VYZ6JXVL(MF HS-,523<O9*C6;;3.>U-D;^)/,^%YMLF-
MGJ3^W@YRDI-=6%3I^U#$6,+6S%FLS1Z>1,XJR:S6%%[F0R>(XT*#1%L!U#SN
M\/BH*]IKV?&$83CWO'\/ZE/X^4X@I5P52"Q#G49I:F]@V[<B1VIO%?92/IPT
M6&TIF7P1C@L.>4LR=G36<7.[DS(X#3D"=$;,\TZ&0]:M6N@L]TQRL+YS#S"]
M*!W]91Z'L>9J1H7<DS?GEU0GGZ(>RCW)J&/T98;Y3D6X Y0#K?=_.4Y:8PT"
MUIMD+-)N;A+Y[CW>0G,PH7N[=)8V3M7C8B6/SC"5%76SO6G@B,J#1(G5 1KB
MH,11#652Q=ZV@B4AT@&6]'J*CBK.=8!;^3'4!^9!56G99YL4I>@C-=>DM%=-
M$K-/CL2.E9(GN.+EC:1S$5*78'H13_Z>I"-@X^NTZ79QU]'HC<H6OJRJW=#;
MIJ%\U%A6JU,#LG;TV<)"></D\R=#@V:F%-0\"%T>.%YR8&$W<N%#_2T@^JHS
MO6CK404,X6,S-.1<QF-RQG6ZE7+I-L5VB3MT2+\LZ:88_%,6U7H2)WU\.O,/
MXNUW<&K]5/D#6YUF.^RP\R&3,[V&[_&D63NACT9H'#SW*?I4:ZHUMJA#UMC7
M6HNF#]B9E?CU*'R)K\NT+&PK']$T=$[SUUH@W7]TLK'VB\0+;P]_I!C)>RVJ
M^[>5^.\ZI_1'D=H1'EPXC.N)E_4A@,>1QE:6TL0U^,>5?5<4\5*K&ONT-!$8
M,GG&B,B_9E.2GKH?I5["K+3Q7QSMWGC75P2H?M&Z,NLX\:,V*&A("/3W"=H9
M-%T/5]FSD3$-Z1LY=HGM('K\.AM^"U!:#C%-:%<2]>>+(!U7!C&=[F&P9_N^
M<DH;JT(J:FL2VN<M#!?PX7/-YC7/8_)=QR<,W>H\[V%<_C1AEH>K/<="IRPG
M\S>NS^ 7X@+>0G\>./+'F15!D#^XXY6X(^?DHXE!419:K0F!\X'VEJU0R.6<
M$K C?HMIC[2J-IVU[,*XK3(QTP.L""^LQ!&Q ;C0TS .W&] /^;,__)EUB1F
MZ]ZK5_Z*5U.?/.1$()A]^19;2PU\0"WK24[[0'_9H<6Y;=]GZ?<=[5>F]X&O
M.L4$H%K]GU83C0)W96W530(X3E-B3U>SE>8"TE.IF%I(/];)H8#QH5Z-L)(P
M)_6^EXS"W;-\H5AE[=H2P7?3Z,^2,K!M2*^TJE:J^'K/-$?)R K12:%9H@O=
MFORR*2%O(JB#SYAR4ZI_G^?T]W#943MN."7IFW.Z!62T9,74;"N$!JX;O+F\
MPVM=$R^/X_9+Y7SD/W;&8L/!K^#8?GG,3V.E%J(M2NQ>5B"B.U]DZ[>:?7DW
M/,I%=@NP8Z1);NLD[-.\4CYQ>7O*^!_X,B%*"[< ';2;0L?A@53V'ZB,MY/A
M^LN?E,-[2SY#F[,-(=5&>_O8NO/XE5X[&L?UEG^#YD'TU&TY+1<R-P'$YI?S
MP;:RI7^P;^*<+5YE<_%6:D.XS9_P."]*(R)U[447!<^FOTF%?Z+/M'!EA]N(
M,I]==E$.U*#N#K/_]IOA[SR!EY2ZO"D/ (> >E'\>O0O=7*Y>-32=,+V<R$@
M>F,/=0L8-E-[,NOU0$[F.X]64,*EU W()FEWWL;FQK(]8(;QU7.3T5\&BV,)
M-TX7(YRJ;'%*9'Y6^W**T\<EWS+%[GNH[KM&"J,BK*=Y]I^LI*+QY_<[<T[K
MOJL3C2;JAZT2B++NDX?&$GK: U9_ 6>J?D^<L<T?(36Y1M/O&D02WFJXY250
MW BU?SD]_9_0YXN(XL7J8-RA3=KDCYJ_)?G1!X2H5I^K"EWV:$%%3:.KIF^&
MSG,NL:-%9JNNQR [AVJTK!^X*;,?&BATC,8]F(?-YA."7+\*LBEG=%615YR;
M6AH\E$@?)M3W#9I5)3F1S->(3-AWU"NT<3_B(1F0BF"0UYQ"CO>\(!8/\Y6T
MG=YZIJDM_KHTG(:4(M+@-4\.206VZ90;B#]73V1 !10Z7S8M7.<.?+:K.4RF
M^F7D\$"IHK9?BXV J*J6L$0*[U6KAG@['9EJD87P_ J;L)H7?;QKR9,'E&??
M]X(AT_P9K$W3:1FP9+E57",Q7#G')#1?[2YU]3UU><_X1J4QS1V=:1YRA4!+
MT@N]] 3O^!>5+Z-52M1/S5*KZPR#T0U%1"J QJ&F3'VV^C_HRX]"H@.>#C?)
MU"4K+8:9M!:G!U'"/.OG@=QH@,6JO>%59CI,(<H8;9!/WAMK+\V61+#4Z'S6
M+'SS?;94E=^0=B9V7W6SJKNX*.[5J-)Z=T*"N>;V!]4:_=VF^&_:J,<E^>)C
M[>*&9'M9S2-TI?+&$[SP04(/I%04JU!EY;RBTBA;;90/_XO-Z.!Y(16\?MP,
MZ_WVFD)8>6&H\,Q-4LM-,]FWV6 Z*@3IMFY]QAFM"C[")*F$_&'+D8NE( "G
M:AC% M=O4LU-[D85L42I@5@.S="-1ER+PKR J?)HI;0= CPD8 K)ZL=(M=-'
M$JVO M9Y.H@LU?F>5F?KTDM$W!5'S:3<^4D^H3/P[N@ ^D\^8\G.? ?Z_\8.
MOOO-L"PQ_NDK&#(ZCC<P0\1YB"4>T!L_(>C\FX2/5#I[@?H*THF-JO1M-R&Y
M/3ZA>49E+48VK:(YRPGCHUI+FQ9]A.F,T*=DA0'JE^T=/Y]<:PE-;CO/ -+O
M3>4V))49 6A(VH& B?#%=\IN,'Z]KR]HC$LJ$1"YG4$5A!X*""?B4O=_KG(X
MM0$Y.W)YBA\9C&N\Y:4@K0V1'DZUYVB9V+ 7[0\HIG/>2\7W+-TGU,UP1H@3
M7+/S__A1&3@OLU /OS K^-&]D_>^^GYEICZZSG"+*LPF0<([9[\0(4)I(8_[
MOO'93,-N=P678EPLCC.Q]:O^Z$A>;W"\K@___DL"?Q+QR3Q1!MYRP>42DO5V
MV\7>^C*31,C? +.S1(+6'A.Y*7T8XW?N+7F&4FC4@ZK(F=1PM'3.+VA2M_*R
M1&_K@7DQF\Z]SA//F+1YQI5:DZ#OJP('HCL&J[.<97&6. SQ%2B$!$6I$*.G
M3\'VGU&([^&+GSD737\@97('J=$;980G<",C%93:+L"NQE#CA:4 0QA4W3.@
MH5Y<+1HQ*L++-<"1B?%B/:NPW2C/7&JVV%D-[:J1?P95G$^\UYJ$BZM-1OBB
M+E,;!>*@-L')3>1_W7#XP%BU9 Z1 UIJJU9%A\6^I/>Z!60CS<;Q#G3ZNVZ*
MH066&*[&/TFMWF)W^_K65)*4ITS)K^GMKI5U.HC..UN^F5TXO4(;-5QYG:?\
M26:]XIC"?PHT)ANTARF=UC@/6+S("8,"H8!%\?QY,1&\+/N5-AY *:;T?3$?
M 3,7=\!FWOI+TY+G,;Y)>:;ES+F,@ =DF-%"6QDX@41B;^-_8_&C81:?RC6Q
MADO\*CR_25"9%,3X@?7HR"^_/.V O"L%O<HU%:)< H-+JJ<R%U'S$##ZIY;*
M*1M,;+]!R @4 V"5'IPIFD\L+8CPJ%:;C%67\M.NL-7WH1=A(2/"XNITNC]?
M!7-*8#I;*QF)11;8AK#.M@)^J$*(!LVST]F2#1Z&/5 QJ-8GK":^L^^FO56C
M':%>C76_IS7M4K?10U=U?ZGNI9N<Q2SS.RX6C!+A<G]X.)P IVY>%6X2#\O+
MD'N/0YG&H[[CF_**@+BBEM/G7A0:N=1%6J/'52:2ART/YM6/,Z$33M,F(!X&
MWH&?I&L;NZ1N$WVV4"H3%[/VW"CUJ5)4 :#I0)/(@)N=I&.1-$W]*+E"Z:=.
MYIF ^D6Y8>XQ2;NIKP#5$C_FLP;.955TN+C>O6X\TL;"-;"AY]FG5'P<3+4H
M6]KDCI)C9N6#>#1LI/HD^IKM#;?HB^[^POT2@F/IP>X83ISX<$\8+@6/W%"I
M:?I01'U!D@BD)QQ9_ ZP:&\4YK6+.-:Q_'VS1/"'/USGTTZ+UK]8*+/-LFD<
MP2$)5'^&?*N1G=("W_D#3.%$CP;-#$/8&#W#/D0K(\1=:$E7<K)N=K9;\I1\
M9++$1#$D']V)[M9B_HP".@B#?9Z?Z/\+!WAEE *=MMX\M!K+;*C6%<Z09A#.
MJR9',I[2V[LW!_0NH[K9Y3R+=>3Y5%G@J[WH^/VU*]S)=_QJ#O%D!-U/P^/4
M0S,4P7RX0+ >MFIH\/O_56$W\?^JWL&]OX>ZD.S_M/+\=0I\^&D>-G#=O$MQ
M'?X/OH_)JD)WV@A7[EV@L690093E"*;RDCQ*QT ZFO=D 9<]'I=4:ES)CLEA
MJ.(_3E55K1@!+[>7&5XS%#.6"P><+D9B2+3M:5(G1FO26<F&_[''ZCJV9)>]
M//?E?+ZHJN_P.L8Q:(,1=5D.( I=L_@':VBV/S!3\)MH89X4GN@R V,ROEU3
M^<<>G-USJNF>KGQ1UY"9X6^R3,<N QYNX\F\OE17.QO_3O[OGNS-3J_!(BBQ
MLQK&5M0VR@/JUKGV])1[\O^ \QGPU.6YP_]W*.2_D_^3R3XV)TAV[93067A)
MB(Q@LU1O]-FZ"X$2) R#4 D(@40]XG0G!Q#@ N@!V.[8H7?KK/_8Z71B>)C^
MVUC(CN[5M.61)A(BTV1U"U#^3ZS(#R?&TM,)A_[4;;< FX5_$ GS+B>M#S4%
M4O @'0NR(PU_L6"^B.W27Q7$-#?>O'9DPCRNO>3_RS _3D2X>/OB^!+8Z[_&
M$C>TYZAQ2F@/=&KW+=AXH&^NPEYB =BX'/D:37R5_$QG1D0W$R%";J)GD%\E
M]=OQ)7^P0%(8V%K4&8A#%TXZ\3MGVYX5@Z(P,QT"0RNYA^5 ^(YYWT/E,1'S
MDM94Z?H9R;M^2J1%HBXL-+F<I=C(RMHUJ_L.$MUFBL&32+,J/*)>"N"!DV9+
M$<;PW955RO/_P=Y;AK6YA7V^P:5X<2ON4#1XL2)!@SO%(3BA!"M%2W$)"5HH
M[E#<*=Y"@!8)[A1H<4H+%"ATNG?WS.SWS/N>,Q_G7.=\65>X0E;@67+?]WK^
MS^_?9M,,G;DK9CY]'2C3L*RA< 99'CNA3)Z_]5,]F$SOCR<.#\TH;5:R;#[:
MNMPG^7C^PO1H/@K'C*QO,JH?'3\[['F_+7/M(=[UNX2+@[]^.XQV9^98U0Y)
MF#\<0+YHJ"S+8F]Y+PVT!2T_8OI4'Q U@"^OFN&K=9"C<>O3?$1V T GXSHS
M/G#Z^##:8/JX=H&"Y#"T\^5A!HO7_KWL%P^%*H[F"?3ZWS1K,9.9177]&&/N
M]>JB3QO3[5T1N5!WU;/#(Z')L%A04D^O@:P47HX#DZF(+ZPS1@Q1ZMYT!QH%
M,T?"5?GU]H'"&4V5U/6OSB*E*"_Q&B>69D+%F(G 7G>B8^56*7WC+_0<:@8;
MRQ)E66PM02HA[-2I2;,K 'DG"U+'ALT;.HG=8G&?9:$+*. ")R"]#P>T02NR
M1WVV*GQ3)@=G'JEP>=2O>A'H:QEBR:G;1&!V8__X4F3W.JPO]_VGB>^_ !&2
M*>]S]WX!,+T?I$C.W&&O*?R#"Y=;U_MQ/_#G/Q3O;Z$*&SJ?OOY_YX-;N_O3
M\WKF=24?64>%K@U=-EL)9RO;6ITE"@'_9_R!_V=_\$&W@&U:8)"DZ\=&,6C^
M_-(;$FI<Q-)J:U^ZOI+"E(\F4Q> T^STX1S=N?FL$UN1Q%&)MQWN4IC&5(@4
M?]%B43F6]G#<+X ^8<0'(!_]HKJ9:M/5J,+'Y./U',; XZ.KPO?__\O_-[_$
MO%M:"OP%*,X!*GC5]9X+MYY)-[^5A5O@<%^+DJ#/PST2=7<4;+T,-$&5&J2<
M5+#7>Y)K!9NRHT>FGAJ2G36U'+G0NFW%YSLTT)3/L@OI;3_J,V02Q*_IQ%&P
M;I4W=')8,6)-)]"<V8<>>8XM:2K\O!4LOP!?E4DFW?"Q0XV;/2FKW;9A)SUV
M=1NXN_!<5YC0@)(LEK5UURATMV9<2XRY@QMR)\"572NF4TP!<# )#.$?&)$R
MA.BO>*'&Y(B8:<"H/C29JA)>-'ES:/CNK#>QX*;R^SK='?U%9U9UQRUKD]MJ
MN=JN"--C_6!4L>VF[ 2(XQ> 6EW]C>7ONGU5<N/@\CY37YB:[G9*+TJ5;^A6
MYWB+_3*Z/#WZ02_+Q9!/-)57@[CAJEU9=L+XX=_DO7\L7;M_]Y);-%]K7"S?
MP>T/[%9IT.P\K[CUP5L@G'D<.ZDYP9\\<%%!:@M_OP@.3=F:'J/C9TM58NAG
M4&)*]76O"D5/5DO:[:D_@/0_,+26T-L0V-+7VQO!:KAQ<WBP_[OO#73MQ\T"
MI!4,FC-Y@;\0@D?@2U!CP.(D[S-0<*-^B)/6INY.GV)?MW;P8&N;9QD.,0JA
M&PNI>5Y>T71"H_MH^E7Q5?B=$.3#;NTV. 4"^#W"A]AW*33M80EQ>Q0WQ?O!
M*66@]0=;NWE?? /^G]]ZW@BD[[:JK6B#C67/M^( )-0,!V F66?$-D*:7PH\
M.MY8MD@ 9NE>8BQ:;/"4@GX!;K[^_&Q[$R@92M9[U+=BI<44B 4F8.?V=,\Z
M9@T^*G=+RSJF<=TTL<$U[$"<WTT!(O'F34S:TMY+-#5GIZ%%<U19J4RPZ<GP
M*]8PAFLL_+N!7R5J-9*H,.2*XU,+,%UYK;_?X;1FE;Q!Z*;-/P>/8[CY[&"_
M;HF>$=P)2JN=TQX'2#C[E^+AN<F_+0DP)5^F)6YQ>O5BQ\"JH-=[M9K_T*R_
M; .C;KTJ]A-V%]E?DCM;K$:?SG*=LIJ8[$QI#73]0A0G!XR1T](3* 0&M<D3
M<2,X._1_! -X,P=_%_TAZ9K$!3ZWCOEI#SL?E5=<.^9]O7YWY<_O*D3%GL"3
M(9XNJ#67'?$WZ6AH26<M.<GO'F!84% SI\+S19[NIP'<%4'$A<B2QGN^SW&V
MV#EA2Y8M.('W&J>CC8Q,+]_"3[C@9GBFA:X)]+P56*+WER(5^5P)W-!AA/^6
ME%Z_.)JKX1#I3^4R&5LFVZEN\@18A'!70GSK<&2@'1-9QBI.MHF#T?P[W+6:
M.1':EEQY C3T52.@P&PK_,94XSPW D%$%3I-39QJ^=RH+=HY>X$ON</A+]9-
M\DU)1:;DN"+G/&)\V].L2+[.>'E9N&[+C*+ ,CEIX8HCUA(AA]!WQLU6))?%
M4LDI"0_PE*.-?&\V_;/8(!$8))>S^,UX(7EU1:0H%9B$*%C 9:U_J:8O?E;B
M9C$]";".C'3=GB[WQ!#?D(H_,)CVS)>V*M@^\AS%)CR:2#7(LP]-_$.@BCMI
M#GSV6B>U3N.,S:F(1[Z(HJB&8 $V5PY1,/B7R(X^I71T_4'-]Q.5A)X'MMS?
M WL&S]/_I_M814YR-BMH\N@!]-,+*R\G.9;C-1Y%5@EW56:+^NPB63%^'KF2
MQ^=Q!M$FV9%M>& KL_Z,\6.X2AJID_NRU+I!_* =5=TX'9N[].L3 S4BV(.;
MD4\V[^;6U'$TW 4UN6/V JH)Z7W(^Y0VV I.&</B63/F=!12=Z#5(!0.T]P@
MK44IB==27F6A+'_<:QU7"A["&(@Y@F*VP*IB.Q5'MP]';;4]5Z<;8-7/JE8V
M!8:  Y762/%9MICXADCYLAMKW0 +( %%#AP 7%$68S%!AW#?W>1MMR-!6@E?
MQXI:Z9A:">;LL0H][V([K?BS.+\0GQ>IRN8O, K'K0V%K*/350'QK5C-K3Q#
M 5P@/ED\ <[0(C5J8IO[S,]W(HB2=*[,/#A,71?44$G%I.60CX2ZJ=D$J?56
MA6D:./H3;I\B$75K/>]>0BA&?=VN''T@%.?),*Q.!B-#D0=^]9-N%M&M;S 0
MG.PN@B9$:N^2<'C*8WH2:9_&TH-+G#WCXYZ\A15%Z128B@!V\!C?\#H^$81"
MX<YOUN;AHS8D^WDYMA;[IW*B:<:UA/6,?'U(N_G"1>OF@6&*C+18 (8!: &
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M%:TLS0]\3]++K-)ZUW+F7C%\Q7(SL&QO%Z*!N[@YCEDM?M)[2UD:&.#_]!=
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MD&%4K:B'^;'BN:&.^,CG^%GM5#J+7D:3*;+ZC[ ;HXM?E.AV=IHBX[M0K08
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M&5W0>2=(9Q=_+_6U;F(2J7J-H0!?2#EW)_+]NB0.[(CCR!YOCN*.[>3Z0TE
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MF%0*G#?:5Z0/NP%VY^'&<.[ 7ML!;;-U[2'AX4TOCMKVX)6!P!E<\ E!AU>
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M\>2;C3MC"C^-!WMG28<?4_+3] D;1D2!WSX,M]RHN+5\;RWK"A5F&L&Z2L'
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MR:Z!@&;:@'6H?_+<O'5X;5N;B;[_6JV1VDOY3HQI0],1H23_-5H!JL,V[6=
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M6$^_CV*+437#P@_SRZ>9FV13\&,9U>V6U;Z9GZ*7KC!&.ZKK)YV-IR8_E?X
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M18)95TI$D:LVX2RFH7MF9INGBP<7'WZ0$X?76<8$>^5P]E [B-69A2)]J-*
M]\Y_6K,&TF0?_,L]C":ABPCLLZ$P#@SVD=\LW&@[1<*8ZV0Y"2;8%9OQM^HS
M3Y22XV69^$[XQ!R6&>P1N>\>P3V*"/\*]RX^ XA)_\OINV02#G!5D1GR/3-]
MK&Y9V!2/)NJK6.&E(D!W@6!7:&YT2G:MU?E.@'[;<F<IW9_AAA56"SU13HDT
M1;:&,I(W HX-34N Z<(Q#A:_@1)/S;(3@=\]VKT:@CN5;@*E'4W3VR+:8HU[
M_['L]MRLYIQ8C N/",*#S.=^Y[),GP*<*X6S^+[3I;1!6G5Z1W#<M'CY5__E
M^Y"$!87WK&V63/YAVM)V34KBLQOVS0]JZX4<<VYFNDR#5EGK&=P(M;CC])OX
MU3\'7:G7O#122;"PVF /B"O-@I,6:^.M$?6JH0^F9&VMV!*+IX&--6,,>Y$4
M2Q4C=X%&A7I:U_6MT*H:K;1I"*%KBF:F=.!0N9F?D\#$UZBT>BG'<.)53L^Z
M[M"_<E#4YL0_9_KDE[1P!$QX^T_88,-OWO>*TY"WM"-MQWMYEGR0K7I1'1,2
MRBRP5E6,&O;/*BWB"-(_#3&L^V#"?;Z#*G&6D+3I7QU,TWA]0$E;O%E--4%,
M=EG]>D(EM'F&X:FOKP9#0[Q$&A!OOT-XEHSR1[:[8FP!!.'>3FU29UG4R)U$
MY#Y<G[4^123(H=#8^UO@N>N>!2E+M8]!HPHL>2@<KJ!5T4[9Q ,'-[&"/]!,
M@Z\NY &]5DP+ _9/P$ /T^4U;V6T-AF?=K>:=5O) C02+FMV] T1]=P?C-W0
M79<OQA1;1I"E-M'ZHZ+ZTZM3IS]-3A.43AYV):I]"1IQ$T5H$QJ<']JCVW%5
MQ3UOU\+:L([OZL*3OI2Z#_V_A2Q;>L2/8NH+J'3I5!=_2_X#?38JXQH>3DBJ
MBV>=S><$0M5 \:L_O)C@ GT/LR(\EM>%";QP10J$Q]V6J*S=TYW.I DA!9*B
MN=31D7!+SOE2E#C-M%&)\P>K*Q"">F-/@X@Y)TP$[R*R)ECF"5)9;W3VUP"8
M]:Q>CW$G/<YE0RV:P5_J2=(#'9EKBD+@?@ )A=1"$674'FV/9!66V3G6ZO\=
MAG9U^E7K%X I9M!MB7''&;#M2>Q#_O2K<N/WM!,5($96%2U[MT'T*/2]U^O,
M,,5[<@H"A.G?P=7#BRZ!>O\F?8.0V X0.X>W)[$-#XMV7 LR[; A"U/[1Z?&
MI9I*$UB2R*Y4S+$NBJZH-C.V,,T&0"#\X=1@$-0@\4"2U99%@'3^*PV.Z=QP
M_AUSGL+ D6D0KV6PP"&,C1V_^JYW5;FF32+7BT)#Y@1V$EW?UD4W]/2H$(;?
M*-Z]:TY[Q*C'I]D V-S0SHBSAEW'YD1Y%>#!"75K:CN,[E,,W\3XW78P.3L4
M9!/8("G+!(-%R!@_56]WA[&E>]T23K*E6(RN@7V!XN'*R_Z-RXPF#RC[\S\4
MM^O',](>:ZZZZU13Q"T723BLV@UO2!IKK/F)R?C?I^;'%B9D@1?\.D&=OKG$
M/MM^2+"? 8 00CZ&ICVY%;K$YA)DMA.14EX/2+7LOQ"9DH M&YHTL1A=X=#W
M:=%B5'UL)I<J+,EG2H'AR_P8?P,SG7PB6!QP&[D/Q/V'$AP*Z+9?IEG-I<BL
MWY&IT:N],GAFP\SJ G=0ZA:TB5=L-0I_6?4:\Y!NY,#UWJ6<K[)?R\%L'E50
MCD7S@#W\!31,0&81_%S[W<HIT=9+(M)6? ;-HO[S#$B3]M.RG&+$\"#PE! [
M9^F4V.*X%CJ>N]B=U-&L\#[@GCH5Z_"YZ<GOS.^'PLJ5E/JKQ6$3:^^7^NO'
MW 2?MNF@9$1BDJ8U,4D@3]TV3RTT=#QDAC85B2V<D\$?&\!2$ZT!/I'""3B]
M]":>5/U*WHV7"2*BHT8XRA\B>,C7-<V2>:!%_FG<K4W_21Y@"9K4\#:S6%L]
M/N>MQ""D68?C5N'$&#HWSI(=_1@G(/;M=SH*:71Q')TZ8\?.W?<:]+-\_I+,
M(O:=.>"W+3"!_7JE ;4N-=B$3P.>4E4KD ?W<L ?,B/-71QTDT.@;[<K-D [
M_TT:K&J^&6M;NFLR)^;<1EA(47(2$,"9I?:5M3*[VYZ7Z3<+F83(T]WQFPH&
M!8]2V7(3N5P*_X$3?#A3C#!9 QIFEG?OCVD&_9BA4[-&-LEZ*3!=?V:/*B6,
M7=5@;ZI+IKTBXLR)%"Z.^Q]$ST]@F?LO1"?-K^&)_"]$[Y4/0:5SG#(-2W)(
M=7VX\[:L<!:F,)Q1G%IQ[_Y,78A_R2? AI],O#)KG]]'=6,FJ=6N26J>R S7
M!P/HQQMX)O3\K29VPOJ=5/ U_3/8*RA,\9XKC?W03]G*3!T,D[I @\SU.<;5
M*,<,NPXOOYO$L^<>\?V*SFM\Q=^%3OM-"SK0+<X0UR%O2*XI[#?*81VUJT34
M]S'^M& V>ON%=7]<X\^JJN?$7S_>T$R"0&#1MTPT%#2,^Q(PMLI\,2U*F#'
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M#P*A2"3/&9XTV:X]BG)HG7[FSO/8CZ'^(^P2YV!NR_LML3IYV]%#A*.<6[<
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M@AF^O])K9-+-R$_,A\Z$-#%"AK$VB)+NT0W'$0>]MN]G#?XQ"A\S30ST<BD
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M]>STPEFV*S4(L[4D:0JW-=T.$G10@]7%Q@>\$(.V.]:=SR:NTD'YR8JOWK"
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M.P912&NF36V?AK"W5G Q3M%H+):XRZZ_#Z6QW(C&7*QF"^U:LW\B^QPPM"8
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MN.4ZL^FAA0R4QFVO)1W &47('47 K6X(IJ21R-06BZ32YIS$ [K6J$90EP$
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MF/(*:H[^?:?[-OGD#' :7),3K>'=3%_&QD$9E#%N#\OL^ :/T"#I<A6K99Y
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MY4<ZKXX!PC<DP;KOANURQ>@VK07\"F5=UW>1X4.)K6%]T'VENEIZLR2%^#\
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M:5B8K?>L#ZC8$M5^CX\_3)1'<!+"J_/_:V[R+U[Q&R9(J<=/J3Z\*HMO.FW
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MQYHL^#(=DC9$P\?J)'S.)D>9>#?%E&,D9KU1U'2(B #XG_]/%+T5I*S:YJ^
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M#. @2O3![6WI\Z$X='S[MQ/A7OJ!W?]S=7WA]6F%W-MD8&6'Q> ?(9K93\J
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MZ7.=JL9LKA%^E0I;:0^P*1N#U*\N*EC'[C+]&P[0*R&RB21*8^WEU@QON^@
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M E$UJB6<_(:+3#Y36\5?:A9P-3#P%AN)9?9#^,3T1)_?'V5(7%[AH/./HK'
MQ7-A_X7BQ.;-;F.,4*6'Z!3R7PBVU5=:]&9.-5(FJUL-"A*+8FML-B3J98:
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M(>]RF?TME1?@_2$-M'X;O:(Q&9CSQ@I];321L0O>O2K00)['Y85T@_<YFWQ
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M[0A!6KH<'9U_4[CW1J7&[3S<_F( \FM-3_^13OSY1*% S+(^-2;>1Y"/VH6
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MPE/TN\QN1@;^2O*5>9'?RA=R(FN GK;AB=L1N#&Z4(&\7:8CF6.+(XA>/]Y
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MQ:0.&MS-:'CEZ:DX_2/,25*BK/.1JL?5#\F)/*HT^;IMC'7G_9/!Z]9B&*,
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M'!)<ZL-KA%H[)DO6E4T4)<:-T,'\6P$-1IAE\B/8FE-%919W4L[;C&LS+>0
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ME4UT>_7'FC6,XF .N="AVD(M^P^6\02D*^W$5NA8S4V++D]B;")?JVEA=:_
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MM[+D5IT!U74ZW\*3RX/K-J@.'V(GGO586NF?!P>,]FH<?%=7I7_U83MR41"
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MRY)O]GY%3!1MTGF$Q[F0C&N3O]\+0M]9_?5=@EGID",BR34>O(>_6K8W.&[
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M^U'C\4NT"0URSVW&F_5JGG?Y)%ZB:1U0\>;D,H/W3UCFW<@.71E4N\JP:0"
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M0M&14WQHR?P8OXN?46'Q"KP8/3LB0R! RD?>0W#A'.'DFK!D+H":VG Q;+1
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M<I- 'Q"EE+J2EACXDQ*)@PLC!$<H:JU4WYW-P\>7>F2KM:T;M9U37;B$PVO
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MSC$/4B@#$!"L_Q?]__OECY0;)>-&M&1M[T=U*0Y)7/QL,_HX<']^T8UJ)A4
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MT.3RKR!+%=W $5/OZ[P[\A8BHO'-CFH;V=/Y7($7]XF)D%P.;#K/^E^\$Z*
M)JGQU WXUNOP5NGZ49VU(Y[=ZR-Q_7LM/S:X;9K+H&; K1\9J,H/P18WW6NI
MG7^#.LVV"UAJ[W+O.KIW$UZ!Q,5OZV?OWTS4U0@%L.I6&S;+9;U@A3;)Y>O
M;+3$B%BJ"@L2N5\"9.:9D]!S'&JSB&O>/_=X$\/;YSU\.?368[G+09Y)"VTT
M$E0\YL$SM98I?7Z-.30$#:I;CFT+$L]==1$-NJGTQ29#YF0@:42GN 5!D;N7
M$%^=>QUK_VO^*OU#%O3U<$$Q(B%3 %VEW[5(S#@):W*5-E]^D"G"??#GE-(K
MNSS=YY[3')Q6UG9&=6R;Z=;K4I<G#UFRJ'V0IDJ;JJ+];%.J]8?RP4N2/S07
M\L(9\W].C"Y?!*X.?=Q$T_[%>WL;)6H1;# 4]JDXD*)>]I_4'IW1^Z=8PI&G
M?_'.7P=M*[X[#@0\_?GA8&F7L&3[6>#OK6_;OUXG-WU_^=/\RG#G;G'RX%OV
MK\??M=X<=,D^O:]4[[R=MOZ+%^_7H/?G?N5BT&Y!X?<_;SVG)%#_1(-V^1Y=
M2#VK&WB9_3.>W-7KBOM%=.TW+O6\\V/S]-X<03KT-RUI"V07Y.N)PKV4G-53
M'[->)<]8@/S<LS?/K%WN CS1_2@?.;2FIL27ET,#X=;%KRHY&FF4$*!3Z]89
M#8 >60=TH2,WX3,1<NRIE@^0:-G\F8GU796YN#FD&K(&OUI6"N,>,9<[%LX+
M9P%*/:QI"?-8FMF&[BE+F9XGD]7MGJJJU_8<<+K.RK].[*A-  )K69=JF[.S
M3$ZM;"9:#A$=N)\K&KA0;WR7&A;F/J2^$W?U:BB)OM@.<ERWEQ*C-\[*?724
M6??0I6N_SGFD'30,MV#BJ?FG5T'!-=JRQ4'W<+Q3KWR,B#\73VMK6O)G]&OQ
MSJ.48K/1K1"';&YOF>Q68.;=@2"L5!+RI<-X'];O@E:3]U<#\O3L$?H5?("H
M^?6[NP8PY K89)!EB@Q:.D):Y\$RY$+/]7V95HU-\#0*Y9FZ-,.STYV.\?%=
MHJ=A:]'U9N4)4;4/O[H]:3/$]6?:*WS@_^/-.2QR1D:LR[_;KFG"=/G^T=.
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MQ) ]D&0J?M?A<4[@K#3J.;#5V/[C\*U*82;"T[0\1#:_QOMD-<E49E^]]YD
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M(#HUWX66^FVUV-;%M21@(<-C-6CW[&QY@'XE/;0"8F%%1.^;V\ Q]\MYFGJ
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MK#S*57IYXQ>T-1F2ED\[M7XL>6011!/>EVJ87$A:Q/<9*ZVX.&7X)KG0:NF
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MS!JG.<>F^23FD3L7XNDZ9U3ZTQ:2A).2/H++I'Q@*-EE?[K895VJ.81JU5"
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M9T]^-\8QQ$BG-:V0J,ETM],QU5<8L;/E^3Q3C58MMD"2/,(THP(,3F;RA*8
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MF7B,@3UJNI$47QF]V?9O[#/4_@7HK#QN]%K&HK_K%L@L!*49*'\/MEVW?)0
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M+M2.5]B=YL;H-%<<W5OV2+(N!6&?!"!ROU!DU7];&/+Z:];D(TAI2UP5B:1
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MO5$K8]^ORF9/;X?&.2QRJXY]X[X+H(E77>D9O$4)[@)*^?-JHO*Z6E5GQEU
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M\/H;OO"0BQ[RR(>D#WGY0S[UT",/)1X://17'_JQAQUX&/8P[V$O?-A'@0,
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MBE?\]2NU5W[@UXA?>^VK[O>JI[[J/UX=O?JVU\BO>?]K&Z]][>L>\+JGO_[
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MN#7&L,>T]3P:B5D.\1T8B]]+JF>J>&?]K@G5V_7]^=YH+5&Q3/[7"R>3I><
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MWZE]91&[FM0HG2SGHY;@K9FX@+,+[-&S/[5HC;.^960^U5!J8YWV46+T_39
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MJI"PR)<_&2&0<N-R91].BLA8/QF14VCMC'JH.=MHMK="BC_WQT[&\J"^3R$
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M/UVV9;\VO=X[T+Z6G8E!&'X]HY*GZK/5Y0.;+^?V_$3U-]QYO8B/ZXN,. <
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MPWW"YE S"  /9>_*QTMG<J&WA[=6QXBIQG[2QX9WU.\1PZMN?.[:]O,Y]NT
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M2S[U_A%%CP26'BL:6>64Q6_$GI%B,M[*@7E*[!6_2ZEPJ_U0[9<G.5C!\KB
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MF,^?SA?1]Z;Q6LYNZ[7*UUAA#R<@27=IX_"6KK9/V^=393Q-6=S-)09-L:#
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M#'WQAI'V9=>*RBT?!069/[)\%<U/^5KJ*[]%CM([ +C?VV!O[Y9M78IWXDM
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M=^"-['DB_4A31)7<TD!R3IN9N_#9UZPYV<[ O\)?X<\+IT4W+KX663E-^GP
ML)4NU$V<_5S -Z>NTG[O]KV?G[:^SFQ\;%WJN3V<^-?IOT[_W=/O<9-+,R))
MEM7#'%(YOBII\J7JEUL967CN1-P9 _)Q5;]/G"-M?RP+5OY@>FLX>%F^6@S.
M'GFA1:\L;%'"VTE^F VA&X2ZLH3FR :K93TN7;&P3_J1^TSXQF#:(MZ+[$#Q
M*@F_7.1U?7=+:I6&M6TR?FCQ-BAA\Z[K?\X@K^UPGA!X9B861KGL;L.,J<&I
MC0X5SE85P^P(#3)5-%3?F,>RNK_8Y#(UTKW.2L?U533('_@KWA_&2(/XR!,G
M3+O]6:?K:,"(%68W0EYC864)F(V1]_>>(@>#N.?TH2'(5EY:PBG>!H260ZV_
M-S0DIH'^C2R&Z9*15=O];@[!9,3*QJFE//A4_;-<"ZC%V,.5UC.]*GD^VA(R
M8@M&:@3UE*?0PHR%!:[.EA!5ID>GS1%>(@OSPL<E7"^\-V>\%>>-DK!5/I,(
M3DX/.L+\)8[]+#?\:+HL1@>-G6?@"!0:*F;OP[/+U8^)7W"[PME_8YEY)= Q
MFR(#%#LJ?KBO^OZ-,FJ&M5)"OWFE9%\;N_?SFY(H?BI94KY^3[D"(<GGQ BQ
M A28C0>7@,G:LW@+SJ-Q\AA3DF_P2N>3,$.A9VX:.9Y,T98#7__8M=I@]9=2
M=C<+K_T!X2;4H=M,-]7&#@!LL2W9H[-EB.SQO<'5*<+RU&SMG*T2=K:LY44C
M<@)(;I"KA#'.5-V)>(W^A(&K:KP?F3-"\%!@'>TQ<M@VXY5@.9P*><Y6CGRW
M>#^D0:X*R6O/K?%,II4!V+WG.2&>D.B^P5HUP7E4\7D1MU%(E\"DEG!M7[W=
MN8O ^"Y35,J^:M/ECTF%+:!4Y_RRB"3.^-PVKA2#RY;C<ETALW_(-:!N*5HN
M+SJG1JQ+>N]?E1Y?]D"HXA@D=B.*"-BN%:OK6Q^" NPUS4>#E*M$XA5J1MYF
M*#G(>900/'RQ!I74RN/RD0*GXK7?3 GN]ZOGO$N)C_.-D*VV&L[X:8W4:K)B
M"RI___4:6I2*]W=<1*OXG^_98WZ?_JWN\-3QD_./F[C0IA ^ 8=)ZZ.L%A>,
M2ZP>\%0SC5:P>O;SRSZYI7C6"HNR/0 ,74HLF\ 0_&OSKNA*7=!.:?,/KS$=
M2>U\?T+0ZA$EN/.]DX%=6J^[(?!L=N=%R H[>Z/!$=T0[[2RK5B9PQRCS ]S
M#>\= ,9F5[S, R%M9G :HVF"C*ZBRF'S(M[.:>F2&;>!&O._J^0]DA((43RQ
M=>=7JI6[Z/88?.F[82.'T>YMX)P6*(_/A&V3#OGSSW\=)31&YL<@6[747,D:
M2ZM<]1]QJ1NLEA6ZQ:(9?3J9N7+4"L/DW)>PD$E8G4MR6BKBSHWFRQ\[.Y\5
MY[WI"7XV\D33<,@B27O, "R7Q1HP+15RD5TV)=",[;C>UTAVW+TJPNFTJR,V
M!99Q%KTQX+VG=UE^:#/9V;G<4=1/>6S]SBFO@G=\JJ\^WN):)6,+09KW .##
MW]UR2/7=765K,MZ'(]60?^0HK?[>K=1AL6TU!.$93+"CL  ?CZ[D: $NHT52
MO!G4[M8BXE=]Z@#@X;@[K^_ASFS29_F<??+M\<GG*4ZJ^M6CD\P@,WJMG=%1
MI8*8?4Q#TJXJKU?7H"-28A6S'([,ZY>Z>%PD#(Y&=00E6.E700\ RL_VO^:J
MFDC!SJ8)C046YR^.NKG+O0<G.3GW!G]3. PR,S2,A^M(CXT4M;S:[ A]%'YS
MPJNFLA&EYQ%5WX$?Z?9C]9R-D?/2[69-H$S6^E$3WS#PU,(3WS .9<BYP!2I
M"@G>:_CB^HY:!11"4=J/RH@/U+J7\;<+H(J,>.^)#KS+Y#*OFB#TF.U:K=\$
M<+"X?@B9GSSI N4>QDV-?N3A'5"PS^2JS9N6"G#6'Q[9<8:_B8!/CFD[#G!+
M#S\N\<8S'6V...NH]#4/W[@$V?F?<?&.WO@_2JO>O/10=7SQ[:C*;L2U1UWZ
M$D1!;25'\9=/'4O2*#,B!X I_9O@^S>4)>/N]=\"&Z1A/1AC) X PV>.&2+!
M)NOAC9<V+Q>]]_U2*2'/S&IHITK4F1<NA38[&SN=V7JEL599D!IW$A=I>D4^
M\X&#PW7GKLX(X+3>UP. #NE5:&U<\MEX,^5U]&5T1%ZL&*T.<O4] J)A/V?)
M&AO42G;P?*.W\<";OC>#QE8!3%=!0S:)97@9H=F'ZM=Q5Z5'R"]V,I)D6.5P
M6)[]MY/+.^"YU6I"VG7IJ6Z%^"!_9Y,$X<J\5'=TS!*VO?>QS8GT;UM%J38Z
M:3]O,V9K\&\IP-^;//MQ-B9W.O-KU^L(GNGS:X(Z(M6/Q;]\8I4-U_KFN_HJ
MI_[9O/S3<8W7QU%E@YK*A/'@;ZHRCE60QPVI'^+D2[GC*U.L38LRSM2[5CRK
M+L<;C#$)FV,X-+\H[1.?)LTS(]4-JP0\"[E'7O<ISQBJF/O2V'8Z)87T+>;!
MS2X.>4+U@YC=NI9%Y^Q4':)OE7T-T5>=DXD? <HP30<C>E']F4FE^J+@(OM"
MXQ+XK86.],*1]3'5O-)FYQKP8_G2;+  [Q^4H"Q]T53*9CP\/.N2:>+N5\Z3
M55?L3:JEU'*Q+=K/-'$(8%%$M@WLR(>U^GL&9N,KV-IE\X*T4GTQ&/,M)Z%"
M/6*V!-.-82U%$NS,<<FK5X;> KVD!$R+;+@\Q"[V^,:U/+LF1'KD,96G9W0&
M7@J^E%?>&7_1[;W>AM*'C_=>JXX[74Q3_9:2FUUFRL&2$O-A+BOPV;R-Q*-M
MF"U2US"U_XB%.8:T0DP2$(=M<%2H242+N$N:(ZD?WKO%@#%91L$0)^E:\.54
M=PF.J3![BWD=J7"W=+U2\Y)52WO7F QK82ZF&SIW6K7D>@E@][47\I)I(+N4
M=#23_LC#$O IZDH41)J+XED!![3J2)(>SI<\WT5[R F=7@&\LD<#E[O<F,PS
M=MT+(\\]%]"*!?)= QI7W/3VB02T\O8JG.R/=:7=Z'ZL,/%KY*,<&T6MDA+Q
M-G9WFW+Y8@5)3?9D6F0Q87F4V47&0M@X6(BM3AT,BJ_71)$7'Y=\:#;EM6NP
M2"TR0-28/TFKZ/76!,OSBQ]]U<52:E*=;N3I'52>XB0*!(/!FO9"2FZOI<J.
MU*?]K,GP9LR67?'4D3 1ZW[*WO>=;/Z8$3*@DJ7\;+YI2HIU!8HXM_(-2)AD
MH<HKH&?;,QI"M'B76:DR><Y&B+R5;P> >;F:53'V)^\]:Y8&@&H21\U6Y, I
M>"*173:X3T,ZD;'%]=)]U^I1EK&:AHCF-@?%.N0)."M- >*>:5/SAX4P2LO5
ME+;=M>59]@XL+8;9*\K[3PP;Z95&MAE/J5VD4!L0MMPS:*3W!.$ <-$E\#HY
M&5[-,7#Y.8DI/M&Z5#S>Q$0;%U8R]'13#HMC#2#_[<ZL ?2.+K"LX67W6J"9
M0X@T7%Z:-@#%MO".[573U(8]W I;+.*UFLOLBZHRR3&_\O>VWZRN&.W-/]^H
M!MUQ-CSJQ28:=6JQ^'L!9) VKL$40Z6\H;8=4UY&H*F9J!K:J+7NL@I#9%,H
M*[RVP$$<5,NAX5\&N D@[=G0-B@6%T @_QB_T(.4XHII$N=0\KATO_^C*G@X
MB0/_L>OBSZ]&ZG\=_'7P3SZ(_912,BYA<Q&1$_PJ3#FGG0Q3CX4RTL;V;T >
M4ET>KYH&&*KQLPQ]>D!7D73J3,Y:B[K9@T$Q(>1?X:_P)X78E""(G?+CC(^R
MM<@L]^PK@E=,LS9F34U]T;)F!B7B0\\^/GF[TX\;\>'<@E; U.V]\NN)A"61
M/Q[Z:.9FSL*&6G8JP.']Q_<1@@M*KAT[PSGIF7D92IENZ:OMH1;+=96<=E?T
MV=GS[^G;B'->*2C_,2/<>%W&&G@:3SVAFMQ_2V3PG-NY-*S;@/YIPXZZB8V*
M9IV'$...^F3BLXAYLPB/O4/!6^95>0C6;A^WTG,H'C.-^&@= S//XXU]4+[S
MI28UXR6L7W+(K\U-:_O3YOMSO2JU;5:MXCV\*X'R'>Y3@9@T]^O*8CWBL<LP
M3BEB3K-\7YDS_ ="0#N6D6?=(KL@/F54=$4GHS&Q_EEAUD CMN5PO7.&6=(0
MBO_H(?/=I\7I]J7@\]<^M!/?^P,+%5E2'H0'8YF-VW'<PN6^IQ*:[*&V&X?C
MP^]5S">'VDJ_(27I$OV#W$*LK4W=YX/5QGS!ANA+3&<7+@66B8D"1]N<BR7*
MDA?>-):+2$ADP!_KW#<H&O.13Y?5=:GUPPQ?K= /C;-*#L(:A_6@7RS%\S'-
M]F3!5U!BH^[?'[X.+1UWNCF>!__AL5"Z<"&78_MF@,>F_ % XKWJEJ'2,QJ[
MBL3PLD>WA,,;!<TSLZ(4 ._*2(]O7<:6;=DP+?5;M'5Q?X2(7:VZ:)*6FF:1
M>*OA<)[O"]/JY &1_K<N_B*]9R\0Q8/2#'W;74NTBT4LFULL=+I\,[92T;9[
M:VZR^NF44O"F@9ZT9C3;$6'\[E>-[^@83^]O]TK!)6+UA]PD^W> .HZ/+2\%
MBT7W+Z=D^0A #+4MH=^+DL#A6:;:V-I)";X#P+X)6 4LL=G"L-R9[9T5&YZI
M.:?^_=7ZE2D3)A1KQ1,'GR?3EW)'BZR87M7G$F"-E&3^CIO&Y6^ 2(G<4?MK
MPN<PK],D!JY&*1Q22>*Z7YCG_,@&G-0O'H2S+QG-RA<UP#K[5H(X[6^)]F$Y
MKRV_BLW"Z!MGRH1^B-6!U^Z^MG@;]LWP/#NOR+:DW"#&@FCO!^I +SF%3?[@
M$Q6OC-W7)FJ:&A<V&77XJV9#'@MEEC1,P*.T: *._P0RA=B<V(VS"-'-=0P;
M=WR8&/YI69FKJ3K)7M2&]&R>I"KHP3DZ6KUPE\ZL .'<92*3:S[*LCCZ-Z,.
MX3+,$9S<3]X*HD<^R P&'8D^?L_K</..#/=>>8W,8FJR5YZ/[;D#P!KDVH_O
M07S;3L<9[+=>GCP K$(TB1LXR9*+H0\_11'O;77[.BN$BM9<E#.O$*:V+3D+
M,@?NQ8]IHOBM,FX4ZDIJI<7RF<IT6Z[B\4)PYE,5,C,)/CKLH6W#B^(YDG4#
MX7>*%1B->.Z]+DB) B>7#EFF1H5Q=^G6O*P<QW*(AS)PBE^]7)(N%GQ+:QCT
M$?^YY>:O0G]>:VS:E3FGTRC?*(35*LXY%SK.5Q!&BL_YW4"[]H3@.-=6M(%R
MEF'R\<T^.4YAAXH^0\Y3<=S?%GI,%LHJ]IA[/GMV1,N(^5T:A> /&0^+P$JJ
M"I;B#@"-' B6]XY$*W4"2WTJ)"5%.@W?>5K>\DO3R0;'91L-3\'SC6SRMRN[
MT@):&741 0'VNK8UC.*#NL?F)GMO+P=+I1#XK81$<O.3Y:[%&UDLB)26E688
MSHLO?YO'854+=*0)">82_3J>#^&Q[&>]82;6I@%%[I*#/4;)%;O/[?T#ZL2O
ME9:,-L?7E9^MA)21F%*0EYQ-3RT:?DI[PU_G:['$ER(BR(Y\8+O!CK["5L#/
M+OC5+?3CU4IM--E%+UJ.84#NFGH"+#-?NY)-NTS ZEA!X1FL#O;T U=36>/V
M[/.+N:)/EG6.<;C!C>< 5899Z,Q1S73]&3,1"\_'I?C_?:HN5Z%*+=RI?@4P
MZ56K9ADW=M  *9]%G0\/\@VRMG<V= ;J*;^O+/R4/9Z $>6#55LMRRKTWW15
M4^:H].4_7.N/'7$7!%/2@7Y(>]/:N!:J_A_H.$JT-OF1[6.B]Y.*,3%(7!'2
M/$HHJSQM0F<9A%2/]S<2@N']#8?&N+B8&^I+D/;.O@'ITKG86S?<P:_WI!YN
M.P4DZ3$W<J[468E67[&4S.Y/*W9,97_=J,P!G@2R3':VD'2.J@@,IO$IG\)Z
M_KPD<FR9V\,]7Q.IS&+ (9[= XZRLE9CBS6]#!FLM]I.OQ!C^-"\K">2V?,(
MT=P5,\1^>N*H;:6::YV]=<EMIKL#.D$M_:Z!P_(/R6MK2?F?GZWI,1]A"LHS
M6Y$Y/6G;8R8CT!5]^-2[@:^8MJ7<A]0QV1M9-U(42>T;Z0P;^/4-<K9E0;%I
MZABS2>CP\Y9H0\U4B3N6GI*F6U^NFP\L+/D\=I*0K.4\K'T;?B%%X:_P5_CS
M@BCG*W=\8W0%0DZBL:(J"'H *+WH+)[->HM1Z.T7R\QOWD>C#A6YO\PJ8/[6
M;L4592]C:@V&LT6*;I:=#9?\1B&BY$15!%5,<K;OF!?UQ#'Q0(KZ!OM->HVW
MY 5F[@PJ.1LE=66;B3TS4$#ERYYD$SZCWE4D[,L4;_K4N2IC2;U5TXB#02@O
MN-GIXN#>:9X&2,I1D4I1RY)12NH+F PRM/[1AVP54?,R,R)F=T64<YYI8>++
M!9.KX./U"UH]3_(Y2YB/*KT-$HRO"S N#_MFD?(\TB^:?$:S,\YQ;Q/E=9&T
MPGDM*#J;*66.-"WCJ1G@[=CA6< >.U^ZX',8+44;1L?N-PI9:H1R-)]920?Q
ML><ZE@SW&HP)(2UO'U\,K"6 !^)*=KME$JS[B8P/-,9/$4=_'9,EHN,8K@E2
MJB9J!)V4'C^XV&O5^P+F8.>IB7,]PVV=7)[Z?,7(2H)_Z)&7<J;!-\;7++?L
M4GOUK4#B^?>A"IG]0:*W5"%QE7U:Z4"IJZUV-02C>L/0P5A\!-F\BTL[V3$3
M2_*<']\$)3MG; ?SZY6QK]166%*(L.UL0UF5^6+?]),OG:1Y*,(^I[?J^2<F
MYXUZ'DM*%V ]-L8N4B*DDI?'$+F#OI7?@3=N^'#/:,F,#*08V9?J%&>&/RO@
MO2Z$\F;T92HR\+2DI,E^)@CV3 :=JLBS+;6:'^_233KW^'N]"-KP%$M0NKW[
M;LY^&5&BX0"PT@-C)$?H^Z] >?#08Z4%5\EKYPKD%1O"^9LHWY%57D_(:RP!
ML\ABF-WBAD-M.']C<0T%2+= 3?WZGEZ21&2/\HX.547FQVS*PYO0G^7Y*##%
M6'M%9'%@B4(K@T.M/R40TF:RXF6C^Y+V#X0:':I1XATGC)*;7*84M[EGVNB6
M*SDO+72>Z]P5![HI#(/@6?:FK@=:SVGQ4"AW!X\AG%:IT@HX;]KEV<N!D)"Z
M-CXMSQ$R:WLB">1$F2 SKK-00UMFVV,VD3BV& 3PBQ<ZC]4;JLCV=,T;>F\A
M$,);EX>NJV+U*O8^ "3C22/D-=8 0F.^5^L(.0;!W>W/.J'QL5P&Q0WLEJ/;
M'@(A[5IMK $ONT.?TVZ*<"#/)+#%QCH@Z-,WE-OHO/ 0N4&3**@6]Q RRDO/
M0;<#7^8R.>_G/<$-'&P/;$3I=B/S6#T)M3(H!D3V&&&2[PE];IU^K#H!"Y&#
MVBLJ1.*F%YJP>4Y2GH1)%MIGFPL>=GYWBY9P@X";7CJ.R)J-C4)D-Q83.YH(
M-&[4*F'S8Q#V:A>_\9"!,\@)0F-50'>,DC=]%@S(_7+N*K7!WWMBI'N=UYZ\
M1K?V*11#M=0N'@ RY-:?-KG\;;+L_0& 98I01ZO.$=HWD5#W@E;AV[I-I,5;
MB*SN!EH)9A*HH29T>XUS-Q+YC7=5;7&_FQ'O<N?7%%;+1/<:GW\@),S:GQ?(
M,S8R5#MG*^>]>RUA0C%FG77E-O93TB>V&/_SCV@%;W,=&798;W]*51H9C]U5
M&9DM0[3PD!6WPP1IA?&GAE_HCED_]Z2;EB_%QF*8+9F>1QETU<1<)_=,,:D1
M=6^(5MLT#HS^2K*M)L5KWTUCF-9."Y#P,XJW08E\!RY')#3B6"FP,,' ,C02
MAJ!="=/[P!(P)Y<S$P5C".-_1WMJ_LH!@,8-[T#K01PTA+5="_0ZS'5T!L?G
M![5]25X__Z6[+B%0[\<Q/4A(K4RK5ILK3325 J?]5BEW5#7>S\9LJA"'ZO8&
M5SQICU5C:-!8^%3[V8&6KR^!US^<RXC9[LC'AP7*H4:[_;T\(NE60R5:M1:2
M:?R@<?&Z1V3"!!]E?W%[F''S6$OV,A241<M&&%M2)T^#R@CE-DYE?#&DF\;R
M*5I>>-7.Z]45&-3ENS1&-:@8LWB2GVN\)S1&5DWQ4):];+UP/!1>6^ ,#FJ'
MWW?FM>5;I;$HGY775K%6B<RRB1JG233MX==^9:)RQPX/#>.G_3\_0Z 5EX7:
MV([OP%%E<*S>+BLL*X&%<J7Y,8VT]J($M2<?NT>>7%SL9DW@TQJ912;P\LRO
M42:&\A(H$QWX8BAC=_#:-*$NRF6")O X/Z@J:1)?1CL;RJN*I"51]*<EJ\OC
MY2'4Y>MVR_NY3-;*U4 U2DP2#@ [3.1-&90=W@4:LL= GQ:>&D0G3"Y$]$XN
M[\=-CPYA&E3&?HLWRO[7I*X2C*'-P9Y01^MBN,DQZ[\DE[P)QT/URF A2"1+
M #EBJ#L&WMC*V(VL@MJK29W+4'H#57Q0(1 NWZSWE)GEC$?5EO3]P3\,=1\*
M"_Z>&A]Y6/)[SAMX,@WY5\1_GXA3YMKU@A(A0X8Y-P8#] Q54NOE&B8+GCVE
MB8SML);NR$RK1N,O<WV>"7W' LOJ[2J:0-]1H\L-K8^A+VP(EB.?G]GK>/=#
M"[%;E*S>$E(IVMOGF+CTUJ<AWE:E#^O#>5,=^8-C%@-70&D!N6=HC6EXG=93
MU?R$AC V>7O9F$^][#Z&H(EB6=2,D[%G1V,4ME6KF#Y%OS?H,M5!'F_A'9]/
M8X9#JH)S3(J2*2]N;@2EX+^]8;?CCH+L%- DO^!:78'V8]%/[(8'@" 1V3UE
MDK9<9EE\X^?6([85[W%[BS-"1.=JTSW=9]Z7,_:[FU]55L7^<(6-WG8EAG=9
MGAD_3JJO;^*X$7WR;8O(S4>Z63VR+TR(!X DO1<)^P]<;7 RT.70)2>XK9VD
M NFP@9H*V+3%JGEYRA?NCP'NA:AVWF&O934T(!B#GJ8J6IGYKQ&]JL[1<+&3
M>;6 1U^O/"Q)!M1U"&8B0BH52"@";YOVY)QB2W:V,=,UI,AF84L-SV*KH+8K
MZ:%=?1<>::I S$I7\DP+=)^ ;4!;&86)P\.6I/!H_2FBG<14O$DFYB+S-':7
M^:;FNT1V88_[BX9R+1LU($'=**FCULZB%22N'S:5UH\^?$2.]:MI!5W2%]91
M2,GWL[44Z_OJ>PC\;FE9OSY5MM!\5&LT$O L#F+:2'[KJI.>4G3IQKU9O9U3
M-L7-CJ;[:U(?G";$RR;B._*OZ,<&'O$1Y/,S,>P?-GH5S7Q$L*NCU\(W^4RT
M80R1.>Z:.;;):%^U&F]*-.1X\U@.7,E^*XCT+1ZTK"MLVNF8WO>'P2O\-0O7
M2B][[!^52D&L:6)<Y 7VMFO)\KQP?D5U"4:M,YH_B[O38^Z9HD^R<US_V:'G
MX-.WYQMGDUI#/$S8=86=WSXC+*L6'G;!^((H]=;OY1K/3EL&+9^;[DV1\= )
MB#.6 5/DY.) C40/K8$R3B:O(O#CLO?!"N6U\X0<(6;@C:"B:[*<_BF-7+;$
M>I'%CVM3O?GFD _VYW<=",'PVQ.O_'F(6Q9D4&&- ,7[B8-(@G71..1&?<J@
MGOVI3;&BLCBKAHCST0'%@N:.%ZK%W>\0.9F82ZH&S;W*WHSN/.2_*CD]4#DJ
MH7#.$/.B7-KE56:4#>8ECNB?CSYW]<UW(6JKJ%#[FM2BZT1?P42F,)OD\D*M
M[H.O9FC;:N,SD#=NEPP&C,WT^T;G26*$/I@57?2TQ>5I\A4,#AHLQC3V4CLE
M9LN?&,<VT33R=&]3S"JR+^*<@X]B^MNAUS&KG9_OF$:;:*69/2X'12A!\IN'
M)_1??(V<%! KD)!?N9<G<E7J?#=3Z-4O_CZR1=\,BPQ-WICUHPX /@YZWXX2
M7\5/'F&4YXZ[K?EVW(LS6GIW].V+#X6G!QPF[,X<W2V\%#>>Y7)!_>.\33Z\
MQW\!&69\1FLG],2^%.79..J4'I.<'=/-,XH["?S3E34@5+"CWM<J&JNB#I_3
ME1VO(']'F?4)*^00@\NZHIE519.#.Y;'_G@MC\E>\36N\/ZJ$UJI[LIT/$(J
M:(<=X9$2Y.RW[C(UC)Y2W'((H:Y[9386F$\-Y>&^/=UCG*N:VG2:: BL.R&<
MY76XR"TDUY!U%,+*TB/AKY%N /:T;[SBH%_UJ$?X\CD$PC1;)/M:8K!]=>8N
M0FW7*UCC*7'*8:SSW&SE#:/8LKD@WG3O:NSQ7TS,_/I23"'1452S)/DEN/B.
M#7.05)D\1QB/>Z<<_VZ^>584D&7@9$,$MWW/?G3TY0?A)?S]P6Z#VG,[AE,:
M3SB+')92W$3*KO*;D2H:^I\W?[66/#4/UNRRTC&_]_C!OOD9";LDRXN%NI.&
M7_FM%/LY#*P[[9+6!2@1@?P'@*ZV,QK"7$=#TC78*HU4C09$8#KJX8:5PD&>
MV8@JVTCM&/T+7$FEIQ]:W#S?_92P&R[>';1N'QX08*UI6]$S*CQR*=[87JA(
M':5YP=S_QS=G\T_(%!6A#YV1!DU-YW%8#3>)QMMB<4LHUE5Z%ZDY].+3-R<*
M3:UDPU#Q.#_JEO$V7W[&)B."OG6M-D2+%__&ZSHY60Y2"ODQ4<&L;V=^9+.6
MU[7G\M1NS^*(-\>#P8M? U,X*TJT^<#5\@_SS4]/^0ZA;#CLP)R';^#,[4Y/
M$6/U38Q.SQ,-$Z,)B?BZDV-!X>PW4D=.EQM.2E2$293,3Z%/8CBTN8J=93%Q
MD<^KG)=M]1OA1^H+SG@9NB^XLE>>&_#($8RN_VENA,>\"KJ4.4[*0MMI3<'+
M,]XL>0O)1_/*/6$%[#].3[KIN?[PW;S;>JWJFB\?8XH])AC;Z2$]Z%SNT%]L
MDR,A\EA8K$=.ZO*5R]>;#)9!)=&MV:M60!V!O&L8;!?I9DZ4I2;G]OP5#BL8
MQI!TP?@-1'/?]MY+S::/QJ"O'-2KA>4<3>8ZZ@F=7QE+.2I$*H['!'W0CQ_3
MUV58$&ASDK"T.)I?)V6L96UXL5DWTZ:4<R"$/.<?=@RR.LA?YC&_70#VUTEA
M^J!B59QS;8LU!\?-1%$#\T3ZR2O;F:V_K&-_8K[#OCAHJG)Y\37B>ZT_5 OQ
MG1$!G&V+JFI[0E.L#@"W');78N3A2)H.?_XM[S+,=H3L1U.6%1/?,("VIR=9
M M$H>^!@5%6"Y\B<E@I_9)MI;!0(M1SX0R$*>FSWNQ8O@?Q#ZW5 M]\4]V#D
M;*P6Z+M"<;E2)9$&GK;QO+6">C^]'C2A9/A?(UE!^O.DE<^CEM0*YB1V4U/[
M O'O/ ]:3:4LD"+B)->HP9C--2^M&>@.:O480J,Y+V+F * "5#R&X*/\UJR!
MA&6V314R#[F;%<FK>$R+II;3T&>2$0-O$VT$IS;FQ^!K=O(I7C@^RDJ@5D>;
M$QL5Q#/>6,4Z1<.L-94I0YQ@M3M% <5\WK11'0(FRKX!5IW<,=_P: O#L)$8
M?CV9#?,]BIMG?&_0JZR!I[&XW'^*IL]_2L2L3_&MK,!X&^1JL&WHY0DZMLVB
MH0X];YF\$XQP59XQ&F:@03"7SUIV#?ZP8]XRD;@IQ37>D%]7LK $O)PSHF<"
M=]JT\8."G88M\]*SZS<QQ=DWL@4P.*OB7;-6:P6<CPE<G>MLL>-[-X^)XT0[
MGAD?H^Z&TH_VX*]5XG?(:<]AALX*I9>!Q$SD7Q'_?2).9<K7 RH<LYE-2%)]
MO!6)HQ)6S USFQZ-43#>A74O@C]UBU=WKKRQE2:GV\! "/<@BEMQC3+5T>#O
M0@,Y.%[;CD8D[; I4)<<C"=/*>+1530TQ+C]&@92K/5WF:8U6UU"8QZO':$Q
M*F"$'*. 4JR5]G>9&J)=:[>)D:GRN<D/XG8JG5Y@.UY[*OC3Z1;E7-:SIHR)
MH@QZIR.+XUX2.M]Y?[@A?U,9^%?$?Y^(\[JDS+SR0@^F3!CE&B9G;3YW1ATZ
MU(VGX6,9]*?8ENGQND@Z&F?<9G"@T'\16B&,<$;$,'S-906&X%U50.EV']-2
MDX*IL5!CMH%?H-P:2U &T%-II9'QEJQNOT ;"/=+,MM36E_$LK+=[%)IKV1I
M8. 37$B#2T]*KRH:GB<Q-TN(YM4P4M7(/VSO%A-I?3_K"NL*E)L&_SV'8FB/
M2OIT%]V.MR<WU?.Q;39A\\R.M= 71?/45;%ZOOQ!G^";L_H-U\S@<I4K731M
M9=I.(MU'A]GF[;V!AN?S+26YG2)F6Z-D__./_+QIW74GL#NFKHW5<Y;6<=N2
MD?E)1L=*_+QWK^7QJDE!$8H(^\$V7MY&7,"<D19/K0R2OGG=KH&^!E7)&ZIV
M+H.Q#MV>O$S+HQHOL(,^RX?.CU$B=L/#;'#"0F6&.G/-P 6@]FM#Z9&EX_":
MUB.YSY83EK]WVM86:I;94*SN%%CGRI[Q(5W7$7&_-.K9/OZ,?96.SP(MGVJ5
M[A4A5$B]U"S(R@.L\C>.>T_@"M+B8,_$5(WU2L0!0(UZ_,KB<PC"XD=1/Q5^
MU&^+8]+BV@LHM4:CCC1?&;ZL\#!XPCQ-WW+RXT6KJ"TY2O(!8'ZX<33>H3%(
MJ<"8-:";*M->( BS5Z0JT/N"/E@(HU*@D0.1/O$Q16@L)I)E6NTV@]49:A]I
M>%=LBN,E8JZC>S,H>\=(Z_*/35(4JD4HP>F/B(Z5W(+7LB5$%K>*<C==NI];
MO!/Q/1U;<9.Z8R) <D?"XEKXA-WD,R7&$%&NF4:5H0],,^SD<8V@*:0T'.E0
M!/O\-/ABS_AR"KY$R:!WFW6'#P(N>S1\:F!=*>/5QLZYN0B?KC@V#B%T=P_$
M^L3\:ZD0'M^X(]_J^'2D;$&<D@./62FZ"CG-ECA=Z<LZ$SH?C20\KG0Y?@FL
MT%.KG+\333JJ.JPGPL//R<9IN++%==@%IZ-H@C()?@4_9_FS-F_N8868>S]2
M BOH4!96?.50*CC_7AL-X6_6M8)XR/3^#J:86$B3K*?^,- N,C\6$473/Q(H
MJX%:"!Y*X-C(ST]=%_:*W$+3TF$UI0Y)P*>8_OZ7*1G/0.[/-;?#-("A9YMZ
MI:_+6+LV<R4%UCQ_C6@ZI^!ODIX>*2QU([CO3C1U.US^F_)#0DF%;FW[_B:M
MDEZ=Z!%WLSIZ,0-M9IT.O>99=$U[0)[YIO9+J\LYA9#E;Y98Z>?[/6;('N*>
M2"7$WBQH.=Z')?FHR[YQ1.VX1 6!\>$WW-VB<YZ28W;90NJS/D'K#\[$/_21
M-3AJF2% -'Z<P,#'/.L)?:&G_^Y: B8>E3AB?3>JO#O>38PD3.F*KLZ^K*K9
MM/R3\";">TCONX^9NC-E?Y$^.PF:KO4+]O,R<T#PC-/7S6.:7* ,,_1%ETXL
ME/W/E=-C%LGB$=[5G=A8#"0](V/*#_)>@D6<LR(.HBC5$-HO,U+O69*#A?4]
M1:D=J=3,NBST=',?4;E_:>Y%Z/\V_L[E(=77N='@[#7 .^,2/NS^^;C"W20N
MPR[Y*IE"H'?LZ3U ,ENT8QGWLFOH7E+@BX9MKA/S72M8\V3)4O?#4MKU^&[1
M^J)-=O$XH)9)"H?X=EM(\K44B[-IYA!W^26CD"0K'-$[:%3NZ-DW ME6V%$/
MKO ZHU)2_Y>/Y]-1#PJ-%5V5E"#&7:6=TR:9E] -XO$&>NN< N7K%Y!+;V;.
MOP4.1N;=I?=/4!!H-P:^19^(IF_LIW5'M)[2862VX--VBRDT^%GPCLZ/LX_>
M1[)(6!6];+)EZQ(O\WC@736R["EQ;^\YI*A'O&BAZ.T8V.@Y%OOA^K-;&S?4
M*JS4#96X\ YHXH#EULZ=,IU$B,X;G>:*DLQ0"*3SQ8VECG6UDOR%<C%A]72+
M9>5,I8:G6J*?=%@U3=R'<1)<)?V6TO=$/[>QJ@L%"(L6ODL.=,WJ=2@%+E]L
M\C'SQ@DL3+Y:9\Q\FZ85#W)2,"&M?T Q*W#%&5V&#/X1Y]NF(!A I=PL/SIU
MQ:U 7U/L&[Y.:LH$KR/@Q)(IK,8O"DFM=%@ >EZ!_R%%Q/#!QYUV=-\9!]2?
M*9"BUN4YJ*FQ> [ST_@@6,]#X04J,LJY0-5H/:1B<",*P4/L#L:O\ET3![7X
M7]KK'9>4%5ZQB&E6=J\*W<2O!]7E%(%QZ2:6Q6&2G]0]/9U-G< 6!5>&]R8S
M6*V*D-IIV#,F7_8_&L=,'3(UWR\;&ZI37[<EUY5VW:$XAV3>"!8;>FE_^EGU
M*O"& E(9V)W+"C5EK"MCL"5%XGQ>DN7?P?Z*^.\3$>9NZA12U,XAG%=3O9B3
MBD]-A3,E[6?DBEE NTJFD_=+16X(\.CC\PVD0/(%T''_=P< W108</5>BJ'N
M334CU,A&LZ;>FH&/3_9DO']3P5()LJ281R1BM?2(ZJ? 9!4A+_:++X@9\9LD
MN*G;U/"(>X7\\HKVCRD/ 8N$=0V+IQO4M-Q1W$#:\(S:,Z)0A=Y(/=A]9;DG
M!05V+R^YVD84PDIH))MEA(2$:^I:9PMM5+<O[Z>+:X'V8OWELZ^0[CN)L\.U
MYU8?,EN6WECIEB&;]?:/SGLMY*46;!O=+#'H>](U A9"FX1AHH@ER]C:9E_C
MW.363[GW@U "/%A)]EO6J?9<\28AJ?/%E?Y<FG&.=J06H>27PZ @F2T6F.WH
MUSL7R>*ZFR-/G,M&O18K\ < 5\Q2=MKNH)D-*3XA9Z*.9$P] %1#RA:QD(6C
M(T]<R\IA'9Y)AC![\IZ 2)5!RI%73U%O#"69)?OYH];E3=S*..=]F;=OFJ:!
M3\A)'$(= ")-:"K[DC.9%;<S\4O+(@X7PT)B$2WV,^A9S#8##TW38>!MS/>5
MH>EVC'0[RI9_P,M?*F!= FUD9$2$T^=5(&T.QR .%._ TC;_22+=V.8P^ME&
MRYZ'XI632&U1I$%P>6DEXFS&MCW=I#7VX\EG&EJF>)(;E&C7) 2B1\BL55[T
MA?O>$_0$H\"9R(0-N]E,77J* T ,(\*!!C3D7.[2=]>%S<NT'O.)HFF'".Z1
MV1@\47&--6 VHS$2.3FO@&,)Z&@B-(1$\38-6BNYK$LC[!41W#.1[1F,FW@"
M?;-B0,<4G]]T+7R/@B?.@;:G?^23U_@PK#C*]#(LA(UTS"=?SR>J@09_,IM(
MBW<=:D.R:%H =<LA3(V/#LMYFWJA(3%*@;.P&;JMMLUX,W^9!N_;6&G,H0,@
M&BCRIOK34%,93/7-_J<DW9EB&+?B.F5J*.D3?3>F+HW9]$$B#TJ#4^N4Z:;>
M:7PQ[)CY5$=CP>UAN$P5*TP+E+VJ1OQA],M3$JT*$NBS'G2%>W!UXN50^]/&
M!+:MM-FV*I8 PMXP(TV])N.])UYV['7\VJBI1=/.&6Q!$Y\AM,+5T4WC"FW&
M5(7WHXJU:B,_'&:,76 ,ZI^=5[S,@^7(=TO;,Z@J([-5=,6FN/[E( ZFYDFW
M*B*^R\-#T_=H(]P/+<0489)E=?_=+ 9^C+ZI$0-7&1UJ0F@TOR>3$Y^N32E*
M_[[QREULWO7;2"J>J";%XMF!)]*5;(0]]V#>Q:F.GS%#2*0+M<&/;GUES<]#
M3BDB$--U:&3 G&P(XK>BS>I5BCOWI-LO8%@_$ *BR4T4U%[C?7Z,3'Y&+>TJ
M/U9J70+],_GKS@K($W"Y@$%DX.S3[J1.[L%\>!--\8[8_8(:':PZ_TBF_7I9
M8 9Y[?PCVJ7K^PF\HT.%7Z!A]"VN4=Y3(]W(]KS?NU1_+R88^6$4Q@H+8:5Q
M=:1[6W?.E(RLVH^G7S1;L^X%0;1,=%/ER($XGE6X0I6+E_G=TO<' #X,([QI
MA-PTTDV7,20THBAF4ZY<H57+C@(-8PVD80$$ VAR];>!]"?">7D5AMAC85D-
M+,T+XX/N1Q0EOCGFD:?"K2A77-\QJH@(0>@.&X&^2\OA%'YMC!N*^;6M#9W'
ME\$HD["/S.F6#[&CFGC.[9]M-:8]7"GP2?<Z;YB&Q6_)+2 8T4W^-*0/XCO_
M5I$F5R#:5\!L7BL"U$V3N^6[9=C?Y[QI KK-BR8LL7 ^J+^H)=5;\8=/4'C<
MR"Q&B>[%BTK':-0ZPMX@M0E*:]ID'@I-%JW)C)L@WM'/$#6IB9>?M68NLZ+L
MZ +6-#(R;!2Q!-5 -U37B5XS1W0%U8E<+Z;2S<&?,'#:CVG2I_UW7^AK*NPH
ML)!:/Y<#0*P6K;G?QJG0^2Y%XWMDGO_*- 6J*(.#ZG;CM\]*7HI]5:5**><=
M#J#?R.D7O*+%L^9GX.E6?PI4C3^!2EV#,78WR(UT^Y_+H*_CL&L(YU_V_K4=
M<%?K?[#W7F%-;=_>,'OK5D$!$50( M*;" $"$MJF2)/>A- )/11!@B8(;!M-
M>F\!Z<4D$" @704" J&3  JH" %"TU"D?\'_><_SW;SOU;DX%_MY!B1KK+GF
MFFO.,<8<OS'FFO$L\=U*U)LDT2>- 6AX<MS4"0-1_?<V9V?^:YNS'Z@ 6>YB
MWYMD3E(8AZ+-YJ<+?B^XMUAQ<8]**:'\ST2AGEL&@V_;7+E#5-ER>=T4@*@H
M7F:HS6PG&NKP"(H%?9V*Y(5CMS2I 39P0JNR3*?#Y.DY>S@:/C@,K9FFGVP0
MK>CAJJNA#L 3UL(2F).>K^.&J;FV4Y'#-$PP<'"L+<N7M6GJ.)J+?!VMO(S8
MN/?#[E?63/RK)=A@[4T$&<7-M1<6I764_^XE^5.P"@W0Z^=!^  [JQ"N^ G_
MA0 J3,IG0WY#QL$ISQ- I+;]9.04^3I6M'!XSE Q0D]U/T+O<#6/?S9MY%_Z
ME_Z':+@/!<)$ 3BL$1ETY7#I"15LQ/^*\R<[P.S86ASI[ID-Z=A._89J/#,<
M[?R2-%O3 R'=(3?@T6YZ"?A$(*E>;H0959Y['7/"8"T(H?+CVLK;'A=7XI"S
MA_Z^,*T3AI<]OT572U%)2I#I\0S7SH#)(+%Q@X><#Z]-WR\I]B;$*)7AT#"5
M7L_7X;!.FB,SHCH8?# 8V85HNQ1-.S/4N@F%$(YA[ZM!ZU&.L&*:(U_.)G0#
MB(G=I)Z>=U49IFZ  0=#Y_/I9?"+LH(#4"<$!A:"3^:% DCX:A7R\VK0R%[U
M.3SF4A@Z&+2#GWN-MGX]6D@<-#0F' P4DQ?%AS3BF5ROYZ?[I('=2A[_\("&
M44PE62V*3]M%J[:T,RTX&)8<MP.)4M+]_6J#AX#\G3%<O_[R07M"TZMJ',)Z
MOK:-Z9<_*IFP1LVD1FB<@[BZ8^BF)1*(@74WQRFI"W H%M^M&/843_I+(5G)
M$EEH$F,<]S4(OL=V[JQW5E)LNDW"P#6)VO56ZJ#J=XO^;:8XL>'\IYQZ9A)7
MKT/3?6KL$>2\QQ:5#^%WT@'!2+=P>L5^!C&2)L7-U*$VAC=6<=^/KA4:/RJS
MK+/,#@KN,$]^8%$YLA*XJUDB8D#[6;O>3-O0E+!RU<I-R4Z.XRLTUD@NZ;]G
M-$3V1I<-[D7]G>M;:C$D&&?=(K7(S4G.-4E)?VVQ2(1S5O<!5F2<,):?JXRV
M(RTHT_,V9(C%"8.8-YRR\L.MW!D,[A2GK06B89@H%J'[W^[U/+\BE/;]&D>I
MZ[NG )0I_ =)W!(!T>9JRA05"]=./!Y[]*OOR0N?N('#S[@0U!7!'TY/#_S/
M<J:R9:T^]4?)>%=UAVM/*3$)!V5+6Z8NOS:USPTQ0%H'XOE^<B"N67H.P+W2
M=BQ@M-%4D;[0^"B=D@ZK1"G> M$;,\<FK]LD/C97UOKARON"?_E_J+Q/*5N\
MF&Z3?AUV175.C2F-(B)(AHT%BEZ$5V:-G0.'IK!_GU2/=?YHO1,3NV#NSVC-
MGNR#S\'?G2Y\[C9QH4G/;=Q@VP&OE.F(Z'GCWV+Q>B^2"J$Z=[EYJ3W.HSO;
MGEG!=WQ?6=\A(*;\<RQ?8  Y8R\HBT9]?9R5I>H_\3E=;1(>T<XQ%HE.R5'\
M9J5Z!B.5F#O&X6Z?T86Q.4XG#$#+1$'#&#/9-I4%IF+><E%9[PKM1T6W/@]X
MF:K[/!M B"/F;R'$8WX(GC TM!@G6J1FI/WC4$8D$E!9E]7]TEU:KJ #XV@>
MS4R!^3'W"E[TLL^P& UT_F-\PC!D=L)PTS@P/E>VG?Q&X.'QSZ[6@:X2S1;(
MMO-I-^6R^B)+=+HK]4\8AFW^*I]></LVSZ7 A,7UW1L"[5::-/ 8?IOG9L K
MFZ27-UW(.X )-[K?M*"X6BQ^LV0:&S(T5//(JS:1O7%GM,[\B"/@^ M^45AN
MS(C6M<#JJRZS+,?2-QZ?DMB3O.1!+(MO&V3BP:[=7MV8=]IS;=Q[&#)(D_=;
M?V"Z]LA/U&,S+V=NZ"^^'\D1]\O.KSD)Z)XP>!>I()"!(6^GDIR+%0HX_SYJ
M@&2%.*(?I(5AEF[W-Q@DK^5*V"U*@L)WHAGG]E;4OS.QV:S^*&)WF>B^?\)0
M=_M/^CT>[:D]@PY M\]#OA])GS"T2#UK%>EZD_NM>6M3O!N^[_;8Z#G@%2.N
MJEP,NP.^.*0 NJSQ_(KKK0$;X1RW5\,5]>"[GNVSJ,P=_>;S7Z01,>+,->Y/
M?LCV*[BF+@JS=/RIPE6;EO=HH<\\:(-3T$* :%Y>"I,GI5+49?W]35N,Q$\8
MTD$G#!F2$9F*)PPII28&)&^,Z"!]X#\7AIP.O$S@T0/3K,@IVY22 85@O4S1
M\@67L7FENP72QF.EK^J7(7%3D052QJ@KZ@=&<_,\"&Q#LOE3^]2J,8'1Q=?A
MGZ 0JG?ZE$1>ZWLUV]V%BQQ[(EF7+L]W+I>9+?H4/37(*M7,EQSJ2A16O*+C
M$V)NV"]I+-$F=:/?)DKUBH[QK<,)CC9EXWSLL*?$P]2@$:%%#6N7)!\/6X_^
MB5=6T4% ">'[98(?^_0S2D4\G"J,26(<4P;N?U;UN4V8MBX8"\NF2FL$84R1
MY<I"CN66XIL?:?$QUA5]YI7?DD7/Q? K*P&0'G>38&D (^XF7E363M/;U?4/
MC5G!31[$<96?862GD&*1PQ>4K*1RD2^R\N,#/;JF[IIA"2 ,H@9*R R_Y34R
M]Q(@?WY>-U%F][_/?--^<>B='9,1Q1?./5(NLL@UPA2.O(A:-F?S+(<VL0CI
M27?%7)'\2I].EL;J4EFB UW?A\M__MS)I0KN=;A<[GE3&>#AZM*NS569[3*;
M?G,:=1=]^5OWLRWOCTV1%\Q<WT>T26BU26@*Z24[7194E^;\, 6)OZF9EY<9
M(F23G,\Z8*@=>9-HV!^-F^]Y?.=@<S:\4)UMF( G$7)SLIV#!#?SXT%R,F(_
MA\M61)J?"P[L19HEP;@HV0DITR\:[Q=((3">XSFDUCF9ROI?$^(5EUWZW]-&
MVQU]/?#QT'":D)N(#]MR6B]'4X1JU<L]@^C\HG'QM8./03?TJBUBZ\P^B8M*
M"9X?RHY5E?6N3EL.: P6+_Z7_J7_.2IB<TUFK!%V+T4=USC%L'"K5EF&6E;L
M5)JMF1=/E^KB#1)]TGDG)/YE_\O^?[/W]M1-DTO[[Y,>7\ZOS(]/]S@URR<,
MCT?3P>FJ*V TK$R^ONQZG#1BW5_)@LG<XXR4/5%I-TO/HERLNM^P?_#>WI(G
M4#]]^2JR?CNH<#<OA]?Q]6"8.P%8K?AS<J;F>8C?_OE) I@D]_,PTV:HGP7I
M&$T ;MQFYR0U8BBA G2_M6!+=<N7&DL MELD[.3,:85WF@]L<-+;@&1T0:VL
ML5(OMWD>.5,56B=]H:$LK02YT<GP3!3\>0V5:Q+^9>[OF!7%+12\6K&.^2E%
MF9\,H87*3"J$N$2I/IJ!.JZ":6?X<7&KX$TH!A9Z6T9ED:!)A?+ AG#O*)X-
M-/0:B !* %.), 503ZA1*!1 Y22U;[BC/4CM5,[93K2G"SG*PG6[=9[S2Q@!
M3%":?D2_S:ZR #</LYLJ]BTYRH,306KF>0A3ECF--#3^W,%AP800'GI%+6HU
MP6B%%S8TMCB8W4W-.Y:%XQ<B5Z#Y&EZ-*MX56?UUI<C,40NO;8,N[Q>3:U),
MM\1J!(+[W[T"\=8:RF8N_,719@O4Q5Q?Z5[:[(VLJ*^93^P*-U,&&S>9"P,J
M+Q_FB/]-<'DN)P4P=C._.-%,HWT_\U*!]:Y C%6UD;67E?GAG)&WBCM'CM"%
M\X T  [9J!E15F"<7T4D7[SZX=-=0)25C-$R8LFX/(HI^'6:B;%%[5B*1?!>
MTK)\[_;--UHOH-B\?B 3?DAF#-(__M"3Q(\<4J,"R#.P&]O?]H?;/(Y+K.NU
M/,@%_N0\_YZB.NB(JLYQ*OJ$H;IF*< ]07DIDN=(AE)]G?22"LQU;:?RPK#-
MA(ZZ^MX ^1#(ZAV'B+GKV.OTXIB+F/C)+>OS$9?4HCK8D[*7'_Y0.PAIG3^-
M]O"](ITP+$?GO^DHX3VZX^!'G1SJ7P7S34TB2+ZK8 %?&(!4RZ[*C"!ILX)I
M';80BAU3XB*_6/8]<7/81<M^P1%29>*@*<P2O/"HE.=HNOIX<_^LCE%"OW$$
ME6-/#"].$X88R=X:G2BVK-]OTTC)+0X>5A]$=^#%Y2NG9S15(++65I66GA)C
MXR<,WY81C\?,EMR__7RH78&!*Q:;7O/0R3*+#I+[R2.DO>[5=R3@$5_3?Q"'
MT8QVPZ*(#_1D_X*[-K&48=-*O^=+IJU$-JTPJS1;^/0?5+]^KA/RUL<69F(X
M,2J0UCI/>.G1=*U,'Z2A/D;D$'O9]Z70U$='_.?"V5:M9V_#:[1+#BS2A>,Z
MI<W059$&,R")TGXKYO*_;A%ONEOPWR-]_#@"G%<U,E1J@>2FY20*RI?>^QN8
MTMKY\NHO-G<1GMST_59IVQ,&&R5J]W8ADGBDU_;@$VXI 9^H!<<@!4/:V,<#
MEI5^Y<$ [Z<0<0]_*.%:; BUG _)KZB:VSDSR0+@&304PE\''0(MXN-@_!^H
MQTM%?(64H\?T\7CTHXFM/3_:;YKWD$6++@5@DBHS"4_YA/_5YK?528?QW=L.
M1S=WES]08=SX@@1>0F0S";A!6*1_DK7F2H;T_A.H<")=V\V92I3I_6FZ(C)1
M5'S-\=6HGI"9M[P(>JM1@.MC-\T[C#Y^P6B.BU:N([/1K]40MSMO<<:<C942
M>3&1G_%=2^E.NY]TN7J;T96_?/ST9DO-)(-*G@O)W06@<0>&C=HV/^;_G#CG
M]M'61F)T].X6%J5109X A#'EN7*PTJK<F:J<I=/[M\9GGWG*F@ DB@H.[5-[
M._/N2*6+$5%+^N5S%6F20?YC;U0Y:$^?I>MI=Q"X(@*+4M;5[:Q$>!-"SJF?
M,$ADF%Y*#QKH<U("F:JB.YKWV<2MU2V5C!4>CSM.W3/X8"6[=:9JXO9\^GL=
M]+@8^T).F\[;<'MU&\'CC[=M_\DMKY/.2X4\=?SC[ZX]QQ;3TM+(F#J0-=OZ
M8YI#BHCI/I.4GZT8[3*:-I2AAJ42X1TYFX?D*.^V\GP8$;[8/-,"H1%#"Y-Y
MG7UU<X?)TS1EOU4<!AH!^D(C/@9BX)C8S;5&9V@(B))#<T!@\9AILA-B>+):
M'GA:Z.LG_QY'6&%[4F\B,"ZLK:P11B^SI;4%Q$S/1BI"'1'5\K*" \S1-"0O
MHOJ\$ZP0Q^L%(R+B_A.4(8'0,%<5TN^:OI!S-NG-40=](>$QL#78:8L0N_G[
M?7.W21]HE^*56?+](>(X#Z\V%EP\PAI1VY44UQ6]YR ;Q7+E'[IVZD<@T -0
M(Y\Z8H;0"P\AW;[ODP^^BE\,]FHGL55/IQ;L[XMSQ.RO'BJ*,0+#<38%V'&D
M%Q_%LF_-LMWI)NIU[O>A%Y/=X*SR$X;K0K3A[X,7W14DZV88Y9]O?7L!*<F#
M^A^7OMNPE[)>_%/X6*;_()XC*[!ONO+VUID:X&JI<*'@T??:8^J2UAP\^9)Q
MZ]=_VFHKTE]4V2Y1K+ N/=2PL]*SDE'4X&01UZQ>UTN<=6RO-9/U^UXV(6T?
M5-^5S1S?]1G_59^3$W#" ('3,:=#;;!3(^ @5-U'8IPP;L#K0A\1?4^ +2'5
M]JX'-V]*[&"H9J*AI'G5N/X^,LX@3!2L#-I+841(W410B"LG#!MG,W=S1@[*
M8M1-S&),2BBZ'AVR&M+"Y0$J>S/^)PPWV1!O@1<G.%H_,?XP+"-.4/H6.,].
MWPV45<GR 974=&N573:X;#0AMVS,IH,6XZ-8.TVGI#Z499>'8/B-;F5YL7<W
MEZK_:G9TE4<C^5^T%H](B)4:38Z?=4GRX(!^CWNI7A9Y'YO])\0>G2ETB?$K
M 62#<8BVPZ+ZDDQ&_PK.;[I2ALUUISB6CE+>6'P<N3FB*5OYHE/\G_>FY8/F
MY9I*IB&6@Z46^>4WS 5]6W,)+W*:F,KT)=[?M!BX^IC0R8^12"Z\+BP,'3+B
ML)@/D^FKNOJ&H)<>*V7\7,E$OWCB7LI'I4'YCY&EAL8QA<I2?:;BD<5"4T75
MPJ(=C,@@O3<952*0-'!;1%V+^/DL]QPH3(2UWH: QT!MYJI6 ])) $+=4H@?
M,_T0;=C_/C=3QJQX6)+7I9DVJ"KT^D;EYHIHJI_5>W$E17Z>";'U5:Z5%]O&
MKHEV5:8BU*M5*&10JDW%<#G,:@47Z6,>Y*^I7&4V,RDWP;B2UPTN5M)'8;(E
M=>X\R[Q?.>)1)=H)MV8HLZ1XT:9?(P&OD5?_.CMGF5I"D@A6:L8XEMKE7?GQ
MK:\'G3=0QJBACQY?LH#7&0435N6FJJ[>HN/2N30SEA1CRX2RJE9U@4@O; :A
M@O?%79D- &<))RSX.F6( DACNU=E8N:)_WL+]/>6Q%7&/O12B66QV8H/2LVZ
MU>[*>5J\ K-]IUVUFH3(O#"D0!S$JP.S9-6R9-7$02K)Y>+I?=U7?ZV8S;K>
M0$33S/(06'6;.YS4T:)T2-6(B 1%3C7D#\T78UPOH=6=,7P#\FZMM)'VD4AB
M7&"+4_3B;+1C'7+?'IZK#BI<!%*T$M;8PAPS>3R&B%X($FB8JFRB[4]NS51]
MW-Z8B2O(&/H[FH@]<K<4;8,DT1:%-9&W,L>==1,E 3X^KB'0 8$CIN >JY+1
M!;'QC7J[I1<4++E%NNLAU 5)I*Z"E5FB4-!SI%7F0YD9>#5H-^L]^_AR(!K6
MD;%#SNFQ9PF_KNM.YIH.+$S8R8?9!P,3U&YX],RMXM"K:@ "7;NPP/C Q=8-
M]VKP$FSP'#XND)(UO%'&1TISF_DE?;0XZGV5Z?L/&9206?E1R0E#!:6:G1RX
M"$I0G@IK"XO2=1FFH3VUL#B2"LT1AEU]^#.?]0X9!5-0+"QX.OBI<YN'3?72
M(](K$O^Y[<[MW'U<F)=CG;JU*'KP;9%H%>_134KE=AW2S@C;9G>+?!$7_M,!
M3LF7$I[8G^_^1KQ9)[Y3@&$<<A3%W@BM)VQO=3Y0F=\ U>1#P0+(!.5IF.V4
M%QR-&.I_@N1O8LYU1+25;9_#)7/V!IP']#@BN2%DA]7S=@U"3I#K:-)J&"74
M9=(/ZJHZ[6MB*?=#B^Z JMHXV<>PW/"""XVC+'P_B.H@FODEY#4MO5Y4C#":
M%5TIUA;6B3:(OYP.^)?]+_O_SBX<U]%/U"^^&\U<DOYJ7!U?V(;#;($P,"0G
MJ>[CFHJR"<O8C#)DF&)GAV_C*6_FW.E!*JPRP^R&"?BG&)BN*0Q"_X:Z!+,!
MD!H+?U]60X=KB4 ,W8/.J7 M'ID"ES43NDT'S,X=9T?^2__2_Q ]9R58*SCH
MHSO]E'1*#!L@/I"@Z_DT=AGAFYPF-(MX!*4@=$,"955A#LU(2$DOVZ,"Y,4?
MBZ1J(P^'9F$ ,N2>@D+51GXL3QCE6QCE7>(U"!")8VFZ1^LK5F9!"0*!UWR@
M0S%5#IHZK..AM1&3*MW&*YBTJKWO18,*?[$.:.)N@_QZ:R[(G_N0SL\)\2K4
M>&T)MF E*X9_WV=Z;VV>!5F2'A&\7R67%+T %!>YIZB!-I\?65$5RC&2\&VC
M UVQC()J8YYRL2 6T?KIX#79-I8;@!F&-K!S3G"S\6V-((1ROA]"[9])5C#9
M;G@^L>L)6N>YY*43!G%)43LZS!KMD_>14G!$:[SI4;S*_7<TDW;X)PYO1J[K
M^Q<Y\O?0%=M. ]EB:9\<PUW1&B6Z51Q>VSDP&Y(\>Y\_.3_[39(WFR?3 HU'
MEJ/^,>WRO9=%]2_R/E[NOSQH'^>8)W[=&^?],[!W\?%$K*_!7;TT2% I!]$\
MJ<*2T<+T31KC1YM:N7!7/:*J()@Z@)A3L?P5OX:(,DCQ,RCQKY)OTT0LMI)
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M="1B<HIW^:2!O-:R3QY'>J<<Q*S0S=4(OH635./G/X.9_JVDX-,CNOD;&5?
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M[M[@:NA_=G/H@9!V;C@C2#(@ O"_-UO@)RO4U<YK#8;8\,,;T4J_4'!"Z^R
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MP]Q9L:IU',YY8U8!)$*V2;VMCRGG7B="TA'>J(8J,A)V[3K;5:-/'*8-' 7
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M_BEBULNO,$8A#D2I$/.)89*05)'-B ,1]W*4=VMEN+Q04B!D"-#ZK5VCB<@
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MKVMT^<H'K5MT&]#[IB5 KJ+E4;.IK^-'4']$-0J:<1MZRZ;'JZYPBX&WQFM
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MH8X'I OCK<I+DSI]9V*O!Z1:"_CF57R00M=C$M"07?O^4;3E;3!3>Y;9+K[
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MNI"@7VV2M^HP&T-)P*X0R@$U/<-R8B +!;]OIFFTM: CJ'M'>I#A\2:M<?]
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M01;,(_OMD3W[[;N9-*6GK*9C?BLEJ8>Q]@O)7V722 7KN*10"RL/2<C'VMC
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M7S)CE?(]$"Q*IKK428*3OK-P],U4V4T*Q]_%?Q?_7?QW\?^_Q9$R>>4O2$]
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M3XXFH<Q",FYHMN8;G++Q37R/ 6<;/\7><3@(H\TV.8$/U)6,+?$O9MUJ>GX
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MK"=XD0%>!/*^@Y !=\)'*9D^1FZCRL=^S>5NN:/@X!BX0%N@D!H5H:%U?[1
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MZ,>W@6)&3E<=IW/75/^=9]+*1G!\\TZ!/1DS,N&X9Y]N&<8$H5[H5X<R#V&
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M_^U+8(32-0QZ V/N1[E=;H><\CC[URMP%R@W,SSM5-=(Z/=S>15 $H>RBML
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MY'2=O+IR<L1SJKX9(TX#\G NQ3H7?%/G/7'[_V+O/8.:[KYPT=!)J(:B"&K
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MG+3&X' ?N;1;:N+#=V0<3,.)D[,&)"?X]1;V,XIM)BJVS JL>8>#S3I2LBV
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M+ED"Q3\</H>.L,0CXBN._0GZ7#5>:17NINA_?%(KD37A?P-'ZN* Y6*-/%?
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M\0\"2?B060>[(X :.7\JC]#YC4,!K:]+3+P8./Q ?7YB)KC"PX_+[T[?.#-
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MIJ..@4J"%$WD9.X]M]HNJF_X4VP\*4Z!)Q7*7>'"\3GG*>DRA^7F\$0,!QJ
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MS-A[MOZ7U88)&4ZRD">ZLKSI(0EI2#4AY4;-M@@?U53>'=.OIFPKG2U>V!.
MJ.G(ZY4XD<Y84PMET-I[J?"-VGQ(]F DH*,,! _\#I+=4'P3F=CS,LUP_:1S
MWX[<1:Z>Q7TO3[RTR4UN4<+KCN?J>S9BD2FQ[XGK;GI6-0;Z=\_H6EI>^"(7
M1L.8/:6)WDH/3DT9$-ER$I=%6II;S9@5F#:9M<N8HV :FM#4XN7I)HSIL,=
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MK]B>U8D#2D6M@G$[PV4I)B5#XY=/-&0H8& 8&!HY\X(K^3V*Z08DR:\0C M
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M;:TI\Y)\(RM2:6*7UJP(.XX\/9K;P93G/M-]Q=$AAQ_/Q8^P&_K9FQFQAT>
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MPQ3U +'OC%7//_@87W;3H69-L/+Z_B1>4Y'(WGK]T.F"2RW[WB' "X!#\@,
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MJ<F[A &2!'GLWM=B(CMAB4ICAL>)Z\ >M;IXATC@VQ4L5\F/J#+14"\ ,D[
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MEK%+"1V>78%#WZAEA;/*^@,4S"%%2&V=VURM:R&KDEQY:8B&* ,G- UY)@>
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MCGX[(PG%'XMUN>\0GU_7P_E @PYW80^#\-U3ND6X9>/X&<+X*\=J_^P90<5
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MT+CH1,[XI#MZ$_5-QQ)6&^;%*^&A0L5N-[@W:?%:&9JJ^9Q!^V$#I7 %?O*
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MFL1A13:[)?T##F](L.K)^!%VSN+=N<F39&569+IUX$#J.(Y@/.A;$VN>$YC
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MC'TED#13$:!%6.5PI2D2G4^'GFR5+=:$*T(KS5VE3DFY>1OC'134BG&T+NX
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M_V2&6#[X=2!N2/O+U,1WA_^1V?(O\;_$_[\GUG;BG$W)BY\.-I;,''_XVE5
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MU7&7:8.+OL_+M^TK<]9-IKW,QG.(@<]#D91J&^5E!A"BI%:Y+ES58%I41['
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M!-VE]__G5][1,1(0@*5XT.14CQR[=@6#!BBJ:,/OS_AK>RY!CU,Y9KFG?QA
MS'A9[?2>L<LL7&:0WD]6QD"G9-V=K5ZP*[O!U/YF5Y")#\P1I#B:8M\;)H']
M5=83 AN=W<CDT,')JK5L;"!J<88CWC95$0!#+4P!@ B+4UK1;V]OV^LD)DFG
M9-J@.W@OD-AN$O1MC2[[V]RW5S#O[!M\:B?%V8Z1!XEB:%J4.[AIB 5,?4"=
M#?O?FD6&(LW%Z'N0XA 201-6JHVQ<S)Z0DX_J'.N/&B\J5*I(2BB1*,X!,>J
M(P/]D_\"6K9\V40A908N (< J)0S]X&&+)G$0??<7!5+;<0@[IU"YB#YE#)
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M_^AT6'@$9WA(!GC987SO9Z4+L#B+H#5EZDU;Z4P-4IQ9W+\;)]7B$&O=)'0
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MW!NO<07[T4@M#_UZBZG"*6J(B61V$O'EC()#;+NZM7CK+>_PWM[Q@:.43,N
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M##4$ .%.X70%2KW>NWEN@?18/\!'PC%^/I=LECC]:!I/%F@2>(&JT@3))Y?
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MH]5:Z>[,NHUC@*VQ#4X"VU[)5:Q:<XN/8SG^)[Z3\^FX3?Q3C6*']38W_Y8
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M3"/77^BNDZ-O9<5Z8;]WX#(/2@\;V+.M2<53X\+0:UGOZ7O .,W5OOH-WO9
M4JV,V @7U^QVA$C/NKWSJP(5V8"$9:0.=T?/RAYLGP4X3Q9NC*7YCL$2@A40
M*0U?X2<7W^42%UMQ&Y<2;3CQA;Y0_]P-Y?\ F<(+'58H/B_OUZY# KVG!V1<
M5CP,TNXWW7]E)7;DC=GQF4RO(#I-G9B+,S/%SBUR>6@;Q^B8L56EOKRC@4:
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MZ\409;O7=*)>E/J]3R]$@^FF6F)JG7B:*" ?]V?[Z/@PD3XEI' L(Z<S.%:
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M8HN<FW7T8W<8HO*;G\AJ)E4_%@#K?-MT_F)JYDV[#HNE?&_I9)=H56%F7>]
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M1A8+%9(R3]ZC+.G7:1OI)[0&CE](]CG>)[8;;&]*)P-MLU07S;5Y'7F14X[
M6')R<@HRAX81NN<^>1L;XS'_-$@P08^4T'.1U^61BK0^_;_D] >)'G#IA/=+
M>EOY4(HMQ&S1^!['UGDD@[B;B/D2_Q2GB1YL[D&&Z5?+W12=&&";1'<3AQ6_
M]P+^34.&Z(/3!'MU4DR"2!<4_K;I>YSA#OBRTC_7-_K<K:LYH]#(I6$@.3_Y
MG->21W#+UYR'H2Z&4FEIUC&UJ4KV+V",Q??;B=W_SDO?[D81O9@F?*>E\FO,
MO\_"N2&XYL<8!#06)NE0&/S'#O:/M HB,K&^Y >A\>4:@ 4M,]W]2V4^)-PZ
MN.$Y_UQPS8B!1Y/@BD."ST0&@F'T5;85MH$1Q99MSRRR,VL8!_-L@QO::RJ0
MZT:0!C=NU%F#$\';FR<R*"113;%E2$1:B&./XV8BUR<9#@C8LB4^TX*8J&'P
M0L!V>&LZ "]>X#ROTNX)G8M7LDJLQ:CO_1Y)O;/!).6D.L560;:*1E2+%G'!
M@RX]9'F0Q^Z+)>/:3PSRLO3>M:!KK8AA\23#!WKF,_1+3><C2D=;QM=/KFR@
M]XQ7WB" \*PNJ:FG3LCV^@-5R$32ZQ<3/YB$. JZ(SIX,CITD+G-DI=H-/5(
MJ;26([SOIP++R-?XK>_YHN.6U[V8_3+>'?"J16#1NP6YD RJYM\BY?_VP#^@
MN[\ 33V?'08IRO%\L5DHII/Z1W? NM*]^R"T:F!!\=T/;B'_UKG$?C1W+6?+
M,V+]#)X[$S;\_+733LM?V3&I5"4&*RY<]BZ6U]I\=?/.'*CV\$_QR.C*+1EO
MK#6EI[+U.SV3QXVGUB^=IF\&O8Z9A-?VF)%4+\I=P2:T/Y+HQ+2NL@SROJ1&
M*\;?Y[D3S(M3B.3KC.FBY6VCLYPR\18#T6J*MS#*?^6-1X=&(QLZ9B1)_&_'
MC2 MY0CH C,L2D+,BV32(Y(P83Y_ >D'NX?,Q6:S[S7$N]= UIK]_FL1^0FE
MQL!# &]\7-1:<M<_0IT>DIT,_KUQ[28G%9Y2O+E<Y)3=R04Q@5,Z"4?D5\S<
MVO9_ 4IE.H7BQ^XSN+%2WV3%9DWZ#QW'F. 1.\E"P\'V] 7P#G4/Z\%3LK\
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M(9A:^=OU,X8K;;0[@?O[_!]DE6:J(:)&UAS00)>&+FI2IN<^U&UYY!ND(\X
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M]=&WM=.AWM#]5N&(YJ@16> #G^&R@D*)NQ8'=WEUZ@')CR/GF8CH*+/[.<O
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M+.WV[QT!V1GP#$]U^D2)Y#>E.2 _<M)]_'G MY,CV,Q'GTM80@PEP63?\S,
MLLP:YD3):^N3R@ L?.O#>+B>B!:0 HK4),0=7J>D$FME/HD+% &]@9H&PB0=
MA&6[;)LHA8F9&OH"5\K<4-IJO9"=M<D\CT,#I7K@RXM3UL;9?. ;L]W#+<Y9
MWTHXM$Q2*C)TJ[[8_Y@_GZ";(7>D%M&0EDS*PRRG0BDWN?S\&Z?9UB%LB.@)
M74#\F\33!YMJ&5?K<@@JC5/OV5N5SG1*K2K/C!2QR:8.M6]'Q32:) 3A_:%#
MA:5]!:8%J)M/4[O+AB?$8;0&W1T$0)E@4@-3L)^;G>Y^,.K1(V0,A_QBX]4J
M'M3'<V1K2 Y-^:3 ;8\_]Q8C3Y3?I5\0%K_Z5C]G'Y8FD]LT@M/(UXO"U%ZX
MT&#BKC+_XZN/7-^SKN3GFYSBZ >"Z%B\\NTN^H/:-:&6C(;/<U,'#!"**M3$
M]\Y%+/@QQE-E-U^S=W!\J&"S&#_&$KM!0_,E9)+OD5!+A?@%:=HR9ZI+."74
MIGS"M\](*HRH+PPUC)IEZ0T?-QG%66ID7K/^ K/GZS4&Q95UBIK6+YQ'_$%,
M2SNNC,^.L=+VD/TF8YGJO<H.FW6;6\,0^Y"/<F@-S#[ROY%\,[;=%&\V\RF'
M=')#K(>!][+:9W64@:N-UWN=<&K:2IV\ 56U( U1L96W/":VE\@Z[1\$SD G
M(Z6M4*=0SR!CHS=$VLD&D^G5/^(,\T_O1R' *[*B! ,$45,_1-FX+:34V<K]
M@90G"*GYJ2=[RF+\ME8$BGB[4P92><5$@JBH\EQ"?I'BF NQXO:;T!:6^2-K
M\LAZ:.Q!;.K!0/%7&=]M7'>@VS*VRD-JYL7:"O:XDGY,$C0C*72 ?BRVJI,J
MBNL^V?)G?GW!*9X/^?*F[8502B#0"$9SC647JZ!3)P;TE)=C9&F;[7<.'8A=
M;U49;_L>G^=(O^;2T*TIL ;#]H(;<V%O,JXG(!]5H%6H,@(CP>&_ SI5A<F<
MHIJ8D?X!5S)]-Q_DF0&K^.@MT?$G$VEGLU,9)A$5/9YP V8K^^:(Q/91;=79
M%J/LD0%W3SG#5EY!H$OA 4G7M(PTLM@/?D%JKZ?E5\6+[_0TFS^@G(=>VCS(
MS4[S+*PX9C^_!KK( \8M"%D.V\(#J/2IXT[V!G&P08NX^M,W$>3HC_/')3P2
M9GF6I@ 5!U:6/2]%W+^H@!PKL<>)-IK4UB$WKS.<!9QU+Y[[C,8NXM_^Y+YW
M'WWS@?I\5(1CVMS\I7JAYI8'FKC+=AJ+TG(3QGYB"Z4C'B>3&XY;W!LUAW/Z
MK<PV?<^?FB5KV"FV[$>=)A(0U[V;7UC+V6[IZ"+'@3W_S2?W&)DZE.D!:I_M
MB7E=.R]^'OV!ZB]?/E4PK6[^9$///X#Z@0(5VN[U;XT)*^4WFA.*/<K5YC<L
M*]BEO\-J<LMG!]$?UEWW&^=J6<6FYTGL,+TI_JE;P#2M^OK6PE%=4 JY2*'U
ME,W(TL;8H]@W<RMY/*VO<^.G>)/G.<F:AXU<-E7%G7G:-_JE&5@3)!J$E=*9
M&QL]ED<2%!&(-+<9(8X#.*+ILY5@>Q?ZUBV4J=[Y1Z)C[46*+LH$Q]<NE<21
MDGJDJ2;CVVSW.XT)^KCS9KDANV7*2E>I(>LK=2VOBW+G"5(NV6+*FY3>75KA
M&<_J*35J$F!!IF+]]\FAT#(?/EV)<?9_@*I:;G'TNGT1EVM^PX]$C,6"D.#=
M#RI[L5/ZX6+B?CG]KJG9BCX'%PL^D;5B:.[TQBD-!#QDJ:/V##Z>TZ*']?8I
ML>O6#(OX9S]Z1]X;O0'?VA+8:OQ!ML]T+=,+<[+56)!A)4AJA_HI\]/"G)2<
MXJ4H&#=M]DFM?69[16/[5:U[7)XVA]D!=6K7?%-KV,96L9JC @/F1ZZ79X\*
MGCCN<-IX H7()QP X=/8T,2^A7IM7BL]'V*I?P ?9][K3:"TK<\34N_F_L <
MU6 !N^[!#)I_ "*;-!ELYZ1%^G<1@7?TX00>HC@";%*T%^+DIDWI-IT.XH&J
M_+&O/L%>&3#A$GAZEX5G;IT^9)@/>3M]@*3E5EHZ6^MW;5F)@WRH8K\-D)A2
M%BIR?/D'0&J\3&5V^N;!Y9/[,I?@&8G0XX3LLS8HVT[94\NKPV=B?\2"&@LP
M1QR/_P .)@Y?HI7^ 0)=_P8_N[G">WB7NJ(:/W$MN!80 9^WF^M"?Y>D#>:2
MI:XU:Z--N<^_F&Q,!CVJ6== O>-<Y3,+=.K)9?*P2+1C6;;.YN6^8ZLT9KA=
MSR 'I,/T2;7:1?+JMKR#1+;B?]U3+HX,A&.D@7%CWZ5>@:MS-HMLI^-R!E1T
M/9JNK91%X\:O@TG*K/8$I1>D>-ZO>L)]PY\ZLE/5R,&T,/V&(J47"P)5@Z90
MC8;T&UP%].V5C$U=Q\S?%YI4E8+8X]M4=J_JM'0KVG1VTY8%:&2/&R5-JJ$E
MR6CN2N(V".ESU+-S[;^7ZZ&SKQ\"Q/X!BH=]\C]VWLK_0>ZP#V$6+7>X425/
M:4IOO9'=_&^7YOIZFW.+2M^/<O5F0\ G</:#1-(,J D7Z"W#%'(K*_.P*.3N
M#CVZ*7,]NP!4:\R_^4),L81;';:;<IU[L*GHVD!6?,);26:BCXRB?5&UW8%H
M[>C LF\8 K^@RK A$YKU4FCR%A'X*-)V/A^R.ZH0/JW3J1J?*ZO+8>QXL_G1
M#<UQ[RR4M,^X[N%K8%U_Y1V">3"00.Z7L&]+M%S"AK)4XV]D %0BVI[9<5R#
MN '%>S>U2N')VQHRK_7Y:7<!980<98&J##P7/L^,*!K-6$8(>:'._OR.'-U,
M(TU8^=^6TM;_^-8\IAHW;]J*!;&Q!=UPYLK8%K99$']M:+GL'OQ.IR,)<RZH
MINDM)0:P8_W/,M1GS NG>\=]"]&\&?6_CV_K8P:'BWJMWOSI4P"7:[MS,,H.
MF+4;9-P@IQ9.^7,895[Z-'9HG!5JD /C*E[%#E3)W#WW>,+M+S!7Z,-CM_'I
M9/6X?OG SU2:Z(2A44F/@RBN'4\4,KW1OBW/;;R8.!#'C] &DB42A%\ZW?P5
MI+6PJ4 UJTT "XV-@0@?H/@ML(1RL,O6;:XDE$0KR'>[7YQ*[I72 KUZ07K.
MM.;N>8^H[92;M%"+M(Z&O3C19"_Z(M.=-=%]+[!4DT70+6B^FHN.PYR(4)GA
M#AM(?N\C\N7W"G4P^3$;^")_Q[')<XF[I>4"/3J*,53L=]5M9S1J$WSJ$O:\
M#7LW-T)&BYK"=TT]V!9N+Z997[#!(L%]TP=?'ASOMNS2YT%UE=9ZU.753@/Q
MC"9PF&F7&'_\4&%J.:31Q %^3N@?K/A3=_ N+N_"@H-SLVRK]*-0#H7I+!@+
ME.DPZ=Q]P=!C4(-%Q>+QA+H"P*2A;7NR<%"WY]+,Q9/2/#7R[,5R*>*VOI8!
M6]K9;T";N+9_OO5-&7O),MS4L&$+14RD"?9KW@J:Q32\K)\*%E?U8_&N7D,)
M0R<NG?9NTB4'PLRRC=G&Y>U%G)7",G4T#5R9*U#:V*5)_#"K&PK3?X#&H!;H
M6^OFUUC(59&7'/1I/U_:KT@\J+0E1EKT_@,HC1E;G@?BRC>,&ME$97M9(9IZ
ML;+YBZTZJ^V*E(&/&U:[2-Y=$Y$CU^-W@@RCW19'CP_R1_)1!K$@(R^:!TG,
M]^_OG71YR(->3+54E\J)C!B&.*\+&6,-*D\(LGG><>^D3A;R/MA7K7LP\@P>
M%OL>(R=E89-OO]3TS[6%9B$\ZPO'06B#;G9_9%7W\IQB(U[^>^8&,#H8$I'\
MQ4,(Y;97]90HW>< <HB'%>SJ<<<41UP0F!3*[$2:($8.(V%]EFK_(7K4''X9
MVFQ15-%1Q#!< RI+Z=0>[?'7M)4KN*%<!C9"J#B60OHU55X-UA,Z*P(NC^U3
M/Q92XMGZB&:ZUJQWM%MZ2^6$-"OOFZ6&';!]',XO)]U\:]H&H14M:B+.X\[<
MPAS94F=L8.LK><"GKF-H9=(*74\_4EAUYS2(T YHF+GT1F,!R@2F$=+0!:^0
M8_\<0Y8].)HGG^& ,!QZMN,__NM*\>/J@:D\9:N0WUIUJ^37*4E: 6;QJ!K.
M.N9;=S@UO"/P5@/)80Y\]=]]'1F*HANW/&Q1N8WO?_RL9]WM^*UO?(YM#J/E
M7,;*IR?+&J5GFB@N<C/]^](%&%7?>P7X49#G8OK^ 7C-OX;6&I3)I7O^UJP\
M[Z'+6,#3Q=-LR@LLZ#&6_\Q/T<&=1TFM"=64U$$E'!=[M1N1!XB"ZS RJNN$
MN9VFV>^LRZISJQ=-(8N!Q=ZQS#5RL238 *[[T)1GAKO_ /<Q=W(I_P!^LPX#
MA,VPS_)I4$A:VA'#C,M/-XY$WH_N06/-H][ 4H">NKP>S62!9](._?DJ3QC!
MNC'KF/KVMSFB2HB#@6UC&_^ZZ$3U:N,K]03%A#08QD[?Q;LI8HP=J$PPQ4)&
M1XTR:3N.06\?6 C;[O:^U9=_AQK9R)D5_ 4WYYV(C&A@9/]K(2(^[N:^O-3H
M"KC\7?VU%QAMB\HI=CT=5ZNV#!JX7S!HGR3OKI>3MZG/T]&DRE7[-'7S"2X&
M\J:.J.C-=4Q.MF(B=&3>!V-DSFU(QE]@$JVT QQ91Q6BE^=<O>Y:TO4N+J49
M3F?-HFY8IE?\EF*VXNK+5 4BBP^UB[RT(C9)/*B+JS2FNKENE20Y4;Y4WR.4
M]P7YOZ#;LQKU5X\/.5D'07\I@2Z1?'HYTI<TNKZYWI.0J!5Y/[:52]&5)ZXD
M4@*#QH#+J%D?@[2[3[K:/UQGZNBGXZ(3J0)\L5A<.V"K>9PWX(C\3SL-,-/T
MF%&3GK!?Z$P7MZKLTJR,4$&+ M/&3BO=BJ(B)6A:)C:</#8XN.1W0/'K1).-
M3H<W5.F"DANVN$.UR\Y(B&EFPIL1<7LC>]/36+/"YG5QWU#2?C-ZE0%B; 4<
MXX-KGBOZ[P29W!CW,.#^V@_NS,\)[>[X=+X!(6E>CG&0B5UT,>5\QAR,04K'
ME"/%Z0!3<Q=89YN8S;3"W>EN?<GV8MN;5-HM8RY,7VAL3#+9\II<B !?B[]S
M2QV+"]>F)>25Y#(T).VG;/#>7I%H #W>F_]D7FY5=>V$!H$A>\$\Z+STA)WU
MVZ^QA"\,PLZ_^5W:'_X#N'M=SH:+POX!.B1_N@\4]+U<+X[NL)O>>G<^J[3>
M<GCI<.=>?KX*^RGZ(&$<YM,77?"WJ&Y :FMH^G%F<;L8W!;U9M+<8\%W?2\'
MIL'!0M'8GKHIQ&.H^:2W38^3E6VLOLB3)"B?355/2RPG,9J%1KDZ>K*@&1S,
M?!*7DHRG9<2 5J]VCC9ECTV.MUMU-UZZ>_:X,M R\[KA_.7?YG"[HF=F:_\
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ML&>_%1]K28.Y19RH5$NE&_PZ6-[/18Y\W,,L34-]E\8J"-D]+1Z;IH-FBY/
ME@CG?P"^_S9P0BNX+--SX:"EL:VQ )H-?-5([LK@:'6N# ?X$S6@(:N/5[E2
MJ$?=B-8$N%4O2%!Z2CXUL+KBU")]I ^U^H@B)8B >E_"'X^*A#*^X*NS56PX
M8JA89B!6O[<A1FK&W*"-A["QL]I:B<-5C&LK9B!-AMSZS#'O*PU F\ZJ&1?A
M, /F/5F@HL16*\L4#++>]*Q;U@5+/8/5J6]D.&F\7\BGL15#?GP;JT.O0):<
M^6JZ*:BRHT[RU7AV(S:D(?@*(OBC3S [+JPD/_+-YZ;*]C(GD%-Z+OU$MGHB
MG:B )E$E1O3O.K\$7R9F25"1H3$$9;5EP*8WEETV>C]=FE,PR4MCOD@S+OT&
MOA.#A->TH;B@[Y^*WMR 6#)5XPE,)_P9CF;]9#??B=G4ADPW;'!8/X@2L'Y;
ME.QU'DHCI6U^HOQZMP:6VE'MT"138ZB>?UM,QRN#"='VQLCAJ9[56D\8MTWP
M>00*1FG$'W,//,JY5V8%\XNU,JIT8,MR-/'B" ;#\Z0SRGHI^RXD?7G#M6NL
M8EB0V).CK/I1"2,XA]B0OHC2GZM$AW=1\6U:W9FE[)@FW&*)&(<G):/5+C\(
MG*]0]/^6+90B+A4S_@'N[HCJO@CTZNWT;8S^ V!]<N_69S9*<)=SS]QIBO:.
M)&3.DN8=TP^&'?H7EN'AQIB9BN5 O;;0B-N4L,Q5$!VO#F5ESU]A3\$20_#&
MGJ%;%>E31(64EG&MMFYII1/=5TQH=,*4:!S$$S^Y@UDUAVWP]O%P:[6%RR:-
MZY0IRSHO%S.7"E.$EL+Z9M9I,QUCFUZ(H;L^7K$X9U,J6:GE@YZ*A2W>N($.
MM6BL]3/';;&FSTJ!P<+]A:9!U_/_+2%<\O[-G^\Y=&M3S-?]/Y)6+6=S"J!>
M%2#5K#S"L7QC=P)^TMB>,HZ]WU5Q7$ VP'GR,'95@FF</K+U1.'7S52I]$&W
M?@34K_+!BL$I[J$Z>M5,46V5+UFP[RB81%NP0MU"&QS(J[]1[7SF24L77O)C
M02+TUS4[[TQ/DUM^R/'>85H*[ZR<^).VV=(&__+<$%/_^':GV8XQV8FMYFDQ
M. .3W)U5V@\1(7N_U,*_7QO:$-';NYTJP23707)#P/YJ.J&M,H8MN!=AKA3N
M;!VSU5D0H5D^&>_;]527" U8PH2";9O9:QAM6K- !G7*"9^ETH1#F>Q/>L!@
ML^>SC'=)1.W@H!\PVAL2C,[[[R=C-/ //H/AZ<7K%XT60I/,:6UU]818L)2[
M/#G\D3/1.FC P:,^SSC*0G?5518DQ^-?(GWL<4%S(?&:;\U@> 10IL, 73@O
M^XKOSFVN1FV:QT!6$IS?._],9B1@V;UA^RDN6@E/4H#HAG.HP4AA;9V!-IAE
M5&>7PI:_EX$V4-\MG?__EBSE[_4^_<5S-X' &/ '><!]EC4V<RL-DH;Y O,6
M\U,,84T67X134":[7^MRJI1$^%WY*RBUF"O=QU@L5)74N-O2W=GR4'Z4V1Y"
M3-J@P#)?4=>]?D)&0\FKO%E<]C09 R'A2'"V Y=BJ6U@C9D'G@!9Q5/K,S$+
M1>Z 3B9, S7DB('27;[($)@*1VJZ"LYL^,I9NTS4 ?YOX3+LT+(@G,"[?F84
M*I+K1TGZ+J4L(3HASRI7JZA6R%XJ>@U.YT7RC%XN)CG>[+NIFS_1L."D>OD;
MK9&I"4;AH95(%J#P&Y.1Q_;,LV7C,I&F!7$I#Q-W1X96-&39ZHC"=M8$GKB*
M4( ]B96UI1:CP'*#[)\&!TH\*>N7T5LABPD9Y\:M("<PP2:^]M\QI#_[AKOM
MGR%6H9"RQG1)18&%E):FM$3*$FC_CU.E_0WS6AV9P1"6T:Z0%F%8]@*[A%+N
M%@+6*_F0S[^XB38QHA5D+T&6*8C,+@8]JPL4=YFH\KF!,FNRREJQ%-4/=4A.
MN-*L,<B\*&F^Z]M[FJZ6-B>@TOH/L"I,:%1_WWCZ3>#^MA,2.=R@@GCQ#S Q
M\)*)X+*DY/C;(=D_@$3/S]W?CMC(1N-5U@BH7N=UNE\T08$9^P^X3@%FN99P
M(<9A=#8G:;.CFOK[*4*TE2*FSQT_7.Q -)E![:(^T>X'*KIL;-3-57+9M$V)
M3C\(:RV\S:$[$N+0GV1,CR?>FA3N,C]2%6H+#8,<R6'R^3SKY8A,N<4DZRX>
M4$OOP"-#UR_4^/4F@,'/'S:83,\)=1?[PR\>VEF(LTPA-#MC)JSDYZSR^8*V
M6BT"(W%M)0K':S7K&UYQOLIAVU\(-;,,+-JO_D,S8T5OWJI@PL*:WO55AK3N
MXVLWK-_9[LG]B$#S*C,K)O/MJ#ILCECSN-21(H/9D\A^"OQ"?EP99#-H2^R6
MFAWN,YDVW]QC4\F(J0">T\*?63<Q7"5;.!4GZPC4!*2D*/BUTC4Z;RG;7@[S
M;"D=3FY\LU\]_>.Z_^<E9/'Q/T#4AKLS5W&(OJ">T5^'!7M31JQ\GB2)%WE]
MJ<1XM@R_E=V6=/VW='N0&]; >(SWLVPW>.F9Y97 L0B]5G3CJ-1+.N8*[+(G
M[XZ*!@XGK$9F]1\W\5Y",O1IO'-Z]]/]+WK7H;/G#@66,6/^];^JU2?8TOHL
M4^&!8FAZ',DC_L=+"-I1Z$[D JLO^A$"'5ZMU2BR(/6I.:PK!-%=TFOU9M-C
MNYR+M76O\*1&.YB3OW5DE-^U1H>I?>&S1%^'L-,KOSK:5B8)5^HWFQ^)_DX2
M0R=EV<H$2[-^\XBM%BIJOU,LVY5DD@X@8Y>BUT]<KD([47_>_+C!\ZX#?WSR
M!OS6U3&S%TK?@YV\K9V43F?SR_6@:?_UQSH@79NUIR6>Z.MNBFM6VA-BP:3+
MK^;<YP6.EJA/$<ITFX=O33^N& 36+3;T_!%RWU8+LHW,V/7II.$A)NG]K4Q,
M\48<ISM4))IM:ED*6Y56V7"H[]SLF(D0/.[V>XNX5U6K:'V>5[2"P# \6&VS
M#:#+*$9 &G*L&!S05FQ!2S1T=E(>.T.Y@@[EJ!#]7O?NG$:K!6BB1='@+8*W
M7A\IN6\PC-5.)E &!^>1\W]?NRJCDG0XL[Y_RD$A\L(]4+?G<YFOQU\7<8I?
M5CR[NZS&X+).1W,F#8$<VFW>^N_A*<&Q0V69]:"R4-@'6]\?J#PUX]>9I[ZR
M*&@5/;FGC9&R,_UP+>:#@;AT_GQ P=]+.'4,/^53V!O#CY]-/AVSD"G!YI4O
M*I/XE=K$B&87P:L0=3>H06%_LE5%SW8?AO(+7NA4\!N'UL(Q5GKF^X;$CK_0
MO9-"*[1[\&OZ!/'S@W6H\M]B?7FMSA91TN\?A/H'3/9VSX[-+CE_E,KXQWQ_
M:0YNV 3RC7[44SY5BMZ.8X]4[[2\=-J#FWSQLSBGZ/D'D-NS_P?0SYVR5M ^
M.UDPKE2TAVU7#O4&KM39QT(CI-JCHHB06Z\39AA\/JM#_)R%+([Y37N?9)S0
M&_X#F(+Z;HFB!,RK3A,]<H?D68CF0X5.&>9A"GZN"CK2H\CRK'X4OB$)$\B^
M86_*"'JV^$3C3>W"6K*VZ=@E["2"X'/P$_B3WBU66J"JIO-F2L<6? <=)^N"
M*- A7#:"/.J8*W&1;QX=6OHRNTM27U"MW,,ZM,\8_TI7=H(?C7YQ=,JHU+;6
M3P_N?R_L%/S$SZUA/6XWG.;[F&)%T+:$ \LPF2Q+#H;<6,0_CE0$N&_J"1,G
MPUMXVU2/>6"65!PB^CA9H-Q\RB;QG6'?2;?X'SFO6K_19X4>*ZSN@Z;[\]J]
M%J4$8Y16C_6D3FO A,!\Y_\D/'TH>[&\I>58MZ<L0VYOG_BY4FG?,MN6WP+V
M15;(LOA-XPBD@@N[1;T57FV/0;\7RI?YF?%6FB*"I]+^@_M#^VTO!N.C'DB'
ME&%'LW)87))B5O0-"^JA^)MY?-%@>A4 :\0C*5!*IYLQG^!RV"R=X(1R\4%8
MQ#RM2]B!(GS['BQU9L'^!)FQZ.3*C&?!K'HAP<\NHEHZ=IYSZN_G_U.A1"C(
M=.CEC\/D%@W31!-X=-?1F5!/U -#?. C'-NL[]0*Y)K\6:;32HOM&:5YR!E+
MJXF5;7F:AR@U[*^AH<%=GFV'S[8L4\BQVX)QC2*&P +SJV:5*7P\O"[!TZ>@
MSK7!Z_;Y:"92O<T-EA;N7Z@Q)* 3PF3"M]F$6+!*,$\2?#49L-3P*C^H\P27
MP=F=,7$M''K0ZM'N>LODJQJPH'I.0"KX&U)WO7 1H%]LMJ"A5=97#@ B/JH>
MN/S,"0 ;1^DW<Z4A[O)W1VDL48-=@<=$8EO&-IYO)%+2-<)G<[23'5SH,746
M@-1T@%@S<QH/2*I::*\VW=;N8O3]A^?HOBCVENXLCXU!FZR\5(=%)H!0 P)"
M5Q6X+0'XI5;1L3^0[PFO,3^6F!-E1&OO9:8Q/:0<*=5[S('N"TXU9".SH*X!
M:155<1N[ B@>*SA'&46]D?DPAA: MLC[W,;TFJ /03 *CG%#.4\^-CX&T<&P
MII(> UGSP-0)EW.J8]Q_G5E3T0$Z!QT;@;^"U_NJ<X1>#) JL-'[%J6F7'=K
M4PQ%<5YHS[2$G<FUO23MPD>]KX"RMV;D@3A)1663$TP-Z]W58\_)\OZ$[GD"
M-5.^9U;DTGSFCE']OO'!Z7B8:=J>ZR)WQ;=N?5///T]XIDP6EIK2'DZQPL6>
MS!6;XH2'AT=!2UD[0W@\XN._V:&C//!"2[#';[UBBZ-/[.G^R?9[C7JZ8WZ!
M_67Q)7BQ:T<JK\5CFJP(Q(3OB+)/B<"\+!]W4*E]FB9!"^-"]MHLL'S6A' 0
M.^C2 XSIP<,SV3$0F]%SD'PW-J/5K<T^GM&V),"+7DQ/P/;54^?  Y?7:>W?
M+&L^"Q#4H"UZ@.1N%J ]@'G-_\%[_CEK-S;ELUE(.&E=#CS"ZMNC9L]CG#"2
M-WQ1R4(7($DO! <1KY:VONARLPM)[@QVZIF=,#/ )U2<36.<TA?_H)'N/4+;
M[1/#O]X719)-HHX?URM/L'6?V-](P&T#>3:Y4?TVDA(\3&RV=NV/(1NF9@_=
MHY:G9XL;W5JSC"&-,<L+KAZ>2EO(FN^\FHU0@S2<IZ0P$; OHH6^Y_\*/-H]
M-L,0O!3Z^:XUHT5.$K.FN[EO\EM.R4(H[Z?YBE\I(YV),<:$$MVM9:99OV#'
M;#00-J:H1OJ@$KODJ'. ?X&[QC V8/)9)/>7-='S:,F%Q>"&/:7W^4^;=,0&
M\UO?6:<CB0,#Y([S:&FD"I2.,[[*^7#T<1VH^!=4*/(YEKH)4"SK)^19)C5-
MY.S?H.BB@C1)\C[RT5!$*!1*Y^J^/GHX]B.9GESW,JJRQT0[SQ)3^_Q/E)J9
M$)B&YSUB(4<"+Z7"V")%=0"7=MX.W*QZ@BXA' O3C-2G%IH-L>FRU0C]3>YJ
MRI7?;X4G-[.XIIVB": 7OO6E7U/)GY#I#G@+:>"P)%5<;GJCIY(*:P9#>3RX
M.8-X]AG-0H?=#=GN/@*<!!,=@XO\DB_BA8PSL^"-2I>&&98G*[29YL]O*0DY
MVVT#KC*QK10#._#2_GXR+GPN)2TN+'N:^SCCDKFTCAMZ3D/&K8A%>T7%_H=1
MU=:P#9(22RLL^J4;M@8V3J;_.0$BEKG/F,X8Q'E?68NZN?A<6)T%?(:F#7-Y
MBM:89:#!? <L310?:PSFEXTM)2?;0W4 &PWN9WJNET9 2W"V8[?S20K+UR:(
M+:<NOOJVI4<:(CYB <A7RM,:AHE5*!E=@^4-GHK\4(QYB;K^/]%W-$)>)<)(
MLU^7E76.X.)IDG/?K,P4<&>F;^%#YFX-U!_:2_RB/R'ON]_G-2#^)K_3YMG[
M)WU='KLR[LC%U\_3UL9]N-J+ZE.\"V#FEJU&XLM\Y.NGGB1D]=1W)?N"\?=O
M2YHM;HDNN);["3W<X:,H?U=HF3NKCK:V=D=F0FR*7WNUE4DEX\PFC4Z> C5Y
M<,I)=W"#ZLF4F&XDYYQCSM'TY^OH_0?Q$3:%VY0:_5V4OWEN4NN''/A EN$A
M^Y+:ZE!7O]O"^X%JO75F.\30_=/=DP]$P\Q#$,GT9)M%(=EU=P5RCVVZ!/?I
MV)[^,:ZB*MIC\I*X;SG/?Y^D!_?$&^EUPG,TSHRN@)4]DS;07[=>+$4XB%_.
M )._M3&:MSC&7)'$J5'F@(U+UTV-I_1)L&VDGS_\9%'RB0N"]N4RRV\PL%NN
MRO4SK2>X.)-RZ:2J.*ZH#D%N 3MG*8F48S?C[!_5KKVW<^'K]C*K8&I2BKV,
M'26TT[]P+BWCS'O<YQW>/>BD@!=OPKO[N3\CVPG+Y.?&K @M63'=+$65'U=V
M'9J$S5*;E[NP)PG!_Y_[;![II%C5/R$KR98%'ABQ@"44G#I9T='.N/5U=CG5
M2HBJ:.'ON">0"="1&K7^X#0]T.,V5#?DS8TP_!/QO.&%8[X?W-.XT=VI=<L!
M C1 QM1<IHK#4U$5AL&QF9K,'X)"_P'"[?,O(BZ2]P\+U'Z7J'==C^<XO-C_
M!W@K:R=O??TJ;^[#+5/LZ-Y?RU=!3^:@3RNF":ZMZ_45'5TCK>RG@]?J^3_0
M*W!0Y@SIM#5\YA[W3YL/?,W2-R9^Z2DTU>VM3>QT1_EEQV\X>!P/>(Q>UR]*
M/NY'3S]Q0Y+)ALN;(31-ZV6.:;L?#.H9%Z@!QO6>D>J0>#+X?I"6-ZU\/K]'
M/'T\'[+E$L$HA;]:TY83E7XJ2WQIPE[SJ9Y#=MD\+@Y>W9[4-VH);AA-]GNO
MMQ_YROY6V>7$YT\\>J"\&;-<_0_P-<W8:HON?2&AW#'55*=U\N@7_I-$[JG_
M>B1\,.N:49BHZPWMMJZ(K^BDQ%-YG,]VMO5)WX\08Q&QC.(:AY7S'('.S7:O
ME,S6 B^4G\I7F=Y!.U99Q9B421[F:UDWYS)V_?+LTGVOAAEGP.<'A7(S\2VA
MB:J?R*VNT6.R-O -6.:LQZ12WNBMJ:[L@#"5G'#%[Q/$BUR#UG4F[RR5W.T_
M<2G)+1OU^@<>ATO&Q1TN@V5C_(A<\&N7$?L0.= "BU1K0,YKCV5Y(()6QX7?
M2C]'G5W&0HCU_1P+_#CG(>?YWJ\>!(*V"SW\[F5[8EE_0ITV#QLX,;!%4<KN
M'(IT"K#ZA/? PCA!:,)9",[E4H3DDS0&;1 ))@WBX5$!3AZ1N9>>^_?NZ8.<
MW'R;/\5Z-=0C,W/FDSKG=(9;VAP2XPN.&U*F!UX-.TBA'.#T-61A.M4&UV*8
M>._F;1]+#DI5/93?,M0CMT7JQ5/1^7O+O['"@WS/Q<VA??TE*'X82=X+]Y?)
M$E3+CN_^=WS]_X&5%+*&%%_^25^*K&75*;,=^9,NTU:>!01[^.XBLRS)^!'J
M))XF^;0!25\' 0O?%Z)G9SL]]O7=&9M DK)*-DA$=]K'-W6?G Y98U[?Q KP
M$A#'A"55BUF+T)]WS2L<S7DT%'A'D!X?A]<(Z7O"<FF;./3UE21) ,+"%;-<
M +9H5G?@5@9]X."F9QW_GW@6B+#HLHMX-N<H1BZ"A??3N#&>[E<:,&%J!YQZ
MA$9PR+5TNXAC4S!_G?&R%:R_D:2*'.*]+=&2=$+7*/RN!1L:9S=2NLB:?!(M
M<=@CT^$JT@Z)JB&?+"CU=7;@M5,+=HQ^X"XUW[>#(Y(CL?;NBV_5X]V1QVQ?
M>9+@W2OWA^Z'><^%I9GH[Z:607AXA/-L[\N[03I9IQ/1+YZB]>;B1(3>JT>6
MQ AAM(@3$FAWHT7;)KN:#&?(_QP/KNX(VW* )4L[Y=Q<ZHHK^828/TUODLHG
MRF[1:!%AR;DS>F6K&K8%2P-T69AXNC.I-4J,V-.5YG^PELNHT^I\,%_:AT2'
M_#1^LU_IL+W(ZW0W,C&PL\'3[>J\\6Z4N<$>Z<0D_1@S>7V#F3;KX>.U?ZJ;
MIN/RK:;N?>2;3TH\?RWV3\_>CN0D^7(CQ$/M_D)ABSXXMR';H.NP/-I1O9!(
M5"7=(V6W;"]7=@S_-GQ'G7Z![HHP17()Q"VXMDCIJF0"D2B55'YN^U5C/+MA
M^MAM49MCHM?D \-4/#TE=G"V_J;T@"9FW[+(E_5H=R"1NW<J$15J2=,(O)(6
M/9>]./[< P#4[9,N6Y'LX?48>_Y<6..+#I9?>?0/P+SV#_!3:)J_5_8?@*QT
MX.41ZE%0VDM,D\89:B$88BI*[6[\EDY<(DRXU3_=[ D#-+%=ELX(9!%7*?>D
M( "42B&R/-7)0Y"WT^=;ZS,1C;W2<3_0'DG/LA/OR*GG(\I_(T3R8Z_:LFE6
MP^PI>PZO35YC@G^] C>=4:CV+R<"CSN>6\S$);2&^NOV,'8KWS4WMQ@1&YTH
M"&/@S;XAK78T?8+\XH7,$1P="#SZ!'/:KG2GU<\D\8<H@G!IM>N]V .O^65[
M_X=VP("#UA\,;>;+2=W ZO?X95V#@J[C*]D2>!I8QLB*6#FGW-<=#SGL..2C
MO,M'/BZ<-;.JJ,3KA9%U&?8,3O?Y_%$7?EW2#!S5RG8%L%BD,$?S_&0V.NO>
M?[/RDWF_868_>4S<*CUZE^RE0N&Z-8632$M8@<$;G[<TQ _9&[;V2Z&1D[JU
M.D0HIJ %2E;H^<#VE9GDM(NWKD%SH:WA(DT"'T:"!5%U9[A4YF/[PZIRV<,1
M#NH.J8J5&6D"Z+/YOW5[IL3"\M7?R[%=CP2'^+D@%48T[FS$GF;MY;V>6&:D
M;Q7P_ \!@O'UEG(0A2B"&=FZ0",4^B8B1KF*NL7JV,RU];=(X.O%-H>ZD49S
M-@)W>+FR!IM,9;BX/J'<F+YH$,4"F[L=ESWHN5_MC,K>V9_05X(/.6V^KVC2
MO%?VP4UEB20+*=5VZ[KI:'[+WUJ,V7!:<[Y[\U_;RG^3'0I>1.@&D5-!AM)N
M]=)8TAZ@Y\0I)3J^&FM"K.H[CV?=X'9LA'!WAN\TO.H$(8G+XRS[)'(06YV;
M;FF+SH_Z56#$E/J<A*.<0<Z(!.4W!G1\0*D<A_29I#8Y@'OVU;I\3@W'>V?]
MKC68+E,P$&Q:6;6;G^8O@23&UN@>/VU=JJ*()<(9/*"3]O0AQC%1R_]8^-#:
M^6B&W??!?<8>5:S$JWFY SWZC_7<"(DEJ:-U+'+SPNW;KWI"QI<7_6''69@/
M+2![T?8#[RP-/?*"YZD:[GU C9]7-B-MW6BM,U>CG ($VKS46$76@M8V:*@)
MY[:N&5<^\OJS0F!%HC-7'0AL,@\PO_MRR5P"UHST:/:,B4XHY4AZQW_)&L"I
MT]J]^3X][S6T?T5\7CX!Q0LK4J,^&8X<F)O<"&"<],PM4*:?RAW(+<Q_V5H8
M<K%Q^+WH4+$+3QV0((AG2"@((/[,($WBZF$H).3ZG%+ DW);!UD?2F2(E!-)
MOTR@S2;I\4 E'1N[(!8[:7P*+D^KM,Q;NN0R3S !JC'^Q/2(7R[GE]52F>[\
M. 8#F=Q@6:>"P/Y#5*PA65]@14PY08L:1F7?[?C'[V!3>Z^?^JB*,G9"!47;
M$8CR1PKS#)_6=.03*3F?H,%TA(8J$%.J35D??COX!U[W]\=1)*Y9$EOGECKS
MDM9:N1?U0RSCJ;N2M,JW7!RO9/%7$EXZL\ZPBL^KC.:;]>^E&K4M>?;$X5OM
MGKV5L@=H0NU*9N$Y5-ABK^^CH5B7^7;1W$6&4_2R]E%V?GHRGH,K"],875FX
MCA;5/T"ZWZN[O ,Z^^)_@$131[40,(7=*?4_@/.JO-P:'(=\222^S'HE]2"T
M6 D(WHIB>_!<%L=IT"*%\-MJLL#V!KZE4-\VQ[8,_P/$K"I\N=E:O2\]%1CS
M5&N_DH69+Z0R6;]RR)]Z^!GBG\4^IUS\C.<1&1.Y6.J"\/4^<A[T$O^U2=]9
MR:BQO#;N0)*=#[YYV.+T6]9^;"/5UC_'H2,[!=ZL2/HPCF9RUD"!#\9"LF0=
MV(;NRMB5T=X/:)NL.[[[:;(NZ;;M^<RQ'RHWPRKCAR@(/%Y,3->VZPY(?7"H
M.$*F&9.2 O!9G*X1T %_]R#*9^,IR;5(73> 2+Y4,V.PY"UY(N4C:[,N=9/S
M#,KE;!"4H#2._ZW+$C)PF+W5_8(?;CBT9\O"6;/BRNO&Y%^@(N8B[0T&,[I+
MN1P8K/%7V.@!44.6154&1H\WL+-8^C;/^^_]O?<L=.)K%IKYVJ49)#\>-P!7
ME-Z9K>97/V2">G&N*+6I6]58UO(+OFA4$X2\^K)B<)?.<S.P8RMT.6-&R6WP
M5'Z^TG3GAB0LQ%HJ?5]4SV^;H?26YXE6]LG/QW8U.]^;V'YT+D@',T]V]TZX
M^YXQ5.CGO6U.Y<2>P4]NUB\FBM#$*_/FCR\BY^85I]DUU_JXNQ]H/"/Q;__3
M('=OYS6BTK,T>SXF8+JVK?\SW+5CC!ON19/E09_%LL2FH:#R8R1>^C%K>DH(
M;Z%-+;5X+\N=D%";2 '^J*]GZ6VBK>1P%D2\9I(%69Z;SWJFTY'.KY34JJ9#
M.$+67L^,_6SV/$DF6MM.MS7P4^N,JVM1%S=;6V9ZIE\)Q)^MAHU. ZU;EY<@
MZ(>?5?XH1C;KUOE.%L;^ZK%*Y^ZNBNGQ-)G'47M[EO[[4#(FZ4V6ENR68=J-
M:X:'D.18(IBXI;Z#RO,</OMITMR(IW?@-C,9ZY07JZ];.2,A8RN4F'7$O"*W
MTWNYM@*WJMXH03#$1.N)[/,J;D.^2*VO\,#[P2MI"K.RV9./5B=[F4%7/^=E
MV<+"6K0%S[<]FOYZ1R @G8*)-N^?8Q?B<##=5JM]H64I[V*!8M$/-PD.M]QC
MW3>G9MC?E%3)7=9?U!IZP1+IA;:-^A/,G:<^;OV6=1V6D_T/MM C9#JCJIGM
MX62N+*JNP5%-T;?B']89T*PSWB:["-+B\]@IW%I&$N82LFH]@=8 HF\H'IF:
M:4YPK8=H6 AFKV@535>\/K!;J[NEHMXS*M,-K6.O,USU0Q!P&(VH"OODI7&Y
MKRMS(63)P+1R"^S5$B2$UH4O(<^R[8LO<7K]6Y_WQ;W?:C:Z3D1P#KJWOW%8
M-J+1YI CTBG32%U@FNIZP>Q>YJ^^D!J#^A3T08I"\<?$_=%._6:'K"Z.JNCS
M=HT-HPW48*JK8>WX)WK,W+:3V"?#[9;>8^> M9\GCPXXP$=8+@0Y)!U!@:.-
ME!/7#VZ3+]$UY4NGW)!+Y,<%J!O<:NF5#5"<31&?.'$X.*]<E<)M\7(2P7G)
M,:FJTE)I;W%NJW,))=()Q<07-*1Y-"NF=-I*&6"717/7UB;K2&QJ NR0_8F,
MH/[DW-)/SM\Z++[-%JB,F]"VXU"4@?".F??^-F[(06G>C<X7']S=.98J]CYF
M\FYISVD:RJM;0:4"N$+C.LM.):L:H'83[VIPPH^,F0ZK]@6M6!5R,C2PN?K?
M*MQ=JU@G=9OX"#AR1R;J&(9\^4W=(W0_KJHTOU4LG&.QZ&1)/._5/7R<5>1D
MR^%O7,X"6WS$G55=XW)JP+]L>\N6%A?J:L'?MR7=*Q*2/]%TM;KQS"/!.7IT
MH5'X!A/F.ATQO?:%IX1GSTC)E"(%9A6F7,DQ4&8A!1.LS0C3E#"8'*01(I2J
MC\2)O56%%G\H=2JSWWMS5;HF?HKS[CAESA?*5P+13HN*X7C+(O"U2*E\;.@\
M-/.TCV-X&I)=9M6\7CX[M!#'V:<FQC6ZASQ.::E2R\R%7M5/9'<?G#5L.1K(
MF[/5#P9\NDND0#$_J7OQIK>-G,$E,\HYO2[WM!R(J&I@C&+X4+CNMHKMM&%\
MMO\"22-)$)L@KR)@#$@6^.^$OGY;C=-LZLAPT?$6X;0?H3;IR40UY>U-3#D*
M@E( '#/0R8\G'U+5D54N<<*=W(BB2:F_[4Y!JFQU'WKLS\A2@#-U#(R2Z;2T
M:>N]QSHCZ<Y<>[EREU]+V5,+O>CE\Q1)7-5UA5>6"_R/I:+RI=0[L4(2?_I<
M/*XW+B#<#GH+.V"PND_VC3#.D@/SD5C1PNB^^J9_Q9W:;6"_LUE^H_)+?#:3
M?WGA 5B1VRT^=+,&:\7TS/\U$Y%@G('PME0R=2WW<.FC-=3K;Z;)3?8?3 ZI
MOC3I+CW:6)\4,$3/@L_G5[:^4-C[N5(X;B&K710=!HS<8MLW0K<%B)T#O0*Q
M=>CV7AL4\O;B$^Y*:M%T%HCCF.67;3Q@?ZXS6[GU(IOZX_IUA. N_MX")\0]
MYH\XQ\^$)D0I69!(E0/P-?\'K&7AZVT&+<CO$;6UT)F9+F"OU]O8M$[=@>E8
M#H_,E/QPSK%!3HH(O1P_\AH[>9&\G@![@6%S>2L%/XE_@!W96?D_W?\Q! )*
MDQ>(N;/[&?L\&:3.\I=5=]C0S_P2-V+IV8.2B?&AQ.&'+B'P=Q&"'59/8RH7
M _KY+RPIYE5+_Q0^]7!);K&N60VGF59] 8_$=4+/_9'[KCZI[AY.8,O,X0M
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M#49=2I(\K.:PDWS3^8K]+.4\[K2P;#;48*A^A;$&GE\0 =%1RBN3_SJ,FO<
M-"B^VY+DEW4L1>LW,:.YNQ4K7G=!'^J2DJEC#5:LQ?R"Y*3I: H'<UB3EXI7
M%"QDW4XQK*'2,T^1.IOSSU;IA:Y*X"%*.8=,"^4./0X/$DWA[KF1V6J+0$17
MGEI#P=EZ-W2QVXAW'0V9Y BGM!>'5<6''?%:"K=-"3L)D9C3,0\!\+I!<GX(
M^M/":..=HU['L)_,;=;K7?@N12-HU\[9!6?I'GUURW"QY1E"Z;BZM+)2:<:T
MA!.==.DAN2=(G$1(U3=YS_,)/M'$-]%LW=(9P\QC!I4AFWJ=="4QVUR27?\
M>1O&)G7/BXF50YX?%=5BZA[HA$,YJ]F>>GR$F.,,%BXC_@'HD:D@/*%%D9$P
M^J$'N\'Q=PR@/\>?KJ<*CP>P=]<3&R5H*-+U\#3,)E7P(3E]O_;3D1F-Z39;
M)5M^D[0<P>VSZ%QB86";(?T(2+JH!@^/>O$(I=Q[*VYQ5;IC=U&9;QV"39"-
MZS)PR7UD1^[.H!-E0IA8C04^>GP;WC*W+$DI?!U+.MG\RPJW]U/'_"ZM>_T?
M8(HC>U1.7,X@4E[JMIK@B<[)5U.7MC873.H>;9#H&#X[ ^A=_HE0VNI)34<P
MC,!%W//(Y=XSJ7>@S?Y B>>LL;#4E5TXX:MQ6Z>)]N!.2/I]R41QNG>!5<N%
M'1G$9(E.D#BL/7]E3 'V+D.Q+JX%Y_M'CWT5=TZO8I4(4PT[51GJI=P->LZ^
M[E2D*=IF(124%S"Y4,65&BOMMW[VY_\XGV41?OU=@X9QZ:S'>(;-D*(-.Q#V
M$W3 #E$OL-BU7.Z?-AY8N5&"1*;;52I9/:BAU[<49,Y%]%G)Y,.(A08GWI.=
M]1TKO\*3=6PU7FR4@+_7X#^:J*;S;AH(R$56I2CI2*&'S5X%]IF=:X_;[-KQ
MPU9S/;>-W=Q.)Y@GANJ#F@4<,3)342.V?9?N^R,QG)%DH"$WE_;%JMC9X/(^
M3]V54^GM"D^P\R)5!N_W]^:0L^VQO]_ HG\Y.\4RR?\!PC>?"3B!FN;^R'TA
M:OTB1W'AW\]^Z3HUG<$B9]FUA,?KN'3QHMCPF,U$Y&#HN<'47]W^@:>-=KH*
M@3;ZW?ADBE9V<LJY6%9A>.\4.W83ZG0R( U@X.=88D\+1["$D3S+0E<#!SW
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MU?8B6>*$;W.B!.72KP[E(NFJ;+_>GO/@6W:Z@W=0)U1?U[O:E)$:C+?OPDL
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MC-_B16/)5&/SS$1O-+/%[)T(BYK):OQ Z<!SBXIN SSM&)O25,]8I'*/O4R
MTE:Z$5*%+":QO@@1\I@"3^<Z-J?NV>O55\>-S'^2NO(\+-JBMZME1'_1K7QK
MPF6%O129OL[YV?OP$63G(_/&=R2,%RG(YD#:L_O]_LN0=0;I>80U,<EIBL6
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MBY[(6Y:=\QIMUJ*F ZOZ?OW]202:G!>MQ/H8Z:MBEE[J]E@Q.?6]J3YSH_Z
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M#'",<2U-DWP(VUVAAVRVODCM06.U]\;<X!> G"S'?=J M'*3?!V.5,7R@DV
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MCYBR%!3FH^K:KMQ[$<%1LG/I<6YR]L.D@!KJN'#F3S""2IC#*"'RATKT0_^
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MO#-A6=2>(@*3?V8[8LG3IG ]5Z)HF'B.E2ZO&S=!?/A;,11RBZ]=5*_2E<%
MM4V %Z)@$>Q4:)P3J\_,NB047MH8GC [D?_Z?S@B>7WA<Q:WG*OF\TH62QQI
M5NV%99JND4GY!!882F;!U8:)@X/.C;HC\OG#2=9:#MV;75D<5S M(\++XYRQ
MDI5R3YA0Y25#3)67!AK,/I?4:$R:1<;S%!6REY>BCI54-?!QQ!0_B-NBYT%@
M%1K3/A5SKMY9D993K-6EE@(\,[+.MT7QYIB-> @<YO?7[U3/4.?(A'+)(M,7
M;Y64I0@<<THH!O7<,D($]NX.+RRXF2N ;?.QC==#0VJ#@/K5A4'UX*[]\I$;
M/I)YN:%-).&['04Q4/\8I\E3EY>$NK>KV[.<P_B0#:E1N\W3W]?9L(Y["@]Q
M$7%)W:];0F[DAX:._LDK-AJN6J_XY6G<=0E*3[M"J%6U<GIHR9QQZBYQ>@F&
M[P@I$6>_9(EFHQ<8/T85C$2G.*5SJQ'C-5IYKM4;=E$>%MU9TY13R#*T'QU,
M,V? 2 Y9@!=;PBF]#>4(UA0H0*+\Y.RR_I,U2WO7O9[2X(Q/(=DG [[^V5[Z
M GPPI&K0[P7A8EA^_S]!*E!VZ)*^;*C]52XL5GNAZ<+ON]*+HSES\2KF ^.<
MJLT&EZ UIA#%*2-1P10I35>5*>0I_ZL60(^6"="C1@LY]*'5I8 8BH^(C+_)
M+KFKX5K="7 ZMFPX6EQ?+MOZ]%*GC2_45KT'FXAC.,F>&Y ,M,JX0P>2"15I
M\WJU^+K9)P8%88XL%9>^UF2HE? H+NI9:*W#EWA^[",U]4P<'GH$7!!OH2)(
M');T$'0IG5I*OX>?%W5^F])O\R#CHCZP3B]_9I_4:'FW)\XQ=H<;Y<.Q'ZZH
MT49",]MJG!?&Q>?N=(YXT>+\HAR-+I;X'H(3R,'H;^1L CXI2;HUQ8U7F3BH
MF0"@%\*6*/ICCNQ_95M?2MO22,TB_.[T$+=10MIY-BF8IRV,Y/#"? 7V2"/,
M=!^99C^I7G[4;+J#$5!YVQIPJJ<A$/Z@"H_.^K)E".LF@R]X!I3*SCL%61C@
M'%ER)4"N!YJ8PJKO3')\7M^3YP]:(L>7P]BR$^H+ZM%O C88C:4T."P4L'1T
M ,UA_F%J0%EQX%6?(U^=(SD 1JV&>W">A_V5!2/$.>P=D&&.?78B%,=.73U]
M6FAR=;G"=,3&U%T*B8?0*6IREB]57\NC%S;6DT(J,,P"]0\AT^$NJMUKLTP>
MJ:X[X\&];",=;I%9KC1+540\G[GZ1W.K1",]5RG"C(Y9"Z,-&4!AZ$/,[_&&
M)ZMG/LK0[1RE1L\;HI0AT&&S*RO'DCVRQ?EX-A@ :H&X[09AXN?2KT7?<%S1
MU5=*A97OLR-GYP2&Y+;7Z4"9XK=%^QLX]N@J+'66&ZC V;=*]IE/F=ZI@!CK
M=>2L+DCS"TDZG15\9K !0NI4=UCTZV%"8TM,!T6*N9,<6D."C".FEPH[0:F%
M E@/,*,_/^Q:G[*KY]IZ:UJDX;;1G\RY7R5].(T)29GB9P=94S6/S.BZBY7W
MF*QT;B3+OLP6:;XLD22^L<8>>T9O#8S@H0]&7Y$-G18V5\C/DRQ6T4%4/RO.
MJ_T&>O,G"<H*#.>BMZMNPGPLXY'[,7*B*W<B5.*4F)%K9J *67YF5#=E'-O\
M&Q9_G+@!VN9F5DBV'[3$:")(;1<D9)4T)$M,G#[SA+J93T:T07I@4"V=<]^2
M;:L&(8/WO1IZ;?.C07 U#"4S4#3I$" &-%]GN,\%\"YC(N7RI3A QVE2?T;,
MEB71EMB7?[QYH(#[7U_\C$&-L_([)S/[O?WJ-\KW"<OVZ?(KD<:@,C5OVBK>
MOM.81H4C/B"L*)>@=(S_Z42)I\NI "!-K!)Z<BK8B58Y],Z >YP>)VEO*:1*
MGR?/T_PV]#Z"<TI,.$H(Z)+?+^HH 3$_M04JFZV"LL;Q;M*<T%.467(,B=]3
M7'3',/U:K>YQILT'2P4VL23]C^"(V6H&)ST,+?,=38D1/\;PDC/T.=3"#/<@
M/0<FM2)1SF8 *&;4!LNO< FU*3_K&<J5?)I-ZR V*^+]=TP:8J8_J4A-F@:5
M*^C?U%T*@1@M 2=*%.;EFTV>:THQ.*[>Z-=1\5M?\?]<-< ZEVL[5-'YJ"<V
M8=<Z<FVAL/B"U6H&-:K_Q(JOL?9\Q>1&\=993(G;QM:(6VY-D/R10HH[O]W:
M(IXCT)\ZZX!#$,Z?@RK>9$_[)5'Y/@D14E5FO,\HI*6GA^ HB4MUY&*\W%5=
M6^#,NC=?\%2NB4UNH[-#<MEMY0;#X<2<I4270AUX1JYBN-F9 F%@<V>S.D*&
M'TD;*OH7SB&FS%,^H?+YCB*2\O=R]K-,PC&X@H( 2P:<HK<8<15B[!8T+9Y6
MDIYQX[JK_W35LL3[<8EDG O;=S2.%"+3G'V9E;0'H^KGGJ@Q*EB@=<*)D:IO
MFT1NU9:I.V"')266QF%3STH1N;&JI;9)C;=A4RJ1J6-:+)W1#?J]3[OYA1C7
MY.90([W7_-F&434"B1-9H2FEG-BR4M,)W7(THV0<P#BD\/:?M-<<]=\5:R=<
MXMCSANMCIN]VP9OVPU3TZ(!O3/4T]? %=XPR300O#X+\C?O!J_(DW5:^.9 @
M4\P06Y&^VTN6_1^;(.$#Q+2FKN'$9 :9OLI%PI8!>#7@P!=.H8M2H=:-UL:>
M:P^HQZ@N?.-_I:74BC/^,.:+#AVM#O9;@#,"Z07U(5TF3ETF4RF%'E]-E*W+
M+I&I!EU.F_ H*4U"UL,L/)Q:F*/+RU9@M*YFP"VPHISD5N6VS?^&4AA*4QWZ
M\=EX<TY _XHE+\QQ5&;[M9YK%$MUQLX=LU=8')A+I%B4_>EAXG5?Q 3?C"*&
MY;39N"40099R'J_*W92Y/M1B=ETBA*-'KMB/Z_CHF(DR^3UFH%EU9V% /O'.
MKIQ<LV]"V]-TE$' CV#0C!3;:MG&.MS=A"F\(#D'?Y$SDD=*D5]L,R%'X)J@
M6%-\IBBQ1]?8UH>5Q%+$QNW=8V!07DH(PD4;P;(&U.&ND!%09_KSR6V3 1<2
M+J K0M*R#]?GF[J6"U8<(A=?="LB@5P0PHFP.!BIB)R1* U?? WL*K@M:H6(
MQ6T@[?E$U 8WX4>C_\2*3LUY?#;, P'$JP>2&';I@+,V-:,#4GJE"U4BSQQS
M?JH;AW/%:^&LMQK+Y]D^R!H9U[H=/UT[!K%D#&(L-+(D*\B]DA^N!WM_)B'M
MU4;($V^OA)?D!FV$,1]3WLF?T;N8B +^Q?3"KQ;!R:%Z1&49HGHV];)DA0V;
M,ZY(NOGEI9$8EG0!@?Q'>X6?7-?UE],;;PRJCGPPS"PD931H!1UT@>TC(*$[
MU$?&3U'2PPZ;(I1MW5<ZZP00((@+R'6<G#O$1">S\>\Y NB!.(M!A   #>BF
MWUB0J#)=E4.?-#<$D#OAIP-^7QM_EPT-0P#]S)9-LGW#,I0D?V0;,:?;FCG+
M%F5X->[I4YTF"Z7,H##64)_3(!U0I5[4P3ON4T/VC=B8'8G2%4>)AN5RO'*:
MJ9/K1^:HG/M:_H*[R7@WJ)B2V6/K@<'CE>J+GK%V:9%C8UJ@_-%.J-9R.)'@
MVZ?(68A>_M#F(.E[2SG#T(!)2?'#VU;,)S/'YW[9+5..0#UJ4SD]X% AMK?J
M?1CLUN^ 04AQU8B5AEZF%7"TG79.L@3G=U*8TV?<= Z,MOE/:P\$K3R5YC (
MTH[,G#8;3TOZRK2YTPYD";MJ5V"1E'L,Q(:P2EH;6!>Z6*-+RD2YXW,(8M%D
M!G_$1"7'9)](UZ[2_(/\_B37/U"F7>!?@+KWG#WDO(67^9B(7"O3OF=@Q30R
M;KC$I8&6;;!=R&74$X-0]BLF@DC")I87FZW;W%%/'^08/WK^?NFUE9[=C]%*
M&ZJ;F_8'7QYJT$=-X=Z!#]HR)9%W9#_Y:YC083H3 (]HXW#R^$Q>W6:M*3.B
M@.-<^P:==LI3E7"<+=1/0^<GE1- W->X365L7-[)\BIDJ) 5Z()<':+V\]K8
M\V&>/VC7"C8DR>SHY\K+<U$M>H MO6U;GH.Y'Z60(=SQ83>>A&%Q8GA%)G]+
MOM_63!NSIB+UW!I/N2SZ3I?#C\ SCO<S?+<RJZ8.!ZY =B*SI85YZ*BN%_@'
M0F,?A#0,9[MBH"]9T3RJ/;6$)#3PUP?9G0^8^,:37'YS5JM!G(1Q('7?4NDG
M>]CO&(PUZD2'_J.J]1(MY PKE"CU8&\'<MXHTV-N:3904-WD,V^:-:T0_<#2
M@#_JT!K:$5Q,KJ'$<_KD\V!S['\2;ES'.W]0R4]6OJ#K?N$-[]EPVU4/UQ]M
M&)Q$N6:/!B-X75V#R_9^Z"Y=4EJ^F4[PEA2STOD.QT%3_4TV;4'XJV$=G7I!
M;7=?W1G\")-(HOB(\_)9:-^W(F1@IZA,O:F KX=:_ZF2$>]ZL=Q(WPR_6LQD
M?7R3:_&%KI>]<J>KDPNWY40K;M&;*T.LN;MO:3C5^&7[R'6&3-!JGMWE$Y'D
MO;"C7J3_X:<S>_2AD=ZPNG2D8Y[ <UDWZ0:PB;?[Y/UKCF;/].E&AY7WT'\F
M_:.T3,_8[,\Y>%#-NW*N7?!P[3"&KC379>O&ER0AM)=#9DP*9_X"*&)Y)G;[
MY@[U$\9)JHWSY2.E#?-\"$1(>6&I9.B\W]=BVLV '0E>'#:$N0U[ (_\OE(V
MNET4WYI4+KN"M!RT?94&&5JT$/C)3M:CP\9DE_>Q=BY>],GG7 >OPL[^1-]0
M52_7]C)4\F3>N>5:1$!":'TG2]#Q(N7S\6",S5X,31W;Q59MI3$I()-T /E\
M,GY^V,!D4,VQ;JU T[ZZ4.Y9%(V3GMIZY2 .]3C; B0)AA\CKA'PFJU*YYRJ
M"O#'+YJY-00[! 5#*=!0\HCLEQI#&7MJ7SB+!FZ4L@[#?0.P?44DU!U!.BI9
M.Q]2,5U.!:!.C+RQ9 G!VFRRQ_0A=ZX*W[HZAD"VJLKL(PFJGCJ\NVC5]."3
MH()RV;.[R4>!%GODI :EVVQCVW=*QD@LUOR?,,?IZW*K1)?;^@-S&0-SM^ N
M(K*2BE)W/3)2+5\RCEDKM?J-IS $;ZN7%TN>DRLU8)^S0DX\(NJ@&?X%LS,Q
M,8Z!X1(4JJF7^G#_8#N)(/0T73:55#;W,(0O,\MXW(^K:4?2+/>5$)%DJY10
M:6&-D.W3&&N_(@?:^>V%\6;(VX+7166FPU(^_G9,Y;^C_$VIWIU;7&=0@Z&*
M$HF&"JOUH\LOJBV:-^9'64%C$!E#AF@CF%M^+5I) E&EF.J#HIB8;0F_4\BQ
M&+1XIU$F9_\ _L8UOBY?0]WGR /.9R:HL<U+WV@345\KC^%35-]AC.:FZ]ZP
MRJ$!X,RHE-F40"G6M!JT9IC/K^@,B;FB#B3PUY<EF15-S_GZ;[J*7.3:0@*(
M43QN$'=@.-ZG91_7<BE6PV[P:(PQ:,3P<D_ HI9.#QVC?7..27#:JP77A%*!
M$/'8X8 &/:Z8Y+V#?M4=COV][(1=LW)\_Z'+^^1V<=-G!:@.H$@7F]4APM#*
M%[]1OJ5NB[AD*#Q:6ILS.I!T+APU_ 4]0QA.\3$1$&K6OZM(B9@(28*S$ORV
M+A7(E DJG ]E2YYDR(!A@CQEIZ%-F^@IW0+91:E!]I*&T0RLTPQQ6R9&O^BP
MLE8NJC#IPENI>\HD])L1UR(0X?7LF 5/GK.?>GKL1_[1B/%^8S9;8>^RHKXU
M75_ES@ WWU2.*T#ZTNLY9PG 4YHBE,5/[6WIK>FFP;\ FP_2JBZAF [F</@*
MNMVL H<E,F(>II8RT@O0.U\QWM5XNL+%_'&U:R 9M3B#GPY>[&%6-%4+BHG'
M\V9:Q/SG% HA0/W/;XU*:N]B<ZL-!I[5G$/>^BE?9)--::K@.Y ][I>DP.,N
MG?O4P3L7<,FMJI'[M ^EP_P7D-&^,R]7.R"X1"I@DSV1RPF<I@5?%#6^JG;K
MO*3\UY72FM"P(EY+3/@$[U(^!\#M]Z8".=EKXU=1X4#CR=@U2?>'E^]\#5;U
MFFJ2!&K6"[?CRL5U&+!N *826H#QRFF'?FK"AZ_TO%877>^1)2VS..@#>5.D
MT=9>&7DN$$A*%0!$_?FEL'*IS"+OB5W9FY3<]"#Z]B[WT>;(1$1,DH:N#BJ)
MIOOOTBN*84*P2/,=UU=X*X%HSU679+\)#;5P!D0.[EZ]Q3<S1=1*KFAYID>4
MT8OF (C->P$ 24E$ ,#_?UMQS!O@V7LW1\ )>B/[';DE<]M")&';_$YCS(Y,
M*2IMEGJCS4*7Q@P5+(7SLG]WRP'__)I#O2Y^_NH;]VE4P((F/2 7/<8<<%03
MEV+$]E@%!]B7R4PJ]6 O%J\^IZJMIR^^%0R:,/#P_V% :UE@. !9-YJQOOA=
MAM/O^5W">'F:\EYR137POKW?P2SYL.[1W>]/'0;Z6K7BGP)T($'K&XU,V QZ
M?WQ86@%+WK+P#H+E0 FZLQ;M.<2>$KOG<T#'41/ZCB"/2L[%RP=<73B?!#&I
MWU/VJ6(I!Q55MW.^3+1JQL?:U,G%#=HLFN(%-(RD!2)26K+-TW:YG<*PP!?-
M#VCMW D]54ZH%YI#N;>EY7F$4^K8"=+<[E?_Q"!E7DDSW.XGWJ$+R2]AN*1%
M?^QE+#!:!WZ[(E%5B-=8,N%L$UE'S^R]P!:>.\.AHS< OZZP1^@J_-BMWOK]
M7_PO_A?_B__%_^+_&P*EH <MTRP)<[4V>X,$P)H\9VM5:HDE%]W1G]?K7+]N
MAT-_HK99M5!QW(C(\]EZW8:!.9<[.3S$!'\5[KX3&R!C<8MGO0;$P3!$5+EG
M"V]V:L!EV4\D8D[R"*9#\U/6A(GE JC3WETU4JWM_L3Q)WE%OPI*I;@T),*/
M7R+NG 0S_,-Y>TH5A10Y)B50&Q-]ED;Y"\@M?U]'6&POBO?D%Y>%9&UK+>Q:
M&V682_6VF, (++^FS-5O+S-T9Z2-Q]!IAWN;?*E!4C9?YJ;P-[[/' UXS/KO
MEO@J%(7$5H94197>+=2/C&U J[+\GGT8<\^@'"TIS:\8W!3X ,6V(.^1F1>\
MWS/(A>3&P%C2M_X"U!(---BL,W;H(?U<"EAKIFD*E;W8E<+LQ7)/K"LF+3?'
M7?3':WBMRMV:7'+!]'32@#8%GZW(&6] $N+K+!4%+#QZ?<2J<^_HR%M0U>3J
MP( 1]F42;)O_R+6B:%@I]5[SW:X=OY-9_2RNMT0LZ>4G_Y]/KT*E[$U;W:5E
MF8["I3.#5?-B,F[R7A1NSS!*V(^+Q?-8E#7HF+:H$HGIJYB)\<N!0ISLHI]L
M; P67ZG6NI4M5^V_'P1QGH+]5B6$>\^(RLD/1B4WNN*RG1@G+<BEG:@,"(:
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MM6HD]0T*,<$T-Y236[8F-]:H(/$H7_OH1^2<@T?FEXPN>SU9UOWF.D/2A/%
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MX<R57V(;?-YO;Q-GQ"(XSU6D!. +5MEC9;F1EE%&PWP,GYB+G7D YEZ!;_X
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MX67;K0C[>_EFV61E:#G3MNJ*?$9(E.9+0=@RI(7' &,3EHME"59?J>)M@\1
MXR)\1<6*+;']Y\[Q,,">A-,1!5.GSC%9BTR]UHPR'1B15V^;QEH7J_$+1-X!
M,0P:>DZYF56["2FYHJS-<TL:9A!4.P )VOTIVWOI54;EU9\BN]\ZN<X'W'GB
MDGL6P;GN)'ET:$1\HR017#-K4K-,2<J/S]8D4@L^#XK:E)ZWX@GS#PE,IU7H
MW O8Y&D,Y=H=IF(,LQMCO#_!5Y'#_=XOF>@JS&-(R9<UF/'S.3KSE5+[HA1T
MFOG3:?"FYK.;7;%V*K4&)3V.6Z:>8!"J!U$ 2JIG=HI/:#VN_7\?+%QP07C/
MB1*@@Z<?_JB(^7C(/3Z3*5/T:XZ99>Z(."^X6X?"4LO?R-SHR-@T)=+J\6U>
M^_TO,:D\;Y_>J6?".I8DX'[%0$LY)K29'^&A# M(UZI6Y?,09$E%EN-KH@Y'
M[Q?S?S[Z5+%\%+.T'>XQE:P/\"KB#,+8L]WKBOI^[ 0VL/.6G#--2O/+(?AL
MQI <BD)P_-VMG!H#?UV_!0+)SH-R))&JT;*N*MV[F!W8P,4S+0 2WM*)<N;D
M1H**9A:PX:F:O;]8$YTI]$W8>098*#,*^6$#?W?N/&:=P<$;<SK<K6RNF][8
M0%<\:#Z#I,\RPU:4'KD0T8>$%D]E\Q\X@J4+1P9DQ#M&Y'5#ZXIU</46O5?;
MU:I#@EIP ,J@(NZIK9)"IC[)XF-.A49"JZ5_( <%, H2KO.SEG1 RI4 YLQ9
M8XS-IY&@$7$4VESU*;N1/" ^$0@ \.OISXA]*RJM4DPHY85V48GM+]\![O$@
M"IFF*\USRTYP3G'^ZD\8G[ VLX8,!H\<;3R_OF*G8TTB'[HY@M(@8_@83U&!
MSAB2('6<RRSXXKL^1Y\J!4[XZI0U:=&85^JI:7+S;;VFS&1)J[P,PP?6(>["
M.;!2;:%'X!H\A#9WVZM]L"=$]R??7MO^NZO04Y"6V^</NOL'UTT>F-RZ'1'2
M>]\<47@<&#52999]V=\L-O:[0&0JY$I:4I-F&&0NQ5;^'A!WPS.D1OO%.]=O
M8DLU?2EX\Z==6JOL%)$.X<Q=7V(.T;?[U<_7^!O0MS@.WH3Z])O_-*N[L=[)
M:79J_)_B_Q3_KQ8WN3+6. <YD6^W0:6C7:8\)H3H4NE9)E&L-;0)/ N[%Q@)
M2O?40B(QZ'87"2<P9<'WJ3J1XQ-' B34NB*V5K34">.<#SZ^J:^L18SK</F6
M7H(@ZI=A"Q0R&%$4 $%3*3SW4.F6$"P0>1DZO>]4-7@RL=)SXWY%E-HEW.=9
M_SGEUY1'JH<G7O//3E9QE5__'J8>#"W_>Y@ZTP+I^=_#U%6<2(\A<WGBVPD&
MHZ#":G<)*@Z@U*;DYU "P9?S"@/+.'AJRKL58&G+BKR9>HK),@M#&SMZ?4O(
M8GQ&]DMH\>63*@XQ$E0QJ5+!+O: @16J6J84<=@XGC( "PO+'-CFCG#]$V@4
M-I7,=HW$:7G-)5^SPUX8]*Q=T>(\:UJB"3A:(4P9E.R_^$_B6E9RUMP\>^YQ
MJ9(>;2RH?.0L(IP+[U2P1B_H# (7(VZ7E2SEN,F$4 >-F,<YX]Q+3"EP0#,.
MS7XYF&:_+//D/^9<[;?3'P!%P??Y1E F^-SJ>0SFV6 /.<4>=":?XHP. QTU
MF4?0\@8E!V6^_UCA7 &6_?9OT?KO@/D?44P=?<B]*6[<I?I U/L>W16FNZ9!
MB?2)U%$"D6TQTO;JL>B#E^I'8WY(-(M!*"/UXJ&-G,7U#NA(NK_'"P*"CF>W
M?6%H61'%@C@[32KCZY*RF?:/X;!+>'Q5G^,.+F^%S>?_"X308Z+N+_*&JN1'
MK&I0)Y,GDQ0.4AH92"9N\(9(NIXO,.^FW*K$G Z.7A5)S8B2!['M+\9)J 3E
M3KGQJK:I/,U(3GB6$E-/]NO/&TP]VN'3V'_9[GJH;B4,@HZH( 8DLJF6_KFK
MOS_\<.2BM46%5<9V;O\P$68-LSQ(8S;W6,R_KJ&8-S@0N,W&;1P-&L&L2@7D
M&XJ^AX]B"#[;'96UJSWT@IR3=NP1\5*XRGASY#]:GB7",W3<0X.,_:73>(>1
MO<T636?&^N56#T3!LE &KKHMH3HNS#M$1PH0C.V(<*YNR]]A9?_O$5\9.+-#
MIR+CNGD4L3(:6D$9N+DD=;A%01M)2X>+BWTO:'/VTHP\=.<:-T0) W8%<;#3
M9B^S>W3CJ!>B F%FVJR=RG$9<4I>.6R&I2*:E*V/B&\0<\=*=)E<]*LQ8CY4
M489='EO8\4WG.)X8CCEA7Y9M>0\66"PDSE%B]O# =IW5_OX+5N@VT-3# 59P
MW0DWD6ZH7J$7I4<CRWT:'^SYSP762H;58RTZ#:E<1O[KH8N1JK,9^DJY4GP<
M-3S 5;)3GNLV!8L$791R2JS)W$)>AC:KB1QJLB%.Z+FE[>Y@?Q,\ 93<,>6&
M=@8O4H9G]X!E8Z98!?\UMYN%7]!-&U5/!L19%3^3F.O,2"/X')2!VA=K<Y/0
M(I8GQSQ$K2LTX[G_&E]4=H@-S'.+V-071MZS<$=[5G/:@=_PWT*4!$^H<4O$
MVS8)'XF$PRZYO6>=+4C@-VB.)63C>"P/.N.3LH -&T>-ZX@*9 L6K[LG3:O1
M#U!^O=CJD/RO,=<^G[C8FX9L9\IO83Q]N9J],%YNGSN1F SUM,1EB0;#.*]5
MV;C+ZS_5'YD.7*A^C5/C'506-RJP+!++N%[5PIJ64&LI;VA;J\V;KTU-21$>
M+L8*6!)M_><V7V7FOH);DMZNJ)P9AK!;U R,#*H4('NP,L4N-KK@8W5-45:K
M.%78EG5'.30^NQRBIX?2R8%SR"438V7S/ZCU&0;\Y?URB<[,4ZPG<?N4;^*/
M4B2W6SI3RI>)_> SEO23Z3KZ*0I"],/<TX]VVNI!TSDD)W\3<T8J64XX_9-_
MC<B3AQ(%0022S.ST[O!I;BN:XY 1,Y/OLSN683C.@<!#*/I%6<Q8+HC\U_G^
M10]8,B(M<WWO='$*W7.-FY/T(M@53< 9<P05DY C-.Q@H848BID#'Q6"-ZN:
M*,U.Q]YH1=LWES<<1S]=<G<YF])#)%AVPEB>AK\W4:6  8)IC_ZUQU>,'"/K
MZ[-QL02Z,EK%NIX^00C ?3L.BMGD54:;?G)S8YJAS7(_6FRZ9!JTXNWH>(53
M#JIP>S+D;G26.IERJI'5O&J8C"7!=\=I^4M99":7&]W_60=L>R8.5$E(R_<H
ML.MJ@MLW\D,XD)L)XGA6LG0Q[;$ZDO9<<BI?V$EJ]76:-D^9,*U$Q[X$>50B
MR,+:+ >.1NO0S:+@S," BH"X?ZPC00N9A=S9LZ[]H&7UI((T-I_?T&Z[W-!(
M].*HSDOX*!VK0T=TX*QQ=@$WA*-/3L_GW;]KIN>?F#7TXBYOAD =A8L-)0TS
M#7+.F@S8L!=4"ZVXF);F'RN F03209\C7#&I-\_T*U SN(MKK:KQ=1@:TJ"U
M0X&\HQQC5Z*!.%9VIB21H#4*$\NAO^P[S4Y9(9TO@5H#2%S^#YA7_*?XWXCU
MUA<33HJLAFM+Z#Q!' (@ADHKZ!<+4O.CV2@S<%V/#'J%",;&,U-C\93XO&%!
MV)M*+_^DX]&!67E]F7<W:X;TZ@MB=,<O\S5NB1<OC"J%1MFFQV5"E;$D0&HG
MHH+@_9N2_]F_ZSY$I'YID[ZCSMNY21E1")+&PW4]&0[HO:=FAN76*!:()N 6
M(%1QPIY-7UO(YH93NR.$X[3O80(WU7);ITH-QU^93'SK:R>>LBOG^]#*]/?Y
MV]F##"H.T_HB5,M;BOTZG*!TI"*[U*-*[SQZ&$$T1#\_N& XMKNBLF^S#$@'
M';Y<FE _4'=%M3=9\Q:,D( 5"+Z&8EU%*7BS9=^BC8T]WM[-:DM^03+^Q-R,
MVSOS+Y"L BT:-OP!V,<\N J*I=2_P7D+W*#2JF+41'1*"7SY!R#O6W;_..O=
MCM&G-W;3/WX.O\PYZ+C[)$=EYD:(P<=S\'>WVKU'OUW>&7Y>O?9J+&_O66?I
MEV_ICQ3F_U/W/W7_AW2K,C[;I#F1SU9O*8DJI7RL3_OH6ES%\O&MPM9>5@B3
MUM(D.R>Q6MK4[TM4(HDV,LI0?).X)I\6[;_UN:!W'E(NZK0K8S/C<=@6+9KC
M"2\RUP8+1FK'Q3V=W93RCB?F5O'$YSY-*=W=7]XA-8>VM1_8O!W]A#Q,WRM$
MN[D9</)Z>?7(0:R#+&R3IL'[(%7V>U%$Q_^VN8^^\*.JN6KOU)I=.0P*^[X)
M\>256\0(,L2:5Y&BC#:_AL>%OC=->7CX ?Y#SL SLN,R75E/>E1#/_Y4XFB?
M<0VA-Z@J[=$!3]14C":-D3#1M;JMP'!GTI[+:TW-DDL"_9"&MQHM9@;!K18'
M22:MR^DM=XDF#3:K.4@&CCR)A64I3PL4;K33BD^L&S+C83[B+_=Z0.B?@M]"
MZEUXPW;$S.AV7TT9AN_M#*%I9.- ;1K(7GW(-&MOW%/C87>F_:V)F ]C14TM
MU0:.P1C7DZY<<:ZRUVY^A<TSWSA(,^BDB3'IL4^3_?DZWX41*XR2GW@GM4JB
M@B03HR$P[23#,4Y%F6^.K@<+6*D#2>]I=:F6L&+6$);)7:TW??(V\AUC<;)&
M0T2T$(.C[6MC8;#Q_X8.^W_J\GIM:^-9%YUY7Z01+(C*!B#B(G.E\!Q+9F3\
M#6*P$9G+Z@,C*K OW$5_MY#,;TB*B\DHLG:?I_^US7V#R<9KSL-5?EK/*:",
M*8;B (0)W5%W!5QC<(_7<WL_EWXCX$D*:)W?^#77JX33H*>K,0WWM+@G<EYE
MOK#.T1G2,9R?XSH<&K@161RQ#UZ?KN4OH_8(TOA?#8#]2VR"+M>B E\'P<('
M5Q#3+?$%:"Z&=\5,1MG,J4FD237')E($)[%K^#V,+(>MH;IM2OP+1U''K%G$
M+IYSTRU/,\.:TL<T:M1Q\P)D?0<ABAE9OS:-'_HBC:_5&S\(^<D=)MI&D\5X
M!'P3=MXM''"YJSX-35],L&O(5\RXGF'P#<TGO)I^&0S=$X9G6 -Q%8?_E-6^
MPPN9T4[-9^]"LOR=8M)K&O%D2-+S40DW>0*_QSTA72=UI41<+.T>]X,[;5XD
M"&^ .C2:Y[L,^\#%@Y_G'Y#*)I.G(XF*<IQR]-<.6\2Z>:"SI@+:N.3GJEJ4
MW@!V;SE-_[4;+\WQ+]XY%H7.)]SGJMHRL!ZU+29L@\T=>J"#'.,\9<QV";HZ
M4]/FA\LE&!V<..M_T^YR+T$G&5&WFBSW]5O7Y-U:M4;TX$YA'_X D IQ'J/<
M*JB&!3E*? IW(69HH=64,XRT0:IN\F G)YIHJ'^NR9,_66L(E(#T(_:)],KR
MGD)L-0F5 3!2&]XGN@HR#.O2C32(OPS2U]?7]7?PZOX9J:@RD>B,2?RV/@0R
MS /LB'F0EGE4'T?[T #IQ#]>4Z,33QEFZZ81_K;A)>W-R[D\<9G3! [";_"$
M_#UM^'_':_P_0??5Y&FT$3W8,$@@H^QF4U?S&L9YP:8H7UQ$:-JHY$6,73;<
M.(U3=%5ZBH!N#'&S!N9H<U!_9E=P?F!_LU$VN/%F_ TNLM16(B[F=JFF(9!!
MQQHXSW8$7[[,;%-K%V.D SB:NR.[,T(=4SE:([)@%9II,4W(:M<.2D-4<XC9
MB5@H>UMQ/,]/MA\I!,PB%L;QYI9JT3+_,9'Z']$=:OLA9)Y*=%%S=PC2;M5H
MN8OAZ;WC9"<"N?+6<.N0W8CI"K33..+K+]:@--<]-*MPM?G%S>*=+E_W0F,R
MMC@PQD,)"S-D51"@_]Y^,\T\JF% BHI5--.@-KX5IM**<Z!/1H\%,G#J9.GK
M7+2$3!Q)E7DR8R,O=.5/""/^AG+D.B(!C\ -(57D[H 618GP#NTHP+\?%/LV
MM[*@Z1[/[E4,BWB5L_YJF;ZXN6+A7:"<6:)A_^:6)#]'R:8X,#@Y*CZ#S)27
MAC;U"<J ?K)-T6PSE9%>S8FO"K[_J>1Z1ZV6@V:I^_B!"^%A[GYVEQ@K-;L5
M(THDD48"U]43@$H6]^29!G*>VP8@FAB/=$<#&@R+IBBG-VY49>=1>5NPB6#Z
MV^=V-W[-1*%AQCAQ]B__H1WB_Z>Z</PV%I\AXSZ(QRV(% DL'?JFO9A?:>*0
M,K\8799B8SU-]XFFF5BH=@;F)C3M[O.4WL7AFS2BF3<M.@MWK:I,ZBW*G*1*
M@^EYA5)F4Q:+0!C#2JI2@&%(U'7^H&MCXLIMO^U?W0F@;%*6'FBA/N2\8Y@7
MC_*H.MC:1,RGGOOY&VWJNZ8=9:EQW9=!V^ZQ@O(*!O\=-V>AOOI8;>1]--F5
MCT\:[_.\TR3.H-VU/]WEHBWTR+N'(YJIW&3S:W#<7OZ:\=V-VMHZ)I_P4\H7
M7;<T@_G]56^*L$1L .A@;V9%HXSJ[T-Z86(T98N0-+V(XU594&;+JTO<_O92
M/7L<UL#V8-]65]T:0Y'6Z-;>/P!%-;5<;^T;S?A[!U_.6BHI/Q<0ELY\.+$G
M4820/IL;N>7FFG>4J/CC +2I1NM77](EK"';T7)'P*X(&;=CRP0.N'$5S6)O
M"4^KOYSCL] >H!SU.W4DFV!0G!FT"$$)E@5\_W06\-/8\;;1IRCJ6_D^Z*.
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M RS!$^$4_IN%@NG5!Z8 WN?DFUYN8X_MQS].2PJ$'_"7PK-CD[+3 GR'? 5
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M,1=A-W&U F7M8K'U/YPE%DTY RT?/3]#51DE5^IX,+,%8P@00^]2:/_-UY<
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M4C!% /O-*.P>87OB$Z%@0+X2'ACOMK!]/^_[2CR))9'63?[V_B R?B;)(YZ
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MS>K7)' DXN\7GDF"$BV5OV#S'5%*<KE;IA3L$M@[FYC. 8?,G;S7%'&<-3"
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M:GO(ZVAWZ<R-:)B4SG4IW:(2LZCV7?().X%00RL,N5MHLJ[(.^H1%>E%<AK
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M*#[)GN&Y ?8H)-8E=Y1L _@RUN ?X$"5^Y%N3/JH[795[!_ V[[(3C"3D'1
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M?A$J8&64J38-3]:4*HY09:UK?7IGN@(E&J*( ?^3N>(M?L_'8-QQ")K JB_
M3THWS,K,:"A6^IJE6$4EQ.@R5HOI3D?MM:P7)1S%ZBK8]G#)7^-02.H]H.L$
M=.U"23LL9XB!?6HDR(GKQ,W>%M %2S^97VWL/X.0+Y@(Z/ 8 HQ9Y<6L!NQW
M5%N^Z9YX26Q;5]#HU1J[!KQE\C.=Q" N"^!N7UH8AR]$*8T94WMGK8($3,XB
M&C<0^*6UG5)G]1W4L/<H(A&(1I$?Y2VL#,1-OW[^9[IWG'OA3>-1R3:?TU3U
M_.!E"E(!5#C\G.Q6ZG^AO/P?+])_@*&3EC0IA&L2_SI%6J.C:8&"[;94C\ S
M<WO/(B*(VPMA9:4R.Z_ G05#8F%RG?RNXBBC";)U&IG,-O-%ICQ!ZHFELC^N
MD(Y0HJ/C55.!0#S36K)0MT:3EGD'R6CL+L0'[<K[L,#- AW&7R!3M#W0AK7;
MOA>!Q__M(M,13O>M]F]C;[M!N$5)_TM9Q)_Y<U4^ATU>0/4D<)T.+X2F4F=W
M*E44;M"-Q;UZ/3(X)"AY0OO:(WY[5"F=[+2KF)#)8,(AL=LXE;[>;<8!6I[!
M3U?6W5QMCRSD_)!32)/V_&B7\#CAL?"[B!2AZ U7UT4.!,NM:F#YJL/U8.]6
M!9.*SOG)X\<>\E16Q"%;/>?HCP<7&*G:!/%#/172'DM7$2[U?COQ4+,Q7TJ2
MQ0+^Q7I1^'Y"/.[RN2"5W>7S9T@Z&4(?0<=N SB_LZ#%=^,_1["7'>M6._95
M=1W^6 0DQ\Q2PUK\^<)V[?LT!#I2\6Z 5ESP\6,S^ZW7R:,+A5*9HS,4MOG:
MRR$9/Q&+>LZFY0#&SE6V^.:FE3S=*\VX]6![*#M6GTW&;U5IHC9$^=I6_@Y$
M4?Y2>^7SWQUO\_]/^]G_'W=(,]WB@O:_GQI]J;*R3@RQZ9IDXYCC_[(CM*LQ
M00T>&QBG6Y1(3A'(@LV[V.*I ^<?1O1\03_O_Y#W/HQWG8L_IA]]"&^3/GY
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M5N(H$18P0HY_N24PY^3V,^[^W2!MYZ6CR[7<R)LQ262L6OM<<WJZ)X1UU&T
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M;,+$\M/\MU(0[:UI156X[ 158\&46&OXT8<.1MT'XHS\'LF^,P&!3O]ZLY9
M_^1]R=_9A8/JJSL!Q75G8C,=B:C28JPXD8D$Q="0Q$D1WAZ"L84RCOD=L2_(
M"JBO7N;\XQ )/<VDF?=9+&I#-9;V<J4\8(*YY@9Z],;Y7@C'.\CLXZVD-*\"
MH9IO<J</]XOF@V]SRS < ^UKMS@QLY#3$?B"JZ;#HS?3H-/.))%D\^RSOB!Q
M%CE6SP13L7W%=IN$>W"U2I\""3EKL+QR9-P!ZI=\:ZN3%]FJP5(<-F0H1MY*
M-K]_:P[RTVL(\TS?JZDODE1KS;2-G52M\5ERF4 5K3TW-&1S<A*P3@B+-PMR
MWR\6*N:YJ\^'/P4ND9G2PS^^?/A&I.\#R1+$-_"<T6[:4O>DJE&O@>J5:9$Y
M#?N8S$O\A4P&+6R[WRP.:M<49MKO+BK+N3>Y&./,N$@:)([:#@6YL,/C@)'Z
M)1BM"A/A;7H\VXD7.#+Q/;MLK0.O _O_T$?FI!JJ<9ORM[IF:41BHQ6LBYKC
MVF'^G:3"_ <(0KXG_FV^)P3#W[>L^3V*V/H[K%*3C0@\^VRT4%LE)9P _ ,5
MZU+I3_O[.3$'5[?W4_.UWOT%N65HPGQ1GY5)DZS+V5(1S2G6/T"$?IW;DY@%
M[JR5X\4?DQ,9'4)\[>]IOC0#,>U\<G-@"SU+GZ70-B1&U>KFM0F'O7N7VG53
MR2%LZFO=TH*$E>V73?3GXJ0H?2Y-,AY"8>/T4WX[JDKNH[2'A9M2[2MEQ\.9
MUSD<:K,_-*M-^'.NJ#MZAUFB. AMT"OL4')4[.?@W!F7W%DUW$GPHC@2>E%L
M;Y*2!,Y$[/\<@I(#_H,J"*0TM"F!D+QRIU.,-2T0N1;9E.]9 9)=RP4<GUS%
MOVQ)0W1G02GL>W;8HPX+>3BSP:4:AAXLYXY-&4EENU+C440\8L(_-)3FS.I-
M^J0 C7J!C[;^,?0>)5 RR<J7C?*IMW*%!>3'!U-G;0*=?I:)W1AA"./L%YKY
MSWN1[Y6C?L=/VZ;AOG/_Y"#[OL/V0JPM2:JK4,OD?*,<P6!YMCTB\\3975FG
M-O?RJGB0U+*0)DK_=XJI==G2B6>)\EYZ]0-?HINDX7N\N\EG_CZ99O!MP/[4
MJLK/S:$ 1U62?0L1F'863X;M2[\D-U=T102UN%&'[^5""S#*U8*#;^(<&49^
M<K]:?+:8?4Z<GY(D[MX[I3JJOM_4ZWI'1L$)H(M'S7<Z\IC$.0^=S3.>^8TH
M">CMVC:D^6HF;,,]X5(EZV>0%],..M:886I]<'(NV2^N BJ E O"\C4%IH\D
M=4)-%S6_YOR@];PY^"2*HS;B%=*^6Z]6BR;R#\#.W\]Z^!3+O[K?5$>W(/J5
M^VY&,<YRR+LUH/N,TFQR0$J3=Z7E6L_[8?77A7+UE.LEAI)3Y/CQ9GD>G5IJ
M>-9X'RN_=G-..F_;PZ%]FCSLRLQ'IK;+M,[CYN>18+"9V1PKWS] =V+=.X\F
M%?$\.J<[![.!%6;'SMD0IPS^4@>Q/5G.&H;OBW%NO7)._>.H]9.></6TI6.F
M N4 _\E"QQ&DI<2<;M.V)_ER;TGT=7 0AX9*X>.(JPY#J%SXYYS@5 NF!O=O
M5#)2 ='>.N)..E,K-?7(\K4SCI:@.L(R4R*5EIAZZ3G]K0&C%"2M.+=K+V2\
MV-.#DQU@YV'Z]R+[2D^_:41'_H:E95<'F 5=\U2=UJ9S(0UW2#/K)%M'$;8_
M@>U<>>A.D1: )1[PD>Z$D*SIG3R7D1@:/5>WE9,=3>5DQ[2=&M,3B5;;O!I_
MX][0"OHH CRHV.5R4EJ1(]>W'R!_JQ2P;\UW[8+'CUQ?1/DN^P7]B;U"CU)M
MFI<35+!@$6!Z[S<CMW,>49WY"2#1, 38)]U&MW7]NM1#4GJ3Z#8-GMAU'<9;
M,O4]_GA+\(Y>R@*R?RSX+)MHZ>=A'-8BF=,Z9^A@<Z\V0Z!G]^'C^LG^I!'E
M_6NI+\NQITW5IG5E5QU.P/VA^:AEH,T3Y>SN"I6>4 \H"&<$]\_Y"/WKZ>9H
M5BEGC9GO9V2FW-!!UX+&07=_<W;] EQO%/J6EDSSBLW2>1'OKIJBW:^[L%L3
MJ>2D6*2?UL"9R97?%O(C_92A=97&LSBN150G?X]A;&*+$=,N,^TK%!2:>08*
M!LE&%/:..Q_(7*\= Z+3 ;4N2R-3B$P, ' =6O:H)@DH%\I5FN!"R9(9030/
MHEQWN$XJ$6;>_1#+X; @$/7C>''N0=$>FCV20.G1;?-32OXK7/E9+\M/5"S"
MS%[3"JH!%O&<45E1G\V[*JX_9&Y27N@_NV;7/JSE4E96)>E W:X8WP:R6-L4
MW!T,?O:!X&6FI[FM6?(>GZ:E+0W@C,(3='^)%<P()B8O+%L@#9/XO+)#3W1L
MI_5S!FT1&B_B$91ZAN(2=:L:HFD*B)'.Y-%+W)(3=E*<!,_\_U R'IKRC*].
M46G,@I+J&@7/^LXCA=!%^ML,?A(*VJ&=!UZ/+ZB=6&K.E'N_]&XV20O"CV-9
MO$)B:,6;11KVZ?9]R;CY:/3=TSTV>SM[BC8'::I=O!AE@9U5&H:$FH.:N*]0
M4\=(\/5#*A8*%%]_+&G@J.<Q'FSRF6N_%-.+$NN)KZDIU1OQ3JHU7B'E;"]V
MS_'K\$Y2CSY0)M46^@5JD\P9,_B=#2(Z:*Z^13T9UQT43P>>^9986WSV@X:%
M=FCP*X!,2R^+<W3J)K"(M2^57\*0)\D*(>(T5Q2F8Q7:YOQ"1"NY@4US0>)A
M!SUEGX+K;;\C(7TZGTJ%ZA0X,UEA6@Y:>3+V8#O+86.]'I-3DCXKOL:YY:II
MB8TR]IXOJ\Y^=,H[50;CF/4*_0"/@_WC[3V65.'7L@UG/\D.V*S7H%K-M#C/
M 25B"'&TKO!LH\_->$B6+086)V>8IRD<X)_#/(:'_[7G-83KE7$1-T_/J]QJ
MMK/!!R=ZT>YH3]IU(96C76V5R2!M=<X&0X"_QG"1K<&R;R'%4J;&4. E>TS@
M9W;E3 6R1)P:&!<[AC9K%KA"+Z<"H(L?]<>4A=ROR8BOP^.(@RG6HXQ$*"2:
M<$UETKX<N QMZKT<UA[JT>>NY:3#;IQ':Y] 36$S1*7HPCVXYCX"OB>;H>'#
MH.-T*.%,QCZC%5&_;O:1G*I! <4J!R;^ T"V?[WG>TX_.5_-T?7<>^1 /NGT
M/9[PL99I]7$HCEKP$:^62%)>-?84\4T%_5!6KM!+^ <XW:GSHB;Y:%2IUY2J
M\!C_T;\<U@3]5$AM7QR#*$8_[06!/%0FSL!D%K:DX4C^PRJ4&L_G&%;=SA:^
MA=G,V]N=O6/+X<WM=PP5K']@PH])U.JUEB #^296J/(E52 5X%U%YK##JTUQ
MVK4J"7H/K_<FQUR/P:-9';2]U[08<=_]M?@SCA7K=+BG/TI&5G8KHT'$8"4W
MHF4],N/=S>2P$?9Y5UQ7T(F#24T*N-OUB[%ZNW]2)*(9E@!&$I$D)GS']RXN
MZ4LQ.W?JL A?(&Y["Z_.+AV'\?3CY'6SL6FY^I!QBNG^84K%H)]:E-['!3(^
M</R?'^.]$8LF6 6NF]/NN8%U1>(T9J!A67L6'H<$"I[<TGI2\UJ4G]5,$5R#
MSG4><8?,@03[;2+ECE\E?D]N)\>;J-L/M0IT[A8S_75LQ*&G.=^V=N)03V_4
MOTD>5YWBO?MNT(V:6F.;>8Q;56W+^JTO)7Y9,LUI^BG.I\Y 1DO>AM(QTXV8
M6@#K;7J:^@@)9UY#(P!+&T)2DU)L9$Z6Z>YXF7#XD'EOO7\<9V?P,7=QY,_?
MA._D,A;)G<H8F)=*"+ 0G;[68#;G!P]@:41@[XG4Q)<12DEALKOLD/56Q G8
M,@J=7'GNQIQ"C>K^H_M[4A83U^0]=L?S O(]:)U0X#5=:N89ONQPM/-<O5F2
MI?(T^#I3U$)":%F%56(LVLK/',D@P+G,''6U WG'>6<'LLX-08[/4)0B$C7G
M<\5&)!<SM>RL.\!5HZBLB0#/C-%)@G#=<\S6C_B4H@9^^W/31CWQ#EZBT!!*
M=G/GZ4+F''B;IF\S-V0JW"46JDIMX_5!APO0] \@%.']SA8N-R+%4/![".GU
M<W"Y:TNN\/V6@U^KWO2VC)W"U"K)W5J^WH*]U/K>FEC2,^8U_ MFBYF#D O;
MP2B/OP5QO[C\/#_<7K2+XTP] 7HQC+"B/N(F2E\SZ4Z?GH[ Y]2<>CA/_L*Y
M,N^T,"?MK$\DL5KG_JD.1,F^6)O"0TW3\A3AFZU:_LZJS1[&VZ4E^Y%S3,9I
MS,&U35NI3 [XNL20P:@6EVN@3G6&OU[M5(!U,L4T7Q1:WLW#Y->8H-=O>+VK
M65GZRB_3<=H$HT8_WOZJ(WCN1=OPD>N4:O%@7E%;:;[J95+WN*26^]*^U5N0
M''Z1C/0RMJ(_@G?E2LNT>'Y5SBV8(VNXQB,U@P8$-U*L?1#("2.[G%0A!?X6
M%5?6DTN@.ODI(&CH:2(8SZ'IVY'],E%<U+O;E1;6/32@,U\59SHA<.HIQ#[[
MB*,*NO9W:>C>\M\X]^.&PXB+P5Z+,3IOA>2D)+@#;_$A TKGXGTN>1AY%'J^
MMTUB4F^O[G(H6A3VJDU>JU#W2\:WSB'1Y]IP%)QQH0/CIN#<9FW).#,GZOPU
M-V)] _@E%'/;SH,?SL9%\ 1/#N([_((Y;M$Q5ODLFEWBBRQS>J$\FZ1^TQ>G
MLZYM:4MRY#L<FCV7Q[VXCF2Z_;%8\D3>P3@WVU>2%)GB[ L,4'?2H'[R5GQ3
MVL@?/F UL%%L^&#@:!==XI+3,:GQBH6MRDOD15KT*_#-:&IJL; _ XI3FE[%
MF?BI@0J1_W)5YSPQJ]Z"9!04:H#4%LG6"4 K52'P0<V(Y<1.3(P$8':*\[YW
M++T7SX\P]=$PKPTYYR41MWRC0J+P74M+?F]?37U!GLTO%/&&K?+3>$EU#2W\
M=G^-Z55NRK('LNG6<#%\W=3%QZN9E"J;O[-?^A6K,K->1+>'*AJK_>(EM'U%
MUKWH>!6JR18 D]?&PC)1).)@O;DC)L?[E60Y-8X<;&8^H,!5X:IKI6@YPVT*
M2AX*7AYQ$O&; B]!MTUBMK38[4I9Q*&6SB$:8R^F2^[]YIZK>6P#.>>X7UT0
M/N'-MC^_]PQ2'+FF6+0_Z?5W6="I*XO&6RLV'"0X?_IT4*SS)U6ZI/>=,X/:
MA1M![^C$%/+WVSQSL\ICB,[<RS<6&DW1?"8DML3@XFI")1L;]HGL=[,+OBCV
MJN@PY(@#@:5D0]?;<O/4K18!SH()G6(LWE,Q9"-\E^5PV:S6RK"E6W+GV;-;
MTBPG]0:OJ*[LE[Z8;Z?.AA@KTJLDPM8]?,MWM?C(B';:ZBOA^<VZQW4^K=+\
MD-N!_6WEP>/>>SF53CA[08RA#@2>*8\A3V#7:<+C\)'(/OD+]Z#8O$2O[,@0
MK3FOB)LB'BO[ML8O,J=K$I!OHW!X!HJA.CR*G--=$-L-9\/8#Y+G0^ SWW_5
M_:+C3+ULSC=@2GWK!ZJWS0H.V?#*N0YO:J(/[6\&7N&=^L6(UZ/A-N;HZL[*
M[:\L,V,K)J78"2^I<&GJ[ME132X+HFCJXE>Q/(LR+@1B_-)\&3\71[,)3\*1
MR_-KCH<NBA:)])"D"]#U;/MVG@I:GIQ5MI!Z&$7'DHYZYQQ#>5J)37&KRB3&
MRIUNW1A/F]W>MLJ^S0B!EY?&A/"H!L;\C>) '9:Y<8=M*F>G^<-:#J:G5L#J
MU'.E206ER;FHAXLZ@K\L'^IL%KJ#DX:C_P$(E@4R;!K\WE+PJQJNOC)RLY[O
M&V2MKLDDU\"G>6J8$(4&JZ#8]!=DLQ@Q^Y&F&0WTU*YL@VXG171=G76HHV_8
MKO.IFN,PM$T]\8NX[$.;_3X[W>(P[;0<Y5XMS<-0=XE&?/-6RGF7K)8%=5I]
M5D*6W2D#[KOW E(T<^9+.9,<*2CNLW2&HYAC$WIX<;J8-8'^8\3;?V6&3]_M
M=%D]I#;H:/KVR<C,/?"H5C"RS6@5,]O?E+7HG%?<'\N%IH:PI;D7,CP21!V?
M?:RR1S'BGTKN 9Z!" ?19P[Z[Q'&-F_/?\F0IV>!+01%XVAX60\^0Z_O:QK[
M! 6<^\UO6"U27I&FJYSV0H,PC),RFW+N/9U_V3[P_X<<\"9LPLU2#\\HC<\9
MU$UJGEX3J#S2\MCAVI'K9^B:J<=:V)RB1T;;$[R .&DX;O9_0=@K!)*/&!15
MCK_8G)J)V#==B$T?BE0,963:4:+'P3.#\MV=8RTEK?=,^>WQLM<;,J'"GMH7
MWUX[()YABGH_<C;+G@=&35U26W#D9TXO.MSYM-U\5Q--@'NMQQ:I9:AS7YHK
M/&\D>_O..8!^V7Z_1'S(6P;JO'NQ)I,.H2.S&R6%+ IR<Y.&0S:7XFD7MGF4
MCI8ZT,DH(^LL?EF6.ICQ4-;?(+^I;>'?[R\XH('D[KD!N04="X*I<X$)N?"_
MBLE]>[F9 [-2S?OKTAJ?-:AQ,)=.(V<]ND=PQD=O9D"1M9PX*7;8_]6T=MC/
M ( <]N5OM)3H4P%+8Y\LR]+XXJX^ZN*IE"I9&LNMIN<KL&W#$%C]F* #^O V
MFMV=95!?TBO.FT"B9C:Q(3OHA<)U.L,A+6^5VPMW"\7]'<TX(OFV7^VRL<YF
MAUT7S;G5^:!-KR$7PE17&D9FU\?JBO'Z#A:Y=_T4@(=+N5<,<\ *^H9-F&#9
M^5ZI .NJ[;_QO_&_\;_Q_RNJ08Y"4XJ9(RL,V$ $U!JL4W5'I$0VSJ!7B24R
M:,-^F"MC@-?TXF^8[89Y,D]@WI06# P+FAV\%L?$0)+5/&HJL7U-:;$B-JLQ
MQI? KMB%C&T"BQN"J=C+7A**Z_3GJS"#_;Q#,\>421MR-)N\,%Q$E363'2_*
MR!"]1Y6I6Y]F\X3B,#2K493>.CI+N8Z$6E5HE=^BW5^1$\*91"8V"8A\5OJ9
M\K]EX&>_(WT$]<_J=SX9;3F]+3Y_DNF[Z_L\+!0YX(P2\1VGM&3K/<]K[,)9
M>1"29KTH=2["WHUT[G\ %PJ*6:,M7Y),'^-\$?.LPB#M5BT-V4OC;2#% +.0
M*VLIP5^+K=:MW-30J_?<!D_]KL4F]/?_K\.TZP:LSO3SZ9)7Q *CPWB(16K)
M.K7O?HND2,T+%AI*'J#CMR+\'(QSN#18+]DSVV/5#Y21.O*DF&9:A7_5!4>Q
MD%*A9HPMUEU='8(!N6XLC-GP6;BHI6SX'RZASLY\56U:;I_Z#+Q5'UW<+%L"
M%!]0B@V>A2TG3BR82<\OF5V1TOGVJ899'B!'A+GT?[)UJ+8Y$^"1Q!0%(A02
M*B?S##"$\:9 W0>_\CE6Z>XR)T6H%>4AA3:=YYJ>E&_JRDQ<&%K4?*7(1? /
MH"8::C).@'8K829_M.W9L1'K9D\4YHQXB0\<@ZNHPV7SO;Q]3%06,L&UH&U6
M_  8$P<I;7PFFN=G,K22]&S,CW@\-.>&L^9"ESM,/N4RPH*NO?P_/R_,0'A7
M6(S4(VVI+A1.6"7(JH>EAW!1I=',$;MF=0>\G0>3(C%Y!C5@^C*"D=2KMFM$
M<P46V>WZ.Z<<,I@-2<ZLKE:[\G[ 4[3=7F9**KZ$I[,I!:@=MDAJ\^8\(IL>
M&HJE9FNVNL38<$B.Y2).7U)!JP,A>">G:/0NA.*/G[E?G5(AZ:=<"&A.GYH-
MJU!&)K$A(Q&[SD=%/]O9G7X=.P*%WO<S&Y<F1\G2N40D &>1>@5(A&=#>$N%
M+8]?_1R)=N>64<]9,->OP\A9D%P#+)H2$KMQK&('UNSX%K(4@"$H3U722D8"
MN8M*?_Z.#HB_"/I]FUB!S^Y>S,^:[H34GD=QSG__:?!P=T..BS]]64%E:!>'
M%K5[V-F52[#:[T5NJ/MI*,9;98'MD3*=A,)/,N*[\WY\P* X0#?;Z'7,N)=%
M@K=MKA7+Y]L#SF61ZD'<DB\,.*30DQIL<^/S(;?EDME]:E"0R?CS&43[)UN1
MB6KN-'^@:$:&3J\6RT8<NT>14%Z!L4Y1G#4GIXHVBV3"WP5SNS27A*3@KB?J
MO;>+V@,2+T!9:276O=LB0;Q"2\$TY6G?@DEZQ68,T+H\&5!I!80^\Y^R\F/(
MAM3\ZZ3Q/F *4GY#24$'$/\.0_N]M_ /4/> ]?MU&.6;=9-7?PGH7=,Q E&;
ML/2[[%#@U4Q9CBIHVR%:Z7,]JVY3Y"22,4#^@%7)0*HT/%IQ X$8\U2K3Y0B
M'H?<RV;@SB5R9JL>U7*GF0<H=!T_VC]EPC+DOJ$@'-6/UND3O:\4\D26?C_Y
MM;7%&ITHR2=)P[Y4 PL&DBH'_6.X#?]E+)A6C##!./EL(N:;'H>5DR_BETI4
MEC0Y1X^N1$A$O_T3G1CMO:-$4OAK%.+='UZ=9:Z=L2*29) 4/!:RN9_K?F68
M5P->%G EV!R-JO8X"3$HS;^HEWV3CA<F;Q<[HB.D<<0PKD,&'7*WT\NQ$#?D
M_/,54<QB4IQ9O*^7[!F5,E>KR 5"=7</P)D5?Z31$B.<(Q$$;P<7-V$ U:^U
M3O>#B1IK_)LWV?)9L-PX=P65VR 4]]KKQ)^_0!@]:JZN:SY27\S5H9Z'42(0
M[,<X9S0U=L/M=HTJL$,M,@52,-1[8XKG^=,>;J:RII'F/P#$_-/?:8-WH?ZR
MH)>@^8^/ :4,T_)IGN5".[*QF^D44BJ89T%A21037]X1SPV)XX%S,\R(G6/@
MWBP:L>OX9QF^-S,COO3YS03PW]LVBTYV]9#F0+4WU1RMW77$GO"[])J4"A+[
M_-^Z=X:W;$K^5OQ+(I:$Y.-6="6;]R\K(JQ/F A?(YJ?GJTK/G^*/KP4=6_I
M0[Y^%G/LWM'XY>:H73K,\CFNN#MP?$>=MZ$A4T*3;Q&3Y2R,Z RO(]8Y]>I'
MFO5+9>=V;8/Q>26:YN!V,P0Z;\8C!1)>_R&Y&]A,*1VDO2_I13JCV[S)V7"<
M]0_ 3O'F>39G2_KES:(<'ITK\GX@\=W[[2T^Y.["&7!S_G>/R36$9#F+?&]R
M-W[3(:,1+"5?.=IE7"Q-D4;&%4@WI2Y?A;G#G"^)\4N1J;7??&,X6]*^Q8QN
MHYG"@(?$-W6GJQ-ZP<Q#O-;+(7KI1)RXH# _W97I_$=\@6O4 .\0*IDR9N6T
M)3?D!"_&<V/S/V<ID'0-R$M(!EGR-+#/7/#GN+0N\O3BA&WL'B\N=8GC%8<I
M\G;Y#C+C5?$VYJDZ9+3NMPWL=;P>FP'A_J1X^VU:4Q@TSV2;NT#I2J0LPSS2
MO!GUTEAS]HJ0TV1"HSM>=N'16:?/^7;:8RHZ0+I9'G?U3J"\R2Q7F,>=FSL/
MFO6YUX(U5T4$]][#TL1C2\?V07G8/]8"M9HXQ=="%;^V9=Y%+#K$.WNNQ]1V
M7C%F6[ZBDJPD9EN&6!D[G0@>;WK^4.ALXGKN<6Z^M!K3M$L=\+83C9&+LQ9N
MZKO-X%_<'U<^UYN/(Z4G:I -+3;>NM"M@?A5I<N55_*\'TZ.&.C\![@@_@<@
MI7(S'X@H7F9\;Y[:JO1.$>D5%[SPOQFP'0MD2/7E?5;;B6=U)52M)I/'4:7#
M_!;LZNUE(<:<RD@D %BVZB?FRK+>M7GSUI/&::'<F7*/>?$G?\C0>U->&ZT6
MJ6F3F3--%NJI*)SKREJX\1;"7-725M8G(<%^:2]I8JS*?AC3&T>T^B3<9W$E
MQ^AWIEM4C=ZGU^PAT8G7Q2I%&L/*K$ZFRR>)_<9?BH&W(L_+!Q6'LK=(,F9Y
M,,5?QY#NVC=:QS<9&EH8:,S5F.=SP0U:.L()<+5];LY!IB;@#P9$C]Y[X&['
M_&TV"]SQ3#?>O>@X[N^*5*_\A5DA70+-$S!?O_5T_Q8WW=3WCVCU1L_9/KMJ
MV[KEE#X/AP6'P+8"BM<$2+UIQ@%TP/(4 ^4P^ZXQN+2-L5U'XX7RD[=98#;%
M/>;M_2_];Q:]DH$)D8&N_[]CK1\=^DPM3_YGK/4QSS673Z_%]-BI=" -BE3O
M!3@XB^O.L68):'!14U04KJEZ$F#CEO+47S;'_0-@$?3$1FPQ&,#7\K4PZ2U+
M1FV:)T$A_$]R)^?J*VX_C+YUQ%*'2!E,NS@P\]H>O-LP%M>P0X%(YZZZ> V=
MA?6R#P6X)B-.PC!YYWK#</5:"MB/G9_#^"C:;*H0W:'/.H?)^4*0<P-<7$F5
M BKY_@MQY5.M )8,3S/*F+3[+"15MM"N]37I%[XL73J#M',AS9><9AGV=...
MP,\9WO;:T#0>HLCKK)5]\^T_TVD!B:-@3CD,8,!3T+L.TA]#IK^:7KO.>^7H
MT. +"2?$V-JK^IXZAZJ$%C5:*MAE)&L@X)FQ8!OT8G%M(]PD/?5SG/"^/.3S
ME^T3P29H >< CX@F@E*JN0E:IUGR&S/1ZRO_0&]_\"=PYXQ0//'?&N:6C9==
MU^FJ(>">*>8X^I]%\RGE8E$4P[;J&NJ&[+Q67=TA35LJK'^ CEKG 9Q)SE%[
MT+"2 S]>-D^@AR_^6^&J:=YD*]LH(I6!Y4N#U7S')!1V+W+P9121;Y;+?UA;
MF R<K0VWYU:)0S=[L^Y%OI/L8.C3%:3^VO/(=D1FZ;=R$?9KUZPIX.>26JA0
M"0!/EXA/@.!4YK^V#WTQZ)%Q ?]?VX<FL-;8HII4I_]K^Y!$DW<_S),R6,TZ
M#&O)7=)M#.S'G?VF&>[0&^Q'WXNH[]#(G-#3OQBM-F=K6-?#&3)H&J0,#]!L
M')LA$KQ-+UPJ&?HT/"E $KU4A?0M8ZVPI^;<6I:24_=B^+EOE>^_A/$3:'8&
MGN;J5]Y#&Z2EL\VYNZ4K&#C@^;D^[*Y9@N/,WY15XUU2@P;S,<8(<#9A/80;
MX8-W=(W))>BJ,.FKHTDF=@IEZ/B@MA(N,GYOV+DHM,!E,UV@68=XW,@>PXG*
M\L+7"?U.\>13$C$C=1OA*FG.!:TY2^NS2]Q4)Y56U9M[(YG&YNHR'E;-:M-3
M%9</4>04N@U1FQ)?J93#I4PS\^]&7G&O'0P[,9U49[D\7B]9!-U=X38S\J$X
MI>7 H*?DRF!8G;I.9H*+,I;N1GB0;M.'1NA,U<R(;NV8"A3^#9S2V8I1(AJ!
M7TU5T%MU[-? 59&$,^I'Z[A*O!&Z.X1V7#+3K8&;HS>@3[DF1)*9E+&<IGRZ
MXAF3+PPD6C$D0I^J0.WX!WB>V;L@-_1)DVT]^=%!R/,5-$S.WT>L&(3&0D-T
M3Y3F<G?7<KTP]3J1 -9E)TX&]7AA(=.X]4]E(;(+I>"N[0V^5QA1H]6_WG =
M)#PCP[ :547MH*<DRYZ=CZ1VT,R@U\=<QTXKVVP+T#S<ZF)5T%0=\(A.[AA7
M9V<#88AWD.);J@TR99S0DH''VY7E&)+<IX;;?&^36[AJQW06TMK+1&MVL!-+
MX+BLA2V&=JR:&0WR8I^YNIP!?XF>."[:E[$F)=)\=Y37NA=/Z:S4*[5,]%7F
M5XAU(E2;L,CN[9-DO*MJL3AT<2L7K9]FB*E=,?6KUGTM"-Y5!-RR_P,8QPX8
M. ["M7,VG,P,;\#V-C6#O8ZB0]T2<^712/1-]LF,.NP]"JZ*M8Y4&KJON8FU
MIWO-Y/SU9#7%/X2R-%6W>=Q9;';*%+5/EHW(,CGA@_6ZOW3LL,<0C@>$\7YD
MJ09I:TWOYX-',S,LM]8CFJ ?.5"O]K'XAR496A&D</S% DY_=?8]5O[I1NIW
MM!_^I[,YXTO +<E>_K^<3?CX_0>*X,O_<C:5Y^#VL9=4@3GR <2Q%^W\E,63
MHH^F;6B)R#L/!BVJ"5Z$DPXU'[%B&'J/H:AA\HCQ)35%+-ERQ]00^CGQ(\79
MQ;/=1%FL*\%'[;./N::YO1W<$Z$]SLWW#XF?W*&7<_5<(RF%,<6P!I&LI-RT
MX"1RA<D ?1-R34SFR#&T:@,_ M#L@&5#P*IOZ(QF[=97Z.F YR"_6;\(7Y68
MGLA"!7+0E>@D[TY'L0 =O8+I_A7N":]-(C.KD?9B[&O^BDW0;_T++MQSC<FY
MGR5@+36>.B?-)!U?JC%N6NM?-ON!'79@:&H',H9-*VL\L]YYPW5:T_$?0*8X
MB<.^>$AC3&5VI$<K<V-A6F'AH;6=\];.R\/@Q%&7NHW8#F\<@^;S2G6E;RYF
M8P;06%9277_8@=X]*=]Q<W6^4-X '"<1I33Y"9]-;^KY/"GYJH$.JMB5=D7^
M$_J6'%T,-TEQJ_J415\BX11]S+\WR"[JVX+,R=D7<I]"TY.?2N'-QVK>D^:!
M5;O$5$)FF]+PN[CH:*=H#D<9E+WRGB>Z _[?U??3OKW#4-$C4P]C4G)C=\\\
MY7T$[[FG9<.]=H">>&R=4!4;XWB=]P=(YH<.XCGR[G #+?;5U68S4L_30'>3
MFF3#!E*OR%@N3<;S#1Z9B]@.!B<74XOKHFOSCM3& ?)NM$+6?3;@"?FK6)$)
MB-8<ZQ))JS^*,+=!(B8Q:KZ=Q,Z6A]UI]5Z?[7@,Q:6(_72V<F*,H?M>A?('
M]\U.G)RD.L6<V/_H:P :=/^UU;B$&X^)*\9AH[&OCF"-I1,W\C))W7/;H?F;
M;_KQJ_55X"]:SGQDHOX_@#,@XDH'M58PB$K@U4A.@UW>+26IZJX#Q!N_Q83J
M$^30-XQVJR(9+?%+%EN7'UEC0U?J/\"5:E+174G&S'Z#G[-F)UJA3ASWW+2T
M2='-H 9=@A^.7:)%X!M2-+(9SX$^L/Z7 M"R3T4KKN$]O4_-O#;>,0=_!1*7
MPTG.) L*0(\W[9#:G<0RJ\ X[1/,WTO$_@<PI&:WQ52^ZVNN"-P)3$%BX&7W
M9HFKMOVNR'6%JV+L#<;7J,U+N'\JQJ"L59I 99(+*_CR*[OC;6NYYOPW,&_P
MSW7.,46265K6N4[>^>0S@DYP35ZZI#D:!S!FW-VV&<<[3:GXKY*G&,V,V-!/
M,JF;W+JCGP0RLRF122EI89S>;]D_S0GR-CUU+,1@8NBNU$#!B!X5_<C\WZD%
M(3IEX79]%OV.X?Y95[\,Z)B"!Y<58)X.@8G?N_,20Y/]%P&6KZ;[E'4JW\/W
M9-\!F077A+XMVTQ0&&^-V"]3JR<0-]"QV7U@Z!*&)K/T)>Z*XY)I=<4R28_M
M(30[)O>82A/.6(\9^R(V=#"XTJ+KY<\IOF0> 2#D %B=%PH,[=-3B/^$NJ1N
M*H^(%C\DVU4)&WAYN!?NVMXD@7_,M9VF&/M,\@V0T;KR+'_<]3O9<GEX8]Z8
M*_A\?FEXFI%J.TU]H72"^(3I1&K!KM WIIS-K=.Y!-;M#N.(>!EX'E:-)4L9
M2@FR;_M/CT^RO:)G0FP)%)T;FO(=*'+U07)&XJ1:C=^2L^93!HS3#6D$&''U
M5SBHO]W-,Y;LY4[NYYTVPA:(U;G&.\.](W(O)BI4(I-+;>N&P.B .,M/_4-*
M<*!?!$1!LJV?FY%]#.F8BV%<P*N;6B(4P.#"'AM.OJ!$CN+(VY+Q&:XXK%%<
MGSK'P8F;U#;CGM"UE'!3QO[W><2MZ%T.Z^M7V_\ E047HPAG1,O]ITF-G0K7
M9H>K!KM[Y>J\I/2JP36^4+<%VMSR*=:@(816%:VAUEZ^_YEX9W;@)>?@=8,R
M1(6$&FH(U4<AU6"=PY2"<?H!R"I0@2SM(EN;2X9,LX4L8@Z"#B!FXWFRJ\W=
M>*%8'@=Z)?UJ8/,-&U5/SW>_AG.'"5;NBL:H!NRZ#0.C@KT W":S&@/KF\VM
M;SVN*70.K@,$T=^EBJ<SDV/B7>>%9-E*!R#ZY*R)F! E*J7@"9:;>Z3.Z*9;
M4&@*LFCJR+7%,R:E<YN=2#'!/1@FE.''9SFCSIK<BX#KP3/'X.SZ "\R=$E#
M(T*;82B,O!UQKGR#:V<> JEJE"@Q,[=UG@ SM!%2N BI4?\\B108Q89=>;I_
M%-N!W4: OF]\_UV,;:P>/#,_DI67G^N?3;4S]^1,=CT4_N?D3(,U$2(%H\,%
M *7:'?^&<O9/ H\V$]V<WG.]J]_RY9%*3D@48Z5@F\WH)4,RL_)6 QO$I'O'
M5%A9C21\?I)H4!6,;J0Q3@>O,)@)M_)&PB:_F]+K#*FF5'.%Q5FGX$WQLHKX
M6Y3^+O&]N#;R_"!9#N^,.V2Q5AF$2JMRC!D;49F87^R9"R<3R$SGN!J<W!$T
MFG#M-]36-GE#VC93?2^C<3FC<LC2JK@*-(&*B:R'@YK\@U?$9!#E>"@TUV!,
M>4U#""6M"D8WAL$)2$R\P5=V) BIJ:U.O(-18.[P,T UQY24B4I!;U*;7+%4
M39(3\ (+I]Q-%^G4 (#F9XJ3/A53TF<=?21=NW<_;Y<[)<<B2K9W).NJ/71D
M]O0FYY4G+LH+<R8HZ$<*RK!=XM(H\N'DB60^VL*Z^0B0*TJR KUF__P*>M[!
M<T8SU9%DXDF%ZF5-=*@+JX$E-O!<XB+'CMUG#0/H6U+O:^PP"I7V3$4%J9UW
MV=5,/F9O[6P8,)?.E@9$XEI#R W5%=[TNZ1V\')^5ZW:1>X]LF==;C@3O>*;
MD.E^N*>T.>3%D!"VSB@\16);JQ?'0I77JJ7&GV<%=NQ.&$;*$))>=.N>6]?H
M+SN$6AF>)Y.D?&<'NKP%_NKG:MSX^H ][F;NUM:&'2WJV9AKAW,+B:=K?MQ8
M?Q%?5NF!)KJUN3IX:J7;G3KO+6)>GS$V(R=.*)X+7R]LL1::%K%@*/;E0(QM
MM&&2Q=2SJ=.QDX1[Z\[^(,IG2:]Y*:A>NW,-6'"75@B-./;7EPK$"TMI/^4E
MS2LTV@JBI$;1;K/^'4<SGEQO3\M+YH"J:D9UJ%)9EE12=<:ZR1- *O0Y@T3]
M\_)QT_SEH@B/ :^(6[8JO#MM2._,T#?%_M3QJE!).#@[/EDD?/NM3LKC8 TW
MK'X2JOE%:F8S)*ST:)<U13NB#WUC^8S5LA4HC:M+4G/8Y ]S,)<P1O2Y1Q'
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MZ&B7,HN*7K>E9K8"-R2M.X -10PZ< U#VJ2FI*P*/KVG^Q&W+5/WW6@OXHE
MMVAFUWUOTU"IYH+32U^A,>$C*+BT1J[X]0(DVZ&QH'M'92Y@1]-I,IA.0H5.
M)DPWL>&SP$J)GI+XQ=/BCI95N1"Q[(?$1RP7<MD9KG<=6OGQAD0C6JK..MO-
M5N.E^1M40;#UKS=**^2/']WK)C!]EO:53,6H+(U)_7;+,6TEWU*LV:"I50*#
M__#5\227(K=(]7Z@T;/PD>/[6T!+%;HEV5AWL=%S.5T5IA%'AZ\D;OVP:J 7
M<+O/)I?KT8NU)9KH\X"%FCY7,1+B$5C.,24E-<TBH4\7K%5#$25I:.R=U(2^
M:ULC"--0!@#>-T>SVI"&&!0.[:< HWX#B.?:#@7VY.(;*#X!3=P/^%2"5*E6
M^BV5";86/E.6P=_P?&ETXGLH2OT&&\$P.R-\:9$#P8_UBBUY0;]CT3$;@I B
M=<1YLOK0-YZ&W,?SE_>ABZ"^3^!POTLW!R."\4_E5UX-OW9V][I?F@0/_0.8
MGQ[=%RGE[=XSA?8JX*A>Q>4J/Z1^3'<JI(VBH!J_B5LR"Q85*Y2MP?;1X<':
MR2.L \<"5(B9!EO=DSH"?3<NX[0U#MP4B,?SI(D/S'BMZ0B8E">WJG$2'M4]
M\.OA\M/,J )"8)X?+W*"N;8"1OR,AD4]#X!SF7@\L''9O]9^923DF0+3I!VZ
MR,RV'9C6*[D=PC.?ROG!TZ9"SO4X/4L6R'3UPOJWO6&@S!\;EC>' 8>MDY*[
M'/R+D)5YCO+YM2Y;KGE.K2?#?AP&B3 5@6!K.9CEOG$46+I(.O$\U[5^VE$]
M%A/0*#C'MAYK4!K6A\E+<N3$TQG1B?4U@QG&4?%BVY%]HG#B[M$PTDH+=^FJ
M^+$%,RI G/!L/Z9^'6<(*0TFCT*:4!#&8+-&:9O5EJKPUP=H2:IN1]5F@:"N
MIL)Z@42X!@'XOM3"\Z?2 U%OG0':R\B'?.>+<U#P_P6GF'[9OX_B5W8UPPSC
MJ9/3RIY74];IA@^Q,?6,J#DU)7S]*B$@6TN+V$41 PU?M(IL33 '=Z/,GT^.
M*,11UX29D.P%ZR*3CG9,X;.*D5"6A>- ,:B>C.@/9N9SF*8]^_2&(Q9<0<G/
MXTN]U49M6+>"U)P@LLU7G^E5H.L[D=<C/R_&"8O7" _TE95)PH[*!3&TZJLU
MC?1*KD]5KPUZ]0_@ :;-Z4L.7(R<_4$;8AGO7R]H%(N_'IO3-.$R$P,9JD4G
ML['A($QI#I(WW1UE)(Q??0QEE>\D=@T2P1W%D'N<O 0%C$CW6<ZIU7#=L<D0
M @H^1U;V'LO#\Z9^=?]Y7_O%W*V!4\2;R3H3'%9#W5T@?F$^?N?2G^B&1/$+
M/*'')BEF.P'F#-XF1B+DA@U8TJ^ N"75BV45)^T(BP!3%62P!0'ZY8!6IT8U
M8GE/\I67>%AO,G_^\3', ACL_7P(ROXA:T:*WQG4^W4#JC:J_5G /KF1S8*>
MJS;WU'\:V/OH2=0M(!A6R1@ H41H+![A&3YYVC?S+&E#08LGNWH/VIW,VVE@
M%YOI4E2LSF" '$=<&HL6_B=LUL'M?P#@@N=1MEFM<XMJ7T8B?PQ)T4]J'Z=Q
MD#D4>X7.P(V)V$6Q3'O #__;Q[SC6[\# 3P']%WB)CKQW3@:&OV>FXO]C^GI
MJT5Y\0W[Q%=_9*K:P<_D-<0AH$G#LYU$@L87/,I#![37WTQ^_'@XO4H3$A&\
M07E#('[BLC[7J5DI^_.>(TJ**38%#7:*8?NF57#=K''>LJA*+"K 8P+0Z8V=
M^+<1NGE:2M#GP7"\3,](%97<0&R.19ED%T]^B\<;5\3+8WTTJ]?'O]$X9)V9
MW:XV)R5.[J/-/!ZC=JK.R^=UBL;U,TK/+/3F&6;MKK&[#=XN5"SBA7[F^=P4
M$CF<ON\:L9#=G47ZL:"?8[:X]_BW#L,OZI:95\P1H7X;0>9D(+/X&#W!JO,C
M0B="P&I]49/SM]3CO]P>E2$S['MV:I4WSH,'[)P+'S0Q8/G"I5YS]<]#O@6U
M3WX016U2.)S1" 6^F$@7[ADI'9M,DP$>DKKHMHOZ<"[PS$X_6T)UA(V%U"@[
MHNE5CH&F2-@X-#%+)6CA'7GHG>JKNY-8:W'G^7R(Z/Y:IR^(7VBUW3?MRXFL
M_[93-*$:(.^ $H!%-2]70V2Y@@G'[3KE*OLFE9GZ.OTR:<3U+[RN'9ISARN3
M&(C_A?+A97#0OA_C(3*[5>$+7;Z?,T+<S<G;/A@BO9^4A0?7H\I6VWG\!"UB
M+:-@^^OZFBYLF ?/=N;HY*$<(G$F39(7(?]C<B=@OL(MRZ9>T+TS !*3U=*1
M8%>,Y=S,=HDNWV7%=&2\(C?>0KR15W@<GLGBIX><G#N*'=]6+3Y$[)$;I1S'
MU0K#7-QXLC,ENXX5'E%!6W&KBX;^-KY?XU2P*.]C9O9/R].;(428[LK"L2>>
M4\_8QCJL"D/YZ?5F>.@G=3:&4J#,*O>$P?.\IS19N.WK%E.LPOG"?4[M.DV6
M_P#2N_I98UFOM^H9N2W']PMTOQ?OEF/KXA\LT%+RA;Q_]X<T*>TN;.(M@X6!
ML:KI/P#9'KUA[0T6MNTDX7O+3;[LFMJ7]PL%26]KA?<B&W[=XI(J7Q'S_,Y!
MO;FV_+LH)&D;#ZRWJM.V@C5/*ND.WM&.F*P#TTP2X]6CM,_)M?0(+R$=.E&L
M:U3+)IZ/'VV%8C:C]9QLZ^UCVXZ]HGS$89RT9NE1O P&>/3N%4U5"DC^ZNW;
M\- I'2G9MO;=$WH)6$@>LZGN#?U A*2U;P<!83JK%(8\3$UI0TU*]@WNH-L=
M#>5AO$[#9>73+_FGL/K8TMYV\8!"Y-FT&,#,$WBYX6CU15JL3Z^PU-"P4.=I
MY6K35 F:(Z2Q75JC?_$\Q\SBS$2:]V!0S#2<L^2WMD1;A_NR7O,X<$X5SM9$
M&=4Q*B4XD7INN1/>&E>(8V/ @;F]2(V?NBFK),U'5%OF5>%037"MRQC'X+-/
MFF!]-8R@< H?]6]<)&\>HVF>"V 8:<,T6'CNJ/GNA0AHO]$T]\JJ?WJ=3\#C
M6\O4"3HJ*HMQ0+_3K0"I*^AWY?QRU>/UC"M(R[1'A6T4[XC=Q\*-FV9G>+IF
M=&H)>[B>\FKJ81N6Q]RE1"5'\EE6=38[I48=E3L)%[MGFE+-7:,M=A)9M"[A
M+T94$>FTV*69Y=+Z$8E[<4_/GL)PN-P[U[B6^Y8$9LDFC_7L['2ATL[#"+S'
MN11!?S($F]H3CU0V8RKL[?Q:>N*5K"&&W)P_?X@:U'+>#*SR?Z1P#1JJ>[1R
M7EMB<^'$58E1A@-8-LZV#@9O7]"\?6W7/J4\3LV*=_+GX,D>E'6[S;=>SF/<
M$S7/N)]N[M=HK-(S(>=@.MQE&OS3>9Q-810ZFS0/>(A8+75];0W/E9VT<'>
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MGT?UF=%)G ZLUP_J( X\=/=;A8[*7>;$80:[._N>;>9^T1SYIB60G]!I33I
M#_$"7@A3I 0^.NV.I_ZU*#>Z\*]0^N? KI\K!X%T/>+DM(D8*:_ FH6_S9 1
M.V1Z70I33#">5(98S4!!3P59X3!.X@4E#MMNK3A_43;^A5>E#O=N8+KV@M7A
M#R-,)RF6$I^%O;WT=X#/6FM_I3\\T&"^9]AAA=P.1<2_1]J&-YY F<GL)B-L
M@K>.G-:-]18L&$^2;N"&Q,E0QE,V?_%K/Y*O'*\4O"(?M<WW=FTQ$4\%TQ9)
M06$=4:>4F^P8;D/0I%G&"'NRP\3#W![#S\7=*Z^PY'VL]15\03*5VA(MQWD?
MNA)BW;A7OK8A8PAT;-)I$EB%AAM::/7F'T#=B<>-6QV#.F88Y^=#S%0<;FTQ
M:>[^ 9J8^! CD4K-VNK2D/HYOO10\H1[;=$\S_G\>XKIW66;O!]U<^><)V:7
MOB5!@3W'N7 Z.?1!1BMBEJ-NX2)]Y7M5_M3 LGJB9]V52^9GM,F"S(.L\>.S
M_1>.^? 6<LY/7]T9R>4JZL6W96PSW%Y^L/];%SI[_G0LG]W[@V5S2,'9>&VF
M0BPY,3<^3\=7(;UR @&7-LN] O6^I6V&+GAN;M;K6F/7 <5WH 7_H_DX(SP^
M0A.J>=2+MSGN:2LS(I--_"88X0TSO3V#<N(#_ADBTC(+$T;\'T*5^T7YCJR.
MJ1Q9H+(VO1<.H[*,^^6\ISCQK%TYJ(Z6&"'["QG^,0K.*U<3BRH.LUFQ+QT$
M(ND-(PT?:!,9C. 4ICBBM3VO9@".2_#_W)-SIQ6Z8LMH[",$KUQEKJV=/W7Q
M-7:$#^,TI6'3!$ME!P_M[1/S]I#J+DFI*1_#D98<=(+F+U(0/=N4272?S7$N
M/<$ HC;I*#^LD$#KY+Z]@+RR5+!H-QZ^8*XH4Y(Y/G;-M2/:_!/[_"^<L#%8
M-4T?T?$$F8HOM1@T%YTW;J:SDS<<^>Q/WWZ]3P\V,V$@3LXQ A2E@AOZSG<*
M>O..TE]=V>X?(+U.0\"7_:ELX\ZIE]*BIO,O@W6-V%Q3B7CU"JX-V4('@_\B
M%2S<H0814]?AE+75"-W*8Z A-'!V@7+6,B--WV/U=&1GRM#X\.9-T%:*,@_?
MK^Q]^BB^5J4^XU@0)-FJ)!'_5UC:3&8U[Y//W%/^=Q6R9Q9RH?-RM,(;E:*$
M@),%F:-O^>\;;%5L!'I1-Y$QC5)TCC$9OR\.I+ZIYL6^CLURFDZ^%Y%S/BQ7
M]%;_L6BH\;ZG:?]_WB!*[S7>+K^_WV@Y*52^W73X!Y"*NB]Q4E(3OSA_'&SP
M?&.-?(N5><MG&<'?%VZ6#N7*S-6;&NE9;/6/#"#\!WBR%+TFW-F@JV$T>JD2
M?:?5D&'Y.7&[.M7J:HP#^V@.7Y<HK^APDGK.9)S)=51PKGC<S(0 4O@<L(T\
M^@<H>H?RHTFY:N^^'VOP/9X 33W;^I6:-2PDMV,A?)G#336YTO_:[<L:L1]'
M]6Y>ASBFR[<@B5A/WMUY45.-/[D"6,L/&T=X5I6I[)E(9&A4LX^SL;$!L7%.
M_];X. O?%N+)U]&$UIIO<9Z*S]$M!XR&6R>E:_PP(2\J$8NQ:1_,2O"%J1P5
MNA-%K6F;,7\?="T,;L\DBKB^%1RF.#X#]B9D86 T_C0X#A\YG-ZTGV4%*9:H
MTO/A@JSF=SB#O_H'Q8Y'CJ<(EE%K EG^?V.0 2*PIFR:S90R#HN*BA( 6%KE
MR?#I5'#I)R&'5ENQX2\HBDFZUZSIH^JDS6%C^K(V=4QYZ43MM,DPG""<(&D
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MGI.XNJC171UA$&FK%^$G7:\TRBP;:DW>^3%R6F[[JUAB^),G@[:ZGN0+;K]
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M\GX'P GX<2+\$RL=<2;:MO8K0_$%8[ +#8NKSUZ#:*5IA?Q4$>U&.M\SR?J
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M4+/TW6V,H[*[6SPM&#O%<._7PH1<\X.$WDE1662++1GVL ETDY%OC&NC(XW
M,250V:K0"28%(?9(B=-SP8VE.8]O6@SY-&K%=2Q[Y>NHYRF/F!;[FS9'3:?[
MFU.7?L[5$5LL6.\<+,% %Q:%[2(:E11%+,M8\@RY;[W:A;[5";27UGM7,UAU
MJ1!#&U2.S>SYJS"IB 7'/'?WLK^+EKQDZX-'9S!?7'A</$:.B4Z+PFA$A,]#
M57_U^W@#$JD'[B\N&;1TO:VX"7ZE[W@]5_NL"VE*I9'#9SSZ,':U8#(AV1MD
M\,%@[(Z"R1HI&28Q8*@" 58?CCZMA&#,&19VO=VEP,Z[&\\4Z2E(.76-4LMH
MO+ 2Q11%I"Q0S5:>[:_][]F7>&=%W1+C41L.Q=*:4WX<:R\+=+7-)4GS29=K
MB9V--=42::OFB=E5XQT'4I?X"G<5ZGZEL9BO\6Y-O^1XWR"4&?:GAL+(@<IW
MNZW(6EONJV$^V$235+.AZT6>_,-6#5M%L%6.;)<FE3"U&@'G9/N?]$M-/ <Y
M#41?*1Z?X<>V 5/,,'0^FK4U&RILZA TV3*I :LAU@22]T97=[_.'#V0CY?%
M.HS&U01>4/7QVG,^@B=E&&V&CS%= AP2O$')1&PE/Z124]Y[%H8M6UI>3W6M
M9&K /-=+%L1IE79F]0Z6LI7?/W_/EW5P)MKQ+7&2-?-5-_RV4B<IK>'F5K]-
MS:CM>V83W.@54)<1$2F2:):<C,2[DF&\VBALWE"O>!ZZ5_^$PCXYVZ\2XWO]
MRU8;*W=W5U[][,LN:UQO0]\FU:)EZ?8G;261J^R&8AX*K>ZW/=I"P2^X4>0J
M4=,6X_+U"W^36<N3M*].9TV@/K>5+&JK N(S6][!*^8T&1(!1F 7'BHQVB.>
MV1:3\R]B]-Z7F6V$"$]:E6$Y%74=)_+7Z#!]44G\K7'/>>-WE9:[YX9FKON<
M.2V.-G,9-XX3O,UF!/P=,$/$UK9ZU6P7)R@GL_I*9%P<] 1.]CO5O&WA\E&X
MJG]*UE3EW(7Y2[-&[(H0"ZNG%CN^GN0$[[:JW#@1%F05FF/<JK-V82$GQ86B
MF?.DG>CV=Z2B-='D'"\,$9M\RED84F\"]%GMT$GB5.-6RQ)Z8N?C/SI:(ILU
MG!GL;IT[O/A\[*-M2(1/A;[6<G<"UZ2:JN3W#&.X8;>U7OYJI$B\*;$GD@N>
M-?2\U#G5@D=TEIOZ2O8; 'JH'<D_3->M)EA1O"A>89,P11UPIU95FZKV80W@
M\^/8Z# C_&GK9@.-FW?%5,/^A(R@=(1@=^I*9[I[N-Q*;\X?D[O5T59=W&&P
M$:<FD+*'V#3*#D7'VU".G(9X_Z3+,XH9EZ@]N0KT*QG4#/9VK!O5OGD-/2KO
M\PTLS3DX=J6.HFC&,_OPNI"_ZDUCSS#YUX N\ZGZ=#N)@C(%FN0DYH:2%UHW
M>B_7>%.;+FA\C^8+QP0YLK32)C4\Y;!9=CP8&'D"[-_)ODZ@)*'XH[TK6" ^
M0;##V0]0)HB.V.1^,WP*NC+8O<ABPO:216[L,*(0]1D9NMTUW0Y"3]V(\U/?
M.<$&S6J@[ZGP+%0M]=^+/8=9<E]!9#LDGM0Y,=/EI^$[F]IO5<7VVKD>F1V1
M>'#BTE"+^IU1ZK[T=/*?#X\3K6?[S4IE,,)%Y0/B3N(+[])(@7+O=,YS, X/
M+_"34&KVQ!OJ[;MAN/%,^IF0=:I#*V-93!'\R^-'5!Z*D?.5#-6BLP4([<O]
MUS Z"1YR2V29B:49J):?2R[3N)13Z@71#L0IK%[BJH/Z,K#)V?G$IUCJ+1Z+
M\!2*#)P= AW2]C$/$.7G VZ[>OZ8W<:Q3<X;&D&+Y*&"+YOC3]Y8A3NI7&E5
M1IP\=I5:EPK\ _RI"\](KM.[ 5>!4[[=5,YO!?F*1TQPYVL*A(CN(0[3A=RE
M@L9(%$ER'JWY;FFME-BX;Q!FX--B%LY""X\H.E"_,3#N!P.N9%JY(-0E8NS6
M?+9&7:9I3\D6[=T]S4ZY,-CIXPC+:7%AY#G2Z@CZ&TRC@L36,'$AQ<.2BX7:
M&?9+.HLM"GYHD\Y#F-B"/,$C"[\7+R]K<2.2?8+#DR,DR?\BD2PM/+8M<<:A
M?:&IMF*C#YO0QT%V;:HZG14O.QDC/#2W4R$J21UU:9O/O> F0N.;Q\NV:9@B
M@<JC3?O"%@7;2,A^U+ SOS#* '>G=(Q8"N!7; -E_,UK%=IVEWZ%QQF+-Y"J
M9U@E4DF1L_<"N>BEBYK9!L1[; CJOW<=M&@;>DKAO\_F*T+%"!>A@P7L88:T
MT7LIF?DNOS79L6@)"X@6B;*>V3 X?4([>V46<((T%H::B)#$.EPVZ26%#8-"
M@OO4R;HL$VUPC=$=!MKU[6>P<5:N:Z9-I@'8)=6/W)<"^1:EU9PG_LR4\17#
M[!;M-I@P*P+"=V,)#<]P5J0&XVLU)=!/GJ;MAQ8]%WU]&;_E1-VP5,&@!4:U
MU!]- 0Q9C%I-_(C%D>OE0 ,-N"/RO55Q'2@1EOAIF]3JT19-T5?=1]OS^G6%
MP7[:1DBF>B@%C5(T5;-4M7'S1*WUGD';L9=@<DO"ZV"XSD#0'/\!L,9Q,Y]Q
MOE8V>ME5H>6D0_R41JN@FYP_8!K01V;Q?'C;<B^N._ZASM@_<I@X?USJM<A+
MF.$#@4BPYNX!7FNT%1HJM*\E0>_:Q_D0G942\S[!NZI?;#9(<TYZD':8XHK;
M]F"DGQD9<'GY#T#3M1]*E$45 ?QK>4+V"*X%\?(2I+@N"L&-B-H2CAKFUGK5
MHR)/H2\=\@._;&\%&,J[6AWB#:8G,3TI/'OQ0>[[&;7MW -^#?-:4L8QD^M
MEH:*U(G+-=7DZ-?%^O9TBY\\(T'[].RQ-Y7OAP_ E3<04.$"QW+WD1SQ>S/7
M7^F7'#0!+2F\MH4&QB()D&AG ]FIHA)P]:P[3=B?9QKWL,".D?RY.='VHX 3
MAB@&+Y)!NLR!E(Y2UXDB/%!?:/_(RWOMN\&9?)%\_0C1K#??F S,=@,>I=^R
M:2[9E1-NKAAU5@M@439G&$HB3!I$V4WDW4MQJ7E)_N8ROA!\X7)N=T6UJKJ;
M8#;-*N\%$,^*$^IJF#5*?O5HZ.EFA-]O5Y#D7>OT1R??,2;.<\/)JD4)IU'
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M.*QD6"O&^Z:]0WKY2N.G1I=3X5R#A:8EIRJ6REFR:=Y]7P!U4@ K'R1KL\7
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MW^_-CXG#8BK#HD0&9@ B Q.R&#/ ;UQ<94)/\)0C%\C_C6T %W1XQM@7.C+
MWUHB5,C":%@D60QBE>?MX)[WTT"[.XC6#O,IW5KI:2GX#VA)K;E=7A0(AIRO
M*+HV,TN&+ 2E@BG]5X+&H<P(?+YD;)PVJ=@ P_>,%O8N8E^&5AKR 6")VGO-
MO^TA6FCA5VM!>N_TVL7=WP_OYF@=Z0N?<=_3ZJ1%(?\!,(&D9L]?V'TNST28
M!HTX:$^H+[,++7RO#?+D?'U:*Z_GF+LHKB;"2%N_3DDKCVGLQ8;G*%0VF'S=
M0*PI"+DT&R@J4ZVC]G9O]O:=F3\\PB]8Y>3C6?O;ONWI"3\=:=;37_>;GW(
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MIY)&+K7P!=T4ZP,\/!#P*!P?JEY9I![Q>& YS)[(A4.[)V:DGD5J1JLR+&;
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MA^?'[XW<=;J-*APW N0AO<?J#'*9SO6]Z.D-CRY7W1UQ0:]90 X,%=Y)NQW
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MG?,/0+7M 9PW*TQ$KY\=;>L,6]ASY>L.SZL-JJ593(_-:@B>Q&:%KU_2J.6
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M$(Z4&M_#H%[&8G6?<R1K_=MO&U'\@F5E!?J+\SADSBQBFZ3](4V=O!6%'T@
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MVZ)4*9*WYI/CF(S,-"IH3KWZZWV"Q*I+[IM\CT;%%^%(58',MAN6&YULDV,
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MG#"-]Y&D7S+I/]S&/T?/N99_-W/!+OR>%WWU>!52W_YJ,B3SY>")2 [??+P
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M,YKX_E;3D#U3VSF@3QI4#Z].Y",W["_A^ZTA9V,'_:0J$4BF=\QV99_%"Y+
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MVGBSMO</N>C#Z0/6)388^>ZU0$F_'@C5[[';@+/<+9==3=O1*?8<E JP43:
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MYP?,8CT #X)T;#;7BY=S_LFD%4\8N.X8L8$2+52K!Z1@J^TZT7:)<2IBVP!
M?8A<\_1,,W/]@NFU<7:\[7)+4HTC\V4ZF>'*[:ID,FM?<".")QL-VJ=6]-E@
M6VF ;].9<@=^XNI4V>E $D\MX5CUP"KUH0X[4!O@#DJ?>OBGFG[J_;RDU4X'
M&&:4J\,NG/."L@SD)RSY"-<'X"QLRO/-?]@$F0N>JD]\KZ/C3>6''IPXD*J5
MCVX50I*-$4QQ!PH:W-AZ! .^&  X4@6P59Z^L^I;(S@95(PC*?8$,/-8OD>P
M?JRJ35^F&5.AO!"7OR '%C3VO6V9+E5S?0*LJ T_OT_7*JP+? *8!(J95R$C
M[-<L\1K#Y @<@[[JM"F]]EK\6KT<%,8GWFI:#O0[*?++K.N6,NASL6'-D9\1
MU][^7#"$M?\8EE[E^#ONFU5DW#XS2\E\3:&J6_T(SENBK*3&.L*6Z=M6<@_B
M55+E($1!4,1XPC03PJO!8/_#-[,,G92=>D9<7L?N:LW"T@SY+P^$C5]<D7!"
M9'V-]U?;-M5*__A0JS;E_Y:2F,&)?U_VTNX3K(RFOE013]WF&[M6B]I6B8A5
M#_P>OH278C%NRKU\]=$%3R/H@H4="-Z8"/RIZ9>IZ/G\BR<QO-83>):KQ9/#
MS7X%G!S#%$<484=+B-H *OKG$7>)E"20K0#E!%",%-9F:6%ZXBO;#"0B(\,>
MBPZ'EJ"VB0[5;U+SZI @=_;;E"'B/RE<X5G!#)!L17L4))S>!"T)_/."1::L
MXO.5]4B>:6#2GO?PFD='_W?!T# PY=M]P*JC72O-J5NDZ[3I^'@[I_;Y927E
M)!<TYY1%^5 ?_Z>R'"XJ^-"V86B4[;+^>F[);6/D7S5/P,?_I)M:L;%IIJ9:
MZG0'8*&HNGNX^\:CI0#Y3LRYSX(0:*A*&B=TYRN$:*;(U@2IZ![0M-9#-RE(
MA]XR]&H?[#-?J*+])T3-OGEQ5 3FC,403\V7O0S_)%A&,]VK>[#,]%X#?(7Q
M?9)87>T(E=/9>:7E\$:].PG&3NFRYJB"G6<(A#-C@G31Q,7ADFU+;23"78KV
M?V+U"MPA?['#L$%=G  H5RWQ]$_\1>4,7<,_V-KM3N/$46 Y?X/QC78FTRMX
M&G^N&$%(%?EG;S92R6MFFQ#D?_X'C,)<V"&5GRZX$"4%?1W#Y)U0K8*MZA7#
MMP0UM=B0CN$-Y,S!#DIQ;?W:T0PUD.WV/PJ5FU#QFU'76-C#?6)VL@H./?"/
MX4?XJ)Y0&KD8D&VGAG5_LV6X?'(SLEC...NM#%N@Z]66*R7[Q;MH9QZZBK?4
M)CH=6'%K7NQWF)XJO4K>B3<.( 4[]^PM=D$*(TX4&[I;)1S)=0_A(:!<&,)K
M/HY2>7&%(25L?DW\MA9NWD%Q@4Y"PHR"*<"*9%L$,E[%78D2!I+QF,V;^B6#
M3$.2<1V?[N$?]2VAFS]I$PBZM4>*JE15^32RQD-4* 1RIE&%L;:Q0[(8:XIN
MORPB#/IZ$0K<AI0QV%[MII\4G?1)R#18H9DFTWP[EF*8!=MU/(J(6XPHF4)7
MU?M%"(/JA%R&(D2\6CJN8FX+=0 ]Q99 *@V$!0RS12D#=&RV)#OV&@N"CCO6
MFAV/1]$(42'8;\W8_RGY$ @W]#0>UH?S!"A'JO ?KA"6\-@7TC-4%>DNW1//
M&$@%0]O^TD(T*"<X5>S?7<MCRXM>O,TTM7TUT@2N(MP:&::Z%IWYQ*94H3-Y
M0_L9$I@VK@3=>^VJ?BZ<L]D175$@%D6D*X"!M*,!#'>((7PXI[R?QV$#E.[_
MCK=*P\P+V_;.S''\<*#*,\%Z>/G@NO<MI4K0#+$+Q"&J N\N47L_1\DVT:'T
MS2+R6J"%M"GE05_OD!BYEJU?4"4T2Y.69L-,L\\(8!JM%7E\99+=.?\BQ<QQ
M-4"/0F]$T!/]PJ%])1=.#@47]V)3D&UWA\JOOO>Z3N%MI;GYP6C[FOD>]R\N
MX201\L;.$8@.J,]2^6)KFM4?OQ4(E)\ K0XP^5J.]Q0E.K2-+<A<S@XT*JHG
M>R63M^*2#_I##V3YU;,P0EJ#</<[E6P0-$-D#[14R1+ZCCPG1KX+[%DJPN@^
M%69+0WW*?$/E8_7@1*]%W)(-P1O9LLZ1]FPSVM44?2@43:MZ;?K>-',.=4Y#
M!:N*(<3WV.PK=].B.=E20;90_B+)U,HN5!%0^4HTD\;0EP S7+?8<3&5UU.\
M17@J;.++HY6#(H:S&@^+XQ)D*]IH)!OB2+V7V$$2^[TM)N0LZ*A$$VD64NV]
MK]LOU+<!VC;+N<EKD8KMLME.BY3)62SXGU,M<W0V;;G<H);C2#W2NW^\BF;N
M(:C]"U%XBL<CT2CV1Q:+UG T+4TO1 MXZ);1P(QRJ[%!"WABW)'4/X1">EF-
M!N/,/'A]]5T@:']MU8*YDNDJ9>T A:IU "-$GT9!Z-THDX?"GT1O2:G:"#+4
M31@W6\\MPQVYY'M0!?W8D:2Y?Z"0)_$1 A=M_B#]CZ8W]V^-;?"8^XA;/:M]
M-F8GXC_!?X4]?PC.4&G%5G)%9OS'?VI6:M_LWW'^_C+=7(/FU[Z\*5N+,.U_
MW[O<-_I@+GJU]QA6>QQB(1@HA5QMTP&U<_%2\%1)GKS0J,LE7A&3S])S1Z7=
M1=W0#/G<Y0C'II%/^2YI>&%E^92PCK.\'+'DK3EH?/-]E-KE2@#_M67WZQ7A
M=_&9DO-E;^N> &6F@[> UU_6G@"?O>O>;7,'GWG^N^5]_07O3UN-6](?>I-_
MQ_8_0JR_3W>?ILO^'\-\C3M/Y,3($R"B[.:N[+QX\E2D5/:75OL3(-!H\.;V
M-UWNG0Z'2=GQ<M*=&??-?? LF]R(P)^!I3]T9U^ZPGH>4S<BZ>T7^_]+WKH,
MK'?BUB9/LD;O.!@C=MY=>:I]4:,;EF,-&=W79D(_ ;[.OOZJ]Z__Y@E0XVK]
M#!Q8+*>D]P20;8_8!3P!SAJ> !_W]*R[C&X7MO_NFCT!3I__<-1>H_@NVOIW
M:O+F[L-UMO<\8\3_:RG6_F3R-S7^WQ\Y]('<BECZG+MDQ$.^\[^+I@CTWE<1
M[OT2G5:YZ6J*_0YC].%MGOKK.-L?H97_#WMO'117].U[-B[!W0,--(T&&FB@
M(;C3. TT%MPAN 4/[MV-2T@:;]R=!'<2-&@2/&@"Q"')_.ZM]^9-O:FI^[M3
M,U/WU?S./Y\_=M7W[+W.6NNL?6J?O;])OS[V_NK_D[WE#CI9'IKZ%^!=_;*7
MK#Y[EC_Y@X'";>^C]<WLHRSI^&C-J^17A4K]?P$G^?\P9L7OT'_T'[XTQ*1^
M!HU.JO@3Y7H[@/<7\-KB+^#%$/:E=^/[LN[;@<Z_@+G[ES-%.(%S'Z=;5/;.
M;LP6Z'VQPG]K^00M:FB]9;_W^UM,_TA,]>/[A6M!MX=BKW^O6MWVO_SH:3$L
M6^88@]$5&'9O[A]_+Y+S%T Z>GFC=>Y5OK!QNG\MX_##YQ^/C?[/AGY, +W%
M_7P]ZE>EX=\#7K9VWI_G\"*\R]RGCA./"?U')23Z%["H]>LX1D+\=ZX9W%3
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M[7]!*_W7$VB25O RR&W3YO=IJ2R-9*<A]L_$]S@%<YZ]^#"A.@DBQ,=O8M#
M]P:\HR8N>NW6SZQO>NT53F04A!,E^,Q>L; I8Q(TM)1UFC*)XEPF7I*7]1CT
MS40FX8:[U@4G55LUT$+"?29%LQ4@(^39JO*+,5LG<-O378F$2*4;-7-HW:/D
MIE:_B[&G^6^N+@I!ERJ;28BM[V6<$-:M8]U".':&+%<NV2-#:=6L,6E4F)T
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M9OR1] J:V:XJ[N0\?*9<]=5[J[38LNK=E[DG7G4OPX>& P5&_7"U23L?N%D
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M"K#BBVF\Z=[[I*4-T>^KD>T&<CM0!OI,92H./Q!,=-7!5.SSN' )=1-YWIN
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MGGJ-O'9.7;RZX=DXQJK5>POJ].NG!O,_KWD#VA-K)Y^GC+_FESB.28-5-*_
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M2BO5=+3A[WC>M84%C5-C+P5^OL^>+DBOY I\=C@E4Q,J)T<#$^P2V[9->=;
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M(V6JW[GS(3VU_";SC,E+=@F97EPA=0YN^MJMDL_E..6'+M@P/@@"O[LF,';
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M3K1GK:JPKZU5V9L<3+R,I)2<E,.UF[U4J@R"2:NU5 1__#3_ /_94$L#!!0
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M:?;?BOV?>DT#XGP\D//X=@-(@,TJ2M8$_O_M8#%GYT[VNV8\DP???L@T@IY
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MI9V*^A!V[DK)MTO?NQP>\I;@DC.F9A?Q.--"L_J#(,#\7FTJQI3!?22+<W:
M38R[--GV'9)V-*=TG]&7]/0$G6M7@]_TO3KY=;[V>;UMWF'IM]9*CW@@ND6S
M/ QC[;Y L5%59JG4?4#^[5NF#UJ P0M$67S[*P*/V?Z?5<N#T,!X>.T3NM.#
M_$X'Z=;ZH6MCAG9^E5>5%8F2<Z>H;T_<^GK5%CYD#7GZ/ER<(\I"#./$L =I
M@04)5'>QLVX[5$]6.RC7U9\S3[)06P4*_J;1D QW=@$7\";'GL<-(ODXNW_,
M*]).J7S5B%M9;7#)?A<>.5J<(U[Y^=N]#R9I  [/NLS.(%'RX1(D+P5R(EH!
M3WF'5@C#W_?0'(IN;9P@^9;9&JR>'C\'R_S X +-WC^_KB+>!<Z\N]8Z.H+T
MA4\N,:QK0!.FNC\74/KCKK?9+:]3F4 CVH_5>64NH^/'Y_<4Z3:F5>L?2!0R
M.?6 <LB.Y[+U?1(EF4"S)?.R[-$I'!EVM)G<]/+07-1+D?0$![N[D?<^8"H(
MAT^U_7ZAJF##?ZTE=*%T)9MIB T&7U,(4-:3X8CYFBG3@SM3^@XUPXC^CE?7
M#)((?CZ)6VNGKCX,KXZ_?%@P^K@$"4ZBC*Q/7V#<!B$8S%_UGM;0#4MO%:7-
M0Q!;#.66SS1!TR\]>\IQ4Z^<^/T]P\VOO;UGYPY<V\0'!#1>#,H11VSW94/@
MB@"']>OV[?_L@6*SGL,>(BGOR?7H3B)X$!'/.@X-]8"&W@+7[<#\Q> DG-9(
M*9W10M7*'C5(%_D1'G$@1'U@;%:]:+;&6DS*4?W4F5*8F@T7*),72(C&\6$/
M#34?""-.^[G*)AB4V1_ZO'RIV>:\2KQAO/+GKX=LSAT?N,(9A%>C5EJ8ZIAP
MO"CN$[IF/98E<#7\X\1;T*F3YJ)0?YGZTG?4X).>N8^V^;HC%_!-GR)2K%=]
M:!W+%-(JG-9[AHZ/"PZZ^JYQR! S]3S3^:GIC1,/;Y7S[&4\AWU.!]7)W:2X
M8SXL656.J$BE/UH2>SS8Z_4O,W[.0#/!]9Y*T\S+.<'?3UO5VI452RAY6Z6,
M7$CCUZS]['12T'H"J8H+K"I2_4P/4(E)K7O>-]-ZNUO0C@]V*-;Y>D]/GVD:
M%2[YS4 ^_BRKW_%8_?=[(R@^+&"@ZK,771&.9!J*"*AE',',N@QD7[D%V_JX
M)<:(9S_F C[$Z4'J5Q(4S]N)0XE.^J_$\3A7MULO1L:Y7[Q;62 Z0_2M.)0X
M !8D1<RG3N9>T =BMCF>VSYQQ:CT,IZ/XDS][/E8V@_&36;2=^H-L(O"4%57
MCI=YJYSY]^D:5C'&GYU(%&5GDRA/T&_A*]:5<R"1X<A^9 JGS%UC2.[HJ2OU
MF_>B)R[JBB6E?,S(Y-$LEWHH(L3;4N8^9# H\2.B8._X:O.RSHEANX!WIU+S
M%S).-ZXY"']0\]QE?=T<CN3THND/N8 TRX<9^0O=,OQW;EX:M&O*1HF[G)WW
MVL)/6H%V-_?BR^MBSR(['?%!<UH7P*NP>&10L*#?!NHU:]^[=_G=,CDALKD7
M:'%?TL+RKY1]2I.P%"R6ASWY/J*:&J+J?1S!$;%C\OC>\6I-*>(,/G29FFI[
MZ.KJ"B8X/-!4L11]E=R@?# : ,0!0%J;3+-#39HMR#:\ W=56_VZ-,2R>_VP
MC68AN)1AKK3QPK_1N^G%3,"=0X4[YIY]:T3Y101J8KXGC>HU'J8^BA%6C=F!
M0[+TP"EJ,+AOB26KL$A,0 ;<K:&28M%U.<6!"R0^UFE26GR^5X7JITVC7+U[
M]8!7\SM'[R.6,I]G'!SZM\BT9>IZ+$X"%+("W6G+)U+LOI@>?VE1ZIOGN7-
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MPLG9'QILWPIZ3=0V<HL@^S?<::IK>4";<AX6!X3G3Z\%#^%CD8)FTA .$C?
MQT!^PXJ4@CX=C0)5#4.U.@?AA\1L^FNRSZ^M?++]FJ/V.Z#'U!T:!&']F.O@
MYN(G+E!+3D->@R=,EZ:M_84US <8-\I_.!2T\6[6CH?]J3KG7VIJ7 JV*VL
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M/.?T<T:9UEMXEIH2/ON;6Y_Q+/-8T&!NP[JXC^FB-$WGK@8+*DC0LSO0#"X
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M"[,>^7/[7<U^I]1^V=P#.LP&^SF%FPOU4&U^CZ[UZ<%/:7%$+M$C& GL@N9
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M#718RB!+VF&QW9X9/-.::2:\_R72AP!:%DM:/SO79GJ27;B9+./8\#LJ\H<
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M-A6KBU<;F@K@*(PN-M<^6\@HRG!T[G.X-/0HE69!_+B])0*^O51$R5V]R_3
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M[8+38X+N0_FBV2=?&=X:'ZKWX;KVODRSW]X%W%^O=H]=#'H@209+GYV 'GN
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M3^G9CKA!&JQ=/NR[&LTI4J/NOJ4>&>=4,#L$A]_-3&9X-*(&\AC&$*"M2#O
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M%,8Z-(RNI?,6C_@46CSXFLCW\ IW8IKGP6\\YG9;&IQYQL:_8N(Q=#SH212
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M'EIL%>\=AC*HZ%4GYMYO)K#]K>^0/KP*]I=T,'RNFK$HN2FJCZ>B(L8]05M
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M+VK3&EQ6573XA9?CW6.918V-;8>+HX_TJF=75%3$G*ZLO+8C1GA+8W8^Y1@
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MV&D&)3Z IAF);"+H24R\"D;J;"&R=,;(\1A1C$/WA;G3>V+MRT_D"-_>M*$
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M+J%H!/AP>A1IYB22CG5_Q12)+=28I%!*8F^/FU2^O3]_,6TF:?[,4CRN421
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MX\JSNVY/ R8:Y _.Y>QF&ZUN,$CWKRHD @2:^9H<<^%T'WZG0!I3ZX*6_DJ
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M(<@%5=\:.UA'C%$-LOL0JW+C7VJO4-[\O_\-BO;_TDA62%KSE#FJ =6/BB$
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M#BK(60X=4*@.#DB16GL4N".K>CE>*=#MTGK06R2MMF!X+1K-,)K5,:*,<R;
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M\M<!_R4M)2G]Z\VO0O[_?Q44$1(2D103%9/\OS[X[8"<N*"KR%8A@2V H)R
MD)P OPM P'44^5OU!(!_.P0$A81%1,7@:DC!)]2MAZLO) 176@2N,?QM)/P]
M("PG(K]YUT%1!:<+8EN"%7??NO-(7.M058?2R;>@]IZ+UZ(E))55-JBJZ>CJ
M;=VVW=C$U&SOOOU6AZV/V-C:'77^[=1I%]<S9SV]O"_Y^/KYAUR_$1J&N1D>
M<SLV+CXA,2DSZVYV3NZ]^WF%18^+2TJ?/"VKKJFMJV]H?-'42>[J[NE]V=<_
M//)N]/W8A_$)&GWZ\\R7V:]S\\RE'\L_62O0ZMJO=@D 0@+_Z_C3=LG![1+\
M-09BO]HE(!CVZP0Y89'-NT3E#SJ)70A6V++[EKCBH3N/JCHDM/:<!)4N7GLK
MJ:QM3--A_FK:WUKVGVM8]#_4LO_=L/_3K@E 6D@ 'CPA.0 %<#F%25N!O^Q?
MPH2^$":$>)*;^8"D$?T+$23RE,18I2ST.!\8X0.T34L6%--/^]IFQRE7+ 9)
MF%G5Z;W/S'B:8WS@-R$^8$CBS1#5^4!T%+[O(]3 ^XA:CIYHN4)R&H!"=(E1
MQ2>O$[<=,6 /3SVF.-.";[[VME<Y*9>?Y&"@W+>&B,0-\0'021;R(*@8I\?B
MP2>H:CY0AWS+(_ !"3'"S,W32PXKR-</:F88;++JT-[N2 -T'AYTY .KY@0)
M_"0?X&6<&_MJT^.88 #FTF23VK;KQB#+/JF"4ZP*XP'GQ""9UN;!SZ5B7R(?
MV(AEH;6Z(&E=]_14"XN;%^GYC&\W#2M9R'BM;OJN>W;':YI/!GC55B]<O^OR
M17;![#&^XS0?"%H<3^]$@2?P\0C094K6_CWV8OE3(EG**+;)G0_$&B>DE(:F
M[A%5*7%]=SG3>>=]M):%*+*&?9(/= 22+AF-A_$D+:F4#S_H>@PQD \< I<P
MJ+-M$.%I@$M*KIII271';;,#K;/3.RG@ON3^FMT)+_5CFF=EO=@Y230+.?9Q
MK ATAPF71LV]A=.=6R,D71^2^0!%LVWJ/GD8[/Z!\F[ZZ.)GMS.4FM6[Z23D
MR,J#Q*8C\;UMJB"EVW)[P%#L2D @4T3G;F>>8AR%L>F<W:;?G#[SP.<ZAY9L
M"];-)W'(\-AEX#LNXR\1-3D:8%H,6P WP5* .J>G@V*-V56/5M\@BXH'RGJ#
MPNL7+8[F9F1TN!<8 A<R=\O@;F-W<0MQDE@O9FE*VT;.'BC6N^P;1?;&[6&.
MW^/#S[+FS!P1]]6.II5=G?NAGU(4=30KYH!&L5(OQP3B@F'3*DD<-)40IVE9
M\[X.!7P+*(+:I'1"W7=SNJJY]S\^L=ID<[+_\=V/0N>9Z'P<XAW<"46$>@I'
MR855S<WGJ> ['"SLP?0.DDA0BP8B;ME!@?8IMFQ'<ME71O!./R.#5S'R[:]V
M#_(:TP1O'4"4WG49Y /B=>YA+!$P/YN&GQSA2:I$,A'.4.STI+MLA^8F)OKV
MY>OX979"?4=QCS&4LV7)^-K^VL8==B<P@JTQ]*'>Q1B2D!'6H(3CRF3DIX9,
MXQ7=H)#.T#')1=W2LN,:A?6)<JXYV].Z$R0?V5T4,Q;XX(2VQ/K '?P,=H?]
M?,"'F)2+%VG;A7N/W/"VQ::D95OE&?-!XW!S^_0=:$?I()G$R]$BY-X.L4>#
M$3S"$U?_]^O]\]P7S$P;=E;4CYDNB:6Y?A!\5K'7>U.T.#7F@(*3M2( F\#2
M$$>Q@2?IQ@?6?><#M_5Y.X@<701X#^^'?]7+); <JR-S>0]+?IAQ2[D/F\UG
MTW/P=!WB6O40YR4?X'XOXJT[RP?R]/E "()'_[;TFN1+0RK0.$/Q7^G!QC=+
M#0/:_"I+M6M/VGLU(1[.OO@>$#/H[U1T\NWIZEH/IF-9V^R\#^=P'1\X?88/
MW$?P@=;1M?OH 4N\L]*/W_$9,V?T1MN*';,(^6M]GS[60P^^LRQQRJ^8X^GU
M:UVK+VX&%KK]0'LU;RHD[>28/8%[R@8?2(&VAS$\02%:/$=QLHLDSE$'W9S!
MVTCU-\OH^'#E)\^:2C+&%*YD+GU\N6N'-'D'Y9LM=:L2RZB=*,6QXB:TB6&*
M>A -9@P^8-;E@.R<J=,G;(0F#PYS4*+)7E6%&]P6DC=:FT5/4K[H.A0])[Y.
MK[3\E,1$C#_@21YDK\=]R-_1#*HLS+"MOO*VC%VN9>)UD\XWUC1GOGJ.KK.6
M>1?< E[9=+,J[L"9@U>.X,28*HPZM@O<AQW;\-0"BEHE;U^ 'YT8RP=J&]*6
M$?%KU&P+KJQ#3=MS>S?7=1^%4[TSMF[Z?5>!['M__:ZV3;Q)?$W\PGWV?LP>
M>B\CA#EF U:H?<GRU*A\330WZ7F*87U=R#BH5ML@?\VUPK=+*!,H:Y.&O>IW
M7 =:#N4SI(![QQ/GEG LGV)4.JXH=*\--OR./GR1=FAJ\B;>MV'?^:M,HFI0
MDP2@N6A]%:%"\L>/4ZB(.*S1-"H%K5+K+F3'+$VX?-U(<MYL;&^\\SLC*Y,*
MN=W1$G=.W3.35++3%LA[PXSO)<7P (A(Y0.W\HV84P]SDUMP33$8U,$;H01G
MMPVG(^H/E!VJ<*JNV:.$V!UEM^F$&-H:*\4'1&*A ;:'+[XN?H' WL'KA_'=
ML!@L-$I![F J/Z1'XNW!]P^?]GO6/H^FRVNUQ5G3&M+O/@O[?5:P58_:L##"
MOLCKY^DW0S_9SOB.LRUN3/WV3^IOB$03BK0_'Y"J=1-7TVX(,Q-U$Q?IN2CI
M)7E_JF'#OFX@TM,Z&*<&HY,8ADS51M4AXMKTYLSPLC[@Y#<F5&^><B;59,L>
MRX%=/>]<1^]7"[@_7B^^I1&52 )/HC^$4"F=06+8*U N^_#7"9?XMLWCO6'4
M,U[1M.]U7S5-LKWK:M),7]RW:+#94951-G]<2#HJ(E:)S!O"UY:VXR>::2TH
M%;P/*BG<,;G%W.15#F5BOT,/3:;+2V)3]@:Q..^74XI)SUZH"FUI3@*V%OZ_
M;9R1/R$/N$VX7CY04]IMI.(.+?;BU_&FRB@W\?Y-O+'F9-S+]R:KGMF_79"S
M :X/G>WA _%XWDO*LAU^J17/!WJ_+1]349YIO*RT???MQ0W=YCH!CW-_(!!)
M-$[@Y6/S1YQJ'T2T/>.FI\+Y!*892V%(>3[0 ./@IA?$-XM)> 4+,1!-*R$Q
M(^BY"1>&+4QHJ6JSOXW5V4V'V;OMU?+3R2@3O321U.L?W;L!R!2YAI;E YY\
M8'R$%I1<:1%&=8S'7QB]C!VJGL('3 W48 /5L=5'^Z^ED3/"9RO#C[TA!TM-
M?CQ<;;,E^_J-E^<QFV+>N;P*%O6)'ZRJJK0VOGOR_5CKY%=*R&3_3I.K&WR.
M%SDT1%K*S^=Z,F-@*@&Z\"1NL??A!M4H',45GL0NMLLX9P?T-,*R>#'F,D\&
M8GB-M 0_&0A1*WE@&%=MX:*^\MQ7*]%T_=G#FS4<W_ !90NLQ2XX*L>Y#[!^
MS*&3PRV[(B+8!E#&/"6HS=:@H(UM7=&POB+3=-TKV_!,);NYP<A35!2D&\]1
M&* %===!3)#"TH+<'F%Z]--KW:#XHZ#E7173'_)V>;JVO5F;M6=& C;^GA]0
MRBU$>1+&;5B-#6\9>'_9\9&.-I2C[)1E3T*; ;BL0KD8-DD:^/$;P^7#@]SO
M;=T?U[U-%__IF(%4AA8[D )\("81M[LTE8,N\=/J)M6$Q2YR]N@616[<]G1R
M\M.4]O"!UP<R-ELP] "%-VI0#*N8^8/CPLT@4<LUS;D/L:YYO.P(IF-GR;=3
M8.N'AU=J$W(=TYUWV:MN9R9[-:UKS]Y5OF1CPM9B3K*4N2EXOV\:8L>XC_B
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MT\3GJX-#T0O&K59=.6/[O=YZN'5O\0^QLR3=8<^*IQ2]/+VWW839D$2:D22
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M6SE"W!3<!HQ15\[S 9GZ5AI>V/7#)^N-22</G[F0Z"IZ\B"PM$X&P)T,0&I
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M[6<)\9>BS5HN9:K;3QUZX_91Q6KF92)IERTU1=YF;DI18-4(9M9J<.]8<VY
M?NRM6!04"0:Q9KF%V,!B7[QBBT+I7+YTLN-;O?JW%5M&#8I4JJP\'VL=V3'M
MM+U*5WOIU@UO89=YE0Y*_%IOYU#<611Y<3WV!%,LU>AZ,UIWNANY/2+TG8GR
M1[=7OT]V*[J]Z.U32Q'H#9][\A<C_C<CQJ*H93"@NF#-X-BF\#[:H6^,=1+
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M['Q)SM@??MH$=/UH?+/\Y-W38\$!/X[<K=KK/SQ3:J+W>823FK2U\(5#YU\
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MR$KFYOU<$?M>_5R\?="%VKW^Z\L>S7_Y;M[J>"%FP8Z9(B^EDYX;$7H5BT4
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M*!"*1JZL?!B;7N4ZUR2EYE296# &8[ULJS>&((:9O/&K1P$TXYL)O<=QZ((
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M/*A5,_5B'A82+&OB5%&RWT*C&@$OZ'HL/2%F2L&LGK(3V)XOJNMG4^G?F*]
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M60.T2HWR]$\]-/WE%<Q3CL;804TQZ#,!)1X#W9282#028JCT*6UH2FJBAL5
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M"00DDKM=AE?SUQB4-F/W=F*G-(@@OIL>C*$^4"_X9&]$T#=:_F]W_)71!-Z
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M:XPNZ!?QW0 GS*P<_#:(VN'UH?=GN8Z"T!8A9OKP!'_FE+8E9\ C! (*@F7
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MBC:1Y@\[@$9'(M9P/9]$7BAX/D3('1IWU6.;AA,<O ^Z9M+&-^L4;"2]3]Y
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M QZ@%QKC'V>EQ@.2LB'5X8&;]L1)XBAS[PBK\JT/.5>PEMP!)+P5'NR]B?,
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MKIR]/<C%0!J4+V]5; :$K[+@;!'<K=D;[AD_'TH6]_-KWR_X)2H.%">\L")
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MAKF"7W'T@X;C.=38^DS5)_8T9")!O&0H(I@'[![?]>(*Y9!*M^\.1'$WK0Y
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M^^QA?=]::^^UUTXO>>ES%KV"C$P24SEB#XANQI8P$JM=1-8 <Y.V^.;D5<'
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MMUKQ:^'K.?(:)I\*WCAK/N189.='.9G)=+\FW"0;0*&(.;H#44%"LQ15%M>
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MW@!!4E3RC',IE"YR@&X/\RR3#F?JC*U\.EMDZCH'KK,FSBU+6BE*:E?R-T>
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M"C.K9UI8[H^S=KP)\<D9Y*U.(?EN?K%J7;T^.DI.>^%F['4"G<4O!@&)0HD
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M3(G[\_ONV(CL,_+,>:>BDZB:<G:?.;L?B"M8U<X)/K%P^91*/1'T?+A]R7I
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M>$?8M-IDLG7R]B">$YS(NCO9P).)1;FI.F FWM[C-A@U27,OH7%@LHM]MB6
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MJ-#D&@ .2;P!+<H1F>W>]&F4F/K[NF%,4=9;;L(>ML:L=:*QNETS+329-$1
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M7SI3&DQGV(Q(/?=(<+&5E*98SP?U<#Y"PX9<9%IG6Y"\<%JA@;NQ X6QTQD
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M(Z[4)B4&! P8H& E.P(H)]W&MQ-A[<,H1LK24&;'?&(8;H <',C*I3+<M=V
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M"Z6(NB9XLRP6!'*)T/YILRG\!!8[%_#+<IG:<=C'HK;D7D!Y5P:-/9G@0SX
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M!:B.VBR@N[]6*J_MI1[7; +U>1G72V5[ \>3CP+B]6PM?[- 7=!P23)]1!2
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M(%K/JEB24C1DO#G;V&*V6+MQ33!*Z*Q].%?ZT!CPD\N1S@0>,#\"2"/WS*>
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M0UZB].$= %5.(WUU;F*G[H4H@#E6^=LEW"H*BLM* -JE#GGR_(Q'8UU_^QV
MS>'R\6EY4L_M6"I<60^WM,_D2MBKB+2ELM^,<2,V4MTG7C%[HY\+;23U JGN
MC;!(K0=S(X\%.+0[VT#W"?CQD6*-7'1"H1\>3.92?UTP?)=80VK H)>B89)-
M_8V$*_][Z^=1P=\4= @EL6K15FA$<T53LO&%^^3S[VK+K8G#%[A7=E=W<_D&
M9K8JOQSKW3"//F&%G6CJ-9>;S-*G?M-DF'9%L/.,5)I,VH0T0IQ2_8U#X[J
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M[FR;JY[OY \,%(CV1Q9>Q-77\3M.8WALG>]<1A+JV*79&%?9N&1IH<B=T4=
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M0>V]9VESIV-[;C:J8QQ<GZ"R,=#PKL[\HKA%765S =K8*#EKZU:\.3E+V!V
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MQ!,JBS_@O%[Q55.V,-^1HZVT*EZO/8UP"\(0TZ07N+!Q4"\IDO?R<SWV!C.
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MQ*Z?<[%FBG7O,-'X_-1(]"7E,#F?;^QW^9HC" @+E1A=[-PXW.WMK>1"8*1
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M0YI;%.1!OLB>^46:*6E-WI(BVB#6*_UW_JA@7LC> B0 EQW\83$R+X% QA%
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M"]N9+",'D,3G7#&C]AGV6.@"!Y'2^-\!)(86L_<,<E(#(1A1LUO7DB.^Z4-
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MPI.F ^$DXX1O)NBMR _$ W0P(A?QD@"WEA=6!03NT4OX/(9 P!AD(*SS,6B
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M$ 5ZMW3])2N#/WG+N2O=$CP"[Z2%=?"."L5'<IT?_;;L7YM.+30+P<])'8"
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M5"NO0,O,0-A(3G1N 6-HT]^I$_]V B4]O4QINV..$S(6-:\_<S]:7.1TT3W
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MN>4(?PW7[^J5%WI@HN<,N7.UTV2+N?:5BD&N'/O $'^@BK8\ ?A5AQ=UH9_
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MN*]074.8S*00)4+N%I!U"]CGGMM\_44":HT AM6Y_RI,CH'7"%3"\_/=&;:
M'X$]8[Q8R!O 3'C#A;HA"RJ)VGQX=4N!5?V.XO%[,VK(?&A42LNP6XQ:4<-'
M5GV]"57\E7CX!P;'&:3C^TXJS'6)2(:M(^)9:1>/?%;ATE5^!;2PE^N%$PW,
M#J9!H PG<"2[)NBRI>FLOE3DH<^Z[+,E2:[@$A&HX"%<K@@X=,B<I5MD1Z(Y
MG.$3PF+D];+!!'[^_SMOV_D1:GC,FZ\4O$&@N,A.D#W@VO/QB#$JO''OC_$.
M-XLE.#':0UZ*N>,CZ?2.I^NH4>.HL!H>@4?45M<$@5K_IFL@]*A(<.?LKHC
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M6\"&TGSYZ=1BU@\79H*!8K$7]W\V?S'>1'WO@\>)-8Z>T7)E235I,>PXLG,
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MNNH$TQWZQ%R$P-$F/'!"B).P0K=8Y+1F64-G=_.KPLW=@H-X54@9(%U,, (
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M2._"(;U+!DJ6)4J2&+-WC%224\=#OWN?V[?1<)>C!LY>RGEU'<[+!TM(YRF
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MH8ETW&$?('@V+;(RG,+CU^RIVHV)2HB8S2H3@:_-<F3/ E=5:NDU%.5!]%"
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MG_]#EM/BM#+4Y_*'V H>3-_#N=WL8U7*%S>Y<?&$RE=1E/"/?*/HXHR]08_
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MQ59E+'*H*C_!#'6L807#%AVKC=][;+A,A*02B(0'LFXGH:%T@9XE0\8X1^W
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M7@<7 [U2K5!#:P6(R:7[ 8Y9K\T+UTIM'$/#P*_#'G]O?3$DE(3I>!*K-&%
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MV+;R&RL,0=$4XLHKMM@?*H4:^3MR&2/*QR9%U/8(8R2IP[>D=*:4W(<AN)8
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MMI0-;'21FU:AQU),B$:="$3:Y]N"K :X4;YNP)+EKL:^=V(_(MIPR#<ZORD
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MR[U!6'<_5ZLDBP=)SZ4,[#:ET0R)XLFQ":"7#2\_8638HS(/>5>0V>1[VMJ
M+5-:DT>/H*W<L^6PA,CZ3P##VQWZ=SJ.I$#""5O?WXM:OY>Q/5Z1S*$S.6(T
MV>7D9"^E'^N3;::5J=PX0J:#N4Q :4(+1O*LV4V1S!MH;!I++ ]@IQM:W;3
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M]=&U0PIGYV.!#TG.-WI^)&GD2S0;[\@$_E8NOA/S::._%7MYQ/N.^-52=HZ
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MB5(Y&"8 .=ZT@##/#<,0W=B[A&/^;.?2?:-5=_/A).4_TBKLZF2R%%/XGB[
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MDA<VVQ55^>UC\N>Y5-;!!L:)171G-J1%57M+@U!+[H!#%0&T&9.I;GN0;W.
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M:!7#9)U+VTZY)=E53.\5,KY)=VOI?LD!:IFT5 J9B=]JSP=TY)I G@"YM<2
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MC F&3\\.& 7?R$<W1G($5IH(>=7095>IJ2^;1W:?K)PO5VU4KXD"K]-2O56
M$-RP3$F/QH1L,\S>.:EUY<TF]UU4C&Q>AXY"7&Q2T>1-74<GMT/Y(KHY739T
M03DU,>MM:H%XF#$6'[ZFD.,IH:R6BZRIB-ZZ1%;7*"<7;5]<OI\+!V=.<U<X
M(JJ/9=*;2]"W2DU9KSS3G,OY,'[JWE"'U<UNW5<K9C"A-B-44"*_KG]PPJNI
M&Y<)06"E2:I2M3R;_EI=;Z,<K ]D*B>G,[XTQF'LK1>-K$7!)PPGS#U>X/Q*
M$'SY3'/SZ%"FLF^R77B#8QI0IA5/V%$YUV#=G>&*ATA$JV8#;'- N,VCUI^+
M7/#<M_--.U,<;,9"$%Y+G8DM.(O5['?H@"G[X57$T22Y3ZEE#<\3J0)?0/B2
M[HY*O3!QXZ/$&B(TI((>:J9^\ ^+=D-$+]V_XF]L M"6)BS<\_&PMGJ)2"=2
M$U&9$(7FXXW%RB\/L"/B?0;.#5Q/23YHQM&^E7TBK)R0(>\<5RO8S3G< C;*
M?<>U7L:FVM^I.9W7UB>NAA]FI.0X_*=YC3?1P^NF4G-2]+#SR+)(JK\>UCF3
MAEK#)-C1E75SY\%MH'XGX\#3J4X!Z=>G_K _S5S9.ET/_.(ER2)W/%.^SQV!
M/HV6B0$85_3;;">19EU H>WF"J0K&RNE0-*.%\. DI@.%R/U'YZL=R?,NUBO
M<:AF-5_!5"C_1+<F.Z=A%FOM$@2$TS/LDKZ-*#=8=6.:Q"/2-,^XPN=?+?W^
M2FNIEA;$3$]N=_',9<3?+#\TO;P1JH]HV^HA!RW:3?:>J*8FF)=I]/68W5M)
M\R7"($HBNGB*>_(_;%<%;1D=(=-Y_/91H[J3$N[I/&!;1.J@$HC0.P[KZQ_L
M=D*1_3\YHE4>IK8X[<(R,[?95S KYY,)VLH]MSO L+;23+%I<"=)5T*F[:5D
MFD"WZ0XZG06RZ@-WO*NP/>O@@ $T9%KW0AY*)AMM%T!V>*SC2C:O0<YOZW)Y
M]&F]U1H)3LGC4+2&>Y[IV6(+CR&'(>.44NNDWRX]UMC<%Y:[/4-_IFLGY"CF
M":V-ML).T6.MBM%J"7AIBGV6'T05XK+ME[7Y81G5:U+'X\##C%\_QWF7SGF2
MLOGFO9<6''3SHD2(]56(B#Q9F[Y;3S9X&K;HLTY@G@/MKSN<[!_/_(WO:Q)5
M[4SO!5^BSW(DT_3@L!ZH #@V0T U74U%&. ?,&2&6*D=OU0\)^<4APDS!O(>
M.65KJY%5 L,%JJKW=04TRE<\YL0E(**V&OB*C" OKD/_S?C<G\S,S+8LG(ZC
MXFY"LN(C]O&2:T:.2\0$?<Q,0E^;Z^#DKL:]0[<.NG\_;QX"DM)5(8 (_O"P
M<KDIK5_+ ?&$:>Z@7V_*^.JF"R+ F>FY?Z^T6Z=1BXGXUC-2RM)VEI9)JFEC
MU/5^_3LHU5'APF]D-^K=0C[#OY;)T;;IU;T9[\Q">1A@2OZ[UKK#BMK2KWRD
MO!D#]#*?#2IN&+[]W)V@+^ ;??-!7$BBUS0)W2F4R:@5+4NQ$AU<;6(<X*\^
M+>.!O=N5BD94\1EK1,:-\0=N/D&Y';;:]260@J@3M:LE7L\96W)P4$J3/(1#
MDHL:IT65OA-B01%6DKJ#4!J\TBMZ9]%UA42=L(6W]X>.G05UK]HJ('55VGWZ
M_&Q,@:1.OS0SHYU<"^9*\T?$@PYT#\R!_HG*]G(J9Z%FC!K&J',@W+!"J_1.
MVU62WN3L>GY\8H1]\B,?\-&E._<VU7!Z\V;?;+2"_1*/D3A3ML)?K:E.J(GZ
MP]!:1X)3/<S-&YK]4UI8[L_"'\/3VF6BP!^FD[WJ+E5J 22,;5.8\$P-'U("
MJ2K7L94NAG,]_BOKW%H+ <3XC[B)]8L'_+TCP,NROM* IE49B.A7"HE]+VSL
M35F+]0<A\9]FQ3:AY?O=S2/2=^):ZC#J7IS,$5OTA1V:WW>!6ZN6J-"*P5GR
MJP4PSPV9GRJ3QM2_XMC3Q!0^3;O*N"KS0;+X15:#31R7)V5I5DGO,M#-,CDO
M_$5D&*S<CN3V30G+F%A "YRJ<JV#YBYN9/U:]C5?TDEYO3[L@$?HU(''8"H9
M#%.$(Z.\U/RA5D5FEGE%\2YM3\?UH-X^F5'R;B.WQZ#ZXQMUKO$?O)(9 C)>
MY,NVN_JH)G7I+.^1_(1%3L-0@(JPGT5CC1$N,;5T& EX/706*K6\;Y\UF1-:
M.K5?PTP64;[WT3FR=H23Y=+BC7+^HTF$L]K (&!\'#%K-2;_'=MSS6F-L5[[
M#JO./IXB4"$&O(YXRN?M(IB(6G2?)HC.KJ,'&GIN([WMLQK3_D U2"B:%@TC
M2J_-!U:6VR_6(V>6>MJ6E%&*8T\4JG;-VSQ0=0C3Q",)>>$,1GO/>[]Q!$B[
MEV*A7-3S<L!*$(UHBUCV3/5MR\YHC\3;*G.Q2+0%*UF,QX^IIU-)ASZ)H^?5
M&9BNPE$>D_$SYEK74BM53S;-_YB%U[+<(5<EENO.VU,CV3KD,ME'*IC]^R$5
M5,7NL!@V+//&_91GV'ZK1X5KSZ96<==!?TF1 ]VS4%8@</Y2<D>PO2(OG>8W
MR^)CC^L [KM7SK^"@K5>E][QFNE-6AYQ[FG-'V3I*Z'+1]2/DP\;>?1;#._0
M#XJ\\$U">,N(&=W8+P)L#.%R)]D3=@WBCP*"XE%N::V:7,U<LVKG6M\[!+(2
M\_! BC2-4/XTO5=G2PP,R!%7RGA=N.$W"LK+O9)25.:1].2RO'2I<R6.#04'
M;E#*M[7Z*+YDWSW=9*/,8B HT=5OG*:"UXN:85 V#'=K@Q.L-DDB:U/;%[G
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M14K[&:S@3M<VG0KMT@C;<"* [%# 8^L/C=;TI)3;Z)+<Q/M4 =-L.P@QC#<
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MB4]I7 $1I9'_OWYUSC&.^ILQR,"8+"I,R-=,=%DWZNL3;1',PO%IH/,6I)?
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M ^EF[2>(X@K F9443MQ,U_51?I'PJUP%VUT>]R)P0!J]ZS6ZG+R4W+Q;2;E
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M4TF=Q'Z D2\MZ,DP.V23^>=/B?L0YL'$M\^\<DKZ>,=V[_X+_PO_"_\+_U?
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M.4ZG&N,Q.K@5-W",>1<9;=[KZV3MA@](6]3"+1^HN]WD[TH ?),09AE;E5]
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M>^NDI66V'_)HC;RI/,WM-NL'VC3@2U7M5_"EMY1$O <%*U7DL7FR,WO"DZ'
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M)FS*VD>M3NH0+ZCZ0J9K?$A73V?Y[U7OR'R:&=U7*)[H+V0J"3A\3S]6'I2
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M_)BPUNY'K4I?L&V*Q<N7ZQ+21W(VBLT#KU68N229?R;.&=J(5B$3=>5UC$#
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M[CK.[:"XGE1<3O?DG2CAKIEZ-<>&*P\NQ%]IQ*/^.HH(_5.Q5G1?0GL_C[6
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M+MQ>],H88W:-Z>?.*8BT0>L/69UKFZ]/3M2S)F6JII6!TJP2\<@SIB '<E\
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M0>L5WEY":J% (5.PRV\ EX%3?9-VG;.5<,HK1&&-3<G.D;0,%-\?E-P;E,G
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M9^/^35F\H>1OX37"HN&@DD6>3IPNU/.H]8?E[2Q%_*B!PFDCE[( @R,(#OA
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M+D6QI/,D-R@*)?[#\O,>T5'XU-A65(=E-RBV+@ZKEU1!70K85:"-A<9T U3
MIUG9RSW>I6;8@]H)!;_H"IY=#,L<C$57XV80G0D)?0I0(*^E\$=6!GD:ZSG_
MJJTVA_RH@=EX?N;91V]'!1,F]DCA-4U&<@5JJC5A$2.AS0J/1-G45,.RZQW'
M< O#>]S'Z 1['2HF,0208)5L(NL<)45.P40#*-,X6>Z5?".XZ?/VF*?B3[W!
MLRV'XA3O*\H33OZ+'AI+-A^3D"1S3R*"5DW)%+U'LN9 <CM;_IU+C0ZA5_2)
M11$^*L+Q;%$_=J:LZ+;-\)ZB<4_LYJQ2S!IP(^KDLO#IT#%.H_UN[;2<@VP
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M,XJ/OCZHI?[U]N17S^_FJ6=^J,=-(6>C,N&O=7_VK4YRCW^D$#V\])4(%"6
MBNO6>__-\F^6?[/\F^7?+/\/%H/0Q56>870L433%+'Y$Q] 8L&W2$):]GQ05
MJY"(1@X!^3Z=G'@S+D141E1R?"$_JIN5<,RP.8B*K%/^Y%[AAKU[%8M&&Y;&
M#H#!8-7'3^_3K](;M$'=<2$G-A*MP8Z<%"*9[CJR=EHD5+>6U%T(94X"_8X0
M\@U^L#%]9IM;89=OZL2')K9ZM>1,_P"I"6&E- 773-GP+K,)KC .H=56I0Y
MO@D)D_>$%*S0XL?[I90\[>?.T0:6S8[33 KNT^7.>G#K-N]H%[!'.J!"0 T
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ME-/&+8HB**8./FQ6QL;[U[]I?-JHR_4(BEK_B)8M3IK$[4EO6S_8&G^J*R\
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M3[ZJ-GV!N:0 %,W:\DV9N)"OK 8LC:Q+N&+03Y&*\W("2B%& 2M3=FV2$P^
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MS"9IBW/=%$,,0GZMON>+=G6@B9@!QJ?B-\[H&G&"/V'-VEWFNEEWM0[3B.D
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M[I,S(W(1.(J>@:Z1$2;;9^=D^_:'BE6RGZNP37Q?H>F.($%A$V+WF]#7TL.
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MWG>ZMROEF^:WJZFTSAAK/=.?W+'7.A).JF.U?GO@VB\\7TN.S>8Z3J*!/ 0
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M+/>5X8FE+=JTDMR7\::K,7PS 5FC<89F+<TP$M4AV6UYS'ZL/ 6XMWJC-GF
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MP(F#B2GF1#H0<?W!]J_%W%<AQ*6I6X!OP2751$NSBNZ16:U9='()<)-*0C5
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MNT]<_0?^$JQV+<!7$+>7^Q#U>@YN+^KBGL+Q#)CA#*(-G"RL>MWD>K$+O"I
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M3[ LTQ>X?@=6MY@<$Y+NFAG,ZG]]HLMN<V%H=6GB]I+TCWE1CD/)K JT<6*
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M<I?PR&92'G1\#%E,YWYDE<GI+$WMV^%E.\YW=CHO):P7V/O!<OOSIC?;!KY
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M3!3S*1C(;N 4VRDM'EX=R#GZK$5'O_=LMZ@R@RV=:*&A?T[MG=;9RP$#!$Q
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M8N+"@15KE2QD^+9IB1GR%/XB[_[V Q@2#JQH0  6A^D!/P\,FQ\MGO?#/T0
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MKU8_&&F]EC1QDQOK33\SH_!HCU7[_3]];YLS OSGS7&-_[SWU?V+]!UD%8$
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M$SC"S5;35GWY-455"K:(7F_S9AU6S!)#1792YO4J:UK:+HE]4"/?//*"'Y7
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MZ0(P$H=I*&<V##U/VA[R$X,9Y1[T:9A&)*$THX%=&N?!D$V3O-D%:&8;C\%
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M-Z-)G363NM_G>'/[(WZD=US2ZL>RJ#G5LU?^];;$]T )#WK26UR)GP#=P/7
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M>UN8N'KUN-_WIJER*WN5AK)*XOU!?OAOBGN<KQ8Q)PR'2099S%.(?$IAAI&
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MBH1!E) 4IL2/H)<DGMPU)'%$A!4?'NYK=KRG106OP4;8)GVD);<= =>0P]Q
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M8VKHKHS+B&])-Q]WM+O8G6RQMS'2!4 TM.6N)ME@N2,:[%%M$T1T ZPN-KX
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MV3[E/L\?;EAY.YE83CORF<4-C./3C./]-V20_5TNOZ[HRW/)?Y%?:Z$ZXXG
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MG Q8"CLY$Q;>P +()$K4+0@[\HWOY@?#@3Z-_P6<@ET+IY8/CP)J.(B>)-<
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M$#B/9!Q[>I9@L2T(__O!8RPVJ[IG@KZHR1/TU1+!';,K)C/KX<:TG+GR>&!
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MP$G([T##!OBM_=?P VJ&/ JP6_#T)-D&D3"JR+L%I$-9>--8[OUJ[S>BU$_
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M+2.KIJ=[Y(*WH]<3&,.AG9E275#J&^T5KAR;&R=$_5T3#XA">1PN(L=U)#Q
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M*0%$ @.2Q1QD.:109QRJU*ME^TDI4^/F2LG]-IH?]9X&THU#KX9G8#)\B<P
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MO5+%NW]NV>)^]>?UJB@^KU="*5E\5FN;OL&^J9G@-%:QDH!JC0 4>098JA5
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M"!F5*;H-?4D)%Z[NW1"W:F9YN]T\K&S)KM*'YEF>9<@LR@0U2S%(2&P3I27
MN30.(**(QEX1EJ?%3,T]V;=EC79Z>JU(+J#J1@'78S4P!?2!J4\'VPX4PC6L
M/25D[/ZT'8:>:$?;=76HKMAEH=]=#E&U832#,4Z%SB"(!38.@208L(SF %*1
M9FG*8HC9M4VQ3PGN$4 W,%%4I=TK[:YMB'T2:F>F" 7?J[;#KN#<)PQ> #9
M-^PNG 9KAGU2Z"OWPNX"XG(K[,Z[_2OQWF[EW(SD1SN@=O'.D4;F_PA@L=(
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MX+Q+0(VC58^2(G];+;:/+Y]>,6:B-<4PC0%E5 !(L004X1@0EF1Q8O?08J<
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MFVWAN>I-J6R/?FF9_FM4&V_+\+?NWUH VK^H, CGIXTW7H'<O1$4'M5K'&\
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M9;")-<\(P%D2$Y4S*;EG=FXXY7P^PW$2>BLO\=Q135.1J<=!?IC!]#C&'WV
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MWQN- R9+.*,3B+PNRQN5HIS-?TE$[C<.T!?F+VRS79L_[VVCFM;2@S(*(9=
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M7XFBM_GG"DTD0^]B=X.:=*[*'QMOSL^%%JOY+NM5<PQFG +:>AK3DE*1HY+
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MY%1AG'.::LLJS4U8"$HA526&B&:4%4CBI'#RV#YN>&P3W\@&C'# 2.>>T^,
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M.T$&WP\9#6<SZPBU)62<XY<7TR^3/\8#2BD7RFC"9$!C9TNLK9 /2-%33Y4
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M)=I-A *B&AGB--;(,FU>?3]L-)^#K"#:)B#R;HR?AN(8?H?7?NY7; T24S*
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MBE+Y**SRT9F(CD(GSY$Z8:=?5ZZ+A%DKNF]F&R"+JVW\"L:0A_.!I4X'"XR
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M-P"=C7,M),0$AG/"K$77+C%)K/**&!L42BMIG;KMP=["/+4*ZMW9U?8(63>
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MJDO=-\:'/I3GR\$*H#9(ZFJ#Z11Z&SG7CL3*,8V4:BBN[Z/OCM&M?-Z\87W
M(S#+-!.49%7Z-J+=)JXTT],T6I\T97']\O7)<M*#"&C$WSX-;<^F@8JO/9[S
M8O;\[//?WKZ_^,?GFE>P=Q_:_67K%@;J7ZN>^]FWMZ/)'[/;&S1 ?UU)G0A
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MH9+&7_QQM(R+'^T%T-)ZGHB0$</CG#%V=5R7&3"9,92 \+4SN4<3V^\8B8Z
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M@GP]3EM>$F3-F.'2$[\(=9W  $0#(Q&H<U9Y_NBMVA8\';[V?KAZ*0G^YU!
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MI@ 9 -6M^?4G"P#O!+D U,):H#T>RQ1)H?+R559F5E;F=#TJ99UUC%%%3"P
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MD62!<>FBYID'UOH>H1ME [=.'1 [\]X5.7)X?J+/N.KOQPPK%C5DS<@=4EI
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M$-BFP>'5U0^3*+PC":4Z1ZI> @7%:'\DQTQ4P6-I'04^0<ZP91-](ZJ5'D8
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M'SAT[A,6Q\IR!*?2Z\OE=(;+Y:OTS\OI<CTR:&U=B]).L:Q)"K7V4$D$+Z6
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M1X.PWRZKH;W^[H;GB??"<*R/#F2UNT[1AF0HP&6M121CK$NW@J+N:XXB*=H
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M_G583DF(H<8GM;916%U[HI%A3E)1V%RRCDQ@X=V.PV[K=0/2F27Z6\IXZ#N
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M\%2\#=-Y\^7LH".0LO\.\IL=-%M?V>1&;QQZ$<O/?WZ;+F[)A>D89%$<(OH
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M?8A6$S[A,_Y]OJH-\^I=\')KIW6,V:.7X)E:UP@CV6F;0!='' L=''8;Q7G
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M4TH 4T84Z70IXD3OZ]LQ=6[#,O:!:#,3W0M"SGL>V6,BN9[YM)[?I$S4UJL
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MG6^>5VW,PK"]?H9$>%]Z/AOC3=]\0[1-5\NK=T,3%4Q$I1%08Z+@P%OPI0Z
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MM*4&QXG1ZB%MO[>]CWUSN^?*+&]+8I>/=X2I758FB9PFYI4'SVS=J9E#(,E
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M,KG]SG)#@5Y)CAG#\GV'>4> M'.)87'2JU;GS44\ DOU$2]J$Z@/8;'Z<5M
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M%"J60ISE#-$C!\VB3]Y+5O[_]JZLMZT<6;_?_U( ]^7E ED'#<R,C4[NS*/
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M;$9TB(?&7MA^*]MW"F]57."'/^MUZ"7FC_/%IZ]D]KL&Y\QAMCE#/0"!VL$
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M+G8] ^:.]4.?B^HQ%)E:J"#HZ9"4\K7%4578&@II/0],9%8L#K_\_F+,IT<
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M>"YH=&U02P$"% ,4    "  X.'=62.78>H('  !9'P  %P
M@ 'Y P  97@S,3$M,C R,C$R,S%X:W!R>"YH=&U02P$"% ,4    "  X.'=6
M_,Q5N7\'  !.'P  %P              @ &P"P  97@S,3(M,C R,C$R,S%X
M:W!R>"YH=&U02P$"% ,4    "  X.'=68B#NQHX%  "G$0  %P
M    @ %D$P  97@S,C$M,C R,C$R,S%X:W!R>"YH=&U02P$"% ,4    "  X
M.'=6 A,+[Y$%  "D$0  %P              @ $G&0  97@S,C(M,C R,C$R
M,S%X:W!R>"YH=&U02P$"% ,4    "  X.'=6OL;:R]BF @# ?Q@ $0
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M              "  5);&0!K<')X+3(P,C(Q,C,Q7V<V+FIP9U!+ 0(4 Q0
M   ( #DX=U92Z6S6=RP# )#$ P 4              "  ;R[&0!K<')X+3(P
M,C(Q,C,Q7V<W+FIP9U!+ 0(4 Q0    ( #DX=U;1QT+X-U   'F<   4
M          "  67H' !K<')X+3(P,C(Q,C,Q7V<X+FIP9U!+ 0(4 Q0    (
M #DX=U8RW[T!C"X!  ^)#  5              "  <XX'0!K<')X+3(P,C(Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    "  Y.'=6.WX(\WRQ  "N]@< %0
M        @ &-9QX :W!R>"TR,#(R,3(S,5]P<F4N>&UL4$L%!@     3 !,
*\P0  #P9'P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
